

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Clinical Packet
August 19, 2015**

Table of Contents

Helpful Hints/Reference Document	2
External Criteria	
Antihypertensive Agents.....	4
Anti-infective Agents.....	6
Agenda	7
Pharmacotherapy Class Re-Reviews	
Pharmacotherapy Review of Central Alpha-Agonists.....	8
Pharmacotherapy Review of Direct Vasodilators.....	39
Pharmacotherapy Review of Peripheral Adrenergic Inhibitors.....	74
Pharmacotherapy Review of Hypotensive Agents, Miscellaneous.....	99
Pharmacotherapy Review of Alpha-Adrenergic Blocking Agents.....	104
Pharmacotherapy Review of Beta-Adrenergic Blocking Agents.....	164
Pharmacotherapy Review of Dihydropyridines.....	322
Pharmacotherapy Review of Calcium-Channel Blocking Agents, Miscellaneous.....	441
Pharmacotherapy Review of Angiotensin-Converting Enzyme Inhibitors.....	506
Pharmacotherapy Review of Angiotensin II Receptor Antagonists.....	634
Pharmacotherapy Review of Mineralocorticoid (Aldosterone) Receptor Antagonists.....	771
Pharmacotherapy Review of Renin Inhibitors.....	854
Pharmacotherapy Review of Loop Diuretics.....	908
Pharmacotherapy Review of Potassium-Sparing Diuretics.....	955
Pharmacotherapy Review of Thiazide Diuretics.....	996
Pharmacotherapy Review of Thiazide-Like Diuretics.....	1066
Pharmacotherapy Review of Vasopressin Antagonists.....	1109
Pharmacotherapy Review of Diuretics, Miscellaneous.....	1133
Pharmacotherapy Review of HCV Antivirals.....	1134

Pharmacy and Therapeutics (P&T) Committee Helpful Hints/Reference Document

P&T Charge

As defined by §22-6-122

The Medicaid Pharmacy and Therapeutics (P&T) Committee shall review and recommend classes of drugs to the Medicaid Commissioner for inclusion in the Medicaid Preferred Drug Plan. Class means a therapeutic group of pharmaceutical agents approved by the FDA as defined by the American Hospital Formulary Service.

The P&T Committee shall develop its preferred drug list recommendations by considering the clinical efficacy, safety and cost effectiveness of a product. Within each covered class, the Committee shall review and recommend drugs to the Medicaid Commissioner for inclusion on a preferred drug list. Medicaid should strive to insure any restriction on pharmaceutical use does not increase overall health care costs to Medicaid.

The recommendations of the P&T Committee regarding any limitations to be imposed on any drug or its use for a specific indication shall be based on sound clinical evidence found in labeling, drug compendia and peer reviewed clinical literature pertaining to use of the drug. Recommendations shall be based upon use in the general population. Medicaid shall make provisions in the prior approval criteria for approval of non-preferred drugs that address needs of sub-populations among Medicaid beneficiaries. The clinical basis for recommendations regarding the PDL shall be made available through a written report that is publicly available. If the recommendation of the P&T Committee is contrary to prevailing clinical evidence found in labeling, drug compendia and/or peer-reviewed literature, such recommendation shall be justified in writing.

Preferred Drug List/Program Definitions

Preferred Drug: Listed on the Agency's Preferred Drug Lists and will not require a prior authorization (PA).

Non Preferred Drug: Covered by the Agency, if it is determined and supported by medical records to be medically necessary, but will require a PA.

Non Covered Drug: In accordance with Medicaid Drug Amendments contained in the Omnibus Budget Reconciliation Act of 1990 (OBRA 90 federal legislation), the Agency has the option to not cover (or pay for) some drugs. Alabama Medicaid does not cover/pay for the following:

- Drugs used for anorexia, weight loss or weight gain, with the exception of those specified by the Alabama Medicaid Agency
- Drugs used to promote fertility with the exception of those specified by the Alabama Medicaid Agency
- Drugs used for cosmetic purposes or hair growth
- Over-the-counter/non prescription drugs, with the exception of those specified by the Alabama Medicaid Agency
- Covered outpatient drugs when the manufacturer requires as a condition of sale that associated test and/or monitoring services be purchased exclusively from the manufacturer or designee
 - DESI (Drug Efficacy Study Implementation [less than effective drugs identified by the FDA]) and IRS (Identical, Related and Similar [drugs removed from the market]) drugs which may be restricted in accordance with Section 1927(d) (2) of the Social Security Act
- Agents when used for the symptomatic relief of cough and colds except for those specified by the Alabama Medicaid Agency
- Prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations and others as specified by the Alabama Medicaid Agency
- Benzodiazepines and barbiturates with the exception of those specified by the Alabama Medicaid Agency
- Agents used to promote smoking cessation, unless authorized for pregnant females or plan first recipients
- Agents when used for the treatment of sexual or erectile dysfunction, unless authorized for pulmonary hypertension.

(From Alabama Medicaid Agency Administrative Code, Chapter 16 and Alabama Medicaid Agency Provider Billing Manual, Chapter 27.)

Prior Authorization (PA): Process that allows drugs that require approval prior to payment to be reimbursed for an individual patient. Drugs may require PA if they are in Non-preferred status or if they required PA prior to the PDL

Medicaid may require prior authorization for generic drugs only in instances when the cost of the generic product is significantly greater than the net cost of the brand product in the same AHFS therapeutic class or when there is a clinical concern regarding safety, overuse or abuse of the product.

Although a product may require PA, the product is considered a covered product and Medicaid will pay for the product only once the PA has been approved.

Override: Process where drugs require approval prior to payment to be reimbursed for an individual patient if the claim falls outside a predetermined limit or criteria. Overrides differ from PA in that drugs or drug classes that require an override will automatically allow payment of the drug unless something on the claim hits a predetermined limit or criteria. The different types of overrides include:

- Maximum Unit Limitations
- Early Refill
- Brand Limit Switchover
- Therapeutic Duplication

Electronic PA (EPA): The EPA system checks patient-specific claims history to determine if pharmacy and medical PA requirements are met at the Point-of-Sale claim submission for a non-preferred drug. If it is determined that all criteria are met and the request is approved, the claim will pay and no manual PA request will be required. Electronic PA results in a reduction in workload for providers because the claim is electronically approved within a matter of seconds with no manual PA required.

Prior Authorization Criteria Definitions

Appropriate Diagnosis: Diagnosis(es) that justifies the need for the drug requested. Diagnosis(es) or ICD-9 code(s) may be used. Use of ICD-9 codes provides specificity and legibility and will usually expedite review.

Prior Treatment Trials: Prior authorization requires that two (2) prescribed generic, OTC or brand name drugs have been utilized unsuccessfully relative to efficacy and/or safety within six (6) months prior to requesting the PA. The PA request must indicate that two (2) generic, OTC or other brand drugs have been utilized for a period of at least thirty (30) days each (14 days for Triptans, 3 days for EENT Vasoconstrictor Agents), **unless** there is an adverse/allergic response or contraindication. If the prescribing practitioner feels there is a medical reason for which the patient should not be on a generic, OTC or brand drug or drug trial, medical justification may be submitted in lieu of previous drug therapy. One prior therapy is acceptable in those instances when a class has only one preferred agent, either generic, OTC, or brand.

Stable Therapy: Allows for approval of a PA for patients who have been determined to be stable on a medication (same drug, same strength) for a specified timeframe and who continue to require therapy. Medications provided through a government or state sponsored drug assistance program for uninsured patients may be counted toward the stable therapy requirement. Medications paid for through insurance, private pay or Medicaid are also counted toward the requirement. Providers will be required to document this information on the PA request form and note the program or method through which the medication was dispensed.

Medical Justification: An explanation of the reason the drug is required and any additional information necessary. Medical justification is documentation to support the physician's choice of the requested course of treatment. Documentation from the patient record (history and physical, tests, past or current medication/treatments, patient's response to treatment, etc) illustrates and supports the physician's request for the drug specified. For example, if a recommended therapy trial is contraindicated by the patient's condition or a history of allergy to a first-line drug, and the physician wants to order a non-preferred drug, documentation from the patient record would support that decision. In addition, medical justification may include peer reviewed literature to support the use of a non-preferred medication.

External Criteria

Antihypertensive Agents

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed 30-day treatment trials with at least two prescribed and preferred antihypertensive agents in this class, either generic, OTC or brand, within the past 6 months or have a documented allergy or contraindication to all preferred agents in this class.
- To meet these prior usage requirements, drugs within this specific classification must be judged against others in the same class (AHFS specific). For example, to qualify for a non-preferred beta-blocker, the patient must have met prior usage requirements of 30-day treatment trials with two other preferred beta-blockers, either generic, OTC or brand.
- For fixed-dose combination products containing drugs from 2 different subclasses, prior therapies must include at least 2 prescribed and preferred agents from either or both respective subclasses.
- For Tektura[®], prior therapies must include at least two prescribed and preferred angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists.
- For Amturnide[®], prior therapies must include a prescribed and preferred angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist, a dihydropyridine and a thiazide diuretic.
- For Exforge HCT[®] and Tribenzor[®], prior therapies must include a prescribed and preferred dihydropyridine, an angiotensin II receptor antagonist and a thiazide diuretic.
- For BiDil[®], in lieu of prior usage requirements, approval may be obtained for adjunctive therapy to standard heart failure therapy (including a diuretic, angiotensin converting enzyme inhibitor or angiotensin II receptor antagonist, and beta-blocker) in self-identified black patients.
- For Samsca[®], patients must have a documented serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction. Patients must also have documentation of being initiated on Samsca[®] in an inpatient setting.

Stable Therapy

- Approval may be given for those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

Medical Justification

- Medical justification may include peer reviewed literature, medical record documentation, or other information specifically requested.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (PA)

- Antihypertensive agents are included in the electronic PA program.

Verbal PA Requests

- Not Applicable

Anti-infective Agents

Appropriate Diagnosis

- The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials

- The patient must also have failed two treatment trials of no less than three-days each, with at least two prescribed and preferred anti-infectives, either generic, OTC, or brand, for the above diagnosis within the past 30 days or have a documented allergy or contraindication to all preferred agents for the diagnosis submitted.
- For Olysio[®] and Victrelis[®], in lieu of prior usage requirements, approval may be obtained for adjunctive therapy to hepatitis C treatment with peginterferon alfa and ribavirin in patients ≥ 18 years of age with genotype 1 chronic hepatitis C and a documented allergy or contraindication to sofosbuvir.
- For Sovaldi[®], Harvoni[®], and Viekira Pak[®] please see separate PA forms for specific information.
- For Olysio[®] in combination with Sovaldi[®], please see Sovaldi[®] specific PA Form.

Stable Therapy

- Patients on anti-infective therapy while institutionalized once discharged or transferred to another setting or patients having a 60 day consecutive stable therapy may continue on that therapy with supportive medical justification or documentation.

Medical Justification

- Medical justification may include peer-reviewed literature, medical record documentation, or other information specifically requested. Approval may also be given, with medical justification, if the medication requested is indicated for first line therapy when there are no other indicated preferred agents available or if indicated by susceptibility testing or evidence of resistance to all preferred agents.

PA Approval Timeframes

- Approval may be given for up to 12 months.

Electronic Prior Authorization (EPA)

- Not Applicable.

Verbal PA Requests

- PA requests that meet prior usage requirement for approval may be accepted verbally.

AGENDA

ALABAMA MEDICAID AGENCY PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

August 19, 2015
9:00 a.m. – 12:00 p.m.

-
1. Opening remarks.....Chair
 2. Approval of May 20, 2015 P&T Committee Meeting minutes.....Chair
 3. Pharmacy program update.....Alabama Medicaid
 4. Oral presentations by manufacturers/manufacturers' representatives
(prior to each respective class review)
 5. Pharmacotherapy class re-reviews.....University of Massachusetts
Clinical Pharmacy Services
 - Central Alpha-Agonists – AHFS 240816
 - Direct Vasodilators – AHFS 240820
 - Peripheral Adrenergic Inhibitors – AHFS 240832
 - Hypotensive Agents, Miscellaneous – AHFS 240892
 - Alpha-Adrenergic Blocking Agents – AHFS 242000
 - Beta-Adrenergic Blocking Agents – AHFS 242400
 - Dihydropyridines – AHFS 242808
 - Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892
 - Angiotensin-Converting Enzyme Inhibitors – AHFS 243204
 - Angiotensin II Receptor Antagonists – AHFS 243208
 - Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
 - Renin Inhibitors – AHFS 243240
 - Loop Diuretics – AHFS 402808
 - Potassium-Sparing Diuretics – AHFS 402816
 - Thiazide Diuretics – AHFS 402820
 - Thiazide-Like Diuretics – AHFS 402824
 - Vasopressin Antagonists – AHFS 402828
 - Diuretics, Miscellaneous – AHFS 402892
 - HCV Antivirals – AHFS 081840
 6. Results of voting announced.....Chair
 7. New business
 - Election of Committee's Chairperson and Vice Chairperson
 8. Next meeting date
 - November 18, 2015
 9. Adjourn

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Central Alpha-Agonists
AHFS Class 240816
August 19, 2015**

I. Overview

Drugs to treat hypertension are among the most frequently prescribed pharmacologic agents. The incidence of hypertension increases with age and the proper selection of an antihypertensive agent is an important issue.^{1,2} While a multitude of neurohormonal, renal, and vascular mechanisms have been proposed as contributors to hypertension, no specific cause can be assigned in most cases.^{3,4} Antihypertensive agents are separated into broad classes depending on which aspect of blood pressure regulation they affect: sodium and water balance, the sympathetic nervous system, resistance from vascular smooth muscle, or the renin-angiotensin-aldosterone system (RAAS).⁵ Most patients will require therapy with more than one agent to achieve adequate blood pressure control. When monotherapy fails to achieve the blood pressure goal, then a second agent from a different class should be added to the treatment regimen.¹

The central alpha-agonists are approved for the treatment of hypertension. They lower blood pressure primarily through stimulation of α_2 -adrenergic receptors in the central nervous system (CNS). This action inhibits sympathetic vasomotor centers, causing decreased sympathetic outflow from the CNS and an associated increase in vagal tone. Sympathetic activity is reduced while parasympathetic activity is increased. This leads to a reduction in total peripheral resistance, systolic and diastolic blood pressure, baroreceptor reflexes, heart rate, and cardiac output.^{3,6-12} Plasma renin activity is also affected by the central alpha-agonists, but the relationship between this and their hypotensive effects has not been fully elucidated. Chronic central alpha-agonist use is associated with sodium and fluid retention, which may require concomitant diuretic therapy.³ Methyldopa is available in combination with a thiazide diuretic. Thiazide diuretics inhibit the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.⁶⁻¹²

The central alpha-agonists that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Central Alpha-Agonists Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Clonidine	tablet, transdermal patch	Catapres ^{®*} , Catapres-TTS ^{®*}	clonidine
Guanfacine	tablet	Tenex ^{®*}	guanfacine
Methyldopa	tablet	N/A	methyldopa
Methyldopate	injection [^]	N/A	methyldopate
Combination Products			
Methyldopa and hydrochlorothiazide	tablet	N/A	methyldopa and hydrochlorothiazide

*Generic is available in at least one dosage form or strength.

[^]Product is primarily administered in an institution.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the central alpha-agonists are summarized in Table 2.

Table 2. Treatment Guidelines Using the Central Alpha-Agonists

Clinical Guideline	Recommendations
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹³</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to

Clinical Guideline	Recommendations
<p>Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁴, Reappraisal of Guidelines on Hypertension Management (2009)¹⁵</p>	<p>assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage.</p> <ul style="list-style-type: none"> • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure

Clinical Guideline	Recommendations
	<p>reduction without indicating a goal that is unproven.</p> <ul style="list-style-type: none"> In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)¹⁶</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP.

Clinical Guideline	Recommendations
	<p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug, is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors,

Clinical Guideline	Recommendations
	<p>angiotensin receptor blockers, and calcium antagonists.</p> <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁷</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-

Clinical Guideline	Recommendations
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁸</p>	<p>blocker.</p> <ul style="list-style-type: none"> To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)¹⁹</p>	<ul style="list-style-type: none"> All antihypertensives can be used to lower blood pressure in chronic kidney disease. Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high coronary artery disease risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group:</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> The Work Group recommends that non-diabetic adults with CKD ND and urine

Clinical Guideline	Recommendations
<p>KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)²⁰</p>	<p>albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure - lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²¹</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>National Heart, Lung, and Blood Institute: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (2012)²²</p>	<ul style="list-style-type: none"> • Losartan, amlodipine, felodipine, fosinopril, lisinopril, metoprolol, and valsartan can be added to the list of medications that are tolerated over short periods, and can reduce blood pressure in children from ages 6 to 17 years, but predominantly is effective in adolescents. For African American children, greater doses of fosinopril may be needed for effective blood pressure control. Trial durations, however, were short, and long-term safety is still in question. <p><u>For children from birth to age three years:</u></p> <ul style="list-style-type: none"> • Routine measurement of blood pressure is not recommended. Blood pressure should be measured when there is a suspicion of renal disease, coarctation of the aorta, or other condition that may be associated with blood pressure elevation. • In these young patients, auscultation of blood pressure is often quite difficult, so measurement with an oscillometric device using an appropriate size cuff is acceptable. The state of the infant or young child (e.g., sleeping, quiet, fussing, crying) is important in the interpretation of blood pressure measurement. • For younger patients, treatment of high blood pressure is often directed at the underlying cause, since primary hypertension is uncommon. <p><u>For children, ages 3 to 11 years:</u></p> <ul style="list-style-type: none"> • Routine measurement of blood pressure during health care visits is recommended. This is true of visits for health maintenance and for visits when the child is ill. • Auscultation should be the method of choice for confirmation of elevated blood pressure measurements using an oscillometric device. The blood pressure percentiles from the <i>Fourth Report</i> based on age, gender, and height percentiles should be used to categorize blood pressure as prehypertension or Stage 1 or Stage 2 hypertension. Blood pressure elevation must be persistent to be considered hypertension. • In this age group, obesity is an increasingly important cause of blood pressure elevation. When obesity is present, therapy should first be directed at improving diet and physical activity behaviors. This age group offers the opportunity to intervene early in the process of obesity development, allowing the clinician to focus on weight maintenance while the child grows, as opposed to weight loss. It also provides an important opportunity to introduce the Dietary Approaches to Stop Hypertension (DASH)-style diet. <p><u>For adolescents, ages 12 to 17 years:</u></p> <ul style="list-style-type: none"> • The approach to the evaluation of blood pressure is similar to that of children ages three to younger than 12 years, but the prevalence of primary hypertension is much more common, and obesity is a major concern as an underlying factor. • Adolescents with obesity are at risk of type 2 diabetes mellitus. Diabetes is a condition for which more aggressive blood pressure lowering is recommended. • In this age group, the level of blood pressure indicating prehypertension is at least 120/80, the same as that for adults. This is because the 90th percentile for adolescents is higher than 120/80 for most ages and height percentiles. • For adolescents with increased body mass index and elevated blood pressure,

Clinical Guideline	Recommendations
	<p>weight loss is the cornerstone of therapy. Both dietary and physical activity behaviors should be addressed, aiming for appropriate energy balance, lower dietary sodium, and a DASH-like dietary pattern.</p> <p><u>For young adults, ages 18 to 21 years:</u></p> <ul style="list-style-type: none"> • Adult cut points for blood pressure in this age group are used to define hypertension. • In this age range, institution of the adult DASH diet is recommended for individuals with prehypertension or hypertension, as is reduction of dietary sodium. Overweight continues to be a major concern in this age group; weight reduction should be promoted through enhanced energy expenditure coupled with reduced energy intake. Physical activity should be promoted, since moderate-to-vigorous physical activity reduces blood pressure levels in adults. • The management of hypertension should follow the recommendations in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the central alpha-agonists are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Central Alpha-Agonists^{6,8-12}

Indication	Single Entity Agents			Combination Products
	Clonidine	Guanfacine	Methyldopa	Methyldopa and HCTZ
Treatment of hypertension	✓ *	✓ *	✓	✓ †

HCTZ=hydrochlorothiazide

*Alone or in combination with other antihypertensive agents.

†This fixed combination drug is not indicated for the initial therapy of hypertension.

IV. Pharmacokinetics

The pharmacokinetic parameters of the central alpha-agonists are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Central Alpha-Agonists⁷

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Clonidine	Oral: 75 to 100 TD: 60	20 to 40	Liver	Renal (40 to 60) Feces (22)	Oral: 22 TD: 12 to 13
Guanfacine	80	70	Liver	Renal (50)	17
Methyldopa	25 to 50	Negligible (% not reported)	Liver	Renal (70) Feces (30 to 50)	1.7
Combination Products					
Methyldopa and HCTZ	Not reported	Not reported	Not reported	Not reported	Not reported

HCTZ=hydrochlorothiazide, TD=transdermal

V. Drug Interactions

Significant drug interactions with the central alpha-agonists are listed in Table 5.

Table 5. Significant Drug Interactions with the Central Alpha-Agonists⁶

Generic Name(s)	Significance Level	Interaction	Mechanism
Central alpha-agonists (clonidine)	1	Beta-adrenergic blockers	The severity of rebound hypertension associated with abrupt withdrawal of clonidine may be greater in patients taking beta-adrenergic blockers. This combination has also been reported to cause paradoxical hypertension. The mechanism of this interaction is unknown.
Central alpha-agonists (clonidine)	1	Tricyclic antidepressants	The antihypertensive effectiveness of clonidine may be decreased. Tricyclic antidepressants may also worsen the rebound reactions, such as hypertension and tachycardia, from abrupt clonidine withdrawal. The mechanism of this interaction is unknown.
Thiazide diuretics (HCTZ)	1	Lithium	Thiazide diuretics may promote enhanced proximal tubular reabsorption of lithium leading to elevated serum concentrations. Thiazide diuretics may increase the therapeutic and toxic effects of lithium.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes.
Central alpha-agonists (clonidine, guanfacine, methyldopa)	2	Tizanidine	An additive effect on alpha ₂ -adrenergic receptors by tizanidine and central alpha-agonists may occur. The potential for symptomatic additive hypotension exists when tizanidine is coadministered with central alpha-agonists.
Central alpha-agonists (clonidine)	2	Verapamil	Sinus bradycardia, AV block and severe hypotension may occur with coadministration of clonidine and verapamil. The mechanism of this interaction is unknown.
Central alpha-agonists (guanfacine)	2	Tricyclic antidepressants	Concomitant use of guanfacine and a tricyclic antidepressant may cause loss of blood pressure control by tricyclic antidepressant inhibition of central alpha ₂ -receptors.
Central alpha-agonists (methyldopa)	2	Iron salts	The gastrointestinal absorption of methyldopa may be decreased by iron salts. The metabolism of methyldopa may also be affected. Therefore, the pharmacologic effects of methyldopa may be decreased.
Central alpha-agonists (methyldopa)	2	Sympathomimetics	The coadministration of methyldopa and sympathomimetics may result in an increased pressor response, possibly resulting in hypertension.
Central alpha-agonists (methyldopa)	2	Monoamine oxidase inhibitors	Metabolites of methyldopa stimulate release of endogenous catecholamines that are usually metabolized by MAOIs,

Generic Name(s)	Significance Level	Interaction	Mechanism
			thereby leading to excessive sympathetic stimulation.
Thiazide diuretics (HCTZ)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia, hyperuricemia and hypotension.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Thiazide diuretics may induce electrolyte disturbances which may predispose patients to digitalis-induced arrhythmias.

HCTZ=hydrochlorothiazide

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the central alpha-agonists are listed in Table 6. Abrupt discontinuation may cause nervousness, palpitations, headache, perspiration, nausea, and agitation. In some cases, sudden discontinuation may cause potentially dangerous rebound hypertension.^{6,7} The boxed warning for methyldopa-hydrochlorothiazide is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Central Alpha-Agonists⁶⁻¹²

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Cardiovascular					
Angina	-	-	-	✓	✓
Arrhythmia	✓	-	-	-	-
Atrioventricular block	✓	-	-	-	-
Bradycardia	✓	-	∩	✓	✓
Carotid sinus sensitivity	-	-	-	✓	✓
Chest pain	<1	-	∩	-	-
Congestive heart failure	✓	-	-	✓	✓
Edema	-	-	-	✓	✓
Electrocardiogram abnormalities	✓	-	-	-	-
Hypotension	-	-	-	✓	✓
Myocarditis	-	-	-	✓	✓
Necrotizing angitis	-	-	-	-	✓
Orthostatic hypotension	3	-	-	✓	✓
Orthostasis	-	-	-	-	-
Palpitations	✓	-	∩	-	-
Pericarditis	-	-	-	✓	✓
Peripheral edema	-	-	-	>10	-
Reynaud's phenomenon	✓	-	-	-	-
Syncope	✓	-	-	<1	-
Tachycardia	✓	-	-	-	-
Central Nervous System					
Agitation	✓	-	-	-	-
Amnesia	-	-	∩	-	-
Anxiety	✓	-	-	1 to 10	-
Ataxia	-	-	-	-	-
Bell's palsy	-	-	-	✓	✓
Confusion	-	-	∩	-	-
Delirium	✓	-	-	-	-

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Decreased mental acuity	-	-	-	✓	✓
Delusional perception	✓	-	-	✓	✓
Depression	✓	-	≤3	1 to 10	✓
Dizziness	16	2	12 to 15	✓	✓
Drowsiness	33	12	-	1 to 10	-
Fatigue	4	6	2 to 10	-	-
Hallucinations	<1	-	-	-	-
Headache	1	5	3 to 13	1 to 10	✓
Insomnia	5	2	≤3	-	-
Involuntary movements	-	-	-	✓	✓
Lightheadedness	-	-	-	✓	✓
Lethargy	-	3	-	-	-
Nervousness	3	1	-	-	-
Nightmares	✓	-	-	✓	✓
Paresthesia	✓	-	-	✓	✓
Parkinsonism	-	-	-	✓	✓
Restlessness	✓	-	-	-	✓
Sedation	10	3	-	✓	✓
Sleep disturbances	✓	-	-	-	-
Somnolence	-	-	5 to 39	-	-
Vertigo	-	-	-	-	✓
Weakness	10	-	2 to 7	✓	✓
Dermatological					
Allergic contact sensitization	-	5	-	-	-
Alopecia	✓	-	-	-	✓
Angioedema	✓	-	-	-	-
Blanching	-	1	-	-	-
Burning	-	3	-	-	-
Contact dermatitis	-	19	-	-	-
Dermatitis	-	-	≤3	-	-
Edema	3	3	-	-	-
Erythema	-	15 to 50	-	-	✓
Excoriation	-	3	-	-	-
Exfoliative dermatitis	-	-	-	✓	✓
Hives	✓	-	-	-	-
Hyperpigmentation	-	5	-	-	-

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Lupus-like syndrome	-	-	-	✓	✓
Morbilloform or macro papular eruptions	-	1	-	-	✓
Photosensitivity	-	-	-	-	✓
Pruritus	7	15 to 50	≤3	-	-
Purpura	-	-	≤3	-	✓
Rash	✓	-	-	✓	✓
Stevens Johnson syndrome	-	-	-	-	✓
Sweating	-	-	≤3	<1	-
Throbbing	-	3	-	-	-
Toxic epidermal necrolysis	-	-	-	✓	✓
Urticaria	✓	<1	-	-	✓
Vasculitis	-	-	-	✓	✓
Vesiculation	-	7	-	-	✓
Endocrine and Metabolic					
Breast enlargement	-	-	-	✓	✓
Erectile dysfunction	✓	-	-	-	-
Electrolyte imbalance	-	-	-	-	✓
Gynecomastia	✓	-	-	✓	✓
Hyperprolactinemia	-	-	-	✓	✓
Impotence	3	2	3 to 7	✓	✓
Lactation	-	-	-	✓	-
Pancreatitis	-	-	-	✓	✓
Sexual dysfunction	3	2	≤3	✓	✓
Sodium retention	-	-	-	<1	-
Weight gain	✓	-	-	-	-
Gastrointestinal					
Abdominal Pain	✓	-	≤3	-	-
Anorexia	1	-	-	-	✓
Colitis	-	-	-	✓	✓
Constipation	10	1	2 to 15	✓	✓
Cramping	-	-	-	-	✓
Diarrhea	-	-	≤3	✓	✓
Distention	-	-	-	✓	✓
Dry mouth	40	25	10 to 54	1 to 10	✓
Dry throat	-	2	-	-	-
Dyspepsia	-	-	≤3	-	-

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Dysphagia	-	-	≤3	-	-
Flatus	-	-	-	✓	✓
Gastritis	-	-	-	-	✓
Nausea	5	1	≤3	✓	✓
Pseudo-obstruction	✓	-	-	-	-
Parotitis	✓	-	-	-	-
Salivary gland pain	✓	-	-	-	-
Sialadenitis	-	-	-	✓	✓
Sore tongue	-	-	-	✓	✓
Taste alteration	-	1	≤3	-	-
Vomiting	5	-	-	✓	✓
Weight gain	1	-	-	✓	✓
Genitourinary					
Glucosuria	-	-	-	-	✓
Interstitial nephritis	-	-	-	-	✓
Micturition difficulties	✓	-	-	-	-
Nocturia	✓	-	-	-	-
Polyuria	-	-	-	-	-
Renal dysfunction	-	-	-	-	✓
Renal failure	-	-	-	-	✓
Testicular disorder	-	-	≤3	-	-
Urinary incontinence	-	-	≤3	<1	-
Urinary retention	1	-	-	-	-
Hematologic					
Agranulocytosis	-	-	-	-	✓
Aplastic anemia	-	-	-	-	✓
Bone marrow depression	-	-	-	✓	✓
Eosinophilia	-	-	-	✓	✓
Granulocytopenia	-	-	-	✓	✓
Hemolytic anemia	-	-	-	✓	✓
Leukopenia	-	-	-	✓	✓
Positive antinuclear antibody test	-	-	-	✓	✓
Positive Rheumatoid factor test	-	-	-	✓	✓
Positive Coombs test	✓	-	-	✓	✓
Thrombocytopenia	✓	-	-	✓	✓
Hepatic					

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Cholestasis	-	-	-	<1	-
Cirrhosis	-	-	-	<1	-
Hepatitis	✓	-	-	✓	✓
Jaundice	-	-	-	✓	✓
Laboratory Test Abnormalities					
Blood urea nitrogen increased	-	-	-	✓	✓
Electrolyte disturbance	-	-	-	-	✓
Creatinine phosphokinase increased	✓	-	-	-	-
Hyperglycemia	✓	-	-	-	✓
Hyperuricemia	-	-	-	-	✓
Liver function test abnormalities	✓	-	-	✓	✓
Musculoskeletal					
Arthralgia	-	-	-	✓	✓
Hypokinesia	-	-	∩	-	-
Leg cramps	✓	-	∩	-	-
Muscle spasms	-	-	-	-	✓
Myalgia	✓	-	-	✓	-
Respiratory					
Dyspnea	-	-	∩	<1	✓
Respiratory distress	-	-	-	-	✓
Rhinitis	-	-	∩	-	-
Other					
Anaphylaxis	-	-	-	-	✓
Blurred vision	✓	-	-	-	✓
Dry eyes	✓	-	-	-	-
Conjunctivitis	-	-	∩	-	-
Drug fever	-	-	-	1 to 10	✓
Fever	✓	-	-	-	✓
Iritis	-	-	∩	-	-
Malaise	1	-	∩	-	-
Nightmares	<1	-	-	-	-
Paresis	-	-	∩	-	-
Paresthesia	-	-	∩	-	-
Tinnitus	-	-	∩	-	-
Vision disturbance	-	-	∩	-	-
Withdrawal syndrome	✓	-	-	-	-

Adverse Events	Single Entity Agents				Combination Products
	Clonidine Oral	Clonidine Transdermal	Guanfacine	Methyldopa	Methyldopa and HCTZ
Xanthopsia	-	-	-	-	✓

✓ Percent not specified
 - Event not reported

Table 7. Boxed Warning for Methyldopa and Hydrochlorothiazide^{6,12}

WARNING
This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.

VII. Dosing and Administration

The usual dosing regimens for the central alpha-agonists are listed in Table 8.

Table 8. Usual Dosing Regimens for the Central Alpha-Agonists⁶⁻¹²

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Clonidine	<u>Hypertension:</u> Tablet: initial, 0.1 mg twice daily; maintenance, 0.1 to 0.6 mg/day in 2 divided doses; maximum, 2.4 mg/day Transdermal: initial, 0.1 mg patch once weekly; maintenance, 0.1 to 0.3 mg patch once weekly; maximum, 2 of the 0.3 mg patches once weekly	Safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials.	Tablet: 0.1 mg 0.2 mg 0.3 mg Transdermal patch: 0.1 mg/24 hours 0.2 mg/24 hours 0.3 mg/24 hours
Guanfacine	<u>Hypertension:</u> Tablet: initial, 1 mg once daily at bedtime; maintenance, 1 to 2 mg once daily; maximum, 3 mg once daily	Safety and efficacy in children under 12 have not been established.	Tablet: 1 mg 2 mg
Methyldopa	<u>Hypertension:</u> Tablet: initial, 250 mg 2 to 3 times daily; maintenance, 500 to 2,000 mg daily in 2 divided doses; maximum dose, 3 g daily	There are no well-controlled clinical trials in pediatric patients. Information on dosing in pediatric patients is supported by evidence from published literature regarding the treatment of hypertension in pediatric patients. <u>Hypertension:</u> Tablet: initial, 10 mg/kg/day in 2 to 4 divided doses; maintenance, titrate up or down until adequate response achieved; maximum, 65 mg/kg/day or 3 g daily, whichever is less	Tablet: 250 mg 500 mg
Combination Products			
Methyldopa and HCTZ	<u>Hypertension:</u> Tablet: initial, 250-15 mg two or three times a day or 250-25 mg twice daily; maximum, HCTZ 50 mg and methyldopa 3 g daily	Safety and efficacy in children have not been established.	Tablet: 250-15 mg 250-25 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Dosage must be individualized, as determined by titration of the individual components. Once the patient has been successfully titrated, methyldopa and HCTZ may be substituted if the previously determined titrated doses are the same as in the combination.		

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the central alpha-agonists are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Central Alpha-Agonists

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Lilja M et al. ²³ (1991) Clonidine 0.1 mg tablets BID vs clonidine 0.2 mg transdermal patch QD	DB, DD, PC, RCT, XO Patients with mild to moderate HTN	N=16 12 weeks	Primary: Change from baseline in supine SBP, standing SBP and heart rate Secondary: Difference in primary endpoints between oral and transdermal clonidine	Primary: Clonidine transdermal patch reduced both supine SBP and DBP by 13/7 mm Hg (P<0.01 and P<0.01) and heart rate by 9 bpm (P<0.01). Oral clonidine reduced only supine SPB by 11 mm Hg (P<0.01). In a standing position, clonidine transdermal patch reduced SBP and DBP by 14/9 mm Hg (P<0.01 and P<0.01) and heart rate by 9 bpm (P<0.01). Oral clonidine reduced only standing heart rate by 8 bpm (P<0.05). Secondary: There were no differences reported in primary endpoints between clonidine transdermal patch and oral clonidine (P value not reported).
Houston et al. ²⁴ (1993) Clonidine transdermal 0.1 to 0.3 mg QD plus nifedipine 60 mg QD (single entity products) vs nifedipine 60 mg QD	OL, PC, PRO Male and nonpregnant female patients between 18 and 75 years of age with mild to moderate HTN and inadequate response to nifedipine	N=42 8 weeks	Primary: Change in seated DBP to less than 90 mmHg at 8 weeks Secondary: Not reported	Primary: Patients on combination therapy experienced a reduction of 16/14 mmHg in the mean seated blood pressure vs placebo (P<0.01) with mean seated blood pressure of 127/87 mmHg. A reduction of 5/10 mmHg in the mean seated blood pressure was seen with combination therapy vs nifedipine monotherapy (P<0.01). A reduction of 18/12 mmHg in the mean standing blood pressure was seen with combination therapy vs placebo (P<0.01). A reduction of 9/9 mmHg in the mean standing blood pressure was seen with combination therapy vs nifedipine monotherapy (P<0.01). Secondary: Not reported
Boyles et al. ²⁵ (1984) Methyldopa 250 to	OL, RCT Patients ≥59 years with isolated	N=21 18 weeks	Primary: Changes in blood pressure from baseline	Primary: At two weeks standing blood pressure fell from a mean of 166/90 mmHg at baseline to 164/88 mmHg with HCTZ monotherapy.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
800 mg/day and HCTZ 25 to 100 mg/day vs HCTZ 25 to 100 mg/day	systolic HTN		Secondary: Not reported	At four weeks standing blood pressure fell from a mean of 164/88 mmHg at the end of the two week HCTZ monotherapy period to 145/811 mmHg at two weeks with combination therapy. At 18 weeks standing blood pressure fell from a mean of 166/90 mmHg at baseline to 132/80 mmHg with combination therapy. Secondary: Not reported
Channick et al. ²⁶ (1981) Methyldopa 250 mg/day and HCTZ 15 mg/day vs chlorthalidone 50 mg/day and reserpine 0.25 mg/day	OL, RCT Patients with HTN	N=56 12 weeks	Primary: Efficacy of blood pressure lowering to goal DBP \leq 90 mmHg Secondary: Adverse effects	Primary: Goal DBP of \leq 90 mmHg was reached in 91% of the chlorthalidone and reserpine group vs 55% in the methyldopa and HCTZ group (P<0.001). Secondary: The incidence of adverse effects was 31% with chlorthalidone and reserpine vs 64% with methyldopa and HCTZ (P<0.02).
Finnerty et al. ²⁷ (1979) Methyldopa 500 mg to 2,000 mg QD vs reserpine 0.125 mg to 0.25 mg QD vs propranolol 80 mg	RCT, SB Patients with HTN unresponsive to hydroflumethiazide monotherapy	N=59 9 weeks	Primary: Percentage of patients achieving a DBP <90 mm Hg Secondary: Not reported	Primary: At trial endpoint, 20 patients (100%) receiving reserpine, 13 of the 19 patients (68.4%) receiving methyldopa and 16 of the 20 patients (80%) receiving propranolol achieved a DBP <90 mm Hg (mean reductions and P values not reported). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>to 320 mg QD</p> <p>All patients received hydroflumethiazide* 50 or 100 mg QD.</p>				
<p>Fernandez et al.²⁸ (1980)</p> <p>Methyldopa 750 mg/day</p> <p>vs</p> <p>chlorothiazide 450 mg/day</p> <p>vs</p> <p>methyldopa and chlorothiazide 250-150 mg/day* (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT, XO</p> <p>Patients with uncomplicated HTN</p>	<p>N=44</p> <p>4 weeks</p>	<p>Primary: Blood pressure lowering efficacy</p> <p>Secondary: Adverse effects</p>	<p>Primary: No significant differences in supine blood pressure for any treatment compared to placebo was observed (P value not reported). However, upright SBP, DBP and mean blood pressure were significantly lower with methyldopa and methyldopa and chlorothiazide compared to placebo (P<0.05 for all).</p> <p>Secondary: Adverse effects were reported as infrequent (P value not reported).</p>
<p>Materson et al.²⁹ (1990)</p> <p>Hydralazine 25, 50 or 100 mg BID</p> <p>vs</p>	<p>DB, MC, RCT</p> <p>Men ≥60 years with HTN not currently receiving antihypertensive therapy and DBP 90 to 114 mm Hg and</p>	<p>N=690</p> <p>12 months</p>	<p>Primary: The average reduction in SBP and DBP, the number of patients achieving the goal blood pressure, the average change in</p>	<p>Primary: Across all four treatments, there was an additional average reduction in BP of 13.1/10.6 mm Hg. The average reduction in SBP from baseline to endpoint for hydralazine, methyldopa, metoprolol and reserpine were -11.5±10.1 (P<0.001), -15.0±13.7 (P<0.001), -13.0±15.4 (P<0.001) and -12.7±11.5 (P<0.001), respectively. There was no significant difference in SBP reductions among the different treatments (P=0.43). The average reduction in DBP from baseline to endpoint for hydralazine, methyldopa,</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>methyldopa 250, 500 or 1,000 mg BID</p> <p>vs</p> <p>metoprolol 50, 100 or 200 mg BID</p> <p>vs</p> <p>reserpine 0.05, 0.10 or 0.25 mg QD</p> <p>All patients received HCTZ 25 to 100 mg QD.</p>	<p>SBP <240 mm Hg or a DBP <100 mm Hg and a SBP <240 mm Hg if currently taking antihypertensive therapy and the blood pressure criteria was met after ≥2 weeks without medication</p>		<p>heart rate</p> <p>Secondary: The rates of drug intolerances, adverse effects</p>	<p>metoprolol and reserpine were -11.3 ± 5.9 ($P < 0.001$), -10.6 ± 6.3 ($P < 0.001$), -10.6 ± 6.7 ($P < 0.001$) and -9.8 ± 6.3 ($P < 0.001$), respectively. There was no significant difference in DBP reductions among the different treatments ($P = 0.59$).</p> <p>The average change in heart rate from baseline to endpoint for hydralazine, methyldopa, metoprolol and reserpine were 1.4 ± 10.5 (P value not significant), -1.6 ± 9.3 (P value not significant), 15.9 ± 11.9 ($P < 0.05$) and -7.9 ± 10.7 ($P < 0.05$), respectively. There was a significant difference in change in heart rate among the different treatments ($P < 0.001$).</p> <p>The percentage of patients achieving the goal blood pressure at endpoint with hydralazine, methyldopa, metoprolol and reserpine were 85.3, 81.7, 76.9 and 72.3%, respectively ($P = 0.28$).</p> <p>Secondary: Drug intolerance, defined as adverse effects prompting dose reduction or discontinuation, was present in 23.3% of patients not achieving goal blood pressure compared to 2.8% of those who did ($P < 0.001$). This was significant with hydralazine, methyldopa and metoprolol, but not with reserpine.</p> <p>There were 27 (10%) treatment discontinuations due to adverse effects (hydralazine [n=3], methyldopa [n=8], metoprolol [n=9] and reserpine [n=7]). There were two treatment discontinuations with methyldopa and one with reserpine due to depression.</p> <p>The overall incidence of volunteered moderate or severe adverse effects, not prompting treatment discontinuation, was significantly greater ($P < 0.01$) with methyldopa (31%) and hydralazine (25%) compared to reserpine (15%) or metoprolol (9%).</p>
<p>McAreavey et al.³⁰ (1984)</p> <p>Hydralazine 12.5 mg QD up to 100 mg BID</p>	<p>DB, PG, RCT</p> <p>Patients with inadequately controlled HTN while receiving</p>	<p>N=238</p> <p>6 months</p>	<p>Primary: Comparative safety and efficacy, target blood pressure <140/95 mm Hg</p>	<p>Primary: Target blood pressure was reached in 25% of patients receiving hydralazine, 23% of patients receiving minoxidil, 19% of patients receiving prazosin, 17% of patients receiving methyldopa and zero percent of patients receiving placebo (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>labetalol 200 mg QD up to 1,600 mg BID</p> <p>vs</p> <p>methyldopa 125 mg QD up to 1,000 mg BID</p> <p>vs</p> <p>prazosin 0.5 mg QD up to 10 mg BID</p> <p>vs</p> <p>placebo</p> <p>Minoxidil as add on therapy was given to men only.</p> <p>Doses were titrated upward at 2-week intervals until target BP or maximum dose was reached.</p>	<p>atenolol 100 mg/day and bendrofluazide* 5 mg/day</p>		<p>Secondary: Not reported</p>	<p>Labetalol had the highest withdrawal rate compared to the other treatments with 78% (P<0.05). Minoxidil had the second highest withdrawal rate with 57% (P<0.05), due to fluid retention. There were no significant differences in withdrawal rates among the other treatments.</p> <p>Secondary: Not reported</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily

Study design abbreviation: DB=double-blind, DD=double-dummy, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, SB=single blind, XO=cross over

Miscellaneous abbreviations: DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HTN=hypertension, SBP=systolic blood pressure

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Central Alpha-Agonists

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Clonidine	tablet, transdermal patch	Catapres ^{®*} , Catapres-TTS ^{®*}	\$\$\$\$-\$\$\$\$\$	\$\$
Guanfacine	tablet	Tenex ^{®*}	\$\$	\$
Methyldopa	tablet	N/A	N/A	\$
Combination Products				
Methyldopa and HCTZ	tablet	N/A	N/A	\$\$\$

*Generic is available in at least one dosage form or strength.
HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

The central alpha-agonists are approved for the treatment of hypertension, and all of the agents are available in a generic formulation.⁶⁻¹² There are several national and international organizations that have published guidelines on the treatment of hypertension. Most of the guidelines do not address the use of the central alpha-agonists.^{1,13-22} Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with

another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.^{1,13-22} Methyldopa is safe and effective to use during pregnancy.¹⁴⁻¹⁶

There are limited head-to-head studies with the central alpha-agonists. Clinical trials have compared combination therapy to monotherapy. In these studies, the more aggressive treatment regimen lowered systolic and diastolic blood pressure to a greater extent than the less-intensive treatment regimen.^{24,25} There does not appear to be any difference in efficacy with the oral or transdermal formulations of clonidine.²³ According to treatment guidelines, most patients will need more than one antihypertensive agent to achieve blood pressure goals.^{1,13-22} Certain guidelines note that that fixed combination antihypertensive medications can favor compliance and simplify medication regimens.^{14,15,19} However, there are no prospective, randomized-controlled trials that have demonstrated better clinical outcomes with any central alpha-agonist fixed-dose combination product compared to the coadministration of the individual components as separate formulations.

The most common adverse events reported with the central alpha-agonists include dizziness, drowsiness, dry mouth, and somnolence. Abrupt discontinuation may cause nervousness, palpitations, headache, perspiration, nausea, and agitation. In some cases, sudden discontinuation may cause potentially dangerous rebound hypertension.⁶⁻¹²

There is insufficient evidence to support that one brand central alpha-agonist is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand central alpha-agonists within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand central alpha-agonist is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
2. Kaplan NM. Hypertension in the population at large. In: Kaplan NM, Flynn JT. *Kaplan's clinical hypertension*. 10th ed. Philadelphia (PA): Lippincott, Williams, and Wilkins; 2010.
3. Saseen JJ, MacLaughlin EJ. Chapter 3: Hypertension. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: a pathophysiologic approach*. 9th edition. New York (NY): McGraw-Hill; 2014. <http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&Sectionid=48811453>. Accessed March 19, 2015.
4. Victor RG, Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E, eds. *Braunwald's heart disease: a textbook of cardiovascular medicine*. 9th ed. Philadelphia (PA): Saunders Elsevier, 2011.
5. Benowitz NL. Antihypertensive agents. In: Katzung BG, editor. *Basic and clinical pharmacology*. 13th ed. New York (NY): McGraw-Hill; 2014.
6. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>.
7. Micromedex[®] Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
8. Catapres[®] [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals; 2012 May.
9. Catapres TTS[®] [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals; 2012 May.
10. Tenex[®] [package insert]. Bridgewater (NJ): Promius Pharma, LLC; 2013 Jul.
11. Methyldopa [package insert]. Morgantown (WV): Mylan Pharmaceuticals; 2012 Oct.
12. Methyldopa and hydrochlorothiazide [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc; 2005 Nov.
13. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
15. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
16. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
17. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
18. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010;56:780-800.
19. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
20. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
21. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
22. National Heart, Lung, and Blood Institute expert panel. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Bethesda (MD): National Heart, Lung, and Blood Institute; 2011. p. 161-83.
23. Lilja M, Juustila H, Sarna S, Jounela AJ. Transdermal and oral clonidine. *Ann Med*. 1991;23(3):265-9.
24. Houston MC, Hays L. Transdermal clonidine as an adjunct to nifedipine-GITS therapy in patients with mild-to-moderate hypertension. *Am Heart J*. 1993;126:918-23.

25. Boyles PW. Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly. *Clin Ther.* 1984;6:793-9.
26. Channick BJ, Kessler WB, Marks AD et al. A comparison of chlorthalidone –reserpine and hydrochlorothiazide –methyldopa as step 2 therapy for hypertension. *Clin Ther.* 1981; 4: 175-83.
27. Finnerty FA Jr, Gyftopoulos A, Berry C, McKenney A. Step 2 regimens in hypertension: an assessment. *JAMA.* 1979 Feb 9;241(6):579-81.
28. Fernandez PG, Zachariah PK, Bryant DG et al. Antihypertensive efficacy of alpha-methyldopa, chlorothiazide and Supres (alpha-methyldopa-chlorothiazide). *Can Med Assoc J.* 1980; 123:284-7.
29. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes: results of a Department of Veterans Affairs cooperative study. *Hypertension.* 1990 Apr;15(4):348-60.
30. McAreavey D, Ramsey LE, Latham L, McLaren AD, Lorimer AR, Reid JL, et al. Third drug trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. *Br Med J (Clin Res Ed).* 1984 Jan 14;288(6411):106-11.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Direct Vasodilators
AHFS Class 240820
August 19, 2015**

I. Overview

The direct vasodilators are approved for the treatment of heart failure and hypertension, as well as for the treatment of hypoglycemia due to hyperinsulinism.¹⁻⁷ Hydralazine and minoxidil interfere with calcium movement within the vascular smooth muscle, which is responsible for initiating and maintaining the contractile state. They exert a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. This leads to decreased arterial blood pressure, decreased peripheral vascular resistance, as well as an increase in heart rate, stroke volume, and cardiac output. Hydralazine is available as a single entity product, as well as in combination with isosorbide dinitrate. Isosorbide dinitrate enters vascular smooth muscle and is converted to nitric oxide, which results in dilatation of peripheral arteries and veins. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart. Dilatation of the arteries reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.^{1,2} The exact mechanism of action of the fixed-dose combination product containing isosorbide dinitrate and hydralazine in the treatment of heart failure has not been established.⁷

Diazoxide is a non-diuretic benzothiadiazine derivative taken orally for the management of symptomatic hypoglycemia. It increases blood glucose levels by inhibiting the release of insulin from the pancreas, as well as by an extrapancreatic effect. The hyperglycemic effect begins within an hour, generally lasts no more than 8 hours, and can be reversed by the administration of insulin or tolbutamide. The inhibition of insulin release by diazoxide is antagonized by alpha-adrenergic blocking agents. The oral preparation does not demonstrate the same effects on blood pressure as the other direct vasodilators.¹⁻³

The direct vasodilators that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Hydralazine and minoxidil are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Direct Vasodilators Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Diazoxide	suspension	Proglycem®	none
Hydralazine	injection, tablet	N/A	hydralazine
Minoxidil	tablet	N/A	minoxidil
Nitroprusside	injection^	Nitropress®	none
Combination Products			
Isosorbide dinitrate and hydralazine	tablet	BiDi1®	none

*Generic is available in at least one dosage form or strength.

^Product is primarily administered in an institution.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the direct vasodilators are summarized in Table 2.

Table 2. Treatment Guidelines Using the Direct Vasodilators

Clinical Guideline	Recommendations
Eighth Joint National Committee (JNC 8):	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥60 years of age to lower blood pressure at systolic blood pressure ≥150 mm Hg or diastolic blood

Clinical Guideline	Recommendations
<p>2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)⁸</p>	<p>pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life.</p> <ul style="list-style-type: none"> • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)⁹</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/ European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁰, Reappraisal of</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium

Clinical Guideline	Recommendations
<p>Guidelines on Hypertension Management (2009)¹¹</p>	<p>channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and</p>

Clinical Guideline	Recommendations
<p>Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)¹²</p>	<p>the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the

Clinical Guideline	Recommendations
	<p>presence of microalbuminuria or overt proteinuria.</p> <ul style="list-style-type: none"> • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹³</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁴</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however,

Clinical Guideline	Recommendations
	<p>the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic.</p> <ul style="list-style-type: none"> • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)¹⁵</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high coronary artery disease risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office

Clinical Guideline	Recommendations
(2012) ¹⁶	<p>blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure - lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)¹⁷</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). Either an ACE inhibitor or ARB is suggested for the treatment of the

Clinical Guideline	Recommendations
	<p>nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day.</p> <ul style="list-style-type: none"> When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American College of Cardiology/American Heart Association: 2009 Focused Update: American College of Cardiology/American Heart Association Guidelines for the Diagnosis and Management of Heart Failure in Adults (2009)¹⁸</p>	<p><u>Patients with reduced left ventricular ejection fraction (LVEF)</u></p> <ul style="list-style-type: none"> The combination of hydralazine and nitrates is recommended to improve outcomes for patients self-described as African-Americans, with moderate to severe symptoms on optimal therapy with ACE inhibitors, β-blockers, and diuretics. The addition of a combination of hydralazine and a nitrate is reasonable for patients with reduced LVEF who are already taking an ACE inhibitor and β-blocker for symptomatic heart failure and who have persistent symptoms. A combination of hydralazine and a nitrate might be reasonable in patients with current or prior symptoms of heart failure and reduced LVEF who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency. <p><u>Treatment of special populations</u></p> <ul style="list-style-type: none"> The combination of a fixed-dose of isosorbide dinitrate and hydralazine to a standard medical regimen for heart failure, including ACE inhibitors and β-blockers, is recommended to improve outcomes for patients self-described as African Americans, with New York Heart Association (NYHA) functional class III or IV heart failure. Others may benefit similarly, but this has not yet been evaluated.
<p>American College of Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)¹⁹</p>	<p><u>Early hospital care- standard medical therapies</u></p> <ul style="list-style-type: none"> Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia. Anti-ischemic and analgesic medications <ul style="list-style-type: none"> Nitrates <ul style="list-style-type: none"> Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. Analgesic therapy <ul style="list-style-type: none"> In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use Beta-adrenergic blockers <ul style="list-style-type: none"> Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac

Clinical Guideline	Recommendations
	<p>pacemaker, active asthma, or reactive airway disease)</p> <ul style="list-style-type: none"> ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. <ul style="list-style-type: none"> ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. ▪ Fibrinolytic therapy in patients with definite NSTEMI-ACS <p>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatid, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. • Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. • Timing of CABG in relation to use of antiplatelet agents

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTEMI-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEMI-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTEMI-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTEMI-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTEMI-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTEMI-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.

Clinical Guideline	Recommendations
<p>Institute for Clinical Systems Improvement: Heart Failure in Adults (2013)²⁰</p>	<p><u>Pharmacologic management:</u></p> <ul style="list-style-type: none"> • Carvedilol, metoprolol succinate (extended-release) and bisoprolol have demonstrated reductions in mortality for patients with all classes of heart failure. These agents should be used before using other generic β-blockers. • ACE inhibitors should be prescribed for all patients with left ventricular systolic dysfunction unless contraindications are present. • If non-African American, ACE inhibitors are recommended for decreasing heart failure mortality than isosorbide dinitrate/hydralazine. In contrast, combination hydralazine and nitrates is recommended for patients self-described as African Americans, with moderate to severe symptoms on optimal therapy with ACE inhibitors, β-blockers, and diuretics. • ARBs should be considered primarily for patients who are intolerant to ACE inhibitors or in patients receiving standard drug therapy (including ACE inhibitors) who continue to show clinical deterioration. • Routine use of ARBs and ACE inhibitors and aldosterone antagonists cannot be recommended. • Diuretics should not be the sole therapy for patients with signs of volume overload; vasoactive drugs should be considered. • In severe heart failure, loop diuretics should be used over thiazide diuretics and combination therapy with thiazide. Loop diuretics are also effective in refractory cases of volume overload. • Patients with NYHA class III-IV heart failure on stable doses of digoxin and ACE inhibitors can reduce mortality by administering aldosterone-blocking agents. • Nesiritide is recommended to be reserved for patients with decompensated heart failure who remain volume overloaded despite aggressive treatment with diuretics/vasodilators display tolerance and/or resistance to vasodilators or diuretics, or demonstrate significant side effects to other vasodilators. • When considering the use of calcium channel blockers, only dihydropyridine calcium channel blockers have been shown safe. Non-dihydropyridine calcium channel blockers can be used in patients with preserved systolic heart failure. <p><u>Pharmacologic management-digoxin</u></p> <ul style="list-style-type: none"> • In patients in normal sinus rhythm with preserved systolic function and mild to moderate heart failure symptoms on optimal therapy, digoxin had no effect on the endpoints of all-cause or cardiovascular mortality or hospitalization. • Serum levels less than 1.0 ng/mL are considered therapeutic. Levels greater than 1.2 have been associated with greater side effects. Serum levels do not always correlate to symptoms of digoxin toxicity. • Digoxin has been found useful: <ul style="list-style-type: none"> ○ In heart failure patients with atrial fibrillation with a rapid ventricular response. ○ In combination with ACE inhibitors in reducing hospitalizations in heart failure patients. • Digoxin should not: <ul style="list-style-type: none"> ○ Be initiated in asymptomatic heart failure patients as it remains unsupported by clinical trials. ○ Be “loaded” either orally or intravenously. Loading doses are generally not needed and steady state generally takes one week to reach. • Monitor for symptoms of toxicity, reduction of renal function or conduction abnormality. • To avoid digitalis toxicity, use lower doses in the elderly and those with renal impairment, check level in one to two weeks after start of therapy in elderly or renal-impaired patients, and be aware of drug interactions with new medications.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> If continuing digoxin therapy in women, it may be reasonable to recommend that lower dosing (0.125 mg/day) should be used and lower serum levels (1.0 or less) should be maintained.
<p>Heart Failure Society of America: 2010 Comprehensive Heart Failure Practice Guideline (2010)²¹</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) is recommended. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)²²</p>	<p><u>Treatments with less-certain benefits in patients with symptomatic (NYHA class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> The combination of hydralazine and isosorbide dinitrate may be considered as an alternative to an ACE inhibitor or ARB, if neither is tolerated, to reduce the risk of heart failure hospitalization and risk of premature death in patients with an ejection fraction $\leq 45\%$ and dilated left ventricular (or ejection fraction $\leq 35\%$). Patients should also receive a β-blocker and a mineralocorticoid receptor antagonist. The combination of hydralazine and isosorbide dinitrate may be considered to reduce the risk of heart failure hospitalization and risk of premature death in patients with an ejection fraction $\leq 45\%$ and dilated left ventricular (or ejection fraction $\leq 35\%$) and persisting symptoms (NYHA class II-IV) despite treatment with a β-blocker, ACE inhibitor (ARB), and a mineralocorticoid receptor antagonist (or ARB). <p><u>Treatment of acute heart failure: vasodilators</u></p> <ul style="list-style-type: none"> There is no robust evidence that vasodilators relieve dyspnea or improve other clinical outcomes; however, they reduce preload and afterload and increase stroke volume. Vasodilators are probably most useful in patients with

Clinical Guideline	Recommendations
	hypertension and should be avoided in patients with systolic blood pressure <110 mm Hg.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the direct vasodilators are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Direct Vasodilators⁴⁻⁷

Indication	Single Entity Agents			Combination Products
	Diazoxide	Hydralazine	Minoxidil	Isosorbide Dinitrate and Hydralazine
Heart Failure				
Treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status				✓
Hypertension				
Treatment of essential hypertension		✓ *		
Treatment of hypertension			✓ †	
Treatment of severe essential hypertension		✓ ‡		
Miscellaneous				
Treatment of hypoglycemia due to hyperinsulinism	✓ §			

*Tablet: Alone or as an adjunct.

†Because of the potential for serious adverse effects, minoxidil tablet is only indicated for the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.

‡Injection: When the drug cannot be given orally or when there is an urgent need to lower blood pressure.

§Associated with the following conditions in adults: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Associated with the following conditions in children: leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. It may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.

IV. Pharmacokinetics

The pharmacokinetic parameters of the direct vasodilators are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Direct Vasodilators²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Diazoxide	Not reported	90	Not reported	Renal (10 to 90)	20 to 36
Hydralazine	38 to 50	88 to 90	Liver, significant (% not reported)	Renal (3 to 14) Feces (3 to 12)	3 to 5
Minoxidil	90 to 100	Insignificant (% not reported)	Liver (90)	Renal (90) Feces (3)	4.2

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Combination Products					
Isosorbide dinitrate and hydralazine	Not reported	Not reported	Not reported	Not reported	Not reported

V. Drug Interactions

Significant drug interactions with the direct vasodilators are listed in Table 5.

Table 5. Significant Drug Interactions with the Direct Vasodilators¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Nitrates and nitrites	1	Phosphodiesterase type 5 inhibitors	Sildenafil may potentiate the hypotensive effects of nitrates. The use of these agents in combination is contraindicated.
Direct vasodilators (diazoxide)	2	Hydantoins	Serum phenytoin levels may be decreased, resulting in a possible decrease in the anticonvulsant actions of phenytoin.
Direct vasodilators (diazoxide)	2	Sulfonylureas	The addition of diazoxide to the regimen of a non-insulin dependent diabetic stabilized on sulfonylurea therapy may result in hyperglycemia.
Direct vasodilators (diazoxide)	2	Thiazide-type diuretics	Hyperglycemia may occur with symptoms similar to diabetes. The mechanism is unknown.
Direct vasodilators (hydralazine)	2	β -blockers	The oral bioavailability of certain high clearance, lipophilic beta-adrenergic blockers (propranolol, metoprolol) may be increased by hydralazine. The pharmacologic effects of both drugs may be increased.

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the direct vasodilators are listed in Table 6. The boxed warning for minoxidil is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Direct Vasodilators¹⁻⁷

Adverse Events	Single Entity Agents			Combination Products
	Diazoxide	Hydralazine	Minoxidil	Isosorbide Dinitrate and Hydralazine
Cardiovascular System				
Angina pectoris	-	✓	✓	16
Cardiovascular collapse	-	-	-	✓
Crescendo angina	-	-	-	✓
Electrocardiogram changes	-	-	60	-
Flushing	-	✓	-	✓
Heart failure	-	-	✓	-
Hypotension	✓	-	-	8
Orthostatic hypotension	-	✓	-	✓
Pallor	-	-	-	✓

Adverse Events	Single Entity Agents			Combination Products
	Diazoxide	Hydralazine	Minoxidil	Isosorbide Dinitrate and Hydralazine
Palpitations	✓	✓	-	4
Paradoxical pressor response	-	✓	-	✓
Peripheral edema	-	✓	7	✓
Pericardial effusion with tamponade	-	-	3	-
Pericarditis	-	-	✓	-
Postural hypotension	-	-	✓	✓
Rebound hypertension	-	-	-	✓
Shock	-	-	-	✓
Syncope	-	-	-	✓
Tachycardia	✓	✓	✓	2
Vascular collapse	-	✓	-	✓
Ventricular tachycardia	-	-	-	4
Central Nervous System				
Anxiety	✓	✓	-	✓
Asthenia	-	✓	-	✓
Chills	-	✓	-	✓
Depression	-	✓	-	✓
Disorientation	-	✓	-	✓
Dizziness	✓	✓	-	32
Fever	✓	✓	-	✓
Headache	✓	✓	-	50
Insomnia	✓	-	-	-
Lightheadedness	-	-	-	✓
Malaise	✓	-	-	-
Polyneuritis	✓	-	-	-
Psychotic reaction	-	✓	-	✓
Restlessness	-	-	-	✓
Dermatological				
Alopecia	✓	-	-	1
Hirsutism	✓	-	-	-
Hypertrichosis	-	-	80	-
Pruritus	✓	✓	-	✓
Purpura	✓	-	-	-
Rash	✓	✓	✓	✓
Stevens-Johnson syndrome	-	-	✓	-
Urticaria	-	✓	-	✓
Endocrine and Metabolic				
Breast lump enlargement	✓	-	-	-
Breast tenderness	✓	-	✓	-
Diabetic ketoacidosis	✓	-	-	-
Fluid and electrolyte imbalance	-	-	✓	-
Fluid retention	✓	-	-	-
Galactorrhea	✓	-	-	-
Gout	✓	-	-	-
Hyperglycemia	✓	-	-	4
Hyperlipidemia	-	-	-	3
Hyperosmolar nonketotic coma	✓	-	-	-
Pancreatitis	✓	-	-	-
Sodium retention	✓	-	-	-
Gastrointestinal				
Abdominal pain	✓	-	-	-
Anorexia	✓	✓	-	✓

Adverse Events	Single Entity Agents			Combination Products
	Diazoxide	Hydralazine	Minoxidil	Isosorbide Dinitrate and Hydralazine
Bowel incontinence	-	-	-	✓
Constipation	-	✓	-	✓
Diarrhea	✓	✓	-	✓
Ileus	✓	-	-	-
Nausea	✓	✓	✓	10
Pancreatic necrosis	✓	-	-	-
Paralytic ileus	-	✓	-	✓
Taste loss (transient)	✓	-	-	-
Vomiting	✓	✓	✓	4
Weight gain	-	-	✓	-
Xerostomia	-	-	-	✓
Genitourinary				
Albuminuria	✓	-	-	-
Azotemia	✓	-	-	-
Blood urea nitrogen increased	-	-	✓	-
Creatine clearance decreased	✓	-	-	-
Dysuria	-	✓	-	✓
Glucosuria	✓	-	-	-
Hematuria	✓	-	-	-
Impotence	-	✓	-	✓
Nephrotic syndrome	✓	-	-	-
Serum creatine increased	-	-	✓	-
Uric acid increased	✓	-	-	-
Urinary output decreased	✓	-	-	-
Urinary incontinence	-	-	-	✓
Hematological				
Agranulocytosis	-	✓	-	✓
Bleeding	✓	-	-	-
Eosinophilia	✓	✓	-	✓
Erythrocyte count reduced	-	✓	✓	✓
Hematocrit decreased	✓	-	✓	-
Hemoglobin decreased	✓	✓	✓	✓
Hemolytic anemia	-	✓	-	✓
Leukopenia	-	✓	✓	✓
Methemoglobinemia	-	-	-	✓
Neutropenia	✓	-	-	-
Thrombocytopenia	✓	✓	✓	✓
Hepatic				
Alkaline phosphatase increased	✓	-	✓	-
ALT increased	✓	-	-	-
Cholecystitis	-	-	-	1
Musculoskeletal				
Arthralgia	-	-	-	1
Muscle cramps	-	✓	-	✓
Myalgia	-	-	-	1
Paresthesia	-	-	-	4
Peripheral neuritis	-	✓	-	✓
Rheumatoid arthritis	-	✓	-	✓
Tendon disorder	-	-	-	1
Tremor	-	✓	-	✓
Weakness	✓	✓	-	14
Ocular				

Adverse Events	Single Entity Agents			Combination Products
	Diazoxide	Hydralazine	Minoxidil	Isosorbide Dinitrate and Hydralazine
Blurred vision	✓	-	-	✓
Cataracts (transient)	✓	-	-	-
Diplopia	✓	-	-	-
Conjunctivitis	-	✓	-	✓
Lacrimation	✓	✓	-	✓
Ring scotoma	✓	-	-	-
Subconjunctival hemorrhage	✓	-	-	-
Respiratory				
Bronchitis	-	-	-	8
Dyspnea	-	✓	-	✓
Nasal congestion	-	✓	-	✓
Pulmonary edema	-	-	✓	-
Rhinitis	-	-	-	4
Sinusitis	-	-	-	4
Other				
Abnormal facial features	✓	-	-	-
Allergic reactions	-	-	-	1
Angioedema	-	-	-	1
Diaphoresis	-	✓	-	1
Drug-induced lupus-like syndrome	-	✓	-	✓
IgG decreased	✓	-	-	-
Lymphadenopathy	✓	-	-	-

✓ Percent not specified
- Event not reported

Table 7. Boxed Warning for Minoxidil¹

WARNING
<p>Minoxidil may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and it can exacerbate angina pectoris. Reserve for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents.</p> <p>In experimental animals, minoxidil caused several kinds of myocardial lesions and other adverse cardiac effects.</p> <p>Administer under close supervision, usually concomitantly with a beta -adrenergic blocking agent, to prevent tachycardia and increased myocardial workload. Usually, it must be given with a diuretic, frequently one acting in the ascending limb of the loop of Henle to prevent serious fluid accumulation. When first administering minoxidil, hospitalize and monitor patients with malignant hypertension and those already receiving guanethidine to avoid too rapid or large orthostatic decreases in blood pressure.</p>

VII. Dosing and Administration

The usual dosing regimens for the direct vasodilators are listed in Table 8.

Table 8. Usual Dosing Regimens for the Direct Vasodilators¹⁻⁷

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Diazoxide	<u>Hypoglycemia due to hyperinsulinism:</u> Suspension: initial, 3 mg/kg/day, divided into 3 equal doses administered every 8 hours; maintenance, 3 to 8 mg/kg divided into 2 or 3 equal doses administered every 8 to 12 hours	<u>Hypoglycemia due to hyperinsulinism in children:</u> Suspension: initial, 3 mg/kg/day, divided into 3 equal doses administered every 8 hours; maintenance, 3 to 8 mg/kg/day divided into 2 or 3 equal doses administered every 8 to 12 hours <u>Hypoglycemia due to hyperinsulinism in infants and newborns:</u> Suspension: initial, 10 mg/kg/day in 3 equal doses administered every 8 hours; maintenance, 8 to 15 mg/kg/day divided into 2 or 3 equal doses every 8 to 12 hours	Suspension: 50 mg/mL
Hydralazine	<u>Essential hypertension:</u> Injection, tablet: initial, 10 mg four times daily for the first 2 to 4 days, followed by 25 mg four times daily for the balance of the first week, then for the second and subsequent weeks, increase dosage to 50 mg four times daily; maintenance, adjust dosage to the lowest effective levels	<u>Essential hypertension:</u> Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of hydralazine in pediatric patients. Injection, tablet: initial, 0.75 mg/kg/day administered in four divided doses; maintenance, dosage may be increased gradually over the next 3 to 4 weeks; maximum, 7.5 mg/kg or 200 mg/day	Injection: 20 mg/mL Tablet: 10 mg 25 mg 50 mg 100 mg
Minoxidil	<u>Hypertension:</u> Tablet: initial, 5 mg/day and increase gradually every 3 days; maintenance, 10 to 40 mg daily in single or divided doses; maximum, 100 mg/day	<u>Hypertension:</u> Tablet: initial, 0.2 mg/kg/day; maintenance, 0.25 to 1 mg/kg/day; maximum, 50 mg/day	Tablet: 2.5 mg 10 mg
Combination Products			
Isosorbide dinitrate and hydralazine	<u>Heart failure:</u> Tablet: initial, 20-37.5 mg 3 times daily; maximum, 40-75 mg (2 tablets) three times daily	The safety and effectiveness have not been established in children.	Tablet: 20-37.5 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the direct vasodilators are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Direct Vasodilators

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Heart Failure				
Unverferth et al. ²³ (1983) Hydralazine 225 mg/day vs ISDN 160 mg/day vs hydralazine and ISDN (individual agents) vs placebo	DB, PC, RCT Patients with idiopathic dilated cardiomyopathy were evaluated to determine the hemodynamic and morphologic effects of vasodilator therapy	N=49 3 months	Primary: Echocardiographic percent change of left ventricular diameter, the systolic time intervals ratio of PEP/LVET, the pulmonary capillary wedge pressure, mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and SVR Secondary: Not reported	Primary: For the percent change in left ventricular diameter and PEP/LVET, a significant improvement with hydralazine and combination therapy (P<0.05) was seen compared to ISDN alone or placebo. Significant decrease with ISDN and combination therapy vs placebo or hydralazine alone (P<0.05) was seen for pulmonary capillary wedge pressure, mean pulmonary artery pressure, and the pulmonary vascular resistance. Hydralazine resulted in a decrease in SVR and increase in cardiac index from 2.5±0.4 to 3.1±0.4 L/min/m ² vs placebo or ISDN alone (P<0.05). Combination therapy resulted in a decrease in SVR and cardiac index increased from 2.3±0.4 to 3.1±0.4 L/min/m ² (P<0.01). There was no improvement in SVR or cardiac index with ISDN alone or with placebo. Myocardial cell diameter decreased from 25.4±3.1 microns at baseline to 23.1±3.8 microns with hydralazine (P<0.05). Combination therapy decreased its cell diameter from 23.9±3.7 to 22.2±2.2 microns (P<0.05). There was no change in the myocardial cell diameter seen in patients treated with ISDN alone or with placebo. Secondary: Not reported
Taylor ²⁴ (2005) A-HeFT	DB, MC, PC, RCT African American	N=1,050 6 to 18 months	Primary: Composite score (all-cause	Primary: Mortality in the fixed-dose ISDN and hydralazine group was 6.2% compared to 10.2% in the placebo group (P=0.02).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ISDN and hydralazine 60-112.5 mg/day in 3 divided doses, titrated up to ISDN and hydralazine 120-225 mg/day in 3 divided doses (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>patients with moderate-to-severe symptomatic heart failure, classified NYHA class III to IV heart failure with dilated ventricles and low ejection fractions</p>		<p>mortality, first hospitalization for heart failure, and quality of life at 6 months as measured by the Minnesota Living with Heart Failure questionnaire)</p> <p>Secondary: Not reported</p>	<p>Survival was increased by 43% in the active treatment arm (HR, 0.57; P=0.02).</p> <p>The composite score and all individual components of the composite score were significantly and positively impacted by treatment with ISDN and hydralazine (primary composite score P=0.01, death from any cause P=0.02, first hospitalization for heart failure P=0.001, change in quality of life score at 6 months P=0.02).</p> <p>The study was prematurely terminated in as a result of the significantly improved survival in the ISDN and hydralazine group.</p> <p>Secondary: Not reported</p>
<p>Taylor et al.²⁵ (2004) A-HeFT</p> <p>ISDN and hydralazine 20-37.5 mg TID, increased to ISDN and hydralazine 40-75 mg TID (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients ≥18 years of age, self-identified as of African descent, with NYHA class III or IV heart failure on standard therapy for ≥3 months and evidence of left ventricular dysfunction within the prior 6 months</p>	<p>N=1,050</p> <p>18 months (mean duration of follow-up was 10 months)</p>	<p>Primary: A composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and quality of life changes</p> <p>Secondary: Individual components of the primary composite score</p>	<p>Primary: From a range of possible scores of -6 to 2 for the composite endpoint, patients in the active treatment group achieved a significantly better score of -0.1±1.9 compared -0.5±2.0 in the placebo group (P=0.01).</p> <p>Secondary: There was a significantly higher mortality rate in the placebo group compared to the ISDN and hydralazine group (6.2 vs 10.2%; P=0.02). Survival was increased by 43% in the active treatment group (HR, 0.57; P=0.02). This led to the early termination of the trial.</p> <p>Compared to the placebo group, the rate of first hospitalization for heart failure was significantly reduced in the ISDN and hydralazine group (16.4 vs 24.4%; P=0.001).</p> <p>There was a significant improvement in quality of life scores found with the ISDN and hydralazine group when compared to the placebo group (-5.6±20.6 vs -2.7±21.2; P=0.02).</p>
<p>Taylor et al.²⁶ (2007) A-HeFT</p>	<p>Post-hoc analysis of A-HeFT</p>	<p>N=1,050</p> <p>Mean duration</p>	<p>Primary: Cause specific mortality, event</p>	<p>Primary: Cardiovascular deaths were significantly reduced in the treatment group compared to the placebo group (5.0 vs 8.5%; P=0.027). Pump failure</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ISDN and hydralazine 20-37.5 mg TID, increased to ISDN and hydralazine 40-75 mg TID (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>Patients ≥18 years of age, self-identified as of African descent, with NYHA class III or IV heart failure on standard therapy for ≥3 months and evidence of left ventricular dysfunction within the prior 6 months</p>	<p>of follow-up was 18 months</p>	<p>free survival (time to either death or first hospitalization and time to first hospitalization for heart failure)</p> <p>Secondary: Subgroup analysis</p>	<p>death was also significantly reduced (75%) compared to the placebo group (0.8 vs 3.0%; P=0.012). There were no significant differences between the groups for other causes of death.</p> <p>In the treatment group event-free survival (death or first hospitalization for heart failure) was significantly improved compared to the placebo group (HR, 0.63; 95% CI, 0.49 to 0.81; P<0.001).</p> <p>The time to first hospitalization for heart failure was also significantly reduced (HR, 0.61; 95% CI, 0.46 to 0.80; P<0.001).</p> <p>Secondary: A consistent beneficial effect was seen in the treatment sub groups (age, sex, baseline BP, history of chronic renal insufficiency, presence of diabetes, cause of heart failure, and baseline medication use) on primary composite score and event-free survival.</p>
<p>Anand et al.²⁷ (2014) A-HeFT</p> <p>ISDN and hydralazine 20-37.5 mg TID, increased to ISDN and hydralazine 40-75 mg TID (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>Post-hoc analysis of A-HeFT</p> <p>Patients ≥18 years of age, self-identified as of African descent, with NYHA class III or IV heart failure on standard therapy for ≥3 months and evidence of left ventricular dysfunction within the prior 6 months</p>	<p>N=1,050</p> <p>Mean duration of follow-up was 18 months</p>	<p>Primary: Mortality, all hospitalizations including recurrences (first hospitalizations only, all hospitalizations including recurrences, 30-day all-cause readmission rates)</p> <p>Secondary: Not reported</p>	<p>Primary: During a median follow-up of 450 days, 86 (8.2%) patients died. The cumulative mortality was significantly lower (HR, 0.57; 95% CI, 0.37 to 0.89; P=0.013) in the treatment group vs the placebo group.</p> <p>When deaths were analyzed as a competing risk for first hospitalizations, the effect (HR) of treatment was 0.88 (95% CI, 0.72 to 1.06; P=0.18) on hospitalization for any cause and 0.61 (95% CI, 0.47 to 0.80; P<0.001) on heart failure hospitalizations.</p> <p>The use of fixed-dose combination product was associated with a significant 25% reduction in all hospitalizations for any cause (HR, 0.75; 95% CI, 0.63 to 0.91; P=0.003) and a 34% reduction in all heart failure hospitalizations (HR, 0.66; 95% CI, 0.52 to 0.83; P<0.001).</p> <p>Of the subjects who had at least one admission for heart failure and were discharged alive, 29 of 123 (23.6%) in the placebo group and 12 of 81 (14.8%) in the combination product group were readmitted for any cause <30 days of being discharged from their first hospitalization for heart failure. This reduction in the 30-day all-cause readmissions by the combination product was not statistically significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
<p>Yancy et al.²⁸ (2007) A-HeFT</p> <p>ISDN and hydralazine 20-37.5 mg TID, increased to ISDN and hydralazine 40-75 mg TID (fixed-dose combination product)</p> <p>vs placebo</p>	<p>ES, OL</p> <p>Patients previously enrolled in A-HeFT with NYHA class I to IV heart failure symptoms while receiving background therapy and satisfying the A-HeFT inclusion criteria</p>	<p>N=158</p> <p>12 months or until ISDN and hydralazine approved by the FDA</p>	<p>Primary: Compliance with study drug, safety, tolerability</p> <p>Secondary: Change in NYHA association class, death, hospitalization for heart failure</p>	<p>Primary: Compliance in the treatment group averaged 87±25%, with no significant difference when compared to the placebo group.</p> <p>There were no significant differences in adverse events between the groups.</p> <p>Secondary: No significant difference was seen in hospitalizations from heart failure according to randomization.</p> <p>The greatest improvement in heart failure symptoms occurred in NYHA class III (at baseline) compared to other classes (P<0.001).</p> <p>Overall most patients were unchanged with 24% showing improved NYHA class and 9% showing a worsening.</p>
<p>Cohn et al.²⁹ (1986) V-HeFT I</p> <p>Hydralazine 300 mg/day plus ISDN 160 mg/day (individual agents, concurrent therapy)</p> <p>vs prazosin 20 mg/day</p> <p>vs</p>	<p>AC, DB, PC, RCT</p> <p>Men with impaired cardiac function and reduced exercise tolerance on digoxin and a diuretic</p>	<p>N=642</p> <p>3 years</p>	<p>Primary: Mortality</p> <p>Secondary: Effect on left ventricular function</p>	<p>Primary: There was a 34% risk reduction in mortality by two years in the hydralazine plus ISDN group compared to placebo (P<0.028).</p> <p>Cumulative mortality rates of 25.6 and 36.2% were observed in the hydralazine plus ISDN group at 2 and 3 years respectively, compared to 34.3 and 46.9% in the placebo group. The results found in the prazosin group were similar to placebo.</p> <p>Secondary: A significant increase in the left ventricular ejection fraction was reported at eight weeks and one year in the hydralazine plus ISDN treatment group, but not in either the prazosin or placebo groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo</p> <p>Cohn et al.³⁰ (1991) V-HeFT II</p> <p>Hydralazine 300 mg/day plus ISDN 160 mg/day</p> <p>vs</p> <p>enalapril 20 mg/day</p>	<p>AC, DB, MC, RCT</p> <p>Men between the ages of 18 and 75 years with chronic heart failure receiving digoxin and diuretic therapy</p>	<p>N=804</p> <p>2 years</p>	<p>Primary: Mortality</p> <p>Secondary: Peak oxygen consumption during exercise, LVEF</p>	<p>Primary: Mortality after two years was significantly lower in the group treated with enalapril (18%) than hydralazine plus isosorbide dinitrate (25%; P=0.016), and overall mortality tended to be lower (P=0.08).</p> <p>The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (NYHA class I or II).</p> <p>Secondary: Peak oxygen consumption during exercise was increased only by hydralazine plus isosorbide dinitrate (P<0.05).</p> <p>While LVEF increased with both regimens during the two years after randomization, LVEF increased more (P<0.05) during the first 13 weeks in the hydralazine plus isosorbide dinitrate group.</p>
<p>Mullens et al.³¹ (2009)</p> <p>Isosorbide dinitrate and hydralazine (I/H) added to an ACE inhibitor or angiotensin receptor blockers</p> <p>vs</p> <p>ACE inhibitor or angiotensin receptor blockers</p> <p>Titration of oral drugs was aimed to wean off parental</p>	<p>PRO</p> <p>Patients ≥18 years of age with advanced decompensate heart failure with a cardiac index <2.2 L/min/m² who were admitted to the hospital for intensive medical therapy</p>	<p>N=239</p> <p>Mean 26.3 months</p>	<p>Primary: All-cause mortality, cardiac transplantation, and first readmission for heart failure after index hospitalization discharge</p> <p>Secondary: Not reported</p>	<p>Primary: Patients receiving I/H had lower all-cause mortality (34 vs 41%; OR, 0.65; 95% CI, 0.43 to 0.99, P=0.04) and lower all-cause mortality/heart failure rehospitalization (70% vs 85%; OR, 0.72; 95% CI, 0.54 to 0.97; P=0.03) compared to the control group. There was no difference in overall cardiac transplantation or heart failure rehospitalization rates among the treatment groups.</p> <p>The improved outcomes in the I/H group was independent of race; however, there was a trend toward improved outcomes in African-Americans (all-cause mortality for whites in the I/H group, OR 0.66; 95% CI, 0.4 to 0.98; P=0.05; all-cause mortality for African-Americans in the I/H group, OR 0.44; 95% CI, 0.23 to 0.85; P=0.01).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
therapy and based on maintaining a target mean arterial pressure of 65 to 70 mm Hg and/or systolic blood pressure >85 mm Hg				
Hypertension				
Johnson et al. ³² (1983) Minoxidil 5 to 40 mg/day as add-on therapy vs hydralazine 25 to 200 mg/day as add-on therapy	DB, RCT Patients with normal renal function receiving HCTZ or propranolol (doses unknown) with DBP >95 mmHg	N=36 28 weeks	Primary: Percentage of patients with DBP <90 mmHg at weeks 4 and 28 Secondary: Not reported	Primary: There were greater response rates (DBP <90 mmHg) with minoxidil (69%) vs hydralazine (35%) at week four. At week 28, there were greater response rates (DBP <90 mmHg) with minoxidil (55%) vs hydralazine (40%). Secondary: Not reported
Bevan et al. ³³ (1993) Captopril (unknown dose) vs hydralazine (unknown dose) vs nifedipine (unknown dose)	DB, PC, RCT Patients with inadequately controlled HTN, despite treatment with atenolol 100 mg/day and bendrofluazide* 5 mg/day	N=160 12 weeks	Primary: Comparative antihypertensive, biochemical, adverse effects Secondary: Not reported	Primary: Mean supine blood pressure changes: captopril 13.4/10.3 mmHg, hydralazine 15.0/10.0 mmHg, and nifedipine 16.8/8.1 mmHg (differences not significant). Erect blood pressure changes were similar; target blood pressure (<140/95 mmHg) was achieved in 33% with captopril, 29% with hydralazine, 17% with nifedipine, and 10% with placebo. Compared to other agents, captopril increased serum potassium (value not reported; P=0.01). Mean changes in serum cholesterol: captopril -0.2 mmol/L, hydralazine -0.8 mmol/L, nifedipine -0.2 mmol/L, and placebo 0.2 mmol/L (P<0.001). Side effects did not differ significantly between the groups. Withdrawal

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				rates: captopril 15%, hydralazine 24%, nifedipine 22%, and placebo 3% (P=0.04).
Julien et al. ³⁴ (1990) Captopril 150 to 300 mg/day vs minoxidil 7.5 to 30 mg/day	DB, PG, RCT Male patients with left ventricular hypertrophy and essential HTN with DBP >95 mmHg who were taking metoprolol 200 mg/day and furosemide 80 mg/day	N=34 6 months	Primary: Blood pressure changes and left ventricular hypertrophy changes as seen on electrocardiogram Secondary: Not reported	Primary: Blood pressure decreased significantly in both groups; captopril (163/102 to 135/89 mmHg) and minoxidil (160/99 to 137/87 mmHg; P<0.001). Electrocardiogram criteria for left ventricular hypertrophy improved with captopril only with a decrease in intraventricular septum, posterior wall, and left ventricular mass (17.4 to 15.9 mm; P<0.05, 14.5 to 13.4 mm; P<0.05 and 236 to 198 g/m ² ; P<0.001, respectively). No changes on electrocardiogram criteria with minoxidil. Secondary: Not reported
McAreavey et al. ³⁵ (1984) Hydralazine 12.5 mg QD up to 100 mg BID vs labetalol 200 mg QD up to 1,600 mg BID vs methyldopa 125 mg QD up to 1,000 mg BID vs prazosin 0.5 mg	DB, PG, RCT Patients with inadequately controlled HTN while receiving atenolol 100 mg/day and bendrofluazide* 5 mg/day	N=238 6 months	Primary: Comparative safety and efficacy, target blood pressure <140/95 mm Hg Secondary: Not reported	Primary: Target blood pressure was reached in 25% of patients receiving hydralazine, 23% of patients receiving minoxidil, 19% of patients receiving prazosin, 17% of patients receiving methyldopa and zero percent of patients receiving placebo (P values not reported). Labetalol had the highest withdrawal rate compared to the other treatments with 78% (P<0.05). Minoxidil had the second highest withdrawal rate with 57% (P<0.05), due to fluid retention. There were no significant differences in withdrawal rates among the other treatments. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD up to 10 mg BID</p> <p>vs</p> <p>placebo</p> <p>Minoxidil as add-on therapy was given to men only.</p>				
<p>Materson et al.³⁶ (1990)</p> <p>Hydralazine 25, 50 or 100 mg BID</p> <p>vs</p> <p>metoprolol 50, 100 or 200 mg BID</p> <p>vs</p> <p>methyldopa 250, 500 or 1,000 mg BID</p> <p>vs</p> <p>reserpine 0.05, 0.10 or 0.25 mg QD</p> <p>All patients received HCTZ 25 to 100 mg QD.</p>	<p>DB, MC, RCT</p> <p>Men ≥ 60 years with HTN not currently receiving antihypertensive therapy with a DBP 90 to 114 mm Hg and a SBP < 240 mm Hg; or a DBP < 100 mm Hg and a SBP < 240 mm Hg if currently taking antihypertensive therapy and the blood pressure criteria was met after ≥ 2 weeks without medication</p>	<p>N=690</p> <p>12 months</p>	<p>Primary: Average reduction in SBP, DBP, the number of patients achieving the goal blood pressure and the average change in heart rate</p> <p>Secondary: Rates of drug intolerances and incidence of adverse effects</p>	<p>Primary: A total of 269 patients were uncontrolled with HCTZ therapy alone and were randomized to receive hydralazine (n=68), methyldopa (n=71), metoprolol (n=65), or reserpine (n=65).</p> <p>A total of 213 of the 269 patients achieved goal blood pressure with the addition of one of four therapies was added to HCTZ and entered the 6 month maintenance phase; 186 patients completed the maintenance phase.</p> <p>Across all four add-on therapies, there was an additional average reduction in blood pressure of 13.1/10.6 mm Hg. The average reduction in SBP (mm Hg)\pmSD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: -11.5 ± 10.1 (P< 0.001), -15.0 ± 13.7 (P< 0.001), -13.0 ± 15.4 (P< 0.001), and -12.7 ± 11.5 (P< 0.001), respectively. There was no statistically significant difference in SBP reductions among the different groups (P=0.43).</p> <p>The average reduction in DBP (mm Hg)\pmSD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: -11.3 ± 5.9 (P< 0.001), -10.6 ± 6.3 (P< 0.001), -10.6 ± 6.7 (P< 0.001), and -9.8 ± 6.3 (P< 0.001), respectively. There was no statistically significant difference in DBP reductions among the different groups (P=0.59).</p> <p>The average change in heart rate (beats per minute) \pmSD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: 1.4 ± 10.5 (P value not significant), -1.6 ± 9.3 (P value not significant), 15.9 ± 11.9 (P< 0.05), and -7.9 ± 10.7 (P< 0.05), respectively.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>There was a statistically significant difference in change in heart rate among the different groups (P<0.001).</p> <p>The percentage of patients achieving the goal blood pressure at endpoint in the hydralazine, methyldopa, metoprolol, and reserpine groups was: 85.3, 81.7, 76.9, and 72.3%, respectively (P=0.28).</p> <p>Secondary: Drug intolerance, defined as adverse effects prompting dose reduction or discontinuation, was present in 23.3% of those not achieving goal blood pressure compared to 2.8% of those achieving the goal blood pressure (P<0.001). This was statistically significant in the hydralazine, methyldopa, and metoprolol groups, but not the reserpine group.</p> <p>There were 27 (10%) study terminations due to adverse drug events: hydralazine (n=3), methyldopa (n=8), metoprolol (n=9), and reserpine (n=7). There were 2 study terminations in the methyldopa-treated group and 1 in the reserpine group due to depression.</p> <p>The overall incidence of volunteered moderate or severe adverse effects, not prompting study termination was significantly greater (P<0.01) with methyldopa (31%) and hydralazine (25%) compared to reserpine (15%) or metoprolol (9%).</p>

*Synonym for bendroflumethiazide.

Drug regimen abbreviations: BID=twice daily, QD=once daily, TID=three times daily

Study abbreviations: AC=active controlled, DB=double blind, ES=extended study, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial

Miscellaneous abbreviations: ACE=angiotensin converting enzyme, CI=confidence interval, DBP=diastolic blood pressure, FDA=Food and Drug Administration, HCTZ=hydrochlorothiazide, HR=hazard ratio, HTN=hypertension, ISDN=isosorbide dinitrate, LVEF=left ventricular ejection fraction, LVET=left ventricular ejection time, NYHA=New York Heart Association, PEP=pre-ejection period, SBP=systolic blood pressure, SD=standard deviation, SVR=systemic vascular resistance

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Direct Vasodilators

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Diazoxide	suspension	Proglycem®	\$\$\$\$\$	N/A
Hydralazine	injection, tablet	N/A	N/A	\$
Minoxidil	tablet	N/A	N/A	\$\$
Combination Products				
Isosorbide dinitrate and hydralazine	tablet	BiDil®	\$\$\$\$\$	N/A

*Generic is available in at least one dosage form or strength.

N/A=not available

X. Conclusions

Diazoxide is a non-diuretic benzothiadiazine derivative taken orally for the management of symptomatic hypoglycemia. It increases blood glucose levels by inhibiting the release of insulin from the pancreas, as well as by an extrapancreatic effect. The hyperglycemic effect begins within an hour and generally last no more than 8 hours. The oral preparation does not demonstrate the same effects on blood pressure as the other direct vasodilators.¹⁻³ Diazoxide is considered a first-line treatment option for hypoglycemia due to hyperinsulinism.³⁷ It is not available in a generic formulation.

Hydralazine and minoxidil are approved for the treatment of hypertension, and both agents are available in a generic formulation.^{1,2,4,5} There are several national and international organizations that have published guidelines on the treatment of hypertension. Most of the guidelines do not provide recommendations on the use of the oral direct vasodilators.⁸⁻¹⁶ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).⁸ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.⁸⁻¹⁵ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.⁸⁻¹⁵ Clinical trials have demonstrated that hydralazine and minoxidil are effective for the treatment of hypertension when added to existing therapy in patients whose blood pressure is inadequately controlled. There are limited head-to-head trials comparing the direct vasodilators.³²⁻³⁶ These agents are associated with several potentially severe adverse effects, which limits their use in the treatment of hypertension.^{1,2}

Hydralazine and isosorbide dinitrate (administered as single entity products) have been used off-label to treat heart failure for many years. The combination of these agents has been shown to reduce mortality compared to placebo in patients receiving standard therapy with digoxin and diuretics.²⁹ However, when hydralazine and isosorbide dinitrate were directly compared to an ACE inhibitor, mortality was significantly lower in the ACE inhibitor group.³⁰ Treatment guidelines for the management of heart failure currently recommend the use of hydralazine and an oral nitrate in patients who do not tolerate an ACE inhibitor or ARB.¹⁸⁻²² The fixed-dose combination of isosorbide dinitrate and hydralazine is FDA-approved for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients.⁷ In the A-HeFT trial, the use of this combination product improved mortality, prolonged time to hospitalization for heart failure, and improved functional status compared to placebo. The patients in this trial were also receiving standard heart failure therapy prior to enrollment (ACE inhibitors, angiotensin II receptor antagonists, β -blockers, diuretics, digoxin, spironolactone).^{7,24-27} The Heart Failure Society of America and the American College of Cardiology Foundation/American Heart Association recommend the use of the fixed-dose combination of isosorbide dinitrate and hydralazine in African American patients with NYHA functional class III or IV heart failure who are on a standard regimen including an ACE inhibitor (or ARB) and a β -blocker.^{18,21} Both hydralazine and isosorbide dinitrate are available generically; however, generic hydralazine is not available in a strength equivalent to the fixed-dose combination product.^{4,6}

Therefore, all brand direct vasodilators within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use. The fixed-dose combination of isosorbide dinitrate and hydralazine (BiDil[®]) should be available through the medical justification portion of the prior authorization process as an adjunct to standard heart failure therapy in self-identified black patients. Due to its limited FDA-approved indications, diazoxide (Proglycem[®]) should be managed through the medical justification portion of the prior authorization process.

XI. Recommendations

No brand direct vasodilator is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
3. Proglycem® [package insert]. Sellersville (PA): Teva Pharmaceuticals USA; 2008 Dec.
4. Hydralazine tablet [package insert]. Sellersville (PA): Teva Pharmaceuticals USA; 2012 Dec.
5. Hydralazine injection [package insert]. Lake Forest (IL): Akorn Inc.; 2013 Feb.
6. Minoxidil® [package insert]. Corona (CA): Watson Pharma, Inc.; 2012 Mar.
7. BiDil® [package insert]. Atlanta (GA): Arbor Pharmaceuticals, LLC; 2013 Mar.
8. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
9. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
11. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
12. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
13. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
14. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
15. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
16. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
17. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
18. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. 2009;119:1977-2016.
19. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
20. Pinkerman C, Sander P, Breeding JE, Brink D, Curtis R, Hayes R, Ojha A, Pandita D, Raikar S, Setterlund L, Sule O, Turner A. Institute for Clinical Systems Improvement. Heart Failure in Adults. Updated July 2013.
21. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. *J Card Fail*. 2010 Jun;16(6):e1-194.
22. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
23. Unverferth DV, Mehegan JP, Magorien RD, Unverferth BJ, Leier CV. Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy. *Am J Cardiol*. 1983 May 1;51(8):1392-8.

24. Taylor AL. The African American Heart Failure Trial: a clinical trial update. *Am J Cardiol.* 2005 Oct 10;96(7B):44-8.
25. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med.* 2004 Nov 11;351(20):2049-57.
26. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al; African-American Heart Failure Trial Investigators. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. *Circulation.* 2007 Apr 3;115(13):1747-53.
27. Anand IS, Win S, Rector TS, Cohn JN, and Taylor AL. Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. *Circ Heart Fail.* 2014 Sep;7(5):759-765.
28. Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, et al. Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). *Am J Cardiol.* 2007 Aug 15;100(4):684-9.
29. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study (VHEFT-I). *N Engl J Med.* 1986; 314:1547-52.
30. Cohn JN, Ziesche S, Johnson G, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med.* 1991 Aug 1;325(5):303-10.
31. Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. *Am J Cardiol* 2009;103:1113-9.
32. Johnson BF, Black HR, Becker R, Weiner B, Angeletti F. A Comparison of minoxidil and hydralazine in non-azotemic hypertensives. *J Hypertens.* 1983 Jun;1(1):103-7.
33. Bevan EG, Pringle SD, Waller PC, Herrick AL, Findlay JG, Murray GD, et al. Comparison of captopril, hydralazine, and nifedipine as third drug in hypertensive patients. *J Hum Hypertens.* 1993 Feb;7(1):83-8.
34. Julien J, Dufloux MA, Prasquier R, Chatellier G, Menard D, Plouin PF, et al. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: A 6 month double-blind comparison. *J Am Coll Cardiol.* 1990 Jul;16(1):137-42.
35. McAreavey D, Ramsey LE, Latham L, McLaren AD, Lorimer AR, Reid JL, et al. Third drug trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. *Br Med J (Clin Res Ed).* 1984 Jan 14;288(6411):106-11.
36. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes: results of a Department of Veterans Affairs cooperative study. *Hypertension.* 1990 Apr;15(4):348-60.
37. Sunehag A., Haymond M. Treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy. In: Basow DS (Ed). *UpToDate* [database on the internet] Waltham (MA): UpToDate; 2015 [cited 2015 Mar]. Available from: <http://www.utdol.com/utd/index.do>.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Peripheral Adrenergic Inhibitors
AHFS Class 240832
August 19, 2015**

I. Overview

Reserpine is approved for the treatment of mild hypertension as monotherapy, as well as adjunctive therapy in more severe forms of hypertension. Additionally, reserpine is approved for the treatment of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.¹⁻³ Reserpine depletes norepinephrine and serotonin stores both centrally and in the peripheral adrenergic nerve endings. It also blocks the transport of norepinephrine into its storage granules. Reserpine depletes catecholamines from the brain and myocardium and increases vagal tone, which may lead to decreased cardiac output, depression, and sedation.¹⁻⁴

The peripheral adrenergic inhibitors that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Reserpine is available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Peripheral Adrenergic Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Reserpine	tablet	N/A	reserpine

PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the peripheral adrenergic inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using the Peripheral Adrenergic Inhibitors

Clinical Guideline	Recommendations
Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014) ⁵	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)⁶</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)⁷, Reappraisal of Guidelines on Hypertension Management (2009)⁸</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider

Clinical Guideline	Recommendations
	<p>medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated.</p> <ul style="list-style-type: none"> • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)⁹</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg. • A SBP goal < 140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be < 85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁰</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment

Clinical Guideline	Recommendations
	<p>as is.</p> <ul style="list-style-type: none"> • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹¹</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease.

Clinical Guideline	Recommendations
<p>Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)¹²</p>	<ul style="list-style-type: none"> • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)¹³</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office

Clinical Guideline	Recommendations
	<p>blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> • Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)¹⁴</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130

Clinical Guideline	Recommendations
	<p>mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.</p> <ul style="list-style-type: none"> • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the peripheral adrenergic inhibitors are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Peripheral Adrenergic Inhibitors³

Indication	Reserpine
Hypertension	
Treatment of mild essential hypertension	✓ *

Indication	Reserpine
Miscellaneous	
Treatment of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication	✓

*Also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension.

IV. Pharmacokinetics

The pharmacokinetic parameters of the peripheral adrenergic inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Peripheral Adrenergic Inhibitors²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Reserpine	30 to 40	96	Liver (>90)	Renal (12) Feces (60)	50 to 100

V. Drug Interactions

Significant drug interactions with the peripheral adrenergic inhibitors are listed in Table 5.

Table 5. Significant Drug Interactions with the Peripheral Adrenergic Inhibitors¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Peripheral adrenergic inhibitors (reserpine)	2	Sympathomimetics	Reserpine potentiates the pressor response of the direct-acting sympathomimetics which may result in hypertension. The pressor response of the indirect-acting agents is decreased by reserpine.
Peripheral adrenergic inhibitors (reserpine)	2	Tetrabenazine	Both reserpine and tetrabenazine inhibit human vesicular monoamine transporter type-2 (VMAT2). Coadministration of tetrabenazine with reserpine may deplete serotonin and norepinephrine in the central nervous system. Pharmacologic effects of tetrabenazine may be increased by reserpine.

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the peripheral adrenergic inhibitors are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Peripheral Adrenergic Inhibitors¹⁻³

Adverse Events	Reserpine
Cardiovascular	
Angina	✓
Arrhythmia	✓
Bradycardia	✓
Edema	✓
Hypotension	✓
Premature ventricular contractions	✓
Syncope	✓
Central Nervous System	

Adverse Events	Reserpine
Depression	✓
Dizziness	✓
Drowsiness	✓
Dull sensorium	✓
Fatigue	✓
Headache	✓
Nervousness	✓
Nightmares	✓
Paradoxical anxiety	✓
Parkinsonism syndrome	✓
Dermatological	
Flushing	✓
Pruritus	✓
Purpura	✓
Rash	✓
Endocrine and Metabolic	
Gynecomastia	✓
Weight gain	✓
Gastrointestinal	
Anorexia	✓
Diarrhea	✓
Dry mouth	✓
Gastric acid secretion increased	✓
Nausea	✓
Salivation increased	✓
Vomiting	✓
Genitourinary	
Impotence	✓
Libido decreased	✓
Hematologic	
Thrombocytopenia purpura	✓
Musculoskeletal	
Muscle ache	✓
Respiratory	
Dyspnea	✓
Epistaxis	✓
Nasal congestion	✓
Other	
Blurred vision	✓
Optic atrophy	✓

✓ Percent not specified

VII. Dosing and Administration

The usual dosing regimens for the peripheral adrenergic inhibitors are listed in Table 7.

Table 7. Usual Dosing Regimens for the Peripheral Adrenergic Inhibitors¹⁻³

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Reserpine	<u>Mild hypertension:</u> Tablet: initial, 0.5 mg daily for 1 to 2 weeks; maintenance, 0.1 to 0.25 mg daily	Not recommended for use in children. If it is to be used in treating a child, the usual recommended starting dose is 20 mcg/kg daily;	Tablet: 0.1 mg 0.25 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<u>Symptoms in agitated psychotic states:</u> Tablet: initial, 0.5 mg daily; maintenance, titrate as necessary	maximum 0.25 mg (daily) dose	

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the peripheral adrenergic inhibitors are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Peripheral Adrenergic Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypertension				
Finnerty et al. ¹⁵ (1980) Reserpine 0.25 mg plus chlorthalidone 50 mg vs reserpine 0.125 mg plus HCTZ 50 mg	DB Patients with essential HTN unresponsive to diet control and diuretic therapy	N=57 6 weeks	Primary: The change in mean DBP from baseline Secondary: Incidence of frequent or severe side effects	Primary: The chlorthalidone plus reserpine group had a mean decrease in DBP of 17.0 mm Hg at study endpoint compared to a mean decrease of 18.6 mm Hg in the HCTZ plus reserpine group. At study completion both treatment groups achieved diastolic control of at least 5 mm Hg below the targeted diastolic goal of 90 mm Hg. Secondary: There were no reports of frequent or severe side effects in either treatment group.
Finnerty et al. ¹⁶ (1979) Reserpine 0.125 mg to 0.25 mg QD vs methyldopa 500 mg to 2,000 mg QD vs propranolol 80 mg to 320 mg QD All patients received hydroflumethiazide* 50	SB Patients with HTN unresponsive to hydroflumethiazide alone	N=59 9 weeks	Primary: Percentage of patients achieving a DBP below 90 mm Hg Secondary: Not reported	Primary: At study endpoint, the DBP below 90 mm Hg was achieved in all 20 patients (100%) treated with hydroflumethiazide plus reserpine, 13 of the 19 patients (68.4%) treated with hydroflumethiazide plus methyldopa, and in 16 of the 20 patients (80%) treated with hydroflumethiazide plus propranolol. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>or 100 mg QD.</p> <p>Krönig et al.¹⁷ (1997)</p> <p>Reserpine 0.1 to 0.2 mg QD plus clopamide* 5 to 10 mg QD</p> <p>vs</p> <p>reserpine 0.1 to 0.2 mg QD</p> <p>vs</p> <p>clopamide* 5 to 10 mg QD</p> <p>vs</p> <p>nitrendipine* 20 to 40 mg QD</p>	<p>AC, MC, PG, RCT</p> <p>German patients ≥18 years with mild to moderate HTN and a DBP of 100 to 114 mm Hg at rest</p>	<p>N=273</p> <p>12 weeks</p>	<p>Primary: The change in sitting DBP and SBP from baseline to weeks 6 and 12, and the number of patients achieving the goal DBP and SBP</p> <p>Secondary: Changes in heart rate, incidence of adverse events, and laboratory safety parameter measurements</p>	<p>Primary: The reduction in DBP was similar in the reserpine, clopamide, and nitrendipine groups at week six (-11.7, -11.9, and -12.3 mm Hg), but was greater in the combination group (-17.1 mm Hg). The difference was statistically significant when the combination group was compared to each of the monotherapy groups (P<0.001) and the nitrendipine group (P=0.002). At week 12, the change in DBP compared to baseline was -12.2, -13.4, and -15.3 mm Hg in the reserpine, clopamide, and nitrendipine groups, compared to -18.1 mm Hg in the combination group.</p> <p>The number of patients in the combination group achieving normal DBP readings, defined as a trough <90 mm Hg) by week six was 55.2% compared to 39.7, 36.2, and 33.3% in the reserpine, clopamide, and nitrendipine groups, (P=0.11). Patients not achieving goal DBP at week six subsequently had their medication doses increased, which resulted in achievement of DBP goal in 65.7% of patients in the combination group, and 35.3, 39.1, and 44.9% in the reserpine, clopamide, and nitrendipine groups, (P<0.0001).</p> <p>The reduction in SBP at week 6 in the combination group (-23.0 mm Hg) was greater compared to the reserpine, clopamide, and nitrendipine groups (-14.0, -13.6, and -11.6 mm Hg); P <0.001), resulting in rates of 62.7, 45.6, 40.6, and 30.4% of patients achieving the goal SBP at week six. Dose titration in those not achieving goal SBP by week six resulted in further SBP reductions in all groups except for the reserpine monotherapy group; and normalization was achieved at 12 weeks in 76.1% of the combination group compared to 44.1, 46.4, and 39.1% of the reserpine, clopamide, and nitrendipine groups compared to baseline.</p> <p>Secondary: Mean baseline heart rates were 74.9, 75.6, 75.2, and 73.8 bpm for the combination, reserpine, clopamide, and nitrendipine groups. Heart rate measurements remained constant in the clopamide and nitrendipine groups and fell in the reserpine and reserpine-clopamide groups by 5.6 and 5.3 beats per minute, by week 12.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The percentages of patients with one or more adverse events experienced by week 12 were almost the same in the combination group versus the reserpine and clopamide monotherapy groups (27 vs 28 and 29%), whereas the incidence of adverse events was 48% in the nitrendipine group (P=0.01).</p> <p>The numbers of patients withdrawing from the study due to adverse experiences were two (3%) each in the reserpine-clopamide group and reserpine groups, five (7%) in the clopamide group, and nine (13%) in the nitrendipine group. Two serious events were investigator-determined as possibly drug related, resulting in study discontinuation; one in the clopamide group at six weeks (uterine bleeding) and one in the nitrendipine group at 12 weeks (tarry stools).</p> <p>The percentage of patients achieving goal DBP without an adverse events was 49% in the combination group, compared to 19, 20, and 12% in the reserpine, clopamide, and nitrendipine groups (P<0.0001).</p> <p>Body weight and electrocardiographic measurements did not change significantly in any group at 12 weeks compared to baseline.</p>
<p>Manyemba et al.¹⁸ (1997)</p> <p>Reserpine 0.25 mg plus HCTZ 25 mg QD</p> <p>vs</p> <p>nifedipine SR 20 mg BID plus HCTZ 25 mg QD</p>	<p>OL, RCT, XO</p> <p>African American patients aged 21 to 65 years with HTN (blood pressure >140/95 mm Hg) after 4 weeks of daily HCTZ therapy</p>	<p>N=32</p> <p>10 weeks</p>	<p>Primary: The change in blood pressure from baseline to the end of each 4-week treatment period</p> <p>Secondary: Not reported</p>	<p>Primary: Reserpine reduced SBP by 15.9 mm Hg (95% CI, 8.4 to 23.4) and DBP by 11.1 mm Hg (95% CI, 7.5 to 14.6).</p> <p>Nifedipine SR reduced SBP by 18.9 mm Hg (95% CI, 12.1 to 25.7) and DBP by 9.6 mm Hg (95% CI, 7.2 to 12.0).</p> <p>There was no significant difference between the two groups.</p> <p>Secondary: Not reported</p>
<p>Materson et al.¹⁹ (1990)</p> <p>Reserpine 0.05, 0.10 or 0.25 mg</p>	<p>DB, MC, RCT</p> <p>Men ≥60 years with HTN not currently receiving</p>	<p>N=690</p> <p>12 months</p>	<p>Primary: Average reduction in SBP, DBP, the number of patients achieving the goal</p>	<p>Primary: A total of 269 patients were uncontrolled with HCTZ therapy alone and were randomized to receive hydralazine (n=68), methyldopa (n=71), metoprolol (n=65), or reserpine (n=65).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD vs metoprolol 50, 100 or 200 mg BID vs hydralazine 25, 50 or 100 mg BID vs methyldopa 250, 500 or 1,000 mg BID</p> <p>All patients received HCTZ 25 to 100 mg QD.</p>	<p>antihypertensive therapy with a DBP 90 to 114 mm Hg and a SBP <240 mm Hg; or a DBP <100 mm Hg and a SBP <240 mm Hg if currently taking antihypertensive therapy and the blood pressure criteria was met after ≥2 weeks without medication</p>		<p>blood pressure and the average change in heart rate</p> <p>Secondary: Rates of drug intolerances and incidence of adverse effects</p>	<p>A total of 213 of the 269 patients achieved goal blood pressure with the addition of one of four therapies was added to HCTZ and entered the 6 month maintenance phase; 186 patients completed the maintenance phase.</p> <p>Across all four add-on therapies, there was an additional average reduction in blood pressure of 13.1/10.6 mm Hg. The average reduction in SBP (mm Hg)±SD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: -11.5±10.1 (P<0.001), -15.0±13.7 (P<0.001), -13.0±15.4 (P<0.001), and -12.7±11.5 (P<0.001), respectively. There was no statistically significant difference in SBP reductions among the different groups (P=0.43).</p> <p>The average reduction in DBP (mm Hg)±SD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: -11.3±5.9 (P<0.001), -10.6±6.3 (P<0.001), -10.6±6.7 (P<0.001), and -9.8±6.3 (P<0.001), respectively. There was no statistically significant difference in DBP reductions among the different groups (P=0.59).</p> <p>The average change in heart rate (beats per minute) ±SD from baseline to endpoint for hydralazine, methyldopa, metoprolol, and reserpine add-on therapies was: 1.4±10.5 (P value not significant), -1.6±9.3 (P value not significant), 15.9±11.9 (P<0.05), and -7.9±10.7 (P<0.05), respectively. There was a statistically significant difference in change in heart rate among the different groups (P<0.001).</p> <p>The percentage of patients achieving the goal blood pressure at endpoint in the hydralazine, methyldopa, metoprolol, and reserpine groups was: 85.3, 81.7, 76.9, and 72.3%, respectively (P=0.28).</p> <p>Secondary: Drug intolerance, defined as adverse effects prompting dose reduction or discontinuation, was present in 23.3% of those not achieving goal blood pressure compared to 2.8% of those achieving the goal blood pressure (P<0.001). This was statistically significant in the hydralazine, methyldopa, and metoprolol groups, but not the reserpine group.</p> <p>There were 27 (10%) study terminations due to adverse drug events:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>hydralazine (n=3), methyldopa (n=8), metoprolol (n=9), and reserpine (n=7). There were 2 study terminations in the methyldopa-treated group and 1 in the reserpine group due to depression.</p> <p>The overall incidence of volunteered moderate or severe adverse effects, not prompting study termination was significantly greater (P<0.01) with methyldopa (31%) and hydralazine (25%) compared to reserpine (15%) or metoprolol (9%).</p>
<p>VA Medical Centers²⁰ (1982)</p> <p>Reserpine 0.25 mg QD plus chlorthalidone 50 mg QD</p> <p>vs</p> <p>reserpine 0.125 mg QD plus chlorthalidone 50 mg QD</p> <p>vs</p> <p>reserpine 0.05 mg QD plus chlorthalidone 50 mg QD</p> <p>vs</p> <p>reserpine 0.125 mg QD plus chlorthalidone 25 mg QD</p>	<p>DB, MC, RCT</p> <p>Patients with mild to moderate HTN who did not achieve normal blood pressure with chlorthalidone therapy alone</p>	<p>N=329</p> <p>12 weeks</p>	<p>Primary: Changes in DBP and SBP readings and the percentage of patients achieving control at a DBP <90 mm Hg and ≥5 mm Hg below baseline</p> <p>Secondary: Side effects</p>	<p>Primary: The reduction in blood pressure (SBP/DBP) when reserpine was added to patient's chlorthalidone therapy averaged 11.0/10.4 mm Hg with chlorthalidone 50 mg plus reserpine 0.25 mg; 9.5/9.4 mm Hg with chlorthalidone 50 mg plus reserpine 0.125 mg; 6.4/8.5 mm Hg with chlorthalidone 50 mg plus reserpine 0.05 mg; and 9.9/9.6 mm Hg with chlorthalidone 25 mg plus reserpine 0.125 mg.</p> <p>The percentage of patients in whom control was achieved at DBP less than 90 mm Hg and at least 5 mm Hg below baseline with either chlorthalidone alone or in with reserpine was: 65% with chlorthalidone 50 mg plus reserpine 0.25 mg; 69% with chlorthalidone 50 mg plus reserpine 0.125 mg; 58% with chlorthalidone 50 mg plus reserpine 0.05 mg; and 56% with chlorthalidone 25 mg plus reserpine 0.125 mg.</p> <p>Secondary: Side effects of lethargy and impotence noted by patients with the 0.05 mg dose of reserpine were one third of the reports noted with the 0.25 mg dose. The incidence of other side effects did not differ.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>VA Cooperative Study²¹ (1977)</p> <p>Reserpine 35 mg plus HCTZ 35 mg (R+T)</p> <p>vs</p> <p>propranolol 40 to 160 mg TID (P), propranolol 40- to 160 mg TID plus HCTZ 35 mg (P+T), propranolol 40 to 160 mg TID plus hydralazine 35 mg (P+H), or propranolol 40 to 160 mg TID plus HCTZ 35 mg plus hydralazine 35 mg (P+T+H)</p>	<p>DB, RCT</p> <p>Men 18 to 59 years with DBP of 90 to 114 mm Hg</p>	<p>N=450</p> <p>18 months</p>	<p>Primary: Percent of patients who achieved a DBP <90 mm Hg at 6 months, heart rate, withdrawal rate</p> <p>Secondary: Not reported</p>	<p>Primary: At six months, significantly more patients in the R+T arm (88%) attained a DBP <90 mm Hg and ≥ 5 mm Hg less than the initial blood pressure compared to the P arm (52%; $P < 0.01$) and the P+H arm (72%; $P < 0.05$). The other arms: P+T (81%) and P+T+H (92%) were not significantly different than the R+T arm.</p> <p>The 12 and 18 month results do not have the statistical validity of the six months results due to the reduced sample size. The following percentage of patients attained DBP <90 mm Hg and ≥ 5 mm Hg less than the initial pressure: R+T=89.1 and 82.6%, P=59.5 and 58.1%, P+T=86.0 and 86.4%, P+H=67.4 and 76.1%, and P+T+H=89.4 and 91.8%.</p> <p>There was not a significance difference in heart rate reductions at six and 18 months between the groups (R+T=5.0\pm1.3 and 5.0\pm1.3 mean change in heart rate, P=9.1\pm1.3 and 9.2\pm1.8, P+T=8.8\pm1.2 and 6.3\pm1.5, P+H=8.9\pm1.3 and 7.8\pm1.5, and P+T+H=5.9\pm1.1 and 7.7\pm1.5).</p> <p>Withdrawals for any reason were similar between the treatment arms and were not statistically significant (R+T=14 patients, P=11, P+T=12, P+H=14, and P+T+H=16).</p>
<p>Kostis et al.²² (1995) SHEP</p> <p>Chlorthalidone 12.5 mg QD</p> <p>vs</p> <p>placebo</p> <p>If goal SBP was not achieved, the</p>	<p>DB, MC, PC, RCT</p> <p>Persons aged ≥ 60 years with isolated systolic HTN defined as a SBP 160 to 219 mm Hg and a DBP <90 mm Hg</p>	<p>N=4,736</p> <p>4.5 years (mean)</p>	<p>Primary: Total mortality, fatal and nonfatal stroke combined, CHD (fatal and nonfatal MI, sudden death, rapid death), cardiovascular disease (also including CHD and stroke)</p>	<p>Primary: There were 2,365 patients randomized to active treatment and 2,371 patients randomized to placebo, with a mean follow-up of 4.5 years. Of the 2,365 patients on active treatment, 193 (8%) received reserpine for an average of 1.7 years (at risk for 2.7 person-years after first exposure); of the 193 patients, 117 (61%) received reserpine for >1 year. Conversely, 757 (32%) were on atenolol with an average exposure of 2 years (at risk for 2,311 person years after first exposure).</p> <p>Incident stroke was observed in 103 patients in the active group and 159 patients in the placebo (RR, 0.64; 95% CI, 0.50 to 0.82). Nonfatal myocardial infarction or coronary heart disease deaths in the active group occurred in 104 patients and 141 in the placebo group (RR, 0.73; 95% CI,</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>dosage of chlorthalidone was increased to 25 mg QD or matching placebo. If goal SBP still not reached, atenolol 25 mg QD or matching placebo was added. Reserpine 0.05 to 0.1 mg QD or matching placebo was used if atenolol was contraindicated or if intolerable side effects with atenolol occurred.</p>			<p>Secondary: Not reported</p>	<p>0.57 to 0.94), while 289 cardiovascular disease events occurred in the active group compared to 414 in the placebo group (RR, 0.68; 95% CI, 0.58 to 0.79).</p> <p>After adjustments for multiple baseline covariates, the relative risks in the reserpine group were 0.65 (95% CI, 0.26 to 1.59) for death, 0.27 (95% CI, 0.04 to 2.26) for stroke, 0.93 (95% CI, 0.29 to 2.96) for coronary heart disease events, and 0.55 (95% CI, 0.20, 1.49) for cardiovascular disease events.</p> <p>The relative risks in the atenolol group after adjustments for multiple baseline covariates were 0.84 (95% CI, 0.54 to 1.30) for death, 1.34 (95% CI, 0.80 to 2.28) for stroke, 1.04 (95% CI, 0.58 to 1.87) for coronary heart disease events and 1.07 (95% CI, 0.71, 1.61) for cardiovascular disease events.</p> <p>Secondary: Not reported</p>
<p>Shamon et al.²³ (2009)</p> <p>Reserpine monotherapy</p> <p>vs</p> <p>placebo or no treatment</p>	<p>MA</p> <p>Patients with primary HTN</p>	<p>N=237 (4 trials)</p> <p>3 to 12 weeks</p>	<p>Primary: Changes in SBP and DBP</p> <p>Secondary: Changes in mean arterial blood pressure and heart rate</p>	<p>Primary: Three trials reported SBP and DBP data. The pooled effect showed a significant reduction in SBP in favor of reserpine compared to placebo (WMD, -7.92; 95% CI, -14.05 to -1.78). There was no significant difference in DBP between reserpine and placebo (WMD, -4.15; 95%CI, -9.19 to 0.90).</p> <p>Secondary: Three trials reported changes in MAP. The pooled effect showed a significant reduction in MAP with reserpine (WMD, -7.10; 95% CI, -11.81 to -2.38). However, there was significant heterogeneity across trials and this effect was no longer significant when random model effect was applied.</p> <p>Two trials reported changes in heart rate. The pooled effect showed a significant reduction in HR with reserpine (WMD, -8.82; 95% CI, -14.20 to -3.43, P=0.001). However, there was significant heterogeneity across trials and this effect was no longer significant when random model effect</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				was applied.
Psychotic States				
Berlant et al. ²⁴ (1986) Reserpine in combination with neuroleptics	RETRO Chronically disabled psychotic patients with symptoms refractory to lithium and neuroleptics	N=36 Duration not specified	Primary: The change in chronically persistent psychotic symptoms and functionality Secondary: Not reported	Primary: There was a moderate to dramatic response rate in 50% of the 36 chronically disabled psychotic patients with the addition of reserpine to neuroleptic and lithium therapies. The observed improvement was distinct compared to the baseline pattern of chronically persistent psychotic symptoms and poor functioning. Female patients and those with schizoaffective or bipolar disorders tended to respond best to treatment. Secondary: Not reported

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily, TID=three times daily

Study design abbreviations: AC=active comparator, DB=double blind, MA=meta-analysis, MC=multicenter, OL=open-label, PG=parallel-group, RCT=randomized controlled trial, RETRO=retrospective, SB=single blind, SR=systematic review, XO=cross over

Miscellaneous abbreviations: CHD=coronary heart disease, CI=confidence interval, DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HR=hazard ratio, HTN=hypertension, MAP=mean arterial pressure, MI=myocardial infarction, RR=relative risk, SBP=systolic blood pressure, SD=standard deviation, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 9. Relative Cost of the Peripheral Adrenergic Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Reserpine	tablet	N/A	N/A	\$\$

N/A=not available

X. Conclusions

Reserpine is approved for the treatment of mild hypertension as monotherapy, as well as adjunctive therapy in more severe forms of hypertension. Additionally, reserpine is approved for the treatment of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.¹⁻³ Reserpine is available in a generic formulation.

There are several national and international organizations that have published guidelines on the treatment of hypertension; however, they do not address the use of reserpine.⁴⁻¹⁴ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).⁶ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.⁴⁻¹⁴ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.⁶⁻¹³

Clinical trials have demonstrated that reserpine is effective for the treatment of hypertension when administered as monotherapy or as a second-line agent.¹⁵⁻²⁴ However, its use is associated with many adverse events, including depression, nasal congestion, and gastrointestinal symptoms.¹⁻³

Therefore, all brand peripheral adrenergic inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand peripheral adrenergic inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
3. Reserpine [package insert]. Princeton (NJ): Sandoz Inc; 2011 Oct.
4. Saseen JJ, MacLaughlin EJ. Chapter 3: Hypertension. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: a pathophysiologic approach*. 9th edition. New York (NY): McGraw-Hill; 2014. <http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&Sectionid=48811453>. Accessed March 19, 2015.
5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
6. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
8. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
9. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
10. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
11. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
12. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
13. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
14. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
15. Finnerty FA Jr. Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. *J Clin Pharmacol*. 1980;20(5-6 Pt 1):357-63.
16. Finnerty FA Jr, Gyftopoulos A, Berry C, McKenney A. Step 2 regimens in hypertension: an assessment. *JAMA*. 1979 Feb 9;241(6):579-81.
17. Krönig B, Pittrow DH, Kirch W, Welzel D, Weidinger G. Different concepts in first-line treatment of essential hypertension. *Hypertension*. 1997 Feb;29(2):651-8.
18. Manyemba J. A randomized crossover comparison of reserpine and sustained-release nifedipine in hypertension. *Cent Afr J Med*. 1997 Dec;43(12):344-9.
19. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes: results of a Department of Veterans Affairs cooperative study. *Hypertension*. 1990 Apr;15(4):348-60.
20. Low doses v standard dose of reserpine. A randomized, double-blind, multi clinic trial in patients taking chlorthalidone. *JAMA*. 1982 Nov 19;248(19):2471-7.
21. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol in the treatment of essential hypertension. *JAMA*. 1977 May 23;237(21):2303-10.
22. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). *Am J Hypertens* 1995;8(12 pt 1):1147-53.
23. Shamon SD, Perez MI. Blood pressure lowering efficacy of reserpine for primary hypertension. *Cochrane Database Syst Rev* 2009;(4):CD007655.

24. Berlant JL. Neuroleptics and reserpine in refractory psychoses. *J Clin Psychopharmacol.* 1986;6:180-4.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Hypotensive Agents, Miscellaneous
AHFS Class 240892
August 19, 2015**

I. Overview

Fenoldopam is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension in adults when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. In pediatric patients, fenoldopam is indicated for the in-hospital, short-term (up to four hours) reduction in blood pressure.¹

Mecamylamine was one of the first oral antihypertensive agents, introduced in the mid-1950s under the trade name Inversine[®]. It was withdrawn from the market in 2009 due to increased competition of antihypertensive drugs and decreasing use of the agent. In March 2013, mecamylamine was issued FDA approval and re-entered the market under the name of Vecamyl[®].^{2,3} Mecamylamine, a ganglionic blocker and secondary amine, inhibits acetylcholine at the autonomic ganglia. This causes blood vessel dilation and an increase in peripheral blood flow resulting in a decrease in blood pressure. Additionally, it blocks central nicotinic cholinergic receptors. Mecamylamine use has diminished due to its ganglionic side effects at antihypertensive doses.^{2,4,5}

The miscellaneous hypotensive agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. This class was last reviewed in May 2013.

Table 1. Miscellaneous Hypotensive Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Fenoldopam	injection [^]	Corlopam [®]	none
Mecamylamine	tablet	Vecamyl [®]	none

*Generic is available in at least one dosage form or strength.
[^]Product is primarily administered in an institution.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

The miscellaneous hypotensive agents are not included in the treatment guidelines and there are no specific recommendations for this drug.

III. Indications

Food and Drug Administration (FDA)-approved indications for the miscellaneous hypotensive agents are listed in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Miscellaneous Hypotensive Agents⁴

Indication	Mecamylamine
Management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.	✓

IV. Pharmacokinetics

The pharmacokinetic parameters for miscellaneous hypotensive agents are summarized in Table 4.

Table 3. Pharmacokinetic Parameters of the Miscellaneous Hypotensive Agents⁵

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Elimination (%)	Half-life (hours)	Active Metabolites
Mecamylamine	Not reported*	Not reported	Renal (100)	24	Not reported

*It is noted that mecamylamine is readily absorbed from the gastrointestinal tract

V. Drug Interactions

There are no reported drug interactions of major or moderate significance with the miscellaneous hypotensive agent, mecamylamine, although the package insert states that patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.^{4,6} Additionally, the action of mecamylamine may be amplified by anesthesia, other antihypertensive agents, and alcohol. The mechanism of these interactions and specific drug agents are not specified.⁴

VI. Adverse Drug Events

The most common adverse reactions reported with the miscellaneous hypotensive agents are noted in Table 5.

Table 5. Adverse Events (%) Reported with the Miscellaneous Hypotensive Agents⁴

Adverse Events	Mecamylamine
Cardiovascular	
Orthostatic dizziness	✓
Postural hypotension	✓
Syncope	✓
Central Nervous System	
Choreiform movements	✓
Convulsions	✓
Mental aberrations	✓
Paresthesias	✓
Tremor	✓
Gastrointestinal	
Anorexia	✓
Constipation	✓
Dry mouth	✓
Glossitis	✓
Ileus	✓
Nausea	✓
Vomiting	✓
Respiratory	
Fibrosis	✓
Interstitial pulmonary edema	✓
Urogenital	
Decreased libido	✓
Impotence	✓
Urinary retention	✓
Other	
Blurred vision	✓
Dilated pupils	✓
Fatigue	✓

Sedation	✓
Weakness	✓

VII. Dosing and Administration

The usual dosing regimens for the miscellaneous hypotensive agents are summarized in Table 6.

Table 6. Usual Dosing for the Miscellaneous Hypotensive Agents⁴

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Mecamylamine	Management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension: Tablet: initial, 2.5 mg twice daily (titrate in increments of 2.5 mg with at least 2 day intervals); average, 25 mg daily, in 3 divided doses (some patients may respond to as little as 2.5 mg daily; however, some patients may require 2 to 4 doses or greater in severe cases when consistent control is difficult to achieve); partial tolerance may develop requiring daily dosage increases	Safety and effectiveness has not been established.	Tablet: 2.5 mg

VIII. Effectiveness

A thorough literature search from 1966 to the present failed to retrieve any clinical studies evaluating the safety and effectiveness of mecamylamine for the treatment of hypertension. The initial clinical trials were conducted in the 1950s. These trials established the drug's efficacy and side effect profile in patients with severe hypertension.²

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Miscellaneous Hypotensive Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Mecamylamine	tablet	Vecamyl [®]	\$\$\$\$\$	N/A

*Generic is available in at least one dosage form or strength.

N/A=not available

X. Conclusions

Although the clinical literature reports that mecamylamine is effective for the management of moderate-to-severe hypertension, its clinical utility is minimal due to its adverse events profile and the availability of newer and more effective agents. Current hypertension treatment guidelines do not mention mecamylamine as a first-line or alternative agent for the treatment of hypertension. Therefore, all brand miscellaneous hypotensive agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand miscellaneous hypotensive agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine cost effective products and possibly designate one or more preferred brands.

XII. References

1. Corlopan® [package insert]. Lake Forest (IL): Hospira, Inc.; 2005 Mar.
2. Young JM, Shytle RD, Sanberg PR, George TP. Mecamylamine: new therapeutic uses and toxicity/risk profile. *Clin Ther.* 2001 Apr;23(4):532-65.
3. Manchester Announces FDA Approval of Vecamyl™ [press release on the Internet]. Fort Collins (CO): Manchester Pharmaceuticals; 2013 May 1 [cited 2015 Mar 25]. Available from: <http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=487170§ionID=&isEPVantage=no>
4. Vecamyl® [Package Insert]. Fort Collins (CO): Manchester Pharmaceuticals, Inc.; 2012 Sep.
5. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
6. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Alpha-Adrenergic Blocking Agents
AHFS Class 242000
August 19, 2015**

I. Overview

The alpha-adrenergic blocking agents are approved for the treatment of benign prostatic hyperplasia (BPH) and hypertension.¹⁻⁶ However, the use of these agents for the treatment of hypertension is somewhat limited due to adverse events. They can cause postural hypotension, reducing the standing systolic blood pressure by more than 10 mm Hg. Syncope with sudden loss of consciousness can also occur, especially with the first few doses, rapid dose increases, or the addition of another antihypertensive agent to the treatment regimen. Unlike diuretics and beta-adrenergic blocking agents, alpha-adrenergic blocking agents do not adversely affect lipids. They have been shown to reduce total cholesterol by 3 to 5% and triglycerides by 3 to 4%, as well as increase high-density lipoprotein cholesterol.⁷ The alpha-adrenergic blocking agents are more commonly used to relieve symptoms of BPH, which is characterized by an enlargement of the prostate gland. BPH is associated with lower urinary tract symptoms, such as frequent daytime urination, nocturia, a sensation of incomplete bladder emptying, and a hesitant, weak, or intermittent urinary stream.^{8,9}

The alpha-adrenergic blocking agents competitively inhibit postsynaptic α_1 -adrenergic receptors, which are classified into three subtypes: α_{1A} , α_{1B} , and α_{1D} .¹⁰⁻¹³ These receptors are located in the smooth muscle cell membrane of the peripheral blood vessels, as well as in various nonvascular smooth muscle and non-muscular tissues.¹¹⁻¹⁵ The alpha-adrenergic blocking agents lower blood pressure by acting peripherally to dilate the blood vessels. They also cause rapid relaxation of smooth muscle in the bladder neck, prostate capsule, and prostatic urethra.^{14,16}

The alpha-adrenergic blocking agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Alpha-Adrenergic Blocking Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Doxazosin	extended-release tablet, tablet	Cardura ^{®*} , Cardura XL [®]	doxazosin
Prazosin	capsule	Minipress ^{®*}	prazosin
Terazosin	capsule	N/A	terazosin

*Generic is available in at least one dosage form or strength.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the alpha-adrenergic blocking agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Alpha-Adrenergic Blocking Agents

Clinical Guideline	Recommendations
Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. In patients < 60 years of age, pharmacologic treatment should be initiated to

Clinical Guideline	Recommendations
(2014)¹⁷	<p>lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg.</p> <ul style="list-style-type: none"> • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹⁸	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁹, Reappraisal of Guidelines on Hypertension Management (2009)²⁰	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone

Clinical Guideline	Recommendations
	<p>antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers,

Clinical Guideline	Recommendations
(2013) ²¹	<p>calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations.</p> <ul style="list-style-type: none"> • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial

Clinical Guideline	Recommendations
	<p>infarction, stroke, heart failure, and CV death.</p> <ul style="list-style-type: none"> Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)²²</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> Patients with an intolerance or contraindication to ACE inhibitors and ARBs. Women of child-bearing potential. People with evidence of increased sympathetic drive. If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> Consider further diuretic therapy with low-dose spironolactone. Consider higher-dose thiazide-like diuretic treatment. If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)²³</p>	<ul style="list-style-type: none"> To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. In secondary prevention patients, the combination therapy should include a

Clinical Guideline	Recommendations
	<p>drug(s) with the appropriate compelling indications.</p> <ul style="list-style-type: none"> • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)²⁴</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)²⁵</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated

Clinical Guideline	Recommendations
	<p>with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²⁶</p>	<p>Hypertension/blood pressure control</p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p>Nephropathy</p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) and is recommended for those with urinary albumin excretion >300 mg/day. When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in

Clinical Guideline	Recommendations
<p>American Urological Association: Update on American Urological Association Guideline on Management of Benign Prostatic Hyperplasia (2011)⁸</p> <p>(Reviewed 2014)</p>	<p>potassium.</p> <p><u>Watchful waiting</u></p> <ul style="list-style-type: none"> • Patients with mild symptoms of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and patients with moderate or severe symptoms who are not bothered by their LUTS should be managed using a strategy of watchful waiting. <p><u>Medical management</u></p> <ul style="list-style-type: none"> • Alfuzosin, doxazosin, tamsulosin, and terazosin are appropriate and effective treatments for patients with bothersome, moderate to severe LUTS secondary to BPH. Although slight differences in adverse events profiles exist among these agents, all four appear to have equal clinical effectiveness. Although head-to-head trials comparing these agents are currently lacking, the available data support this contention. There were no published studies on silodosin in peer-reviewed literature prior to the cut-off date for the literature search for this guideline. • The older, less costly, generic α-adrenergic blocking agents remain reasonable choices. These agents require dose titration and blood pressure monitoring. • As prazosin and the nonselective α-adrenergic blocking agent phenoxybenzamine were not reviewed in the course of this guideline revision, the 2003 guideline statement indicating that the data were insufficient to support a recommendation for the use of these two agents as treatments for LUTS secondary to BPH remains true. • The combination of an α-adrenergic blocking agent and a 5α-reductase inhibitor is an appropriate and effective treatment for patients with LUTS associated with demonstrable prostatic enlargement based on volume measurement, prostate specific antigen level as a proxy for volume and/or enlargement on digital rectal exam. • Men with LUTS secondary to BPH and with planned cataract surgery should avoid the initiation of α-adrenergic blocking agent until the completion of cataract surgery. • 5α-reductase inhibitors may be used to prevent progression of LUTS secondary to BPH and to reduce the risk of urinary retention and future prostate-related surgery. • 5α-reductase inhibitors should not be used in men with LUTS secondary to BPH without prostatic enlargement. • 5α-reductase inhibitors are an appropriate and effective treatment for men with LUTS secondary to BPH who have demonstrable prostate enlargement. • Finasteride is an appropriate and effective treatment in men with refractory hematuria presumably due to prostatic bleeding. Dutasteride may also be an effective agent based on expert opinion. • There is insufficient evidence to recommend using 5α-reductase inhibitors preoperatively for the prevention of bleeding during transurethral resection of the prostate. • Anticholinergic agents are an appropriate and effective treatment for the management of LUTS secondary to BPH in men without an elevated post-void residual volume and when LUTS are predominantly irritative. • Prior to initiation of an anticholinergic, baseline post-void residual urine should be assessed; use with caution in patients with a volume >250 to 300 mL. • No dietary supplement, combination phytotherapeutic agent or other nonconventional therapy is recommended for the management of LUTS secondary to BPH. • At this time, the available data do not suggest that saw palmetto has a clinically meaningful effect on LUTS secondary to BPH.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> The paucity of published, high quality, single extract clinical trials of Urtica dioica do not provide a sufficient evidence base with which to recommend for or against its use for the treatment of LUTS secondary to BPH.
<p>European Association of Urology: Guideline on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), including Benign Prostatic Obstruction (BPO) (2015)⁹</p>	<p>Conservative treatments of male LUTS</p> <ul style="list-style-type: none"> Men with mild symptoms are appropriate for watchful waiting. Watchful waiting should consist of education, reassurance, periodic monitoring and lifestyle advice. Men with LUTS should always be offered lifestyle advice prior to or concurrent with treatment. <p>Pharmacological management</p> <ul style="list-style-type: none"> α-adrenergic blocking agents should be offered to men with moderate to severe LUTS. 5α-reductase inhibitors should be offered to men who have moderate to severe LUTS and an enlarged prostate. 5α-reductase inhibitors can prevent disease progression with regard to acute urinary retention and need for surgery. Muscarinic receptor antagonists may be used in men with moderate to severe LUTS who have predominantly bladder storage symptoms; however, caution is advised in men with bladder outlet obstruction. Phosphodiesterase 5 inhibitors reduce moderate to severe LUTS in men with or without erectile dysfunction. The Guidelines Panel has not made any specific recommendations on phytotherapy for the treatment of male LUTS because of product heterogeneity, limited regulatory framework, and methodological limitations of the published trials and meta-analyses. Vasopressin analogue (desmopressin) can be used for the treatment of nocturia due to nocturnal polyuria. Combination treatment with an α-adrenergic blocking agent and a 5α-reductase inhibitor can be offered to men with troublesome moderate-to-severe LUTS, enlarged prostate, and reduced Qmax (men likely to develop disease progression). Combination treatment with an α-adrenergic blocking agent and a muscarinic receptor antagonist may be considered in patients with troublesome moderate to severe LUTS if symptom relief has been insufficient with the monotherapy of either drug; however, caution is warranted in men with bladder outlet obstruction.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the alpha-adrenergic blocking agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Alpha-Adrenergic Blocking Agents³⁻⁶

Indication	Doxazosin	Prazosin	Terazosin
Benign Prostatic Hyperplasia			
Treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with benign prostatic hyperplasia	✓ * (immediate-release)		
Treatment of signs and symptoms of benign prostatic hypertension	✓ (extended-release)		
Treatment of symptomatic benign prostatic hyperplasia			✓

Indication	Doxazosin	Prazosin	Terazosin
Hypertension			
Treatment of hypertension	✓ † (immediate-release)	✓ †	✓ †

*May be used in all benign prostatic hyperplasia patients whether hypertensive or normotensive. In patients with hypertension and benign prostatic hyperplasia, both conditions were effectively treated with doxazosin monotherapy.

†Alone or in combination with other antihypertensive agents.

IV. Pharmacokinetics

The pharmacokinetic parameters of the alpha-adrenergic blocking agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Alpha-Adrenergic Blocking Agents²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Doxazosin	IR: 65 ER: 54 to 59	98	Liver, extensive (% not reported)	Renal (9) Feces (63)	IR: 22 ER: 15 to 19
Prazosin	56 to 63	92 to 97	Liver, extensive (% not reported)	Renal (<1) Feces, extensive (% not reported)	2 to 3
Terazosin	90	90 to 94	Liver, extensive (% not reported)	Renal (40) Feces (55 to 60)	9 to 12

ER=extended-release, IR=immediate-release

V. Drug Interactions

Significant drug interactions with the alpha-adrenergic blocking agents are listed in Table 5.

Table 5. Significant Drug Interactions with the Alpha-Adrenergic Blocking Agents¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Alpha-adrenergic blocking agents (doxazosin, prazosin, terazosin)	2	Phosphodiesterase type 5 Inhibitors	Hypotension may occur when alpha blockers and phosphodiesterase type 5 inhibitors are co-administered. Alpha blockers and phosphodiesterase type 5 inhibitors may exert additive pharmacologic activity.
Alpha-adrenergic blocking agents (prazosin)	2	β-blockers	Unknown mechanism. Postural hypotension may be increased with concurrent therapy.
Alpha-adrenergic blocking agents (prazosin)	2	Verapamil	Unknown mechanism. Verapamil may increase serum prazosin concentration and increase sensitivity to prazosin-induced postural hypotension.

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the alpha-adrenergic blocking agents are listed in Table 6. These agents can cause marked hypotension and syncope with sudden loss of consciousness with the first few doses. This “first-dose” effect can be minimized by administration of the first dose at bedtime. Hypotension and

syncope can also occur with dose increases, addition of other antihypertensives, and therapy interruptions. The elderly are more at risk for this adverse reaction.

Table 6. Adverse Drug Events (%) Reported with the Alpha-Adrenergic Blocking Agents¹⁻⁶

Adverse Events	Doxazosin	Prazosin	Terazosin
Cardiovascular			
Angina	<1	✓	-
Arrhythmia	1	-	<1
Atrial fibrillation	-	-	<1
Bradycardia	<1	✓	-
Chest pain	1 to 2	-	<1
Edema	3 to 4	1 to 4	-
Flushing	1	✓	-
Hypotension	1 to 2	✓	-
Myocardial infarction	<1	-	-
Orthostatic hypotension	<2	1 to 4	1 to 4
Palpitations	1 to 2	5	≤4
Peripheral edema	-	-	1 to 6
Peripheral ischemia	<1	-	-
Syncope	1 to 2	1 to 4	≤1
Tachycardia	<1	<1	≤2
Vasodilation	-	-	<1
Central Nervous System			
Abnormal thinking	<1	-	-
Agitation	<1	-	-
Amnesia	<1	-	-
Anxiety	1	-	<1
Ataxia	1	-	-
Cerebrovascular accident	<1	-	-
Confusion	<1	-	-
Decreased energy	-	7	-
Depersonalization	<1	-	-
Depression	1	1 to 4	-
Dizziness	5 to 19	10	9 to 19
Drowsiness	-	8	-
Emotional lability	<1	-	-
Fatigue	8 to 12	-	-
Fever	<1	-	<1
Hallucinations	-	<1	-
Headache	5 to 14	8	-
Hypertonia	1	-	-
Insomnia	1	✓	<1
Kinetic disorders	1	-	-
Migraine	<1	-	-
Nervousness	2	1 to 4	-
Paranoia	<1	-	-
Paresis	<1	-	-
Paresthesia	<1	<1	≤3
Somnolence	1 to 5	-	4 to 5
Stroke	<1	-	-
Vertigo	2 to 4	1 to 4	1
Dermatological			
Alopecia	-	<1	-
Lichen planus	-	<1	-
Pallor	<1	-	-

Adverse Events	Doxazosin	Prazosin	Terazosin
Rash	1	1 to 4	<1
Pruritus	1	<1	<1
Urticaria	<1	<1	-
Endocrine and Metabolic			
Breast pain	<1	-	-
Gout	<1	-	<1
Gynecomastia	<1	✓	-
Pancreatitis	-	<1	-
Gastrointestinal			
Abdominal pain	2	<1	<1
Anorexia	<1	-	-
Appetite decreased	<1	-	-
Cholestasis	<1	-	-
Constipation	1	1 to 4	<1
Diarrhea	2	1 to 4	<1
Dyspepsia	1 to 2	-	<1
Fecal incontinence	<1	-	-
Flatulence	1	-	<1
Gastroenteritis	<1	-	-
Nausea	1 to 3	5	2 to 4
Vomiting	<1	1 to 4	<1
Xerostomia	2	1 to 4	<1
Genitourinary			
Hematuria	<1	-	-
Impotence	1	<1	≤2
Libido decreased	-	-	<1
Micturition abnormality	<1	-	-
Nocturia	<1	-	-
Polyuria	2	-	<1
Priapism	<1	<1	<1
Renal calculus	<1	-	-
Sexual dysfunction	2	-	-
Urinary frequency	-	1 to 4	-
Urinary incontinence	1	<1	<1
Urinary tract infection	1	-	<1
Hematologic			
Leukopenia	<1	-	-
Neutropenia	<1	-	-
Purpura	<1	-	-
Thrombocytopenia	<1	-	<1
Hepatic			
Jaundice	<1	-	-
Liver function tests increased	<1	<1	-
Laboratory Test Abnormalities			
Hypokalemia	<1	-	-
Musculoskeletal			
Arthralgia	1	✓	<1
Arthritis	1	-	<1
Back pain	2 to 3	-	≤2
Extremity pain	-	-	<1
Joint disorder	-	-	<1
Muscle cramps	1	-	-
Muscle weakness	1	-	7 to 11
Myalgia	1	-	<1

Adverse Events	Doxazosin	Prazosin	Terazosin
Neck pain	-	-	<1
Pain	2	✓	-
Shoulder pain	-	-	<1
Weakness	<1	7	-
Respiratory			
Bronchitis	-	-	<1
Bronchospasm	<1	-	-
Cough	-	-	<1
Dyspnea	1 to 3	1 to 4	2 to 3
Epistaxis	1	1 to 4	<1
Hepatitis	<1	-	-
Nasal congestion	-	1 to 4	2 to 6
Pharyngitis	-	-	<1
Respiratory disorder	1	-	-
Respiratory tract infection	5	-	-
Rhinitis	3	-	<1
Sinusitis	-	-	≤3
Special Senses			
Abnormal vision	1 to 2	-	<1
Blurred vision	-	1 to 4	≤2
Cataracts	-	<1	-
Conjunctivitis	1	-	<1
Hypoesthesia	<1	-	-
Intraoperative floppy iris syndrome	<1	<1	<1
Pigmentary mottling and serous retinopathy	-	<1	-
Sclera reddened	-	1 to 4	-
Tinnitus	1	<1	<1
Parosmia	<1	-	-
Other			
Allergic reaction	<1	✓	<1
Anaphylaxis	-	-	<1
Diaphoresis	1	✓	<1
Facial edema	1	-	<1
Infection	<1	-	-
Influenza-like symptoms	1	-	≤2
Lymphadenopathy	<1	-	-
Rigors	<1	-	-
Vasculitis	-	✓	-

✓ Percent not specified
- Event not reported

VII. Dosing and Administration

The usual dosing regimens for the alpha-adrenergic blocking agents are listed in Table 7. Treatment should be initiated at bedtime and at the lowest dose to minimize the likelihood of the “first-dose” effect. Dosages should be titrated up slowly to achieve the desired response. If therapy is interrupted for more than a few days, the initial dosing regimen and titration schedule should be reinstated. Other antihypertensive agents should be added cautiously to reduce the risk of developing significant hypotension.¹⁻⁶

Table 7. Usual Dosing Regimens for the Alpha-Adrenergic Blocking Agents¹⁻⁶

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Doxazosin	<u>Benign prostatic hyperplasia:</u> Extended-release: initial, 4 mg once	Safety and efficacy in children have not been	Extended-release tablet:

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>daily; maintenance, 4 to 8 mg daily; maximum, 8 mg/day</p> <p>Tablet: initial, 1 mg once daily; maintenance, 1 to 8 mg once daily; maximum, 8 mg/day</p> <p><u>Hypertension:</u> Tablet: initial, 1 mg once daily; maintenance, 1 to 16 mg once daily; maximum, 16 mg/day</p>	<p>established.</p>	<p>4 mg 8 mg</p> <p>Tablet: 1 mg 2 mg 4 mg 8 mg</p>
Prazosin	<p><u>Hypertension:</u> Capsule: initial, 1 mg two to three times a day; maintenance, 6 to 15 mg/day in divided doses; maximum, 40 mg/day</p>	<p>Safety and efficacy in children have not been established.</p>	<p>Capsule: 1 mg 2 mg 5 mg</p>
Terazosin	<p><u>Benign prostatic hyperplasia:</u> Capsule: initial, 1 mg at bedtime; maintenance, 1 to 10 mg/day; maximum, 20 mg/day</p> <p><u>Hypertension:</u> Capsule: initial, 1 mg at bedtime; maintenance, 1 to 20 mg once daily; maximum, 20 mg/day</p>	<p>Safety and efficacy in children have not been established.</p>	<p>Capsule: 1 mg 2 mg 5 mg 10 mg</p>

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the alpha-adrenergic blocking agents are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Alpha-Adrenergic Blocking Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Benign Prostatic Hyperplasia				
<p>Lee et al.²⁷ (2011)</p> <p>α-adrenergic blocking agent</p> <p>vs</p> <p>no α-adrenergic blocking agent</p> <p>All patients were receiving finasteride.</p> <p>Patients were divided into 2 groups based on treatment pattern (α-adrenergic blocking agent monotherapy vs α-adrenergic blocking agent combined with finasteride) and further divided into 4 subgroups based on severity of storage symptoms (IPSS</p>	<p>MC, RETRO</p> <p>Patients ≥ 50 years of age with LUTS consistent with moderate to severe BPH</p>	<p>N=1315</p> <p>4 years</p>	<p>Primary: Prostate volume, PSA, IPSS, Q_{max}</p> <p>Secondary: Not reported</p>	<p>Primary: All groups showed significant improvements in IPSS total scores, IPSS voiding subscores and QOL at one year (P values not reported). Total IPSS from baseline to year four decreased by -11.5 in group IV compared to -0.18 in group I (P<0.001), -6.1 in group II (P=0.97) and -2.6 in group III (P=0.031). However, IPSS storage subscores only improved in patients with high (≥ 6) storage subscores at baseline (P value not reported). After one year, prostate volume and PSA were reduced by 21.3 and 47.0%, respectively, in the combination groups compared to an increase of 9 and 18%, respectively, in the monotherapy groups (P<0.001 for both).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>storage domain score ≥ 6 vs < 6).</p> <p>Group I was classified as monotherapy and storage scores < 6, group II as monotherapy and storage scores ≥ 6, group III as combination therapy and storage scores < 6 and group IV as combination therapy and storage scores ≥ 6.</p>				
<p>Demir et al.²⁸ (2009)</p> <p>Doxazosin 4 mg QD</p> <p>Patients were grouped into 2 groups according to self-reported erectile status: patients who reported the presence of erectile dysfunction (group I) and patients who reported the absence of erectile dysfunction (group</p>	<p>RETRO</p> <p>Males > 40 years of age who had been in a steady sexual relationship for the past 6 months and were admitted to urology clinics with complaints of BPH</p>	<p>N=64</p> <p>6 weeks</p>	<p>Primary: Not reported</p> <p>Secondary: Not reported</p>	<p>Primary Endpoints: Not reported</p> <p>Secondary Endpoints: Not reported</p> <p>Mean reductions in total IPSS and quality of life compared to baseline were -7.7 ± 6.1 and 1.5 ± 1.5 ($P=0.006$ and $P=0.024$, respectively). Treatment with doxazosin also resulted in significant improvements in Q_{max} over baseline (3.2 ± 4.6 mL/s; $P=0.002$). Both groups exhibited significant improvements in IPSS and quality of life scores over baseline ($P < 0.001$ for both). Improvements in LUTS appeared to be numerically greater in group II; however, quality of life was the only parameter for which a significant improvement was seen compared to group I (-1.0 ± 1.8 vs -1.9 ± 1.1, for groups I and II respectively; $P=0.018$).</p> <p>Mean International Index of Erectile Function erectile function domain scores increased in group I and slightly decreased in group II when compared to baseline. Mean changed of other International Index of</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
II)				<p>Erectile Function domains were not significant in either group. When stratified according to erectile dysfunction severity, the mean changes in International Index of Erectile Function erectile function domain scores over baseline were: 4.3 ± 6.0, 0.3 ± 5.3, -1.2 ± 1.6 in those participants with severe, moderate, and mild erectile dysfunction, respectively.</p> <p>No serious adverse events were observed during the treatment course in either group.</p>
<p>Sun et al.²⁹ (abstract) (2010)</p> <p>Doxazosin SR 4 mg QD</p> <p>At week 4, subjects who achieved an increase in $Q_{max} \geq 3$ mL/s and a $\geq 30\%$ reduction in the total IPSS continued on doxazosin SR 4 mg for the remaining 4 weeks; all other subjects were titrated up to 8 mg QD.</p>	<p>OL, PM</p> <p>Taiwanese males with BPH</p>	<p>N=80</p> <p>8 weeks</p>	<p>Primary: Change from baseline Q_{max} and IPSS</p> <p>Secondary: Safety</p>	<p>Primary Endpoints: Baseline Q_{max} and IPSS were 10.7 ± 3.4 mL/s and 20.6 ± 5.4, respectively. At week eight, a significant increase from baseline in Q_{max} of 3.3 ± 4.6 mL/s (95% CI, 2.2 to 4.4, $P < 0.001$) and a significant decrease in total IPSS of -8.9 ± 7.0 (95% CI, -10.5 to -7.3; $P < 0.001$) was observed.</p> <p>Secondary Endpoints: The most common treatment-related adverse event was dizziness.</p>
<p>Kirby et al.³⁰ (2001)</p> <p>Doxazosin vs</p>	<p>2 DB, MC, PG, RCT</p> <p>Men 50 to 80 years of age with BPH</p>	<p>N=1,475</p> <p>17 weeks</p>	<p>Primary: Change from baseline in IPSS and Q_{max}</p> <p>Secondary: Sexual function,</p>	<p>Primary: A 45% significant decrease from baseline in IPSS was attained with both formulations of doxazosin compared to a 34% decrease with placebo after 13 weeks ($P < 0.001$ vs placebo). Doxazosin SR was as effective as doxazosin in improving IPSS with a least squares mean difference of 0.07 (SEM, 0.28; 95% CI, -0.47 to 0.61; $P = 0.799$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>doxazosin SR</p> <p>vs</p> <p>placebo</p> <p>Comparison with placebo was evaluated in 1 of the 2 trials.</p>			<p>tolerability</p>	<p>Effect on Q_{max} was also comparable between the two doxazosin formulations; a least square mean difference of 0.19 (SEM, 0.23; 95% CI, -0.27 to 0.64; P=0.426) was reported. The improvements were significantly greater compared to placebo (P<0.001 for both).</p> <p>Secondary: Only the non-PC trial evaluated sexual function. Both formulations of doxazosin demonstrated modest but significant improvements in sexual function from baseline as measured by the IIEF (P≤0.001 for doxazosin SR and P<0.05 for doxazosin).</p> <p>Forty one percent of patients receiving doxazosin SR, 54% of patients receiving doxazosin and 39% of patients receiving placebo experienced adverse events (P<0.001 for differences among treatments). Headache, dizziness, respiratory tract infections and asthenia were the most frequently reported side effects of active treatment.</p>
<p>Keten et al.³¹ (2015)</p> <p>Doxazosin XL 4 mg (group 1)</p> <p>vs</p> <p>doxazosin XL 8 mg (group 2)</p> <p>Patients with an inadequate response to 4 mg treatment were switched to 8 mg after one month (group 1b)</p>	<p>PRO</p> <p>Patients aged >45 years, with a total PSA <4 ng/mL, IPSS of >7, and Q_{max} ≤15 mL/s</p>	<p>N=162</p> <p>4 months</p>	<p>Primary: IPSS, Q_{max}, quality of life (QoL) score</p> <p>Secondary: Not reported</p>	<p>Primary: From the time of presentation to the first month follow-up, the IPSS and QoL values had decreased more in group 2 compared with group 1 (P_{IPSS}=0.028, P_{Q_{max}}=0.206, P_{QoL}=0.038, and P_{PVR}=0.070).</p> <p>The comparison of the patients in Group 1b who used 4 and 8 mg doxazosin XL for one month showed that during the use of 4 mg doxazosin XL, the change in the IPSS was 1.3 ± 1.3 units, and during the use of 8 mg doxazosin XL, the change was 3.6 ± 2.5 units (P<0.001). The change in the Q_{max} values for 4 and 8 mg doxazosin XL was found to be 1.6 ± 1.8 and 3.2 ± 2.7 mL/s, respectively (P=0.019). For the 4 mg doxazosin XL, the QoL values increased by 0.4 ± 0.6 units, and during the use of 8 mg doxazosin XL, the QoL values decreased by 1.8 ± 0.7 units (P<0.001).</p> <p>No difference was found concerning the adverse reactions between the groups (P>0.05).</p> <p>Secondary: Not reported</p>
<p>Samli et al.³²</p>	<p>RCT, XO</p>	<p>N=50</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2004) Doxazosin 8 mg QD vs terazosin 10 mg QD	Men with LUTS associated with BPH	3 months	Change from baseline in IPSS and Qmax Secondary: Not reported	The proportion of patients who showed improvement in both IPSS and Qmax were 44 and 40% of patients receiving doxazosin and Terazosin, respectively. After three months, both treatments resulted in a significantly increased Qmax (P<0.001) and a significantly decreased IPSS (P<0.01). The number of patients who did not show improvement and had to switch to the other treatment was 19. Of these patients, two showed improvement in both IPSS and Qmax, two showed improvement in IPSS only and 15 did not show any improvement. Secondary: Not reported
Kaplan et al. ³³ (1997) Doxazosin 4 to 8 mg QD vs terazosin 5 to 10 mg QD	OL, PRO Men >80 years of age with BPH	N=36 6 months	Primary: Change from baseline in Qmax and AUA SS Secondary: Not reported	Primary: There was significant improvement in Qmax (P<0.008) and AUA SS (P<0.01) with both treatments. There were small, nonsignificant decreases in blood pressure with both treatments. Secondary: Not reported
Kaplan et al. ³⁴ (1995) Doxazosin 4 mg QD in the morning vs doxazosin 4 mg QD in the evening vs terazosin 5 mg QD in the morning	RCT Men without HTN and symptomatic prostatism	N=43 4 to 17 months	Primary: Changes from baseline in Boyarsky symptom score, Qmax and blood pressure; adverse events Secondary: Not reported	Primary: There were significant improvements in Boyarsky symptom scores and Qmax with all four treatments (P<0.05), with no significant differences between the treatments (P values not reported). Adverse events were significantly decreased with evening doses (P<0.05). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs terazosin 5 mg QD in the evening				
Bozlu et al. ³⁵ (2004) Doxazosin 4 mg QD vs terazosin 5 mg QD vs alfuzosin 2.5 mg TID vs tamsulosin 0.4 mg QD	RETRO Patients with LUTS suggestive of BPH with and without diabetes	N=281 6 months	Primary: Change from baseline in IPSS, bother score, Qmax and PVR Secondary: Not reported	Primary: Doxazosin, terazosin and alfuzosin significantly improved IPSS, bother scores, Qmax and PVR compared to baseline (P<0.001). IPSS and bother scores were significantly improved in diabetic patients compared to nondiabetic patients (P<0.01). There was no significant differences among the treatments in the improvement rates of any of the parameters (P>0.05). Secondary: Not reported
Xue et al. ³⁶ (2007) Doxazosin SR 4 mg QD vs tamsulosin 0.2 mg QD	RCT Chinese men with confirmed BPH	N=117 8 weeks	Primary: Efficacy, safety Secondary: Not reported	Primary: Both treatments significantly improved the IPSS (total, irritative subscore, and obstructive subscore; P=0.001 for all) and Qmax (P=0.001). Other differences between groups were not statistically significant. Secondary: Not reported
Rahardjo et al. ³⁷ (2006)	MC, OL, RCT Patients with LUTS	N=101 6 weeks	Primary: Changes from baseline in IPSS,	Primary: The total IPSS decreased significantly with both tamsulosin and doxazosin compared to baseline (P<0.001), with tamsulosin being associated with a

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Doxazosin 2 mg QD vs tamsulosin 0.2 mg QD	due to BPH		Qmax, average urinary flow rate and residual urine; safety Secondary: Not reported	significant decrease compared to doxazosin (P=0.036). Qmax, average urinary flow rate and residual urine significantly improved with tamsulosin only (P<0.001, P<0.001, and P<0.05, respectively). There were no significant differences in SBP or DBP with tamsulosin; however, doxazosin resulted in significant differences in SBP (P<0.01) but not in DBP (P value not reported) at the end of the study. Tamsulosin was well tolerated; only three patients (six percent) receiving tamsulosin reported an adverse event (dizziness), while 11 patients (22%) with doxazosin reported an adverse event (dizziness), one of whom withdrew from the trial. Secondary: Not reported
Pompeo et al. ³⁸ (2006) Doxazosin SR 4 mg QID vs tamsulosin 0.4 mg QID	DB, DD, RCT Brazilian patients with BPH	N=165 12 week	Primary: Absolute and percentage change from baseline in symptoms measured by IPSS Secondary: Quality of life question from the IPSS and questions six and seven of the SFAQ	Primary: Doxazosin and tamsulosin improved IPSS with no significant differences between the two after 12 weeks. During weeks four to eight, tamsulosin demonstrated a slower improvement (P<0.001) in IPSS compared to doxazosin. Secondary: The proportion of satisfied patients did not change over the course of the trial with doxazosin, while it did change significantly between weeks four and eight with tamsulosin (P=0.006); suggesting that a change for the better was observed earlier with doxazosin. After 12 weeks, the proportion of patients with little or no difficulty at ejaculation (question six of SFAQ) was significantly higher with doxazosin (P=0.019). Both treatments were well tolerated.
Johnson et al. ³⁹ (2007) Doxazosin 2, 4, or 8 mg QD vs	PC, RCT Men with LUTS suggestive of BPH	N=3,047 4 years	Primary: Efficacy (mean reduction in self-reported nightly nocturia at 1 and 4 years)	Primary: The number of men reporting one or more episodes of nocturia who finished ≥12 months of the trial came to a total of 2,583. Mean nocturia was similar with all treatments at baseline. Mean nocturia was reduced after one year by 0.35, 0.40, 0.54 and 0.58 with placebo, finasteride, doxazosin and combination therapy, respectively. Reductions with doxazosin and combination therapy were significantly greater compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
finasteride 5 mg QD vs doxazosin 2, 4, or 8 mg QD plus finasteride 5 mg QD vs placebo			Secondary: Not reported	placebo (P<0.05). After four years, nocturia was also significantly reduced in patients receiving doxazosin and combination therapy (P<0.05 vs placebo). In men >70 years of age (n=495) all treatments significantly reduced nocturia after one year (Finasteride, 0.29; Doxazosin, 0.46 and combination therapy, 0.42) compared to placebo (0.11; P<0.05 for all). Secondary: Not reported
Crawford et al. ⁴⁰ (2006) Doxazosin 4 to 8 mg QD vs finasteride 5 mg QD vs doxazosin 4 to 8 mg QD plus finasteride 5 mg QD vs placebo	PC, RCT Men with LUTS suggestive of BPH	N=737 4 years	Primary: Time to overall clinical progression of BPH (either a confirmed ≥ 4 point increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection) Secondary: Not reported	Primary: The rate of overall clinical progression of BPH events with placebo was 4.5 per 100 person-years, for a cumulative incidence (among men who had at least four years of follow up data) of 17%. The risk of BPH progression was significantly greater with placebo with a baseline TPV ≥ 31 mL compared to a baseline TPV <31 mL (P<0.0001). The risk of BPH progression was significantly greater with placebo with a baseline PSA ≥ 1.6 ng/dL compared to a baseline PSA <1.6 ng/dL (P=0.0009). The risk of BPH progression was significantly greater with placebo with a baseline Qmax <10.6 mL/second compared to a baseline Qmax ≥ 10.6 mL/second (P=0.011) The risk of BPH progression was significantly greater with placebo with a baseline PVR ≥ 39 mL compared to a baseline PVR <39 mL (P=0.0008). The risk of BPH progression was significantly greater with placebo with baseline age ≥ 62 years compared to those aged <62 years (P=0.0002). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
<p>Kaplan et al.⁴¹ (2006)</p> <p>Doxazosin 4 to 8 mg QD</p> <p>vs</p> <p>finasteride 5 mg QD</p> <p>vs</p> <p>doxazosin 4 to 8 mg QD plus finasteride 5 mg QD</p> <p>vs</p> <p>placebo</p>	<p>PC, RCT</p> <p>Men with LUTS suggestive of BPH</p>	<p>N=3,047</p> <p>4 years</p>	<p>Primary:</p> <p>Overall clinical progression of BPH (either a confirmed ≥ 4 point increase in AUA SS, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection)</p> <p>Secondary:</p> <p>Need for invasive therapy for BPH, change from baseline in AUA SS and Qmax</p>	<p>Primary:</p> <p>In patients with a small prostate (baseline TPV >25 mL) combination therapy was no better than doxazosin for decreasing the risk of clinical progression of BPH and need for invasive therapy as well as improving AUA SS and Qmax. However, in patients with a moderate sized (25 to >40 mL) or enlarged (≥ 40 mL) gland, combination therapy led to a clinical benefit in these outcomes that was “superior” to that of doxazosin or finasteride (P<0.05).</p> <p>Secondary:</p> <p>In men with baseline TPV <25 mL, there was no difference in the risk of invasive therapy for combination therapy relative to doxazosin or finasteride. However, in the baseline TPV subgroups of 25 to <40 and ≥ 40 mL there was a significant and marked percent risk decrease in invasive therapy, of around 60 to 80%, for combination therapy compared to doxazosin (P<0.05).</p> <p>In men with baseline TPV <25 mL, the improvement after four years in AUA SS for combination therapy relative to doxazosin was not different, whereas the improvement for combination therapy compared to finasteride was significantly different in favor of combination therapy (P<0.05).</p> <p>In the baseline TPV subgroups of 25 to <40 and ≥ 40 mL, the improvement in AUA SS with combination therapy was significantly better than that for doxazosin and finasteride (P<0.05).</p>
<p>Kaplan et al.⁴² (2008)</p> <p>Doxazosin 4 to 8 mg/day</p> <p>vs</p> <p>finasteride 5 mg/day</p> <p>vs</p>	<p>DB, PC, RCT</p> <p>Men ≥ 50 years of age with an AUA SS of 8 to 30 and a Qmax of 4 to 15 ml/second with a voided volume of ≥ 125 mL</p>	<p>N=3,047</p> <p>Mean</p> <p>4.5 years</p>	<p>Primary:</p> <p>TPV</p> <p>Secondary:</p> <p>Not reported</p>	<p>Primary:</p> <p>Long-term treatment with finasteride alone or in combination with doxazosin led to a consistent reduction in TPV of approximately 25% compared to placebo in men with a relatively small prostate (baseline TPV less than 25 mL and 25 to 30 mL) as well as those with a moderate size (greater than 30 to less than 40 mL) or enlarged prostate (40 mL or greater).</p> <p>Secondary:</p> <p>Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
doxazosin 4 to 8 mg/day and finasteride 5 mg/day vs placebo				
Kirby et al. ⁴³ (2003) PREDICT Doxazosin 1 to 8 mg QD vs finasteride 5 mg QD vs doxazosin 1 to 8 mg QD plus finasteride 5 mg QD vs placebo	DB, MC, PC, PRO, RCT Men 50 to 80 years of age with BPH and an enlarged prostate	N=1,095 52 weeks	Primary: Change from baseline in Qmax and IPSS Secondary: Tolerability	Primary: Doxazosin (3.6±0.3 mL/second) and combination therapy (3.8±0.3 mL/second) were associated with a significantly greater improvement in Qmax after one year compared to finasteride (1.8±0.3 mL/second; P≤0.0001) or placebo (1.4±0.3 mL/second; P≤0.0001). There were no differences between doxazosin and combination therapy or finasteride and placebo (P values not reported). Similar results were found with total IPSS. Again, doxazosin (3.6±0.3 mL/second) and combination therapy (3.8±0.3 mL/second) caused a significantly greater improvement in score over finasteride alone (1.8±0.3 mL/second; P<0.01) or placebo (1.4±0.3 mL/second; P≤0.0001). There were no differences between doxazosin and combination therapy or finasteride and placebo (P values not reported). Secondary: Doxazosin use increased the risk of asthenia, dizziness and hypotension, while impotence was reported most frequently with combination therapy.
Fwu et al. ⁴⁴ MTOPS (2013) Doxazosin 4 or 8 mg QD	DB, MC, RCT Patients ≥50 years of age with an AUA-SS of 8 to 30, a Qmax of 4 to 15	N=2,872 4 years	Primary: Change in quality of life (QoL) using Benign Prostatic Hyperplasia Impact Index (BII),	Primary: Changes in the MOS-SF-36 scores from baseline to year four of follow-up by treatment group demonstrated a statistically significant reduction (worsening) for the subscales of physical functioning, role limitations due to physical problems, bodily pain, general health perception, and vitality in all treatment groups, except bodily pain in men assigned to finasteride. No

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs finasteride 5 mg QD vs doxazosin 4 or 8 mg QD plus finasteride 5 mg QD vs placebo</p>	<p>mL/second, and a minimum voided volume of 125 mL</p>		<p>IPSS-QoL, and annually by the Outcomes Study Short-Form 36 (MOS-SF-36) Secondary: Not reported</p>	<p>significant change was observed in mental health in any treatment group. The subscale with the greatest reduction was role limitations due to physical problems. The decrease was greatest in the placebo group (-8.83, 95% CI, -12.09 to -5.58) and least in finasteride (-6.97, -10.19 to -3.74). The differences in changes for MOS-SF-36 subscales and summary scores between drug groups and placebo group were not statistically significant. Similarly, neither significant differences nor important effect sizes of the subscales and summary scores were observed when drug groups were compared with each other at year four. Compared with men assigned to placebo, men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year four. Men assigned to each of the drug groups also experienced a significant improvement in the IPSS-QoL compared with those assigned to placebo. Secondary: Not reported</p>
<p>Djavan et al.⁴⁵ (1999) Doxazosin vs terazosin vs alfuzosin vs tamsulosin</p>	<p>MA Men with LUTS suggestive of benign prostatic obstruction</p>	<p>N=6,333 (PC trials) N=507 (comparative trials)</p>	<p>Primary: Changes from baseline in total symptom score and maximum urinary flow rate, tolerability Secondary: Not reported</p>	<p>Primary: There was no difference in efficacy among the four treatments. Alfuzosin (IR 2.5 mg TID), alfuzosin (SR 5 mg BID), terazosin (5 to 10 mg/day), doxazosin (4 to 8 mg/day) and tamsulosin (0.4 mg/day) all produced comparable improvements in LUTS and Qmax (P values not reported). The total symptom score improved by 30 to 40% and the Qmax by 16 to 25%. Alfuzosin and tamsulosin were better tolerated than terazosin and doxazosin. Alfuzosin and tamsulosin had similar withdrawal rates as placebo. With terazosin and doxazosin, an additional 4 to 10% of patients withdrew from due to intolerance (P value not reported). Tamsulosin had less effect on blood pressure than alfuzosin (P value not reported). Tamsulosin also caused less symptomatic orthostatic hypotension than terazosin (P value not reported). Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Nickel et al. ⁴⁶ (2008) Doxazosin 4 to 8 mg/day vs terazosin 1 to 10 mg/day vs alfuzosin 10 mg/day vs tamsulosin 0.4 mg/day vs placebo	MA Men with BPH	26 trials 4 weeks to 4.5 years	Primary: Vascular-related adverse events with α 1-adrenergic blockers including dizziness, hypotension, or syncope Secondary: Efficacy based on change from baseline of Q _{max} and change from baseline of AUA SI or IPSS	Primary: Treatment with α 1-adrenergic blockers was associated with a significant increase in the development of a vascular-related adverse event compared to placebo (OR, 2.54; 95% CI, 2.00 to 3.23; P<0.0001). There was a higher risk of developing the primary composite end-point compared to placebo for alfuzosin (P=0.005), terazosin (P<0.0001), doxazosin (P<0.0001), and doxazosin SR (P<0.0001). Secondary: Alpha1-adrenergic blockers improved Q _{max} by 1.32 mL/min compared to placebo (95% CI, 1.07 to 1.57; P<0.0001). The WMD in AUA SI/IPSS for all α 1-adrenergic blockers was -1.92 points compared to placebo (95% CI, -2.71 to -1.14); P<0.0001).
MacDonald et al. ⁴⁷ (2005) Doxazosin, tamsulosin, or finasteride vs alfuzosin vs	SR (11 trials) Men with symptomatic BPH	N=3,901 4 to 26 weeks	Primary: Change from baseline in IPSS Secondary: Change from baseline in Q _{max} and urinary symptom scores, adverse effects, incidence of treatment	Primary: In the two trials comparing alfuzosin to other α -adrenergic blocking agents, doxazosin demonstrated the greatest improvement in IPSS (WMD, 1.70; 95% CI, 0.76 to 1.64; P=0.05). One trial evaluated alfuzosin vs finasteride or alfuzosin plus finasteride. Alfuzosin, both alone or in combination, significantly improved LUTS compared to finasteride. When compared to placebo, alfuzosin demonstrated a greater improvement in the IPSS with a WMD of -1.8 points (95% CI, -2.49 to -1.11). Secondary: No difference was found among α -adrenergic blocking agents in Q _{max} , while alfuzosin and tamsulosin (0.4 mg) demonstrated similar

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
alfuzosin plus finasteride or placebo			discontinuation	<p>improvements in Boyarsky symptom scores.</p> <p>Alfuzosin, finasteride and combination treatment all had similar changes in Qmax; however, a subgroup analysis showed greater improvement in patients with obstruction with alfuzosin and combination therapy over finasteride.</p> <p>Qmax was 2.6 mL/second (10 to 54%) with alfuzosin vs 1.1 mL/second with placebo (2 to 29%). Alfuzosin demonstrated benefit over placebo in the mean urinary symptom score with a WMD of -0.90 point (95% CI, -0.94 to -0.87).</p> <p>The incidences of adverse events as well as withdrawal rates were comparable among α-adrenergic blocking agents. Vasodilatory effects were similar with alfuzosin, finasteride and combination therapy, whereas impotence occurred significantly more often with finasteride and in combination therapy. Discontinuation of treatment was higher with alfuzosin than finasteride and lower with alfuzosin compared to combination therapy. Dizziness was the most frequently reported side effect with alfuzosin compared to placebo. Postural hypotension, syncope and somnolence were reported in less than two percent of patients treated with alfuzosin, but more often than with placebo. Withdrawal rates were similar between treatments.</p>
<p>Tsujii et al.⁴⁸ (2000)</p> <p>Prazosin 0.5 to 1 mg BID</p> <p>vs</p> <p>terazosin 0.5 to 1 mg BID</p> <p>vs</p> <p>tamsulosin 0.1 to</p>	<p>RCT, XO</p> <p>Patients with symptomatic BPH</p>	<p>N=121</p> <p>4 weeks</p>	<p>Primary: Changes from baseline in symptom score, Qmax, average urinary flow rate, PVR and blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: Terazosin was associated with a significant improvement in four out of nine symptoms compared to tamsulosin (P<0.05).</p> <p>There were significant increases in Qmax with prazosin, and in average urinary flow rate with tamsulosin (P<0.05 for both).</p> <p>There were no significant changes in PVR with any of the treatments.</p> <p>Significant reductions in blood pressure were observed in the hypertensive patients with prazosin, terazosin and tamsulosin (P<0.05 for all). In the normotensive patients, no significant changes in blood pressure were observed with any of the treatments.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
0.2 QD				Secondary: Not reported
<p>Tsai et al.⁴⁹ (2007)</p> <p>Group A: Terazosin (generic) 1 to 4 mg QD for 6 weeks (Period 1), followed by terazosin (brand Hytrin®*) 1 to 4 mg QD for 6 weeks (Period 2)</p> <p>vs</p> <p>Group B: Terazosin (brand Hytrin®*) 1 to 4 mg QD for 6 weeks (Period 1), followed by terazosin (generic) 1 to 4 mg QD for six weeks (Period 2)</p>	<p>OL, RCT</p> <p>Adult men in Taiwan newly diagnosed with symptomatic BPH who had not previously received treatment for BPH</p>	<p>N=53</p> <p>13 weeks</p>	<p>Primary: Change from baseline in IPSS, tolerability</p> <p>Secondary: Not reported</p>	<p>Primary: After two and six weeks, no significant between-product differences were found in mean (SD) decreases from baseline in IPSS total score (generic, 2.46 [0.84] and 2.46 [1.00], respectively; branded, 1.56 [0.60] and 2.87 [0.71]) (P=0.29). After six weeks, the between-product difference in mean (SD) increase from baseline in Qmax was nonsignificant (generic, 2.36 [0.90] mL/s; branded, 2.03 [0.62] mL/s) (P=0.72).</p> <p>A total of 86 treatment emergent adverse events were reported (45 with the generic drug; 41 with the branded drug), all of which were considered by the investigator as non-serious except for one case of acute epididymitis, which occurred with the generic drug. The most common adverse events reported with the generic and branded formulations were dizziness (7/48 [14.6%] and 10/50 [20.0%], respectively) and peripheral edema (1/48 [2.1%] and 3/50 [6.0%]). No significant differences in the prevalence of adverse events were found between the two treatments.</p> <p>Secondary: Not reported</p>
<p>Yang et al.⁵⁰ (2007)</p> <p>Terazosin 2 mg QD for 1 week</p> <p>Those patients with continued LUTS after the</p>	<p>RCT</p> <p>Patients diagnosed with LUTS due to BPH</p>	<p>N=69</p> <p>7 weeks</p>	<p>Primary: Change from baseline in IPSS</p> <p>Secondary: Not reported</p>	<p>Primary: IPSS was significantly improved with both treatments after the initial first week, and the reduction of IPSS with combination therapy was significantly greater compared to terazosin (P<0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS with combination therapy. Differences in Qmax and residual urine from baseline were noted with both treatments, but there was no difference between the treatments (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
initial treatment were allocated randomly to: terazosin 2 mg QD for 6 weeks vs terazosin 2 mg QD plus tolterodine 2 mg BID for 6 weeks				The incidence of adverse effects with combination therapy was higher compared to terazosin. The most commonly reported adverse effects were mouth dryness, which is associated with anticholinergic drugs such as tolterodine. Secondary: Not reported
Dong et al. ⁵¹ (2009) Terazosin vs tamsulosin	MA (12 trials) Patients with BPH	N=2,816 4 weeks	Primary: IPSS, quality of life, Qmax, Qave, residual volume, prostate volume, adverse effects Secondary: Not reported	Primary: After four weeks of treatment, tamsulosin demonstrated a significant improvement in IPSS compared to terazosin (WMD, -1.24; 95% CI, -1.98 to -0.51; P=0.0009). There was no significant difference in quality of life between the treatment groups (WMD, -0.04; 95% CI, -0.16 to 0.24), Qmax (WMD, -0.38; 95% CI, -1.18 to 0.41), Qave (WMD, -0.39; 95% CI, -0.84 to 0.06), residual volume (WMD, -4.32; 95% CI, -10.96 to 2.33), or prostate volume (WMD, -0.28; 95% CI, -3.37 to 2.81). Fewer patients experienced dizziness (RR, 0.38; 95% CI, 0.30 to 0.48), severe hypotension (RR, 0.16; 95% CI, 0.04 to 0.68), and dry mouth (RR, 0.14; 95% CI, 0.03 to 0.77) with tamsulosin compared to patients receiving terazosin. Secondary: Not reported
Lepor et al. ⁵² (1996) Terazosin 1 to 10 mg QD vs	DB, MC, RCT Men 45 to 80 years of age with symptomatic BPH	N=1,229 1 year	Primary: Change from baseline in AUA SS and Qmax Secondary: Not reported	Primary: A significantly greater reduction in symptom scores were observed with terazosin and combination therapy compared to finasteride and placebo (6.1, 6.2, 3.2 and 2.6 points respectively; P<0.001 for terazosin vs finasteride, combination therapy vs finasteride, terazosin vs placebo and combination therapy vs placebo). There was no difference in scores noted between terazosin and combination therapy (P=1.00) or finasteride and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
finasteride 5 mg QD vs finasteride 5 mg QD plus terazosin 1 to 10 mg QD vs placebo				placebo (P=0.63). Terazosin and combination therapy was also associated with a greater increase in Qmax compared to finasteride or placebo (2.7, 3.2, 1.6 and 1.4 mL/second). Differences between finasteride and terazosin, finasteride and combination therapy, combination therapy and placebo and terazosin and placebo all reached statistical significance (P<0.001 for all comparisons), whereas the difference between terazosin and combination therapy (P=0.15) and finasteride and placebo (P=0.07) did not. Secondary: Not reported
Liu et al. ⁵³ (2009) Terazosin 2 mg/day vs amlodipine 5 mg/day vs terazosin 2 mg/day and amlodipine 5 mg/day	DB, PG, RCT Men ≥50 years of age with Stage 1 or 2 essential HTN (SBP 140 to 180 mm Hg and/or DBP 90 to 110 mm Hg) and with LUTS (IPSS ≥10)	N=360 28 days	Primary: Reduction in the total and sub-scores of the IPSS and blood pressure Secondary: Not reported	Primary: Treatment with terazosin and amlodipine monotherapy led to a similar reduction in the total IPSS (6.7 vs 6.9). There were no significant difference in the reduction in the bladder outlet obstruction sub-score (4.0 vs 4.1), OAB sub-score (2.9 vs 2.6), or quality of life score (1.1 vs 1.2) with amlodipine compared to terazosin. Treatment with terazosin and amlodipine led to a greater reduction in the QOL score (1.4 vs 1.1, P<0.05) compared to amlodipine monotherapy. There was no significant difference in the reduction in the total IPSS (7.8), bladder outlet obstruction sub-score (4.8), or OAB sub-score (3.2) with terazosin and amlodipine compared to amlodipine alone or terazosin alone. The rate of the responders (defined as patients with a reduction of 40% or more in the total IPSS, bladder outlet obstruction sub-score, OAB sub-score, or quality of life score or total IPSS of <8) were similar between the amlodipine group (36.1, 41.2, 46.2, and 33.6%, respectively) and terazosin group (39.3, 46.2, 39.3, and 41.0%, respectively). The rate of responders in the OAB sub-score was significantly greater in the terazosin and amlodipine group than in the terazosin group (53.8 vs 39.3%, P<0.05). The rate of responders in the quality of life score was significantly greater in the terazosin + amlodipine group than in the amlodipine group (47.1 vs 33.6%, P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The mean reduction in SBP and DBP was greater with amlodipine than terazosin (21.8/10.0 vs 11.9/6.5 mm Hg, P<0.01). The greatest reduction in SBP and DBP (25.2/12.6 mm Hg) occurred in the terazosin and amlodipine group (P<0.01 vs terazosin and P<0.05 vs amlodipine).</p> <p>The rates of blood pressure control were greater in the amlodipine group (63.9%) and the terazosin and amlodipine group (73.1%) than in the terazosin group (36.8%, both P<0.001).</p> <p>Secondary: Not reported</p>
<p>Wilt et al.⁵⁴ (2000)</p> <p>Terazosin</p> <p>vs</p> <p>other α-adrenergic blocking agents, finasteride, finasteride plus terazosin or placebo</p>	<p>SR (17 trials)</p> <p>Men with symptomatic benign prostatic obstruction</p>	<p>N=5,151</p> <p>4 to 52 weeks</p>	<p>Primary: Change from baseline in urological symptom scale scores</p> <p>Secondary: Urodynamic measures, adverse effects</p>	<p>Primary: Boyarsky symptom score improved by 37% with terazosin and by 15% with placebo. AUA SS scores improved by 38% with terazosin compared to 20% with finasteride and 17% with placebo. Terazosin was comparable to tamsulosin (40 and 43%, respectively) in improving IPSS (P values not reported).</p> <p>Secondary: The improvement in Qmax reported with terazosin (22%) was similar to other α-adrenergic blocking agents, but higher compared to finasteride (15%) and placebo (11%). Side effects, including dizziness, asthenia, headache and postural hypotension, occurred more often with terazosin compared to placebo. Rates of discontinuation with terazosin were higher than other α-adrenergic blocking agents, but similar to finasteride and placebo.</p>
<p>Wilt et al.⁵⁵ (2002)</p> <p>Other α-adrenergic blocking agents, Permixon^{®*} or placebo</p> <p>vs</p>	<p>SR (14 trials)</p> <p>Men with BPH and LUTS</p>	<p>N=4,122</p> <p>4 to 26 weeks</p>	<p>Primary: Change from baseline in urological symptom scale scores</p> <p>Secondary: Changes from baseline in Qmax,</p>	<p>Primary: The WMD in the Boyarsky symptom score for tamsulosin compared to placebo was -1.1 points (95% CI, -1.49 to -0.72) or a 12% improvement with 0.4 mg and -1.6 points (95% CI, -2.3 to -1.0) or a 16% improvement with 0.8 mg.</p> <p>Secondary: The WMD in Qmax was 1.1 mL/second with both tamsulosin 0.4 and 0.8 mg (95% CI, 0.59 to 1.51 with 0.4 mg; 95% CI, 0.65 to 1.48 with 0.8 mg).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
tamsulosin 0.2 to 0.8 mg QD			adverse effects	Tamsulosin was reported to be as effective as other α -adrenergic blocking agents or Permixon [®] in the improvement of LUTS and Qmax. Dizziness, rhinitis and abnormal ejaculation occurred significantly more often with tamsulosin than placebo. The rates of adverse events and withdrawal increased with higher doses of tamsulosin. Terazosin was associated with a higher rate of discontinuation than low dose tamsulosin.
Hypertension				
Hayduk et al. ⁵⁶ (1987) Doxazosin 1 to 16 mg QD vs terazosin 1 to 20 mg QD	DB, MC, RCT Patients with high blood pressure	N=55 14 weeks	Primary: Proportion of patients achieving blood pressure success and normalization (blood pressure \leq 90 mm Hg), safety Secondary: Not reported	Primary: Blood pressure success was higher with doxazosin compared to terazosin (73 vs 64%; P value not reported). Blood pressure normalization was higher with doxazosin compared to terazosin (65 vs 57%; P value not reported). The incidence of treatment-related side effects was higher with terazosin compared to doxazosin (39 vs 30%; P value not reported). Secondary: Not reported
Torvik et al. ⁵⁷ (1986) Doxazosin 1 to 16 mg QD vs prazosin 0.5 to 10 mg BID vs placebo	DB Patients with essential HTN	N=172 12 weeks	Primary: Changes from baseline in blood pressure, heart rate, and plasma lipid profiles Secondary: Not reported	Primary: Doxazosin and prazosin both produced significant reductions in blood pressure compared to placebo (P<0.05 to P<0.005). There was no significant difference between the three treatments in changes in plasma lipid profiles or heart rate (P values not reported). There was a significant baseline reduction in TG only with doxazosin (P<0.05). Secondary: Not reported
Fukiyama et al. ⁵⁸ (1991)	DB, MC, RCT Patients with	N=126 12 weeks	Primary: Changes from baseline in blood	Primary: There was no significant difference between the two treatments in reductions in blood pressure (P=0.7826); however, both treatments

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Doxazosin vs prazosin	essential HTN		pressure and heart rate Secondary: Not reported	produced significant reductions from baseline (P<0.001). No significant changes in heart rate were observed with either treatment (P value not reported). Secondary: Not reported
DePlanque et al. ⁵⁹ (1991) Doxazosin QD vs prazosin BID	DB, DD, PG Patients with mild or moderate essential HTN not adequately controlled by diuretics and β -blockers	N=43 14 weeks	Primary: Changes from baseline in blood pressure, heart rate and serum lipid levels; calculated CHD risk using the Framingham equation Secondary: Not reported	Primary: There was no difference between the two treatments in changes in SBP (P value not significant), heart rate (P value not significant) or serum lipid levels (P value not reported). Doxazosin was associated with a significantly greater reduction in standing (P=0.01) and supine (P=0.04) DBP compared to prazosin. At the end of the trial, 84.2 and 56.5% of patients receiving doxazosin and prazosin achieved therapeutic success (P value not reported). Doxazosin (P=0.02) was associated with a greater reduction from baseline in the calculated risk of CHD compared to prazosin (P value not significant). Secondary: Not reported
Deger et al. ⁶⁰ (1986) Prazosin BID vs terazosin QD vs placebo	DB, MC, PC Patients with mild to moderate HTN	N=174 14 weeks	Primary: Changes from baseline in blood pressure and heart rate Secondary: Not reported	Primary: Terazosin was associated with a significant reduction in supine and standing DBP compared to placebo (P \leq 0.05). Prazosin was not associated with a significant reduction in supine DBP, but was associated with a significant reduction in mean standing DBP compared to placebo (P values not reported). There was no difference in the changes in heart rate between the two treatments (P value not reported). Secondary: Not reported
Ruoff et al. ⁶¹ (1986)	DB, PG, RCT	Study 1 N=54	Primary: Blood pressure,	Primary: Study 1- There was no significant difference in blood pressure changes

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p><u>Study 1:</u> Prazosin</p> <p>vs</p> <p>terazosin</p> <p>vs</p> <p>placebo</p> <p><u>Study 2:</u> Terazosin</p> <p>vs</p> <p>HCTZ</p> <p><u>Study 3:</u> Terazosin and HCTZ</p> <p>vs</p> <p>prazosin and HCTZ</p>	<p>Patients with mild to moderate HTN</p>	<p>Study 2 N=37</p> <p>Study 3 N=28</p>	<p>pulse rate, body weight, laboratory tests, physical examinations, ECG</p> <p>Secondary: Not reported</p>	<p>between the terazosin and prazosin treatment groups.</p> <p>Study 2- HCTZ produced a significantly greater reduction in supine DBP compared to terazosin. There were no significant differences in standing blood pressure between the HCTZ and terazosin treatment groups.</p> <p>Study 3- There were no significant differences in blood pressure between the treatment groups.</p> <p>The drug treatments did not produce significant changes in pulse rates, body weights, laboratory test results, physical examinations, or electrocardiograms.</p> <p>Secondary: Not reported</p>
<p>Neaton et al.⁶² (1993) TOMHS</p> <p>Doxazosin 2 to 4 mg QD</p> <p>vs</p> <p>chlorthalidone 15</p>	<p>DB, MC, PC, RCT</p> <p>Patients with mild HTN (DBP <100 mm Hg)</p>	<p>N=902</p> <p>4.4 years</p>	<p>Primary: Blood pressure, quality of life, side effects, blood lipid levels and analysis of other serum components, echocardiographic changes, and incidence of</p>	<p>Primary: There was a significant reduction in blood pressure in all the active treatment groups compared to placebo (-15.9 vs -9.1 mm Hg for SBP and -12.3 vs -8.6 mm Hg for DBP; P<0.0001).</p> <p>There were no major differences in blood pressure lowering between the 5 active treatment groups (P=0.10).</p> <p>TC was significantly reduced more in the doxazosin group than in the amlodipine, chlorthalidone, and placebo groups (P<0.01). The reduction in</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>to 30 mg QD</p> <p>vs</p> <p>acebutolol 400 mg QD</p> <p>vs</p> <p>amlodipine 5 mg QD</p> <p>vs</p> <p>enalapril 5 to 10 mg QD</p> <p>vs</p> <p>placebo</p>			<p>cardiovascular events</p> <p>Secondary: Not reported</p>	<p>LDL-C was significantly more in doxazosin group than in the amlodipine, chlorthalidone, and placebo groups. Reduction in TG was significantly larger with the doxazosin, enalapril, and amlodipine groups than acebutolol group (P<0.01).</p> <p>The lowest level of fasting insulin was observed with doxazosin; fasting insulin was lower than placebo in all drug groups.</p> <p>Secondary: Not reported</p>
<p>Liebson et al.⁶³ (1995) TOMHS</p> <p>Doxazosin</p> <p>vs</p> <p>chlorthalidone</p> <p>vs</p> <p>acebutolol</p> <p>vs</p> <p>amlodipine</p>	<p>DB, PC, RCT</p> <p>Patients with mild HTN</p>	<p>N=844</p> <p>4 years</p>	<p>Primary: Changes in blood pressure and pulse, changes in left ventricular mass from baseline to end of study period as assessed by ECG</p> <p>Secondary: Not reported</p>	<p>Primary: All drug treatment groups showed significantly greater reduction of blood pressure compared to placebo (mean decrease of 16/12 vs 9/9 mm Hg; P<0.001).</p> <p>Pulse rate decreased by 10 bpm for the acebutolol group compared to 1 to 3 bpm for the other treatment groups.</p> <p>All drug treatment groups and the placebo group showed significant decreases (10 to 15%) in left ventricular mass. The chlorthalidone group showed the largest decrease in left ventricular mass at 34 g compared to 24 to 27 g for the other treatment groups.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs enalapril vs placebo				
Brown et al. ⁶⁴ (1995) <u>Study A:</u> Doxazosin, followed by amlodipine, followed by doxazosin and amlodipine vs <u>Study B:</u> Enalapril, followed by amlodipine, followed by enalapril and amlodipine	DB, RCT, XO Patients with moderate or severe HTN	N=24 18 weeks	Primary: Blood pressure and heart rate, foot volume as measure of edema, plasma noradrenaline concentration Secondary: Not reported	Primary: <u>Study A:</u> The decrease in blood pressure was significantly greater than the sum of the blood pressure falls at the end of the single drug treatment periods. The reduction in blood pressure was greater with amlodipine than doxazosin (P<0.01). The reduction in blood pressure was greater with combination than amlodipine (P<0.001). No significant changes in heart rate were observed. One subject developed ankle edema. The plasma noradrenaline concentration did not change significantly during the single drug treatment periods, but doubled at the end of the combination treatment period (P<0.05). <u>Study B:</u> The reduction in blood pressure was significantly greater with amlodipine than enalapril (P<0.05). The reduction in blood pressure was significantly greater with combination than amlodipine (P<0.05) with the exception of erect blood pressure. No significant changes in heart rate were noted. No significant difference in foot volume was observed between treatments. The plasma noradrenaline was significantly higher than at baseline (P<0.01). Secondary: Not reported
Deary et al. ⁶⁵ (2002) Doxazosin 1 to 4	DB, XO Hypertensive patients, aged 18 to	N=34 42 weeks (6 week	Primary: Blood pressure, heart rate	Primary: All drug treatments caused significant decreases in blood pressure. Bendroflumethiazide performed significantly worse (P=0.0016) and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs amlodipine 5 mg/day vs lisinopril 2.5 to 10 mg/day vs bisoprolol 5 mg/day vs bendroflumethiazide* 2.5 mg/day vs placebo	55 years old	treatment of each drug or placebo, then the 7 th week was a repeat of each patient's most effective, tolerated drug)	Secondary: Not reported	bisoprolol performed significantly better (P=0.004) than amlodipine. When the most effective drugs for each patient were tabulated, all drugs included in the study except for bendroflumethiazide, were represented. Secondary: Not reported
Hayduk et al. ⁶⁶ (1987) <u>Study 1:</u> Doxazosin 1 to 16 mg QD vs prazosin 1 to 20 mg BID	DB, MC Patients with HTN	<u>Study 1:</u> N=903 10 to 24 week trial; therapy continued for up to 62 weeks <u>Study 2:</u> N=52	Primary: Blood pressure, heart rate Secondary: Not reported	Primary: Blood pressure lowering effect of doxazosin was similar to that of the other antihypertensive drugs. There was no significant difference in the heart rate with the doxazosin treated group. The β -blockers demonstrated clinically significant bradycardia. Both doxazosin and terazosin were equally efficacious, but doxazosin was effective at significantly lower doses.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs HCTZ 25 to 100 mg QD vs nadolol 40 to 160 mg QD vs atenolol 50 to 100 mg QD vs metoprolol 100 to 200 mg BID vs placebo <u>Study 2:</u> Doxazosin 16 mg QD vs terazosin 20 mg QD		12 weeks		Secondary: Not reported
Trost et al. ⁶⁷ (1987) Doxazosin 1 to 16	DB, MC, PG Patients with HTN	N=104 6 months	Primary: Blood pressure, serum lipid changes	Primary: There was no significant difference in the supine and standing blood pressures between the two treatment groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD vs HCTZ 25 to 100 mg QD			Secondary: Not reported	There was significantly greater reduction in total TG (P=0.002) and TC concentration (P=0.006) and significantly greater increase in HDL-C:TC (P=0.001) in the doxazosin arm compared to the HCTZ arm. Secondary: Not reported
Grimm et al. ⁶⁸ (1996) Doxazosin 2 to 16 mg vs HCTZ 25 to 50 mg	DB, PG, RCT Patients with HTN	N=107 1 year	Primary: Blood pressure, heart rate, biochemistries, lipids/lipoproteins, quality of life, ECGs, adverse effects Secondary: Not reported	Primary: There were no significant differences in blood pressure lowering, heart rate, quality of life measures, or serious adverse effects between the two treatment groups. The doxazosin treated group experienced a more favorable high density lipoprotein /total cholesterol ratio (P≤0.01) compared to the hydrochlorothiazide group. Both drug treatments showed significant reduction in left ventricular mass (P<0.001) and wall thickness (P<0.05). The left ventricular systolic and diastolic internal dimensions were significantly less in the HCTZ group compared to the doxazosin group. Secondary: Not reported
Ferrara et al. ⁶⁹ (1993) Doxazosin 1 to 16 mg QD vs captopril 25 to 150 mg QD	MC, OL, PG Patients with hypercholesterolemia and HTN	N=224 14 weeks	Primary: Blood pressure (normalized blood pressure defined as standing diastolic pressure ≤90 mm Hg), serum lipid levels, quality of life Secondary: Not reported	Primary: Blood pressure was significantly reduced with both drugs (P<0.001). A total of 73% of the doxazosin group and 67% of the captopril group achieved normalized blood pressure. Serum TC level was significantly improved with both drugs (P<0.001). The HDL-C concentration was only significantly increased in the doxazosin group (P<0.001). The calculated 10-year risk for the development of CHD was significantly reduced with both drug treatments (P<0.001). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Derosa et al.⁷⁰ (2005)</p> <p>Doxazosin 4 mg QD</p> <p>vs</p> <p>irbesartan 300 mg QD</p>	<p>DB, PG, RCT</p> <p>Patients with type 2 diabetes and mild HTN</p>	<p>N=96</p> <p>1 year</p>	<p>Primary: Blood pressure, glucose metabolism, lipid parameters</p> <p>Secondary: Not reported</p>	<p>Primary: Blood pressure was significantly reduced in both treatment groups compared to baseline (P<0.01).</p> <p>Irbesartan was significantly better in lowering blood pressure compared to doxazosin (P<0.05).</p> <p>Doxazosin significantly reduced glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, TC, LDL-C, HDL-C, and TG (P≤0.05 for all parameters).</p> <p>As monotherapy, neither of the drugs achieved adequate blood pressure control.</p> <p>Secondary: Not reported</p>
<p>Taylor et al.⁷¹ (1988)</p> <p>Doxazosin 1 to 16 mg QD</p> <p>vs</p> <p>enalapril 10 to 40 mg QD</p>	<p>DB, PG</p> <p>Patients with mild or moderate essential HTN</p>	<p>N=67</p> <p>18 weeks</p>	<p>Primary: Blood pressure (therapeutic success defined as standing DBP ≤90 mm Hg), lipid parameters</p> <p>Secondary: Not reported</p>	<p>Primary: A total of 74% of the doxazosin group achieved therapeutic success compared to 81% of the enalapril group.</p> <p>Blood pressures were significantly reduced in both groups.</p> <p>There were no significant changes in the lipid profile observed for either drug.</p> <p>Secondary: Not reported</p>
<p>Wessels et al.⁷² (1991)</p> <p>Doxazosin QD</p> <p>vs</p> <p>enalapril QD</p>	<p>DB, DD, PC, RCT</p> <p>Patients with mild or moderate essential HTN</p>	<p>N=54</p> <p>12 weeks</p>	<p>Primary: Blood pressure, heart rate, serum lipid profile, calculated CHD risk</p> <p>Secondary: Not reported</p>	<p>Primary: Both drugs produced significant reductions in blood pressure (P<0.05).</p> <p>There was no significant change in heart rate with both drugs.</p> <p>Doxazosin showed a significant reduction in the total serum cholesterol concentration (P<0.05). Doxazosin also showed a decrease in triglyceride level (P value not significant) and an increase in HDL-C/total cholesterol ratio (P value not significant).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Coronary heart disease risk reduction was significant and greater in the doxazosin group compared to the enalapril group (-27.58 vs -18.49%, $P<0.02$). Secondary: Not reported
Hjordahl et al. ⁷³ (1987) Doxazosin QD vs HCTZ QD	DB, RCT Patients with mild to moderate essential HTN	N=115 24 weeks	Primary: Blood pressure, heart rate, lipid profile, side effects Secondary: Not reported	Primary: There was no significant difference between treatment groups for blood pressure and heart rate except HCTZ produced significantly greater supine SBP than doxazosin ($P=0.04$). There were significant reductions in TC ($P=0.006$) and total TG ($P=0.018$) for the doxazosin group. Eleven patients of the HCTZ group had an abnormally low potassium level and seven of the HCTZ treated group had abnormally high uric acid concentrations. Secondary: Not reported
Ott et al. ⁷⁴ (1987) Doxazosin 1 to 16 mg QD vs atenolol 50 to 100 mg QD	DB, MC, RCT Patients with mild to moderate HTN	N=126 20 weeks	Primary: Blood pressure, heart rate Secondary: Not reported	Primary: There was no significant difference between treatment groups in blood pressure. Both drugs reduced heart rate, but atenolol produced a significantly greater decrease in heart rate than doxazosin ($P<0.001$). Secondary: Not reported
Frick et al. ⁷⁵ (1986) Doxazosin 1 to 16 mg QD vs	DB, DD, MC, RCT Patients with mild to moderate essential HTN	N=152 1 year	Primary: Blood pressure, heart rate, lipid profile Secondary: Not reported	Primary: At endpoint, there was greater blood pressure reduction with atenolol than doxazosin. This was statistically significant only in the supine position ($P<0.05$). Doxazosin reduced the heart rate slightly, while atenolol produced a marked bradycardia ($P<0.0001$).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atenolol 50 to 100 mg QD				HDL-C:TC was raised in the doxazosin group and lowered in the atenolol group (P=0.001). TG levels decreased in the doxazosin group and increased in the atenolol group (-5.0 vs 42.7%; P<0.001). Secondary: Not reported
Daae et al. ⁷⁶ (1998) Doxazosin QD vs atenolol QD	DB, MC, PG Patients with mild to moderate HTN	N=228 1 year followed by a 4-year OL, ES	Primary: Blood pressure, heart rate, lipid profile, calculated risk of developing CHD in 10 years using the Framingham equation Secondary: Not reported	Primary: Both groups showed similar decreases in blood pressure. The doxazosin-treated group had a significantly greater reduction from baseline in CHD risk than the atenolol-treated group (P<0.05). TC significantly decreased from baseline in both treatment groups (P≤0.05), with no statistically significant difference between the groups. HDL-C (P<0.01), the HDL-C:TC (P<0.01), and TG levels (P<0.01) significantly improved in the doxazosin group compared to the atenolol group. Secondary: Not reported
Talseth et al. ⁷⁷ (1991) Doxazosin (mean dose used: 5.2 mg QD) vs atenolol (mean dose used: 66.4 mg QD)	PG, RCT Patients with mild and moderate HTN	N=164 3 years	Primary: Blood pressure, heart rate, lipids profile, calculated CHD risk using the Framingham equation Secondary: Not reported	Primary: Both drugs produced similar reductions in blood pressure. Atenolol produced a significant decrease in heart rate (P<0.05), while doxazosin did not change the heart rate significantly. Doxazosin significantly reduced TG levels (P<0.001), increased HDL-C levels (P<0.001), and increased the HDL-C:TC (P<0.001) compared to atenolol. The calculated CHD risk was significantly increased with atenolol (P<0.05) and significantly decreased with doxazosin (P<0.05) from baseline. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Carruthers et al. ⁷⁸ (1993) Doxazosin QD vs atenolol QD	RCT Patients with mild to moderate systemic HTN and normal serum lipid	N=191 24 weeks	Primary: Calculated CAD risk using the Framingham formula Secondary: Not reported	Primary: Doxazosin treatment produced a significantly greater reduction in CHD risk compared to atenolol (P=0.0074). The relative risk of CHD was reduced to 0.92 in the atenolol group (P=0.144) and 0.74 in the doxazosin group (P=0.0001) from baseline. Secondary: Not reported
Searle et al. ⁷⁹ (1990) Doxazosin 11 mg (mean dose) vs placebo All patients received atenolol 100 mg/day.	DB, MC, RCT Patients with mild to moderate essential HTN	N=87 12 weeks	Primary: Changes from baseline in blood pressure, heart rate and serum lipids Secondary: Not reported	Primary: Doxazosin was associated with significant reductions in blood pressure compared to placebo (17.0/12.3 vs 6.2/6.7 mm Hg; P<0.05). The supine blood pressure was decreased by 13.2/9.8 mm Hg with doxazosin compared to 9.2/6.0 mm Hg with placebo (P value not reported). Only minor, nonsignificant changes in serum lipids and heart rate were observed between the two treatments (P value not reported). Secondary: Not reported
Ohta et al. ⁸⁰ (2007) Doxazosin 1 to 2 mg QD to BID Treatment was added to calcium channel blockers, ARBs and ACE inhibitors.	RETRO Patients with HTN that had poorly controlled blood pressure	N=41 3 months (mean follow up 170 days)	Primary: Changes from baseline in blood pressure and blood chemistry Secondary: Not reported	Primary: Blood pressure decreased from 152±14/81±12 to 135±14/70±11 mm Hg after the addition of doxazosin at a mean dose of 1.5 mg/day (P<0.001). When good SBP control was defined as <140 mm Hg, the prevalence of patients with good SBP control increased from 24 to 61% with the addition of doxazosin (P<0.01). Similarly, the prevalence of patients with good DBP control (<90 mm Hg) increased from 78 to 98% (P<0.01). Patients whose SBP decreased >10 mm Hg (n=25) showed significantly higher baseline SBP, TC and LDL-C compared to those who showed less SBP reduction (<10 mm Hg; P<0.01). Comparable reductions in blood pressure were obtained between obese

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>patients (BMI ≥ 25, change in blood pressure at three months: $-15 \pm 15 / -12 \pm 9$ mm Hg, n=18) and non-obese patients ($-14 \pm 19 / -7 \pm 8$ mm Hg, n=23).</p> <p>Secondary: Not reported</p>
<p>de Alvaro et al.⁸¹ (2006) ASOCIA</p> <p>Doxazosin SR 4 mg QD, increased to 8 mg/day at week 4 if required</p> <p>Added to entry medication.</p>	<p>MC, PRO</p> <p>Patients with HTN ($>140 / >90$ mm Hg) on previous antihypertensive medication who were uncontrolled</p>	<p>N=3,631</p> <p>16 weeks</p>	<p>Primary: Proportion of patients achieving goal blood pressure ($<140 / <90$ mm Hg), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: The proportion of patients achieving goal blood pressure after four weeks of add on therapy with doxazosin was 39% and increased to 61% after 16 weeks. SBP and DBP (mean\pmSEM) decreased, respectively, from $161.6 \pm 0.2 / 95.1 \pm 0.1$ mm Hg at baseline to $142.2 \pm 0.2 / 84.1 \pm 0.1$ mm Hg after four weeks (P<0.0001) and to $136.8 \pm 0.2 / 80.6 \pm 0.2$ mm Hg after 16 weeks (P<0.0001).</p> <p>Adverse events occurred in 108 patients (3.0%), with 57 (1.6%) related to the study treatment. In 17 patients (0.5%), serious adverse events were described, but only one was related to the study drug.</p> <p>Secondary: Not reported</p>
<p>Os et al.⁸² (2006)</p> <p>Doxazosin 4 mg QD</p> <p>vs</p> <p>doxazosin 2 mg QD</p> <p>vs</p> <p>doxazosin SR 4 mg QD</p>	<p>DB, PG, RCT</p> <p>Patients 18 to 80 years of age with mild to moderate essential HTN (sitting DBP 95 to 110 mm Hg and SBP <180 mm Hg)</p>	<p>N=310</p> <p>9 weeks</p>	<p>Primary: Efficacy, safety</p> <p>Secondary: Not reported</p>	<p>Primary: All groups had a significant decrease in blood pressure at all study visits compared to baseline. The proportion of patients who reached goal sitting DBP (<90 mm Hg) was similar among the three treatment groups, except at week one, when more patients in the doxazosin SR group had obtained the goal compared to those in the doxazosin 2 mg group (40.6 vs 22.3%; P=0.005). The proportion of patients who reached sitting SBP (<140 mm Hg) goal was similar among groups.</p> <p>Adverse event profiles among the groups were similar.</p> <p>Secondary: Not reported</p>
<p>Materson et al.⁸³ (1994)</p>	<p>DB, MC, RCT</p> <p>Men with DBP of</p>	<p>N=1,292</p> <p>1 year</p>	<p>Primary: Success as defined by DBP ≤ 95 mm</p>	<p>Primary: Success rates were 59% for diltiazem, 51% for atenolol, 50% for clonidine, 46% for HCTZ, 42% for captopril, 42% for prazosin, and 25%</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Prazosin 4 to 20 mg QD</p> <p>vs</p> <p>HCTZ 12.5 to 50 mg QD</p> <p>vs</p> <p>atenolol 25 to 100 mg QD</p> <p>vs</p> <p>captopril 25 to 100 mg QD</p> <p>vs</p> <p>clonidine 0.2 to 0.6 mg QD</p> <p>vs</p> <p>diltiazem SR 120 to 360 mg QD</p> <p>vs</p> <p>placebo</p>	<p>95 to 109 mm Hg</p>		<p>Hg at 1 year</p> <p>Secondary: Not reported</p>	<p>for placebo (P<0.001 between diltiazem and HCTZ, atenolol and prazosin).</p> <p>The rates of adverse effects leading to termination of treatment were highest with prazosin at 13.8% and clonidine at 10.1%, which was significantly different from captopril at 4.8%, atenolol at 2.2%, HCTZ at 1.1%, diltiazem at 5.5%, and placebo at 6.4%.</p> <p>Successful blood pressure control was highest with diltiazem at 64% in African Americans, highest with captopril at 55% in younger whites, and highest with atenolol at 68% in older whites.</p> <p>Secondary: Not reported</p>
<p>McAreavey et al.⁸⁴ (1984)</p> <p>Prazosin 0.5 mg QD up to 10 mg BID</p>	<p>DB, PG, RCT</p> <p>Patients with inadequately controlled HTN while receiving</p>	<p>N=238</p> <p>6 months</p>	<p>Primary: Comparative safety and efficacy, target blood pressure <140/95 mm Hg</p>	<p>Primary: Target blood pressure was reached in 25% of patients receiving hydralazine, 23% of patients receiving minoxidil, 19% of patients receiving prazosin, 17% of patients receiving methyldopa and zero percent of patients receiving placebo (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>hydralazine 12.5 mg QD up to 100 mg BID</p> <p>vs</p> <p>labetalol 200 mg QD up to 1,600 mg BID</p> <p>vs</p> <p>methyldopa 125 mg QD up to 1,000 mg BID</p> <p>vs</p> <p>placebo</p> <p>Minoxidil as add on therapy was given to men only.</p> <p>Doses were titrated upward at 2 week intervals until target BP or maximum dose was reached.</p>	<p>atenolol 100 mg/day and bendrofluazide* 5 mg/day</p>		<p>Secondary: Not reported</p>	<p>Labetalol had the highest withdrawal rate compared to the other treatments with 78% (P<0.05). Minoxidil had the second highest withdrawal rate with 57% (P<0.05), due to fluid retention. There were no significant differences in withdrawal rates among the other treatments.</p> <p>Secondary: Not reported</p>
<p>Chrysant et al.⁸⁵ (1986)</p> <p>Terazosin</p>	<p>DB, MC, PC, RCT</p> <p>Patients with inadequate control</p>	<p>N=138</p> <p>Duration not specified</p>	<p>Primary: Changes from baseline in blood pressure, physical</p>	<p>Primary: There was a significant mean reduction in supine DBP with the terazosin compared to placebo (7.3 vs 0.6 mm Hg; P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	of essential HTN		examination and ECG Secondary: Not reported	There were no significant changes between treatments in physical examinations or ECGs. Secondary: Not reported
Holtzman et al. ⁸⁶ (1988) Terazosin vs placebo in combination with atenolol	DB, MC, PC Patients with HTN	N=92 10 weeks	Primary: Changes from baseline in blood pressure and lipid profiles Secondary: Not reported	Primary: There was a significant reduction in supine and standing blood pressure (P<0.05), TC (P<0.05) and LDL-C plus VLDL-C (P<0.05) with terazosin. Secondary: Not reported
Casas et al. ⁸⁷ (2005) ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents, calcium-channel blocking agents, or combinations) vs ACE inhibitor or ARBs compared to placebo	MA (127 trials) Studies in adults that examined the effect of any drug treatment with a blood pressure lowering action on progression of renal disease	N=not reported 4.2 years (mean)	Primary: Doubling of serum creatinine, and ESRD Secondary: Serum creatinine, urine albumin excretion and GFR	Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups. A small reduction in ESRD was observed in patients receiving ACE inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups. Secondary: Small reductions in serum creatinine and in SBP were noted when ACE inhibitors or ARBs were compared to other antihypertensives (P=0.01). Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001). Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Specific agents and doses were not specified.				
Outcomes Trials				
<p>ALLHAT⁸⁸⁻⁹⁰ (2000, 2003, 2004)</p> <p>Doxazosin 2 to 8 mg QD</p> <p>vs</p> <p>chlorthalidone 12.5 to 25 mg QD</p>	<p>AC, DB, RCT</p> <p>Patients ≥ 55 years of age with HTN and ≥ 1 CHD risk factor</p>	<p>N=24,335</p> <p>3.3 years</p>	<p>Primary: Combined occurrence of CHD death or nonfatal MI</p> <p>Secondary: All-cause mortality, stroke, combined CHD (CHD death, nonfatal MI, revascularization procedures and hospitalized angina), stroke, combined cardiovascular disease (CHD death, nonfatal MI, stroke, revascularization procedures, angina, CHF and PAD)</p>	<p>Primary: There was no difference in risk of the combined primary endpoint between the two treatments (P=0.71).</p> <p>Secondary: There was no difference in risk of all-cause mortality between the two treatments (P=0.71).</p> <p>Compared to chlorthalidone, doxazosin was associated with a significantly higher risk of stroke (RR, 1.19; 95% CI, 1.01 to 1.40; P=0.04) and combined cardiovascular disease (RR, 1.25; 95% CI, 1.17 to 1.33; P<0.001).</p> <p>The risk of CHF doubled with doxazosin compared to chlorthalidone (P<0.001).</p> <p>Doxazosin was associated with a significantly higher risk of angina (RR, 1.16; P<0.001) and coronary revascularization (RR, 1.15; P=0.05).</p> <p>No difference between the two treatments were observed for risk of PAD (RR, 1.07; P=0.50)</p>
<p>Wright et al.⁹¹ (2008) ALLHAT</p> <p>Doxazosin</p> <p>vs</p> <p>chlorthalidone</p>	<p>DB, RCT</p> <p>Hypertensive individuals with and without metabolic/ cardiometabolic syndrome</p>	<p>N=42,418</p> <p>3.2 years (median follow-up)</p>	<p>Primary: Fatal CHD or nonfatal MI</p> <p>Secondary: Heart failure, combined cardiovascular disease, stroke,</p>	<p>Primary: No differences were noted among the four treatment groups, regardless of race or metabolic/cardiometabolic syndrome status for the primary end point (fatal CHD or nonfatal MI).</p> <p>Secondary: Significantly higher rates of heart failure were consistent across all treatment comparisons in those with metabolic/cardiometabolic syndrome. RRs were 1.50 (95% CI, 1.18 to 1.90), 1.49 (1.17 to 1.90), and 1.88 (1.42</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs amlodipine</p> <p>vs lisinopril</p>			ESRD	<p>to 2.47) in African American participants and 1.25 (1.06 to 1.47), 1.20 (1.01 to 1.41), and 0.82 (1.51 to 2.19) in non-African American participants for amlodipine, lisinopril, and doxazosin comparisons with chlorthalidone, respectively.</p> <p>Higher rates for combined cardiovascular disease were observed with lisinopril and chlorthalidone (RR, 1.24; 95% CI, 1.09 to 1.40; RR, 1.10; 95% CI, 1.02 to 1.19, respectively) and doxazosin and chlorthalidone comparisons (RR, 1.37; 95% CI, 1.19 to 1.58; RR, 1.18; 95% CI, 1.08 to 1.30, respectively) in African American and non-African American participants with metabolic/cardiometabolic syndrome.</p> <p>Higher rates of stroke were seen in African American participants only (RR, 1.37; 95% CI, 1.07 to 1.76 for the lisinopril and chlorthalidone comparison, and RR, 1.49; 95% CI, 1.09 to 2.03 for the doxazosin and chlorthalidone comparison). African American patients with metabolic/cardiometabolic syndrome also had higher rates of end-stage renal disease (RR, 1.70; 95% CI, 1.13 to 2.55) with lisinopril compared to chlorthalidone.</p>
<p>Dahlöf et al.⁹² (2005) ASCOT-BPLA</p> <p>Amlodipine 5 to 10 mg and if needed perindopril 4 to 8 mg</p> <p>or</p> <p>atenolol 50 to 100 mg and if needed bendroflumethiazide* 1.25 to 2.5 mg</p>	<p>MC, RCT</p> <p>Patients with HTN</p>	<p>N=19,257</p> <p>5.5 years</p>	<p>Primary: Nonfatal MI and fatal CHD</p> <p>Secondary: Nonfatal MI, and fatal CHD, total coronary endpoint, total cardiovascular events and procedures, all-cause mortality, cardiovascular mortality, fatal and nonfatal stroke, fatal and nonfatal heart failure, silent MI, unstable</p>	<p>Primary: The trial was halted early due to findings that patients on the amlodipine and perindopril regimen had fewer of the primary endpoints (P=0.1052) and lower rates of fatal and nonfatal stroke (P=0.0003), total cardiovascular events and procedures (P<0.0001), all-cause mortality (P=0.025), and incidence of developing diabetes (P<0.0001).</p> <p>There was a greater reduction in blood pressure by an average of 2.7/1.9 mm Hg in the amlodipine-based regimen compared to the atenolol-based regimen.</p> <p>There was no significant difference in the percent of patients (25%) that stopped therapy because of an adverse event between the two treatment groups. However, a significantly greater proportion of patients in the amlodipine-based regimen stopped the trial therapy early because of serious adverse events compared to the atenolol-based regimen (P<0.0001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>If goal blood pressure was still not achieved, doxazosin 4 to 8 mg was added to the regimen.</p>			<p>angina, chronic stable angina, PAD, life-threatening arrhythmias, development of diabetes mellitus, development of renal impairment</p>	<p>Secondary: Patients on the amlodipine-perindopril regimen had fewer fatal and nonfatal strokes (P=0.0003), total cardiovascular events and procedures (P<0.0001), and all-cause mortality (P=0.025). Patients on the amlodipine and perindopril regimen had less chance of developing diabetes (P<0.0001).</p>
<p>Chapman et al.⁹³ (2007) ASCOT-BPLA Atenolol 50 to 100 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); bendroflumethiazide* plus potassium 1.25 to 2.5 mg plus doxazosin were added for additional blood pressure control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen vs</p>	<p>Subanalysis of ASCOT-BPLA evaluating effects of spironolactone on treatment-resistant HTN Patients 40 to 79 years of age with HTN and ≥3 cardiovascular risk factors, with SBP ≥160 mm Hg and/or DBP ≥100 mm Hg (not on antihypertensive therapy) or SBP ≥140 mm Hg and/or DBP ≥90 mm Hg (on antihypertensive therapy)</p>	<p>N=1,411 1.3 years</p>	<p>Primary: Change in DBP and SBP, adverse effects Secondary: Not reported</p>	<p>Primary: Spironolactone-treated patients lead to a significant 21.9 mm Hg reduction in SBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 20.8 to 23.0 mm Hg; P<0.001). Spironolactone-treated patients lead to a significant 9.5 mm Hg reduction in DBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 9.0 to 10.1; P<0.001). Spironolactone-treated patients exhibited small but significant decreases in sodium, LDL-C and TC as well as increases in potassium, glucose, creatinine and HDL-C (P<0.05). The most common adverse effect reported in the trial was gynecomastia in men (P value not reported). Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
amlodipine 5 to 10 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); perindopril 4 to 8 mg and doxazosin were added for additional control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen				

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, IR=immediate-release, QD=once daily, QID=four times daily, SR=sustained-release, TID=three times daily

Study design abbreviations: AC=active comparator, DB=double blind, DD=double dummy, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group,

PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, SR=systematic review, XO=cross over

Miscellaneous abbreviations: AUA-SS=American Urology Association Symptom Score, BPH=benign prostatic hyperplasia, CAD=coronary artery disease, CHD=coronary artery disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, ECG=electrocardiogram, ESRD=end stage renal disease, GFR=glomerular filtration rate, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HTN=hypertension, IIEF=International Index of Erectile Function, IPSS=International Prostate Symptom Score, LDL-C=low-density lipoprotein cholesterol, LUTS=lower urinary tract symptoms, MI=myocardial infarction, OAB=overactive bladder, OR=odds ratio, PAD=peripheral artery disease, PSA=prostate-specific antigen, PVR=post-void residual urine volume, Qave=average urinary flow rate, Qmax=maximum urinary flow rate, RR=relative risk, SBP=systolic blood pressure, SD=standard deviation, SEM=standard error of mean, SFAQ= Sexual Function Abbreviated Questionnaire, TC=total cholesterol, TG=triglycerides, TPV=total prostate volume, VLDL-C=very low-density lipoprotein cholesterol, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 9. Relative Cost of the Alpha-Adrenergic Blocking Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Doxazosin	extended-release tablet, tablet	Cardura ^{®*} , Cardura XL [®]	\$\$\$	\$
Prazosin	capsule	Minipress ^{®*}	\$\$\$	\$
Terazosin	capsule	N/A	N/A	\$

*Generic is available in at least one dosage form or strength.

N/A=not available

X. Conclusions

The alpha-adrenergic blocking agents are approved for the treatment of benign prostatic hyperplasia (BPH) and hypertension.¹⁻⁶ All of the agents are available in a generic formulation. Treatment guidelines on the management of BPH recommend the use of an alpha-adrenergic blocking agent or a 5 α -reductase inhibitor in patients with moderate-to-severe symptoms. Alpha-blockers can quickly improve symptoms and flow rate, while the 5 α -reductase inhibitors have the potential for long-term reduction in prostate volume.^{8,9} Available data suggests that the combination is also effective. Clinical trials have demonstrated similar efficacy among the various alpha-adrenergic blocking agents for the treatment of BPH.²⁷⁻⁹³

There are several national and international organizations that have published guidelines on the treatment of hypertension. Most of the guidelines do not address the use of the alpha-adrenergic blocking agents.¹⁷⁻²⁶ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹⁷ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.^{17-20,22-24} Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹⁷⁻²⁶

Several clinical trials have demonstrated that the alpha-adrenergic blocking agents effectively lower blood pressure when administered as monotherapy or in combination with other antihypertensive agents. Comparative studies have demonstrated similar efficacy when the alpha-blockers were directly compared to each other, as well as when they were compared to ACE inhibitors, β -blockers, calcium-channel blocking agents and thiazide-type diuretics.⁵⁶⁻⁸⁷ The ALLHAT trial evaluated the effects of doxazosin on cardiovascular morbidity and mortality. Treatment with doxazosin increased the risk of stroke and cardiovascular events; however, it provided other benefits including improvements in insulin resistance and lipid parameters.⁸⁸⁻⁹¹

There is insufficient evidence to support that one brand alpha-adrenergic blocking agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand alpha-adrenergic blocking agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand alpha-adrenergic blocking agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
3. Cardura® [package insert]. New York (NY): Pfizer Inc; 2013 Nov.
4. Cardura XL® [package insert]. New York, NY: Pfizer Inc; 2011 Jul.
5. Minipress® [package insert]. New York, NY: Pfizer Inc; 2015 Feb.
6. Terazosin [package insert]. Weston (FL): Apotex Corp.; 2011 Jun.
7. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. *Ann Intern Med.* 1995;122:133-41.
8. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol.* 2011 May;185(5):1793-803.
9. Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) [guideline on the Internet]. Bern (Switzerland): European Association of Urology; 2015 Mar [cited 2015 Mar]. Available from: <http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>.
10. Frishman WH. Alpha and beta-adrenergic blocking drugs. In: Cardiovascular pharmacotherapeutics. 2nd ed. Frishman WH, Sonnenblick EH, Sica DA, editors. New York (NY): McGraw Hill; 2003; 67-97.
11. Schwinn DA, Roehrborn CG. A₁ adrenoceptor subtypes and lower urinary tract symptoms. *Int J Urol.* 2008 Mar;15(3):193-9.
12. Cheng TO. Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study? *Int J Cardiol.* 2006;107:275-6.
13. Berecek KH, Carey RM. Adrenergic and dopaminergic receptors and actions. In: Izzo JL Jr, Sica DA, Black HR. Hypertension primer: the essentials of high blood pressure. Dallas (TX): American Heart Association; 2008. p. 39-43.
14. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. *Drugs.* 1995;49(2):295-320.
15. Rudis MI, Dasta JF. Use of vasopressors and inotropes in the pharmacotherapy of shock. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 6th edition. New York (NY): McGraw-Hill; 2005. p. 461-78.
16. Cunningham GR, Kadmon D. Medical treatment of benign prostatic hyperplasia. In: UpToDate, O'Leary MP (Ed), UpToDate, Waltham, MA, 2015.
17. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014 Feb 5;311(5):507-20.
18. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens.* 2003 Nov;21(11):1983-92.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2007 Jun;25(6):1105-87.
20. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension.* 2009;27(11):2121-58.
21. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
22. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
23. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension.* 2010; 56:780-800.
24. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* 2004 May;43(5 Suppl 1):S1-290.

25. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl.* 2012 Dec;2(5):337-414.
26. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1-S93.
27. Lee JY, Lee SH, Kim SJ, Kim CS, Lee HM, Kim CI, et al. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. *Urology.* 2011 Jan;77(1):171-6.
28. Demir O, Ozdemir I, Bozkurt O, Aslan G, Esen AA. The effect of α -blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. *Asian Journal of Andrology.* 2009;11:716-22.
29. Sun GH, Tsui KH, Wu TT, Chang CH, Cheng CL, Schou M. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia. *Kaohsiung J Med Sci.* 2010;26(10):532-9.
30. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoe K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. *BJU Int.* 2001;87:192-200.
31. Keten T, Aslan Y, Balci M, et al. Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia. *Urology.* 2015 Jan;85(1):189-194.
32. Samli MM, Dincel C. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. *Urol Int.* 2004;73:125-9.
33. Kaplan SA, Te AE, Ikeguchi E, et al. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. *Br J Urol.* 1997;80:875-9.
34. Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. *Eur Urol.* 28(3):223-8, 1995.
35. Bozlu M, Ulusoy E, Cayan S, et al. A comparison of four different α 1-blockers in benign prostatic hyperplasia patients with and without diabetes. *Scand J Urol Nephrol.* 2004;38:391-5.
36. Xue Z, Zhang Y, Ding Q, et al. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. *Int J Urol.* 2007 Feb;14(2):118-22.
37. Rahardjo D, Soebadi D, Sugandi S, et al. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. *Int J Urol.* 2006 Nov;13(11):1405-9.
38. Pompeo AC, Rosenblatt C, Bertero E, et al. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. *Int J Clin Pract.* 2006 Oct;60(10):1172-7.
39. Johnson TM 2nd, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. *J Urol.* 2007 Nov;178(5):2045-50.
40. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. *J Urol.* 2006 Apr;175(4):1422-6.
41. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. *J Urol.* 2006 Jan;175(1):217-20.
42. Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. *J Urol* 2008;180:1030-2.
43. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. *Urology.* 2003;61(1):119-26.
44. Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. *J Urol.* 2013 Jul;190(1):187-193.
45. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α ₁-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. *Eur Urol.* 1999;36:1-13.

46. Nickel JC, Sander S, Moon TD, et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. *Int J Clin Pract* 2008;62:1547-59.
47. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. *Urology*. 2005;66:780-8.
48. Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. *Int J Urol*. 2000 Jun;7(6):199-205.
49. Tsai YS, Lan SK, Ou JH, et al. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. *Clin Ther*. 2007 Apr;29(4):670-82.
50. Yang Y, Zhao XF, Li HZ, et al. Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. *Chin Med J (Engl)*. 2007 Mar 5;120(5):370-4.
51. Dong Z, Wang Z, Yang K, et al. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. *Syst Biol Reprod Med* 2009;55:129-36.
52. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. *N Eng J Med*.1996;355:533-9.
53. Liu H, Liu P, Mao G, et al. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. *Urology* 2009;74:130-6.
54. Wilt T, Howe RW, Rutks I, MacDonald R. Terazosin for benign prostatic hyperplasia. *Cochrane Database of Systemic Reviews* 2000, Issue 1. Art. No.: CD003851. DOI: 10.1002/14651858. CD003851.
55. Wilt T, MacDonald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. *Cochrane Database of Systemic Reviews* 2002, Issue 4. Art No.: CD002081. DOI: 10.1002/14651858. CD002081.
56. Hayduk K and Schneider HT. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. *Am J Cardiol*. 1987;59:95G-8G.
57. Torvik D and Madsbu HP. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. *Br J Clin Pharmacol*. 1986;21 Suppl 1:69S-75S.
58. Fukiyama K, Omae T, Limura O, et al. A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension. *Am Heart J*. 1991;121:317-22.
59. DePlanque BA. A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics. *Am Heart J*. 1991;121:304-11.
60. Deger G. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension *Am J Med*. 1986 May 23;80(5B):62-7.
61. Ruoff G. Comparative trials of terazosin with other antihypertensive agents. *Am J Med*. 1986;80(5B):42-8.
62. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. *JAMA*. 1993;270(6):713-24.
63. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). *Circulation*. 1995;91:698-706.
64. Brown MJ and Dickerson JEC. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. *J Hypertens*. 1995;13:701-7.
65. Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. *J Hypertens*. 2002 Apr;20(4):771-7.
66. Hayduk K. Efficacy and safety of doxazosin in hypertension therapy. *Am J Cardiol*. 1987;59:35G-39G.
67. Trost BN, Weidmann P, Riesen W, et al. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. *Am J Cardiol*. 1987;59:99G-104G.
68. Grimm RH, Flack JM, Schoenberger JA, et al. Alpha-blockade and thiazide treatment of hypertension: a double-blind randomized trial comparing doxazosin and hydrochlorothiazide. *Am J Hypertens*. 1996;9:445-54.
69. Ferrara LA, Di Marino L, Russo O, et al. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients: the doxazosin-captopril in hypercholesterolemic hypertensives study. *Hypertension*. 1993;21:97-104.
70. Derosa G, Cicero AFG, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. *J Cardiovasc Pharmacol*. 2005;45(6):599-604.
71. Taylor SH, Lee PS, Sharma SK. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension. *Am Heart J*. 1988;116:1820-5.

72. Wessels F. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension. *Am Heart J.* 1991;121:299-303.
73. Hjortdahl P, von Krogh H, Daae L, et al. A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension. *Acta Med Scand.* 1987;221(5):427-34.
74. Ott P, Storm TL, Krusell LR, et al. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. *Am J Cardiol.* 1987;59(14):73G-77G.
75. Frick MH, Halttunen P, Himanen P, et al. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. *Br J Clin Pharmacol.* 1986;21(Supp 1):55S-62S.
76. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. *Blood Press.* 1998;7:39-45.
77. Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. *Am Heart J.* 1991;121:280-5.
78. Carruthers G, Dessain P, Fodor G, et al. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. *Am J Cardiol.* 1993;71(7):575-81.
79. Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. *Eur J Clin Pharmacol.* 1990;39:299-300.
80. Ohta Y, Tsuchihashi T, Onaka U, et al. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. *Hypertens Res.* 2007 Apr;30(4):301-6.
81. de Alvaro F, Hernández-Presa MA; ASOCIA Study. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study. *J Cardiovasc Pharmacol.* 2006 Feb;47(2):271-6.
82. Os I. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. *Int J Clin Pharmacol Ther.* 2006 Mar;44(3):99-106.
83. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men – A comparison of six antihypertensive agents with placebo. *N Engl J Med.* 1994;330(23):914-21.
84. McAreavey D, Ramsey LE, Latham L, McLaren AD, Lorimer AR, Reid JL, et al. Third drug trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. *Br Med J (Clin Res Ed).* 1984 Jan 14;288(6411):106-11.
85. Chrysant SG. Experience with terazosin administered in combination with other antihypertensive agents. *Am J Med.* 1986;80:5(B):55-61.
86. Holtzman JL, Kaihlanen PM, Rider JA, et al. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. *Arch Intern Med.* 1988;148(3):539-43.
87. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet.* 2005 Dec 10;366:2026-33.
88. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA.* 2000;283:1967-75.
89. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus [alpha]-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA.* 2003;42(3):239-46.
90. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. *J Clin Hypertens.* 2004;6(3):116-25.
91. Wright JT, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med.* 2008 Jan 28;168(2):207-17.
92. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. *Lancet.* 2005;366(9489):895-906.
93. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension.* 2007 Apr;49(4):839-45.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Beta-Adrenergic Blocking Agents
AHFS Class 242400
August 19, 2015**

I. Overview

The beta-adrenergic blocking agents (β -blockers) are approved for the treatment of angina, arrhythmias, essential tremor, heart failure, hypertension, hypertrophic aortic stenosis, migraine prophylaxis, myocardial infarction, and pheochromocytoma.¹⁻³² Propranolol recently became the first agent Food and Drug Administration-approved for the treatment of proliferating infantile hemangioma requiring systemic therapy.^{17,33} The β -blockers differ with regards to their adrenergic-receptor blocking, membrane stabilizing and intrinsic sympathomimetic activities, as well as lipophilicity.¹⁻³² There are at least three distinct types of β receptors distributed throughout the body (β_1 , β_2 , and β_3). β_1 receptors are located predominantly in the heart and kidneys. β_2 receptors are located in the lungs, gastrointestinal tract, liver, uterus, vascular smooth muscle, and skeletal muscle. β_3 -receptors are located in fat cells. β -blockers primarily exert their effects through a blockade of β_1 and β_2 receptor subtypes. Agents that have a greater affinity for β_1 receptors are considered to be cardioselective. These agents may be safer in patients with asthma, chronic obstructive pulmonary disease, and peripheral vascular disease because they produce less inhibition of β_2 receptors, which mediate vasoconstriction and bronchospasm. Cardioselectivity is dose dependent; therefore, β_2 blockade can occur at higher doses with these agents.^{32,34} Carvedilol and labetalol also block α -adrenergic receptors, which would be expected to reduce peripheral vascular resistance to a greater extent than other β -blockers.^{32,34}

The β -blockers are available as single entity agents, as well as fixed-dose combination products. Each of the combination products contains a thiazide-type diuretic. The thiazide-type diuretics inhibit the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.^{1,2,26-31}

The beta-adrenergic blocking agents that are included in this review are listed in Table 1 and comparative information on cardioselectivity is highlighted in Table 2. This review encompasses all dosage forms and strengths. All of the agents are available in a generic formulation, with the exception of nebivolol and penbutolol. This class was last reviewed in May 2013.

Table 1. Beta-Adrenergic Blocking Agents Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Acebutolol	capsule	Sectral ^{®*}	acebutolol
Atenolol	tablet	Tenormin ^{®*}	atenolol
Betaxolol	tablet	N/A	betaxolol
Bisoprolol	tablet	Zebeta ^{®*}	bisoprolol
Carvedilol	extended-release capsule, tablet	Coreg ^{®*} , Coreg CR [®]	carvedilol
Esmolol	injection [^]	Brevibloc ^{®*}	none
Labetalol	injection, tablet	Trandate ^{®*}	labetalol
Metoprolol	extended-release tablet, injection, tablet	Lopressor ^{®*} , Toprol-XL ^{®*}	metoprolol
Nadolol	tablet	Corgard ^{®*}	nadolol
Nebivolol	tablet	Bystolic [®]	none
Penbutolol	tablet	Levadol [®]	none
Pindolol	tablet	N/A	pindolol
Propranolol	extended-release capsule, injection, solution, tablet	Hemangeol [®] , Inderal LA ^{®*} , InnoPran XL [®]	propranolol
Sotalol	injection, tablet, solution	Betapace ^{®*} , Betapace AF ^{®*} , Sorine ^{®*} , Sotylize [®]	sotalol

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Timolol	tablet	N/A	timolol
Combination Products			
Atenolol and chlorthalidone	tablet	Tenoretic ^{®*}	atenolol and chlorthalidone
Bisoprolol and hydrochlorothiazide	tablet	Ziac ^{®*}	bisoprolol and hydrochlorothiazide
Metoprolol and hydrochlorothiazide	extended-release tablet, tablet	Dutoprol [®] , Lopressor HCT ^{®*}	metoprolol and hydrochlorothiazide
Nadolol and bendroflumethiazide	tablet	Corzide ^{®*}	nadolol and bendroflumethiazide
Propranolol and hydrochlorothiazide	tablet	N/A	propranolol and hydrochlorothiazide

*Generic is available in at least one dosage form or strength.

^Product is primarily administered in an institution.

PDL=Preferred Drug List

N/A=Not available

Table 2. Selected Pharmacologic Properties of the Beta-Adrenergic Blocking Agents¹⁻³²

Generic Name(s)	Adrenergic-Receptor Blocking Activity	Membrane Stabilizing Activity	Intrinsic Sympathomimetic Activity
Acebutolol	β_1^*	+†	+
Atenolol	β_1^*	0	0
Betaxolol	β_1^*	+	0
Bisoprolol	β_1^*	0	0
Carvedilol	$\alpha_1 - \beta_1 - \beta_2$	++	0
Labetalol	$\alpha_1 - \beta_1 - \beta_2$	0	+
Metoprolol	β_1^*	0†	0
Nadolol	$\beta_1 - \beta_2$	0	0
Nebivolol	β_1^*	0	0
Penbutolol	$\beta_1 - \beta_2$	0	+
Pindolol	$\beta_1 - \beta_2$	+	++
Propranolol	$\beta_1 - \beta_2$	++	0
Sotalol	$\beta_1 - \beta_2$	0	0
Timolol	$\beta_1 - \beta_2$	0	0

0=none; +=low; ++=moderate; +++ =high

*Inhibits β_2 receptors (bronchial and vascular) at higher doses.

†Detectable only at doses much greater than required for β blockade.

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the beta-adrenergic blocking agents are summarized in Table 3.

Table 3. Treatment Guidelines Using the Beta-Adrenergic Blocking Agents

Clinical Guideline	Recommendations
American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina	<ul style="list-style-type: none"> Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin converting enzyme (ACE) inhibitors and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with

Clinical Guideline	Recommendations
(2007) ³⁵	<p>chronic kidney disease or diabetes.</p> <ul style="list-style-type: none"> • Long-acting calcium channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) $\leq 40\%$ and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF $\leq 40\%$. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF $\leq 40\%$ and have either diabetes or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease.
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease (2013)³⁶</p>	<p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education. <p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia ($>10\%$), β-blockers should be considered. • In patients with vasospastic angina, calcium channel blockers and nitrates

Clinical Guideline	Recommendations
	<p>should be considered and beta-blockers avoided.</p> <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: Management of Stable Ischemic Heart Disease (2012)³⁷</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin is contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of</p>	<p>Early hospital care- standard medical therapies</p>

Clinical Guideline	Recommendations
<p>Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)³⁸</p>	<ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients

Clinical Guideline	Recommendations
	<p>with NSTEMI-ACS in the absence of beta-blocker therapy.</p> <ul style="list-style-type: none"> ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg,

Clinical Guideline	Recommendations
	<p>prasugrel 60 mg, or ticagrelor 180 mg.</p> <ul style="list-style-type: none"> ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. <ul style="list-style-type: none"> ● Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. ● Timing of CABG in relation to use of antiplatelet agents <ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about

Clinical Guideline	Recommendations
	<p>medication type, purpose, dose, frequency, side effects, and duration of use.</p> <ul style="list-style-type: none"> ○ For patients who are post-NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. <ul style="list-style-type: none"> ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)³⁹</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> ● Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. ● Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class \geqIII. ● Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. ● Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. ● Calcium channel blockers are recommended in patients with vasospastic angina. ● Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. ● Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> ● β-blockers are recommended in all patients with reduced left ventricular (LV) systolic function (LVEF \leq40%). ● ACE inhibitors are indicated within 24 hours in all patients with LVEF \leq40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. ● ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. ● ARBs are recommended for patients who are intolerant to ACE inhibitors, with

Clinical Guideline	Recommendations
	<p>preference given to agents and doses of proven efficacy.</p> <ul style="list-style-type: none"> • Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF $\leq 35\%$ and either diabetes or heart failure, without significant renal dysfunction (serum creatinine >2.5 mg/dL for men and >2.0 mg/dL for women) or hyperkalemia. • Statin therapy with target LDL-C levels <70 mg/dL initiated early after admission is recommended.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of ST-Elevation Myocardial Infarction (2013)⁴⁰</p>	<p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> • Oral β-blockers should be initiated within the first 24 hours in patients with an ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval >24 seconds, second or third degree heart block, active asthma, reactive airway disease). • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: Renin-Angiotensin-Aldosterone System Inhibitors</u></p> <ul style="list-style-type: none"> • An angiotensin-converting enzyme (ACE) inhibitor should be administered within the first 24 hours to all patients with STEMI with anterior location, HF, or ejection fraction (EF) $\leq 40\%$, unless contraindicated. • An angiotensin receptor blocker (ARB) should be given to patients with STEMI who have indications for but are intolerant of ACE inhibitors. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF $\leq 40\%$ and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)⁴¹</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients

Clinical Guideline	Recommendations
	<p>receiving drug-eluting stent.</p> <ul style="list-style-type: none"> • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. • In selected patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
<p>National Institute for Health and Clinical Excellence: Myocardial Infarction: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)⁴²</p>	<p>Drug therapy</p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs: <ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker. ○ Statin. • Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. • Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> • Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. • Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during this time, it should be completed within 4 to 6 weeks of hospital discharge. • Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. • Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. • Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> • Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. • Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. • For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. • Special considerations should be made for people with dyspepsia. • After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for <i>Helicobacter pylori</i> should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). • Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. • Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago). <p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> • After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. • β-blockers should be continued indefinitely after an acute MI. • After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> • Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. • If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> • For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. • Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)⁴³</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> • Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p><u>Treatment of Stage B heart failure</u></p> <ul style="list-style-type: none"> • In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) • In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-

Clinical Guideline	Recommendations
	<p>release metoprolol succinate]) should be used to prevent HF. (LoE: B)</p> <ul style="list-style-type: none"> • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p>Pharmacological treatment for Stage C HFrEF</p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p>Pharmacological treatment for Stage C HFpEF</p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C)

Clinical Guideline	Recommendations
	<p><u>Treatment of Stage D (advanced/refractory) HF</u></p> <ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)⁴⁴</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF ($<35\%$) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients

Clinical Guideline	Recommendations
	<p>following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker.</p> <ul style="list-style-type: none"> • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without

Clinical Guideline	Recommendations
	<p>left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker.</p> <ul style="list-style-type: none"> • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of

Clinical Guideline	Recommendations
	<p>heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients.</p> <ul style="list-style-type: none"> • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart

Clinical Guideline	Recommendations
	<p>failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention.</p> <ul style="list-style-type: none"> • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)⁴⁵</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing

Clinical Guideline	Recommendations
	<p>the risk of premature death).</p> <ul style="list-style-type: none"> Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. Step 3: <ul style="list-style-type: none"> Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>American Heart Association/ American College of Cardiology/ Heart Rhythm Society: Guideline for the</p>	<p>Recommendations for risk-based antithrombotic therapy:</p> <p>Class I</p> <ul style="list-style-type: none"> In patients with atrial fibrillation (AF), antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke, bleeding and the patient's values and preferences

Clinical Guideline	Recommendations
<p>Management of Patients with Atrial Fibrillation (2014)⁴⁶</p>	<p>(Level of Evidence: C).</p> <ul style="list-style-type: none"> • Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF pattern is paroxysmal, persistent, or permanent (Level of Evidence: B). • In patients with nonvalvular AF, the CHA₂DS₂-VASc score is recommended for assessment of stroke risk (Level of Evidence: B). • For patients with AF who have mechanical heart valves, warfarin is recommended and the target international normalized ratio (INR) should be based on type and location of the prosthesis (Level of Evidence: B). • For patients with nonvalvular AF with prior stroke, TIA, or a CHA₂DS₂-VASc score ≥ 2, oral anticoagulants are recommended. Options include warfarin (INR 2.0 to 3.0) (Level of Evidence: A), dabigatran, rivaroxaban, or apixaban (Level of Evidence: B). • For patients treated with warfarin, the INR should be determined at least weekly during initiation of antithrombotic therapy and at least monthly when anticoagulation (INR in range) is stable (Level of Evidence: A). • For patients with nonvalvular AF unable to maintain a therapeutic INR level with warfarin, use of a direct thrombin or factor Xa inhibitor is recommended (Level of Evidence: C). • Re-evaluation of the need for and choice of antithrombotic therapy at periodic intervals is recommended to reassess stroke and bleeding risks (Level of Evidence: C). • Bridging therapy with UFH or LMWH is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions regarding bridging therapy should balance the risks of stroke and bleeding (Level of Evidence: C). • For patients with AF without mechanical heart valves who require interruption of warfarin or newer anticoagulants for procedures, decisions about bridging therapy (LMWH or UFH) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated (Level of Evidence: C). • Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be re-evaluated when clinically indicated and at least annually (Level of Evidence: B). • For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> • For patients with nonvalvular AF and a CHA₂DS₂-VASc score of 0, it is reasonable to omit antithrombotic therapy (Level of Evidence: B). • For patients with nonvalvular AF with a CHA₂DS₂-VASc score of ≥ 2 and who have end-stage chronic kidney disease (creatinine clearance < 15 mL/min) or who are on hemodialysis, it is reasonable to prescribe warfarin (INR 2.0 to 3.0) for oral anticoagulation (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> • For patients with nonvalvular AF and a CHA₂DS₂-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered (Level of Evidence: C). • For patients with nonvalvular AF and moderate-to-severe chronic kidney disease with a CHA₂DS₂-VASc score of ≥ 2, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran, rivaroxaban, or apixaban), but safety and efficacy have not been established (Level of Evidence: C). • In patients with AF undergoing PCI, bare-metal stents may be considered to minimize the required duration of dual antiplatelet therapy. Anticoagulation may be interrupted at the time of the procedure to reduce the risk of bleeding at the site of peripheral arterial puncture (Level of Evidence: C).

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Following coronary revascularization (percutaneous or surgical) in patients with AF and a CHA₂DS₂-VASc score of ≥ 2, it may be reasonable to use clopidogrel (75 mg once daily) concurrently with oral anticoagulants but without aspirin (Level of Evidence: B). <p>Class III: No Benefit</p> <ul style="list-style-type: none"> • The direct thrombin inhibitor, dabigatran, and the factor Xa inhibitor, rivaroxaban, are not recommended in patients with AF and end-stage chronic kidney disease or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> • The direct thrombin inhibitor, dabigatran, should not be used in patients with AF and a mechanical heart valve (Level of Evidence: B). <p>Recommendations for rate control:</p> <p>Class I</p> <ul style="list-style-type: none"> • Control of the ventricular rate using a beta blocker or nondihydropyridine (non-DHP) calcium channel blocker (CCB) is recommended for patients with paroxysmal, persistent, or permanent AF (Level of Evidence: B). • Intravenous administration of a beta blocker or non-DHP CCB is recommended to slow the ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Level of Evidence: B). • In patients who experience AF-related symptoms during activity, the adequacy of heart rate control should be assessed during exertion, adjusting pharmacological treatment as necessary to keep the ventricular rate within the physiological range (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> • A heart rate control (resting heart rate <80 beats per minute [bpm]) strategy is reasonable for symptomatic management of AF (Level of Evidence: B). • Intravenous amiodarone can be useful for rate control in critically ill patients without pre-excitation (Level of Evidence: B). • Atrioventricular (AV) nodal ablation with permanent ventricular pacing is reasonable to control heart rate when pharmacological therapy is inadequate and rhythm control is not achievable (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> • A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and left ventricular systolic function is preserved (Level of Evidence: B). • Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> • AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications (Level of Evidence: C). • Non-DHP CCBs should not be used in patients with decompensated HF as these may lead to further hemodynamic compromise (Level of Evidence: C). • In patients with pre-excitation and AF, digoxin, non-DHP CCBs, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in ventricular fibrillation. (Level of Evidence: B). • Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, myocardial infarction, systemic embolism, or cardiovascular death (Level of Evidence: B). <p>Recommendations for Thromboembolism Prevention:</p>

Clinical Guideline	Recommendations
	<p>Class I</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the CHA₂DS₂-VASc score and the method used to restore sinus rhythm (Level of Evidence: B). For patients with AF or atrial flutter of more than 48 hours duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least four weeks after cardioversion unless contraindicated (Level of Evidence: C). For patients with AF or atrial flutter of less than 48-hour duration and with high risk stroke, intravenous heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after cardioversion, followed by long-term anticoagulation therapy (Level of Evidence: C). Following cardioversion for AF of any duration, the decision regarding long-term anticoagulation therapy should be based on the thromboembolic risk profile (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of 48-hour duration or longer or of unknown duration who have not been anticoagulated for the preceding three weeks, it is reasonable to perform a TEE prior to cardioversion and proceed with cardioversion if no LA thrombus is identified, including in the LAA, provided that anticoagulation is achieved before TEE and maintained after cardioversion for at least four weeks (Level of Evidence: B). For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least three weeks prior to and four weeks after cardioversion (Level of Evidence: C). <p>Class IIb</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of less than 48-hour duration who are at low thromboembolic risk, anticoagulation (heparin, LMWH, or a new oral anticoagulant) or no antithrombotic therapy may be considered for cardioversion, without the need for post cardioversion oral anticoagulation (Level of Evidence: C). <p><u>Recommendations for pharmacological cardioversion</u></p> <p>Class I</p> <ul style="list-style-type: none"> Flecainide, dofetilide, propafenone, and intravenous ibutilide are useful for pharmacological cardioversion of AF or atrial flutter, provided contraindications to the selected drug are absent (Level of Evidence: A). <p>Class IIa</p> <ul style="list-style-type: none"> Administration of oral amiodarone is a reasonable option for pharmacological cardioversion of AF (Level of Evidence: A). Propafenone or flecainide (“pill-in-the-pocket”) in addition to a beta blocker or non-DHP CCB is reasonable to terminate AF outside the hospital once this treatment has been observed to be safe in a monitored setting for selected patients (Level of Evidence: B). <p>Class III: Harm</p> <ul style="list-style-type: none"> Dofetilide therapy should not be initiated out of hospital because of the risk of excessive QT prolongation that can cause torsades de pointes (Level of Evidence: B). <p><u>Recommendations for antiarrhythmic drugs to maintain sinus rhythm</u></p> <p>Class I</p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C). • The following antiarrhythmic drugs are recommended in patients with AF to maintain sinus rhythm, depending on underlying heart disease and comorbidities (Level of Evidence: A): <ul style="list-style-type: none"> ○ Amiodarone ○ Dofetilide ○ Dronedarone ○ Flecainide ○ Propafenone ○ Sotalol • The risks of the antiarrhythmic drug, including proarrhythmia, should be considered before initiating therapy with each drug (Level of Evidence: C). • Because of its potential toxicities, amiodarone should only be used after consideration of risks and when other agents have failed or are contraindicated (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> • A rhythm-control strategy with pharmacological therapy can be useful in patients with AF for the treatment of tachycardia-induced cardiomyopathy (Level of Evidence: C). <p>Class IIb</p> <ul style="list-style-type: none"> • It may be reasonable to continue current antiarrhythmic drug therapy in the setting of infrequent, well-tolerated recurrences of AF when the drug has reduced the frequency or symptoms of AF (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> • Antiarrhythmic drugs for rhythm control should not be continued when AF becomes permanent (Level of Evidence: C), including dronedarone (Level of Evidence: B). • Dronedarone should not be used for treatment of AF in patients with New York Heart Association class III and IV HF or patients who have had an episode of decompensated HF in the past 4 weeks. (Level of Evidence: B). <p>Upstream therapy</p> <p>Class IIa</p> <ul style="list-style-type: none"> • An angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> • Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension (Level of Evidence: B). • Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery (Level of Evidence: A). <p>Class III: No Benefit</p> <ul style="list-style-type: none"> • Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease (Level of Evidence: B).
<p>National Institute for Health and Clinical Excellence: Atrial Fibrillation: The Management of Atrial Fibrillation (2014)⁴⁷</p>	<p>Interventions to prevent stroke</p> <ul style="list-style-type: none"> • Do not offer stroke prevention to people aged <65 years with atrial fibrillation (AF) and no risk factors other than their sex (that is, very low risk of stroke equating to CHA₂DS₂-VASc score of 0 for men or 1 for women). • Consider anticoagulation for men with a CHA₂DS₂-VASc score of 1. Take the bleeding risk into account. • Offer anticoagulation to people with a CHA₂DS₂-VASc score of 2 or above, taking bleeding risk into account.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences. • Apixaban <ul style="list-style-type: none"> ○ Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorization, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: <ul style="list-style-type: none"> ▪ Prior stroke of transient ischemic attack (TIA). ▪ Age 75 years or older. ▪ Hypertension. ▪ Diabetes mellitus. ▪ Symptomatic heart failure. • Dabigatran etexilate <ul style="list-style-type: none"> ○ Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors: <ul style="list-style-type: none"> ▪ Previous stroke, TIA, or systemic embolism. ▪ Left ventricular ejection fraction (LVEF) <40%. ▪ Symptomatic heart failure (HF) of New York Heart Association (NYHA) class 2 or above. ▪ Age 75 years or older. ▪ Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease, or hypertension. • Rivaroxaban <ul style="list-style-type: none"> ○ Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular AF with one or more risk factors such as: <ul style="list-style-type: none"> ▪ Congestive heart failure. ▪ Hypertension. ▪ Age 75 years or older. ▪ Diabetes mellitus. ▪ Prior stroke or TIA. • The decision about whether to start treatment with a new oral anticoagulant should be made after an informed discussion between the clinician and the person about the risks and benefits of the agent compared with the alternatives, including warfarin. For people who are taking warfarin, the potential risks and benefits of switching to a different oral agent should be considered in light of their level of international normalized ratio (INR) control. <p><u>Assessing anticoagulation control with vitamin K antagonists</u></p> <ul style="list-style-type: none"> • Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR: <ul style="list-style-type: none"> ○ Use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing. ○ Exclude measurements taken during the first six weeks of treatment. ○ Calculate TTR over a maintenance period of at least six months. • Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following: <ul style="list-style-type: none"> ○ Two INR values higher than 5 or one INR value higher than 8 within the past six months. ○ Two INR values less than 1.5 within the past six months. ○ TTR <65%. • When assessing anticoagulation, take into account and if possible address the following factors that may contribute to poor anticoagulation control: Cognitive function, adherence, illness, drug interactions, and lifestyle factors including

Clinical Guideline	Recommendations
	<p>diet and alcohol consumption.</p> <ul style="list-style-type: none"> • If poor anticoagulation control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss these with the person. <p><u>When to offer rate and rhythm control</u></p> <ul style="list-style-type: none"> • Offer rate control as the first-line strategy to people with AF, except in people whose AF has a reversible cause, who have HF thought to be primarily caused by AF, with new-onset AF, with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm, and for whom a rhythm control strategy would be more suitable based on clinical judgement. <p><u>Rate control</u></p> <ul style="list-style-type: none"> • Offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium channel blocker (CCB) as initial monotherapy to people with AF who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities, and preferences when considering drug treatment. • Consider digoxin monotherapy for people with non-paroxysmal AF only if they are sedentary. • If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any two of the following: a beta-blocker, diltiazem, and digoxin. • Do not offer amiodarone for long-term rate control. <p><u>Rhythm control</u></p> <ul style="list-style-type: none"> • Consider pharmacological and/or electrical rhythm control for people with AF whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful. <p><u>Drug treatment for long-term rhythm control</u></p> <ul style="list-style-type: none"> • Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated comorbidities, risks of treatment, and likelihood of recurrence of AF. • If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker as first-line treatment unless there are contraindications. • If beta-blockers are contraindicated or unsuccessful, assess the suitability of alternative drugs for rhythm control, taking comorbidities into account. • Dronedaron is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation: <ul style="list-style-type: none"> ○ Whose AF is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option and after alternative options have been considered AND ○ Who have at least one of the following cardiovascular risk factors: <ul style="list-style-type: none"> ▪ Hypertension requiring drugs of at least two different classes. ▪ Diabetes mellitus. ▪ Previous TIA, stroke, or systemic embolism. ▪ Left atrial diameter of 50 mm or greater, OR ▪ Age ≥ 70 years, AND ○ Who do not have left ventricular systolic dysfunction, AND ○ Who do not have a history of, or current, HF. • People who do not meet the criteria above who are currently receiving dronedaron should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Consider amiodarone for people with left ventricular impairment or HF. • Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischemic or structural heart disease. • Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the-pocket' strategy should be considered and discussed with the person.
<p>American College of Chest Physicians: Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery (2005)⁴⁸</p>	<ul style="list-style-type: none"> • β-blockers and nondihydropyridine calcium channel blockers are recommended as first- and second-line agents to control ventricular response rate in AF after cardiac surgery. Digoxin has shown little efficacy in this patient population. • Current medical evidence does not support the use of digitalis for the prevention of postoperative AF. • No recommendation can be made regarding the use of digoxin for rhythm control of postoperative AF or atrial flutter. • Agents with proarrhythmic properties and those that are contraindicated in patients with coronary artery disease have not been shown to be effective in controlling the ventricular response rate in AF after cardiac surgery. • Amiodarone is the recommended first-line agent for pharmacologic rhythm control of postoperative AF or atrial flutter in patients with depressed left ventricular function who do not need urgent electrical cardioversion. • Sotalol and Class Ia antiarrhythmics are the recommended first-line agents for pharmacologic rhythm control of postoperative AF or atrial flutter in patients with coronary artery disease without CHF. • When prophylaxis to prevent postoperative AF is indicated, β-blockers are the recommended agents. • Sotalol may be an alternative therapy to prevent postoperative AF, but its ability to cause toxicity may not make it a favorable option. • Amiodarone may also be considered as an alternative therapy to β-blockers to prevent postoperative AF, but its ability to cause toxicity may not make it a favorable option.
<p>American College of Cardiology/American Heart Association/ European Society of Cardiology Committee for Practice Guidelines: Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2006)⁴⁹</p>	<p><u>Drug therapy for ventricular arrhythmias</u></p> <ul style="list-style-type: none"> • β-blockers are currently the mainstay of pharmacologic therapy for the treatment of arrhythmias, due to their safety profile and effectiveness. • Other than β-blockers, alternative antiarrhythmic agents currently available have not been proven effective in the primary management of patients with life-threatening ventricular arrhythmias or in the prevention of sudden cardiac death. • For patients that are arrhythmia-prone, antiarrhythmic agents may be effective as adjunctive therapy in particular situations. • Caution should be used when any antiarrhythmic agent is used for therapy, as there are many side effects associated with these agents. • β-blockers, or alternatively, amiodarone or sotalol, may be used in patients with ventricular tachycardia who do not meet criteria for an implantable cardioverter-defibrillator. • Sotalol or, alternatively the combination of β-blockers and amiodarone, may be used in patients with implantable cardioverter-defibrillators who have recurrent ventricular tachycardia/ventricular fibrillation with frequent appropriate implantable cardioverter-defibrillator firing. <p><u>Ventricular arrhythmia and sudden cardiac death related to specific pathology</u></p> <p>Left ventricular dysfunction due to prior MI:</p> <ul style="list-style-type: none"> • Amiodarone, often in combination with β-blockers, can be useful for patients with left ventricular dysfunction due to prior MI and symptoms due to ventricular tachycardia unresponsive to β-blocking agents. • Sotalol is reasonable therapy to reduce symptoms resulting from ventricular tachycardia for patients with left ventricular dysfunction due to prior MI

Clinical Guideline	Recommendations
	<p>unresponsive to β-blocking agents.</p> <ul style="list-style-type: none"> • Alternative therapies to the implantable cardioverter-defibrillator to improve symptoms due to frequent episodes of sustained ventricular tachycardia or ventricular fibrillation in patients with left ventricular dysfunction due to prior MI include agents such as amiodarone or sotalol. • To reduce symptoms in patients due to recurrent hemodynamically stable ventricular tachycardia with left ventricular dysfunction due to prior MI and who cannot or refuse to have an implantable cardioverter-defibrillator implanted, amiodarone may be used as an alternative therapy. • To improve symptoms in patients with left ventricular dysfunction due to prior MI and recurrent hemodynamically stable ventricular tachycardia whose LVEF is >40% and an implantable cardioverter-defibrillator is not appropriate, amiodarone may be considered an alternative treatment option. • In patients with left ventricular dysfunction due to prior MI where an implantable cardioverter-defibrillator is indicated but is not appropriate or desired by the patient, amiodarone may be considered an alternative treatment option. • Prophylactic antiarrhythmic drug therapy is not indicated to reduce mortality in patients with asymptomatic nonsustained ventricular arrhythmias. • Class Ic antiarrhythmic agents are not recommended in patients with a past history of MI. <p><u>Congenital heart disease:</u></p> <ul style="list-style-type: none"> • Prophylactic antiarrhythmic therapy is not indicated for asymptomatic patients with congenital heart disease and isolated premature ventricular contractions. <p><u>Metabolic and inflammatory conditions:</u></p> <ul style="list-style-type: none"> • Antiarrhythmic therapy can be useful in patients with symptomatic non-sustained ventricular tachycardia or sustained ventricular tachycardia during the acute phase of myocarditis. <p><u>Pericardial disease:</u></p> <ul style="list-style-type: none"> • Prophylactic antiarrhythmic therapy generally is not indicated for primary prevention of sudden cardiac death in patients with pulmonary arterial hypertension or other pulmonary conditions. <p><u>Ventricular arrhythmias associated with cardiomyopathies</u></p> <p><u>Dilated cardiomyopathy (nonischemic):</u></p> <ul style="list-style-type: none"> • Amiodarone may be considered for sustained ventricular tachycardia or ventricular fibrillation in patients with nonischemic dilated cardiomyopathy. <p><u>Hypertrophic cardiomyopathy</u></p> <ul style="list-style-type: none"> • Amiodarone therapy can be effective for treatment in patients with hypertrophic cardiomyopathy with a history of sustained ventricular tachycardia and/or ventricular fibrillation when implantable cardioverter-defibrillator is not feasible. • Amiodarone may be considered for primary prophylaxis against sudden cardiac death in patients with hypertrophic cardiomyopathy who have one or more major risk factor for sudden cardiac death, if implantable cardioverter-defibrillator implantation is not feasible. <p><u>Arrhythmogenic right ventricular cardiomyopathy</u></p> <ul style="list-style-type: none"> • Amiodarone or sotalol can be effective for treatment of sustained ventricular tachycardia or ventricular fibrillation in patients with arrhythmogenic right ventricular cardiomyopathy when implantable cardioverter-defibrillator

Clinical Guideline	Recommendations
	<p>implantation is not feasible.</p> <p><u>Heart failure</u></p> <ul style="list-style-type: none"> • Amiodarone, sotalol and/or other β-blockers are recommended pharmacological adjuncts to implantable cardioverter-defibrillator therapy to suppress symptomatic ventricular tachyarrhythmias (both sustained and nonsustained) in otherwise optimally treated patients with heart failure. • Amiodarone is indicated for the suppression of acute hemodynamically compromising ventricular or supraventricular tachyarrhythmias when cardioversion and/or correction of reversible causes have failed to terminate the arrhythmia or prevent its early recurrence. • Amiodarone, sotalol, and/or β-blockers may be considered as pharmacological alternatives to implantable cardioverter-defibrillator therapy to suppress symptomatic ventricular tachyarrhythmias (both sustained and nonsustained) in optimally treated patients with heart failure for whom implantable cardioverter-defibrillator therapy is not feasible. <p><u>Genetic arrhythmia syndromes</u></p> <p><u>Long QT syndrome:</u></p> <ul style="list-style-type: none"> • β-blockers are recommended for patients with a long QT syndrome clinical diagnosis (i.e., in the presence of prolonged QT interval). • Implantation of an implantable cardioverter-defibrillator along with use of β-blockers is recommended for long QT syndrome patients with previous cardiac arrest and who have reasonable expectation of survival with a good functional status for more than one year. • β-blockers can be effective to reduce sudden cardiac death in patients with a molecular long QT syndrome analysis and normal QT interval. • Implantation of an implantable cardioverter-defibrillator with continued use of β-blockers can be effective to reduce sudden cardiac death in long QT syndrome patients experiencing syncope and/or ventricular tachycardia while receiving β-blockers and who have reasonable expectation of survival with a good functional status for more than one year. <p><u>Short QT syndrome and Brugada syndrome:</u></p> <ul style="list-style-type: none"> • Quinidine might be reasonable for the treatment of electrical storm in patients with Brugada syndrome. <p><u>Catecholaminergic polymorphic ventricular tachycardia:</u></p> <ul style="list-style-type: none"> • β-blockers are indicated for patients who are clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia on the basis of the presence of spontaneous or documented stress-induced ventricular arrhythmias. • β-blockers can be effective in patients without clinical manifestations when the diagnosis of catecholaminergic polymorphic ventricular tachycardia is established during childhood based on genetic analysis. • β-blockers may be considered for patients with catecholaminergic polymorphic ventricular tachycardia who were genetically diagnosed in adulthood and never manifested clinical symptoms of tachyarrhythmias. <p><u>Arrhythmias in structurally normal hearts</u></p> <p><u>Idiopathic ventricular tachycardia:</u></p> <ul style="list-style-type: none"> • Drug therapy with β-blockers and/or calcium channel blockers can be useful in patients with structurally normal hearts with symptomatic ventricular tachycardia arising from the right ventricle. <p><u>Ventricular arrhythmias and sudden cardiac death related to specific populations</u></p>

Clinical Guideline	Recommendations
	<p>Pregnancy:</p> <ul style="list-style-type: none"> In pregnant women with the long QT syndrome who have had symptoms, it is beneficial to continue β-blocker medications throughout pregnancy and afterward, unless there are definite contraindications. <p>Elderly:</p> <ul style="list-style-type: none"> The dosing and titration schedule of antiarrhythmic drugs prescribed to elderly patients should be adjusted to the altered pharmacokinetics of such patients.
<p>European Society of Cardiology: Guidelines on diagnosis and management of hypertrophic cardiomyopathy (2014)⁵⁰</p>	<ul style="list-style-type: none"> Patients with symptomatic left ventricular outflow tract obstruction should be treated initially with non-vasodilating β-blockers titrated to maximum tolerable dose. If β-blockers alone are ineffective, disopyramide titrated to a maximum tolerated dose (usually 400 to 600 mg/day) may be added. Verapamil can be used when β-blockers are contraindicated or ineffective, but close monitoring is required in patients with severe obstruction (≥ 100 mmHg) or elevated pulmonary artery systolic pressures, as it can provoke pulmonary edema. Nifedipine and other dihydropyridine calcium antagonists are not recommended. Low-dose loop or thiazide diuretics may be used cautiously to improve dyspnea, but it is important to avoid hypovolemia. In patients without left ventricular outflow tract obstruction, An ACE inhibitor (or ARB if ACE inhibitor not tolerated) should be considered, in addition to a β-blocker, for patients who have an LVEF $< 50\%$, to reduce the risks of HF hospitalization and premature death.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)⁵¹</p>	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)⁵²</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)⁵³, Reappraisal of Guidelines on Hypertension Management (2009)⁵⁴</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)⁵⁵</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP > 160 mmHg or DBP > 110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg. • A SBP goal < 140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be < 85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal < 140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used,

Clinical Guideline	Recommendations
	<p>but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina).</p> <ul style="list-style-type: none"> • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)⁵⁶ Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is

Clinical Guideline	Recommendations
	<p>required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes.</p> <ul style="list-style-type: none"> • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)⁵⁷</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction

Clinical Guideline	Recommendations
(2004) ⁵⁸	<p>(diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers).</p> <ul style="list-style-type: none"> • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)⁵⁹</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion > 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> The Work Group recommends that in children with CKD ND, blood pressure - lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)⁶⁰</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American Academy of Family Physicians: Treatment of Acute Migraine Headache (2011)⁶¹</p>	<p><u>General treatment principles</u></p> <ul style="list-style-type: none"> • Because relatively few trials have directly compared the different medication classes available to treat acute migraine, definitive treatment algorithms cannot be developed. • Nonsteroidal anti-inflammatory drugs (NSAIDs) or caffeine-containing combination analgesics may be first-line treatment for mild to moderate migraine, or severe migraine that has previously responded to these agents. • Triptans are considered first-line abortive treatment of moderate to severe migraine, or mild attacks that have not responded to nonprescription medicines. Ergotamine-containing compounds may also be reasonable in this situation.
<p>American Academy of Family Physicians: Medications for Migraine Prophylaxis (2006)⁶²</p>	<ul style="list-style-type: none"> • First-line therapies for migraine prophylaxis in adults include propranolol, timolol, amitriptyline, divalproex, sodium valproate, and topiramate. • Second-line therapies for migraine prophylaxis in adults (listed by evidence of effectiveness) include gabapentin, naproxen, naproxen sodium, timed-release dihydroergotamine mesylate, candesartan, lisinopril, atenolol, metoprolol, nadolol, fluoxetine, verapamil, magnesium, vitamin B2, coenzyme Q10, hormone therapy, feverfew, and botulinum toxin type A injections.
<p>American Academy of Neurology/ American Headache Society: Evidence-based guideline update:</p>	<ul style="list-style-type: none"> • The following medications are established as effective and should be offered for migraine prevention: <ul style="list-style-type: none"> ○ Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate ○ β-Blockers: metoprolol, propranolol, timolol

Clinical Guideline	Recommendations
<p>Pharmacologic treatment for episodic migraine prevention in adults (2012)⁶³</p>	<ul style="list-style-type: none"> ○ Triptans: frovatriptan for short-term menstrually associated migraine prevention ● The following medications are probably effective and should be considered for migraine prevention: <ul style="list-style-type: none"> ○ Antidepressants: amitriptyline, venlafaxine ○ β-Blockers: atenolol, nadolol ○ Triptans: naratriptan, zolmitriptan for short-term menstrually associated migraine prevention
<p>European Federation of Neurological Societies: Guideline on the Drug Treatment of Migraine - Revised Report of an European Federation of Neurological Societies Task Force (2009)⁶⁴</p>	<ul style="list-style-type: none"> ● Prophylactic drugs for the treatment of migraine with good efficacy and tolerability and evidence of efficacy are β-blockers, calcium-channel blockers, antiepileptic drugs, NSAIDs, antidepressants, and miscellaneous drugs. ● The use of all these drugs is based on empirical data rather than on proven pathophysiological concepts. ● There is no commonly accepted indication for starting a prophylactic treatment. Prophylactic drug treatment of migraine should be considered and discussed with the patient when 1) the quality of life, business duties, or school attendance are severely impaired; 2) frequency of attacks per month is two or higher; 3) migraine attacks do not respond to acute drug treatment; or 4) frequent, very long, or uncomfortable auras occur. ● The recommended drugs of first choice are β-blockers (metoprolol or propranolol), calcium-channel blockers (flunarizine), and antiepileptic drugs (valproic acid or topiramate). ● Drugs of second choice include amitriptyline, venlafaxine, naproxen, and bisoprolol. ● Drugs of third choice include acetylsalicylic acid, gabapentin, magnesium, riboflavin, coenzyme Q10, candesartan, lisinopril, and methylsergide. ● β-blockers are clearly effective in migraine prophylaxis and very well studied. The best evidence has been obtained for metoprolol and propranolol. Bisoprolol, timolol and atenolol might be effective, but evidence is less convincing compared with propranolol and metoprolol. ● The calcium-channel blocker, flunarizine, has been shown to be effective in migraine prophylaxis in several studies. ● Valproic acid and topiramate are two antiepileptic drugs with evidence of efficacy in more than one placebo-controlled trial. The efficacy rates are comparable to those of metoprolol, propranolol, and flunarizine. Topiramate is also efficacious in the prophylaxis of chronic migraine and may have some effect in migraine with medication overuse.
<p>National Cancer Institute: Pheochromocytoma and Paraganglioma Treatment (PDQ®) (2013)⁶⁵</p>	<ul style="list-style-type: none"> ● If tachycardia develops or if blood pressure control is not optimal with α-adrenergic blockade, a β-blocker (e.g., metoprolol or propranolol) can be added, but only after α-blockade. ● A β-blocker must never be initiated before α-blockade; doing so blocks β-blocker mediated vasodilation and results in unopposed α-blocker receptor mediated vasoconstriction, which can lead to a life-threatening crisis.
<p>American Academy of Neurology: Practice Parameter: Therapies for Essential Tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology (2005)⁶⁶, Evidence-based guideline update:</p>	<ul style="list-style-type: none"> ● Propranolol and primidone are agents that are most commonly used to treat essential tremor (ET). ● It is recommended that propranolol, long-acting propranolol, or primidone be offered to patients who want treatment for limb tremor in ET, depending on concurrent medical conditions and potential side effects. ● It is recommended that either primidone or propranolol be used as initial therapy to treat limb tremor in ET. ● It is recommended that atenolol and sotalol be considered for treatment of limb tremor associated with ET, and propranolol may be considered as a treatment option for head tremor in patients with ET. ● Nadolol may be considered a treatment option for limb tremor associated with ET.

Clinical Guideline	Recommendations
<p>Treatment of essential tremor (2011 update)⁶⁷</p> <p>Reaffirmed April 2014</p>	<ul style="list-style-type: none"> • Pindolol is not recommended for treatment of limb tremor in ET. • Due to the lack of evidence, a recommendation regarding the use of metoprolol in the treatment of limb tremor in ET cannot be provided. • The combination of primidone and propranolol may be used to treat limb tremor when the use of a single agent does not adequately decrease tremor. • The dosages of propranolol and primidone may need to be increased after 12 months of therapy when treating limb tremor in ET. • Levetiracetam and 3,4-diaminopyridine should not be considered for treatment of limb tremor in ET. • Clinicians may choose not to consider flunarizine for treatment of limb tremor in ET. • The evidence is insufficient to make recommendations regarding the use of pregabalin, zonisamide, or clozapine

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the beta-adrenergic blocking agents are noted in Tables 4 and 5. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 4. FDA-Approved Indications for the Beta-Adrenergic Blocking Agents³⁻³¹

Indications	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Angina Pectoris									
Long-term management of angina pectoris		✓ *					✓ †	✓	
Cardiac Arrhythmias									
Management of ventricular premature beats	✓								
Heart Failure									
Mild to severe chronic heart failure of ischemic or cardiomyopathic origin to increase survival and, also, to reduce the risk of hospitalizations					✓				
Stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin							✓ (succinate)		
Hypertension									
Control of blood pressure in severe hypertension						✓ (injection)			
Essential hypertension					✓ ‡				
Hypertension	✓ ‡	✓ ‡	✓ ‡	✓ ‡		✓ ‡ (tablet)	✓ ‡	✓ ‡	✓ ‡
Myocardial Infarction									
Hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality		✓					✓ (tartrate)		
Reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure)					✓				

*Due to coronary atherosclerosis.

†Metoprolol succinate: To reduce angina attacks and to improve exercise tolerance.

‡May be used in combination with other antihypertensive agents.

NYHA=New York Heart Association

Table 5. FDA-Approved Indications for the Beta-Adrenergic Blocking Agents³⁻³¹

Indications	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendroflumethiazide	Propranolol and HCTZ
Angina Pectoris										
Angina pectoris			✓ * (Inderal LA®, tablet)							
Cardiac Arrhythmias										

Indications	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendroflu-methiazide	Propranolol and HCTZ
Abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measure fail			✓ (injection)							
Control ventricular rate in patients with atrial fibrillation and a rapid ventricular response			✓ (tablet)							
Control ventricular rate in life-threatening digitalis-induced arrhythmias			✓ (injection)							
Documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening				✓ † (Betapace [®] , Sotylize [®])						
Maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/atrial flutter who are currently in sinus rhythm				✓ † (Betapace AF [®] , Sotylize [®])						
Persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures			✓ (injection)							
Short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate			✓ (injection)							
Hypertension										
Hypertension		✓ ‡	✓ ‡ (oral§)		‡	✓	✓	✓ ¶	✓	✓
Mild to moderate arterial hypertension	✓ ‡									
Hypertrophic Subaortic Stenosis										
Improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis			✓ (Inderal LA [®] , tablet)							
Myocardial Infarction										
Reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable			✓ (tablet)							
Reduce cardiovascular mortality and reinfarction in patients who have survived the acute phase of myocardial infarction and are clinically stable					✓					
Other										
Adjunct to alpha-adrenergic blockade			✓ (tablet)							

Indications	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendroflu-methiazide	Propranolol and HCTZ
to control blood pressure and reduce symptoms of catecholamine-secreting tumors										
Familial or hereditary essential tremor			✓ (tablet)							
Treatment of proliferating infantile hemangioma requiring systemic therapy			✓ (Hemangeol®)							
Prophylaxis of migraine headache			✓ (Inderal LA®, tablet)		✓					

*Angina pectoris due to coronary atherosclerosis to decrease angina frequency and increase exercise tolerance.

†Intravenous sotalol can substitute for oral sotalol in patients who are unable to take sotalol orally.

‡May be used in combination with other antihypertensive agents.

§Inderal LA® and propranolol tablet are not indicated in the management of hypertensive emergencies.

|| Not indicated for initial treatment of hypertension.

¶Dutoprol® may be used in combination with other antihypertensive agents. Lopressor HCT® is not indicated for initial treatment of hypertension.

HCTZ=hydrochlorothiazide, NYHA=New York Heart Association

IV. Pharmacokinetics

The pharmacokinetic parameters of the beta-adrenergic blocking agents are listed in Table 6. The lipophilic properties vary among the agents. The higher the lipid solubility, the higher the potential to cross the blood brain barrier and increase the risk of central nervous system adverse events, including dizziness and drowsiness.^{32,34}

Table 6. Pharmacokinetic Parameters of the Beta-Adrenergic Blocking Agents²

Generic Name(s)	Bio-availability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)	Lipid Solubility
Single Entity Agents						
Acebutolol	40	26	Liver	Renal (30 to 40) Bile (3 to 8) Feces (56)	3 to 4	Low
Atenolol	50	16	Not reported	Renal (40 to 50) Feces (50)	6 to 7	Low
Betaxolol	84 to 93	50	Liver, extensive (% not reported)	Renal (>80)	14 to 22	Low
Bisoprolol	80	30	Liver (50)	Renal (50) Feces (<2)	9 to 12	Low
Carvedilol	21 to 35	98	Liver, extensive (% not reported)	Renal (16) Feces (60)	6 to 10	Moderate
Labetalol	25	50	Liver, extensive (% not reported)	Renal (55 to 60) Feces (50)	5 to 8	Moderate
Metoprolol	50 to 77	12	Liver, extensive (% not reported)	Renal (95)	3 to 7	Moderate
Nadolol	20 to 40	28 to 30	None	Renal (25) Feces (77)	20 to 24	Low
Nebivolol	12 to 96	98	Liver, extensive (% not reported)	Renal (<1) Feces (13 to 44)	12 to 19	High
Penbutolol	100	80 to 98	Liver, extensive (% not reported)	Renal (90)	17 to 26	High
Pindolol	87 to 90	40 to 60	Liver (60 to 65)	Renal (35 to 40) Feces (6 to 9)	3 to 4	Moderate
Propranolol	30 to 70	93	Liver (50 to 70)	Renal (<1)	3 to 4	High
Sotalol	60 to 100	0	Liver, minor	Renal (66 to 75)	7 to 18	Low
Timolol	61	<10	Liver (80)	Renal (20)	2 to 4	Low-Moderate
Combination Products						
Atenolol and chlorthalidone	50/65	16/75	Not reported/ Liver (% not reported)	Renal (40 to 50) Feces (50)/ Renal (60)	6 to 7/ 40 to 60	Low/not reported
Bisoprolol and HCTZ	80/ 50 to 75	30/ 40 to 68	Liver (50)/ not reported	Renal (50) Feces (<2)/ Renal (>95)	9 to 12/ 6 to 15	Low/not reported
Metoprolol and HCTZ	Not reported	12/68	Liver, extensive (% not reported)/ not reported	Renal (95)/ Renal (72 to 97)	3 to 7/ 10 to 17	Moderate/ not reported
Nadolol and bendroflumethiazide	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Propranolol and HCTZ	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the beta-adrenergic blocking agents (β -blockers) are listed in Table 7.

Table 7. Significant Drug Interactions with the Beta-Adrenergic Blocking Agents¹

Generic Name(s)	Significance Level	Interaction	Mechanism
β -blockers (acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, sotalol, timolol)	1	Verapamil	May be synergistic or additive effects. Verapamil may inhibit oxidative metabolism of certain β -blockers. Additive QT interval prolongation is possible with sotalol.
β -blockers (nadolol, penbutolol, pindolol, propranolol, sotalol, timolol)	1	Epinephrine	Nonselective β blockade allows α - receptor effects of epinephrine to predominate. Increasing vascular resistance leads to a rise in blood pressure and reflex bradycardia.
β -blockers (nadolol, penbutolol, pindolol, propranolol, sotalol, timolol)	1	Sympathomimetics	Nonselective β -blockers may block the action of beta-agonists, potentially resulting in severe bronchospasm in asthmatics.
Thiazides (hydrochlorothiazide, chlorthalidone, bendroflumethiazide)	1	Lithium	Decreased lithium clearance may occur with thiazide use. This may lead to increased serum lithium levels and possibly lithium toxicity. Monitor plasma lithium levels and symptoms of toxicity, and adjust the dose as needed.
Thiazides (hydrochlorothiazide, bendroflumethiazide)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes. The coadministration of dofetilide with a thiazide diuretic is contraindicated.
β -blockers (sotalol)	1	Bepidil	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility.
β -blockers (sotalol)	1	Chloroquine	Prolonged QT interval and cardiac arrhythmias are a potential when sotalol and chloroquine are coadministered.
β -blockers (sotalol)	1	Class IA or IC Antiarrhythmic Agents	Class IA and IC antiarrhythmics and sotalol may cause additive pharmacologic and adverse cardiovascular effects when co-administered.
β -blockers (sotalol)	1	Dofetilide	The risk of cardiovascular toxicity, including torsades de pointes, may be increased by co-administration of dofetilide and sotalol. Pharmacologic effects of dofetilide and sotalol on electrical conduction of the heart may be additive.
β -blockers (sotalol)	1	Dronedarone	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility.
β -blockers (sotalol)	1	Droperidol	Arrhythmias resulting from the potential for additive QT prolongation should be

Generic Name(s)	Significance Level	Interaction	Mechanism
			considered as a possibility.
β-blockers (sotalol)	1	Fluconazole	Coadministration of fluconazole and sotalol may increase the risk of potentially fatal cardiac arrhythmias (torsades de pointes), especially in seriously ill patients and/or patients receiving high dose fluconazole.
β-blockers (sotalol)	1	Haloperidol	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility.
β-blockers (sotalol)	1	Maprotiline	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility.
β-blockers (sotalol)	1	Methadone	Prolongation of the QT interval with possible development of cardiac arrhythmias, including torsades de pointes, should be considered when sotalol is co-administered with methadone.
β-blockers (sotalol)	1	Nilotinib	Additive QT prolongation may occur during coadministration of nilotinib and sotalol.
β-blockers (sotalol)	1	Pentamidine	Prolongation of the QT interval with possible development of cardiac arrhythmias, including torsades de pointes, should be considered when sotalol is co-administered with pentamidine.
β-blockers (sotalol)	1	Perflutren	Additive QT interval prolongation may occur during coadministration of perflutren and sotalol.
β-blockers (sotalol)	1	Phenothiazines	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when sotalol and phenothiazines are co-administered.
β-blockers (sotalol)	1	Phosphodiesterase type 5 Inhibitors	Phosphodiesterase type 5 inhibitors and sotalol may cause additive adverse effects when co-administered. Prolonged QT interval with the potential for cardiac arrhythmias may occur.
β-blockers (sotalol)	1	Pimozide	Sotalol and pimozide may cause additive adverse effects when co-administered. Cardiovascular toxicity, including torsades de pointes, may occur due to additive QT-interval prolongation.
β-blockers (sotalol)	1	Quinolones	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility.
β-blockers (sotalol)	1	Serotonin Receptor Antagonists Antiemetics	The risk of QT-interval prolongation and cardiac arrhythmias caused by serotonin receptor antagonist antiemetics may be increased by co-administration of sotalol.
β-blockers (sotalol)	1	Tetrabenazine	Additive QT prolongation may occur during coadministration of tetrabenazine and sotalol.
β-blockers	1	Tyrosine Kinase	Additive QT interval prolongation is a

Generic Name(s)	Significance Level	Interaction	Mechanism
(sotalol)		Receptor Inhibitor	possibility when tyrosine kinase receptor inhibitors are coadministered with sotalol.
β-blockers (sotalol)	1	Ziprasidone	Arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when sotalol and ziprasidone are co-administered.
β-blockers (acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Clonidine	B-blocker inhibition of β ₂ receptor mediated vasodilation leaves peripheral α ₂ -receptor mediated vasoconstriction unopposed to clonidine stimulation.
β-blockers (acebutolol, atenolol, betaxolol, carvedilol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Diltiazem	Additive AV nodal blockade may lead to synergistic bradycardia
β-blockers (acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, timolol)	2	Flecainide	Unknown mechanism. Combination may result in additive bradycardia and cardiac arrest
β-blockers (acebutolol, atenolol, betaxolol, carvedilol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Nonsteroidal Anti-inflammatory Drugs	NSAIDs may inhibit renal prostaglandin synthesis, allowing unopposed pressor systems to produce hypertension.
β-blockers (acebutolol, atenolol, betaxolol, carvedilol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Quinazolines	Unknown mechanism. Additive vasodilation may increase risk of hypotension, specifically orthostatic hypotension. Generally occurs with the addition of prazosin to chronic β-blocker therapy, not β-blocker added to chronic prazosin therapy
β-blockers (bisoprolol, carvedilol, nadolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Insulin	β-blockers blunt sympathetic mediated responses to hypoglycemia.
β-blockers (atenolol, carvedilol, metoprolol, nadolol, pindolol, propranolol, sotalol)	2	Lidocaine	Reduced hepatic lidocaine metabolism and possibly a minor component of diminished hepatic blood flow.
β-blockers (bisoprolol, carvedilol, metoprolol, pindolol, propranolol, timolol)	2	Cimetidine	Cimetidine may reduce hepatic first-pass extraction, decrease liver blood flow, and inhibit hepatic metabolism of β-blockers.

Generic Name(s)	Significance Level	Interaction	Mechanism
β-blockers (nadolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Meglitinides	Unknown mechanism. Possible increase in hypoglycemic activity of meglitinides.
β-blockers (nadolol, penbutolol, pindolol, propranolol, sotalol, timolol)	2	Theophyllines	Pharmacologic antagonism. B-blockers may reduce the n-demethylation of theophylline.
β-blockers (atenolol, carvedilol, metoprolol, propranolol, timolol)	2	Quinidine	Oxidative metabolism of certain β-blockers may be inhibited by quinidine.
β-blockers (carvedilol, metoprolol, nebivolol, propranolol, timolol)	2	Terbinafine	Terbinafine inhibits CYP2D6 and may result in increased plasma concentrations of certain β-blockers.
β-blockers (carvedilol, metoprolol, propranolol, timolol)	2	Diphenhydramine	Inhibition of CYP2D6-mediated β-blocker metabolism may decrease the metabolism of certain β-blockers resulting in excessive cardiovascular effects.
β-blockers (metoprolol, nebivolol, propranolol, timolol)	2	Serotonin Reuptake Inhibitors	Inhibition of CYP2D6 enzyme may decrease the metabolism of metoprolol resulting in excessive pharmacologic activity.
β-blockers (metoprolol, propranolol, sotalol)	2	Amiodarone	Additive pharmacologic effects of both drugs may result in severe bradycardia, hypotension, or cardiac arrest. Possible additive QT interval prolongation with sotalol and amiodarone.
β-blockers (pindolol, propranolol, sotalol)	2	Phenothiazines	Chlorpromazine may inhibit the first-pass hepatic metabolism of propranolol and increase its pharmacologic effects. Certain β-blockers may inhibit the metabolism of phenothiazines increasing the risk for cardiac side effects, including torsades de pointes.
β-blockers (carvedilol, metoprolol, propranolol)	2	Rifamycins (rifabutin, rifampin, rifapentine)	Possible decrease in oral bioavailability of carvedilol resulting in first-pass metabolism.
β-blockers (carvedilol, metoprolol, propranolol)	2	Thiamines	Hyperthyroidism appears to cause increased clearance of β-blockers with a high extraction ration. This may be the result of increased liver blood flow, first-pass metabolism and volume of distribution.
Thiazide diuretics (HCTZ, chlorthalidone, bendroflumethiazide)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia though an unknown mechanism; therefore the combination should be avoided. When used together, blood and urine glucose levels should be frequently monitored, and dosage reductions may be required.
Thiazide diuretics	2	Digitalis glycosides	Thiazide diuretics may induce electrolyte

Generic Name(s)	Significance Level	Interaction	Mechanism
(HCTZ, chlorthalidone, bendroflumethiazide)			disturbances which may predispose patients to digitalis-induced arrhythmias. Measure plasma levels of potassium and magnesium, supplement low levels, and use dietary sodium restriction or potassium-sparing diuretics to prevent further losses.
β-blockers (metoprolol, propranolol)	2	Hydralazine	Hydralazine increases systemic availability of some β-blockers, probably by transient increase in splanchnic blood flow and decreasing first-pass hepatic metabolism.
β-blockers (metoprolol, propranolol)	2	Propafenone	Propafenone increases plasma β-blocker level by decreasing first-pass metabolism and reducing systemic clearance. Both drugs are oxidized by the hepatic CYP450 system, and propafenone appears to inhibit the metabolism of the β-blocker.
β-blockers (atenolol)	2	Ampicillin	The bioavailability of atenolol may be decreased by impaired gastrointestinal absorption induced by ampicillin.
β-blockers (carvedilol)	2	Cyclosporine	Unknown mechanism. Carvedilol may increase plasma concentrations of cyclosporine and dose reduction may be required.
β-blockers (carvedilol)	2	Digoxin	Carvedilol may increase digoxin bioavailability. Possible additive depression of myocardial conduction and decreased renal tubular digoxin secretion.
β-blockers (labetalol)	2	Inhalation anesthetics	Additive myocardial depressant effects possibly resulting in excessive hypotension.
β-blockers (propranolol)	2	Mefloquine	Additive slowing of cardiac conduction possibly resulting in lengthening of the QT interval
β-blockers (propranolol)	2	Triptans	Unknown mechanism. Possible inhibition of triptan metabolism (monoamine oxidase-A) by propranolol resulting in enhanced pharmacologic effects and plasma concentrations.
β-blockers (sotalol)	2	Cisapride	Prolongation of the QT interval with possible development of cardiac arrhythmias, including torsades de pointes, should be considered when cisapride is co-administered with sotalol.
β-blockers (sotalol)	2	H1 Antagonists	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when sotalol and H-1 antagonists are coadministered.
β-blockers (sotalol)	2	Iloperidone	Prolonged QT interval and cardiac arrhythmias are a potential when sotalol and iloperidone are used concomitantly.
β-blockers (sotalol)	2	Macrolides	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a

Generic Name(s)	Significance Level	Interaction	Mechanism
			possibility when sotalol and macrolides are coadministered.
β-blockers (sotalol)	2	Mefloquine	Co-administration of mefloquine and sotalol may cause cardiovascular toxicity, including electrocardiographic abnormalities such as QT interval prolongation
β-blockers (sotalol)	2	Mibefradil	Co-administration of sotalol and mibefradil may cause cardiovascular toxicity.
β-blockers (sotalol)	2	Paliperidone	Prolongation of the QT interval with possible development of cardiac arrhythmias, including torsades de pointes, should be considered when paliperidone is co-administered with sotalol.
β-blockers (sotalol)	2	Propafenone	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered when sotalol and propafenone are coadministered.
β-blockers (sotalol)	2	Saquinavir	Coadministration of sotalol with saquinavir/ritonavir may be associated arrhythmias due to potential additive effects on prolongation of the QT interval.
β-blockers (sotalol)	2	Tricyclic Antidepressants	The rare occurrence of arrhythmias resulting from the potential for additive QT prolongation should be considered as a possibility when tricyclic antidepressants and sotalol are coadministered.

CYP=cytochrome P450 isoenzymes, HCTZ=hydrochlorothiazide
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the beta-adrenergic blocking agents are listed in Tables 8 and 9. The boxed warnings for the beta-adrenergic blocking agents are listed in Tables 10 through 15.

Table 8. Adverse Drug Events (%) Reported with the Beta-Adrenergic Blocking Agents¹⁻³¹

Adverse Events	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Cardiovascular									
Angina	-	-	<2	-	1 to 6	-	-	-	-
Arrhythmia	-	-	<2	<1	-	-	-	<1	-
Arterial/vascular insufficiency	-	-	-	-	-	-	1	-	<1
Bradycardia	1 to 10	1 to 10	6 to 8	<1	2 to 10	<1	2 to 16	1 to 10	<1
Cardiogenic shock	-	-	-	-	-	-	✓	-	-
Cerebrovascular accident	-	-	-	-	≤4	-	-	-	-
Chest pain	2	1 to 10	2 to 7	1 to 2	-	-	1	<1	<1
Cold extremities	-	1 to 10	2	<1	-	-	1	1 to 10	-
Congestive heart failure	1 to 10	1 to 10	<2	<1	-	<1	1	1 to 10	-
Edema	2	1 to 10	≤2	<1	5 to 6	≤2	-	1 to 10	-
Flushing	-	-	-	<1	-	1	-	-	-
Heart block	✓	1 to 10	<2	-	≤4	<1	5	-	-
Hypertension	-	-	<2	-	≤4	-	-	-	-
Hypotension	1 to 10	1 to 10	<2	<1	9 to 20	1 to 5	1 to 27	-	-
Myocardial ischemia	-	-	-	-	-	-	-	-	<1
Orthostatic hypotension	-	-	-	<1	-	-	-	<1	-
Palpitations	✓	-	2	<1	≤4	-	1	1 to 10	-
Peripheral circulation reduced	-	-	-	-	<1	-	-	1 to 10	-
Peripheral edema	-	-	-	-	1 to 7	-	1	-	1
Postural hypotension	-	-	-	-	≤4	-	-	-	-
Rhythm disturbance	-	-	-	<1	-	-	-	-	-
Shortness of breath	-	-	-	-	-	-	✓	-	-
Syncope	-	-	<2	<1	3 to 8	<1	1	-	<1
Ventricular arrhythmias	✓	-	-	-	-	-	-	-	-
Central Nervous System									
Abnormal dreams	2	-	<1	-	-	-	-	-	-
Anxiety	1 to 10	-	-	<1	-	-	✓	-	-
Concentration decreased	-	-	-	-	<1	-	-	-	-
Confusion	-	1 to 10	-	<1	-	-	✓	<1	-
Depression	2	1 to 10	<1	<1	1 to 10	-	5	1 to 10	-
Diaphoresis	-	-	<2	-	<1	-	-	-	-
Dizziness	6	1 to 10	-	<1	2 to 32	1 to 20	2 to 10	-	2 to 4
Drowsiness	-	-	-	-	-	-	-	>10	-
Fatigue	11	1 to 10	3 to 10	6 to 8	4 to 24	1 to 11	1 to 10	-	-
Fever	-	-	<2	-	1 to 10	-	-	-	-
Hallucinations	-	<1	<2	<1	-	-	✓	<1	2 to 5
Headache	6	1 to 10	-	<1	5 to 8	2	✓	<1	-

Adverse Events	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Hyper/hypoesthesia	1 to 10	-	-	1 to 2	1 to 10	-	-	-	-
Insomnia	3	1 to 10	1 to 5	2 to 3	1 to 10	-	✓	>10	6 to 9
Lethargy	-	1 to 10	3	-	-	-	-	-	1
Malaise	-	-	<2	<1	1 to 10	-	-	-	-
Memory loss	-	-	<2	<1	<1	-	✓	-	-
Mental impairment	-	1 to 10	-	-	-	-	-	-	-
Nervousness	-	-	-	<1	<1	-	✓	<1	-
Nightmares/vivid dreams	-	1 to 10	-	-	<1	-	✓	-	-
Paresthesia	-	-	-	<1	-	-	✓	-	-
Psychosis	-	<1	-	-	-	-	-	-	-
Sleep disturbance	-	-	-	<1	-	-	✓	-	-
Somnolence	-	-	-	<1	1 to 10	3	✓	-	-
Vertigo	-	-	-	<1	1 to 10	1 to 2	✓	-	<1
Dermatologic									
Acne	-	-	-	<1	-	-	-	-	-
Alopecia	-	<1	<2	<1	<1	<1	✓	-	-
Dermatitis	-	-	-	<1	-	-	-	-	✓
Eczema	-	-	-	<1	-	-	-	-	-
Erythema multiforme	-	-	-	-	<1	-	-	-	-
Exfoliative dermatitis	-	-	-	-	<1	-	-	-	-
Photosensitivity	-	-	-	-	<1	-	✓	-	-
Pruritus	1 to 10	-	-	<1	<1	1	5	-	<1
Psoriasisiform rash	-	<1	-	<1	-	<1	-	-	-
Psoriasis (exacerbated)	-	-	-	<1	-	-	✓	-	<1
Purpura	-	-	-	<1	-	-	-	-	-
Rash	2	-	1	<1	<1	1	5	-	<1
Scalp tingling	-	-	-	-	-	≤7	-	-	-
Stevens-Johnson syndrome	-	-	-	-	<1	-	-	-	-
Sweating, excessive	-	-	-	-	-	-	✓	-	-
Systemic lupus erythematosus	✓	-	-	-	-	-	-	-	-
Toxic epidermal necrolysis	-	-	-	-	<1	-	-	-	-
Urticaria	-	-	-	-	-	<1	✓	-	<1
Endocrine and Metabolic									
Diabetes (exacerbated)	-	-	<2	-	1 to 10	-	✓	-	-
Gout	-	-	-	<1	1 to 10	-	-	-	-
Libido decreased	-	-	-	-	-	-	✓	-	-
Gastrointestinal									
Abdominal pain	1 to 10	-	-	<1	1 to 10	-	✓	-	1 to 10
Anorexia	✓	-	<2	-	-	-	-	-	-
Constipation	4	1 to 10	<2	<1	-	-	1	1 to 10	-
Cramping	-	-	-	-	-	-	-	-	-
Diarrhea	4	1 to 10	2	3 to 4	-	-	5	1 to 10	2 to 3
Dyspepsia	4	-	4 to 5	<1	-	≤4	-	-	-
Epigastric distress	-	-	-	-	-	-	-	-	-
Flatulence	3	-	-	-	-	-	1	-	-
Gastritis/gastric irritation	-	-	-	<1	-	-	-	-	-

Adverse Events	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Gastrointestinal hemorrhage	-	-	-	-	<1	-	-	-	-
Heartburn	-	-	-	-	-	-	1	-	-
Melena	-	-	-	-	1 to 10	-	-	-	-
Nausea	4	1 to 10	2 to 6	2	2 to 9	≤19	1	1 to 10	1 to 3
Pancreatitis	-	-	-	-	<1	-	-	-	-
Peptic ulcer	-	-	-	<1	-	-	-	-	-
Periodontitis	-	-	-	-	1 to 10	-	-	-	-
Retroperitoneal fibrosis	-	-	-	-	-	-	✓	-	-
Stomach discomfort	-	-	-	-	-	-	-	1 to 10	-
Taste disorder	-	-	<2	<1	-	1	✓	-	-
Vomiting	1 to 10	-	<2	1 to 2	1 to 6	≤3	✓	1 to 10	<1
Weight gain	-	-	<2	<1	10 to 12	-	✓	-	-
Xerostomia	✓	-	<2	<1	<1	-	-	-	-
Genitourinary									
Cystitis	-	-	<2	<1	-	-	-	-	-
Diabetes insipidus	-	-	-	-	-	<1	-	-	-
Dysuria	1 to 10	-	<2	-	-	-	-	-	-
Ejaculatory failure	-	-	-	-	-	≤5	-	-	-
Hematuria	-	-	-	-	1 to 10	-	-	-	-
Impotence	1 to 10	1 to 10	-	<1	1 to 10	1 to 4	✓	-	<1
Libido decreased	-	-	<2	<1	<1	-	-	-	-
Micturition (frequency)	3	-	-	-	-	-	-	-	-
Nocturia	1 to 10	-	-	-	-	-	-	-	-
Polyuria	-	-	-	<1	-	-	-	-	-
Sexual ability decreased	-	-	-	-	-	-	-	>10	-
Urinary incontinence	-	-	-	-	<1	-	-	-	-
Urinary retention	✓	-	-	-	-	<1	-	-	-
Hematologic									
Agranulocytosis	-	-	-	-	<1	-	✓	-	-
Anemia (aplastic/hemolytic)	-	-	<2	-	1 to 10	-	-	-	-
Claudication	-	-	-	-	-	-	✓	-	-
Leukopenia	-	-	-	<1	<1	-	-	<1	-
Pancytopenia	-	-	-	-	<1	-	-	-	-
Prothrombin decreased	-	-	-	-	1 to 10	-	-	-	-
Purpura	-	-	<2	-	1 to 10	-	-	-	-
Thrombocytopenia	-	<1	<2	<1	1 to 10	-	✓	<1	1 to 10
Hepatic									
Cholestatic jaundice	-	-	-	-	<1	<1	-	-	-
Hepatic impairment	✓	-	-	-	<1	<1	-	-	-
Hepatitis	-	-	-	-	-	<1	✓	-	-
Increase liver enzymes	-	<1	-	-	-	-	-	-	<1
Transaminases increase	✓	-	<2	<1	1 to 10	4	✓	-	-
Laboratory Test Abnormalities									
Alkaline phosphatase increased	✓	-	-	-	-	-	✓	-	-
Hypercalcemia	-	-	-	-	<1	-	-	-	-
Hypercholesterolemia	-	-	<2	-	1 to 4	-	-	-	1 to 10

Adverse Events	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Hyperglycemia	-	-	<2	-	-	-	-	-	-
Hyperkalemia	-	-	<2	<1	1 to 10	-	-	-	-
Hypernatremia	-	-	-	-	-	-	-	-	-
Hyperphosphatemia	-	-	-	-	3 to 6	-	-	-	-
Hypertriglyceridemia	-	-	-	<1	1	-	-	-	-
Hyperuricemia	-	-	<2	<1	1 to 10	-	-	-	1 to 10
Hypervolemia	-	-	-	-	≤4	-	-	-	-
Hypoglycemia	-	-	<2	<1	1 to 10	-	-	-	-
Hyponatremia	-	-	-	-	1 to 10	-	-	-	-
Hypokalemia	-	-	<2	-	1 to 10	-	-	-	-
Lactate dehydrogenase increased	-	-	-	-	-	-	✓	-	-
Musculoskeletal									
Arthralgia	-	-	3 to 5	1 to 10	1 to 6	-	✓	-	-
Arthritis	-	-	-	-	-	-	✓	-	-
Asthenia	-	-	-	≤2	-	-	-	-	-
Back pain	1 to 10	-	-	<1	2 to 7	-	-	-	-
Joint pain	1 to 10	-	-	<1	-	-	-	-	-
Muscle cramps	-	-	<2	<1	1 to 10	-	-	-	-
Muscle pain	-	-	-	<1	-	-	✓	-	-
Muscle spasm	-	-	-	-	-	-	-	-	-
Myalgia	2	-	-	-	-	-	-	-	-
Neuralgia	-	-	<2	-	<1	-	-	-	-
Paresthesia	-	-	-	-	-	≤5	-	-	1 to 10
Peripheral ischemia	✓	-	-	-	-	-	-	-	-
Restlessness	-	-	-	<1	-	-	-	-	-
Tremor	-	-	<2	<1	-	-	-	-	-
Toxic myopathy	-	-	-	-	-	<1	-	-	-
Twitching	-	-	<2	<1	-	-	-	-	-
Weakness	-	-	-	-	7 to 11	1	-	-	1 to 10
Renal									
Blood urea nitrogen increased	-	-	-	<1	≤6	≤8	-	-	1 to 10
Creatinine increase	-	-	-	<1	1 to 10	-	-	-	-
Glycosuria	-	-	-	-	1 to 10	-	-	-	-
Hematuria	-	-	-	1 to 10	-	-	-	-	-
Interstitial nephritis	-	-	-	-	<1	-	-	-	-
Renal colic	-	-	-	<1	-	-	-	-	-
Renal failure/dysfunction	-	-	-	-	1 to 10	-	-	-	<1
Respiratory									
Asthma	-	-	-	<1	<1	-	-	-	-
Bronchitis	-	-	-	<1	-	-	-	-	-
Bronchospasm	-	-	-	<1	<1	<1	1	1 to 10	<1
Cough	1	-	<2	<1	5 to 8	-	-	-	-
Dyspnea	4	<1	2	1 to 2	>3	2	1 to 3	<1	≤1
Eosinophilic pneumonitis	-	-	-	-	<1	-	-	-	-
Interstitial pneumonitis	-	-	-	-	<1	-	-	-	-
Nasal congestion	-	-	-	-	1	1 to 6	-	-	-

Adverse Events	Single Entity Agents (A-N)								
	Acebutolol	Atenolol	Betaxolol	Bisoprolol	Carvedilol	Labetalol	Metoprolol	Nadolol	Nebivolol
Nasopharyngitis	-	-	-	-	4	-	-	-	-
Pharyngitis	1 to 10	-	2	<1	-	-	-	-	-
Pleurisy	✓	-	-	-	-	-	-	-	-
Pneumonitis	✓	-	-	-	-	-	-	-	-
Pulmonary edema	-	-	-	-	>3	-	-	-	<1
Pulmonary granulomas	✓	-	-	-	-	-	-	-	-
Respiratory failure/distress	-	-	-	-	<1	-	-	-	-
Rhinitis	2	-	-	3 to 4	2	-	✓	-	-
Sinus congestion	-	-	-	-	1	-	-	-	-
Sinusitis	-	-	-	2	-	-	-	-	-
Upper respiratory infection	-	-	-	5	-	-	-	-	-
Wheezing	1 to 10	<1	-	-	-	-	1	-	-
Special Senses									
Abnormal/blurred vision	2	-	-	-	1 to 5	1	✓	-	-
Blepharitis	-	-	<2	-	-	-	-	-	-
Cataract	-	-	<2	-	-	-	-	-	-
Conjunctivitis	1 to 10	-	-	-	-	-	-	-	-
Dry eyes	1 to 10	-	-	-	-	-	✓	-	-
Eye pain	1 to 10	-	-	<1	-	-	-	-	-
Hearing decreased	-	-	<2	<1	<1	-	-	-	-
Lacrimation, abnormal	-	-	-	<1	-	-	-	-	-
Tinnitus	-	-	<2	<1	<1	-	-	-	-
Visual disturbances	-	-	<2	<1	-	-	✓	-	-
Other									
Allergy/allergic reaction	-	-	-	-	1 to 10	-	-	-	-
Anaphylactoid reaction	-	-	-	-	<1	<1	-	-	-
Angioedema	-	-	-	-	-	<1	-	-	<1
Cholecystitis	-	-	-	-	-	-	-	-	-
Cutaneous vasculitis	-	-	-	<1	-	-	-	-	-
Diaphoresis	-	-	-	-	-	≤4	-	-	-
Gangrene	-	-	-	-	-	-	✓	-	-
Hypersensitivity	-	-	-	-	-	<1	-	-	<1
Lupus syndrome	✓	<1	-	-	-	<1	-	-	-
Metabolic acidosis	-	-	<2	-	-	-	-	-	-
Necrotizing angitis	-	-	-	-	-	-	-	-	-
Peyronie's disease	-	<1	<2	<1	-	<1	<1	-	-
Positive antinuclear antibody test	-	<1	5	<1	1 to 10	<1	-	-	-
Tinnitus	-	-	-	-	-	-	✓	-	-

✓ Percent not specified
-Event not reported

Table 9. Adverse Drug Events (%) Reported with the Beta-Adrenergic Blocking Agents¹⁻³¹

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendo-flumethiazide	Propranolol and HCTZ
Cardiovascular										
Angina	-	-	✓	-	✓	-	-	-	-	✓
Arrhythmia	1 to 10	-	-	5	✓	-	<1	-	<1	-
Arterial/vascular insufficiency	-	-	✓	-	-	-	-	1	-	✓
Atrioventricular nodal disturbances	-	-	✓	-	-	-	-	-	-	✓
Bradycardia	<1	≤2	6	13 to 16	1 to 10	1 to 10	<1	2 to 16	1 to 10	6
Cardiac failure/arrest	-	-	-	-	✓	-	-	-	-	-
Cardiogenic shock	-	-	✓	-	-	-	-	✓	-	✓
Chest pain	-	3	2 to 4	3 to 16	-	1 to 10	1 to 2	1	<1	2 to 4
Cold extremities	<1	≤2	✓	<1	✓	1 to 10	<1	1	1 to 10	✓
Congestive heart failure	1 to 10	<1	✓	5	-	1 to 10	<1	1	1 to 10	✓
Edema	<1	6	2	8	✓	1 to 10	<1	-	1 to 10	2
Electrocardiogram abnormal	-	-	-	7	-	-	-	-	-	-
Flushing	-	-	-	-	-	-	<1	-	-	-
Heart block	<1	≤2	-	-	✓	1 to 10	-	5	-	-
Hypotension	<1	≤2	✓	6	✓	1 to 10	1 to 10	1 to 27	-	1 to 10
Myocardial contractility impaired	-	-	✓	-	-	-	<1	<1	-	<1
Myocardial ischemia	-	-	-	-	-	-	-	-	-	-
Orthostatic hypotension	-	-	-	-	-	-	1 to 10	1 to 10	<1	1 to 10
Palpitations	-	≤1	-	14	✓	-	<1	1	1 to 10	-
Peripheral circulation reduced	-	-	-	3	-	-	-	-	1 to 10	-
Peripheral edema	-	-	-	-	-	-	-	1	-	-
Rhythm disturbance	-	-	-	-	-	-	<1	-	-	-
Shortness of breath	-	-	-	-	-	-	-	✓	-	-
Syncope	-	≤2	✓	5	-	-	<1	1	-	✓
Tachycardia	-	≤2	-	-	-	-	-	-	-	-
Torsade de pointes	-	-	-	1 to 4	-	-	-	-	-	-
Thrombosis, mesenteric arterial	-	-	✓	-	-	-	-	-	-	✓
Central Nervous System										
Abnormal dreams	-	-	3	-	-	-	-	-	-	3
Amnesia	-	-	✓	-	-	-	-	-	-	✓
Anxiety	-	-	-	4	✓	-	<1	✓	-	-
Catatonia	-	-	✓	-	-	-	-	-	-	✓
Cerebral ischemia	-	-	-	-	✓	-	-	-	-	-
Cerebral vascular accident	-	-	-	-	✓	-	-	-	-	-
Cognitive dysfunction	-	-	✓	-	-	-	-	-	-	✓
Confusion	<1	-	✓	6	✓	1 to 10	<1	✓	<1	✓
Depression	1 to 10	-	1 to 3	4	✓	1 to 10	<1	5	1 to 10	1 to 3
Disorientation	-	-	-	-	✓	-	-	-	✓	-
Dizziness	1 to 10	9	2 to 11	20	1 to 10	1 to 10	<1	2 to 10	-	2 to 11
Drowsiness	-	-	2	-	-	-	-	-	>10	2

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendro-flumethiazide	Propranolol and HCTZ
Emotional lability	-	-	✓	<1	-	-	-	-	-	✓
Fatigue	1 to 10	8	3 to 17	20	1 to 10	1 to 10	6 to 8	1 to 10	✓	3 to 17
Hallucinations	-	<1	✓	-	✓	<1	<1	✓	<1	✓
Headache	1 to 10	-	1 to 9	8	-	1 to 10	<1	✓	<1	1 to 9
Hyper/hypoesthesia	-	-	-	-	-	-	1 to 2	-	-	-
Insomnia	<1	10	3 to 8	-	✓	1 to 10	2 to 3	✓	>10	3 to 8
Lethargy	<1	-	4	-	-	1 to 10	-	-	-	4
Lightheadedness	-	-	✓	12	-	-	-	-	-	✓
Malaise	-	-	-	-	-	-	<1	-	-	-
Memory loss	-	-	-	-	✓	-	<1	✓	-	-
Mental impairment	-	-	-	-	-	1 to 10	-	-	-	-
Nervousness	-	7	2	-	✓	-	<1	✓	<1	2
Nightmares/vivid dreams	<1	5	✓	-	✓	1 to 10	-	✓	✓	✓
Paresthesia	-	-	-	-	-	<1	<1	✓	-	-
Psychosis	-	-	✓	-	-	<1	-	-	-	✓
Sleep disturbance	-	-	-	8	-	-	<1	✓	-	-
Somnolence	-	-	✓	-	✓	-	<1	✓	✓	✓
Vertigo	-	-	✓	<1	-	-	<1	✓	-	✓
Dermatologic										
Acne	-	-	-	-	-	-	<1	-	-	-
Alopecia	-	-	✓	<1	✓	<1	<1	<1	-	<1
Cutaneous ulcers	-	-	✓	-	-	-	-	-	-	✓
Dermatitis	-	-	✓	-	-	-	-	-	-	✓
Eczematous eruptions	-	-	✓	-	-	-	-	-	-	✓
Erythema multiforme	-	-	✓	-	-	-	<1	<1	✓	<1
Exfoliative dermatitis	-	-	✓	-	-	-	<1	<1	✓	<1
Hyperkeratosis	-	-	✓	-	-	-	-	-	-	✓
Nail changes	-	-	✓	-	-	-	-	-	-	✓
Oculomucocutaneous reactions	-	-	✓	-	-	-	-	-	-	✓
Photosensitivity	-	-	-	<1	-	1 to 10	1 to 10	1 to 10	✓	1 to 10
Pruritus	-	1	✓	<1	-	-	<1	5	-	✓
Pseudo pemphigoid	-	-	-	-	✓	-	-	-	-	-
Psoriasiform rash	-	-	✓	-	✓	<1	<1	-	-	✓
Psoriasis (exacerbated)	-	-	-	-	✓	-	<1	✓	✓	-
Purpura	-	-	-	-	-	<1	<1	-	✓	-
Rash	-	-	0 to 2	5	✓	<1	<1	5	-	0 to 2
Red crusted skin	-	-	-	<1	-	-	-	-	-	-
Skin necrosis after extravasation	-	-	-	<1	-	-	-	-	-	-
Stevens-Johnson syndrome	-	-	✓	-	-	-	<1	<1	-	<1
Sweating, excessive	-	≤2	2	<1	-	-	-	✓	-	2
Toxic epidermal necrolysis	-	-	✓	-	-	-	<1	<1	✓	<1
Ulcers	-	-	✓	-	-	-	-	-	-	✓
Urticaria	-	-	✓	5	✓	<1	-	✓	-	✓
Endocrine and Metabolic										

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendro-flumethiazide	Propranolol and HCTZ
Diabetes (exacerbated)	-	-	-	-	-	-	-	✓	✓	-
Glycosuria	-	-	-	-	-	<1	-	-	-	-
Gout	-	-	-	-	-	<1	<1	-	-	-
Hypoglycemia masked	-	-	-	-	✓	-	-	-	-	-
Libido decreased	-	-	-	-	✓	-	-	✓	-	-
Gastrointestinal										
Abdominal pain	-	-	1	-	-		<1	✓	-	1
Anorexia	-	-	✓	-	✓	1 to 10	1 to 10	1 to 10	✓	1 to 10
Constipation	-	-	0 to 2	-	-	1 to 10	<1	1	1 to 10	0 to 2
Cramping	-	-	✓	-	-				✓	✓
Diarrhea	1 to 10	≤2	2 to 7	7	✓	1 to 10	3 to 4	5	1 to 10	2 to 7
Dry mouth	-	-	-	-	✓				-	-
Dyspepsia	1 to 10	-	1 to 7	-	✓		<1		✓	1 to 7
Epigastric distress	-	-	-	-	-	1 to 10	1 to 10	1 to 10	-	1 to 10
Flatulence	-	-	4	2	-			1	-	4
Gastritis/gastric irritation	-	-	-	-	-	-	<1			
Heartburn	-	-	-	-	-	-	-	1	-	-
Ischemic colitis	<1	-	✓	-	-				-	✓
Melena	-	-	-	-	-				✓	-
Nausea	1 to 10	5	1 to 6	10	✓	1 to 10	2	1	1 to 10	1 to 6
Pancreatitis	-	-	-	-	-	<1		<1	-	<1
Peptic ulcer	-	-	-	-	-	-	<1			
Periodontitis	-	-	-	-	-				✓	-
Retroperitoneal fibrosis	-	-	-	-	✓			✓	-	-
Stomach discomfort	-	-	✓	3 to 6	-				1 to 10	✓
Taste disorder	-	-	-	-	-		<1	✓	✓	-
Vomiting	-	≤2	✓	10	-	<1	1 to 2	✓	1 to 10	✓
Weight gain	-	≤2	-	-	-		<1	✓	-	-
Xerostomia	-	-	-	-	-	-	<1	-	-	-
Genitourinary										
Cystitis	-	-	-	-	-	-	<1	-	-	-
Impotence	-	≤2	1	2	✓	1 to 10	<1	✓	-	1
Interstitial nephritis	-	-	✓	-	-	-	-	-	-	✓
Micturition (frequency)	-	-	1	-	-	-	-	-	-	1
Oliguria	-	-	✓	-	-	-	-	-	-	✓
Polyuria	-	≤2	-	-	-	<1	<1	-	-	-
Proteinuria	-	-	✓	-	-	-	-	-	-	✓
Sexual ability decreased	-	-	-	3	-	-	<1	-	>10	-
Hematologic										
Agranulocytosis	-	-	✓	-	-	<1	-	<1	-	<1
Anemia (aplastic/hemolytic)	-	-	-	-	-	<1	-	<1	✓	<1
Bleeding	-	-	-	2	-	-	-	-	-	-
Claudication	-	-	-	-	✓	-	-	✓	-	-
Eosinophilia	-	-	-	<1	-	-	-	-	-	-

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendro-flumethiazide	Propranolol and HCTZ
Leukopenia	-	-	-	<1	-	<1	<1	<1	<1	<1
Prothrombin decreased	-	-	-	-	-	-	-	-	✓	-
Purpura	<1	-	✓	-	-	<1	-	-	-	✓
Thrombocytopenia	<1	-	✓	<1	-	<1	<1	<1	<1	✓
Hepatic										
Cholestatic jaundice	-	-	-	-	-	-	-	-	✓	-
Hepatic impairment	-	-	-	-	-	<1	-	<1	-	<1
Hepatitis	-	-	-	-	-	-	-	✓	-	-
Increase liver enzymes	-	7	-	-	-	<1	-	-	-	-
Transaminases increase	-	-	✓	<1	-	-	<1	✓	-	✓
Laboratory Test Abnormalities										
Alkaline phosphatase increased	-	<1	✓	-	-	-	-	✓	-	✓
Electrolyte imbalance	-	-	-	-	-	-	-	-	✓	-
Hypercalcemia	-	-	-	-	-	<1	-	<1	-	<1
Hypercholesterolemia	-	-	-	-	-	-	-	-	-	-
Hyperglycemia	-	-	✓	-	-	<1	-	-	-	✓
Hyperkalemia	-	-	✓	-	-	-	<1	-	-	✓
Hyperlipidemia	-	-	✓	<1	-	-	-	-	-	✓
Hypernatremia	-	-	-	-	-	<1	-	-	-	-
Hyperphosphatemia	-	-	-	-	-	-	-	-	✓	-
Hypertriglyceridemia	-	-	-	-	-	-	<1	-	✓	-
Hyperuricemia	-	<1	-	-	-	<1	<1	-	-	-
Hypoglycemia	<1	-	✓	-	-	-	<1	-	-	✓
Hypokalemia	-	-	-	-	-	1 to 10	-	1 to 10	-	1 to 10
Hyponatremia	-	-	-	-	-	<1	-	-	-	-
Lactate dehydrogenase increased	-	<1	-	-	-	-	-	✓	-	-
Musculoskeletal										
Arthralgia	1 to 10	7	1	-	-	-	1 to 10	✓	-	1
Arthritis	-	-	-	-	-	-	-	✓	-	-
Arthropathy	-	-	✓	-	-	-	-	-	-	✓
Asthenia	-	-	-	-	-	-	≤2	-	-	-
Back pain	-	-	-	3	-	-	<1	-	-	-
Carpal Tunnel syndrome	-	-	✓	-	-	-	-	-	-	✓
Extremity pain	-	-	-	7	-	-	-	-	-	-
Joint pain	-	-	-	-	-	-	<1	-	-	-
Muscle cramps	-	3	-	-	-	<1	<1	-	✓	-
Muscle pain	-	10	-	-	-	-	<1	✓	-	-
Myalgia	-	-	1	<1	-	<1	-	-	-	1
Myasthenia gravis exacerbated	-	-	-	-	✓	-	-	-	-	-
Myotonus	-	-	✓	-	-	-	-	-	-	✓
Neuralgia	-	-	-	-	-	-	-	-	✓	-
Paralysis	-	-	-	<1	-	-	-	-	-	-
Paresthesia	-	3	✓	4	✓	-	-	-	-	✓
Polyarthritis	-	-	✓	-	-	-	-	-	-	✓

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendro-flumethiazide	Propranolol and HCTZ
Restlessness	-	-	-	-	-	<1	<1	-	-	--
Tremor	-	-	-	-	-	-	<1	-	✓	-
Twitching	-	-	-	-	-	-	<1	-	-	-
Weakness	-	4	1	13	-	<1	-	-	✓	1
Renal										
Blood urea nitrogen increase	-	-	✓	-	-	-	<1	-	-	✓
Creatinine increase	-	-	-	-	-	-	<1	-	-	-
Hematuria	-	-	-	-	-	-	1 to 10	-	-	-
Interstitial nephritis	-	-	-	-	-	-	-	<1	-	-
Renal colic	-	-	-	-	-	-	<1	-	-	-
Renal failure	-	-	-	-	-	-	-	<1	-	-
Respiratory										
Asthma	-	-	-	2	-	-	<1	-	-	-
Bronchitis	-	-	-	-	-	-	<1	-	-	-
Bronchospasm	<1	-	✓	-	✓	-	<1	1	1 to 10	✓
Cough	<1	-	1	-	✓	-	<1	-	-	1
Dyspnea	-	5	1 to 6	21	1 to 10	<1	1 to 2	1 to 3	<1	1 to 6
Eosinophilic pneumonitis	-	-	-	-	-	-	-	<1	-	<1
Laryngospasm	-	-	✓	-	-	-	-	-	-	✓
Nasal congestion	-	-	-	-	✓	-	-	-	-	-
Nasopharyngitis	-	-	-	-	-	-	-	-	✓	-
Pharyngitis	-	-	✓	-	-	-	<1	-	-	✓
Pulmonary edema	-	-	✓	<1	✓	-	-	-	-	✓
Respiratory failure	-	-	✓	-	✓	-	-	<1	-	<1
Rhinitis	-	-	1	-	-	-	3 to 4	✓	-	1
Sinusitis	-	-	-	-	-	-	2	-	-	-
Upper respiratory infection	-	-	5	5 to 8	-	-	5	-	-	5
Wheezing	-	≤2	✓	-	-	<1	-	1	✓	✓
Special Senses										
Abnormal/blurred vision	-	-	3	-	-	-	-	✓	-	3
Burning	-	≤2	-	-	-	-	-	-	-	-
Corneal sensitivity decrease	-	-	-	-	✓	-	-	-	-	-
Cystoid macular edema	-	-	-	-	✓	-	-	-	-	-
Diplopia	-	-	-	-	✓	-	-	-	-	-
Dry eyes	-	-	-	-	✓	-	-	✓	-	-
Eye discomfort/pain	-	≤2	-	-	-	-	<1	-	-	-
Hearing decreased	-	-	-	-	-	-	<1	-	-	-
Hyperemia of conjunctiva	-	-	✓	-	-	-	-	-	-	✓
Keratitis	-	-	-	-	✓	-	-	-	-	-
Lacrimation abnormal	-	-	-	-	-	-	<1	-	✓	-
Mydriasis	-	-	✓	-	-	-	-	-	-	✓
Ocular discharge	-	-	-	-	✓	-	-	-	-	-
Ocular pain	-	-	-	-	✓	-	-	-	-	-
Ptosis	-	-	-	-	✓	-	-	-	-	-

Adverse Events	Single Entity Agents (O-Z)					Combination Products				
	Penbutolol	Pindolol	Propranolol	Sotalol	Timolol	Atenolol and Chlor-thalidone	Bisoprolol and HCTZ	Metoprolol and HCTZ	Nadolol and Bendro-flumethiazide	Propranolol and HCTZ
Refractive changes	-	-	-	-	✓	-	-	-	-	-
Tinnitus	-	-	-	-	✓	-	<1	-	-	-
Visual disturbances	-	≤2	✓	5	✓	-	<1	✓	-	✓
Xerophthalmia	-	-	✓	-	-	-	-	-	-	✓
Other										
Allergy	-	-	-	-	✓	-	-	<1	-	<1
Anaphylactoid reaction	-	-	✓	-	-	-	-	-	-	✓
Angioedema	-	-	-	-	✓	-	-	-	✓	-
Cholecystitis	-	-	-	-	-	<1	-	-	-	-
Cutaneous vasculitis	-	-	-	-	-	<1	<1	-	-	-
Gangrene	-	-	-	-	-	-	-	✓	-	-
Hypervolemia	-	-	-	-	-	-	-	-	✓	-
Lupus syndrome	-	-	✓	-	✓	<1	-	-	✓	✓
Mesenteric arterial thrombosis	<1	-	-	-	-	-	-	-	-	-
Necrotizing angitis	-	-	-	-	-	<1	-	-	-	-
Peyronie's disease	-	-	✓	-	✓	<1	<1	<1	-	✓
Positive antinuclear antibody test	-	-	-	-	-	<1	<1	-	-	-
Tinnitus	-	-	-	-	-	-	-	✓	-	-

✓ Percent not specified

- Event not reported

Table 10. Boxed Warning for Atenolol¹

WARNING
Advise patients with coronary artery disease who are being treated with atenolol against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with β -blockers. The last two complications may occur with or without preceding exacerbation of the angina pectoris. As with other β -blockers, when discontinuation of atenolol is planned, observe the patient carefully and advise the patient to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstated, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly, even in patients treated only for hypertension.

Table 11. Boxed Warning for Metoprolol¹

WARNING
Ischemic heart disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered metoprolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of one to two weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstate metoprolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without their health care provider's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol tartrate therapy abruptly, even in patients treated only for hypertension.

Table 12. Boxed Warning for Nadolol¹

WARNING
Exacerbation of ischemic heart disease following abrupt withdrawal: Hypersensitivity to catecholamines has been observed in patients withdrawn from β -blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of one to two weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstitute nadolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly, even in patients treated only for hypertension.

Table 13. Boxed Warning for Propranolol¹

WARNING
Angina pectoris: There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without a health care provider's advice. If propranolol therapy is interrupted and exacerbation of angina occurs, it is usually advisable to reinstitute propranolol therapy and take other measures appropriate for the management of angina pectoris. Because coronary artery disease may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.

Table 14. Boxed Warning for Sotalol¹

WARNING
To minimize the risk of induced arrhythmia, place patients initiated or reinitiated on sotalol AF or sotalol for a minimum of three days (on their maintenance dose) in a facility that can provide cardiac resuscitation, continuous electrocardiographic monitoring, and calculations of creatinine clearance. Calculate creatinine clearance prior to dosing. Do not substitute sotalol for sotalol AF because of significant differences in labeling (i.e., patient package insert, dosing administration, safety information).

Table 15. Boxed Warning for Timolol¹

WARNING
Exacerbation of ischemic heart disease following abrupt withdrawal: Hypersensitivity to catecholamines has been observed in patients withdrawn from β -blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered timolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of one to two weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstitute timolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption of discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue timolol therapy abruptly, even in patients treated only for hypertension.

VII. Dosing and Administration

The usual dosing regimens for the beta-adrenergic blocking agents are listed in Table 16.

Table 16. Usual Dosing Regimens for the Beta-Adrenergic Blocking Agents³⁻³¹

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Acebutolol	<p><u>Hypertension:</u> Capsule: initial, 400 mg/day, twice daily dosing may be required for adequate control; maintenance, 200 to 1,200 mg/day in two divided doses; maximum, 1,200 mg/day</p> <p><u>Ventricular arrhythmias:</u> Capsule: initial: 200 mg twice daily; maintenance, gradual increase until optimal response, usually 600 to 1,200 mg/day; maximum, 1,200 mg/day</p>	Safety and efficacy in children have not been established.	Capsule: 200 mg 400 mg
Atenolol	<p><u>Angina pectoris:</u> Tablet: initial, 50 mg once daily; maintenance, if optimal response not achieved after one week, increase to 100 mg daily; maximum, 200 mg/daily</p> <p><u>Hypertension:</u> Tablet: initial: 50 mg once daily; maintenance, if optimal response not achieved, increase dose to 100 mg once daily; maximum, 100 mg/day</p> <p><u>Myocardial infarction:</u></p>	Safety and efficacy in children have not been established.	Tablet: 25 mg 50 mg 100 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	Tablet: 50 mg twice daily, or 100 mg once daily for 6 to 9 days or until hospital discharge		
Betaxolol	<u>Hypertension:</u> Tablet: initial, 10 mg once daily; maintenance, if optimal response not seen after seven to 14 days, may increase the dose to 20 mg/day; maximum, 40 mg/day	Safety and efficacy in children have not been established.	Tablet: 10 mg 20 mg
Bisoprolol	<u>Hypertension:</u> Tablet: initial, 2.5 to 5 mg once daily; maintenance, if optimal control is not achieved, dose may be increased to 10 mg daily and again to 20 mg/day if needed; maximum, 20 mg/day	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg
Carvedilol	<p><u>Heart failure:</u> Extended-release capsule: initial, 10 mg once daily; maintenance, if tolerated, double the dose at intervals of >14 days as needed; maximum, 80 mg once daily</p> <p>Tablet: initial, 3.125 mg twice daily; maintenance, if tolerated, double the dose at intervals of >14 days as needed up to 50 mg twice daily; maximum, 25 mg twice daily (patients ≤85 kg) or 50 mg twice daily (patients >85 kg)</p> <p><u>Hypertension:</u> Extended-release capsule: initial, 20 mg once daily; maintenance, if tolerated, double the dose every seven to 14 days as needed; maximum, 80 mg once daily</p> <p>Tablet: initial, 6.25 mg twice daily; maintenance, if tolerated, double the dose every seven to 14 days as needed; maximum, 25 mg twice daily</p> <p><u>Myocardial Infarction:</u> Capsule ER: initial, 10 to 20 mg once daily; maintenance: if tolerated, double the dose every 3 to 10 days as needed up to a maximum of 80 mg once daily</p> <p>Tablet IR: initial, 6.25 mg twice daily; maintenance: if tolerated, double the dose every 3 to 10 days as needed up to a maximum of 25 mg twice daily</p>	Safety and efficacy in children have not been established.	Extended-release capsule: 10 mg 20 mg 40 mg 80 mg Tablet: 3.125 mg 6.25 mg 12.5 mg 25 mg
Labetalol	<u>Hypertension:</u> Injection, tablet: initial: 100 mg twice daily; maintenance, titrate by increments of 100 mg twice daily every two to three days, usual dose is 200 to 400 mg twice daily; larger doses may be administered three times daily to improve tolerability;	Safety and efficacy in children have not been established.	Injection: 5 mg/mL Tablet: 100 mg 200 mg 300 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	maximum, doses of 1,200 to 2,400 mg/day have been used		
Metoprolol	<p><u>Angina pectoris:</u> Extended-release tablet: initial, 100 mg once daily; maintenance, gradually increase dose in weekly intervals; maximum, 400 mg/day</p> <p>Injection, tablet: initial, 100 mg/day in two divided doses; maintenance, gradually increase dose in weekly intervals, usual dose is 100 to 400 mg/day; maximum, 400 mg/day</p> <p><u>Heart failure:</u> Extended-release tablet (NYHA Class II): initial, 25 mg/day; maintenance, double the dose every two weeks up to 200 mg/day or highest dose tolerated</p> <p>Extended-release tablet (NYHA Class >II): initial, 12.5 mg/day; maintenance, double the dose every two weeks up to 200 mg/day or highest dose tolerated</p> <p><u>Hypertension:</u> Extended-release tablet: initial, 25 to 100 mg once daily; maintenance, gradually increase dose in weekly intervals up to 400 mg/day</p> <p>Injection, tablet: initial, 50 to 100 mg/day in single or divided doses; maintenance, gradually increase dose in weekly intervals, usual dose is 100 to 450 mg/day; maximum, 450 mg/day</p> <p><u>Myocardial infarction:</u> Injection, tablet: initial, 100 mg twice daily; maintenance, 100 mg twice daily for at least three months</p>	<p><u>Hypertension in children ≥6 years of age:</u> Extended-release tablet: initial: 1 mg/kg once daily (maximum: 50 mg once daily); maintenance, adjust dose to optimal response up to 2 mg/kg or 200 mg/day; maximum, 2 mg/kg/day or 200 mg/day</p> <p>Safety and efficacy in children <6 years of age have not been established.</p>	<p>Extended-release tablet (succinate): 25 mg 50 mg 100 mg 200 mg</p> <p>Injection (tartrate): 5 mg/5 mL</p> <p>Tablet (tartrate): 25 mg 50 mg 100 mg</p>
Nadolol	<p><u>Angina pectoris:</u> Tablet: initial, 40 mg once daily; maintenance, increase dose by 40 to 80 mg every three to seven days until optimal response; maximum, 240 mg/day</p> <p><u>Hypertension:</u> Tablet: initial, 40 mg once daily; maintenance, increase dose gradually by 40 to 80 mg increments every seven to 21 days until optimal response; maximum, 320 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 20 mg 40 mg 80 mg
Nebivolol	<u>Hypertension:</u> Tablet: initial: 5 mg once daily;	Safety and efficacy in children have not been	Tablet: 2.5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	maintenance, increase in two week intervals until optimal response; maximum, 40 mg/day	established.	5 mg 10 mg 20 mg
Penbutolol	<u>Hypertension:</u> Tablet: initial, 20 mg once daily; maintenance, 20 mg once daily, usual dose 10 to 40 mg once daily; maximum, 80 mg/day	Safety and efficacy in children have not been established.	Tablet: 20 mg
Pindolol	<u>Hypertension:</u> Tablet: initial, 5 mg twice daily; maintenance, after three to four weeks, may be increase by 10 mg/day increments as needed; maximum, 60 mg/day	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg
Propranolol	<p><u>Angina pectoris:</u> Extended-release capsule (Inderal LA[®]): initial, 80 mg once daily; maintenance, may gradually increase dose in three to seven day increments up to 160 mg once daily or higher, usual dose is 160 mg daily; maximum, 320 mg/day</p> <p>Solution, tablet: maintenance, 80 to 320 mg/day administered in two, three or four divided doses; maximum, 320 mg/day</p> <p><u>Cardiac arrhythmias:</u> Injection (ventricular arrhythmias): usual dose, 1 to 3 mg</p> <p>Solution, tablet (atrial fibrillation): maintenance, 10 to 30 mg in three to four divided doses before meals and at bedtime</p> <p><u>Essential tremor:</u> Solution, tablet: initial, 40 mg twice daily; maintenance, usual dose is 120 mg/day; maximum, 320 mg/day</p> <p><u>Hypertension:</u> Extended-release capsule (Inderal LA[®]): initial, 80 mg once daily; maintenance, may titrate dose up to 120 mg/day or higher, usual dose is 120 to 160 mg/day; maximum, 640 mg/day</p> <p>Extended-release capsule (InnoPran XL[®]): initial, 80 mg once daily at bedtime (around 10 pm); maintenance, may titrate dose up to 120 mg/day; maximum, 120 mg/day</p> <p>Solution, tablet: initial, 40 mg twice daily; maintenance, gradually increase the dose up to 640 mg/day divided into two</p>	<p><u>Infantile hemangioma:</u> <u>Solution (Hemangeol[®]):</u> Initiate treatment at 5 weeks to 5 months; initial, 0.15 mL/kg (0.6 mg/kg) twice daily at least 9 hours apart; after one week increase to 0.3 mL/kg (1.1 mg/kg) twice daily; after another week increase the dose to 0.4 mL/kg (1.7 mg/kg) twice daily and maintain for six months, readjusting for weight changes</p> <p><u>Safety and effectiveness for infantile hemangioma have not been established in pediatric patients greater than one year of age</u></p>	<p>Extended-release capsule: 60 mg 80 mg 120 mg 160 mg</p> <p>Injection: 1 mg/mL</p> <p>Solution: 4.28 mg/mL 20 mg/5 mL 40 mg/5 mL</p> <p>Tablet: 10 mg 20 mg 40 mg 60 mg 80 mg</p>

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>to three doses, usual dose is 120 to 240 mg/day divided into two to three doses; maximum, 640 mg/day</p> <p><u>Hypertrophic subaortic stenosis:</u> Extended-release capsule (Inderal LA[®]): maintenance, 80 to 160 mg once daily</p> <p>Solution, tablet: 20 to 40 mg three to four times daily before meals and at bedtime</p> <p><u>Migraine:</u> Extended-release capsule (Inderal LA[®]): initial, 80 mg once daily; maintenance, may increase dose gradually up to 160 to 240 mg once daily, usual dose is 160 to 240 mg once daily; maximum, 240 mg/day</p> <p>Solution, tablet: initial, 80 mg daily in divided doses; maintenance, increase dose gradually up to 160 to 240 mg/day; maximum, 240 mg/day</p> <p><u>Myocardial Infarction:</u> Solution, tablet: initial, 40 mg three times daily; maintenance, after one month, titrate up to 60 to 80 mg three times daily as tolerated, usual dose is 180 to 240 mg in divided doses; maximum, 240 mg/day</p> <p><u>Pheochromocytoma:</u> Solution, tablet (operable tumors): 60 mg/day in divided doses for three days preoperatively as adjunct to alpha-adrenergic blockade</p> <p>Solution, tablet (inoperable tumors): 30 mg/day in divided doses as adjunct to alpha-adrenergic blockade</p>		
Sotalol	<p><u>Cardiac arrhythmias:</u> Solution, tablet (Betapace AF[®], Sotylize[®]; maintenance of normal sinus rhythm): initial, 80 mg twice daily; maintenance, increase dose gradually with three days between increments up to 120 mg twice daily; maximum, 160 mg twice daily</p> <p>Solution, tablet (Betapace[®], Sotylize[®]; ventricular arrhythmias): initial, 80 mg twice daily; maintenance, increase dose gradually with three days between increments up to 120 to 160 mg twice daily; maximum, 480 to 640 mg/day</p>	<p><u>Cardiac arrhythmias in children >2 years of age:</u> Solution, tablet (Betapace AF[®], Sotylize[®]; maintenance of normal sinus rhythm): initial, 30 mg/m² three times daily; maintenance, increase dose gradually with three days between increments up to 60 mg/m² three times daily; maximum, 60 mg/m² three times</p>	<p>Injection: 150 mg/10 mL</p> <p>Solution: 5 mg/mL</p> <p>Tablet: 80 mg 120 mg 160 mg 240 mg</p>

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
		<p>daily; neotate dosing available for Sotylize®</p> <p>Solution, tablet (Betapace®, Sotylize®; ventricular Arrhythmias): initial, 30 mg/m² three times daily; maintenance, increase dose gradually with three days between increments up to 60 mg/m² three times daily; maximum, 60 mg/m² three times daily; neotate dosing available for Sotylize®</p>	
Timolol	<p><u>Hypertension:</u> Tablet: initial, 10 mg twice daily; maintenance, increase dose gradually in seven day increments up to 60 mg/day, usual dose is 20 to 40 mg/day; maximum, 60 mg/day divided into two doses</p> <p><u>Migraine:</u> Tablet: initial, 10 mg twice daily; maintenance, may increase dose up to 30 mg/day; maximum, 30 mg/day divided into two doses</p> <p><u>Myocardial infarction:</u> Tablet: 10 mg twice daily</p>	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg 20 mg
Combination Products			
Atenolol and chlorthalidone	<p><u>Hypertension:</u> Tablet: initial: 50-25 mg once daily; maintenance, if optimum response is not achieved after one to two weeks, may increase to 100-25 mg once daily</p>	Safety and efficacy in children have not been established.	Tablet: 50-25 mg 100-25 mg
Bisoprolol and HCTZ	<p><u>Hypertension:</u> Tablet: initial, 2.5-6.25 mg once daily; maintenance, may titrate dose every seven to 14 days; maximum, 20-12.5 mg once daily</p>	Safety and efficacy in children have not been established.	Tablet: 2.5-6.25 mg 5-6.25 mg 10-6.25 mg
Metoprolol and HCTZ	<p><u>Hypertension:</u> Extended-release tablet: dosing must be individualized, the usual dose of metoprolol is 25 to 100 mg/day, and the usual dose of HCTZ is 12.5 to 50 mg/day</p> <p>Tablet: initial, 100-25 mg/day in single or divided doses; maintenance, may titrate dose gradually until desired effect is achieved, usual dose of metoprolol is 100 to 450 mg/day, and usual dose of HCTZ is 12.5 to 50 mg/day, may be</p>	Safety and efficacy in children have not been established.	<p>Extended-release tablet: 25-12.5 mg 50-12.5 mg 100-12.5 mg</p> <p>Tablet: 50-25 mg 100-25 mg 100-50 mg</p>

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	administered in single or divided doses		
Nadolol and bendroflumethiazide	<u>Hypertension:</u> Tablet: initial, 40-5 mg once daily; maintenance, if desired effect is not achieved, may increase dose to 80-5 mg once daily	Safety and efficacy in children have not been established.	Tablet: 40-5 mg 80-5 mg
Propranolol and HCTZ	<u>Hypertension:</u> Tablet: initial, 40-25 mg twice daily; maintenance, may gradually increase dose until desired response is achieved up to 160 to 480 mg/day; maximum, 160 mg of propranolol	Safety and efficacy in children have not been established.	Tablet: 40-25 mg 80-25 mg

HCTZ=hydrochlorothiazide, NYHA=New York Heart Association

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the beta-adrenergic blocking agents are summarized in Table 17.

Table 17. Comparative Clinical Trials with the Beta-Adrenergic Blocking Agents

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Angina				
Pandhi et al. ⁶⁸ (1985) Acebutolol 100 to 400 mg TID vs propranolol 40 to 160 mg TID vs placebo	DB, XO Patients with classical anginal symptoms of effort with ≥ 7 attacks per week and angina being stable for ≥ 8 to 12 weeks	N=24 18 weeks	Primary: Incidence of anginal attack, number of nitroglycerin tablets used, exercise tolerance, side effects Secondary: Not reported	Primary: Both acebutolol and propranolol significantly reduced the incidence of anginal attacks per week compared to placebo ($P < 0.001$ for both groups), but the difference between the two groups was not significant ($P > 0.05$). Both acebutolol and propranolol significantly reduced the number of nitroglycerin tablets used per week compared to placebo ($P < 0.001$ for both groups), but the difference between the two groups was not significant ($P > 0.05$). Both acebutolol and propranolol significantly improved exercise tolerance compared to placebo ($P < 0.001$), but the difference between the two groups was not significant ($P > 0.05$). Side effects reported (i.e., insomnia, sweating, bitter taste, heart burn, muscle weakness) were similar between the two treatment groups. Clinical significance of the side effects was not reported. Secondary: Not reported
Jackson et al. ⁶⁹ (1980) Atenolol 25, 50, 100, and 200 mg/day, each dose administered for a 2 week period vs	XO Adult patients with clinically stable exercise-induced angina for ≥ 3 months	N=10 12 weeks	Primary: Anginal attack rate, nitroglycerin consumption, exercise data Secondary: Not reported	Primary: Compared to placebo, atenolol reduced the angina attack rate during all periods ($P < 0.001$). A dose response was present with a decreasing number of attacks with increasing dosage. Doses of 100 and 200 mg were significantly more effective to 25 mg ($P < 0.001$ for both), but there was no significant difference between the 50 and 100 mg, or 100 and 200 mg (P values not reported). Nitroglycerin consumption declined in a parallel, dose-related fashion. Compared to placebo, all doses of atenolol decreased nitroglycerin consumption significantly ($P < 0.001$), with no significant difference

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo</p> <p>All patients received SB placebo for the first 4 weeks of the trial.</p>				<p>between 50 vs 100 and 200 mg, or 100 vs 200 mg (P values not reported).</p> <p>All doses of atenolol significantly reduced resting and exercise heart rate at three hours (P<0.001) and 24 hours (P<0.001) after ingestion. Atenolol was significantly more effective at 100 and 200 mg, with no significant difference between the two doses (P value not reported). The maximal exercise double product (heart rate times SBP) at the occurrence of chest pain was significantly reduced at peak and trough testing with all atenolol doses (P<0.001 for all), but 100 and 200 mg were significantly more effective than 25 and 50 mg (P<0.001 for both). The amount of exercise necessary to produce angina three hours after drug ingestion was increased by all atenolol doses; however, only 50 (P<0.001), 100 (P<0.005) and 200 mg (P<0.001) showed significant improvement compared to placebo.</p> <p>Secondary: Not reported</p>
<p>Kardas et al.⁷⁰ (2007)</p> <p>Betaxolol 20 mg QD</p> <p>vs</p> <p>metoprolol 50 mg BID</p>	<p>OL, PG, RCT</p> <p>Patients 40 to 75 years with ischemic heart disease NYHA class I to II, no prior β-blocker treatment, and whose mental state enabled conscious participation in the study</p>	<p>N=112</p> <p>8 weeks</p>	<p>Primary: Overall compliance</p> <p>Secondary: Drug effectiveness, health-related QOL</p>	<p>Primary: The overall compliance significantly higher in the betaxolol group compared to the metoprolol group (86.5\pm21.3 vs 76.1\pm26.3%, respectively; P=0.002).</p> <p>Secondary: There was not a significant difference in chest pain episodes observed between the betaxolol and metoprolol groups compared from baseline (0.42/week and 0.46/week change in episodes, respectively; P>0.05).</p> <p>Overall, QOL dimensions were similar among both treatment groups, with the exception of physical function in which a significantly greater improvement was observed in the betaxolol group compared to the metoprolol group (42.9 vs 15.2 patients improved, respectively; P<0.01).</p>
<p>van der Does et al.⁷¹ (1999)</p> <p>Carvedilol 25 to 50 mg BID</p>	<p>DB, MC, RCT</p> <p>Patients \leq80 years of age with CHD and chronic stable angina for \geq2 months, exertional</p>	<p>N=368</p> <p>3 months</p>	<p>Primary: Moderate anginal pain and time to ST- 1-mm segment depression</p> <p>Secondary:</p>	<p>Primary: Compared to baseline, both carvedilol and metoprolol significantly decreased time to anginal pain during exercise test (+77s [+20 to +140] and +76 [+25 to +155], respectively; P<0.001 for both).</p> <p>Compared to baseline, both carvedilol and metoprolol significantly decreased time to ST- 1-mm segment depression during exercise test</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs metoprolol 50 to 100 mg BID	angina with symptoms improving after taking short acting nitrates or after a period of rest, and 1 exercise test performed that was limited by moderate anginal pain		Not reported	(+75.5 s [+47 to +154 s] and +60 [0 to +146 s], respectively; P<0.001 for both). Carvedilol significantly improved the time to 1-mm ST-segment depression compared to metoprolol (RR, 1.386; 95% CI, 1.045 to 1.839; P<0.05) Secondary: Not reported
Weiss et al. ⁷² (1998) Carvedilol 12.5 to 50 mg BID vs placebo	DB, MC, XO Patients with 2 stress tests which evoked ischemic signs and symptoms	N=122 12 weeks	Primary: Efficacy, safety Secondary: Not reported	Primary: The carvedilol 25 and 50 mg groups significantly reduced the time to angina compared to placebo (25 mg: 337 s, P=0.0039; 50 mg: 345 s; P<0.001 vs 316 s). The carvedilol 25 and 50 mg groups significantly reduced the time to 1-mm ST-segment depression compared to placebo (25 mg: 313 s; 50 mg: 323 s vs 301 s; P<0.0001 for both). The percentage of patients reporting any adverse experience was slightly less in those receiving placebo (placebo: 28.4%; 12.5 mg: 33.1%; 25 mg: 34.5%; 50 mg: 31.9%). Adverse events included dizziness, fatigue, headache, dyspepsia, and any hypotensive event. The clinical significance of the adverse events was not reported. Secondary: Not reported
Hauf-Zachariou et al. ⁷³ (1997) Carvedilol 25 mg BID vs verapamil 120 mg	DB, MC, PG, RCT Patients 18 to 75 years with a confirmed diagnosis of CAD, exertional chest pain relieved by rest or glyceryl trinitrate for ≥ 2 months and 2	N=313 12 weeks	Primary: Total exercise time, time to onset of angina, and time to 1 mm ST-segment depression, blood pressure, heart rate, rate pressure product	Primary: There was not a significant difference in total exercise time observed between the carvedilol (increased from 378 s to 436 s) and verapamil (increased from 386 s to 438 s) groups (RR, 1.14; 90% CI, 0.85±1.52). There was not a significant difference observed between the carvedilol and verapamil groups in time to onset of angina (increase from 296 s to 325 s vs 285 s to 326 s) and in time to 1 mm ST-segment depression (increase from 267 s to 298 s vs 286 s to 302 s).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
TID	exercise tests with signs and symptoms of ischemia		Secondary: Not reported	<p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced SBP (from 175 to 166 mm Hg) compared to verapamil (from 173 to 173 mm Hg).</p> <p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced heart rate (from 123 to 112 mm Hg) compared to verapamil (from 124 to 120 mm Hg).</p> <p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced rate pressure product (from 21564 to 18802 mm Hg) compared to verapamil (from 21488 to 20992 mm Hg).</p> <p>Secondary: Not reported</p>
<p>Savanitto et al.⁷⁴ (1996)</p> <p><u>Weeks 1 to 6:</u> Metoprolol ER 200 mg QD</p> <p>vs</p> <p>nifedipine 20 mg BID</p> <p><u>Weeks 7 to 10:</u> Metoprolol ER 200 mg QD plus placebo</p> <p>vs</p> <p>metoprolol ER 200 mg QD and nifedipine 20 mg BID</p>	<p>DB, MC, RCT</p> <p>Patients with typical anginal symptoms that had been stable for approximately 6 months, who showed a positive response to exercise stress testing with 23 min of exercise tolerance and were in sinus rhythm and had an analyzable ST segment on ECG</p>	<p>N=280</p> <p>6 weeks</p>	<p>Primary: Angina frequency, exercise tolerance, safety</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>At week six, both metoprolol (mean change, -1.95; 95 % CI, -1.25 to -2.64) and nifedipine (mean change, -1.57; 95 % CI, -0.69 to -2.45) significantly reduced the frequency of angina compared to baseline, but there was not a statistical difference between groups. At the end of 10 weeks, there was not a statistical difference observed between the groups.</p> <p>At week six, both metoprolol and nifedipine significantly increased the mean exercise time to 1-mm ST-segment depression compared to baseline (both P<0.01); but metoprolol was significantly more effective than nifedipine (P<0.05).</p> <p>At week 10, the groups randomized to combination therapy had a further increase in time to 1-mm ST-segment depression (P<0.05 vs placebo).</p> <p>There were 14 cardiovascular events including one sudden death, three acute myocardial infarctions, eight cases of unstable angina, one of syncope and one of stroke and the incidence of these events did not differ among the treatment groups.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs nifedipine 20 mg BID plus placebo				
Turner et al. ⁷⁵ (1978) Propranolol 40 to 240 mg/day, administered in 4 divided doses vs nadolol 40 to 240 mg/day, administered in 2 divided doses vs placebo	DB, PC, RCT, XO Men with ischemic heart disease with presence of stable angina pectoris and absence of acute MI during the preceding 4 months, ECG evidence of myocardial ischemia during treadmill exercise testing and/or arteriographic evidence of >60% obstruction of the lumen of ≥2 major coronary arteries, the absence of CHF, a resting DBP <90 mm Hg, absence of contra- indications to β-blocker therapy and the absence of other cardiac or severe systemic disease	N=14 Up to 18 weeks	Primary: Glyceryl trinitrate consumption, exercise tolerance, heart rate Secondary: Not reported	Primary: Mean glyceryl trinitrate consumption decreased significantly from placebo with both propranolol and nadolol (P<0.05 for all). There was no significant difference between propranolol and nadolol, with nadolol 240 mg/day producing a significant decrease in consumption of glyceryl trinitrate compared to 160 mg/day (P<0.05). Both treatments resulted in similar improvements in exercise tolerance (30%; P<0.01) and external work performed (48%; P<0.01). A slightly greater suppression of heart rate during exercise was observed with nadolol compared to propranolol (P<0.05). Both treatments resulted in significant decreases in resting heart rate; however, the rate corrected systolic time intervals changed very little from control. The effects of the two treatments could not be differentiated by echocardiography or phonocardiography. Secondary: Not reported
Arrhythmias				
Lui et al. ⁷⁶ (1983)	DB, PC, RCT, XO Adult patients with	N=25 Not reported	Primary: Resting heart rate, ventricular	Primary: Both doses of acebutolol produced a significant decrease in heart rate (P<0.01 for both), with no significant differences between 200 and 400 mg

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Acebutolol 200 or 400 mg/day</p> <p>vs</p> <p>placebo</p>	<p>≥30 ventricular ectopic beats per hour on 3 control ambulatory monitoring</p>		<p>arrhythmias, paired ventricular ectopic beats, ventricular tachycardia, electro-physiologic effects, adverse events</p> <p>Secondary: Not reported</p>	<p>(P value not reported).</p> <p>Mean ventricular ectopic beat reduction from the control period was 34.9% during the two placebo periods. Following acebutolol, mean ectopic beat suppression was greater, although not significantly different when compared to placebo, at 44.9 and 49.5% using 200 and 400 mg, respectively (P values not reported).</p> <p>Nineteen of the 25 patients achieved episodes of paired ventricular ectopic beats (couplets) on control ambulatory monitoring. The mean reduction of paired beats was significantly higher than placebo (48.8%) with 70.5 (P<0.05) and 74.5% (P<0.01) with acebutolol 200 and 400 mg, respectively.</p> <p>Five patients who had ventricular tachycardia during both control and placebo periods had complete suppression during acebutolol treatment.</p> <p>Mean QRS and QTc intervals revealed no significant difference as compared to the control period.</p> <p>There were no significant adverse effects related to acebutolol administration. Patients did not develop any bronchospasm, significant bradycardia, heart block, CHF or any central nervous system adverse effect.</p> <p>Secondary: Not reported</p>
<p>Lee et al.⁷⁷ (2008)</p> <p>Amiodarone</p> <p>vs</p> <p>sotalol</p> <p>vs</p>	<p>RETRO</p> <p>Patients with AF and/or CHF (NYHA class ≥III) and an implantable cardioverter defibrillator</p>	<p>N=55</p> <p>2.6 years</p>	<p>Primary: Cumulative rates of inappropriate shocks</p> <p>Secondary: Not reported</p>	<p>Primary: Amiodarone demonstrated a significantly lower rate of inappropriate shock was compared β-blocker group (27.3 vs 70.6% at four years; P=0.003). This demonstrated an 83% reduction compared to the β-blockers (HR, 0.17; 95% CI, 0.05 to 0.64; P=0.008).</p> <p>There was not a significant difference in rates of inappropriate shocks observed between the amiodarone and sotalol groups (27.3 vs 54.3% at four years; P=0.29).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>β-blockers (agents not specified)</p> <p>Doses of the agents were not specified</p>				<p>There was not a significant difference in rates of inappropriate shocks observed between the sotalol and β-blocker groups (54.3 vs 70.6% at four years; P=0.16).</p> <p>Secondary: Not reported</p>
<p>Connolly et al.⁷⁸ (2006) OPTIC</p> <p>β-blocker (bisoprolol, carvedilol or metoprolol)</p> <p>vs</p> <p>sotalol 240 mg/day in two to three divided doses</p> <p>vs</p> <p>amiodarone 200 mg QD plus β-blocker (bisoprolol, carvedilol or metoprolol)</p> <p>Amiodarone was loaded at 400 mg BID for 2 weeks, followed by 400 mg/day for 4 weeks, and then</p>	<p>DB, MC, RCT</p> <p>Patients who received an implantable cardioverter defibrillator within 21 days of randomization, had sustained ventricular tachycardia, ventricular fibrillation or cardiac arrest, LVEF ≤40%, inducible ventricular tachycardia or ventricular fibrillation by programmed ventricular stimulation with LVEF ≤40% or unexplained syncope with ventricular tachycardia or ventricular</p>	<p>N=412</p> <p>12 months</p>	<p>Primary: Implantable cardioverter defibrillator shock for any reason</p> <p>Secondary: Not reported</p>	<p>Primary: Shocks occurred in 41 patients (38.5%) in the β-blocker group, 26 (24.3%) in the sotalol group, and 12 (10.3%) in the amiodarone plus β-blocker group.</p> <p>A reduction in the risk of shock was observed with use of amiodarone plus β-blocker or sotalol vs β-blocker alone (HR, 0.44; 95% CI, 0.28 to 0.68; P<0.001).</p> <p>The amiodarone plus β-blocker group significantly reduced the risk of shock compared to β-blocker alone (HR, 0.27; 95% CI, 0.14 to 0.52; P<0.001) and sotalol (HR, 0.43; 95% CI, 0.22 to 0.85; P=0.02).</p> <p>Sotalol did not significantly reduce the risk of shock compared to the β-blocker alone group (HR, 0.61; 95% CI, 0.37 to 1.01; P=0.055).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
200 mg/day until then end of the study	fibrillation, inducible by programmed stimulation			
Balcetyte-Harris et al. ⁷⁹ (2002) Esmolol 0.5 mg/kg over 5 minutes then 0.05 mg/kg/min titrated to heart rate of 55 to 65 bpm and SBP >100 mm Hg for up to 24 hours vs oral β -blocker (metoprolol \geq 50 mg/day was the preferred agent)	OL, RCT Patients referred for elective CABG without concomitant valve replacement who were in sinus rhythm	N=50 72 hours	Primary: Development of AF lasting >30 mins Secondary: Development of adverse events, hypotension (SBP <90 mm Hg), symptomatic bradycardia or CHF (left ventricular failure)	Primary: There was not a significant difference in development of AF after CABG between the esmolol and β -blocker group (seven [26%] vs six [26%] patients, respectively). Secondary: Significantly more patients in the esmolol group experienced significant adverse events compared to the patients in the β -blocker group (11 [41%] vs one [4%] patient(s), respectively; P=0.006). Significantly more patients in the esmolol group experienced hypotension compared to the patients in the β -blocker group (eight vs one patient(s), respectively; P=0.03). There was not a statistically significant difference between the esmolol and the β -blocker group in the development bradycardia requiring pacing (two vs zero patients, respectively) and in left ventricular failure (one vs zero patient(s), respectively).
Kettering et al. ⁸⁰ (2002) Metoprolol 25 to 200 mg/day vs sotalol 40 to 480 mg/day	PRO, RCT Symptomatic patients between 18 and 80 years with sustained ventricular tachycardia and/or ventricular fibrillation requiring an implantable cardioverter defibrillator	N=100 2 years	Primary: Ventricular tachycardia or ventricular fibrillation recurrence requiring implantable cardioverter defibrillator intervention Secondary: Total mortality	Primary: There was not a significant difference in ventricular tachycardia/ventricular fibrillation recurrence rates observed between the metoprolol group (33 patients) and the sotalol group (30 patients; P=0.68). After one year of treatment, 46.3% of patients in the metoprolol group and 54.7% of patients in the sotalol group were free of a recurrence of ventricular tachycardia or ventricular fibrillation (P=0.68). After two years, rates were 31.5 and 36.6%, respectively. Secondary: There was not a significant difference in mortality rates observed between the metoprolol group (eight deaths) and the sotalol group (six patients; P=0.43).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Seidl et al.⁸¹ (1998)</p> <p>Metoprolol 50 mg/day</p> <p>vs</p> <p>sotalol 80 mg/day</p> <p>The doses of the study medications were titrated to the maximum titrates dose.</p>	<p>OL, RCT</p> <p>Patients >18 years of age requiring treatment if life-threatening ventricular tachycardia/ventricular fibrillation who required an implantable cardioverter defibrillator due to non-inducible or drug refractory (≥ 1 unsuccessful antiarrhythmic trial) arrhythmias</p>	<p>N=70</p> <p>26\pm16 months</p>	<p>Primary: Recurrence of ventricular tachycardia requiring antitachycardia pacing, fast ventricular tachycardia or ventricular fibrillation requiring implantable cardioverter defibrillator, discharges, total mortality</p> <p>Secondary: Not reported</p>	<p>Primary: Actuarial rates for absence of ventricular tachycardia recurrence were significantly higher in the metoprolol group vs the sotalol group at one and two years (83 and 80 vs 57 and 51%, respectively; P=0.016).</p> <p>Actuarial rates for absence of recurrence of a fast ventricular tachycardia or ventricular fibrillation were significantly higher in the metoprolol group vs the sotalol group one and two years (88 and 80 vs 54 and 46%, respectively; P=0.002)</p> <p>Actuarial survival rates at one and two years were not significantly different between the metoprolol and sotalol groups (94 and 91 vs 86 and 83%, respectively; P=0.287)</p> <p>Secondary: Not reported</p>
<p>Steeds et al.⁸² (1999)</p> <p>Sotalol 80 mg BID</p> <p>vs</p> <p>atenolol 50 mg QD</p>	<p>OL, PRO, RCT, XO</p> <p>Symptomatic patients >50 years of age with paroxysmal AF documented on ECG</p>	<p>N=47</p> <p>2 months</p>	<p>Primary: Frequency of paroxysmal AF</p> <p>Secondary: Average and total duration of paroxysmal AF, total ectopic count, symptom assessments</p>	<p>Primary: There was not a significant difference in frequency of episodes of paroxysmal AF observed between the sotalol and atenolol groups (median difference, 0 min; 95% CI, 0 to 1; P=0.47).</p> <p>Secondary: There was not a significant difference in average duration of episodes of paroxysmal AF observed between the sotalol and atenolol groups (median difference, 0 min; 95% CI, 0 to 1 min; P=0.31) or in total duration of episodes of paroxysmal AF (median difference, 0 min; 95% CI, -1 to 2 min; P=0.51).</p> <p>There was not a significant difference in total ectopic count observed between the sotalol and atenolol groups (median difference, -123; 95% CI, -362 to 135; P=0.14) during either treatment period.</p> <p>There was not a significant difference in tolerance and symptom scores</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				observed between the sotalol and atenolol groups (median difference, -5; 95% CI, -20 to 5; P=0.26)
Essential Tremor				
Calzetti et al. ⁸³ (1981) Metoprolol 150 mg/dose vs propranolol 120 mg/dose vs placebo	DB, PC, RCT Patients 19 to 72 years with essential tremor and symptomatic for ≥1 year prior to the study	N=23 3 weeks	Primary: Tremor magnitude, heart rate, blood pressure Secondary: Not reported	Primary: Both metoprolol (47±9.7%) and propranolol (55±5.0%) significantly decreased tremor magnitude from baseline compared to placebo (22±7.3%; P<0.01 for both treatments compared to placebo), but there was not a significant difference observed between the metoprolol and propranolol groups. Both propranolol (0.073) and metoprolol (0.01) significantly diminished the normal increase in pulse rate on standing (P<0.01) and placebo had no effect on such pulse rate. There was not a significant difference observed between the metoprolol and propranolol groups. Both metoprolol and propranolol significantly reduced the SBP from baseline compared to placebo, in the supine and standing positions (P<0.05). Secondary: Not reported
Yetimalar et al. ⁸⁴ (2005) Propranolol 120 mg/day vs olanzapine 20 mg/day	DB, RCT, XO Patients with essential tremor and previous therapy with ≥1 medications for essential tremor without significant benefit, which was withdrawn ≥1 month before study drug was given	N=38 74 days	Primary: Tremor, global QOL Secondary: Not reported	Primary: After 30 days, both propranolol and olanzapine significantly reduced the all tremor evaluation measures (i.e., speaking, eating, dressing, writing working) compared to baseline (P=0.000), but at the end of the study, olanzapine significantly improved all tremor evaluation measures (P<0.05) except hygiene (P =0.08) as compared to propranolol. Both propranolol (63%) and olanzapine (87%) significantly improved global QOL from baseline, but olanzapine significantly improved the global QOL score compared to propranolol (4.5±0.7 vs 3.6±0.9; P=0.000). Secondary: Not reported
Gironell et al. ⁸⁵ (1999)	DB, PC, XO Patients with	N=16 66 days	Primary: Tremor Clinical Rating Scale,	Primary: Both gabapentin and propranolol significantly reduced the clinical examination and motor task performance components of the Tremor

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Propranolol 40 mg TID vs gabapentin 400 mg TID vs placebo</p>	<p>moderate to severe essential tremor that was chronic (≥ 5 years), persistent, and bilateral postural tremor with or without kinetic tremor involving hands or forearms, with no other neurological abnormalities or explanation for tremor</p>		<p>accelerometric recordings, self-reported disability scale Secondary: Not reported</p>	<p>Clinical Rating Scale compared to placebo (-3.10 ± 1.10; $P=0.01$ and -4.50 ± 1.10; $P=0.001$, respectively), and significant differences were not observed between the gabapentin and propranolol groups (1.40 ± 1.16; $P=0.23$).</p> <p>Both gabapentin and propranolol significantly reduced the activities of daily living component of the Tremor Clinical Rating Scale compared to placebo (-3.03 ± 1.46; $P<0.05$ and -4.95 ± 1.46; $P=0.002$, respectively), and significant differences were not observed between the gabapentin and propranolol groups (1.92 ± 1.46; $P=0.20$).</p> <p>Both gabapentin and propranolol significantly reduced the patient's subjective assessment of the Tremor Clinical Rating Scale compared to placebo (1.37 ± 0.46; $P=0.006$ and 1.44 ± 0.46; $P=0.004$, respectively). Significant differences were not observed between the gabapentin and the propranolol groups (-0.07 ± 0.46; $P=0.89$).</p> <p>Both gabapentin and propranolol significantly reduced the absolute power of the dominant frequency peak of accelerometry compared to placebo (-2352.0 ± 1153.3; $P=0.05$ and -2282.14 ± 1116.58; $P=0.05$, respectively), but significant differences were not observed between the gabapentin and the propranolol groups (-70.39 ± 1165.22; $P=0.95$).</p> <p>Gabapentin significantly reduced the self-reported disability scale score more than placebo (-6.04 ± 2.75; $P=0.04$) and propranolol did not (-4.48 ± 2.75; $P=0.11$), but there were no significant differences between the gabapentin and propranolol groups (-1.55 ± 2.75; $P=0.58$).</p> <p>Secondary: Not reported</p>
Heart Failure				
<p>CIBIS Investigators and Committees⁸⁶ (1994) CIBIS</p>	<p>DB, MC, PC, PG, RCT Patients 18 to 75 years with NYHA functional class III</p>	<p>N=641 1.9 years</p>	<p>Primary: Total mortality Secondary: Tolerability, analysis critical</p>	<p>Primary: There was no statistical significance between bisoprolol and placebo in total mortality (53 vs 67; RR, 0.80; 95% CI, 0.56 to 1.15; $P=0.22$).</p> <p>Secondary: Bisoprolol was well tolerated with no between group difference in</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Bisoprolol 1.25 to 5 mg QD</p> <p>vs</p> <p>placebo</p> <p>All patient received standard therapy (diuretic and vasodilator)</p>	<p>or IV due to idiopathic dilated cardiomyopathy, ischemia, HTN or valvular heart disease, a LVEF of <40%, and background therapy with a diuretic and a vasodilator</p>		<p>events</p>	<p>premature treatment withdrawals (82 on placebo, 75 on bisoprolol; not significant).</p> <p>Significantly fewer patients in the bisoprolol group required hospitalization for cardiac decompensation (90 in placebo versus 61 in bisoprolol; P<0.01), and more patients improved by at least one NYHA functional class (48 on placebo versus 68 on bisoprolol; P=0.04) by the end of follow-up period.</p>
<p>CIBIS-II Investigators and Committees⁸⁷ (1999)</p> <p>CIBIS-II</p> <p>Bisoprolol 1.25 to 10 mg QD added to usual therapy (diuretic and vasodilator)</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Symptomatic patients 18 to 80 years in NYHA class III or IV, with LVEF of 35% or less receiving standard therapy with diuretics and ACE inhibitor or other vasodilator</p>	<p>N=2,647</p> <p>1.3 years</p>	<p>Primary: All-cause mortality</p> <p>Secondary: All-cause hospital admissions, cardiovascular mortality, cardiovascular mortality and cardiovascular hospital admissions (composite endpoint), permanent premature treatment withdrawals</p>	<p>Primary: CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. All-cause mortality was significantly lower with bisoprolol than on placebo (156 [11.8%] vs 228 [17.3%] deaths, respectively; HR, 0.66; 95% CI, 0.54 to 0.81; P<0.0001).</p> <p>Significantly fewer sudden deaths among patients on bisoprolol than in those on placebo (48 [3.6%] vs 83 [6.3%] deaths, respectively; HR, 0.56; 95% CI, 0.39 to 0.80; P=0.0011).</p> <p>Secondary: All-cause hospital admissions was significantly lower with bisoprolol than on placebo (440 [33%] vs 513 [39%] patients, respectively; HR, 0.80; 95% CI, 0.71 to 0.91; P=0.0006).</p> <p>All-cardiovascular deaths was significantly lower with bisoprolol than on placebo (119 [9%] vs 161 [12%] patients, respectively; HR, 0.71; 95% CI, 0.56 to 0.90; P=0.0049).</p> <p>Occurrence of composite endpoints of all cardiovascular deaths and cardiovascular admissions was significantly lower with bisoprolol than on placebo (388 [29%] vs 463 [35%] patients, respectively; HR, 0.79; 95% CI, 0.69 to 0.90; P=0.0004).</p> <p>Occurrence of treatment withdrawals was not statistically different between bisoprolol and the placebo group (194 [15%] vs 192 [15%])</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				patients, respectively; HR, 1.00; 95% CI, 0.82 to 1.22; P=0.98).
<p>Contini et al.⁸⁸ (2013) CARNEBI</p> <p>Bisoprolol vs carvedilol vs nebivolol</p> <p>each at maximal clinically tolerated dose</p>	<p>RCT, XO</p> <p>Patients aged 18 to 80 years with diagnosis of either idiopathic or ischemic dilated cardiomyopathy, previous evidence of LVEF ≤ 40%, NYHA class I to III with stable clinical conditions and optimized drug regimen</p>	<p>N=61</p> <p>Each patient performed a 2-month therapy with each β-blocker</p>	<p>Primary: Clinical conditions, quality of life, laboratory data, echocardiographic evaluation, spirometry, alveolar capillary membrane diffusion, chemoreceptor response, cardiopulmonary exercise test, and response to hypoxia during constant workload exercise</p> <p>Secondary: Not reported</p>	<p>Primary: Clinical conditions, NYHA class, Minnesota questionnaire, renal function, hemoglobin concentration, brain natriuretic peptide, Echocardiographic data, and Doppler data were unaffected by the different β-blockers studied.</p> <p>Carbon monoxide diffusing capacity was lower on Carvedilol (18.3 ± 4.8* mL/min/mm Hg) compared to Nebivolol (19.9 ± 5.1) and Bisoprolol (20.0 ± 5.0) due to membrane diffusion 20% reduction (*= P< 0.0001). Constant workload exercise showed in hypoxia a faster VO₂ (oxygen uptake) kinetic and a lower ventilation with Carvedilol. Peripheral and central sensitivity to CO₂ was lower in Carvedilol while response to hypoxia was higher in Bisoprolol.</p> <p>Secondary: Not reported</p>
<p>Willenheimer et al.⁸⁹ (2005) CIBIS-III</p> <p>Bisoprolol 1.25 to 10 mg QD vs enalapril 2.5 to 10 mg BID</p>	<p>BE, MC, OL, PG, RCT</p> <p>Patients ≥65 years with stable mild to moderate CHF (NYHA class II to III), LVEF of ≤35% ≥3 months prior to randomization, not on an ACE inhibitor, β-blocker or ARB therapy and no clinically relevant fluid</p>	<p>N=1,010</p> <p>1.22±0.42 years</p>	<p>Primary: Combined all-cause mortality or hospitalization</p> <p>Secondary: Combined end point at the end of the monotherapy phase and the individual components of the primary end point, cardiovascular death and</p>	<p>Primary: There were 178 patients (35.2%) with a primary end point of combined all-cause mortality or all-cause hospitalization in the bisoprolol-first group, compared to 186 (36.8%) patients in the enalapril-first group (absolute difference, -1.6%; 95% CI, -7.6 to 4.4; HR, 0.94; 95% CI, 0.77 to 1.16; non-inferiority for bisoprolol-first vs enalapril-first treatment; P=0.019).</p> <p>Secondary: The combined endpoint at the end of the monotherapy phase occurred in 109 patients in the bisoprolol-first group compared to 108 patients in the enalapril-first group (HR, 1.02; 95% CI, 0.78 to 1.33; between-group difference P=0.90); 23 vs 32 patients died, respectively (HR, 0.72; 95% CI, 0.42 to 1.24; between-group difference P=0.24); and 99 vs 92 patients had been a hospitalization, respectively (HR, 1.08; 95% CI, 0.81 to 1.43;</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	retention of diuretic adjustment within the 7 days prior to randomization		cardiovascular hospitalization, permanent treatment cessation and the need for early introduction of the second drug as indicators of drug tolerability	<p>between-group difference P=0.59).</p> <p>There were 65 deaths in the bisoprolol-first group, as compared to 73 in the enalapril-first group (HR, 0.88; 95% CI, 0.63 to 1.22; between-group difference P=0.44).</p> <p>In the bisoprolol-first group, 151 patients were hospitalized, compared to 157 patients in the enalapril-first group (HR, 0.95; 95% CI, 0.76 to 1.19; between-group difference P=0.66).</p> <p>There was not a significant difference in cardiovascular death rate observed between the bisoprolol-first (55) and enalapril-first (56) treatment groups (HR, 0.97; 95% CI, 0.67 to 1.40; between-group difference P=0.86).</p> <p>During the monotherapy phase, 35 (6.9%) patients in the bisoprolol-first group permanently discontinued therapy, compared to 49 (9.7%) patients in the enalapril-first group. During the combined-therapy phase, 19 patients (4.2%) in the bisoprolol-first group permanently discontinued bisoprolol therapy and 47 (10.4%) discontinued enalapril therapy. In the enalapril-first group, 24 patients (5.5%) permanently discontinued bisoprolol and 16 (3.7%) discontinued enalapril.</p> <p>There was not a statistical significant difference observed in the early introduction of the second drug between the bisoprolol-first group (39 [7.7%] patients) compared to the enalapril-first group (37 [7.3%] patients; P=0.81).</p>
Packer et al. ⁹⁰ (2001) COPERNICUS Carvedilol 3.125 to 25 mg BID vs placebo	DB, MC, PC, RCT Patients with severe chronic heart failure as a result of ischemic or nonischemic cardiomyopathy, dyspnea or fatigue at rest or on	N=2,280 10.4 months	Primary: Total mortality Secondary: Combined risk of death or hospitalization for any reason, withdrawal rates	Primary: The study was stopped early due to statistical significance. The annual mortality in the placebo group was 19.7% (190) versus 12.8% (130 deaths) in the carvedilol group, a 35% reduction in mortality (95% CI, 19 to 48%; P<0.00013). Secondary: Carvedilol reduced the combined risk of death or hospitalization for any reason by 24% compared to placebo (425 vs 507 patients; 95% CI, 13 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	minimal exertion for ≥ 2 months and a LVEF $< 25\%$ despite appropriate conventional therapy with diuretics, and an ACE inhibitor, or ARB			33%; $P < 0.001$) Withdrawal rates were significantly higher in the placebo group compared to the carvedilol group (18.5 vs 14.8; $P = 0.02$).
Packer et al. ⁹¹ (2002) COPERNICUS Carvedilol 3.125 mg BID, titrated up to 25 mg BID vs placebo	DB, PC, RCT Patients with dyspnea or fatigue at rest or on minimal exertion for ≥ 2 months and a LVEF $< 25\%$ as a result of an ischemic or nonischemic cardiomyopathy, being treated with a diuretic and either an ACE inhibitor or ARB	N=2,289 10.4 months	Primary: All-cause mortality Secondary: Combined risk of death or hospitalization for any reason, combined risk of death or hospitalization for any cardiovascular reason, combined risk of death or hospitalization for heart failure, patient global assessment	Primary: The annual mortality rate with placebo was 19.7% per patient year of follow up, which was reduced to 12.8% by treatment with carvedilol, corresponding to a 35% reduction in the risk of death ($P = 0.00013$). Secondary: Carvedilol reduced the risk of death or any hospitalization by 24% ($P = 0.00004$). Carvedilol reduced the combined risk of death or hospitalization for cardiovascular reason by 27% ($P = 0.0002$) and the combined risk of death or hospitalization for heart failure by 31% ($P = 0.000004$). Patients receiving carvedilol spent 27% fewer days in the hospital for any reason ($P = 0.005$) and 40% fewer days in the hospital for heart failure ($P < 0.0001$). More patients receiving carvedilol felt improved and fewer patients felt worse compared to patients receiving placebo after six months of maintenance therapy ($P = 0.0009$). Patients receiving carvedilol were less likely to experience a serious adverse event ($P = 0.002$), especially worsening heart failure, sudden death, cardiogenic shock or ventricular tachycardia.
Packer et al. ⁹² (1996)	DB, PC, RCT Patients with	N=1,094 6 to 12 months	Primary: All-cause mortality,	Primary: Thirty one (7.8%) patients receiving placebo died compared to 22 (3.2%) deaths in patients receiving carvedilol; this difference represents a 65%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Carvedilol 3.125 mg BID, titrated up to 50 mg BID vs placebo	symptoms of heart failure for ≥ 3 months and an ejection fraction $\leq 35\%$, despite ≥ 2 months of treatment with diuretics and an ACE inhibitor (if tolerated)		cardiovascular morbidity Secondary: Not reported	decrease in the risk of death (95% CI, 39 to 80; $P < 0.001$). Treatment with carvedilol was associated with a large decrease in the risk of dying of progressive heart failure and in the risk of sudden death. Ninety eight (14.1%) patients receiving carvedilol and 78 patients (19.6%) receiving placebo had at least one hospitalization for cardiovascular causes; this difference represents a 27% reduction in the risk of hospitalization (95% CI, 3 to 45; $P = 0.036$). Secondary: Not reported
Dargie et al. ⁹³ (2001) CAPRICORN Carvedilol 6.25 to 25 mg BID mg vs placebo	DB, MC, PC, RCT Patients 18 years and older with a stable MI occurring 3 to 21 days prior to randomization, LVEF $\leq 40\%$ and ACE inhibitor therapy for ≥ 48 hours	N=1,959 1.3 years	Primary: All-cause mortality, all-cause mortality or cardiovascular hospital admissions Secondary: Sudden death, hospital admission for heart failure, recurrent nonfatal MI, all-cause mortality or recurrent nonfatal MI	Primary: There was not a significant difference observed between the carvedilol and placebo groups in the combined endpoint of all-cause mortality and hospital admissions due to cardiovascular events (340 [35%] vs 367 [37%], respectively; HR, 0.92; 95% CI, 0.80 to 1.07; $P = 0.296$). All-cause mortality alone was statistically better in the carvedilol group than the placebo group (116 [12%] vs 151 [15%], respectively; HR, 0.77; 95% CI, 0.60 to 0.98; $P = 0.031$). Secondary: There was not a significant difference observed between the carvedilol and placebo groups in sudden death (51 [5%] vs 69 [7%], respectively; HR, 0.74; 95% CI, 0.51 to 1.06; $P = 0.098$) or in hospital admissions for heart failure (118 [12%] vs 138 [14%], respectively; HR, 0.86; 95% CI, 0.67 to 1.09; $P = 0.215$). The carvedilol group, compared to placebo, experienced significantly lower rates of nonfatal MIs (34 [3%] vs 57 [6%], respectively; HR, 0.59; 95% CI, 0.39 to 0.90; $P = 0.014$) and all-cause mortality or recurrent nonfatal MI (139 [14%] vs 192 [20%], respectively; HR, 0.71; 95% CI, 0.57 to 0.89; $P = 0.002$).
Krum et al (abstract). ⁹⁴ (1995)	DB, PC, RCT Patients with severe chronic HF	N=56 14 weeks	Primary: Cardiac performance; symptom score;	Primary: Compared to placebo, carvedilol improved cardiac performance, as reflected by an increase of LVEF ($P = 0.005$) and stroke volume index ($P = 0.010$), and a decrease in pulmonary wedge pressure ($P = 0.003$), mean

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Carvedilol 25 mg BID</p> <p>vs</p> <p>placebo</p>	<p>receiving digitalis, diuretics and an ACE inhibitor (if tolerated)</p>		<p>combined risk of death, worsening heart failure, and life-threatening ventricular tachycardia</p> <p>Secondary: Not reported</p>	<p>right atrial pressure (P=0.002) and systemic vascular resistance (P=0.017).</p> <p>Compared to placebo, carvedilol improved symptom scores (P=0.002), functional class (P=0.013) and submaximal exercise tolerance (P=0.006).</p> <p>The combined risk of death, worsening heart failure and life-threatening ventricular tachyarrhythmia was lower with carvedilol compared to placebo (P=0.028).</p> <p>Carvedilol was associated with more dizziness and advanced heart block.</p> <p>Secondary: Not reported</p>
<p>Bristow et al.⁹⁵ (1996)</p> <p>Carvedilol 6.25 mg BID</p> <p>vs</p> <p>carvedilol 12.5 mg BID</p> <p>vs</p> <p>carvedilol 25 mg BID</p> <p>vs</p> <p>placebo</p> <p>All patients remained on their standard medications.</p>	<p>DB, MC, PC, RCT</p> <p>Symptomatic (≥ 3 months) patients, 18 to 85 years with stable heart failure from ischemic or nonischemic dilated cardiomyopathy, an LVEF of $\leq 35\%$, a 6-minute walk test between 150 to 425 m and on stable doses of diuretics and ACE inhibitors for 2 weeks before baseline testing</p>	<p>N=345</p> <p>6 months</p>	<p>Primary: Submaximal exercise improvement</p> <p>Secondary: Minnesota questionnaire, changes in NYHA functional class, changes in LVEF, hospitalization, changes in signs and symptoms of heart failure, occurrence of adverse clinical experiences, survival</p>	<p>Primary: There were no differences on submaximal exercise with any dose compared to placebo. Walk distances between in each group ranged between 300 to 400 m in both the 6-minute and 9-minute walk tests; P=0.50 and P=0.27, respectively).</p> <p>Secondary: There were no significant changes in the overall Minnesota Questionnaire scores incorporating both physical and emotional dimensions (changes from baseline in the placebo and low-, medium-, and high-dose carvedilol groups of -7.3, -7.9, -7.3, and -6.6, respectively; P=0.512 in difference from placebo).</p> <p>There were no significant improvements in NYHA functional classes in the carvedilol groups compared to placebo (actual values not reported; P=0.64).</p> <p>Carvedilol treatment resulted in a dose-related significant improvement in LVEF; carvedilol 6.25 mg (~5 ejection fraction units; P<0.005), 12.5 mg (~6 ejection fraction units; P<0.005) and 25 mg (~7.5 ejection fraction units; P<0.0001) compared to placebo (2 ejection fraction unit improvement).</p> <p>The mean number of hospitalizations per patient were significantly</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>reduced in each of the carvedilol groups (~0.1 hospitalizations) compared to placebo (~0.35; P<0.01).</p> <p>Bradycardia was significantly higher in the carvedilol 12.5 mg group (10 [11%]) and the 25 mg group (10 [11%]) compared to placebo (1 [1%]; P<0.05). Also, dizziness was significantly higher in the carvedilol 25 mg group (34 [38%]) compared to the placebo group (19 [23%]; P<0.05). The clinical significance of these advents was not mentioned.</p> <p>There was a dose-related, statistically significant reduction in mortality in the carvedilol-treated groups, with respective mortality rates of 6.0% for the carvedilol 6.25 mg group (RR, 0.356; 95% CI, 0.127 to 0.998; P<0.05), 6.7% for the 12.5 mg group (HR, 0.416; 95% CI, 0.158 to 1.097; P=0.07), and 1.1% in the 25 mg group (HR, 0.067; 95% CI, 0.009 to 0.512; P<0.001) compared to 15.5% mortality in the placebo group.</p> <p>Combining all three carvedilol arms of the study compared to the placebo arm showed statistical significance in all-cause mortality, risk reduced by 73% (P<0.001).</p>
<p>Poole-Wilson et al.⁹⁶ (2003) COMET</p> <p>Carvedilol 25 mg BID</p> <p>vs</p> <p>metoprolol 50 mg BID</p>	<p>DB, MC, PG, RCT</p> <p>Patients with NYHA class II to IV heart failure, admission for a cardiovascular reason in the previous 2 years, an LVEF of <35%, and were stable and optimized with diuretics for ≥2 weeks and ACE inhibitor for ≥4 weeks unless not tolerated</p>	<p>N=3,029</p> <p>58 months</p>	<p>Primary: All-cause mortality, composite endpoint of mortality or all-cause admission</p> <p>Secondary: Not reported</p>	<p>Primary: All-cause mortality was significantly lower in the carvedilol group compared to the metoprolol group (512 [34%] vs 600 [40%], respectively; HR, 0.83; 95% CI, 0.74 to 0.93; P=0.0017).</p> <p>Cardiovascular deaths were significantly lower in the carvedilol group compared to the metoprolol group (438 [29%] vs 534 [35%], respectively; HR, 0.80; 95% CI, 0.70 to 0.90; P=0.0004).</p> <p>There was not a significant difference in the composite endpoints of all-cause mortality or all-cause admission observed between the carvedilol and metoprolol groups (1,116 [74%] vs 1,160 [76%], respectively; HR, 0.94; 95% CI, 0.86 to 1.02; P=0.122).</p> <p>Secondary: Not reported</p>
<p>Packer et al.⁹⁷</p>	<p>MA (19 trials)</p>	<p>N=2,779</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2001) Carvedilol 50 to 100 mg/day vs metoprolol 50 to 150 mg/day or metoprolol ER 150 to 200 mg/day or placebo	Patients with NYHA class II or III and LVEF dysfunction	8.3 months	Change in LVEF Secondary: Not reported	In the six placebo-controlled trials, metoprolol significantly increased the mean LVEF by 0.063 ± 0.002 compared to the increase with placebo of 0.025 ± 0.001 (difference of 0.038 ± 0.005 ; $P < 0.0001$). In the nine placebo-controlled trials, carvedilol significantly increased the mean LVEF by 0.079 ± 0.001 compared to the increase with placebo of 0.012 ± 0.001 (difference of 0.065 ± 0.005 ; $P < 0.0001$). Comparing the two agents, carvedilol increased the LVEF significantly greater than metoprolol (difference of 0.026 ± 0.007 ; $P = 0.0002$). In the four direct comparator trials, carvedilol significantly increased the mean LVEF by 0.089 ± 0.002 compared to the increase with metoprolol of 0.055 ± 0.002 (difference of 0.029 ± 0.011 ; $P = 0.009$). Secondary: Not reported
Arumanayagam et al. ⁹⁸ (2001) Carvedilol 25 mg BID vs metoprolol 50 mg BID	DB, RCT Symptomatic Chinese patients with CHF and LVEF of $< 45\%$	N=24 12 weeks	Primary: Plasma total antioxidant status, erythrocyte superoxide dismutase and glutathione peroxidase Secondary: Not reported	Primary: Neither carvedilol nor metoprolol significantly reduced total antioxidant status activities after 12 weeks of therapy (1.65 ± 0.06 to 1.68 ± 0.09 and 1.44 ± 0.05 to 1.51 ± 0.06 mmol/L, respectively). Carvedilol significantly reduced erythrocyte superoxide dismutase activity after 12 weeks of therapy, (986 ± 46 to 871 ± 22 U/g Hb; $P < 0.001$), but metoprolol did not (790 ± 43 to 836 ± 46 U/g Hb). Carvedilol significantly reduced glutathione peroxidase activity after 12 weeks of therapy, (145 ± 7 to 132 ± 9 U/g Hb; $P < 0.05$), but metoprolol did not (143 ± 8 to 138 ± 9 U/g Hb). Secondary: Not reported
Sanderson et al. ⁹⁹ (1999) Carvedilol 25 mg BID	DB, PG, RCT Symptomatic patients with CHF, LVEF of $< 45\%$, and on standard therapy	N=51 12 weeks	Primary: Symptom score (QOL questionnaire and NYHA class), exercise tolerance	Primary: A significant improvement in symptom scores from baseline were experienced in both the carvedilol (17.2 ± 3 to 8.1 ± 2 ; $P < 0.001$) and metoprolol (13.1 ± 1.8 to 4.8 ± 1.4 ; $P < 0.001$) groups, but there was not a significant difference between the agents.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>metoprolol 50 mg BID</p> <p>All patients continued on their standard therapy.</p>	<p>(diuretics, digoxin and ACE inhibitor)</p>		<p>time, LVEF</p> <p>Secondary: Not reported</p>	<p>A significant improvement in NYHA class from baseline were experienced in both the carvedilol (2.6±0.11 to 2.2±0.12; P<0.001) and metoprolol (2.7±0.09 to 2.1±0.09; P<0.001) groups, but there was not a significant difference between the agents.</p> <p>A significant improvement in exercise tolerance time from baseline were experienced in both the carvedilol (1122±51 to 1194±63; P<0.05) and metoprolol (1164±46 to 1263±52; P<0.01) groups, but there was not a significant difference between the agents.</p> <p>A significant improvement in LVEF from baseline were experienced in both the carvedilol (26±1.8 to 35±2.6; P<0.001) and metoprolol (25±1.8 to 31±2.5; P<0.001) groups, but there was not a significant difference between the agents.</p> <p>Secondary: Not reported</p>
<p>Lechat et al.¹⁰⁰ (1998)</p> <p>β-blockers (bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol)</p> <p>vs</p> <p>placebo</p>	<p>MA (18 trials)</p> <p>Patients with NYHA class I to IV chronic heart failure</p>	<p>N=3,023</p> <p>1.5 to 15 months</p>	<p>Primary: All-cause mortality, hospitalizations due to heart failure, combination of all-cause mortality and hospitalizations for worsened heart failure, changes in functional status, changes in LVEF</p> <p>Secondary: Not reported</p>	<p>Primary: All endpoints showed a significant effect for β-blockers (P<0.05).</p> <p>β-blockers demonstrated a 32% reduction in risk of death compared to placebo (130 vs 156 deaths; 95% CI, 12% to 47%; P=0.003).</p> <p>β-blockers demonstrated a 41% reduction in hospitalizations due to heart failure compared to placebo (166 vs 223 hospitalizations; 95% CI, 26% to 52%; P<0.001).</p> <p>β-blockers demonstrated a 37% reduction in the combination of mortality and morbidity compared to placebo (239 vs 293; 95% CI, 24% to 49%; P<0.001).</p> <p>β-blockers demonstrated a 32% increase in the likelihood of improvement in NYHA class (95% CI, 1% to 74%; P=0.04) and a 30% decrease in the likelihood of worsening NYHA (95% CI, 4% to 50%; P=0.03) compared to placebo</p> <p>β-blockers demonstrated a 29% increase in ejection fraction compared to</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>placebo (0.23±0.04 vs 0.31±0.04; P<10⁻⁹).</p> <p>β-adrenergic agents did not differ in respect to any outcome measure except that reduction in mortality risk. Beta selective agents were less robust than the nonselective agents (P=0.049).</p> <p>Secondary: Not reported</p>
<p>Brophy et al.¹⁰¹ (2001)</p> <p>β-blockers (bisoprolol, bucindolol, carvedilol, metoprolol and nebivolol)</p> <p>vs placebo</p>	<p>MA (22 trials)</p> <p>Patients with CHF of various etiologies</p>	<p>N=10,135</p> <p>3 to 23 months</p>	<p>Primary: Overall mortality, hospitalizations for CHF</p> <p>Secondary: Not reported</p>	<p>Primary: β-blockers significantly reduced mortality compared to placebo (444 vs 624; OR, 0.65; 95% CI, 0.53 to 0.80).</p> <p>β-blockers significantly reduced hospitalizations due to CHF compared to placebo (540 vs 754; RR, 0.64; 95% CI, 0.53 to 0.79).</p> <p>The probability that β-blocker therapy reduced total mortality and hospitalizations for congestive heart failure was almost 100%. The best estimates of these advantages are 3.8 lives saved and four fewer hospitalizations per 100 patients treated in the first year after therapy. The probability that these benefits are clinically significant (>2 lives saved or >2 fewer hospitalizations per 100 patients treated) is 99%.</p>
<p>Whorlow et al.¹⁰² (2000)</p> <p>β-blockers (bisoprolol, bucindolol, carvedilol metoprolol, nebivolol)</p> <p>vs placebo</p>	<p>MA (18 trials)</p> <p>Patients with NYHA class IV heart failure currently taking background therapy (ACE inhibitors and diuretics with or without digoxin)</p>	<p>N=8,119</p> <p>3 to 21 months</p>	<p>Primary: Mortality in NYHA class IV patients</p> <p>Secondary: Not reported</p>	<p>Primary: β-blockers demonstrated a 29% reduction in mortality compared to placebo in patients with NYHA class IV (RR, 0.71; 95% CI, 0.52 to 0.96).</p> <p>The 29% risk reduction is similar to risk reduction seen with β-adrenergic blockers in other NYHA classes.</p> <p>β-blockers demonstrated a 32% reduction in mortality compared to placebo in patients with NYHA class I to IV (HR, 0.68; 95% CI, 0.61 to 0.77).</p> <p>Secondary: Not reported</p>
<p>Bouzamondo et al.¹⁰³ (2003)</p>	<p>MA</p> <p>Randomized</p>	<p>N=not specified</p>	<p>Primary: Overall mortality, hospitalized for</p>	<p>Primary: β-blockers reduced overall mortality by 22% compared to placebo (95% CI, 16% to 28%).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>β-blockers (bisoprolol, bucindolol, carvedilol, and metoprolol)</p> <p>vs</p> <p>placebo</p>	<p>controlled evaluating patients with heart failure depending on NYHA class</p>	<p>Duration varied</p>	<p>worsening heart failure</p> <p>Secondary: Not reported</p>	<p>β-blockers reduced hospitalizations due to worsening heart failure by 24% compared to placebo (95% CI, 20% to 29%).</p> <p>Benefits were similar for bisoprolol, metoprolol, and carvedilol regardless of NYHA class.</p> <p>Secondary: Not reported</p>
<p>Jabbour et al.¹⁰⁴ (2010)</p> <p>β-blockers (bisoprolol, carvedilol, metoprolol)</p>	<p>OL, XO</p> <p>Patients with NYHA class I to III heart failure with a subgroup of patients with coexisting COPD</p>	<p>N=51</p> <p>16 weeks</p>	<p>Primary: Post-bronchodilator FEV₁</p> <p>Secondary: Not reported</p>	<p>Primary: FEV₁ was significantly higher in patients receiving bisoprolol vs carvedilol, both in those with coexisting COPD (P<0.01) and without (P=0.02).</p> <p>There was a significant difference between all patients receiving carvedilol versus those receiving metoprolol (P=0.04), however, when compared for coexisting COPD, there was no difference in FEV₁.</p> <p>There was no significant difference for all patients, those with COPD, or those with CHF only when metoprolol and bisoprolol were compared.</p>
<p>MERIT-HF Study Group¹⁰⁵ (1999)</p> <p>MERIT-HF</p> <p>Metoprolol CR/XL 12.5 mg up to 200 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Symptomatic patients 40 to 80 years in NYHA class II to IV, with LVEF of 40% or less stabilized on standard therapy (diuretic and vasodilator)</p>	<p>N=3,991</p> <p>1 year</p>	<p>Primary: All-cause mortality, all-cause mortality in combination with all-cause admission to hospital (time to first event)</p> <p>Secondary: Not reported</p>	<p>Primary: Study was stopped early on the recommendation of the independent safety committee. All-cause mortality was significantly lower in the metoprolol CR/XL group than in the placebo group (145 [7.2%] vs 217 [11.0 %] deaths, RR, 0.66; 95% CI, 0.53 to 0.81; P=0.00009).</p> <p>There were significantly fewer sudden deaths in the metoprolol CR/XL group than in the placebo group (79 vs 132; RR, 0.59; 95% CI, 0.45 to 0.78; P=0.0002) and deaths from worsening heart failure (30 vs 58; RR, 0.51; 95% CI, 0.33 to 0.79; P=0.0023).</p> <p>Study drug was permanently stopped early in 13.9% of the patients in the metoprolol CR/XL group and in 15.3% of patients in the placebo group (RR, 0.90; 95% CI, 0.77 to 1.06).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Goldstein et al.¹⁰⁶ (2001) MERIT-HF</p> <p>Metoprolol CR/XL 12.5 mg, titrated up to 200 mg QD</p> <p>vs</p> <p>placebo</p>	<p>Sub group analysis of MERIT-HF</p> <p>Patients with NYHA Class III to IV heart failure with LVEF <25%</p>	<p>N=795</p> <p>1 year</p>	<p>Primary: All-cause mortality, composite of all-cause mortality and all-cause admission to hospital (time to first event)</p> <p>Secondary: Not reported</p>	<p>Not reported</p> <p>Primary: There were 45 deaths (11.7% per patient year of follow-up) with metoprolol and 72 deaths (19.1%) with placebo. Metoprolol decreased total mortality by 39%, sudden death by 45% and death due to worsening heart failure by 55%.</p> <p>Metoprolol also decreased the combined end points of all-cause mortality or all-cause hospitalization by 29%, all-cause mortality or hospitalization for worsening heart failure by 44% and cardiac death or nonfatal MI by 46%.</p> <p>Metoprolol reduced the total number of hospitalizations (all-cause) by 27% (0.709 vs 0.965 per patient year of follow up; P=0.0037).</p> <p>During the up titration phase of the trial, the cumulative numbers of patients hospitalized (all-cause) were: 17 vs 21 after two weeks, 28 vs 30 after four weeks, 39 vs 40 after six weeks, 46 vs 56 after eight weeks and 76 vs 102 after three months. The total number of hospitalizations for cardiovascular causes was reduced by 34% (0.475 vs 0.715 per patient year of follow up; P=0.0005) and for worsening heart failure by 45% (0.273 vs 0.497; P<0.0001).</p> <p>Improvement in NYHA functional class was recorded in 46.2 vs 36.7% of patients receiving metoprolol and placebo (P=0.0031).</p> <p>Secondary: Not reported</p>
<p>Waagstein et al.¹⁰⁷ (1993) MDC</p> <p>Metoprolol 5 mg BID, titrated up to 100 to 150 mg/day</p> <p>vs</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 16 to 75 years of age with symptomatic dilated cardiomyopathy, an ejection fraction <40% and being</p>	<p>N=383</p> <p>18 months</p>	<p>Primary: Combined all-cause mortality and clinical deterioration to a point at which cardiac transplantation would normally be</p>	<p>Primary: Thirty eight patients receiving placebo reached the primary endpoint compared to 25 patients receiving metoprolol, which corresponded to a risk reduction of 34% (95% CI, -6 to 62; P=0.058).</p> <p>With regard to the individual endpoints, 21 patients met the non-fatal endpoint of need for heart transplantation; two and 19 patients receiving metoprolol and placebo (P=0.0001). During the 12 or 18 months of follow up, all-cause mortality were 23 and 21 patients receiving metoprolol and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo</p>	<p>treated with diuretics, ACE inhibitors and nitrates</p>		<p>offered as a treatment option</p> <p>Secondary: Cardiac function, exercise capacity, QOL, hospital admission or emergency visits for HF treatment</p>	<p>placebo (P value not reported).</p> <p>Secondary: There was a significantly greater increase in ejection fraction with metoprolol compared to placebo by six and 12 months (P value not reported).</p> <p>QOL improved significantly more with metoprolol compared to placebo (P=0.01).</p> <p>With metoprolol, exercise capacity was significantly greater at six and 12 months compared to baseline (P=0.0006 and P=0.0007). With placebo there was a significant improvement from baseline at six months (P=0.007), but not at 12 months (P=0.46). The difference between the two treatments was significant only at 12 months (P=0.046).</p> <p>There was no difference between the treatments in the number of patients readmitted to the hospital (28 vs 20%; P=0.12), but the number of readmissions for all patients in the group was significantly lower with metoprolol (83 vs 51) as was the mean number of readmissions per patient (0.47 vs 0.28; P<0.04).</p>
<p>Di Lenarda et al.¹⁰⁸ (1999)</p> <p>Metoprolol 142±44 mg QD</p> <p>vs</p> <p>carvedilol 12.5 mg to 50 mg BID</p>	<p>OL, PG, RCT</p> <p>Symptomatic (>12 months) patients with stable dilated cardiomyopathy, LVEF of ≤40% and who poorly responded to chronic treatment with metoprolol plus conventional therapy (metoprolol plus ACE inhibitor, digitalis, diuretics), persistent moderate-</p>	<p>N=30</p> <p>12 months</p>	<p>Primary: Improvement in left ventricular function and remodeling</p> <p>Secondary: Effects on symptoms, QOL, exercise tolerance, ventricular arrhythmias</p>	<p>Primary: LVEF significantly improved in the carvedilol group (7±3%) compared to the metoprolol group (-1±2%; P=0.045).</p> <p>LV end-systolic volume was significantly improved in the carvedilol group (-7±5) compared to the metoprolol group (6±4 mL/m²; P=0.047). There was not a significant difference in LV end-diastolic volume observed between the carvedilol (-8±7) and the metoprolol group (7±6 mL/m²; P=0.053).</p> <p>Secondary: There was not a significant difference observed in the NYHA class, the Heart Failure Score, the Minnesota “Living With Heart Failure” Questionnaire and submaximal exercise tolerance did not significantly change between the carvedilol and metoprolol groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	to-severe left ventricular dysfunction and reduced exercise tolerance			Carvedilol, compared to metoprolol, demonstrated a positive effect on ventricular ectopic beats (-12±9 vs 62±50 n/h; P=0.05) and couplets (-0.5±0.4 vs 1.5±0.6 n/h; P=0.048), but not a significant effect on episodes of nonsustained ventricular tachycardia (-0.02±0.03 vs 0.03±0.01).
Maack et al. ¹⁰⁹ (2001) Metoprolol 12.5 to 100 mg BID vs carvedilol 3.125 to 25 mg BID	OL, XO Patients with stable NYHA class I to III heart failure due to ischemic or idiopathic dilated cardiomyopathy and an LVEF of <35%	N=80 6 months	Primary: Change in LVEF and change in baseline hemodynamic properties (left ventricular end diastolic, end systolic volume, NYHA class) Secondary: Not reported	Primary: After six months of treatment, LVEF improved in the carvedilol group (32±3 to 36±4%; P<0.05 vs baseline) and in the metoprolol group (27±4 to 30±5%; P<0.05 vs baseline). There was not a statistical difference between the agents. There were no differences between the groups in left ventricular end diastolic, end systolic volume, NYHA functional class or any other hemodynamic parameters at rest. Secondary: Not reported
Metra et al. ¹¹⁰ (2000) Metoprolol 5 to 100 mg BID vs carvedilol 3.125 to 50 mg BID All patients continued on their usual treatment for heart failure.	DB, PRO, RCT Symptomatic (≥6 months) patients with CHF caused by ischemic or nonischemic cardiomyopathy, NYHA class II to IV, LVEF ≤35% and a peak oxygen uptake ≤25 mL/kg-1/min-1 and on constant background therapy (furosemide and ACE inhibitor or ARB) for 1 week prior to the study	N=150 15 months	Primary: Change in LVEF Secondary: Hemodynamic variables at rest and peak exercise, maximal and submaximal exercise tolerance, QOL, NYHA functional class, frequency of death and urgent transplantation	Primary: Both agents significantly increased LVEF from baseline (P<0.001 for both), but carvedilol increased LVEF significantly greater at the than metoprolol (10.9±11 vs 7.2±7.7%; P=0.038). Secondary: At the end of the study, both agents carvedilol and metoprolol increased stroke volume and stroke work indexes and decreased mean pulmonary artery pressure, pulmonary wedge pressure, and heart rate from baseline (all P<0.05 from baseline). However, the increase in stroke volume and stroke work indexes during exercise and the decreases in mean pulmonary artery pressure and pulmonary wedge pressure at both rest and exercise were greater with carvedilol than with metoprolol (all P<0.05). Carvedilol increased rest and exercise cardiac index from baseline (both P<0.05). Heart rate declined with both drugs at rest and exercise, but the decrease in exercise heart rate with carvedilol was greater than with metoprolol

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>($P < 0.05$ for the difference between the groups).</p> <p>Both metoprolol and carvedilol significantly improved NYHA class, 6-minute walk distance, and QOL scores from baseline (all $P < 0.05$), and there were no differences between the two treatments.</p> <p>Overall, 21 patients in the metoprolol group and 17 patients in the carvedilol group died or underwent urgent transplantation.</p>
Hypertension				
<p>Reim et al.¹¹¹ (1985)</p> <p>Acebutolol 400 mg QD</p> <p>vs</p> <p>propranolol 160 mg QD</p>	<p>DB, MC, XO</p> <p>Patients 18 to 70 years with essential HTN and blood pressure of $>150/90$ mm Hg</p>	<p>N=18</p> <p>14 weeks</p>	<p>Primary: Blood pressure and heart rate during ergometer exercise test</p> <p>Secondary: Not reported</p>	<p>Primary: There was not a significant difference observed between the acebutolol and propranolol groups in decreases in blood pressure (systolic and diastolic) and heart rate at rest ($P=0.123$, $P=0.230$ and $P=0.210$, respectively).</p> <p>At the ergometer 25 watt load, heart rate and DBP were not significantly different between acebutolol and propranolol ($P=0.087$ and $P=0.068$, respectively), but SBP was significantly lower in the acebutolol group ($P=0.042$)</p> <p>At the higher ergometer loads of 50 and 75 watts, acebutolol had a significantly lower increase in SBP and heart rate compared to propranolol during exercise (50 watts: $P=0.004$ and $P=0.012$, respectively; 75 watts: $P=0.005$ and $P=0.001$, respectively), but there was not a significant difference observed between the groups in DBP in the 50 and 75 watt loads ($P=0.057$ and $P=0.058$, respectively).</p> <p>At the highest ergometer load of 100 watts, acebutolol significantly reduced systolic and DBPs and heart rate compared to propranolol ($P=0.003$, $P=0.001$, and $P=0.001$, respectively).</p> <p>Secondary: Not reported</p>
<p>Fogari et al.¹¹² (1984)</p> <p><u>Weeks 1 to 4:</u></p>	<p>RCT, SB</p> <p>Patients 61 to 80 years inadequately</p>	<p>N=38</p> <p>6 months</p>	<p>Primary: Changes in blood pressure</p>	<p>Primary: After the first four weeks, atenolol (from 177.5 to 161.1 mm Hg) significantly reduced blood pressure compared to baseline, but chlorthalidone did not (from 176.6 to 179.1 mm Hg).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Atenolol 50 mg QD vs chlorthalidone 12.5 mg QD</p> <p><u>Weeks 5 to study end:</u> atenolol and chlorthalidone 50-12.5 mg QD (fixed-dose combination product)</p>	<p>controlled (SBP >170 mm Hg and/or DBP >100 mm Hg) on antihypertensive medications</p>		<p>Secondary: Not reported</p>	<p>The combination atenolol-chlorthalidone therapy significantly reduced mean standing SBP and DBP, supine SBP and DBP, supine and standing heart rate, compared to previous therapies (P<0.001 for all comparisons).</p> <p>The combination atenolol-chlorthalidone therapy significantly reduced mean standing SBP and DBP, supine SBP and DBP, supine and standing heart rate, compared to atenolol and chlorthalidone monotherapy (P<0.001 or P<0.01 for all comparisons).</p> <p>Mean blood pressure reduction obtained by the atenolol and chlorthalidone combination product was 30/15 mm Hg in the standing position (P<0.001).</p> <p>Serum potassium increased with atenolol-chlorthalidone (4.45 mEq/L) compared to chlorthalidone alone (4.01 mEq/L; P<0.001).</p> <p>Secondary: Not reported</p>
<p>Leonetti et al.¹¹³ (1986)</p> <p>Atenolol 50 mg QD vs atenolol 100 mg QD vs chlorthalidone 12.5 mg QD</p>	<p>DB, RCT</p> <p>Patients 24 to 68 years with mild to moderate HTN (WHO stage I or II), with supine DBP ≥95 mm Hg at the end of the 4-week washout period</p>	<p>N=28 16 weeks</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: Mean supine blood pressure was significantly reduced in all treatment groups compared to placebo: 153±18/93±9 mm Hg for atenolol 50 mg patients, 155±22/91±8 mm Hg for atenolol 100 mg patients, 148±17/93±11 mm Hg for chlorthalidone 12.5 mg patients, and 144±16/89±6 mm Hg for the atenolol-chlorthalidone combination patients. All of the changes in blood pressure were significant (P<0.01) versus placebo.</p> <p>Supine SBP was lower with atenolol-chlorthalidone than with the atenolol 100 mg alone (P<0.05).</p> <p>Upright SBP was lower with atenolol-chlorthalidone than with atenolol 50 mg alone (P<0.05) and atenolol 100 mg alone (P<0.05).</p> <p>Mean supine heart rate was 77±7 bpm after placebo which decreased to 69±10 bpm (P<0.01) after atenolol 50 mg, to 67±6 bpm (P<0.01) after atenolol 100 mg, to 77±10 bpm (P=not significant, was not reported) after</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
atenolol and chlorthalidone 50-12.5 mg QD (fixed-dose combination product)				<p>chlorthalidone alone.</p> <p>Chlorthalidone alone demonstrated a significant reduction in serum potassium levels compared to placebo (3.88 vs 4.09 mEq/L; $P < 0.05$) and no change when the atenolol-chlorthalidone combination was compared to placebo (3.98 vs 4.09; $P = \text{not significant}$, value was not reported).</p> <p>Chlorthalidone alone and atenolol-chlorthalidone demonstrated a significant increase in serum uric acid levels compared to placebo (4.90 ± 1.52 mg/dL, 5.07 ± 1.33 mg/dL, respectively, vs 4.24 ± 1.12 for placebo; $P < 0.05$ for both).</p> <p>All treatments were well tolerated. Some adverse events reported included dyspnea, precordial discomfort and cold extremities. Incidence, severity and P values were not reported.</p>
<p>Nissinen et al.¹¹⁴ (1980)</p> <p>Atenolol 100 mg QD plus chlorthalidone 25 mg in the morning</p> <p>vs</p> <p>atenolol and chlorthalidone 100-25 mg in the morning (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>DB, RCT</p> <p>Patients with newly diagnosed mild to moderate HTN (supine DBP 100 mm Hg on ≥ 3 occasions)</p>	<p>N=23</p> <p>16 weeks</p>	<p>Primary: Changes in blood pressure and heart rate</p> <p>Secondary: Not reported</p>	<p>Primary: Each of the active drug combinations lowered standing, supine, and post-exercise blood pressure significantly compared to placebo at two and four weeks ($P < 0.001$, $P < 0.01$ and $P < 0.05$). There was not a statistical difference between the active treatment regimens (P value not significant).</p> <p>Each of the active drug combinations lowered standing, supine, and post-exercise heart rate significantly compared to placebo at two and four weeks ($P < 0.001$, $P < 0.01$ and $P < 0.05$). There was not a statistical difference between the active treatment regimens (P value not significant).</p> <p>Side effects did not differ between treatment groups and placebo in terms of frequency or severity. Reported side effects included dizziness, headache and tiredness.</p> <p>Secondary: Not reported</p>
Johnson et al. ¹¹⁵ (2009)	RCT	N=368	Primary: Blood pressure	Primary: When analyzed by order of initiation of the two drugs, the response to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Atenolol 50 to 100 mg QD for 9 weeks, followed by atenolol 50 to 100 mg QD and HCTZ 12.5 to 25 mg QD for 9 weeks</p> <p>vs</p> <p>HCTZ 12.5 to 25 mg QD for 9 weeks, followed by HCTZ 12.5 to 25 mg QD and atenolol 50 to 100 mg QD for 9 weeks</p>	<p>Patients 17 to 65 years of age mild to moderate essential HTN</p>	<p>15 to 18 weeks</p>	<p>lowering effect of drug initiation order: the addition of a β-blocker to a thiazide versus the addition of a thiazide to a β-blocker</p> <p>Secondary: Not reported</p>	<p>HCTZ and atenolol was greater overall than that seen for atenolol and HCTZ (P=0.0007 and P<0.0001).</p> <p>This study suggests that initiation of HCTZ followed by atenolol results in greater blood pressure lowering as compared with initiation in the reverse order, with differences that are potentially clinically important.</p> <p>Secondary: Not reported</p>
<p>Dhakam et al.¹¹⁶ (2008)</p> <p>Atenolol 50 mg QD</p> <p>vs</p> <p>nebivolol 5 mg QD</p> <p>vs</p> <p>placebo QD</p>	<p>DB, RCT, XO</p> <p>Never-treated subjects with isolated systolic HTN</p>	<p>N=16</p> <p>17 weeks</p>	<p>Primary: Change in central blood pressure</p> <p>Secondary: Change in peripheral blood pressure, AIX, aPWV and N-terminal proBNP.</p>	<p>Primary: There was not a statistically significant difference observed in the change in aortic SBP between the nebivolol and atenolol groups (125±3 vs 127±3 mm Hg; P=0.4), but both agents were significantly better than placebo (131±2 mm Hg).</p> <p>There was not a statistically significant difference observed in the change in aortic DBP between the nebivolol and atenolol groups (75±2 vs 73±2 mm Hg; P=0.3), but both agents were better than placebo (82±2 mm Hg).</p> <p>Secondary: There was not a statistically significant difference observed in the change in brachial SBP between the nebivolol and atenolol groups (136±3 vs 137±3 mm Hg; P=0.4), but both agents were significantly better than placebo (149±3 mm Hg).</p> <p>There was not a statistically significant difference observed in the change</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>in brachial DBP between the nebivolol and atenolol groups (75 ± 2 vs 73 ± 2 mm Hg; $P=0.5$), but both agents were better than placebo (82 ± 2 mm Hg).</p> <p>There was a statistically significant reduction in AIX in the atenolol group compared to the nebivolol group (32 ± 2 vs $28 \pm 2\%$; $P=0.4$), but both agents were significantly better than placebo ($22 \pm 2\%$).</p> <p>There was not a statistically significant difference observed in the reduction of aPWV in the atenolol group compared to the nebivolol group (8.9 ± 0.3 vs 9.1 ± 0.3 m/s; $P=0.2$), but both agents were significantly better than placebo (10.0 ± 0.4 m/s; P was not reported).</p> <p>There was not a statistically significant difference observed in the rise in N-terminal pro-BNP in the atenolol group compared to the nebivolol group (157 vs 138 pg/mL; $P=0.6$), but both agents were significantly better than placebo (75 mg/mL).</p>
<p>Fogari et al.¹¹⁷ (1997)</p> <p>Atenolol 50 mg QD</p> <p>vs</p> <p>nebivolol 5 mg QD</p>	<p>DB, PG, RCT</p> <p>Patients 18 to 70 years of age with stable type 2 diabetes ($HbA_{1c} \leq 8\%$ during previous 6 months with diet and/or oral therapy stable for ≥ 6 months), and mild to moderate HTN (DBP ≥ 95 and < 116 mm Hg) at the end of the 4-week run-in period with placebo</p>	<p>N=30</p> <p>6 months</p>	<p>Primary: Changes in blood pressure, heart rate, 24-hour urinary C-peptide excretion, HbA_{1c}, plasma glucose, lipid levels</p> <p>Secondary: Euglycemic hyperinsulinemic clamp test (body glucose utilization)</p>	<p>Primary: Both atenolol and nebivolol significantly reduced blood pressure and heart rate from baseline ($P < 0.001$ for all measures), but there was not a significant difference between the treatment groups at weeks 0, 2, and 24 ($P > 0.05$ for all measures).</p> <p>There no significant changes from baseline in mean 24-hour urinary C-peptide excretion, HbA_{1c}, plasma glucose, and lipid levels ($P > 0.05$). There were also no significant differences observed between treatment groups in any of these measures ($P > 0.05$).</p> <p>Secondary: There was not a significant decrease from baseline in mean values for whole body glucose utilization observed in neither the atenolol group nor the nebivolol group (mean decrease of 0.9 vs 2.6%, respectively; $P > 0.05$) and the groups were significant from each other ($P > 0.05$).</p>
<p>Dietz et al.¹¹⁸ (2008)</p> <p>Atenolol 50 to 100</p>	<p>DB, MC, RCT</p> <p>Patients ≥ 18 years of age with HTN</p>	<p>N=694</p> <p>12 weeks</p>	<p>Primary: Changes in mean sitting SBP and mean sitting DBP,</p>	<p>Primary: Treatment with aliskiren and atenolol combination therapy led to a significantly greater reduction in mean sitting SBP by 17.3 mm Hg compared to aliskiren monotherapy (difference, -2.9 mm Hg; $P=0.039$) or</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg and atenolol 50 to 100 mg QD</p>	<p>(mean sitting DBP \geq95 and <110 mm Hg)</p>		<p>rates of blood pressure control (<140/90 mm Hg), pulse pressure and pulse rate, plasma renin concentration, plasma renin activity</p> <p>Secondary: Not reported</p>	<p>atenolol monotherapy (difference, -3.0 mm Hg; P=0.034). There was no difference between mean sitting SBP reductions with aliskiren and atenolol monotherapy (difference, -0.1 mm Hg; P=0.954).</p> <p>Treatment with aliskiren and atenolol combination therapy led to a significantly greater reduction in mean sitting DBP by 14.1 mm Hg compared to aliskiren monotherapy (difference, -2.9 mm Hg; P<0.001), but not atenolol monotherapy (difference, -0.5 mm Hg; P=0.545). Reductions in mean sitting DBP with atenolol were larger compared to those observed with aliskiren (difference, 2.4 mm Hg; P=0.003).</p> <p>Rates of blood pressure control were higher with aliskiren and atenolol combination therapy (51.3%) compared to aliskiren monotherapy (36.1%, P<0.001) or atenolol monotherapy (42.2%, P=0.009). There was no significant difference in blood pressure control rates between aliskiren and atenolol monotherapy (P=0.388).</p> <p>Mean pulse pressure was reduced by 3.0 mm Hg with aliskiren and atenolol combination therapy and aliskiren monotherapy. Atenolol monotherapy did not affect pulse pressure. Aliskiren monotherapy did not affect pulse rate. Significant mean reductions in pulse rate of >10 bpm were observed with atenolol monotherapy and the aliskiren and atenolol combination (P<0.001 vs aliskiren monotherapy for both).</p> <p>Aliskiren monotherapy increased plasma renin concentration by 241% and aliskiren/atenolol increased plasma renin concentration by 85% (P=0.010 vs aliskiren). Atenolol monotherapy decreased plasma renin concentration by 24% (P<0.001 vs aliskiren and aliskiren/atenolol). Aliskiren, atenolol and aliskiren/atenolol reduced plasma renin activity by 65, 52, and 61%, respectively.</p> <p>Secondary: Not reported</p>
<p>Wald et al.¹¹⁹ (2008)</p> <p>Atenolol 25 mg</p>	<p>DB, DD, RCT, XO</p> <p>Patients \geq 40 years enrolled in a HTN</p>	<p>N=47</p> <p>16 weeks</p>	<p>Primary: Reduction in blood pressure</p>	<p>Primary: The mean reductions in SBP in the atenolol alone, lisinopril alone and atenolol plus lisinopril groups were 16.1, 12.5 and 22.9 mm Hg, respectively. The mean reductions in DBP in the atenolol alone, lisinopril</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD</p> <p>vs</p> <p>lisinopril 5mg QD</p> <p>vs</p> <p>lisinopril 5 mg and atenolol 25 mg QD</p> <p>vs</p> <p>placebo</p>	<p>or anticoagulation clinic</p>		<p>Secondary: Not reported</p>	<p>alone and atenolol plus lisinopril groups were 9.8, 6.8 and 13.9 mm Hg, respectively. The reductions with lisinopril plus atenolol group were significantly higher than either agent as monotherapy (P<0.001).</p> <p>Secondary: Not reported</p>
<p>Pareek et al.¹²⁰ (2010)</p> <p>Atenolol 25 to 50 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 5 mg and atenolol 25 to 50 mg QD</p>	<p>AC, MC, OL, RCT</p> <p>Adults with either untreated or pretreated essential HTN</p>	<p>N=190</p> <p>12 weeks</p>	<p>Primary: Change in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>Primary: At the end of four weeks, the mean change in SBP (-30.0±10.4 vs -25.08±9.05; P=0.008) and DBP (-18.10±7.45 vs -14.78±7.48; P=0.021) was significantly greater in the low-dose combination therapy as compared to the low-dose monotherapy.</p> <p>At the end of 12 weeks, the mean SBP (127.82±8.90 vs 138.0±14.4; P=0.001) and mean DBP (81.73±8.78 vs 87.35±5.50; P=0.011) were significantly lower in the high-dose combination group as compared to the high-dose monotherapy group.</p> <p>Secondary: Not reported</p>
<p>Chapman et al.¹²¹ (2007)</p> <p>ASCOT-BPLA</p> <p>Atenolol 50 to 100 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in</p>	<p>Subanalysis of ASCOT-BPLA evaluating effects of spironolactone on treatment-resistant HTN</p> <p>Patients 40 to 79 years of age with HTN and ≥3</p>	<p>N=1,411</p> <p>1.3 years</p>	<p>Primary: Change in DBP and SBP, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: Spironolactone-treated patients lead to a significant 21.9 mm Hg reduction in SBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 20.8 to 23.0 mm Hg; P<0.001).</p> <p>Spironolactone-treated patients lead to a significant 9.5 mm Hg reduction in DBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 9.0 to 10.1; P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>diabetic patients); bendroflumethiazide* plus potassium 1.25 to 2.5 mg plus doxazosin were added for additional blood pressure control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p> <p>vs</p> <p>amlodipine 5 to 10 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); perindopril 4 to 8 mg and doxazosin were added for additional control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p>	<p>cardiovascular risk factors, with SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg (not on antihypertensive therapy) or SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg (on antihypertensive therapy)</p>			<p>Spironolactone-treated patients exhibited small but significant decreases in sodium, LDL-C and TC as well as increases in potassium, glucose, creatinine and HDL-C ($P < 0.05$).</p> <p>The most common adverse effect reported in the trial was gynecomastia in men (P value not reported).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Pepine et al.¹²² (2006) INVEST</p> <p>Atenolol (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p> <p>vs</p> <p>verapamil SR (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist strategy)</p>	<p>Post hoc analysis of INVEST</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: Risk for adverse outcome associated with baseline factors, follow-up blood pressure and drug treatments</p> <p>Secondary: Not reported</p>	<p>Primary: Previous heart failure (adjusted HR, 1.96), as well as diabetes (HR, 1.77), increased age (HR, 1.63), United States residency (HR, 1.61), renal impairment (HR, 1.50), stroke/TIA (HR, 1.43), smoking (HR, 1.41), MI (HR, 1.34), PVD (HR, 1.27), and revascularization (HR, 1.15) predicted increased risk.</p> <p>Follow-up SBP <140 mm Hg (HR, 0.82) or DBP <90 mm Hg (HR, 0.70) and trandolapril with verapamil SR (HR, 0.78 and 0.79) were associated with reduced risk.</p> <p>Secondary: Not reported</p>
<p>Hilleman et al.¹²³ (1999)</p> <p>Monotherapy (atenolol, HCTZ, captopril, enalapril, lisinopril, amlodipine,</p>	<p>MA (82 trials)</p> <p>Patients with mild-to-moderate essential HTN</p>	<p>N=not reported</p> <p>≥4 weeks</p>	<p>Primary: Absolute change in supine DBP from baseline</p> <p>Secondary: Percent of patients who achieved blood pressure control, safety</p>	<p>Primary: The mean absolute decrease in supine DBP ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least. When studies were weighted by sample size, amlodipine and benazepril, atenolol, lisinopril, and verapamil showed the greatest blood pressure effect.</p> <p>Secondary: The average percentage of patients defined as controlled after treatment varied from 53.5 to 79.0%, with amlodipine and benazepril (74.3%) and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
diltiazem, nifedipine, verapamil vs amlodipine and benazepril (fixed-dose combination)				lisinopril (79.0%) showing the highest percentage control (P=0.096). The incidence of adverse events ranged from 12.1 to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% and 14.1%, respectively) and nifedipine the highest incidence. Lisinopril demonstrated significantly less overall side effects compared to nifedipine (P=0.030). Nifedipine demonstrated a higher withdrawal rate due to side effects compared to atenolol, HCTZ, enalapril, amlodipine, and diltiazem (P=0.002). Although amlodipine and benazepril had the lowest rate of withdrawals due to adverse events, lack of significant change was due to the low number of cohorts available for analysis.
Davidov et al. ¹²⁴ (1988) Betaxolol 10 to 40 mg QD vs propranolol 40 to 160 mg BID	DB, MC, RCT Patients 21 to 73 years with mild to moderate HTN (supine DBP of 95 to 115 mm Hg)	N=141 24 weeks	Primary: Change in blood pressure and heart rate Secondary: Not reported	Primary: Both betaxolol and propranolol significantly reduced SBP from baseline (7±2.5 and 7±2.0 mm Hg; P<0.01 for both). Both betaxolol and propranolol significantly reduced DBP from baseline (11±0.9 and 9±1.2 mm Hg; P<0.01 for both). Both betaxolol and propranolol significantly heart rate from baseline (6±1.3 and 7±1.1 bpm; P<0.01 for both). At the end of the study, there was not a significant difference in response between groups. Secondary: Not reported
Czuriga et al. ¹²⁵ (2003) NEBIS Bisoprolol 5 mg QD vs nebivolol 5 mg QD	MC, PG, RCT, SB Patients 30 to 65 years with mild to moderate HTN, a DBP 95 to 110 mm Hg and a SBP ≤180 mm Hg at the end of the placebo run-in period who were	N=273 16 weeks	Primary: Percentage of responders achieving DBP normalization (≤90 mm Hg) or a DBP reduction of at least 10 mm Hg and heart sitting rate	Primary: There was not a significant difference between percentage of responders between the nebivolol group (92%) and the bisoprolol group (89.6%). There was not a significant difference in the mean change in blood pressure observed between the nebivolol and bisoprolol (SBP: -20.5±12.9 vs -20.0±12.0 mm Hg, respectively; P=0.7434) and DBP (-15.7±6.4 vs -16.0 ± 6.8 mm Hg, respectively; P=0.8230). There was not a significant difference in mean heart rate observed between

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	either newly diagnosed or previously treated hypertensives and required a change of therapy in consequence of side-effects or poor compliance		Secondary: Adverse events, symptom questionnaire	<p>the nebivolol (68.7±8.5 per minute) and the bisoprolol group (68.1±7.5 per minute).</p> <p>Secondary: There was not significant difference in rates of adverse events reported between the nebivolol (eight patients [5.8%]) and the bisoprolol group (12 patients [8.9%]; P>0.05). All adverse events were either mild (55%) or moderate (45%) in intensity.</p> <p>Both treatments demonstrated a significant reduction in the basal score index at visit 5 (nebivolol, -0.7 vs bisoprolol, -0.5; P<0.02), but there was no significant difference between treatment groups (P>0.05).</p>
<p>Stoschitzky et al.¹²⁶ (2006)</p> <p>Bisoprolol 10 mg on day 1, then 5 mg QD</p> <p>vs</p> <p>carvedilol 50 mg on day 1, then 25 mg BID</p> <p>vs</p> <p>nebivolol 10 mg on day 1, then 5 mg QD</p>	<p>DB, PC, RCT, XO</p> <p>Male patients between 22 and 34 years with a height between 177 and 189 cm, and body weight between 66 and 86 k</p>	<p>N=16</p> <p>1 week</p>	<p>Primary: Heart rate and blood pressure at rest and exercise</p> <p>Secondary: Effects on nocturnal melatonin release, QOL</p>	<p>Primary: Compared to baseline, heart rate at exercise was decreased at three hours after the first dose by bisoprolol (-24%), carvedilol (-17%) and nebivolol (-15%); (P<0.05 for each group). Bisoprolol was significantly better than nebivolol (P<0.05).</p> <p>Compared to baseline, heart rate at exercise was decreased at 24 hours after the first dose by bisoprolol (-18%), carvedilol (12 hours; -15%) and nebivolol (-13%); (P<0.05 for each group). There was not a statistical significance observed between the groups.</p> <p>Compared to baseline, heart rate at exercise was decreased at 24 hours after the respective last dose at the end of one week of chronic administration by bisoprolol (-14%), carvedilol (12 hours; -15%) and nebivolol (-13%); (P<0.05 in all cases). There was not a statistical significance observed between the groups.</p> <p>All of the agents significantly decreased SBP both at rest and exercise at three and 24 hrs after the first dose as well at 24 hr after the last dose after seven days of chronic administration (P<0.05 in all cases). None of the agents had a significant effect on DBP at rest or at exercise.</p> <p>Secondary: Compared to placebo, nocturnal melatonin release was decreased by bisoprolol (-44%, P<0.05) whereas nebivolol (-16%) and carvedilol</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(-19%) had no effect. Total QOL with carvedilol (8.0±0.8) was slightly but significantly lower than that with placebo (8.6±0.4), nebivolol (8.5±0.6) and bisoprolol (8.4±0.5); (P<0.05 in all cases).
Lewin et al. ¹²⁷ (1993) Bisoprolol and HCTZ 5-6.25 mg QD (fixed-dose combination product) vs placebo	MC, PC Adult patients with stable mild to moderate (sitting DBP 95 to 114 mm Hg) essential HTN	N=36 4 weeks	Primary: Changes in 24-hr ambulatory daytime and nighttime blood pressure Secondary: Not reported	Primary: There were statistically significant reductions in blood pressure and pulse (P<0.01) at weeks two and four of treatment. There were statistically significant reductions (P<0.01) in 24 hr SBP and DBP, daytime and nighttime blood pressure, compared to the end of the placebo phase. There was a reduction in systolic and diastolic load also (P<0.01). The combination was well tolerated. The scores from the overall QOL questionnaire indicated an improvement with the combination (P=0.02).
Benetos et al. ¹²⁸ (2000) Bisoprolol and HCTZ 2.5-6.25 mg QD (fixed-dose combination product) vs amlodipine 5 mg QD	DB, MC, PG, RCT Patients over 60 years with supine SBP 160 to 210 mm Hg and DBP <90 mm Hg	N=164 12 weeks	Primary: Changes in blood pressure, heart rate, adverse events, QOL scores Secondary: Not reported	Primary: Both bisoprolol and HCTZ and amlodipine significantly reduced SBP (-20.0±13.7 and -19.6±14.2 mm Hg, respectively; P<0.001) and DBP (-4.5±7.4 and -2.4±8.4 mm Hg, respectively from baseline to week 12, but there was not a significant difference between the agents (SBP; P=0.85 and DBP; P=0.09). Bisoprolol and HCTZ significantly reduced heart rate from baseline, but amlodipine did not (-7.6±8.4 [P<0.001] and -0.2±11.4 bpm, respectively). Bisoprolol and HCTZ significantly reduced heart rate when compared to amlodipine (P=0.0001). Overall adverse events were not significantly different between the amlodipine and the bisoprolol and HCTZ group (39 and 40%, respectively). Adverse events reported included headache, leg edema, fatigue and bradycardia but severity of events was not reported. Overall QOL scores were not significantly different between the amlodipine and the bisoprolol and HCTZ group.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Prisant et al.¹²⁹ (1995)</p> <p>Bisoprolol and HCTZ 2.5-6.25, 5-6.25, or 10-6.25 mg/day (fixed-dose combination product)</p> <p>vs</p> <p>enalapril 5, 10, or 20 mg</p> <p>vs</p> <p>amlodipine 2.5, 5, or 10 mg</p>	<p>DB, MC, PG, RCT</p> <p>Patients ≥21 years with mild to moderate essential HTN, (average sitting DBP 95 to 114 mm Hg) each treatment was once daily and titrated to effect</p>	<p>N=218</p> <p>17 weeks</p>	<p>Primary: Mean change from baseline in SBP and DBP, lab measurements, adverse events, QOL questionnaire</p> <p>Secondary: Not reported</p>	<p>Secondary: Not reported</p> <p>Primary: Mean decreases in SBP and DBP from baseline were 13.4/10.7 mm Hg for bisoprolol and HCTZ patients, 12.8/10.2 mm Hg for amlodipine patients, and 7.3/6.6 mm Hg for enalapril patients. The hypotensive effects were significant for all three groups (P<0.001).</p> <p>SBP and DBP mean changes from baseline for the bisoprolol and HCTZ group and the amlodipine group were greater than the change from baseline for the enalapril group (P<0.01).</p> <p>Response rates (DBP ≤90 mm Hg or ≥10 mm Hg decrease from baseline) were 71% for the bisoprolol and HCTZ group, 69% for the amlodipine group, and 45% for the enalapril group. The response rates for the bisoprolol and HCTZ and the amlodipine groups differed significantly from the enalapril group (P<0.01).</p> <p>Twenty nine percent of bisoprolol patients had adverse experiences compared to 42% of amlodipine patients (P=0.12). Nearly 47% of enalapril patients had adverse experience compared to bisoprolol (P=0.04). Adverse events reported included headache, fatigue, peripheral edema, and dizziness.</p> <p>Drug related adverse events were 16% for the bisoprolol and HCTZ patients, 21% for the amlodipine patients, and 23% for the enalapril patients. There was no significant difference between the groups.</p> <p>Enalapril demonstrated a mean decrease from baseline of 7.9 mg/dL for TC (P=0.02 vs amlodipine) and 6.6 mg/dL for LDL-C (P=0.04 vs amlodipine) which were not significantly different from the increase from the bisoprolol and HCTZ group of 1.7 mg/dL (P=0.07 vs enalapril) for TC and +0.6 mg/dL in LDL-C. However, the increase in TGs was highest for bisoprolol and HCTZ-treated patients compared to amlodipine- and enalapril-treated patients (P=0.08, for bisoprolol and HCTZ vs enalapril).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				There was not a significant difference from baseline or between treatment groups in QOL scores: 0.9 for the bisoprolol and HCTZ group, 0.5 for the amlodipine group, and 2.3 for the enalapril group.
Frishman et al. ¹³⁰ (1994) Bisoprolol 2, 5, 10, or 40 mg QD vs HCTZ 6.25 or 25 mg QD vs bisoprolol plus HCTZ, all possible combinations	DB, MC, PC, RCT Patients 21 years and older with mild to moderate essential HTN whose weight was 35% of the ideal for height and frame and mean sitting DBP was stable and between 95 to 115 mm Hg	N=512 12 weeks	Primary: Changes in DBP and SBP Secondary: Not reported	Primary: All treatment groups (all doses) of bisoprolol, HCTZ and the combination of bisoprolol and HCTZ significantly reduced sitting DBP from baseline (P<0.01). The reduction in blood pressure was significantly greater as the doses of the bisoprolol, HCTZ and the combination of bisoprolol-HCTZ were increased (P<0.05). The combination bisoprolol and HCTZ significantly reduced sitting DBP compared to the separate agents as monotherapy (P<0.01). With higher doses of HCTZ, there was a significantly higher incidence of hypokalemia, defined as potassium <3.5 mmol/L (P<0.01). Incidence of hyperuricemia also significantly increased with the increase in HCTZ dose (P<0.01). Adverse events associated with hypokalemia and hyperuricemia were not reported. As the dose of bisoprolol was increased, the frequency and severity of adverse events reported significantly increased (P<0.05). Adverse events reported included asthenia, diarrhea, dyspepsia and somnolence, but severity of effects was not reported. Secondary: Not reported
Frishman et al. ¹³¹ (1995) Bisoprolol 5 mg QD vs HCTZ 25 mg QD	DB, MC, PC, PG, RCT Patients ≥21 years with mild to moderate (stage II or II) systemic HTN whose body weight was not >10%	N=547 10 weeks	Primary: Changes in blood pressure and adverse events Secondary: Not reported	Primary: All active treatment groups significantly reduced sitting DBP and SBP from baseline compared to placebo (P<0.01). Addition of HCTZ 6.25 mg contributed significantly to the blood pressure lowering effects of bisoprolol 5 mg. The combination bisoprolol and HCTZ 5-6.25 mg produced a significantly greater reduction in mean sitting DBP from baseline (-12.6±0.5 mm Hg)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs bisoprolol and HCTZ 5-6.25 mg QD (fixed-dose combination product) vs placebo</p>	<p>below or 35% above the ideal weight for height and frame, and were off all antihypertensive medications before study entry and sitting DBP was 95 to 115 mm Hg on 3 consecutive weekly visits</p>			<p>compared to bisoprolol 5 mg alone (-10.5±0.5 mm Hg; P=0.02) and HCTZ 25 mg alone (-8.5±0.5 mm Hg; P<0.01). Bisoprolol 5 mg monotherapy was significantly better a reducing DBP compared to HCTZ 25 mg alone (P=0.03).</p> <p>The combination bisoprolol and HCTZ 5-6.25 mg produced a significantly greater reduction in mean sitting SBP from baseline (-15.8 mm Hg) compared to bisoprolol 5 mg alone (-10 mm Hg; P<0.01) and HCTZ 25 mg alone (-15.8 mm Hg; P<0.01). There was not a significant difference in mean reduction between bisoprolol 5 mg alone and HCTZ 25 mg alone.</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination had a 73% response rate compared to 61% for the bisoprolol group and 47% for the HCTZ group.</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination was found to be significantly more effective compared to bisoprolol 5 mg or HCTZ 25 mg in all subgroups of patients regardless of age, race, gender, or smoking history (P>0.05 for all comparisons).</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination did not have an increase in frequency or severity of adverse events. The adverse events were comparable to that in the placebo group and frequency among groups was not significant. The most common adverse events reported were headache, dizziness, fatigue, and cough.</p> <p>Significantly greater number patients in the HCTZ 25 mg group (6.5%) experienced hypokalemia (potassium <3.4 mEq/L) compared to the bisoprolol 5 mg group (0.7%; P<0.01), the bisoprolol and HCTZ combination group (0.7%; P<0.01), and placebo (0%; P<0.01).</p> <p>Hyperglycemia occurred in 7.4% of patients in the HCTZ 25 mg group, which was significantly higher than in the placebo group (5.2%; P=0.03). Also, the incidence of hyperuricemia (uric acid >7.5 mg/dL) was significantly higher in the HCTZ 25 mg group (24.4%) compared to placebo (2.7%; P<0.01).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Hamaad et al. ¹³² (2007) Carvedilol 3.125 to 25 mg BID vs bisoprolol 1.25 to 10 mg QD	RCT Patients with stable LVEF of <40% and treated with diuretic and ACE inhibitor or ARB	N=31 12 weeks	Primary: Blood pressure, heart rate responses and both time and frequency domain heart rate variability Secondary: Not reported	Primary: Carvedilol significantly reduced DBP from baseline to week 12 of therapy (stage 6), but bisoprolol did not: 10±16 mm Hg (P=0.045) and 7±16 mm Hg, respectively (P=0.159), but there was not a significant difference between groups. Both carvedilol and bisoprolol significantly reduced SBP from baseline to week 12 of therapy (stage 6): 18±28 mm Hg (P=0.045) and 12±16 mm Hg, respectively (P<0.003) but there was not a significant difference between groups. Both carvedilol and bisoprolol significantly decreased mean heart rate from baseline to week 12 of therapy (stage 6): 25±20 bpm and 23±10 bpm, respectively (P<0.01 for both agents vs baseline) but there was not a significant difference between groups (P=0.708). Neither carvedilol nor bisoprolol significantly increased four of the five heart rate variability indices measured including SDNN, RMSSD, low frequency power or high frequency power. But both carvedilol and bisoprolol significantly increased triangular index from baseline to week 12 of therapy (stage 6): 7±6 (P<0.01) and 5±6 (P=0.01), respectively, but there was not a significant difference between groups. Secondary: Not reported
Erdogan et al. ¹³³ (2011) Carvedilol 25 mg QD for 1 month vs nebivolol 5 mg QD for 1 month	DB, PC, PRO, RCT, XO Patients with mild to moderate HTN	N=20 2 months	Primary: Blood pressure, heart rate Secondary: Safety	Primary: Treatment with carvedilol (133.8±9/86.6±8.6 mmHg) and nebivolol (134±8.7/85.6±7.4 mmHg) significantly decreased SBP and DBP compared to placebo (143.9±8.9/94.4±9.2 mmHg; P<0.05). There was no difference between carvedilol and nebivolol (P>0.05). Mean heart rate was significantly decreased after initiating treatment with carvedilol (70.2±5.2 bpm) and nebivolol (64.9±3.9 bpm) compared to placebo (78.8±5.2; P<0.05). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
All patients went through a 10 day placebo run in period.				No adverse events were reported with either treatment.
Saunders et al. ¹³⁴ (1987) Labetalol 100 to 800 mg BID vs propranolol 40 to 320 mg	DB, PG Patients with mild to moderate HTN	N=153 Duration not specified	Primary: Blood pressure, heart rate Secondary: Not reported	Primary: Labetalol was significantly better than propranolol at the end of monotherapy at lowering DBP (P<0.05) but there was no difference in lowering SBP. Propranolol was significantly better at lowering heart rate compared to labetalol (P<0.01). No difference in the decrease in blood pressure after a diuretic was added. Secondary: Not reported
McAreavey et al. ¹³⁵ (1984) Labetalol 200 mg QD up to 1,600 mg BID vs prazosin 0.5 mg QD up to 10 mg BID vs hydralazine 12.5 mg QD up to 100 mg BID vs	DB, PG, RCT Patients with inadequately controlled HTN while receiving atenolol 100 mg/day and bendrofluzide* 5 mg/day	N=238 6 months	Primary: Comparative safety and efficacy, target blood pressure <140/95 mm Hg Secondary: Not reported	Primary: Target blood pressure was reached in 25% of patients receiving hydralazine, 23% of patients receiving minoxidil, 19% of patients receiving prazosin, 17% of patients receiving methyldopa and zero percent of patients receiving placebo (P values not reported). Labetalol had the highest withdrawal rate compared to the other treatments with 78% (P<0.05). Minoxidil had the second highest withdrawal rate with 57% (P<0.05), due to fluid retention. There were no significant differences in withdrawal rates among the other treatments. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>methyldopa 125 mg QD up to 1,000 mg BID</p> <p>vs</p> <p>placebo</p> <p>Minoxidil as add on therapy was given to men only.</p> <p>Doses were titrated upward at 2 week intervals until target blood pressure or maximum dose was reached.</p>				
<p>Wright et al.¹³⁶ (2002) AASK</p> <p>Metoprolol 50 to 200 mg/day</p> <p>vs</p> <p>ramipril 2.5 to 10 mg/day</p> <p>vs</p> <p>amlodipine 5 to 10 mg/day</p>	<p>DB, MC, RCT</p> <p>Patients were self-identified African Americans aged 18 to 70 years with HTN and a GFR between 20 and 65 mL/min/ 1.73 m² and no other identified cause of renal insufficiency</p>	<p>N=1,094</p> <p>3-6.4 years</p>	<p>Primary: Rate of change in GFR (grouped by usual blood pressure [MAP goal 102 to 107 mm Hg] vs lower blood pressure [\leq92 mm Hg])</p> <p>Secondary: Clinical composite outcome (reduction in GFR by 50% or more, ESRD, or death)</p>	<p>Primary: No significant difference in primary outcome was reported between the usual blood pressure group compared to the lower blood pressure group (P=0.24).</p> <p>None of the drug group comparisons showed consistently significant differences in the GFR slope.</p> <p>Secondary: The lower blood pressure goal did not significantly reduce the rate of the clinical composite outcome (risk reduction for lower blood pressure group, 2%; 95% CI, -22 to 21; P=0.85).</p> <p>Ramipril resulted in significant risk reductions in the clinical composite outcomes compared to amlodipine (38%; 95% CI, 14 to 56; P=0.004) and metoprolol (22%; 95% CI, 1 to 38; P=0.04).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Dafgard et al.¹³⁷ (1981)</p> <p>Metoprolol and HCTZ 200-25 mg QD in the morning (fixed-dose combination product)</p> <p>vs</p> <p>HCTZ 50 mg QD in the morning</p> <p>vs</p> <p>HCTZ 25 mg QD in the morning</p>	<p>DB, MC, RCT</p> <p>Patients with essential HTN (WHO stages I or II) not adequately controlled ($\geq 160/95$ mm Hg) on HCTZ 25 mg/day</p>	<p>N=31</p> <p>32 weeks</p>	<p>Primary: Blood pressure, heart rate, adverse events, laboratory values</p> <p>Secondary: Not reported</p>	<p>There was no significant difference in the clinical composite outcome between the amlodipine and metoprolol groups.</p> <p>Primary: After the eight week run-in period with HCTZ 25 mg alone, the mean supine blood pressure was significantly reduced from 183/110 to 172/103 mm Hg ($P<0.01/P<0.01$). The increased dose of HCTZ 50 mg following the run-in period did not further significantly reduce the mean blood pressure (165/104 mm Hg).</p> <p>A small but statistically significant reduction in supine heart rate was seen when the HCTZ dose was increased from 25 to 50 mg (82 down to 78 bpm; $P<0.05$).</p> <p>After the 12 week double-blind period, the mean supine blood pressure was 153/98 mm Hg in the HCTZ 50 mg group. After the 12 week follow-up period, there was not any additional decrease in blood pressure (153/97 mm Hg).</p> <p>Fixed-dose combination product of metoprolol and HCTZ produced a significant reduction in supine blood pressure after 12 weeks of therapy from 172/105 mm Hg on HCTZ 25 mg alone to 154/97 mm Hg on the combination therapy ($P<0.001/P<0.01$). Similar results were found with the standing blood pressure reductions, from 165/108 to 147/97 mm Hg ($P<0.001/P<0.001$).</p> <p>After the eight week run-in period, the supine heart rate was 80 bpm which decreased to 64 bpm with the metoprolol and HCTZ fixed-dose combination ($P<0.001$). The values for standing heart rate demonstrated similar significant reductions (85 to 66 bpm; $P<0.001$).</p> <p>After the additional 12 week follow-up, the patients in the metoprolol and HCTZ fixed-dose combination group did not demonstrate a significant further reduction in heart rate or blood pressure in any position.</p> <p>Both agents were tolerated and the most common adverse events reported included insomnia, headache, tiredness, and shortness of breath. The majority of events were mild, few were moderate, and none were severe.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The only significant changes in laboratory values occurred with the HCTZ 25 and 50 mg groups, where an increase in serum uric acid was observed from 0.30 to 0.34 and 0.35 mmol/L, respectively (P<0.01 and P<0.05; respectively).</p> <p>Secondary: Not reported</p>
<p>Smilde et al.¹³⁸ (1983)</p> <p>Metoprolol 400 mg QD in the morning for 5 weeks, followed by metoprolol and HCTZ 200-25 mg QD in the morning (fixed-dose combination product) (group 1)</p> <p>vs</p> <p>metoprolol and HCTZ 200-25 mg QAM for 5 weeks (fixed-dose combination product), followed by metoprolol 400 mg QD in the morning for 5 weeks (group 2)</p>	<p>DB, PG, RCT, XO</p> <p>Patients <65 years with essential HTN (supine DBP ≥95 mm Hg) not controlled on metoprolol 200 mg alone</p>	<p>N=37</p> <p>15 weeks</p>	<p>Primary: Changes in DBP, SBP, and heart rate</p> <p>Secondary: Not reported</p>	<p>Primary: Both group 1 and 2 significantly reduced DBP (P<0.01) from baseline and the two groups were not significantly different from each other.</p> <p>The combination products significantly reduced SBP from baseline (P<0.05, P<0.01 depending on comparison)</p> <p>Group 2 significantly reduced heart rate at the end of the study compared to baseline (P<0.05).</p> <p>Clinically relevant changes in laboratory parameters or mean body weight were not observed between the groups.</p> <p>Secondary: Not reported</p>
<p>Liedholm et al.¹³⁹ (1981)</p> <p>Metoprolol and</p>	<p>RCT</p> <p>Patients 18 to 72 years with mild to</p>	<p>N=55</p> <p>12 weeks</p>	<p>Primary: Change in blood pressure</p>	<p>Primary: In group A, there was a significant decrease in supine blood pressure from 189/112 to 172/105 mm Hg with metoprolol monotherapy and further reduction to 148/92 mm Hg with the metoprolol and HCTZ 100-12.5 mg</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 100-12.5 mg BID (fixed-dose combination product) (group A)</p> <p>vs</p> <p>metoprolol and HCTZ 100-25 mg BID (fixed-dose combination product) (group B)</p> <p><u>Extended Study:</u> Metoprolol and HCTZ 100-12.5 mg, 2 tablets QD in the morning (fixed-dose combination product)</p>	<p>moderate essential HTN (WHO I or II)</p> <p><u>Extended Study:</u> OL</p> <p>Those patients who participated in the initial trial, had poor blood pressure control on existing antihypertensive therapy, and were being treated with a β-blocker and additional diuretic therapy</p>	<p><u>Extended Study:</u> N=49</p> <p>6 months</p>	<p>Secondary: Not reported</p>	<p>($P<0.001/P<0.001$).</p> <p>In group B, there was a significant decrease in supine blood pressure from 184/111 to 170/104 mm Hg with metoprolol monotherapy and further reduced to 152/96 mm Hg with metoprolol and HCTZ 100-25 mg ($P<0.01/P<0.05$) after 12 weeks.</p> <p>Supine heart rate fell in group A from 78 to 68 bpm with metoprolol monotherapy ($P<0.001$). No further heart rate reduction was noted with the metoprolol and HCTZ 100-12.5 mg. In group B, supine heart rate fell from 76 to 69 bpm ($P<0.05$). No further heart rate reduction was seen with metoprolol and HCTZ 100-25 mg.</p> <p>In group A, serum sodium fell from 143 to 140 mmol/L ($P<0.01$). In group B, serum potassium fell with from 4.4 to 4.0 mmol/L ($P<0.001$).</p> <p><u>Extended Study:</u> After six months of extended the therapy, there was no further significant reductions in supine or standing blood pressure, but there was a reduction in standing DBP from 97 to 95 mm Hg ($P<0.05$).</p>
<p>Materson et al.¹⁴⁰ (1990)</p> <p>Metoprolol 50, 100 or 200 mg BID</p> <p>vs</p> <p>hydralazine 25, 50 or 100 mg BID</p> <p>vs</p> <p>methyldopa 250, 500 or 1,000 mg</p>	<p>DB, MC, RCT</p> <p>Men ≥ 60 years with HTN not currently receiving antihypertensive therapy and DBP 90 to 114 mm Hg and SBP < 240 mm Hg or a DBP < 100 mm Hg and a SBP < 240 mm Hg if currently taking antihypertensive therapy and the</p>	<p>N=690</p> <p>12 months</p>	<p>Primary: The average reduction in SBP and DBP, the number of patients achieving the goal blood pressure, the average change in heart rate</p> <p>Secondary: The rates of drug intolerances, adverse effects</p>	<p>Primary: Across all four treatments, there was an additional average reduction in BP of 13.1/10.6 mm Hg. The average reduction in SBP from baseline to endpoint for hydralazine, methyldopa, metoprolol and reserpine were -11.5\pm10.1 ($P<0.001$), -15.0\pm13.7 ($P<0.001$), -13.0\pm15.4 ($P<0.001$) and -12.7\pm11.5 ($P<0.001$), respectively. There was no significant difference in SBP reductions among the different treatments ($P=0.43$). The average reduction in DBP from baseline to endpoint for hydralazine, methyldopa, metoprolol and reserpine were -11.3\pm5.9 ($P<0.001$), -10.6\pm6.3 ($P<0.001$), -10.6\pm6.7 ($P<0.001$) and -9.8\pm6.3 ($P<0.001$), respectively. There was no significant difference in DBP reductions among the different treatments ($P=0.59$).</p> <p>The average change in heart rate from baseline to endpoint for hydralazine, methyldopa, metoprolol and reserpine were 1.4\pm10.5 (P value</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>BID</p> <p>vs</p> <p>reserpine 0.05, 0.10 or 0.25 mg QD</p> <p>All patients received HCTZ 25 to 100 mg QD.</p>	<p>blood pressure criteria was met after ≥ 2 weeks without medication</p>			<p>not significant), -1.6 ± 9.3 (P value not significant), 15.9 ± 11.9 ($P < 0.05$) and -7.9 ± 10.7 ($P < 0.05$), respectively. There was a significant difference in change in heart rate among the different treatments ($P < 0.001$).</p> <p>The percentage of patients achieving the goal blood pressure at endpoint with hydralazine, methyldopa, metoprolol and reserpine were 85.3, 81.7, 76.9 and 72.3%, respectively ($P = 0.28$).</p> <p>Secondary: Drug intolerance, defined as adverse effects prompting dose reduction or discontinuation, was present in 23.3% of patients not achieving goal blood pressure compared to 2.8% of those who did ($P < 0.001$). This was significant with hydralazine, methyldopa and metoprolol, but not with reserpine.</p> <p>There were 27 (10%) treatment discontinuations due to adverse effects (hydralazine [n=3], methyldopa [n=8], metoprolol [n=9] and reserpine [n=7]). There were two treatment discontinuations with methyldopa and one with reserpine due to depression.</p> <p>The overall incidence of volunteered moderate or severe adverse effects, not prompting treatment discontinuation, was significantly greater ($P < 0.01$) with methyldopa (31%) and hydralazine (25%) compared to reserpine (15%) or metoprolol (9%).</p>
<p>Greathouse.¹⁴¹ (2010)</p> <p>Nebivolol 5, 10 or 20 mg QD</p> <p>vs</p> <p>placebo</p> <p>All patients entered a 4 to 6 week washout, SB,</p>	<p>DB, PC, PG, RCT</p> <p>Patients ≥ 18 years of age with stage I to II HTN (average sitting DBP ≥ 95 and ≤ 109 mm Hg)</p>	<p>N=811</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting DBP at trough drug concentration (24\pm2 hours after the previous morning's dose)</p> <p>Secondary: Mean changes in trough sitting SBP, responder rate</p>	<p>Primary: Least squares mean reductions in trough sitting DBP at week 12 were significantly greater with all doses of nebivolol compared to placebo ($P = 0.002$ for 5 mg and $P < 0.001$ for 10 and 20 mg).</p> <p>All doses of nebivolol reduced peak sitting DBP in a dose-dependent manner. The least squares mean reductions in peak sitting DBP following treatment with 5, 10, and 20 mg of nebivolol were -10.5, -11.6, and -12.2 mm Hg ($P < 0.001$ vs placebo for all).</p> <p>Secondary: All doses of nebivolol resulted in least squares mean reductions in trough sitting SBP from baseline, with only the 20 mg dose reaching significance</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo run in period.</p>			<p>(mean trough SBP <90 mm Hg or a decrease of ≥ 10 mm Hg from baseline), safety and tolerability</p>	<p>compared to patients receiving placebo ($P < 0.001$). All doses of nebivolol reduced peak sitting SBP in a dose-dependent manner. The least squares mean reductions with nebivolol in peak sitting SBP were -7.7, -10.7 and -4.7 mm Hg ($P = 0.004$ vs placebo for 10 mg and $P < 0.001$ vs placebo for 20 mg).</p> <p>Significantly more patients receiving nebivolol were treatment responders compared to placebo (66.0 [$P = 0.009$ vs placebo], 66.8 [$P = 0.005$ vs placebo] and 68.9% [$P = 0.002$ vs placebo] vs 49.3%).</p> <p>A total of 27 (36.0%) and 311 (42.5%) patients receiving placebo and nebivolol experienced an adverse event. The most commonly reported adverse events for the combined nebivolol group (all doses) compared to the placebo group were headache (7.5 vs 5.3%), fatigue (3.8 vs 1.3%) and nasopharyngitis (3.7 vs 4.0%).</p>
<p>Neutel et al.¹⁴² (2010)</p> <p>Nebivolol 5, 10 or 20 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, PG, RCT</p> <p>Patients ≥ 18 years of age with stage I to II HTN who were inadequately controlled by antihypertensive medication (SBP ≥ 90 and ≤ 109 mm Hg) and stable on a regimen of antihypertensive medications consisting of ≥ 1 and ≤ 2 of an ACE inhibitor, ARB or diuretic</p>	<p>N=669</p> <p>12 weeks</p>	<p>Primary: Change in mean clinic sitting DBP at trough (24\pm3 hours after previous morning's dose)</p> <p>Secondary: Change in mean trough sitting SBP and mean sitting DBP, change in mean sitting SBP at peak (two to three hours after dosing), mean peak and trough supine and standing DBP and SBP, mean 24 hour DBP and SBP as measured by</p>	<p>Primary: Addition of nebivolol to background antihypertensive therapy led to significant additional blood pressure reductions compared to placebo. Nebivolol 5, 10, and 20 mg significantly lowered trough sitting DBP by -3.3, -3.5, and -4.6 mm Hg, respectively ($P < 0.001$ for all doses).</p> <p>Secondary: Nebivolol 5, 10 and 20 mg significantly lowered trough sitting SBP by -5.7, -3.7, and -6.2 mm Hg, respectively ($P < 0.001$ for 5 and 20 mg and $P = 0.015$ for 10 mg).</p> <p>Reductions in trough blood pressure in the standing and supine positions were comparable to sitting blood pressure reductions for all nebivolol doses.</p> <p>All doses of nebivolol also significantly reduced peak sitting DBP (-3.2, -4.0, and -4.3 mm Hg) and sitting SBP (-5.7, -5.6, and -5.9 mm Hg) at week 12 compared to placebo ($P < 0.001$ for both).</p> <p>Reductions from baseline to week 12 in peak blood pressure with nebivolol in both supine and standing positions were consistent with those for sitting DBP and sitting SBP (data not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			ambulatory blood pressure monitoring, responder rate (sitting SBP <90 mm Hg or an absolute reduction ≥ 10 mm Hg)	After 12 weeks, the proportion of patients responding to treatment was significantly higher with nebivolol 5 mg (53.0%; $P=0.028$), 10 mg (60.1%; $P=0.001$) and 20 mg (65.1%; $P<0.001$) compared to placebo (41.3%). In addition, a significantly higher percentage of patients receiving nebivolol achieved blood pressure control (<140/90 mm Hg) (43.0, 41.3 and 52.7 vs 29.3%; $P\leq 0.029$).
Weiss et al. ¹⁴³ (2011) Nebivolol 1.25 to 30 or 40 mg/day vs placebo	Pooled analysis of 3 PC, RCT, SB Patients with stage I-II HTN	N=2,016 ≥ 12 weeks	Primary: Mean change from baseline in sitting DBP, sitting SBP, and heart rate at 12 weeks Secondary: Safety	Primary: Compared to placebo, reductions in DBP, SBP, and heart rate were significantly greater with nebivolol at the recommended dosages of 5-30/40 mg/day ($P<0.001$ for all). Secondary: The most commonly reported adverse events were headache (7.1 vs 5.9%), fatigue (3.6 vs 1.5%), and nasopharyngitis (3.1 vs 4.4%).
Rosei et al. ¹⁴⁴ (2003) Nebivolol 5 mg QD vs lisinopril 20 mg QD	DB, MC, PG, RCT Patients between 24 and 65 years with mild to moderate uncomplicated essential HTN that was newly diagnosed, or previous antihypertensive therapy was withdrawn at >1 month before active treatment, and had a sitting DBP of >95 and <114 mm Hg	N=65 12 weeks	Primary: Response rates, changes in sitting blood pressure Secondary: Standing blood pressure, sitting and standing heart rate	Primary: There was not a significant difference in response rates observed between the two treatment groups. Both treatment groups significantly reduced sitting SBP ($P<0.0001$) and DBP ($P<0.0001$) throughout the study compared to baseline but there were no significant differences observed between the treatment groups at most visits, but at week eight, DBP was significantly lower in the nebivolol group compared to the lisinopril group ($P<0.05$). Secondary: There was not a significant difference observed between treatment groups in standing blood pressure measurements. Both treatment groups significantly reduced sitting heart rate ($P<0.01$) throughout the study compared to baseline but there were no significant differences observed between the treatment groups at most visits, but at week eight, heart rate were significantly lower in the nebivolol group compared to the lisinopril group ($P<0.05$).
Mazza et al. ¹⁴⁵	DB, MC, PG, RCT	N=168	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2002)</p> <p>Nebivolol 2.5 to 5 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p>	<p>Patients between 65 to 89 years of age with mild to moderate essential HTN and DBP ranging from 95 to 114 mm Hg</p>	<p>16 weeks</p>	<p>Change in sitting blood pressure, response rates</p> <p>Secondary: Standing blood pressure changes, standing and sitting heart rate changes</p>	<p>There was not a significant difference observed between the amlodipine and nebivolol treatments groups in changes in sitting DBP (blood pressure values and P values not reported). At weeks four and eight, a slightly lower sitting SBP was observed in per-protocol patients in the amlodipine groups vs those in the nebivolol group (blood pressure values not reported, $P < 0.005$).</p> <p>Response rates were not significantly difference between the amlodipine group and the nebivolol group (86 vs 88%, respectively). The percentage of patients who reached normalization (blood pressure $< 140/90$ mm Hg) was no significant between the amlodipine and the nebivolol groups (47 vs 50%).</p> <p>Secondary: There were significant differences in standing blood pressure observed between the groups.</p> <p>Heart rate was significantly lower in the nebivolol group compared to the amlodipine group at all treatment visits ($P < 0.001$).</p> <p>Patients in the amlodipine group experienced a significantly greater rate of headache (seven vs five patients) and ankle edema (12 vs zero patients) compared to the patients in the nebivolol group ($P < 0.05$ for both).</p>
<p>Van Bortel et al.¹⁴⁶ (2005)</p> <p>Nebivolol 5 mg QD</p> <p>vs</p> <p>losartan 50 mg QD</p> <p>If after 6 weeks, DBP was not normalized, then HCTZ 12.5 mg</p>	<p>DB, MC, PG, RCT</p> <p>Patients < 70 years of age with DBP at randomization between 95 and 114 mm Hg</p>	<p>N=314</p> <p>12 weeks</p>	<p>Primary: Effects on blood pressure, overall QOL</p> <p>Secondary: Comparison of different aspects of QOL</p>	<p>Primary: At the end of 12 weeks, both nebivolol and losartan significantly reduced SBP compared to baseline ($P < 0.0001$ for both), but the agents were not significantly different from each other.</p> <p>Both agents also significantly decreased DBP compared to baseline ($P < 0.0001$), but nebivolol significantly reduced DBP compared to losartan ($P < 0.02$).</p> <p>At the end of 12 weeks, both nebivolol and losartan significantly improved QOL scores compared to baseline ($P < 0.007$), but the agents were not significantly different from each other.</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
QD was added to therapy				At week 12 there was not a significant difference observed in the individual questions of the QOL questionnaire between the groups. Questions inquired about headaches, lightheadedness, sleepiness, flushing, and sexual function.
Van Bortel et al. ¹⁴⁷ (2008) Nebivolol vs ACE inhibitor, ARB, β -blocker, calcium channel blocker, or placebo	MA 12 RCTs involving >25 patients with essential HTN where nebivolol 5 mg QD was compared to placebo or other active drugs for >1 month	N=2,653 Duration varied	Primary: Antihypertensive effect and tolerability Secondary: Not reported	Primary: Overall, higher response rates were observed with nebivolol than all other antihypertensive agents combined (OR, 1.41; 95% CI, 1.15 to 1.73; P=0.001) and compared to the ACE inhibitors (OR, 1.92; 1.30 to 2.85; P=0.001), but response rates to nebivolol were similar to β -blockers (OR, 1.29; 95% CI, 0.81 to 2.04; P=0.283), calcium channel blockers (OR, 1.19; 95% CI, 0.83 to 1.70; P=0.350) and losartan (OR, 1.35; 95% CI, 0.84 to 2.15; P=0.212). Overall, a higher percentage of patients obtained normalized blood pressure with nebivolol compared to the other antihypertensive agents combined (OR, 1.35; 95% CI, 1.07 to 1.72; P=0.012). A higher percentage of patient receiving nebivolol obtained normalized blood pressure compared to losartan (OR, 1.98; 95% CI, 1.24 to 3.15; P=0.004) and calcium channel blockers (OR, 1.96; 95% CI, 1.05 to 1.96; P=0.024), but not when compared to other β -blockers (OR, 1.29; 95% CI, 0.81 to 1.65; P=0.473). Overall, the percentage of adverse events was significantly lower with nebivolol compared to the other antihypertensive agents combined (OR, 0.59; 95% CI, 0.48 to 0.72; P<0.001) and similar to placebo (OR, 1.16; 95% CI, 0.76 to 1.67; P=0.482). In comparing nebivolol to the individual treatments, nebivolol had a lower percentage of adverse events compared to losartan (OR, 0.52; 95% CI, 0.30 to 0.89; P=0.016), the other β -blockers (OR, 0.56; 95% CI, 0.36 to 0.85; P=0.007) and calcium channel blockers (OR, 0.49; 95% CI 0.33 to 0.72; P<0.001), but was similar to ACE inhibitors (OR, 0.75; 95% CI 0.52 to 1.08). Secondary: Not reported
Veterans Administration Cooperative Study	DB, RCT Men 20 to 69 years	N=365 12 weeks	Primary: Changes in blood pressure, change in	Primary: DBP of <90 mm Hg was achieved in 49% of the nadolol patients, 46% of the bendroflumethiazide patients, and 85% of the combination patients.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Group on Antihypertensive Agents¹⁴⁸ (1983)</p> <p>Nadolol 80 to 240 mg QD in the morning</p> <p>vs</p> <p>bendroflumethiazide 5 to 10 mg* QD in the morning</p> <p>vs</p> <p>nadolol and bendroflumethiazide*</p>	<p>with pretreatment DBP of 95 to 114 mm Hg</p>		<p>blood pressure among races, heart rate, adverse events, laboratory values</p> <p>Secondary: Not reported</p>	<p>There was a significantly higher percentage of patients who achieved the DBP goal compared to the nadolol alone group and bendroflumethiazide group alone (P<0.01 for both).</p> <p>The reduction in SBP was significantly greater in the combination group compared to the nadolol alone and bendroflumethiazide group (-25.3±1.4, -10.5±1.6, and -17.4±1.7 mm Hg, respectively; P<0.001 for both) and bendroflumethiazide produced a significantly greater reduction compared to nadolol alone (P<0.01).</p> <p>The reduction of DBP in white patients was significantly greater than the decrease in African American (decrease of 15.6 vs 9.6 mm Hg, respectively; P<0.001). In addition, 77% of white patients achieved DBP of <90 mm Hg compared to only 31% of African American patients (P<0.001).</p> <p>Adverse events were infrequent. The most common were impotence, lethargy, weakness, and postural dizziness, which occurred more often with bendroflumethiazide than nadolol.</p> <p>Significant reductions in average heart rate from baseline were observed with nadolol alone (decrease by 16.1 bpm; P<0.001) and with the combination product (decrease by 15.8 bpm; P<0.001).</p> <p>Serum potassium levels significantly decreased from baseline in the bendroflumethiazide group by -0.57±0.06 mEq/L (P<0.001) and in the combination group by -0.44±0.05 mEq/L (P<0.001).</p> <p>Serum uric acid levels significantly increased from baseline in the bendroflumethiazide group by 1.7±0.2 mg/dL (P<0.001), in the nadolol group by 0.4±0.1 mg/dL (P<0.01) and in the combination group by -1.9±0.1 mg/dL (P<0.001).</p> <p>Fasting glucose levels significantly increased from baseline in the bendroflumethiazide group by 6.1±2.1 mg/dL (P<0.001) and in the combination group by 7.4±1.1 mg/dL (P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Cholesterol significantly increased from baseline in the bendroflumethiazide group by 11.5±4.3 mg/dL (P<0.001).</p> <p>TGs significantly increased from baseline in the bendroflumethiazide group by 34.6±14.8 mg/dL (P<0.01), in the nadolol group by 38.7±13.2 mg/dL (P<0.01) and in the combination group by 67.8±11.9 mg/dL (P<0.001).</p> <p>Secondary: Not reported</p>
<p>Frick et al.¹⁴⁹ (1978)</p> <p>Penbutolol 40 mg BID</p> <p>vs</p> <p>propranolol 160 mg BID</p>	<p>DB, XO</p> <p>Patients 29 to 64 years of age with HTN</p>	<p>N=20</p> <p>13 weeks</p>	<p>Primary: Blood pressure, heart rate</p> <p>Secondary: Not reported</p>	<p>Primary: Penbutolol significantly reduced supine and standing blood pressures (both SBP and DBP) from baseline (P<0.05). Propranolol also significantly reduced blood pressures from baseline (SBP: P<0.02 and diastolic: P<0.01), but there was not significant difference between agents.</p> <p>Penbutolol significantly reduced supine and standing heart rates from baseline (from 76±10 to 61±9; P<0.001 and from 85±13 to 67±8; P<0.001, respectively). Propranolol also significantly reduced heart rates from baseline (to 59±8; P<0.001 and to 63±7; P<0.001, respectively), but there was not significant difference between agents.</p> <p>Secondary: Not reported</p>
<p>Finnerty et al.¹⁵⁰ (1979)</p> <p>Propranolol 80 mg to 320 mg QD</p> <p>vs</p> <p>reserpine 0.125 mg to 0.25 mg QD</p> <p>vs</p>	<p>SB</p> <p>Patients with HTN unresponsive to hydroflumethiazide alone</p>	<p>N=59</p> <p>9 weeks</p>	<p>Primary: Percentage of patients achieving a DBP below 90 mm Hg</p> <p>Secondary: Not reported</p>	<p>Primary: At study endpoint, the DBP below 90 mm Hg was achieved in all 20 patients (100%) treated with hydroflumethiazide plus reserpine, 13 of the 19 patients (68.4%) treated with hydroflumethiazide plus methyldopa, and in 16 of the 20 patients (80%) treated with hydroflumethiazide plus propranolol.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>methyldopa 500 mg to 2,000 mg QD</p> <p>All patients received hydro-flumethiazide* 50 or 100 mg QD.</p>				
<p>VA Cooperative Study¹⁵¹ (1977)</p> <p>Propranolol 40 to 160 mg TID (P), propranolol 40- to 160 mg TID plus HCTZ 35 mg (P+T), propranolol 40 to 160 mg TID plus hydralazine 35 mg (P+H), or propranolol 40 to 160 mg TID plus HCTZ 35 mg plus hydralazine 35 mg (P+T+H)</p> <p>vs</p> <p>reserpine 35 mg plus HCTZ 35 mg (R+T)</p>	<p>DB, RCT</p> <p>Men 18 to 59 years with DBP of 90 to 114 mm Hg</p>	<p>N=450</p> <p>18 months</p>	<p>Primary: Percent of patients who achieved a DBP <90 mm Hg at 6 months, heart rate, withdrawal rate</p> <p>Secondary: Not reported</p>	<p>Primary: At six months, significantly more patients in the R+T arm (88%) attained a DBP <90 mm Hg and ≥ 5 mm Hg less than the initial blood pressure compared to the P arm (52%; $P < 0.01$) and the P+H arm (72%; $P < 0.05$). The other arms: P+T (81%) and P+T+H (92%) were not significantly different than the R+T arm.</p> <p>The 12 and 18 month results do not have the statistical validity of the six months results due to the reduced sample size. The following percentage of patients attained DBP <90 mm Hg and ≥ 5 mm Hg less than the initial pressure: R+T=89.1 and 82.6%, P=59.5 and 58.1%, P+T=86.0 and 86.4%, P+H=67.4 and 76.1%, and P+T+H=89.4 and 91.8%.</p> <p>There was not a significance difference in heart rate reductions at six and 18 months between the groups (R+T=5.0\pm1.3 and 5.0\pm1.3 mean change in heart rate, P=9.1\pm1.3 and 9.2\pm1.8, P+T=8.8\pm1.2 and 6.3\pm1.5, P+H=8.9\pm1.3 and 7.8\pm1.5, and P+T+H=5.9\pm1.1 and 7.7\pm1.5).</p> <p>Withdrawals for any reason were similar between the treatment arms and were not statistically significant (R+T=14 patients, P=11, P+T=12, P+H=14, and P+T+H=16).</p>
<p>Stevens et al.¹⁵² (1982)</p> <p><u>Dose-finding phase:</u></p>	<p>DB, PG, RCT</p> <p>Patients with mild to moderate essential HTN</p>	<p>N=158</p> <p>25 weeks</p>	<p>Primary: Mean changes of SBP and DB, heart rate, lab values</p>	<p>Primary: After the 12 week dose finding-phase, 94% of patients had a decrease ≥ 10 mm Hg in DBP. The mean SBP and DBP reduced from 158.0 (± 17.3)/105.6 (± 6.0) mm Hg to 131.5 (± 14.4)/86.4 (± 6.7) mm Hg ($P < 0.001$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Propranolol 80, 160, 240, or 320 mg/day in 2 divided doses</p> <p>vs</p> <p>propranolol and HCTZ 80-50, 160-50, 240-50, 320-50 mg/day in 2 divided doses (fixed-dose combination product)</p> <p><u>Double-blind phase:</u> Propranolol and HCTZ (fixed-dose combination product)</p> <p>vs</p> <p>propranolol</p> <p>vs</p> <p>HCTZ</p>	<p>(DBP 100 to 125 mm Hg)</p>		<p>Secondary: Not reported</p>	<p>After the 10 week portion of the study, there were significantly greater increases (P<0.05) in mean SBP or DBP with propranolol and HCTZ alone vs the combination product of propranolol and HCTZ from the end of the dose-finding to the last four biweekly visits to the mean of those visits, and to the last visit. The mean increases of SBP and DBP at the endpoint were: propranolol, 10.2/6.3 mm Hg; HCTZ 13.1/9.3 mm Hg; propranolol-HCTZ combination product 3/1.5 mm Hg.</p> <p>There was a significant decrease in heart rate as the dose of propranolol was increased though the trial (P>0.30).</p> <p>The only lab value that showed a statistically significant change was serum chloride. The percent of patients that fell outside of the normal range were as follows: propranolol 6/36 (17%), HCTZ 14/37 (38%), and combination 4/28 (14%); P<0.05.</p> <p>Secondary: Not reported</p>
<p>de Leeuw et al.¹⁵³ (1997)</p> <p>Verapamil SR and trandolapril 180-2 mg/day, atenolol and chlorthalidone</p>	<p>DB, MC, PC, RCT</p> <p>Patients 18 to 70 years of age with essential HTN (WHO I or II) newly or</p>	<p>N=205</p> <p>12 weeks</p>	<p>Primary: Changes in supine blood pressure, standing blood pressure response rates, normalization rates</p>	<p>Primary: Each of the three treatments was significantly more effective than placebo in reducing seated DBP. Changes in DBP were as follows: verapamil SR and trandolapril, -13 (95% CI, -16 to -9); atenolol and chlorthalidone, -13 (95% CI, -16 to -9); lisinopril and HCTZ, -12 (95% CI, -15 to -9) and placebo, -3 (95% CI, -7 to 0) (P=0.0001 for all vs placebo), but there was not a significance among the treatments (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>100-25 mg/day, or lisinopril and HCTZ 20-12.5 mg/day (fixed-dose combination products)</p> <p>vs</p> <p>placebo</p> <p>All patients entered a SB, placebo 4 week run in period.</p>	<p>unsuccessfully treated, with supine DBP 101 to 114 mm Hg in week 4 of the run in period</p>		<p>Secondary: Not reported</p>	<p>Each of the three treatments was significantly more effective than placebo in reducing seated SBP. Changes in SBP were as follows: verapamil SR and trandolapril, -27 (95% CI, -33 to -21); atenolol and chlorthalidone, -28 (95% CI, -34 to -22); lisinopril and HCTZ, -23 (95% CI, -29 to -17) and placebo, -3 (95% CI, -9 to 3) (P=0.0001 for all vs placebo), but there was not a significance among the treatments (P values not reported).</p> <p>Effects on standing blood pressure demonstrated similar results as the effects on sitting blood pressure (P values not reported).</p> <p>Normalization of DBP (<90 mm Hg), corrected for placebo, were significantly higher with all treatments compared to placebo (verapamil SR and trandolapril, 33% [95% CI, 16 to 50; P<0.0005]; atenolol and chlorthalidone, 31% [95% CI, 14 to 48; P<0.002] and lisinopril and HCTZ, 25% [95% CI, 9 to 42; P<0.005]).</p> <p>Response rates (normalization of DBP or a reduction in DBP >10 mm Hg), corrected for placebo, were significantly higher with all treatments compared to placebo (verapamil SR and trandolapril, 40% [95% CI, 22 to 58; P<0.0001], atenolol and chlorthalidone, 44% [95% CI, 27 to 61; P<0.0001] and lisinopril and HCTZ, 37% [95% CI, 19 to 55; P<0.0002]).</p> <p>Secondary: Not reported</p>
<p>Casas et al.¹⁵⁴ (2005)</p> <p>ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents,</p>	<p>MA (127 trials)</p> <p>Studies in adults that examined the effect of any drug treatment with a blood pressure lowering action on progression of renal disease</p>	<p>N=not reported</p> <p>4.2 years (mean)</p>	<p>Primary: Doubling of serum creatinine, and ESRD</p> <p>Secondary: Serum creatinine, urine albumin excretion and GFR</p>	<p>Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>A small reduction in ESRD was observed in patients receiving ACE inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>Secondary: Small reductions in serum creatinine and in SBP were noted when ACE</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>calcium-channel blocking agents, or combinations)</p> <p>vs</p> <p>ACE inhibitor or ARBs compared to placebo</p> <p>Specific agents and doses were not specified.</p>				<p>inhibitors or ARBs were compared to other antihypertensives (P=0.01).</p> <p>Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001).</p> <p>Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.</p>
<p>Baguet et al.¹⁵⁵ (2007)</p> <p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren)</p> <p>Drugs were used as monotherapy,</p>	<p>MA</p> <p>Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>N=10,818</p> <p>8 to 12 weeks</p>	<p>Primary: Weighted average reductions in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>Primary: Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>				<p>ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>
Post Myocardial Infarction and Other Cardiovascular Outcomes Trials				
<p>Gottlieb et al.¹⁵⁶ (2001)</p> <p>Atenolol vs metoprolol vs propranolol vs other (not specified)</p>	<p>RETRO</p> <p>Patients discharged from the hospital with the diagnosis of an acute MI and on a β-blocker</p>	<p>N=69,338</p> <p>2 years</p>	<p>Primary: Mortality rates at 1 and 2 year(s)</p> <p>Secondary: Not reported</p>	<p>Primary: β-blockers demonstrated a 40% overall reduction in mortality compared to those patient who did not receive β-blocker therapy.</p> <p>One year mortality rates in the three groups were metoprolol 8.32% (CI, 8.07 to 8.58, atenolol 8.16% (CI, 7.76 to 8.58), propranolol 9.55% (CI, 9.69 to 10.48), and other 9.19% (CI, 8.16 to 10.33).</p> <p>Two year mortality rates in the three groups were metoprolol 13.52% (CI, 13.21 to 13.84), atenolol 13.41% (CI, 12.91 to 13.93), propranolol 15.91% (CI, 14.83 to 17.05), and other 15.17% (CI, 13.88 to 16.56). There were no differences between atenolol and metoprolol at the end of the two years, both of which were statistically better than propranolol.</p> <p>Compared to metoprolol, patients discharged on propranolol had 15% increased mortality at one year and 18% increased mortality at two years, which were significantly higher than metoprolol.</p> <p>Secondary: Not reported</p>
Testa et al. ¹⁵⁷	Observational	N=972	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2014) Patients taking atenolol vs Patients not taking atenolol	Patients aged ≥ 65 years with isolated HTN	12 years	Mortality Secondary: Not reported	Univariate analysis shows that elderly participants taking atenolol show greater mortality than those not taking atenolol (52.4 vs 66.7%; $P=0.047$). Cox regression analysis on 12-year mortality showed that age, number of diseases, number of drugs, basic activity of daily living $\geq 1\%$, and social support score were predictive; whereas female sex and Mini-Mental State Examination score were protective of long-term mortality. Additionally, pulse arterial pressure (HR, 1.02; 95% CI, 1.01 to 1.03; $P=0.035$) and atenolol use (HR, 1.89; 95% CI, 1.03 to 4.25; $P<0.05$) were predictive of long-term mortality. Secondary: Not reported
Black et al. ¹⁵⁸ (2003) CONVINCE Atenolol 50 mg QD vs verapamil ER 180 mg QD vs HCTZ 12.5 mg QD	AC, DB, MC, RCT Patients 55 years of age and older with HTN and ≥ 1 risk factor for cardiovascular disease	N=16,476 3 years	Primary: Composite first occurrence of acute MI, stroke or cardiovascular disease-related death Secondary: Cardiovascular endpoints expanded, all-cause mortality, cancer, hospitalization for bleeding, incidence of primary endpoints between 6AM and noon, adverse events	Primary: There was no significant difference between the verapamil treatment group and the atenolol or HCTZ treatment groups in the composite primary endpoint (HR, 1.02; 95% CI, 0.88 to 1.18; $P=0.77$). Secondary: There was no significant difference between the verapamil treatment group and the atenolol or HCTZ treatment group in rates of cardiovascular-related hospitalization ($P=0.31$), death (all-cause mortality) ($P=0.32$) and cancer rates ($P=0.46$). Patients treated with verapamil experienced a significantly higher rate of death or bleeding unrelated to stroke (HR, 1.54; 95% CI, 1.15 to 2.04; $P=0.003$). Primary endpoints did not differ significantly based on time of day ($P=0.43$). Patients treated with verapamil were more likely to withdraw for adverse events or symptoms than those treated with atenolol or HCTZ ($P=0.02$).
Dahlöf et al. ¹⁵⁹ (2002) LIFE	DB, DD, PG, RCT Patients 55 to 80 years old with	N=9,193 ≥ 4 years	Primary: Composite of cardiovascular death, MI and	Primary: SBP fell by 30.2 and 29.1 mm Hg in the losartan and atenolol groups, respectively (treatment difference, $P=0.017$) and DBP fell by 16.6 and 16.8 mm Hg, respectively (treatment difference, $P=0.37$). MAP was 102.2

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>essential HTN (sitting SBP/DBP 160 to 200 to 95 to 115 mm Hg) and left ventricular hypertrophy</p>		<p>stroke</p> <p>Secondary: All-cause mortality, hospitalization for angina or heart failure, revascularization procedures, resuscitated cardiac arrest, new-onset diabetes</p>	<p>and 102.4 mm Hg, respectively (P value not significant). Heart rate decreased more in patients assigned to atenolol than losartan (-7.7 vs -1.8 beats/minute, respectively; P<0.0001).</p> <p>Compared to atenolol, the primary composite occurred in 13.0% fewer patients receiving losartan (RR, 0.87; 95% CI, 0.77 to 0.98; P=0.021).</p> <p>While there was no difference in the incidence cardiovascular mortality (P=0.206) and MI (P=0.491), losartan treatment resulted in a 24.9% relative risk reduction in stroke compared to atenolol (P=0.001).</p> <p>Secondary: A 25% lower incidence of new-onset diabetes was reported with losartan compared to atenolol (P=0.001). There was no significant difference among the other secondary end points between the two treatment groups.</p> <p>Note: At end point or end of follow-up, 18 and 26% of patients on losartan were receiving HCTZ alone or with other drugs, respectively. In the atenolol group, 16 and 22% of patients were receiving HCTZ alone or with other drugs, respectively.</p>
<p>Julius et al.¹⁶⁰ (2004) LIFE Black Subset</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>Post hoc analysis</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=523</p> <p>≥4 years</p>	<p>Primary: Composite of cardiovascular death, MI and stroke</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to atenolol (11.2%), losartan in the United States African American population resulted in a greater incidence of the composite end point (17.4%; P=0.033).</p> <p>HRs favored atenolol across all parameters (P=0.246 for cardiovascular mortality, P=0.140 for MI, and P=0.030 for stroke).</p> <p>In African American patients, blood pressure reduction was similar in both groups, and regression of electrocardiographic-left ventricular hypertrophy was greater with losartan.</p> <p>Secondary: Not reported</p>
<p>Lindholm et al.¹⁶¹</p>	<p>Post hoc analysis</p>	<p>N=1,195</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2002) LIFE Diabetic Subset</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>≥4 years</p>	<p>Composite of cardiovascular death, MI and stroke</p> <p>Secondary: All-cause mortality</p>	<p>Compared to atenolol, losartan resulted in a 24% decrease in the primary composite end point (P=0.031).</p> <p>Losartan treatment resulted in a 37% risk reduction in cardiovascular deaths vs atenolol (P=0.028).</p> <p>Losartan treatment resulted in a 39% risk reduction in all-cause mortality vs atenolol (P=0.002).</p> <p>Mean blood pressure fell to 146/79 mm Hg in losartan patients and 148/79 mm Hg in atenolol patients.</p> <p>Secondary: Mortality from all causes was 63 and 104 in the losartan and atenolol groups, respectively (RR, 0.61; P=0.002).</p>
<p>Kjeldsen et al.¹⁶² (2002) LIFE Isolated Systolic Hypertension Subset</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>Post hoc analysis</p> <p>Patients 55 to 80 years old with isolated systolic HTN (SBP of 160 to 200 mm Hg and DBP <90 mm Hg) and left ventricular hypertrophy</p>	<p>N=1,326</p> <p>≥4 years</p>	<p>Primary: Composite of cardiovascular death, MI, or stroke</p> <p>Secondary: All-cause mortality</p>	<p>Primary: Compared to atenolol, losartan resulted in a trend towards a 25% reduction in the primary end point (P=0.06).</p> <p>Losartan treatment resulted in a 46% risk reduction in cardiovascular mortality (P=0.01) and 40% risk reduction in stroke compared to atenolol (P=0.02). There was no difference in the incidence of MI.</p> <p>Blood pressure was reduced by 28/9 and 28/9 mm Hg in the losartan and atenolol arms.</p> <p>Secondary: Patients receiving losartan also had reductions in all-cause mortality (28%; P<0.046).</p>
<p>Fossum et al.¹⁶³ (2006)</p>	<p>DB, DD, PG, RCT</p>	<p>N=81</p>	<p>Primary: Amount and</p>	<p>Primary: The amount of plaque decreased in the losartan group and increased in the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ICARUS, a LIFE substudy</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>3 years</p>	<p>density of atherosclerotic lesions in the common carotid arteries and carotid bulb</p> <p>Secondary: Not reported</p>	<p>atenolol group, though the difference between groups was not statistically significant (P=0.471).</p> <p>Patients in the atenolol group had a greater increase in plaque index compared to the losartan group, though the difference between groups was not statistically significant (P=0.742)</p> <p>Secondary: Not reported</p>
<p>Kizer et al.¹⁶⁴ (2005) (LIFE substudy)</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>DB, DD, PG, RCT</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=9,193</p> <p>≥4 years</p>	<p>Primary: Reduction in the risk of different stroke subtypes and neurological deficits</p> <p>Secondary: Not reported</p>	<p>Primary: The risk of fatal stroke was significantly decreased in the losartan group compared to the atenolol group (P=0.032).</p> <p>The risk of atherothrombotic stroke was significantly decreased in the losartan group compared to the atenolol group (P=0.001).</p> <p>Comparable risk reductions were observed for hemorrhagic and embolic stroke but did not reach statistical significance.</p> <p>The risk of recurrent stroke was significantly reduced in the losartan arm compared to the atenolol arm (P=0.017).</p> <p>The number of neurological deficits per stroke was similar (P=0.68), but there were fewer strokes in the losartan group for nearly every level of stroke severity.</p> <p>Secondary: Not reported</p>
<p>Wachtell et al.¹⁶⁵ (2005)</p>	<p>DB, DD, PG, RCT</p>	<p>N=8,851 (patients in</p>	<p>Primary: Incidence of new-</p>	<p>Primary: Significantly fewer patients in the losartan group experienced new-onset</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(LIFE substudy)</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>LIFE with no baseline history of AF but at risk for AF)</p> <p>≥4 years</p>	<p>onset AF and outcome</p> <p>Secondary: Not reported</p>	<p>AF compared to the atenolol group (P<0.001).</p> <p>Randomization to losartan treatment was associated with a 33% lower rate of new onset AF independent of other risk factors (P<0.001).</p> <p>Patients in the losartan group had a 40% lower rate of composite events consisting of cardiovascular death, fatal or non-fatal stroke, and fatal or non-fatal MI (P=0.03).</p> <p>Significantly fewer strokes occurred in the losartan group compared to the atenolol group (P=0.01), and there was a trend toward fewer MIs in the losartan group (P=0.16).</p> <p>There was no significant difference in cardiovascular mortality between groups.</p> <p>In contrast, the atenolol group experienced significantly fewer hospitalizations for heart failure (P=0.004) and a trend toward fewer sudden cardiac deaths (P=0.07).</p> <p>Secondary: Not reported</p>
<p>Wachtell et al.¹⁶⁶ (2005) (LIFE substudy)</p> <p>Atenolol 50 to 100 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>All patients received HCTZ 12.5 to 25 mg/day</p>	<p>DB, DD, PG, RCT</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=342 (LIFE patients with AF at the start of the LIFE study)</p> <p>≥4 years</p>	<p>Primary: Cardiovascular morbidity and mortality</p> <p>Secondary: Not reported</p>	<p>Primary: Patients with a history of AF had significantly higher rates of cardiovascular and all-cause mortality, fatal and non-fatal stroke, heart failure, revascularization and sudden cardiac death compared to patients without AF (P<0.001).</p> <p>Patients with a history of AF had similar rates of MI and hospitalization for angina pectoris (P≥0.209).</p> <p>The primary composite endpoint of cardiovascular mortality, stroke and MI occurred in significantly fewer patients in the losartan group compared to the atenolol group (P=0.009).</p> <p>The difference in MI between groups was not significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
if need for blood pressure control.				Treatment with losartan trended toward lower all-cause mortality (P=0.09) and fewer pacemaker implantations (P=0.065). Secondary: Not reported
Dahlöf et al. ¹⁶⁷ (1991) Hypertension (STOP) Atenolol 50 mg QD, HCTZ 25 mg QD plus amiloride 2.5 mg QD, metoprolol 100 mg QD, or pindolol 5 mg QD vs placebo	DB, MC, RCT Swedish men and women 70 to 84 years old with treated or untreated essential HTN defined as SBP \geq 180 mm Hg with a DBP of \geq 90 mm Hg, or DBP >105 mm Hg irrespective of the SBP measured on 3 separate occasions during a 1-month placebo run-in phase in previously untreated patients	N=1,627 25 months	Primary: Frequency of stroke, MI, and other cardiovascular death Secondary: Not reported	Primary: The active treatments significantly reduced the number of all primary endpoints (94 vs 58; RR, 0.60; 95% CI, 0.43 to 0.85; P=0.0031), frequency of stroke (53 vs 29; RR, 0.53; 95% CI, 0.33 to 0.86; P=0.0081) and frequency of other cardiovascular deaths (13 vs 4; RR, 0.30; 95% CI, 0.07 to 0.97) compared to placebo. There was not a statistically significant decrease observed in the rate of MI between the active treatments and placebo (28 vs 25; RR, 0.87; 95% CI, 0.49 to 1.56). Secondary: Not reported
Hansson et al. ¹⁶⁸ (1999) HYPERTENSION -2 (STOP) <u>Conventional drug group</u> Atenolol 50 mg QD, HCTZ 25 mg QD plus amiloride 2.5 mg QD, metoprolol 100 mg QD, or pindolol 5	BE, MC, OL, RCT Swedish men and women between 70 to 84 years old with treated or untreated essential with HTN on 3 separate occasions defined by SBP \geq 180 mm Hg, DBP >105 mm Hg, or both	N=6,614 60 months	Primary: Combined fatal stroke, MI, and other fatal cardiovascular disease; combined fatal and nonfatal stroke, MI, and other cardiovascular Mortality Secondary:	Primary: The combined fatal mortality endpoints occurred in 221 of the 2,213 patients in the conventional drugs group and in 438 of 4,401 in the newer drugs group (RR, 0.99; 95% CI, 0.84 to 1.16; P=0.89). The combined fatal and nonfatal mortality endpoints occurred in 460 patients taking conventional drugs and in 887 taking newer drugs (RR, 0.96; 95% CI, 0.86 to 1.08; P=0.49). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg QD</p> <p>vs</p> <p><u>Newer drug group</u> ACE inhibitors (enalapril 10 mg QD or lisinopril 10 mg QD) or calcium channel blockers (felodipine 2.5 mg QD, or isradipine 2 to 5 mg QD)</p>			Not reported	
<p>Dalhof et al.¹⁶⁹ (2005) ASCOT-BPLA</p> <p>Atenolol 50 to 100 mg/day adding bendroflumethiazide* 1.25 to 2.5 mg/day and potassium as needed</p> <p>vs</p> <p>amlodipine 5 to 10 mg/day adding perindopril 4 to 8 mg/day as needed</p> <p>If blood pressure was still not achieved, doxazosin 4 to 8</p>	<p>MC, OL, RCT</p> <p>Patients 40 to 79 years of age with HTN and ≥ 3 other cardiovascular risk factors (left ventricular hypertrophy, other specified abnormalities on ECG, type 2 diabetes, PAD, history of stroke or TIA, male, age ≥ 55 years, microalbuminuria or proteinuria, smoking, TC:HDL-C ratio ≥ 6, or family history of CHD)</p>	<p>N=19,257</p> <p>5.5 years</p>	<p>Primary: Nonfatal MI (including silent MI) and fatal CHD</p> <p>Secondary: All-cause mortality, total stroke, primary end points minus silent MI, all coronary events, total cardiovascular events and procedures, cardiovascular mortality, nonfatal and fatal heart failure, effects on primary end point and on total cardiovascular events and</p>	<p>Primary: No statistically significant difference in nonfatal MI and fatal CHD was reported between the amlodipine plus perindopril group compared to the atenolol plus bendroflumethiazide groups (HR, 0.90; 95% CI, 0.79 to 12; P=0.1052).</p> <p>Secondary: Significantly greater reductions in the following secondary end points were observed with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: all- cause mortality (P=0.0247), total stroke (P=0.0003), primary end points minus silent MI (P=0.0458), all coronary events (P=0.0070), total cardiovascular events and procedures (P<0.0001), and cardiovascular mortality (P=0.0010).</p> <p>There were no significant differences in nonfatal and fatal heart failure between the two treatment groups (P=0.1257).</p> <p>The study was terminated early due to higher mortality and worse outcomes on several secondary end points observed in the atenolol study group.</p> <p>Tertiary: Significantly greater reductions in the following end points were observed</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day was added to the regimen.			<p>procedures among prespecified subgroups</p> <p>Tertiary: Silent MI, unstable angina, chronic stable angina, PAD, life-threatening arrhythmias, development of diabetes, development of renal impairment</p>	<p>with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: unstable angina (P=0.0115), PAD (P=0.0001), development of diabetes (P<0.0001), and development of renal impairment (P=0.0187).</p> <p>There were no significant differences in the incidence of silent MI (P=0.3089), chronic stable angina (P=0.8323) or life-threatening arrhythmias (P=0.8009) between the two treatment groups.</p> <p>There was no significant difference in the percent of patients who stopped therapy because of an adverse event between the two treatment groups (overall 25%). There was, however, a significant difference in favor of amlodipine plus perindopril in the proportion of patients who stopped trial therapy because of a serious adverse events (2 vs 3%; P<0.0001).</p>
<p>Pepine et al.¹⁷⁰ (2003) INVEST</p> <p>Atenolol 50 mg/day (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p> <p>vs</p> <p>verapamil SR 240 mg/day (step 1), then add trandolapril if</p>	<p>MC, OL, RCT</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: First occurrence of death (all cause), nonfatal MI or stroke</p> <p>Secondary: Cardiovascular death, angina, cardiovascular hospitalization, angina, blood pressure control (SBP/DBP <140/90 mm Hg or <130/85 mm Hg if diabetic or renal impairment), safety</p>	<p>Primary: At 24 months, in the calcium antagonist strategy subgroup, 81.5% of patients were taking verapamil SR, 62.9% trandolapril, and 43.7% HCTZ. In the non-calcium antagonist strategy, 77.5% of patients were taking atenolol, 60.3% HCTZ, and 52.4% trandolapril.</p> <p>After a follow-up of 61,835 patient-years (mean, 2.7 years per patient), 2,269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in calcium antagonist strategy vs 10.17% in non-calcium antagonist strategy; RR, 0.98; 95% CI, 0.90 to 16; P=0.57).</p> <p>Secondary: There was no significant difference in the rate of cardiovascular death (P=0.94) or cardiovascular hospitalization (P=0.59) between the two treatment groups.</p> <p>At 24 months, angina episodes decreased in both groups, but the mean frequency was lower in the calcium antagonist strategy group (0.77 episodes/week) compared to the non-calcium antagonist strategy group (0.88 episodes/week; P=0.02).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist strategy)</p> <p>Trandolapril was recommended for all patients with heart failure, diabetes, or renal insufficiency.</p>				<p>Two-year blood pressure control was similar between groups. The blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of calcium antagonist strategy patients and 64.0% (systolic) and 88.1% (diastolic) of non-calcium antagonist strategy patients. A total of 71.7% of calcium antagonist strategy patients and 70.7% of non-calcium antagonist strategy patients achieved an SBP <140 mm Hg and DBP <90 mm Hg.</p> <p>Both regimens were generally well tolerated. Patients in the calcium antagonist strategy group reported constipation and cough more frequently than patients in the non-calcium antagonist strategy group, while non-calcium antagonist strategy patients experienced more dyspnea, lightheadedness, symptomatic bradycardia and wheezing (all were statistically significant with $P \leq 0.05$).</p>
<p>Mancia et al.¹⁷¹ (2007) INVEST</p> <p>Atenolol 25 to 200 mg QD vs verapamil SR 120 to 480 mg QD</p>	<p>MC, open blinded endpoint, PRO, RCT</p> <p>Patients with HTN, requiring drug therapy (BP>140/90 or >130/80 mm Hg if diabetic or with renal impairment), and CAD</p>	<p>N=22,576 24 months</p>	<p>Primary: Occurrence of death, nonfatal MI and nonfatal stroke</p> <p>Secondary: Blood pressure control rates</p>	<p>Primary: Rates (death, nonfatal MI and nonfatal stroke) were similar for both treatment groups (P value not reported).</p> <p>Secondary: Rates of death, MI and stroke declined as the number of office visits for which blood pressure was controlled increased ($P < 0.001$).</p>
<p>Bangalore et al.¹⁷² (2008) INVEST</p> <p>Verapamil SR 120 to 480 mg QD vs atenolol 25 to 200 mg QD</p>	<p>INVEST substudy</p> <p>Patients 50 years of age and older with hypertension requiring drug therapy (blood pressure >140/90 or >130/80 mm Hg if diabetic or with renal impairment), and documented</p>	<p>N=22,576 24 months</p>	<p>Primary: First occurrence of death, nonfatal MI, nonfatal stroke</p> <p>Secondary: Death, total MI, total stroke</p>	<p>Primary: No significant difference was observed between groups in the primary endpoint ($P = 0.30$).</p> <p>Among patients with the primary outcome, no significant difference was observed between groups in the risk of death ($P = 0.94$).</p> <p>There was no significant difference between groups in the risk of nonfatal MI ($P = 0.41$).</p> <p>There was a trend toward a 29% reduction in the risk of nonfatal stroke in the verapamil group compared to the atenolol group ($P = 0.06$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Trandolapril and/or HCTZ were added to control blood pressure.	coronary artery disease			<p>Secondary: The risks of fatal and nonfatal MI were similar between groups.</p> <p>No significant differences were observed between groups in fatal and nonfatal stroke (P=0.18).o</p>
<p>Iliuta et al.¹⁷³ (2009)</p> <p>Betaxolol 20 mg/day</p> <p>vs</p> <p>metoprolol 100 mg BID</p>	<p>OL, MC</p> <p>Patients who were admitted for CABG surgery</p>	<p>N=1352</p> <p>30 days</p>	<p>Primary: Mortality, in-hospital occurrence of AF, total hospital stay and immobilization (days)</p> <p>Secondary: Not reported</p>	<p>Primary: Betaxolol significantly decreased 30 day mortality (P=0.001) and in-hospital AF (P=0.0001) compared to metoprolol.</p> <p>Patients taking betaxolol were less likely to be hospitalized for >15 days (9.94 vs 13.27, P=0.01) or immobilized for >3 days (5.19 vs 8.26, p=0.002) compared to metoprolol.</p> <p>Secondary: Not reported</p>
<p>Jonsson et al.¹⁷⁴ (2005)</p> <p>Carvedilol 6.25 to 25 mg BID</p> <p>vs</p> <p>atenolol 12.5 to 50 mg BID</p>	<p>OL, RCT</p> <p>Patients between 18 to 80 years of age with chest pain consistent with an acute MI, admitted to the hospital 24 hours after onset and a confirmed diagnosis with significant increase in cardiac enzymes</p>	<p>N=232</p> <p>1.5±1.3 years</p>	<p>Primary: Change in global or regional LVEF after 12 months, cardiovascular endpoints, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: At baseline, mean global LVEF was 54.8% in the carvedilol and 53.0% in the atenolol group and increased after 12 months to 57.1% in the carvedilol and 56.0% in the atenolol group. There was not a significant difference between treatment groups for change in global or regional LVEF (values were not reported).</p> <p>There was not a significant difference in the rates of occurrence of the first serious cardiovascular events observed between the carvedilol and atenolol groups after adjustment for diuretic use (0.247 vs 0.299; RR, 0.83; 95% CI, 0.56 to 1.23; P=0.39).</p> <p>Of the nonserious adverse events reported, a greater incidence of colds hand and feet were reported in the atenolol group (38 [33.3%]) compared to the carvedilol group (24 [20%]; P=0.025).</p> <p>Secondary: Not reported</p>
<p>Pasternak et al.¹⁷⁵ (2014)</p>	<p>RETRO</p> <p>Danish patients</p>	<p>N=11,664</p> <p>Up to 3 years</p>	<p>Primary: All-cause mortality</p>	<p>Primary: The cumulative incidence of all-cause mortality was 18.3 and 18.8% in the carvedilol and metoprolol groups, respectively. After adjustment for</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Carvedilol vs metoprolol succinate	aged 50 to 84 years with HF and LVEF ≤40% who received carvedilol or metoprolol succinate treatment	(Median 2.4)	Secondary: Cardiovascular mortality	propensity score, the risk of mortality did not differ significantly between carvedilol and metoprolol users (aHR, 0.99; 95% CI, 0.88 to 1.11). Secondary: The risk of cardiovascular mortality was not significantly different between carvedilol and metoprolol users (aHR, 1.05; 95% CI, 0.88 to 1.26).
Olsson et al. ¹⁷⁶ (1992) Metoprolol 100 mg BID vs placebo	MA (5 trials) Patients with a past history of MI	N=5,474 3 months to 3 years	Primary: All-cause mortality, sudden deaths Secondary: Not reported	Primary: Metoprolol significantly reduced all-cause mortality compared to placebo (188 vs 223 deaths; P=0.036). Metoprolol significantly reduced sudden deaths compared to placebo (62 vs 104 deaths; P=0.002). Secondary: Not reported
Piccini et al. ¹⁷⁷ (2014) Amiodarone vs sotalol vs no antiarrhythmic drug (AAD)	RETRO Patients with CAD and AF	N=2,838 Median follow-up 4.2 years	Primary: All-cause mortality Secondary: Not reported	Primary: In unadjusted and adjusted settings, mortality rates were lower in patients treated with sotalol compared with amiodarone or no AAD. After adjustment for baseline characteristics only, the 1-year mortality rate was 10% in those treated with sotalol, 20% in those treated with amiodarone, and 14% in those treated with no AAD (no P-value reported). Landmark analysis at 60 days and one year was also performed. After adjustment and weighting, sotalol was associated with improved survival from 0 to 60 days compared with amiodarone (HR, 0.14; 95% CI, 0.06 to 0.32) but not at later time points (≥60 days or ≥1 year). Similarly, compared with no AAD therapy, sotalol was not associated with improved survival beyond 60 days. Cumulative survival after one year in patients treated with sotalol vs no AAD was also not improved (P=0.64). Secondary: Not reported
No authors listed (abstract). ¹⁷⁸ (1983)	DB, MC, PC, RCT Patients <75 years of age surviving an	N=1,884 12 to 33 months	Primary: All-cause mortality Secondary:	Primary: Long term treatment with timolol improved prognosis. A significant difference in life table mortality of 39.3% between treatments was observed (13.3 vs 21.9%; P=0.0003). The difference was due to a lower

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Timolol vs placebo	acute MI		Not reported	rate of sudden cardiac death with timolol compared to placebo (7.7 vs 13.9%; P=0.0001). Secondary: Not reported
Patel et al. ¹⁷⁹ (2014) β-blocker therapy (carvedilol, metoprolol succinate, and bisoprolol at their respective guideline-recommended target doses of 50, 200, and 10 mg/day) vs no β-blocker therapy	RETRO Medicare patients in the OPTIMIZE-HF registry (having a primary discharge diagnosis of HF), aged ≥65 years with EF ≥40% who were eligible for new discharge prescriptions of β-blockers	N=2,198 (1099 propensity-matched pairs) Up to 6 years (Median 2.2)	Primary: composite endpoint of all-cause mortality or HF rehospitalization Secondary: All-cause mortality, HF rehospitalization, and all-cause rehospitalization	Primary: Discharge prescriptions for β-blockers to older HF with preserved ejection fraction patients who were not receiving these drugs prior to admission had no association with the primary composite endpoint during a median of 2.2 years of follow-up (HR, 1.03; 95% CI, 0.94 to 1.13; P=0.569). This association was homogeneous across various clinically relevant subgroups. Secondary: HRs for all-cause mortality and HF rehospitalization associated with a prescription for initiation of beta-blocker therapy were 0.99 (95% CI, 0.90 to 1.10; P=0.897) and 1.17 (95% CI, 1.03 to 1.34; P=0.014), respectively. The latter association lost significance when higher EF cutoffs of ≥45%, ≥50% and ≥55% were used.
Hansson et al. ¹⁸⁰ (2000) NORDIL Conventional therapy (diuretic, β-blocker or both) vs diltiazem 180 to 360 mg QD	BE, MC, OL, PRO, RCT Patients 50 to 74 years of age with DBP ≥100 mm Hg and previously untreated	N=10,881 4.5 years	Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI	Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97). Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04). Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17). Other endpoints were not statistically different between the groups

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				including cardiovascular death (P=0.41), all cardiac events (P=0.57) and congestive heart failure (P=0.42).
Messerli et al. ¹⁸¹ (1998) β-blockers (atenolol, metoprolol or pindolol) vs diuretics (amiloride, chlorthalidone, HCTZ, HCTZ and triamterene [fixed-dose combination product], or thiazide)	MA 10 RCTs lasting ≥1 year, which used as first line agents diuretics and/or β-blockers and reported morbidity and mortality outcomes in patients ≥60 years of age with HTN	N=16,164 1 year	Primary: Cardiovascular morbidity and mortality, all-cause morbidity Secondary: Not reported	Primary: Diuretic treatment significantly reduced the odds for cardiovascular mortality by 25% (OR, 0.75; 95% CI, 0.64 to 0.87), while β-blockers did not reduce cardiovascular mortality (OR, 0.98; 95% CI, 0.78 to 1.23; P values not reported). Diuretic treatment significantly reduced the odds for all-cause mortality by 14% (OR, 0.86; 95% CI, 0.77 to 0.96), while β-blockers did not reduce all-cause mortality (OR, 1.05; 95% CI, 0.88 to 1.25; P values not reported). Secondary: Not reported
Wysong et al. ¹⁸² (2007) β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol) vs other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-	MA 13 RCTs evaluating patients ≥18 years of age with HTN	N=91,561 Duration varied	Primary: All-cause mortality Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions	Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04). Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
angiotensin system inhibitors)				<p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>
<p>Lindholm et al.¹⁸³ (2005)</p> <p>β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol, or propranolol)</p> <p>vs</p> <p>other antihypertensive therapies (amiloride, amlodipine,</p>	<p>MA</p> <p>13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in $\geq 50\%$ of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both</p>	<p>N=105,951</p> <p>2.1 to 10.0 years</p>	<p>Primary: Stroke, MI, all-cause mortality</p> <p>Secondary: Not reported</p>	<p>Primary: The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001).</p> <p>The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported).</p> <p>The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>bendroflumethiazide*, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil)</p> <p>or</p> <p>placebo</p>				
<p>Freemantle et al.¹⁸⁴ (1999)</p> <p>β-blockers (acebutolol, alprenolol, atenolol, betaxolol, carvedilol, labetalol, oxprenolol*, pindolol, practolol*, propranolol, sotalol, timolol and xamoterol*)</p> <p>vs</p> <p>control (agents were not specified)</p>	<p>MA (82 trials)</p> <p>Patients with acute or past MI</p>	<p>N=54,234</p> <p>6 to 48 months</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Nonfatal reinfarction and withdrawal from treatment</p>	<p>Primary: The pooled random effects in short term trials demonstrated a mortality rate of 10.5% (3,062 out of 29,260 patients) which is a 4% reduction compared to the controlled groups (OR, 0.96; 95% CI, 0.85 to 1.08).</p> <p>The pooled random effects in long term trials demonstrated a mortality rate of 9.7% (2415 out of 24974 patients) which is 23% reduction when compared to the controlled groups (OR, 0.77; 95% CI, 0.69 to 0.85).</p> <p>Individually, only four drugs achieved a statistically significant reduction in the death: propranolol (OR, 0.71; CI, 0.59 to 0.85]), timolol (OR, 0.59; CI, 0.46 to 0.77), metoprolol (OR, 0.80; CI, 0.66 to 0.96; and acebutolol (OR, 0.49; CI, 0.25 to 0.93).</p> <p>Secondary: A reduction in nonfatal re-infarctions of 0.9 events in every 100 (0.3 to 1.6) annually is suggested by this analysis; therefore about 107 patients would require treatment for one year to avoid one nonfatal reinfarction.</p> <p>Overall, 5,151 of 21,954 patients (23.5%) withdrew from treatment. with withdrawal occurring more often in the β-blocker groups. When comparing to placebo, the difference in annualized rate of withdrawal was 1.16 in 100 patients treated (1.16; 95% CI, 0.56 to 1.76).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Miscellaneous				
Schellenburg et al. ¹⁸⁵ (2008) Metoprolol 47.5 to 142.5 mg/day vs nebivolol 5 mg/day	DB, PRO, RCT Patients 18 to 65 years of age with the diagnosis of migraine with/ without aura, ≥ 1 year history, onset prior to 50 years of age, written record of attacks for the previous 3 months and ≥ 2 attack/month during screening	N=38 30 weeks	Primary: Number of migraine attacks Secondary: Onset of action, duration of attacks, responder rate, severity, use of pain medication, migraine disability assessment, QOL score	Primary: There was not a significant difference in the frequency of migraine attacks observed between metoprolol and nebivolol (1.3 ± 1.0 vs 1.6 ± 1.5 , respectively; P value not reported). Secondary: There was not a significant difference in any of the secondary endpoints observed between metoprolol and nebivolol (P values not reported). Use of acute pain medication decreased with both treatments, as well as accompanying symptoms. Both patient and physician evaluations of disability and disease status were similarly favorable to the two treatments (P values not reported).
Silberstein et al. ¹⁸⁶ (2011) Propranolol ER 240 mg/day vs placebo	DB, MC, PC, RCT Patients with chronic migraine inadequately controlled (≥ 10 headaches/month) with topiramate (50 to 100 mg/day)	N=191 6 months	Primary: 28 day moderate to severe headache rate reduction at six months (weeks 16 to 24) compared to baseline (weeks -4 to 0) Secondary: Not reported	Primary: The six month reduction in moderate to severe 28 day headache rate and total 28 day headache rate for combination therapy vs topiramate was not significantly different (4.0 vs 4.5 days; P=0.57 and 6.2 vs 6.1; P=0.91). Secondary: Not reported
Tfelt-Hansen et al. ¹⁸⁷ (1984) Timolol 10 mg BID vs propranolol 80 mg BID	DB, PC, RCT, XO Patients 18 to 65 years of age with a history of 2 to 6 common migraine attacks per month	N=96 40 weeks	Primary: Frequency, duration and severity of attacks; number of responders ($\geq 50\%$ reduction in the frequency of attacks compared to baseline)	Primary: Both timolol and propranolol decreased the frequency of attacks from baseline (P<0.01 for both). For severity of headache attacks, a small but significant reduction was observed with timolol (P<0.05 vs baseline). There was no effect on duration of attacks with either timolol or propranolol. The number of responders was significantly higher with timolol (n=44)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs placebo</p> <p>All patients entered a 4 week pretreatment period.</p>			<p>Secondary: Frequency of attacks with associated symptoms, frequency of attacks requiring relief medication</p>	<p>and propranolol (n=48) compared to placebo (n=24; P<0.01 for both).</p> <p>Secondary: Both timolol and propranolol decreased the frequency of attacks associated with nausea or frequency of attacks associated with symptomatic therapy (P<0.01 for both vs baseline).</p>
<p>Linde et al.¹⁸⁸ (2004)</p> <p>Propranolol 60 to 320 mg/day</p> <p>vs placebo or another agent (calcium channel blockers, other β-blockers or other agent)</p>	<p>MA</p> <p>26 randomized and quasi-randomized clinical trials of ≥4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult patients with migraine</p>	<p>N=5,072</p> <p>4 to 30 weeks</p>	<p>Primary: Headache and migraine frequency</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to placebo, propranolol showed a significant advantage in response to treatment with overall RR of response (“responder ratio”) of 1.94 (95% CI, 1.61 to 2.35).</p> <p>Compared to placebo, propranolol showed a significant advantage for the reduction of frequency of migraines with overall mean difference of -0.40 (95% CI, -0.56 to -0.24).</p> <p>Propranolol did not demonstrate a significantly greater response to treatment compared to calcium channel blockers with an overall responder ratio of 1.00 (95% CI, 0.92 to 1.09).</p> <p>Propranolol did not demonstrate a significantly greater reduction in migraine frequency compared to calcium channel blockers with an overall mean difference of -0.02 (95% CI, 0.12 to 0.08).</p> <p>In the three trials comparing propranolol and nadolol, the overall responder ratio favored nadolol (responder ratio, 0.60; 95% CI, 0.37 to 0.97), but the results of the three trials were contradictory.</p> <p>In the three trials comparing propranolol and metoprolol, there was not a significant difference observed in the overall responder ratio between the two treatments (responder ratio, 0.78; 95% CI, 0.56 to 1.09).</p> <p>Propranolol did not demonstrate a significantly greater reduction in migraine frequency compared to other β-blockers with an overall mean difference of -0.01 (95% CI, 0.24 to 0.22).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>A quantitative MA was not performed on trials comparing propranolol to other drugs due to the great variety of comparator drugs used. One trial was significantly in favor of propranolol (vs amitriptyline), five with a trend in favor of propranolol, 11 showing no difference, two with a trend in favor of the comparator drug and one not interpretable; one of the two comparisons of propranolol alone and propranolol in combination with amitriptyline was classified as no difference, and the other as showing a trend in favor of the combination (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Léauté-Labrèze et al.¹⁸⁹ (2015)</p> <p>Propranolol (1 or 3 mg/kg/day, divided into two daily doses)</p> <p>vs</p> <p>placebo BID</p>	<p>DB, PC, RCT</p> <p>Patients 35 to 150 days of age with a proliferating infantile hemangioma requiring systemic therapy</p>	<p>N=460</p> <p>24 to 96 weeks</p>	<p>Primary: Success (complete or nearly complete resolution of the target hemangioma) or failure of trial treatment at week 24 versus baseline according to centralized evaluation</p> <p>Secondary: Success or failure of trial treatment according to on-site assessments by the investigator at week 48 versus baseline</p>	<p>Primary: At the time of the interim analysis (188 patients completing 24 weeks of therapy), 2 of 25 patients (8%) receiving placebo had successful treatment at week 24, as compared with 4 of 41 patients (10%) receiving 1 mg/kg/day of propranolol for 3 months, 3 of 39 patients (8%) receiving 3 mg/kg/day for 3 months, 15 of 40 patients (38%) receiving 1 mg/kg/day for 6 months (P=0.004 for the comparison with placebo), and 27 of 43 patients (63%) receiving 3 mg/kg/day for 6 months (P<0.001 for the comparison with placebo).</p> <p>Overall, 61 of 101 patients (60%) assigned to the selected propranolol regimen and 2 of 55 patients (4%) assigned to placebo had successful treatment at week 24 (P<0.001).</p> <p>Improvement between baseline and week 5 (according to centralized assessment) occurred in 88% of patients assigned to the selected regimen and 5% of patients assigned to placebo (P<0.001).</p> <p>Secondary: Not reported</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, CR=controlled-release, ER=extended-release, QD=once daily, SR=sustained-release, TID=three times daily, XL=extended-release
Study design abbreviations: AC=active comparator, BE=blinded endpoint, DB=double blind, DD=double dummy, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, SB=single blind, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitor, AF=atrial fibrillation, AIx=augmentation index, aPWV=aortic pulse wave velocity, ARB=angiotensin II receptor blocker, CABG=coronary artery bypass graft, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, COPD=chronic obstructive pulmonary disease, DBP=diastolic blood pressure, ECG=electrocardiogram, ESRD=end stage renal disease, FEV₁=forced expiratory volume in one second, GFR=glomerular filtration rate, HDL-C=high-density lipoprotein cholesterol, HR=hazard ratio, HTN=hypertension, LDL-C=low-density lipoprotein cholesterol, LVEF=left ventricular ejection fraction, MAP=mean arterial pressure, MI=myocardial infarction, NYHA=New York Heart Association, OR=odds ratio, PAD=peripheral arterial disease, pro-BNP= pro-B-type natriuretic peptide, PVD=peripheral vascular disease, QOL=quality of life, RMSSD=root mean square of successive RR intervals, RR=relative risk, SBP=systolic blood pressure, SDNN=standard deviation of the normal RR intervals, TC=total cholesterol, TG=triglyceride, TIA=transient ischemic attack, WHO=World Health Organization

Additional Evidence

Dose Simplification

Nissinen et al. evaluated newly diagnosed hypertensive patients who received atenolol 100 mg and chlorthalidone 25 mg given as single entity products or as a fixed-dose combination. Each of the active drug combinations significantly lowered standing, supine and postexercise blood pressure. There was no significant difference among the treatment regimens.¹¹⁴

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 18. Relative Cost of the Beta-Adrenergic Blocking Agents

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Acebutolol	capsule	Sectral ^{®*}	\$\$\$\$	\$
Atenolol	tablet	Tenormin ^{®*}	\$\$\$\$	\$\$\$\$
Betaxolol	tablet	N/A	N/A	\$
Bisoprolol	tablet	Zebeta ^{®*}	\$\$\$\$\$	\$\$
Carvedilol	extended-release capsule, tablet	Coreg ^{®*} , Coreg CR [®]	\$\$\$\$\$	\$
Labetalol	injection, tablet	Trandate ^{®*}	\$\$\$	\$\$\$
Metoprolol	extended-release tablet, injection, tablet	Lopressor ^{®*} , Toprol-XL ^{®*}	\$\$\$\$\$	\$
Nadolol	tablet	Corgard ^{®*}	\$\$\$\$\$	\$\$\$\$
Nebivolol	tablet	Bystolic [®]	\$\$\$\$\$	N/A
Penbutolol	tablet	Levitol [®]	\$\$\$\$	N/A
Pindolol	tablet	N/A	N/A	\$\$\$
Propranolol	extended-release capsule, injection,	Hemangeol [®] , Inderal LA ^{®*} , InnoPran XL [®]	\$\$\$\$\$	\$\$\$\$

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
	solution, tablet			
Sotalol	injection, tablet, solution	Betapace [®] *, Betapace AF [®] *, Sorine [®] *, Sotylize [®]	\$\$\$\$\$	\$
Timolol	tablet	N/A	N/A	\$\$\$
Combination Products				
Atenolol and chlorthalidone	tablet	Tenoretic [®] *	\$\$	\$\$\$
Bisoprolol and HCTZ	tablet	Ziac [®] *	\$\$	\$
Metoprolol and HCTZ	extended-release tablet, tablet	Dutoprol [®] , Lopressor HCT [®] *	\$\$\$	\$\$\$
Nadolol and bendroflumethiazide	tablet	Corzide [®] *	\$\$\$	\$\$\$
Propranolol and HCTZ	tablet	N/A	N/A	\$\$\$

*Generic is available in at least one dosage form or strength.
HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

All of the beta-adrenergic blocking agents (β -blockers) are approved for the treatment of hypertension, with the exception of sotalol.¹⁻³¹ Some of the products are also approved for the treatment of angina, arrhythmias, essential tremor, heart failure, hypertension, hypertrophic aortic stenosis, infantile hemangiomas, migraine prophylaxis, myocardial infarction, and pheochromocytoma.¹⁻²¹ These agents differ with regards to their adrenergic-receptor blockade, membrane stabilizing and intrinsic sympathomimetic activities, as well as lipophilicity.^{1,2,34} All of the agents are available in a generic formulation, with the exception of nebivolol and penbutolol.

Several national and international guidelines address the use of β -blockers.³⁴⁻⁶⁵ Due to improvements in cardiovascular morbidity and mortality, treatment guidelines recommend the use of a β -blocker in patients with the following conditions: acute coronary syndromes, angina, arrhythmias, coronary artery disease, heart failure, left ventricular dysfunction, and post-myocardial infarction.³⁵⁻⁶⁷ There are several published guidelines on the treatment of hypertension. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.⁵²⁻⁵⁹ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).⁵¹ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.⁵¹⁻⁵⁹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.⁵¹⁻⁵⁷ β -blockers are recommended as one of several initial options for the prevention of migraine headaches (metoprolol and propranolol), as well as for the treatment of essential tremor (propranolol).^{61-64,66,67} Although no uniform guidelines for the treatment of infantile hemangiomas are currently available, the new oral solution formulation of propranolol, under the brand name Hemangeol[®], is now the first agent to gain FDA-approval for this indication.¹⁷ Propranolol is considered the first-line agent for infantile hemangiomas requiring systemic treatment.³³

Numerous clinical trials have shown that the β -blockers can effectively lower blood pressure when administered alone or in combination with other antihypertensive agents. Comparative studies have demonstrated similar efficacy among the β -blockers.¹¹¹⁻¹⁵⁵ Most patients will require more than one antihypertensive agent to achieve blood pressure goals.⁵¹⁻⁵⁷ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{53,54,58} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations.¹¹⁴

In patients with chronic stable angina, β -blockers improve exercise tolerance and reduce the frequency of attacks. Head-to-head trials have demonstrated similar efficacy among several of the β -blockers.⁶⁸⁻⁷⁵ In patients with heart failure, β -blockers (bisoprolol, carvedilol, and metoprolol succinate) have been shown to reduce mortality, sudden

death, cardiovascular deaths, and death due to heart failure. Clinical trials supporting the use of carvedilol in patients with mild-to-severe heart failure were conducted with the immediate-release formulation.^{86-93,96,100-103,105-107} Data to support the use of the extended-release capsules for the treatment of heart failure is based on pharmacokinetic and pharmacodynamic parameters that demonstrated bioequivalence with the immediate-release formulation.⁸

In general, adverse events are similar among the β -blockers. Common adverse effects include fatigue, cold hands, dizziness, and weakness.¹⁻³¹ β -blockers that are more selective for the β_1 -receptors (atenolol and metoprolol) may be safer to use in those with reactive airway disease as they are less likely to cause bronchospasm.^{32,34}

There is insufficient evidence to support that one brand beta-adrenergic blocking agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand beta-adrenergic blocking agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand beta-adrenergic blocking agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Mar]. Available from: <http://online.factsandcomparisons.com>
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
3. Sektal [package insert]. Bridgewater (NJ): Promius Pharma, LLC; 2008 Apr.
4. Tenormin® [package insert]. Wilmington (DE): AstraZeneca LP; 2012 Oct.
5. Kerlone® [package insert]. Bridgewater (NJ): Sanofi-Aventis; 2008 Sep.
6. Zebeta® [package insert]. Pomona (NY): Duramed Pharmaceuticals; 2011 Feb.
7. Coreg® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2011 Feb.
8. Coreg CR® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2011 Feb.
9. Trandate® [package insert]. San Diego (CA): Prometheus Laboratories Inc.; 2010 Nov.
10. Labetalol injection [package insert]. Schaumburg (IL): SAGENT Pharmaceuticals; 2011 Jan.
11. Lopressor® [package insert]. East Hanover (NJ): Validus Pharmaceuticals LLC; 2013 Mar.
12. Toprol-XL® [package insert]. Wilmington (DE): AstraZeneca LP; 2014 May.
13. Corgard® [package insert]. New York (NY): Pfizer Inc; 2013 Jul.
14. Bystolic® [package insert]. St. Louis (MO): Forest Pharmaceuticals; 2011 Dec.
15. Levatol® [package insert]. Smyrna (GA): Schwarz Pharma; 2011 May.
16. Pindolol® [package insert]. Morgantown (WV): Mylan Pharmaceuticals, Inc.; 2010 Jun.
17. Hemangeol® [package insert]. Parsippany (NJ): Pierre Fabre Pharmaceuticals, Inc.; 2014 Mar.
18. Inderal LA® [package insert]. Cranford (NJ): Akrimax Pharmaceuticals, LLC; 2012 Jun.
19. InnoPran XL® [package insert]. Cranford (NJ): Akrimax Pharmaceuticals, LLC; 2013 Nov.
20. Propranolol injection [package insert]. Schaumburg (IL): APP Pharmaceuticals, LLC; 2008 Feb.
21. Propranolol tablet [package insert]. Corona (CA): Watson Pharma, Inc.; 2009 Mar.
22. Betapace® [package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc; 2011 Aug.
23. Betapace AF® [package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals; 2011 Aug.
24. Sotalol injection [package insert]. Lake Bluff (IL): Academic Pharmaceuticals Inc.; 2009 Aug.
25. Timolol [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2006 Aug.
26. Tenoretic® [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2012 Oct.
27. Ziac® [package insert]. Pomona (NY): Duramed Pharmaceuticals, Inc; 2011 May.
28. Dutoprol® [package insert]. Cary (NC): Covis Pharmaceuticals, Inc; 2014 Mar.
29. Lopressor HCT® [package insert]. Suffern (NY): Novartis Pharmaceuticals Corporation; 2011 Mar.
30. Corzide® [package insert]. New York (NY): Pfizer, Inc; 2013 Jul.
31. Propranolol and hydrochlorothiazide [package insert]. Morgantown (WV): Mylan Pharmaceuticals, Inc.; 2012 Jul.
32. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
33. Metry DW. Management of infantile hemangiomas. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Mar]. Available from: <http://www.utdol.com/utd/index.do>.
34. Podrid PJ. Major side effects of beta blockers. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Mar]. Available from: <http://www.utdol.com/utd/index.do>.
35. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
36. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/eh296.
37. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
38. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman

- SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
39. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
 40. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.
 41. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.
 42. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.
 43. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
 44. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
 45. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
 46. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.
 47. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. CG180. 2014. <http://www.nice.org.uk/guidance/CG180>.
 48. Mckeown PP, Gutterman D. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. *Chest*. 2005 Aug;128(2 Suppl):1S-5S.
 49. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation*. 2006;114(10):e385-e484.
 50. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. *European Heart Journal* 2014;35:2733–2779. doi:10.1093/eurheartj/ehu284.
 51. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
 52. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
 53. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
 54. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
 55. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.

56. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
57. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
58. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
59. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
60. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1-S93.
61. Gilmore B, Michael M. Treatment of acute migraine headache. *Am Fam Physician*. 2011 Feb 1;83(3):271-80.
62. Modi S, Lowder DM. Medications for migraine prophylaxis. *Am Fam Physician*. 2006 Jan 1;73(1):72-8.
63. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. *Neurology* 2012;78(17):1337-1345.
64. Evers S, Afra J, Frese A, et al.; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. *Eur J Neurol* 2009;16:968-81.
65. National Cancer Institute. Pheochromocytoma and paraganglioma treatment (PDQ®) [Internet]. Bethesda (MD): National Institutes of Health (US), National Cancer Institute; 2012 Nov 19 [cited 2015 Mar]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/pheochromocytoma/healthprofessional/allpages>.
66. Zesiewicz TA, Elble RJ, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, et al. Practice Parameter: Therapies for essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2005 Jun 28;64(12):2008-20.
67. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: Treatment of essential tremor. *Neurology* 2011;77(19):1752-1755.
68. Pandhi P, Sethi V, Sharma BK, Wahi PL, Sharma PL. Double blind cross-over clinical trial of acebutolol and propranolol in angina pectoris. *Int J Clin Pharmacol Ther Toxicol*. 1985 Nov;23(11):598-600.
69. Jackson G, Schwartz J, Kates RE, Winchester M, Harrison DC. Atenolol: once-daily cardioselective beta blockade for angina pectoris. *Circulation*. 1980;61(3):555-60.
70. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. *Vasc Health Risk Manag*. 2007 Jun;3(2):235-42.
71. van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrügge W, König S, Griffiths M, Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. *Am J Cardiol*. 1999 Mar 1;83(5):643-9.
72. Weiss R, Ferry D, Pickering E, Smith LK, Dennish G 3rd, Krug-Gourley S, et al; Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. *Am J Cardiol*. 1998 Oct 15; 82(8):927-31.
73. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. *Eur J Clin Pharmacol*. 1997;52(2):95-100.
74. Savonitto S, Ardissino D, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. *J Am Coll Cardiol*. 1996 Feb;27(2):311-6.
75. Turner GG, Nelson RR, Nordstrom LA, Diefenthal HC, Gobel FL. Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. *Br Heart J*. 1978;40:1361-70.
76. Lui HK, Lee G, Dhurandhar R, Hungate EJ, Laddu A, Dietrich P, et al. Reduction of ventricular ectopic beats with oral acebutolol: a double-blind, randomized crossover study. *Am Heart J*. 1983;105:722-6.
77. Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, et al. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. *Circ J*. 2008 Jan;72(1):102-5.
78. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of β -blockers, amiodarone plus β -blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. *JAMA*. 2006 Jan 11;295:165-71.
79. Balcetyte-Harris N, Tamis JE, Homel P, Menchavez E, Steinberg JS. Randomized study of early intravenous esmolol versus oral beta-blockers in preventing post-CABG atrial fibrillation in high risk patients identified by signal-averaged ECG: Results of a pilot study. *A N E*. 2002 Apr;7(2):86-91.

80. Kettering K, Mewis C, Dörnberger V, Vonthein R, Bosch RF, Kühlkamp V. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. *Pacing Clin Electrophysiol*. 2002 Nov;25(11):1571-6.
81. Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. *Am J Cardiol*. 1998 Sep 15;82(6):744-8.
82. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomized, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. *Heart*. 1999 Aug;82(2):170-5.
83. Calzetti S, Findley LJ, Gresty MA, Perucca E. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. *J Neurol Neurosurg Psychiatry*. 1981 Jul;44(9):814-9.
84. Yetimalar Y, Gulumser I, Kurt T, Basoglu M. Olanzapine versus propranolol in essential tremor. *Clin Neurol Neurosurg*. 2005 Dec;108(1):32-5.
85. Gironell A, Kulisevsky J, Barbanoj M, López-Villegas D, Hernández G, Pascual-Sedano B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. *Arch Neurol*. 1999 Apr;56(4):475-80.
86. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation*. 1994 Oct;90(4):1765-73.
87. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet*. 1999 Jan 2;353(9146):9-13.
88. Contini M, Apostolo A, Cattadori G, et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. Bisoprolol in moderate heart failure: the CARNEBI trial. *Int J Cardiol*. 2013 Oct 3;168(3):2134-2140.
89. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation*. 2005 Oct 18;112(16):2426-35.
90. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001 May 31;344(22):1651-8.
91. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation*. 2002;106:2194-99.
92. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med*. 1996 May 23; 334(21):1349-55.
93. Dargie HJ; CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*. 2001 May 5;357(9266):1385-90.
94. Krum H, Sackner-Berstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure (abstract). *Circulation*. 1995;92:1499-506.
95. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. *Circulation*. 1996 Dec 1;94(11):2807-16.
96. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, et al; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*. 2003 Jul 5;362(9377):7-13.
97. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. *Am Heart J*. 2001 Jun;141(6):899-907.
98. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol in heart failure: a double-blind randomized controlled trial. *J Cardiovas Pharmacol*. 2001 Jan;37(1):48-54.
99. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, Woo KS. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. *J Am Coll Cardiol*. 1999 Nov 1;34(5):1522-8.
100. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. *Circulation*. 1998 Sep 22;98(12):1184-91.

101. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. *Ann Intern Med.* 2001 Apr 3;134(7):550-60.
102. Whorlow SL, Krum H. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. *Am J Cardiol.* 2000 Oct 15;86(8):886-9.
103. Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker benefit according to severity of heart failure. *Eur J Heart Fail.* 2003 Jun;5(3):281-9.
104. Jabbour A, Macdonald, PS, Keogh AM, Kotlyar E, Mellekjaer S, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease. *J Am Coll Cardiol* 2010;55:1780-7.
105. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) *Lancet.* 1999 Jun 12;353(9169):2001-7.
106. Goldstein S, Fagerberg B, Hjalmarsen A, Kjekshus J, Waagstein F, Wedel H, et al. Metoprolol controlled release/extended release in patients with severe heart failure. *J Am Coll Cardiol.* 2001;38:932-8.
107. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet.* 1993 Dec 11;342(8885):1441-6.
108. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. *J Am Coll Cardiol.* 1999 Jun;33(7):1926-34.
109. Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stäblein A, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. *J Am Coll Cardiol.* 2001 Oct;38(4):939-46.
110. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. *Circulation.* 2000 Aug 1;102(5):546-51.
111. Reim HG, Wagner W. Hemodynamic effects of acebutolol and propranolol in hypertensive patients during exercise. *Int J Clin Pharmacol Ther Toxicol.* 1985 May;23(5):238-43.
112. Fogari R, Zoppi A. Half-strength atenolol-chlorthalidone combination (Tenoretic mite) in the treatment of elderly hypertensive patients. *Int J Clin Pharmacol Ther Toxicol.* 1984 Jul;22(7):386-93.
113. Leonetti G, Pasotti C, Capra A. Low-dose atenolol-chlorthalidone combination for treatment of mild hypertension. *Int J Clin Pharmacol Ther Toxicol.* 1986 Jan;24(1):43-7.
114. Nissinen A, Tuomilehto J. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. *Pharmatherapeutica.* 1980;2(7):462-8.
115. Johnson JA, Gong Y, Bailey KR, et al. Hydrochlorothiazide and atenolol combination antihypertensive therapy: Effects of drug initiation order. *Clin Pharmacol Ther.* 2009;86:533-9.
116. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. *J Hypertens.* 2008 Feb;26(2):351-6.
117. Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P, Van Nueten L, Vertommen C. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. *J Hum Hypertens.* 1997 Nov;11(11):753-7.
118. Dietz R, Dechend R, Yu C, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. *J Renin Angiotensin Aldosterone Syst* 2008;9:163-175.
119. Wald DS, Law M, Mills S, Bestwick JP, Morris JK, Wald NJ. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. *Clin Ther.* 2008 Nov;30(11):2030-9.
120. Pareek A, Salkar H, Mulay P, Desai S, Chandurkar N, Redkar N. A randomized, comparative, multicenter, evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertension patients. *Am J Ther.* 2010;17:46-52.
121. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension.* 2007 Apr;49(4):839-45.
122. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol.* 2006;47(3):547-51.
123. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. *J Hum Hypertens.* 1999;13:477-83.

124. Davidov ME, Glazer N, Wollam G, Zager PG, Cangiano J. Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. *Am J Hypertens*. 1988 Jul;1(3 Pt 3):206S-210S.
125. Czuriga I, Rieicansky I, Bodnar J, Fulop T, Kruzszicz V, Kristof E, Edes I, For The NEBIS Investigators ; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). *Cardiovasc Drugs Ther*. 2003 May;17(3):257-63.
126. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. *Cardiology*. 2006;106(4):199-206.
127. Lewin AJ, Lueg MC, Targum S, et al. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. *Clin Cardiol*. 1993 Oct;16(10):732-6.
128. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. *Am Heart J*. 2000 Oct;140(4):E11.
129. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose combination therapy: an alternative first-line approach to hypertension treatment. *Am Heart J*. 1995 Aug;130(2):359-66.
130. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. *Arch Intern Med*. 1994 Jul 11;154(13):1461-8.
131. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. *J Clin Pharmacol*. 1995 Feb;35(2):182-8.
132. Hamaad A, Lip GYH, Nicholls D, MacFadyen RJ. Comparative dose titration response to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. *Cardiovasc Drugs Ther*. 2007 Sep 26;21:437-44.
133. Erdogan O, Ertem B, Altun A. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. *Anadolu Kardiyol Derg*. 2011;11:310-3.
134. Saunders E, Curry C, Hinds J, Kong BW, Medakovic M, Poland M, Roper K. Labetalol compared with propranolol in the treatment of black hypertensive patients. *J Clin Hypertens*. 1987 Sep;3(3):294-302.
135. McAreavey D, Ramsey LE, Latham L, McLaren AD, Lorimer AR, Reid JL, et al. Third drug trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. *Br Med J (Clin Res Ed)*. 1984 Jan 14;288(6411):106-11.
136. Wright JT Jr, Bakris G, Greene T, et al. Effects of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA*. 2002 Nov 20;288(19):2421-31.
137. Dafgard T, Forsen B, Lindahl T. Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension. *Ann Clin Res*. 1981;13 Suppl 30:37-44.
138. Smilde JG. Comparison of the antihypertensive effect of a double dose of metoprolol versus the addition of hydrochlorothiazide to metoprolol. *Eur J Clin Pharmacol*. 1983;25(5):581-3.
139. Liedholm H, Ursing D. Antihypertensive effect and tolerability of two fixed combination of metoprolol and hydrochlorothiazide followed by a long-term tolerance study with one combination. *Ann Clin Res*. 1981;13 Suppl 30:45-53.
140. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes: results of a Department of Veterans Affairs cooperative study. *Hypertension*. 1990 Apr;15(4):348-60.
141. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. *Clin Cardiol*. 2010;33(4):E20-E7.
142. Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. *J Hum Hyperten*. 2010;24:64-73.
143. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. *Clin Ther*. 2011;33:1150-61.
144. Rosei EA, Rizzoni D, Comini S, Boari G; Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. *Blood Press Suppl*. 2003 May;1:30-5.

145. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. *Blood Press.* 2002;11(3):182-8.
146. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. *Am J Hypertens.* 2005 Aug;18(8):1060-6.
147. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs.* 2008;8(1):35-44.
148. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. *Am J Cardiol.* 1983 Dec 1;52(10):1230-37.
149. Frick MH, Hartikainen M, Pörsti P. Penbutolol, a new non-selective beta-adrenergic blocking compound in the treatment of hypertension. A comparison with propranolol. *Ann Clin Res.* 1978 Apr;10(2):105-6.
150. Finnerty FA Jr, Gyftopoulos A, Berry C, McKenney A. Step 2 regimens in hypertension: an assessment. *JAMA.* 1979 Feb 9;241(6):579-81.
151. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol in the treatment of essential hypertension. *JAMA.* 1977 May 23;237(21):2303-10.
152. Stevens JD, Mullane JF. Propranolol-hydrochlorothiazide combination in essential hypertension. *Clin Ther.* 1982;4(6):497-509.
153. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. *J Hypertens.* 1997 Jan;15(1):87-91.
154. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet.* 2005 Dec 10;366:2026-33.
155. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig.* 2007;27(11):735-53.
156. Gottlieb SS, McCarter RJ. Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. *Am J Cardiol.* 2001 Apr 1;87(7):823-6.
157. Testa G, Cacciatore F, Della-Morte D, et al. Atenolol use is associated with long-term mortality in community-dwelling older adults with hypertension. *Geriatr Gerontol Int.* 2014 Jan;14(1):153-158.
158. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al; CONVINCe Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. *JAMA.* 2003 Apr 23-30;289(16):2073-82.
159. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002 Mar 23;359(9311):995-1003.
160. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. *J Am Coll Cardiol.* 2004;43:1047-55.
161. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359:1004-10.
162. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al, Snapinn S, Wedel H; LIFE (Losartan Intervention for End point Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for End point Reduction (LIFE) substudy. *JAMA.* 2002 Sep 25;288(12):1491-8.
163. Fossum E, Olsen M, Hoiieggen A, Wachtell K, Reims H, Kjeldsen S et al. Long-term effects of a losartan-compared with and atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. *J Clin Hypertens.* 2006;8:169-73.
164. Kizer J, Dahlöf B, Kjeldsen S, Julius S, Beevers G, de Faire U et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. *Hypertension.* 2005;45:46-52.
165. Wachtell K, Lehto M, Gerds E, Olsen M, Hornestam B, Dahlöf B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. *J Am Coll Cardiol.* 2005;45:712-9.
166. Wachtell K, Hornestam B, Lehto M, Slotwiner D, Gerds E, Olsen M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the losartan intervention for endpoint reduction in hypertension (LIFE) study. *J Am Coll Cardiol.* 2005;45:705-11.

167. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet*. 1991 Nov 23;338(8778):1281-5.
168. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstén B, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 (STOP) study. *Lancet*. 1999 Nov 20;354(9192):1751-6.
169. Dahlöf B, Sever PS, Poulter NR, et al; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. *Lancet*. 2005 Sep 10;366(9489):895-906.
170. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. *JAMA*. 2003 Dec 3;290(21):2805-16.
171. Mancia G, Messerli F, Bakris G et al. Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension*. 2007;50:299-305.
172. Bangalore S, Messerli F, Cohen J, Bacher P, Sleight P, Mancia G, et al. Verapamil-sustained release-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. *Am Heart J*. 2008;156:241-7.
173. Iliuta L, Christodorescu R, Filipescu D, Moldovan H, Radulescu B, Vasile R. Prevention of perioperative atrial fibrillation with beta blockers in coronary surgery: betaxolol versus metoprolol. *Interact Cardiovasc Thorac Surg*. 2009;9:89-93.
174. Jonsson G, Abdelnoor M, Müller C, Kjeldsen SE, Os I, Westheim A. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. *Cardiology*. 2005 Mar 21;103(3):148-55.
175. Pasternak B, Svanström H, Melbye M, Hviid A. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. *JAMA Intern Med*. 2014 Oct;174(10):1597-1604.
176. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. *Eur Heart J*. 1992 Jan;13(1):28-32.
177. Piccini JP, Al-Khatib SM, Wojdyla DM, et al. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. *Am J Cardiol*. 2014;114(5):716-722.
178. No authors listed. A multicenter study on timolol in secondary prevention after myocardial infarction (abstract). *Acta Med Scand Suppl*. 1983;674:1-129.
179. Patel K, Fonarow GC, Ekundayo OJ, et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. *Int J Cardiol*. 2014 May 15;173(3):393-401.
180. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000 Jul 29;356(9227):359-65.
181. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA*. 1998 Jun 17;279(23):1903-7.
182. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
183. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1545-53.
184. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*. 1999 Jun 26;318(7200):1730-7.
185. Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K. Nebivolol and metoprolol for treating migraine: An advance in β -blocker treatment? *Headache*. 2008 Jan;48(1):118-25.
186. Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Matthew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology*. 2012;78:976-84.
187. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis a double-blind multicenter trial. *Acta Neurol Scand*. 1984;69:1-8.
188. Linde K, Rossmagel K. Propranolol for migraine prophylaxis. *Cochrane Database Syst Rev*. 2004;(2):CD003225. doi: 10.1002/14651858.CD003225.pub2.

189. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. *N Engl J Med.* 2015 Feb 19;372(8):735-46.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Dihydropyridines
AHFS Class 242808
August 19, 2015**

I. Overview

The movement of calcium ions is essential for the function of all types of muscle, including cardiac and vascular smooth muscle. When this flow is reduced, the result is a weakening of muscle contraction and relaxation of muscle tissue.¹⁻³ Relaxation of coronary vascular smooth muscle increases the flow of oxygenated blood into the myocardium, while relaxation of arteriolar smooth muscle decreases peripheral vascular resistance.³⁻⁵ Both coronary and systemic vasodilation serve to reduce cardiac workload. The calcium-channel blocking agents include dihydropyridines and nondihydropyridines. Although they have different binding sites on the L-type calcium channel, both block the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The nondihydropyridines also block the T-type calcium channel in the atrioventricular node.¹⁻⁵

The dihydropyridines are approved for the treatment of angina and hypertension. Amlodipine is also indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented coronary artery disease.^{1,2,6-21} They are potent vasodilators and have little effect on cardiac muscle contractility or conduction. The dihydropyridines are available in a variety of single entity formulations. Amlodipine is also available in combination with benazepril, olmesartan, valsartan, or valsartan-hydrochlorothiazide. Angiotensin converting enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II, and also inhibit the breakdown of bradykinin, a potent vasodilator. Angiotensin II receptor antagonists block the angiotensin II receptor subtype AT₁, preventing the negative effects of angiotensin II, regardless of its origin. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.^{1,2}

The dihydropyridines that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products with the exception of clevidipine and amlodipine-olmesartan are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Dihydropyridines Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Amlodipine	tablet	Norvasc ^{®*}	amlodipine
Clevidipine	injection [^]	Cleviprex [®]	none
Felodipine	extended-release tablet	N/A	felodipine
Isradipine	capsule	N/A	isradipine
Nicardipine	capsule, injection	Cardene-Dex ^{®^} , Cardene IV ^{®*} , Cardene-NACL ^{®^}	nicardipine
Nifedipine	capsule, extended-release tablet	Adalat CC ^{®*} , Afeditab CR ^{®*} , Nifedical XL ^{®*} , Procardia ^{®*} , Procardia XL ^{®*}	nifedipine
Nimodipine	capsule*, solution	Nymalize [®]	nimodipine
Nisoldipine	extended-release tablet*	Sular ^{®*}	nisoldipine
Combination Products			
Amlodipine and benazepril	capsule	Lotrel ^{®*}	amlodipine and benazepril
Amlodipine and olmesartan	tablet	Azor [®]	none
Amlodipine and valsartan	tablet	Exforge ^{®*}	none
Amlodipine, valsartan, and hydrochlorothiazide	tablet	Exforge HCT ^{®*}	none

*Generic is available in at least one dosage form or strength.
^Product is primarily administered in an institution.
PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the dihydropyridines are summarized in Table 2.

Table 2. Treatment Guidelines Using the Dihydropyridines

Clinical Guideline	Recommendations
<p>American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007)²²</p>	<ul style="list-style-type: none"> • Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. • Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. • Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin converting enzyme (ACE) inhibitors and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes. • Long-acting calcium channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) \leq40% and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF \leq40%. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF \leq40% and have either diabetes or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease.
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease</p>	<p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education.

Clinical Guideline	Recommendations
(2013) ²³	<p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia (>10%), β-blockers should be considered. • In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided. <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons; Management of Stable Ischemic Heart Disease</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin is contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also

Clinical Guideline	Recommendations
(2012) ²⁴	<p>have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated.</p> <ul style="list-style-type: none"> • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)²⁵</p>	<p><u>Early hospital care- standard medical therapies</u></p> <ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation $< 90\%$, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval > 0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-

Clinical Guideline	Recommendations
	<p>blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol.</p> <ul style="list-style-type: none"> ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. <ul style="list-style-type: none"> ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or

Clinical Guideline	Recommendations
	<p>major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered.</p> <ul style="list-style-type: none"> ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</p> <ul style="list-style-type: none"> ● Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatid, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. ● Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. ● Timing of CABG in relation to use of antiplatelet agents

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTEMI-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEMI-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTEMI-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTEMI-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist,

Clinical Guideline	Recommendations
	<p>aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTEMI-ACS should be minimized to the extent possible to limit the risk of bleeding.</p> <ul style="list-style-type: none"> ○ Proton pump inhibitors should be prescribed in patients with NSTEMI-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)²⁶</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> • Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. • Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class ≥III. • Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. • Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. • Calcium channel blockers are recommended in patients with vasospastic angina. • Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. • Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> • β-blockers are recommended in all patients with reduced left ventricular (LV) systolic function (LVEF ≤40%). • ACE inhibitors are indicated within 24 hours in all patients with LVEF ≤40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. • ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. • ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. • Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF ≤35% and either diabetes or heart failure, without significant renal dysfunction (serum creatinine >2.5 mg/dL for men and >2.0 mg/dL for women) or hyperkalemia. • Statin therapy with target LDL-C levels <70 mg/dL initiated early after admission is recommended. •
<p>American College of Cardiology/American Heart Association: Guideline for the Management of ST-Elevation Myocardial Infarction (2013)²⁷</p>	<p><u>Routine medical therapies: calcium channel blockers</u></p> <ul style="list-style-type: none"> • Evidence demonstrates that beneficial effect on infarct size or the rate of reinfarction when calcium channel blocker therapy was initiated during either the acute or convalescent phase of ST-segment elevation myocardial infarction (STEMI). However, calcium channel blockers may be useful to relieve ischemia, lower blood pressure, or control the ventricular response rate to atrial fibrillation in patients who are intolerant to β-blockers. • Use of immediate-release nifedipine is contraindicated in patients with STEMI due to hypotension and reflex sympathetic activation with tachycardia. <p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> • Oral β-blockers should be initiated within the first 24 hours in patients with an

Clinical Guideline	Recommendations
	<p>ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval >24 seconds, second or third degree heart block, active asthma, reactive airway disease).</p> <ul style="list-style-type: none"> • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: Renin-Angiotensin-Aldosterone System Inhibitors</u></p> <ul style="list-style-type: none"> • An angiotensin-converting enzyme (ACE) inhibitor should be administered within the first 24 hours to all patients with STEMI with anterior location, HF, or ejection fraction (EF) $\leq 40\%$, unless contraindicated. • An angiotensin receptor blocker (ARB) should be given to patients with STEMI who have indications for but are intolerant of ACE inhibitors. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF $\leq 40\%$ and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)²⁸</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients receiving drug-eluting stent. • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In selected patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
<p>National Institute for Health and Clinical Excellence: Myocardial Infarction: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)²⁹</p>	<p><u>Drug therapy</u></p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs: <ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker. ○ Statin. • Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. • Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. • Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> • Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. • Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during

Clinical Guideline	Recommendations
	<p>this time, it should be completed within 4 to 6 weeks of hospital discharge.</p> <ul style="list-style-type: none"> • Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. • Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. • Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> • Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. • Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. • For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. • Special considerations should be made for people with dyspepsia. • After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for <i>Helicobacter pylori</i> should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). • Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. • Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago). <p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into

Clinical Guideline	Recommendations
	<p>consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes.</p> <ul style="list-style-type: none"> Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. β-blockers should be continued indefinitely after an acute MI. After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)³⁰</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p><u>Treatment of Stage B heart failure</u></p> <ul style="list-style-type: none"> In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) In patients with MI, statins should be used to prevent HF. (LoE: A) ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) Nondihydropyridine calcium channel blockers may be harmful in patients with

Clinical Guideline	Recommendations
	<p data-bbox="570 205 797 233">low LVEF. (LoE: C)</p> <p data-bbox="526 264 1019 291">Pharmacological treatment for Stage C HFrEF</p> <ul data-bbox="526 298 1419 1377" style="list-style-type: none"> <li data-bbox="526 298 1365 359">• Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) <li data-bbox="526 363 1419 424">• Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) <li data-bbox="526 428 1398 541">• ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) <li data-bbox="526 546 1419 638">• Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) <li data-bbox="526 642 1419 940">• Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) <li data-bbox="526 945 1377 1058">• The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) <li data-bbox="526 1062 1382 1123">• Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) <li data-bbox="526 1127 1406 1241">• Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) <li data-bbox="526 1245 1398 1306">• Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) <li data-bbox="526 1310 1344 1371">• Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p data-bbox="526 1409 1024 1436">Pharmacological treatment for Stage C HFpEF</p> <ul data-bbox="526 1442 1419 1656" style="list-style-type: none"> <li data-bbox="526 1442 1382 1503">• Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) <li data-bbox="526 1507 1419 1568">• Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) <li data-bbox="526 1572 1386 1656">• The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p data-bbox="526 1690 1036 1717">Treatment of Stage D (advanced/refractory) HF</p> <ul data-bbox="526 1724 1328 1900" style="list-style-type: none"> <li data-bbox="526 1724 1328 1785">• Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) <li data-bbox="526 1789 1382 1900">• Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and

Clinical Guideline	Recommendations
	<p>preserve end-organ performance. (LoE: C)</p> <ul style="list-style-type: none"> • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)³¹</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF ($<35\%$) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF $<40\%$. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia.

Clinical Guideline	Recommendations
	<p data-bbox="524 233 1390 291"><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul data-bbox="524 300 1411 478" style="list-style-type: none"> <li data-bbox="524 300 1411 384">• ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. <li data-bbox="524 392 1411 478">• If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p data-bbox="524 512 1008 541"><u>Managing heart failure in special populations</u></p> <ul data-bbox="524 548 1419 877" style="list-style-type: none"> <li data-bbox="524 548 1419 632">• The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. <li data-bbox="524 640 1419 758">• A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. <li data-bbox="524 766 1419 877">• As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p data-bbox="524 913 1027 942"><u>Patients with heart failure and preserved LVEF</u></p> <ul data-bbox="524 949 1414 1503" style="list-style-type: none"> <li data-bbox="524 949 1414 978">• ACE inhibitors or ARBs should be considered in this patient population. <li data-bbox="524 984 1414 1102">• ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. <li data-bbox="524 1110 1414 1169">• Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. <li data-bbox="524 1178 1414 1295">• Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. <li data-bbox="524 1304 1414 1362">• Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. <li data-bbox="524 1371 1414 1455">• Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. <li data-bbox="524 1463 1414 1503">• Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p data-bbox="524 1537 911 1566"><u>Patients with heart failure and CAD</u></p> <ul data-bbox="524 1572 1398 1659" style="list-style-type: none"> <li data-bbox="524 1572 1398 1659">• Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p data-bbox="524 1692 992 1722"><u>Patients with heart failure and hypertension</u></p> <ul data-bbox="524 1728 1414 1900" style="list-style-type: none"> <li data-bbox="524 1728 1414 1871">• Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. <li data-bbox="524 1879 1414 1900">• Patients with asymptomatic left ventricular dysfunction and left ventricular

Clinical Guideline	Recommendations
	<p>dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated ($>130/80$ mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent.</p> <ul style="list-style-type: none"> • If blood pressure remains $>130/80$ mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF ($<40\%$). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF ($<40\%$). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF $\leq 40\%$. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF $\leq 40\%$. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever

Clinical Guideline	Recommendations
	<p>possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients.</p> <ul style="list-style-type: none"> • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing

Clinical Guideline	Recommendations
	<p>therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention.</p> <ul style="list-style-type: none"> • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)³²</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate

Clinical Guideline	Recommendations
	<p>response to a β-blocker.</p> <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. Step 3: <ul style="list-style-type: none"> Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in</p>	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life.

Clinical Guideline	Recommendations
<p>Adults (2014)³³</p>	<ul style="list-style-type: none"> • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure <90 mm Hg. • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure <140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure <140 mm Hg and goal diastolic blood pressure <90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)³⁴</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)³⁵, Reappraisal of Guidelines on Hypertension Management (2009)³⁶</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE

Clinical Guideline	Recommendations
	<p>inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology:</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p>

Clinical Guideline	Recommendations
<p>2013 Guidelines for the management of arterial hypertension (2013)³⁷</p>	<p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not

Clinical Guideline	Recommendations
	<p>recommended and should not be used for primary or secondary prevention of CVD.</p> <ul style="list-style-type: none"> • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other

Clinical Guideline	Recommendations
	<p>antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria.</p> <ul style="list-style-type: none"> • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists

Clinical Guideline	Recommendations
	<p>and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers.</p> <ul style="list-style-type: none"> • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)³⁸</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks:</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple

Clinical Guideline	Recommendations
<p>Management of High Blood Pressure in Blacks (2010)³⁹</p>	<p>antihypertensive drugs will be required in most hypertensive blacks.</p> <ul style="list-style-type: none"> • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)⁴⁰</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office

Clinical Guideline	Recommendations
<p>for the Management of Blood Pressure in Chronic Kidney Disease (2012)⁴¹</p>	<p>blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the

Clinical Guideline	Recommendations
	<p>90th percentile for age, sex, and height.</p> <ul style="list-style-type: none"> The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)⁴²</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"><li data-bbox="526 207 1398 264">• Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease.<li data-bbox="526 268 1398 359">• An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g).<li data-bbox="526 363 1398 485">• Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day.<li data-bbox="526 489 1398 573">• When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the dihydropyridines are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Dihydropyridines⁶⁻²¹

Indication(s)	Single Entity Agents							Combination Products			
	Amlodipine	Felodipine	Isradipine	Nicardipine	Nifedipine	Nimodipine	Nisoldipine	Amlodipine and Benazepril	Amlodipine and Olmesartan	Amlodipine and Valsartan	Amlodipine and Valsartan and HCTZ
Angina Pectoris											
Treatment of chronic stable angina	✓ *			✓ (IR)†							
Treatment of chronic stable angina without evidence of vasospasm in patients who remain symptomatic despite adequate doses of β-blockers and/or organic nitrates or who cannot tolerate those agents					✓ (capsule, ER tablet)						
Treatment of vasospastic angina	✓ ‡				✓ (capsule, ER tablet)§						
Coronary Artery Disease (CAD)											
Reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%	✓										
Hypertension											
Treatment of hypertension	✓	✓	✓ ¶	✓ #	✓ (ER)		✓	✓	✓	✓	✓ **
Miscellaneous											
Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V)						✓					

*Alone or in combination with other antianginal agents.

†Alone or in combination with β-blockers.

‡Confirmed or suspected vasospastic angina. Alone or may be used in combination with other antianginal agents.

§Vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm.

|| Alone or in combination with other antihypertensive agents.

¶Alone or in combination with thiazide-type diuretics.

#Cardene IV[®] is indicated for the short term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.

**This fixed combination drug is not indicated for the initial therapy of hypertension.

ER=extended-release, IR=immediate-release

IV. Pharmacokinetics

The pharmacokinetic parameters of the dihydropyridines are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Dihydropyridines²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Amlodipine	64 to 90	93	Liver, extensive	Renal (70) Feces (20 to 25)	30 to 60
Felodipine	13 to 20	>99	Liver, extensive	Renal (70) Feces (10)	11 to 16
Isradipine	14 to 24	95 to 97	Liver, complete	Renal (60 to 65) Feces (30)	8
Nicardipine	35	>95	Liver, nearly 100%	Renal (60) Feces (35)	8 to 12
Nifedipine	IR: rapid and complete ER: 84 to 89	92 to 98	Liver, extensive	Renal (80) Feces (20)	2
Nimodipine	13	>95	Liver, extensive	Renal (% not reported) Feces (% not reported)	1 to 2
Nisoldipine	5	>99	Liver, extensive	Renal (60 to 80) Feces (6 to 12)	7 to 12
Combination Products					
Amlodipine and benazepril	64 to 90/≥37	93/93	Liver, extensive (90)/ Liver, extensive (% not reported)	Renal (60)/ Renal (20) Feces (11 to 12)	48/ 10 to 11
Amlodipine and olmesartan	64 to 90/26	93/99	Liver, extensive (90)/ Intestinal wall (100)	Renal (60)/ Renal (35 to 50) Feces (50 to 65)	45/7
Amlodipine and valsartan	64 to 90/25	93/95	Liver, extensive (90)/ Not reported	Renal (60)/ Renal (13) Feces (83)	30 to 50/ 6
Amlodipine and valsartan and HCTZ	64 to 90/ 25/ 50 to 75	93/ 95/ 40 to 68	Liver, extensive (90)/ Liver, minimal (20)/ Not metabolized	Renal (60)/ Renal (7 to 13) Feces (83)/ Renal (>61)	45/ 6 to 9/ 6 to 15

ER=extended-release, HCTZ=hydrochlorothiazide, IR=immediate-release

V. Drug Interactions

Significant drug interactions with the dihydropyridines are listed in Table 5.

Table 5. Significant Drug Interactions with the Dihydropyridines¹

Generic Name(s)	Significance Level	Interaction	Mechanism
ARBs (olmesartan, valsartan)	1	Potassium-sparing diuretics	The risk of hyperkalemia may be increased when potassium-sparing diuretics are co-administered with ACE inhibitors or ARBs.

Generic Name(s)	Significance Level	Interaction	Mechanism
Amlodipine	1	Simvastatin	Simvastatin plasma concentrations may be elevated, increasing the risk of toxicity (e.g., myositis, rhabdomyolysis).
ACE inhibitors (benazepril)	1	Aldosterone blockers	Serious hyperkalemia, possibly with cardiac arrhythmias or arrest, may occur with the combination of aldosterone blockers and benazepril.
ACE inhibitors (benazepril)	1	Potassium-sparing diuretics	The risk of hyperkalemia may be increased when potassium-sparing diuretics are co-administered with ACE inhibitors or ARBs.
Nifedipine	1	Macrolide antibiotics	Inhibition of nifedipine metabolism (CYP3A4) by macrolide and related antibiotics may lead to elevated nifedipine plasma concentrations, increasing the pharmacologic effects and risk of adverse reactions (e.g., severe hypotension).
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes.
Thiazide diuretics (HCTZ)	1	Lithium	Thiazide diuretics may promote enhanced proximal tubular reabsorption of lithium leading to elevated serum concentrations. Thiazide diuretics may increase the therapeutic and toxic effects of lithium.
Dihydropyridines (felodipine, nifedipine, nimodipine, nisoldipine)	2	Azole antifungals	Dihydropyridine serum levels may increase resulting from a decrease metabolism due to CYP3A4 inhibition by azole antifungal agents.
Dihydropyridines (amlodipine, nimodipine,)	2	HCV protease inhibitors	Dihydropyridine serum levels may increase resulting from a decrease metabolism due to CYP3A4 inhibition by protease inhibitors.
Dihydropyridines (nifedipine,)	2	HIV protease inhibitors	Dihydropyridine serum levels may increase resulting from a decrease metabolism due to CYP3A4 inhibition by protease inhibitors.
felodipine, nifedipine	2	Barbiturates	Metabolism of felodipine may be increased due to induction of mixed function oxidases by barbiturates, causing an increase in first-pass metabolism and decreased bioavailability, reducing the effects of felodipine.
ARBs (olmesartan, valsartan)	2	ACE Inhibitors	Coadministration of ARBs and ACE inhibitors may be associated with an increased risk of renal dysfunction and/or hyperkalemia.
ARBs (olmesartan, valsartan)	2	Lithium	Elevations in plasma lithium levels may occur.
ARBs (olmesartan, valsartan)	2	Potassium preparations	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may

Generic Name(s)	Significance Level	Interaction	Mechanism
			occur with the combination of olmesartan and potassium preparations.
Dihydropyridines (felodipine,)	2	Erythromycin	Felodipine/nifedipine serum levels may increase due to inhibition of CYP3A by erythromycin.
Dihydropyridines (felodipine, nifedipine, nisoldipine)	2	Hydantoins	Dihydropyridine serum levels may decrease due to increased first-pass metabolism of nifedipine or nisoldipine caused by hydantoins.
ACE inhibitors (benazepril)	2	Aliskiren	The risk of hyperkalemia may be increased when aliskiren is coadministered with benazepril.
ACE inhibitors (benazepril)	2	Everolimus	The risk of angioedema may be increased with concurrent administration of everolimus and benazepril.
ACE inhibitors (benazepril)	2	HIV protease inhibitors	Pharmacologic effects of benazepril may be increased by HIV protease inhibitors.
ACE inhibitors (benazepril)	2	Imidazoles	Imidazoles may increase the plasma concentrations and pharmacologic effects of benazepril.
ACE inhibitors (benazepril)	2	NSAIDs	The antihypertensive effects of benazepril may be decreased by NSAIDs. Nephrotoxicity associated with benazepril or NSAIDs may be increased by this drug combination.
ACE inhibitors (benazepril)	2	Lithium	Pharmacologic effects of lithium may be increased by benazepril. Elevated lithium serum concentrations with toxicity may occur.
ACE inhibitors (benazepril)	2	Potassium preparations	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur with the combination of benazepril and potassium preparations.
ACE inhibitors (benazepril)	2	Trimethoprim	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur with the combination of trimethoprim and benazepril.
ACE inhibitors (benazepril)	2	Vasopressin receptor antagonists	Plasma concentrations of benazepril may be increased by co-administration of vasopressin receptor antagonists.
Dihydropyridines (nicardipine)	2	Cyclosporine	Cyclosporine serum levels may increase due to inhibited metabolism by nicardipine.
Dihydropyridines (felodipine, nifedipine)	2	Carbamazepine	Carbamazepine may decrease plasma concentrations and effects of nifedipine.
Dihydropyridines (nifedipine)	2	Cimetidine	The pharmacologic effects of nifedipine may be increased by cimetidine. The mechanism of this interaction is unknown.
Dihydropyridines (nifedipine)	2	Cisapride	Possible increased rate of nifedipine absorption, resulting from enhanced GI motility may lead to elevated serum nifedipine concentrations, increasing

Generic Name(s)	Significance Level	Interaction	Mechanism
			the therapeutic and adverse effects.
Dihydropyridines (nifedipine)	2	Melatonin	Melatonin may interfere with the antihypertensive effect of nifedipine.
Dihydropyridines (nifedipine)	2	Quinidine	Plasma concentrations and pharmacologic effects of quinidine may be decreased by nifedipine. Plasma concentrations and pharmacologic effects of nifedipine may be increased by quinidine.
Dihydropyridines (nifedipine)	2	Rifamycins	Nifedipine effects may be decreased due induced metabolism of nifedipine by CYP3A4, which is induced by rifamycins.
Dihydropyridines (nifedipine)	2	Tacrolimus	Tacrolimus serum levels may be elevated due to inhibition of metabolism by nifedipine.
Thiazide diuretics (HCTZ)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia though an unknown mechanism; therefore the combination should be avoided.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Thiazide diuretics may induce electrolyte disturbances which may predispose patients to digitalis-induced arrhythmias.

ACE inhibitors=angiotensin converting enzyme inhibitors, ARB=angiotensin II receptor blocker, CYP=cytochrome P450 isoenzyme, HCTZ=hydrochlorothiazide, HIV=human immunodeficiency virus, NSAID=nonsteroidal anti-inflammatory drug, Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the dihydropyridines are listed in Tables 6 and 7. The boxed warnings for the dihydropyridines are listed in Tables 8 through 12.

Table 6. Adverse Drug Events (%) Reported with the Dihydropyridines (Amlodipine-containing Products)^{1,6,18-21}

Adverse Events	Single Entity Agents	Combination Products			
	Amlodipine	Amlodipine and Benazepril	Amlodipine and Olmesartan	Amlodipine and Valsartan	Amlodipine and Valsartan and HCTZ
Cardiovascular					
Arrhythmia	-	-	-	✓	-
Atrial fibrillation	-	-	-	1	-
Bradycardia	-	-	-	1	-
Cardiac murmur	-	-	-	✓	-
Chest pain	-	-	-	1	-
Edema	2 to 11	2	2 to 15	✓	7
Hypotension	-	-	✓	✓	-
Orthostatic hypotension	-	-	✓	1	-
Palpitations	1 to 5	✓	1 to 5	✓	-
Peripheral ischemia	1	-	-	1	-
Peripheral edema	18 to 26	✓	18 to 26	5 to 8	-
Pitting edema	-	-	-	✓	-
Postural hypotension	-	-	-	1	-
Pulse irregularity	-	-	-	✓	-
Tachycardia	-	-	-	✓	✓
Vasculitis	1	-	-	1	-
Ventricular tachycardia	1	-	-	1	-
Central Nervous System					

Adverse Events	Single Entity Agents	Combination Products			
	Amlodipine	Amlodipine and Benazepril	Amlodipine and Olmesartan	Amlodipine and Valsartan	Amlodipine and Valsartan and HCTZ
Abnormal dreams	1	-	-	1	-
Agitation	1	-	-	✓	-
Amnesia	1	-	-	✓	-
Anxiety	-	-	-	3	-
Apathy	1	-	-	✓	-
Asthenia	-	-	✓	✓	-
Ataxia	-	-	-	✓	-
Carpal tunnel syndrome	-	-	-	✓	-
Cervicobrachial syndrome	-	-	-	✓	-
Depersonalization	1	-	-	1	-
Depression	-	-	-	✓	-
Dizziness	1	1	1 to 3	2	8
Headache	7	2	-	11	5
Hypoesthesia	-	-	-	✓	-
Insomnia	-	-	-	✓	-
Migraine	-	-	-	✓	-
Nervousness	1	✓	-	1	-
Paresthesia	-	-	-	✓	-
Peripheral neuropathy	1	-	-	1	-
Postural dizziness	-	✓	-	1	<1
Pyrexia	-	-	-	✓	-
Sciatica	-	-	-	✓	-
Sinus headache	-	-	-	✓	-
Somnolence	<2	✓	<2	3	✓
Syncope	-	✓	-	1	✓
Tremor	-	-	-	1	✓
Vertigo	1	-	-	✓	-
Dermatologic					
Alopecia	-	-	✓	✓	-
Cold and clammy skin	1	-	-	✓	-
Dermatitis	-	-	-	✓	-
Eczema	-	-	-	✓	-
Erythema	-	-	-	✓	-
Erythema multiforme	1	-	-	1	-
Exanthema	-	-	-	✓	-
Flushing	1 to 3	✓	1 to 5	✓	-
Hyperhidrosis	-	-	-	✓	-
Pruritus	1	-	✓	✓	✓
Rash	1 to 2	✓	✓	✓	✓
Rash, erythematous	-	-	-	1	-
Rash, maculopapular	✓	-	-	1	-
Skin discoloration	1	-	-	✓	-
Skin dryness	1	-	-	✓	-
Urticaria	1	-	✓	✓	-
Endocrine and Metabolic					
Gout	-	-	-	✓	-
Gynecomastia	✓	-	✓	-	-
Diabetes mellitus	-	-	-	✓	-
Thirst	1	-	-	1	-
Gastrointestinal					
Abdominal discomfort	-	-	-	✓	-
Abdominal distension	-	-	-	✓	-
Abdominal pain	2	✓	-	3	-
Anorexia	1	-	-	1	-
Colitis	-	-	-	✓	-
Constipation	1	✓	-	✓	✓
Diarrhea	✓	✓	-	3	✓
Dry mouth	✓	✓	-	✓	✓
Dyspepsia	-	-	-	✓	2
Dysphagia	1	-	-	1	-
Flatulence	1	-	-	✓	-
Gastritis	-	-	-	✓	✓
Gastroenteritis	-	-	-	✓	-
Hemorrhoids	-	-	-	✓	✓

Adverse Events	Single Entity Agents	Combination Products			
	Amlodipine	Amlodipine and Benazepril	Amlodipine and Olmesartan	Amlodipine and Valsartan	Amlodipine and Valsartan and HCTZ
Increased appetite	-	-	-	✓	-
Jaundice	✓	-	✓	-	-
Loose stools	1	-	-	✓	-
Nausea	3	✓	-	3	2
Pancreatitis	1	-	-	1	-
Vomiting	-	-	✓	✓	-
Genitourinary					
Cystitis	-	-	-	✓	-
Dysuria	-	-	-	✓	-
Erectile dysfunction	-	-	-	✓	✓
Hematuria	-	-	-	✓	-
Impotence	-	✓	-	✓	-
Micturition disorder	1	-	-	1	-
Nephrolithiasis	-	-	-	✓	-
Nocturia	1	-	✓	1	-
Pollakiuria	-	-	-	✓	-
Polyuria	-	✓	-	✓	-
Sexual dysfunction	1	-	-	1	-
Urinary frequency	1	-	✓	✓	-
Urinary tract infection	-	-	-	✓	-
Hematological					
Leukopenia	-	-	-	1	-
Purpura	1	-	-	1	-
Thrombocytopenia	1	-	-	1	-
Laboratory Test Abnormalities					
Blood urea nitrogen increased	-	-	-	5 to 17	-
Creatinine increases	-	-	-	✓	-
Hepatic enzyme elevations	✓	-	✓	✓	-
Hypercholesterolemia	-	-	-	✓	-
Hyperglycemia	1	-	-	1	-
Hyperkalemia	-	✓	-	3 to 10	-
Musculoskeletal					
Arthralgia	-	-	-	✓	✓
Arthrosis	1	-	-	1	-
Back pain	1	✓	-	✓	2
Hypertonia	-	-	-	✓	-
Joint sprain	-	-	-	✓	-
Joint swelling	-	-	-	✓	✓
Limb injury	-	-	-	✓	-
Malaise	1	-	-	1	-
Muscle cramps	1	✓	-	1	-
Muscle spasms	-	-	-	✓	2
Muscle weakness	-	-	-	✓	✓
Musculoskeletal chest pain	-	-	-	✓	-
Myalgia	1	✓	-	✓	-
Osteoarthritis	-	-	-	✓	✓
Pain	1	-	-	✓	-
Rhabdomyolysis	✓	-	✓	-	-
Twitching	1	-	-	✓	-
Respiratory					
Bronchitis	-	-	-	✓	-
Cough	-	3	-	2	✓
Dysphonia	-	-	-	✓	-
Dyspnea	-	-	-	1	-
Epistaxis	1	-	-	✓	-
Influenza	-	-	-	2	-
Nasal congestion	-	-	-	✓	✓
Nasopharyngitis	-	-	-	4	2
Pharyngitis	-	✓	-	✓	-
Pharyngolaryngeal pain	-	-	-	✓	✓
Pharyngotonsillitis	-	-	-	✓	-
Pneumonia	-	-	-	✓	-
Rhinitis	-	-	-	✓	-

Adverse Events	Single Entity Agents	Combination Products			
	Amlodipine	Amlodipine and Benazepril	Amlodipine and Olmesartan	Amlodipine and Valsartan	Amlodipine and Valsartan and HCTZ
Seasonal allergies	-	-	-	✓	-
Sinus congestion	-	-	-	✓	-
Sinusitis	-	-	-	✓	-
Upper respiratory tract infection	-	-	-	3	-
Special Senses					
Abnormal visual accommodation	-	-	-	✓	-
Conjunctivitis	1	-	-	1	-
Diplopia	1	-	-	1	-
Eye pain	1	-	-	1	-
Ear pain	-	-	-	✓	-
Parosmia	1	-	-	✓	-
Taste perversion	-	-	-	✓	-
Tinnitus	1	-	-	✓	-
Visual disturbance	-	-	-	✓	-
Xerophthalmia	1	-	-	✓	-
Other					
Acute renal failure	-	-	✓	✓	-
Allergic reaction	1	-	✓	1	-
Angioedema	1	-	✓	1	-
Contusion	-	-	-	✓	-
Epicondylitis	-	-	-	✓	-
Fatigue	4.5	-	-	✓	2
Gingival hyperplasia	1	-	-	1	-
Hot flush	1	-	-	✓	-
Hypersensitivity	-	-	-	✓	-
Lymphadenopathy	-	-	-	✓	-
Rigors	1	-	-	1	-
Tooth abscess	-	-	-	✓	-
Toothache	-	-	-	✓	-
Tonsillitis	-	-	-	✓	-
Viral infection	-	-	-	✓	-
Weight gain	1	-	-	1	-
Weight loss	1	-	-	1	-

✓ Percent not specified
- Event not reported

Table 7. Adverse Drug Events (%) Reported with the Dihydropyridines (Drugs B - Z)^{1,7-17}

Adverse Events	Felodipine	Isradipine	Nicardipine	Nifedipine	Nimodipine	Nisoldipine
Cardiovascular						
Angina (increased)	-	-	6	-	-	2
Arrhythmia	1 to 2	-	-	-	-	-
Atrial fibrillation	-	≤1	<1	-	-	-
Bradycardia	-	-	-	-	≤1	-
Cardiac failure	-	≤1	-	-	-	-
Cerebrovascular accident	-	-	-	-	-	1
Chest pain	1 to 2	-	-	-	-	-
Edema	-	4 to 36	≤1	-	≤1	-
Electrocardiogram abnormalities	-	-	≤1	-	≤1	-
Epistaxis	-	≤1	-	-	-	-
Erythromelalgia	-	-	-	1	-	-
Hypotension	1 to 2	≤1	-	5	1 to 50	-
Myocardial infarction	1 to 2	≤1	≤1	✓	-	-
Orthostatic hypotension	-	-	-	-	-	1
Palpitations	<3	1 to 5	3 to 4	<7	-	3
Pedal edema	-	-	6 to 8	-	-	-
Peripheral edema	2 to 17	-	✓	7 to 10	-	22
Pericarditis	-	-	1	-	-	-
Peripheral ischemia	-	-	✓	-	-	-
Postural hypotension	-	-	≤1	-	-	-
Pulse irregularity	1 to 2	-	-	-	-	-
Rebound vasospasm	-	-	-	-	1	-

Adverse Events	Felodipine	Isradipine	Nicardipine	Nifedipine	Nimodipine	Nisoldipine
Tachycardia	1 to 2	1 to 3	1 to 4	-	≤1	-
Vasodilatation/vasodilation	-	-	1 to 5	-	-	4
Ventricular fibrillation	-	≤1	-	1	-	-
Ventricular tachycardia	-	-	≤1	-	-	-
Central Nervous System						
Anxiety	1 to 2	-	✓	-	-	-
Asthenia	2 to 4	1 to 6	-	<3	-	-
Ataxia	-	-	-	1	-	-
Balance difficulties	-	-	-	<2	-	-
Chills	-	-	-	<2	-	1
Confusion	-	-	✓	-	-	-
Depression	1 to 2	≤1	✓	1	≤1	-
Dizziness	3 to 4	3 to 8	1 to 7	4 to 27	-	5
Drowsiness	-	≤1	-	-	-	-
Fatigue	-	3 to 9	-	6	-	-
Headache	11 to 15	10 to 22	6 to 15	10 to 23	≤1	22
Insomnia	1 to 2	≤1	≤1	<3	-	-
Irritability	1 to 2	-	-	-	-	-
Migraine	-	-	-	1	-	1
Nervousness	1 to 2	≤1	≤1	<7	-	-
Numbness	-	≤1	-	-	-	-
Paresthesia	1 to 2	≤1	≤1	<3	-	-
Sleep disturbance	-	-	-	<2	-	-
Somnolence	1 to 2	-	≤1	<3	-	-
Stroke	-	≤1	-	-	-	-
Syncope	1 to 2	≤1	<1	-	-	-
Transient ischemic attack	-	≤1	-	-	-	-
Tremor	-	-	≤1	<8	-	-
Vertigo	-	-	✓	1	-	-
Dermatologic						
Acne	-	-	-	-	≤1	-
Alopecia	-	-	-	<1	-	-
Dermatitis	-	-	-	1 to 2	-	-
Erythema	1 to 2	-	-	-	-	-
Flushing	4 to 7	1 to 5	6 to 10	3 to 25	-	-
Hematoma	-	-	-	-	1	-
Hyperhidrosis	-	≤1	11	<2	-	-
Pruritus	-	≤1	-	<2	1	-
Rash	<2	≤3	<1	<3	1 to 2	2
Urticaria	1 to 2	≤1	-	<2	-	-
Endocrine and Metabolic						
Breast pain	-	-	-	1	-	-
Decreased libido	1 to 2	-	-	-	-	-
Gout	-	-	-	1	-	-
Gynecomastia	1 to 2	-	-	-	-	-
Gastrointestinal						
Abdominal discomfort	-	≤5	-	<2	-	-
Abdominal pain	1 to 2	<1	-	<3	-	-
Acid regurgitation	1 to 2	-	-	-	-	-
Anorexia	-	-	-	-	-	1
Colitis	-	-	-	-	-	1
Constipation	<2	1 to 4	≤1	3	-	-
Diarrhea	1 to 2	≤3	-	<2	2 to 4	-
Dry mouth	1 to 2	≤1	≤1	<3	-	-
Dyspepsia	1 to 4	-	1 to 2	3 to 11	-	-
Dysphagia	-	-	-	-	-	1
Flatulence	1 to 2	-	-	<2	-	1
Gastritis	-	-	-	-	-	1
Gastrointestinal hemorrhage	-	-	-	-	1	1
Gastrointestinal symptoms	-	-	-	-	≤2	-
Hepatitis	-	-	-	-	1	1
Increased appetite	-	≤1	-	-	-	1
Jaundice	-	-	-	-	1	-
Nausea	1 to 2	1 to 5	2 to 5	3 to 11	≤1	2
Vomiting	1 to 2	≤1	≤5	-	-	-
Genitourinary						
Decreased libido	-	≤1	-	-	-	-

Adverse Events	Felodipine	Isradipine	Nicardipine	Nifedipine	Nimodipine	Nisoldipine
Dysuria	1 to 2	≤1	-	1	-	-
Hematuria	-	-	-	1	-	-
Impotence	1 to 2	≤1	✓	<3	-	-
Nocturia	-	≤1	-	1	-	-
Pollakiuria	-	1 to 3	-	-	-	-
Polyuria	1 to 2	-	-	1 to 3	-	-
Sexual dysfunction	-	-	-	<2	-	-
Urinary frequency/urgency	1 to 2	-	-	-	-	-
Hematological						
Anemia	1 to 2	-	-	<1	1	-
Leukopenia	-	≤1	-	-	-	-
Thrombocytopenia	-	-	✓	-	1	-
Laboratory Test Abnormalities						
Hepatic enzyme elevations	1 to 2	≤1	✓	-	≤1	-
Hyponatremia	-	-	-	-	1	-
Musculoskeletal						
Arthralgia	1 to 2	-	✓	<3	-	-
Back pain	1 to 2	≤1	-	1	-	-
Hypertonia	-	-	✓	1	-	-
Inflammation	-	-	-	<2	-	-
Joint sprain	1 to 2	≤1	-	-	-	-
Malaise	-	-	≤1	1	-	1
Muscle cramps	1 to 2	≤1	-	3 to 8	≤1	-
Muscle weakness	-	≤1	-	10 to 12	-	-
Musculoskeletal chest pain	1 to 2	2 to 3	-	<3	-	-
Myalgia	1 to 2	-	1	1	-	-
Neck pain	-	≤1	✓	-	-	-
Pain	-	-	≤1	<3	-	-
Stiffness	-	-	-	<2	-	-
Respiratory						
Bronchitis	1 to 2	-	-	-	-	-
Cough	1 to 2	≤1	-	1 to 6	-	-
Dyspnea	1 to 2	<3	≤1	3 to 6	≤1	-
Epistaxis	1 to 2	-	-	1	-	-
Influenza/flu-like illness	1 to 2	-	-	-	-	1
Nasal congestion	1 to 2	≤1	✓	2 to 6	-	-
Nasopharyngitis	1 to 2	-	-	-	-	-
Pharyngitis	-	-	-	-	-	5
Pharyngolaryngeal pain	-	≤1	-	-	-	-
Shortness of breath	-	≤1	-	<2	1	-
Sinusitis	1 to 2	-	✓	1	-	3
Sore throat	-	-	✓	6	-	-
Upper respiratory tract infection	1 to 4	-	-	1	-	-
Special Senses						
Abnormal visual accommodation	-	-	✓	1	-	-
Blurred vision	-	-	✓	<2	-	-
Conjunctivitis	-	-	✓	-	-	-
Ear pain/disorder	-	-	✓	-	-	-
Taste perversion	-	-	-	1	-	-
Tinnitus	-	-	✓	<5	-	-
Visual disturbance	1 to 2	≤1	-	<5	-	-
Other						
Allergic reaction	-	-	✓	-	-	-
Angioedema	1 to 2	-	-	-	-	-
Cellulitis	-	-	-	-	-	1
Contusion	1 to 2	-	-	-	-	-
Facial edema	-	-	-	-	-	1
Fever	-	≤1	-	<2	-	1
Gingival hyperplasia	1 to 2	-	-	-	-	1
Glossitis	-	-	-	-	-	1
Hot flush	-	-	✓	-	-	-
Infection	-	-	✓	-	-	-
Rigors	-	-	-	1	-	-
Warm sensation	1 to 2	-	-	-	-	-
Weight gain	-	≤1	-	1	-	-

✓ Percent not specified
- Event not reported

Table 8. Boxed Warning for Amlodipine and Benazepril¹⁹

WARNING
When pregnancy is detected, discontinue amlodipine and benazepril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Table 9. Boxed Warning for Amlodipine and Olmesartan¹⁸

WARNING
When pregnancy is detected, discontinue amlodipine and olmesartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Table 10. Boxed Warning for Amlodipine and Valsartan²⁰

WARNING
When pregnancy is detected, discontinue amlodipine and valsartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Table 11. Boxed Warning for Amlodipine and Valsartan and Hydrochlorothiazide²¹

WARNING
When pregnancy is detected, discontinue amlodipine and valsartan and hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Table 12. Boxed Warning for Nimodipine¹

WARNING
Do not administer nimodipine intravenously or by other parenteral routes. Deaths and serious, life-threatening adverse reactions have occurred when the contents of nimodipine capsules have been injected parenterally.

VII. Dosing and Administration

The usual dosing regimens for the dihydropyridines are listed in Table 13.

Table 13. Usual Dosing Regimens for the Dihydropyridines^{1,2,6-21}

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Amlodipine	<u>Angina pectoris (chronic stable and vasospastic):</u> Tablet: maintenance, 5 to 10 mg/day; maximum, 10 mg/day <u>Coronary artery disease:</u> Tablet: maintenance, 5 to 10 mg/day; maximum, 10 mg/day <u>Hypertension:</u> Tablet: initial, 5 mg/day; maintenance, 5 to 10 mg/day; maximum, 10 mg/day	<u>Hypertension in children 6 to 17 years of age:</u> Tablet: Initial, 2.5 mg/day; maintenance, 2.5 to 5 mg/day; maximum, 5 mg/day Safety and efficacy in children <6 years of age have not been established.	Tablet: 2.5 mg 5 mg 10 mg
Felodipine	<u>Hypertension:</u> Extended-release tablet:	Safety and efficacy in children have not been	Extended-release tablet: 2.5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	initial, 5 mg/day; maintenance, 2.5 to 10 mg/day	established.	5 mg 10 mg
Isradipine	<u>Hypertension:</u> Capsule: initial, 2.5 mg twice daily; maximum, 20 mg/day	Safety and efficacy in children have not been established.	Capsule: 2.5 mg 5 mg
Nicardipine	<u>Angina pectoris (chronic stable):</u> Capsule: initial, 20 mg three times daily; maintenance, 20 to 40 mg three times daily <u>Hypertension:</u> Capsule: initial, 20 mg three times daily; maintenance, 20 to 40 mg three times daily Injection: titrate dose to achieve the desired blood pressure reduction; individualize dosage depending on the blood pressure to be obtained and the response of the patient	Safety and efficacy in children have not been established.	Capsule: 20 mg 30 mg Injection: 20 mg/200 mL 40 mg/200 mL 25 mg/10 mL
Nifedipine	<u>Angina pectoris (chronic stable)</u> Capsule: initial, 10 mg three times daily; maintenance, 10 to 20 mg three times daily; maximum, 180 mg/day Extended-release tablet: initial, 30 or 60 mg/day; maintenance, 30 to 90 mg/day; maximum, 120 mg/day <u>Angina pectoris (vasospastic):</u> Capsule: initial, 10 mg three times daily; maintenance, 20 to 30 mg three to four times daily; maximum, 180 mg/day Extended-release tablet: initial, 30 or 60 mg/day; maintenance, 30 to 90 mg/day; maximum, 120 mg/day <u>Hypertension:</u> Extended-release tablet:	Safety and efficacy in children have not been established.	Capsule: 10 mg 20 mg Extended-release tablet: 30 mg 60 mg 90 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	initial, 30 or 60 mg/day; maintenance, 30 to 90 mg/day; maximum, 120 mg/day		
Nimodipine	<u>Subarachnoid hemorrhage:</u> Capsule, solution : 60 mg every 4 hours for 21 consecutive days	Safety and efficacy in children have not been established.	Capsule: 30 mg Solution: 60 mg/20 mL
Nisoldipine	<u>Hypertension:</u> Extended-release tablet: initial, 20 mg once daily; maintenance, 20 to 40 mg/day; maximum, 60 mg/day Extended-release tablet (Sular® only): initial, 17 mg once daily; maintenance, 17 to 34 mg/day; maximum, 34 mg/day	Safety and efficacy in children have not been established.	Extended-release tablet: 8.5 mg 17 mg 20 mg 25.5 mg 30 mg 34 mg 40 mg
Combination Products			
Amlodipine and benazepril	<u>Hypertension:</u> Capsule: initial, 2.5-10 mg once daily; maintenance, individualize and adjust dosage according to clinical response, dose once daily	Safety and efficacy in children have not been established.	Capsule: 2.5-10 mg 5-10 mg 5-20 mg 5-40 mg 10-20 mg 10-40 mg
Amlodipine and olmesartan	<u>Hypertension:</u> Tablet: initial, 5-20 mg once daily; maximum, 10- 40 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5-20 mg 5-40 mg 10-20 mg 10-40 mg
Amlodipine and valsartan	<u>Hypertension:</u> Tablet: initial, 5-160 mg once daily; maximum, 10- 320 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5-160 mg 5-320 mg 10-160 mg 10-320 mg
Amlodipine and valsartan and HCTZ	<u>Hypertension:</u> Tablet: maximum, 10-320- 25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5-160-12.5 mg 5-160-25 mg 10-160-12.5 mg 10-160-25 mg 10-320-25 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the dihydropyridines are summarized in Table 14.

Table 14. Comparative Clinical Trials with the Dihydropyridines

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Angina				
Koenig et al. ⁴³ (1997) Amlodipine 5 to 10 mg QD for 4 weeks vs felodipine ER 5 to 10 mg QD for 4 weeks	DB, PRO, RCT, XO Patients, age 30 to 80 years, who have a history of angina, a positive exercise-stress test or positive 24-hour ambulatory monitoring, and ≥ 6 ischemic episodes in 24 hours	N=52 8 weeks	Primary: Number of ST-segment depressions in 24 hours of ambulatory monitoring Secondary: Total and mean duration of each ST-segment depression episode, maximum ST depression, length of ischemic episode, adverse events	Primary: Significant reductions from baseline were seen in both groups for the number of ST-segment depressions, from 19.9 at baseline for both groups to 2.3 for amlodipine and 2.4 for felodipine ($P < 0.001$ for both from baseline; $P = 0.83$ between treatments). Secondary: Total and mean duration of each ST-segment depression episode, maximum ST depression and length of ischemic episode were significantly different from baseline for both treatment groups but treatments were not significantly different ($P < 0.001$ for all from baseline, $P = 0.53$, $P = 0.40$, $P = 0.68$, $P = 0.35$, respectively between treatments). Adverse event rates similar between the treatments.
Savanitto et al. ⁴⁴ (1996) <u>Weeks 1 to 6:</u> Nifedipine 20 mg BID vs metoprolol ER 200 mg QD <u>Weeks 7 to 10:</u>	DB, MC, RCT Patients with typical anginal symptoms that had been stable for approximately 6 months, who showed a positive response to exercise stress testing with 23 min of exercise tolerance and were in sinus	N=280 6 weeks	Primary: Angina frequency, exercise tolerance, safety Secondary: Not reported	Primary: At week six, both metoprolol (mean change, -1.95; 95 % CI, -1.25 to -2.64) and nifedipine (mean change, -1.57; 95 % CI, -0.69 to -2.45) significantly reduced the frequency of angina compared to baseline, but there was not a statistical difference between groups. At the end of 10 weeks, there was not a statistical difference observed between the groups. At week six, both metoprolol and nifedipine significantly increased the mean exercise time to 1-mm ST-segment depression compared to baseline (both $P < 0.01$); but metoprolol was significantly more effective than nifedipine ($P < 0.05$). At week 10, the groups randomized to combination therapy had a further

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>nifedipine 20 mg BID plus placebo vs metoprolol ER 200 mg QD plus placebo vs metoprolol ER 200 mg QD and nifedipine 20 mg BID</p>	<p>rhythm and had an analyzable ST segment on ECG</p>			<p>increase in time to 1-mm ST-segment depression (P<0.05 vs placebo).</p> <p>There were 14 cardiovascular events including one sudden death, three acute myocardial infarctions, eight cases of unstable angina, one of syncope and one of stroke and the incidence of these events did not differ among the treatment groups.</p> <p>Secondary: Not reported</p>
Cardiovascular Outcomes Trials				
<p>Pitt et al.⁴⁵ (2000) PREVENT Amlodipine 5 to 10 mg QD vs placebo</p>	<p>DB, MC, PC, RCT Men and women, age 30 to 80 years with angiographic evidence of CAD, DBP <95 mm Hg, TC 325 mg/dL, FBG <200 mg/dL</p>	<p>N=825 3 years</p>	<p>Primary: Change in mean minimal diameter with a quantitative coronary angiography</p> <p>Secondary: Progression of atherosclerosis in the carotid arteries assessed by B-mode ultrasonography for intimal-medial thicknesses, all-cause mortality, occurrence of major fatal/nonfatal vascular events or procedures,</p>	<p>Primary: Change, reduction, in the minimal diameter was similar between the amlodipine group and the placebo group (0.084 vs 0.0095 P=0.38).</p> <p>Secondary: Amlodipine treatment significantly decreased the progression of atherosclerosis as compared to placebo treatment, a 0.013 mm decrease for the amlodipine group vs a 0.033 mm increase with placebo (P=0.007).</p> <p>There was no difference in all-cause mortality between amlodipine and placebo.</p> <p>There was no difference in occurrence of fatal and nonfatal vascular events between the treatment groups (HR, 0.82; 95% CI, 0.47 to 1.42).</p> <p>Amlodipine treatment significantly reduced the occurrence of hospitalized CHF and unstable angina (HR, 0.65; 95% CI, 0.47 to 0.91) and coronary revascularizations (HR, 0.57; 95% CI, 0.41 to 0.81) and combined overall procedures (HR, 0.69; 95% CI, 0.52 to 0.92).</p> <p>There was no significant difference between groups in rates of adverse events: cancer rate (HR, 2.13; 95% CI, 0.90 to 5.21) and bleeding episode</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Dahlöf et al.⁴⁶ (2005) ASCOT-BPLA</p> <p>Amlodipine 5 to 10 mg/day adding perindopril 4 to 8 mg/day as needed</p> <p>vs</p> <p>atenolol 50 to 100 mg/day adding bendroflumethiazide* 1.25 to 2.5 mg/day and potassium as needed</p> <p>If blood pressure was still not achieved, doxazosin 4 to 8 mg/day was added to the regimen.</p>	<p>MC, OL, RCT</p> <p>Patients 40 to 79 years of age with HTN and ≥3 other cardiovascular risk factors (left ventricular hypertrophy, other specified abnormalities on ECG, type 2 diabetes, PAD, history of stroke or TIA, male, age ≥55 years, microalbuminuria or proteinuria, smoking, TC:HDL-C ratio ≥6, or family history of CHD)</p>	<p>N=19,257</p> <p>5.5 years</p>	<p>adverse events</p> <p>Primary: Nonfatal MI (including silent MI) and fatal CHD</p> <p>Secondary: All-cause mortality, total stroke, primary end points minus silent MI, all coronary events, total cardiovascular events and procedures, cardiovascular mortality, nonfatal and fatal heart failure, effects on primary end point and on total cardiovascular events and procedures among prespecified subgroups</p> <p>Tertiary: Silent MI, unstable angina, chronic stable angina, PAD, life-threatening arrhythmias, development of diabetes,</p>	<p>(HR, 1.42; 95% CI, 0.88 to 2.30).</p> <p>Primary: No statistically significant difference in nonfatal MI and fatal CHD was reported between the amlodipine plus perindopril group compared to the atenolol plus bendroflumethiazide groups (HR, 0.90; 95% CI, 0.79 to 12; P=0.1052).</p> <p>Secondary: Significantly greater reductions in the following secondary end points were observed with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: all- cause mortality (P=0.0247), total stroke (P=0.0003), primary end points minus silent MI (P=0.0458), all coronary events (P=0.0070), total cardiovascular events and procedures (P<0.0001), and cardiovascular mortality (P=0.0010).</p> <p>There were no significant differences in nonfatal and fatal heart failure between the two treatment groups (P=0.1257).</p> <p>The study was terminated early due to higher mortality and worse outcomes on several secondary end points observed in the atenolol study group.</p> <p>Tertiary: Significantly greater reductions in the following end points were observed with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: unstable angina (P=0.0115), PAD (P=0.0001), development of diabetes (P<0.0001), and development of renal impairment (P=0.0187).</p> <p>There were no significant differences in the incidence of silent MI (P=0.3089), chronic stable angina (P=0.8323) or life-threatening arrhythmias (P=0.8009) between the two treatment groups.</p> <p>There was no significant difference in the percent of patients who stopped therapy because of an adverse event between the two treatment groups (overall 25%). There was, however, a significant difference in favor of amlodipine plus perindopril in the proportion of patients who stopped trial</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			development of renal impairment	therapy because of a serious adverse events (2 vs 3%; P<0.0001).
<p>Chapman et al.⁴⁷ (2007) ASCOT-BPLA</p> <p>Atenolol 50 to 100 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); bendroflumethiazide* plus potassium 1.25 to 2.5 mg plus doxazosin were added for additional blood pressure control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p> <p>vs</p> <p>amlodipine 5 to 10 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in</p>	<p>Subanalysis of ASCOT-BPLA evaluating effects of spironolactone on treatment-resistant HTN</p> <p>Patients 40 to 79 years of age with HTN and ≥3 cardiovascular risk factors, with SBP ≥160 mm Hg and/or DBP ≥100 mm Hg (not on antihypertensive therapy) or SBP ≥140 mm Hg and/or DBP ≥90 mm Hg (on antihypertensive therapy)</p>	<p>N=1,411</p> <p>1.3 years</p>	<p>Primary: Change in DBP and SBP, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: Spironolactone-treated patients lead to a significant 21.9 mm Hg reduction in SBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 20.8 to 23.0 mm Hg; P<0.001).</p> <p>Spironolactone-treated patients lead to a significant 9.5 mm Hg reduction in DBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 9.0 to 10.1; P<0.001).</p> <p>Spironolactone-treated patients exhibited small but significant decreases in sodium, LDL-C and TC as well as increases in potassium, glucose, creatinine and HDL-C (P<0.05).</p> <p>The most common adverse effect reported in the trial was gynecomastia in men (P value not reported).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>diabetic patients); perindopril 4 to 8 mg and doxazosin were added for additional control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p>				
<p>Nissen et al.⁴⁸ (2004) CAMELOT Amlodipine 10 mg/day vs enalapril 20 mg/day vs placebo</p>	<p>DB, MC, PC, RCT Patients 30 to 79 years of age requiring coronary angiography for evaluation for chest pain or PCI and a diastolic pressure <100 mm Hg, with or without treatment</p>	<p>N=1,991 2 years</p>	<p>Primary: Composite of cardiovascular events (cardiovascular death, nonfatal MI, resuscitated cardiac arrest, coronary revascularization, hospitalization for angina pectoris, hospitalization for CHF, fatal or nonfatal stroke or TIA, and any new diagnosis of PVD), nominal change in percent atheroma volume (substudy) Secondary: Incidence of adverse events; all-cause mortality,</p>	<p>Primary: Cardiovascular events occurred in 23.1% of placebo-treated patients, 16.6% amlodipine-treated patients (HR, 0.69; 95% CI, 0.54 to 0.88; P=0.003) and 20.2% enalapril-treated patients (HR, 0.85; 95% CI, 0.67 to 1.7; P=0.16). The primary end point comparison for enalapril vs amlodipine was not significant (HR, 0.81; 95% CI, 0.63 to 1.4; P=0.10). Secondary: Coronary revascularization was reduced in the amlodipine group from 15.7 to 11.8% (HR, 0.73; 95% CI, 0.54 to 0.98; P=0.03). Hospitalization for angina was reduced in the amlodipine group from 12.8 to 7.7% (HR, 0.58; 95% CI, 0.41 to 0.82; P=0.002). Individual components of the primary end point generally showed fewer events with enalapril treatment vs placebo, but none of the comparisons reached statistical significance. For components of the primary end point, only the rate of hospitalization for angina showed a statistically significant difference between amlodipine and enalapril (HR, 0.59; 95% CI, 0.42 to 0.84; P=0.003). A trend toward fewer episodes of revascularization in patients undergoing intervention at baseline was observed for amlodipine vs enalapril (HR, 0.66; 95% CI, 0.40 to 1.6; P=0.09).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			incidence of revascularization in vessels that had undergone previous stent placement	<p>The mean change in percent atheroma volume was 0.5% for amlodipine (P=0.12 vs placebo), 0.8% for enalapril (P=0.32 vs placebo) and 1.3% for placebo. In patients with SBP greater than the mean, the amlodipine group showed a significantly slower progression (0.2%) compared to placebo (2.3%; P=0.02). Compared to baseline, intravascular ultrasound showed progression in patients receiving placebo (P<0.001), a trend toward progression with enalapril (P=0.08) and no progression in patients receiving amlodipine (P=0.31). For the amlodipine group, correlation between blood pressure reduction and progression was r=0.19 (P=0.07).</p> <p>Discontinuation from the study for treatment-emergent adverse events was low, averaging 0.4% and not statistically significant between the three treatment groups.</p> <p>The only statistically significant difference in secondary end points was that amlodipine demonstrated a significant reduction in revascularization after previous stent placement compared to placebo (4.1 vs 7.9%; HR, 0.49; 95% CI, 0.31 to 0.78; P=0.002). The rate of revascularization was lower than enalapril (6.2%) but not statistically significant (HR, 0.66; 95% CI, 0.40 to 1.6; P=0.09).</p>
<p>ALLHAT⁴⁹ (2002) ALLHAT Amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day vs chlorthalidone 12.5 to 25 mg/day</p>	<p>DB, MC, RCT Patients ≥55 years with HTN and ≥1 additional CHD risk factor</p>	<p>N=33,357 4.9 years (mean)</p>	<p>Primary: Combined fatal CHD or nonfatal MI Secondary: All-cause mortality, fatal and nonfatal stroke, combined CHD, combined cardiovascular disease (combined CHD, stroke, treated angina without</p>	<p>Primary: There were no significant differences in the primary outcome between lisinopril (11.4%), amlodipine (11.3%), and chlorthalidone (11.5%). Secondary: All-cause mortality did not differ between groups. Five year SBPs were significantly higher in the lisinopril (2 mm Hg; P<0.001) and amlodipine groups (0.8 mm Hg; P=0.03) compared to chlorthalidone, and five year DBPs were significantly lower with amlodipine (0.8 mm Hg; P<0.001). Amlodipine had a higher six year rate of heart failure compared to chlorthalidone (10.2 vs 7.7%; RR, 1.38; 95% CI, 1.25 to 1.52). Lisinopril had a higher six year rate of combined cardiovascular disease</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			hospitalization, heart failure, and PAD)	(33.3 vs 30.9%; RR, 1.10; 95% CI, 1.05 to 1.16); stroke (6.3 vs 5.6%; RR, 1.15; 95% CI, 1.02 to 1.30) and heart failure (8.7 vs 7.7%; RR, 1.19; 95% CI, 1.07 to 1.31).
Black et al. ⁵⁰ (2008) ALLHAT Amlodipine 2.5 to 10 mg QD vs lisinopril 10 to 40 mg QD vs chlorthalidone 12.5 to 25 mg QD	MC, RCT Men and women, age 55 years old and older, with HTN and metabolic syndrome	N=17,515 4.9 years (mean)	Primary: Fatal coronary heart disease and nonfatal MI Secondary: All cause mortality, fatal and nonfatal stroke, combined coronary heart disease, combined cardiovascular disease	Primary: For patients with metabolic syndrome, there was no significant difference in rates of coronary heart disease and nonfatal MI with amlodipine vs chlorthalidone (RR, 0.96; 95% CI, 0.79 to 1.16), or lisinopril vs chlorthalidone (RR, 1.15; 95% CI, 0.88 to 1.27). Secondary: For patients with metabolic syndrome, there were no significant differences found between amlodipine vs chlorthalidone in all secondary endpoints (P value not significant). For patients without metabolic syndrome, amlodipine treatment was associated with significantly more heart failure, but in patients with metabolic syndrome, there was no difference (P=0.03). Patients with metabolic syndrome who received lisinopril experienced more heart failure and cardiovascular disease than those who received chlorthalidone (RR, 1.31; 95% CI, 1.04 to 1.64 and RR, 1.19; 95% CI, 1.07 to 1.32).
Rahman et al. ⁵¹ (2012) ALLHAT Amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day vs chlorthalidone	Long-term, post-trial, follow-up Patients in ALLHAT stratified based on eGFR	N=31,350 4 to 8 years	Primary: Cardiovascular mortality Secondary: Total mortality, CHD, cardiovascular disease, stroke, heart failure, ESRD	Primary: After an average of 8.8 years of follow-up, total mortality was significantly higher in patients with moderate/severe eGFR reduction (eGFR <60 mL/min/1.73 m ²) compared to patients with normal/increased (eGFR ≥90 mL/min/1.73 m ²) and mildly reduced eGFR (eGFR 60 to 89 mL/min/1.73 m ²) (P<0.001). In patients with moderate/severe eGFR reduction, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Secondary: No significant differences were observed for any of the secondary endpoints among eGFR reduction groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
12.5 to 25 mg/day				
Muntner et al. ⁵² (2014) ALLHAT Chlorthalidone 12.5 to 25 mg/day vs amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day	Post-hoc analysis of ALLHAT Patients in ALLHAT with 5, 6, or 7 visits in 6 to 28 months of follow-up	N=24,004 6 to 28 months	Primary: Visit-to-visit variability (VVV) of blood pressure Secondary: Not reported	Primary: Each measure of VVV of SBP was lower among participants randomized to chlorthalidone and amlodipine compared with those randomized to lisinopril. All four VVV of SBP metrics were lower among participants randomized to amlodipine vs chlorthalidone after full multivariable adjustment. After multivariable adjustment including mean SBP across visits and compared with participants randomized to chlorthalidone, participants randomized to amlodipine had a 0.36 (standard error [SE]: 0.07) lower standard deviation (SD) of SBP and participants randomized to lisinopril had a 0.77 (SE=0.08) higher SD of SBP. Results were consistent using other VVV of SBP metrics. These data suggest chlorthalidone and amlodipine are associated with lower VVV of SBP than lisinopril. Secondary: Not reported
Ogihara et al. ⁵³ (2008) CASE-J Amlodipine 2.5 to 10 mg QD vs candesartan 4 to 12 mg QD	AC, MC, OL, RCT Patients with high risk HTN (SBP \geq 140 mm Hg or DBP \geq 90 mm Hg in patients <70 years old or SBP \geq 160 mm Hg or DBP \geq 90 mm Hg in patients \geq 70 years old), with either type 2 diabetes, history of stroke or ischemic attack, left ventricular hypertrophy, proteinuria or serum creatinine \geq 1.3	N=4,703 Up to 4 years	Primary: First fatal or nonfatal cardiovascular event Secondary: All-cause death, new-onset diabetes, discontinuation due to adverse events	Primary: A total of 134 patients experienced a cardiovascular event in each treatment regimen (HR, 1.0; 95% CI, 0.78 to 1.27; P=0.969). Secondary: All-cause death rates did not differ between treatments, 73 deaths in the candesartan group and 86 in the amlodipine group. New-onset diabetes occurred in significantly fewer patients in the candesartan group than the amlodipine group (HR, 0.64; 95% CI, 0.43 to 0.97; P=0.033). A total of 125 (5.4%) patients in the candesartan group and 134 (5.8%) of patients in the amlodipine group discontinued due to adverse events.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	mg/dL			
<p>Julius et al.⁵⁴ (2004) VALUE</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>valsartan 80 to 160 mg QD</p>	<p>DB, PG, RCT</p> <p>Patients ≥50 years old with treated or untreated HTN and history of cardiovascular disease, stroke, or diabetes, previous medications were discontinued at trial onset</p>	<p>N=15,245</p> <p>4.2 years (mean)</p>	<p>Primary: Time to first cardiac event (cardiac morbidity and mortality)</p> <p>Secondary: Fatal and nonfatal MI, fatal and nonfatal heart failure and fatal and nonfatal stroke, all-cause mortality, new onset diabetes</p>	<p>Primary: There were no differences in the primary composite end point between the valsartan and amlodipine groups (10.6 vs 10.4%; P=0.49).</p> <p>Secondary: There was a higher incidence of myocardial infarction (4.8 vs 4.1%; P=0.02) in patients receiving valsartan than amlodipine.</p> <p>There was no difference in the incidence of heart failure (4.6 vs 5.3%; P=0.12), stroke (4.2 vs 3.7%; P=0.08), and all-cause mortality (11 vs 10.8%; P=0.45) between valsartan- and amlodipine-treated patients.</p> <p>New onset diabetes occurred less with valsartan (13.1%) vs amlodipine (16.4%; P<0.001).</p> <p>Combined target blood pressure (<140/90 mm Hg) was achieved in 58% and 62% of patients receiving valsartan and amlodipine, respectively.</p>
<p>Zanchetti et al.⁵⁵ (2006) VALUE</p> <p>Amlodipine 5 mg QD</p> <p>vs</p> <p>valsartan 80 mg QD</p>	<p>Subgroup analysis of VALUE</p> <p>Patients with HTN</p>	<p>N=15,245</p> <p>4.2 years</p>	<p>Primary: Time to first cardiac event, analyzed by subgroup</p> <p>Secondary: MI, heart failure and stroke</p>	<p>Primary: The only significant result of the analyses by subgroup for time to first cardiac event was sex; women in the valsartan group experienced more cardiac events as compared to men in the valsartan group (HR for women, 1.21; 95% CI, 1.13 to 1.42; HR for men, 0.94; 95% CI, 0.82 to 1.17; P=0.016).</p> <p>The VALUE trial showed no difference in the primary outcome as well as in cardiac morbidity and mortality between amlodipine treatment and valsartan treatment. SBP and DBP were lower, as was incidence of MI, in the amlodipine treatment group as compared to the valsartan group.</p> <p>Secondary: Male patients treated with valsartan had a significantly lower incidence of heart failure than males treated with amlodipine (P<0.001 for male vs female difference; for men, HF rates with valsartan were 4.1% vs amlodipine 5.8% [HR, 0.73; 95% CI, 0.60 to 0.88]; for women, rates were valsartan 5.3% vs amlodipine 4.6%, [HR, 1.18; 95% CI, 0.95 to 1.47]).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Patients without a history of stroke had a greater reduction in stroke risk if treated with amlodipine (valsartan 3.4% vs amlodipine 2.6%; HR, 1.34; 95% CI, 1.19 to 1.65).
Jamerson et al. ⁵⁶ (2008) ACCOMPLISH Amlodipine 5 mg QD and benazepril 20 mg QD vs benazepril 20 mg QD and HCTZ 12.5 mg QD	AC, DB, MC, RCT Patients >60 years of age with HTN and at high risk of cardiovascular events	N=11,506 36 months (mean)	Primary: The composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization. Secondary: Death from cardiovascular causes, nonfatal MI, and nonfatal stroke	Primary: There were 552 primary-outcome events in the benazepril plus amlodipine group (9.6%) and 679 events in the benazepril plus HCTZ group (11.8%). The absolute risk reduction with benazepril plus amlodipine therapy was 2.2% and the relative risk reduction was 19.6% compared to benazepril plus HCTZ (HR, 0.80; 95% CI, 0.72 to 0.90; P<0.001). Secondary: For the secondary end point of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, there were 288 (5%) events in the benazepril plus amlodipine group compared to 364 (6.3%) events in the benazepril plus HCTZ group. The absolute risk reduction with benazepril plus amlodipine therapy was 1.3% and the RR reduction was 21.2% compared to benazepril plus HCTZ (HR, 0.79; 95% CI, 0.67 to 0.92; P=0.002).
Bakris et al. ⁵⁷ (2010) ACCOMPISH Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on benazepril and amlodipine 20-5 mg (fixed-dose	Prespecified subanalysis of ACCOMPISH Men and women >60 years of age with HTN and at high risk for cardiovascular events (history of coronary events, MI, revascularization, or	N=11,482 2.9 years (mean duration)	Primary: Time to first event of doubling of serum creatinine concentration or end stage renal disease (defined as eGFR <15 mL/min/1.73 m ² or need for chronic dialysis) Secondary:	Primary: There were fewer chronic kidney disease events in the benazepril and amlodipine group (2.0% of patients) compared to the benazepril and HCTZ group (3.7%; HR, 0.52; 95% CI, 0.41 to 0.65; P<0.0001). Secondary: The composite endpoint of progression of chronic kidney disease and all-cause mortality was lower in the benazepril and amlodipine group (6.0%) compared to the benazepril and HCTZ group (8.1%; HR, 0.73; 95% CI, 0.64 to 0.84; P<0.0001). There was a slower decline in eGFR in the benazepril and amlodipine group compared to the benazepril and HCTZ group (-0.88 vs -4.22 mL/min/1.73 m ² ; P=0.01). Of the patients with baseline microalbuminuria, there was a reduction in the urinary

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>combination product)</p> <p>vs</p> <p>benazepril and HCTZ 40-12.5 to 40-25 mg/day, followed by forced titration after 1 month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)</p>	<p>stroke; impaired renal function; PAD, left ventricular hypertrophy; or diabetes)</p>		<p>Progression of chronic kidney disease plus death, change in albuminuria, and change in eGFR</p>	<p>albumin:creatinine in the benazepril and HCTZ group of -63.8% (median change) compared to a median change of -29.0% in the benazepril and amlodipine group (P<0.0001).</p> <p>There was a higher percentage of patients reporting peripheral edema in the benazepril and amlodipine group compared to the benazepril and HCTZ group (P<0.0001).</p>
<p>Weber et al.⁵⁸ (2010) ACCOMPLISH</p> <p>Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on benazepril and amlodipine 20-5 mg (fixed-dose combination product)</p> <p>vs</p> <p>benazepril and HCTZ 40-12.5 to 40-25 mg/day,</p>	<p>Prespecified subanalysis of ACCOMPISH</p> <p>Men and women >60 years of age with HTN and at high risk for cardiovascular events (history of coronary events, MI, revascularization, or stroke; impaired renal function; peripheral arterial disease, left ventricular hypertrophy; or diabetes)</p>	<p>N=6,946</p> <p>Mean treatment duration 29.7 months for benazepril and amlodipine group and 29.5 months for benazepril and HCTZ group</p>	<p>Primary: Primary: Time to first event (composite of cardiovascular event and death from cardiovascular causes)</p> <p>Secondary: Composite of cardiovascular events (the primary endpoint excluding fatal events) and composite of death from cardiovascular disease, nonfatal stroke and nonfatal</p>	<p>Primary: The primary endpoint occurred in 8.8% of diabetic patients in the benazepril and amlodipine group and 11.0% in the benazepril and HCTZ group (HR, 0.79; P=0.003; NNT, 46). In high risk diabetic patients, 13.6% of patients in the benazepril and amlodipine group and 17.3% in the benazepril and HCTZ group (HR, 0.77, P=0.007; NNT, 28).</p> <p>Secondary: Due to early termination, the study had limited power to detect differences in the diabetic subgroups.</p> <p>Peripheral edema was higher in the benazepril and amlodipine group compared to the benazepril and HCTZ group.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
followed by forced titration after one month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)	(Subanalysis of patients with diabetes)		MI	
<p>Weber et al.⁵⁹ (2013) ACCOMPLISH</p> <p>Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on benazepril and amlodipine 20-5 mg (fixed-dose combination product)</p> <p>vs</p> <p>benazepril and HCTZ 40-12.5 to 40-25 mg/day, followed by forced titration after 1 month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)</p>	<p>Subanalysis of ACCOMPLISH based on body size</p> <p>Patients >60 years of age with HTN and at high risk of cardiovascular events</p>	N=11,482	<p>Primary: Composite of cardiovascular death or nonfatal MI or stroke</p> <p>Secondary: Cardiovascular death, total MI, total stroke</p>	<p>Primary: In patients receiving benazepril and HCTZ, the primary endpoint (per 1,000 patient-years) was 30.7 in normal weight (BMI <25), 21.9 in overweight (BMI ≥25 to <30), and 18.2 in obese patients (BMI ≥30) (overall P=0.0034). In patients receiving benazepril and amlodipine, the primary endpoint did not differ between the three BMI groups (18.2, 16.9, and 16.5, respectively; P=0.9721). In obese patients, primary event rates were similar between the two treatments, but rates were significantly lower with benazepril and amlodipine in overweight patients (HR, 0.76; 95% CI, 0.59 to 0.94; P=0.0369) and normal weight patients (HR, 0.57; 95% CI, 0.39 to 0.84; P=0.0037).</p> <p>Secondary: Comparing obese and overweight patients, event rates were all numerically lower, but not significantly lower, in obese patients. Cardiovascular deaths were significantly lower in overweight patients compared to normal weight patients (HR, 0.57; 95% CI, 0.37 to 0.89; P=0.0125). Cardiovascular death (HR, 0.40; 95% CI, 0.25 to 0.63; P<0.0001) and total stroke (HR, 0.60; 95% CI, 0.37 to 0.96; P=0.0335) were significantly lower in obese patients compared to normal weight patients.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Bakris et al.⁶⁰ (2013) ACCOMPLISH HCTZ 12.5 to 25 mg QD and benazepril 20 to 40 mg QD (B+H) vs benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD (B+A)</p>	<p>Post hoc analysis Patients included in the ACCOMPLISH trial (>60 years of age with HTN and at high risk of cardiovascular events) stratified by presence of known CAD at baseline</p>	<p>N=11,506 36 months (mean)</p>	<p>Primary: The composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization. Secondary: Death from cardiovascular causes, nonfatal MI, and nonfatal stroke</p>	<p>Primary: Among the patients with CAD, 13% in the B+A group and 16% in the B+H group reached the primary end point, representing an absolute risk reduction of 3% and a hazard reduction of 18%. The difference in event rates of the composite primary end point between the B+A and B+H groups was significant (HR, 0.80; 95% CI, 0.69 to 0.92; P=0.0016). Among the patients without CAD, fewer patients in the B+A treatment arm (204 of 3,096) reached the primary end point compared with those in the B+H arm (251 of 3,095). The difference in event rates between the B+A and B+H groups was significant (HR, 0.81; 95% CI, 0.67 to 0.98; P=0.026). A comparison of patients with and without CAD event rates for the primary end points demonstrated that the patients with CAD had a greater CV event rate than those without CAD (15 vs 7%; P<0.0001). Secondary: The composite secondary end point of CV mortality, MI, and stroke occurred in 5.74% in the B+A group and 8% in the B+H group, resulting in an absolute risk reduction of 1.95% and a hazard reduction of 25% (HR, 0.73; 95% CI, 0.59 to 0.9; P=0.033). The rate of all-cause mortality differed significantly between the treatment arms (HR, 0.77; 95% CI, 0.6 to 0.99; P=0.042). Among the patients without CAD, the rates of CV mortality, MI, and stroke did not differ between the two arms (HR, 0.86; 95% CI, 0.68 to 1.08). The secondary end point events were lower in the group of patients without CAD.</p>
<p>Hansson et al.⁶¹ (1999) STOP-Hypertension Felodipine 2.5 mg or isradipine 2.5 mg QD vs</p>	<p>MC, OL, PRO, RCT Men and women, age 70 to 84 years with HTN (SBP \geq180 mm Hg or DBP \geq105 mm Hg or both)</p>	<p>N=6,614 4 years</p>	<p>Primary: Fatal stroke, fatal MI, other fatal cardiovascular events Secondary: Blood pressure</p>	<p>Primary: The rate of prevention of cardiovascular deaths was similar in all groups (RR, 0.97 to 1.4; 95% CI, 0.86 to 1.26). Fatal cardiovascular events, including fatal stroke and fatal myocardial infarction MI, occurred in 19.8 per 1,000 patient-years in the β-blocker and/or HCTZ group, in the felodipine or isradipine group and in the enalapril or lisinopril group (RR, 0.99; 95% CI, 0.84 to 1.16). The RR of cardiovascular death in patients in the enalapril or lisinopril</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>enalapril 10 mg or lisinopril 10 mg QD</p> <p>vs</p> <p>atenolol 50 mg or metoprolol 100 mg or pindolol 5 mg QD and/or HCTZ 25 mg with amiloride 2 to 5 mg QD</p>				<p>group as compared to the felodipine or isradipine group was 14 (95% CI, 0.86 to 1.26; P=0.67.)</p> <p>Secondary: Decreases in blood pressure were similar among the groups.</p>
<p>Borhani et al.⁶² (1996) MIDAS</p> <p>Isradipine 2.5 to 5 mg BID</p> <p>vs</p> <p>HCTZ 12.5 to 25 mg QD</p>	<p>DB, MC, positive-control, RCT</p> <p>Patients, average of 58.5 years old, with HTN</p>	<p>N=883</p> <p>3 years</p>	<p>Primary: Rate of progression of intimal-medial thickness in carotid arteries</p> <p>Secondary: Rate of cardiovascular events (MI, stroke, CHF, angina, sudden death), rate of non-major cardiovascular events and procedures (TIAs, dysrhythmia, aortic valve replacement, femoral popliteal bypass graft), blood pressure</p>	<p>Primary: There was no difference in the rate of progression of intimal-medial thickness between the treatment groups (P=0.68).</p> <p>Secondary: The rate of cardiovascular events was greater in the isradipine group than in the HCTZ group (5.65 vs 3.17%; P=0.07).</p> <p>The rate of non-major cardiovascular events was greater in the isradipine group than in the HCTZ group (9.05 vs 5.22%; P=0.02).</p> <p>There was a significant decrease in SBP in the HCTZ group as compared to isradipine (-19.5 vs -16.0 mm Hg; P=0.002).</p> <p>There was no difference in change in DBP (both groups, -13.0 mm Hg).</p>
<p>National Intervention</p>	<p>DB, RCT</p>	<p>N=414</p>	<p>Primary: Cardiovascular</p>	<p>Primary: There was no difference in rate of cardiovascular complications during the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Cooperative Study⁶³ (1999) NICS-EH</p> <p>Nicardipine SR 20 mg BID</p> <p>vs</p> <p>trichlor-methiazide* 2 mg QD</p>	<p>Patients age 60 years old and older with a SBP between 160 to 220 mm Hg and a DBP <115 mm Hg and no history of cardiovascular complications</p>	<p>5 years</p>	<p>complications</p> <p>Secondary: Blood pressure, pulse, side effects, laboratory values</p>	<p>study period (P=0.923).</p> <p>There was no difference in the number of patients experiences left ventricular hypertrophy on ECG (P=0.975).</p> <p>Secondary: Both groups experienced significant reductions in blood pressure from baseline (P=0.000).</p> <p>There was no significant difference in pulse rate between the groups.</p> <p>Side-effect rates did not differ between the groups (P=0.897).</p> <p>More patients in the trichlormethiazide group than in the nicardipine group had abnormal lab results at the end of the study; differences were significant for serum sodium levels (decreased in the trichlormethiazide group) and uric acid levels (increased with trichlormethiazide).</p>
<p>Lichtlen et al.⁶⁴ (1990) INTACT</p> <p>Nifedipine 80 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients, age 65 years and younger, demonstrating early CAD who were not candidates for invasive therapeutic procedures</p>	<p>N=348</p> <p>3 years</p>	<p>Primary: Progression of coronary artery disease detected on angiogram (change in minimal diameter, percent stenosis, transition into occlusion, new stenosis)</p> <p>Secondary: Critical clinical events (cardiac death, nonfatal MI, unstable angina, need for procedure, heart failure, severe arrhythmias),</p>	<p>Primary: In patients without study deviations, there were no significant differences in number of stenoses and occlusions per patient (nifedipine=3.7, placebo=3.88; P=0.437). The distribution among the arteries of the occlusions was not different between groups.</p> <p>The progression of stenosis was significant from baseline but changes were not significantly different between the groups (P<0.006 for all vs baseline; P>0.585 for group comparisons).</p> <p>Secondary: There was no difference between nifedipine treatment and placebo in number of critical events, 44 events in 24 patients receiving nifedipine vs 52 events in 35 patients in the placebo group (P=0.278).</p> <p>The nifedipine group had significantly fewer new lesions as compared to the placebo group: 78 (0.58 lesions/patients) vs 118 (0.8 lesions/patient) (P=0.031).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			progression of new lesions	
<p>Brown et al.⁶⁵ (2000) INSIGHT</p> <p>Nifedipine 30 mg QD</p> <p>vs</p> <p>amiloride and HCTZ 2.5-25 mg QD (fixed-dose combination product)</p> <p>Doses were doubled or atenolol 25 to 50 mg or enalapril 5 to 10 mg was added.</p>	<p>DB, MC, PRO, RCT</p> <p>Patients, age 55 to 80 years old with HTN (blood pressure \geq150/95 mm Hg or SBP \geq160 mm Hg) and \geq1 cardiovascular risk factor</p>	<p>N=6,575</p> <p>3 years</p>	<p>Primary: Composite death from any cardiovascular cause together with nonfatal stroke, MI, or heart failure</p> <p>Secondary: Total mortality, death from a vascular cause, nonfatal vascular event</p>	<p>Primary: There was no difference in composite cardiovascular deaths between the groups. Events occurred in 200 (6.3%) patients in the nifedipine group and 182 (5.8%) of the amiloride and HCTZ group (18.2 vs 16.5 events per 1,000 patient-years; P=0.34).</p> <p>Secondary: There was no difference in all-cause mortality (P=0.62), death from a vascular cause (P=0.67) and in nonfatal vascular events (P=0.50) between the treatment groups.</p>
<p>Estacio et al.⁶⁶ (1998) ABCD</p> <p>Nisoldipine 10 to 60 mg/day</p> <p>vs</p> <p>enalapril 5 to 40 mg/day</p>	<p>DB, PRO, RCT</p> <p>Patients between the ages of 40 and 74 years with NIDDM, baseline DBP \geq90 mm Hg and receiving no antihypertensive medications at the time of randomization</p>	<p>N=470</p> <p>67 months</p>	<p>Primary: Effect of intensive (target DBP of 75 mm Hg) or moderate (target DBP between 80 to 89 mm Hg) blood pressure control on the incidence and progression of complications of diabetes; compare enalapril to nisoldipine as a</p>	<p>Primary: Analysis of the 470 patients in the trial who had HTN (DBP \geq90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations between the two study medications throughout the five years of follow-up.</p> <p>Secondary: Nisoldipine was associated with a higher incidence of fatal and nonfatal MI than enalapril (RR, 7.0; 95% CI, 2.3 to 21.4).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			first-line antihypertensive agent Secondary: Incidence of MI	
Hypertension				
Sheehy et al. ⁶⁷ (2000) Amlodipine 2.5 to 10 mg QD vs felodipine 2.5 to 10 mg QD	RETRO Patients, age 65 years and older, with HTN	N=7,818 Duration not reported	Primary: Prescription renewal, drug switch rates, compliance rates, office visits Secondary: Not reported	Primary: Patients prescribed amlodipine had a greater compliance rate, 67.9%, than those prescribed felodipine 66.2% (P<0.01). Discontinuation rates were higher in the felodipine group by 27%. Amlodipine treatment resulted in more continuous months of treatment (69.2), than felodipine treatment (57.8) (P<0.01). Renewal rates were significantly larger in the amlodipine group (89.0%), than the felodipine group (85.6%) (P<0.01). Switch rates were significantly larger, 5 times, in the felodipine group (10.2%) than the amlodipine group (1.9%) (P<0.01). Visits to specialists occurred significantly more in patients treated with amlodipine than felodipine, (OR, 1.14; 95% CI, 1.8 to 1.20). Secondary: Not reported
Van der Krogt et al. ⁶⁸ (1996) Amlodipine 5 to 10 mg QD vs felodipine ER 5 to	DB, MC, PG, RCT Patients, age 18 to 75 years old, with mild to moderate HTN (DBP ≥95 mm Hg and ≤114 mm Hg)	N=201 12 weeks	Primary: Number of responders (DBP ≤90 mm Hg after 12 weeks of monotherapy or decrease of >10 mm Hg if baseline DBP >100 mm Hg) who did not	Primary: Amlodipine treatment resulted in significantly more responders than felodipine treatment (P=0.046): 68% (69 of 101) of the amlodipine group were responders. 53% (49 of 92) of the felodipine group were responders. 32% (32 of 101) of the amlodipine group were not responders. 47% (43 of 92) of the felodipine group were not responders. Secondary: The decreases in SBP and DBP from baseline were significant within each

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
10 mg QD			experience serious adverse events Secondary: Blood pressure, adverse events	group, but were similar between the groups (amlodipine SBP and DBP 12 weeks vs baseline; $P<0.001$, felodipine SBP and DBP 12 weeks vs baseline; $P<0.001$, amlodipine 12 week change vs felodipine 12 week change; $P>0.05$). Adverse events were experienced by 33% of the amlodipine group and 42% of the felodipine group. Significantly more patients in the felodipine group experienced serious adverse events (9 patients who experienced 17 serious events vs two patients who experienced three serious events; $P=0.048$).
Mounier-Vehier et al. ⁶⁹ (2002) Amlodipine 5 mg QD vs nicardipine 60 mg/day, divided 2 to 3 times daily	DB, MC, PG RCT Men and women, age 60 years and older with isolated systolic HTN (SBP 160 to 208 mm Hg) and DBP <90 mm Hg	N=133 90 days	Primary: Mean difference in SBP from baseline to day 90 Secondary: Mean difference in DBP, pulse pressure, heart rate, percent of patients with normal blood pressure (<140/90 mm Hg), safety	Primary: The decrease in SBP from baseline was significant within each group, but were similar between the groups (amlodipine day 90 vs baseline; $P=0.0001$, nicardipine day 90 vs baseline; $P=0.0001$, amlodipine 90 day change vs nicardipine 90 day change; $P=0.38$). Secondary: The decrease in DBP from baseline was significant within each group but similar between the groups (amlodipine day 90 vs baseline; $P=0.0001$; nicardipine day 90 vs baseline; $P=0.0003$, amlodipine 90 day change vs nicardipine 90 day change; $P=0.12$). The decrease in pulse pressure from baseline was significant within each group but similar between the groups (amlodipine day 90 vs baseline, $P=0.0001$; nicardipine day 90 vs baseline, $P=0.0001$; amlodipine 90 day change vs nicardipine 90 day change, $P=0.88$). There was no difference between the groups in heart rate ($P=0.60$). At day 90, 25.9, and 23.4% of the amlodipine and nicardipine groups had achieved normal blood pressure ($P=0.76$). The numbers of people in each group reporting at least 1 adverse event were similar, 23 in the amlodipine group and 20 in the nicardipine group.
Kes et al. ⁷⁰ (2003)	MC, OL, RCT Patients with HTN	N=155 12 weeks	Primary: Change in DBP	Primary: There was no significant difference in DBP between the amlodipine group and nifedipine group at 12 weeks ($P=0.436$).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>nifedipine 30 to 60 mg QD</p>			<p>Secondary: Not reported</p>	<p>Secondary: Not reported</p>
<p>Ryuzaki et al.⁷¹ (2007) i-TECHO</p> <p>Amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>nifedipine CR 20 to 80 mg QD</p>	<p>OL, RCT, XO</p> <p>Patients treated for HTN (SBP >140 mm Hg or DBP >90 mm Hg)</p>	<p>N=55</p> <p>12 weeks (6 weeks per treatment)</p>	<p>Primary: Average home blood pressure readings, pulse rates, clinic blood pressure and pulse readings</p> <p>Secondary: Not reported</p>	<p>Primary: The morning home SBP and DBP readings were lower in the nifedipine group than the amlodipine group (SBP 131±8 vs 133±10 mm Hg; P<0.05, DBP 80±8 vs 81±8 mm Hg; P<0.05).</p> <p>There were no significant differences in evening home blood pressure readings (P>0.05).</p> <p>There was no significant difference in rates of achieving target blood pressure between the groups (P<0.05).</p> <p>Morning home pulse rates were greater in the nifedipine group than the amlodipine group (70±9 vs 69±9 beats/min; P<0.05).</p> <p>There were no significant differences between the groups in evening home pulse rates (P>0.05).</p> <p>The clinic SBP and DBP readings were significantly lower in the nifedipine group than in the amlodipine group (P<0.05).</p> <p>There were no significant differences between the groups in clinic pulse rates (P>0.05).</p> <p>Secondary: Not reported</p>
<p>Saito et al.⁷² (2007) ADVANCE-Combi</p>	<p>DB, RCT</p> <p>Patients with untreated essential HTN with sitting</p>	<p>N=514</p> <p>16 weeks</p>	<p>Primary: Target blood pressure, achievement rate</p>	<p>Primary: Target blood pressure achievement rates were higher for the nifedipine treatment group than the amlodipine group (P<0.001).</p> <p>Patients in the amlodipine group were more likely to require additional</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine 2.5 to 5 mg QD</p> <p>vs</p> <p>nifedipine CR 20 to 40 mg QD</p> <p>Valsartan 40 to 80 mg was added on if blood pressure goal not met.</p>	<p>SBP \geq160 mm Hg or DBP \geq100 mm Hg; or previously treated with sitting SBP \geq150 mm Hg or DBP \geq95 mm Hg</p>		<p>Secondary: Safety</p>	<p>treatment with valsartan or a dose increase of amlodipine (P<0.05).</p> <p>The reduction in blood pressure from baseline was greater in the nifedipine group (-34.0/-20.1) than in the amlodipine group (-27.0/-15.9; P<0.05).</p> <p>Secondary: Adverse event rates were not significantly different between the groups, 12.4% in the nifedipine group vs 7.6% of the amlodipine group (P=0.07).</p>
<p>Pepine et al.⁷³ (2003) CESNA-II</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>nisoldipine ER 20 to 40 mg QD</p>	<p>DB, DD, PG, MC, RCT</p> <p>Men and women with HTN (DBP 90-109 mm Hg) and CAD</p>	<p>N=not specified</p> <p>6 weeks</p>	<p>Primary: Change from baseline in DBP at 6 weeks</p> <p>Secondary: Exercise duration, antihypertensive responder rate (% of patients with DBP <90 mm Hg), exercise test responder rate (increase in time by 20% and 60 seconds)</p>	<p>Primary: At six weeks, the mean SBP and mean DBP for the two treatment groups were not significantly different from each other and mean reductions in blood pressure were similar: amlodipine SBP/DBP 138/83 mm Hg, a decrease of 13/11 mm Hg, vs nisoldipine 137/81 mm Hg, a decrease of 15/13 mm Hg (P values not significant).</p> <p>Secondary: Both treatment groups experienced increases in exercise duration, increased by 21 seconds in the amlodipine group and 23 seconds in the nisoldipine group (P=0.268).</p> <p>Antihypertensive and exercise responder rates were similar between the groups (antihypertensive rates: 78% for amlodipine and 87% for nisoldipine; P>0.05 for both).</p>
<p>Whitcomb et al.⁷⁴ (2000)</p> <p>Amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>nisoldipine ER 10</p>	<p>DB, DD, MC, RCT</p> <p>Men and women, age 21 to 75 years, with HTN</p>	<p>N=161</p> <p>8 weeks</p>	<p>Primary: Between treatment comparison of change from baseline in DBP</p> <p>Secondary: Change from baseline in SBP,</p>	<p>Primary: Treatment with amlodipine resulted in a significantly larger change from baseline in DBP (between-group difference 2.7 mm Hg; P=0.005). However, a pre-specified difference of greater than 5 mm Hg in least mean squares, here 1.1 to 4.3 mm Hg, showed that the treatments were similar in reduction of DBP.</p> <p>Secondary: Amlodipine treatment resulted in a significantly larger change from</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to 40 mg QD			heart rate, percent of patients who responded	baseline in SBP than nisoldipine treatment (P value not reported, least mean square difference >5 mm Hg). At week eight, more patients in the amlodipine group were responders, 79%, as compared to the nisoldipine group, 60% (P=0.004).
White et al. ⁷⁵ (2003) CESNA-III Amlodipine 5 to 10 mg QD vs nisoldipine ER 20 to 60 mg QD	DB, MC, PRO, RCT African American patients with HTN (blood pressure of 92 mm Hg to 114 mm Hg and SBP <200 mm Hg)	N=192 12 weeks	Primary: ABPM change from baseline in DBP in mean 24 hour period Secondary: ABPM change in SBP, awake and asleep blood pressure, changes in clinic blood pressure and pulse	Primary: The decrease from baseline in DBP was similar between the groups: -16.0±2.3 mm Hg for nisoldipine and -15.0±2.3 mm Hg for amlodipine (P=0.500). Secondary: The decrease from baseline in SBP was similar between the groups: -23.0±2.7 mm Hg for nisoldipine and -19.9±2.7 mm Hg for amlodipine (P=0.067). The changes from baseline in awake and asleep SBP and DBP were not significantly different between the groups except for awake SBP, for which the nisoldipine group had a larger reduction, -19.2 vs -15.9 mm Hg (P=0.045). The changes from baseline in clinic blood pressure and pulse were similar between the groups (P>0.05 for SBP and DBP; P=0.362).
Lenz et al. ⁷⁶ (2001) Amlodipine 5 to 10 mg QD vs nisoldipine 10 to 20 mg QD	OL, XO Patients, 35 to 70 years old, with HTN, (SBP 140 to 179 mm Hg and DBP 90 to 109 mm Hg), stable on amlodipine for ≥3 months prior to switch to nisoldipine	N=21 10 weeks	Primary: 24-hr ABPM Secondary: Not reported	Primary: No significant difference in ABPM was found after patients switched from amlodipine to nisoldipine for the following: systolic nighttime, daytime and 24-hr blood pressure, diastolic nighttime and daytime blood pressure (P>0.05 for all). 24-hr DBP was significantly lower with amlodipine treatment than with nisoldipine treatment (75±10 vs 77±8.5 mm Hg; P=0.017). Secondary: Not reported
Drummond et al. ⁷⁷ (2007)	AC, DB, MC, PG, RCT	N=545 6 weeks	Primary: Change in DBP at 6 weeks	Primary: DBP reduction was significantly greater in the combination therapy group compared to those in the amlodipine 5 mg group (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine 5 mg QD vs amlodipine 10 mg QD vs aliskiren and amlodipine 150-5 mg QD (fixed-dose combination product)</p> <p>Patients not responding to amlodipine 5 mg QD at the end of 4 week single-blind run-in period received combination therapy, continuation of amlodipine 5 mg QD or titration to amlodipine 10 mg QD.</p>	<p>Patients 18 years of age and older with mild to moderate HTN</p>		<p>Secondary: SBP, comparison of SBP and DBP reductions between combination therapy group and amlodipine 10 mg group, proportion of patients responding to treatment, and proportion of patients achieving blood pressure control</p>	<p>Secondary: SBP reduction was significantly greater in the combination therapy group compared to those in the amlodipine 5 mg group (P<0.0001).</p> <p>No significant differences were observed in DBP or SBP reduction between the combination therapy group and the amlodipine 10 mg group (P=0.6167 and P=0.2666 respectively).</p> <p>The proportion of patients responding to treatment was significantly higher in the combination therapy group compared to the amlodipine 5 mg group (P<0.0001). No significant difference was observed between the combination therapy group and the amlodipine 10 mg group (P value not reported).</p> <p>The proportion of patients achieving blood pressure control was significantly higher in the combination therapy group compared to the amlodipine 5 mg group (P<0.0001). No significant difference was observed between the combination therapy group and the amlodipine 10 mg group (P=0.5229).</p>
<p>Benetos et al.⁷⁸ (2000)</p> <p>Amlodipine 5 mg QD vs</p>	<p>DB, MC, PG, RCT</p> <p>Patients over 60 years with supine SBP 160 to 210 mm Hg and DBP <90 mm Hg</p>	<p>N=164</p> <p>12 weeks</p>	<p>Primary: Changes in blood pressure, heart rate, adverse events, QOL scores</p> <p>Secondary:</p>	<p>Primary: Both bisoprolol and HCTZ and amlodipine significantly reduced SBP (-20.0±13.7 and -19.6±14.2 mm Hg, respectively; P<0.001) and DBP (-4.5±7.4 and -2.4±8.4 mm Hg, respectively from baseline to week 12, but there was not a significant difference between the agents (SBP; P=0.85 and DBP; P=0.09).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
bisoprolol and HCTZ 2.5-6.25 mg QD (fixed-dose combination product)			Not reported	<p>Bisoprolol and HCTZ significantly reduced heart rate from baseline, but amlodipine did not (-7.6±8.4 [P<0.001] and -0.2±11.4 bpm, respectively).</p> <p>Bisoprolol and HCTZ significantly reduced heart rate when compared to amlodipine (P=0.0001).</p> <p>Overall adverse events were not significantly different between the amlodipine and the bisoprolol and HCTZ group (39 and 40%, respectively). Adverse events reported included headache, leg edema, fatigue and bradycardia but severity of events was not reported.</p> <p>Overall QOL scores were not significantly different between the amlodipine and the bisoprolol and HCTZ group.</p> <p>Secondary: Not reported</p>
<p>Prisant et al.⁷⁹ (1995)</p> <p>Amlodipine 2.5, 5, or 10 mg</p> <p>vs</p> <p>bisoprolol and HCTZ 2.5-6.25, 5-6.25, or 10-6.25 mg/day (fixed-dose combination product)</p> <p>vs</p> <p>enalapril 5, 10, or 20 mg</p>	<p>DB, MC, PG, RCT</p> <p>Patients ≥21 years with mild to moderate essential HTN, (average sitting DBP 95 to 114 mm Hg) each treatment was once daily and titrated to effect</p>	<p>N=218</p> <p>17 weeks</p>	<p>Primary: Mean change from baseline in SBP and DBP, lab measurements, adverse events, QOL questionnaire</p> <p>Secondary: Not reported</p>	<p>Primary: Mean decreases in SBP and DBP from baseline were 13.4/10.7 mm Hg for bisoprolol and HCTZ patients, 12.8/10.2 mm Hg for amlodipine patients, and 7.3/6.6 mm Hg for enalapril patients. The hypotensive effects were significant for all three groups (P<0.001).</p> <p>SBP and DBP mean changes from baseline for the bisoprolol and HCTZ group and the amlodipine group were greater than the change from baseline for the enalapril group (P<0.01).</p> <p>Response rates (DBP ≤90 mm Hg or ≥10 mm Hg decrease from baseline) were 71% for the bisoprolol and HCTZ group, 69% for the amlodipine group, and 45% for the enalapril group. The response rates for the bisoprolol and HCTZ and the amlodipine groups differed significantly from the enalapril group (P<0.01).</p> <p>Twenty nine percent of bisoprolol patients had adverse experiences compared to 42% of amlodipine patients (P=0.12). Nearly 47% of enalapril patients had adverse experience compared to bisoprolol (P=0.04). Adverse events reported included headache, fatigue, peripheral edema, and dizziness.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Drug related adverse events were 16% for the bisoprolol and HCTZ patients, 21% for the amlodipine patients, and 23% for the enalapril patients. There was no significant difference between the groups.</p> <p>Enalapril demonstrated a mean decrease from baseline of 7.9 mg/dL for TC (P=0.02 vs amlodipine) and 6.6 mg/dL for LDL-C (P=0.04 vs amlodipine) which were not significantly different from the increase from the bisoprolol and HCTZ group of 1.7 mg/dL (P=0.07 vs enalapril) for TC and +0.6 mg/dL in LDL-C. However, the increase in TGs was highest for bisoprolol and HCTZ-treated patients compared to amlodipine- and enalapril-treated patients (P=0.08, for bisoprolol and HCTZ vs enalapril).</p> <p>There was not a significant difference from baseline or between treatment groups in QOL scores: 0.9 for the bisoprolol and HCTZ group, 0.5 for the amlodipine group, and 2.3 for the enalapril group.</p>
<p>Mazza et al.⁸⁰ (2002)</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>nebivolol 2.5 to 5 mg QD</p>	<p>DB, MC, PG, RCT</p> <p>Patients between 65 to 89 years of age with mild to moderate essential HTN and DBP ranging from 95 to 114 mm Hg</p>	<p>N=168</p> <p>16 weeks</p>	<p>Primary: Change in sitting blood pressure, response rates</p> <p>Secondary: Standing blood pressure changes, standing and sitting heart rate changes</p>	<p>Primary: There was not a significant difference observed between the amlodipine and nebivolol treatments groups in changes in sitting DBP (blood pressure values and P values not reported). At weeks four and eight, a slightly lower sitting SBP was observed in per-protocol patients in the amlodipine groups vs those in the nebivolol group (blood pressure values not reported, P<0.005).</p> <p>Response rates were not significantly difference between the amlodipine group and the nebivolol group (86 vs 88%, respectively). The percentage of patients who reached normalization (blood pressure <140/90 mm Hg) was no significant between the amlodipine and the nebivolol groups (47 vs 50%).</p> <p>Secondary: There were significant differences in standing blood pressure observed between the groups.</p> <p>Heart rate was significantly lower in the nebivolol group compared to the amlodipine group at all treatment visits (P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Hollenberg et al.⁸¹ (2003)</p> <p>Amlodipine 2.5 mg/day</p> <p>vs</p> <p>eplerenone 50 mg/day</p> <p>Both medications were titrated to a maximum of 200 (eplerenone) or 10 (amlodipine) mg/day to achieve a SBP<140 mm Hg.</p>	<p>RCT</p> <p>Patients ≥50 years of age, with untreated SBP between 140 to 190 mm Hg</p>	<p>N=269</p> <p>24 weeks</p>	<p>Primary: Change in SBP and DBP, discontinuation rate, symptom distress index, SF-36 Health Survey</p> <p>Secondary: Not reported</p>	<p>Patients in the amlodipine group experienced a significantly greater rate of headache (seven vs five patients) and ankle edema (12 vs zero patients) compared to the patients in the nebivolol group (P<0.05 for both).</p> <p>Primary: Both treatments exhibited similar reductions in SBP and DBP from baseline (P=0.01).</p> <p>The dropout rate was 50% greater in amlodipine-treated patients compared to eplerenone-treated patients (P value not reported).</p> <p>Symptom distress (technique used to assess the influence of drug treatment on QOL) index was assessed and results favored eplerenone therapy (P=0.03).</p> <p>SF-36 Health Survey showed no significant difference between the two treatments (P value not reported).</p> <p>Both treatments experienced similar incidences of adverse effects (P value not reported). Eplerenone-treated patients did not experience breast pain/tenderness, breast enlargement, changes in menstruation, gynecomastia or loss of libido.</p> <p>Secondary: Not reported</p>
<p>White et al.⁸² (2003)</p> <p>Amlodipine 2.5 mg/day</p> <p>vs</p> <p>eplerenone 50 mg/day</p> <p>Both medications were titrated to a</p>	<p>AC, DB, MC, RCT</p> <p>Patients ≥50 years of age with systolic HTN (seated clinic SBP 150 to 165 mm Hg with a pulse pressure ≥70 mm Hg or 165 to 200 mm Hg with a DBP ≤95 mm Hg)</p>	<p>N=269</p> <p>24 weeks</p>	<p>Primary: Mean change from baseline in SBP, DBP, 24 hour ambulatory BP, pulse pressure, and heart rate at week 24; urine albumin/creatinine ratio; adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Mean reduction in SBP from baseline was comparable in eplerenone- and amlodipine-treated patients (P=0.83).</p> <p>Eplerenone-treated patients exhibited significant reductions in DBP from baseline at 24 weeks of therapy compared to amlodipine-treated patients (P=0.014).</p> <p>The two treatments exhibited comparable decreases in 24 hour ambulatory BP, pulse pressure and heart rate after 24 weeks of therapy (P>0.05).</p> <p>Eplerenone-treated patients exhibited a significant reduction from baseline in the urine albumin/creatinine ratio compared to amlodipine-treated</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>maximum of 200 (eplerenone) or 10 (amlodipine) mg/day to achieve a SBP<140 mm Hg.</p>				<p>patients (P=0.002).</p> <p>Treatment-emergent adverse events were reported in 64 and 70% of eplerenone- and amlodipine-treated patients. The only adverse event that was significant between the two treatments was the incidence of edema (3.7 vs 25.5%; P<0.05). There were no reports of gynecomastia, breast tenderness or menstrual irregularities with either treatment.</p> <p>Secondary: Not reported</p>
<p>Jordan et al.⁸³ (2007)</p> <p>Amlodipine 5 to 10 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>aliskiren 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>irbesartan 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p>	<p>DB, DD, MC, PG, RCT</p> <p>Obese men and women (BMI ≥30 kg/m²) ≥18 years with essential HTN (mean sitting DBP 95 to 109 mm Hg and SBP <180 mm Hg) who had not responded to 4 weeks of treatment with HCTZ 25 mg</p>	<p>N=489</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting DBP with aliskiren 300 mg plus HCTZ vs HCTZ alone at 8 weeks</p> <p>Secondary: Comparisons of mean sitting DBP and SBP with aliskiren plus HCTZ vs the other treatment groups, percentage of responders (mean sitting DBP <90 mm Hg or ≥10 mm Hg reduction from baseline), proportion of patients achieving blood pressure control (mean sitting blood pressure <140/90</p>	<p>Primary: Aliskiren 300 mg added to HCTZ 25 mg significantly reduced mean sitting DBP compared to HCTZ alone at week eight (mean difference, -4.0; P<0.0001).</p> <p>Secondary: Aliskiren 300 mg added to HCTZ caused numerically larger reductions in mean sitting DBP and SBP compared to amlodipine 10 mg plus HCTZ and irbesartan 300 mg plus HCTZ at week eight, but there were no statistically significant differences between treatment groups (P>0.05).</p> <p>Responder rates were significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0193) and week 12 (P=0.004) but comparable to responder rates observed with amlodipine plus HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>The proportion of patients achieving blood pressure control was significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0005) and week 12 (P=0.0001) but not statistically different than amlodipine plus HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>Plasma renin activity significantly increased (P<0.05) during four weeks of HCTZ monotherapy. Combination with aliskiren neutralized this increase and led to an overall significant reduction in plasma renin activity compared to pretreatment baseline (P<0.05) whereas amlodipine and irbesartan led to further significant increases (P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 25 mg QD (existing therapy)			mm Hg), plasma renin activity, safety and tolerability	All of the study treatments were generally well tolerated. Amlodipine plus HCTZ (45.2%) was associated with a higher incidence of adverse events than the other treatment groups (36.1 to 39.3%), largely due to a higher rate of peripheral edema (11.1 vs 0.8 to 1.6%).
Messerli et al. ⁸⁴ (2002) Amlodipine and benazepril 5-10 mg to 5-20 mg QD (fixed-dose combination product)	OL Patients ≥18 years with mild-to-moderate HTN taking amlodipine 5 to 10 mg with inadequate blood pressure (DBP ≥90 mm Hg, Group 1) or intolerance with amlodipine (DBP ≤90 mm Hg with edema, Group 2)	N=7,912 4 weeks	Primary: Change in mean sitting DBP (group 1), and percentage of patients whose edema improved (group 2) Secondary: Group 1-change in mean sitting SBP	Primary: In Group 1, mean reduction in DBP at week four was 11.5 mm Hg (95% CI, -11.8 to -11.3 mm Hg; P<0.001). Mean DBP declined from 96.5 (baseline) to 84.9 mm Hg (at 4 weeks). In Group 2, 85% of patients saw improvement in edema with 42% of patients experiencing complete resolution after receiving combination therapy (95% CI, 83 to 87). Secondary: In Group 1, mean reduction in SBP at week four was 15.6 mm Hg (95% CI, -16.0 to -15.2 mm Hg; P<0.001).
Chrysant et al. ⁸⁵ (2012) Study 1: Benazepril 40 mg/day (Group 1) vs amlodipine and benazepril 5-40 mg/day, up titrated to 10-40 mg/day after 4 weeks. (fixed-dose combination product) (Group 2) Study 2:	Post-hoc analysis of 2 trials Patients with HTN	N=1,013 14 weeks	Primary: Change in baseline mean sitting DBP and mean sitting SBP, rate of blood pressure control (<140/90 mm Hg), rate of blood pressure control (mean sitting DBP <90 mm Hg or ≥10 mm Hg decrease from baseline) Secondary: Safety	Primary: Pooled results demonstrate that combination therapy resulted in significantly greater lowering of mean sitting DBP and mean seated SBP compared to benazepril or amlodipine (P<0.001). Amlodipine and benazepril 10-20 mg/day resulted in significantly greater blood pressure reductions in White patients (mean sitting DBP: 12.99 mm Hg; mean sitting SBP: 13.72 mm Hg) compared to Black patients (8.80 and 8.72 mm Hg) (P<0.004). Amlodipine and benazepril 10-40 mg/day resulted in similar reductions in blood pressure in both White and Black patients. The proportion of patients who achieved blood pressure control with amlodipine and benazepril 10-40 mg/day was similar between White and Black patients (60.7%), whereas with amlodipine and benazepril 10-20 mg/day the rate of control was higher with White patients (61.2 vs 39.4%; P<0.023). There was no difference in the proportion of patients who responded to treatment between Black and White patients with amlodipine and benazepril 10-40 mg/day (74.8 vs 77%; P<0.639). The proportion of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine and benazepril 10-20 mg/day, uptitrated to 10-40 mg/day after 2 weeks (Group 3)</p> <p>vs</p> <p>amlodipine and benazepril 10-20 mg/day (fixed-dose combination product) (Group 4)</p> <p>vs</p> <p>amlodipine 10 mg/day (Group 5)</p>				<p>patients who responded to amlodipine and benazepril 10-20 mg/day was significantly lower in Black patients (50.7 vs 73.5%; P<0.007).</p> <p>Secondary: There were no serious clinical or metabolic side effects reported, with the exception of pedal edema which occurred more frequently with amlodipine monotherapy.</p>
<p>Messerli et al.⁸⁶ (2000)</p> <p><u>Study 1:</u> Amlodipine and benazepril 5-10 mg to 5-20 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>nifedipine 30 to 60 mg/day</p> <p><u>Study 2:</u> Amlodipine and</p>	<p>2 DB, MC, RCT</p> <p>Patients 18 to 80 years of age with uncomplicated essential HTN</p>	<p>N=1,079</p> <p>8 weeks</p>	<p>Primary: Change in DBP from baseline</p> <p>Secondary: Change from baseline in SBP and heart rate</p>	<p>Primary: Study 1 Significant reductions in DBP were observed with benazepril and amlodipine 10-5 and 20-5 mg (-9.4 and -9.7 mm Hg, respectively) compared to nifedipine 30 mg (-7.0 mm Hg; P<0.05), but not nifedipine 60 mg (-8.5; P>0.05).</p> <p>Study 2 Benazepril and amlodipine 10-5 (-8.9 mm Hg) and 20-5 mg (-9.1 mm Hg) produced significantly greater reductions in DBP than amlodipine 5 mg (-6.8 mm Hg; P<0.05), but not amlodipine 10 mg (-8.7 mm Hg; P>0.05).</p> <p>Secondary: Study 1 Significant reductions in SBP were observed with benazepril and amlodipine 20-5 mg (-11.6 mm Hg) compared to nifedipine 30 mg (-7.9 mm Hg; P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>benazepril 5-10 mg to 5-20 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p>				<p>Significantly less edema was reported with combination therapies (3.1 to 3.8%; $P \leq 0.001$) compared to nifedipine 60 mg (15.5%; $P = 0.008$) but not nifedipine 30 mg (5.4%).</p> <p>Study 2 Significant reductions in SBP were observed with benazepril and amlodipine 20-5 mg (-9.1 mm Hg) compared to amlodipine 5 mg (-5.3 mm Hg; $P < 0.05$). There were no significant difference in SBP between amlodipine 10 mg and the combination therapies.</p> <p>Significantly less edema ($P < 0.001$) was reported with amlodipine 5 mg (4.9%) and combination therapies (1.5 to 2.2%) compared to amlodipine 10 mg (23.6%).</p>
<p>Jamerson et al.⁸⁷ (2004)</p> <p>Amlodipine and benazepril 5-20 and 10-20 mg/day (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine 5 to 10 mg/day</p>	<p>DB, MC, PG, RCT</p> <p>Men and women 18 to 80 years of age with stage 2 HTN</p>	<p>N=364</p> <p>12 weeks</p>	<p>Primary: Percentage of patients with SBP reduction ≥ 25 mm Hg (if baseline < 180 mm Hg) or ≥ 32 mm Hg (if baseline ≥ 180 mm Hg)</p> <p>Secondary: Percentage of patients with DBP reduction ≥ 15 mm Hg (if baseline < 110 mm Hg) or ≥ 20 mm Hg (if baseline ≥ 110 mm Hg), percentage of patients meeting goal of 140/90 and $\leq 130/85$ mm Hg, mean reduction in SBP and DBP and</p>	<p>Primary: Significantly more patients on combination therapy (74.2%) met the primary end point than patients on amlodipine monotherapy (53.9%; $P < 0.0001$). The time by which 50% of patients attained the primary end point was four weeks shorter among patients randomized to combination therapy compared to those randomized to monotherapy ($P < 0.0001$).</p> <p>Secondary: Significantly more patients on combination therapy met the DBP end point than patients on amlodipine monotherapy (67.0 vs 48.3%; $P = 0.0003$).</p> <p>Patients on combination therapy had significantly greater mean SBP reductions (-25.5 vs -20.5 mm Hg; $P = 0.0003$) and DBP reductions (-14.3 vs -10.4 mm Hg; $P = 0.0001$) than patients on amlodipine monotherapy.</p> <p>Significantly more patients on combination therapy met the BP goal of $< 140/90$ mm Hg than patients on amlodipine monotherapy (61.0 vs 43.3%; $P = 0.0007$).</p> <p>Significantly more patients on combination therapy met the BP goal of $< 130/85$ mm Hg than patients on amlodipine monotherapy (35.7 vs 19.1%; $P = 0.0004$).</p> <p>The incidence of peripheral edema was significantly higher in the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			incidence of edema	amlodipine monotherapy group (23.3 vs 12.6%; P=0.0102). There was no significant difference in the incidence of other adverse events.
Neutel et al. ⁸⁸ (2005) SELECT Amlodipine and benazepril 5-20 mg/day (fixed-dose combination product) vs amlodipine 5 mg/day vs benazepril 20 mg/day	DB, RCT Patients with stage 2 systolic HTN	N=443 8 weeks	Primary: Reduction in SBP, proportion of patients achieving blood pressure control Secondary: Not reported	Primary: Significantly greater SBP reductions were achieved with combination therapy compared to amlodipine or benazepril monotherapy (P<0.0001). Significantly more patients on combination therapy met blood pressure goals than on monotherapy (P<0.0001). No significant difference was noted in the incidence of adverse events. Adverse events were low in all three treatment arms, with less peripheral edema in the combination group than in the amlodipine-treated group. Secondary: Not reported
Kuschnir et al. ⁸⁹ (1996) Amlodipine-benazepril 5/20 mg QD (fixed-dose combination) vs amlodipine 5 mg QD vs	DB, MC, PC, PG, RCT Men and women 21 to 80 years of age with uncomplicated primary HTN	N=308 8 weeks	Primary: Reduction in mean sitting DBP, SBP and percentage of patients with DBP <90 mm Hg or ≥10 mm Hg reduction	Primary: All treatment groups significantly reduced mean sitting DBP compared to placebo (P<0.001). Combination amlodipine/benazepril had significantly greater reductions in DBP (-13.2 mm Hg; P<0.001) compared to amlodipine (-8.8 mm Hg) and benazepril (-6.7 mm Hg) monotherapy. Combination amlodipine and benazepril had significantly greater reductions in SBP (-24.7 mm Hg; P<0.001) compared to amlodipine (-16.2 mm Hg) and benazepril (-12.4 mm Hg). Significantly more patients on combination amlodipine and benazepril reached DBP <90 mm Hg or ≥10 mm Hg reduction (87.0%; P≤0.005)

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
benazepril 20 mg QD vs placebo				compared to amlodipine (67.5%) and benazepril (53.3%). Adverse events considered to be drug related occurred in 15.6% of patients receiving amlodipine and benazepril, 24.7% of patients receiving amlodipine, 6.5% of patients on benazepril and 11.7% of patients on placebo.
Chrysant et al. ⁹⁰ (2007) Amlodipine and benazepril 10-40 mg QD for 6 weeks (fixed-dose combination product) vs amlodipine and benazepril 10-40 mg QD for 2 weeks, followed by 20-40 mg QD for 4 weeks (fixed-dose combination product) vs amlodipine 10 mg QD for 6 weeks	DB, MC, RCT Men and women ≥18 years of age with mean sitting DBP ≥95 mm Hg not adequately controlled with amlodipine 10 mg/day monotherapy	N=812 6 weeks	Primary: Reduction in mean sitting DBP and SBP, reductions in ambulatory blood pressure, successful response (mean sitting DBP <90 mm Hg or decrease of ≥10 mm Hg from baseline), safety Secondary: Not reported	Primary: Treatment with benazepril 40 mg and amlodipine 10 and benazepril 20 mg and amlodipine 10 mg resulted in a decrease of mean sitting SBP and DBP by 13.3/12.7 and 12.1/11.6 mm Hg, respectively, compared to monotherapy (6.6/8.5 mm Hg; P<0.0001). Benazepril 40 mg and amlodipine 10 mg and benazepril 40 mg and amlodipine 20 mg decreased ambulatory SBP and DBP by 9.9/6.7 and 7.4/5.2 mm Hg, respectively, compared to monotherapy (P<0.0001). Both combination therapy groups resulted in more responders than monotherapy (74 and 65 vs 54%; P<0.0001 and P<0.0085, respectively). Combination therapy had significantly greater reductions in sitting SBP (-17 mm Hg; P<0.0001) compared to amlodipine monotherapy (-5 mm Hg). The incidence of pedal edema was lower but not significantly different in the combination therapy groups compared to monotherapy (4.5, 5.5 vs 9.2%, respectively; P value not significant). No significant metabolic side effects were noted among the combination therapy groups. Secondary: Not reported
Chrysant et al. ⁹¹ (2004) Amlodipine and benazepril	DB, RCT Men and women (mean age 53 years) with mean sitting	N=329 8 weeks	Primary: Reduction in mean sitting DBP and SBP, reduction in standing DBP and	Primary: Combination therapy had significantly greater reductions in sitting SBP (-17 mm Hg; P<0.0001) compared monotherapy (-5 mm Hg). Combination therapy had significantly greater reductions in sitting DBP (-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
5-40 mg QD for 4 weeks, followed by 10-40 mg QD for 4 weeks (fixed-dose combination product) vs benazepril 40 mg QD for 8 weeks	DBP \geq 95 mm Hg not adequately controlled with benazepril 40 mg/day monotherapy		SBP, and change in heart rate, safety Secondary: Not reported	14 mm Hg; P<0.0001) compared to monotherapy (-7 mm Hg). Combination therapy had significantly greater reductions in standing SBP (-17 mm Hg; P<0.0001) compared to monotherapy (-6 mm Hg). Combination therapy had significantly greater reductions in standing DBP (-14 mm Hg; P<0.0001) compared to monotherapy (-7 mm Hg). No significant differences in heart rate were observed (P>0.05). No significant differences in adverse events were reported (P>0.05). Secondary: Not reported
Fogari et al. ⁹² (1997) Amlodipine and benazepril 2.5-10 to 5-10 mg QD (fixed-dose combination product) vs benazepril 10 mg QD	DB, MC, PC, RCT Men and women 24 to 73 years of age (mean 55 years) with HTN inadequately controlled with ACE inhibitor monotherapy	N=448 8 weeks	Primary: Reduction in mean sitting DBP Secondary: Reduction in sitting SBP, standing DBP and SBP, and percentage of patients with DBP <90 mm Hg (deemed excellent response) or a \geq 10 mm Hg reduction (deemed good response)	Primary: Significantly greater reductions in sitting DBP were observed with benazepril 10 mg and amlodipine 2.5 mg (-5.3 mm Hg, 97.5% CI, -8.3 to -2.4; P=0.0001) and benazepril 10 mg and amlodipine 5 mg (-4.5 mm Hg, 97.5% CI, -7.4 to -1.6; P=0.0006) compared to benazepril monotherapy. Secondary: Significantly greater reductions in sitting SBP were seen with benazepril 10 mg and amlodipine 2.5 mg (-7.9 mm Hg, 97.5% CI, -12.3 to -3.5; P=0.0001) and benazepril 10 mg and amlodipine 5 mg (-7.9 mm Hg, 97.5% CI, -12.2 to -3.6; P=0.0000) compared to benazepril monotherapy. Significantly greater reductions in standing DBP and SBP were also reported with the combination therapy compared to benazepril monotherapy (P \leq 0.001). Significantly more patients had excellent or good response with benazepril 10 mg and amlodipine 2.5 mg (69.2%; P=0.0004) and 10-5 mg (65.8%; P=0.02) compared to benazepril monotherapy (40.5%). Tolerability was good in the three treatment groups and no significant abnormal laboratory data was detected.
Minami et al. ⁹³	OL	N=15	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2007)</p> <p>Losartan 50 mg/day and HCTZ 12.5 mg/day</p> <p>vs</p> <p>candesartan 8 mg QD or amlodipine 5 mg QD</p>	<p>Japanese outpatients with essential HTN treated for ≥ 2 months with either candesartan or amlodipine and 24-hour ambulatory blood pressure $\geq 135/80$ mm Hg</p>	<p>12 months</p>	<p>Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>In patients who had previously received candesartan, 24-hr blood pressure decreased significantly from 137/89 mm Hg to 126/81 mm Hg after three months ($P < 0.05/P < 0.001$) and to 123/81 mm Hg after 12 months ($P < 0.01/P < 0.001$) of treatment with losartan and HCTZ.</p> <p>In patients who had previously received amlodipine, 24-hr blood pressure decreased significantly from 137/81 to 125/75 mm Hg after three months ($P < 0.05/P < 0.05$) and to 124/77 mm Hg after 12 months ($P < 0.05/P$ value not significant) of treatment with losartan and HCTZ.</p> <p>There were significant decreases in SBP during the daytime, nighttime and early morning after 12 months in both groups.</p> <p>No adverse changes in the indices of glucose or lipid metabolism were observed in either group.</p> <p>Secondary: Not reported</p>
<p>Hilleman et al.⁹⁴ (1999)</p> <p>Amlodipine-benazepril (fixed-dose combination)</p> <p>vs</p> <p>monotherapy (atenolol, HCTZ, captopril, enalapril, lisinopril, amlodipine, diltiazem, nifedipine, verapamil)</p>	<p>MA</p> <p>Patients with mild-to-moderate essential hypertension</p>	<p>82 trials</p> <p>≥ 4 weeks</p>	<p>Primary: Absolute change in supine DBP from baseline</p> <p>Secondary: Percent of patients who achieved blood pressure control, safety</p>	<p>Primary: The mean absolute decrease in supine DBP ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least. When studies were weighted by sample size, amlodipine and benazepril, atenolol, lisinopril, and verapamil showed the greatest blood pressure effect.</p> <p>Secondary: The average percentage of patients defined as controlled after treatment varied from 53.5 to 79.0%, with amlodipine and benazepril (74.3%) and lisinopril (79.0%) showing the highest percentage control ($P = 0.096$).</p> <p>The incidence of adverse events ranged from 12.1 to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% and 14.1%, respectively) and nifedipine the highest incidence. Lisinopril demonstrated significantly less overall side effects compared to nifedipine ($P = 0.030$).</p> <p>Nifedipine demonstrated a higher withdrawal rate due to side effects compared to atenolol, HCTZ, enalapril, amlodipine, and diltiazem</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				(P=0.002). Although amlodipine and benazepril had the lowest rate of withdrawals due to adverse events, lack of significant change was due to the low number of cohorts available for analysis.
Jamerson et al. ⁹⁵ (2007) ACCOMPLISH Amlodipine 5 mg QD plus benazepril 20 mg QD vs benazepril 20 mg QD plus HCTZ 12.5 mg QD	DB, MC, RCT Patients >60 years of age with HTN and at high risk of cardiovascular events	N=10,704 Analysis performed at 6 months (complete trial duration 5 years)	Primary: Changes in mean SBP from baseline to 6 months, blood pressure control rates (SBP/DBP <140/90 mm Hg or <130/89 mm Hg for patients with diabetes and chronic kidney disease) Secondary: Not reported	Primary: At baseline, 97% of subjects were treated with antihypertensive medications at entry, but only 37% of participants had blood pressure control. Mean blood pressure fell from 145/80 to 132/74 mm Hg after six months of treatment with either combination regimen (P<0.001). The six month blood pressure control rate was 73% in the overall trial (78% in the United States), 43% in diabetics, and 40% in patients with renal disease. Of the patients uncontrolled, 61% were not on maximal medications. Secondary: Not reported
Malacco et al. ⁹⁶ (2002) Amlodipine and benazepril 5-10 mg QD (fixed-dose combination product) vs captopril and HCTZ 50-25 mg QD (fixed-dose combination product)	DB, MC, RCT Patients with mild to moderate arterial HTN (sitting DBP >95 mm Hg and/or SBP >160 mm Hg) inadequately controlled by monotherapy with an ACE inhibitor, calcium-channel blocking agent or diuretic	N=397 12 weeks	Primary: Reduction in sitting DBP and SBP Secondary: Percentage of patients responding to therapy (DBP<90 mm Hg, reduction in DBP ≥10 mm Hg or SBP ≥20 mm Hg, or SBP <150 mm Hg)	Primary: Significantly lower sitting DBP (-2.7 mm Hg; P<0.001) and SBP (-3.7 mm Hg; P<0.001) were achieved with amlodipine and benazepril compared to captopril and HCTZ. Secondary: Significantly more amlodipine and benazepril patients responded to therapy (94.8%) compared to captopril and HCTZ (86.0%; P=0.004). No differences in adverse events were reported between the two treatment groups.
Kereiakes et al. ⁹⁷ (2007)	DB, DD, MC, PG, RCT	N=190	Primary: Change in mean	Primary: Patients treated with olmesartan and HCTZ experienced significantly

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Benazepril 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then benazepril 20 mg/day plus amlodipine 5 mg/day for 4 weeks, then benazepril 20 mg/day plus amlodipine 10 mg/day for 4 weeks</p> <p>vs</p> <p>olmesartan 20 mg/day for 2 weeks, then 40 mg/day for 2 weeks then olmesartan and HCTZ 40-12.5 mg/day for 4 weeks increased to 40-25 mg for 4 weeks</p>	<p>Patients with stage 2 HTN</p>	<p>12 weeks</p>	<p>seated SBP at the end of week 12</p> <p>Secondary: DBP at the end of week 12, percent of patients attaining blood pressure goals of <140/90, <130/85, and <130/80 mm Hg</p>	<p>greater reductions in mean seated SBP at week 12 than patients treated with benazepril plus amlodipine (least square mean change, -32.5 vs -26.5 mm Hg; P=0.024; least square mean treatment difference, -6.0 mm Hg; 95% CI, -11.1 to -0.8).</p> <p>Secondary: The least square mean change for reduction in DBP approached statistical significance with olmesartan and HCTZ compared to benazepril plus amlodipine at week 12 (P=0.056).</p> <p>The percentage of patients achieving goal rates at the end of the study for olmesartan and HCTZ and benazepril plus amlodipine were 66.3 and 44.7% (P=0.006) for <140/90 mm Hg, 44.9 vs 21.2% (P=0.001) for <130/85 mm Hg, and 32.6 and 14.1% (P=0.006) for <130/80 mm Hg.</p> <p>Both treatments were well tolerated.</p>
<p>Tatti et al.⁹⁸ (1998) FACET</p> <p>Amlodipine 10 mg QD</p>	<p>OL, PRO, RCT</p> <p>Men and women, diagnosed with HTN (SBP >140 mm Hg or DBP >90 mm Hg) and non-</p>	<p>N=380</p> <p>Up to 3.5 years</p>	<p>Primary: Blood pressure</p> <p>Secondary: Fasting serum glucose, serum creatinine, plasma</p>	<p>Primary: Both treatment groups significantly lowered SBP and DBP from baseline (P<0.05).</p> <p>SBP was lower in the amlodipine group by 4 mm Hg than in the fosinopril group (P<0.01). There was no difference in DBP, both groups decreased by 8 mm Hg.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>fosinopril 20 mg QD</p> <p>If blood pressure was not controlled on monotherapy, the other study drug was added.</p>	<p>insulin dependent diabetes</p>		<p>insulin, HbA_{1c}, TC, HDL-C, TG, fibrinogen, microalbuminuria</p>	<p>Amlodipine was added by 30.7% of the fosinopril group and fosinopril was added by 26.2% of the amlodipine group (P>0.1).</p> <p>Secondary: No difference between the groups was found for serum creatinine, HbA_{1c}, and triglycerides at the endpoint (P>0.05).</p> <p>Fasting serum glucose, serum insulin and microalbuminuria were significantly lower at endpoint for both groups but not significantly different from each other (P>0.05).</p> <p>Total cholesterol increased in both groups, and high-density lipoprotein cholesterol increased significantly in the fosinopril group (P<0.05).</p> <p>No difference in fibrinogen levels was observed between the groups at the end of the trial (P>0.05).</p>
<p>Miranda et al.⁹⁹ (2008)</p> <p>Amlodipine 2.5 to 10 mg and ramipril 2.5 to 10 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 10 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Adults 40 to 79 years of age with stage 1 or 2 essential HTN</p>	<p>N=222</p> <p>18 weeks</p>	<p>Primary: Change in SBP and DBP</p> <p>Secondary: Safety and tolerability</p>	<p>Primary: The mean changes in ambulatory BP were greater with amlodipine and ramipril compared to amlodipine monotherapy (SBP, -20.21 vs -15.31 mm Hg and DBP, -11.61 vs -8.42 mm Hg, respectively; both, P=0.002]. There was no significant difference among the treatment groups in office BP (SBP, -26.60 vs -22.97 mm Hg and DBP, -16.48 vs -14.48 mm Hg; both, P value not significant).</p> <p>Secondary: Twenty-nine patients (22.1%) treated with combination therapy and 41 patients (30.6%) treated with monotherapy experienced ≥1 adverse event considered possibly related to study drug. The combination-therapy group had lower prevalence of edema (7.6 vs 18.7%; P=0.011) and a similar prevalence of dry cough (3.8 vs 0.8%; P value not significant).</p>
<p>Fogari et al.¹⁰⁰ (2007)</p> <p>CANDIA</p> <p>Amlodipine 10 mg QD</p>	<p>DB, MC, RCT</p> <p>Patients, 20 to 80 years old, with mild to moderate uncomplicated HTN</p>	<p>N=203</p> <p>8 weeks</p>	<p>Primary: Decrease in DBP</p> <p>Secondary: Sitting SBP, reduction of the</p>	<p>Primary: There was no significant difference in the mean decrease in DBP between treatment groups; the difference in final DBP was -0.02 mm Hg (95% CI, -1.48 to 1.52f; P=0.979).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs candesartan 16 mg and HCTZ 12.5 mg QD	not controlled on monotherapy with an antihypertensive (SBP <180 mm Hg and DBP 90 to 110 mm Hg)		orthostatic blood pressure at least two minutes after standing, change in heart rate, percentage of patients normalized (DBP <90 mm Hg and SBP <140 mm Hg), percentage of responders (reduction in DBP \geq 5 mm Hg)	<p>There was no significant difference between the groups at week eight for the following: sitting SBP (P=0.835), heart rate (P<0.500), orthostatic SBP (P=0.883), orthostatic DBP (P=0.264), percentage of patients normalized (P=10), percentage of responders (P=0.900).</p> <p>The number of patients reporting an adverse event was greater in the amlodipine group (P=0.001).</p> <p>The number of patients reporting an adverse drug-related event was greater in the amlodipine group (P<0.001).</p> <p>Changes in blood chemistry and other secondary measurements were not significantly different between the treatment groups.</p>
Ribeiro et al. ¹⁰¹ (2007) LAMHYST Amlodipine 5 to 10 mg QD vs losartan 50 to 100 mg QD	DB, DD, RCT Males and females, age 18 to 79 years old, with diagnosis of mild (>95 mm Hg but <115 mm Hg) to moderate essential HTN and not taking an antihypertensive medication (within last 4 weeks)	N=194 12 weeks	Primary: Difference between treatment groups in mean change in ABPM for last 9 hours of treatment and during drug holiday Secondary: Not reported	<p>Primary: After 12 weeks, mean reductions in SBP were significantly larger in the amlodipine group than the losartan group (-18.1 vs -10.1 mm Hg; P<0.001). Mean reductions in DBP were significantly larger in the amlodipine group than the losartan group (-18.1 vs -10.1 mm Hg; P<0.05).</p> <p>Mean increases in SBP were similar between the groups during the two day drug holiday (P>0.05).</p> <p>After the two day drug holiday, SBP was lower than baseline in both groups (P<0.001), with the amlodipine group SBP remaining significantly lower (P<0.01).</p> <p>Mean increases in DBP were similar between the groups during the two day drug holiday (P>0.05). After the two day drug holiday, DBP was lower than baseline in both groups (P=0.0001), with the amlodipine group DBP remaining significantly lower (P<0.05).</p> <p>Secondary: Not reported</p>
Oparil et al. ¹⁰² (1996)	DB, DD, MC, RCT Patients with HTN	N=900 12 weeks	Primary: Efficacy, tolerability, effects	Primary: DBP reductions after 4, 8, and 12 weeks of therapy were clinically comparable (losartan group: 7.3, 10.4, and 11.1 mm Hg, respectively;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>losartan 50 to 100 mg QD</p> <p>If goal DBP (≤ 90 mm Hg) was not attained, drug doses could be doubled and/or HCTZ mg was added.</p>			<p>on QOL</p> <p>Secondary: Not reported</p>	<p>amlodipine group: 7.9, 11.2, and 11.8 mm Hg, respectively; P value not significant).</p> <p>Similar reductions in SBP were seen for both treatment groups (P value not significant).</p> <p>The percentage of patients reaching goal DBP (≤ 90 mm Hg) or DBP ≥ 90 mm Hg with a ≥ 10 mm Hg decrease from baseline) was comparable for the two groups, with 68% of patients in the losartan group and 71% of patients in the amlodipine group reaching goal.</p> <p>Significantly more patients in the amlodipine group had drug-related adverse experiences (27 vs 13%; P=0.029). Edema was more common in patients receiving the amlodipine regimen than in those receiving the losartan regimen (11 vs 1%; P=0.004).</p> <p>Overall QOL was not different in the two treatment groups.</p> <p>Secondary: Not reported</p>
<p>Chrysant et al.¹⁰³ (2008) COACH</p> <p>Amlodipine 5 to 10 mg QD and olmesartan 10 to 40 mg</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>olmesartan 10 to</p>	<p>DB, MC, PC, RCT</p> <p>Patients, age 18 years and older, with seated DBP of 95 to 120 mm Hg</p>	<p>N=1,940</p> <p>8 weeks</p>	<p>Primary: Change from baseline in seated DBP at week 8</p> <p>Secondary: Change from baseline in seated SBP at week 8; mean change from baseline in seated DBP and SBP at weeks 2, 4, 6 and 8 without last observation carried forward; proportion of</p>	<p>Primary: All active treatments and placebo resulted in significant decreases in seated DBP at week eight (P<0.001). Reductions in seated DBP with monotherapy treatment ranged from -8.3 to -12.7 mm Hg; reductions with combination therapy ranged from -13.8 to -19.0 mm Hg. All combinations reduced seated DBP significantly greater than either component as monotherapy at the same dosage (P<0.001).</p> <p>Secondary: All active treatments and placebo resulted in significant decreases in seated SBP at week eight (P<0.001 for treatment, P=0.024 for placebo). All combinations reduced seated SBP significantly greater either component as monotherapy at the same dosage (P<0.001).</p> <p>The proportion of patients achieving goal blood pressures were: 20.0 to 36.3% of patients receiving olmesartan monotherapy, 21.1 to 32.5% of patients receiving amlodipine monotherapy, 35.0 to 53.2% of patients</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>40 mg QD vs placebo</p>			<p>patients achieving blood pressure goal (<140/90 mm Hg or <130/80 mm Hg); safety</p>	<p>receiving combination therapy, and 8.8% of patients receiving placebo.</p> <p>Combination therapy resulted in significantly greater achievement of goal blood pressure than monotherapy (P<0.005).</p> <p>No difference in overall rates of adverse events across the different treatment groups was seen. Nearly 27% of patients experienced a drug-related adverse event.</p> <p>Changes in laboratory values were not considered clinically significant nor followed a consistent pattern with treatment: none of the changes were considered clinically significant. Platelet counts increased significantly from baseline (statistically) for patients receiving amlodipine, however the increase was <10% and not deemed clinically relevant.</p>
<p>Chrysant et al.¹⁰⁴ (2009) COACH</p> <p>Amlodipine 5 to 10 mg QD and olmesartan 10 to 40 mg</p> <p>HCTZ 12.5 to 25 mg could be added if blood pressure was not controlled (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes).</p>	<p>OL, ES</p> <p>Patients ≥ 18 years of age with essential HTN (seated DBP ≥95 and <120 mm Hg)</p>	<p>N=1,684</p> <p>44 weeks OL therapy (52 weeks total study duration including 8 week DB phase)</p>	<p>Primary: Reduction in mean sitting SBP DBP, change in mean sitting SBP and DBP, percentage of patients achieving blood pressure goal (<140/90 mm Hg or <130/80 mm Hg for patients with diabetes)</p>	<p>Primary: Mean sitting DBP decreased from 101.5 mm Hg at baseline to 81.9 mm Hg and mean sitting SBP decreased from 163.6 mm Hg at baseline to 131.2 mm Hg at week 52.</p> <p>Approximately 31% of patients remained on amlodipine 5 mg and olmesartan 40 mg. Increasing the dose of amlodipine to 10 mg in combination with olmesartan 40 mg produced further decreases in mean sitting DBP of 4.8 mm Hg and mean sitting SBP of 7.3 mm Hg. Addition of HCTZ 12.5 mg to amlodipine 10 mg and olmesartan 40 mg decreased mean sitting DBP by 4.5 mm Hg and mean sitting SBP by 7.7 mm Hg. Doubling the HCTZ dose from 12.5 to 25 mg decreased mean sitting DBP and mean sitting SBP by an additional 6.0 mm Hg and 9.9 mm Hg, respectively. Patients who received the triple therapy had the greatest mean sitting SBP reduction (36.1 mm Hg).</p> <p>Approximately 67% of patients achieved blood pressure goal by week 52. The blood pressure goal achievement was 80% for amlodipine and olmesartan 5/40 mg, 70.6% for amlodipine and olmesartan 10/40 mg, 66.6% for amlodipine and olmesartan and HCTZ 10/40/12.5 mg, and 46.3% for amlodipine and olmesartan and HCTZ 10/40/25 mg.</p> <p>The addition of HCTZ 25 mg enabled more patients to achieve blood</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>pressure targets of <140/90 mm Hg (77.7%), <130/85 mm Hg (47.5%), and <130/80 mm Hg (36.4%) compared to the other treatment regimens.</p> <p>No major safety issues emerged with long-term therapy. The frequency of edema ranged from 8.9% in patients treated with amlodipine 5 mg and olmesartan 40 mg to 14.5% in patients treated with amlodipine 10 mg and olmesartan 40 mg plus HCTZ 25 mg. Other treatment-emergent adverse events experienced by ≥3% of patients included upper respiratory tract infection (6.5%), nasopharyngitis (5.2%), extremity pain (4.1%), sinusitis (3.6%), arthralgia (3.3%), and back pain (3.1%). headache (2.0%), hypotension (1.8%), and fatigue (1.6%). The incidence of cough was 0.4%.</p>
<p>Oparil et al.¹⁰⁵ (2009) COACH</p> <p>Amlodipine 5 to 10 mg QD and olmesartan 10 to 40 mg</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>olmesartan 10 to 40 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, factorial, MC, PC, RCT</p> <p>Patients ≥18 years of age with seated DBP 95 to 120 mm Hg, with a subgroup analysis based on HTN (stage 1: SBP 140 to 159 mm Hg or DBP 90 to 99 mm Hg; stage 2: SBP ≥160 mm Hg or DBP ≥100 mm Hg) and no prior antihypertensive medication</p>	<p>N=1,940</p> <p>8 weeks</p>	<p>Primary: Mean change in DBP and SBP at week 8 for each subgroup</p> <p>Secondary: Proportion of patients achieving blood pressure goal (<140/90 mm Hg or <130/80 mm Hg)</p>	<p>Primary: Reductions in mean DBP as a result of combination treatment were similar between subgroups. Patients with stage 1 HTN achieved reductions of 14.8 to 15.8 mm Hg and patients with stage 2 HTN achieved reductions of 13.6 to 19.8 mm Hg. Reductions in mean SBP as a result of combination treatment resulted in greater reductions in patients with stage 2 HTN (25.1 to 32.7 mm Hg) compared to stage 1 HTN (17.7 to 23.7 mm Hg) (P value not reported).</p> <p>Reductions in mean DBP and SBP were similar between those with no prior antihypertensive treatment and those with prior hypertensive treatment.</p> <p>Secondary: The proportion of patients with stage 1 HTN who received combination treatment and achieved blood pressure goal was 65.6 to 80.0%, compared to 40.5 to 66.7% of those who received monotherapy (P<0.0001 across treatments).</p> <p>The proportion of patients with stage 2 HTN who received combination treatment and achieved BP goal was 40.5 to 49.2%, compared to 13.1 to 29.2% of those who received monotherapy (P<0.0001).</p> <p>Results of patients with baseline SBP ≥180 mm Hg were similar to other subgroups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Braun et al (abstract).¹⁰⁶ (2009)</p> <p>Amlodipine 10 mg plus olmesartan 20 mg QD</p> <p>If patients were uncontrolled after 4 weeks, they were changed to amlodipine and valsartan 10-160 mg QD.</p>	<p>OL, PRO</p> <p>Patients with DBP 100 to 109 mm Hg</p>	<p>N=257</p> <p>8 weeks</p>	<p>Primary: Reduction in SBP and DBP</p> <p>Secondary: Adverse events</p>	<p>Primary: Following treatment with amlodipine and olmesartan, SBP/DBP decreased by 19.2±12.4/14.4±7.4 mm Hg.</p> <p>The number of patients who progressed to treatment with amlodipine and valsartan was 175. Additional reductions in SBP of 7.9 mm Hg and DBP of 3.9 mm Hg were seen (P<0.0001 for both).</p> <p>Secondary: Both treatments were well tolerated and reported adverse events were consistent with drug profiles.</p>
<p>Littlejohn et al.¹⁰⁷ (2009)</p> <p>Amlodipine 2.5 to 10 mg QD and telmisartan 20 to 80 mg QD</p> <p>vs</p> <p>telmisartan 20 to 80 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients ≥18 years of age with Stage 1 or 2 HTN (DBP ≥95 and ≤119 mm Hg)</p>	<p>N=2,607</p> <p>8 weeks</p>	<p>Primary: Change in the in-clinic seated diastolic BP</p> <p>Secondary: Change in the in-clinic seated SBP, DBP and SBP response (DBP <90 mm Hg, decrease in DBP ≥10 mm Hg, SBP <140 mm Hg, decrease in SBP ≥15 mm Hg), and BP control (DBP <90 mm Hg and SBP <140 mm Hg)</p>	<p>Primary: Both telmisartan (irrespective of amlodipine dosage; P<0.0001) and amlodipine (irrespective of telmisartan dosage; P<0.0001) significantly lowered the in-clinic DBP.</p> <p>The greatest reduction in blood pressure was with telmisartan 80 mg plus amlodipine 10 mg (SBP/DBP -26.4/-20.1 mm Hg; P<0.05 vs both monotherapies).</p> <p>DBP and SBP response was achieved by 91.2 and 90.4% of patients in the telmisartan 80 mg plus amlodipine 10 mg group, respectively.</p> <p>More than 50% of patients treated with combination therapy achieved blood pressure control, with the highest percentages (76.5% [overall control] and 85.3% [DBP control]) being achieved by patients treated with telmisartan 80 mg plus amlodipine 10 mg.</p> <p>A total of 37.3% of patients reported at least one adverse event. The most commonly reported adverse events were headache (5.4%) and peripheral edema (4.4%). Headache was more frequent in the placebo group (10.9%) compared to the telmisartan monotherapy (5.9%), amlodipine monotherapy (6.0%), and combination therapy (4.7%). The incidence of</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				peripheral edema was highest in the amlodipine 10 mg group (17.8%); however, this rate was lower when amlodipine was used in combination with telmisartan: 11.4% (telmisartan 20 mg and amlodipine 10 mg), 6.2% (telmisartan 40 mg and amlodipine 10 mg), and 11.3% (telmisartan 80 mg and amlodipine 10 mg).
<p>Littlejohn et al.¹⁰⁸ (2009)</p> <p>Telmisartan and amlodipine 40-5 mg QD (fixed-dose combination product)</p> <p>Vs</p> <p>telmisartan and amlodipine 40-10 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan and amlodipine 80-5 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan and amlodipine 80-10 mg QD (fixed-dose combination product)</p>	<p>DB, DD, MC, PC, PG, RCT</p> <p>Patients ≥18 years of age with stage 1 or 2 HTN (DBP ≥95 and ≤119 mm Hg), with a subgroup analysis including patients with DBP ≥100 mm Hg at baseline</p>	<p>N=1,078</p> <p>8 weeks</p>	<p>Primary: Change in DBP from baseline to study end point</p> <p>Secondary: Change from baseline to study end in SBP; percent of patients achieving a DBP response (DBP <90 mm Hg) and SBP response (SBP <140 mm Hg or reduction from baseline ≥15 mm Hg); percent of patients achieving BP control (SBP/DBP <140/<90 mm Hg) and DBP control (<90 mm Hg) and safety</p>	<p>Primary: Significant reductions in DBP were seen from baseline to study end for both dual therapy and monotherapy (P values not reported).</p> <p>Amlodipine 5 and 10 mg with telmisartan 40 and 80 mg significantly reduced DBP compared to respective monotherapies (P values not reported).</p> <p>Secondary: Amlodipine 5 and 10 mg with telmisartan 40 and 80 mg significantly reduced SBP compared to respective monotherapies (P values not reported).</p> <p>Combination therapy resulted in a greater DBP and SBP response than monotherapy (P values not reported).</p> <p>The highest rate of BP control was achieved with amlodipine 10 mg with telmisartan 80 mg.</p> <p>Rates of adverse events were similar between dual therapy and monotherapy. Incidences of adverse events were 4.40% with telmisartan monotherapy, 11.00% with amlodipine monotherapy and 11.75% with combination therapy. The most commonly reported events were headache and peripheral edema. Patients receiving amlodipine 10 mg had the highest incidence of peripheral edema; however rates were lower when amlodipine was used in combination with telmisartan.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
product) vs respective monotherapies, dosing frequency not specified				
Sharma et al. ¹⁰⁹ (2007) Telmisartan and amlodipine 40-5 mg QD (fixed-dose combination) vs amlodipine 5 mg QD	DB, MC, RCT Patients 18 to 65 years of age with established stage 2 uncomplicated essential HTN	N=210 12 weeks	Primary: SBP/DBP reductions and responder rates (SBP/DBP <130/<80 mm Hg) Secondary: Not reported	Primary: There was a significant reduction from baseline in mean SBP in both groups (telmisartan and amlodipine, from 176.3 to 128.0 mm Hg; amlodipine, from 171.8 to 143.4 mm Hg; both, P<0.05 vs baseline). There was a significant reduction in SBP from baseline in the telmisartan and amlodipine and amlodipine groups (-27.4 and -16.6%, respectively; P<0.05 within group and between groups). There was a significant reduction from baseline in mean DBP in both treatment groups (telmisartan and amlodipine, from 100.9 to 93.8 mm Hg; amlodipine, from 99.7 to 94.3 mm Hg; both, P<0.05). There was a 20.2% reduction in mean DBP in the telmisartan and amlodipine group, which was significantly greater compared to the reduction of 12.7% observed in the amlodipine group (P<0.05 between groups and within both groups). A total of 87.3% of patients receiving telmisartan and amlodipine reached the target SBP/DBP goal, compared to 69.3% of patients receiving amlodipine (P<0.05). A total of 16.0% of patients in the telmisartan and amlodipine group experienced adverse events compared to 15.4% of patients in the amlodipine group (P value not significant). The most common adverse events in the telmisartan and amlodipine group were peripheral edema (8.5%), headache (5.7%), dizziness and cough (3.8%), and diarrhea (1.9%). Secondary: Not reported
Neutel et al. ¹¹⁰	DB, MC, PG, RCT	N=858	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2012) TEAMSTA</p> <p>Telmisartan and amlodipine 80-10 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan 80 mg QD</p> <p>vs</p> <p>amlodipine 10 mg QD</p>	<p>Patients \geq18 years of age with severe HTN</p>	<p>8 weeks</p>	<p>Change in baseline blood pressure, blood pressure goal and response rates</p> <p>Secondary: Safety</p>	<p>Reductions in seated trough cuff blood pressure (-47.5/-18.7 mm Hg) were significantly greater with combination therapy compared to telmisartan ($P<0.001$) or amlodipine ($P=0.002$). Significant reductions with combination therapy were observed at one, two, four, and six weeks.</p> <p>Blood pressure goal and response rates were consistently higher with combination therapy (50.4 and 91.4 to 99.7%) compared to monotherapy with either agent (24.1 and 69.3 to 91.5% and 35.6 and 83.9 to 98.5%).</p> <p>Secondary: Combination therapy was well tolerated and fewer adverse events were reported with combination therapy compared to amlodipine (12.6 vs 16.4%). Peripheral edema was reported more frequently with amlodipine compared to combination therapy (13.2 vs 9.3%).</p>
<p>Maciejewski et al.¹¹¹ (2006)</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>valsartan 80 to 160 mg QD</p> <p>If blood pressure exceeded 140/90 while on highest treatment dose, HCTZ 12.5mg/day was added to the regimen.</p>	<p>DB, PRO, RCT, XO</p> <p>African-Americans, older than 35 years, with baseline blood pressure $>140/90$ mm Hg and not on antihypertensive treatment</p>	<p>N=20</p> <p>8 to 10 weeks for each arm with 2 week washout period before crossover</p>	<p>Primary: Comparison of 24-hr ABPM recordings</p> <p>Secondary: Magnitude of change from baseline in SBP and DBP with each treatment, percent of patients who achieved goal $<140/<90$ with each treatment based on clinic blood pressure measurements</p>	<p>Primary: There was no difference between the groups based on 24-hr ABPM: SBP amlodipine 130 ± 8 vs valsartan 127 ± 17 ($P=0.350$) and DBP amlodipine 82 ± 5 vs valsartan 84 ± 16 ($P=0.430$).</p> <p>Secondary: There was no difference between groups in magnitude of change from baseline in blood pressure (amlodipine $-25\pm 8/-18\pm 7$ vs valsartan $-25\pm 9/-16\pm 7$; $P=0.61$), and in percent of patients achieving goal blood pressure, 70% in the valsartan group and 75% in the amlodipine group ($P=0.62$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Ichihara et al.¹¹² (2006)</p> <p>Amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>valsartan 40 to 160 mg QD</p>	<p>RCT</p> <p>Patients with untreated HTN (clinic SBP >140 mm Hg and/or DBP >90 mm Hg; or ABPM SBP >135 mm Hg and/or DBP >98 mm Hg)</p>	<p>N=100</p> <p>12 months</p>	<p>Primary: ABPM and clinic blood pressure</p> <p>Secondary: Pulse wave velocity, carotid intima-media thickness, urinary albumin excretion</p>	<p>Primary: Both treatments resulted in significant decreases in blood pressure, both ambulatory and clinic, over 12 months from baseline; blood pressure decreases were similar between treatment groups (between treatments: clinic SBP P=0.34; clinic DBP P=0.85; 24 hour ABPM P=0.14).</p> <p>Blood pressure variability decreased significantly in the amlodipine group compared to the valsartan group, where there was no change in blood pressure variability (P<0.01).</p> <p>Secondary: The decrease in pulse wave velocity was significant from baseline for both groups, but not significantly different from each other (P<0.05 from baseline).</p> <p>Intima-media thickness was not changed significantly from baseline for either treatment (P>0.05 for both from baseline).</p> <p>Urinary albumin excretion in the valsartan group decreased significantly both from baseline and compared to amlodipine treatment (P<0.05 from baseline, P value for comparison not reported).</p>
<p>Karpov et al.¹¹³ (2012)</p> <p>Amlodipine and valsartan 5-80, 5-160, 10-160 mg QD (fixed-dose combination product)</p>	<p>OL, OS, PRO</p> <p>Patients with HTN</p>	<p>N=8,336</p> <p>3 months</p>	<p>Primary: Baseline reductions in blood pressure, blood pressure control (<140/90 mm Hg)</p> <p>Secondary: Safety</p>	<p>Primary: Reductions in blood pressure were dose related. Overall, mean reductions in blood pressure ranged from 165.0/99.3 mm Hg at baseline to 128.7/80.4 mm Hg at 12 weeks (-36.3/-18.9 mm Hg; P<0.0001).</p> <p>A total of 77.7% of patients achieved blood pressure control.</p> <p>Secondary: A total of 5.3% of patients reported adverse events. The incidence of edema declined from 10.4% at baseline to 8.5% at trial end.</p>
<p>Philipp et al.¹¹⁴ (2007)</p> <p><u>Study 1</u></p> <p>Amlodipine 2.5 to 5 mg and valsartan</p>	<p>DB, MC, PC, RCT</p> <p>Males and females, ages 18 years and older with HTN (mean sitting DBP</p>	<p>N=1,911</p> <p>8 weeks</p>	<p>Primary: Mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP,</p>	<p>Primary: All treatments significantly decreased mean sitting DBP from baseline (P<0.05).</p> <p>Combination treatment resulted in significantly greater blood pressure reduction than either monotherapy (P<0.05 for all combinations compared</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>40 to 320 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 5 mg QD</p> <p>vs</p> <p>valsartan 40 to 320 mg QD</p> <p>vs</p> <p>placebo</p>	<p>≥95 mm Hg and <110 mm Hg)</p>		<p>response rate (proportion of patients with mean sitting DBP <90 mm Hg or a ≥10 mm Hg reduction from baseline), control rate (proportion of patients with mean sitting DBP <90 mm Hg), adverse events (combined with study 2)</p>	<p>to respective doses of monotherapy except amlodipine 2.5 mg and valsartan 40 mg QD).</p> <p>Secondary: All treatments significantly decreased mean sitting SBP from baseline (P<0.05).</p> <p>Combination treatment resulted in significantly greater blood pressure reduction than either monotherapy (P<0.05 for all combinations compared to respective doses of monotherapy).</p> <p>Response rates were significantly different from placebo for all treatment groups (P<0.05).</p> <p>Response rates for combination products were significantly different than each monotherapy for the following combinations: amlodipine 5 mg plus valsartan 80 mg, amlodipine 5 mg plus valsartan 40 mg and amlodipine 2.5 mg plus valsartan 80 mg (P<0.05 for each combination compared to both monotherapy).</p> <p>Response rates for all combinations produced significantly improved compared to either one of the monotherapies except amlodipine 2.5 mg plus valsartan 40 mg (P<0.05 for each combination compared to one of the respective monotherapy).</p> <p>Control rates with therapy were significantly better than placebo, with the highest control rate achieved with amlodipine 5 mg plus valsartan 320 mg (P<0.05 compared to placebo, P value not reported for others).</p> <p>Adverse event rates were not significantly different among combination treatment, amlodipine treatment, and placebo.</p> <p>Adverse event rates were significantly different between amlodipine plus valsartan and valsartan monotherapy (P<0.05).</p> <p>The most commonly reported adverse events for combination treatment were: peripheral edema, headache, nasopharyngitis, upper respiratory tract</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				infection and dizziness. Peripheral edema occurred significantly less frequently in the combination treatment group than the amlodipine monotherapy group (5.4 vs 8.7%; P=0.014) and significantly more frequently than in the valsartan monotherapy group (5.4 vs 2.1%; P<0.001). Peripheral edema occurrence in the valsartan group was similar to the rate in the placebo group.
<p>Philipp et al.¹¹⁵ (2007)</p> <p><u>Study 2</u> Amlodipine 10 mg and valsartan 160 or 320 mg QD</p> <p>vs</p> <p>amlodipine 10 mg QD</p> <p>vs</p> <p>valsartan 160 to 320 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Male and females, ages 18 years and older with hypertension (mean sitting DBP \geq95 mm Hg and <110 mm Hg)</p>	<p>N=1,250</p> <p>8 weeks</p>	<p>Primary: Mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, response rate (proportion of patients with mean sitting DBP <90 mm Hg or a \geq10 mm Hg reduction from baseline), control rate (proportion of patients with mean sitting DBP <90 mm Hg), adverse events (combined with study 1)</p>	<p>Primary: Mean sitting DBP was significantly reduced for both combination as compared to the individual components and to placebo (P<0.05).</p> <p>Secondary: Response rates and control rates for combination treatments were significantly greater than valsartan monotherapy therapy and placebo therapy, but not different from amlodipine monotherapy (P<0.05).</p> <p>Adverse event rates were not significantly different between combination treatment, amlodipine treatment and placebo.</p> <p>Adverse event rates were significantly different between amlodipine plus valsartan and valsartan monotherapy (P<0.05).</p>
<p>Philipp et al (abstract).¹¹⁶ (2011)</p> <p>Amlodipine and valsartan 10-160 or 10-320 mg/day (fixed-dose combination product)</p>	<p>Post-hoc analysis</p> <p>Patients with HTN</p>	<p>N=834</p> <p>Not reported</p>	<p>Primary: Rate of blood pressure control (<140/90 mm Hg), change in baseline blood pressure</p> <p>Secondary: Safety</p>	<p>Primary: Two weeks after starting therapy, blood pressure control rates were greater with amlodipine and valsartan 10-320 mg/day (49%) vs monotherapies (32 to 38%) and placebo (16%). Consistent results were observed in patients with stage 1 and 2 HTN. Among patients receiving combination therapy, statistically significant differences were observed at endpoint vs comparators. At all baseline blood pressure levels, the probability of achieving a blood pressure <140/90 or <130/80 mm Hg was greater with combination therapy compared to monotherapies and placebo.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs amlodipine 10 mg/day vs valsartan 160 or 320 mg/day vs placebo				Secondary: Overall adverse events incidence was similar with combination therapy vs monotherapies and placebo.
Schunkert et al. ¹¹⁷ (2009) Amlodipine and valsartan 10-160 mg QD (fixed-dose combination product) vs amlodipine 10 mg QD	RCT, MC, DB, AC Patients ≥18 years of age with mild to moderate essential HTN (mean sitting DBP ≥90 mm Hg and <110 mm Hg) who were inadequately controlled on amlodipine 10 mg	N=944 8 weeks	Primary: Change from baseline in mean sitting DBP Secondary: Change from baseline in mean sitting SBP, responder rate (mean sitting DBP <90 mm Hg or ≥10 mm Hg reduction from baseline) and DBP control rate (mean sitting DBP <90 mm Hg)	Primary: At week eighth, a significantly greater reduction from baseline in msDBP was observed with amlodipine and valsartan (11.4 mm Hg) compared to amlodipine monotherapy (9.3 mm Hg; P<0.0001). Secondary: At week eight, a significantly greater reduction from baseline in msSBP was observed with amlodipine and valsartan (12.9 mm Hg) compared to amlodipine monotherapy (10.0 mm Hg; P<0.0001). The mean reductions in mean sitting SBP/mean sitting DBP were 24.4/17.2 and 21.6/15.0 mm Hg for the amlodipine and valsartan and amlodipine monotherapy, respectively The responder rate was significantly greater with amlodipine and valsartan (79.0%) than with amlodipine monotherapy (70.1%; P=0.0011). The percentage of patients with controlled DBP was significantly higher with amlodipine and valsartan (77.8%) compared to amlodipine monotherapy (66.5%; P<0.0001). The incidence of peripheral edema was higher with amlodipine monotherapy (9.4%) compared to amlodipine and valsartan (7.6%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Ke et al.¹¹⁸ (2010)</p> <p>Amlodipine and valsartan 5-80 mg QD (fixed-dose combination)</p> <p>vs</p> <p>amlodipine 5 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Hypertensive patients 18 to 86 years of age with mean sitting DBP ≥ 95 and < 110 mm Hg who were inadequately controlled on amlodipine 5 mg for 4 weeks</p>	<p>N=698</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, diastolic response rate (mean sitting DBP < 90 mm Hg or ≥ 10 mm Hg decrease from baseline), diastolic control rate (mean sitting DBP < 90 mmHg) and overall BP control rate (mean sitting SBP/DBP $< 140/90$ mmHg)</p>	<p>Primary: At week eight, the reduction in mean sitting DBP was greater with amlodipine and valsartan (11.4/9.7 mm Hg) compared to amlodipine (7.4/7.1 mm Hg; $P < 0.0001$).</p> <p>Secondary: At week eight, the diastolic control and response rates were significantly greater in the amlodipine and valsartan compared to amlodipine monotherapy (diastolic control, 75.5 vs. 64.5%; $P = 0.0002$ and response rates, 79.3 vs. 66.8% [$P < 0.0001$], respectively).</p> <p>The proportion of patients achieving overall blood pressure control was greater in the amlodipine and valsartan group compared to amlodipine monotherapy (69.2 vs. 57.6%, $P = 0.0013$). More than 50% of patients not adequately controlled on amlodipine monotherapy achieved blood pressure control after two weeks of therapy with amlodipine and valsartan.</p> <p>In a subgroup of patients, there was a significant reduction in 24-hr mean blood pressure from baseline with amlodipine and valsartan (-7.3/-6.3 mm Hg; $P < 0.0001$). There was no significant difference with amlodipine from baseline (-0.2/+0.3 mm Hg; $P > 0.05$).</p>
<p>Destro et al.¹¹⁹ (2008)</p> <p>Ex-EFFeCTS</p> <p>Amlodipine and valsartan 5-160 mg QD for 2 weeks, followed by 10-160 mg QD for 6 weeks (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine 5 mg</p>	<p>DB, MC, RCT</p> <p>Patients ≥ 18 years of age with stage 2 HTN (mean sitting SBP ≥ 160 mm Hg)</p>	<p>N=646</p> <p>8 weeks</p>	<p>Primary: Mean changes in mean sitting SBP at week 4</p> <p>Secondary: Change from baseline in mean sitting DBP at week 4; change in mean sitting blood pressure at weeks 2, 4, and 8; overall blood pressure control rate at week 8 (mean</p>	<p>Primary: At week four, reductions in mean sitting SBP were significantly greater in patients receiving amlodipine and valsartan (30.1 mm Hg) than in those receiving amlodipine (23.5 mm Hg; $P < 0.0001$).</p> <p>At week four, mean sitting SBP reductions in patients with baseline mean sitting SBP ≥ 180 mm Hg were greater for amlodipine and valsartan (40.1 mm Hg) than for those receiving amlodipine (-31.7 mm Hg; $P = 0.0018$).</p> <p>Secondary: At week four, reductions in mean sitting DBP were significantly greater in patients receiving amlodipine and valsartan (12.5 mm Hg) than in those receiving amlodipine (8.6 mm Hg; $P < 0.0001$) and all other time points (data not provided).</p> <p>At week four, 45.3% of patients were controlled on amlodipine and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD for 2 weeks, followed by 10 mg QD for 6 weeks</p> <p>HCTZ 12.5 mg could be added at week 4 if mean sitting SBP was ≥ 130 mm Hg.</p>			<p>sitting SBP/DBP $< 140/90$ mm Hg)</p>	<p>valsartan compared to 23.8% on amlodipine monotherapy. At week eight, corresponding control rates were 53.0 and 31.1%, respectively ($P < 0.0001$).</p>
<p>Flack et al.¹²⁰ (2009) EX-STAND</p> <p>Amlodipine and valsartan 5-160 mg QD for 2 weeks, followed by 10-160 mg QD for 10 weeks</p> <p>vs</p> <p>amlodipine 5 mg QD for 2 weeks, then 10 mg QD for 10 weeks</p> <p>If SBP was ≥ 130 mm Hg at week 4, amlodipine and valsartan could be titrated to 10-320 mg dose. At week 8, HCTZ 12.5 mg was optionally added to both amlodipine and</p>	<p>AC, DB, MC, RCT</p> <p>African American patients ≥ 18 years of age with stage 2 HTN (mean sitting SBP ≥ 160 and < 200 mm Hg)</p>	<p>N=572</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting SBP from baseline to week 8</p> <p>Secondary: Change in mean sitting SBP from baseline to week 8; change from baseline in mean sitting SBP and DBP after 2, 4, 8 and 12 weeks of treatment; blood pressure control ($< 140/90$ mmHg) after 12 weeks of therapy</p>	<p>Primary: At week eight, treatment with amlodipine and valsartan significantly decreased mean sitting SBP (33.3 mm Hg) compared to amlodipine monotherapy (26.6 mm Hg; $P < 0.0001$).</p> <p>Secondary: Amlodipine and valsartan produced significantly greater reductions in mean sitting DBP from baseline compared to amlodipine monotherapy throughout the study: week two (9.7 vs 6.9 mm Hg; $P = 0.0001$), week four (13.2 vs 10.7 mm Hg; $P = 0.0008$), week eight (14.0 vs 11.2 mm Hg; $P = 0.0002$), and week 12 (16.1 vs 12.8 mm Hg; $P < 0.0001$).</p> <p>At week eight, 49.8% of patients in the amlodipine and valsartan group and 30.2% in the amlodipine monotherapy group had their blood pressure controlled to $< 140/90$ mm Hg (OR, 2.4; $P < 0.0001$). At week 12, 57.2% of patients in the amlodipine and valsartan group and 35.9% in the amlodipine monotherapy group attained blood pressure $< 140/90$ mm Hg (OR, 2.5; $P < 0.0001$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
valsartan and amlodipine if SBP \geq 130 mm Hg.				
Schrader et al. ¹²¹ (2009) Amlodipine and valsartan 5-160 mg QD for 12 weeks (fixed-dose combination product) vs amlodipine 10 mg QD for 8 weeks, followed by amlodipine and valsartan 5-160 mg QD for 4 weeks (fixed-dose combination product)	DB, MC, RCT Hypertensive patients who were \geq 55 years of age with mean sitting SBP \geq 130 and \leq 160 mm Hg who were inadequately controlled on amlodipine 5 mg for 4 weeks	N=1,183 12 weeks	Primary: Change in mean sitting systolic SBP Secondary: Change in mean sitting SBP and DBP, SBP control rate (mean sitting SBP <130 mm Hg), overall blood pressure control rate (blood pressure <140/90 mm Hg for nondiabetic patients and <130/80 mm Hg for diabetic patients), and SBP response (mean sitting SBP <130 mm Hg or \geq 20 mm Hg reduction from baseline)	Primary: At week eight, there was a greater reduction in mean sitting SBP with amlodipine and valsartan (-8.01 mm Hg) than with amlodipine (-5.95 mm Hg; P<0.001 for non-inferiority and P=0.002 for superiority). Secondary: Non-inferiority was also observed at week four (-8.29 vs -6.29; P<0.001) and week eight (-8.23 vs -6.13; P<0.001) in mean sitting SBP, at week 4 (-5.02 vs -4.23; P<0.001) and week eight (-4.70 vs -4.06; P<0.001) in mean sitting DBP, and at week 12 after the switch from amlodipine to amlodipine and valsartan (-9.13 vs -8.16; P<0.001 for mean sitting SBP and -5.52 vs -4.90; P<0.001 for mean sitting DBP). Systolic control with amlodipine and valsartan was greater than with amlodipine at week four (34.98 vs 24.83%; P<0.001) and week eight (34.28 vs 26.21%; P=0.019), and similar after the switch from amlodipine 10 mg to amlodipine and valsartan at week 12 (38.04 vs 31.81%; P=0.162). SBP response rates were higher with amlodipine and valsartan than with amlodipine at week four (37.20 vs 26.72%, P<0.001) and week eight [36.57 vs 27.77%; P=0.009), and similar after the switch from amlodipine to amlodipine and valsartan at week 12 (40.36 vs 35.76%; P=0.347). The incidence of peripheral edema was significantly lower with amlodipine and valsartan than with amlodipine (6.6 vs 31.1%, P<0.001). Peripheral edema resolved in 56% patients who switched from amlodipine and valsartan without the loss of effect on blood pressure reduction.
Sinkiewicz et al. ¹²² (2009) Amlodipine and valsartan 10-160 mg or 5-160 mg	AC, DB, MC, RCT Patients \geq 18 years of age with essential HTN (mean sitting DBP \geq 90 mm Hg)	N=947 8 weeks	Primary: Change from baseline in mean DBP Secondary:	Primary: At week eight, a significantly greater reduction in mean DBP was observed with both amlodipine and valsartan combinations (10-160 mg: -11.5 mm Hg, 5-160 mg: -9.6 mm Hg; P<0.0001 for both) compared to valsartan monotherapy (-6.7 mm Hg).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD (fixed-dose combination product)</p> <p>vs</p> <p>valsartan 160 mg QD</p>	<p>and <110 mm Hg) who were inadequately controlled on valsartan 160 mg</p>		<p>Change from baseline in mean sitting SBP, responder rate (mean DBP <90 mm Hg or ≥10 mm Hg reduction from baseline), and DBP control rate (mean DBP < 90 mm Hg)</p>	<p>Secondary:</p> <p>At week eight, a significantly greater reduction in mean SBP was observed in both amlodipine and valsartan combinations (10-160 mg: -14.3 mm Hg, 5-160 mg: -12.2 mm Hg; P<0.0001 for both) compared to valsartan monotherapy (-8.3 mm Hg).</p> <p>Overall mean SBP/DBP reductions of 22.5/15.5 and 21.3/13.7 mm Hg were observed in the amlodipine and valsartan 10-160 and 5-160 mg treatment groups, respectively compared to 16.7/11.4 mm Hg in the valsartan 160 mg group. The amlodipine and valsartan 10-160 mg combination showed a significantly greater reduction in mean SBP/DBP compared to amlodipine and valsartan 5-160 mg (P<0.001).</p> <p>Responder rates were higher in both amlodipine and valsartan groups (10-160 mg: 81% [P<0.0001]; 5-160 mg: 68% [P=0.0018], respectively) compared to valsartan monotherapy (57%).</p> <p>Peripheral edema was the most frequent adverse event, which was reported in 9.1% of patients receiving amlodipine and valsartan (10-160 mg), 0.9% of patients receiving amlodipine and valsartan (5-160 mg), and 1.3% of patients receiving valsartan monotherapy.</p>
<p>Fogari et al.¹²³ (2009)</p> <p>Amlodipine and valsartan 5 to 10-160 mg/day (fixed-dose combination)</p> <p>vs</p> <p>irbesartan and HCTZ 300-12.5 to 25 mg/day (fixed-dose combination product)</p>	<p>Blind end endpoint, OL, PG, PRO, RCT</p> <p>Patients 75 to 89 years of age with moderate essential HTN (SBP ≥160, DBP >95 to <110 mm Hg)</p>	<p>N=94</p> <p>24 weeks</p>	<p>Primary:</p> <p>Proportion of patients achieving DBP <90 mm Hg</p> <p>Secondary:</p> <p>Changes in ambulatory blood pressure, lying and standing changes in blood pressure, safety</p>	<p>Primary:</p> <p>The proportion of patients receiving valsartan and amlodipine and irbesartan and HCTZ who achieved blood pressure <140/<90 mm Hg was 82.9 and 85.1% (P value not significant between groups).</p> <p>Secondary:</p> <p>Both treatment combinations resulted in a significant decrease in ambulatory blood pressure without any differences between treatment groups (P<0.001 from baseline, P>0.05 between groups).</p> <p>Results were similar between groups for lying SBP/DBP but patients receiving irbesartan and HCTZ experienced greater changes in ambulatory blood pressure than those receiving valsartan and amlodipine (17.2/9.0 vs 10.1/1.9 mm Hg; P<0.05 for SBP and P<0.01 for DBP).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Changes from baseline in serum potassium (decrease) and uric acid (increase) were significant for those receiving irbesartan and HCTZ, but not valsartan and amlodipine (P<0.05 for irbesartan and HCTZ).
<p>Poldermans et al.¹²⁴ (2007)</p> <p>Amlodipine 5 to 10 mg QD and valsartan 160 mg QD</p> <p>vs</p> <p>lisinopril 10 to 20 mg and HCTZ 12.5 mg QD</p>	<p>AC, DB, MC, PG, RCT</p> <p>Males and females, ages 18 years and older with HTN (mean DBP ≥110 mm Hg and <120 mm Hg)</p>	<p>N=130</p> <p>6 weeks</p>	<p>Primary: Safety/adverse events, vital signs, hematology, biochemistry variables</p> <p>Secondary: Efficacy (mean DBP, response rate, proportion of patients with mean DBP <90 mm Hg or a ≥10 mm Hg reduction from baseline)</p>	<p>Primary: Both treatments were well tolerated, 26 (40.6%) of patients receiving amlodipine and valsartan and 21 (31.8%) of patients receiving lisinopril and HCTZ reported an adverse events and most were not considered drug related.</p> <p>Peripheral edema was reported more often in the amlodipine and valsartan group than the lisinopril and HCTZ group (7.7 vs 1.5%) and cough was reported less often in the amlodipine and valsartan group than the receiving lisinopril and hydrochlorothiazide group (1.6 vs 3.0%).</p> <p>No difference was found between the treatments in changes in laboratory values or biochemistry variables.</p> <p>Secondary: Both treatments led to a reduction in mean SBP and DBP (P<0.0001 for both from baseline) but were not significantly different from each other. Mean blood pressure for each group at study end: amlodipine and valsartan 135.0/83.6 mm Hg and lisinopril and HCTZ 138.7/85.2 mm Hg.</p> <p>The response rate was similar among the groups (100 vs 95.5%; P value not significant).</p>
<p>Calhoun et al.¹²⁵ (2009)</p> <p>Amlodipine and valsartan and HCTZ 10-320-25 mg QD (fixed-dose combination product)</p> <p>vs</p>	<p>DB, MC, RCT</p> <p>Patients 18 to 85 years of age with moderate to severe essential HTN</p>	<p>N=2,271</p> <p>8 weeks</p>	<p>Primary: Difference in mean sitting diastolic blood pressure and mean sitting systolic blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: At each assessment after week three, a significantly greater proportion of patients receiving triple therapy achieved overall blood pressure control (<140/90 mm Hg) compared to those receiving any of the dual therapies (P<0.0001 for all).</p> <p>At end point, 70.8% of patients in the triple therapy group achieved control, compared to 48.3% for valsartan and HCTZ, 54.1% for amlodipine and valsartan, and 44.8% for amlodipine and HCTZ (P<0.0001 for all).</p> <p>Triple therapy improved blood pressure control significantly better than</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>valsartan and HCTZ 320-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and valsartan 10-320 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and HCTZ 10-25 mg QD (fixed-dose combination product)</p>				<p>any of the dual therapies.</p> <p>Secondary: Not reported</p>
<p>Calhoun et al.¹²⁶ (2009)</p> <p>Amlodipine and valsartan and HCTZ 10-320-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>valsartan and HCTZ 320-25 mg QD (fixed-dose combination product)</p>	<p>Secondary analysis</p> <p>Patients 18 to 85 years of age with moderate to severe HTN (mean SBP/DBP $\geq 145/\geq 100$ mm Hg)</p>	<p>N=2,271</p> <p>8 weeks</p>	<p>Primary: Proportion and mean SBP of patients with mean SBP reductions ≥ 60, ≥ 50, ≥ 40, ≥ 30 and ≥ 20 mm Hg at week three and at the end of the study</p> <p>Secondary: Changes from baseline in mean SBP based upon baseline severity,</p>	<p>Primary: The proportion of patients with mean SBP reductions ≥ 20 mm Hg was greater with triple therapy than dual therapy at week three (74.5 vs 58.8 to 65.5%) and at study endpoint (87.6 vs 75.8 to 81.5%).</p> <p>More patients who received triple therapy, as compared to dual therapy, achieved mean SBP reductions of ≥ 30, ≥ 40, ≥ 50 and ≥ 60 mm Hg at week three and at study endpoint (P value not reported).</p> <p>In patients with severe SBP (≥ 180 mm Hg), triple therapy resulted in significantly greater reductions than those for each dual therapy at week three (P<0.01), except for amlodipine/valsartan (P=0.11).</p> <p>Secondary: Patients with higher baseline mean SBP had greater reductions in mean SBP than those with lower baseline mean SBP. Changes in mean SBP</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
product) vs amlodipine and valsartan 10-320 mg QD (fixed-dose combination product) vs amlodipine and HCTZ 10-25 mg QD (fixed-dose combination product)			SBP control rates, safety	were significantly greater for triple therapy than dual therapy for all baseline SBP (P<0.05), except for valsartan and HCTZ and amlodipine and HCTZ in patients with baseline mean SBP 150 to <160 mm Hg (P value not reported). Significantly more patients (91.8%) receiving triple therapy achieved SBP control (≥ 20 mm Hg reduction or mean SBP <140 mm Hg) compared to those receiving amlodipine and HCTZ (80.1%), valsartan and HCTZ (80.8%) or valsartan and amlodipine (85.7%) (P<0.01 for all). The overall incidence of adverse events was comparable across treatments, regardless of baseline blood pressure severity.
Pareek et al. ¹²⁷ (2010) Amlodipine 2.5 to 5 mg and atenolol 25 to 50 mg QD vs atenolol 25 to 50 mg QD	AC, MC, OL, RCT Adults with either untreated or pretreated essential HTN	N=190 12 weeks	Primary: Change in SBP and DBP Secondary: Not reported	Primary: At the end of four weeks, the mean change in SBP (-30.0 \pm 10.4 vs -25.08 \pm 9.05; P=0.008) and DBP (-18.10 \pm 7.45 vs -14.78 \pm 7.48; P=0.021) was significantly greater in the low-dose combination therapy as compared to the low-dose monotherapy. At the end of 12 weeks, the mean SBP (127.82 \pm 8.90 vs 138.0 \pm 14.4; P=0.001) and mean DBP (81.73 \pm 8.78 vs 87.35 \pm 5.50; P=0.011) were significantly lower in the high-dose combination group as compared to the high-dose monotherapy group. Secondary: Not reported
Gustin et al. ¹²⁸ (1996) Felodipine 5 to 10 mg QD vs	XO Patients with HTN, stable on nifedipine for ≥ 3 months were switched to felodipine	N=127 2 months	Primary: Blood pressure Secondary: Side effects and use of supplemental	Primary: There was no difference in SBP before and after switching agents. However, there was a difference in DBP, which was slightly lower (-2 \pm 2 mm Hg) with felodipine than with nifedipine treatment (P<0.05). Secondary: Reported adverse events by patients and providers did not differ between

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
nifedipine 30 to 60 mg QD			antihypertensive agents	the agents, with the most commonly reported side effect for both groups being leg swelling/edema. There was no difference in use of supplemental antihypertensive agents and heart rate between treatments ($P>0.05$ for both).
Karotsis et al. ¹²⁹ (2006) Felodipine 5 mg QD vs lisinopril 10 mg QD vs chlorthalidone 12.5 mg QD vs valsartan 80 mg QD All patients also received diltiazem 240 mg QD.	RCT Patients 25 to 79 years of age with uncontrolled HTN (average office blood pressure >140/90 mm Hg for all or >153/85 mm Hg for diabetics or patients <65 years of age, confirmed on 2 office visits \geq 1 week apart) after \geq 4 weeks of OL monotherapy with diltiazem at 240 mg QD	N=211 8 weeks	Primary: Blood pressure Secondary: Not reported	Primary: There was a significant decline in both office and home SBP and DBP during the trial with all treatments. The antihypertensive effect was more pronounced and reached significance when home blood pressure monitoring was used in comparison to office blood pressure without the white-coat effect ($P<0.001$ for all blood pressure changes). With or without the white-coat effect, blood pressure still declined and the differences were significant ($P<0.0001$ for all blood pressure changes). Secondary: Not reported
Manyemba et al. ¹³⁰ (1997) reserpine 0.25 mg QD plus HCTZ 25 mg QD vs	OL, RCT, XO African American patients aged 21 to 65 years with HTN (blood pressure >140/95 mm Hg) after 4 weeks of	N=32 10 weeks	Primary: The change in blood pressure from baseline to the end of each 4-week treatment period	Primary: Reserpine reduced SBP by 15.9 mm Hg (95% CI, 8.4 to 23.4) and DBP by 11.1 mm Hg (95% CI, 7.5 to 14.6). Nifedipine SR reduced SBP by 18.9 mm Hg (95% CI, 12.1 to 25.7) and DBP by 9.6 mm Hg (95% CI, 7.2 to 12.0). There was no significant difference between the two groups.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
nifedipine SR 20 mg BID plus HCTZ 25 mg QD plus	daily HCTZ therapy		Secondary: Not reported	Secondary: Not reported
Lindholm et al. ¹³¹ (2005) Other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide*, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil) or placebo vs β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol, or propranolol)	MA 13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both	N=105,951 2.1 to 10.0 years	Primary: Stroke, MI, all-cause mortality Secondary: Not reported	Primary: The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001). The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported). The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14). Secondary: Not reported
Van Bortel et al. ¹³²	MA	N=2,653	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2008)</p> <p>ACE inhibitor, ARB, β-blocker, calcium channel blocker, or placebo</p> <p>vs</p> <p>nebivolol</p>	<p>12 RCTs involving >25 patients with essential HTN where nebivolol 5 mg QD was compared to placebo or other active drugs for >1 month</p>	<p>Duration varied</p>	<p>Antihypertensive effect and tolerability</p> <p>Secondary: Not reported</p>	<p>Overall, higher response rates were observed with nebivolol than all other antihypertensive agents combined (OR, 1.41; 95% CI, 1.15 to 1.73; P=0.001) and compared to the ACE inhibitors (OR, 1.92; 1.30 to 2.85; P=0.001), but response rates to nebivolol were similar to β-blockers (OR, 1.29; 95% CI, 0.81 to 2.04; P=0.283), calcium channel blockers (OR, 1.19; 95% CI, 0.83 to 1.70; P=0.350) and losartan (OR, 1.35; 95% CI, 0.84 to 2.15; P=0.212).</p> <p>Overall, a higher percentage of patients obtained normalized BP with nebivolol compared to the other antihypertensive agents combined (OR, 1.35; 95% CI, 1.07 to 1.72; P=0.012). A higher percentage of patient receiving nebivolol obtained normalized BP compared to losartan (OR, 1.98; 95% CI, 1.24 to 3.15; P=0.004) and calcium channel blockers (OR, 1.96; 95% CI, 1.05 to 1.96; P=0.024), but not when compared to other β-blockers (OR, 1.29; 95% CI, 0.81 to 1.65; P=0.473).</p> <p>Overall, the percentage of adverse events was significantly lower with nebivolol compared to the other antihypertensive agents combined (OR, 0.59; 95% CI, 0.48 to 0.72; P<0.001) and similar to placebo (OR, 1.16; 95% CI, 0.76 to 1.67; P=0.482). In comparing nebivolol to the individual treatments, nebivolol had a lower percentage of adverse events compared to losartan (OR, 0.52; 95% CI, 0.30 to 0.89; P=0.016), the other β-blockers (OR, 0.56; 95% CI, 0.36 to 0.85; P=0.007) and calcium channel blockers (OR, 0.49; 95% CI 0.33 to 0.72; P<0.001), but was similar to ACE inhibitors (OR, 0.75; 95% CI 0.52 to 1.08).</p> <p>Secondary: Not reported</p>
<p>Wiysonge et al.¹³³ (2007)</p> <p>Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-</p>	<p>MA</p> <p>13 RCTs evaluating patients \geq18 years of age with HTN</p>	<p>N=91,561</p> <p>Duration varied</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse</p>	<p>Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>			<p>reactions</p>	<p>Secondary:</p> <p>There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>
<p>Baguet et al.¹³⁴ (2007)</p> <p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan,</p>	<p>MA</p> <p>Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>N=10,818</p> <p>8 to 12 weeks</p>	<p>Primary: Weighted average reductions in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren)</p> <p>Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>				<p>observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>
Renal Effects				
<p>Esnault et al.¹³⁵ (2008)</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p>	<p>MC, DB, PC, RCT</p> <p>Nondiabetic, adult patients with estimated creatinine clearance of 20 to 60 ml/min</p>	<p>N=263</p> <p>3 years</p>	<p>Primary: Change in GFR measured yearly by blood clearance</p> <p>Secondary: Composite of renal</p>	<p>Primary: No statistically significant difference was found between amlodipine and enalapril in GFR decline (-4.92 and -3.98 mL/min., respectively, at last observation).</p> <p>Secondary: No statistically significant difference was found between amlodipine and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
enalapril 5 to 20 mg/day			events and tolerability	enalapril in the composite secondary end point after a median follow-up of 2.9 years, including in the subgroup of patients with proteinuria >1 g/d at baseline.
Agodoa et al. ¹³⁶ (2001) AASK Amlodipine 5 to 10 mg QD vs ramipril 2.5 to 10 mg QD	DB, MC, RCT African American patients, age 18 to 70 years old, with hypertensive renal disease (GFR 20 to 65 mL/min)	N=1,094 4 years	Primary: Rate of change in GFR (GFR slope) Secondary: Composite of: confirmed reduction GFR by 50% or by 25 mL/min for baseline, ESRD	Primary: The average decline in GFR was slower, by 36% in the ramipril group as compared to the amlodipine group (P=0.002). However, during the first three months, GFR increased more in the amlodipine group than the ramipril group (P<0.001). The mean total slope did not differ between the groups (P=0.38). Secondary: The risk reduction for the composite secondary outcome was significantly greater for the ramipril group than the amlodipine group (P=0.005). The rate of ESRD was significantly lower in the ramipril group (P=0.01).
Wright et al. ¹³⁷ (2002) AASK Amlodipine 5 to 10 mg/day vs metoprolol 50 to 200 mg/day vs ramipril 2.5 to 10 mg/day	DB, MC, RCT Patients were self-identified African Americans aged 18 to 70 years with HTN and a GFR between 20 and 65 mL/min/ 1.73 m ² and no other identified cause of renal insufficiency	N=1,094 3 to 6.4 years	Primary: Rate of change in GFR (grouped by usual blood pressure [MAP goal 102 to 107 mm Hg] vs lower blood pressure [\leq 92 mm Hg]) Secondary: Clinical composite outcome (reduction in GFR by 50% or more, ESRD, or death)	Primary: No significant difference in primary outcome was reported between the usual blood pressure group compared to the lower blood pressure group (P=0.24). None of the drug group comparisons showed consistently significant differences in the GFR slope. Secondary: The lower blood pressure goal did not significantly reduce the rate of the clinical composite outcome (risk reduction for lower blood pressure group, 2%; 95% CI, -22 to 21; P=0.85). Ramipril resulted in significant risk reductions in the clinical composite outcomes compared to amlodipine (38%; 95% CI, 14 to 56; P=0.004) and metoprolol (22%; 95% CI, 1 to 38; P=0.04). There was no significant difference in the clinical composite outcome between the amlodipine and metoprolol groups.
Lewis et al. ¹³⁸ (2001) IDNT	DB, MC, PC, PRO, RCT Patients 30 to 70	N=1,715 2.6 years	Primary: Composite of risk of doubling serum creatinine, ESRD,	Primary: Compared to placebo, irbesartan 300 mg/day resulted in a 20% lower relative risk of the composite primary outcome (P=0.02). Irbesartan treatment was associated with a 33% lower risk of doubling serum

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amlodipine 10 mg/day</p> <p>vs</p> <p>irbesartan 300 mg/day</p> <p>vs</p> <p>placebo</p>	<p>years old, with type 2 diabetes mellitus, HTN, and nephropathy</p>		<p>or death from any cause</p> <p>Secondary: Composite of death from cardiovascular causes, nonfatal MI, heart failure requiring hospitalization, permanent neurologic deficit caused by a cerebrovascular event, or lower limb amputation</p>	<p>creatinine (P=0.003) and 23% trend towards lower risk of ESRD (P=0.07) compared to placebo. There was no significant difference in risk of death from any cause for irbesartan compared to placebo (P=0.57).</p> <p>Compared to amlodipine, irbesartan treatment resulted in a 23% lower risk of composite primary outcome (P=0.006). Irbesartan treatment was associated with a 37% lower risk of doubling serum creatinine vs amlodipine (P<0.001) and 23% trend towards lower risk of ESRD vs amlodipine (P=0.07). There was no significant difference in risk of death from any cause (P=0.80).</p> <p>Secondary: There were no significant differences in the secondary cardiovascular composite end point (P=0.40 and P=0.79 for irbesartan vs placebo and amlodipine, respectively).</p>
<p>Viberti et al.¹³⁹ (2002) MARVAL</p> <p>Amlodipine 5 mg QD</p> <p>vs</p> <p>valsartan 80 mg QD</p> <p>A target blood pressure of 135/85 mm Hg was aimed for by dose-doubling followed by the addition of bendrofluazide* and doxazosin</p>	<p>AC, DB, RCT</p> <p>Patients 35 to 75 years old with type 2 diabetes mellitus and microalbuminuria, with or without HTN</p>	<p>N=332</p> <p>24 weeks</p>	<p>Primary: Change in UAER; proportion of patients who returned to normal albuminuria</p> <p>Secondary: Proportion of patients returning to normoalbuminuria</p>	<p>Primary: Valsartan resulted in a UAER reduction of 44% at 24 weeks compared to baseline vs an 8% reduction with amlodipine (P<0.001). Valsartan lowered UAER similarly in both the hypertensive and normotensive groups.</p> <p>Over the study period, blood pressure reductions were similar between the two treatments and at no time point was there a between-group significant difference in blood pressure values in either the hypertensive or the normotensive subgroup.</p> <p>Secondary: The proportion of patients returning to normal albuminuria was greater with valsartan (29.9%) vs amlodipine (14.5%; P=0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
whenever needed.				
Bakris et al. ¹⁴⁰ (2008) GUARD Amlodipine and benazepril (fixed-dose combination product) vs benazepril and HCTZ (fixed-dose combination product)	DB, RCT Hypertensive, albuminuric type 2 diabetic patients, mean age 58 years were randomized to receive either initial fixed-dose combination product	N=322 52 weeks	Primary: Change in urinary albumin to creatinine ratio after 1 year of initial treatment with either fixed-dose combination, blood pressure reductions Secondary: Proportion who progressed to overt diabetic nephropathy, safety	Primary: Both combinations significantly reduced the urinary albumin to creatinine ratio compared to baseline (P<0.0001). The median percent change was -72.1% for benazepril and HCTZ and -40.5% for amlodipine and benazepril (P<0.0001). Both regimens significantly reduced SBP and DBP compared to baseline (P<0.0001). The mean reduction in both SBP and DBP was greater in the amlodipine-based arm than in the HCTZ-based arm; however, significance in favor of the amlodipine regimen was observed only for DBP (SBP -20.5 vs -18.8; P=0.19; DPB -13.1 vs -9.97; P=0.02). A greater proportion of patients who had microalbuminuria at baseline and treated with benazepril and HCTZ compared to amlodipine and benazepril attained normalization of the urinary albumin to creatinine ratio, defined as <30 mg/g (69.2 vs 47.8%; P=0.0004). Secondary: The percentage of patients progressing to overt proteinuria was similar for both groups. Overall, both study drugs were well tolerated. Adverse reactions possibly related to the study medications occurred in 11.4 and 3.6% of patients receiving amlodipine and benazepril and benazepril and HCTZ, respectively. They included peripheral edema (7.8 vs 2.4%, respectively), fatigue (1.2% in each group), pitting edema (1.2 vs 0.0%), face edema (0.6 vs 0.0%) and thirst (0.6 vs 0.0%). More patients receiving the HCTZ-based regimen (10.8%) discontinued study drug than with the amlodipine-based regimen due to side effects (5.4%).
Casas et al. ¹⁴¹ (2005) ACE inhibitor or ARBs compared to placebo	MA (127 trials) Studies in adults that examined the effect of any drug treatment with a blood pressure	N=not reported 4.2 years (mean)	Primary: Doubling of serum creatinine, and ESRD Secondary: Serum creatinine,	Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups. A small reduction in ESRD was observed in patients receiving ACE

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents, calcium-channel blocking agents, or combinations)</p> <p>Specific agents and doses were not specified.</p>	<p>lowering action on progression of renal disease</p>		<p>urine albumin excretion and GFR</p>	<p>inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>Secondary: Small reductions in serum creatinine and in SBP were noted when ACE inhibitors or ARBs were compared to other antihypertensives (P=0.01).</p> <p>Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001).</p> <p>Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.</p>
Miscellaneous				
<p>Rosendorff et al.¹⁴² (2009)</p> <p>Amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>olmesartan 20 to 40 mg QD</p>	<p>AC, DB, RCT</p> <p>Adults with HTN and left ventricular hypertrophy</p>	<p>N=102</p> <p>52 weeks</p>	<p>Primary: Change in left ventricular mass from baseline to 52 weeks</p> <p>Secondary: Change in left ventricular mass after 26 weeks of treatment</p>	<p>Primary: Mean\pmSD left ventricular masses of 252.9\pm73.06 g in the olmesartan group and 236.9\pm59.94 g in the amlodipine group at baseline were decreased to 248.2\pm69.31 and 223.9\pm53.18 g, respectively, after 52 weeks of therapy. Neither of these changes was significantly different from baseline, and the difference between the two treatment groups was not significant.</p> <p>Secondary: At 26 weeks, adjusted percent changes in left ventricular mass were 8.0% with olmesartan and 6.0% with amlodipine. Changes occurring at the 26-week assessment were not significantly different from baseline or from each other.</p>
<p>Luscher et al.¹⁴³ (2009)</p> <p>ENCORE II</p> <p>Nifedipine 30 to</p>	<p>DB, MC, PC, RCT</p> <p>Adults undergoing coronary angiography with or</p>	<p>N=226</p> <p>18 to 24 months</p>	<p>Primary: The effect of nifedipine compared to placebo on</p>	<p>Primary: The change in mean luminal diameter averaged 13.9\pm16.5% with nifedipine and 7.7\pm18% with placebo. The difference between groups was 6.3% (95% CI, 1.6 to 10.9; P=0.0088).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
60 mg QD vs placebo	without PCI		acetylcholine-induced coronary vascular response at the highest dose of acetylcholine at baseline and follow-up Secondary: Effect of nifedipine on the percent change in plaque volume as assessed by intravascular ultrasound	Secondary: Neither the difference in absolute nor relative changes in mean plaque volume as measure by intravascular ultrasound between treatments was significant (P=0.84 and 0.66, respectively).
Schmid-Elsaesser et al. ¹⁴⁴ (2006) Nimodipine continuous infusion of 1 mg/hr for 6 hours, followed by 2.0 mg/hr Vs magnesium sulfate bolus infusion 10 mg/kg, followed by continuous infusion of 30 mg/kg QD	RCT Patients with aneurismal subarachnoid hemorrhage	N=104 7 days	Primary: Incidence of clinical vasospasm and transcranial Doppler angiographic vasospasm, and infarction attributable to vasospasm Secondary: Incidence of angiographic vasospasm	Primary: There was no significant difference between the groups in number of patients experiencing clinical vasospasm or transcranial doppler/angiographic vasospasm: 14 patients (27%) in the nimodipine group vs eight patients (15%) in the magnesium group (P=0.193); 17 (33%) in the nimodipine group vs 20 (38%) in the magnesium group (P=0.792). No difference between the groups was found in incidence of cerebral infarction, 11 (22%) in the nimodipine group vs 10 (19%) in the magnesium group. Secondary: There were no significant differences in incidence of angiographic vasospasm, neuronal markers or Glasgow outcome scores (all values: P>0.05).
Liu et al (abstract). ¹⁴⁵ (2011)	MA (8 trials) Patients receiving	N=1,514 Not reported	Primary: Not reported	Primary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Nimodipine vs placebo	prophylactic nimodipine for aneurismal subarachnoid hemorrhage		Secondary: Not reported	<p>Secondary: Not reported</p> <p>Compared to placebo, fully recovered (all cases) patients increased 64% with nimodipine (OR, 1.64; 95% CI, 1.26 to 2.13; P=0.002; NNT, -1.048), fully recovered or moderately disabled (all cases) patients increased 79% (OR, 1.79; 95% CI, 1.28 to 2.51; P=0.0007; NNT, -5.889), patient death (in cerebral vasospasm cases) decreased 74% (OR, 0.26; 95% CI, 0.09 to 0.71; P=0.008; NNT, 2.298), the incidence of symptomatic cerebral vasospasm decreased 46% (OR, 0.54; 95% CI, 0.42 to 0.69; P<0.00001; NNT, 1.952), the incidence of delayed neurological function deficits (all cases) decreased 38% (OR, 0.62; 95% CI 0.50 to 0.78; P<0.0001; NNT, 1.078), the occurrence of cerebral infarction (on CT scan) decreased 58% (OR, 0.58; 95% CI, 0.42 to 0.81; P=0.001; NNT, 3.314), the occurrence of cerebral infarction (in cerebral vasospasm cases) decreased 65% (OR, 0.35; 95% CI, 0.17 to 0.69; P=0.003; NNT, 3.688), and the occurrence of cerebral infarction (all cases) decreased 48% (OR, 0.52; 95% CI, 0.41 to 0.66; P<0.00001; NNT, 1.196). The difference in recurrent hemorrhage and adverse reactions between the nimodipine and placebo was not statistically significant (recurrent hemorrhage: OR, 0.75; 95% CI, 0.50 to 1.11; P=0.15; adverse reaction: OR, 1.13; 95% CI, 0.71 to 1.81; P = 0.59).</p> <p>Secondary: Not reported</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, CR=controlled-release, ER=extended-release, QD=once daily, SR=sustained-release

Study design abbreviations: AC=active comparator, DB=double blind, DD=double dummy, ES=extended-release, MA=meta analysis, MC=multicenter, OL=open label, OS=observational, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitor, ABPM=ambulatory blood pressure monitoring, ARB=angiotensin II receptor blocker, BMI=body mass index, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, CT=computed tomography, DBP=diastolic blood pressure, ECG=electrocardiogram, ESRD=end stage renal disease, FBG=fasting blood glucose, GFR=glomerular filtration rate, HbA_{1c}=glycosylated hemoglobin, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HTN=hypertension, HR=hazard ratio, LDL-C=low-density lipoprotein cholesterol, MI=myocardial infarction, MMSE=Mini Mental State Examination, NIDDM=non-insulin dependent diabetes mellitus, NNT=number needed to treat, OR=odds ratio, PAD=peripheral artery disease, PCI=percutaneous coronary intervention, PVD=peripheral vascular disease, QOL=quality of life, RR=relative risk, SBP=systolic blood pressure, SD=standard deviation, TC=total cholesterol, TG=triglyceride, TIA=transient ischemic attack, UAER=urinary albumin excretion rate

Additional Evidence

Dose Simplification

Taylor et al. evaluated adherence rates in patients receiving a fixed-dose combination of amlodipine and benazepril compared to patients receiving an ACE inhibitor and a long-acting dihydropyridine calcium-channel blocking agent as separate formulations. There was no significant difference in adherence in younger subjects (18 to 39 year olds); however, overall adherence was higher in patients receiving amlodipine/benazepril fixed-dose combination product compared to those receiving separate formulations (80.8 vs 73.8%; $P < 0.001$).¹⁴⁶ Dickson et al. also evaluated adherence rates with the fixed-dose combination of amlodipine/benazepril compared to the administration of an ACE inhibitor and dihydropyridine calcium-channel blocking agent as separate formulations in an elderly Medicaid population. Over a 12 month period, adherence rates were higher in patients receiving the fixed-dose combination product compared to those receiving separate formulations (63.4 vs 49.0%; $P < 0.0001$).¹⁴⁷ Gerbino et al. assessed adherence rates in patients receiving the fixed-dose combination of amlodipine/benazepril or an ACE inhibitor and dihydropyridine calcium-channel blocking agent administered as separate formulations. Adherence rates were 69.2% for patients who received the antihypertensive agents as separate formulations compared to 87.9% for patients receiving the fixed-dose combination product ($P < 0.0001$).¹⁴⁸

Stable Therapy

Lenz et al. compared the 24-hour blood pressure control in patients stabilized on amlodipine who were then converted to nisoldipine. After three months, blood pressure control was similar between treatments, except for average 24-hour diastolic blood pressure, where nisoldipine treatment resulted in slightly greater readings (by 2 mm Hg).⁷⁶ Gustin et al. reviewed medical records of hypertensive patients who were switched from long-acting nifedipine to felodipine. This resulted in slightly lower diastolic blood pressure measurements (78 vs 80 mm Hg; $P < 0.05$). Adverse events and supplemental medication use were similar between the agents.¹²⁷ Sapienza et al. measured the impact of converting long-term care patients previously on high dose calcium-channel blocking agents or dual therapy with an ACE inhibitor and calcium-channel blocking agents to the fixed-dose combination of amlodipine/benazepril. There was no significant change in blood pressure following the conversion; however, there was a significant reduction in the number of patients reporting ≥ 1 drug-related adverse event (22 vs 4; $P < 0.05$).¹⁴⁹

Impact on Physician Visits

Sheehy et al. conducted a comparative review of patients receiving amlodipine or felodipine. The investigators found an increased number of specialist visits in the amlodipine group (odds ratio, 1.14; 95% confidence interval, 1.8 to 1.20); however, this same group of patients receiving amlodipine had significantly better compliance and refill rates and fewer medication switches.⁶⁷

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 15. Relative Cost of the Dihydropyridines

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Amlodipine	tablet	Norvasc [®] **	\$\$	\$
Felodipine	extended-release tablet	N/A	N/A	\$\$\$
Isradipine	capsule*, extended- release tablet	N/A	N/A	\$\$\$\$\$
Nicardipine	capsule, injection, sustained-release capsule	Cardene IV [®] *, Cardene SR [®]	\$\$\$\$\$	\$\$
Nifedipine	capsule, extended- release tablet	Adalat CC [®] *, Procardia [®] *, Procardia XL [®] *	\$\$\$	\$\$\$\$
Nimodipine	capsule, solution	Nymalize [®]	\$\$\$\$\$	\$\$\$
Nisoldipine	extended-release tablet*	Sular [®] **	\$\$\$\$\$	\$\$\$\$\$
Combination Products				
Amlodipine and benazepril	capsule	Lotrel [®] **	\$\$\$\$	\$\$
Amlodipine and olmesartan	tablet	Azor [®]	\$\$\$\$\$	N/A
Amlodipine and valsartan	tablet	Exforge [®] *	\$\$\$\$\$	\$\$\$\$\$
Amlodipine, valsartan, and HCTZ	tablet	Exforge HCT [®] *	\$\$\$\$	\$\$\$\$

*Generic is available in at least one dosage form or strength.

HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

All of the dihydropyridines, with the exception of nimodipine, are approved for the treatment of hypertension. Amlodipine, nicardipine, and nifedipine are also indicated for the treatment of angina. Additionally, amlodipine reduces the risk of hospitalization due to angina and reduces the risk of coronary revascularization procedures in patients with recently documented coronary artery disease.^{1,2,6-21} Amlodipine is available in combination with benazepril, olmesartan, valsartan, or valsartan-hydrochlorothiazide. It should be noted that the amlodipine and telmisartan fixed-dose combination product and the amlodipine, olmesartan, and hydrochlorothiazide fixed-dose combination product are included in the angiotensin II receptor antagonists class review (AHFS Class 243208). In addition, the amlodipine and aliskiren fixed-dose combination product and the amlodipine, aliskiren, and hydrochlorothiazide fixed-dose combination product are included in the renin inhibitor class review (AHFS Class 243240). All of the products with the exception of clevidipine and amlodipine-olmesartan are available in a generic formulation.

There are several national and international guidelines that provide recommendations regarding the use of calcium-channel blocking agents.²²⁻⁴² For the treatment of chronic angina, β -blockers are recommended as initial therapy; however, long-acting calcium-channel blocking agents may be used if β -blockers are contraindicated or if additional therapy is required.²²⁻²⁸ Calcium-channel blocking agents are recommended as initial therapy in patients

with variant/vasospastic angina.^{23,26} For the treatment of heart failure, ACE inhibitors, ARBs, aldosterone antagonists, and isosorbide dinitrate/hydralazine are recommended as initial therapy. In general, calcium-channel blocking agents are not recommended in the management of heart failure; however, amlodipine or felodipine may be added if patients have angina or uncontrolled blood pressure.³⁰⁻³² There are several published guidelines on the treatment of hypertension. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.³³⁻⁴¹ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).³³ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.³³⁻⁴¹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.³³⁻⁴¹

Numerous clinical trials have shown that the dihydropyridines can effectively lower systolic and diastolic blood pressure when administered alone or in combination with other agents. In trials comparing combination therapy to monotherapy, the more aggressive treatment regimens lowered blood pressure to a greater extent than the less-intensive treatment regimens. Some comparative trials have demonstrated slight differences in blood pressure effects among the various dihydropyridines; however, the clinical significance of these differences remains to be established.⁶⁷⁻¹³⁴ Most patients will require more than one antihypertensive agent to achieve blood pressure goals.³³⁻⁴¹ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{35,36,40,146-148} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations. The dihydropyridines have been shown to favorably affect cardiovascular morbidity and mortality, and several studies have demonstrated comparable efficacy with β -blockers, diuretics, ACE inhibitors, ARBs.⁴⁵⁻⁶⁶

There is insufficient evidence to support that one brand dihydropyridine is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand dihydropyridines within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand dihydropyridine is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Apr]. Available from: <http://online.factsandcomparisons.com>
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Apr]. Available from: <http://www.thomsonhc.com/>.
3. Kannam JP, Aroesty JM, Gersh BJ. Calcium channel blockers in the management of stable angina pectoris. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Apr]. Available from: <http://www.uptodate.com/utd/index.do>.
4. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
5. Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
6. Norvasc® [package insert]. New York (NY): Pfizer Inc; 2015 Mar.
7. Felodipine [package insert]. Mahwah (NJ): Glenmark Generics Inc., USA; 2013 Jun.
8. Isradipine [package insert]. Parsippany (NJ): Watson Pharma, Inc.; 2014 Jun.
9. Cardene SR® [package insert]. Bedminster (NJ): EKR Therapeutics, Inc.; 2010 Jun.
10. Nicardipine capsule [package insert]. Pulaski (TN): AvKARE, Inc.; 2013 Aug.
11. Procardia® [package insert]. New York (NY): Pfizer Inc; 2015 Jan.
12. Procardia XL® [package insert]. New York (NY): Pfizer Inc; 2015 Jan.
13. Adalat® CC [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2011 Feb.
14. Nimodipine [package insert]. Detroit (MI): Caraco Pharmaceutical Laboratories, Ltd.; 2012 Aug.
15. Nymalize® [package insert]. Atlanta (GA): Arbor Pharmaceuticals, Inc.; 2013 May.
16. Sular® [package insert]. Atlanta (GA): Shionogi Pharma, Inc.; 2015 Mar.
17. Nisoldipine extended-release tablet [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2010 Jan.
18. Azor® [package insert]. Parsippany (NJ): Daiichi-Sankyo, Inc; 2014 Sep.
19. Lotrel® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014 Dec.
20. Exforge® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp; 2014 Sep.
21. Exforge HCT® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp; 2014 Sep.
22. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
23. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/eh296.
24. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
25. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
26. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
27. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.
28. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.

29. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.
30. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
31. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
32. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
33. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
34. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
35. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
36. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
37. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
38. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
39. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
40. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
41. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
42. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
43. Koenig W, Hoher M. Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial. *J Cardiovasc Pharmacol*. 1997;29(4):520-4.
44. Savonitto S, Ardissio D, Egstrup K, Rasmussen K, Bae EA, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. *J Am Coll Cardiol*. 1996 Feb;27(2):311-6.
45. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. *Circulation*. 2000;102(13):1503-10.
46. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. *Lancet*. 2005 Sep 10-16;366(9489):895-906.
47. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension*. 2007 Apr;49(4):839-45.
48. Nissen SE, Tuzcu EM, Libby P, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*. 2004;292(18):2217-25.
49. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients

- randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002 Dec 18;288(23):2981-97.
50. Black HR, Davis B, Barzilay J, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Diabetes Care*. 2008 Feb;31(2):353-60.
 51. Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, et al. Long-term renal and cardiovascular outcomes in antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR. *Clin J Am Soc Nephrol*. 2012;7:989-1002.
 52. Muntner P, Levitan EB, Lynch AI, et al. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *J Clin Hypertens (Greenwich)*. 2014 May;16(5):323-330.
 53. Ogihara T, Nakao K, Fukui T, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. *Hypertension*. 2008 Feb;51(2):393-8.
 54. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004 Jun 19;363(9426):2022-31.
 55. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. *J Hypertens*. 2006 Nov;24(11):2163-8.
 56. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. *N Engl J Med* 2008;359:2417-28.
 57. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. *Lancet*. 2010 Apr 3;375(9721):1173-81.
 58. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol*. 2010 Jun 29;56(1):77-85.
 59. Weber MA, Jamerson K, Bakris G, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. *Lancet*. 2013;381:537-45.
 60. Bakris G, Briasoulis A, Dahlöf B, et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. *Am J Cardiol*. 2013 Jul 15;112(2):255-259.
 61. Hansson L, Lindholm LH, Ekblom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999 Nov 20;354(9192):1751-6.
 62. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. *JAMA*. 1996; 276:785-791.
 63. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. *Hypertension*. 1999 Nov;34(5):1129-33.
 64. Lichtlen PR, Hugenholz PG, Rafflenbeul W, et al. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy Cardiovasc Ther. 1990 Aug;4 Suppl 5:1047-68.
 65. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GTS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet*. 2000; 356:366-72.
 66. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. *Am J Cardiol*. 1998;82(9B):9R-14R.
 67. Sheehy O, LeLorier J. Patterns of amlodipine and felodipine use in an elderly Quebec population. *Can J Cardiol*. 2000;16(9):1109-17.
 68. Van Der Krogt J, Brand R, Dawson E. Amlodipine versus extended-release felodipine in general practice: A randomized, parallel-group study in patients with mild-to-moderate hypertension. *Curr Therap Res*. 1996; 57 (3):145-58.

69. Mounier-Vehier C, Jaboureck O, Emeriau JP, Bernaud C, Clerson P, Carre A. Randomized, comparative, double-blind study of amlodipine vs nifedipine as a treatment of isolated systolic hypertension in the elderly. *Fundam Clin Pharmacol.* 2002;16(6):537-44.
70. Kes S, Caglar N, Canberk A, et al. Treatment of mild-to-moderate hypertension with calcium-channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. *Curr Med Res Opin.* 2003; 19(3):226-37.
71. Ryuzaki M, Nakamoto H, Nishida E et al. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium-channel blockers for hypertension (I-TECHO trial). *J Hypertens.* 2007 Nov;25(11):2352-8.
72. Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: The Adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. *J Hypertens.* 2007 Nov;25(11):2352-8.
73. Pepine CJ, Cooper-DeHoff RM, et al. Comparative Efficacy and Safety of Nisoldipine and Amlodipine (CESNA-II) Study Investigators. Comparison of effects of nisoldipine-extended-release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *Am J Cardiol.* 2003; 91(3):274-9.
74. Whitcomb C, Enzmann G, Pershadsingh HA, et al. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension. *Int J Clin Pract.* 2000;54(8):509-13.
75. White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. *Am J Hypertens.* 2003;16(9 Pt 1):739-45.
76. Lenz TL, Wurdeman RL, Hilleman DE. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. *Pharmacotherapy.* 2001;21(8):898-903.
77. Drummond W, Munger M, Essop M, Maboudian M, Khan M, Keefe D. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. *J Clin Hypertens.* 2007;9:742-50.
78. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. *Am Heart J.* 2000 Oct;140(4):E11.
79. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose combination therapy: an alternative first-line approach to hypertension treatment. *Am Heart J.* 1995 Aug;130(2):359-66.
80. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. *Blood Press.* 2002;11(3):182-8.
81. Hollenberg HK, Williams GH, Anderson H et al. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium-channel blocking agent in patients with systolic hypertension. *Arch Intern Med.* 2003;163(13):1543-8.
82. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. *Hypertension* 2003;41(5):1021-6.
83. Jordan J, Engeli S, Boye S, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension.* 2007 May;49:1047-55.
84. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine and benazepril versus monotherapy of amlodipine in a practice-based setting. *Am J Hypertens.* 2002 Jun;15(6):550-6.
85. Chrysant SG. Blood pressure effects of high-dose amlodipine-benazepril combination in black and white hypertensive patients not controlled on monotherapy. *Drugs RD.* 2012;12(2):57-64.
86. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. *Am J Cardiol.* 2000 Dec 1;86:1182-7.
87. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium-channel blocker combination therapy achieves superior blood pressure control compared with calcium-channel blocker monotherapy in patients with stage 2 hypertension. *Am J Hypertens.* 2004 Jun;17(6):495-501.
88. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. *J Clin Hypertens.* 2005 Nov;7(11):641-6.
89. Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. *Clin Ther.* 1996;18(6):1213-24.

90. Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. *Blood Press Suppl.* 2007 Mar;1:10-7.
91. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. *Am J Hypertens.* 2004 Jul;17(7):590-6.
92. Fogari R, Corea L, Cardoni O, et al. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. *J Cardiovasc Pharmacol.* 1997 Oct;30(4):497-503.
93. Minami J, Abe C, Akashiba A, Takahashi T, Kameda T, Ishimitsu T, Matsuoka H. Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. *Int Heart J.* 2007 Mar;48(2):177-86.
94. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. *J Hum Hypertens.* 1999;13:477-83.
95. Jamerson K, Bakris GL, Dahlof B, et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. *Blood Press.* 2007;16(2):80-6.
96. Malacco E, Piazza S, Carretta R, et al; Italian Blood Pressure Study Group. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. *Int J Clin Pharmacol Ther.* 2002 Jun;40(6):263-9.
97. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. *Am J Cardiovasc Drugs.* 2007;7(5):36-72.
98. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. *Diabetes Care.* 1998; 21:597-603.
99. Miranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study. *Clin Ther* 2008;30:1618-28.
100. Fogari R, Mugellini A, Derosa G; CANDIA (CANdesartan and DIuretic vs Amlodipine in hypertensive patients) Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. *J Renin Angiotensin Aldosterone Syst.* 2007 Sep;8(3):139-44.
101. Ribeiro AB, Mion D Jr, Marin MJ, et al; Latin American Hypertension Study (LAMHYST) Group. Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension. *J Int Med Res.* 2007 Nov-Dec;35(6):762-72.
102. Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. *Clin Ther.* 1996 Jul-Aug;18(4):608-25.
103. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. *Clin Ther.* 2008 Apr;30(4):587-604.
104. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. *J Clin Hypertens (Greenwich)* 2009;11:475-82.
105. Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. *J Cardiovasc Pharmacol.* 2009;54(5):427-36.
106. Braun N, Ulmer HJ, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination (abstract). *Current Medical Research & Opinion.* 2009;25(2):421-30.
107. Littlejohn TW 3rd, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. *J Clin Hypertens (Greenwich)* 2009;11:207-13.
108. Littlejohn T, Majul C, Olver R, Seeber M, Kobe M, Guthrie R et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4x4 factorial study. *Postgrad Med.* 2009;121(2):5-14.
109. Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan

- and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. *Clin Ther* 2007;29:2667-76.
110. Neutel JM, Mancina G, Black HR, Dahlof B, Defeo H, Ley L, et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. *J Clin Hypertens (Greenwich)*. 2012 Apr;14(4):206-215.
111. Maciejewski S, Mohiuddin SM, Packard KA, et al. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring. *Pharmacotherapy*. 2006 Jul;26(7):889-95.
112. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. *J Hum Hypertens*. 2006 Oct;20(10):787-94.
113. Karpov Y, Dongre N, Vighorchik A, Sastravaha K. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. *Adv Ther*. 2012;29(2):134-147.
114. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. *Clin Ther*. 2007 Apr;29(4):563-80.
115. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. *Clin Ther*. 2007 Apr;29(4):563-80.
116. Philipp T, Glazer RD, Wernsing M, Yen J. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension (abstract). *J Amer Soc Hyperten*. 2011;5(5):417-424.
117. Schunkert H, Glazer RD, Wernsing M, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. *Curr Med Res Opin* 2009;25:2655-62.
118. Ke Y, Zhu D, Hong H, et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. *Curr Med Res Opin* 2010;26:1705-13.
119. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. *J Am Society Hypertension* 2008;2:294-302.
120. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. *J Hum Hypertens* 2009;23:479-89.
121. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. *Int J Clin Pract* 2009;63:217-25.
122. Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. *Curr Med Res Opin* 2009;25:315-24.
123. Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. *Archives of Gerontology and Geriatrics*. 2009;48:401-5.
124. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. *Clin Ther*. 2007 Feb;29(2):279-89.
125. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized controlled trial. *Hypertension* 2009;54:32-9.
126. Calhoun D, Crikelair N, Yen J, Glazer R. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. *Adv Ther*. 2009;26(11):1012-23.
127. Pareek A, Salkar H, Mulay P, Desai S, Chandurkar N, Redkar N. A randomized, comparative, multicenter, evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertension patients. *Am J Ther* 2010;17:46-52.
128. Gustin G, White WB, Taylor S, Daragjati C. Clinical outcome of a mandatory formulary switch for dihydropyridine calcium-channel blocker therapy at a Veteran's Administration Medical Center. *Am J Hypertens*. 1996;9(4 Pt 1):312-6.

129. Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. *Clin Exp Hypertens*. 2006;28(7):655-62.
130. Manyemba J. A randomized crossover comparison of reserpine and sustained-release nifedipine in hypertension. *Cent Afr J Med*. 1997 Dec;43(12):344-9.
131. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1545-53.
132. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs*. 2008;8(1):35-44.
133. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
134. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig*. 2007;27(11):735-53.
135. Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study. *Clin Ther* 2008;30:482-98.
136. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA*. 2001 Jun 6;285(21):2719-28.
137. Wright JT Jr, Bakris G, Green T, et al. Effect of blood pressure lowering and antihypertensive kidney disease: results from the AASK trial. *JAMA*. 2002; 288:2421-31.
138. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*. 2001 Sep 20;345(12):851-60.
139. Viberti G, Wheelon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation*. 2002 Aug 6;106(6):672-8.
140. Bakris GL, Toto RD, McCullough PA, et al; on behalf of GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney Int*. 2008 Jun;73(11):1303-9.
141. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet*. 2005 Dec 10;366:2026-33.
142. Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. *Am J Cardiol* 2009;104:359-65.
143. Luscher TF, Pieper M, Tendera M, et al. A randomized, placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. *Euro Heart J* 2009;30:1590-7.
144. Schmid-Elsaesser R, Kunz M, Zausinger S, et al. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. *Neurosurgery*. 2006 Jun;58(6):1054-65.
145. Liu GJ, Zhang LLP, Wang ZJ, Xu LL, He GH, Zeng YJ, et al. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. *CNS Neurol Disord Drug Targets*. 2011;10(7):834-44.
146. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. *Congest Heart Fail*. 2003 Nov-Dec;9(6):324-32.
147. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. *Am J Cardiovasc Drugs* 2008;1:45-50.
148. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. *Am J Health Syst Pharm* 2007;64:1279-83.
149. Sapienza S, Sacco P, Floyd K, et al. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. *Clin Ther* 2003;25:1872-87.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Calcium-Channel Blocking Agents, Miscellaneous
AHFS Class 242892
August 19, 2015**

I. Overview

The movement of calcium ions is essential for the function of all types of muscle, including cardiac and vascular smooth muscle. When this flow is reduced, the result is a weakening of muscle contraction and relaxation of muscle tissue.¹⁻³ Relaxation of coronary vascular smooth muscle increases the flow of oxygenated blood into the myocardium, while relaxation of arteriolar smooth muscle decreases peripheral vascular resistance. Both coronary and systemic vasodilation serve to reduce cardiac workload. The calcium-channel blocking agents include dihydropyridines and miscellaneous agents (nondihydropyridines). Although they have different binding sites on the L-type calcium channel, both block the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The nondihydropyridines also block the T-type calcium channel in the atrioventricular node.¹⁻⁵

The miscellaneous calcium-channel blocking agents include diltiazem and verapamil, which are approved for the treatment of angina, arrhythmias, and hypertension.^{1,2,6-16} Diltiazem is a potent coronary vasodilator, but is only a mild arterial vasodilator. Although it decreases atrioventricular (AV) node conduction, diltiazem does not have negative inotropic properties.^{1,2,6-11} Verapamil dilates coronary and peripheral arteries. It also slows conduction through the AV node, and has negative inotropic and chronotropic effects.^{1,2,12-16} Both diltiazem and verapamil are available in a variety of modified-release delivery systems that alter their pharmacokinetic properties, including onset and duration of action.^{1,2}

The miscellaneous calcium-channel blocking agents that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Diltiazem and verapamil are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Calcium-Channel Blocking Agents, Miscellaneous Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Diltiazem	extended-release capsule, extended-release tablet, injection, tablet	Cardizem ^{®*} , Cardizem CD ^{®*} , Cardizem LA ^{®*} , Matzim LA ^{®*} , Tiazac ^{®*}	diltiazem
Verapamil	extended-release capsule, extended-release tablet, injection, tablet	Calan ^{®*} , Calan SR ^{®*} , Verelan ^{®*} , Verelan PM ^{®*}	verapamil

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the miscellaneous calcium-channel blocking agents are summarized in Table 2.

Table 2. Treatment Guidelines Using the Calcium-Channel Blocking Agents, Miscellaneous

Clinical Guideline	Recommendations
American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With	<ul style="list-style-type: none"> Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin converting enzyme (ACE) inhibitors and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals

Clinical Guideline	Recommendations
<p>Chronic Stable Angina (2007)¹⁷</p>	<p>of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes.</p> <ul style="list-style-type: none"> • Long-acting calcium channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) $\leq 40\%$ and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF $\leq 40\%$. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF $\leq 40\%$ and have either diabetes or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease.
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease (2013)¹⁸</p>	<p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education. <p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia (>10%), β-blockers should be considered.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided. <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: Management of Stable Ischemic Heart Disease (2012)¹⁹</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin is contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of</p>	<p><u>Early hospital care- standard medical therapies</u></p>

Clinical Guideline	Recommendations
<p>Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)²⁰</p>	<ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin)

Clinical Guideline	Recommendations
	<p>not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI.</p> <ul style="list-style-type: none"> ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. <ul style="list-style-type: none"> • Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. • Timing of CABG in relation to use of antiplatelet agents <ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> • Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTEMI-ACS and have initial angina lasting more

Clinical Guideline	Recommendations
	<p>than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services.</p> <ul style="list-style-type: none"> ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEMI-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTEMI-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTEMI-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTEMI-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTEMI-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)²¹</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> ● Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. ● Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class ≥III. ● Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. ● Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. ● Calcium channel blockers are recommended in patients with vasospastic angina. ● Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. ● Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> ● β-blockers are recommended in all patients with reduced left ventricular (LV) systolic function (LVEF ≤40%). ● ACE inhibitors are indicated within 24 hours in all patients with LVEF ≤40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. ● ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. ● ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. ● Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF ≤35% and either diabetes or heart failure, without significant renal dysfunction

Clinical Guideline	Recommendations
	<p>(serum creatinine >2.5 mg/dL for men and >2.0 mg/dL for women) or hyperkalemia.</p> <ul style="list-style-type: none"> • Statin therapy with target LDL-C levels <70 mg/dL initiated early after admission is recommended.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of ST-Elevation Myocardial Infarction (2013)²²</p>	<p><u>Routine medical therapies: calcium channel blockers</u></p> <ul style="list-style-type: none"> • Evidence demonstrates that beneficial effect on infarct size or the rate of reinfarction when calcium channel blocker therapy was initiated during either the acute or convalescent phase of ST-segment elevation myocardial infarction (STEMI). However, calcium channel blockers may be useful to relieve ischemia, lower blood pressure, or control the ventricular response rate to atrial fibrillation in patients who are intolerant to β-blockers. • Use of immediate-release nifedipine is contraindicated in patients with STEMI due to hypotension and reflex sympathetic activation with tachycardia. <p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> • Oral β-blockers should be initiated within the first 24 hours in patients with an ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval >24 seconds, second or third degree heart block, active asthma, reactive airway disease). • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: Renin-Angiotensin-Aldosterone System Inhibitors</u></p> <ul style="list-style-type: none"> • An angiotensin-converting enzyme (ACE) inhibitor should be administered within the first 24 hours to all patients with STEMI with anterior location, HF, or ejection fraction (EF) \leq40%, unless contraindicated. • An angiotensin receptor blocker (ARB) should be given to patients with STEMI who have indications for but are intolerant of ACE inhibitors. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF \leq40% and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)²³</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin

Clinical Guideline	Recommendations
	<p>and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI.</p> <ul style="list-style-type: none"> • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients receiving drug-eluting stent. • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. • In selected patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
<p>National Institute for Health and Clinical Excellence: Myocardial Infarction:</p>	<p><u>Drug therapy</u></p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs: <ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker.

Clinical Guideline	Recommendations
<p>Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)²⁴</p>	<ul style="list-style-type: none"> ○ Statin. • Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. • Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. • Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> • Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. • Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during this time, it should be completed within 4 to 6 weeks of hospital discharge. • Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. • Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. • Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> • Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. • Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. • For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. • Special considerations should be made for people with dyspepsia. • After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for <i>Helicobacter pylori</i> should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). • Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. • Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago). <p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for

Clinical Guideline	Recommendations
	<p>anticoagulation.</p> <ul style="list-style-type: none"> • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> • After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. • β-blockers should be continued indefinitely after an acute MI. • After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> • Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. • If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> • For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. • Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist. •
<p>American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)²⁵</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> • Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C)

Clinical Guideline	Recommendations
	<p>Treatment of Stage B heart failure</p> <ul style="list-style-type: none"> • In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) • In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p>Pharmacological treatment for Stage C HFrEF</p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p>Pharmacological treatment for Stage C HFpEF</p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE:

Clinical Guideline	Recommendations
	<p>C)</p> <ul style="list-style-type: none"> The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p>Treatment of Stage D (advanced/refractory) HF</p> <ul style="list-style-type: none"> Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)²⁶</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. Administration of an aldosterone antagonist is recommended for patients with

Clinical Guideline	Recommendations
	<p>New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF (<35%) while receiving standard therapy, including diuretics.</p> <ul style="list-style-type: none"> • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are

Clinical Guideline	Recommendations
	<p>preferred in patients with decreased systolic function.</p> <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination

Clinical Guideline	Recommendations
	<p>therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response.</p> <ul style="list-style-type: none"> • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)²⁷</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e.,

Clinical Guideline	Recommendations
	<p>reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death).</p> <ul style="list-style-type: none"> Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. Step 3: <ul style="list-style-type: none"> Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>American Heart Association/ American College of Cardiology/ Heart Rhythm Society:</p>	<p><u>Recommendations for risk-based antithrombotic therapy:</u></p> <p>Class I</p> <ul style="list-style-type: none"> In patients with atrial fibrillation (AF), antithrombotic therapy should be individualized based on shared decision-making after discussion of the absolute

Clinical Guideline	Recommendations
<p>Guideline for the Management of Patients with Atrial Fibrillation (2014)²⁸</p>	<p>and relative risks of stroke, bleeding and the patient's values and preferences (Level of Evidence: C).</p> <ul style="list-style-type: none"> • Selection of antithrombotic therapy should be based on the risk of thromboembolism irrespective of whether the AF pattern is paroxysmal, persistent, or permanent (Level of Evidence: B). • In patients with nonvalvular AF, the CHA₂DS₂-VASc score is recommended for assessment of stroke risk (Level of Evidence: B). • For patients with AF who have mechanical heart valves, warfarin is recommended and the target international normalized ratio (INR) should be based on type and location of the prosthesis (Level of Evidence: B). • For patients with nonvalvular AF with prior stroke, TIA, or a CHA₂DS₂-VASc score ≥ 2, oral anticoagulants are recommended. Options include warfarin (INR 2.0 to 3.0) (Level of Evidence: A), dabigatran, rivaroxaban, or apixaban (Level of Evidence: B). • For patients treated with warfarin, the INR should be determined at least weekly during initiation of antithrombotic therapy and at least monthly when anticoagulation (INR in range) is stable (Level of Evidence: A). • For patients with nonvalvular AF unable to maintain a therapeutic INR level with warfarin, use of a direct thrombin or factor Xa inhibitor is recommended (Level of Evidence: C). • Re-evaluation of the need for and choice of antithrombotic therapy at periodic intervals is recommended to reassess stroke and bleeding risks (Level of Evidence: C). • Bridging therapy with UFH or LMWH is recommended for patients with AF and a mechanical heart valve undergoing procedures that require interruption of warfarin. Decisions regarding bridging therapy should balance the risks of stroke and bleeding (Level of Evidence: C). • For patients with AF without mechanical heart valves who require interruption of warfarin or newer anticoagulants for procedures, decisions about bridging therapy (LMWH or UFH) should balance the risks of stroke and bleeding and the duration of time a patient will not be anticoagulated (Level of Evidence: C). • Renal function should be evaluated prior to initiation of direct thrombin or factor Xa inhibitors and should be re-evaluated when clinically indicated and at least annually (Level of Evidence: B). • For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> • For patients with nonvalvular AF and a CHA₂DS₂-VASc score of 0, it is reasonable to omit antithrombotic therapy (Level of Evidence: B). • For patients with nonvalvular AF with a CHA₂DS₂-VASc score of ≥ 2 and who have end-stage chronic kidney disease (creatinine clearance < 15 mL/min) or who are on hemodialysis, it is reasonable to prescribe warfarin (INR 2.0 to 3.0) for oral anticoagulation (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> • For patients with nonvalvular AF and a CHA₂DS₂-VASc score of 1, no antithrombotic therapy or treatment with an oral anticoagulant or aspirin may be considered (Level of Evidence: C). • For patients with nonvalvular AF and moderate-to-severe chronic kidney disease with a CHA₂DS₂-VASc score of ≥ 2, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (e.g., dabigatran, rivaroxaban, or apixaban), but safety and efficacy have not been established (Level of Evidence: C). • In patients with AF undergoing PCI, bare-metal stents may be considered to minimize the required duration of dual antiplatelet therapy. Anticoagulation may be interrupted at the time of the procedure to reduce the risk of bleeding and the

Clinical Guideline	Recommendations
	<p>site of peripheral arterial puncture (Level of Evidence: C).</p> <ul style="list-style-type: none"> Following coronary revascularization (percutaneous or surgical) in patients with AF and a CHA₂DS₂-VASc score of ≥ 2, it may be reasonable to use clopidogrel (75 mg once daily) concurrently with oral anticoagulants but without aspirin (Level of Evidence: B). <p>Class III: No Benefit</p> <ul style="list-style-type: none"> The direct thrombin inhibitor, dabigatran, and the factor Xa inhibitor, rivaroxaban, are not recommended in patients with AF and end-stage chronic kidney disease or on hemodialysis because of the lack of evidence from clinical trials regarding the balance of risks and benefits (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> The direct thrombin inhibitor, dabigatran, should not be used in patients with AF and a mechanical heart valve (Level of Evidence: B). <p><u>Recommendations for rate control:</u></p> <p>Class I</p> <ul style="list-style-type: none"> Control of the ventricular rate using a beta blocker or nondihydropyridine (non-DHP) calcium channel blocker (CCB) is recommended for patients with paroxysmal, persistent, or permanent AF (Level of Evidence: B). Intravenous administration of a beta blocker or non-DHP CCB is recommended to slow the ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Level of Evidence: B). In patients who experience AF-related symptoms during activity, the adequacy of heart rate control should be assessed during exertion, adjusting pharmacological treatment as necessary to keep the ventricular rate within the physiological range (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> A heart rate control (resting heart rate <80 beats per minute [bpm]) strategy is reasonable for symptomatic management of AF (Level of Evidence: B). Intravenous amiodarone can be useful for rate control in critically ill patients without pre-excitation (Level of Evidence: B). Atrioventricular (AV) nodal ablation with permanent ventricular pacing is reasonable to control heart rate when pharmacological therapy is inadequate and rhythm control is not achievable (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and left ventricular systolic function is preserved (Level of Evidence: B). Oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> AV nodal ablation with permanent ventricular pacing should not be performed to improve rate control without prior attempts to achieve rate control with medications (Level of Evidence: C). Non-DHP CCBs should not be used in patients with decompensated HF as these may lead to further hemodynamic compromise (Level of Evidence: C). In patients with pre-excitation and AF, digoxin, non-DHP CCBs, or intravenous amiodarone should not be administered as they may increase the ventricular response and may result in ventricular fibrillation. (Level of Evidence: B). Dronedarone should not be used to control the ventricular rate in patients with permanent AF as it increases the risk of the combined endpoint of stroke, myocardial infarction, systemic embolism, or cardiovascular death (Level of Evidence: B).

Clinical Guideline	Recommendations
	<p>Recommendations for Thromboembolism Prevention:</p> <p>Class I</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with warfarin (INR 2.0 to 3.0) is recommended for at least three weeks prior to and four weeks after cardioversion, regardless of the CHA₂DS₂-VASc score and the method used to restore sinus rhythm (Level of Evidence: B). For patients with AF or atrial flutter of more than 48 hours duration that requires immediate cardioversion for hemodynamic instability, anticoagulation should be initiated as soon as possible and continued for at least four weeks after cardioversion unless contraindicated (Level of Evidence: C). For patients with AF or atrial flutter of less than 48-hour duration and with high risk stroke, intravenous heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after cardioversion, followed by long-term anticoagulation therapy (Level of Evidence: C). Following cardioversion for AF of any duration, the decision regarding long-term anticoagulation therapy should be based on the thromboembolic risk profile (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of 48-hour duration or longer or of unknown duration who have not been anticoagulated for the preceding three weeks, it is reasonable to perform a TEE prior to cardioversion and proceed with cardioversion if no LA thrombus is identified, including in the LAA, provided that anticoagulation is achieved before TEE and maintained after cardioversion for at least four weeks (Level of Evidence: B). For patients with AF or atrial flutter of 48-hour duration or longer, or when the duration of AF is unknown, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for at least three weeks prior to and four weeks after cardioversion (Level of Evidence: C). <p>Class IIb</p> <ul style="list-style-type: none"> For patients with AF or atrial flutter of less than 48-hour duration who are at low thromboembolic risk, anticoagulation (heparin, LMWH, or a new oral anticoagulant) or no antithrombotic therapy may be considered for cardioversion, without the need for post cardioversion oral anticoagulation (Level of Evidence: C). <p>Recommendations for pharmacological cardioversion</p> <p>Class I</p> <ul style="list-style-type: none"> Flecainide, dofetilide, propafenone, and intravenous ibutilide are useful for pharmacological cardioversion of AF or atrial flutter, provided contraindications to the selected drug are absent (Level of Evidence: A). <p>Class IIa</p> <ul style="list-style-type: none"> Administration of oral amiodarone is a reasonable option for pharmacological cardioversion of AF (Level of Evidence: A). Propafenone or flecainide (“pill-in-the-pocket”) in addition to a beta blocker or non-DHP CCB is reasonable to terminate AF outside the hospital once this treatment has been observed to be safe in a monitored setting for selected patients (Level of Evidence: B). <p>Class III: Harm</p> <ul style="list-style-type: none"> Dofetilide therapy should not be initiated out of hospital because of the risk of excessive QT prolongation that can cause torsades de pointes (Level of Evidence: B). <p>Recommendations for antiarrhythmic drugs to maintain sinus rhythm</p> <p>Class I</p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C). • The following antiarrhythmic drugs are recommended in patients with AF to maintain sinus rhythm, depending on underlying heart disease and comorbidities (Level of Evidence: A): <ul style="list-style-type: none"> ○ Amiodarone ○ Dofetilide ○ Dronedarone ○ Flecainide ○ Propafenone ○ Sotalol • The risks of the antiarrhythmic drug, including proarrhythmia, should be considered before initiating therapy with each drug (Level of Evidence: C). • Because of its potential toxicities, amiodarone should only be used after consideration of risks and when other agents have failed or are contraindicated (Level of Evidence: C). <p>Class IIa</p> <ul style="list-style-type: none"> • A rhythm-control strategy with pharmacological therapy can be useful in patients with AF for the treatment of tachycardia-induced cardiomyopathy (Level of Evidence: C). <p>Class IIb</p> <ul style="list-style-type: none"> • It may be reasonable to continue current antiarrhythmic drug therapy in the setting of infrequent, well-tolerated recurrences of AF when the drug has reduced the frequency or symptoms of AF (Level of Evidence: C). <p>Class III: Harm</p> <ul style="list-style-type: none"> • Antiarrhythmic drugs for rhythm control should not be continued when AF becomes permanent (Level of Evidence: C), including dronedarone (Level of Evidence: B). • Dronedarone should not be used for treatment of AF in patients with New York Heart Association class III and IV HF or patients who have had an episode of decompensated HF in the past 4 weeks. (Level of Evidence: B). <p>Upstream therapy</p> <p>Class IIa</p> <ul style="list-style-type: none"> • An angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction (Level of Evidence: B). <p>Class IIb</p> <ul style="list-style-type: none"> • Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension (Level of Evidence: B). • Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery (Level of Evidence: A). <p>Class III: No Benefit</p> <ul style="list-style-type: none"> • Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease (Level of Evidence: B).
<p>National Institute for Health and Clinical Excellence: Atrial Fibrillation: The Management of Atrial Fibrillation (2014)²⁹</p>	<p>Interventions to prevent stroke</p> <ul style="list-style-type: none"> • Do not offer stroke prevention to people aged <65 years with atrial fibrillation (AF) and no risk factors other than their sex (that is, very low risk of stroke equating to CHA₂DS₂-VASc score of 0 for men or 1 for women). • Consider anticoagulation for men with a CHA₂DS₂-VASc score of 1. Take the bleeding risk into account. • Offer anticoagulation to people with a CHA₂DS₂-VASc score of 2 or above, taking bleeding risk into account.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Discuss the options for anticoagulation with the person and base the choice on their clinical features and preferences. • Apixaban <ul style="list-style-type: none"> ○ Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorization, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: <ul style="list-style-type: none"> ▪ Prior stroke of transient ischemic attack (TIA). ▪ Age 75 years or older. ▪ Hypertension. ▪ Diabetes mellitus. ▪ Symptomatic heart failure. • Dabigatran etexilate <ul style="list-style-type: none"> ○ Dabigatran etexilate is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more of the following risk factors: <ul style="list-style-type: none"> ▪ Previous stroke, TIA, or systemic embolism. ▪ Left ventricular ejection fraction (LVEF) <40%. ▪ Symptomatic heart failure (HF) of New York Heart Association (NYHA) class 2 or above. ▪ Age 75 years or older. ▪ Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease, or hypertension. • Rivaroxaban <ul style="list-style-type: none"> ○ Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular AF with one or more risk factors such as: <ul style="list-style-type: none"> ▪ Congestive heart failure. ▪ Hypertension. ▪ Age 75 years or older. ▪ Diabetes mellitus. ▪ Prior stroke or TIA. • The decision about whether to start treatment with a new oral anticoagulant should be made after an informed discussion between the clinician and the person about the risks and benefits of the agent compared with the alternatives, including warfarin. For people who are taking warfarin, the potential risks and benefits of switching to a different oral agent should be considered in light of their level of international normalized ratio (INR) control. <p><u>Assessing anticoagulation control with vitamin K antagonists</u></p> <ul style="list-style-type: none"> • Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR: <ul style="list-style-type: none"> ○ Use a validated method of measurement such as the Rosendaal method for computer-assisted dosing or proportion of tests in range for manual dosing. ○ Exclude measurements taken during the first six weeks of treatment. ○ Calculate TTR over a maintenance period of at least six months. • Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following: <ul style="list-style-type: none"> ○ Two INR values higher than 5 or one INR value higher than 8 within the past six months. ○ Two INR values less than 1.5 within the past six months. ○ TTR <65%. • When assessing anticoagulation, take into account and if possible address the following factors that may contribute to poor anticoagulation control: Cognitive function, adherence, illness, drug interactions, and lifestyle factors including diet

Clinical Guideline	Recommendations
	<p>and alcohol consumption.</p> <ul style="list-style-type: none"> • If poor anticoagulation control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss these with the person. <p><u>When to offer rate and rhythm control</u></p> <ul style="list-style-type: none"> • Offer rate control as the first-line strategy to people with AF, except in people whose AF has a reversible cause, who have HF thought to be primarily caused by AF, with new-onset AF, with atrial flutter whose condition is considered suitable for an ablation strategy to restore sinus rhythm, and for whom a rhythm control strategy would be more suitable based on clinical judgement. <p><u>Rate control</u></p> <ul style="list-style-type: none"> • Offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium channel blocker (CCB) as initial monotherapy to people with AF who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities, and preferences when considering drug treatment. • Consider digoxin monotherapy for people with non-paroxysmal AF only if they are sedentary. • If monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any two of the following: a beta-blocker, diltiazem, and digoxin. • Do not offer amiodarone for long-term rate control. <p><u>Rhythm control</u></p> <ul style="list-style-type: none"> • Consider pharmacological and/or electrical rhythm control for people with AF whose symptoms continue after heart rate has been controlled or for whom a rate-control strategy has not been successful. <p><u>Drug treatment for long-term rhythm control</u></p> <ul style="list-style-type: none"> • Assess the need for drug treatment for long-term rhythm control, taking into account the person's preferences, associated comorbidities, risks of treatment, and likelihood of recurrence of AF. • If drug treatment for long-term rhythm control is needed, consider a standard beta-blocker as first-line treatment unless there are contraindications. • If beta-blockers are contraindicated or unsuccessful, assess the suitability of alternative drugs for rhythm control, taking comorbidities into account. • Dronedarone is recommended as an option for the maintenance of sinus rhythm after successful cardioversion in people with paroxysmal or persistent atrial fibrillation: <ul style="list-style-type: none"> ○ Whose AF is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option and after alternative options have been considered AND ○ Who have at least one of the following cardiovascular risk factors: <ul style="list-style-type: none"> ▪ Hypertension requiring drugs of at least two different classes. ▪ Diabetes mellitus. ▪ Previous TIA, stroke, or systemic embolism. ▪ Left atrial diameter of 50 mm or greater, OR ▪ Age \geq70 years, AND ○ Who do not have left ventricular systolic dysfunction, AND ○ Who do not have a history of, or current, HF. • People who do not meet the criteria above who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Consider amiodarone for people with left ventricular impairment or HF. • Do not offer class 1c antiarrhythmic drugs such as flecainide or propafenone to people with known ischemic or structural heart disease. • Where people have infrequent paroxysms and few symptoms, or where symptoms are induced by known precipitants (such as alcohol, caffeine), a 'no drug treatment' strategy or a 'pill-in-the-pocket' strategy should be considered and discussed with the person.
<p>American College of Chest Physicians: Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery (2005)³⁰</p>	<ul style="list-style-type: none"> • β-blockers and nondihydropyridine calcium channel blockers are recommended as first- and second-line agents to control ventricular response rate in AF after cardiac surgery. Digoxin has shown little efficacy in this patient population. • Current medical evidence does not support the use of digitalis for the prevention of postoperative AF. • No recommendation can be made regarding the use of digoxin for rhythm control of postoperative AF or atrial flutter. • Agents with proarrhythmic properties and those that are contraindicated in patients with coronary artery disease have not been shown to be effective in controlling the ventricular response rate in AF after cardiac surgery. • Amiodarone is the recommended first-line agent for pharmacologic rhythm control of postoperative AF or atrial flutter in patients with depressed left ventricular function who do not need urgent electrical cardioversion. • Sotalol and Class Ia antiarrhythmics are the recommended first-line agents for pharmacologic rhythm control of postoperative AF or atrial flutter in patients with coronary artery disease without CHF. • When prophylaxis to prevent postoperative AF is indicated, β-blockers are the recommended agents. • Sotalol may be an alternative therapy to prevent postoperative AF, but its ability to cause toxicity may not make it a favorable option. • Amiodarone may also be considered as an alternative therapy to β-blockers to prevent postoperative AF, but its ability to cause toxicity may not make it a favorable option.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)³¹</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)³²</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/ European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)³³, Reappraisal of Guidelines on Hypertension Management (2009)³⁴</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely

Clinical Guideline	Recommendations
	<p>to be well tolerated.</p> <ul style="list-style-type: none"> • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)³⁵</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension.

Clinical Guideline	Recommendations
	<p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP > 160 mmHg or DBP > 110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced.

Clinical Guideline	Recommendations
	<p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)³⁶ Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly:

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. ● If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. ● If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. ● For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. ● If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. ● Resistant hypertension should be considered with clinic blood pressure remains $>140/90$ mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. ● For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)³⁷</p>	<ul style="list-style-type: none"> ● To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. ● Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. ● Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. ● In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. ● Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. ● In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. ● Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. ● ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on</p>	<ul style="list-style-type: none"> ● All antihypertensives can be used to lower blood pressure in chronic kidney disease. ● Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. ● Antihypertensive regimens should be simplified as much as possible and long-

Clinical Guideline	Recommendations
<p>Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)³⁸</p>	<p>acting agents should be used when possible.</p> <ul style="list-style-type: none"> • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)³⁹</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion > 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated

Clinical Guideline	Recommendations
	<p>with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> • Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)⁴⁰</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Patients with blood pressure $>120/80$ mmHg should be advised on lifestyle

Clinical Guideline	Recommendations
	<p>changes to reduce blood pressure.</p> <ul style="list-style-type: none"> • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the miscellaneous calcium-channel blocking agents are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Calcium-Channel Blocking Agents, Miscellaneous^{1,2,8-18}

Indication	Diltiazem	Verapamil
Angina Pectoris		
Angina due to coronary artery spasm	✓ (tablet, ER capsule [Cardizem CD [®]])	
Chronic stable angina	✓	✓ (tablet)
Unstable angina		✓ (tablet)
Vasospastic angina		✓ (tablet)
Arrhythmias		
Control of ventricular rate at rest and during stress in patients with chronic atrial flutter		✓ (tablet)

and/or atrial fibrillation in association with digitalis		
Prophylaxis of repetitive paroxysmal supraventricular tachycardia		✓ (tablet)
Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias	✓ (injection)	✓ (injection)
Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation	✓ (injection)	✓ (injection)
Hypertension		
Hypertension	✓ * (ER)	✓

*May be used alone or in combination with other antihypertensive agents.
ER=extended-release

IV. Pharmacokinetics

The pharmacokinetic parameters of the miscellaneous calcium-channel blocking agents are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Calcium-Channel Blocking Agents, Miscellaneous²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Diltiazem*	35 to 40	77 to 93	Liver, extensive (% not reported)	Renal (35) Feces (60 to 65)	3 to 10
Verapamil*	20 to 35	88 to 94	Liver (65 to 80)	Renal (70) Feces (9 to 16)	4 to 12

*Immediate-release

V. Drug Interactions

Significant drug interactions with the miscellaneous calcium-channel blocking agents are listed in Table 5.

Table 5. Significant Drug Interactions with the Calcium-Channel Blocking Agents, Miscellaneous¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	1	Ibrutinib	Diltiazem inhibits CYP3A4 metabolism of ibrutinib, thereby increasing plasma concentrations, pharmacologic effects, and risk of toxicity (e.g., hemorrhage, renal toxicity).
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	1	Lomitapide	Diltiazem inhibits CYP3A4 metabolism of lomitapide, thereby increasing plasma concentrations, pharmacologic effects, and risk of adverse reactions, including hepatotoxicity.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	1	Narcotic Analgesics	Calcium-channel blocking agents, miscellaneous may increase plasma concentrations of narcotic analgesics, increasing the potential for enhanced pharmacologic effects and toxicity. Inhibition of CYP3A4 isoenzyme by Calcium-channel blocking agents, miscellaneous may decrease the metabolic elimination of narcotic analgesics.
Calcium-channel blocking agents, miscellaneous	1	Colchicine	Plasma concentrations of colchicine may be increased by diltiazem. Colchicine toxicity may occur. Inhibition of CYP3A4

Generic Name(s)	Significance Level	Interaction	Mechanism
(diltiazem)			and/or efflux transporter P-glycoprotein diltiazem may increase the absorption and decrease the metabolic elimination of colchicine.
Calcium-channel blocking agents, miscellaneous (diltiazem)	1	Macrolides	Increased serum levels of macrolide antibiotics may result if administered with diltiazem, due to diltiazem's inhibitory effect on CYP3A4. Coadministration should be avoided.
Calcium-channel blocking agents, miscellaneous (diltiazem)	1	Statins	Plasma concentrations and pharmacologic effects of statins may be increased by coadministration of diltiazem. The risk of myopathy and rhabdomyolysis may be increased. Inhibition of CYP3A4 isoenzymes by diltiazem may decrease the metabolic elimination of statins.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	β -Blockers	Effects of β -blockers and diltiazem may be increased, close monitoring of cardiac function is recommended. Diltiazem may inhibit the metabolism of some β -blockers (atenolol, metoprolol and propranolol), leading to increased effects of these β -blockers.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Colchicine	Plasma concentrations of colchicine may be increased by verapamil. Colchicine toxicity may occur. Inhibition of CYP3A4 and/or efflux transporter P-glycoprotein verapamil may increase the absorption and decrease the metabolic elimination of colchicine.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Digoxin	Verapamil may alter the pharmacokinetics and increase serum concentrations of digoxin. Verapamil may decrease nonrenal and total digoxin clearance.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Dofetilide	Increase serum levels and effects of dofetilide may occur if coadministered with verapamil, increasing the risk of arrhythmia.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Erythromycin	Plasma concentration of erythromycin may be increased by concurrent use of verapamil. Concurrent use should be avoided because elevated concentrations of erythromycin have been associated with an increased risk for sudden death from cardiac causes. Inhibition of CYP3A4 isoenzymes by verapamil may decrease the metabolic elimination of erythromycin. Elevated concentrations of erythromycin have been associated with prolongation of the QT interval, torsades de pointes, and an increased risk of sudden death.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Macrolides & Ketolides	Increased verapamil serum levels and effects may occur if coadministered, due to inhibition of verapamil metabolism by macrolide antibiotics.
Calcium-channel	1	Quinidine	Pharmacologic effects of quinidine may be

Generic Name(s)	Significance Level	Interaction	Mechanism
blocking agents, miscellaneous (verapamil)			increased. This combination may produce marked hypotension. Verapamil inhibits the hepatic metabolism of quinidine.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	2	Carbamazepine	Increased serum levels of carbamazepine may result if administered with diltiazem, increasing the risk of greater effect and toxicity, due to inhibition of carbamazepine metabolism by diltiazem.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	2	Cyclosporine	Increased serum levels of cyclosporine may result if administered with diltiazem, due to inhibition of cyclosporine metabolism by diltiazem.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	2	Everolimus	Pharmacologic effects and plasma concentrations of everolimus may be increased by diltiazem. Inhibition of CYP3A4 and P-glycoprotein by diltiazem may decrease the metabolic elimination of everolimus.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	2	Ranolazine	Increased serum levels of ranolazine may result if administered with diltiazem, due to diltiazem's inhibitory effect on CYP3A4. Coadministration should be avoided due to the increased risk of QTc prolongation, torsades de pointes arrhythmias and death.
Calcium-channel blocking agents, miscellaneous (diltiazem, verapamil)	2	Vasopressin Receptor Antagonists	Plasma concentrations and pharmacologic effects of vasopressin receptor antagonists may be increased by diltiazem. Inhibition of CYP3A isoenzymes by diltiazem may decrease the metabolic elimination of vasopressin receptor antagonists.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	Benzodiazepines	Increased serum levels of benzodiazepines may result if administered with diltiazem, increasing the risk of central nervous system depression, due to decreased metabolism of benzodiazepines.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	β -Blockers	Increased serum levels of β -blockers may result if administered with diltiazem, increasing the risk of symptomatic bradycardia, due to decreased metabolism of β -blockers and additive pharmacologic effects.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	Cilostazol	Pharmacologic effects of cilostazol may be increased by diltiazem. Elevated plasma concentrations with toxicity may occur. Inhibition of CYP3A4 isoenzymes by diltiazem may decrease the metabolic elimination of cilostazol.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	Corticosteroids	Diltiazem may increase the pharmacologic effects of corticosteroids. Inhibition of CYP3A4 isoenzymes by diltiazem may decrease the metabolic elimination of corticosteroids.
Calcium-channel blocking agents,	2	Digoxin	Increased serum levels of digoxin may result, increasing the risk of digoxin

Generic Name(s)	Significance Level	Interaction	Mechanism
miscellaneous (diltiazem)			toxicity, if administered with diltiazem, due to decreased renal clearance of digoxin.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	HIV Protease Inhibitors	Plasma concentrations and pharmacologic effects of diltiazem may be increased by HIV protease inhibitors. An additive effect on the PR interval has also been demonstrated. Plasma concentrations and pharmacologic effects of diltiazem may be increased by HIV protease inhibitors.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	Macrolide immunosuppressives	Plasma trough concentrations of macrolide immunosuppressives may be increased by diltiazem. Neurologic toxicity may occur. Diltiazem may increase the plasma trough concentrations of macrolide immunosuppressives. Neurologic toxicity may occur.
Calcium-channel blocking agents, miscellaneous (diltiazem)	2	Theophyllines	The pharmacologic and toxic effects of theophyllines may be increased due to the inhibition of metabolism of theophylline by diltiazem.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Aldosterone Blockers	Verapamil may increase plasma concentrations and pharmacologic or toxic effects of aldosterone blockers. Inhibition of CYP3A4 isoenzymes by verapamil may decrease the metabolic elimination of aldosterone blockers.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Clonidine	Sinus bradycardia, atrioventricular block and severe hypotension may occur with coadministration of clonidine and verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Dronedarone	Plasma concentrations and pharmacologic effects of dronedarone may be increased by verapamil. Dronedarone may also increase the plasma concentrations and pharmacologic effects of verapamil. Additionally, verapamil may enhance the electrophysiologic effects of dronedarone.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Flecainide	Increased risk of cardiotoxic effects may occur when flecainide and verapamil are coadministered. Cardiogenic shock or asystole may develop. Pharmacologic effects may be additive or synergistic.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	HMG CoA reductase inhibitors	Increased serum levels of HMG CoA reductase inhibitors may result, increasing the risk of toxicities, such as myositis and rhabdomyolysis, if coadministered with verapamil, due to decreased metabolism of HMG CoA reductase inhibitors.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Nondepolarizing muscle relaxants	Increased serum levels of nondepolarizing muscle relaxants may result, increasing the risk of respiratory depression, if coadministered with verapamil, due to calcium's role on muscle contraction.
Calcium-channel	2	Quinazolines	The combination of verapamil and

Generic Name(s)	Significance Level	Interaction	Mechanism
blocking agents, miscellaneous (verapamil)			quinazolines may produce an acute hypotensive effect which is greater than when either drug is taken alone. Verapamil may decrease the first-pass hepatic metabolism and increase the bioavailability of quinazolines.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Rifampin	Decreased serum levels of verapamil may result if coadministered with rifampin, due to increased metabolism of verapamil.

CYP=cytochrome P450 isoenzymes, HIV=human immunodeficiency virus, HMG CoA=3-hydroxy-3-methyl-glutaryl-CoA
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the miscellaneous calcium-channel blocking agents are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Calcium-Channel Blocking Agents, Miscellaneous^{1,2,6-16}

Adverse Events	Diltiazem	Verapamil
Cardiovascular		
Angina	-	<1
Arrhythmia	<2	-
Atrial fibrillation	-	✓
Atrioventricular dissociation	-	<1
Atrioventricular block	2 to 8	1 to 2
Bradycardia	2 to 6	1
Bundle branch block	<2	-
Chest pain	-	<1
Claudication	-	<1
Congestive heart failure	<2	2
Edema	2 to 15	-
Extrasystoles	2	-
Flushing	1 to 2	1
Hypotension	<4	3
Myocardial infarction	-	<1
Palpitations	1 to 2	<1
Peripheral edema	2 to 8	2 to 4
Postural hypotension	-	<1
Syncope	<2	<1
Tachycardia	<2	-
Vasodilation	2 to 3	-
Ventricular fibrillation	-	✓
Central Nervous System		
Cerebrovascular accident	-	<1
Confusion	-	<1
Depression	<2	-
Dizziness	3 to 10	1 to 5
Fatigue	-	2 to 5
Headache	5 to 12	1 to 12
Insomnia	-	<1
Lethargy	-	3
Nervousness	2	-

Adverse Events	Diltiazem	Verapamil
Paresthesia	-	1
Psychotic symptoms	-	<1
Sleep disturbance	-	1
Somnolence	-	<1
Tremor	<2	<1
Vertigo	-	<1
Dermatologic		
Alopecia	-	<1
Ecchymosis	-	<1
Erythema multiforme	-	<1
Hair color change	-	✓
Hyperhidrosis	-	<1
Hyperkeratosis	-	<1
Petechiae	<2	-
Photosensitivity	<2	-
Rash	1 to 4	1 to 2
Stevens-Johnson syndrome	<2	-
Toxic epidermal necrolysis	<2	-
Endocrine and Metabolic		
Gout	1 to 2	-
Gynecomastia	-	<1
Hyperprolactinemia/galactorrhea	-	<1
Gastrointestinal		
Abdominal discomfort	-	<1
Constipation	<4	7 to 12
Diarrhea	1 to 2	2
Dry mouth	-	<1
Dysgeusia	<2	-
Dyspepsia	1 to 6	3
Gingival hyperplasia	<2	<19
Nausea	-	1 to 3
Vomiting	2	-
Genitourinary		
Acute renal failure	-	✓
Albuminuria	-	-
Crystalluria	-	-
Impotence	-	<1
Nocturia	-	-
Polyuria	-	<1
Sexual dysfunction	-	-
Spotty menstruation	-	<1
Hematological		
Hemolytic anemia	<2	-
Purpura	-	<1
Thrombocytopenia	<2	-
Laboratory Test Abnormalities		
Alkaline phosphatase increase	<2	-
ALT increased	<2	-
AST increased	<2	-
Liver enzyme elevations	-	1
Musculoskeletal		
Arthralgia	-	<1
Extrapyramidal symptoms	<2	-
Muscle cramps	-	<1

Adverse Events	Diltiazem	Verapamil
Myalgia	2	1
Pain	6	2
Paresthesia	-	1
Weakness	1 to 4	-
Respiratory		
Bronchitis	1 to 4	-
Cough	≤3	✓
Dyspnea	1 to 6	1
Pharyngitis	2 to 6	-
Rhinitis	<10	-
Sinus congestion	1 to 2	-
Other		
Abnormal visual accommodation	-	<1
Allergic reaction	<2	-
Amblyopia	<2	-
Amnesia	<2	-
Blurred vision	-	<1
Flu-like syndrome	-	4
Parkinsonian syndrome	-	✓
Tinnitus	-	<1

- ✓ Percent not specified
- Event not reported

VII. Dosing and Administration

The usual dosing regimens for the miscellaneous calcium-channel blocking agents are listed in Table 7.

Table 7. Usual Dosing Regimens for the Calcium-Channel Blocking Agents, Miscellaneous^{1,2,8-18}

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Diltiazem	<p><u>Angina pectoris (chronic stable):</u> Extended-release capsule: initial, 120 mg/day; maintenance, 180 to 480 mg/day; maximum, 480 mg/day</p> <p>Extended-release tablet: initial, 180 mg once daily; maximum, 360 mg/day</p> <p>Tablet: initial, 30 mg four times daily; maintenance, 180 to 360 mg/day</p> <p><u>Angina pectoris (due to coronary artery spasm):</u> Extended-release capsule (Cardizem CD[®]): initial, 120 or 180 mg once daily; maintenance, adjust dosage to each patient's needs</p> <p>Tablet: initial, 30 mg four</p>	Safety and efficacy in children have not been established.	<p>Extended-release capsule: 60 mg 90 mg 120 mg 180 mg 240 mg 300 mg 360 mg 420 mg</p> <p>Extended-release tablet: 120 mg 180 mg 240 mg 300 mg 360 mg 420 mg</p> <p>Injection: 5 mg/mL 100 mg</p> <p>Tablet:</p>

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>times daily; maintenance, 180 to 360 mg/day</p> <p><u>Arrhythmias:</u> Injection: weight based dosing administered intravenously</p> <p><u>Hypertension:</u> Extended-release capsule: initial, 180 to 240 mg once daily; maintenance, 180 to 480 mg/day; maximum, 540 mg/day</p> <p>Extended-release tablet: initial, 180 to 240 mg once daily; maintenance, 120 to 540 mg/day; maximum, 540 mg/day</p>		<p>30 mg 60 mg 90 mg 120 mg</p>
Verapamil	<p><u>Angina pectoris (chronic stable, unstable, and vasospastic):</u> Tablet: maintenance, 80 to 120 mg three times a day</p> <p><u>Arrhythmias:</u> Injection: weight based dosing administered by slow intravenous injection</p> <p>Tablet: maintenance, 240 to 480 mg/day, divided (three to four times daily)</p> <p><u>Hypertension:</u> Tablet: initial, 80 mg three times daily; maintenance, 360 to 480 mg/day divided (three to four times daily); maximum, 480 mg/day</p> <p>Extended-release tablet: maintenance, 180 to 480 mg/day</p>	<p>Safety and efficacy of oral verapamil in children have not been established.</p> <p><u>Arrhythmias in children 0 to 15 years of age:</u> Injection: weight based dosing administered by slow intravenous injection</p>	<p>Extended-release capsule 100 mg 120 mg 180 mg 200 mg 240 mg 300 mg 360 mg</p> <p>Extended-release tablet: 120 mg 180 mg 240 mg</p> <p>Injection: 2.5 mg/mL</p> <p>Tablet: 40 mg 80 mg 120 mg</p>

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the miscellaneous calcium-channel blocking agents are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Calcium-Channel Blocking Agents, Miscellaneous

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Angina				
De Rosa et al. ⁴¹ (1998) Diltiazem SR 300 mg QD vs verapamil SR 240 mg QD	DB, XO Men and women 48 to 72 years of age, with stable exertional angina, a positive test for myocardial ischemia and documented coronary artery disease	N=20 12 weeks	Primary: Exercise tolerance test: time to onset of angina, time to 1-mm ST-segment depression and total exercise duration Secondary: Heart rate, angina frequency, nitroglycerin use and adverse events	Primary: Time to onset of angina increased significantly in both groups compared to the placebo group (verapamil vs placebo; P<0.05 and diltiazem vs placebo; P<0.005). Time to 1-mm ST-segment depression increased significantly in both groups compared to the placebo group (verapamil vs placebo; P<0.05 and diltiazem vs placebo; P<0.005). Total exercise duration increased significantly in both groups compared to the placebo group (verapamil vs placebo; P<0.05 and diltiazem vs placebo; P<0.005). For each primary endpoint, there was no significant difference between the treatment groups. Secondary: Heart rates were similar between the treatment groups, except resting heart rate was significantly lower in the diltiazem group as compared to the verapamil group (68.5 vs 75.9; P<0.05). Angina frequency and nitroglycerin use decreased significantly in the diltiazem group compared to the placebo group (P<0.05) and to the verapamil group (P<0.05). Edema and flushing were most frequently reported. Similar rates of adverse events were reported for both treatments.
Chugh et al. ⁴² (2001) Diltiazem 240 mg	DB, DD, PG, RCT Patients with stable angina, blood	N=67 4 weeks	Primary: Treadmill exercise test: time to onset of angina, time to	Primary: Both treatment groups, and all doses, had significant increases in time to onset of angina from baseline (P<0.001 for all). There was no significant difference between the treatment groups (P=0.838) and between dose

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD for 2 weeks then 360 mg QD for 2 weeks</p> <p>vs</p> <p>amlodipine 5 mg QD for 2 weeks then 10 mg QD for 2 weeks</p>	<p>pressure in the range of 100/60 to 170/110 mm Hg and a positive ischemic response on a treadmill test, history of angiography</p>		<p>1-mm ST-segment depression</p> <p>Secondary: Heart rate, blood pressure, number of angina episodes and use of nitrates</p>	<p>levels (P=0.144) in time to onset of angina.</p> <p>Both treatment groups, and all doses, had significant increases in time to 1-mm ST-segment depression from baseline, except the low-dose amlodipine group (P<0.004, except P=0.063). There was no significant difference between the treatment groups and between dose levels (P=0.114) in time to 1-mm ST-segment depression (P=0.691).</p> <p>Secondary: There was no significant difference between the groups in heart rate at rest or maximal exercise.</p> <p>There was no significant difference between the groups in blood pressure at rest or maximal exercise, except SBP at rest was higher in the diltiazem group (137 to 143 vs 129 to 135 mm Hg; P=0.029).</p> <p>Both treatments reduced the number of angina episodes and the use of nitrates, but these results were not statistically different between the groups (P value not reported).</p>
<p>van Kesteren et al.⁴³ (1998)</p> <p>Diltiazem CR 90 to 120 mg BID</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p>	<p>DB, MC</p> <p>Men and women 41 to 77 years of age with a history of stable angina pectoris, a positive exercise tolerance test, and positive thallium scan or positive coronary angiogram</p>	<p>N=132</p> <p>8 weeks</p>	<p>Primary: Exercise tolerance test: time to 1-mm ST-segment depression, time to onset of chest pain, time to end of exercise (exercise duration)</p> <p>Secondary: Safety</p>	<p>Primary: Diltiazem and amlodipine treatment resulted in significant increases in time to 1-mm ST-segment depression as compared to baseline (P<0.0001). Treatments were not significantly different from each other (P>0.05).</p> <p>Diltiazem and amlodipine treatment resulted in significant increases in time to onset of chest pain at four and eight weeks, (10 and 13% for amlodipine; P<0.0001; 5 and 7% for diltiazem; P=0.009). Treatments were not significantly different from each other (P>0.05).</p> <p>Amlodipine treatment resulted in a significant increase in total exercise duration as compared to baseline (P=0.0002), however the change from baseline for diltiazem was not significantly increased (P=0.43). There was no significant difference between the treatment groups at endpoint.</p> <p>Secondary: Ten patients (15.2%) in the amlodipine group and 17 patients (25.8%) in the diltiazem group reported an adverse event; two patients from the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				amlodipine group and six patients from the diltiazem group subsequently withdrew from the study.
<p>Frishman et al.⁴⁴ (1999)</p> <p>Diltiazem 240 to 480 mg at bedtime</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD plus atenolol 50 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 30 to 80 years of age with chronic stable angina pectoris, evidence of exercise-induced ST-segment depression ≥ 1 mm and other evidence of cardiac disease</p>	<p>N=551</p> <p>4 week</p>	<p>Primary: Exercise tolerance test (symptom-limited exercise duration, time ≥ 1-mm ST-segment depression and time to moderate angina)</p> <p>Secondary: 48-hour Holter-determined number of ischemic episodes, mean and total duration of ischemia, maximal depth of ST depression, heart rate at onset of ischemia</p>	<p>Primary: Treatment with verapamil, amlodipine, and amlodipine plus atenolol resulted in significantly better results than patients treated with placebo in: symptom-limited exercise duration, time ≥ 1-mm ST-segment depression and time to moderate angina ($P \leq 0.01$ for all vs placebo).</p> <p>Secondary: Treatment with verapamil, amlodipine, and amlodipine plus atenolol resulted in significantly fewer ischemic episodes in 48-hour Holter monitoring ($P = 0.003$ for verapamil vs placebo).</p> <p>Treatment with amlodipine monotherapy resulted in a significant increase in duration of ischemic episode ($P \leq 0.05$ vs verapamil vs amlodipine plus atenolol and vs placebo).</p> <p>Treatment with verapamil and amlodipine plus atenolol resulted in a decrease in duration of ischemic episodes as compared to treatment with amlodipine and placebo ($P \leq 0.05$ for each).</p> <p>Heart rate at the onset of ischemic episode was significantly lower in the verapamil group and in the amlodipine plus atenolol group ($P \leq 0.05$ vs amlodipine) and higher in the amlodipine group ($P \leq 0.05$ vs verapamil, vs amlodipine plus atenolol and vs placebo).</p>
<p>Hauf-Zachariou et al.⁴⁵ (1997)</p> <p>Verapamil 120 mg TID</p> <p>vs</p> <p>carvedilol 25 mg BID</p>	<p>DB, MC, PG, RCT</p> <p>Patients 18 to 75 years with a confirmed diagnosis of CAD, exertional chest pain relieved by rest or glyceryl trinitrate for ≥ 2 months and 2 exercise tests with signs and symptoms</p>	<p>N=313</p> <p>12 weeks</p>	<p>Primary: Total exercise time, time to onset of angina, and time to 1 mm ST-segment depression, blood pressure, heart rate, rate pressure product</p> <p>Secondary:</p>	<p>Primary: There was not a significant difference in total exercise time observed between the carvedilol (increased from 378 s to 436 s) and verapamil (increased from 386 s to 438 s) groups (RR, 1.14; 90% CI, 0.85±1.52).</p> <p>There was not a significant difference observed between the carvedilol and verapamil groups in time to onset of angina (increase from 296 s to 325 s vs 285 s to 326 s) and in time to 1 mm ST-segment depression (increase from 267 s to 298 s vs 286 s to 302 s).</p> <p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced SBP (from 175 to 166 mm Hg) compared to</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	of ischemia		Not reported	<p>verapamil (from 173 to 173 mm Hg)).</p> <p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced heart rate (from 123 to 112 mm Hg) compared to verapamil (from 124 to 120 mm Hg)).</p> <p>At peak exercise and at maximum comparable workload, carvedilol significantly reduced rate pressure product (from 21564 to 18802 mm Hg) compared to verapamil (from 21488 to 20992 mm Hg)).</p> <p>Secondary: Not reported</p>
Cardiovascular Outcomes				
<p>Boden et al.⁴⁶ (2002) INTERCEPT</p> <p>Diltiazem 300 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PG, PRO, RCT</p> <p>Patients 75 years of age and younger, with acute MI, without CHF and who received a thrombolytic agent</p>	<p>N=874</p> <p>Up to 6 months</p>	<p>Primary: Composite first-event rate of: cardiac death, nonfatal reinfarction or refractory ischemia</p> <p>Secondary: Composite of first occurrence of cardiac death, nonfatal reinfarction, recurrent ischemia, composite of cardiac death, nonfatal reinfarction, need for myocardial revascularization, safety</p>	<p>Primary: There was no significant difference between diltiazem treatment and placebo treatment in composite event rate (131 primary outcome events occurred in the placebo group and 97 occurred in the diltiazem group; P=0.07).</p> <p>Secondary: Rates of all composite nonfatal cardiac events (nonfatal reinfarction combined with refractory ischemia or all recurrent ischemia or need for revascularization) significantly favored the diltiazem group over the placebo group (P=0.05, P=0.05, P=0.03 respectively).</p> <p>Rates of cardiac death, nonfatal reinfarction, refractory ischemia and all recurrent ischemia were similar between the diltiazem group and the placebo group, however the need for revascularization favored the diltiazem group (P=0.67, P=0.47, P=0.07, P=0.07, P=0.03).</p> <p>There was no increase in rates of CHF, bleeding, cancer or cerebrovascular accidents in the diltiazem group.</p>
<p>Gibson et al.⁴⁷ (2000)</p>	<p>RETRO combined subgroup analysis</p>	<p>N=817</p>	<p>Primary: All cause mortality</p>	<p>Primary: Patients receiving treatment (either agent) had a 42% lower mortality rate</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Diltiazem 60 mg QID or verapamil 120 mg TID vs placebo	of 2 RCT Patients suffering acute non-Q-wave MI	12 to 18 months	Secondary: Combined cardiac events	than those receiving placebo (P=0.010). Secondary: Patients receiving treatment (either agent) had a 31% lower event rate (death or recurrent MI) than those receiving placebo (P<0.006).
Hansson et al. ⁴⁸ (2000) NORDIL Diltiazem 180 to 360 mg QD vs conventional therapy (diuretic, β-blocker or both)	BE, MC, OL, PRO, RCT Patients 50 to 74 years of age with DBP ≥100 mm Hg and previously untreated	N=10,881 4.5 years	Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI	Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97). Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04). Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17). Other endpoints were not statistically different between the groups including cardiovascular death (P=0.41), all cardiac events (P=0.57 and congestive heart failure (P=0.42).
Pepine et al. ⁴⁹ (2003) INVEST Verapamil SR 240 mg/day (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist	MC, OL, RCT Patients with essential HTN	N=22,576 24 months	Primary: First occurrence of death (all cause), nonfatal MI or stroke Secondary: Cardiovascular death, angina, cardiovascular hospitalization, angina, blood pressure control (SBP/DBP	Primary: At 24 months, in the calcium antagonist strategy subgroup, 81.5% of patients were taking verapamil SR, 62.9% trandolapril, and 43.7% HCTZ. In the non-calcium antagonist strategy, 77.5% of patients were taking atenolol, 60.3% HCTZ, and 52.4% trandolapril. After a follow-up of 61,835 patient-years (mean, 2.7 years per patient), 2,269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in calcium antagonist strategy vs 10.17% in non-calcium antagonist strategy; RR, 0.98; 95% CI, 0.90 to 16; P=0.57). Secondary: There was no significant difference in the rate of cardiovascular death

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>strategy)</p> <p>vs</p> <p>atenolol 50 mg/day (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p> <p>Trandolapril was recommended for all patients with heart failure, diabetes, or renal insufficiency.</p>			<p><140/90 mm Hg or <130/85 mm Hg if diabetic or renal impairment), safety</p>	<p>(P=0.94) or cardiovascular hospitalization (P=0.59) between the two treatment groups.</p> <p>At 24 months, angina episodes decreased in both groups, but the mean frequency was lower in the calcium antagonist strategy group (0.77 episodes/week) compared to the non-calcium antagonist strategy group (0.88 episodes/week; P=0.02).</p> <p>Two-year blood pressure control was similar between groups. The blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of calcium antagonist strategy patients and 64.0% (systolic) and 88.1% (diastolic) of non-calcium antagonist strategy patients. A total of 71.7% of calcium antagonist strategy patients and 70.7% of non-calcium antagonist strategy patients achieved an SBP <140 mm Hg and DBP <90 mm Hg.</p> <p>Both regimens were generally well tolerated. Patients in the calcium antagonist strategy group reported constipation and cough more frequently than patients in the non-calcium antagonist strategy group, while non-calcium antagonist strategy patients experienced more dyspnea, lightheadedness, symptomatic bradycardia and wheezing (all were statistically significant with P≤0.05).</p>
<p>Mancia et al.⁵⁰ (2007) INVEST</p> <p>Verapamil SR 120 to 480 mg QD</p> <p>vs</p> <p>atenolol 25 to 200 mg QD</p>	<p>MC, open blinded endpoint, PRO, RCT</p> <p>Patients with HTN, requiring drug therapy (BP>140/90 or >130/80 mm Hg if diabetic or with renal impairment), and CAD</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: Occurrence of death, nonfatal MI and nonfatal stroke</p> <p>Secondary: Blood pressure control rates</p>	<p>Primary: Rates (death, nonfatal MI and nonfatal stroke) were similar for both treatment groups (P value not reported).</p> <p>Secondary: Rates of death, MI and stroke declined as the number of office visits for which blood pressure was controlled increased (P<0.001).</p>
<p>Pepine et al.⁵¹ (2006) INVEST</p>	<p>Post hoc analysis of INVEST</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: Risk for adverse outcome associated</p>	<p>Primary: Previous heart failure (adjusted HR, 1.96), as well as diabetes (HR, 1.77), increased age (HR, 1.63), United States residency (HR, 1.61), renal</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Verapamil SR (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist strategy)</p> <p>vs</p> <p>atenolol (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p>	<p>Patients with essential HTN</p>		<p>with baseline factors, follow-up blood pressure and drug treatments</p> <p>Secondary: Not reported</p>	<p>impairment (HR, 1.50), stroke/TIA (HR, 1.43), smoking (HR, 1.41), MI (HR, 1.34), PVD (HR, 1.27), and revascularization (HR, 1.15) predicted increased risk.</p> <p>Follow-up SBP <140 mm Hg (HR, 0.82) or DBP <90 mm Hg (HR, 0.70) and trandolapril with verapamil SR (HR, 0.78 and 0.79) were associated with reduced risk.</p> <p>Secondary: Not reported</p>
<p>Bangalore et al.⁵² (2008) INVEST</p> <p>Verapamil SR 120 to 480 mg QD</p> <p>vs</p> <p>atenolol 25 to 200 mg QD</p> <p>Trandolapril</p>	<p>INVEST substudy</p> <p>Patients 50 years of age and older with hypertension requiring drug therapy (blood pressure >140/90 or >130/80 mm Hg if diabetic or with renal impairment), and documented coronary artery</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: First occurrence of death, nonfatal MI, nonfatal stroke</p> <p>Secondary: Death, total MI, total stroke</p>	<p>Primary: No significant difference was observed between groups in the primary endpoint (P=0.30).</p> <p>Among patients with the primary outcome, no significant difference was observed between groups in the risk of death (P=0.94).</p> <p>There was no significant difference between groups in the risk of nonfatal MI (P=0.41).</p> <p>There was a trend toward a 29% reduction in the risk of nonfatal stroke in the verapamil group compared to the atenolol group (P=0.06).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and/or HCTZ were added to control blood pressure.	disease			<p>Secondary: The risks of fatal and nonfatal MI were similar between groups.</p> <p>No significant differences were observed between groups in fatal and nonfatal stroke (P=0.18).</p>
<p>Brunner et al.⁵³ (2007) INVEST</p> <p>Verapamil SR 240 mg and trandolapril 1 to 4 mg</p>	<p>Post hoc analysis of INVEST</p> <p>Patients with essential HTN</p>	<p>N=1,832</p> <p>24 months</p>	<p>Primary: Factors influencing blood pressure response to trandolapril add-on therapy</p> <p>Secondary: Not reported</p>	<p>Primary: Trandolapril decreased mean unadjusted SBP and DBP by -9.1 and -4.1 mm Hg, respectively. The percentage of patients with blood pressure under control (<140/90 mm Hg) increased from 6.7 to 41.3% (P<0.0001).</p> <p>Adjusted blood pressure response was significantly associated with age and baseline SBP and DBP (P<0.0001). Whereas the decrease in SBP was more pronounced in younger patients, the opposite was observed for DBP decrease.</p> <p>DBP response was significantly associated with race. Specifically, the adjusted DBP decrease was significantly smaller in Hispanics and African Americans than whites (P=0.0032 and P=0.0069, respectively). However, Hispanics achieved a decrease in SBP and an increase in blood pressure control similar to the other ethnic groups.</p> <p>Secondary: Not reported</p>
<p>Black et al.⁵⁴ (2003) CONVINCE</p> <p>Verapamil ER 180 mg QD</p> <p>vs</p> <p>atenolol 50 mg QD</p> <p>vs</p> <p>HCTZ 12.5 mg</p>	<p>AC, DB, MC, RCT</p> <p>Patients 55 years of age and older with HTN and ≥1 risk factor for cardiovascular disease</p>	<p>N=16,476</p> <p>3 years</p>	<p>Primary: Composite first occurrence of acute MI, stroke or cardiovascular disease-related death</p> <p>Secondary: Cardiovascular endpoints expanded, all-cause mortality, cancer,</p>	<p>Primary: There was no significant difference between the verapamil treatment group and the atenolol or HCTZ treatment groups in the composite primary endpoint (HR, 1.02; 95% CI, 0.88 to 1.18; P=0.77).</p> <p>Secondary: There was no significant difference between the verapamil treatment group and the atenolol or HCTZ treatment group in rates of cardiovascular-related hospitalization (P=0.31), death (all-cause mortality) (P=0.32) and cancer rates (P=0.46).</p> <p>Patients treated with verapamil experienced a significantly higher rate of death or bleeding unrelated to stroke (HR, 1.54; 95% CI, 1.15 to 2.04; P=0.003).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
QD			hospitalization for bleeding, incidence of primary endpoints between 6AM and noon, adverse events	<p>Primary endpoints did not differ significantly based on time of day (P=0.43).</p> <p>Patients treated with verapamil were more likely to withdraw for adverse events or symptoms than those treated with atenolol or HCTZ (P=0.02).</p>
<p>Lindholm et al.⁵⁵ (2005)</p> <p>Other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide*, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil)</p> <p>or</p> <p>placebo</p> <p>vs</p> <p>β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol, or propranolol)</p>	<p>MA</p> <p>13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both</p>	<p>N=105,951</p> <p>2.1 to 10.0 years</p>	<p>Primary: Stroke, MI, all-cause mortality</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001).</p> <p>The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported).</p> <p>The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Wysong et al.⁵⁶ (2007)</p> <p>Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>	<p>MA</p> <p>13 RCTs evaluating patients ≥18 years of age with HTN</p>	<p>N=91,561</p> <p>Duration varied</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions</p>	<p>Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p> <p>Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Hypertension				
<p>Wright et al.⁵⁷ (2004)</p> <p>Diltiazem graded-release 360 to 540 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p>	<p>AC, DB, MC, PG, RCT</p> <p>Male and female African Americans patients 18 to 80 years of age with hypertension (DBP 85 to 109 mm Hg and SBP <180 mm Hg)</p>	<p>N=268</p> <p>12 weeks</p>	<p>Primary: Change from baseline in DBP during first 4 hours of awakening as recorded by ambulatory blood pressure monitoring</p> <p>Secondary: Changes from baseline in BP, heart rate, rate-pressure product, safety</p>	<p>Primary: Reductions in DBP during the first four hours after awakening, and from 6AM to noon, were significantly greater in the diltiazem group than in the amlodipine group (-13.12 vs -9.65 mm Hg; P=0.0049 and -11.97 vs -8.75 mm Hg; P=0.0019).</p> <p>Secondary: Reductions in SBP during the first four hours after awakening and between 6AM and noon, were similar between the groups (P<0.0768 and P<0.9470).</p> <p>Mean 24-hour SBP reductions were significantly greater in the amlodipine group than in the diltiazem group (-14.08 vs -10.64; P=0.0022).</p> <p>Reductions in heart rate were significantly greater in the diltiazem group than in the amlodipine group (24 hour mean: -4.88 vs 1.77; P<0.0001).</p> <p>Reductions in rate-pressure product were significantly greater in the diltiazem group than in the amlodipine group (24 hour mean: -1,493 vs -881; P<0.0008).</p> <p>In the diltiazem and amlodipine groups respectively, 1.5 and 2.2% discontinued early due to adverse events.</p>
<p>White et al.⁵⁸ (2004)</p> <p>Diltiazem ER 240 to 540 mg at bedtime</p> <p>vs</p> <p>ramipril 5 to 20 mg at bedtime</p>	<p>DB, MC, PG, RCT</p> <p>Men and women, with hypertension: DBP 90 to 110 mm Hg</p>	<p>N=261</p> <p>10 weeks</p>	<p>Primary: Change in early morning DBP from baseline</p> <p>Secondary: Change in SBP from baseline, heart rate, heart rate × systolic blood pressure product, 24-hr ambulatory</p>	<p>Primary: Changes in early morning DBP were significantly larger in the diltiazem group than in the ramipril group (-15 vs -8 mm Hg; P<0.001).</p> <p>Secondary: Changes in early morning SBP were significantly larger in the diltiazem group than in the ramipril group (-18 vs -13 mm Hg; P=0.002).</p> <p>Decreases in heart rate and heart-rate systolic BP product were significantly larger in the diltiazem group than in the ramipril group (-8.9 vs -2.7 beats/min; P<0.0001 and -2518 vs -1393; P<0.0001).</p> <p>Reductions in DBP and heart rate and increases in the rate-pressure</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			monitoring, safety	<p>product measured by 24-hr ambulatory monitoring and clinic monitoring were significantly greater for diltiazem than for ramipril ($P < 0.0001$ for all).</p> <p>50% of diltiazem patients and 40% of ramipril patients reported experiencing any adverse event; edema and cough respectively were most frequently reported for each treatment. Withdrawal rates from the study were low and similar between the groups.</p>
<p>Rosei et al.⁵⁹ (1997) VHAS</p> <p>Verapamil SR 240 mg QD</p> <p>vs</p> <p>chlorthalidone 25 mg QD</p>	<p>DB (1st 6 months), MC, PG, RCT</p> <p>Patients 40 to 65 years of age, with HTN (SBP ≥ 160 mm Hg and DBP ≥ 95 mm Hg)</p>	<p>N=1,414</p> <p>2 years</p>	<p>Primary: Blood pressure</p> <p>Secondary: Cardiovascular events, adverse events</p>	<p>Primary: Both treatments significantly reduced SBP and DBP compared to baseline, however reductions did not significantly differ between treatments (verapamil reduction, 27.6/17.0 mm Hg vs chlorthalidone reduction, 28.6/16.6 mm Hg; $P < 0.01$ for each vs baseline).</p> <p>Goal DBP was achieved in 69.3% of patients receiving verapamil and 66.9% of patients receiving chlorthalidone (P value not reported).</p> <p>Secondary: Serum TC levels and heart rate decreased significantly in the verapamil group as compared to baseline and the chlorthalidone group (TC; $P < 0.01$ for both, heart rate; $P < 0.05$).</p> <p>The number of nonfatal cardiovascular events was similar between the groups, 37 in the verapamil group and 39 in the chlorthalidone group (P value not reported).</p> <p>The number of cardiovascular deaths was similar between the groups, five in the verapamil group and four in the chlorthalidone group (P value not reported).</p> <p>Hypokalemia and hyperuricemia occurred significantly more frequently in the chlorthalidone group than in the verapamil group ($P < 0.01$ for both).</p> <p>Two hundred and thirty six patients reported 403 adverse events in the chlorthalidone group and 230 patients reported 387 adverse events in the verapamil group. Asthenia was the most commonly reported adverse event in the chlorthalidone group and constipation was the most commonly</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				reported adverse event in the verapamil group.
Ruggenenti et al. ⁶⁰ (2004) BENEDICT Trandolapril 2 mg/day vs verapamil SR 240 mg/day vs trandolapril and verapamil SR 2-180 mg/day (fixed-dose combination) vs placebo	DB, MC, RCT Patients ≥40 years with type 2 diabetes (not exceeding 25 years) and HTN (SBP ≥130 mm Hg and/or DBP ≥85 mm Hg) but with normoalbuminuria (urinary albumin excretion rate of <20 mcg/minute)	N=1,204 3.6 years (median)	Primary: Development of persistent microalbuminuria comparing combination therapy to placebo, acceleration factor Secondary: Primary end point comparing trandolapril and verapamil monotherapy to placebo, blood pressure, adverse events	Primary: The primary outcome was reached in 5.7% of patients receiving combination therapy vs 10.0% for patients receiving placebo. The estimated acceleration factor (which quantifies the effect of one treatment relative to another in accelerating or slowing disease progression) adjusted for predefined baseline characteristics was 0.39 for the comparison between verapamil plus trandolapril and placebo (P=0.01). Secondary: The primary outcome was reached in 6.0% of patients receiving trandolapril, 11.9% receiving verapamil, and 10.0% receiving placebo. The estimated acceleration factor was 0.47 for trandolapril vs placebo (P=0.01) and 0.83 for verapamil vs placebo (P=0.54). Trandolapril plus verapamil and trandolapril alone delayed the onset of microalbuminuria by factors of 2.6 and 2.1, respectively. Throughout the study the average trough SBP/DBP was 139/80 mm Hg for patients receiving trandolapril plus verapamil, 139/81 mm Hg for trandolapril, 141/82 mm Hg for verapamil and 142/83 mm Hg for placebo. The comparison was significant (P≤0.002) between trandolapril plus verapamil or trandolapril alone vs placebo, but not for verapamil vs placebo. Serious adverse events were similar in all treatment groups.
Messerli et al. ⁶¹ (2006) Verapamil SR 240 mg QD vs trandolapril 4 mg QD	DB, MC, PC, PG, RCT Patients, 21 years old and older with DBP of 95 to 114 mm Hg	N=581 6 weeks	Primary: Blood pressure Secondary: Not reported	Primary: All 3 treatment groups had significant blood pressure reductions from baseline (P<0.01 for all). Patients receiving the combination of trandolapril and verapamil had significantly greater reductions in blood pressure as compared to patients receiving trandolapril or verapamil alone (P<0.01 for both comparisons). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs verapamil SR 240 mg and trandolapril 4 mg QD (separate entities)				
Karlberg et al. ⁶² (2000) Trandolapril 2 mg/day vs verapamil 240 mg/day vs trandolapril and verapamil 2-180 mg/day (fixed-dose combination)	DB, MC, PRO, RCT, XO Patients with uncomplicated primary HTN (sitting DBP between 95 and 115 mm Hg) between the ages of 20 to 80 years	N=226 2 months	Primary: Change in blood pressure and rate pressure product Secondary: Predictive value of plasma concentrations of active renin regarding the blood pressure response to the different treatment regimens, safety	Primary: The mean fall in blood pressure was significantly greater with the combination (20/15 mm Hg; P<0.00054), as compared to trandolapril (14/11 mm Hg) or verapamil (13/11) mm Hg. The difference between verapamil and trandolapril was not significant. Rate pressure product decreased significantly more on the combination (P<0.001) than on trandolapril or verapamil alone. Secondary: There was a significant positive correlation between blood pressure fall and plasma concentrations of active renin (e.g., the higher the initial active renin, the better the blood pressure response to trandolapril [P<0.045 for SBP and P<0.004 for DBP]). No relationships were found for either verapamil or the combination. All treatments were well tolerated and safe.
Van Bortel et al. ⁶³ (2008) ACE inhibitor, ARB, β-blocker, calcium channel blocker, or placebo vs neбиволол	MA 12 RCTs involving >25 patients with essential HTN where neбиволол 5 mg QD was compared to placebo or other active drugs for >1 month	N=2,653 Duration varied	Primary: Antihypertensive effect and tolerability Secondary: Not reported	Primary: Overall, higher response rates were observed with neбиволол than all other antihypertensive agents combined (OR, 1.41; 95% CI, 1.15 to 1.73; P=0.001) and compared to the ACE inhibitors (OR, 1.92; 1.30 to 2.85; P=0.001), but response rates to neбиволол were similar to β-blockers (OR, 1.29; 95% CI, 0.81 to 2.04; P=0.283), calcium channel blockers (OR, 1.19; 95% CI, 0.83 to 1.70; P=0.350) and losartan (OR, 1.35; 95% CI, 0.84 to 2.15; P=0.212). Overall, a higher percentage of patients obtained normalized blood pressure with neбиволол compared to the other antihypertensive agents combined (OR, 1.35; 95% CI, 1.07 to 1.72; P=0.012). A higher percentage

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>of patient receiving nebivolol obtained normalized blood pressure compared to losartan (OR, 1.98; 95% CI, 1.24 to 3.15; P=0.004) and calcium channel blockers (OR, 1.96; 95% CI, 1.05 to 1.96; P=0.024), but not when compared to other β-blockers (OR, 1.29; 95% CI, 0.81 to 1.65; P=0.473).</p> <p>Overall, the percentage of adverse events was significantly lower with nebivolol compared to the other antihypertensive agents combined (OR, 0.59; 95% CI, 0.48 to 0.72; P<0.001) and similar to placebo (OR, 1.16; 95% CI, 0.76 to 1.67; P=0.482). In comparing nebivolol to the individual treatments, nebivolol had a lower percentage of adverse events compared to losartan (OR, 0.52; 95% CI, 0.30 to 0.89; P=0.016), the other β-blockers (OR, 0.56; 95% CI, 0.36 to 0.85; P=0.007) and calcium channel blockers (OR, 0.49; 95% CI 0.33 to 0.72; P<0.001), but was similar to ACE inhibitors (OR, 0.75; 95% CI 0.52 to 1.08).</p> <p>Secondary: Not reported</p>
<p>Hilleman et al.⁶⁴ (1999)</p> <p>Amlodipine-benazepril (fixed-dose combination)</p> <p>vs</p> <p>monotherapy (atenolol, HCTZ, captopril, enalapril, lisinopril, amlodipine, diltiazem, nifedipine, verapamil)</p>	<p>MA</p> <p>Patients with mild to moderate essential HTN</p>	<p>82 trials</p> <p>≥ 4 weeks</p>	<p>Primary: Absolute change in supine DBP from baseline</p> <p>Secondary: Percent of patients who achieved blood pressure control, safety</p>	<p>Primary: The mean absolute decrease in supine DBP ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least. When studies were weighted by sample size, amlodipine and benazepril, atenolol, lisinopril, and verapamil showed the greatest blood pressure effect.</p> <p>Secondary: The average percentage of patients defined as controlled after treatment varied from 53.5 to 79.0%, with amlodipine and benazepril (74.3%) and lisinopril (79.0%) showing the highest percentage control (P=0.096).</p> <p>The incidence of adverse events ranged from 12.1 to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% and 14.1%, respectively) and nifedipine the highest incidence. Lisinopril demonstrated significantly less overall side effects compared to nifedipine (P=0.030).</p> <p>Nifedipine demonstrated a higher withdrawal rate due to side effects compared to atenolol, HCTZ, enalapril, amlodipine, and diltiazem</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Casas et al.⁶⁵ (2005)</p> <p>ACE inhibitor or ARBs compared to placebo</p> <p>vs</p> <p>ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents, calcium-channel blocking agents, or combinations)</p> <p>Specific agents and doses were not specified.</p>	<p>MA (127 trials)</p> <p>Studies in adults that examined the effect of any drug treatment with a blood pressure lowering action on progression of renal disease</p>	<p>N=not reported</p> <p>4.2 years (mean)</p>	<p>Primary: Doubling of serum creatinine, and ESRD</p> <p>Secondary: Serum creatinine, urine albumin excretion and GFR</p>	<p>(P=0.002). Although amlodipine and benazepril had the lowest rate of withdrawals due to adverse events, lack of significant change was due to the low number of cohorts available for analysis.</p> <p>Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>A small reduction in ESRD was observed in patients receiving ACE inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>Secondary: Small reductions in serum creatinine and in SBP were noted when ACE inhibitors or ARBs were compared to other antihypertensives (P=0.01).</p> <p>Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001).</p> <p>Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.</p>
Miscellaneous				
<p>Siu et al.⁶⁶ (2009)</p> <p>Diltiazem IV 0.25 mg/kg to 10 mg/kg</p> <p>vs</p>	<p>OL, RCT</p> <p>Patients who presented to the emergency room with symptomatic acute atrial fibrillation for <48</p>	<p>N=150</p> <p>3 years</p>	<p>Primary: Sustained ventricular rate control (<bpm) within 24 hours</p> <p>Secondary: Time to ventricular</p>	<p>Primary: The time to ventricular control for the 45 patients assigned to diltiazem was achieved 90% of the time compared to digoxin (74%) and amiodarone (74%) (P<0.0001).</p> <p>Secondary: The median time to ventricular control was significantly shorter in the diltiazem group (3 hours, 1-21 hours) compared to the digoxin (6 hours, 3</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
digoxin IV 0.5 mg to 0.25 mg vs amiodarone IV 300 mg to 10 mg/kg	hours and rapid ventricular rate >120 bpm necessitating hospitalization		control, atrial fibrillation symptom improvement, hospital stay, and adverse events	to 15 hours, P<0.001) and amiodarone groups (7 hours, 1 to 18 hours, P=0.003). The diltiazem group had the largest reduction in atrial fibrillation frequency score and severity score (P<0.0001). Length of hospital stay was significantly shorter in the diltiazem group (3.9±1.6 days) compared to digoxin (4.7±2.1 days, P=0.023) and amiodarone groups (4.7±2.2 days, P=0.038).

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, CR=controlled-release, ER=extended-release, IV=intravenous, QD=once daily, SR=sustained-release, TID=three times daily

Study design abbreviations: AC=active comparator, BE=blinded endpoint, DB=double blind, DD=double dummy, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, ESRD=end stage renal disease, GFR=glomerular filtration rate, HCTZ=hydrochlorothiazide, HTN=hypertension, HR=hazard ratio, MI=myocardial infarction, OR=odds ratio, PVD=peripheral vascular disease, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TIA=transient ischemic attack

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 9. Relative Cost of the Calcium-Channel Blocking Agents, Miscellaneous

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Diltiazem	extended-release capsule, extended-release tablet, injection, tablet	Cardizem ^{®*} , Cardizem CD ^{®*} , Cardizem LA [®] , Matzim LA [®] , Tiazac ER ^{®*}	\$\$\$	\$\$
Verapamil	extended-release capsule, extended-release tablet, injection, tablet	Calan ^{®*} , Calan SR ^{®*} , Verelan ^{®*} , Verelan PM ^{®*}	\$\$\$\$\$	\$\$\$

*Generic is available in at least one dosage form or strength.

X. Conclusions

The miscellaneous calcium-channel blocking agents are approved for the treatment of angina, arrhythmias and hypertension.^{1,2,6-16} Diltiazem and verapamil are available in a variety of modified-release delivery systems that alter their pharmacokinetic properties, including onset and duration of action.^{1,2} Both drugs are available in a generic formulation. It should be noted that the verapamil and trandolapril fixed-dose combination product is included in the angiotensin converting enzyme inhibitor class review (AHFS Class 243204).

There are several national and international guidelines that provide recommendations regarding the use of calcium-channel blocking agents.¹⁷⁻⁴⁰ For the treatment of chronic angina, β -blockers are recommended as initial

therapy; however, long-acting calcium-channel blocking agents may be used if β -blockers are contraindicated or if additional therapy is required.¹⁷⁻²² Calcium-channel blocking agents are recommended as initial therapy in patients with variant/vasospastic angina.^{18,21} Verapamil may be considered for secondary prevention of cardiovascular disease in patients with no heart failure in whom β -blockers are contraindicated.²³ Treatment options for atrial fibrillation include ventricular rate control or drug therapy to maintain sinus rhythm. The AFFIRM, RACE and HOT CAFE trials demonstrated similar outcomes with rate control compared to rhythm control strategies. β -blockers and nondihydropyridine calcium-channel blocking agents are recommended for patients with persistent or permanent atrial fibrillation, either alone or in combination with digoxin.²⁸⁻³⁰ For the treatment of heart failure, ACE inhibitors, ARBs, aldosterone antagonists, and isosorbide dinitrate/hydralazine are recommended as initial therapy. In general, calcium-channel blocking agents are not recommended for the routine treatment of heart failure; however, verapamil and diltiazem may be considered in patients with preserved left ventricular ejection fraction who have atrial fibrillation requiring ventricular rate control (with intolerance to β -blockers), angina, or hypertension.²⁴⁻²⁶ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.³¹⁻³⁷ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).³¹ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.³¹⁻³⁹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.³¹⁻³⁹

Clinical trials demonstrate that diltiazem and verapamil can effectively treat angina and improve blood pressure.^{41-45,57-65} Both agents have been shown to reduce mortality and cardiovascular event rates compared to placebo.⁴⁷ Evidence suggests that there is no overall difference between diltiazem and verapamil compared to other antihypertensive agents (β -blockers, atenolol, diuretics) in reducing cardiovascular events and mortality in patients with hypertension.⁴⁸⁻⁵⁴

There is insufficient evidence to support that one brand miscellaneous calcium-channel blocking agent is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand miscellaneous calcium-channel blocking agents within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand miscellaneous calcium-channel blocking agent is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Apr]. Available from: <http://online.factsandcomparisons.com>
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Apr]. Available from: <http://www.thomsonhc.com/>.
3. Kannam JP, Aroesty JM, Gersh BJ. Calcium channel blockers in the management of stable angina pectoris. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Apr]. Available from: <http://www.uptodate.com/utd/index.do>.
4. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
5. Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
6. Cardizem® [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2014 Nov.
7. Cardizem CD® [package insert]. Kansas City (MO): sanofi-aventis U.S. LLC; 2010 Nov.
8. Cardizem LA® [package insert]. North Chicago (IL): Abbott Laboratories; 2015 Mar.
9. Matzim LA® [package insert]. Corona (CA): Watson Laboratories, Inc.; 2011 Oct.
10. Tiazac® [package insert]. Mississauga (ON): Biovail Corporation; 2010 Nov.
11. Diltiazem injection [package insert]. Lake Forest (IL): Akorn, Inc.; 2008 Jun.
12. Calan® [package insert]. New York (NY): Pfizer Inc; 2013 Oct.
13. Calan® SR [package insert]. New York (NY): Pfizer Inc; 2013 Oct.
14. Verelan® [package insert]. Princeton (NJ): Kremers Urban Pharmaceutical Inc.; 2014 Jun.
15. Verelan PM® [package insert]. Princeton (NJ): Kremers Urban Pharmaceutical Inc.; 2014 Oct.
16. Verapamil injection [package insert]. Shirley (NY): American Regent, Inc.; 2006 Jan.
17. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
18. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/ehs296.
19. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
20. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
21. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
22. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.
23. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.
24. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.

25. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
26. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail.* 2010;16(6):e1-e194.
27. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J.* 2012;33:1787-1847.
28. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022.
29. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. CG180. 2014. <http://www.nice.org.uk/guidance/CG180>.
30. Snow V, Wiess KB, LeFevre M, et al. Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. *Ann Intern Med.* 2003 Dec 16;139(12):1009-17.
31. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014 Feb 5;311(5):507-20.
32. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens.* 2003 Nov;21(11):1983-92.
33. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2007 Jun;25(6):1105-87.
34. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension.* 2009;27(11):2121-58.
35. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
36. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
37. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension.* 2010; 56:780-800.
38. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* 2004 May;43(5 Suppl 1):S1-290.
39. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl.* 2012 Dec;2(5):337-414.
40. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
41. De Rosa ML, Giordano A, Melfi M, Della Guardia D, Ciaburri F, Rengo F. Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. *Int J Cardiol.* 1998;63(1):27-35.
42. Chugh SK, Dighal K, Hutchinson T, McDonald CJ, Miller AJ, Lahiri A. A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina. *J Cardiovasc Pharmacol.* 2001 38(3):356-64.
43. van Kesteren HA, Withagen AJ. A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled-release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. *Cardiovasc Drugs Ther.* 1998;12 Suppl 3:233-7.
44. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. *Am J Cardiol.* 1999 Feb 15;83(4):507-14.

45. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. *Eur J Clin Pharmacol.* 1997;52(2):95-100.
46. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomized placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) *Lancet.* 2002; 355(9217):1751-6.
47. Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem post infarction trial and the second Danish verapamil infarction trial studies. *Am J Cardiol.* 2000; 86(3):275-9.
48. Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet.* 2000;356(9227):359-65.
49. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. *JAMA.* 2003 Dec 3;290(21):2805-16.
50. Mancia G, Messerli F, Bakris G et al. Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension* 2007;50:299-305.
51. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol.* 2006;47(3):547-51.
52. Bangalore S, Messerli F, Cohen J, Bacher P, Sleight P, Mancia G, et al. Verapamil-sustained release-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. *Am Heart J.* 2008;156:241-7.
53. Brunner M, Cooper-DeHoff RM, Gong Y, et al; for the INVEST Investigators. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). *Am J Cardiol.* 2007;99:1549-54.
54. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA.* 2003;289(16):2073-82.
55. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet.* 2005 Oct 29-Nov 4;366(9496):1545-53.
56. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev.* 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
57. Wright JT Jr, Sica DA, Gana TJ, Bohannon K, Pascual LG, Albert KS. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. *Am J Hypertens.* 2004;17(9):734-42.
58. White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. *Am Heart J.* 2004;148(4):628-34.
59. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. *J Hypertens.* 1997;15(11):1337-44.
60. Ruggenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. *N Engl J Med.* 2004 Nov 4;351(19):1941-51.
61. Messerli F, Frishman Wh, Elliott W et al. Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. *Blood Pressure* 2006;16:6-9.
62. Karlberg BE, Andrup M, Oden A; on behalf of the Swedish Tarka Trialists. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. *Blood Pressure* 2000;9:140-5.
63. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs.* 2008;8(1):35-44.
64. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. *J Hum Hypertens.* 1999;13:477-83.
65. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet.* 2005 Dec 10;366:2026-33.

66. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. *Crit Care Med* 2009;37:2174-79.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Angiotensin-Converting Enzyme Inhibitors
AHFS Class 243204
August 19, 2015**

I. Overview

The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure. Excessive activity of the RAAS may lead to hypertension, as well as fluid and electrolyte disorders. Renin catalyzes the conversion of angiotensinogen to angiotensin I. Angiotensin I is then cleaved to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase). Angiotensin II can increase blood pressure by direct vasoconstriction, as well as through actions on the brain and autonomic nervous system. In addition, angiotensin II stimulates aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental effects, which include ventricular hypertrophy and remodeling and myocyte apoptosis.¹⁻²

The ACE inhibitors are approved for the treatment of diabetic nephropathy, heart failure, hypertension, and post-myocardial infarction.³⁻²⁵ They block the conversion of angiotensin I to angiotensin II, and also inhibit the breakdown of bradykinin, which is a potent vasodilator. However, this increase in bradykinin also leads to an increase in adverse effects, including cough.³⁻²⁵ The ACE inhibitors are available as single entity products, as well as in combination with hydrochlorothiazide or verapamil. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride. Verapamil dilates coronary and peripheral arteries. It also slows conduction through the AV node, and has negative inotropic and chronotropic effects.^{24,25}

The angiotensin-converting enzyme inhibitors that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Angiotensin-Converting Enzyme Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Benazepril	tablet	Lotensin ^{®*}	benazepril
Captopril	tablet	N/A	captopril
Enalapril	solution, tablet	Epaned [®] , Vasotec ^{®*}	enalapril
Enalaprilat	injection [^]	N/A	enalaprilat dihydrate
Fosinopril	tablet	N/A	fosinopril
Lisinopril	tablet	Prinivil ^{®*} , Zestril ^{®*}	lisinopril
Moexipril	tablet	Univasc ^{®*}	moexipril
Perindopril	tablet	N/A	perindopril
Quinapril	tablet	Accupril ^{®*}	quinapril
Ramipril	capsule	Altace ^{®*}	ramipril
Trandolapril	tablet	Mavik ^{®*}	trandolapril
Combination Products			
Benazepril and hydrochlorothiazide	tablet	Lotensin HCT ^{®*}	benazepril and hydrochlorothiazide
Captopril and hydrochlorothiazide	tablet	N/A	captopril and hydrochlorothiazide
Enalapril and hydrochlorothiazide	tablet	Vaseretic ^{®*}	enalapril and hydrochlorothiazide
Fosinopril and hydrochlorothiazide	tablet	N/A	fosinopril and hydrochlorothiazide
Lisinopril and hydrochlorothiazide	tablet	Prinzide ^{®*} , Zestoretic ^{®*}	lisinopril and hydrochlorothiazide

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Moexipril and hydrochlorothiazide	tablet	N/A	moexipril and hydrochlorothiazide
Quinapril and hydrochlorothiazide	tablet	Accuretic ^{®*}	quinapril and hydrochlorothiazide
Trandolapril and verapamil	extended-release tablet	Tarka ^{®*}	trandolapril and verapamil

*Generic is available in at least one dosage form or strength.

^Product is primarily administered in an institution.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the angiotensin-converting enzyme inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using the Angiotensin-Converting Enzyme Inhibitors

Clinical Guideline	Recommendations
American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007) ²⁶	<ul style="list-style-type: none"> Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin-converting enzyme inhibitors (ACE inhibitors) and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes. Long-acting calcium-channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) of $\leq 40\%$ and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF of $\leq 40\%$. ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF $\leq 40\%$ and have either diabetes or heart failure. It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. Annual influenza vaccination is recommended in patients with

Clinical Guideline	Recommendations
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease (2013)²⁷</p>	<p>cardiovascular disease.</p> <p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education. <p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia (>10%), β-blockers should be considered. • In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided. <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin is contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all

Clinical Guideline	Recommendations
<p>Cardiovascular Nurses Association/ Society of Thoracic Surgeons: Management of Stable Ischemic Heart Disease (2012)²⁸</p>	<p>patients with normal left ventricular (LV) function following MI or acute coronary syndromes.</p> <ul style="list-style-type: none"> • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)²⁹</p>	<p><u>Early hospital care- standard medical therapies</u></p> <ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation $< 90\%$, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24

Clinical Guideline	Recommendations
	<p>hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease)</p> <ul style="list-style-type: none"> ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. <ul style="list-style-type: none"> ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. ● Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p><u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u></p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatid, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. • Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional

Clinical Guideline	Recommendations
	<p>85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time).</p> <ul style="list-style-type: none"> ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. ● Timing of CABG in relation to use of antiplatelet agents <ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatid or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTEMI-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEMI-ACS without contraindications who are treated with an ischemia-guided strategy.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTEMI-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTEMI-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTEMI-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTEMI-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)³⁰</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> ● Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. ● Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class ≥III. ● Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. ● Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. ● Calcium channel blockers are recommended in patients with vasospastic angina. ● Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. ● Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> ● β-blockers are recommended in all patients with reduced left ventricular (LV) systolic function (LVEF ≤40%). ● ACE inhibitors are indicated within 24 hours in all patients with LVEF ≤40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. ● ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. ● ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. ● Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF ≤35% and either diabetes or heart failure, without significant renal dysfunction (serum creatinine >2.5 mg/dL for men and >2.0 mg/dL for women) or hyperkalemia. ● Statin therapy with target LDL-C levels <70 mg/dL initiated early after admission is recommended.
<p>American College of Cardiology/American Heart Association: Guideline for the</p>	<p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> ● Oral β-blockers should be initiated within the first 24 hours in patients with an ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output

Clinical Guideline	Recommendations
<p>Management of ST-Elevation Myocardial Infarction (2013)³¹</p>	<p>state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval >24 seconds, second or third degree heart block, active asthma, reactive airway disease).</p> <ul style="list-style-type: none"> • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: renin-angiotensin-aldosterone system inhibitors</u></p> <ul style="list-style-type: none"> • An ACE inhibitor should be administered within the first 24 hours to all patients with ST-segment elevation myocardial infarction with anterior location, heart failure, or ejection fraction $\leq 40\%$, unless contraindicated. • An ARB should be given to patients who have indications for but are intolerant of ACE inhibitors. • ACE inhibitors are reasonable for all patients with no contraindications to their use. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF $\leq 40\%$ and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)³²</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients receiving drug-eluting stent. • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In selected patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
<p>National Institute for Health and Clinical Excellence: Myocardial Infarction: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)³³</p>	<p><u>Drug therapy</u></p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs: <ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker. ○ Statin. • Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. • Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. • Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> • Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. • Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum

Clinical Guideline	Recommendations
	<p>tolerated or target dose is reached. If it is not possible to complete the titration during this time, it should be completed within 4 to 6 weeks of hospital discharge.</p> <ul style="list-style-type: none"> • Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. • Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. • Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> • Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. • Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. • For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. • Special considerations should be made for people with dyspepsia. • After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for Helicobacter pylori should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). • Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. • Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago). <p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person’s wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> • After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. • β-blockers should be continued indefinitely after an acute MI. • After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> • Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. • If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> • For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. • Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)³⁴</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> • Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) • Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p><u>Treatment of Stage B heart failure</u></p> <ul style="list-style-type: none"> • In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) • In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a

Clinical Guideline	Recommendations
	<p>reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively)</p> <ul style="list-style-type: none"> • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p>Pharmacological treatment for Stage C HFrEF</p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p>Pharmacological treatment for Stage C HFpEF</p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p>Treatment of Stage D (advanced/refractory) HF</p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)³⁵</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF \leq40%, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF \leq40%. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF ($<$35%) while receiving standard therapy, including diuretics.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function.

Clinical Guideline	Recommendations
	<p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF ($<$35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and

Clinical Guideline	Recommendations
	<p>volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used.</p> <ul style="list-style-type: none"> • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients

Clinical Guideline	Recommendations
<p>of Acute and Chronic Heart Failure (2012)³⁶</p>	<p>with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death.</p> <ul style="list-style-type: none"> • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ◦ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ◦ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ◦ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Step 3: <ul style="list-style-type: none"> ○ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ○ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ○ Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> • A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)³⁷</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.

Clinical Guideline	Recommendations
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)³⁸</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)³⁹, Reappraisal of Guidelines on Hypertension Management (2009)⁴⁰</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)⁴¹</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug

Clinical Guideline	Recommendations
	<p>treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension.</p> <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP > 160 mmHg or DBP > 110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg. • A SBP goal < 140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be < 85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal < 140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be

Clinical Guideline	Recommendations
	<p>used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina).</p> <ul style="list-style-type: none"> • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)⁴² Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ People with evidence of increased sympathetic drive. ● If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. ● If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. ● For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. ● If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. ● Resistant hypertension should be considered with clinic blood pressure remains $>140/90$ mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. ● For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)⁴³</p>	<ul style="list-style-type: none"> ● To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. ● Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. ● Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. ● In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. ● Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. ● In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. ● Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. ● ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and</p>	<ul style="list-style-type: none"> ● All antihypertensives can be used to lower blood pressure in chronic kidney disease. ● Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. ● Antihypertensive regimens should be simplified as much as possible and

Clinical Guideline	Recommendations
<p>Antihypertensive Agents in Chronic Kidney Disease (2004)⁴⁴</p>	<p>long-acting agents should be used when possible.</p> <ul style="list-style-type: none"> • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)⁴⁵</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg

Clinical Guideline	Recommendations
	<p>diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> • Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)⁴⁶</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood

Clinical Guideline	Recommendations
	<p>pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.</p> <ul style="list-style-type: none"> • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

*Agent is not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the angiotensin-converting enzyme inhibitors are noted in Tables 3 and 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Angiotensin-Converting Enzyme Inhibitors^{3-14,24}

Indication(s)	Single Entity Agents									
	Benaze- pril	Capto- pril	Enala- pril	Fosino- pril	Lisino- pril	Moexi- pril	Perindo- pril	Quina- pril	Rami- pril	Trandola- pril
Cardiovascular Risk Reduction										
In patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes									✓	
Stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction							✓			
Diabetic Nephropathy										
Treatment of diabetic nephropathy in patients with type 1 insulin-dependent diabetes and retinopathy		✓								
Heart Failure										
Congestive heart failure		✓ *	✓ *							
Heart failure				✓ †	✓ ‡			✓ †		
Hypertension										
Hypertension	✓ §	✓	✓	✓ §	✓	✓ §	✓	✓ §	✓ §	✓
Left Ventricular Dysfunction										
Decrease the rate of the development of overt heart failure and decrease the incidence of hospitalization for heart failure in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35%)			✓							

Indication(s)	Single Entity Agents									
	Benazepril	Captopril	Enalapril	Fosinopril	Lisinopril	Moexipril	Perindopril	Quinapril	Ramipril	Trandolapril
Myocardial Infarction										
Hemodynamically stable patients within 24 hours of acute myocardial infarction to improve survival					✓					
Improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients		✓								
Stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction									✓	
Stable patients who have evidence of left ventricular systolic dysfunction or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction										✓

*Usually in combination with diuretics and digitalis.

† As adjunctive therapy when added to conventional therapy including diuretics with or without digitalis.

‡ As adjunctive therapy in patients who are not responding adequately to diuretics and digitalis.

§ May be used alone or in combination with thiazide diuretics.

|| May be used alone or in combination with other antihypertensive agents.

Table 4. FDA-Approved Indications for the Angiotensin-Converting Enzyme Inhibitors¹⁵⁻²⁴

Indication(s)	Combination Products								
	Benazepril and HCTZ	Captopril And HCTZ	Enalapril and HCTZ	Fosinopril and HCTZ	Lisinopril and HCTZ	Moexipril and HCTZ	Quinapril and HCTZ	Trandolapril and Verapamil	
Hypertension									
Hypertension	✓ *	✓	✓ *	✓ *	✓ *	✓ *	✓ *	✓ *	

*This fixed combination product is not indicated for the initial therapy of hypertension.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the angiotensin-converting enzyme inhibitors are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the Angiotensin-Converting Enzyme Inhibitors²⁵

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Benazepril	37	96.7	Liver, extensive (% not reported)	Renal (33) Bile (12)	22*
Captopril	70 to 75	25 to 30	Liver (50)	Renal (95)	1.9†
Enalapril	60	50 to 60	Liver (70)	Renal (61) Feces (33)	11*
Fosinopril	30 to 36	89 to 100	Liver, extensive (% not reported)	Renal (44) Feces (46)	12*
Lisinopril	25	Minimal (% not reported)	Liver (7)	Renal (29) Feces (69)	12†
Moexipril	13 to 22	50 to 70	Liver, extensive (% not reported)	Renal (13) Feces (50)	2 to 10*
Perindopril	20 to 30	60	Liver (88 to 96)	Renal (75) Feces (25)	3 to 10*
Quinapril	50	97	Liver, extensive (% not reported)	Renal (50 to 60) Feces (33)	2 to 25*
Ramipril	60	73	Liver, extensive (% not reported)	Renal (40 to 60) Feces (40)	13 to 17*
Trandolapril	10	80	Liver, extensive (% not reported)	Feces (66) Renal (33)	16 to 24*
Combination Products					
Benazepril and HCTZ	37/70	96.7/40 to 70	Liver, extensive (% not reported)/ not reported	Feces (11 to 12/ Renal (70)	22*/10
Captopril and HCTZ	70 to 75/70	25 to 30/ not reported	Liver (50%)/ not reported	Renal (>95)/ Renal (% not reported)	<3/2.5
Enalapril and HCTZ	60/70	Not reported/40	Not reported/ Liver, minimal (% not reported)	Renal (61)/ Renal (60)	11/5.6 to 14.8
Fosinopril and HCTZ	36/50 to 80	95/67.9	Liver (% not reported)/ Not reported	Not reported/ Renal (61)	Not reported/ 5 to 15
Lisinopril and HCTZ	25/not reported	Not reported/ Not reported	Not reported/ Not reported	Not reported/ Not reported	Not reported/ Not reported
Moexipril and HCTZ	13*/60 to 80	50*/21 to 24	Liver (% not reported)/ Not metabolized	Feces (1) Renal (1)/ Feces (not reported) Renal (60)	1.3/ 5.6 to 14.8
Quinapril and HCTZ	60/50 to 80	97/67.9	Liver (% not reported)/ Not metabolized	Renal (96)/ Renal (61)	2 to 25*/ 4 to 15
Trandolapril and verapamil	10/20 to 35	80/90	Liver, extensive (% not reported)/ Liver, extensive (% not reported)	Feces (66) Renal (33)/ Feces (16) Renal (70)	6/6 to 11

*Metabolites
†Parent compound
HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the angiotensin-converting enzyme inhibitors are listed in Table 6.

Table 6. Significant Drug Interactions with the Angiotensin-Converting Enzyme Inhibitors²⁴

Generic Name(s)	Significance Level	Interaction	Mechanism
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	1	Potassium-sparing diuretics	Combining ACE inhibitors and potassium-sparing diuretics may result in elevated serum potassium concentrations in certain high-risk patients.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	β-Blockers	Verapamil may inhibit oxidative metabolism of certain β-blockers. The effects of both drugs may be increased.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Colchicine	Plasma concentrations of colchicine may be increased by verapamil. Colchicine toxicity may occur.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Dofetilide	Verapamil can increase portal blood flow, increasing the rate of dofetilide absorption. There may be an increased risk of ventricular arrhythmias, including torsades de pointes.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Macrolides and ketolides	Macrolides and ketolides may increase the plasma concentrations and pharmacological effects of verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	1	Narcotic analgesics	Verapamil may increase plasma concentrations of narcotic analgesics when used concurrently.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics increase potassium excretion. Hypokalemia may occur, increasing the risk of torsades de pointes.
Thiazide diuretics (HCTZ)	1	Lithium	Thiazide diuretics decrease the renal clearance of lithium which leads to increased serum lithium levels. Lithium toxicity has occurred.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	2	Aliskiren	The risk of hyperkalemia may be increased when ACE inhibitors are combined with aliskiren.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril,	2	Angiotensin II receptor antagonists	The risk of hyperkalemia may be increased when ACE inhibitors are combined with angiotensin II receptor antagonists.

Generic Name(s)	Significance Level	Interaction	Mechanism
perindopril, quinapril, ramipril,trandolapril)			
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	2	Indomethacin	Indomethacin inhibits prostaglandin synthesis. The hypotensive effect of ACE inhibitors may be reduced.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	2	NSAIDs and salicylates	NSAIDs and salicylates inhibit prostaglandin synthesis. The hypotensive and vasodilator effects of the ACE inhibitor may be reduced.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	2	Potassium preparations	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur with the combination of ACE inhibitors and potassium preparations.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril)	2	Trimethoprim	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur with the combination of ACE inhibitors and trimethoprim.
ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, trandolapril)	2	Lithium	Through an unknown mechanism, ACE inhibitors may increase lithium levels, which results in neurotoxicity.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Aldosterone blockers	Plasma concentrations and pharmacologic or toxic effects of aldosterone blockers may be increased by verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Carbamazepine	Verapamil appears to impair the hepatic metabolism of carbamazepine. Carbamazepine levels may increase, resulting in an increase in pharmacologic and toxic effects.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Clonidine	Sinus bradycardia, atrioventricular block and severe hypotension may occur with coadministration of clonidine and verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Cyclosporine	Verapamil may inhibit cyclosporine metabolism leading to increased cyclosporine levels and toxicity.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Digitalis glycosides	Verapamil may alter the pharmacokinetics and increase serum concentrations of digoxin.
Calcium-channel blocking agents,	2	Dronedarone	Plasma concentrations and pharmacologic effects of

Generic Name(s)	Significance Level	Interaction	Mechanism
miscellaneous (verapamil)			dronedarone may be increased by verapamil. Dronedarone may also increase the plasma concentrations and pharmacologic effects of verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Everolimus	Pharmacologic effects and plasma concentrations of everolimus may be increased by verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Flecainide	Increased risk of cardiotoxic effects may occur when flecainide and verapamil are coadministered.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	HMG CoA reductase inhibitors	Verapamil may inhibit the first-pass metabolism of certain HMG CoA reductase inhibitors (e.g., simvastatin and lovastatin) which results in increased plasma concentrations and risk of toxicity.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Nondepolarizing muscle relaxants	The effects of the nondepolarizing muscle relaxants may be enhanced and respiratory depression may be prolonged. The mechanism probably involves blockade of calcium-channels in skeletal muscle at the postsynaptic muscle membrane site.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Quinidine	Verapamil can prolong the half-life of quinidine by interfering with clearance. There is an increased risk for hypotension, bradycardia, ventricular tachycardia and atrioventricular block.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Ranolazine	Plasma concentrations and pharmacologic effects of ranolazine may be increased by co-administration of verapamil.
Calcium-channel blocking agents, miscellaneous (verapamil)	2	Rifampin	First-pass hepatic metabolism of verapamil may be increased, resulting in lowered bioavailability and reduced effectiveness of oral verapamil.
Thiazide diuretics (HCTZ)	2	Diazoxide	Hyperglycemia may occur with symptoms similar to diabetes. The mechanism is unknown.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Diuretic-induced electrolyte disturbances may predispose the patient to digitalis-induced cardiac arrhythmias.

ACE inhibitor=angiotensin converting enzyme inhibitor, HCTZ=hydrochlorothiazide, HMG CoA=3-hydroxy-3-methyl-glutaryl-CoA, NSAID=nonsteroidal anti-inflammatory drug
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the angiotensin-converting enzyme inhibitors are listed in Tables 7 and 8. The boxed warning for the angiotensin-converting enzyme inhibitors is listed in Table 9.

Table 7. Adverse Drug Events (%) Reported with the Angiotensin-Converting Enzyme Inhibitors-Single Entity Agents^{3-14,24,25}

Adverse Events	Benazepril	Captopril	Enalapril	Fosinopril	Lisinopril	Moexipril	Perindopril	Quinapril	Ramipril	Trandolapril
Cardiovascular										
Angina	<1	<1	2	<1	-	<1	-	<1	<1 to 3	-
Bradycardia	-	-	<1	<1	<1	-	-	-	<1	<5
Cardiac arrest	-	✓	<1	✓	<1	-	✓	-	✓	-
Cerebrovascular accident	-	✓	<1	<1	<1	<1	<1	<1	<1	-
Chest pain	-	1	2	<2	3	>1	2	2	<1	<1
Hypotension	<1	✓	1 to 7	1 to 4	1 to 10	<1	<1	3	<1	<1
Myocardial infarction	-	<1	<1	<1	<1	<1	<1	<1	<1	-
Orthostatic hypotension	<1	✓	1 to 2	<2	<1	<1	<1	<1	2	-
Palpitations	<1	1	<1	<1	<1	<1	<1	<1	<1	<1
Peripheral edema	<1	-	-	-	<1	>1	-	-	-	-
Rhythm disturbances	-	✓	<1	<1	-	<1	-	<1	-	-
Tachycardia	-	1	<1	<1	<1	-	-	<1	<1	-
Central Nervous System										
Anxiety	<1	-	-	-	-	<1	<1	-	<1	<1
Ataxia	-	✓	<1	-	<1	-	-	-	-	-
Depression	-	✓	<1	<1	-	-	2	<1	<1	-
Dizziness	4	-	1 to 8	2 to 12	5 to 12	4	8	4 to 8	2 to 4	1 to 23
Fatigue	2	-	1 to 3	≥1	3	2	-	3	2	-
Headache	6	-	2 to 5	≥1	4 to 6	>1	24	2	-	-
Insomnia	<1	-	<1	<1	<1	<1	3	<1	<1	<1
Malaise	-	-	-	-	<1	<1	<1	<1	<1	-
Nervousness	<1	✓	<1	<1	<1	<1	1	<1	<1	-
Paresthesias	<1	-	<1	<1	<1	-	2	<1	<1	<1
Peripheral edema	<1	-	-	-	-	>1	-	-	-	-
Somnolence/drowsiness	2	✓	<1	<1	<1	<1	1	<1	<1	<1
Vertigo	-	-	2	<1	<1	-	<1	<1	<1 to 2	<1
Dermatologic										
Alopecia	<1	-	<1	-	<1	<1	-	<1	-	-
Diaphoresis	<1	-	<1	<1	<1	<1	<1	<1	<1	-
Erythema multiforme	-	✓	<1	-	-	-	<1	-	<1	-
Exfoliative dermatitis	-	✓	<1	✓	-	-	✓	<1	-	-
Flushing	<1	<1	<1	<1	<1	2	-	-	-	<1
Pemphigus/pemphigoid	<1	✓	<1	-	<1	-	-	<1	-	<1
Photosensitivity	<1	✓	<1	<1	<1	<1	-	<1	-	-
Pruritus	<1	2	<1	<1	-	<1	<1	<1	<1	<1
Rash	<1	4 to 7	<1	<1	<1	2	2	1	<1	<1
Stevens-Johnson syndrome	<1	✓	<1	-	✓	-	-	-	<1	-
Toxic epidermal necrolysis	-	-	<1	-	✓	-	-	-	<1	-

Adverse Events	Benazepril	Captopril	Enalapril	Fosinopril	Lisinopril	Moexipril	Perindopril	Quinapril	Ramipril	Trandolapril
Urticaria	-	-	<1	<1	<1	<1	-	<1	<1	-
Gastrointestinal										
Abdominal pain	-	-	2	<1	2	<1	3	1	<1	<1
Anorexia	-	-	<1	-	-	-	-	-	<1	-
Constipation	<1	-	<1	<1	<1	<1	<1	<1	<1	<1
Diarrhea	-	-	1 to 2	>1	3 to 4	3	4	2	≤1	<1
Dry mouth	-	-	<1	<1	<1	<1	<1	<1	<1	-
Dysgeusia	-	2 to 4	-	-	-	-	-	-	-	-
Dyspepsia	-	✓	<1	-	<1	>1	<1	<1	<1	<6
Hepatitis	-	✓	<1	<1	<1	<1	-	<1	<1	-
Nausea	1	-	1	1 to 2	2	>1	2	2	2	-
Pancreatitis	<1	✓	<1	<1	<1	<1	✓	<1	<1	<1
Vomiting	<1	-	1	1 to 2	<1	<1	2	2	2	<1
Genitourinary										
Decreased libido	<1	-	-	<1	<1	-	-	-	-	<1
Impotence	<1	✓	<1	-	1	-	-	<1	<1	<1
Oliguria	-	<1	<1	-	<1	<1	-	-	-	-
Urinary tract infection	<1	-	1	-	<1	-	3	<1	-	-
Musculoskeletal										
Arthralgia	<1	✓	✓	<1	<1	<1	<1	<1	<1	-
Arthritis	<1	-	✓	✓	<1	-	1	-	<1	-
Muscle cramps	-	-	<1	<1	<1	-	-	-	-	<1
Myalgia	<1	✓	✓	<1	<1	1	<1	-	<1	5
Respiratory										
Asthma	<1	✓	<1	-	<1	-	-	-	-	-
Bronchitis	<1	-	1	-	<1	-	<1	-	-	-
Bronchospasm	-	✓	<1	<1	<1	<1	-	2 to 4	-	-
Cough	1	<2	1 to 2	2 to 10	1 to 4	6	6 to 12	2 to 4	8	2 to 35
Dyspnea	<1	-	1	≥1	<1	<1	<1	-	<1	<1
Pharyngitis	-	-	-	<1	<1	2	3	<1	-	-
Rhinitis	-	✓	-	<1	<1	>1	5	-	-	-
Sinusitis	<1	-	-	<1	<1	>1	<5	-	-	-
Upper respiratory tract infection	-	-	<1	2	2	>1	7	-	✓	<1
Miscellaneous										
Anemia	✓	<1	-	✓	<1	<1	-	<1	<1	-
Angioedema	<1	<1	✓	<1	<1	<1	<1	<1	<1	<1
Asthenia	<1	✓	1 to 2	-	1	-	8	-	2	3
Blurred vision	-	✓	<1	-	<1	-	-	-	-	-
Eosinophilia	-	✓	✓	✓	<1	-	-	-	<1	-
Fever	-	✓	<1	<1	<1	-	<1	-	<1	-
Syncope	<1	✓	1 to 2	<1	<2	<1	<1	<1	<2	6
Tinnitus	-	-	<1	<1	<1	<1	2	-	<1	-
Vasculitis	-	✓	✓	-	<1	-	✓	-	<1	-

✓ Percent not specified
- Event not reported

Table 8. Adverse Drug Events (%) Reported with the Angiotensin-Converting Enzyme Inhibitors-Combination Products¹⁵⁻²⁵

Adverse Event	Benazepril and HCTZ	Captopril and HCTZ	Enalapril and HCTZ	Fosinopril and HCTZ	Lisinopril and HCTZ	Moexipril and HCTZ	Quinapril and HCTZ	Trandolapril and Verapamil
Cardiovascular								
Angina	-	0.2 to 0.3	-	-	-	-	-	✓
Angioedema	-	-	-	-	-	-	-	0.15
Atrioventricular block first degree	-	-	-	-	-	-	-	3.9
Atrioventricular block second degree	-	-	-	-	-	-	-	✓
Bradycardia	-	-	-	-	-	-	-	1.8
Bundle branch block	-	-	-	-	-	-	-	✓
Cardiac arrest	-	✓	-	-	-	-	-	
Cerebrovascular accident	-	✓	-	-	-	-	-	
Chest pain	-	1	-	0.5 to <2.0	-	>1	1	2.2
Hypotension	0.6	✓	-	-	1.4	>1	-	✓
Myocardial infarction	-	0.2 to 0.3	-	-	-	-	-	✓
Near syncope	-	-	-	-	-	-	-	✓
Nonspecific ST-T changes	-	-	-	-	-	-	-	✓
Orthostatic hypotension	0.3 to 3.5	✓	2.3	1.8	0.5	<1	≥0.5 to <1.0	
Palpitations	-	1	0.5 to 2.0	-	-	-	≥0.5 to <1.0	✓
Premature ventricular contractions	-	-	-	-	-	-	-	✓
Tachycardia	-	1	-	-	-	-	-	✓
Central Nervous System								
Depression	-	✓	-	-	-	-	-	
Dizziness	6.3	-	8.6	3.2	7.5	1.4	4.8	3.1
Drowsiness	-	-	-	-	-	-	-	✓
Fatigue	5.2	-	3.9	3.9	3.7	1	2.9	2.8
Headache	3.1	-	5.5	7	5.2	>1	6.7	8.9
Hypesthesia	-	-	-	-	-	-	-	✓
Insomnia	✓	-	0.5 to 2.0	-	-	-	1.2	
Loss of balance	-	-	-	-	-	-	-	✓
Paresthesia	-	-	-	-	-	-	-	✓
Somnolence/drowsiness	1.2	✓	-	-	-	-	1.2	
Vertigo	-	-	-	-	-	-	-	✓
Dermatologic								
Flushing	0.3 to 1.0	0.2 to 0.5	✓	0.5 to <2.0	-	-	-	✓
Pruritus	-	2	-	-	-	-	✓	✓
Rash	-	4 to 7	✓	0.5 to <2.0	1.2	>1	-	✓
Stevens-Johnson syndrome	✓	✓	✓	✓	-	-	✓	
Gastrointestinal								
Abdominal pain	-	-	-	-	-	-	1.7	
Constipation	-	-	-	-	-	-	-	3.3
Diarrhea	0.3 to 1.0	✓	2.1	0.5 to <2.0	2.5	>1	1.4	1.5
Dry mouth	-	-	-	-	-	-	-	✓
Dysgeusia	-	2 to 4	-	-	-	-	-	
Dyspepsia	-	✓	-	-	-	-	-	✓
Hepatitis	-	✓	-	-	-	-	-	
Jaundice	✓	✓	✓	✓	-	<1	✓	

Adverse Event	Benazepril and HCTZ	Captopril and HCTZ	Enalapril and HCTZ	Fosinopril and HCTZ	Lisinopril and HCTZ	Moexipril and HCTZ	Quinapril and HCTZ	Trandolapril and Verapamil
Nausea	1.4	-	2.5	✓	2.2	>1	✓	1.5
Pancreatitis	-	✓	-	-	-	-	-	-
Genitourinary								
Decreased libido	-	✓	-	✓	-	-	-	-
Endometriosis	-	-	-	-	-	-	-	✓
Hematuria	-	-	-	-	-	-	-	✓
Impotence	1.2	-	2.2	-	1.2	>1	≥0.5 to <1.0	✓
Nocturia	-	-	-	-	-	-	-	✓
Oliguria	-	0.1 to 0.2	-	-	-	-	-	-
Polyuria	-	-	-	-	-	-	-	✓
Proteinuria	-	-	-	-	-	-	-	✓
Musculoskeletal								
Arthralgias	-	-	-	-	-	-	-	✓
Back pain	-	-	-	-	-	-	-	2.2
Gout	-	-	-	-	-	-	-	✓
Hypertonia	1.5	-	-	-	-	-	-	-
Joint pain	-	-	-	-	-	-	-	1.7
Muscle cramps	-	-	2.7	-	2	-	-	-
Musculoskeletal pain	-	-	-	2	-	-	-	-
Myalgia	-	✓	-	-	-	-	2.4	✓
Pain in the extremity	-	-	-	-	-	-	-	1.1
Respiratory								
Bronchitis	-	-	-	-	-	-	1.2	1.5
Cough	2.1	0.5 to 2.0	3.5	5.6	3.9	3	3.2	4.6
Dyspnea	-	-	-	-	-	-	-	1.3
Rhinitis	-	✓	-	-	-	-	2	-
Upper respiratory tract congestion	-	-	-	-	-	-	-	2.4
Upper respiratory tract infection	-	-	-	2.3	2.2	>1	1.3	5.4
Miscellaneous								
Abnormal mentation	-	-	-	-	-	-	-	✓
Anemia	-	≤0.2	-	-	-	-	-	-
Angioedema	0.3	0.1	0.5 to 2.0	0.5 to <2.0	0.3 to 1.0	>1	0.1	-
Anxiety	-	-	-	-	-	-	-	✓
Asthenia	-	✓	2.4	-	1.8	<1	≥0.5 to <1.0	-
Blurred vision	-	✓	-	-	-	-	-	-
Decreased leukocytes	-	-	-	-	-	-	-	✓
Decreased neutrophils	-	-	-	-	-	-	-	✓
Edema	-	-	-	-	-	-	-	1.3
Eosinophilia	-	✓	-	-	-	-	-	-
Epistaxis	-	-	-	-	-	-	-	✓
Fever	-	✓	-	-	-	-	-	-
Increased liver enzymes	-	-	-	-	-	-	-	2.8
Malaise	-	-	-	-	-	-	-	✓
Neutropenia	-	✓	-	0.5 to <2.0	-	-	-	-
Syncope	-	✓	-	-	-	<1	-	0.1

Angiotensin-Converting Enzyme Inhibitors
AHFS Class 243204

Adverse Event	Benaze- pril and HCTZ	Capto- pril and HCTZ	Enala- pril and HCTZ	Fosino- pril and HCTZ	Lisino- pril and HCTZ	Moexi- pril and HCTZ	Quina- pril and HCTZ	Trandola- pril and Verapamil
Viral infection	-	-	-	-	-	-	1.9	
Weakness	-	-	-	-	-	-	-	✓

HCTZ=hydrochlorothiazide

- ✓ Percent not specified
- Event not reported

Table 9. Boxed Warning for the Angiotensin-Converting Enzyme Inhibitors²⁴

WARNING
When pregnancy is detected, discontinue therapy as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

VII. Dosing and Administration

The usual dosing regimens for the angiotensin-converting enzyme inhibitors are listed in Table 10.

Table 10. Usual Dosing Regimens for the Angiotensin-Converting Enzyme Inhibitors³⁻²⁵

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Benazepril	<u>Hypertension:</u> Tablet: initial, 10 mg once daily (for patients not receiving diuretics); maintenance, 20 to 40 mg/day as a single dose or in two equally divided doses; maximum, >80 mg/day has not been evaluated	<u>Hypertension for children 7 to 16 years of age:</u> Tablet: initial, 0.2 mg/kg once daily; maximum, >0.6 mg/kg (or in excess of 40 mg daily) has not been studied Safety and efficacy in children <7 years of age have not been established.	Tablet: 5 mg 10 mg 20 mg 40 mg
Captopril	<u>Diabetic nephropathy:</u> Tablet: maintenance, 25 mg three times daily <u>Heart failure:</u> Tablet: initial, 25 mg three times daily; maximum, 450 mg/day <u>Hypertension:</u> Tablet: initial, 25 mg two to three times daily; maintenance, after one to two weeks can increase to 50 mg two to three times daily; maximum: 450 mg/day <u>Myocardial infarction (left ventricular dysfunction after myocardial infarction):</u> Tablet: initial, 6.25 mg once, followed by 12.5 mg three times daily; target maintenance, 50 mg three times daily	Safety and efficacy in children have not been established.	Tablet: 12.5 mg 25 mg 50 mg 100 mg
Enalapril	<u>Heart failure:</u> Solution, tablet: initial, 2.5 mg/day; maintenance, 2.5 to 20 mg two times daily; maximum, 40 mg/day in divided doses <u>Hypertension:</u> Solution, tablet: initial, 5 mg once daily; maintenance, 10 to 40 mg/day as a single dose or in two divided	<u>Hypertension in children 1 month to 16 years of age:</u> Solution, tablet: initial, 0.08 mg/kg (up to 5 mg) once daily; maximum, >0.58 mg/kg (or in excess of 40 mg) has not been studied Safety and efficacy in children <1 month have not	Solution: 1 mg/mL Tablet: 2.5 mg 5 mg 10 mg 20 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	doses <u>Left ventricular dysfunction:</u> Solution ,tablet: initial, 2.5 mg two times daily; target maintenance, 10 mg/day in divided doses	been established.	
Fosinopril	<u>Heart failure:</u> Tablet: initial, 10 mg once daily; maintenance, 20 to 40 mg/day; maximum, 40 mg once daily <u>Hypertension:</u> Tablet: initial, 10 mg once daily; maintenance, 20 to 40 mg/day in a single or divided dose(s); maximum, 80 mg/day	<u>Hypertension in children 6 to 16 years of age:</u> Tablet (>50 kg): 5 to 10 mg once daily Safety and efficacy in children <6 years of age have not been established.	Tablet: 10 mg 20 mg 40 mg
Lisinopril	<u>Heart failure:</u> Tablet: initial, 5 mg once daily; maintenance, 5 to 20 mg once daily <u>Hypertension:</u> Tablet: initial, 10 mg once daily; maintenance, 20 to 40 mg once daily <u>Post-myocardial infarction:</u> Tablet: initial, 5 mg every 24 hours for two doses, followed by 10 mg every day for 6 weeks	<u>Hypertension in children 6 to 16 years of age:</u> Initial: 0.07 mg/kg (up to 5 mg) once daily; doses >0.61 mg/kg (or in excess of 40 mg) have not been studied Safety and efficacy in children <6 years of age have not been established.	Tablet: 2.5 mg 5 mg 10 mg 20 mg 30 mg 40 mg
Moexipril	<u>Hypertension:</u> Tablet: initial, 7.5 mg once daily; maintenance, 7.5 to 30 mg/day in a single or divided dose(s); maximum, 60 mg/day	Safety and efficacy in children have not been established.	Tablet: 7.5 mg 15 mg
Perindopril	<u>Cardiovascular risk reduction (coronary artery disease):</u> Tablet: initial: 4 mg once daily for 2 weeks; maintenance, increase as tolerated to 8 mg once daily <u>Hypertension:</u> Tablet: initial, 4 mg once daily; maintenance, 4 to 8 mg/day in a single or divided dose(s); maximum, 16 mg/day	Safety and efficacy in children have not been established.	Tablet: 2 mg 4 mg 8 mg
Quinapril	<u>Heart failure:</u> Tablet: initial, 5 mg twice daily; maintenance, titrate at weekly intervals to 10 to 20 mg two times daily <u>Hypertension:</u> Tablet: initial, 10 to 20 mg once daily; maintenance, 20 to 80 mg/day in a single or divided dose(s)	Safety and efficacy in children have not been established.	Tablet: 5 mg 10 mg 20 mg 40 mg
Ramipril	<u>Cardiovascular risk reduction:</u>	Safety and efficacy in	Capsule:

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>Capsule: initial, 2.5 mg once daily for one week, followed by 5 mg once daily for three weeks; maintenance, 10 mg once daily</p> <p><u>Hypertension:</u> Capsule: initial, 2.5 mg once daily; maintenance, 2.5 to 20 mg/day in single or divided dose(s)</p> <p><u>Post-myocardial infarction (heart failure after myocardial infarction):</u> Capsule: initial, 2.5 mg twice daily; target maintenance, 5 mg twice daily</p>	children have not been established.	1.25 mg 2.5 mg 5 mg 10 mg
Trandolapril	<p><u>Post-myocardial infarction (left ventricular dysfunction or heart failure after myocardial infarction):</u> Tablet: initial, 1 mg once daily; maintenance, titrate as tolerated to target of 4 mg once daily</p> <p><u>Hypertension:</u> Tablet: initial, 1 mg once daily in non-African American patients and 2 mg once daily in African American patients; maintenance, 2 to 4 mg once daily</p>	Safety and efficacy in children have not been established.	Tablet: 1 mg 2 mg 4 mg
Combination Products			
Benazepril and HCTZ	<p><u>Hypertension:</u> Tablet: initial, 10-12.5 or 20-12.5 mg/day if not adequately controlled on benazepril monotherapy; maintenance, titrate dose by clinical effect</p>	Safety and efficacy in children have not been established.	Tablet: 5-6.25 mg 10-12.5 mg 20-12.5 mg 20-25 mg
Captopril and HCTZ	<p><u>Hypertension:</u> Tablet: initial, 25-5 mg once daily; titrate dose by clinical effect; maximum, 150-50 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 25-15 mg 25-25 mg 50-15 mg 50-25 mg
Enalapril and HCTZ	<p><u>Hypertension:</u> Tablet: maximum, four tablets of 5-12.5 mg or two tablets of 10-25 mg</p>	Safety and efficacy in children have not been established.	Tablet: 5-12.5 mg 10-25 mg
Fosinopril and HCTZ	<p><u>Hypertension:</u> Tablet: titrate dose by clinical effect</p>	Safety and efficacy in children have not been established.	Tablet: 10-12.5 mg 20-12.5 mg
Lisinopril and HCTZ	<p><u>Hypertension:</u> Tablet: initial, 10-12.5 or 20-12.5 mg/day after failure on monotherapy; titrate dose by clinical effect; maximum, 80-50 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 10-12.5 mg 20-12.5 mg 20-25 mg
Moexipril and HCTZ	<p><u>Hypertension:</u> Tablet: initial, 7.5-12.5, 15-12.5, or 15-25 mg/day; maintenance, titrate</p>	Safety and efficacy in children have not been established.	Tablet: 7.5-12.5 mg 15-12.5 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	dose by clinical effect; maximum, 30-50 mg/day		15-25 mg
Quinapril and HCTZ	<u>Hypertension:</u> Tablet: initial, 10-12.5 or 20-12.5 mg/day; maintenance, titrate dose by clinical effect	Safety and efficacy in children have not been established.	Tablet: 10-12.5 mg 20-12.5 mg 20-25 mg
Trandolapril and verapamil	<u>Hypertension:</u> Extended-release tablet: 1 to 4-120 to 180 mg/day in a single or divided dose(s)	Safety and efficacy in children have not been established.	Extended-release tablet: 1-240 mg 2-180 mg 2-240 mg 4-240 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the angiotensin-converting enzyme inhibitors are summarized in Table 11.

Table 11. Comparative Clinical Trials with the Angiotensin-Converting Enzyme Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cardiovascular Disease				
<p>Jamerson et al.⁴⁷ (2008) ACCOMPLISH</p> <p>Benazepril 20 to 40 mg QD and HCTZ 12.5 to 25 mg QD</p> <p>vs</p> <p>benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Patients >60 years of age with HTN and at high risk of cardiovascular events</p>	<p>N=11,506</p> <p>36 months (mean)</p>	<p>Primary: The composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.</p> <p>Secondary: Death from cardiovascular causes, nonfatal MI, and nonfatal stroke</p>	<p>Primary: There were 552 primary-outcome events in the benazepril plus amlodipine group (9.6%) and 679 events in the benazepril plus HCTZ group (11.8%). The absolute risk reduction with benazepril plus amlodipine therapy was 2.2% and the relative risk reduction was 19.6% compared to benazepril plus HCTZ (HR, 0.80; 95% CI, 0.72 to 0.90; P<0.001).</p> <p>Secondary: For the secondary end point of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, there were 288 (5%) events in the benazepril plus amlodipine group compared to 364 (6.3%) events in the benazepril plus HCTZ group. The absolute risk reduction with benazepril plus amlodipine therapy was 1.3% and the RR reduction was 21.2% compared to benazepril plus HCTZ (HR, 0.79; 95% CI, 0.67 to 0.92; P=0.002).</p>
<p>Weber et al.⁴⁸ (2010) ACCOMPLISH</p> <p>Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on</p>	<p>Prespecified subanalysis of ACCOMPISH</p> <p>Men and women >60 years of age with HTN and at high risk for cardiovascular events (history of</p>	<p>N=6,946</p> <p>Mean treatment duration 29.7 months for benazepril and amlodipine group and 29.5 months for</p>	<p>Primary: Primary: Time to first event (composite of cardiovascular event and death from cardiovascular causes)</p>	<p>Primary: The primary endpoint occurred in 8.8% of diabetic patients in the benazepril and amlodipine group and 11.0% in the benazepril and HCTZ group (HR, 0.79; P=0.003; NNT, 46). In high risk diabetic patients, 13.6% of patients in the benazepril and amlodipine group and 17.3% in the benazepril and HCTZ group (HR, 0.77, P=0.007; NNT, 28).</p> <p>Secondary: Due to early termination, the study had limited power to detect differences in the diabetic subgroups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>benazepril and amlodipine 20-5 mg (fixed-dose combination product)</p> <p>vs</p> <p>benazepril and HCTZ 40-12.5 to 40-25 mg/day, followed by forced titration after one month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)</p>	<p>coronary events, MI, revascularization, or stroke; impaired renal function; peripheral arterial disease, left ventricular hypertrophy; or diabetes)</p> <p>(Subanalysis of patients with diabetes)</p>	<p>benazepril and HCTZ group</p>	<p>Secondary: Composite of cardiovascular events (the primary endpoint excluding fatal events) and composite of death from cardiovascular disease, nonfatal stroke and nonfatal MI</p>	<p>Peripheral edema was higher in the benazepril and amlodipine group compared to the benazepril and HCTZ group.</p>
<p>Weber et al.⁴⁹ (2013) ACCOMPLISH</p> <p>Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on benazepril and amlodipine 20-5 mg (fixed-dose combination product)</p> <p>vs</p>	<p>Subanalysis of ACCOMPLISH based on body size</p> <p>Patients >60 years of age with HTN and at high risk of cardiovascular events</p>	<p>N=11,482</p> <p>Duration not specified</p>	<p>Primary: Composite of cardiovascular death or nonfatal MI or stroke</p> <p>Secondary: Cardiovascular death, total MI, total stroke</p>	<p>Primary: In patients receiving benazepril and HCTZ, the primary endpoint (per 1,000 patient-years) was 30.7 in normal weight (BMI <25), 21.9 in overweight (BMI ≥25 to <30), and 18.2 in obese patients (BMI ≥30) (overall P=0.0034). In patients receiving benazepril and amlodipine, the primary endpoint did not differ between the three BMI groups (18.2, 16.9, and 16.5, respectively; P=0.9721). In obese patients, primary event rates were similar between the two treatments, but rates were significantly lower with benazepril and amlodipine in overweight patients (HR, 0.76; 95% CI, 0.59 to 0.94; P=0.0369) and normal weight patients (HR, 0.57; 95% CI, 0.39 to 0.84; P=0.0037).</p> <p>Secondary: Comparing obese and overweight patients, event rates were all numerically lower, but not significantly lower, in obese patients. Cardiovascular deaths were significantly lower in overweight patients compared to normal weight patients (HR, 0.57; 95% CI, 0.37 to 0.89; P=0.0125). Cardiovascular death (HR, 0.40; 95% CI, 0.25 to 0.63;</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
benazepril and HCTZ 40-12.5 to 40-25 mg/day, followed by forced titration after 1 month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)				P<0.0001) and total stroke (HR, 0.60; 95% CI, 0.37 to 0.96; P=0.0335) were significantly lower in obese patients compared to normal weight patients.
Swedberg et al. ⁵⁰ (1992) CONSENSUS II Enalapril 5 to 20 mg/day vs placebo Treatment was started with an IV infusion of 1 mg of enalaprilat administered over 3 hours followed by oral enalapril 6 hours after the infusion was stopped.	DB, MC, PC, PG, RCT Patients who presented within 24 hours of the onset of acute MI symptoms	N=6,090 180 days	Primary: Mortality rates within 6 months Secondary: Mortality within 1 month, cause of death, re-infarction, or worsening heart failure	Primary: Mortality rates according to life-table analysis between the enalapril and placebo groups at six months were not significantly different (11 vs 10.2%; P=0.26). The RR associated with enalapril treatment and based on the mortality curves was 1.10 (95% CI, 0.93 to 1.29). Secondary: Mortality rates between the enalapril and placebo groups at one month were not significantly different (7.2 vs 6.3%; P=0.26). Death due to progressive heart failure occurred more frequently in patients treated with enalapril than placebo (4.3 vs 3.4%; P=0.06). There were no significant differences in the rate of reinfarction between the enalapril or placebo groups (P value not significant). Change in therapy because of heart failure occurred more in the placebo group (P<0.006) but there were no significant differences in hospitalization for heart failure (P value not significant). Note: The first CONSENSUS trial excluded patients with a recent MI or unstable angina. The study was stopped early after recruiting 6,090 of the intended 9,000 patients since more patients had died on the drug than on placebo (although the difference was not statistically significant).
Wing et al. ⁵¹ (2003)	MC, OL, PRO, RCT	N=6,083	Primary: All cardiovascular	Primary: By the end of the study, blood pressure had decreased to a similar extent in

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ANBP2</p> <p>Enalapril</p> <p>vs</p> <p>HCTZ</p> <p>The choice of the specific agent and dose was made by the family practitioner.</p>	<p>Patients 65 to 84 years of age with average SBP while sitting of ≥ 160 mm Hg or an average DBP of ≥ 90 mm Hg (if the SBP was ≥ 140 mm Hg)</p>	<p>4.1 years (median)</p>	<p>events or death from any cause (both initial and subsequent fatal and nonfatal cardiovascular events)</p> <p>Secondary: Not reported</p>	<p>both groups (a decrease of 26/12 mm Hg).</p> <p>There were 695 cardiovascular events or deaths from any cause in the ACE inhibitor group (56.1 per 1,000 patient-years; HR, 0.89; 95% CI, 0.79 to 1.0; P=0.05) compared to 736 in the diuretic group (59.8 per 1,000 patient-years).</p> <p>The beneficial effects of ACE inhibitor treatment were more evident in male subjects (HR, 0.83; 95% CI, 0.71 to 0.97; P=0.02).</p> <p>The rates of nonfatal cardiovascular events and MI decreased with ACE inhibitor treatment, whereas a similar number of strokes occurred in each group (although there were more fatal strokes in the ACE inhibitor group).</p> <p>Secondary: Not reported</p>
<p>Nissen et al.⁵² (2004)</p> <p>CAMELOT</p> <p>Enalapril 10 to 20 mg/day</p> <p>vs</p> <p>amlodipine 5 to 10 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients 30 to 79 years of age requiring coronary angiography for evaluation for chest pain or PCI and a diastolic pressure < 100 mm Hg, with or without treatment</p>	<p>N=1,991</p> <p>2 years</p>	<p>Primary: Composite of cardiovascular events (cardiovascular death, nonfatal MI, resuscitated cardiac arrest, coronary revascularization, hospitalization for angina pectoris, hospitalization for CHF, fatal or nonfatal stroke or TIA, and any new diagnosis of PVD), nominal change in percent atheroma volume (substudy)</p>	<p>Primary: Cardiovascular events occurred in 23.1% of placebo-treated patients, 16.6% amlodipine-treated patients (HR, 0.69; 95% CI, 0.54 to 0.88; P=0.003) and 20.2% enalapril-treated patients (HR, 0.85; 95% CI, 0.67 to 1.17; P=0.16).</p> <p>The primary end point comparison for enalapril vs amlodipine was not significant (HR, 0.81; 95% CI, 0.63 to 1.04; P=0.10).</p> <p>Secondary: Coronary revascularization was reduced in the amlodipine group from 15.7 to 11.8% (HR, 0.73; 95% CI, 0.54 to 0.98; P=0.03). Hospitalization for angina was reduced in the amlodipine group from 12.8 to 7.7% (HR, 0.58; 95% CI, 0.41 to 0.82; P=0.002).</p> <p>Individual components of the primary end point generally showed fewer events with enalapril treatment vs placebo, but none of the comparisons reached statistical significance.</p> <p>For components of the primary end point, only the rate of hospitalization for angina showed a statistically significant difference between amlodipine</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			<p>Secondary: Incidence of adverse events; all-cause mortality, incidence of revascularization in vessels that had undergone previous stent placement</p>	<p>and enalapril (HR, 0.59; 95% CI, 0.42 to 0.84; P=0.003). A trend toward fewer episodes of revascularization in patients undergoing intervention at baseline was observed for amlodipine vs enalapril (HR, 0.66; 95% CI, 0.40 to 1.6; P=0.09).</p> <p>The mean change in percent atheroma volume was 0.5% for amlodipine (P=0.12 vs placebo), 0.8% for enalapril (P=0.32 vs placebo) and 1.3% for placebo. In patients with SBP greater than the mean, the amlodipine group showed a significantly slower progression (0.2%) compared to placebo (2.3%; P=0.02). Compared to baseline, intravascular ultrasound showed progression in patients receiving placebo (P<0.001), a trend toward progression with enalapril (P=0.08) and no progression in patients receiving amlodipine (P=0.31). For the amlodipine group, correlation between blood pressure reduction and progression was r=0.19 (P=0.07).</p> <p>Discontinuation from the study for treatment-emergent adverse events was low, averaging 0.4% and not statistically significant between the three treatment groups.</p> <p>The only statistically significant difference in secondary end points was that amlodipine demonstrated a significant reduction in revascularization after previous stent placement compared to placebo (4.1 vs 7.9%; HR, 0.49; 95% CI, 0.31 to 0.78; P=0.002). The rate of revascularization was lower than enalapril (6.2%) but not statistically significant (HR 0.66, 95% CI, 0.40 to 1.6; P=0.09).</p>
<p>Pitt et al.⁵³ (2003) 4E-Left Ventricular Hypertrophy Study Enalapril 40 mg QD vs</p>	<p>AC, DB, PG, RCT Patients with left ventricular hypertrophy, a history of HTN and predominantly in sinus rhythm</p>	<p>N=153 9 months</p>	<p>Primary: Change in left ventricular mass as assessed by MRI</p> <p>Secondary: Reduction in SBP and DBP, response rate (DBP <90 mm Hg), change in urine albumin creatinine ratio</p>	<p>Primary: Both treatments were associated with a significant reduction in left ventricular mass from baseline (P<0.001). The difference in left ventricular mass reduction from baseline between the two treatments was not significant (P=0.258).</p> <p>While enalapril plus eplerenone therapy demonstrated a significantly greater reduction in left ventricular mass from baseline compared to eplerenone therapy (P=0.007); the effect was not statistically different from that observed with enalapril therapy (P=0.107).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>eplerenone 200 mg QD</p> <p>vs</p> <p>enalapril 10 mg plus eplerenone 200 mg</p> <p>If the blood pressure was uncontrolled on study medication at week 8, OL HCTZ 12.5 to 25 mg/day and/or amlodipine 10 mg/day were allowed.</p>				<p>The SBP was reduced significantly more in enalapril plus eplerenone-treated patients compared to eplerenone-treated patients (P=0.048). The other treatment groups exhibited statistically comparable reductions from baseline in mean SBP and DBP (P value not reported).</p> <p>While 70.0% of eplerenone-treated patients responded to therapy, 40.7% of enalapril-treated patients responded (P=0.003). In addition, 79.6% of enalapril plus eplerenone-treated patients responded to therapy compared to 40.7% enalapril-treated patients (P=0.001).</p> <p>Enalapril plus eplerenone therapy was associated with a significant reduction in urine albumin creatinine ratio compared to either eplerenone or enalapril therapy (P<0.05).</p> <p>Adverse events were reported with similar incidence among all treatment groups (P value not reported). Cough was significant in enalapril-treated patients compared to eplerenone-treated patients (P=0.033). Two cases of gynecomastia were reported (one eplerenone- and one enalapril plus eplerenone-treated patients). Four patients (three enalapril- and one enalapril plus eplerenone-treated patients) experienced impotence during the trial. Seven eplerenone-, two enalapril- and three enalapril plus eplerenone-treated patients experienced serious hyperkalemia (≥ 6.0 mmol/L).</p>
<p>Hansson et al.⁵⁴ (1999) STOP-Hypertension</p> <p>Enalapril 10 mg or lisinopril 10 mg QD</p> <p>vs</p> <p>felodipine 2.5 mg or isradipine 2.5 mg QD</p>	<p>MC, OL, PRO, RCT</p> <p>Men and women, age 70 to 84 years with HTN (SBP ≥ 180mm Hg or DBP ≥ 105 mm Hg or both)</p>	<p>N=6,614</p> <p>4 years</p>	<p>Primary: Fatal stroke, fatal MI, other fatal cardiovascular events</p> <p>Secondary: Blood pressure</p>	<p>Primary: The rate of prevention of cardiovascular deaths was similar in all groups (RR, 0.97 to 1.14; 95% CI, 0.86 to 1.26).</p> <p>Fatal cardiovascular events, including fatal stroke and fatal myocardial infarction MI, occurred in 19.8 per 1,000 patient-years in the β-blocker and/or HCTZ group, in the felodipine or isradipine group and in the enalapril or lisinopril group (RR, 0.99; 95% CI, 0.84 to 1.16).</p> <p>The RR of cardiovascular death in patients in the enalapril or lisinopril group as compared to the felodipine or isradipine group was 1.14 (95% CI, 0.86 to 1.26; P=0.67.)</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs atenolol 50 mg or metoprolol 100 mg or pindolol 5 mg QD and/or HCTZ 25 mg with amiloride 2 to 5 mg QD				Decreases in blood pressure were similar among the groups.
ALLHAT ⁵⁵ (2002) ALLHAT Lisinopril 10 to 40 mg/day vs amlodipine 2.5 to 10 mg/day vs chlorthalidone 12.5 to 25 mg/day Doses were titrated to achieve a goal blood pressure of <140/90 mm Hg.	DB, MC, RCT Patients ≥55 years with HTN and ≥1 additional CHD risk factor	N=33,357 4.9 years (mean)	Primary: Combined fatal CHD or nonfatal MI Secondary: All-cause mortality, fatal and nonfatal stroke, combined CHD, combined cardiovascular disease (combined CHD, stroke, treated angina without hospitalization, heart failure, and PAD)	Primary: There were no significant differences in the primary outcome between lisinopril (11.4%), amlodipine (11.3%), and chlorthalidone (11.5%). Secondary: All-cause mortality did not differ between groups. Five year SBPs were significantly higher in the lisinopril (2 mm Hg; P<0.001) and amlodipine groups (0.8 mm Hg; P=0.03) compared to chlorthalidone, and five year DBPs were significantly lower with amlodipine (0.8 mm Hg; P<0.001). Amlodipine had a higher six year rate of heart failure compared to chlorthalidone (10.2 vs 7.7%; RR, 1.38; 95% CI, 1.25 to 1.52). Lisinopril had a higher six year rate of combined cardiovascular disease (33.3 vs 30.9%; RR, 1.10; 95% CI, 1.05 to 1.16); stroke (6.3 vs 5.6%; RR, 1.15; 95% CI, 1.02 to 1.30) and heart failure (8.7 vs 7.7%; RR, 1.19; 95% CI, 1.07 to 1.31).
Black et al. ⁵⁶ (2008) ALLHAT Amlodipine 2.5 to	MC, RCT Men and women, age 55 years old and older, with HTN and	N=17,515 4.9 years (mean)	Primary: Fatal coronary heart disease and nonfatal MI	Primary: For patients with metabolic syndrome, there was no significant difference in rates of coronary heart disease and nonfatal MI with amlodipine vs chlorthalidone (RR, 0.96; 95% CI, 0.79 to 1.16), or lisinopril vs chlorthalidone (RR, 1.15; 95% CI, 0.88 to 1.27).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
10 mg QD vs lisinopril 10 to 40 mg QD vs chlorthalidone 12.5 to 25 mg QD	metabolic syndrome		Secondary: All cause mortality, fatal and nonfatal stroke, combined coronary heart disease, combined cardiovascular disease	Secondary: For patients with metabolic syndrome, there were no significant differences found between amlodipine vs chlorthalidone in all secondary endpoints (P value not significant). For patients without metabolic syndrome, amlodipine treatment was associated with significantly more heart failure, but in patients with metabolic syndrome, there was no difference (P=0.03). Patients with metabolic syndrome who received lisinopril experienced more heart failure and cardiovascular disease than those who received chlorthalidone (RR, 1.31; 95% CI, 1.14 to 1.64 and RR, 1.19; 95% CI, 1.07 to 1.32).
Rahman et al. ⁵⁷ (2012) ALLHAT Lisinopril 10 to 40 mg/day vs amlodipine 2.5 to 10 mg/day vs chlorthalidone 12.5 to 25 mg/day	Long-term, post-trial, follow-up Patients in ALLHAT stratified based on eGFR	N=31,350 4 to 8 years	Primary: Cardiovascular mortality Secondary: Total mortality, CHD, cardiovascular disease, stroke, heart failure, ESRD	Primary: After an average of 8.8 years of follow-up, total mortality was significantly higher in patients with moderate/severe eGFR reduction (eGFR <60 mL/min/1.73 m ²) compared to patients with normal/increased (eGFR ≥90 mL/min/1.73 m ²) and mildly reduced eGFR (eGFR 60 to 89 mL/min/1.73 m ²) (P<0.001). In patients with moderate/severe eGFR reduction, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Secondary: No significant differences were observed for any of the secondary endpoints among eGFR reduction groups.
Muntner et al. ⁵⁸ (2014) ALLHAT Chlorthalidone 12.5 to 25 mg/day	Post-hoc analysis of ALLHAT Patients in ALLHAT with 5, 6, or 7 visits in 6 to 28 months of follow-up	N=24,004 6 to 28 months	Primary: Visit-to-visit variability (VVV) of blood pressure Secondary: Not reported	Primary: Each measure of VVV of SBP was lower among participants randomized to chlorthalidone and amlodipine compared with those randomized to lisinopril. All four VVV of SBP metrics were lower among participants randomized to amlodipine vs chlorthalidone after full multivariable adjustment.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day</p>				<p>After multivariable adjustment including mean SBP across visits and compared with participants randomized to chlorthalidone, participants randomized to amlodipine had a 0.36 (standard error [SE]: 0.07) lower standard deviation (SD) of SBP and participants randomized to lisinopril had a 0.77 (SE=0.08) higher SD of SBP. Results were consistent using other VVV of SBP metrics. These data suggest chlorthalidone and amlodipine are associated with lower VVV of SBP than lisinopril.</p> <p>Secondary: Not reported</p>
<p>Fox et al.⁵⁹ (2003) EUROPA Perindopril 8 mg QD vs placebo</p>	<p>DB, MC, PC, RCT Patients ≥18 years of age with evidence of CHD (e.g., MI >3 months before screening, percutaneous or surgical coronary revascularization >6 months before screening, 70% narrowing of 1 or more major coronary arteries, history of chest pain) and without clinical heart failure or uncontrolled HTN</p>	<p>N=12,218 4.2 years (mean)</p>	<p>Primary: Composite of cardiovascular death, MI, or cardiac arrest Secondary: Composite of total mortality, nonfatal MI, hospital admission for unstable angina, and cardiac arrest with successful resuscitation; cardiovascular mortality and nonfatal MI; individual components of the secondary outcomes and revascularization, stroke, and admission for heart failure</p>	<p>Primary: Patients treated with perindopril had a significant reduction in the primary outcome compared to patients treated with placebo (8 vs 10%; RR reduction, 20%; 95% CI, 9 to 29; P=0.0003). The benefit began to appear at one year and gradually increased throughout the trial.</p> <p>Secondary: Compared to placebo, treatment with perindopril was associated with reductions in all secondary end points. However, not all changes were significant.</p> <p>There was a 14% reduction in total mortality, nonfatal MI, unstable angina, and cardiac arrest (P=0.0009).</p> <p>There was a 22% reduction in nonfatal MI with perindopril (P=0.001).</p> <p>Total mortality was 11% lower with perindopril but this finding was not significant (P=0.1).</p> <p>Hospital admission for heart failure was significantly reduced with perindopril by 39% (P=0.002).</p>
<p>PREAMI</p>	<p>DB, MC, PC, PG,</p>	<p>N=1,252</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Investigators ⁶⁰ (2006) Perindopril 8 mg/day vs placebo	RCT Patients ≥ 65 years with LVEF $\geq 40\%$ and recent acute MI	12 months	Composite of death, hospitalization for heart failure or left ventricular remodeling Secondary: Cardiovascular death, hospitalization for reinfarction or angina, revascularization	The primary end point occurred in 35% of patients taking perindopril and 57% of patients on placebo, with an absolute risk reduction of 0.22 (95% CI, 0.16 to 0.28; $P < 0.001$). A total of 126 patients (28%) and 226 patients (51%) in the perindopril and placebo groups, respectively, experienced remodeling ($P < 0.001$). The mean increase in left ventricular end-diastolic volume was 0.7 mL with perindopril compared to 4.0 mL with placebo ($P < 0.001$). Secondary: Cardiovascular death, hospitalization for subsequent acute MI or angina or revascularization was infrequent and not modified by treatment. Conclusion: Perindopril treatment for one year reduced progressive left ventricular remodeling but was not associated with better clinical outcomes.
ADVANCE Collaborative Group ⁶¹ (2007) Perindopril (2 to 4 mg) and indapamide (0.625 to 1.25 mg) QD vs placebo	DB, MC, PC, RCT Adults 55 years of age or older who were diagnosed with type 2 diabetes at age 30 or older, and a history of cardiovascular disease or ≥ 1 other risk factor for cardiovascular disease	N=11,140 Mean 4.3 years	Primary: Composites of major macrovascular and microvascular events (death from cardiovascular disease, nonfatal stroke, nonfatal MI, or new renal or diabetic eye disease) Secondary: Macrovascular and microvascular endpoints analyzed separately	Primary: The relative risk of a major macrovascular or microvascular event was reduced by 9% (861 [15.5%] active vs 938 [16.8%] placebo; HR, 0.91, 95% CI 0.83 to 1.0, $P = 0.04$). Secondary: The RR of death from cardiovascular disease was reduced by 18% (211 [3.8%] active vs 257 [4.6%] placebo; 0.82, 0.68-0.98, $p = 0.03$) and death from any cause was reduced by 14% (408 [7.3%] active vs 471 [8.5%] placebo; 0.86, 0.75-0.98, $P = 0.03$).
HOPE Investigators ⁶² (2000)	DB, RCT, two-by-two factorial trial	N=9,297 5 years	Primary: Composite of death from	Primary: Fewer patients on ramipril than placebo (14.0 vs 17.8%, respectively) died of cardiovascular causes or had a MI or stroke (RR, 0.78; 95% CI, 0.70 to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Ramipril 10 mg QD vs placebo</p>	<p>Men and women ≥55 years old with history of CAD, stroke, PVD, or diabetes and ≥1 other cardiovascular risk factor and who were not known to have a low ejection fraction (<40%) or heart failure</p>	<p>(mean)</p>	<p>cardiovascular causes, MI, or stroke and each outcome separately</p> <p>Secondary: Death from any cause, revascularization, hospitalization for unstable angina or heart failure, and complications related to diabetes</p> <p>Other end points: Worsening angina, cardiac arrest, heart failure, unstable angina with ECG changes, and the development of diabetes</p>	<p>0.86; P<0.001).</p> <p>Treatment with ramipril reduced the rates of death from cardiovascular causes (RR, 0.74; P<0.001), MI (RR, 0.80; P<0.001), and stroke (RR, 0.68; P<0.001).</p> <p>Secondary: The risk of death from any cause was also significantly reduced by treatment with ramipril (RR, 0.84; P=0.005).</p> <p>Significantly fewer patients treated with ramipril underwent revascularization compared to placebo (RR, 0.85; P=0.002).</p> <p>Fewer hospitalizations for heart failure were reported with ramipril vs placebo but the risk reduction was not statistically significant (RR, 0.88; P=0.25).</p> <p>Fewer complications related to diabetes were reported in patients receiving ramipril (RR, 0.84; P=0.03).</p> <p>Other end points: Significantly fewer patients treated with ramipril than placebo group had the following: worsening angina (RR, 0.89; P=0.004), cardiac arrest (RR, 0.62; P=0.02), heart failure (RR 0.77; P<0.001), and new diagnosis of diabetes (RR, 0.66; P<0.001). There was no difference between treatment groups for unstable angina with ECG changes (RR, 0.97; P=0.76).</p>
<p>ONTARGET Investigators⁶³ (2008)</p> <p>Ramipril 10 mg/day vs telmisartan 80 mg/day</p>	<p>DB, MC, PC, RCT</p> <p>Patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage</p>	<p>N=25,620</p> <p>56 months (median follow-up)</p>	<p>Primary: Death from cardiovascular causes, MI, stroke or hospitalization for heart failure</p> <p>Secondary: Composite of death from cardiovascular</p>	<p>Primary: The primary outcome occurred in 16.5, 16.7, and 16.3% of patients receiving ramipril, telmisartan and combination therapy, respectively.</p> <p>Secondary: The composite of death from cardiovascular causes, MI or stroke occurred in 14.1% of patients in the ramipril group and 13.9% of patients in the telmisartan group (RR, 0.99; 95% CI, 0.91 to 17; P=0.001 for non-inferiority). Combination therapy was not significantly better than ramipril alone (RR, 0.99; 95% CI, 0.92 to 17).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ramipril 10 mg/day and telmisartan 80 mg/day			causes, MI or stroke; heart failure, worsening or new angina, new diagnosis diabetes mellitus, new atrial fibrillation, renal impairment, revascularization procedures	There were no significant differences in the rates of secondary outcomes, except for renal dysfunction, which occurred in 10.2% of patients receiving ramipril, 10.6% of patients receiving telmisartan and 13.5% of patients receiving combination therapy (P<0.001 vs ramipril; P value not reported vs telmisartan). As compared to the ramipril group, the telmisartan group had lower rates of cough (1.1 vs 4.2%; P<0.001) and angioedema (0.1 vs 0.3%; P=0.01) and a higher rate of hypotensive symptoms (2.6 vs 1.7%; P<0.001); the rate of syncope was the same in the two groups (0.2%). As compared to the ramipril group, combination therapy had an increased risk of hypotensive symptoms (4.8 vs 1.7%; P<0.001), syncope (0.3 vs 0.2%; P=0.03) and renal dysfunction (13.5 vs 10.2%; P<0.001).
Redon et al. ⁶⁴ (2012) ONTARGET Ramipril 10 mg/day vs telmisartan 80 mg/day vs ramipril 10 mg/day and telmisartan 80 mg/day	Post-hoc analysis Patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage	N=25,584 56 months (median follow-up)	Primary: Composite of cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalized heart failure Secondary: Not reported	Primary: The primary outcome occurred in 20.2% (n=1,938) and 14.2% (n=2,276) of diabetic and nondiabetic patients. Compared to nondiabetic patients, diabetic patients had a significantly higher risk for the primary endpoint (HR, 1.48; 95% CI, 1.38 to 1.57) and cardiovascular death (HR, 1.56; 95% CI, 1.42 to 1.71), MI (HR, 1.30; 95% CI, 1.17 to 1.46), stroke (HR, 1.39; 95% CI, 1.23 to 1.56), and CHF hospitalization (HR, 2.06; 95% CI, 1.82 to 2.32). Cardiovascular risk was significantly higher in diabetic patients compared to nondiabetic patients regardless of changes in SBP during treatment. In all patients, progressively greater SBP reductions were accompanied by reduced risk for the primary outcome only if baseline SBP levels ranged from 143 to 155 mm Hg; except for stroke, there was no benefit in fatal and nonfatal cardiovascular outcomes by reducing SBP <130 mm Hg. Secondary: Not reported
Mann et al. ⁶⁵ (2013) ONTARGET Ramipril	Subanalysis Patients in the ONTARGET trial with diabetes	N=3163 with CKD N=6465 no CKD	Primary: Composite of death from cardiovascular cause, nonfatal MI,	Primary: The stroke rate in all participants with diabetes was not different between the treatment groups, 1.19 and 1.22 per 100 patient-years in those on dual and monotherapy, respectively (HR, 0.99; 95% CI, 0.82 to 1.20). The results were consistent in those with or without renal disease (P value for

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
with telmisartan	mellitus	56 months	<p>nonfatal stroke or hospitalization for CHF</p> <p>Secondary: composite renal outcome for this analysis was defined posthoc as chronic dialysis (>2 months) or a doubling of baseline serum creatinine</p>	<p>interaction =0.60; 1.59 vs 1.55 and 1.01 vs 1.08 strokes per 100 patient-years, respectively). Results for other major outcomes indicated no differences and no interaction of renal subgroups with treatment effects.</p> <p>Secondary: Dialysis-dependent acute kidney injury tended to occur more frequently in those allocated to dual than with monotherapy, 0.14 vs 0.08 cases per 100 patient-years, (HR, 1.55; 95% CI, 0.84 to 2.85), and hyperkalemia was more frequent, 1.82 vs 1.07 cases per 100 patient-years (HR, 1.71; 95% CI, 1.44 to 2.02). Both adverse outcomes were more frequent in those with renal disease; however, the excess due to dual therapy was similar in those with and without renal disease.</p>
<p>PEACE Trial Investigators⁶⁶ (2004) PEACE</p> <p>Trandolapril 4 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Patients ≥50 years of age with stable CAD and normal or slightly reduced left ventricular function (LVEF >40%)</p>	<p>N=8,290</p> <p>4.8 years (median)</p>	<p>Primary: Combined rate of nonfatal MI, death from cardiovascular causes, or coronary revascularization procedures</p> <p>Secondary: Composite of death from cardiovascular causes, nonfatal MI, revascularization, unstable angina, new CHF, stroke, PVD, and cardiac arrhythmia</p>	<p>Primary: No significant differences in the primary outcome measures between trandolapril and placebo were reported (21.9 vs 22.5%; HR, 0.96; 95% CI, 0.88 to 16; P=0.43).</p> <p>Secondary: No significant differences in secondary outcome measures between trandolapril and placebo were reported (P>0.05).</p> <p>Side effects leading to discontinuation of study medication occurred in 14.4% of patients receiving trandolapril and 6.5% of patients receiving placebo (P<0.001). The rates of cough (39.1 vs 27.5%; P<0.01) and syncope (4.8 vs 3.9%; P=0.04) were higher in patients receiving trandolapril vs placebo.</p> <p>Note: This trial was conducted in low-risk patients with stable CAD and normal or slightly reduced left ventricular function. However, the HOPE trial was conducted in patients with coronary or other vascular disease or with diabetes and another cardiovascular risk factor and the EUROPA trial was conducted in patients with evidence of CHD.</p>
Pilote et al. ⁶⁷ (2004)	RETRO	N=7,512	Primary: 1-year mortality	Primary: Captopril (HR, 1.56; 95% CI, 1.13 to 2.15), enalapril (HR, 1.47; 95% CI,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Captopril (50 mg), enalapril (10 mg), fosinopril (10 mg), lisinopril (10 mg), perindopril (4 mg), quinapril (20 mg), and ramipril (5 mg)</p>	<p>Patients ≥65 years who were hospitalized for acute myocardial infarction and filled a prescription for an ACE inhibitor within 30 days of discharge and who continued to receive the same drug for ≥1 year</p>	<p>Average of 2.3 years since discharge</p>	<p>following an acute MI Secondary: Readmissions due to cardiac complications</p>	<p>1.14 to 1.89), fosinopril (HR, 1.71; 95% CI, 1.29 to 2.25), lisinopril (HR, 1.28; 95% CI, 0.98 to 1.67), and quinapril (HR, 1.58; 95% CI, 1.10 to 2.82) were associated with higher mortality than was ramipril. No statistically significant difference was reported between perindopril and ramipril (HR, 0.98; 95% CI, 0.60 to 1.60). Secondary: Enalapril (HR, 1.44; 95% CI, 1.13 to 2.01) and fosinopril (HR, 1.83; 95% CI, 1.27 to 2.62) were associated with higher readmission rates for CHF than ramipril. Readmissions for unstable angina and recurrent MI were similar across all prescription groups.</p>
<p>Dalhof et al.⁶⁸ (2005) ASCOT-BPLA Amlodipine 5 to 10 mg/day adding perindopril 4 to 8 mg/day as needed vs atenolol 50 to 100 mg/day adding bendroflumethiazide* 1.25 to 2.5 mg/day and potassium as needed If blood pressure was still not achieved, doxazosin 4 to 8 mg/day was added to the regimen.</p>	<p>MC, OL, RCT Patients 40 to 79 years of age with HTN and ≥3 other cardiovascular risk factors (left ventricular hypertrophy, other specified abnormalities on ECG, type 2 diabetes, PAD, history of stroke or TIA, male, age ≥55 years, microalbuminuria or proteinuria, smoking, TC:HDL-C ratio ≥6, or family history of CHD)</p>	<p>N=19,257 5.5 years</p>	<p>Primary: Nonfatal MI (including silent MI) and fatal CHD Secondary: All-cause mortality, total stroke, primary end points minus silent MI, all coronary events, total cardiovascular events and procedures, cardiovascular mortality, nonfatal and fatal heart failure, effects on primary end point and on total cardiovascular events and procedures among prespecified</p>	<p>Primary: No statistically significant difference in nonfatal MI and fatal CHD was reported between the amlodipine plus perindopril group compared to the atenolol plus bendroflumethiazide groups (HR, 0.90; 95% CI, 0.79 to 1.2; P=0.1052). Secondary: Significantly greater reductions in the following secondary end points were observed with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: all-cause mortality (P=0.0247), total stroke (P=0.0003), primary end points minus silent MI (P=0.0458), all coronary events (P=0.0070), total cardiovascular events and procedures (P<0.0001), and cardiovascular mortality (P=0.0010). There were no significant differences in nonfatal and fatal heart failure between the two treatment groups (P=0.1257). The study was terminated early due to higher mortality and worse outcomes on several secondary end points observed in the atenolol study group. Tertiary: Significantly greater reductions in the following end points were observed with amlodipine plus perindopril compared to atenolol plus bendroflumethiazide: unstable angina (P=0.0115), PAD (P=0.0001),</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			<p>subgroups</p> <p>Tertiary: Silent MI, unstable angina, chronic stable angina, PAD, life-threatening arrhythmias, development of diabetes, development of renal impairment</p>	<p>development of diabetes (P<0.0001), and development of renal impairment (P=0.0187).</p> <p>There were no significant differences in the incidence of silent MI (P=0.3089), chronic stable angina (P=0.8323) or life-threatening arrhythmias (P=0.8009) between the two treatment groups.</p> <p>There was no significant difference in the percent of patients who stopped therapy because of an adverse event between the two treatment groups (overall 25%). There was, however, a significant difference in favor of amlodipine plus perindopril in the proportion of patients who stopped trial therapy because of a serious adverse events (2 vs 3%; P<0.0001).</p>
<p>Chapman et al.⁶⁹ (2007) ASCOT-BPLA</p> <p>Atenolol 50 to 100 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); bendroflumethiazide* plus potassium 1.25 to 2.5 mg plus doxazosin were added for additional blood pressure control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25</p>	<p>Subanalysis of ASCOT-BPLA evaluating effects of spironolactone on treatment-resistant HTN</p> <p>Patients 40 to 79 years of age with HTN and ≥3 cardiovascular risk factors, with SBP ≥160 mm Hg and/or DBP ≥100 mm Hg (not on antihypertensive therapy) or SBP ≥140 mm Hg and/or DBP ≥90 mm Hg (on antihypertensive therapy)</p>	<p>N=1,411</p> <p>1.3 years</p>	<p>Primary: Change in DBP and SBP, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: Spironolactone-treated patients lead to a significant 21.9 mm Hg reduction in SBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 20.8 to 23.0 mm Hg; P<0.001).</p> <p>Spironolactone-treated patients lead to a significant 9.5 mm Hg reduction in DBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 9.0 to 10.1; P<0.001).</p> <p>Spironolactone-treated patients exhibited small but significant decreases in sodium, LDL-C and TC as well as increases in potassium, glucose, creatinine and HDL-C (P<0.05).</p> <p>The most common adverse effect reported in the trial was gynecomastia in men (P value not reported).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg was added to the regimen</p> <p>vs</p> <p>amlodipine 5 to 10 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); perindopril 4 to 8 mg and doxazosin were added for additional control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p>				
<p>Pepine et al.⁷⁰ (2003) INVEST</p> <p>Verapamil SR 240 mg/day (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4)</p>	<p>MC, OL, RCT</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: First occurrence of death (all cause), nonfatal MI or stroke</p> <p>Secondary: Cardiovascular death, angina, cardiovascular hospitalization, angina, blood pressure control</p>	<p>Primary: At 24 months, in the calcium antagonist strategy subgroup, 81.5% of patients were taking verapamil SR, 62.9% trandolapril, and 43.7% HCTZ. In the non-calcium antagonist strategy, 77.5% of patients were taking atenolol, 60.3% HCTZ, and 52.4% trandolapril.</p> <p>After a follow-up of 61,835 patient-years (mean, 2.7 years per patient), 2,269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in calcium antagonist strategy vs 10.17% in non-calcium antagonist strategy; RR, 0.98; 95% CI, 0.90 to 16; P=0.57).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(calcium antagonist strategy)</p> <p>vs</p> <p>atenolol 50 mg/day (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p> <p>Trandolapril was recommended for all patients with heart failure, diabetes, or renal insufficiency.</p>			<p>(SBP/DBP <140/90 mm Hg or <130/85 mm Hg if diabetic or renal impairment), safety</p>	<p>There was no significant difference in the rate of cardiovascular death (P=0.94) or cardiovascular hospitalization (P=0.59) between the two treatment groups.</p> <p>At 24 months, angina episodes decreased in both groups, but the mean frequency was lower in the calcium antagonist strategy group (0.77 episodes/week) compared to the non-calcium antagonist strategy group (0.88 episodes/week; P=0.02).</p> <p>Two-year blood pressure control was similar between groups. The blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of calcium antagonist strategy patients and 64.0% (systolic) and 88.1% (diastolic) of non-calcium antagonist strategy patients. A total of 71.7% of calcium antagonist strategy patients and 70.7% of non-calcium antagonist strategy patients achieved an SBP <140 mm Hg and DBP <90 mm Hg.</p> <p>Both regimens were generally well tolerated. Patients in the calcium antagonist strategy group reported constipation and cough more frequently than patients in the non-calcium antagonist strategy group, while non-calcium antagonist strategy patients experienced more dyspnea, lightheadedness, symptomatic bradycardia and wheezing (all were statistically significant with P≤0.05).</p>
<p>Lindhholm et al.⁷¹ (2005)</p> <p>Other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide*, captopril, diltiazem, enalapril,</p>	<p>MA</p> <p>13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular</p>	<p>N=105,951</p> <p>2.1 to 10.0 years</p>	<p>Primary: Stroke, MI, all-cause mortality</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001).</p> <p>The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported).</p> <p>The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil) or placebo vs β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol, or propranolol)	morbidity or both			Secondary: Not reported
Wysong et al. ⁷² (2007) Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors) vs β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)	MA 13 RCTs evaluating patients ≥18 years of age with HTN	N=91,561 Duration varied	Primary: All-cause mortality Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions	Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04). Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09). CHD risk was not significantly different between β-blocker therapy and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>
<p>Blood Pressure Lowering Treatment Trialists' Collaboration⁷³ (2007)</p> <p>ACE inhibitors (17 trials)</p> <p>vs</p> <p>ARBs (9 trials)</p>	<p>MA</p> <p>Patients with high blood pressure, diabetes, history or CHD or cerebrovascular disease</p>	<p>N=146,838 (26 trials)</p> <p>Variable duration</p>	<p>Primary:</p> <p>Nonfatal myocardial infarction or death from CHD, including sudden death; heart failure causing death or requiring hospitalization; nonfatal stroke or death from cerebrovascular disease</p> <p>Secondary:</p> <p>Not reported</p>	<p>Primary:</p> <p>From a total of 146,838 individuals with high blood pressure or an elevated risk of cardiovascular disease, major cardiovascular events were documented in 22,666 patients during follow-up. The analyses showed comparable blood pressure-dependent reductions in risk with ACE inhibitors and ARBs ($P \geq 0.3$ for all three outcomes).</p> <p>ACE inhibitors produced a blood pressure-independent reduction in the relative risk of CHD of approximately 9% (95% CI, 3 to 14%). No similar effect was detected for ARBs, and there was some evidence of a difference between ACE inhibitors and ARBs in this regard ($P=0.002$).</p> <p>For both stroke and heart failure, there was no evidence of any blood pressure-independent effects of either ACE inhibitors or ARBs.</p> <p>Secondary:</p> <p>Not reported</p>
Cerebrovascular Disease				
PROGRESS ⁷⁴	DB, MC, PC, RCT	N=6,105	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2001)</p> <p>Perindopril 4 mg/day</p> <p>vs</p> <p>perindopril 4 mg/day and indapamide 2 to 2.5 mg/day</p> <p>vs</p> <p>placebo</p>	<p>Patients with a history of prior stroke or TIA within the previous 5 years</p>	<p>4 years</p>	<p>Fatal or nonfatal stroke</p> <p>Secondary: Fatal or disabling stroke, total major vascular events comprising the composite of nonfatal stroke, nonfatal MI, or death due to any vascular cause (including unexplained sudden death); total and cause specific deaths; hospital admissions</p>	<p>Patients receiving active treatment experienced a 28% reduction in nonfatal or fatal stroke (95% CI, 17 to 38; P<0.0001).</p> <p>There were similar reductions in the risk of stroke in hypertensive and non-hypertensive subgroups (32 vs 27%; P<0.01)</p> <p>A trend towards a greater effect of active treatment among patients treated with combination therapy (43% risk reduction) than in those treated with single drug therapy (5% risk reduction) was reported.</p> <p>Secondary: There was a 33% reduction in fatal or disabling strokes in the active treatment group.</p> <p>Active treatment reduced the risk of total major vascular events by 26% (P=0.02).</p> <p>There were no significant differences between active treatment and placebo in total deaths from vascular or nonvascular causes.</p> <p>Among those assigned active treatment, there was a 9% RR reduction in hospitalization, with a median reduction of 2.5 days in the time spent in the hospital during follow-up.</p> <p>Combination therapy with perindopril plus indapamide reduced blood pressure by 12/5 mm Hg and stroke risk by 43%. Single drug therapy reduced blood pressure by 5/3 mm Hg and produced no discernible reduction in the risk of stroke.</p>
<p>Arima et al.⁷⁵ (2011) PROGRESS</p> <p>Perindopril 4 mg/day</p> <p>vs</p>	<p>Post-hoc analysis</p> <p>Patients with a history of prior stroke or TIA within the previous 5 years</p>	<p>N=4,283</p> <p>4 years</p>	<p>Primary: Total major vascular events (nonfatal stroke, nonfatal MI, or vascular death)</p> <p>Secondary: Not reported</p>	<p>Primary: Among all patients, active treatment reduced the RR of major vascular events by 27% (95% CI, 10 to 41) in patients with isolated systolic HTN, by 28% (95% CI, -29 to 60) in patients with isolated diastolic HTN, and by 32% (95% CI, 17 to 45%) in patients with systolic-diastolic HTN. There was no evidence of differences in the magnitude of the effects of treatment among different types of HTN.</p> <p>Blood pressure reductions and RRs were consistently greater with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
perindopril 4 mg/day and indapamide 2 to 2.5 mg/day vs placebo				combination therapy compared to single drug therapy (mean SBP difference, 12.3 vs 3.9 mm Hg, 7.7 vs 4.3 mm Hg, and 13.5 vs 5.2 mm Hg; RR reduction of major vascular events 34 vs 16%, 63 vs -78%, and 45 vs 10% for isolated systolic HTN, isolated diastolic HTN, and systolic-diastolic HTN). Secondary: Not reported
Heart Failure				
Pfeffer et al. ⁷⁶ (1992) SAVE Captopril up to 50 mg TID vs placebo	DB, MC, PC, RCT Patients 21 to 80 years of age who had an acute MI within 3 to 16 days and left ventricular dysfunction with a LVEF ≤40%, but without overt heart failure or symptoms of myocardial ischemia	N=2,231 42 months (average)	Primary: Mortality from all causes, mortality from cardiovascular causes, mortality combined with a decrease in ejection fraction ≥9 units, cardiovascular morbidity, combination of cardiovascular mortality and morbidity Secondary: Not reported	Primary: Mortality from all causes was significantly reduced in the captopril group (20%) vs placebo group (25%) for a 19% reduction in the risk of mortality from all causes (95% CI, 3 to 25; P=0.019). The incidence of fatal cardiovascular events was consistently reduced in the captopril group with a 21% reduced risk of mortality from cardiovascular causes (P=0.014). The incidence of nonfatal major cardiovascular events was consistently reduced in the captopril group with a 25% reduced risk of recurrent MI (P=0.015), 37% reduced risk for the development of severe heart failure (P<0.001), and 22% reduced risk of CHF requiring hospitalization (P=0.019). Long-term captopril administration was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events. Secondary: Not reported
Pitt et al. ⁷⁷ (1997) ELITE Captopril 50 mg TID	DB, MC, PG, RCT Patients ≥65 years with symptomatic heart failure (NYHA class II to IV and LVEF ≤40%), and	N=722 1 year	Primary: Change in renal function Secondary: Composite of death and/or hospital	Primary: No difference between losartan and captopril was reported in the rate of persistent rise in serum creatinine concentrations (10.5% for both groups). Secondary: Death and/or hospital admission for heart failure was recorded in 9.4% of patients receiving losartan and 13.2% for patients receiving captopril (risk

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs losartan 50 mg QD	no history of prior ACE inhibitor therapy		admission for heart failure, all-cause mortality, admission for heart failure, NYHA class, admission for MI or unstable angina	reduction, 32%; 95% CI, -4 to 55; P=0.075). This risk reduction was primarily due to a decrease in all-cause mortality (4.8 vs 8.7%; risk reduction, 46%; 95% CI, 5 to 69; P=0.035). Admissions with heart failure were the same in both groups (5.7%), as was improvement in NYHA functional class from baseline. Admission to hospital for any reason was less frequent with losartan than with captopril treatment (22.2 vs 29.7%; P=0.014). More patients discontinued therapy due to adverse events with captopril (20.8%) than losartan (12.2%; P=0.002).
Pitt et al. ⁷⁸ (2000) ELITE II Captopril 50 mg TID vs losartan 50 mg QD	DB, MC, PG, RCT Patients ≥60 years old with symptomatic heart failure (NYHA II to IV and LVEF ≤40%), and no history of prior ACE inhibitor therapy	N=3,152 555 days (mean follow-up)	Primary: All-cause mortality Secondary: Composite of sudden cardiac death or resuscitated cardiac arrest	Primary: No significant difference in all-cause mortality was reported between losartan (17.7%) and captopril (15.9%; HR, 1.13; 95% CI, 0.95 to 1.35; P=0.16). Secondary: Sudden death or resuscitated cardiac arrest was observed in 9.0% of patients receiving losartan and 7.3% of patients receiving captopril (HR, 1.25; 95% CI; 0.98 to 1.60; P=0.08). Significantly fewer patients in the losartan group (excluding those who died) discontinued study treatment because of adverse events (9.7 vs 14.7%; P<0.001), including cough (0.3 vs 2.7%). Note: ELITE II trial was a larger follow-up trial to the ELITE I trial to confirm the secondary end point from the ELITE I trial, which reported a greater reduction in all-cause mortality with losartan compared to captopril.
Dickstein et al. ⁷⁹ (2002) OPTIMAAL Captopril 50 mg TID vs	DB, MC, PG, RCT Patients ≥50 years with an acute MI and signs or symptoms of heart failure during the acute phase or a new	N=5,477 2.7 years (mean)	Primary: All-cause mortality Secondary: Composite of sudden cardiac death or resuscitated	Primary: No significant difference in all-cause mortality was reported between patients receiving losartan and captopril (18 vs 16%, respectively; RR, 1.13; 95% CI, 0.99 to 1.28; P=0.07). Secondary: No significant difference in sudden cardiac death or resuscitated cardiac arrest was reported between patients receiving losartan and captopril (9%

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
losartan 50 mg QD	Q-wave anterior infarction or reinfarction		cardiac arrest	vs 7; RR, 1.19; 95% CI, 0.98 to 1.43; P=0.07). Losartan was significantly better tolerated than captopril, with fewer patients discontinuing study medication (17 vs 23%; P<0.0001).
Pfeffer et al. ⁸⁰ (2003) VALIANT Captopril 50 mg TID vs valsartan 160 mg BID vs valsartan 80 mg BID and captopril 50 mg TID	DB, MC, RCT Patients ≥18 years of age with an acute MI that was complicated by clinical or radiologic signs of heart failure and/or evidence of left ventricular systolic dysfunction	N=14,703 24.7 months	Primary: All-cause mortality Secondary: Death from cardiovascular causes, recurrent MI, hospitalization for heart failure	Primary: No significant difference in all-cause mortality was reported between valsartan monotherapy and captopril monotherapy (P=0.98). No significant difference in all-cause mortality was observed between valsartan plus captopril combination therapy and captopril monotherapy (P=0.73). Secondary: The rate of death from cardiovascular causes, reinfarction, or hospitalization for heart failure was not significantly different between valsartan and captopril monotherapy (P=0.20). The rate of death from cardiovascular causes, reinfarction, or hospitalization for heart failure was not significantly different between valsartan and captopril combination therapy and captopril monotherapy (P=0.37). Combination therapy had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group and cough, rash, and taste disturbance were more common in the captopril group.
CONSENSUS Trial Study Group ⁸¹ (1987) CONSENSUS Enalapril 2.5 to 40 mg/day vs	DB, MC, PC, PG, RCT Patients with severe CHF (NYHA class IV symptoms), patients with recent MI and unstable angina were excluded	N=253 188 days (average)	Primary: 6-month mortality and the cause of death Secondary: 12-month mortality and overall mortality	Primary: Mortality at six months was 26 and 44% for patients in the enalapril and placebo groups, respectively, for an overall reduction of 40% for enalapril (P=0.002). Secondary: At 12 months, enalapril reduced mortality by 31% compared to placebo (P=0.001). By the end of the study, there had been 50 deaths in the enalapril group and 68 deaths in the placebo group for a reduction of 27% (P=0.003). The

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
placebo				entire reduction in total mortality was found to be among patients with progressive heart failure (a reduction of 50%), whereas no difference was seen in the incidence of sudden cardiac death. Note: The study was stopped early due to clear benefit with enalapril.
SOLVD Investigators ⁸² (1991) SOLVD Enalapril 2.5 to 20 mg/day vs placebo	DB, MC, PC, RCT Patients with CHF and LVEF \leq 35% receiving conventional therapy	N=2,569 41.4 months (average)	Primary: Mortality, rate of hospitalization for heart failure Secondary: Not reported	Primary: Death was reported in 35.2 and 39.7% of patients receiving enalapril and placebo, respectively (risk reduction, 16%; 95% CI, 5 to 26; P=0.0036). Although reductions in mortality were observed in several categories of cardiac deaths, the largest reduction occurred among the deaths attributed to progressive heart failure (risk reduction, 22%; 95% CI, 6 to 35). There was little apparent effect of treatment on deaths classified as due to arrhythmia without pump failure. Fewer patients died or were hospitalized for worsening heart failure (risk reduction, 26%; 95% CI, 18 to 34; P<0.0001). Secondary: Not reported
SOLVD Investigators ⁸³ (1992) SOLVD Enalapril 2.5 mg to 20 mg/day vs placebo	DB, MC, PC, RCT Patients 21 to 80 years of age with heart disease and an ejection fraction of \leq 35% who were not receiving diuretics, digoxin or vasodilators for the treatment of heart failure	N=4,228 37.4 months (average)	Primary: All-cause mortality, incidence of heart failure, rate of hospitalization for heart failure Secondary: Not reported	Primary: Enalapril resulted in an 8% reduction in risk for all-cause mortality (P=0.30). The difference was entirely due to a reduction in deaths due to cardiovascular causes, primarily progressive heart failure (risk reduction, 12%; P=0.12). In the placebo group, 30.2% of patients developed heart failure compared to 20.7% for enalapril (risk reduction, 37%; P<0.001). Rates of first hospitalization and multiple hospitalizations for CHF were higher with placebo (12.9 and 4.8%) than enalapril (8.7 and 2.7%; both P<0.001). The total number of deaths and cases of heart failure were lower in the enalapril group than in the placebo group (risk reduction, 29%; P<0.001). In addition, fewer patients given enalapril died or were hospitalized for heart failure (risk reduction, 20%; P<0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
McKelvie et al. ⁸⁴ (1999) RESOLVD Enalapril 10 mg BID vs candesartan 4 to 16 mg QD vs candesartan 4 to 8 mg QD and enalapril 10 mg BID	DB, PG, MC, RCT Patients with CHF (NYHA classes II to IV), a 6 minute walk distance of 500 meters or less, and an ejection fraction <40%	N=768 43 weeks	Primary: Change in 6-minute walk distance Secondary: Change in NYHA functional class, QOL, ejection fraction, ventricular volumes, neurohormone levels, safety	Primary: There were no significant differences among the groups with regards to the 6-minute walk distance over the 43 week study period. Secondary: There were no significant differences among the groups with regards to the NYHA functional class or QOL at 18 or 43 weeks. Ejection fraction increased more with candesartan plus enalapril than monotherapy with either agent; however, the difference was not statistically significant (P value not significant). End-diastolic volumes (P<0.01) and end-systolic volumes (P<0.05) increased less with combination therapy than with monotherapy with either agent. Aldosterone decreased with combination therapy at 17 but not 43 weeks compared to candesartan or enalapril (P<0.05). Brain natriuretic peptide decreased with combination therapy compared to candesartan and enalapril alone (P<0.01). Blood pressure decreased with combination therapy compared to candesartan or enalapril alone (P<0.05). Compared to enalapril, potassium decreased with candesartan use (P<0.05) and increased with candesartan plus enalapril (P<0.05). The proportion of patients with potassium levels ≥ 5.5 mmol/L was not significantly different among the treatment groups. There were no significant differences in creatinine, mortality, or hospitalizations for CHF or any cause among the three groups.
Willenheimer et al. ⁸⁵ (2005) CIBIS-III Enalapril 2.5 to 10	BE, MC, OL, PG, RCT Patients ≥ 65 years with stable mild to moderate CHF	N=1,010 1.22 \pm 0.42 years	Primary: Combined all-cause mortality or hospitalization Secondary:	Primary: There were 178 patients (35.2%) with a primary end point of combined all-cause mortality or all-cause hospitalization in the bisoprolol-first group, compared to 186 (36.8%) patients in the enalapril-first group (absolute difference, -1.6%; 95% CI, -7.6 to 4.4; HR, 0.94; 95% CI, 0.77 to 1.16; non-inferiority for bisoprolol-first vs enalapril-first treatment;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg BID</p> <p>vs</p> <p>bisoprolol 1.25 to 10 mg QD</p>	<p>(NYHA class II to III), LVEF of $\leq 35\%$ ≥ 3 months prior to randomization, not on an ACE inhibitor, β-blocker or ARB therapy and no clinically relevant fluid retention of diuretic adjustment within the 7 days prior to randomization</p>		<p>Combined end point at the end of the monotherapy phase and the individual components of the primary end point, cardiovascular death and cardiovascular hospitalization, permanent treatment cessation and the need for early introduction of the second drug as indicators of drug tolerability</p>	<p>P=0.019).</p> <p>Secondary: The combined endpoint at the end of the monotherapy phase occurred in 109 patients in the bisoprolol-first group compared to 108 patients in the enalapril-first group (HR, 1.02; 95% CI, 0.78 to 1.33; between-group difference P=0.90); 23 vs 32 patients died, respectively (HR, 0.72; 95% CI, 0.42 to 1.24; between-group difference P=0.24); and 99 vs 92 patients had been a hospitalization, respectively (HR, 1.08; 95% CI, 0.81 to 1.43; between-group difference P=0.59).</p> <p>There were 65 deaths in the bisoprolol-first group, as compared to 73 in the enalapril-first group (HR, 0.88; 95% CI, 0.63 to 1.22; between-group difference P=0.44).</p> <p>In the bisoprolol-first group, 151 patients were hospitalized, compared to 157 patients in the enalapril-first group (HR, 0.95; 95% CI, 0.76 to 1.19; between-group difference P=0.66).</p> <p>There was not a significant difference in cardiovascular death rate observed between the bisoprolol-first (55) and enalapril-first (56) treatment groups (HR, 0.97; 95% CI, 0.67 to 1.40; between-group difference P=0.86).</p> <p>During the monotherapy phase, 35 (6.9%) patients in the bisoprolol-first group permanently discontinued therapy, compared to 49 (9.7%) patients in the enalapril-first group. During the combined-therapy phase, 19 patients (4.2%) in the bisoprolol-first group permanently discontinued bisoprolol therapy and 47 (10.4%) discontinued enalapril therapy. In the enalapril-first group, 24 patients (5.5%) permanently discontinued bisoprolol and 16 (3.7%) discontinued enalapril.</p> <p>There was not a statistical significant difference observed in the early introduction of the second drug between the bisoprolol-first group (39 [7.7%] patients) compared to the enalapril-first group (37 [7.3%] patients; P=0.81).</p>
Cohn et al. ⁸⁶	AC, DB, MC, RCT	N=804	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(1991) V-HEFT II Enalapril 20 mg/day vs hydralazine 300 mg plus isosorbide dinitrate 160 mg/day	Men between the ages of 18 and 75 years with chronic heart failure receiving digoxin and diuretic therapy	2 years	Mortality Secondary: Peak oxygen consumption during exercise, LVEF	Mortality after two years was significantly lower in the group treated with enalapril (18%) than hydralazine plus isosorbide dinitrate (25%; P=0.016), and overall mortality tended to be lower (P=0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (NYHA class I or II). Secondary: Peak oxygen consumption during exercise was increased only by hydralazine plus isosorbide dinitrate (P<0.05). While LVEF increased with both regimens during the two years after randomization, LVEF increased more (P<0.05) during the first 13 weeks in the hydralazine plus isosorbide dinitrate group.
Tu et al. ⁸⁷ (2005) Enalapril vs lisinopril, ramipril, and other ACE inhibitors (benazepril, captopril, cilazapril*, fosinopril, perindopril, quinapril, and trandolapril)	RETRO Patients >65 years with newly diagnosed CHF initiated on ACE inhibitors who survived ≥30 days after hospital discharge	N=6,753 ≤2 years	Primary: Combined end point of readmission for CHF as a primary diagnosis or mortality Secondary: CHF readmission alone and mortality alone	Primary: Relative to enalapril users, there were no significant differences in combined end point of readmission for CHF or mortality with lisinopril (adjusted HR, 1.18; 95% CI, 0.94 to 1.23), ramipril (adjusted HR, 1.16; 95% CI, 0.92 to 1.24) or other ACE inhibitors (adjusted HR, 1.12; 95% CI, 0.90 to 1.17). Secondary: There were no significant differences among groups in readmission for CHF: enalapril 13% (adjusted HR, 1.0; 95% CI, 0.92 to 1.32), lisinopril 15% (adjusted HR, 1.11; 95% CI, 0.99 to 1.45), and other ACE inhibitors 15% (adjusted HR, 1.13; 95% CI, 0.96 to 1.34). There were no significant differences among groups in mortality: enalapril 12% (adjusted HR, 1.0; 95% CI, 0.90 to 1.31), lisinopril 13% (adjusted HR, 1.19; 95% CI, 0.78 to 1.20), and other ACE inhibitors 11% (adjusted HR, 0.94; 95% CI, 0.78 to 1.13).
Packer et al. ⁸⁸ (1999) ATLAS	DB, RCT Patients with NYHA class II, III, or IV	N=3,164 39 to 58 months	Primary: All-cause mortality Secondary:	Primary: High-dose lisinopril was associated with a nonsignificant 8% lower risk of all-cause mortality compared to low-dose lisinopril (P=0.128).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Lisinopril 2.5 to 5 mg/day (low dose) vs lisinopril 32.5 to 35 mg/day (high dose)	symptoms of heart failure associated with a LVEF \leq 30% despite treatment with diuretics for \geq 2 months		cardiovascular mortality, hospitalizations (for any reason and for cardiovascular reasons), combinations of the primary and secondary end points	Secondary: Cardiovascular mortality was reported in 40.2 and 37.2% of patients receiving low-dose and high-dose lisinopril, respectively (P=0.073). High-dose lisinopril resulted in a 12% lower risk of death or hospitalizations for any reason (P=0.002), a 9% lower risk of cardiovascular mortality and hospitalization for cardiovascular reason (P=0.027) and 24% fewer hospitalizations for heart failure (P=0.002). Dizziness and renal insufficiency were observed more frequently in the high-dose group, but the two groups were similar in the number of patients requiring discontinuation of the study medication.
AIRE Study Investigators ⁸⁹ (1993) AIRE Ramipril 2.5 to 5 mg BID vs placebo	DB, MC, PC, RCT Patients \geq 18 years of age with acute MI and clinical evidence of heart failure	N=2,006 15 months	Primary: All-cause mortality Secondary: First event in an individual patient (death, progression to severe or resistant heart failure, reinfarction, or stroke)	Primary: On the intention-to-treat analysis, all-cause mortality was significantly lower for patients randomized to receive ramipril (17%) than placebo (23%). The observed risk reduction was 27% (95% CI, 11 to 40; P=0.002). Secondary: Analysis of prespecified secondary outcomes revealed a 19% risk reduction in the ramipril group compared to placebo (95% CI, 5 to 31; P=0.008).
Kober et al. ⁹⁰ (1995) TRACE Trandolapril 1 to 4 mg QD vs placebo Medication was started between	DB, MC, PC, RCT Men and women >18 years who were hospitalized with a recent MI and an LVEF \leq 35%	N=1,749 24 to 50 months	Primary: Death from any cause Secondary: Death from a cardiovascular cause, sudden death, progression to severe heart failure (defined as the first of the following events:	Primary: During the study, 34.7% of patients in the trandolapril group died compared to 42.3% in the placebo group (P=0.001). The relative risk of death in the trandolapril group was 0.78 compared to placebo (95% CI, 0.67 to 0.91). Secondary: Trandolapril reduced the risk of death from cardiovascular causes (RR, 0.75; 95% CI, 0.63 to 0.89; P=0.001) and sudden death (RR, 0.76; 95% CI, 0.59 to 0.98; P=0.03). Progression to severe heart failure was less frequent in the trandolapril group (RR, 0.71; 95% CI, 0.56 to 0.89; P=0.003).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
day 3 and 7 after the myocardial infarction.			hospital admission for heart failure, death due to progressive heart failure, or heart failure necessitating the administration of open-label ACE inhibition), recurrent infarction, change in the wall-motion index	<p>The risk of recurrent fatal or nonfatal MI was not significantly reduced (RR, 0.86; 95% CI, 0.66 to 1.13; P=0.29).</p> <p>After three months, the mean change from the base-line index was 0.09 in the trandolapril group and 0.06 in the placebo group (P=0.03) but this statistically significant difference was absent at six and 12 months.</p>
<p>Galløe et al.⁹¹ (2006)</p> <p>Trandolapril 0.5 mg (0, 1, 2 or 4 tablets QD) plus bumetanide 0.5 mg (0, 1, 2 or 4 tablets BID)</p> <p>Treatment was combined to achieve 16 different dosage combinations.</p>	<p>DB, DD, RCT, multiple XO</p> <p>Patients with previous MI ≥ 3 years ago, had medical treatment for heart failure and ejection fraction between 0.36 and 0.54 estimated by echocardiography</p>	<p>N=16</p> <p>14 days</p>	<p>Primary: Patient reported QOL</p> <p>Secondary: Effects on kidney function, left ventricular function and blood pressure</p>	<p>Primary: Bumetanide 0.5 mg-treated patients experienced a 12% increase in well-being, but higher doses of bumetanide decreased patient's well-being by 12% compared to placebo (P<0.002). Increasing doses of bumetanide tended to increase tiredness (P=0.072). There were no significant effects of bumetanide therapy on the patients' opinion of their health, degree of dyspnea, appetite or work capacity.</p> <p>Secondary: Bumetanide therapy increased 24 hour urine production in a straight dose-dependent manner (P<0.0001), while trandolapril therapy had no effect (P=0.53). Bumetanide and trandolapril therapy did not alter the 24 hour creatinine excretion and creatinine clearance (P=0.33, P=0.11 and P=0.53, P=0.97, respectively).</p> <p>Bumetanide therapy decreased left ventricular function and increased heart rate in a dose-dependent manner (P<0.001). Left ventricular function was also nonsignificantly decreased with trandolapril therapy (P>0.062).</p> <p>Trandolapril therapy significantly reduced SBP by maximally of 7.6 mm Hg (5.8%) with the lowest dose of 0.5 mg/day (P=0.007). Bumetanide therapy had no significant effect on DBP (P=0.23).</p>
Galloe et al. ⁹²	DB, PC, RCT, XO	N=16	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2006)</p> <p>Trandolapril 0.5 mg (0, 1, 2, or 4 tablets QD)</p> <p>vs</p> <p>bumetanide 0.5 mg (0, 1, 2, or 4 tablets BID)</p>	<p>Men and women with previous MI ≥ 3 years ago, had medical treatment for heart failure and ejection fraction between 0.36 and 0.54 estimated by echo-cardiography (wall motion index)</p>	<p>14 days</p>	<p>Patient reported QOL</p> <p>Secondary: Effects on the involved organs: kidney function, left ventricular function, blood pressure</p>	<p>Patient's well-being increased 12% with 0.5 mg bumetanide BID but higher doses bumetanide decreased patient's well-being by 12% compared to placebo ($P < 0.002$). Increasing doses of bumetanide tended to increase tiredness ($P = 0.072$). There were no statistically significant effects of bumetanide on the patient's opinion of their health, degree of dyspnea, appetite or work capacity.</p> <p>Secondary: Bumetanide increased 24-hour urine production in a straight dose-dependent manner ($P < 0.0001$) while trandolapril had no effect ($P = 0.53$). Bumetanide and trandolapril did not alter the 24-hour creatinine excretion and creatinine clearance ($P = 0.33$, $P = 0.11$ and $P = 0.53$, $P = 0.97$, respectively).</p> <p>Bumetanide decreased left ventricular function and increased heart rate in a dose dependent manner ($P < 0.001$). Left ventricular function was also decreased with trandolapril but did not reach statistically significant. ($P > 0.062$).</p> <p>Trandolapril significantly reduced SBP by maximally of 7.6 mm Hg (5.8%) with the lowest dose of 0.5 mg/day ($P = 0.007$). Bumetanide had no significant effect on DBP ($P = 0.23$).</p>
<p>Lee et al.⁹³ (2004)</p> <p>ARBs</p> <p>vs</p> <p>placebo (\pmACE inhibitor)</p> <p>vs</p> <p>ACE inhibitor monotherapy</p>	<p>MA</p> <p>Patients with chronic heart failure and high-risk acute MI</p>	<p>N=38,080</p> <p>Duration varied</p>	<p>Primary: All-cause mortality and heart failure hospitalizations</p> <p>Secondary: Not reported</p>	<p>Primary: ARBs were associated with reduced all-cause mortality (OR, 0.83) and heart failure hospitalizations (OR, 0.64) vs placebo.</p> <p>There was no difference in all-cause mortality (OR, 1.06) and heart failure hospitalization (OR, 0.95) between ARBs and ACE inhibitors.</p> <p>When ARBs were combined with ACE inhibitors, all-cause mortality was not reduced (OR, 0.97) but heart failure hospitalizations were reduced (OR, 0.77) compared to treatment with ACE inhibitors alone.</p> <p>Two RCT comparing ARBs with ACE inhibitors in patients with high-risk acute MI did not reveal differences in all-cause mortality or heart failure hospitalization.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Hypertension				
<p>Kuschnir et al.⁹⁴ (1996)</p> <p>Benazepril 20 mg/day and amlodipine 5 mg/day</p> <p>vs</p> <p>amlodipine 5 mg/day</p> <p>vs</p> <p>benazepril 20 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Men and women 21 to 80 years of age with uncomplicated primary HTN</p>	<p>N=308</p> <p>8 weeks</p>	<p>Primary: Reduction in mean sitting DBP, SBP and percentage of patients with DBP <90 mm Hg or a ≥10 mm Hg reduction</p> <p>Secondary: Not reported</p>	<p>Primary: All treatment groups significantly reduced mean sitting DBP compared to placebo (P<0.001).</p> <p>Combination therapy had significantly greater reductions in DBP (-13.2 mm Hg; P<0.001) compared to amlodipine (-8.8 mm Hg) and benazepril (-6.7 mm Hg) monotherapy.</p> <p>Combination therapy had significantly greater reductions in SBP (-24.7 mm Hg; P<0.001) compared to amlodipine (-16.2 mm Hg) and benazepril (-12.4 mm Hg).</p> <p>Significantly more patients on combination therapy reached DBP <90 mm Hg or a ≥10 mm Hg reduction (87.0%; P≤0.005) compared to amlodipine (67.5%) and benazepril (53.3%) monotherapy.</p> <p>Adverse events considered to be drug related occurred in 15.6% of patients receiving combination therapy, 24.7% of patients receiving amlodipine monotherapy, 6.5% of patients on benazepril monotherapy and 11.7% of patients on placebo (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Neutel et al.⁹⁵ (2005) SELECT</p> <p>Benazepril and amlodipine 20-5 mg/day (fixed dose combination product)</p> <p>vs</p>	<p>DB, RCT</p> <p>Patients with stage 2 systolic HTN</p>	<p>N=443</p> <p>8 weeks</p>	<p>Primary: Reduction in SBP, proportion of patients achieving blood pressure control</p> <p>Secondary: Not reported</p>	<p>Primary: Significantly greater SBP reductions were achieved with combination therapy compared to amlodipine or benazepril monotherapy (P<0.0001).</p> <p>Significantly more patients on combination therapy met blood pressure goals than on monotherapy (P<0.0001).</p> <p>No significant difference was noted in the incidence of adverse events. Adverse events were low in all three treatment arms, with less peripheral edema in the combination group than in the amlodipine-treated group.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
amlodipine 5 mg/day vs benazepril 20 mg/day				Secondary: Not reported
Chrysant ⁹⁶ (2004) Amlodipine and benazepril 5-40 mg QD for 4 weeks, followed by 10-40 mg QD for 4 weeks (fixed-dose combination product) vs benazepril 40 mg/day for 8 weeks	DB, RCT Men and women (mean age 53 years) with mean sitting DBP \geq 95 mm Hg not adequately controlled with benazepril 40 mg/day monotherapy	N=329 8 weeks	Primary: Reduction in mean sitting DBP and SBP, reduction in standing DBP and SBP, and change in heart rate, safety Secondary: Not reported	Primary: Combination therapy had significantly greater reductions in sitting SBP (-17 mm Hg; P<0.0001) compared monotherapy (-5 mm Hg). Combination therapy had significantly greater reductions in sitting DBP (-14 mm Hg; P<0.0001) compared to monotherapy (-7 mm Hg). Combination therapy had significantly greater reductions in standing SBP (-17 mm Hg; P<0.0001) compared to monotherapy (-6 mm Hg). Combination therapy had significantly greater reductions in standing DBP (-14 mm Hg; P<0.0001) compared to monotherapy (-7 mm Hg). No significant differences in heart rate were observed (P>0.05). No significant differences in adverse events were reported (P>0.05). Secondary: Not reported
Fogari et al. ⁹⁷ (1997) Benazepril 10 mg QD vs amlodipine and benazepril	DB, MC, PC, RCT Men and women 24 to 73 years of age (mean 55 years) with HTN inadequately controlled with ACE inhibitor monotherapy	N=448 8 weeks	Primary: Reduction in mean sitting DBP Secondary: Reduction in sitting SBP, standing DBP and SBP, and percentage of	Primary: Significantly greater reductions in sitting DBP were observed with benazepril 10 mg and amlodipine 2.5 mg (-5.3 mm Hg, 97.5% CI, -8.3 to -2.4; P=0.0001) and benazepril 10 mg and amlodipine 5 mg (-4.5 mm Hg, 97.5% CI, -7.4 to -1.6; P=0.0006) compared to benazepril monotherapy. Secondary: Significantly greater reductions in sitting SBP were seen with benazepril 10 mg and amlodipine 2.5 mg (-7.9 mm Hg, 97.5% CI, -12.3 to -3.5; P=0.0001) and benazepril 10 mg and amlodipine 5 mg (-7.9 mm Hg,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
2.5-10 to 5-10 mg QD (fixed-dose combination product)			patients with DBP <90 mm Hg (deemed excellent response) or a ≥10 mm Hg reduction (deemed good response)	<p>97.5% CI, -12.2 to -3.6; P=0.0000) compared to benazepril monotherapy.</p> <p>Significantly greater reductions in standing DBP and SBP were also reported with the combination therapy compared to benazepril monotherapy (P≤0.001).</p> <p>Significantly more patients had excellent or good response with benazepril 10 mg and amlodipine 2.5 mg (69.2%; P=0.0004) and 10-5 mg (65.8%; P=0.02) compared to benazepril monotherapy (40.5%).</p> <p>Tolerability was good in the three treatment groups and no significant abnormal laboratory data was detected.</p>
<p>Chrysant et al.⁹⁸ (2012)</p> <p>Study 1: Benazepril 40 mg/day (Group 1)</p> <p>vs</p> <p>amlodipine and benazepril 5-40 mg/day, up titrated to 10-40 mg/day after 4 weeks (fixed-dose combination product) (Group 2)</p> <p>Study 2: Amlodipine and benazepril 10-20 mg/day, uptitrated to 10-40 mg/day after 2 weeks</p>	<p>Post-hoc analysis of 2 trials</p> <p>Patients with HTN</p>	<p>N=1,013</p> <p>14 weeks</p>	<p>Primary: Change in baseline mean sitting DBP and mean sitting SBP, rate of blood pressure control (<140/90 mm Hg), rate of blood pressure control (mean sitting DBP <90 mm Hg or ≥10 mm Hg decrease from baseline)</p> <p>Secondary: Safety</p>	<p>Primary: Pooled results demonstrate that combination therapy resulted in significantly greater lowering of mean sitting DBP and mean seated SBP compared to benazepril or amlodipine (P<0.001). Amlodipine and benazepril 10-20 mg/day resulted in significantly greater blood pressure reductions in White patients (mean sitting DBP: 12.99 mm Hg; mean sitting SBP: 13.72 mm Hg) compared to Black patients (8.80 and 8.72 mm Hg) (P<0.004). Amlodipine and benazepril 10-40 mg/day resulted in similar reductions in blood pressure in both White and Black patients.</p> <p>The proportion of patients who achieved blood pressure control with amlodipine and benazepril 10-40 mg/day was similar between White and Black patients (60.7%), whereas with amlodipine and benazepril 10-20 mg/day the rate of control was higher with White patients (61.2 vs 39.4%; P<0.023).</p> <p>There was no difference in the proportion of patients who responded to treatment between Black and White patients with amlodipine and benazepril 10-40 mg/day (74.8 vs 77%; P<0.639). The proportion of patients who responded to amlodipine and benazepril 10-20 mg/day was significantly lower in Black patients (50.7 vs 73.5%; P<0.007).</p> <p>Secondary: There were no serious clinical or metabolic side effects reported, with the exception of pedal edema which occurred more frequently with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(Group 3)</p> <p>vs</p> <p>amlodipine and benazepril 10-20 mg/day (fixed-dose combination product) (Group 4)</p> <p>vs</p> <p>amlodipine 10 mg/day (Group 5)</p>				<p>amlodipine monotherapy.</p>
<p>Messerli et al.⁹⁹ (2000)</p> <p><u>Study 1:</u> Amlodipine and benazepril 5-10 mg to 5-20 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>nifedipine 30 to 60 mg/day</p> <p><u>Study 2:</u> Amlodipine and benazepril 5-10 mg to 5-20 mg QD (fixed-dose combination</p>	<p>2 DB, MC, RCT</p> <p>Patients 18 to 80 years of age with uncomplicated essential HTN</p>	<p>N=1,079</p> <p>8 weeks</p>	<p>Primary: Change in DBP from baseline</p> <p>Secondary: Change from baseline in SBP and heart rate</p>	<p>Primary: Study 1 Significant reductions in DBP were observed with benazepril and amlodipine 10-5 and 20-5 mg (-9.4 and -9.7 mm Hg, respectively) compared to nifedipine 30 mg (-7.0 mm Hg; P<0.05), but not nifedipine 60 mg (-8.5; P>0.05).</p> <p>Study 2 Benazepril and amlodipine 10-5 (-8.9 mm Hg) and 20-5 mg (-9.1 mm Hg) produced significantly greater reductions in DBP than amlodipine 5 mg (-6.8 mm Hg; P<0.05), but not amlodipine 10 mg (-8.7 mm Hg; P>0.05).</p> <p>Secondary: Study 1 Significant reductions in SBP were observed with benazepril and amlodipine 20-5 mg (-11.6 mm Hg) compared to nifedipine 30 mg (-7.9 mm Hg; P<0.05).</p> <p>Significantly less edema was reported with combination therapies (3.1 to 3.8%; P≤0.001) compared to nifedipine 60 mg (15.5%; P=0.008) but not nifedipine 30 mg (5.4%).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
product) vs amlodipine 5 to 10 mg QD				Study 2 Significant reductions in SBP were observed with benazepril and amlodipine 20-5 mg (-9.1 mm Hg) compared to amlodipine 5 mg (-5.3 mm Hg; P<0.05). There were no significant difference in SBP between amlodipine 10 mg and the combination therapies. Significantly less edema (P<0.001) was reported with amlodipine 5 mg (4.9%) and combination therapies (1.5 to 2.2%) compared to amlodipine 10 mg (23.6%).
Hilleman et al. ¹⁰⁰ (1999) Benazepril and amlodipine (fixed-dose combination product) vs monotherapy (atenolol, HCTZ, captopril, enalapril, lisinopril, amlodipine, diltiazem, nifedipine, verapamil)	MA Patients with mild-to-moderate essential HTN	82 trials ≥4 weeks	Primary: Absolute change in supine DBP from baseline Secondary: Percent of patients who achieved blood pressure control, safety	Primary: The mean absolute decrease in supine DBP ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least. When studies were weighted by sample size, amlodipine and benazepril, atenolol, lisinopril, and verapamil showed the greatest blood pressure effect. Secondary: The average percentage of patients defined as controlled after treatment varied from 53.5 to 79.0%, with amlodipine and benazepril (74.3%) and lisinopril (79.0%) showing the highest percentage control (P=0.096). The incidence of adverse events ranged from 12.1 to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% and 14.1%, respectively) and nifedipine the highest incidence. Lisinopril demonstrated significantly less overall side effects compared to nifedipine (P=0.030). Nifedipine demonstrated a higher withdrawal rate due to side effects compared to atenolol, HCTZ, enalapril, amlodipine, and diltiazem (P=0.002). Although amlodipine and benazepril had the lowest rate of withdrawals due to adverse events, lack of significant change was due to the low number of cohorts available for analysis.
Jamerson et al. ¹⁰¹ (2007) ACCOMPLISH Benazepril 20 to 40 mg QD and	DB, MC, RCT Patients >60 years of age with HTN and at high risk of cardiovascular	N=10,704 Analysis performed at 6 months (complete trial)	Primary: Changes in mean SBP from baseline to 6 months, blood pressure control rates (SBP/DBP	Primary: At baseline, 97% of subjects were treated with antihypertensive medications at entry, but only 37% of participants had blood pressure control. Mean blood pressure fell from 145/80 to 132/74 mm Hg after six months

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 12.5 to 25 mg QD</p> <p>vs</p> <p>benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD</p>	<p>events</p>	<p>duration 5 years)</p>	<p><140/90 mm Hg or <130/89 mm Hg for patients with diabetes and chronic kidney disease)</p> <p>Secondary: Not reported</p>	<p>of treatment with either combination regimen (P<0.001).</p> <p>The six month blood pressure control rate was 73% in the overall trial (78% in the United States), 43% in diabetics, and 40% in patients with renal disease. Of the patients uncontrolled, 61% were not on maximal medications.</p> <p>Secondary: Not reported</p>
<p>Kereiakes et al.¹⁰² (2007)</p> <p>Benazepril 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then benazepril 20 mg/day plus amlodipine 5 mg/day for 4 weeks, then benazepril 20 mg/day plus amlodipine 10 mg/day for 4 weeks</p> <p>vs</p> <p>olmesartan 20 mg/day for 2 weeks, then 40 mg/day for 2 weeks then olmesartan and</p>	<p>DB, DD, MC, PG, RCT</p> <p>Patients with stage 2 HTN</p>	<p>N=190</p> <p>12 weeks</p>	<p>Primary: Change in mean seated SBP at the end of week 12</p> <p>Secondary: DBP at the end of week 12, percent of patients attaining blood pressure goals of <140/90, <130/85, and <130/80 mm Hg</p>	<p>Primary: Patients treated with olmesartan and HCTZ experienced significantly greater reductions in mean seated SBP at week 12 than patients treated with benazepril plus amlodipine (least square mean change, -32.5 vs -26.5 mm Hg; P=0.024; least square mean treatment difference, -6.0 mm Hg; 95% CI, -11.1 to -0.8).</p> <p>Secondary: The least square mean change for reduction in DBP approached statistical significance with olmesartan and HCTZ compared to benazepril plus amlodipine at week 12 (P=0.056).</p> <p>The percentage of patients achieving goal rates at the end of the study for olmesartan and HCTZ and benazepril plus amlodipine were 66.3 and 44.7% (P=0.006) for <140/90 mm Hg, 44.9 vs 21.2% (P=0.001) for <130/85 mm Hg, and 32.6 and 14.1% (P=0.006) for <130/80 mm Hg.</p> <p>Both treatments were well tolerated.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 40-12.5 mg/day for 4 weeks increased to 40-25 mg for 4 weeks				
<p>Waeber et al.¹⁰³ (2001)</p> <p>Valsartan 80 mg QD, which was switched to valsartan 80 mg and HCTZ 12.5 mg QD or valsartan 80 mg and benazepril 10 mg QD</p>	<p>OL, RCT</p> <p>Patients with mild-to-moderate uncontrolled HTN (DBP ≥90) while on valsartan monotherapy</p>	<p>N=327</p> <p>4 weeks</p>	<p>Primary: Efficacy and safety</p> <p>Secondary: Not reported</p>	<p>Primary: The two combinations produced an additional blood pressure reduction compared to monotherapy (P<0.001 for both), with similar DBP reductions reported for the two combination groups (-4.5 mm Hg with valsartan plus HCTZ and -3.3 mm Hg with valsartan plus benazepril).</p> <p>SBP reductions of -6.7 and -3.2 mm Hg with valsartan plus HCTZ and valsartan plus benazepril, respectively, were reported (P=0.1).</p> <p>At the end of the trial, the blood pressure of the responders to valsartan monotherapy was lower than that of patients requiring combination therapy.</p> <p>Valsartan given alone or in association with HCTZ or benazepril was well tolerated.</p> <p>Secondary: Not reported</p>
<p>Malacco et al.¹⁰⁴ (2002)</p> <p>Captopril and HCTZ 50-25 mg/day (fixed-dose combination)</p> <p>vs</p> <p>amlodipine and benazepril 5-10 mg/day (fixed-dose</p>	<p>DB, MC, RCT</p> <p>Patients with mild-to-moderate arterial HTN (sitting DBP >95 mm Hg and/or SBP >160 mm Hg) inadequately controlled by monotherapy with an ACE inhibitor, calcium-channel blocking agent or diuretic</p>	<p>N=397</p> <p>12 weeks</p>	<p>Primary: Reduction in sitting DBP and SBP</p> <p>Secondary: Percentage of patients responding to therapy (DBP<90 mm Hg, reduction in DBP ≥10 mm Hg or SBP ≥20 mm Hg, or SBP <150 mm</p>	<p>Primary: Significantly lower sitting DBP (-2.7 mm Hg; P<0.001) and SBP (-3.7 mm Hg; P<0.001) were achieved with amlodipine and benazepril compared to captopril and HCTZ.</p> <p>Secondary: Significantly more amlodipine and benazepril patients responded to therapy (94.8%) compared to captopril and HCTZ (86.0%; P=0.004).</p> <p>No differences in adverse events were reported between the two treatment groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>combination)</p> <p>Elliot et al.¹⁰⁵ (1999)</p> <p>Enalapril 10 mg QD</p> <p>vs</p> <p>enalapril and felodipine ER 5-5 mg/day (fixed-dose combination)</p> <p>After 6 weeks, all patients received the fixed-dose combination for an additional 6 weeks.</p>	<p>DB, PG, PRO, RCT, XO</p> <p>Patients with sitting DBP >95 mm Hg and <115 mm Hg</p>	<p>N=217</p> <p>12 weeks</p>	<p>Hg)</p> <p>Primary: Change in sitting DBP, proportion of responders (DBP <90 mm Hg or a reduction of >10 mm Hg)</p> <p>Secondary: Not reported</p>	<p>Primary: Patients receiving combination therapy had significantly greater reductions in sitting SBP and DBP compared to baseline (P<0.05 and P<0.01, respectively).</p> <p>More patients receiving combination therapy were classified as responders than patients receiving enalapril monotherapy (59 vs 41%; P<0.01).</p> <p>When patients originally taking 10 mg enalapril were crossed over to the combination therapy for an additional six weeks, there was a further blood pressure reduction and increase in response rate, with loss of significant differences compared to those treated continuously with the combination for the entire 12 weeks.</p> <p>There were no significant differences in tolerability between the regimens.</p> <p>Secondary: Not reported</p>
<p>Prisant et al.¹⁰⁶ (1995)</p> <p>Enalapril 5, 10, or 20 mg</p> <p>vs</p> <p>bisoprolol and HCTZ 2.5-6.25, 5-6.25, or 10-6.25 mg/day (fixed-dose combination product)</p> <p>vs</p>	<p>DB, MC, PG, RCT</p> <p>Patients ≥21 years with mild to moderate essential HTN, (average sitting DBP 95 to 114 mm Hg) each treatment was once daily and titrated to effect</p>	<p>N=218</p> <p>17 weeks</p>	<p>Primary: Mean change from baseline in SBP and DBP, lab measurements, adverse events, QOL questionnaire</p> <p>Secondary: Not reported</p>	<p>Primary: Mean decreases in SBP and DBP from baseline were 13.4/10.7 mm Hg for bisoprolol and HCTZ patients, 12.8/10.2 mm Hg for amlodipine patients, and 7.3/6.6 mm Hg for enalapril patients. The hypotensive effects were significant for all three groups (P<0.001).</p> <p>SBP and DBP mean changes from baseline for the bisoprolol and HCTZ group and the amlodipine group were greater than the change from baseline for the enalapril group (P<0.01).</p> <p>Response rates (DBP ≤90 mm Hg or ≥10 mm Hg decrease from baseline) were 71% for the bisoprolol and HCTZ group, 69% for the amlodipine group, and 45% for the enalapril group. The response rates for the bisoprolol and HCTZ and the amlodipine groups differed significantly from the enalapril group (P<0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>amlodipine 2.5, 5, or 10 mg</p>				<p>Twenty nine percent of bisoprolol patients had adverse experiences compared to 42% of amlodipine patients (P=0.12). Nearly 47% of enalapril patients had adverse experience compared to bisoprolol (P=0.04). Adverse events reported included headache, fatigue, peripheral edema, and dizziness.</p> <p>Drug related adverse events were 16% for the bisoprolol and HCTZ patients, 21% for the amlodipine patients, and 23% for the enalapril patients. There was no significant difference between the groups.</p> <p>Enalapril demonstrated a mean decrease from baseline of 7.9 mg/dL for TC (P=0.02 vs amlodipine) and 6.6 mg/dL for LDL-C (P=0.04 vs amlodipine) which were not significantly different from the increase from the bisoprolol and HCTZ group of 1.7 mg/dL (P=0.07 vs enalapril) for TC and +0.6 mg/dL in LDL-C. However, the increase in TGs was highest for bisoprolol and HCTZ-treated patients compared to amlodipine- and enalapril-treated patients (P=0.08, for bisoprolol and HCTZ vs enalapril).</p> <p>There was not a significant difference from baseline or between treatment groups in QOL scores: 0.9 for the bisoprolol and HCTZ group, 0.5 for the amlodipine group, and 2.3 for the enalapril group.</p>
<p>Ruilope et al.¹⁰⁷ (2001)</p> <p>Enalapril 5 mg QD (titration to 10 mg followed by 20 mg was allowed every 3 weeks)</p> <p>vs</p> <p>eprosartan 600 mg QD (titration to 800 mg QD was allowed after 3</p>	<p>DB, MC, PG, RCT</p> <p>Patients greater than 65 years of age with essential HTN, either newly diagnosed or for whom a change in existing antihypertensive medication is indicated due to poor control</p>	<p>N=334</p> <p>12 weeks</p>	<p>Primary: Mean change from baseline in sitting SBP</p> <p>Secondary: Normalization rate for sitting SBP and DBP, response rate for sitting SBP and DBP, mean change from baseline in DBP</p>	<p>Primary: No significant difference between groups in change from baseline in sitting SBP was observed (P=0.76).</p> <p>Secondary: No significant difference between groups in change from baseline in sitting DBP was observed (P=0.84).</p> <p>BP response rates for SBP and DBP were significantly greater for eprosartan at week three (P≤0.033) but the significant difference had disappeared by endpoint (P≥0.49).</p> <p>Normalization rates for SBP were low in both groups (P value not reported).</p> <p>Normalization rates for DBP were higher in both groups than SBP</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
weeks)				normalization rates (P value not reported).
Karlberg et al. ¹⁰⁸ (1999) TEES Enalapril 5 to 20 mg QD vs telmisartan 20 to 80 mg QD HCTZ 12.5 or 25 mg QD could be added to either group as needed to reach DBP goal (≤ 90 mm Hg).	DB, DD, MC, PG, RCT Patients ≥ 65 years of age with mild- to moderate HTN	N=278 26 weeks	Primary: Change from baseline in supine SBP and DBP Secondary: Proportion of responders, safety	Primary: Both treatments had similar rates of HCTZ use. Both treatments showed comparable decreases in blood pressure. Mean changes in DBP were -12.8 mm Hg for telmisartan and -11.4 mm Hg for enalapril (P=0.074). Mean changes in SBP were -22.1 mm Hg for telmisartan and -20.1 mm Hg for enalapril (P=0.350). Secondary: Overall, 63 and 62% of patients responded to telmisartan and enalapril, respectively, with a DBP of < 90 mm Hg. Both regimens provided effective blood pressure lowering over the 24-hour dosing interval, as determined by ambulatory blood pressure monitoring. Both regimens were well tolerated; however, the enalapril group had a higher incidence of cough than the telmisartan group (15.8 vs 6.5%; P value reported).
Estacio et al. ¹⁰⁹ (1998) ABCD Enalapril 5 to 40 mg/day vs nisoldipine 10 to 60 mg/day	DB, PRO, RCT Patients between the ages of 40 and 74 years with NIDDM, baseline DBP ≥ 90 mm Hg and receiving no antihypertensive medications at the time of randomization	N=470 67 months	Primary: Effect of intensive (target DBP of 75 mm Hg) or moderate (target DBP between 80 to 89 mm Hg) blood pressure control on the incidence and progression of complications of diabetes; compare enalapril to nisoldipine as a first-line antihypertensive agent	Primary: Analysis of the 470 patients in the trial who had HTN (DBP ≥ 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations between the two study medications throughout the five years of follow-up. Secondary: Nisoldipine was associated with a higher incidence of fatal and nonfatal MI than enalapril (RR, 7.0; 95% CI, 2.3 to 21.4).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Secondary: Incidence of MI	
Williams et al. ¹¹⁰ (2004) Enalapril 10 mg QD vs eplerenone 50 mg QD vs Both medications were titrated to 200 (eplerenone) or 40 (enalapril) mg/day if needed for optimal blood pressure control (DBP < 90 mm Hg).	AC, DB, MC, PG, RCT Patients ≥18 years of age with stage 1 to 2 HTN (seated DBP ≥90 but <110 mm Hg, with a seated SBP <190 mm Hg)	N=499 12 months	Primary: Change in seated trough DBP at 6 months Secondary: Change in seated trough SBP at 6 months, reduction in SBP and DBP at 12 months, reduction in urine albumin/ creatinine ratio, adverse events	Primary: At six months, both treatments exhibited comparable reductions in DBP from baseline (P=0.91). Secondary: At six months, both treatments exhibited comparable reductions in SBP from baseline (P=0.20). At 12 months, both treatments exhibited comparable reductions in SBP and DBP from baseline (P=0.25 and P=0.33). Eplerenone-treated patients exhibited a significant reduction from baseline in urine albumin/creatinine ratio compared to enalapril-treated patients (61.5 vs 25.7%; P=0.01). There were no significant differences in overall treatment-emergent adverse events between the two treatments (P value not reported). There were no sex hormone related adverse events in eplerenone-treated patients. There were no clinically significant differences between the two treatments in any of the laboratory tests assessed. There were two eplerenone- and enalapril-treated patients that experienced hyperkalemia of ≥5.5 mmol/L.
Tatti et al. ¹¹¹ (1998) FACET Fosinopril 20 mg QD vs amlodipine 10 mg QD	OL, PRO, RCT Men and women, diagnosed with HTN (SBP >140 mm Hg or DBP >90 mm Hg) and non-insulin dependent diabetes	N=380 Up to 3.5 years	Primary: Blood pressure Secondary: Fasting serum glucose, serum creatinine, plasma insulin, HbA _{1c} , TC, HDL-C, TG, fibrinogen, microalbuminuria	Primary: Both treatment groups significantly lowered SBP and DBP from baseline (P<0.05). SBP was lower in the amlodipine group by 4 mm Hg than in the fosinopril group (P<0.01). There was no difference in DBP, both groups decreased by 8 mm Hg. Amlodipine was added by 30.7% of the fosinopril group and fosinopril was added by 26.2% of the amlodipine group (P>0.1). Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>If blood pressure was not controlled on monotherapy, the other study drug was added.</p>				<p>No difference between the groups was found for serum creatinine, HbA_{1c}, and triglycerides at the endpoint (P>0.05).</p> <p>Fasting serum glucose, serum insulin and microalbuminuria were significantly lower at endpoint for both groups but not significantly different from each other (P>0.05).</p> <p>Total cholesterol increased in both groups, and high-density lipoprotein cholesterol increased significantly in the fosinopril group (P<0.05).</p> <p>No difference in fibrinogen levels was observed between the groups at the end of the trial (P>0.05).</p>
<p>Whelton et al.¹¹² (1990)</p> <p>Lisinopril 10 to 40 mg QD</p> <p>vs</p> <p>captopril 25 to 100 mg BID</p> <p>Doses were titrated until patients responded to treatment (defined by a decrease in office DBP to <90 mm Hg or ≥10 mm Hg decrease from baseline).</p>	<p>DB, MC, PG, RCT</p> <p>Patients with mild-to-moderate essential HTN</p>	<p>N=70</p> <p>Up to 8 weeks</p>	<p>Primary: Reduction in blood pressure in both ambulatory and office settings</p> <p>Secondary: Not reported</p>	<p>Primary: Lisinopril-treated patients showed significantly greater reductions in SBP and DBP measured by 24-hour ambulatory blood pressure monitoring compared to captopril-treated patients (P=0.023 and P=0.007, respectively). Greater reductions (P<0.05) were also noted in patients receiving lisinopril at hours 10 to 12, suggesting two blood pressure troughs for those receiving captopril.</p> <p>The difference in mean reductions between treatment groups from baseline to the final visit approached statistical significance for office SBP (P=0.06) and DBP (P=0.09) in favor of patients receiving lisinopril.</p> <p>Both drugs were well tolerated, and no patients withdrew from either treatment group.</p> <p>Secondary: Not reported</p>
<p>Strasser et al.¹¹³ (2007)</p> <p>Lisinopril 20 to 40</p>	<p>AC, DB, DD, MC, PG, RCT</p> <p>Men and women</p>	<p>N=183</p> <p>8 weeks</p>	<p>Primary: Safety</p> <p>Secondary:</p>	<p>Primary: Both active treatments were well tolerated with an incidence of adverse events of 32.8% for aliskiren and 29.3% for lisinopril. The proportion of patients discontinuing treatment due to adverse events was 3.2% for</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD vs aliskiren 150 to 300 mg QD HCTZ may be added if additional blood pressure control was required.	with uncomplicated severe HTN (mean sitting DBP 105 to 119 mm Hg)		Change in mean sitting DBP and SBP, percentage of responders	aliskiren and 3.4% for lisinopril. The most frequently reported adverse events in both groups were headache, nasopharyngitis and dizziness. Secondary: Aliskiren showed similar reductions from baseline to lisinopril in mean sitting DBP (-18.5 vs -20.1 mm Hg) and SBP (-20.0 and -22.3 mm Hg). Responder rates were 81.5% with aliskiren and 87.9% with lisinopril. Approximately half of patients required the addition of HCTZ to achieve blood pressure control (53.6% for aliskiren and 44.8% for lisinopril).
Rosei et al. ¹¹⁴ (2003) Lisinopril 20 mg QD vs nebivolol 5 mg QD	DB, MC, PG, RCT Patients between 24 and 65 years with mild to moderate uncomplicated essential HTN that was newly diagnosed, or previous antihypertensive therapy was withdrawn at >1 month before active treatment, and had a sitting DBP of >95 and <114 mm Hg	N=65 12 weeks	Primary: Response rates, changes in sitting blood pressure Secondary: Standing blood pressure, sitting and standing heart rate	Primary: There was not a significant difference in response rates observed between the two treatment groups. Both treatment groups significantly reduced sitting SBP (P<0.0001) and DBP (P<0.0001) throughout the study compared to baseline but there were no significant differences observed between the treatment groups at most visits, but at week eight, DBP was significantly lower in the nebivolol group compared to the lisinopril group (P<0.05). Secondary: There was not a significant difference observed between treatment groups in standing blood pressure measurements. Both treatment groups significantly reduced sitting heart rate (P<0.01) throughout the study compared to baseline but there were no significant differences observed between the treatment groups at most visits, but at week eight, heart rate were significantly lower in the nebivolol group compared to the lisinopril group (P<0.05).
Wald et al. ¹¹⁵ (2008) Lisinopril 5mg QD	DB, DD, RCT, XO Patients ≥ 40 years enrolled in a HTN or anticoagulation clinic	N=47 16 weeks	Primary: Reduction in blood pressure Secondary: Not reported	Primary: The mean reductions in SBP in the atenolol alone, lisinopril alone and atenolol plus lisinopril groups were 16.1, 12.5, and 22.9 mm Hg, respectively. The mean reductions in DBP in the atenolol alone, lisinopril alone and atenolol plus lisinopril groups were 9.8, 6.8, and 13.9 mm Hg, respectively. The reductions with lisinopril plus atenolol group were

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs atenolol 25 mg QD vs lisinopril 5 mg and atenolol 25 mg QD vs placebo				significantly higher than either agent as monotherapy (P<0.001). Secondary: Not reported
Karotsis et al. ¹¹⁶ (2006) Lisinopril 10 mg QD vs chlorthalidone 12.5 mg QD vs felodipine 5 mg QD vs valsartan 80 mg QD All patients also received diltiazem	RCT Patients 25 to 79 years of age with uncontrolled HTN (average office blood pressure >140/90 mm Hg for all or >153/85 mm Hg for diabetics or patients <65 years of age, confirmed on 2 office visits ≥1 week apart) after ≥4 weeks of OL monotherapy with diltiazem at 240 mg QD	N=211 8 weeks	Primary: Blood pressure Secondary: Not reported	Primary: There was a significant decline in both office and home SBP and DBP during the trial with all treatments. The antihypertensive effect was more pronounced and reached significance when home blood pressure monitoring was used in comparison to office blood pressure without the white-coat effect (P<0.001 for all blood pressure changes). With or without the white-coat effect, blood pressure still declined and the differences were significant (P<0.0001 for all blood pressure changes). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
240 mg QD.				
McInnes et al. ¹¹⁷ (2000) Lisinopril and HCTZ 10-12.5 mg/day (fixed-dose combination product) vs candesartan and HCTZ 8-12.5 mg/day (fixed-dose combination product)	DB, DD, MC, PG, RCT Patients 20 to 80 years of age with mild-to-moderate HTN on prior antihypertensive monotherapy	N=355 26 weeks	Primary: Mean changes in DBP Secondary: Mean changes in SBP and heart rate, proportion of responders and controlled patients, safety	Primary: Changes in mean sitting DBP did not differ significantly between the groups (mean difference, 0.5 mm Hg; P=0.20). Secondary: No significant differences between the groups were reported for mean sitting SBP, heart rate, proportion of responders and controlled patients. Both regimens were well tolerated but a greater percentage of those in the lisinopril based group (80 vs 69%) had a least one side effect (P=0.020). The proportion of patients spontaneously reporting cough (23.1 vs 4.6%) and discontinuing therapy due to adverse events (12.0 vs 5.9%) was also higher in the lisinopril based group compared to the candesartan based group.
Poldermans et al. ¹¹⁸ (2007) Lisinopril 10 to 20 mg QD and HCTZ 12.5 mg QD vs amlodipine 5 to 10 mg QD and valsartan 160 mg QD	AC, DB, MC, PG, RCT Males and females, ages 18 years and older with HTN (mean DBP ≥110 mm Hg and <120 mm Hg)	N=130 6 weeks	Primary: Safety/adverse events, vital signs, hematology, biochemistry variables Secondary: Efficacy (mean DBP, response rate, proportion of patients with mean DBP <90 mm Hg or a ≥10 mm Hg reduction from baseline)	Primary: Both treatments were well tolerated, 26 (40.6%) of patients receiving amlodipine and valsartan and 21 (31.8%) of patients receiving lisinopril and HCTZ reported an adverse events and most were not considered drug related. Peripheral edema was reported more often in the amlodipine and valsartan group than the lisinopril and HCTZ group (7.7 vs 1.5%) and cough was reported less often in the amlodipine and valsartan group than the receiving lisinopril and hydrochlorothiazide group (1.6 vs 3.0%). No difference was found between the treatments in changes in laboratory values or biochemistry variables. Secondary: Both treatments led to a reduction in mean SBP and DBP (P<0.0001 for both from baseline) but were not significantly different from each other. Mean blood pressure for each group at study end: amlodipine and valsartan 135.0/83.6 mm Hg and lisinopril and HCTZ 138.7/85.2 mm Hg.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Duprez et al.¹¹⁹ (2010) AGELESS</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>ramipril 5 to 10 mg QD</p> <p>The addition of HCTZ was allowed at week 12 and amlodipine was allowed at week 22 in patients not achieving adequate blood pressure control.</p>	<p>AC, DB, MC, RCT</p> <p>Patients ≥65 years of age with essential HTN (mean sitting SBP ≥140 and <180 mm Hg and mean sitting DBP <110mm Hg)</p>	<p>N=901</p> <p>36 weeks</p>	<p>Primary: Change in mean seated SBP at week 12</p> <p>Secondary: Change in mean sitting SBP at week 36, change in mean sitting DBP at week 12 and week 36, percentage of patients who achieved blood pressure control (mean sitting SBP/DBP <140/90 mm Hg in non-diabetic patients and <130/80 mm Hg in diabetic patients) at week 12 and week 36, percentage of patients who required add-on therapy</p>	<p>The response rate was similar among the groups (100 vs 95.5%; P value not significant).</p> <p>Primary: At week 12, aliskiren lowered mean sitting SBP by 14 mm Hg and ramipril decreased mean sitting SBP by 11.6 mm Hg (difference, -2.3 mm Hg; 95% CI, -4.3 to -0.3). Aliskiren monotherapy showed statistically non-inferior (P<0.001) and statistically superior (P=0.02) reductions in mean sitting SBP compared with ramipril monotherapy.</p> <p>Secondary: At week 22, aliskiren decreased mean sitting SBP by 19.6 mm Hg and ramipril decreased mean sitting SBP by 17 mm Hg (difference, -2.4 mm Hg; 95% CI, -4.5 to -0.3; P=0.03).</p> <p>At week 36, aliskiren decreased mean sitting SBP by 20 mm Hg and ramipril decreased mean sitting SBP by 18.1 mm Hg (difference, -1.9 mm Hg; 95% CI, -4.0 to 0.2; P=0.07).</p> <p>At week 12, aliskiren decreased mean sitting DBP by 5.1 mm Hg and ramipril decreased mean sitting DBP by 3.6 mm Hg (difference, -1.5 mm Hg; 95% CI, -2.6 to -0.5; P<0.01).</p> <p>At week 22, aliskiren decreased mean sitting DBP by 8.2 mm Hg and ramipril decreased mean sitting DBP by 7.3 mm Hg (difference, -0.8 mm Hg; 95% CI, -2.0 to 0.3; P=0.14).</p> <p>At week 36, aliskiren decreased mean sitting DBP by 8.2 mm Hg and ramipril decreased mean sitting DBP by 7.0 mm Hg (difference, -1.2 mm Hg; 95% CI, -2.3 to -0.1; P=0.03).</p> <p>The percentage of patients achieving blood pressure control was significantly greater with aliskiren (42%) compared to ramipril (33%) at week 12 (P<0.01). At week 22, a significantly greater proportion of patients achieved blood pressure control with aliskiren (62%) compared to ramipril (50%; P<0.001). At week 36, similar blood pressure control rates were achieved with aliskiren (59%) and ramipril (51%; P=0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>By week 36, a significantly greater percentage of patients receiving ramipril compared to aliskiren required additional HCTZ (56 vs 46%; P<0.01).</p> <p>By week 36, a greater percentage of patients receiving ramipril (16%) compared to aliskiren (12%) required add-on therapy with both HCTZ and amlodipine (P=0.048).</p> <p>More patients receiving aliskiren were receiving monotherapy (42%) than patients receiving ramipril (29%) at week 36.</p>
<p>Anderson et al.¹²⁰ (2008)</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>ramipril 5 to 10 mg QD</p> <p>The addition of HCTZ was allowed in patients not achieving adequate blood pressure control.</p> <p>The study did not specifically analyze the effects of HCTZ on either treatment regimen.</p>	<p>AC, DB, MC, PC, RCT</p> <p>Men and women ≥18 years with essential HTN (mean sitting DBP 90 to 109 mm Hg)</p>	<p>N=842</p> <p>26 weeks</p>	<p>Primary: Change in mean sitting DBP at week 26</p> <p>Secondary: Change in mean sitting SBP at week 26, change in mean sitting SBP and DBP at week 6 and 12 (comparing aliskiren and ramipril monotherapy), proportion achieving blood pressure control (<140/90 mm Hg), proportion achieving SBP control (<140 mm Hg), safety</p>	<p>Primary: Reductions in mean sitting DBP at week 26 were significantly greater with aliskiren-based therapies (-13.2 mm Hg) compared to ramipril-based therapies (-12.0 mm Hg; P=0.0250).</p> <p>Secondary: Reductions in mean sitting SBP at week 26 were significantly greater with aliskiren-based therapies (-17.9 mm Hg) compared to ramipril-based therapies (-15.2 mm Hg; P=0.0036).</p> <p>Mean changes in sitting SBP were significantly greater with aliskiren (-12.9 and -14.0 mm Hg, respectively) compared to ramipril (-10.5 and -11.3, respectively) at weeks six and 12 (P=0.0041 and P=0.0027, respectively).</p> <p>Mean changes in sitting DBP were not significantly greater with aliskiren (-10.5 and -11.3 mm Hg, respectively) compared to ramipril (-9.5 and -9.7, respectively) at week six, but were significantly greater at week 12 (P=0.0689 and P=0.0056, respectively).</p> <p>The proportion of patients achieving overall blood pressure control (<140/90 mm Hg) was significantly higher with aliskiren-based therapy (61.4%) compared to ramipril-based therapy (53.1%; P=0.0205) at week 26. Also, the proportion of patients achieving SBP control (<140 mm Hg) was significantly higher with aliskiren-based therapy (72.5%) compared to ramipril-based therapy (64.1%; P=0.0075) at week 26.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The majority of adverse events reported during the active treatment period were mild or moderate in intensity and transient. Most events occurred at a similar incidence in the two groups with the exception of cough which was considered treatment-related in 5.5% of patients receiving ramipril vs 2.1% of patients receiving aliskiren.</p>
<p>Miranda et al.¹²¹(2008)</p> <p>Ramipril 2.5 to 10 mg QD and amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 10 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Adults 40 to 79 years of age with stage 1 or 2 essential HTN</p>	<p>N=222</p> <p>18 weeks</p>	<p>Primary: Change in SBP and DBP</p> <p>Secondary: Safety and tolerability</p>	<p>Primary: The mean changes in ambulatory BP were greater with amlodipine and ramipril compared to amlodipine monotherapy (SBP, -20.21 vs -15.31 mm Hg and DBP, -11.61 vs -8.42 mm Hg, respectively; both, P=0.002]. There was no significant difference among the treatment groups in office BP (SBP, -26.60 vs -22.97 mm Hg and DBP, -16.48 vs -14.48 mm Hg; both, P value not significant).</p> <p>Secondary: Twenty-nine patients (22.1%) treated with combination therapy and 41 patients (30.6%) treated with monotherapy experienced ≥1 adverse event considered possibly related to study drug. The combination-therapy group had lower prevalence of edema (7.6 vs 18.7%; P=0.011) and a similar prevalence of dry cough (3.8 vs 0.8%; P value not significant).</p>
<p>Bönnner et al.¹²² (2013)</p> <p>Azilsartan (AZL) 20mg titrated to 40 mg</p> <p>vs</p> <p>azilsartan (AZL) 20mg titrated to 80 mg</p> <p>vs</p> <p>ramipril (RAM) 2.5 mg titrated to 10 mg</p>	<p>DB, RCT</p> <p>Patients ≥18 years of age with clinic systolic blood pressure (SBP) 150 to 180 mm Hg</p>	<p>N=884</p> <p>24 weeks</p>	<p>Primary: Change in trough, seated clinic SBP</p> <p>Secondary: Change from baseline to week 24 in trough, seated clinic DBP, measures of ambulatory BP, and BP response rates</p>	<p>Primary: After 24 weeks of treatment, trough, sitting, clinic SBP decreased significantly in all the groups. The changes from baseline were significantly greater for the AZL 40 and 80 mg treatment groups (-20.6±0.95 and -21.2±0.95 mm Hg, respectively) than for RAM 10 mg (-12.2±0.95 mm Hg). The differences between the AZL-treated subjects and the RAM-treated subjects were -8.4 mm Hg for AZL 40 and -9.0 mm Hg for AZL 80 (P<0.001 for both comparisons).</p> <p>Secondary: Change in trough, sitting, DBP was -10.2±0.55 mm Hg in the AZL 40 mg group, -10.5±0.55 mm Hg in the AZL 80 mg and -4.9±0.56 mm Hg in the RAM 10 mg group.</p> <p>AZL 40 and 80 mg reduced ambulatory SBP and DBP significantly more than RAM for all ABPM time intervals evaluated, including 24-hour mean, mean daytime, mean nighttime and mean trough pressure.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The differences between the AZL and RAM groups proportion of subjects achieving SBP and DBP response criteria were highly significant (P<0.001). More subjects achieved a reduction in clinic BP to <140/90 mm Hg and/or a reduction in BP\geq20/10 mm Hg at week 24 following treatment with AZL compared with RAM (54.0% and 53.6% for AZL 40 and 80 mg vs 33.8% with RAM 10 mg, respectively; P<0.001).</p>
<p>Williams et al.¹²³ (2009) PRISMA I and PRISMA II</p> <p>Ramipril 2.5 mg QD for 2 weeks then force titration to 5 mg QD for 6 weeks then 10 mg QD for 6 weeks</p> <p>vs</p> <p>telmisartan 40 mg QD for 2 weeks then force titration to 80 mg QD for 12 weeks</p>	<p>Pooled analysis: blinded endpoint, OL, PRO, RCT</p> <p>Patients \geq18 years of age with mild- to moderate HTN</p>	<p>N=1,613</p> <p>14 weeks</p>	<p>Primary: Change from baseline in mean ambulatory BP during the final 6 hours of the 24-hour dosing interval</p> <p>Secondary: Change from baseline in mean ambulatory blood pressure during the 24-hour dosing interval, morning, daytime and nighttime ambulatory blood pressure, 24-hour blood pressure load, treatment response, blood pressure control</p>	<p>Primary: A significantly greater reduction in mean ambulatory blood pressure during the last six hours of the 24-hour dosing interval was observed with telmisartan 80 mg group compared to ramipril 5 and 10 mg (P<0.0001).</p> <p>Secondary: Significantly greater reductions in mean 24-hour, morning, daytime, nighttime and 24-hour blood pressure load were observed with telmisartan 80 mg compared to ramipril 5 and 10 mg (P<0.0001).</p> <p>Significantly greater reductions in treatment response and blood pressure control rates were observed with telmisartan 80 mg compared to ramipril 5 and 10 mg (P<0.0001).</p>
<p>O'Brien et al.¹²⁴ (2007)</p> <p>Aliskiren 150 mg QD for 3 weeks, then HCTZ 25 mg QD was added for</p>	<p>3 OL studies</p> <p>Men and women 18 to 80 years with ambulatory SBP \geq140 and \leq180 mm Hg without</p>	<p>N=67</p> <p>6 to 9 weeks</p>	<p>Primary: Change in daytime systolic ABPM with combination therapy compared with monotherapy</p>	<p>Primary: Aliskiren coadministered with HCTZ (P=0.0007) or ramipril (P=0.03) led to significantly greater reductions in daytime systolic ABPM compared to monotherapy. There was a trend for a reduction in daytime systolic ABPM with the addition of aliskiren to irbesartan; however, this trend was not statistically significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>an additional 3 weeks (if ABPM remained \geq135/85 mm Hg)</p> <p>vs</p> <p>irbesartan 150 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p> <p>vs</p> <p>ramipril 5 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p>	<p>treatment</p>		<p>Secondary: Change in daytime diastolic ABPM, nighttime systolic and diastolic ABPM, daytime and nighttime heart rates, plasma renin activity</p>	<p>Secondary: Aliskiren plus HCTZ significantly lowered daytime diastolic ABPM compared to aliskiren monotherapy (P=0.0006). Changes in nighttime systolic and diastolic ABPM followed similar trends but did not achieve statistical significance (P=0.06 and P=0.09, respectively). No changes in heart rate were observed with either aliskiren regimen.</p> <p>Aliskiren added to irbesartan did not significantly change diastolic ABPM compared to irbesartan monotherapy; however, nighttime systolic and diastolic ABPM were significantly reduced (P<0.05 for all). No changes in heart rate were observed with either irbesartan regimen.</p> <p>Mean diastolic ABPM was significantly decreased with the addition of aliskiren 150 mg (P<0.05) but not aliskiren 75 mg to ramipril monotherapy. Both aliskiren doses significantly decreased nighttime systolic and diastolic ABPM (P<0.05 for all). No changes in heart rate were observed with either ramipril regimen.</p> <p>Aliskiren alone significantly inhibited plasma renin activity by 65% (P<0.0001), while ramipril and irbesartan monotherapy increased renin activity by 90 and 175%, respectively. When aliskiren was coadministered with HCTZ, ramipril or irbesartan, plasma renin activity remained similar to baseline levels or decreased.</p>
<p>Tytus et al.¹²⁵ (2007)</p> <p>Trandolapril 1 to 4 mg/day</p> <p>At 14 weeks after treatment initiation, subjects not achieving blood pressure</p>	<p>MC, OL, PRO</p> <p>Patients with stage 1 or 2 HTN who were treatment naïve (82%) or uncontrolled on a diuretic (11%) or calcium-channel blocker (7%); uncontrolled HTN</p>	<p>N=1,683</p> <p>26 weeks</p>	<p>Primary: Percentage of patients reaching target blood pressure at 14 weeks</p> <p>Secondary: Percentages of subjects with stage 1 and 2 HTN who</p>	<p>Primary: At 14 weeks of treatment, 71.2% of patients who were treated with trandolapril monotherapy reached SBP/DBP <140/90 mm Hg.</p> <p>Secondary: At 26 weeks, 73.4% of patients achieved a target level of SBP/DBP <140/90 mm Hg. Of the 683 subjects with stage 2 HTN, 64.6% achieved the target level after 14 weeks of trandolapril and 67.9% after 26 weeks.</p> <p>At 14 weeks, 78.8% of subjects treated with a trandolapril regimen experienced a decrease in SBP of \geq20 mm Hg or a decrease in DBP of \geq10</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
targets could receive a combination of trandolapril 4 mg/day plus verapamil 240 mg/day with or without a diuretic.	was defined as $\geq 140/90$ mm Hg in subjects with no other risk factors or $\geq 130/80$ mm Hg in subjects with diabetes or kidney disease		achieved target blood pressure, percentages of subjects who achieved a drop in SBP of ≥ 20 mm Hg and/or DBP ≥ 10 mm Hg, absolute changes in SBP and DBP, adverse events	mm Hg. Statistically significant ($P < 0.001$) and clinically relevant mean decreases in SBP of -16.1 mm Hg and in DBP of -8.8 mm Hg were observed from four weeks of treatment onward for the overall study population. The mean reductions in SBP and DBP were -21.5 and -11.9 mm Hg, respectively at 14 weeks ($P < 0.001$), and -22.4 and -12.7 mm Hg, respectively, at 26 weeks ($P < 0.001$). A total of 343 predominantly mild, nonserious adverse events were attributed to the study drugs, reported by 15.3% of the 1,650 subjects. The most frequently reported nonserious adverse events were cough (6.3%); gastrointestinal disorders (2.3%), predominantly nausea; and headache (2.1%). No serious adverse events were attributed to the study treatment.
Tytus et al. ¹²⁶ (2011) MAVIKtory Trandolapril 1 to 2 mg/day With or without existing antihypertensive therapy.	MC, OS Patients with HTN	N=8,787 6 months	Primary: Proportion of patients reaching blood pressure targets, safety Secondary: Not reported	Primary: The target of $< 140/90$ mm Hg was achieved by 67.3% of patients. The lower mean target of $133.4/83.3$ mm Hg for nondiabetic patients and $128.6/79.3$ mm Hg for diabetic patients were achieved by 52.2%. Mean reductions from baseline to trial end were 19.4 mm Hg (95% CI, -19.9 to -19.0) in SBP and 10.1 mm Hg (95% CI, -10.4 to -9.8) in DBP. Cough was the most commonly reported adverse event (4.2%). Secondary: Not reported
Pauly et al. ¹²⁷ (1994) Trandolapril 4 mg QD vs captopril 50 mg BID If blood pressure	DB, MC, RCT Patients between 21 to 65 years with mild-to-moderate essential HTN (DBP of 95 to 115 mm Hg)	N=180 16 weeks	Primary: Morning pre-dosing supine DBP at 8 weeks of monotherapy Secondary: Supine SBP at 8 weeks of monotherapy, blood pressure at 16 weeks of	Primary: Significantly greater mean reductions in supine DBP in the trandolapril group vs captopril group were observed after eight weeks of monotherapy (-13.5 vs -10.1 mm Hg; $P = 0.007$). Secondary: Differences in supine SBP between treatment groups approached significance after eight weeks of monotherapy ($P = 0.06$). Both SBP and DBP were significantly reduced at all time points compared to baseline for both treatment groups at the end of the study ($P < 0.05$).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
was not normalized at 8 weeks, HCTZ 25 mg was added.			therapy (including 8 weeks of monotherapy and 8 weeks of combination therapy with HCTZ)	<p>The proportion of patients whose blood pressure normalized (supine and standing blood pressure $\leq 160/90$ mm Hg) at the end of the study was 61% for trandolapril and 44% for captopril ($P=0.02$).</p> <p>The overall proportion of responders (DBP fell by ≥ 10 or to <90 mm Hg) was significantly greater in the trandolapril group (77%) than in the captopril group (58%; $P<0.007$).</p>
Vaur et al. ¹²⁸ (1995) Trandolapril 2 mg QD in the morning vs enalapril 20 mg QD in the morning	DB, RCT Patients between 18 to 70 years with mild-to-moderate primary HTN	N=88 3 weeks	<p>Primary: 24-hour ambulatory SBP and DBP over an active 24-hour period and subsequent 24-hour period (to mimic a missed dose)</p> <p>Secondary: Not reported</p>	<p>Primary: Both trandolapril and enalapril showed similar reductions in SBP and DBP over the 24-hour period. In the trandolapril group, SBP and DBP decreased from 148/92 to 135/83 mm Hg ($P<0.001$). In the enalapril group, SBP and DBP decreased from 143/91 to 133/83 mm Hg ($P<0.001$).</p> <p>The trough/peak ratio on active treatment was 90% (SBP) and 54% (DBP) in the trandolapril group and 49% (SBP and DBP) in the enalapril group. Following the missed dose, trough/peak ratio decreased to 58% (SBP)/36% (DBP) for trandolapril and 10% (SBP)/19% (DBP) for enalapril. The blood pressure control was better sustained with trandolapril, such that significant falls in blood pressure were observed during the daytime, nighttime and early morning periods after a missed dose, whereas during the same periods, enalapril only significantly reduced blood pressure in the daytime period.</p> <p>Secondary: Not reported</p>
Karlberg et al. ¹²⁹ (2000) Trandolapril 2 mg/day vs verapamil 240 mg/day vs	DB, MC, PRO, RCT, XO Patients with uncomplicated primary HTN (sitting DBP between 95 and 115 mm Hg) between the ages of 20 to 80 years	N=226 2 months	<p>Primary: Change in blood pressure and rate pressure product</p> <p>Secondary: Predictive value of plasma concentrations of active renin regarding the blood</p>	<p>Primary: The mean fall in blood pressure was significantly greater with the combination (20/15 mm Hg; $P<0.00054$), as compared to trandolapril (14/11 mm Hg) or verapamil (13/11 mm Hg). The difference between verapamil and trandolapril was not significant.</p> <p>Rate pressure product decreased significantly more on the combination ($P<0.001$) than on trandolapril or verapamil alone.</p> <p>Secondary: There was a significant positive correlation between blood pressure fall and plasma concentrations of active renin (e.g., the higher the initial active</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
trandolapril and verapamil 2-180 mg/day (fixed-dose combination)			pressure response to the different treatment regimens, safety	renin, the better the blood pressure response to trandolapril [P<0.045 for SBP and P<0.004 for DBP]). No relationships were found for either verapamil or the combination. All treatments were well tolerated and safe.
<p>Pepine et al.¹³⁰ (2006) INVEST</p> <p>Verapamil SR (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist strategy)</p> <p>vs</p> <p>atenolol (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p>	<p>Post hoc analysis of INVEST</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: Risk for adverse outcome associated with baseline factors, follow-up blood pressure and drug treatments</p> <p>Secondary: Not reported</p>	<p>Primary: Previous heart failure (adjusted HR, 1.96), as well as diabetes (HR, 1.77), increased age (HR, 1.63), United States residency (HR, 1.61), renal impairment (HR, 1.50), stroke/TIA (HR, 1.43), smoking (HR, 1.41), MI (HR, 1.34), PVD (HR, 1.27), and revascularization (HR, 1.15) predicted increased risk.</p> <p>Follow-up SBP <140 mm Hg (HR, 0.82) or DBP <90 mm Hg (HR, 0.70) and trandolapril with verapamil SR (HR, 0.78 and 0.79) were associated with reduced risk.</p> <p>Secondary: Not reported</p>
Brunner et al. ¹³¹ (2007) INVEST	<p>Post hoc analysis of INVEST</p> <p>Patients with</p>	<p>N=1,832</p> <p>24 months</p>	<p>Primary: Factors influencing blood pressure response to</p>	<p>Primary: Trandolapril decreased mean unadjusted SBP and DBP by -9.1 and -4.1 mm Hg, respectively. The percentage of patients with blood pressure under control (<140/90 mm Hg) increased from 6.7 to 41.3% (P<0.0001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Verapamil SR 240 mg and trandolapril 1 to 4 mg	essential HTN		trandolapril add-on therapy Secondary: Not reported	Adjusted blood pressure response was significantly associated with age and baseline SBP and DBP (P<0.0001). Whereas the decrease in SBP was more pronounced in younger patients, the opposite was observed for DBP decrease. DBP response was significantly associated with race. Specifically, the adjusted DBP decrease was significantly smaller in Hispanics and African Americans than whites (P=0.0032 and P=0.0069, respectively). However, Hispanics achieved a decrease in SBP and an increase in blood pressure control similar to the other ethnic groups. Secondary: Not reported
Cifkova et al. ¹³² (2000) Verapamil and trandolapril 180-2 mg QD (fixed-dose combination) (VT) vs captopril and HCTZ 50-25 mg QD (fixed-dose combination) (CH) After 16 weeks, patients were switched to the other fixed combination for an additional 16	AC, OL, RCT, XO Caucasian patients aged 18 to 75 years with mild-to-moderate essential HTN (SBP 140 to 209 mm Hg and DBP 90 to 119 mm Hg)	N=100 8 months	Primary: LDL-C Secondary: Other lipid parameters (HDL-C, TC, TG, apolipoproteins AI and B, lipoprotein(a)), blood pressure parameters	Primary: LDL-C was not significantly different between the two treatment groups (P=0.909). Secondary: All secondary lipid parameters remained unaltered except for HDL-C which was significantly higher with VT (1.39 vs 1.35 mmol/L; P<0.03). Serum potassium declined while uric acid and glucose increased on CH (P<0.001 for all). While there were no significant differences with respect to adjusted mean DBP, adjusted mean SBP was slightly higher on treatment with VT than with CH. These differences reached statistical significance for the 24-hour and night-time means, although the absolute adjusted mean treatment differences were only 2.3 mm Hg (P=0.02) and 3.5 mm Hg (P=0.01), respectively. The number of patients who achieved DBP <90 mm Hg at the end of each treatment did not differ (56% VT vs 46% CH; P value not significant). Heart rate was significantly lower in the VT group than the CH group (treatment differences ranged from 2.8 to 4.5 bpm; P≤0.001 for all).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>weeks.</p> <p>de Leeuw et al.¹³³ (1997)</p> <p>Verapamil SR and trandolapril 180-2 mg/day, atenolol and chlorthalidone 100-25 mg/day, or lisinopril and HCTZ 20-12.5 mg/day (fixed-dose combination products)</p> <p>vs</p> <p>placebo</p> <p>All patients entered a SB, placebo 4 week run in period.</p>	<p>DB, MC, PC, RCT</p> <p>Patients 18 to 70 years of age with essential HTN (WHO I or II) newly or unsuccessfully treated, with supine DBP 101 to 114 mm Hg in week 4 of the run in period</p>	<p>N=205</p> <p>12 weeks</p>	<p>Primary: Changes in supine blood pressure, standing blood pressure response rates, normalization rates</p> <p>Secondary: Not reported</p>	<p>Primary: Each of the three treatments was significantly more effective than placebo in reducing seated DBP. Changes in DBP were as follows: verapamil SR and trandolapril, -13 (95% CI, -16 to -9); atenolol and chlorthalidone, -13 (95% CI, -16 to -9); lisinopril and HCTZ, -12 (95% CI, -15 to -9) and placebo, -3 (95% CI, -7 to 0) (P=0.0001 for all vs placebo), but there was not a significance among the treatments (P values not reported).</p> <p>Each of the three treatments was significantly more effective than placebo in reducing seated SBP. Changes in SBP were as follows: verapamil SR and trandolapril, -27 (95% CI, -33 to -21); atenolol and chlorthalidone, -28 (95% CI, -34 to -22); lisinopril and HCTZ, -23 (95% CI, -29 to -17) and placebo, -3 (95% CI, -9 to 3) (P=0.0001 for all vs placebo), but there was not a significance among the treatments (P values not reported).</p> <p>Effects on standing blood pressure demonstrated similar results as the effects on sitting blood pressure (P values not reported).</p> <p>Normalization of DBP (<90 mm Hg), corrected for placebo, were significantly higher with all treatments compared to placebo (verapamil SR and trandolapril, 33% [95% CI, 16 to 50; P<0.0005]; atenolol and chlorthalidone, 31% [95% CI, 14 to 48; P<0.002] and lisinopril and HCTZ, 25% [95% CI, 9 to 42; P<0.005]).</p> <p>Response rates (normalization of DBP or a reduction in DBP >10 mm Hg), corrected for placebo, were significantly higher with all treatments compared to placebo (verapamil SR and trandolapril, 40% [95% CI, 22 to 58; P<0.0001], atenolol and chlorthalidone, 44% [95% CI, 27 to 61; P<0.0001] and lisinopril and HCTZ, 37% [95% CI, 19 to 55; P<0.0002]).</p> <p>Secondary: Not reported</p>
<p>Stanton et al.¹³⁴(2010)</p> <p>Aliskiren 300 mg</p>	<p>MA</p> <p>Adults with mild to moderate essential</p>	<p>N=4,877 (8 trials)</p> <p>4 to 12 weeks</p>	<p>Primary: Paradoxical blood pressure rises, as well as the</p>	<p>Primary: There were no significant differences among the pooled aliskiren, irbesartan, losartan, valsartan, ramipril, and HCTZ groups in the incidence of SBP increases >10 mm Hg (P=0.30) and >20 mm Hg (P=0.28) or DBP</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD</p> <p>vs</p> <p>irbesartan, losartan, valsartan, ramipril, HCTZ, placebo</p>	<p>HTN</p>		<p>percentage of patients with SBP increases (>10 or >20 mm Hg) or DBP increases (>5 or >10 mm Hg) from baseline</p> <p>Secondary: Not reported</p>	<p>increases >5 mm Hg (P=0.65) and >10 mm Hg (P=0.5).</p> <p>Increases in SBP and DBP occurred significantly more frequently in the pooled placebo group than the aliskiren group (P<0.001).</p> <p>Secondary: Not reported</p>
<p>Van Bortel et al.¹³⁵ (2008)</p> <p>ACE inhibitor, ARB, β-blocker, calcium channel blocker, or placebo</p> <p>vs</p> <p>nebivolol</p>	<p>MA</p> <p>12 RCTs involving >25 patients with essential HTN where nebivolol 5 mg QD was compared to placebo or other active drugs for >1 month</p>	<p>N=2,653</p> <p>Duration varied</p>	<p>Primary: Antihypertensive effect and tolerability</p> <p>Secondary: Not reported</p>	<p>Primary: Overall, higher response rates were observed with nebivolol than all other antihypertensive agents combined (OR, 1.41; 95% CI, 1.15 to 1.73; P=0.001) and compared to the ACE inhibitors (OR, 1.92; 1.30 to 2.85; P=0.001), but response rates to nebivolol were similar to β-blockers (OR, 1.29; 95% CI, 0.81 to 2.04; P=0.283), calcium channel blockers (OR, 1.19; 95% CI, 0.83 to 1.70; P=0.350) and losartan (OR, 1.35; 95% CI, 0.84 to 2.15; P=0.212).</p> <p>Overall, a higher percentage of patients obtained normalized blood pressure with nebivolol compared to the other antihypertensive agents combined (OR, 1.35; 95% CI, 1.07 to 1.72; P=0.012). A higher percentage of patient receiving nebivolol obtained normalized blood pressure compared to losartan (OR, 1.98; 95% CI, 1.24 to 3.15; P=0.004) and calcium channel blockers (OR, 1.96; 95% CI, 1.05 to 1.96; P=0.024), but not when compared to other β-blockers (OR, 1.29; 95% CI, 0.81 to 1.65; P=0.473).</p> <p>Overall, the percentage of adverse events was significantly lower with nebivolol compared to the other antihypertensive agents combined (OR, 0.59; 95% CI, 0.48 to 0.72; P<0.001) and similar to placebo (OR, 1.16; 95% CI, 0.76 to 1.67; P=0.482). In comparing nebivolol to the individual treatments, nebivolol had a lower percentage of adverse events compared to losartan (OR, 0.52; 95% CI, 0.30 to 0.89; P=0.016), the other β-blockers (OR, 0.56; 95% CI, 0.36 to 0.85; P=0.007) and calcium channel blockers (OR, 0.49; 95% CI 0.33 to 0.72; P<0.001), but was similar to ACE inhibitors (OR, 0.75; 95% CI 0.52 to 1.08).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
<p>Baguet et al.¹³⁶ (2007)</p> <p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren)</p> <p>Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered</p>	<p>MA</p> <p>Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>N=10,818</p> <p>8 to 12 weeks</p>	<p>Primary: Weighted average reductions in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>Primary: Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.				
Diabetes/Diabetic Nephropathy/Renal Dysfunction				
<p>Bakris et al.¹³⁷ (2010) ACCOMPLISH</p> <p>Benazepril and amlodipine 40-5 to 40-10 mg/day, followed by forced titration after 1 month on benazepril and amlodipine 20-5 mg (fixed-dose combination product)</p> <p>vs</p> <p>benazepril and HCTZ 40-12.5 to 40-25 mg/day, followed by forced titration after 1 month on benazepril and HCTZ 20-12.5 mg (fixed-dose combination product)</p>	<p>Prespecified subanalysis of ACCOMPISH</p> <p>Men and women >60 years of age with HTN and at high risk for cardiovascular events (history of coronary events, MI, revascularization, or stroke; impaired renal function; PAD, left ventricular hypertrophy; or diabetes)</p>	<p>N=11,482</p> <p>2.9 years (mean duration)</p>	<p>Primary: Time to first event of doubling of serum creatinine concentration or end stage renal disease (defined as eGFR <15 mL/min/1.73 m² or need for chronic dialysis)</p> <p>Secondary: Progression of chronic kidney disease plus death, change in albuminuria, and change in eGFR</p>	<p>Primary: There were fewer chronic kidney disease events in the benazepril and amlodipine group (2.0% of patients) compared to the benazepril and HCTZ group (3.7%; HR, 0.52; 95% CI, 0.41 to 0.65; P<0.0001).</p> <p>Secondary: The composite endpoint of progression of chronic kidney disease and all-cause mortality was lower in the benazepril and amlodipine group (6.0%) compared to the benazepril and HCTZ group (8.1%; HR, 0.73; 95% CI, 0.64 to 0.84; P<0.0001). There was a slower decline in eGFR in the benazepril and amlodipine group compared to the benazepril and HCTZ group (-0.88 vs -4.22 mL/min/1.73 m²; P=0.01). Of the patients with baseline microalbuminuria, there was a reduction in the urinary albumin:creatinine in the benazepril and HCTZ group of -63.8% (median change) compared to a median change of -29.0% in the benazepril and amlodipine group (P<0.0001).</p> <p>There was a higher percentage of patients reporting peripheral edema in the benazepril and amlodipine group compared to the benazepril and HCTZ group (P<0.0001).</p>
Hou et al. ¹³⁸ (2007)	OL, PRO, RCT	N=360	Primary: Time to composite	Primary: Compared to the conventional dosages, optimal antiproteinuric dosages of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ROAD</p> <p>Benazepril 10 mg/day vs individual up-titration (10 to 40 mg/day with median dose of 20 mg/day)</p> <p>or</p> <p>losartan 50 mg/day vs individual up-titration (50 to 200 mg/day with median dose of 100 mg/day)</p> <p>Up-titration was performed to optimal antiproteinuric and tolerated dosages, and then these dosages were maintained.</p>	<p>Patients aged 18 to 70 years with proteinuria and chronic renal insufficiency who did not have diabetes</p>	<p>3.7 years (median follow-up)</p>	<p>of doubling of serum creatinine, ESRD or death</p> <p>Secondary: Changes in level of proteinuria, rate of progression of renal disease</p>	<p>benazepril and losartan that were achieved through up-titration were associated with a 51 and 53% reduction in the risk for the primary end point (P=0.028 and P=0.022, respectively).</p> <p>There was no statistically significant difference between benazepril and losartan in the overall relative risk reduction at their respective optimal antiproteinuric dosages or at conventional dosages.</p> <p>Secondary: Optimal antiproteinuric dosages of benazepril and losartan at comparable blood pressure control, achieved a greater reduction in both proteinuria and the rate of decline in renal function compared to their conventional dosages.</p> <p>There was no significant difference in proteinuria reduction between benazepril and losartan at both conventional and optimal antiproteinuric dosages. Changes in renal function were similar between benazepril and losartan arms at both conventional and optimal antiproteinuric doses (P>0.05).</p> <p>There was no significant difference for the overall incidence of major adverse events between groups that were given conventional and optimal dosages in any of the treatment arms.</p>
<p>Bakris et al.¹³⁹ (2008) GUARD</p> <p>Benazepril and HCTZ (fixed-dose combination)</p> <p>vs</p>	<p>DB, RCT</p> <p>Hypertensive, albuminuric type 2 diabetic patients, mean age 58 years were randomized to receive either initial fixed-dose</p>	<p>N=322</p> <p>52 weeks</p>	<p>Primary: Change in urinary albumin to creatinine ratio after 1 year of initial treatment with either fixed-dose combination, blood pressure</p>	<p>Primary: Both combinations significantly reduced the urinary albumin to creatinine ratio compared to baseline (P<0.0001). The median percent change was -72.1% for benazepril and HCTZ and -40.5% for amlodipine and benazepril (P<0.0001).</p> <p>Both regimens significantly reduced SBP and DBP compared to baseline (P<0.0001). The mean reduction in both SBP and DBP was greater in the amlodipine-based arm than in the HCTZ-based arm; however, significance</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
amlodipine and benazepril (fixed-dose combination)	combination product		reductions Secondary: Proportion who progressed to overt diabetic nephropathy, safety	in favor of the amlodipine regimen was observed only for DBP (SBP, -20.5 vs -18.8; P=0.19; DPB, -13.1 vs -9.97; P=0.02). A greater proportion of patients who had microalbuminuria at baseline and treated with benazepril and HCTZ compared to amlodipine and benazepril attained normalization of the urinary albumin to creatinine ratio, defined as <30 mg/g (69.2 vs 47.8%; P=0.0004). Secondary: The percentage of patients progressing to overt proteinuria was similar for both groups. Overall, both study drugs were well tolerated. Adverse reactions possibly related to the study medications occurred in 11.4 and 3.6% of patients receiving amlodipine and benazepril and benazepril and HCTZ, respectively. They included peripheral edema (7.8 vs 2.4%, respectively), fatigue (1.2% in each group), pitting edema (1.2 vs 0.0%), face edema (0.6 vs 0.0%) and thirst (0.6 vs 0.0%). More patients receiving the HCTZ-based regimen (10.8%) discontinued study drug than with the amlodipine-based regimen due to side effects (5.4%).
Esnault et al. ¹⁴⁰ (2008) Enalapril 5 to 20 mg/day vs amlodipine 5 to 10 mg QD	MC, DB, PC, RCT Nondiabetic, adult patients with estimated creatinine clearance of 20 to 60 ml/min	N=263 3 years	Primary: Change in GFR measured yearly by blood clearance Secondary: Composite of renal events and tolerability	Primary: No statistically significant difference was found between amlodipine and enalapril in GFR decline (-4.92 and -3.98 mL/min., respectively, at last observation). Secondary: No statistically significant difference was found between amlodipine and enalapril in the composite secondary end point after a median follow-up of 2.9 years, including in the subgroup of patients with proteinuria >1 g/d at baseline.
Barnett et al. ¹⁴¹ (2004) DETAIL Enalapril 20 mg/day	DB, MC, PG, RCT Patients aged 35 to 80 years with type 2 diabetes and HTN	N=250 5 years	Primary: Change in the GFR Secondary: Annual changes in GFR, serum creatinine level,	Primary: After five years, GFR decreased by 17.9 mL/minute/1.73 m ² with telmisartan compared to 14.9 mL/min/1.73 m ² with enalapril (mean difference, -3.0 mL/min/1.73 m ² ; 95% CI, -7.6 to 1.6). Therefore, the changes in GFR were comparable between the groups. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs telmisartan 80 mg/day			urinary albumin excretion, and blood pressure; rates of ESRD and cardiovascular events; all-cause mortality	The effects of the two agents on the secondary end points were not significantly different after five years.
Mogensen et al. ¹⁴² (2000) CALM Lisinopril 20 mg QD vs candesartan 16 mg QD vs lisinopril 20 mg QD plus candesartan 16 mg QD Patients received 12 weeks monotherapy followed by an additional 12 weeks of monotherapy or combination therapy.	DB, DD, MC, PG, RCT Patients 30 to 75 years old with HTN, type 2 diabetes, and microalbuminuria	N=199 24 weeks	Primary: Blood pressure and urinary albumin:creatinine ratio Secondary: Not reported	Primary: At 12 weeks, mean reductions in DBP were 9.7 mm Hg (P<0.001) and 9.5 mm Hg (P<0.001), respectively, and in urinary albumin:creatinine ratio were 46% (P<0.001) and 30% (P<0.001) for lisinopril and candesartan, respectively. Compared to either agent alone, at 24 weeks the combination of lisinopril plus candesartan resulted in 16.3 mm Hg reduction in mean DBP vs 10.4 mm Hg for candesartan alone (P<0.001) and 10.7 mm Hg for lisinopril alone (P<0.001). The reduction in urinary albumin:creatinine ratio with combination treatment (50%) was greater than with lisinopril alone (39%; P<0.001) and candesartan alone (24%; P=0.05). All treatments were generally well tolerated. Secondary: Not reported
Fried et al. ¹⁴³ (2013)	DB, MA, RCT	N=1448	Primary: First occurrence of	The trial was stopped early because the absolute risk of serious adverse events appeared to be greater than the potential benefit of reducing

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>VA NEPHRON-D</p> <p>Losartan with lisinopril</p> <p>vs</p> <p>losartan alone</p>	<p>Veterans with proteinuric diabetic kidney disease, an estimated GFR of 30.0 to 89.9 ml/minute/1.73 m², and a urinary albumin-to-creatinine ratio of ≥300</p>	<p>Median follow-up 2.2 years</p>	<p>a decline in the eGFR (an absolute decrease of ≥30 ml/minute/1.73 m² if the eGFR was ≥60 ml/minute/1.73 m² at randomization or a relative decrease of ≥50% if the eGFR was <60 ml/minute/1.73 m²), ESRD, or death</p> <p>Secondary: First occurrence of a decline in the eGFR or ESRD</p> <p>Tertiary: CV events, slope of change in eGFR, and change in albuminuria at 1 year</p>	<p>primary end-point events.</p> <p>Primary: There were 152 primary end-point events in the monotherapy group (21.0%) and 132 in the combination-therapy group (18.2%). The risk of the primary end point did not differ significantly between the two groups.</p> <p>Secondary: There were 101 secondary end-point events (a decline in the estimated GFR or ESRD) in the monotherapy group (14.0%) and 77 events in the combination-therapy group (10.6%). There was no significant between-group difference in mortality or ESRD (Table 2), though the number of ESRD events was small.</p> <p>Tertiary: There was no significant difference in the rate of cardiovascular events between the two groups. There was no significant difference in treatment effect on the decline in the estimated GFR (P=0.17). During adjustment of the losartan dose, the median urinary albumin-to-creatinine ratio declined from 959 to 807 (P=0.001). There was a further decline from randomization to 1 year, with a greater decline in the combination-therapy group (from 786 to 517) than in the monotherapy group (from 829 to 701) (P<0.001).</p>
<p>DREAM Trial Investigators¹⁴⁴ (2006)</p> <p>DREAM</p> <p>Ramipril up to 15 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PRO, RCT, 2-by-2 factorial design</p> <p>Adults aged 30 years or more with impaired fasting glucose and/or impaired glucose tolerance and no previous</p>	<p>N=5,269</p> <p>3 years (median)</p>	<p>Primary: Composite of newly diagnosed diabetes or death</p> <p>Secondary: Regression to normoglycemia, glucose levels, composite of cardiac and renal</p>	<p>Primary: The composite primary outcome did not differ significantly between the ramipril group (18.1%; HR, 0.91; 95% CI, 0.81 to 1.03; P=0.15) and the placebo group (19.5%).</p> <p>Secondary: Participants receiving ramipril were more likely to have regression to normoglycemia than those receiving placebo (HR, 1.16; 95% CI, 1.07 to 1.27; P=0.001).</p> <p>At the end of the study, the median fasting plasma glucose level was not</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	cardiovascular disease		events (were not yet analyzed at the time of this publication)	significantly lower in the ramipril group than in the placebo group (P=0.07), though plasma glucose levels two hours after an oral glucose load were significantly lower in the ramipril group (P=0.01).
GISEN Group ¹⁴⁵ (1997) REIN Ramipril 1.25 mg/day vs placebo	DB, PC, RCT Patients between 18 and 70 years who were either normotensive (<140/90 mm Hg) or hypertensive with chronic nephropathy and persistent proteinuria, who had not received ACE inhibition therapy for ≥ 2 months	N=166 16 months	Primary: Rate of GFR decline, extent to which this effect was dependent on the drug's antiproteinuric effect Secondary: Blood pressure control, time to doubling of baseline serum creatinine or progression to end-stage renal failure, cardiovascular complications, total and cardiovascular mortality	Primary: Mean rate of GFR decline per month was significantly lower in the ramipril group than in the placebo group (0.53 mL/min vs 0.88 mL/min; P=0.03). Among the ramipril-assigned patients, percentage reduction in proteinuria was inversely correlated with decline in GFR (P=0.035) and predicted the reduction in risk of doubling of baseline creatinine or end-stage renal failure (18 ramipril vs 40 placebo; P=0.04). Secondary: Blood pressure control and the overall number of cardiovascular events were similar in the two treatment groups. Fifty-eight patients (18 in the ramipril group and 40 in the placebo group) reached the combined end point of doubling of baseline serum creatinine concentration or end-stage renal failure (P=0.02). The risk of progression was still significantly reduced after adjustment for changes in SBP (P=0.04) and DBP (P=0.04) with ramipril, but not after adjustment for changes in proteinuria. Note: Originally, 352 patients were placed into stratum 1 (urinary protein excretion exceeding 1 g/24 hours) or stratum 2 (urinary protein excretion exceeding 3.0 g/24 hours). At the second planned interim analysis, the difference in decline in GFR between the ramipril and placebo groups in stratum 2 was highly significant (P=0.001). The Independent Adjudicating Panel therefore decided to open the randomization code and do the final analysis in this stratum while stratum 1 continued in the trial.
Uresin et al. ¹⁴⁶ (2007) Aliskiren 150 to 300 mg QD	DB, MC, RCT Patients ≥ 18 years of age with type 1 or type 2 diabetes	N=837 8 weeks	Primary: Change in mean sitting DBP Secondary:	Primary: Aliskiren monotherapy, ramipril monotherapy, and aliskiren and ramipril combination therapy lowered mean sitting DBP by 11.3, 10.7, and 12.8 mm Hg, respectively. Treatment with aliskiren and ramipril combination therapy produced significantly greater reductions from baseline in mean

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>ramipril 5 to 10 mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg and ramipril 5 to 10 mg QD</p>	<p>mellitus and stage 1 to 2 HTN (mean sitting DBP) >95 and <110 mm Hg)</p>		<p>Change in mean sitting SBP, proportion of patients with a successful response to treatment (trough mean sitting DBP <90 mm Hg and/or ≥10 mm Hg reduction from baseline), rates of blood pressure control (blood pressure <130/80 mm Hg), changes from baseline in 24-hour ABPM measurements, and changes in biomarkers (plasma renin concentration, plasma renin activity, aldosterone)</p>	<p>sitting DBP compared to either aliskiren monotherapy (P=0.043) or ramipril monotherapy (P=0.004). Aliskiren 300 mg was statistically non-inferior (P=0.0002) to ramipril 10 mg for the change in mean sitting DBP.</p> <p>Secondary: Aliskiren monotherapy, ramipril monotherapy, and aliskiren and ramipril combination therapy lowered mean sitting SBP by 14.7, 12.0, and 16.6 mm Hg, respectively. Treatment with aliskiren and ramipril combination therapy produced significantly greater reductions from baseline in mean sitting SBP compared to ramipril monotherapy (P<0.0001), but not aliskiren monotherapy (P=0.088). Aliskiren monotherapy was statistically superior to ramipril for the change in mean sitting SBP (P=0.021).</p> <p>The proportion of patients with a successful response to therapy was similar for aliskiren and ramipril combination therapy (74.1%) and aliskiren monotherapy (73.1%). The responder rates in both groups were significantly higher (P<0.05) compared to ramipril monotherapy (65.8%).</p> <p>Rates of blood pressure control with aliskiren and ramipril combination pressure (13.1%) were not significantly different compared to aliskiren monotherapy (8.2%) or ramipril monotherapy (8.4%).</p> <p>All treatments significantly lowered mean 24-hour ambulatory blood pressure. Aliskiren and ramipril combination therapy was significantly more effective compared to ramipril monotherapy in lowering 24-hour mean ambulatory DBP (P=0.034). There was no significant difference in 24-hour ambulatory SBP compared to ramipril monotherapy.</p> <p>Aliskiren significantly reduced plasma renin activity from baseline as monotherapy (by 66%, P<0.0001) or in combination with ramipril (by 48%, P<0.0001).</p>
<p>Agodoa et al.¹⁴⁷ (2001) AASK</p> <p>Ramipril 2.5 to 10 mg QD</p>	<p>DB, MC, RCT</p> <p>African American patients, age 18 to 70 years old, with hypertensive renal</p>	<p>N=1,094</p> <p>4 years</p>	<p>Primary: Rate of change in GFR (GFR slope)</p> <p>Secondary: Composite of:</p>	<p>Primary: The average decline in GFR was slower, by 36% in the ramipril group as compared to the amlodipine group (P=0.002). However, during the first three months, GFR increased more in the amlodipine group than the ramipril group (P<0.001). The mean total slope did not differ between the groups (P=0.38).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs amlodipine 5 to 10 mg QD	disease (GFR 20 to 65 mL/min)		confirmed reduction GFR by 50% or by 25 mL/min for baseline, ESRD	Secondary: The risk reduction for the composite secondary outcome was significantly greater for the ramipril group than the amlodipine group (P=0.005). The rate of ESRD was significantly lower in the ramipril group (P=0.01).
Wright et al. ¹⁴⁸ (2002) AASK Ramipril 2.5 to 10 mg/day vs amlodipine 5 to 10 mg/day vs metoprolol 50 to 200 mg/day	DB, MC, RCT Patients were self-identified African Americans aged 18 to 70 years with HTN and a GFR between 20 and 65 mL/min/ 1.73 m ² and no other identified cause of renal insufficiency	N=1,094 3-6.4 years	Primary: Rate of change in GFR (grouped by usual blood pressure [MAP goal 102 to 107 mm Hg] vs lower blood pressure [\leq 92 mm Hg]) Secondary: Clinical composite outcome (reduction in GFR by 50% or more, ESRD, or death)	Primary: No significant difference in primary outcome was reported between the usual blood pressure group compared to the lower blood pressure group (P=0.24). None of the drug group comparisons showed consistently significant differences in the GFR slope. Secondary: The lower blood pressure goal did not significantly reduce the rate of the clinical composite outcome (risk reduction for lower blood pressure group, 2%; 95% CI, -22 to 21; P=0.85). Ramipril resulted in significant risk reductions in the clinical composite outcomes compared to amlodipine (38%; 95% CI, 14 to 56; P=0.004) and metoprolol (22%; 95% CI, 1 to 38; P=0.04). There was no significant difference in the clinical composite outcome between the amlodipine and metoprolol groups.
Bianchi et al. ¹⁴⁹ (2010) Ramipril 10 mg and atorvastatin 10 mg QD (conventional therapy) vs spironolactone 25 mg, ramipril 10	RCT, OL Patients with a clinical diagnosis of idiopathic chronic glomerulonephritis and urine protein-creatinine ratio >1 g/g	N=128 36 months	Primary: Changes over time in proteinuria and eGFR Secondary: Adverse events, drop outs	Primary: SBP decreased more in the intensive-therapy group (from 156.6 to 113.5 mm Hg) than in the conventional therapy group (from 155.7 to 122.7 mm Hg; P<0.01). Urine protein excretion decreased from 2.65 to 0.45 g/g creatinine with intensive therapy (P<0.001). With conventional therapy, urine protein excretion decreased from 2.60 to 1.23 g/g creatinine (P<0.001). With intensive therapy, eGFR did not significantly change over time (64.6 vs 62.9 mL/min/1.73 m ²). With conventional therapy, eGFR decreased from 62.5 to 55.8 mL/min/1.73 m ² (P<0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg, irbesartan 300 mg, and atorvastatin 10 mg QD (intensive therapy)</p> <p>The addition of diuretics, calcium antagonists, β-blockers or α1-receptor antagonists were added to achieve blood pressure <130/80 mm Hg</p>				<p>Secondary: In the conventional therapy group, eight patients discontinued the study due to hyperkalemia, cough, and rapid deterioration in kidney function. In the intensive therapy group, 15 dropped out due to hyperkalemia, cough, and hypotension. Nine patients in the intensive therapy group developed gynecomastia. Twelve patients on conventional and 31 on intensive therapy had to interrupt the study temporarily because of low blood pressure. No patient developed an increase in creatine kinase, alanine aminotransferase, and alkaline phosphatase levels during the study.</p>
<p>Chrysostomou et al.¹⁵⁰ (2006)</p> <p>Ramipril 5 mg/day plus spironolactone 25 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus irbesartan 150 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus placebo and placebo</p>	<p>DB, PC, RCT</p> <p>Patients 18 to 75 years of age, with a 24 hour urinary protein excretion >1.5 g/24 hours on ≥ 2 occasions ≥ 3 months apart, serum creatinine level ≤ 200 $\mu\text{mol/L}$ with <20% variability in the preceding 3 months and treatment with an ACE inhibitor ≥ 6 months</p>	<p>N=41</p> <p>6 months</p>	<p>Primary: Change in 24 hour urinary protein excretion at three months</p> <p>Secondary: Change in 24 hour urinary protein excretion at six months, change in blood pressure and creatinine clearance, adverse effects</p>	<p>Primary: Compared to ramipril-treated patients, the 24 hour urinary protein excretion reduction at three months was significantly greater in ramipril plus spironolactone-treated patients (P=0.004).</p> <p>Ramipril-, irbesartan- and spironolactone-treated patients exhibited a significant reduction in 24 hour urinary protein excretion compared to ramipril-treated patients (P<0.001).</p> <p>There was no significant difference in 24 hour urinary protein excretion with ramipril- and ramipril plus irbesartan-treated patients (P=1.00).</p> <p>At three months, spironolactone-treated patients exhibited a significant reduction in proteinuria from baseline (P\leq0.001). In contrast, non-spironolactone-treated patients did not experience a significant reduction in proteinuria from baseline (P=0.840).</p> <p>Secondary: At six months, spironolactone-treated patients exhibited the greatest reduction in proteinuria compared to the other treatments (P<0.05).</p> <p>At six months, DBP was higher among ramipril monotherapy-treated</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs spironolactone 25 mg/day plus irbesartan 150 mg/day and ramipril 5 mg/day				patients compared to the other treatments (P=0.046). There was no difference in SBP among the treatments (P value not reported). There were no differences in creatinine clearance among the treatments (P>0.05). Gynecomastia was not observed with any of the treatments.
Nakao et al. ¹⁵¹ (2003) COOPERATE Trandolapril 3 mg/day vs losartan 100 mg/day vs trandolapril and losartan at equivalent doses	DB, MC, PC, RCT Patients aged 18 to 70 years with chronic nephropathy (nondiabetic renal disease)	N=263 3 years	Primary: Composite of time to doubling of serum creatinine or ESRD Secondary: Changes in blood pressure, daily urinary protein excretion, adverse effects	Primary: The combined end point was reached in 11% of patients in the combination trandolapril and losartan group compared to 23% of patients in the trandolapril (P=0.018) and 23% of patients in the losartan group (P=0.016). Secondary: Mean SBP and DBP reductions were similar among the three treatment groups (P=0.109). All patients receiving active treatment had significant decreases in urinary protein excretion, but the greatest difference was seen with the combination trandolapril and losartan group compared to trandolapril or losartan (-75.6, -44.3, and -42.1%, respectively; P=0.01). The frequency of adverse events did not differ between groups, although a slightly higher occurrence of hyperkalemia and dry cough was recorded in the trandolapril and combination groups than in the losartan group.
Ruggenenti et al. ¹⁵² (2004) BENEDICT Trandolapril 2 mg/day vs verapamil SR 240	DB, MC, RCT Patients ≥40 years with type 2 diabetes (not exceeding 25 years) and HTN (SBP ≥130 mm Hg and/or DBP ≥85 mm Hg) but with normoalbuminuria (urinary albumin	N=1,204 3.6 years (median)	Primary: Development of persistent microalbuminuria comparing combination therapy to placebo, acceleration factor Secondary: Primary end point	Primary: The primary outcome was reached in 5.7% of patients receiving combination therapy vs 10.0% for patients receiving placebo. The estimated acceleration factor (which quantifies the effect of one treatment relative to another in accelerating or slowing disease progression) adjusted for predefined baseline characteristics was 0.39 for the comparison between verapamil plus trandolapril and placebo (P=0.01). Secondary: The primary outcome was reached in 6.0% of patients receiving trandolapril, 11.9% receiving verapamil, and 10.0% receiving placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg/day</p> <p>vs</p> <p>trandolapril and verapamil SR 2-180 mg/day (fixed-dose combination)</p> <p>vs</p> <p>placebo</p>	<p>excretion rate of <20 mcg/minute)</p>		<p>comparing trandolapril and verapamil monotherapy to placebo, blood pressure, adverse events</p>	<p>The estimated acceleration factor was 0.47 for trandolapril vs placebo (P=0.01) and 0.83 for verapamil vs placebo (P=0.54).</p> <p>Trandolapril plus verapamil and trandolapril alone delayed the onset of microalbuminuria by factors of 2.6 and 2.1, respectively.</p> <p>Throughout the study the average trough SBP/DBP was 139/80 mm Hg for patients receiving trandolapril plus verapamil, 139/81 mm Hg for trandolapril, 141/82 mm Hg for verapamil and 142/83 mm Hg for placebo. The comparison was significant (P≤0.002) between trandolapril plus verapamil or trandolapril alone vs placebo, but not for verapamil vs placebo.</p> <p>Serious adverse events were similar in all treatment groups.</p>
<p>Casas et al.¹⁵³ (2005)</p> <p>ACE inhibitor or ARBs compared to placebo</p> <p>vs</p> <p>ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents, calcium-channel blocking agents, or combinations)</p> <p>Specific agents</p>	<p>MA (127 trials)</p> <p>Studies in adults that examined the effect of any drug treatment with a blood pressure lowering action on progression of renal disease</p>	<p>N=not reported</p> <p>4.2 years (mean)</p>	<p>Primary: Doubling of serum creatinine, and ESRD</p> <p>Secondary: Serum creatinine, urine albumin excretion and GFR</p>	<p>Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>A small reduction in ESRD was observed in patients receiving ACE inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>Secondary: Small reductions in serum creatinine and in SBP were noted when ACE inhibitors or ARBs were compared to other antihypertensives (P=0.01).</p> <p>Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001).</p> <p>Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and doses were not specified.				
Strippoli et al. ¹⁵⁴ (2004) ACE inhibitors vs placebo or ARBs vs placebo or ACE inhibitors vs ARBs	MA Patients with diabetic nephropathy	43 trials ≥6 months (range 6 to 63.6 months)	Primary: All-cause mortality, renal outcomes (ESRD, doubling of serum creatinine, microalbuminuria to macroalbuminuria) Secondary: Not reported	Primary: ACE inhibitors significantly reduced all-cause mortality compared to placebo or no treatment (RR, 0.79; 95% CI, 0.63 to 0.99; P=0.04). There was a nonsignificant trend for reduction in ESRD (P=0.07) and doubling of serum creatinine (P=0.08) with ACE inhibitors compared to placebo or no treatment. ACE inhibitors significantly reduced the risk of progression from microalbuminuria to macroalbuminuria (P=0.0007) and increased regression back to normoalbuminuria (P<0.0001) compared to placebo or no treatment. ARBs did not significantly reduce all-cause mortality compared to placebo or no treatment (RR, 0.99; 95% CI, 0.85 to 1.17; P=0.95). ARBs significantly reduced the risk of ESRD (P=0.001) and doubling of serum creatinine (P=0.004). ARBs significantly decreased the risk of progression to macroalbuminuria (P=0.001) and increased regression to normoalbuminuria (P=0.02) compared to placebo or no treatment. The three trials that compared ACE inhibitors to ARBs did not report on all-cause mortality, ESRD or doubling of serum creatinine. Progression from microalbuminuria to macroalbuminuria was reported in one trial (N=92) and there was no significant difference in risk, with the point estimate favoring ACE inhibitors (RR, 0.16; 95% CI, 0.02 to 1.44). Regression from microalbuminuria to normoalbuminuria in 1 trial showed a nonsignificant difference in the risk. Secondary: Not reported
Strippoli et al. ¹⁵⁵ (2006) ACE inhibitors vs placebo	MA Patients with diabetic kidney disease	N=12,067 (49 trials) ≥6 months	Primary: All-cause mortality, ESRD, doubling of serum creatinine concentration, progression from micro- to	Primary: There was no significant difference in the risk of all-cause mortality for ACE inhibitors vs placebo or no treatment (RR, 0.91; 95% CI, 0.71 to 1.17) and ARBs vs placebo or no treatment (RR, 0.99; 95% CI, 0.85 to 1.17). No statistically significant reduction in the risk of all-cause mortality was found in the three studies that compared ACE inhibitors with ARBs (RR, 0.92; 95% CI, 0.31 to 2.78).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>or ARBs vs placebo or ACE inhibitors vs ARBs</p>			<p>macroalbuminuria, regression from micro- to normoalbuminuria, drug-related toxicity (including cough, headache, hyperkalemia, impotence and pedal edema)</p> <p>Secondary: Not reported</p>	<p>A subgroup analysis of studies showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACE inhibitors (RR, 0.78; 95% CI, 0.61 to 0.98) but not when using half or less than half the maximum tolerable dose of ACE inhibitors (RR, 1.18; 95% CI, 0.41 to 3.44).</p> <p>There was a significant reduction in the risk of ESRD with ACE inhibitors and ARBS compared to placebo or no treatment (RR, 0.60; 95% CI, 0.39 to 0.93 and RR, 0.78; 95% CI, 0.67 to 0.91, respectively). There was a significant reduction in the risk of doubling of serum creatinine concentration with ACE inhibitors and ARBS (RR, 0.68; 95% CI, 0.47 to 1.0 and RR, 0.79; 95% CI, 0.67 to 0.93, respectively).</p> <p>ACE inhibitors and ARBS significantly reduced the risk of progression from micro- to macroalbuminuria (RR, 0.45; 95% CI, 0.29 to 0.69 and RR, 0.49; 95% CI, 0.32 to 0.75, respectively). ACE inhibitors and ARBS significantly increased the regression from micro- to normoalbuminuria compared to placebo or no treatment (RR, 3.06; 95% CI, 1.76 to 5.35 and RR, 1.42; 95% CI, 1.15 to 1.93, respectively).</p> <p>The seven studies that compared ACE inhibitors to ARBS did not report the outcome of ESRD or doubling of serum creatinine. Progression from micro- to macroalbuminuria and from micro- to normoalbuminuria were evaluated each in one trial and showed a nonsignificant difference in the risk between ACE inhibitors and ARBS.</p> <p>ACE inhibitors were associated with a significant increase in the risk of cough but not hyperkalemia, headache or impotence when compared to placebo or no treatment. ARBS were associated with a significant increase in the risk of hyperkalemia but not cough or headache compared to placebo or no treatment.</p> <p>Secondary: Not reported</p>
Miscellaneous				
Montalescot et al. ¹⁵⁶	AC, DB, MC, RCT	N=429	Primary: Change from	Primary: High-sensitivity C-reactive protein levels were comparable in both

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2009) ARCHIPELAGO Enalapril 10 mg QD, followed by 20 mg QD on day 15 vs irbesartan 150 mg QD, followed by 300 mg QD on day 15	Adults with non-ST elevation ACS	60 days	baseline in high-sensitivity C-reactive protein at day 60 Secondary: Changes in other inflammatory markers such as troponin I	treatment groups (irbesartan: 15.2 mg/L at baseline, 6.5 mg/L at day 60; absolute change of -8.7 mg/L; enalapril: 12.6 mg/L at baseline, 5.5 mg/L at day 60; absolute change of -7.1 mg/L, P value not significant). Secondary: Similarly, mean levels of markers of myocardial injury (troponin I) and endothelial dysfunction (microalbuminuria) also decreased from baseline to day 60, with no significant differences between treatment groups.
Dagenais et al. ¹⁵⁷ (2008) Ramipril 15 mg or rosiglitazone 8 mg QD vs placebo	DB, PC, RCT Adults >30 years with impaired fasting glucose or impaired glucose tolerance without known cardiovascular disease or renal insufficiency	N=5,269 3 years	Primary: Composite cardiorenal outcome (first occurrence of any cardiovascular death, nonfatal MI, stroke, new heart failure, progression to microalbuminuria or proteinuria, renal insufficiency requiring dialysis or transplantation) Secondary: Subcomponents of the primary analysis	Primary: Compared to placebo, neither ramipril (15.7 vs 16.0%; HR, 0.98; P=0.75) nor rosiglitazone (15.0 vs 16.8%; HR, 0.87; P=0.07) reduced the risk of the cardiorenal composite outcome. Secondary: Ramipril had no impact on the cardiovascular disease and renal components. Rosiglitazone increased heart failure (0.53 vs 0.08%; HR, 7.04; P=0.01), but reduced the risk of the renal component (HR, 0.80; P=0.005).
Belluzzi et al. ¹⁵⁸ (2009)	DB, PC, RCT Adults with lone	N=62 3 years	Primary: Relapse of atrial fibrillation as	Primary: At the end of the study, atrial fibrillation relapses were observed in three ramipril-treated patients and in 10 control patients (P<0.03).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Ramipril 5mg QD vs placebo	atrial fibrillation without heart disease or HTN		determined by clinical assessment, ECG, 24 hour Holter monitor, and questionnaire collection. Secondary: Not reported	Secondary: Not reported
Hansson et al. ¹⁵⁹ (1998) HOT Aspirin 75 mg QD vs placebo A 5 step antihypertensive treatment regimen: 1) felodipine 5 mg QD, 2) ACE inhibitor or β -blocker, 3) dose titrations, 4) dose titrations, 5) diuretic.	MC, RCT, OL Adults with HTN and a DBP between 100 and 115 mm Hg	N=18,790 3.8 years	Primary: Major cardiovascular events (fatal and nonfatal, fatal and nonfatal stroke, and all other cardiovascular deaths) Secondary: Not reported	Primary: There were 9.9, 10.0, and 9.3 major cardiovascular events per 1,000-patients years, respectively, in the DBP \leq 90, DBP \leq 85, and DBP \leq 80 treatment groups (P=0.50), thus suggesting that the reduction of DBP below 90 mm Hg does not provide any mortality or morbidity advantage. Aspirin reduced major cardiovascular events by 15% (P=0.03) and all MI by 36% (P=0.002), with no effect on stroke. There were seven fatal bleeds in the aspirin group and eight in the placebo group, and 129 versus 70 non-fatal major bleeds in the two groups, respectively (P<0.001). Secondary: Not reported

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, ER=extended-release, QD=once daily, SR=sustained-release, TID=three times daily

Study design abbreviations: AC=active-controlled, BE=blinded endpoint, DB=double blind, DD=double dummy, MA=meta-analysis, MC=multicenter, OL=open label, OS=observational, PC=placebo controlled, PG=parallel group, PRO=prospective, RETRO=retrospective, RCT=randomized controlled trial, SB=single-blind, XO=crossover

Miscellaneous abbreviations: ABPM=ambulatory blood pressure monitoring, ACE inhibitor=angiotensin converting enzyme inhibitor, ACS=acute coronary syndrome, ARB=angiotensin II receptor blocker, BMI=body mass index, CAD=coronary artery disease, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure,

ECG=electrocardiogram, eGFR=estimated glomerular filtration rate, ESRD=end stage renal disease, GFR=glomerular filtration rate, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HR=hazard ratio, HTN=hypertension, IV=intravenous, LDL-C=low-density lipoprotein cholesterol, LVEF=left ventricular ejection fraction, MAP=mean arterial pressure, MI=myocardial

infarction, MMSE=Mini Mental State Examination, MRI=magnetic resonance imaging, NIDDM=non-insulin dependent diabetes mellitus, NNT=number needed to treat, NYHA=New York Heart Association, OR=odds ratio, PAD=peripheral arterial disease, PCI=percutaneous coronary intervention, PVD=peripheral vascular disease, QOL=quality of life, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TG=triglyceride, TIA=transient ischemic attack, WHO=World Health Organization

Additional Evidence

Dose Simplification

Taylor et al. evaluated adherence rates with amlodipine and benazepril fixed-dose combination compared to an ACE inhibitor plus a long-acting dihydropyridine administered as separate formulations. There was no significant difference in adherence in younger subjects (18 to 39 year olds); however, in all age group combined, adherence rates were higher with amlodipine and benazepril compared to the use of an ACE inhibitor plus a long-acting dihydropyridine (80.8 vs 73.8%; P<0.001).¹⁶⁰ Dickson et al. evaluated adherence rates with amlodipine and benazepril fixed-dose combination compared to an ACE inhibitor plus a long-acting dihydropyridine administered as separate formulations in an elderly Medicaid population. Over a 12 month period, adherence rates were reported to be significantly higher with fixed-dose combination product compared to the administration of an ACE inhibitor and dihydropyridine as separate formulations (63.4 vs 49.0%; P<0.0001).¹⁶¹ Dezzi et al. also reported significantly higher compliance rates at 12 months in patients receiving fixed-dose lisinopril and hydrochlorothiazide (68.7%) or enalapril and hydrochlorothiazide (70.0%) vs administration of the components as separate formulations (57.8 and 57.5%, respectively; P<0.05 for both comparisons).¹⁶²

Stable Therapy

Sapienza et al. evaluated the impact of converting long-term care patients from high-dose calcium-channel blockers or ACE inhibitor plus calcium-channel blockers to a fixed-dose combination of amlodipine/benazepril. There was no significant change in blood pressure from baseline following the conversion; however, there was a significant reduction (81.8%) in the number of patients reporting ≥1 drug-related adverse event (22 vs 4; P<0.05), particularly edema (75% reduction).¹⁶³

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 12. Relative Cost of the Angiotensin-Converting Enzyme Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Benazepril	tablet	Lotensin®*	\$\$	\$
Captopril	tablet	N/A	N/A	\$\$\$\$
Enalapril	solution, tablet	Epaned®, Vasotec®*	\$\$\$\$\$	\$\$
Fosinopril	tablet	N/A	N/A	\$\$
Lisinopril	tablet	Prinivil®*, Zestril®*	\$\$\$	\$
Moexipril	tablet	Univasc®*	\$\$\$	\$\$\$\$
Perindopril	tablet	N/A	N/A	\$\$\$
Quinapril	tablet	Accupril®*	\$\$\$	\$
Ramipril	capsule	Altace®*	\$\$\$\$	\$
Trandolapril	tablet	Mavik®*	\$\$	\$\$
Combination Products				
Benazepril and HCTZ	tablet	Lotensin HCT®*	\$\$\$	\$\$\$\$
Captopril and HCTZ	tablet	N/A	N/A	\$
Enalapril and HCTZ	tablet	Vaseretic®*	\$\$	\$
Fosinopril and HCTZ	tablet	N/A	N/A	\$\$\$\$
Lisinopril and HCTZ	tablet	Prinzide®*, Zestoretic®*	\$\$	\$\$\$\$
Moexipril and HCTZ	tablet	N/A	\$\$	\$\$\$
Quinapril and HCTZ	tablet	Accuretic®*	\$\$\$	\$\$
Trandolapril and verapamil	extended-release tablet	Tarka®	\$\$\$\$	N/A

*Generic is available in at least one dosage form or strength.
HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

All of the angiotensin-converting enzyme (ACE) inhibitors are approved for the treatment of hypertension. Some of the products are also approved for the treatment of diabetic nephropathy, heart failure, and post-myocardial infarction.³⁻²³ The ACE inhibitors are available as single entity products, as well as in combination with hydrochlorothiazide or verapamil. All of the products are available in a generic formulation.

There are numerous national and international guidelines that recommend the use of ACE inhibitors in patients with the following conditions: acute coronary syndrome, cerebrovascular disease, coronary artery disease, diabetes, diabetic nephropathy, heart failure, hypertension, left ventricular dysfunction, left ventricular hypertrophy, previous myocardial infarction, and renal disease. In general, guidelines do not give preference to one ACE inhibitor over another.²⁶⁻⁴⁶ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.³⁷⁻⁴³ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).³⁷ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.³⁷⁻⁴⁶ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.³⁷⁻⁴⁴

In clinical trials, the ACE inhibitors have been shown to reduce cardiovascular morbidity and mortality, preserve renal function in patients with nephropathy, and effectively lower blood pressure when administered as monotherapy or in combination with other antihypertensive agents.⁴⁷⁻¹⁵⁵ Most patients will need more than one antihypertensive agent to achieve blood pressure goals. The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{37-43,160-162} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations.

There is insufficient evidence to support that one brand angiotensin-converting enzyme inhibitor is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand angiotensin-converting enzyme inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand angiotensin-converting enzyme inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
2. Colucci WS. Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 May]. Available from: <http://www.utdol.com/utd/index.do>.
3. Lotensin[®] [package insert]. Parsippany (NJ): Validus Pharmaceuticals LLC; 2015 Jan.
4. Captopril [package insert]. Parsippany (NJ): Wockhardt USA LLC; 2014 Jun.
5. Epaned[®] [package insert]. Greenwood Village (CO): Silvergate Pharmaceuticals, Inc; 2014 Sep.
6. Vasotec[®] [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2014 Dec.
7. Fosinopril [package insert]. Fort Lauderdale (FL): Andrx Pharmaceuticals, Inc.; 2008 Nov.
8. Prinivil[®] [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2013 Feb.
9. Zestril[®] [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2014 Dec.
10. Univase[®] [package insert]. Smyrna (GA): UCB, Inc.; 2012 Sep.
11. Perindopril [package insert]. Columbus (OH): Roxane Laboratories; 2015 Apr.
12. Accupril[®] [package insert]. New York (NY): Pfizer Inc; 2014 May.
13. Altace[®] [package insert]. Bristol (TN): King Pharmaceuticals; 2013 May.
14. Mavik[®] [package insert]. North Chicago (IL): AbbVie Inc.; 2014 Dec.
15. Lotensin HCT[®] [package insert]. Parsippany (NJ): Validus Pharmaceuticals LLC; 2014 Dec.
16. Captopril and hydrochlorothiazide [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2006 Mar.
17. Vaseretic[®] [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2014 Dec.
18. Fosinopril and hydrochlorothiazide [package insert]. Edison (NJ): Heritage Pharmaceuticals Inc.; 2014 Jan.
19. Prinizide[®] [package insert]. Whitehouse Station (NJ). Merck & Co, Inc; 2013 Feb.
20. Zestoretic[®] [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2014 Dec.
21. Uniretic[®] [package insert]. Smyrna (GA): UCB, Inc.; 2013 Feb.
22. Accuretic[®] [package insert]. New York (NY): Pfizer; 2014 Jul.
23. Tarka[®] [package insert]. North Chicago (IL): AbbVie Inc.; 2014 Dec.
24. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 May]. Available from: <http://online.factsandcomparisons.com>
25. Micromedex[®] Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 May]. Available from: <http://www.thomsonhc.com/>.
26. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
27. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/ehf296.
28. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
29. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
30. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
31. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.

32. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.
33. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.
34. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
35. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
36. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
37. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
38. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
39. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
40. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
41. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
42. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
43. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
44. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
45. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
46. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
47. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. *N Engl J Med* 2008;359:2417-28.
48. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol*. 2010 Jun 29;56(1):77-85.
49. Weber MA, Jamerson K, Bakris G, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. *Lancet*. 2013;381:537-45.
50. Swedberg K, Held P, Kjerkshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction results of the cooperative New Scandinavian enalapril survival study II (CONSENSUS II). *N Engl J Med*. 1992 Sep 3;327(10):678-84.
51. Wing LMH, Reid CM, Ryan P, et al; for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003 Feb 13;348(7):583-92.

52. Nissen SE, Tuzcu EM, Libby P, et al; for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*. 2004 Nov 10;292(18):2217-26.
53. Pitt B, Reichek N, Willenbrock R, Zannad F, Philips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation*. 2003;108(15):1831-8.
54. Hansson L, Lindholm LH, Ekblom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999 Nov 20;354(9192):1751-6.
55. ALLHAT Officers and Coordinators for ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002 Dec 18;288(23):2981-97.
56. Black HR, Davis B, Barzilay J, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Diabetes Care*. 2008 Feb;31(2):353-60.
57. Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, et al. Long-term renal and cardiovascular outcomes in antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR. *Clin J Am Soc Nephrol*. 2012;7:989-1002.
58. Muntner P, Levitan EB, Lynch AI, et al. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *J Clin Hypertens (Greenwich)*. 2014 May;16(5):323-330.
59. Fox KM, Bertrand M, Ferrari R, et al. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003 Sep 6;362:782-8.
60. PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized perindopril and remodeling in elderly with acute myocardial infarction (PREAMI) study. *Arch Intern Med*. 2006 Mar 27;166:659-66.
61. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomized controlled trial. *Lancet* 2007;370:829-40.
62. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000 Jan 20;342:145-53.
63. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547-59.
64. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes. *J Am Coll Cardiol*. 2012;59(1):78-83.
65. Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. *J Hypertens*. 2013 Feb;31(2):414-21.
66. The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. *N Engl J Med*. 2004 Nov 11;351(20):2058-68.
67. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? *Ann Intern Med*. 2004 Jul 20;141(2):102-12.
68. Dahlof B, Sever PS, Poulter NR, et al; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. *Lancet*. 2005 Sep 10;366(9489):895-906.
69. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension*. 2007 Apr;49(4):839-45.

70. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. *JAMA*. 2003 Dec 3;290(21):2805-16.
71. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1545-53.
72. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
73. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *J Hypertens*. 2007 Jun;25(5):951-8.
74. PROGRESS Collaborative group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. *Lancet*. 2001 Sep 29;358:1033-41.
75. Arima H, Anderson C, Omae T, Woodward M, Hata J, Murakami Y, et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial. *Stroke*. 2011;42:2339-2341.
76. Pfeffer MA, Braunwald E, Moye LA, et al; on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. *N Engl J Med*. 1992 Sep 3;327(10):669-77.
77. Pitt B, Segal R, Martinez FA, et al; on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*. 1997 Mar 15;349:747-52.
78. Pitt B, Poole-Wilson PA, Segal R, et al; on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study, ELITE II. *Lancet*. 2000 May 6;355:1582-7.
79. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. *Lancet*. 2002 Sep 7;360:752-60.
80. Pfeffer MA, McMurray JJV, Velazquez EJ, et al; for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003 Nov 13;349:1893-906.
81. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study. *N Engl J Med*. 1987 Jun 4;316(23):1429-35.
82. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*. 1991 Aug 1; 325(5):293-302.
83. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med*. 1992 Sep 3;327(10):685-91.
84. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators. *Circulation*. 1999 Sep 7;100:1056-64.
85. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation*. 2005 Oct 18;112(16):2426-35.
86. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*. 1991 Aug 1;325:303-10.
87. Tu K, Mamdani M, Kopp A, Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. *Am J Cardiology*. 2005 Jan 15;95:283-6.
88. Packer M, Poole-Wilson PA, Armstrong PW, et al; on behalf of the ATLAS Study Group. Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. *Circulation*. 1999 Dec 7;100:2312-18.
89. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet*. 1993;342:821-28.

90. Kober L, Torp-Pedersen C, Carlsen JE, et al; for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med.* 1995 Dec 21;333(25):1670-6.
91. Galløe AM, Skagen K, Christensen NJ, Nielsen SL, Frandsen EK, Bie P, et al. Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. *J Clin Pharm Ther.* 2006 Apr;31(2):139-47.
92. Galløe AM, Skagen K, Christensen NJ, Nielsen SL, Frandsen EK, Bie P, et al. Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. *J Clin Pharm Ther.* 2006 Apr;31(2):139-47.
93. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med.* 2004 Nov 2;141(9):693-704.
94. Kuschner E, Acuna E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. *Clin Ther.* 1996;18(6):1213-24.
95. Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. *J Clin Hypertens.* 2005 Nov;7(11):641-6.
96. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. *Am J Hypertens.* 2004 Jul;17(7):590-6.
97. Fogari R, Corea L, Cardoni O, et al. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. *J Cardiovasc Pharmacol.* 1997 Oct;30(4):497-503.
98. Chrysant SG. Blood pressure effects of high-dose amlodipine-benazepril combination in black and white hypertensive patients not controlled on monotherapy. *Drugs RD.* 2012;12(2):57-64.
99. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. *Am J Cardiol.* 2000 Dec 1;86:1182-7.
100. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. *J Hum Hypertens.* 1999;13:477-83.
101. Jamerson K, Bakris GL, Dahlof B, et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. *Blood Press.* 2007;16(2):80-6.
102. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. *Am J Cardiovasc Drugs.* 2007;7(5):36-72.
103. Waerber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. *J Hypertens.* 2001 Nov;19(11):2097-104.
104. Malacco E, Piazza S, Carretta R, et al; Italian Blood Pressure Study Group. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. *Int J Clin Pharmacol Ther.* 2002 Jun;40(6):263-9.
105. Elliott WJ, Montoro R, Smith D, et al. Comparison of two strategies for intensifying antihypertensive treatment: low-dose combination (enalapril plus felodipine ER) versus increased dose of monotherapy (enalapril). *Am J Hypertens.* 1999 Jul;12:691-6.
106. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose combination therapy: an alternative first-line approach to hypertension treatment. *Am Heart J.* 1995 Aug;130(2):359-66.
107. Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. *Blood Pressure.* 2001;10:223-9.
108. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. *J Hypertens.* 1999 Feb;17(2):293-302.
109. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med.* 1998 Mar 5;338(10):645-52.
110. Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. *Am J of Cardiol.* 2004;93(8):990-6.

111. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. *Diabetes Care*. 1998; 21:597-603.
112. Whelton A, Miller WE, Dunne, Jr B, et al. Once-daily lisinopril compared with twice-daily captopril in the treatment of mild-to-moderate hypertension: assessment of office and ambulatory blood pressure. *J Clin Pharmacol*. 1990 Dec;30(12):1074-80.
113. Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. *J Hum Hypertens*. 2007 Oct;21(10):780-7.
114. Rosei EA, Rizzoni D, Comini S, Boari G; Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. *Blood Press Suppl*. 2003 May;1:30-5.
115. Wald DS, Law M, Mills S, Bestwick JP, Morris JK, Wald NJ. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. *Clin Ther*. 2008 Nov;30(11):2030-9.
116. Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. *Clin Exp Hypertens*. 2006;28(7):655-62.
117. McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. *J Hum Hypertens*. 2000 Apr;14(4):263-9.
118. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. *Clin Ther*. 2007 Feb;29(2):279-89.
119. Duprez D, Munger M, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. *J Hum Hypertens* 2010;24:600-608.
120. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. *J Hypertens*. 2008;26(3):589-99.
121. Miranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study. *Clin Ther* 2008;30:1618-28.
122. Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. *J Hum Hypertens*. 2013 Aug;27(8):479-86.
123. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. *J Hum Hypertens*. 2009 Sep;23(9):610-9.
124. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. *Hypertension*. 2007 Feb;49(2):276-84.
125. Tyttus RH, Burgess ED, Assouline L, Vanjaka A. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naïve and concurrently treated adult hypertensive subjects (TRAIL). *Clin Ther*. 2007 Feb;29(2):305-15.
126. Tyttus RH, Assouline L, Vanjaka A. Blood pressure control rates with an antihypertensive regimen including trandolapril in a Canadian usual-care setting. *Adv Ther*. 2011;28(9):789-798.
127. Pauly NC, Safar ME; for the Investigator Study Group. Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. *J Cardiovasc Pharmacol*. 1994;23 Suppl 4:s73-6.
128. Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. *J Cardiovasc Pharmacol*. 1995;Jul;26(1):127-31.
129. Karlberg BE, Andrup M, Oden A; on behalf of the Swedish Tarka Trialists. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. *Blood Pressure* 2000;9:140-5.
130. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol*. 2006;47(3):547-51.

131. Brunner M, Cooper-DeHoff RM, Gong Y, et al; for the INVEST Investigators. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). *Am J Cardiol.* 2007;99:1549-54.
132. Cifkova R, Nakov R, Novozamska E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. *J Hum Hypertens* 2000;14:347-54.
133. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. *J Hypertens.* 1997 Jan;15(1):87-91.
134. Stanton AV, Gradman AH, Schmieder RE, et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials. *Hypertension* 2010;55:54-60.
135. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs.* 2008;8(1):35-44.
136. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig.* 2007;27(11):735-53.
137. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. *Lancet.* 2010 Apr 3;375(9721):1173-81.
138. Hou FF, Xie D, Zhang X, et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. *J Am Soc Nephrol.* 2007;18:1889-98.
139. Bakris GL, Toto RD, McCullough PA, et al; on behalf of GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney Int.* 2008 Jun;73(11):1303-9.
140. Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study. *Clin Ther* 2008;30:482-98.
141. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med.* 2004 Nov 4;351:1953-61.
142. Morgensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ.* 2000 Dec 9;321:1440-4.
143. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med.* 2013 Nov 14;369(20):1892-903.
144. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. *N Engl J Med.* 2006 Oct 12;355(15):1551-62.
145. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet.* 1997 Jun 28;349:1857-63.
146. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. *J Renin Angiotensin Aldosterone Syst* 2007;8:190-8.
147. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA.* 2001 Jun 6;285(21):2719-28.
148. Wright JT Jr, Bakris G, Greene T, et al. Effects of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002 Nov 20;288(19):2421-31.
149. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular disease. *Am J Kidney Dis* 2010;55:671-81.
150. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. *Clin J Am Soc Nephrol.* 2006 Mar;1(2):256-62.
151. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. *Lancet.* 2003 Jan 11;361:117-24.

152. Ruggenenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. N Engl J Med. 2004 Nov 4;351(19):1941-51.
153. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005 Dec 10;366:2026-33.
154. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004 Sep 30; 329:828-38.
155. Strippoli GFM, Bonifati C, Craig M, Navaneethan DS, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease (review). Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257.
156. Montalescot G, Drexler H, Gallo R, et al. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. Euro Heart J 2009;30:2733-41.
157. The Dream Trial Investigators. Results of the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 2008;31:1007-1014.
158. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009;53:24-9.
159. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
160. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-32.
161. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008;1:45-50.
162. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Managed Care 2000;9:S2-6.
163. Sapienza S, Sacco P, Floyd K, et al. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther 2003;25:1872-87.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Angiotensin II Receptor Antagonists
AHFS Class 243208
August 19, 2015**

I. Overview

The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure. Excessive activity of the RAAS may lead to hypertension, as well as fluid and electrolyte disorders.^{1,2} Renin catalyzes the conversion of angiotensinogen to angiotensin I. Angiotensin I is then cleaved to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase).¹ Angiotensin II can increase blood pressure by direct vasoconstriction, as well as through actions on the brain and autonomic nervous system.^{1,2} In addition, angiotensin II stimulates aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental effects, including ventricular hypertrophy, remodeling, and myocyte apoptosis.^{1,2}

The angiotensin II receptor antagonists are approved for the treatment of diabetic nephropathy, heart failure, hypertension and post-myocardial infarction.³⁻²⁰ Since angiotensin II may be generated through other pathways that do not depend upon ACE, blockade of angiotensin II by ACE inhibitors is incomplete. Angiotensin II receptor antagonists block the angiotensin II receptor subtype AT₁, preventing the negative effects of angiotensin II, regardless of its origin. They do not appear to affect bradykinin and may be an option for patients who cannot tolerate ACE inhibitors.^{21,22} All of the angiotensin II receptor antagonists are available as single entity products, as well as in combination with hydrochlorothiazide or chlorthalidone. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride. Telmisartan and olmesartan are also available in combination with amlodipine, a nondihydropyridine calcium-channel blocking agent, which is a potent vasodilator.^{22,23}

The angiotensin II receptor antagonists that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All single entity products with the exception of azilsartan and olmesartan, are available generically. Fixed-dose combination products candesartan and hydrochlorothiazide, irbesartan and hydrochlorothiazide, losartan and hydrochlorothiazide, telmisartan and amlodipine, telmisartan and hydrochlorothiazide, and valsartan and hydrochlorothiazide are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Angiotensin II Receptor Antagonists Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Azilsartan	tablet	Edarbi [®]	none
Candesartan	tablet	Atacand ^{®*}	none
Eprosartan	tablet	Teveten ^{®*}	eprosartan
Irbesartan	tablet	Avapro ^{®*}	irbesartan
Losartan	tablet	Cozaar ^{®*}	losartan
Olmесartan	tablet	Benicar [®]	none
Telmisartan	tablet	Micardis ^{®*}	none
Valsartan	tablet	Diovan ^{®*}	valsartan
Combination Products			
Azilsartan and chlorthalidone	Tablet	Edarbyclor [®]	none
Candesartan and hydrochlorothiazide	tablet	Atacand HCT ^{®*}	candesartan and hydrochlorothiazide
Eprosartan and hydrochlorothiazide	tablet	Teveten HCT [®]	none
Irbesartan and hydrochlorothiazide	tablet	Avalide ^{®*}	irbesartan and hydrochlorothiazide

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Losartan and hydrochlorothiazide	tablet	Hyzaar ^{®*}	losartan and hydrochlorothiazide
Olmesartan and amlodipine and hydrochlorothiazide	tablet	Tribenzor [®]	none
Olmesartan and hydrochlorothiazide	tablet	Benicar HCT [®]	none
Telmisartan and amlodipine	tablet	Twynsta ^{®*}	none
Telmisartan and hydrochlorothiazide	tablet	Micardis HCT ^{®*}	none
Valsartan and hydrochlorothiazide	tablet	Diovan HCT ^{®*}	valsartan and hydrochlorothiazide

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the angiotensin II receptor antagonists are summarized in Table 2.

Table 2. Treatment Guidelines Using the Angiotensin II Receptor Antagonists

Clinical Guideline	Recommendations
American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007) ²³	<ul style="list-style-type: none"> Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin-converting enzyme inhibitors (ACE inhibitors) and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes. Long-acting calcium-channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) of $\leq 40\%$ and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF of $\leq 40\%$. ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF $\leq 40\%$ and have either diabetes or heart failure. It is beneficial to start and continue β-blocker therapy indefinitely in all

Clinical Guideline	Recommendations
	<p>patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated.</p> <ul style="list-style-type: none"> • Annual influenza vaccination is recommended in patients with cardiovascular disease.
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease (2013)²⁴</p>	<p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education. <p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia (>10%), β-blockers should be considered. • In patients with vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided. <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin in

Clinical Guideline	Recommendations
<p>Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: Management of Stable Ischemic Heart Disease (2012)²⁵</p>	<p>contraindicated.</p> <ul style="list-style-type: none"> • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (2014)²⁶</p>	<p><u>Early hospital care- standard medical therapies</u></p> <ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation $< 90\%$, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac

Clinical Guideline	Recommendations
	<p>event associated with their use</p> <ul style="list-style-type: none"> ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. ● Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0

Clinical Guideline	Recommendations
	<p>mg/dL in women) or hyperkalemia ($K > 5.0$ mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF < 0.40, diabetes mellitus, or heart failure.</p> <ul style="list-style-type: none"> • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely. ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatid, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. • Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the

Clinical Guideline	Recommendations
	<p>last subcutaneous enoxaparin dose eight to 12 hours before PCI.</p> <ul style="list-style-type: none"> ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. <ul style="list-style-type: none"> ● Timing of CABG in relation to use of antiplatelet agents <ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatid or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. <p><u>Late hospital care, hospital discharge, and posthospital discharge care</u></p> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. ○ Before hospital discharge, patients who are post-NSTEMI-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTEMI-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEMI-ACS

Clinical Guideline	Recommendations
	<p>without contraindications who are treated with an ischemia-guided strategy.</p> <ul style="list-style-type: none"> ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTEMI-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTEMI-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTEMI-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTEMI-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)²⁷</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> ● Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. ● Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class ≥III. ● Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. ● Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. ● Calcium channel blockers are recommended in patients with vasospastic angina. ● Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. ● Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> ● β-blockers are recommended in all patients with reduced left ventricular (LV) systolic function (LVEF ≤40%). ● ACE inhibitors are indicated within 24 hours in all patients with LVEF ≤40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. ● ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. ● ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. ● Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF ≤35% and either diabetes or heart failure, without significant renal dysfunction (serum creatinine >2.5 mg/dL for men and >2.0 mg/dL for women) or hyperkalemia. ● Statin therapy with target LDL-C levels <70 mg/dL initiated early after admission is recommended.
<p>American College of Cardiology/American Heart Association: Guideline for the</p>	<p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> ● Oral β-blockers should be initiated within the first 24 hours in patients with an ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output

Clinical Guideline	Recommendations
<p>Management of ST-Elevation Myocardial Infarction (2013)²⁸</p>	<p>state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval >24 seconds, second or third degree heart block, active asthma, reactive airway disease).</p> <ul style="list-style-type: none"> • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: renin-angiotensin-aldosterone system inhibitors</u></p> <ul style="list-style-type: none"> • An ACE inhibitor should be administered within the first 24 hours to all patients with ST-segment elevation myocardial infarction with anterior location, heart failure, or ejection fraction $\leq 40\%$, unless contraindicated. • An ARB should be given to patients who have indications for but are intolerant of ACE inhibitors. • ACE inhibitors are reasonable for all patients with no contraindications to their use. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF $\leq 40\%$ and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation (2012)²⁹</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated indefinitely after STEMI. • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients receiving drug-eluting stent. • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. • In selected patients who receive aspirin and clopidogrel, low-dose

Clinical Guideline	Recommendations
	<p>rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk.</p> <ul style="list-style-type: none"> • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
<p>National Institute for Health and Clinical Excellence: Myocardial Infarction: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)³⁰</p>	<p><u>Drug therapy</u></p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs: <ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker. ○ Statin. • Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. • Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. • Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> • Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. • Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during

Clinical Guideline	Recommendations
	<p>this time, it should be completed within 4 to 6 weeks of hospital discharge.</p> <ul style="list-style-type: none"> • Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. • Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. • Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> • Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. • Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. • For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. • Special considerations should be made for people with dyspepsia. • After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for Helicobacter pylori should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). • Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. • Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. • Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. • Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago). <p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into

Clinical Guideline	Recommendations
	<p>consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes.</p> <ul style="list-style-type: none"> Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. β-blockers should be continued indefinitely after an acute MI. After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)³¹</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p><u>Treatment of Stage B heart failure</u></p> <ul style="list-style-type: none"> In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) In patients with MI, statins should be used to prevent HF. (LoE: A) ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) Nondihydropyridine calcium channel blockers may be harmful in patients

Clinical Guideline	Recommendations
	<p data-bbox="581 205 862 233">with low LVEF. (LoE: C)</p> <p data-bbox="537 264 1032 291">Pharmacological treatment for Stage C HFrEF</p> <ul data-bbox="537 296 1414 1377" style="list-style-type: none"> <li data-bbox="537 296 1377 359">• Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) <li data-bbox="537 363 1370 426">• Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) <li data-bbox="537 430 1409 548">• ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) <li data-bbox="537 552 1349 636">• Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) <li data-bbox="537 640 1409 947">• Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) <li data-bbox="537 951 1386 1068">• The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) <li data-bbox="537 1073 1393 1136">• Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) <li data-bbox="537 1140 1382 1257">• Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) <li data-bbox="537 1262 1409 1325">• Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) <li data-bbox="537 1329 1354 1377">• Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p data-bbox="537 1409 1032 1436">Pharmacological treatment for Stage C HFpEF</p> <ul data-bbox="537 1440 1398 1661" style="list-style-type: none"> <li data-bbox="537 1440 1393 1503">• Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) <li data-bbox="537 1507 1354 1570">• Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) <li data-bbox="537 1575 1398 1661">• The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p data-bbox="537 1692 1044 1719">Treatment of Stage D (advanced/refractory) HF</p> <ul data-bbox="537 1724 1338 1902" style="list-style-type: none"> <li data-bbox="537 1724 1338 1787">• Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) <li data-bbox="537 1791 1393 1902">• Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and

Clinical Guideline	Recommendations
	<p>preserve end-organ performance. (LoE: C)</p> <ul style="list-style-type: none"> • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)³²</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF \leq40%, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF \leq40%. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia.

Clinical Guideline	Recommendations
	<p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains $>130/80$ mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of $<130/80$ mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a

Clinical Guideline	Recommendations
	<p>β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent.</p> <ul style="list-style-type: none"> • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower

Clinical Guideline	Recommendations
	<p>doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention.</p> <ul style="list-style-type: none"> • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)³³</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ○ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ○ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ○ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. • Step 3: <ul style="list-style-type: none"> ○ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ○ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ○ Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> • A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.

Clinical Guideline	Recommendations
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)³⁴</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)³⁵</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)³⁶,</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient

Clinical Guideline	Recommendations
<p>Reappraisal of Guidelines on Hypertension Management (2009)³⁷</p>	<p>populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight

Clinical Guideline	Recommendations
	<p>glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.</p>
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)³⁸</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated

Clinical Guideline	Recommendations
	<p data-bbox="581 205 816 233">systolic hypertension.</p> <p data-bbox="537 264 1008 291"><u>Treatment strategies in hypertensive women</u></p> <ul data-bbox="537 298 1409 852" style="list-style-type: none"> <li data-bbox="537 298 1409 384">• Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. <li data-bbox="537 390 1409 449">• If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. <li data-bbox="537 455 1409 514">• Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. <li data-bbox="537 520 1409 606">• Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. <li data-bbox="537 613 1409 699">• In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. <li data-bbox="537 705 1409 764">• In women with child-bearing potential RAS blockers are not recommended and should be avoided. <li data-bbox="537 770 1409 852">• Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p data-bbox="537 888 1019 915"><u>Treatment strategies in patients with diabetes</u></p> <ul data-bbox="537 921 1409 1289" style="list-style-type: none"> <li data-bbox="537 921 1409 1008">• While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. <li data-bbox="537 1014 1409 1041">• A SBP goal <140 mmHg is recommended in patients with diabetes. <li data-bbox="537 1047 1409 1075">• The DBP target in patients with diabetes is recommended to be <85 mmHg. <li data-bbox="537 1081 1409 1167">• All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. <li data-bbox="537 1173 1409 1232">• It is recommended that individual drug choice takes comorbidities into account. <li data-bbox="537 1239 1409 1289">• Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p data-bbox="537 1325 1300 1352"><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul data-bbox="537 1358 1409 1850" style="list-style-type: none"> <li data-bbox="537 1358 1409 1478">• Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. <li data-bbox="537 1484 1409 1661">• As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. <li data-bbox="537 1667 1409 1787">• It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. <li data-bbox="537 1793 1409 1850">• BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p data-bbox="537 1885 1224 1913"><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists.

Clinical Guideline	Recommendations
	<p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. <ul style="list-style-type: none"> • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)³⁹</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. • If further diuretic therapy for resistant hypertension at step 4 is not tolerated

Clinical Guideline	Recommendations
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)⁴⁰</p>	<p>or is contraindicated or ineffective, consider an α-blocker or β-blocker.</p> <ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)⁴¹</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p>

Clinical Guideline	Recommendations
<p>Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)⁴²</p>	<ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> • Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)⁴³</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy.

Clinical Guideline	Recommendations
	<p data-bbox="537 233 678 264"><u>Nephropathy</u></p> <ul data-bbox="537 264 1406 636" style="list-style-type: none"><li data-bbox="537 264 1406 327">• Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease.<li data-bbox="537 327 1406 422">• An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g).<li data-bbox="537 422 1406 537">• Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day.<li data-bbox="537 537 1406 636">• When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the angiotensin II receptor antagonists are noted in Tables 3 and 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Angiotensin II Receptor Antagonists-Single Entity Agents³⁻¹⁰

Indication(s)	Single Entity Agents							
	Azil-sartan	Cande-sartan	Epro-sartan	Irbe-sartan	Lo-sartan	Olme-sartan	Telmi-sartan	Val-sartan
Cardiovascular Risk Reduction								
Reduce the risk of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction								✓
Reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients ≥55 years of age at high risk of developing major cardiovascular events who are unable to take an angiotensin converting enzyme inhibitor							✓	
Reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy					✓ *			
Heart Failure								
Heart failure (New York Heart Association functional class II to IV)								✓
Heart failure (New York Heart Association functional class II to IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤40%) to reduce cardiovascular death and to reduce heart failure hospitalizations		✓						
Hypertension								
Hypertension, alone or in combination with other antihypertensive agents	✓	✓	✓	✓	✓	✓	✓	✓
Nephropathy in Type 2 Diabetic Patients								
Diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension				✓	✓			

*There is evidence that this benefit does not apply to Black patients.

Table 4. FDA-Approved Indications for the Angiotensin II Receptor Antagonists-Combination Products¹¹⁻²⁰

Indication(s)	Combination Products									
	Azilsartan and chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
Cardiovascular Risk Reduction										
Reduce the risk of stroke in patients with hypertension and left					✓ *					

Indication(s)	Combination Products									
	Azilsartan and chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
ventricular hypertrophy										
Hypertension										
Hypertension	✓	✓ †	✓ †‡	✓	✓ §	✓ †	✓ †	✓ ‡	✓ †	✓

*There is evidence that this benefit does not apply to Black patients.

†This fixed dose combination is not indicated for initial therapy.

‡May be used alone or in combination with other antihypertensive agents.

§This fixed dose combination is not indicated for initial therapy, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the angiotensin II receptor antagonists are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the Angiotensin II Receptor Antagonists²²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Azilsartan	60	>99	Liver (% not reported)	Feces (55%) Renal (42%)	11
Candesartan	15	>99	Intestinal wall (>99)	Feces (67) Renal (33)	9
Eprosartan	13	98	Liver (20)	Feces (90) Renal (7)	5 to 9
Irbesartan	60 to 80	90	Liver (50 to 70)	Feces (65) Renal (20)	11 to 15
Losartan	25 to 35	99	Liver (14)	Feces (50 to 60) Renal (13 to 35)	2
Olmesartan	26	99	Intestinal wall (100)	Feces (50 to 65) Renal (35 to 50)	13
Telmisartan	42 to 58	>99	Liver (<3)	Feces (97)	24
Combination Products					
Azilsartan and Chlorthalidone	60/not reported	>99/75	Liver (% not reported)/ Not reported	Feces (55%) Renal (42%)/ Renal, major (% not reported)	12/45
Candesartan and HCTZ	15/70	>99/40	Liver, minimal (% not reported)/ Not metabolized	Feces (67%) Renal (26%)/ Renal (61)	5.1 to 10.5/ 5.6 to 14.8
Eprosartan and HCTZ	13/70	98/40	Liver (20)/ Not metabolized	Feces (90) Renal (7)/ Renal (61)	5 to 9/ 5.6 to 14.8
Irbesartan and HCTZ	60 to 80/not reported	90/40	Liver (% not reported)/ Not metabolized	Feces, majority (% not reported) Renal (20)/ Renal (61)	10 to 12/ 11 to 15
Losartan and HCTZ	33/not reported	Not reported/not reported	Systemic (% not reported)/ Not metabolized	Feces (60) Renal (35)/ Renal (% not reported)	2/ 5.6 to 14.8
Olmesartan and amlodipine and HCTZ	26/ 64 to 90/ Not reported	99/ 93/ Not reported	Intestinal wall, extensive/ Liver (90)/ Not reported	Feces (50 to 65) Renal (35 to 50)/ Renal (10)/ Renal (61)	13/ 30 to 50/ 5.6 to 14.8
Olmesartan and HCTZ	26/Not reported	99/Not reported	Hydrolysis (complete)/Not metabolized	Feces (% not reported) Renal (35 to 50)/ Renal (61)	13/ 5.6 to 14.8
Telmisartan and amlodipine	64 to 90/ 42 to 58	99.5/93	Hepatic, minimal (% not reported)/ Hepatic (90)	Feces (>97) Renal (<1)/ Feces (20 to 25) Renal (10)	24/ 30 to 50
Telmisartan	42 to 58/Not	Not reported/Not	Not reported/Not	Feces (97)/	24/

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
and HCTZ	reported	reported	reported	Renal (61)	5.6 to 14.8
Valsartan and HCTZ	25/70	95/40 to 70	Liver, minimal (% not reported)/ Not reported	Feces (83) Renal (13)/ Renal (70)	6 to 9/ 10 to 12

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the angiotensin II receptor antagonists are listed in Table 6.

Table 6. Significant Drug Interactions with the Angiotensin II Receptor Antagonists²¹

Generic Name(s)	Significance Level	Interaction	Mechanism
ARBs (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	1	Potassium-sparing diuretics	ARBs and potassium-sparing diuretics may increase serum potassium levels, leading to additive or synergistic effects.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes.
Thiazide diuretics (HCTZ)	1	Lithium	Thiazide diuretics decrease the renal clearance of lithium which leads to increased serum lithium levels. Lithium toxicity has occurred.
ARBs (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	2	Lithium	Angiotensin II receptor antagonists may decrease lithium renal excretion by enhancing its reabsorption. Lithium levels may increase, resulting in an increase in pharmacologic and toxic effects of lithium.
ARBs (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	2	Trimethoprim	Angiotensin II receptor antagonists and trimethoprim may act additively or synergistically to inhibit renal excretion of potassium, increasing the risk of hyperkalemia.
Dihydropyridines (amlodipine)	2	HIV protease inhibitors	Pharmacologic effects of amlodipine may be enhanced by protease inhibitors.
Dihydropyridines (amlodipine)	2	Imidazoles	Imidazoles may increase the plasma concentrations and pharmacologic effects of amlodipine.
Thiazide diuretics (HCTZ)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia though an unknown mechanism; therefore the combination should be avoided.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Diuretic-induced electrolyte disturbances may predispose the patient to digitalis-induced cardiac arrhythmias.

ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor antagonist, HCTZ=hydrochlorothiazide, HIV=human immunodeficiency virus

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the angiotensin II receptor antagonists are listed in Table 7. The most common adverse drug events reported with amlodipine and hydrochlorothiazide are listed in Table 8. The boxed warning for the angiotensin II receptor antagonists is listed in Table 9.

Table 7. Adverse Drug Events (%) Reported with the Combination Angiotensin II Receptor Antagonists-Single Entity Agents^{3-10,21,22}

Adverse Events	Single Entity Agents							
	Azilsartan	Candesartan	Eprosartan	Irbesartan	Losartan	Olmesartan	Telmisartan	Valsartan
Cardiovascular								
Chest pain	-	>1	≥1	≥1	≥1	>0.5	1	-
Hypertension	-	-	-	<1	-	-	-	-
Hypotension	-	-	<1	<1	<1	-	-	<1
Orthostatic hypotension	-	-	✓	✓	-	-	-	-
Tachycardia	-	≥0.5	<1	≥1	<1	>0.5	>0.3	-
Central Nervous System								
Anxiety/nervousness	-	≥0.5	<1	≥1	<1	-	>0.3	>0.2
Depression	-	≥0.5	1	<1	<1	-	>0.3	-
Dizziness	≥0.3	4	≥1	≥1	4	3	1	>1
Dizziness, postural	≥0.3	-	-	-	-	-	-	-
Fatigue	-	>1	2	4	-	>0.5	1	2
Headache	-	≥1	≥1	≥1	≥1	>1	1	>1
Insomnia	-	-	<1	-	1	>0.5	>0.3	>0.2
Dermatological								
Rash	-	≥0.5	<1	≥1	<1	>0.5	>0.3	>0.2
Gastrointestinal								
Abdominal pain	-	>1	2	≥1	≥1	>0.5	1	2
Diarrhea	2	>1	≥1	3	2	>1	3	>1
Dyspepsia/heartburn	-	≥0.5	≥1	2	1	>0.5	1	>0.2
Nausea/vomiting	≥0.3	>1	<1	≥1	≥1	>0.5	1	>1
Genitourinary								
Albuminuria	-	>1	<1	-	-	-	-	-
Hematuria	-	≥0.5	<1	-	-	>1	-	-
Urinary tract infection	-	-	4	≥1	<1	>0.5	1	-
Laboratory Test Abnormalities								
Creatine phosphokinase increased	-	≥0.5	<1	-	-	>1	-	-
Decreased hematocrit	0.4	-	-	-	-	-	-	-
Decreased hemoglobin	0.2	-	-	-	-	-	-	-
Decreased red blood counts	0.3	-	-	-	-	-	-	-
Hyperglycemia	-	≥0.5	<1	-	-	>1	-	-
Hyperkalemia	-	✓	-	✓	✓	-	-	✓
Hypertriglyceridemia	-	≥0.5	1	-	-	>1	-	-
Hypokalemia	-	-	✓	-	-	-	-	-
Musculoskeletal								
Arthralgia	-	>1	2	-	<1	>0.5	>0.3	>1
Muscle cramp	-	-	-	-	1.1	-	-	>0.2
Muscle spasm	≥0.3	-	-	-	-	-	-	-

Adverse Events	Single Entity Agents							
	Azilsartan	Candesartan	Eprosartan	Irbesartan	Losartan	Olmesartan	Telmisartan	Valsartan
Myalgia	-	≥0.5	≥1	-	1	>0.5	1	>0.2
Pain (includes back and leg)	-	3	<1	≥1	1 to 2	>1	1 to 3	>0.2
Trauma	-	-	-	2	-	-	-	-
Respiratory								
Bronchitis	-	>1	≥1	-	<1	>1	>0.3	-
Cough	≥0.3	>1	4	3	3	-	1	>1
Influenza/influenza-like symptoms	-	-	<1	≥1	<1	>1	1	-
Nasal congestion	-	-	-	-	2	-	-	-
Pharyngitis	-	2	4	≥1	≥1	>1	1	>1
Rhinitis	-	2	4	≥1	<1	>1	>0.3	>1
Sinus disorder	-	-	-	≥1	2	-	-	-
Sinusitis	-	>1	≥1	-	1	>1	3	>1
Upper respiratory tract infection	-	6	8	9	8	>1	7	>1
Miscellaneous								
Allergic reactions	-	✓	✓	✓	✓	✓	✓	✓
Angioedema	-	✓	✓	✓	✓	✓	✓	✓
Asthenia	≥0.3	-	-	-	-	-	-	-
Edema	-	>1	≥1	≥1	≥1	>0.5	1	>1
Fatigue	≥0.3	-	-	-	-	-	-	-
Inflicted injury	-	-	2	-	-	>1	-	-
Viral infection	-	-	2	-	-	-	-	3

✓ Percent not specified
- Event not reported

Table 8. Adverse Drug Events (%) Reported with the Combination Angiotensin II Receptor Antagonists-Combination Products¹¹⁻²²

Adverse Event	Azilsartan and Chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
Cardiovascular										
Abnormal electrocardiogram	-	≥0.5	-	-	-	-	-	-	-	-
Angina	-	<0.5	-	-	-	-	-	-	-	-
Bradycardia	-	≥0.5	-	-	-	-	-	-	-	-
Chest pain	-	≥0.5	-	2	-	-	>1	-	-	>0.2
Extrasystoles	-	≥0.5	-	-	-	-	-	-	-	-
Hypotension	1.7	-	-	0.6 to 0.9	0.6	-	-	<2.0	<2	>0.2 to 1.0
Myocardial infarction	-	<0.5	-	-	-	-	-	-	-	-
Palpitations	-	≥0.5	-	-	1.4	-	-	-	-	>0.2
Syncope	0.3	-	-	-	-	1	-	<2.0	-	✓
Tachycardia	-	≥0.5	-	1	-	-	-	-	<2	>0.2
Central Nervous System										
Anxiety	-	≥0.5	-	≥1	-	-	-	-	-	>0.2
Asthenia	-	≥0.5	-	-	≥1	-	-	-	-	>0.2
Depression	-	≥0.5	-	-	-	-	-	-	-	✓

Adverse Event	Azilsartan and Chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
Dizziness	8.9	2.9	4.1	1 to 8	5.7	-	9	3.0	1 to 7	>0.2 to 6.0
Headache	-	2.9	3.4	1.0 to 5.5	≥1	6.4	>2	-	≥2	-
Hypesthesia	-	≥0.5	-	-	-	-	-	-	-	-
Insomnia	-	≥0.5	-	-	-	-	-	-	-	>0.2
Nervousness	-	-	-	≥1	-	-	-	-	-	-
Paresthesia	-	≥0.5	-	-	-	-	-	-	-	>0.2
Somnolence	-	-	-	-	-	-	-	-	-	>0.2
Vertigo	-	≥0.5	-	-	-	-	>1	-	-	>0.2
Dermatological										
Alopecia	-	-	-	-	-	-	✓	-	-	✓
Dermatitis	-	≥0.5	-	-	-	-	-	-	-	-
Eczema	-	≥0.5	-	-	-	-	-	-	-	-
Pruritus	-	≥0.5	-	-	-	-	✓	-	-	✓
Rash	-	≥0.5	-	≥1	1.4	-	>1	-	<2	>0.2
Sweating	-	≥0.5	-	-	-	-	-	-	-	>0.2
Urticaria	-	-	-	✓	-	-	✓	-	-	-
Gastrointestinal										
Abdominal pain	-	≥0.5	-	2	1.2	-	>1	-	<2	>0.2
Constipation	-	-	-	-	-	-	-	-	-	✓
Diarrhea	-	≥0.5	-	≥1	≥1	2.6	>1	-	3	>0.2
Dry mouth	-	-	-	-	-	-	-	-	-	>0.2
Dyspepsia	-	≥0.5	-	2	-	-	>1	-	<2	>0.2
Flatulence	-	-	-	-	-	-	-	-	-	>0.2
Gastritis	-	≥0.5	-	-	-	-	-	-	-	-
Gastroenteritis	-	≥0.5	-	-	-	-	>1	-	-	>0.2
Hepatic function abnormal	-	≥0.5	-	-	-	-	-	-	-	-
Hepatitis	-	-	-	✓	-	-	-	-	-	✓
Nausea	-	≥0.5	-	3	≥1	3.0	3	-	2	>0.2
Vomiting	-	≥0.5	-	3	-	-	✓	-	<2	>0.2
Laboratory Test Abnormalities										
Bilirubin increased	-	✓	-	-	✓	-	-	-	✓	-
Blood urea nitrogen increased	-	≥0.5	-	-	0.6	-	1.3	-	2.8	>0.2
Creatine phosphokinase increased	-	≥0.5	-	-	-	-	>1	-	-	-
Hematocrit decreased	-	✓	-	-	✓	-	0.4	-	0.6	-
Hemoglobin decreased	-	✓	-	-	✓	-	-	-	1.2	-
Hyperglycemia	-	≥0.5	-	-	-	-	>1	-	-	-
Hyperkalemia	-	-	-	0.2 to 1.2	-	-	✓	-	-	✓
Hyperlipidemia	-	-	-	-	-	-	>1	-	-	-
Hyperuricemia	-	≥0.5	-	-	-	-	4	-	-	-
Hypokalemia	-	≥0.5	-	0.6 to 0.9	-	-	-	-	<2	-
Serum creatinine increased	-	✓	-	-	0.8	-	-	-	1.4	-
Thrombocytopenia	-	-	-	-	✓	-	-	-	-	-

Adverse Event	Azilsartan and Chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
Transaminase levels increased	-	≥0.5	-	-	✓	-	>1	-	✓	✓
Musculoskeletal										
Arthralgia	-	≥0.5	-	-	-	-	>1	-	-	>0.2
Arthritis	-	≥0.5	-	-	-	-	>1	-	-	-
Arthrosis	-	≥0.5	-	-	-	-	-	-	-	-
Back pain	-	3.3	2.6	-	2.1	-	>1	2.2	<2	>0.2
Joint swelling	-	-	-	-	-	2.1	-	-	-	-
Leg cramps	-	≥0.5	-	-	-	-	-	-	-	-
Muscle cramps	-	-	-	≥1	-	-	-	-	-	>0.2
Muscle spasms	-	-	-	-	-	3.1	-	-	-	-
Muscle weakness	-	-	-	-	-	-	-	-	-	✓
Musculoskeletal pain	-	-	-	6	-	-	-	-	-	-
Myalgia	-	≥0.5	0.4	-	-	-	>1	-	-	>0.2
Pain in extremity	-	-	-	-	-	-	-	-	-	>0.2
Rhabdomyolysis	-	-	-	✓	-	-	✓	-	-	✓
Sciatica	-	≥0.5	-	-	-	-	-	-	-	-
Respiratory										
Bronchitis	-	≥0.5	-	-	≥1	-	-	-	<2	>0.2
Bronchospasm	-	-	-	-	-	-	-	-	-	✓
Cough	-	≥0.5	-	≥1	2.6	-	>1	-	≥2	>0.2
Dyspnea	-	≥0.5	-	-	-	-	-	-	-	>0.2
Epistaxis	-	≥0.5	-	-	-	-	-	-	-	✓
Nasal congestion	-	-	-	-	-	-	-	-	-	>0.2
Nasopharyngitis	-	-	-	-	-	3.5	-	-	2.4	-
Pharyngitis	-	≥0.5	-	≥1	≥1	-	-	-	<2	✓
Pharyngolaryngeal pain	-	-	-	-	-	-	-	-	-	>0.2
Rhinitis	-	≥0.5	-	≥1	-	-	-	-	-	-
Sinus abnormality	-	-	-	≥1	-	-	-	-	-	-
Sinus congestion	-	-	-	-	-	-	-	-	-	>0.2
Sinusitis	-	≥0.5	-	-	1.2	-	-	-	4	>0.2
Upper respiratory tract infection	-	3.6	0.4	≥1	6.1	2.8	7	-	8	>0.2
Miscellaneous										
Abnormal vision	-	-	-	-	-	-	-	-	-	✓
Acute renal failure	-	-	-	-	-	-	✓	-	-	-
Allergy	-	-	-	1	-	-	-	-	-	-
Anaphylaxis	-	-	-	-	-	-	-	-	-	✓
Angioedema	-	<0.5	-	✓	✓	-	✓	-	-	✓
Appetite increased	-	-	-	-	-	-	-	-	-	✓
Conjunctivitis	-	≥0.5	-	-	-	-	-	-	-	-
Cystitis	-	≥0.5	-	-	-	-	-	-	-	-
Dehydration	-	-	-	-	-	-	-	-	-	✓
Dysuria	-	-	-	-	-	-	-	-	-	✓
Edema	-	-	-	3	1.3	-	-	<2.0	-	-

Adverse Event	Azilsartan and Chlorthalidone	Candesartan and HCTZ	Eprosartan and HCTZ	Irbesartan and HCTZ	Losartan and HCTZ	Olmesartan and Amlodipine and HCTZ	Olmesartan and HCTZ	Telmisartan and Amlodipine	Telmisartan and HCTZ	Valsartan and HCTZ
Erectile dysfunction	-	-	-	-	-	-	-	-	-	>0.2
Facial edema	-	-	-	-	-	-	✓	-	-	-
Fatigue	2.0	≥0.5	1.9	6	≥1	4.2	-	-	3	>0.2
Fever	-	-	-	-	-	-	-	-	-	>0.2
Flushing	-	-	-	-	-	-	-	-	-	✓
Gout	-	-	-	-	-	-	-	-	-	✓
Hematuria	-	≥0.5	-	-	-	-	>1	-	-	-
Inflicted injury	-	≥0.5	-	-	-	-	-	-	-	-
Influenza-like symptoms	-	2.5	-	3	-	-	-	-	2	>0.2
Infection	-	≥0.5	-	-	-	-	-	-	-	-
Libido decreased	-	-	-	-	-	-	-	-	-	✓
Pain	-	≥0.5	-	-	-	-	-	-	≥2	-
Peripheral edema	-	≥0.5	-	-	-	7.7	>1	4.8	-	>0.2
Pollakiuria	-	-	-	-	-	-	-	-	-	>0.2
Renal impairment	-	-	-	-	-	-	-	-	-	✓
Sunburn	-	-	-	-	-	-	-	-	-	✓
Tinnitus	-	≥0.5	-	-	-	-	-	-	-	>0.2
Urinary tract infection	-	≥0.5	-	≥1	-	2.4	>2	-	≥2	-
Urination abnormal	-	-	-	2	-	-	-	-	-	>0.2
Vasculitis	-	-	-	-	-	-	-	-	-	✓
Viral infection	-	≥0.5	-	-	-	-	-	-	-	✓

✓ Percent not specified

- Event not reported

HCTZ=hydrochlorothiazide

Table 9. Boxed Warning for the Angiotensin II Receptor Antagonists²²

WARNING
When pregnancy is detected, discontinue therapy as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.

VII. Dosing and Administration

The usual dosing regimens for the angiotensin II receptor antagonists are listed in Table 10.

Table 10. Usual Dosing Regimens for the Angiotensin II Receptor Antagonists³⁻²²

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Azilsartan	<u>Hypertension:</u> Tablet: initial, 40 or 80 mg once daily; maintenance, 80 mg once daily	Safety and efficacy in children have not been established.	Tablet: 40 mg 80 mg
Candesartan	<u>Heart Failure:</u> Tablet: initial, 4 mg once daily; maintenance, 32 mg once daily <u>Hypertension:</u> Tablet: initial, 16 mg once daily when used as monotherapy in patients who are not volume-depleted; maintenance: 8 to 32 mg/day in a single or divided dose(s)	<u>Hypertension in children 1 to 6 years of age:</u> Tablet: initial, 0.02 mg/kg/day; maintenance, 0.05 to 0.4 mg/kg/day <u>Hypertension in children 7 to 17 years of age and <50 kg:</u> Tablet: initial, 4 to 8 mg/day; maintenance, 2 to 16 mg/day <u>Hypertension in children 7 to 17 years of age and >50 kg:</u> Tablet: initial, 8 to 16 mg/day; maintenance, 4 to 32 mg/day Safety and efficacy in children with heart failure have not been established.	Tablet: 4 mg 8 mg 16 mg 32 mg
Eprosartan	<u>Hypertension:</u> Tablet: initial, 600 mg once daily when used as monotherapy in patients who are not volume-depleted; maintenance, 400 to 800 mg/day in a single or divided dose(s)	Safety and efficacy in children have not been established.	Tablet: 400 mg 600 mg
Irbesartan	<u>Diabetic nephropathy:</u> Tablet: 300 mg once daily <u>Hypertension:</u> Tablet: initial, 150 mg once daily in patients who are not volume-depleted; maximum, 300 mg once daily	Safety and efficacy in children have not been established.	Tablet: 75 mg 150 mg 300 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Losartan	<p><u>Cardiovascular risk reduction (hypertension and left ventricular hypertrophy):</u> Tablet: initial, 50 mg once daily; maintenance, 100 mg once daily</p> <p><u>Diabetic nephropathy:</u> Tablet: initial, 50 mg once daily; maintenance, dose should be increased to 100 mg once daily based on blood pressure response</p> <p><u>Hypertension:</u> Tablet: initial, 50 mg once daily in patients who are not volume-depleted; maintenance, 25 to 100 mg/day in a single or divided dose(s)</p>	<p><u>Hypertension in children ≥6 years of age:</u> Tablet: initial, 0.7 mg/kg once daily (up to 50 mg total); maximum, >1.4 mg/kg/day (or in excess of 100 mg) have not been studied</p> <p>Safety and efficacy in children <6 years of age have not been established.</p>	Tablet: 25 mg 50 mg 100 mg
Olmesartan	<p><u>Hypertension:</u> Tablet: initial, 20 mg once daily when used as monotherapy in patients who are not volume depleted; maximum, 40 mg once daily</p>	<p><u>Hypertension in children 6 to 16 years of age and 20 to <35 kg:</u> Tablet: initial, 10 mg once daily; maximum, 20 mg once daily</p> <p><u>Hypertension in children 6 to 16 years of age ≥35 kg:</u> Tablet: initial, 20 mg once daily; maximum, 40 mg once daily</p> <p>Safety and efficacy in children <6 years of age have not been established.</p>	Tablet: 5 mg 20 mg 40 mg
Telmisartan	<p><u>Cardiovascular risk reduction:</u> Tablet: 80 mg once daily</p> <p><u>Hypertension:</u> Tablet: initial, 40 mg once daily; maximum: 80 mg per day</p>	<p>Safety and efficacy in children have not been established.</p>	Tablet: 20 mg 40 mg 80 mg
Valsartan	<p><u>Cardiovascular risk reduction (post-myocardial infarction):</u> Tablet: initial, 20 mg twice daily; maintenance, 160 mg twice daily</p> <p><u>Heart Failure:</u> Tablet: Initial, 40 mg twice daily; maintenance, up titrate to 80 to 160 mg twice daily; maximum, 320 mg in divided doses</p> <p><u>Hypertension:</u> Tablet: initial, 80 to 160 mg once daily when used as monotherapy in patients who are not volume depleted; maintenance, 80 to 320</p>	<p><u>Hypertension in children 6 to 16 years of age:</u> Tablet: initial, 1.3 mg/kg once daily (up to 40 mg total) administered as a tablet or suspension; maximum, >2.7 mg/kg/day (or in excess of 160 mg) have not been studied</p> <p>Safety and efficacy in children with hypertension <6 years of age, or with heart failure, or for cardiovascular risk reduction have not been</p>	Tablet: 40 mg 80 mg 160 mg 320 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	mg once daily	established.	
Combination Products			
Azilsartan and chlorthalidone	<u>Hypertension:</u> Tablet: initial, 40-12.5 mg once daily; maintenance, 40-25 mg once daily; maximum, 40-25 mg /day	Safety and efficacy in children have not been established.	Tablet: 40-12.5 mg 40-25 mg
Candesartan and HCTZ	<u>Hypertension:</u> Tablet: 16-12.5 to 32-25 mg/day	Safety and efficacy in children have not been established.	Tablet: 16-12.5 mg 32-12.5 mg 32-25 mg
Eprosartan and HCTZ	<u>Hypertension:</u> Tablet: maintenance, 600-12.5 mg once daily when used in patients who are not volume-depleted; maximum, 600-25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 600-12.5 mg 600-25 mg
Irbesartan and HCTZ	<u>Hypertension:</u> Tablet: initial, 150-12.5 mg once daily; maximum, 300-25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 150-12.5 mg 300-12.5 mg
Losartan and HCTZ	<u>Cardiovascular risk reduction (hypertension and left ventricular hypertrophy):</u> Tablet: initial, 50-12.5 mg once daily; maintenance, 100-12.5 mg once daily; maximum, 100-25 mg once daily <u>Hypertension:</u> Tablet: initial, 50-12.5 mg once daily; maintenance, 100-12.5 mg once daily; maximum, 100-25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 50-12.5 mg 100-12.5 mg 100-25 mg
Olmesartan and amlodipine and HCTZ	<u>Hypertension:</u> Tablet: maximum, 40-10-25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 20-5-12.5 mg 40-5-12.5 mg 40-5-25 mg 40-10-12.5 mg 40-20-25 mg
Olmesartan and HCTZ	<u>Hypertension:</u> Tablet: 20-12.5 to 40-25 mg/day	Safety and efficacy in children have not been established.	Tablet: 20-12.5 mg 40-12.5 mg 40-25 mg
Telmisartan and amlodipine	<u>Hypertension:</u> Tablet: initial, 40-5 or 80-5 mg once daily; maintenance, titrate as needed; maximum , 80-10 mg once daily	Safety and efficacy in children have not been established.	Tablet: 40-5 mg 40-10 mg 80-5 mg 80-10 mg
Telmisartan and HCTZ	<u>Hypertension:</u> Tablet: 40-12.5 to 80-25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 40-12.5 mg 80-12.5 mg 80-25 mg
Valsartan and HCTZ	<u>Hypertension:</u> Tablet: 80-12.5 to 320-25 mg	Safety and efficacy in children have not been	Tablet: 80-12.5 mg

Angiotensin II Receptor Antagonists
AHFS Class 243208

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	once daily	established.	160-12.5 mg 160-25 mg 320-12.5 mg 320-25 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the angiotensin II receptor antagonists are summarized in Table 11.

Table 11. Comparative Clinical Trials with the Angiotensin II Receptor Antagonists

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cardiovascular Risk Reduction				
Pfeffer et al. ⁴⁴ (2003) VALIANT Captopril 50 mg TID vs valsartan 160 mg BID vs valsartan 80 mg BID and captopril 50 mg TID	DB, MC, RCT Patients ≥18 years of age with an acute MI that was complicated by clinical or radiologic signs of heart failure and/or evidence of left ventricular systolic dysfunction	N=14,703 24.7 months	Primary: All-cause mortality Secondary: Death from cardiovascular causes, recurrent MI, hospitalization for heart failure	Primary: No significant difference in all-cause mortality was reported between valsartan monotherapy and captopril monotherapy (P=0.98). No significant difference in all-cause mortality was observed between valsartan plus captopril combination therapy and captopril monotherapy (P=0.73). Secondary: The rate of death from cardiovascular causes, reinfarction, or hospitalization for heart failure was not significantly different between valsartan and captopril monotherapy (P=0.20). The rate of death from cardiovascular causes, reinfarction, or hospitalization for heart failure was not significantly different between valsartan and captopril combination therapy and captopril monotherapy (P=0.37). Combination therapy had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group and cough, rash, and taste disturbance were more common in the captopril group.
Dickstein et al. ⁴⁵ (2002) OPTIMAAL Captopril 50 mg TID vs losartan 50 mg QD	DB, MC, PG, RCT Patients ≥50 years with an acute MI and signs or symptoms of heart failure during the acute phase or a new Q-wave anterior infarction or	N=5,477 2.7 years (mean)	Primary: All-cause mortality Secondary: Composite of sudden cardiac death or resuscitated cardiac arrest	Primary: No significant difference in all-cause mortality was reported between patients receiving losartan and captopril (18 vs 16%, respectively; RR, 1.13; 95% CI, 0.99 to 1.28; P=0.07). Secondary: No significant difference in sudden cardiac death or resuscitated cardiac arrest was reported between patients receiving losartan and captopril (9 vs 7%; RR, 1.19; 95% CI, 0.98 to 1.43; P=0.07).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	reinfarction			Losartan was significantly better tolerated than captopril, with fewer patients discontinuing study medication (17 vs 23%; P<0.0001).
Graham et al. ⁴⁶ (2014) Olmesartan vs other ARBs	Cohort, RETRO Medicare patients (age 65 years or older) who filled at least one ARB prescription and had no recorded prescription for an ACE inhibitor or ARB 6 months prior to initiating a study drug. Results also stratified by diabetes or no diabetes	N=882,727 Mean duration of study drug use was 130 days	Primary: Acute MI, stroke, and all-cause mortality enriched for acute cardiovascular death Secondary: Not reported	Primary: In the combined study population, there was no difference in the HRs for acute MI or stroke. The HR for death was reduced for olmesartan compared with other ARB users (HR, 0.82; 95% CI, 0.73 to 0.93; P=0.002). In strata defined by presence or absence of diabetes, there was no difference in risk between users of olmesartan and other ARBs for any study endpoint at lower doses of therapy, regardless of duration of use. With high-dose therapy, the risk of acute MI was nonsignificantly increased in diabetic patients treated for 6 months or longer with olmesartan. For nondiabetic patients, the risk of acute MI was statistically significantly reduced with high-dose olmesartan over all durations combined. There was no effect of dose or duration on stroke risk with olmesartan in diabetic or nondiabetic patients. Mortality risk was increased in diabetic patients treated with high-dose olmesartan for 6 months or longer (HR, 2.03; 95% CI, 1.09 to 3.75; P=0.02) and was reduced in nondiabetic patients during the first 6 months of olmesartan use (HR, 0.72; 95% CI, 0.55 to 0.96; P=0.02), and with use of 6 months or longer (HR, 0.46; 95% CI, 0.24 to 0.86; P=0.01). Secondary: Not reported
Diabetes/Diabetic Nephropathy/Renal Disease				
Mogensen et al. ⁴⁷ (2000) CALM Lisinopril 20 mg QD vs candesartan 16 mg QD	DB, DD, MC, PG, RCT Patients 30 to 75 years old with HTN, type 2 diabetes, and microalbuminuria	N=199 24 weeks	Primary: Blood pressure and urinary albumin:creatinine ratio Secondary: Not reported	Primary: At 12 weeks, mean reductions in DBP were 9.7 mm Hg (P<0.001) and 9.5 mm Hg (P<0.001), respectively, and in urinary albumin:creatinine ratio were 46% (P<0.001) and 30% (P<0.001) for lisinopril and candesartan, respectively. Compared to either agent alone, at 24 weeks the combination of lisinopril plus candesartan resulted in 16.3 mm Hg reduction in mean DBP vs 10.4 mm Hg for candesartan alone (P<0.001) and 10.7 mm Hg for lisinopril alone (P<0.001). The reduction in urinary albumin:creatinine ratio with combination treatment (50%) was greater than with lisinopril alone (39%; P<0.001) and candesartan

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>lisinopril 20 mg QD plus candesartan 16 mg QD</p> <p>Patients received 12 weeks monotherapy followed by an additional 12 weeks of monotherapy or combination therapy.</p>				<p>alone (24%; P=0.05).</p> <p>All treatments were generally well tolerated.</p> <p>Secondary: Not reported</p>
<p>Lewis et al.⁴⁸ (2001) IDNT</p> <p>Irbesartan 300 mg/day</p> <p>vs</p> <p>amlodipine 10 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PRO, RCT</p> <p>Patients 30 to 70 years old, with type 2 diabetes mellitus, HTN, and nephropathy</p>	<p>N=1,715</p> <p>2.6 years</p>	<p>Primary: Composite of risk of doubling serum creatinine, ESRD, or death from any cause</p> <p>Secondary: Composite of death from cardiovascular causes, nonfatal MI, heart failure requiring hospitalization, permanent neurologic deficit caused by a cerebrovascular event, or lower limb amputation</p>	<p>Primary: Compared to placebo, irbesartan 300 mg/day resulted in a 20% lower relative risk of the composite primary outcome (P=0.02). Irbesartan treatment was associated with a 33% lower risk of doubling serum creatinine (P=0.003) and 23% trend towards lower risk of ESRD (P=0.07) compared to placebo. There was no significant difference in risk of death from any cause for irbesartan compared to placebo (P=0.57).</p> <p>Compared to amlodipine, irbesartan treatment resulted in a 23% lower risk of composite primary outcome (P=0.006). Irbesartan treatment was associated with a 37% lower risk of doubling serum creatinine vs amlodipine (P<0.001) and 23% trend towards lower risk of ESRD vs amlodipine (P=0.07). There was no significant difference in risk of death from any cause (P=0.80).</p> <p>Secondary: There were no significant differences in the secondary cardiovascular composite end point (P=0.40 and P=0.79 for irbesartan vs placebo and amlodipine, respectively).</p>
<p>Parving et al.⁴⁹</p>	<p>DB, MC, PC, RCT</p>	<p>N=590</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2001) IRMA2 Irbesartan 150 or 300 mg/day vs placebo	Patients with HTN, type 2 diabetes mellitus and microalbuminuria	2 years	Time to onset of diabetic nephropathy Secondary: Changes in level of albuminuria and creatinine clearance and restoration of normoalbuminuria	The primary end point was reached in 5.2% of patients in the irbesartan 300 mg group (P<0.001) and 9.7% of patients in the irbesartan 150 mg group (P=0.08) compared to 14.9% of patients receiving placebo. Secondary: Irbesartan reduced the level of urinary albumin excretion by 38% in patients receiving the 300 mg dose and 24% in patients receiving the 150 mg dose vs 2% for placebo (P<0.001 for the combined irbesartan groups vs placebo and P<0.001 for the 300 vs 150 mg doses). There was no significant difference in the decline in creatinine clearance among the 3 groups. Restoration of normoalbuminuria was observed in 34% of patients receiving irbesartan 300 mg (P=0.006), 24% of patients receiving irbesartan 150 mg and 21% with placebo.
Persson et al. ⁵⁰ (2009) Irbesartan 300 mg QD vs aliskiren 300 mg QD vs aliskiren 300 mg QD and irbesartan 300 mg QD vs placebo	DB, RCT, XO Adults with type 2 diabetes, HTN, and albuminuria	N=26 Four 2-month treatment periods	Primary: Albuminuria (urinary albumin excretion rate) Secondary: 24-hour blood pressure and GFR	Primary: Treatment with aliskiren led to a significant reduction in albuminuria by 48% compared to placebo (P<0.001). Treatment with irbesartan led to a significant reduction in albuminuria by 58% compared to placebo (P<0.001). There was no significant difference in albuminuria between aliskiren and irbesartan (P value not reported). The combination of aliskiren and irbesartan significantly reduced albuminuria by 71% compared to placebo (P<0.001), which was also significantly better than with monotherapy (P<0.001 for aliskiren and P=0.028 for irbesartan). Secondary: SBP and DBP 24-hr blood pressure were reduced by 3 and 4 mm Hg, respectively by aliskiren (P value not significant and P=0.009, respectively), 12 and 5 mm Hg, respectively by irbesartan (P<0.001 and P=0.002, respectively), and 10 and 6 mm Hg, respectively with the combination (P=0.001 and P <0.001, respectively) compared to placebo. There was no significant change in 24-hr blood pressure with irbesartan compared to combination therapy. GFR was significantly reduced 4.6 mL/min/1.73 m ² with aliskiren (P=0.037), 8.0 mL/min/1.73 m ² with irbesartan (P<0.001), and 11.7 mL/min/1.73 m ² with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				the combination (P<0.001) compared to placebo.
<p>Chrysostomou et al.⁵¹ (2006)</p> <p>Ramipril 5 mg/day plus spironolactone 25 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus irbesartan 150 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus placebo and placebo</p> <p>vs</p> <p>spironolactone 25 mg/day plus irbesartan 150 mg/day and ramipril 5 mg/day</p>	<p>DB, PC, RCT</p> <p>Patients 18 to 75 years of age, with a 24 hour urinary protein excretion >1.5 g/24 hours on ≥2 occasions ≥3 months apart, serum creatinine level ≤200 μmol/L with <20% variability in the preceding 3 months and treatment with an ACE inhibitor ≥6 months</p>	<p>N=41</p> <p>6 months</p>	<p>Primary: Change in 24 hour urinary protein excretion at three months</p> <p>Secondary: Change in 24 hour urinary protein excretion at six months, change in blood pressure and creatinine clearance, adverse effects</p>	<p>Primary: Compared to ramipril-treated patients, the 24 hour urinary protein excretion reduction at three months was significantly greater in ramipril plus spironolactone-treated patients (P=0.004).</p> <p>Ramipril-, irbesartan- and spironolactone-treated patients exhibited a significant reduction in 24 hour urinary protein excretion compared to ramipril-treated patients (P<0.001).</p> <p>There was no significant difference in 24 hour urinary protein excretion with ramipril- and ramipril plus irbesartan-treated patients (P=1.00).</p> <p>At three months, spironolactone-treated patients exhibited a significant reduction in proteinuria from baseline (P≤0.001). In contrast, non-spironolactone-treated patients did not experience a significant reduction in proteinuria from baseline (P=0.840).</p> <p>Secondary: At six months, spironolactone-treated patients exhibited the greatest reduction in proteinuria compared to the other treatments (P<0.05).</p> <p>At six months, DBP was higher among ramipril monotherapy-treated patients compared to the other treatments (P=0.046). There was no difference in SBP among the treatments (P value not reported).</p> <p>There were no differences in creatinine clearance among the treatments (P>0.05).</p> <p>Gynecomastia was not observed with any of the treatments.</p>
<p>Bianchi et al.⁵² (2010)</p> <p>Ramipril 10 mg and atorvastatin 10 mg QD</p>	<p>RCT, OL</p> <p>Patients with a clinical diagnosis of idiopathic chronic glomerulonephritis</p>	<p>N=128</p> <p>36 months</p>	<p>Primary: Changes over time in proteinuria and eGFR</p> <p>Secondary:</p>	<p>Primary: SBP decreased more in the intensive-therapy group (from 156.6 to 113.5 mm Hg) than in the conventional therapy group (from 155.7 to 122.7 mm Hg; P<0.01).</p> <p>Urine protein excretion decreased from 2.65 to 0.45 g/g creatinine with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(conventional therapy)</p> <p>vs</p> <p>spironolactone 25 mg, ramipril 10 mg, irbesartan 300 mg, and atorvastatin 10 mg QD (intensive therapy)</p> <p>The addition of diuretics, calcium antagonists, β-blockers or α1-receptor antagonists were added to achieve blood pressure <130/80 mm Hg</p>	<p>and urine protein-creatinine ratio >1 g/g</p>		<p>Adverse events, drop outs</p>	<p>intensive therapy (P<0.001). With conventional therapy, urine protein excretion decreased from 2.60 to 1.23 g/g creatinine (P<0.001).</p> <p>With intensive therapy, eGFR did not significantly change over time (64.6 vs 62.9 mL/min/1.73 m²). With conventional therapy, eGFR decreased from 62.5 to 55.8 mL/min/1.73 m² (P<0.01).</p> <p>Secondary: In the conventional therapy group, eight patients discontinued the study due to hyperkalemia, cough, and rapid deterioration in kidney function. In the intensive therapy group, 15 dropped out due to hyperkalemia, cough, and hypotension. Nine patients in the intensive therapy group developed gynecomastia. Twelve patients on conventional and 31 on intensive therapy had to interrupt the study temporarily because of low blood pressure. No patient developed an increase in creatine kinase, alanine aminotransferase, and alkaline phosphatase levels during the study.</p>
<p>Brenner et al.⁵³ (2001) RENAAL</p> <p>Losartan 50 to 100 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Patients 31 to 70 years of age with HTN, type 2 diabetes mellitus and nephropathy on conventional antihypertensive therapy</p>	<p>N=1,513</p> <p>3.4 years</p>	<p>Primary: Composite of risk of doubling of serum creatinine, ESRD, or death from any cause</p> <p>Secondary: Composite of morbidity and mortality from cardiovascular causes, proteinuria, rate of progression of renal disease</p>	<p>Primary: Compared to placebo, losartan resulted in a 16% reduction of composite primary end point (P=0.02).</p> <p>Losartan treatment produced a 25% reduction of doubling serum creatinine vs placebo (P=0.006) and 28% reduction in ESRD vs placebo (P=0.002).</p> <p>No differences in mortality were reported (P=0.88).</p> <p>Secondary: There was no significant difference between the losartan and placebo groups in the composite end point of morbidity and mortality from cardiovascular causes.</p> <p>Losartan treatment led to an average reduction in the level of proteinuria by</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				35% (P<0.001 vs placebo). Losartan reduced the rate of decline in renal function by 18% (P=0.01 vs placebo).
Hou et al. ⁵⁴ (2007) ROAD Benazepril 10 mg/day vs individual up-titration (10 to 40 mg/day with median dose of 20 mg/day) or losartan 50 mg/day vs individual up-titration (50 to 200 mg/day with median dose of 100 mg/day) Up-titration was performed to optimal antiproteinuric and tolerated dosages, and then these dosages were maintained.	OL, PRO, RCT Patients aged 18 to 70 years with proteinuria and chronic renal insufficiency who did not have diabetes	N=360 3.7 years (median follow-up)	Primary: Time to composite of doubling of serum creatinine, ESRD or death Secondary: Changes in level of proteinuria, rate of progression of renal disease	Primary: Compared to the conventional dosages, optimal antiproteinuric dosages of benazepril and losartan that were achieved through up-titration were associated with a 51 and 53% reduction in the risk for the primary end point (P=0.028 and P=0.022, respectively). There was no statistically significant difference between benazepril and losartan in the overall relative risk reduction at their respective optimal antiproteinuric dosages or at conventional dosages. Secondary: Optimal antiproteinuric dosages of benazepril and losartan at comparable blood pressure control, achieved a greater reduction in both proteinuria and the rate of decline in renal function compared to their conventional dosages. There was no significant difference in proteinuria reduction between benazepril and losartan at both conventional and optimal antiproteinuric dosages. Changes in renal function were similar between benazepril and losartan arms at both conventional and optimal antiproteinuric doses (P>0.05). There was no significant difference for the overall incidence of major adverse events between groups that were given conventional and optimal dosages in any of the treatment arms.
Fried et al. ⁵⁵ (2013) VA NEPHRON-D	DB, MA, RCT Veterans with proteinuric diabetic	N=1448 Median follow-up	Primary: First occurrence of a decline in the eGFR (an absolute	The trial was stopped early because the absolute risk of serious adverse events appeared to be greater than the potential benefit of reducing primary end-point events.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Losartan with lisinopril vs losartan alone</p>	<p>kidney disease, an estimated GFR of 30.0 to 89.9 ml/minute/1.73 m², and a urinary albumin-to-creatinine ratio of ≥300</p>	<p>2.2 years</p>	<p>Primary: decrease of ≥30 ml/minute/1.73 m² if the eGFR was ≥60 ml/minute/1.73 m² at randomization or a relative decrease of ≥50% if the eGFR was <60 ml/minute/1.73 m², ESRD, or death</p> <p>Secondary: First occurrence of a decline in the eGFR or ESRD</p> <p>Tertiary: CV events, slope of change in eGFR, and change in albuminuria at 1 year</p>	<p>Primary: There were 152 primary end-point events in the monotherapy group (21.0%) and 132 in the combination-therapy group (18.2%). The risk of the primary end point did not differ significantly between the two groups.</p> <p>Secondary: There were 101 secondary end-point events (a decline in the estimated GFR or ESRD) in the monotherapy group (14.0%) and 77 events in the combination-therapy group (10.6%). There was no significant between-group difference in mortality or ESRD (Table 2), though the number of ESRD events was small.</p> <p>Tertiary: There was no significant difference in the rate of cardiovascular events between the two groups. There was no significant difference in treatment effect on the decline in the estimated GFR (P=0.17). During adjustment of the losartan dose, the median urinary albumin-to-creatinine ratio declined from 959 to 807 (P=0.001). There was a further decline from randomization to 1 year, with a greater decline in the combination-therapy group (from 786 to 517) than in the monotherapy group (from 829 to 701) (P<0.001).</p>
<p>Nakao et al.⁵⁶ (2003) COOPERATE Trandolapril 3 mg/day vs losartan 100 mg/day vs trandolapril and</p>	<p>DB, MC, PC, RCT Patients aged 18 to 70 years with chronic nephropathy (nondiabetic renal disease)</p>	<p>N=263 3 years</p>	<p>Primary: Composite of time to doubling of serum creatinine or ESRD</p> <p>Secondary: Changes in blood pressure, daily urinary protein excretion, adverse effects</p>	<p>Primary: The combined end point was reached in 11% of patients in the combination trandolapril and losartan group compared to 23% of patients in the trandolapril (P=0.018) and 23% of patients in the losartan group (P=0.016).</p> <p>Secondary: Mean SBP and DBP reductions were similar among the three treatment groups (P=0.109).</p> <p>All patients receiving active treatment had significant decreases in urinary protein excretion, but the greatest difference was seen with the combination trandolapril and losartan group compared to trandolapril or losartan (-75.6, -44.3, and -42.1%, respectively; P=0.01).</p> <p>The frequency of adverse events did not differ between groups, although a</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
losartan at equivalent doses				slightly higher occurrence of hyperkalemia and dry cough was recorded in the trandolapril and combination groups than in the losartan group.
Mann et al. ⁵⁷ (2009) TRANSCEND Telmisartan 80 mg QD vs placebo	DB, MC, PC, RCT Adults with known cardiovascular disease or diabetes with end-organ damage but without macroalbuminuria or heart failure who cannot tolerate ACE inhibitors	N=5927 56 months	Primary: Composite outcome: first occurrence of dialysis, renal transplant, doubling of serum creatinine, or death Secondary: Changes in the eGFR, progression of proteinuria, and individual components of the primary outcome	Primary: The composite outcome of dialysis, doubling of serum creatinine, or death did not significantly differ between the telmisartan and placebo groups (412 patients [14.0%] vs 381 patients [12.8%]; HR, 1.10 [CI, 0.95 to 1.26]; P=0.193). The incidence of the composite outcome of dialysis or doubling of serum creatinine was similar with telmisartan and placebo (58 patients [1.96%] vs 46 patients [1.55%]; HR, 1.29 [95% CI, 0.87 to 1.89]; P=0.20). Secondary: Doubling of serum creatinine was more frequent with telmisartan than with placebo (56 vs 36 patients; P=0.031). Decreases in eGFR were greater with telmisartan than with placebo (mean change in eGFR, -3.2 mL /min per 1.73 m ² [SD, 18.3] vs -0.26 mL/min per 1.73 m ² [SD, 18.0]; P <0.001).
Foulquier et al. ⁵⁸ (2014) TRANSCEND Telmisartan 80 mg QD vs placebo	Post-hoc analysis Patients in the TRANSCEND trial stratified by hypertensive and nonhypertensive	N=5927 56 months	Primary: Composite outcome: first occurrence of dialysis, renal transplant, doubling of serum creatinine, or death Secondary: Changes in the eGFR, progression of proteinuria, and individual components of the primary outcome	Primary: For the primary four-fold endpoint, No difference in the effect of treatment between hypertensive and nonhypertensive patients was found. No significant improvement with telmisartan over placebo in both hypertensive and nonhypertensive patients was seen. Secondary: New onset of LVH, evaluated by ECG, was significantly less in hypertensive and nonhypertensive patients treated with telmisartan (hypertensive patients: -36%; P=0.0002; nonhypertensive patients: -58%; P=0.027). Albuminuria increased less with telmisartan than with placebo in the hypertensive population, as the risks for new microalbuminuria and macroalbuminuria were lower than with placebo (P=0.0004 and P=0.009, respectively). In the nonhypertensive population, the risks were not modified by the treatment. However, according to the interaction tests, there is no difference in the effect of telmisartan in hypertensive and nonhypertensive patients, suggesting that telmisartan might also reduce the new onset of

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				microalbuminuria and macroalbuminuria in nonhypertensive patients.
Barnett et al. ⁵⁹ (2004) DETAIL Enalapril 20 mg/day vs telmisartan 80 mg/day	DB, MC, PG, RCT Patients aged 35 to 80 years with type 2 diabetes and HTN	N=250 5 years	Primary: Change in the GFR Secondary: Annual changes in GFR, serum creatinine level, urinary albumin excretion, and blood pressure; rates of ESRD and cardiovascular events; all-cause mortality	Primary: After five years, GFR decreased by 17.9 mL/minute/1.73 m ² with telmisartan compared to 14.9 mL/min/1.73 m ² with enalapril (mean difference, -3.0 mL/min/1.73 m ² ; 95% CI, -7.6 to 1.6). Therefore, the changes in GFR were comparable between the groups. Secondary: The effects of the two agents on the secondary end points were not significantly different after five years.
Galle et al. ⁶⁰ (2008) Telmisartan 80 mg QD vs valsartan 160 mg QD Additional antihypertensive therapy was allowed.	DB, MC, PG, PRO, RCT, non-inferiority study Hypertensive patients (SBP/DBP >130/80 mm Hg) with type 2 diabetes, proteinuria and serum creatinine ≤3.0 mg/dL	N=885 12 months	Primary: Change from baseline in the 24-hour proteinuria Secondary: Changes in 24-hour albuminuria, eGFR and inflammatory parameters	Primary: Telmisartan and valsartan produced comparable reductions in 24-hour urinary protein excretion rates: geometric mean reduction was 33% for both telmisartan and valsartan. Secondary: No significant differences between treatments were seen in changes from baseline in 24-hour urinary albumin excretion rate and GFR at 12 months. With both treatments, greater renoprotection was seen among patients with better blood pressure control. No significant changes in C-reactive protein were noted for either group at 12 months.
Fogari et al. ⁶¹ (2007) Telmisartan and amlodipine 40 to 160-2.5 QD (fixed-dose combination)	DB, MC, RCT Patients 35 to 70 years of age with essential HTN, type 2 diabetes mellitus and	N=210 64 weeks	Primary: Blood pressure, UAER, creatinine clearance, plasma potassium, fasting glycemia, and HbA _{1c}	Primary: High-dose telmisartan/low-dose amlodipine and low-dose telmisartan/high-dose amlodipine combination produced a similar reduction in SBP and DBP with no significant difference between the two regimens at any time of the study. With increasing doses of telmisartan (40, 80, 120, and 160 mg), SBP and DBP

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>telmisartan and amlodipine 40-2.5 mg QD (fixed-dose combination)</p>	<p>microalbuminuria (UAER >30 and <300 mg/24 hr)</p>		<p>Secondary: Not reported</p>	<p>values were reduced from baseline by 16 and 10 mm Hg, respectively (P<0.01), 24 and 21 mm Hg, respectively (P<0.001), 23 and 21 mm Hg, respectively (P<0.001), and 24 and 21 mm Hg, respectively (P<0.001).</p> <p>With increasing dose of amlodipine (2.5, 5, 7.5, and 10 mg) SBP and DBP values were reduced from baseline by 16 and 10 mm Hg, respectively (P<0.01), 25 and 22 mm Hg, respectively (P<0.001), 25 and 21 mm Hg, respectively (P<0.001), and 25 and 22 mm Hg, respectively (P<0.001).</p> <p>Reductions of UAER from baseline were of 34.6 mg/24 hr (P<0.05 vs baseline), 62.9 mg/24 hr (P<0.01 vs baseline and P<0.05 vs A group), 86.5 mg/24 hr (P<0.001 vs baseline and P<0.01 vs A group) and 102 mg/24 hr (P<0.0001 vs baseline and P<0.001 vs A group) for telmisartan 40, 80, 120, and 160 mg/amlodipine 2.5 mg daily, respectively.</p> <p>Reductions of UAER from baseline were of 35.1 mg/24 hr (P<0.05 vs baseline), 46.2 mg/24 hr (P<0.03 vs baseline), 50.3 mg/24 hr (P<0.03 vs baseline), and 45 mg/24 hr (P<0.03 vs baseline) for amlodipine-telmisartan 2.5-40, 5-40, 7.5-40, and 10-40 mg/day, respectively.</p> <p>Creatinine clearance did not significantly change with either treatment. Neither combination affected levels of plasma potassium or fasting glucose. The HbA_{1c} levels were not significantly influenced by either treatment.</p>
<p>Viberti et al.⁶² (2002) MARVAL</p> <p>Valsartan 80 mg QD</p> <p>vs</p> <p>amlodipine 5 mg QD</p> <p>A target blood pressure of 135/85</p>	<p>AC, DB, RCT</p> <p>Patients 35-75 years old with type 2 diabetes mellitus and microalbuminuria, with or without HTN</p>	<p>N=332</p> <p>24 weeks</p>	<p>Primary: Change in UAER; proportion of patients who returned to normal albuminuria</p> <p>Secondary: Proportion of patients returning to normoalbuminuria</p>	<p>Primary: Valsartan resulted in a UAER reduction of 44% at 24 weeks compared to baseline vs an 8% reduction with amlodipine (P<0.001). Valsartan lowered UAER similarly in both the hypertensive and normotensive groups.</p> <p>Over the study period, blood pressure reductions were similar between the two treatments and at no time point was there a between-group significant difference in blood pressure values in either the hypertensive or the normotensive subgroup.</p> <p>Secondary: The proportion of patients returning to normal albuminuria was greater with valsartan (29.9%) vs amlodipine (14.5%; P=0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mm Hg was aimed for by dose-doubling followed by the addition of bendrofluazide* and doxazosin whenever needed.				
<p>Casas et al.⁶³ (2005)</p> <p>ACE inhibitor or ARBs compared to placebo</p> <p>vs</p> <p>ACE inhibitor or ARBs compared to other antihypertensive drugs (β-adrenergic blocking agents, α-adrenergic blocking agents, calcium-channel blocking agents, or combinations)</p> <p>Specific agents and doses were not specified.</p>	<p>MA (127 trials)</p> <p>Studies in adults that examined the effect of any drug treatment with a blood pressure lowering action on progression of renal disease</p>	<p>N=not reported</p> <p>4.2 years (mean)</p>	<p>Primary: Doubling of serum creatinine, and ESRD</p> <p>Secondary: Serum creatinine, urine albumin excretion and GFR</p>	<p>Primary: Treatment with ACE inhibitors or ARBs resulted in a nonsignificant reduction in the risk of doubling of creatinine vs other antihypertensives (P=0.07) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>A small reduction in ESRD was observed in patients receiving ACE inhibitors or ARBs compared to other antihypertensives (P=0.04) with no differences in the degree of change of SBP or DBP between the groups.</p> <p>Secondary: Small reductions in serum creatinine and in SBP were noted when ACE inhibitors or ARBs were compared to other antihypertensives (P=0.01).</p> <p>Small reduction in daily urinary albumin excretion in favor of ACE inhibitor or ARBs were reported when these agents were compared to other antihypertensives (P=0.001).</p> <p>Compared to other drugs, ACE inhibitors or ARBs had no effect on the GFR.</p>
<p>Strippoli et al.⁶⁴ (2004)</p> <p>ACE inhibitors</p>	<p>MA</p> <p>Patients with diabetic nephropathy</p>	<p>43 trials</p> <p>≥ 6 months (range 6 to 63.6)</p>	<p>Primary: All-cause mortality, renal outcomes (ESRD, doubling of serum creatinine,</p>	<p>Primary: ACE inhibitors significantly reduced all-cause mortality compared to placebo or no treatment (RR, 0.79; 95% CI, 0.63 to 0.99; P=0.04). There was a nonsignificant trend for reduction in ESRD (P=0.07) and doubling of serum creatinine (P=0.08) with ACE inhibitors compared to placebo or no treatment.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo or ARBs vs placebo or ACE inhibitors vs ARBs		months)	microalbuminuria to macroalbuminuria) Secondary: Not reported	ACE inhibitors significantly reduced the risk of progression from microalbuminuria to macroalbuminuria (P=0.0007) and increased regression back to normoalbuminuria (P<0.0001) compared to placebo or no treatment. ARBs did not significantly reduce all-cause mortality compared to placebo or no treatment (RR, 0.99; 95% CI, 0.85 to 1.17; P=0.95). ARBs significantly reduced the risk of ESRD (P=0.001) and doubling of serum creatinine (P=0.004). ARBs significantly decreased the risk of progression to macroalbuminuria (P=0.001) and increased regression to normoalbuminuria (P=0.02) compared to placebo or no treatment. The three trials that compared ACE inhibitors to ARBs did not report on all-cause mortality, ESRD or doubling of serum creatinine. Progression from microalbuminuria to macroalbuminuria was reported in one trial (N=92) and there was no significant difference in risk, with the point estimate favoring ACE inhibitors (RR, 0.16; 95% CI, 0.02 to 1.44). Regression from microalbuminuria to normoalbuminuria in 1 trial showed a nonsignificant difference in the risk. Secondary: Not reported
Strippoli et al. ⁶⁵ (2006) ACE inhibitors vs placebo or ARBs vs placebo	MA Patients with diabetic kidney disease	N=12,067 (49 trials) ≥6 months	Primary: All-cause mortality, ESRD, doubling of serum creatinine concentration, progression from micro- to macroalbuminuria, regression from micro- to normoalbuminuria, drug-related toxicity (including cough, headache, hyperkalemia, impotence and pedal	Primary: There was no significant difference in the risk of all-cause mortality for ACE inhibitors vs placebo or no treatment (RR, 0.91; 95% CI, 0.71 to 1.17) and ARBs vs placebo or no treatment (RR, 0.99; 95% CI, 0.85 to 1.17). No statistically significant reduction in the risk of all-cause mortality was found in the three studies that compared ACE inhibitors with ARBs (RR, 0.92; 95% CI, 0.31 to 2.78). A subgroup analysis of studies showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACE inhibitors (RR, 0.78; 95% CI, 0.61 to 0.98) but not when using half or less than half the maximum tolerable dose of ACE inhibitors (RR, 1.18; 95% CI, 0.41 to 3.44). There was a significant reduction in the risk of ESRD with ACE inhibitors and ARBs compared to placebo or no treatment (RR, 0.60; 95% CI, 0.39 to 0.93 and RR, 0.78; 95% CI, 0.67 to 0.91, respectively). There was a significant

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>or</p> <p>ACE inhibitors</p> <p>vs</p> <p>ARBs</p>			<p>edema)</p> <p>Secondary: Not reported</p>	<p>reduction in the risk of doubling of serum creatinine concentration with ACE inhibitors and ARBS (RR, 0.68; 95% CI, 0.47 to 1.0 and RR, 0.79; 95% CI, 0.67 to 0.93, respectively).</p> <p>ACE inhibitors and ARBS significantly reduced the risk of progression from micro- to macroalbuminuria (RR, 0.45; 95% CI, 0.29 to 0.69 and RR, 0.49; 95% CI, 0.32 to 0.75, respectively). ACE inhibitors and ARBS significantly increased the regression from micro- to normoalbuminuria compared to placebo or no treatment (RR, 3.06; 95% CI, 1.76 to 5.35 and RR, 1.42; 95% CI, 1.15 to 1.93, respectively).</p> <p>The seven studies that compared ACE inhibitors to ARBS did not report the outcome of ESRD or doubling of serum creatinine. Progression from micro- to macroalbuminuria and from micro- to normoalbuminuria were evaluated each in one trial and showed a nonsignificant difference in the risk between ACE inhibitors and ARBS.</p> <p>ACE inhibitors were associated with a significant increase in the risk of cough but not hyperkalemia, headache or impotence when compared to placebo or no treatment. ARBS were associated with a significant increase in the risk of hyperkalemia but not cough or headache compared to placebo or no treatment.</p> <p>Secondary: Not reported</p>
Heart Failure				
<p>Cohn et al.⁶⁶ (2001) Val-HeFT</p> <p>Valsartan 160 mg BID</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Patients ≥18 years old with a cardiovascular history and NYHA II to IV heart failure</p>	<p>N=5,010</p> <p>2 years</p>	<p>Primary: Mortality and composite end point of morbidity and mortality</p> <p>Secondary: Change in NYHA class, ejection fraction, signs and symptoms of heart failure, QOL</p>	<p>Primary: Compared to placebo, valsartan resulted in no significant differences in all-cause mortality.</p> <p>Patients treated with valsartan experienced a 13% decrease in the composite end point (P=0.009) and 27% decrease in heart failure hospitalizations (P<0.001).</p> <p>Secondary: Treatment with valsartan resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure and QOL as compared to placebo (P<0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				In a post hoc analysis of the combined end point and mortality in subgroups defined according to baseline treatments with ACE inhibitors or β -blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.
Pfeffer et al. ⁶⁷ (2003) CHARM Overall Programme Candesartan 32 mg/day (\pm ACE inhibitor) vs placebo (\pm ACE inhibitor)	DB, PC, PG, RCT Summary of all CHARM sub-studies	N=7,599 37.7 months	Primary: All-cause mortality (Overall Programme) and cardiovascular death or hospital admission for CHF (all of the component trials) Secondary: Not reported	Primary: In the overall analysis, candesartan 32 mg daily resulted in an 18% decreased risk of all-cause mortality compared to placebo (23 vs 25%; unadjusted HR, 0.91; 95% CI, 0.83 to 1.0; P=0.055; covariate adjusted HR, 0.90; 95% CI, 0.82 to 0.99; P=0.032). Annual mortality rates were 8.1 and 8.8% for patients treated with candesartan and placebo, respectively. The lower mortality in patients treated with candesartan vs placebo was attributed to fewer cardiovascular deaths (18 vs 20%; unadjusted HR, 0.88; 95% CI, 0.79 to 0.97; P=0.012). Hospital admissions for CHF were significantly fewer in patients treated with candesartan than placebo (20 vs 24%; P<0.0001). Secondary: Not reported
McMurray et al. ⁶⁸ (2003) CHARM-Added Candesartan 32 mg/day in patients already taking ACE inhibitors vs placebo in patients already taking ACE inhibitors	DB, MC, PC, RCT Patients \geq 18 years old with LVEF \leq 40%, NYHA II to IV heart failure and treatment with an ACE inhibitor at a constant dose for 30 days or longer	N=2,548 41 months	Primary: Composite of cardiovascular death and hospitalization for heart failure Secondary: Composites of primary end point and MI, nonfatal stroke and coronary revascularization	Primary: Compared to placebo, candesartan 32 mg/day when added to ACE inhibitors resulted in a 15% reduction in the primary end point (P=0.011), 16% decrease in cardiovascular deaths (P=0.029) and 17% reduction in heart failure hospitalizations (P=0.014). Secondary: Fewer patients experienced cardiovascular death, hospital admission for CHF, MI, stroke, or coronary revascularization in the candesartan group (42.9%) compared to placebo (46.9%; P=0.015).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Granger et al. ⁶⁹ (2003) CHARM-Alternative Candesartan 32 mg/day vs placebo	DB, PC, RCT Patients ≥18 years old with LVEF ≤40%, NYHA II to IV heart failure and intolerance to ACE inhibitors	N=2,028 33.7 months	Primary: Composite of cardiovascular death and hospitalization for heart failure Secondary: Composites of primary end point and MI, nonfatal stroke and coronary revascularization	Primary: Compared to placebo, candesartan 32 mg/day resulted in a 30% reduction of the composite end point (P<0.0001). A 20% decrease in cardiovascular death (P=0.02) and 39% reduction in heart failure hospitalizations (P<0.0001) were noted in patients treated with candesartan compared to placebo. Study drug discontinuation rates were similar in the candesartan (30%) and placebo (29%) groups. Secondary: Fewer patients experienced cardiovascular death, hospital admission for CHF, MI, stroke, or coronary revascularization in the candesartan group (39.1%) compared to placebo (44.9%; P<0.0001).
Yusuf et al. ⁷⁰ (2003) CHARM-Preserved Candesartan 32 mg/day vs placebo	DB, PC, RCT Patients ≥18 years old with preserved ejection fraction (>40%) and symptomatic heart failure	N=3,025 36.6 months	Primary: Composite of cardiovascular death and hospitalization for heart failure Secondary: Composites of primary end point and MI, nonfatal stroke and coronary revascularization	Primary: Compared to placebo, candesartan 32 mg/day resulted in an insignificant 14% trend towards lower incidence of the primary end point (P=0.051). Candesartan significantly reduced the risk of heart failure hospitalization (16%; P=0.047) but did not significantly decrease the risk of cardiovascular death (P=0.635). Secondary: The composite of cardiovascular death, hospitalization for CHF, MI, and stroke was significantly lower in the candesartan group compared to placebo (25.6 vs 28.4%; P=0.037). There was no significant difference in the composite of cardiovascular death, hospital admission for CHF, MI, stroke, or coronary revascularization in the candesartan group (30.4%) compared to placebo (32.9%; P=0.130).
Castagno et al. ⁷¹ (2012) CHARM Candesartan 32 mg/day (±ACE	Subgroup analysis according to baseline heart rate and LVEF Patients with	N=7,597 Duration varied	Primary: Composite of cardiovascular death or heart failure hospital stay	Primary: Patients with the highest heart rate tertile had worse outcomes when compared to patients in the lowest heart rate group (HR, 1.23; 95% CI, 1.11 to 1.36; P<0.001). The relationship between heart rate and outcomes was similar across LVEF categories, and was not influenced by use of β-blockers (P>0.10 for both endpoints).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
inhibitor) vs placebo (±ACE inhibitor)	chronic heart failure		Secondary: Not reported	Secondary: Not reported
Pitt et al. ⁷² (1997) ELITE Captopril 50 mg TID vs losartan 50 mg QD	DB, MC, PG, RCT Patients ≥65 years with symptomatic heart failure (NYHA class II to IV and LVEF ≤40%), and no history of prior ACE inhibitor therapy	N=722 1 year	Primary: Change in renal function Secondary: Composite of death and/or hospital admission for heart failure, all-cause mortality, admission for heart failure, NYHA class, admission for MI or unstable angina	Primary: No difference between losartan and captopril was reported in the rate of persistent rise in serum creatinine concentrations (10.5% for both groups). Secondary: Death and/or hospital admission for heart failure was recorded in 9.4% of patients receiving losartan and 13.2% for patients receiving captopril (risk reduction, 32%; 95% CI, -4 to 55; P=0.075). This risk reduction was primarily due to a decrease in all-cause mortality (4.8 vs 8.7%; risk reduction, 46%; 95% CI, 5 to 69; P=0.035). Admissions with heart failure were the same in both groups (5.7%), as was improvement in NYHA functional class from baseline. Admission to hospital for any reason was less frequent with losartan than with captopril treatment (22.2 vs 29.7%; P=0.014). More patients discontinued therapy due to adverse events with captopril (20.8%) than losartan (12.2%; P=0.002).
Pitt et al. ⁷³ (2000) ELITE II Captopril 50 mg TID vs losartan 50 mg QD	DB, MC, PG, RCT Patients ≥60 years old with symptomatic heart failure (NYHA II to IV and LVEF ≤40%), and no history of prior ACE inhibitor therapy	N=3,152 555 days (mean follow-up)	Primary: All-cause mortality Secondary: Composite of sudden cardiac death or resuscitated cardiac arrest	Primary: No significant difference in all-cause mortality was reported between losartan (17.7%) and captopril (15.9%; HR, 1.13; 95% CI, 0.95 to 1.35; P=0.16). Secondary: Sudden death or resuscitated cardiac arrest was observed in 9.0% of patients receiving losartan and 7.3% of patients receiving captopril (HR, 1.25; 95% CI, 0.98 to 1.60; P=0.08). Significantly fewer patients in the losartan group (excluding those who died) discontinued study treatment because of adverse events (9.7 vs 14.7%; P<0.001), including cough (0.3 vs 2.7%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Note: ELITE II trial was a larger follow-up trial to the ELITE I trial to confirm the secondary end point from the ELITE I trial, which reported a greater reduction in all-cause mortality with losartan compared to captopril.
McKelvie et al. ⁷⁴ (1999) RESOLVD Enalapril 10 mg BID vs candesartan 4 to 16 mg QD vs candesartan 4 to 8 mg QD and enalapril 10 mg BID	DB, MC, PG, RCT Patients with CHF (NYHA classes II to IV), a 6 minute walk distance of 500 meters or less, and an ejection fraction <40%	N=768 43 weeks	Primary: Change in 6-minute walk distance Secondary: Change in NYHA functional class, QOL, ejection fraction, ventricular volumes, neurohormone levels, safety	Primary: There were no significant differences among the groups with regards to the 6-minute walk distance over the 43 week study period. Secondary: There were no significant differences among the groups with regards to the NYHA functional class or QOL at 18 or 43 weeks. Ejection fraction increased more with candesartan plus enalapril than monotherapy with either agent; however, the difference was not statistically significant (P value not significant). End-diastolic volumes (P<0.01) and end-systolic volumes (P<0.05) increased less with combination therapy than with monotherapy with either agent. Aldosterone decreased with combination therapy at 17 but not 43 weeks compared to candesartan or enalapril (P<0.05). Brain natriuretic peptide decreased with combination therapy compared to candesartan and enalapril alone (P<0.01). Blood pressure decreased with combination therapy compared to candesartan or enalapril alone (P<0.05). Compared to enalapril, potassium decreased with candesartan use (P<0.05) and increased with candesartan plus enalapril (P<0.05). The proportion of patients with potassium levels ≥5.5 mmol/L was not significantly different among the treatment groups. There were no significant differences in creatinine, mortality, or hospitalizations for CHF or any cause among the three groups.
Lee et al. ⁷⁵ (2004) ARBs vs	MA Patients with chronic heart failure and high-risk acute MI	N=38,080 Duration varied	Primary: All-cause mortality and heart failure hospitalizations Secondary:	Primary: ARBs were associated with reduced all-cause mortality (OR, 0.83) and heart failure hospitalizations (OR, 0.64) vs placebo. There was no difference in all-cause mortality (OR, 1.06) and heart failure hospitalization (OR, 0.95) between ARBs and ACE inhibitors.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo (\pmACE inhibitor)</p> <p>vs</p> <p>ACE inhibitor monotherapy</p>			Not reported	<p>When ARBs were combined with ACE inhibitors, all-cause mortality was not reduced (OR, 0.97) but heart failure hospitalizations were reduced (OR, 0.77) compared to treatment with ACE inhibitors alone.</p> <p>Two RCT comparing ARBs with ACE inhibitors in patients with high-risk acute MI did not reveal differences in all-cause mortality or heart failure hospitalization.</p> <p>Secondary: Not reported</p>
Hypertension				
<p>Rakugi et al.⁷⁶ (2012)</p> <p>Azilsartan 20 to 40 mg QD</p> <p>vs</p> <p>candesartan 8 to 12 mg QD</p>	<p>DB, MC, RCT</p> <p>Japanese patients with grade I or II essential HTN</p>	<p>N=622</p> <p>16 weeks</p>	<p>Primary: Change in baseline mean sitting DBP at week 16</p> <p>Secondary: Change in baseline mean sitting SBP at week 16</p>	<p>Primary: After 16 weeks, the mean baseline change in sitting DBP was -12.4 and -9.8 mm Hg with azilsartan and candesartan (difference, -2.6; 95% CI, -4.08 to -1.22; P=0.0003).</p> <p>Secondary: After 16 weeks, the mean baseline change in sitting SBP was -21.8 and -17.5 mm Hg with azilsartan and candesartan (difference, -4.4 mm Hg; 95% CI, -6.53 to -2.20; P<0.0001).</p>
<p>Sica et al.⁷⁷ (2001)</p> <p>Azilsartan 40 or 80 mg QD</p> <p>vs</p> <p>valsartan 320 mg QD</p>	<p>DB, MC, RCT</p> <p>Patients with primary HTN</p>	<p>N=984</p> <p>24 weeks</p>	<p>Primary: Change in baseline 24 hour mean ambulatory and clinic SBP</p> <p>Secondary: Change in baseline 24 hour mean ambulatory and clinic DBP</p>	<p>Primary: Azilsartan 40 and 80 mg/day significantly lowered 24 hour mean ambulatory systolic blood pressure (-14.9 and -15.3 mm Hg) compared to valsartan 320 mg/day (-11.3 mm Hg; P<0.001). Clinic SBP reductions were consistent with ambulatory blood pressure results. (-14.9 and -16.9 vs -11.6 mm Hg; P=0.015 and P<0.001).</p> <p>Secondary: Reductions in 24 hour mean and clinic DBP were significantly greater with azilsartan compared to valsartan (P\leq0.001 for all comparisons).</p>
<p>Cushman et al.⁷⁸ (2012)</p>	<p>DB, RCT</p> <p>Patients with clinic</p>	<p>N=1,071</p> <p>12 weeks</p>	<p>Primary: Change in baseline clinical SBP</p>	<p>Primary: Changes in clinic SBP were significantly greater with azilsartan and chlorthalidone (-42.5\pm0.8 and -44.0\pm0.8 mm Hg) compared to olmesartan and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Azilsartan and chlorthalidone 40-25 or 80-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>olmesartan and HCTZ 40-25 mg QD (fixed-dose combination product)</p>	<p>SBP 160 to 190 mm Hg and DBP \leq119 mm Hg</p>		<p>Secondary: Change in baseline ambulatory SBP, safety</p>	<p>HCTZ (-37.1\pm0.8 mm Hg; P<0.0001).</p> <p>Secondary: Changes in ambulatory SBP were significantly greater with azilsartan and chlorthalidone (-33.9\pm0.8 and -36.3\pm0.8 mm Hg) compared to olmesartan and HCTZ (-27.5\pm0.8 mm Hg; P<0.0001).</p> <p>Adverse events leading to discontinuation of study medications were 7.9, 14.5, and 7.1% of patients receiving azilsartan and chlorthalidone 40-25 mg/day, azilsartan and chlorthalidone 80-25 mg/day, and olmesartan and HCTZ.</p>
<p>Bönnner et al.⁷⁹ (2013)</p> <p>Azilsartan (AZL) 20mg titrated to 40 mg</p> <p>vs</p> <p>azilsartan (AZL) 20mg titrated to 80 mg</p> <p>vs</p> <p>ramipril (RAM) 2.5 mg titrated to 10 mg</p>	<p>DB, RCT</p> <p>Patients \geq18 years of age with clinic systolic blood pressure (SBP) 150 to 180 mm Hg</p>	<p>N=884</p> <p>24 weeks</p>	<p>Primary: Change in trough, seated clinic SBP</p> <p>Secondary: Change from baseline to week 24 in trough, seated clinic DBP, measures of ambulatory BP, and BP response rates</p>	<p>Primary: After 24 weeks of treatment, trough, sitting, clinic SBP decreased significantly in all the groups. The changes from baseline were significantly greater for the AZL 40 and 80 mg treatment groups (-20.6\pm0.95 and -21.2\pm0.95 mm Hg, respectively) than for RAM 10 mg (-12.2\pm0.95 mm Hg). The differences between the AZL-treated subjects and the RAM-treated subjects were -8.4 mm Hg for AZL 40 and -9.0 mm Hg for AZL 80 (P<0.001 for both comparisons).</p> <p>Secondary: Change in trough, sitting, DBP was -10.2\pm0.55 mm Hg in the AZL 40 mg group, -10.5\pm0.55 mm Hg in the AZL 80 mg and -4.9\pm0.56 mm Hg in the RAM 10 mg group.</p> <p>AZL 40 and 80 mg reduced ambulatory SBP and DBP significantly more than RAM for all ABPM time intervals evaluated, including 24-hour mean, mean daytime, mean nighttime and mean trough pressure.</p> <p>The differences between the AZL and RAM groups proportion of subjects achieving SBP and DBP response criteria were highly significant (P<0.001). More subjects achieved a reduction in clinic BP to <140/90 mm Hg and/or a reduction in BP\geq20/10 mm Hg at week 24 following treatment with AZL compared with RAM (54.0% and 53.6% for AZL 40 and 80 mg vs 33.8% with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				RAM 10 mg, respectively; P<0.001).
Lithell et al. ⁸⁰ (2003) SCOPE Candesartan 16 mg/day vs placebo Patients also received conventional therapy with diuretics, ACE inhibitors, β -blockers, and calcium-channel blocking agents	DB, MC, PC, PG, RCT Patients 70 to 89 years of age with mild-to-moderate HTN (SBP 160 to 179 mm Hg and/or DBP 90 to 99 mm Hg) and MMSE scores \geq 24	N=4,964 3.7 years	Primary: First major coronary event including cardiovascular death, nonfatal MI, or nonfatal stroke Secondary: cardiovascular death, nonfatal and fatal stroke and MI, cognitive function	Primary: Results showed no significant difference in the primary end point between candesartan and placebo (P=0.19). Secondary: Candesartan treatment reduced nonfatal stroke by 27.8% (P=0.04) and all stroke by 23.6% (P=0.056) compared to placebo. There were no significant differences in MI and cardiovascular mortality. Mean MMSE score fell from 28.5 to 28.0 in the candesartan group and from 28.5 to 27.9 in the control group (P=0.20). The proportion of patients who had a significant cognitive decline or developed dementia was not different in the 2 groups.
Baguet et al. ⁸¹ (2006) Candesartan 8 mg QD vs losartan 50 mg QD vs placebo	DB, RCT Patients with mild-to-moderate essential HTN (DBP 95 to 115 mm Hg)	N=256 6 weeks	Primary: Change in mean ambulatory DBP from baseline to the 0-24 hour period after the last dose of study medication Secondary: Change in mean ambulatory SBP from baseline to the 0-24 hour period after the last dose of study medication, change in DBP and	Primary: At the end of the six weeks, the mean change in DBP between the baseline and the 0-24 hour period after the last dose of study medication was greater in patients receiving candesartan 8 mg compared to losartan (-7.3 vs -5.1 mm Hg; P<0.05) or placebo (0.3 mm Hg; P<0.001). Secondary: The mean change in SBP between the baseline and the 0-24 hour period after the last dose of study medication was greater in patients receiving candesartan (-10.8 mm Hg) or losartan (-8.8 mm Hg) than placebo (1.2 mm Hg; P<0.001). Candesartan was associated with a greater reduction in DBP and SBP relative to placebo, when compared to losartan during both the daytime and nighttime, and between 12 and 24 hours after dosing (P<0.001). Both active treatments were well tolerated.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			SBP during the daytime and nighttime, change in DBP and SBP between 12 and 24 hours after dosing	
Ohma et al. ⁸² (2000) Candesartan 16 mg vs losartan 50 mg All patients received HCTZ 12.5 mg QD.	DB, MC, RCT Patients aged 20 to 80 years with mild-to-moderate uncontrolled HTN while on monotherapy (any kind of medication)	N=340 12 weeks	Primary: Change in sitting DBP Secondary: SBP, proportion of responders, safety and tolerability	Primary: Greater reductions in DBP were reported with candesartan and HCTZ vs losartan and HCTZ (-10.4 vs -7.8 mm Hg; P=0.016). Secondary: Greater decreases in SBP were reported with candesartan and HCTZ (-19.4 mm Hg) vs losartan and HCTZ (-13.7 mm Hg; P=0.004). The proportion of patients achieving a DBP ≤90 mm Hg was greater with candesartan and HCTZ (60.9 vs 49.3%; P=0.044). There were eight withdrawals due to adverse effects in the candesartan and HCTZ group and 12 in the losartan and HCTZ group. The most common adverse effects were headache, tachycardia/palpitations, dizziness, and fatigue.
Mengden et al. ⁸³ (2011) CHILI CU Soon Candesartan and HCTZ 32-12.5 or 32-25 mg QD (fixed-dose combination)	MC, OL, PRO High risk patients ≥18 years of age with uncontrolled HTN, on prior antihypertensive agents, and presence of additional cardiovascular risk factors	N=4,131 10 weeks	Primary: Change in baseline office blood pressure and ambulatory blood pressure, safety Secondary: Not reported	Primary: Baseline office blood pressure was 162.1±14.8/94.7±9.2 mm Hg, and after ten weeks, a reduction to 131.7±10.5/80.0±6.6 mm Hg was achieved (P<0.0001). Reductions in blood pressure were comparable irrespective of prior or concurrent medications. Baseline ambulatory blood pressure was 158.2/93.7 mm Hg during the day and 141.8/85.2 mm Hg during the night. After ten weeks, ambulatory blood pressure reduced to 133.6/80.0 and 121.0/72.3 mm Hg, respectively. During the trial, 49 adverse events were reported in 1.19% of patients receiving combination therapy. Of these events, seven were regarded as serious, and most of the events were related to the nervous system or cardiac disorders. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
McInnes et al. ⁸⁴ (2000) Candesartan and HCTZ 8-12.5 mg/day (fixed-dose combination product) vs lisinopril and HCTZ 10-12.5 mg/day (fixed-dose combination product)	DB, DD, MC, PG, RCT Patients 20 to 80 years of age with mild-to-moderate HTN on prior antihypertensive monotherapy	N=355 26 weeks	Primary: Mean changes in DBP Secondary: Mean changes in SBP and heart rate, proportion of responders and controlled patients, safety	Primary: Changes in mean sitting DBP did not differ significantly between the groups (mean difference, 0.5 mm Hg; P=0.20). Secondary: No significant differences between the groups were reported for mean sitting SBP, heart rate, proportion of responders and controlled patients. Both regimens were well tolerated but a greater percentage of those in the lisinopril based group (80 vs 69%) had a least one side effect (P=0.020). The proportion of patients spontaneously reporting cough (23.1 vs 4.6%) and discontinuing therapy due to adverse events (12.0 vs 5.9%) was also higher in the lisinopril based group compared to the candesartan based group.
Fogari et al. ⁸⁵ (2007) CANDIA Candesartan 16 mg and HCTZ 12.5 mg QD vs amlodipine 10 mg QD	DB, MC, RCT Patients, 20 to 80 years old, with mild to moderate uncomplicated HTN not controlled on monotherapy with an antihypertensive (SBP <180 mg Hg and DBP 90 to 110 mg Hg)	N=203 8 weeks	Primary: Decrease in DBP Secondary: Sitting SBP, reduction of the orthostatic blood pressure at least two minutes after standing, change in heart rate, percentage of patients normalized (DBP <90 mm Hg and SBP <140 mm Hg), percentage of responders (reduction in DBP ≥5 mm Hg)	Primary: There was no significant difference in the mean decrease in DBP between treatment groups; the difference in final DBP was -0.02 mm Hg (95% CI, -1.48 to 1.52 mm Hg; P=0.979). Secondary: There was no significant difference between the groups at week eight for the following: sitting SBP (P=0.835), heart rate (P<0.500), orthostatic SBP (P=0.883), orthostatic DBP (P=0.264), percentage of patients normalized (P=10), percentage of responders (P=0.900). The number of patients reporting an adverse event was greater in the amlodipine group (P=0.001). The number of patients reporting an adverse drug-related event was greater in the amlodipine group (P<0.001). Changes in blood chemistry and other secondary measurements were not significantly different between the treatment groups.
Robles et al. ⁸⁶ (2008)	MC, OL, PRO	N=549	Primary: Changes in blood	Primary: Blood pressure decreased significantly (P<0.0001) in both diabetic and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ESTEPP Eprosartan 600 mg QD	Patients with mild-to-moderate HTN with and without diabetes, mean age 65 years for patients with diabetes and 63 years for patients without diabetes	16 weeks	pressure, compliance, adverse effects Secondary: Not reported	nondiabetic patients (SBP 25.9 vs 26.0 mm Hg), DBP (12.5 vs 13.2 mm Hg), MAP (16.9 vs 17.5 mm Hg) and pulse pressure (13.4 vs 12.8 mm Hg). Pulse pressure/MAP ratio showed a significant reduction in diabetics and nondiabetics. Treatment compliance did not differ between the groups (diabetics 98.0% vs nondiabetics 92.2%). The adverse effect rate was 7% in diabetic patients and 2.8% in nondiabetics. Secondary: Not reported
Ruilope et al. ⁸⁷ (2001) Eprosartan 600 mg QD (titration to 800 mg QD was allowed after 3 weeks) vs enalapril 5 mg QD (titration to 10 mg followed by 20 mg was allowed every 3 weeks)	DB, MC, PG, RCT Patients greater than 65 years of age with essential HTN, either newly diagnosed or for whom a change in existing antihypertensive medication is indicated due to poor control	N=334 12 weeks	Primary: Mean change from baseline in sitting SBP Secondary: Normalization rate for sitting SBP and DBP, response rate for sitting SBP and DBP, mean change from baseline in DBP	Primary: No significant difference between groups in change from baseline in sitting SBP was observed (P=0.76). Secondary: No significant difference between groups in change from baseline in sitting DBP was observed (P=0.84). BP response rates for SBP and DBP were significantly greater for eprosartan at week 3 (P<0.033) but the significant difference had disappeared by endpoint (P>0.49). Normalization rates for SBP were low in both groups (P value not reported). Normalization rates for DBP were higher in both groups than SBP normalization rates (P value not reported).
Sachse et al. ⁸⁸ (2002) Eprosartan 600 mg QD vs eprosartan 600 mg	DB, MC, PG, PRO, RCT Patients 18 years of age and older with mild- to moderate HTN	N=309 8 weeks	Primary: Trough sitting DBP Secondary: Trough sitting SBP and HR, proportion of patients whose sitting DBP had normalized,	Primary: Significantly greater reductions in sitting DBP were observed at study endpoint in the eprosartan and HCTZ group compared to the eprosartan monotherapy group (P=0.001). Secondary: Significantly greater reductions in sitting SBP were observed at study endpoint in the eprosartan and HCTZ group compared to the eprosartan monotherapy group (P=0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
and HCTZ 12.5 mg QD			proportion of responders (defined as normal sitting DBP or sitting DBP ≤ 100 mm Hg and decreased from baseline by at least 10 mm Hg)	No significant difference was observed between groups in the proportion of patients whose sitting DBP had normalized ($P=0.10$). The response rate was significantly higher in the eprosartan and HCTZ group compared to the eprosartan monotherapy group ($P=0.004$).
Ambrosioni et al. ⁸⁹ 2010 INSIST Eprosartan and HCTZ 600-12.5 mg QD (fixed-dose combination product) vs losartan and HCTZ 50-12.5 mg QD (fixed-dose combination product)	DB, DD, MC, PG, PC, RCT Patients 60 years of age and older meeting the WHO criteria for grade 2 systolic HTN	N=155 6 weeks	Primary: Mean change from end of wash-out period to the end of combination therapy in ABPM SBP Secondary: Pulse pressure, SBP at daytime, SBP at nighttime, SBP in the last 4 hours before taking study medication, hourly SBP, response rate	Primary: No significant difference was observed between the eprosartan and losartan groups in mean change in ABPM SBP ($P \geq 0.075$). Secondary: No significant differences were observed between groups in any secondary endpoints.
Gradman et al. ⁹⁰ (2005) Irbesartan 150 mg QD vs aliskiren 150 to 600 mg QD	DB, MC, PC, PG, RCT Men and women, age 18 years or older, with mild-to-moderate essential HTN (mean sitting DBP ≥ 95 mm Hg and < 110 mm Hg)	N=652 8 weeks	Primary: Change in mean sitting DBP and SBP Secondary: Proportion of patients achieving blood pressure control ($< 140/90$ mm Hg), safety	Primary: Decreases in mean sitting DBP at eight weeks were significantly greater with all doses of aliskiren compared to placebo ($P < 0.001$). The least-squares mean reductions in trough DBP for aliskiren 150, 300, and 600 mg were 9.3, 11.8, and 11.5 mm Hg, respectively, vs 6.3 mm Hg for placebo. Decreases in mean sitting SBP at eight weeks were significantly greater with all doses of aliskiren compared to placebo ($P < 0.001$). The least-squares mean reductions in trough SBP for aliskiren 150, 300, and 600 mg were 11.4, 15.8, and 15.7 mm Hg, respectively, vs 5.3 mm Hg for placebo.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo				<p>The antihypertensive effect of aliskiren 150 mg was comparable to irbesartan 150 mg with reductions of 8.9 and 12.5 mm Hg for mean sitting DBP and SBP, respectively. Aliskiren 300 and 600 mg produced significantly greater mean sitting DBP reductions than irbesartan 150 mg (P<0.05). While the reductions in mean sitting SBP were greater with aliskiren 300 and 600 mg than irbesartan 150 mg, these differences were not statistically significant).</p> <p>Secondary: The percentage of patients achieving blood pressure control was significantly greater with all doses of aliskiren (37.8%-150 mg, 50.0%-300 mg, 45.7%-600 mg) and irbesartan (33.8%) compared to placebo (20.8%; P<0.05). More patients on aliskiren 300 and 600 mg achieved blood pressure control compared to irbesartan (P<0.05).</p> <p>Drug-related adverse events for both aliskiren and irbesartan were comparable to placebo and the most commonly reported adverse events were headache, dizziness, and diarrhea. The number of patients discontinuing therapy was similar in all groups.</p>
<p>Jordan et al.⁹¹ (2007)</p> <p>Irbesartan 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>aliskiren 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p>	<p>DB, DD, MC, PG, RCT</p> <p>Obese men and women (BMI ≥30 kg/m²) ≥18 years with essential HTN (mean sitting DBP 95 to 109 mm Hg and SBP <180 mm Hg) who had not responded to 4 weeks of treatment with HCTZ 25 mg</p>	<p>N=489</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting DBP with aliskiren 300 mg plus HCTZ vs HCTZ alone at 8 weeks</p> <p>Secondary: Comparisons of mean sitting DBP and SBP with aliskiren plus HCTZ vs the other treatment groups, percentage of responders (mean sitting DBP <90 mm Hg or ≥10 mm</p>	<p>Primary: Aliskiren 300 mg added to HCTZ 25 mg significantly reduced mean sitting DBP compared with HCTZ alone at week eight (mean difference, -4.0; P<0.0001).</p> <p>Secondary: Aliskiren 300 mg added to HCTZ caused numerically larger reductions in mean sitting DBP and SBP compared with amlodipine 10 mg plus HCTZ and irbesartan 300 mg plus HCTZ at week eight, but there were no statistically significant differences between treatment groups (P>0.05).</p> <p>Responder rates were significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0193) and week 12 (P=0.004) but comparable to responder rates observed with amlodipine plus HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>The proportion of patients achieving blood pressure control was significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0005) and week 12 (P=0.0001) but not statistically different than amlodipine plus</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>amlodipine 5 to 10 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>HCTZ 25 mg QD (existing therapy)</p>			<p>Hg reduction from baseline), proportion of patients achieving blood pressure control (mean sitting blood pressure <140/90 mm Hg), plasma renin activity, safety and tolerability</p>	<p>HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>Plasma renin activity significantly increased (P<0.05) during four weeks of HCTZ monotherapy. Combination with aliskiren neutralized this increase and led to an overall significant reduction in plasma renin activity compared with pretreatment baseline (P<0.05) whereas amlodipine and irbesartan led to further significant increases (P<0.05).</p> <p>All of the study treatments were generally well tolerated. Amlodipine plus HCTZ (45.2%) was associated with a higher incidence of adverse events than the other treatment groups (36.1 to 39.3%), largely due to a higher rate of peripheral edema (11.1 vs 0.8 to 1.6%).</p>
<p>O'Brien et al.⁹² (2007)</p> <p>Irbesartan 150 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p> <p>vs</p> <p>aliskiren 150 mg QD for 3 weeks, then HCTZ 25 mg QD was added for an additional 3 weeks (if ABPM remained \geq135/85 mm Hg)</p> <p>vs</p>	<p>3 OL studies</p> <p>Men and women 18 to 80 years with ambulatory SBP \geq140 and \leq180 mm Hg without treatment</p>	<p>N=67</p> <p>6 to 9 weeks</p>	<p>Primary: Change in daytime systolic ABPM with combination therapy compared with monotherapy</p> <p>Secondary: Change in daytime diastolic ABPM, nighttime systolic and diastolic ABPM, daytime and nighttime heart rates, plasma renin activity</p>	<p>Primary: Aliskiren coadministered with HCTZ (P=0.0007) or ramipril (P=0.03) led to significantly greater reductions in daytime systolic ABPM compared to monotherapy. There was a trend for a reduction in daytime systolic ABPM with the addition of aliskiren to irbesartan; however, this trend was not statistically significant.</p> <p>Secondary: Aliskiren plus HCTZ significantly lowered daytime diastolic ABPM compared to aliskiren monotherapy (P=0.0006). Changes in nighttime systolic and diastolic ABPM followed similar trends but did not achieve statistical significance (P=0.06 and P=0.09, respectively). No changes in heart rate were observed with either aliskiren regimen.</p> <p>Aliskiren added to irbesartan did not significantly change diastolic ABPM compared to irbesartan monotherapy; however, nighttime systolic and diastolic ABPM were significantly reduced (P<0.05 for all). No changes in heart rate were observed with either irbesartan regimen.</p> <p>Mean diastolic ABPM was significantly decreased with the addition of aliskiren 150 mg (P<0.05) but not aliskiren 75 mg to ramipril monotherapy. Both aliskiren doses significantly decreased nighttime systolic and diastolic ABPM (P<0.05 for all). No changes in heart rate were observed with either ramipril regimen.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
ramipril 5 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks				Aliskiren alone significantly inhibited plasma renin activity by 65% (P<0.0001), while ramipril and irbesartan monotherapy increased renin activity by 90 and 175%, respectively. When aliskiren was coadministered with HCTZ, ramipril or irbesartan, plasma renin activity remained similar to baseline levels or decreased.
Derosa et al. ⁹³ (2005) Irbesartan 300 mg QD vs doxazosin 4 mg QD	DB, PG, RCT Patients with type 2 diabetes and mild HTN	N=96 1 year	Primary: Blood pressure, glucose metabolism and lipid parameters Secondary: Not reported	Primary: Blood pressure was significantly reduced in both treatment groups compared to baseline (P<0.01). Irbesartan was significantly better in lowering blood pressure compared to doxazosin (P<0.05). Doxazosin significantly reduced glycosylated hemoglobin, fasting plasma glucose, fasting plasma insulin, TC, LDL-C, HDL-C, and TG (P≤0.05 for all parameters). As monotherapy, neither of the drugs achieved adequate blood pressure control. Secondary: Not reported
Neutel et al. ⁹⁴ (2006) Irbesartan 150 to 300 mg QD vs irbesartan and HCTZ 150 to 300-12.5 to 25 mg QD (fixed-dose combination)	AC, DB, MC, RCT Patients ≥18 years with severe HTN who were untreated (seated DBP ≥110 mm Hg) or currently receiving antihypertensive monotherapy with DBP ≥100 mm Hg	N=737 7 weeks	Primary: Proportion of patients with DBP <90 mm Hg at week 5 Secondary: Proportion of patients who achieved seated SBP/DBP <140/90 mm Hg	Primary: Significantly more patients on combination therapy achieved seated DBP <90 mm Hg at week five compared to monotherapy (47.2 vs 33.2%; P=0.0005). Secondary: Significantly more patients attained SBP/DBP <140/90 mm Hg at week five (34.6 vs 19.2%, respectively; P<0.0001), while the mean difference between combination and monotherapy in seated DBP and SBP was 4.7 and 9.7 mm Hg, respectively (P<0.0001). Greater and more rapid blood pressure reduction with irbesartan and HCTZ was achieved without additional side effects.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Neutel (abstract).⁹⁵ (2011)</p> <p>Irbesartan and HCTZ 150-12.5 mg QD, up titrated to 300-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>irbesartan 150 mg QD, up titrated to 300 mg QD</p>	<p>Post-hoc analysis of 2 PRO, RCT</p> <p>Patients with uncontrolled or untreated moderate to severe HTN who are obese or who have diabetes</p>	<p>N=1,268</p> <p>7 weeks (severe HTN)</p> <p>12 weeks (moderate HTN)</p>	<p>Primary: Changes in baseline blood pressure, blood pressure goal rate</p> <p>Secondary: Safety</p>	<p>Primary: After seven to eight weeks of treatment, SBP/DBP decreased in patients with diabetes by 26.9/17.8 and 21.8/15.8 mm Hg with combination irbesartan and HCTZ and irbesartan treatment, respectively (P=0.09/P=0.27). In obese patients, SBP/DBP decreased by 29.4/20.2 and 20.1/15.9 mm Hg with combination irbesartan and HCTZ and irbesartan treatment, respectively (P<0.0001).</p> <p>More patients with type 2 diabetes achieved a blood pressure goal of <130/80 mm Hg at week seven to eight with combination irbesartan and HCTZ treatment compared to irbesartan (12 vs 5%; P=0.22). Significantly more obese patients achieved blood pressure goals with combination irbesartan and HCTZ treatment compared to irbesartan (48 vs 23%; P<0.0001).</p> <p>Secondary: Treatment emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or BMI status. In patients with moderate or severe HTN and with a BMI \geq30 kg/m², initial treatment with combination irbesartan and HCTZ was more effective compared to irbesartan.</p>
<p>Neutel et al.⁹⁶ (2008)</p> <p>Irbesartan and HCTZ 300-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>irbesartan 300 mg QD</p> <p>vs</p> <p>HCTZ 25 mg QD</p>	<p>AC, DB, RCT</p> <p>Patients with moderate HTN (seated SBP 160 to 179 mm Hg when DBP <110 mm Hg; or DBP 100 to 109 mm Hg when SBP <180 mm Hg)</p>	<p>N=538</p> <p>12 weeks</p>	<p>Primary: Change in SBP after week 8</p> <p>Secondary: Change from baseline in DBP at weeks 8 and 12, SBP at week 12, proportion of responders (SBP <140 mm Hg and DBP <90 mm Hg) at weeks 8 and 12</p>	<p>Primary: At week eight, there was a reduction in SBP of 27.1 mm Hg with irbesartan and HCTZ compared to 22.1 mm Hg with irbesartan monotherapy (P=0.0016) and 15.7 mm Hg with HCTZ (P<0.0001).</p> <p>Secondary: At week eight, there was a reduction in DBP of 14.6 mm Hg with irbesartan and HCTZ compared to 11.6 mm Hg with irbesartan monotherapy (P=0.0013) and 7.3 mm Hg with HCTZ (P<0.0001).</p> <p>A significantly greater percentage of patients reached a treatment goal of SBP <140 mm Hg and DBP <90 mm Hg by week eight with irbesartan and HCTZ (53.4%) compared to irbesartan (40.6%; P=0.0254) and HCTZ (20.2%; P<0.0001) alone.</p> <p>Treatment was well tolerated in all three treatment groups with a slight increase in adverse events in the combination therapy group.</p>
Weir et al. ⁹⁷	Pooled analysis of 2	N=796	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2007) Irbesartan and HCTZ 300-25 mg QD (fixed-dose combination)	DB, MC, RCT Patients with stage 1 or 2 HTN evaluated according to age	7 to 8 weeks	Antihypertensive efficacy, tolerability Secondary: Not reported	SBP/DBP reductions (27 to 31/16 to 22 mm Hg) were similar regardless of age, obesity and type 2 diabetes status and were greater in high- vs low-risk patients. Dizziness (2.0 to 3.7%), hypotension (0 to 0.7%), and syncope (0%) were rare and not centered in any subgroup. There was no hypotension in the elderly or in patients with type 2 diabetes. Secondary: Not reported
Bobrie et al. ⁹⁸ (2005) Irbesartan and HCTZ 150-12.5 mg QD (fixed-dose combination product) vs valsartan and HCTZ 80-12.5 mg QD (fixed-dose combination product)	OL, RCT Patients whose blood pressure remained uncontrolled after 5 weeks of HCTZ 12.5 mg QD	N=464 8 weeks	Primary: Blood pressure reductions, safety Secondary: Not reported	Primary: Irbesartan and HCTZ produced greater reductions in average SBP and DBP measured by home blood pressure monitoring than valsartan and HCTZ (SBP, -13.0 vs -10.6 mm Hg; P=0.0094; DBP, -9.5 vs -7.4 mm Hg; P=0.0007). These differences were more pronounced in the morning than in the evening. Normalization rates observed with home blood pressure monitoring (SBP <135 mm Hg and DBP <85 mm Hg) were significantly greater with irbesartan and HCTZ than with valsartan and HCTZ (50.2 vs 33.2%; P=0.0003). The overall safety was similar in the two groups.
Stanton et al. ⁹⁹ (2003) Losartan 100 mg QD vs aliskiren 37.5 to 300 mg QD	AC, DB, MC, RCT Men and women 21 to 70 years of age with mild-to-moderate HTN (SBP ≥140 mm Hg)	N=226 4 weeks	Primary: Change in daytime ambulatory SBP Secondary: Changes in clinic SBP and DBP, plasma renin activity, plasma aliskiren levels, adverse events	Primary: A dose-dependent reduction in daytime ambulatory SBP was observed with increasing aliskiren doses (with mean changes of -0.40 mm Hg with aliskiren 37.5 mg, -5.3 mm Hg with aliskiren 75 mg, -8.0 mm Hg with aliskiren 150 mg, and -11 mm Hg with aliskiren 300 mg; P=0.0002). The change in daytime SBP with losartan 100 mg (-10.9 mm Hg) was significantly different than aliskiren 37.5 mg, but not the other higher aliskiren dosages). Secondary: Clinic SBP and DBP, both in the sitting and standing positions, decreased with aliskiren in a dose-dependent manner, whereas heart rate was unaltered. The

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>decreases in clinic blood pressures were similar for losartan 100 mg and aliskiren 150 and 300 mg.</p> <p>Dose-dependent reductions in plasma renin activity were also observed (median change -55, -60, -77, and -83% with 37.5, 75, 150, and 300 mg aliskiren, respectively; P=0.0008). By contrast, plasma renin activity increased by 110% with losartan 100 mg.</p> <p>Rate of adverse events was 22% with aliskiren 37.5 mg, 35% with aliskiren 75 mg, 25% with aliskiren 150 mg, 23% with aliskiren 300 mg, and 32% with losartan 100 mg. There was no increase in the number of adverse events when increasing the dose of aliskiren.</p>
<p>Ribeiro et al.¹⁰⁰ (2007) LAMHYST Losartan 50 to 100 mg QD vs amlodipine 5 to 10 mg QD</p>	<p>DB, DD, RCT Males and females, age 18 to 79 years old, with diagnosis of mild (>95 mm Hg but <115 mm Hg) to moderate essential HTN and not taking an antihypertensive medication (within last 4 weeks)</p>	<p>N=194 12 weeks</p>	<p>Primary: Difference between treatment groups in mean change in ABPM for last 9 hours of treatment and during drug holiday</p> <p>Secondary: Not reported</p>	<p>Primary: After 12 weeks, mean reductions in SBP were significantly larger in the amlodipine group than the losartan group (-18.1 vs -10.1 mm Hg; P<0.001). Mean reductions in DBP were significantly larger in the amlodipine group than the losartan group (-18.1 vs -10.1 mm Hg; P<0.05).</p> <p>Mean increases in SBP were similar between the groups during the two day drug holiday (P>0.05).</p> <p>After the two day drug holiday, SBP was lower than baseline in both groups (P<0.001), with the amlodipine group SBP remaining significantly lower (P<0.01).</p> <p>Mean increases in DBP were similar between the groups during the two day drug holiday (P>0.05). After the two day drug holiday, DBP was lower than baseline in both groups (P=0.0001), with the amlodipine group DBP remaining significantly lower (P<0.05).</p> <p>Secondary: Not reported</p>
<p>Oparil et al.¹⁰¹ (1996) Losartan 50 to 100 mg QD</p>	<p>DB, DD, MC, RCT Patients with HTN</p>	<p>N=900 12 weeks</p>	<p>Primary: Efficacy, tolerability, effects on QOL</p>	<p>Primary: DBP reductions after 4, 8, and 12 weeks of therapy were clinically comparable (losartan group: 7.3, 10.4, and 11.1 mm Hg, respectively; amlodipine group: 7.9, 11.2, and 11.8 mm Hg, respectively; P value not significant).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>If goal DBP (≤ 90 mm Hg) was not attained, drug doses could be doubled and/or HCTZ mg was added.</p>			<p>Secondary: Not reported</p>	<p>Similar reductions in SBP were seen for both treatment groups (P value not significant).</p> <p>The percentage of patients reaching goal DBP (≤ 90 mm Hg) or DBP ≥ 90 mm Hg with a ≥ 10 mm Hg decrease from baseline) was comparable for the two groups, with 68% of patients in the losartan group and 71% of patients in the amlodipine group reaching goal.</p> <p>Significantly more patients in the amlodipine group had drug-related adverse experiences (27 vs 13%; $P=0.029$). Edema was more common in patients receiving the amlodipine regimen than in those receiving the losartan regimen (11 vs 1%; $P=0.004$).</p> <p>Overall QOL was not different in the two treatment groups.</p> <p>Secondary: Not reported</p>
<p>Dahlöf et al.¹⁰² (2002) LIFE</p> <p>Losartan 50 to 100 mg QD</p> <p>vs</p> <p>atenolol 50 to 100 mg QD</p> <p>HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>DB, DD, PG, RCT</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200 to 95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=9,193</p> <p>≥ 4 years</p>	<p>Primary: Composite of cardiovascular death, MI and stroke</p> <p>Secondary: All-cause mortality, hospitalization for angina or heart failure, revascularization procedures, resuscitated cardiac arrest, new-onset diabetes</p>	<p>Primary: SBP fell by 30.2 and 29.1 mm Hg in the losartan and atenolol groups, respectively (treatment difference, $P=0.017$) and DBP fell by 16.6 and 16.8 mm Hg, respectively (treatment difference, $P=0.37$). MAP was 102.2 and 102.4 mm Hg, respectively (P value not significant). Heart rate decreased more in patients assigned to atenolol than losartan (-7.7 vs -1.8 beats/minute, respectively; $P<0.0001$).</p> <p>Compared to atenolol, the primary composite occurred in 13.0% fewer patients receiving losartan (RR, 0.87; 95% CI, 0.77 to 0.98; $P=0.021$).</p> <p>While there was no difference in the incidence cardiovascular mortality ($P=0.206$) and MI ($P=0.491$), losartan treatment resulted in a 24.9% relative risk reduction in stroke compared to atenolol ($P=0.001$).</p> <p>Secondary: A 25% lower incidence of new-onset diabetes was reported with losartan compared to atenolol ($P=0.001$). There was no significant difference among the other secondary end points between the two treatment groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Note: At end point or end of follow-up, 18 and 26% of patients on losartan were receiving HCTZ alone or with other drugs, respectively. In the atenolol group, 16 and 22% of patients were receiving HCTZ alone or with other drugs, respectively.
Julius et al. ¹⁰³ (2004) LIFE Black Subset Losartan 50 to 100 mg QD vs atenolol 50 to 100 mg QD HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.	Post hoc analysis Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy	N=523 ≥4 years	Primary: Composite of cardiovascular death, MI and stroke Secondary: Not reported	Primary: Compared to atenolol (11.2%), losartan in the United States African American population resulted in a greater incidence of the composite end point (17.4%; P=0.033). HRs favored atenolol across all parameters (P=0.246 for cardiovascular mortality, P=0.140 for MI, and P=0.030 for stroke). In African American patients, blood pressure reduction was similar in both groups, and regression of electrocardiographic-left ventricular hypertrophy was greater with losartan. Secondary: Not reported
Lindholt et al. ¹⁰⁴ (2002) LIFE Diabetic Subset Losartan 50 to 100 mg QD vs atenolol 50 to 100 mg QD HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.	Post hoc analysis Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy	N=1,195 ≥4 years	Primary: Composite of cardiovascular death, MI and stroke Secondary: All-cause mortality	Primary: Compared to atenolol, losartan resulted in a 24% decrease in the primary composite end point (P=0.031). Losartan treatment resulted in a 37% risk reduction in cardiovascular deaths vs atenolol (P=0.028). Losartan treatment resulted in a 39% risk reduction in all-cause mortality vs atenolol (P=0.002). Mean blood pressure fell to 146/79 mm Hg in losartan patients and 148/79 mm Hg in atenolol patients. Secondary: Mortality from all causes was 63 and 104 in the losartan and atenolol groups, respectively (RR, 0.61; P=0.002).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Kjeldsen et al.¹⁰⁵ (2002) LIFE Isolated Systolic Hypertension Subset Losartan 50 to 100 mg QD vs atenolol 50 to 100 mg QD HCTZ 12.5 to 25 mg QD was added if needed for blood pressure control.</p>	<p>Post hoc analysis Patients 55 to 80 years old with isolated systolic HTN (SBP of 160 to 200 mm Hg and DBP <90 mm Hg) and left ventricular hypertrophy</p>	<p>N=1,326 ≥4 years</p>	<p>Primary: Composite of cardiovascular death, MI, or stroke Secondary: All-cause mortality</p>	<p>Primary: Compared to atenolol, losartan resulted in a trend towards a 25% reduction in the primary end point (P=0.06). Losartan treatment resulted in a 46% risk reduction in cardiovascular mortality (P=0.01) and 40% risk reduction in stroke compared to atenolol (P=0.02). There was no difference in the incidence of MI. Blood pressure was reduced by 28/9 and 28/9 mm Hg in the losartan and atenolol arms. Secondary: Patients receiving losartan also had reductions in all-cause mortality (28%; P<0.046).</p>
<p>Fossum et al.¹⁰⁶ (2006) ICARUS, a LIFE substudy Losartan 50 to 100 mg/day vs atenolol 50 to 100 mg/day All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>DB, DD, PG, RCT Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=81 3 years</p>	<p>Primary: Amount and density of atherosclerotic lesions in the common carotid arteries and carotid bulb Secondary: Not reported</p>	<p>Primary: The amount of plaque decreased in the losartan group and increased in the atenolol group, though the difference between groups was not statistically significant (P=0.471). Patients in the atenolol group had a greater increase in plaque index compared to the losartan group, though the difference between groups was not statistically significant (P=0.742) Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Kizer et al.¹⁰⁷ (2005) LIFE substudy</p> <p>Losartan 50 to 100 mg/day</p> <p>vs</p> <p>atenolol 50 to 100 mg/day</p> <p>All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>DB, DD, PG, RCT</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=9,193</p> <p>≥4 years</p>	<p>Primary: Reduction in the risk of different stroke subtypes and neurological deficits</p> <p>Secondary: Not reported</p>	<p>Primary: The risk of fatal stroke was significantly decreased in the losartan group compared to the atenolol group (P=0.032).</p> <p>The risk of atherothrombotic stroke was significantly decreased in the losartan group compared to the atenolol group (P=0.001).</p> <p>Comparable risk reductions were observed for hemorrhagic and embolic stroke but did not reach statistical significance.</p> <p>The risk of recurrent stroke was significantly reduced in the losartan arm compared to the atenolol arm (P=0.017).</p> <p>The number of neurological deficits per stroke was similar (P=0.68), but there were fewer strokes in the losartan group for nearly every level of stroke severity.</p> <p>Secondary: Not reported</p>
<p>Wachtell et al.¹⁰⁸ (2005) LIFE substudy</p> <p>Losartan 50 to 100 mg/day</p> <p>vs</p> <p>atenolol 50 to 100 mg/day</p> <p>All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.</p>	<p>DB, DD, PG, RCT</p> <p>Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy</p>	<p>N=8,851 (patients in LIFE with no baseline history of atrial fibrillation but at risk for atrial fibrillation)</p> <p>≥4 years</p>	<p>Primary: Incidence of new-onset atrial fibrillation and outcome</p> <p>Secondary: Not reported</p>	<p>Primary: Significantly fewer patients in the losartan group experienced new-onset atrial fibrillation compared to the atenolol group (P<0.001).</p> <p>Randomization to losartan treatment was associated with a 33% lower rate of new onset atrial fibrillation independent of other risk factors (P<0.001).</p> <p>Patients in the losartan group had a 40% lower rate of composite events consisting of cardiovascular death, fatal or non-fatal stroke, and fatal or non-fatal MI (P=0.03).</p> <p>Significantly fewer strokes occurred in the losartan group compared to the atenolol group (P=0.01), and there was a trend toward fewer MIs in the losartan group (P=0.16).</p> <p>There was no significant difference in cardiovascular mortality between groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				In contrast, the atenolol group experienced significantly fewer hospitalizations for heart failure (P=0.004) and a trend toward fewer sudden cardiac deaths (P=0.07). Secondary: Not reported
Wachtell et al. ¹⁰⁹ (2005) LIFE substudy Losartan 50 to 100 mg/day vs atenolol 50 to 100 mg/day All patients received HCTZ 12.5 to 25 mg/day if need for blood pressure control.	DB, DD, PG, RCT Patients 55 to 80 years old with essential HTN (sitting SBP/DBP 160 to 200/95 to 115 mm Hg) and left ventricular hypertrophy	N=342 (LIFE patients with AF at the start of the LIFE study) ≥4 years	Primary: Cardiovascular morbidity and mortality Secondary: Not reported	Primary: Patients with a history of atrial fibrillation had significantly higher rates of cardiovascular and all-cause mortality, fatal and non-fatal stroke, heart failure, revascularization and sudden cardiac death compared to patients without atrial fibrillation (P<0.001). Patients with a history of atrial fibrillation had similar rates of MI and hospitalization for angina pectoris (P≥0.209). The primary composite endpoint of cardiovascular mortality, stroke and MI occurred in significantly fewer patients in the losartan group compared to the atenolol group (P=0.009). The difference in MI between groups was not significant. Treatment with losartan trended toward lower all-cause mortality (P=0.09) and fewer pacemaker implantations (P=0.065). Secondary: Not reported
Van Bortel et al. ¹¹⁰ (2005) Losartan 50 mg QD vs nebivolol 5 mg QD If after 6 weeks,	DB, MC, PG, RCT Patients <70 years of age with DBP at randomization between 95 and 114 mm Hg	N=314 12 weeks	Primary: Effects on blood pressure, overall QOL Secondary: Comparison of different aspects of QOL	Primary: At the end of 12 weeks, both nebivolol and losartan significantly reduced SBP compared to baseline (P<0.0001 for both), but the agents were not significantly different from each other. Both agents also significantly decreased DBP compared to baseline (P<0.0001), but nebivolol significantly reduced DBP compared to losartan (P<0.02). At the end of 12 weeks, both nebivolol and losartan significantly improved QOL scores compared to baseline (P<0.007), but the agents were not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
DBP was not normalized, then HCTZ 12.5 mg QD was added to therapy				<p>significantly different from each other.</p> <p>Secondary: At week 12 there was not a significant difference observed in the individual questions of the QOL questionnaire between the groups. Questions inquired about headaches, lightheadedness, sleepiness, flushing, and sexual function.</p>
<p>Flack et al.¹¹¹ (2003)</p> <p>Losartan 50 mg QD</p> <p>vs</p> <p>eprenone 50 mg QD</p> <p>vs</p> <p>placebo</p> <p>Doses were increased if blood pressure remained uncontrolled.</p>	<p>DB, MC, PG, RCT</p> <p>Men and women ≥18 years old, with mild to moderate HTN, with SBP <180 mm Hg and DBP 95 to 109 mm Hg (off medication) or if patients were receiving antihypertensive therapy their blood pressure was <140/90 mm Hg</p>	<p>N=551</p> <p>16 weeks</p>	<p>Primary: Mean change from baseline in DBP at 16 weeks</p> <p>Secondary: Mean change from baseline at 16 weeks in SBP, SBP and DBP within and between racial groups, response rate (defined as the percentage of patients with DBP <90 mm Hg or DBP ≥90 mm Hg but ≥10 mm Hg below baseline), urinary albumin/creatinine ratio, effect of eplerenone in patients with various baseline renin and aldosterone levels, adverse effects</p>	<p>Primary: At 16 weeks, patients randomized to eplerenone exhibited significantly greater mean changes in DBP from baseline compared to either losartan- or placebo-treated groups (P<0.001).</p> <p>Secondary: At 16 weeks, patients randomized to eplerenone exhibited significantly greater mean changes in SBP from baseline compared to either losartan- or placebo-treated groups (P<0.001).</p> <p>At 16 weeks, African American patients randomized to eplerenone exhibited significantly greater mean changes in SBP and DBP from baseline compared to the placebo-treated African American patients (P<0.001).</p> <p>At 16 weeks, African American patients randomized to eplerenone exhibited significantly greater mean changes in SBP and DBP from baseline compared to the losartan-treated African American patients (P≤0.001).</p> <p>At 16 weeks, white patients randomized to eplerenone exhibited significantly greater mean changes in SBP and DBP from baseline compared to the placebo-treated white patients (P=0.001). However, the difference in SBP- and DBP-lowering effects was not significant different between the eplerenone ad losartan groups (P=0.126, P=0.068, respectively).</p> <p>Significantly greater percentage of patients randomized to eplerenone exhibited a positive response to therapy compared to either placebo (64.5 vs 41.2%; P<0.001) or losartan group (64.5 vs 48.3%; P=0.003).</p> <p>The eplerenone group (regardless of race) exhibited statistically significant improvement in urinary albumin/creatinine ratio from baseline compared to placebo (P=0.003). However, the difference in urinary albumin/creatinine ratio</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>change from baseline was not significantly different between the eplerenone and losartan groups (P=0.652).</p> <p>Compared to losartan, eplerenone was more effective in lowering SBP and DBP in patients with low-moderate baseline renin levels (P<0.05). However, the difference was not statistically significant in patients with high baseline renin levels.</p> <p>Compared to losartan, eplerenone was more effective in lowering SBP in patients with low or high baseline aldosterone levels (P<0.05). However, the difference was not statistically significant in patients with moderate baseline aldosterone levels.</p> <p>Compared to losartan, eplerenone was more effective in lowering DBP in patients with low baseline aldosterone levels (P<0.05). However, the difference was not statistically significant in patients with moderate-high baseline aldosterone levels.</p> <p>There were no significant differences in the incidence of adverse events noted in eplerenone, placebo or losartan groups. The reported incidence of gynecomastia, breast pain, menstrual abnormalities, impotence, hyperkalemia and decreased libido with eplerenone was low and comparable to losartan and placebo.</p>
<p>Hood et al.¹¹² (2007) SALT</p> <p>Losartan 100 mg/day vs spironolactone 50 mg/day vs</p>	<p>DB, RCT, XO</p> <p>Adult patients with seated blood pressure of 140/90 to 170/110 mm Hg, plasma renin of ≤12 mU/L, plasma aldosterone-renin ratio >750, previous fall in SBP ≥20 mm Hg after 1 month of OL treatment with spironolactone 50</p>	<p>N=57 42 weeks</p>	<p>Primary: Change in blood pressure and plasma renin from baseline between spironolactone 100 mg/day and bendroflumethiazide 5 mg/day</p> <p>Secondary: Change in blood pressure and plasma renin from baseline</p>	<p>Primary: Spironolactone 100 mg/day- and bendroflumethiazide 5 mg/day-treated patients did not exhibit a significant difference in BP reduction from baseline (P value not reported).</p> <p>Secondary: Spironolactone 50 mg/day-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.01).</p> <p>Losartan 100 mg-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
spironolactone 100 mg/day vs amiloride 20 mg/day vs amiloride 40 mg/day vs bendroflumethiazide* 2.5 mg/day vs bendroflumethiazide* 5 mg/day vs placebo	mg/day		between amiloride and other diuretics and between lower and higher doses of each diuretic	High-dose bendroflumethiazide- and amiloride-treated patients exhibited significantly greater reductions in blood pressure compared to the lower doses (P<0.05). Spironolactone-treated patients exhibited a four-fold increase in baseline renin level compared to a two-fold increase observed in bendroflumethiazide-treated patients (P=0.003).
Maeda et al. ¹¹³ (2012) ARCH Losartan and HCTZ (fixed-dose combination product)	MC, OL, OS, PRO Patients 20 to 80 years of age with HTN uncontrolled by either ARB monotherapy or combination with and ARB and a	N=614 52 weeks	Primary: Change in blood pressure at 3 months Secondary: Not reported	Primary: Blood pressure decreased significantly to 138.0/78.2 mm Hg by month three (P<0.001), and 36.2% of patients were able to achieve target blood pressure (P<0.05). The hypotensive effect lasted for one year (P<0.001) and was found equally in patients receiving losartan-HCTZ and losartan-HCTZ plus a calcium channel blocker.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	calcium channel blocker			Secondary: Not reported
Ueda et al (abstract). ¹¹⁴ (2012) MAPPY Losartan and HCTZ 50-12.5 mg QD (fixed-dose combination product) vs losartan 100 mg QD	MC, OL, PG, PRO, RCT Patients with morning HTN	N=216 Duration not specified	Primary: Change in baseline SBP, blood pressure control rate Secondary: Safety	Secondary: Not reported Primary: Morning SBP was reduced from 150.3±10.1 to 131.5±11.5 mm Hg with combination therapy (P<0.001) and from 151.0±9.3 to 142.5±13.6 mm Hg with high dose losartan therapy (P<0.001). The morning SBP reduction was significantly greater with combination therapy group compared to high dose losartan therapy (P<0.001). Combination therapy decreased evening SBP from 141.6±13.3 to 125.3±13.1 mm Hg (P<0.001), and high dose losartan therapy decreased evening SBP from 138.9±9.9 to 131.4±13.2 mm Hg (P<0.01). Although both therapies improved target blood pressure achievement rates in the morning and evening (P<0.001 for both), combination therapy significantly increased the achievement rates compared to high dose losartan therapy (P<0.001 and P<0.05, respectively). Secondary: Combination therapy decreased urine albumin excretion (P<0.05) whereas high-dose therapy reduced serum uric acid. Both therapies indicated strong adherence and few adverse effects (P<0.001).
Salerno et al. ¹¹⁵ (2004) Losartan and HCTZ 50-12.5 to 100-25 mg QD (fixed-dose combination product) vs losartan 50 to 100 mg QD	DB, RCT Patients with severe HTN	N=585 6 weeks	Primary: Proportion of patients achieving goal blood pressure Secondary: Adverse events	Primary: Almost twice as many patients achieved goal blood pressure at four weeks on losartan 50 mg and HCTZ 12.5 mg vs losartan 50 to 100 mg monotherapy (P=0.002). Almost three times as many patients achieved goal blood pressure at six weeks with losartan and HCTZ vs losartan monotherapy (P<0.001). Adverse experiences on losartan and HCTZ (43%) were significantly less than with losartan monotherapy (53%).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Doses were titrated as needed to reach blood pressure goal (<90 mm Hg).				
<p>Minami et al.¹¹⁶ (2007)</p> <p>Losartan 50 mg/day and HCTZ 12.5 mg/day</p> <p>Candesartan 8 mg QD (n=10) or amlodipine 5 mg QD (n=5) administered to all patients for 2 months prior to switch to losartan plus HCTZ.</p>	<p>OL</p> <p>Japanese outpatients with essential HTN treated for ≥ 2 months with either candesartan or amlodipine and 24-hour ambulatory blood pressure $\geq 135/80$ mm Hg</p>	<p>N=15</p> <p>12 months</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: In patients who had previously received candesartan, 24-hour blood pressure decreased significantly from 137/89 mm Hg to 126/81 mm Hg after three months ($P<0.05/P<0.001$) and to 123/81 mm Hg after 12 months ($P<0.01/P<0.001$) of treatment with losartan and HCTZ.</p> <p>In patients who had previously received amlodipine, 24-hour blood pressure decreased significantly from 137/81 to 125/75 mm Hg after three months ($P<0.05/P<0.05$) and to 124/77 mm Hg after 12 months ($P<0.05/P$ value not significant) of treatment with losartan and HCTZ.</p> <p>There were significant decreases in SBP during the daytime, nighttime and early morning after 12 months in both groups.</p> <p>No adverse changes in the indices of glucose or lipid metabolism were observed in either group.</p> <p>Secondary: Not reported</p>
<p>Lacourcière et al.¹¹⁷ (2003) PROBE</p> <p>Losartan and HCTZ 50-12.5 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan and</p>	<p>DB, MC, OL, RCT</p> <p>Patients ≥ 18 years of age with mild-to-moderate essential HTN</p>	<p>N=597</p> <p>6 weeks</p>	<p>Primary: Mean changes in ambulatory DBP</p> <p>Secondary: Mean changes in ambulatory SBP, 24-hour DBP, safety</p>	<p>Primary: During the last six hours of the dosing interval, telmisartan 40 mg and HCTZ 12.5 mg and telmisartan 80 mg and HCTZ 12.5 mg reduced mean DBP to a greater extent vs losartan 50 mg and HCTZ 12.5 mg. Treatment differences between the groups were 1.8 mm Hg ($P<0.05$) and 2.5 mm Hg ($P<0.001$) lower, respectively, with the telmisartan and HCTZ arms.</p> <p>Secondary: Telmisartan 40 mg and HCTZ 12.5 mg and telmisartan 80 mg and HCTZ 12.5 mg produced greater reductions in ambulatory SBP vs losartan 50 mg and HCTZ 12.5 mg of 2.5 and 3.4 mm Hg, respectively, during the last six hours of the dosing interval ($P<0.05$), and of 2.1 and 3.4 mm Hg, respectively, over the entire 24-hour dosing interval ($P<0.05$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 40-12.5 mg QD (fixed-dose combination product) vs telmisartan and HCTZ 80-12.5 mg QD (fixed-dose combination product)				Telmisartan 80 mg and HCTZ 12.5 mg also lowered mean 24-hour DBP by 2.3 mm Hg more than losartan 50 mg and HCTZ 12.5 mg (P<0.001). All treatments were well tolerated.
Brunner et al. ¹¹⁸ (2006) Olmesartan 20 mg QD vs candesartan 8 mg QD	DB, RCT Patients with mainly mild-to-moderate HTN	N=635 8 weeks	Primary: 24-hour antihypertensive efficacy (with particular emphasis on blood pressure control during the early morning period), proportion of patients who achieved various ABPM goals (SBP/DBP <125/80 mm Hg) Secondary: Not reported	Primary: After eight weeks, significantly greater proportions of patients treated with olmesartan achieved 24-hour and daytime ABPM goals 25.6 and 18.3%, respectively) compared to candesartan (14.9%; P<0.001 and 9.6%; P=0.002, respectively). During the last four hours of 24-hour ABPM, the proportion of patients who achieved goals was significantly greater with olmesartan (33.3%) than candesartan (22.9%; P<0.001). Similarly, during the last two hours of 24-hour ABPM, the proportion of patients who achieved these blood pressure goals was higher with olmesartan (26.9 and 19.9%) compared to candesartan (19.6%; P=0.028 and 14.3%; P=0.061). Secondary: Not reported
Punzi et al. ¹¹⁹ (2012) Olmesartan 20 mg QD, up titrated to 40 mg QD vs	DB, PRO, RCT Patients with HTN no previously treated or previously treated with antihypertensive medications	N=941 8 weeks	Primary: Change in baseline seated cuff DBP at week 8 Secondary: Mean change in seated cuff SBP at	Primary: Olmesartan produced significantly greater LSM reductions in seated cuff DBP compared to losartan in treatment-naïve (-9.7±1.0 vs -6.6±1.0 mm Hg; P=0.0232) and treatment-experienced patients (-9.6±0.5 vs -7.3±0.5 mm Hg; P=0.0013). Secondary: Both treatment-naïve (-12.1±1.2 vs -8.5±1.3 mm Hg; P=0.0379) and

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
losartan 50 mg QD, up titrated to 100 mg QD			weeks 4 and 8 and seated cuff DBP at week 4, blood pressure target rates, safety	<p>treatment-experienced patients (-12.0±0.7 vs -8.5±0.7 mm Hg; P=0.0006) receiving olmesartan had significantly greater reductions in baseline cuff seated SBP compared to losartan at week 4. Similar results were observed at week eight (P=0.0178 and P=0.0016).</p> <p>A similar trend in significantly greater baseline reductions with olmesartan compared to losartan was observed at week four for seated cuff DBP in treatment-naïve (LSM difference, -2.3±1.10; P=0.0337) and treatment-experienced patients (LSM difference, -2.7±0.67; P<0.0001).</p> <p>A significantly greater proportion of treatment-naïve patients receiving olmesartan achieved a seated cuff blood pressure goal of <140/90 mm Hg with olmesartan compared to losartan (34.1 vs 19.0%; P=0.0109). Similar results were observed in treatment-experienced patients (31.0 vs 19.6%; P=0.0008).</p> <p>Treatment-emergent adverse events were reported in 30.5 and 31.4% of treatment-naïve and treatment-experienced patients receiving olmesartan. Corresponding proportions for losartan were 33.0 and 31.2%. Most events were mild to moderate in severity.</p>
<p>Oparil et al.¹²⁰ (2001)</p> <p>Olmesartan 20 mg QD</p> <p>vs</p> <p>irbesartan 150 mg QD, losartan 50 mg QD, or valsartan 80 mg QD</p>	<p>DB, MC, PG, RCT</p> <p>Patients ≥18 years old (mean age 52 years) with essential HTN (cuff DBP ≥100 mm Hg and ≤115 mm Hg and mean daytime DBP ≥90 mm Hg and <120 mm Hg)</p>	<p>N=588</p> <p>8 weeks</p>	<p>Primary: Change in seated cuff DBP at week 8</p> <p>Secondary: Change in seated cuff SBP at week 8, 24-hour DBP and SBP, adverse events</p>	<p>Primary: The mean reductions in seated cuff DBP at week eight were significantly greater with olmesartan (11.5 mm Hg) than with irbesartan (9.9 mm Hg; P=0.0412), losartan (8.2 mm Hg; P=0.0002) and valsartan (7.9 mm Hg; P<0.0001).</p> <p>The clinical significance of a few mm Hg DBP difference between the groups is unknown.</p> <p>Secondary: Reductions of cuff SBP were not significantly different among the four ARBs and ranged from 8.4 to 11.3 mm Hg.</p> <p>The reduction in mean 24-hour DBP with olmesartan (8.5 mm Hg) was significantly greater than reductions with losartan and valsartan (6.2 and 5.6 mm Hg, respectively) and showed a trend toward significance when compared to irbesartan (7.4 mm Hg; P=0.087).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The reduction in mean 24-hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsartan (9.0 and 8.1 mm Hg, respectively) and equivalent to the reduction with irbesartan (11.3 mm Hg).</p> <p>All drugs were well tolerated with the incidence of adverse events reported in 30.6% of patients in the olmesartan group, 35.6% for irbesartan, 32.0% for losartan, and 44.8% for valsartan.</p>
<p>Chrysant et al.¹²¹ (2004)</p> <p>Olmesartan 10 to 40 mg QD and HCTZ 12.5 to 25 mg QD</p> <p>vs</p> <p>olmesartan 10 to 40 mg QD</p> <p>vs</p> <p>HCTZ 12.5 to 25 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, RCT, factorial design</p> <p>Patients with a baseline mean seated DBP of 110 to 115 mm Hg</p>	<p>N=502</p> <p>8 weeks</p>	<p>Primary: Change in DBP at week 8</p> <p>Secondary: Change in SBP at week 8</p>	<p>Primary: Olmesartan and HCTZ produced greater reductions in seated DBP at week eight than did monotherapy with either component. All olmesartan and HCTZ combinations significantly reduced DBP compared to placebo in a dose-dependent manner.</p> <p>Reductions in mean trough DBP were 8.2, 16.4, and 21.9 mm Hg with placebo, olmesartan 20 mg plus HCTZ 12.5 mg, and olmesartan 40 mg plus HCTZ 25 mg, respectively.</p> <p>Secondary: Olmesartan and HCTZ produced greater reductions in seated SBP at week eight than did monotherapy with either component. All olmesartan and HCTZ combinations significantly reduced DBP compared to placebo in a dose-dependent manner.</p> <p>Reductions in mean trough SBP were 3.3, 20.1, and 26.8 mm Hg with placebo, olmesartan 20 mg plus HCTZ 12.5 mg, and olmesartan 40 mg plus HCTZ 25 mg, respectively.</p> <p>All treatments were well tolerated.</p>
<p>Kereiakes et al.¹²² (2007)</p> <p>Benazepril 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then</p>	<p>DB, DD, MC, PG, RCT</p> <p>Patients with stage 2 HTN</p>	<p>N=190</p> <p>12 weeks</p>	<p>Primary: Change in mean seated SBP at the end of week 12</p> <p>Secondary: DBP at the end of week 12, percent of</p>	<p>Primary: Patients treated with olmesartan and HCTZ experienced significantly greater reductions in mean seated SBP at week 12 than patients treated with benazepril plus amlodipine (least square mean change, -32.5 vs -26.5 mm Hg; P=0.024; least square mean treatment difference, -6.0 mm Hg; 95% CI, -11.1 to -0.8).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>benazepril 20 mg/day plus amlodipine 5 mg/day for 4 weeks, then benazepril 20 mg/day plus amlodipine 10 mg/day for 4 weeks</p> <p>vs</p> <p>olmesartan 20 mg/day for 2 weeks, then 40 mg/day for 2 weeks then olmesartan and HCTZ 40-12.5 mg/day for 4 weeks increased to 40-25 mg for 4 weeks</p>			<p>patients attaining blood pressure goals of <140/90, <130/85, and <130/80 mm Hg</p>	<p>The least square mean change for reduction in DBP approached statistical significance with olmesartan and HCTZ compared to benazepril plus amlodipine at week 12 (P=0.056).</p> <p>The percentage of patients achieving goal rates at the end of the study for olmesartan and HCTZ and benazepril plus amlodipine were 66.3 and 44.7% (P=0.006) for <140/90 mm Hg, 44.9 vs 21.2% (P=0.001) for <130/85 mm Hg, and 32.6 and 14.1% (P=0.006) for <130/80 mm Hg.</p> <p>Both treatments were well tolerated.</p>
<p>Chrysant et al.¹²³ (2008) COACH</p> <p>Olmesartan 10 to 40 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>vs</p>	<p>DB, MC, PC, RCT</p> <p>Patients, age 18 years and older, with seated DBP of 95 to 120 mm Hg</p>	<p>N=1,940</p> <p>8 weeks</p>	<p>Primary: Change from baseline in seated DBP at week 8</p> <p>Secondary: Change from baseline in seated SBP at week 8, mean change from baseline in seated DBP and SBP at weeks 2, 4, 6 and 8</p>	<p>Primary: All active treatments and placebo resulted in significant decreases in seated DBP at week eight (P<0.001). Reductions in seated DBP with monotherapy treatment ranged from -8.3 to -12.7 mm Hg; reductions with combination therapy ranged from -13.8 to -19.0 mm Hg. All combinations reduced seated DBP significantly greater than either component as monotherapy at the same dosage (P<0.001).</p> <p>Secondary: All active treatments and placebo resulted in significant decreases in seated SBP at week eight (P<0.001 for treatment, P=0.024 for placebo). All combinations reduced seated SBP significantly greater either component as monotherapy at the same dosage (P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>olmesartan 10 to 40 mg and amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>placebo</p>			<p>without last observation carried forward, proportion of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg), safety</p>	<p>The proportion of patients achieving goal blood pressures were: 20.0 to 36.3% of patients receiving olmesartan monotherapy, 21.1 to 32.5% of patients receiving amlodipine monotherapy, 35.0 to 53.2% of patients receiving combination therapy, and 8.8% of patients receiving placebo.</p> <p>Combination therapy resulted in significantly greater achievement of goal blood pressure than monotherapy (P<0.005).</p> <p>No difference in overall rates of adverse events across the different treatment groups was seen. Nearly 27% of patients experienced a drug-related adverse event.</p> <p>Changes in laboratory values were not considered clinically significant nor followed a consistent pattern with treatment: none of the changes were considered clinically significant. Platelet counts increased significantly from baseline (statistically) for patients receiving amlodipine, however the increase was <10% and not deemed clinically relevant.</p>
<p>Chrysant et al.¹²⁴ (2009) COACH</p> <p>Olmesartan 10 to 40 mg QD and amlodipine 5 to 10 mg QD</p> <p>HCTZ 12.5 to 25 mg could be added if blood pressure was not controlled (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes).</p>	<p>OL, ES</p> <p>Patients ≥ 18 years of age with essential HTN (seated DBP ≥95 and <120 mm Hg)</p>	<p>N=1,684</p> <p>44 weeks OL therapy (52 weeks total study duration including 8 week DB phase)</p>	<p>Primary: Reduction in mean sitting SBP DBP, change in mean sitting SBP and DBP, percentage of patients achieving blood pressure goal (<140/90 mm Hg or <130/80 mm Hg for patients with diabetes)</p>	<p>Primary: Mean sitting DBP decreased from 101.5 mm Hg at baseline to 81.9 mm Hg and mean sitting SBP decreased from 163.6 mm Hg at baseline to 131.2 mm Hg at week 52.</p> <p>Approximately 31% of patients remained on amlodipine 5 mg and olmesartan 40 mg. Increasing the dose of amlodipine to 10 mg in combination with olmesartan 40 mg produced further decreases in mean sitting DBP of 4.8 mm Hg and mean sitting SBP of 7.3 mm Hg. Addition of HCTZ 12.5 mg to amlodipine 10 mg and olmesartan 40 mg decreased mean sitting DBP by 4.5 mm Hg and mean sitting SBP by 7.7 mm Hg. Doubling the HCTZ dose from 12.5 to 25 mg decreased mean sitting DBP and mean sitting SBP by an additional 6.0 mm Hg and 9.9 mm Hg, respectively. Patients who received the triple therapy had the greatest mean sitting SBP reduction (36.1 mm Hg).</p> <p>Approximately 67% of patients achieved blood pressure goal by week 52. The blood pressure goal achievement was 80% for amlodipine and olmesartan 5/40 mg, 70.6% for amlodipine and olmesartan 10/40 mg, 66.6% for amlodipine and olmesartan and HCTZ 10/40/12.5 mg, and 46.3% for amlodipine and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>olmesartan and HCTZ 10/ 40/25 mg.</p> <p>The addition of HCTZ 25 mg enabled more patients to achieve blood pressure targets of <140/90 mm Hg (77.7%), <130/85 mm Hg (47.5%), and <130/80 mm Hg (36.4%) compared to the other treatment regimens.</p> <p>No major safety issues emerged with long-term therapy. The frequency of edema ranged from 8.9% in patients treated with amlodipine 5 mg and olmesartan 40 mg to 14.5% in patients treated with amlodipine 10 mg and olmesartan 40 mg plus HCTZ 25 mg. Other treatment-emergent adverse events experienced by ≥3% of patients included upper respiratory tract infection (6.5%), nasopharyngitis (5.2%), extremity pain (4.1%), sinusitis (3.6%), arthralgia (3.3%), and back pain (3.1%). headache (2.0%), hypotension (1.8%), and fatigue (1.6%). The incidence of cough was 0.4%.</p>
<p>Oparil et al.¹²⁵ (2009) COACH</p> <p>Amlodipine 5 to 10 mg QD and olmesartan 10 to 40 mg</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>vs</p> <p>olmesartan 10 to 40 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, factorial, MC, PC, RCT</p> <p>Patients ≥18 years of age with seated DBP 95 to 120 mm Hg, with a subgroup analysis based on HTN (stage 1: SBP 140 to 159 mm Hg or DBP 90 to 99 mm Hg; stage 2: SBP ≥160 mm Hg or DBP ≥100 mm Hg) and no prior antihypertensive medication</p>	<p>N=1,940</p> <p>8 weeks</p>	<p>Primary: Mean change in DBP and SBP at week 8 for each subgroup</p> <p>Secondary: Proportion of patients achieving blood pressure goal (<140/90 mm Hg or <130/80 mm Hg)</p>	<p>Primary: Reductions in mean DBP as a result of combination treatment were similar between subgroups. Patients with stage 1 HTN achieved reductions of 14.8 to 15.8 mm Hg and patients with stage 2 HTN achieved reductions of 13.6 to 19.8 mm Hg. Reductions in mean SBP as a result of combination treatment resulted in greater reductions in patients with stage 2 HTN (25.1 to 32.7 mm Hg) compared to stage 1 HTN (17.7 to 23.7 mm Hg) (P value not reported).</p> <p>Reductions in mean DBP and SBP were similar between those with no prior antihypertensive treatment and those with prior hypertensive treatment.</p> <p>Secondary: The proportion of patients with stage 1 HTN who received combination treatment and achieved blood pressure goal was 65.6 to 80.0%, compared to 40.5 to 66.7% of those who received monotherapy (P<0.0001 across treatments).</p> <p>The proportion of patients with stage 2 HTN who received combination treatment and achieved BP goal was 40.5 to 49.2%, compared to 13.1 to 29.2% of those who received monotherapy (P<0.0001).</p> <p>Results of patients with baseline SBP ≥180 mm Hg were similar to other subgroups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Braun et al (abstract).¹²⁶ (2009)</p> <p>Amlodipine 10 mg plus olmesartan 20 mg QD</p> <p>If patients were uncontrolled after 4 weeks, they were changed to amlodipine and valsartan 10-160 mg QD.</p>	<p>OL, PRO</p> <p>Patients with DBP 100 to 109 mm Hg</p>	<p>N=257</p> <p>8 weeks</p>	<p>Primary: Reduction in SBP and DBP</p> <p>Secondary: Adverse events</p>	<p>Primary: Following treatment with amlodipine and olmesartan, SBP/DBP decreased by 19.2±12.4/14.4±7.4 mm Hg.</p> <p>The number of patients who progressed to treatment with amlodipine and valsartan was 175. Additional reductions in SBP of 7.9 mm Hg and DBP of 3.9 mm Hg were seen (P<0.0001 for both).</p> <p>Secondary: Both treatments were well tolerated and reported adverse events were consistent with drug profiles.</p>
<p>Chrysant et al.¹²⁷ (2012) TRINITY</p> <p>Olmesartan and amlodipine and HCTZ 40-10-25 mg/day (fixed-dose combination product)</p> <p>vs</p> <p>component dual-combination treatments</p>	<p>DB, MC, PG, RCT</p> <p>Patients ≥18 years of age with mean sitting blood pressure ≥140/100 mm Hg or ≥160/90 mm Hg (off antihypertensive medication)</p>	<p>N=2,492</p> <p>12 weeks</p>	<p>Primary: Change in baseline mean sitting DBP</p> <p>Secondary: Change in baseline mean sitting SBP, blood pressure goal rate, safety</p>	<p>Primary: In both Black and non-Black patients, triple combination treatment resulted in significantly greater reductions in mean sitting DBP compared to combination therapies (P≤0.0001). Overall, triple combination treatment reduced LSM mean sitting blood pressure by -37.1/20.8 and -38.9/21.8 mm Hg in Black and non-Black patients at week 12 (P<0.0001 vs combination therapies).</p> <p>Secondary: In both Black and non-Black patients, triple combination treatment resulted in significantly greater reductions in mean sitting SBP compared to combination therapies (P<0.0001).</p> <p>A significantly greater proportion of patients receiving triple combination treatment achieved blood pressure goal compared to combination therapies, regardless of race.</p> <p>No new safety concerns were identified with any treatment. The majority of treatment emergent adverse events were mild to moderate in severity. Treatment emergent adverse events occurred in 366 (52.0%) and 921 (57.6%) Black and non-Black patients.</p>
<p>Chrysant et al (abstract).¹²⁸</p>	<p>Subgroup analysis</p>	<p>N=not reported</p>	<p>Primary: Change in baseline</p>	<p>Primary: The prespecified changes in blood pressure from baseline for the diabetes</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(2012) TRINITY Olmesartan and amlodipine and HCTZ 40-10-25 mg/day (fixed-dose combination product) vs component dual-combination treatments	Patients ≥18 years of age with HTN and diabetes	12 weeks	blood pressure, blood pressure control rate Secondary: Safety	subgroup receiving triple combination treatment were significantly greater compared to the dual-combination treatments (P≤0.0013). Significantly more patients with diabetes receiving triple combination treatment achieved goal blood pressure (<130/80 mm Hg) compared to patients receiving dual combination treatments (P≤0.0092). Secondary: Most treatment-emergent adverse events were mild to moderate in severity.
Kereiakes et al. ¹²⁹ (2011) TRINITY Olmesartan and amlodipine and HCTZ 40-10-25 mg/day (fixed-dose combination product) vs component dual-combination treatments	ES, OL Patients ≥18 years of age with mean sitting blood pressure ≥140/100 mm Hg or ≥160/90 mm Hg (off antihypertensive medication)	N=2,112 40 weeks	Primary: Efficacy, safety Secondary: Not reported	Primary: Mean changes in blood pressure from baseline to week 52 were comparable for all treatments. The proportion of patients receiving triple combination treatment who achieved blood pressure goals at week 52 ranged between 44.5 to 79.8% depending on the dose; lower doses were associated with a smaller proportion of patients achieving blood pressure goals. No new safety concerns were identified. Most adverse events and drug-related adverse events were considered to be of mild to moderate severity. One hundred and six patients reported a serious adverse event and five drug-related adverse events. Serious drug-related adverse events included acute renal insufficiency, presyncope, and hypotension in three patients; acute renal insufficiency with hyperkalemia in one patients; and syncope in one patient. Secondary: Not reported
Punzi, HA ¹³⁰ (2014) Once daily olmesartan	OL, PRO, blinded-endpoint Adults on 1, 2, or 3 antihypertensive	N=40 2 to 9 day screening period,	Primary: Mean change from baseline in 24 hour SBP ABPM at day 1	Primary: At day 1, treatment with OM/AM/HCTZ resulted in a significant mean reduction from baseline in ambulatory SBP reduction of 5.55 ± 1.3 mmHg (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
medoxomil (OM)/ amlodipine besylate (AM)/ HCTZ 40/10/25 mg	medications and not at goal BP, defined as less than 140/90 mmHg or less than 130/80 mmHg if they had diabetes or renal disease	followed by 4 to 6 weeks of open- label treatment	Secondary: Mean change from baseline in 24 hour DBP ABPM at day 1, the change from baseline in mean trough seated BP at weeks 1, 2, 3, and 4	Secondary: Significant proportion of patients (90%) receiving OM/AM/HCTZ achieved the seated BP goal of < 140/90 mmHg at week 4, with 97% achieving <140 mmHg. The proportion of patients achieving the 24 hour ambulatory BP target of <130/80 mmHg was 84% at week 4. At day 1, for the secondary endpoints, treatment with OM/AM/HCTZ resulted in a significant mean reduction from baseline in ambulatory DBP of 2.55 ± 1.0 (P<0.0052), seated cuff SBP reduction of 9.78 ± 1.5 (P<0.0001), and seated cuff DBP reduction of 4.13 ± 1.4 (P<0.0052).
Sharma et al. ¹³¹ (2012) Telmisartan vs placebo All patients are receiving amlodipine	DB, PG, RCT Patients with type 2 diabetes and stage 1 or 2 HTN	N=981 8 weeks	Primary: Change in mean seated trough cuff SBP at weeks 8 Secondary: Blood pressure goal rates; change in mean seated trough cuff SBP at weeks 1, 2, and 4; safety	Primary: After eight weeks, significantly greater reductions in mean seated trough cuff SBP was achieved with telmisartan compared to placebo (-29.0 vs -22.9 mm Hg; P<0.0001). Secondary: After eight weeks, 71.4 and 53.8% of patients achieved blood pressure goal (<140/90 mm Hg) with telmisartan compared to placebo. A blood pressure goal of <130/80 mm Hg was achieved by 36.4 and 17.9% of patients receiving telmisartan and placebo. Significant reductions in mean seated trough cuff SBP with telmisartan were evidence from week one (P<0.0001) and continued throughout the trial. The most common adverse events were peripheral edema, headache, and dizziness.
Williams et al. ¹³² (2009) PRISMA I and PRISMA II Ramipril 2.5 mg QD for 2 weeks then force titration to 5 mg QD for 6 weeks then 10 mg	Pooled analysis: blinded endpoint, OL, PRO, RCT Patients ≥ 18 years of age with mild- to moderate HTN	N=1,613 14 weeks	Primary: Change from baseline in mean ambulatory BP during the final 6 hours of the 24-hour dosing interval Secondary: Change from	Primary: A significantly greater reduction in mean ambulatory blood pressure during the last six hours of the 24-hour dosing interval was observed with telmisartan 80 mg group compared to ramipril 5 and 10 mg (P<0.0001). Secondary: Significantly greater reductions in mean 24-hour, morning, daytime, nighttime and 24-hour blood pressure load were observed with telmisartan 80 mg compared to ramipril 5 and 10 mg (P<0.0001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD for 6 weeks</p> <p>vs</p> <p>telmisartan 40 mg QD for 2 weeks then force titration to 80 mg QD for 12 weeks</p>			<p>baseline in mean ambulatory blood pressure during the 24-hour dosing interval, morning, daytime and nighttime ambulatory blood pressure, 24-hour blood pressure load, treatment response, blood pressure control</p>	<p>Significantly greater reductions in treatment response and blood pressure control rates were observed with telmisartan 80 mg compared to ramipril 5 and 10 mg (P<0.0001).</p>
<p>Karlberg et al.¹³³ (1999) TEES</p> <p>Enalapril 5 to 20 mg QD</p> <p>vs</p> <p>telmisartan 20 to 80 mg QD</p> <p>HCTZ 12.5 or 25 mg QD could be added to either group as needed to reach DBP goal (≤90 mm Hg)</p>	<p>DB, DD, MC, PG, RCT</p> <p>Patients ≥65 years of age with mild- to moderate HTN</p>	<p>N=278</p> <p>26 weeks</p>	<p>Primary: Change from baseline in supine SBP and DBP</p> <p>Secondary: Proportion of responders, safety</p>	<p>Primary: Both treatments had similar rates of HCTZ use.</p> <p>Both treatments showed comparable decreases in blood pressure. Mean changes in DBP were -12.8 mm Hg for telmisartan and -11.4 mm Hg for enalapril (P=0.074). Mean changes in SBP were -22.1 mm Hg for telmisartan and -20.1 mm Hg for enalapril (P=0.350).</p> <p>Secondary: Overall, 63 and 62% of patients responded to telmisartan and enalapril, respectively, with a DBP of <90 mm Hg. Both regimens provided effective blood pressure lowering over the 24-hour dosing interval, as determined by ambulatory blood pressure monitoring.</p> <p>Both regimens were well tolerated; however, the enalapril group had a higher incidence of cough than the telmisartan group (15.8 vs 6.5%; P value reported).</p>
<p>Xi et al.¹³⁴ (2008)</p> <p>Telmisartan</p> <p>vs</p>	<p>MA</p> <p>Patients with HTN</p>	<p>N=1,832 (11 trials)</p> <p>Variable duration</p>	<p>Primary: Reduction in DBP and SBP</p> <p>Secondary: Therapeutic</p>	<p>Primary: Use of telmisartan resulted in a significant reduction in clinic DBP (WMD, 1.52; 95% CI, 0.85 to 2.19) and SBP (WMD, 2.77; 95% CI, 1.90 to 3.63) when compared to losartan.</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
losartan			response of DBP and SBP, tolerability	<p>There was also a significant reduction in 24-hour mean ambulatory DBP (WMD, 2.49; 95% CI, 0.56 to 4.42) and SBP (WMD, 2.47; 95% CI, 0.40 to 4.55) with telmisartan as compared to losartan.</p> <p>There was a significant increase in therapeutic response of DBP (RR, 1.14; 95% CI, 1.04 to 1.23) and SBP response (RR, 1.10; 95% CI, 1.01 to 1.20) with telmisartan as compared to losartan.</p> <p>Both telmisartan and losartan were well tolerated.</p>
<p>Sharma et al.¹³⁵ (2007)</p> <p>Telmisartan and amlodipine 40-5 mg QD (fixed-dose combination)</p> <p>vs</p> <p>amlodipine 5 mg QD</p>	<p>DB, MC, RCT</p> <p>Patients 18 to 65 years of age with established stage II uncomplicated essential HTN</p>	<p>N=210</p> <p>12 weeks</p>	<p>Primary: SBP/DBP reductions and responder rates (SBP/DBP <130/<80 mm Hg)</p> <p>Secondary: Not reported</p>	<p>Primary: There was a significant reduction from baseline in mean SBP in both groups (telmisartan and amlodipine, from 176.3 to 128.0 mm Hg; amlodipine, from 171.8 to 143.4 mm Hg; both, P<0.05 vs baseline). There was a significant reduction in SBP from baseline in the telmisartan and amlodipine and amlodipine groups (-27.4% and -16.6%, respectively; P<0.05 within group and between groups).</p> <p>There was a significant reduction from baseline in mean DBP in both treatment groups (telmisartan and amlodipine, from 100.9 to 93.8 mm Hg; amlodipine, from 99.7 to 94.3 mm Hg; both, P<0.05). There was a 20.2% reduction in mean DBP in the telmisartan and amlodipine group, which was significantly greater compared to the reduction of 12.7% observed in the amlodipine group (P<0.05 between groups and within both groups).</p> <p>A total of 87.3% of patients receiving telmisartan and amlodipine reached the target SBP/DBP goal, compared to 69.3% of patients receiving amlodipine (P<0.05).</p> <p>A total of 16.0% of patients in the telmisartan and amlodipine group experienced adverse events compared to 15.4% of patients in the amlodipine group (P value not significant). The most common adverse events in the telmisartan and amlodipine group were peripheral edema (8.5%), headache (5.7%), dizziness and cough (3.8%), and diarrhea (1.9%).</p> <p>Secondary: Not reported</p>
Littlejohn et al. ¹³⁶	DB, MC, PC, RCT	N=2,607	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2009)</p> <p>Telmisartan 20 to 80 mg and amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>telmisartan 20 to 80 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 10 mg QD</p> <p>vs</p> <p>placebo</p>	<p>Patients ≥ 18 years of age with Stage 1 or 2 HTN (DBP ≥ 95 and ≤ 119 mm Hg)</p>	<p>8 weeks</p>	<p>Change in the in-clinic seated diastolic BP</p> <p>Secondary: Change in the in-clinic seated SBP, DBP and SBP response (DBP < 90 mm Hg, decrease in DBP ≥ 10 mm Hg, SBP < 140 mm Hg, decrease in SBP ≥ 15 mm Hg), and BP control (DBP < 90 mm Hg and SBP < 140 mm Hg)</p>	<p>Both telmisartan (irrespective of amlodipine dosage; $P < 0.0001$) and amlodipine (irrespective of telmisartan dosage; $P < 0.0001$) significantly lowered the in-clinic DBP.</p> <p>The greatest reduction in blood pressure was with telmisartan 80 mg plus amlodipine 10 mg (SBP/DBP -26.4/-20.1 mm Hg; $P < 0.05$ vs both monotherapies).</p> <p>DBP and SBP response was achieved by 91.2 and 90.4% of patients in the telmisartan 80 mg plus amlodipine 10 mg group, respectively.</p> <p>More than 50% of patients treated with combination therapy achieved blood pressure control, with the highest percentages (76.5% [overall control] and 85.3% [DBP control]) being achieved by patients treated with telmisartan 80 mg plus amlodipine 10 mg.</p> <p>A total of 37.3% of patients reported at least one adverse event. The most commonly reported adverse events were headache (5.4%) and peripheral edema (4.4%). Headache was more frequent in the placebo group (10.9%) compared to the telmisartan monotherapy (5.9%), amlodipine monotherapy (6.0%), and combination therapy (4.7%). The incidence of peripheral edema was highest in the amlodipine 10-mg group (17.8%); however, this rate was lower when amlodipine was used in combination with telmisartan: 11.4% (telmisartan 20 mg and amlodipine 10 mg), 6.2% (telmisartan 40 mg and amlodipine 10 mg), and 11.3% (telmisartan 80 mg and amlodipine 10 mg).</p>
<p>Littlejohn et al.¹³⁷ (2009)</p> <p>Telmisartan and amlodipine 40-5 mg QD (fixed-dose combination product)</p> <p>Vs</p> <p>telmisartan and</p>	<p>DB, DD, MC, PC, PG, RCT</p> <p>Patients ≥ 18 years of age with stage 1 or 2 HTN (DBP ≥ 95 and ≤ 119 mm Hg), with a subgroup analysis including patients with DBP ≥ 100 mm Hg at baseline</p>	<p>N=1,078</p> <p>8 weeks</p>	<p>Primary: Change in DBP from baseline to study end point</p> <p>Secondary: Change from baseline to study end in SBP; percent of patients achieving a DBP response (DBP < 90)</p>	<p>Primary: Significant reductions in DBP were seen from baseline to study end for both dual therapy and monotherapy (P values not reported).</p> <p>Amlodipine 5 and 10 mg with telmisartan 40 and 80 mg significantly reduced DBP compared to respective monotherapies (P values not reported).</p> <p>Secondary: Amlodipine 5 and 10 mg with telmisartan 40 and 80 mg significantly reduced SBP compared to respective monotherapies (P values not reported).</p> <p>Combination therapy resulted in a greater DBP and SBP response than</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>amlodipine 40-10 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan and amlodipine 80-5 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>telmisartan and amlodipine 80-10 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>respective monotherapies, dosing frequency not specified</p>			<p>mm Hg) and SBP response (SBP <140 mm Hg or reduction from baseline \geq15 mm Hg); percent of patients achieving BP control (SBP/DBP <140/<90 mm Hg) and DBP control (<90 mm Hg) and safety</p>	<p>monotherapy (P values not reported).</p> <p>The highest rate of BP control was achieved with amlodipine 10 mg with telmisartan 80 mg.</p> <p>Rates of adverse events were similar between dual therapy and monotherapy. Incidences of adverse events were 4.40% with telmisartan monotherapy, 11.00% with amlodipine monotherapy and 11.75% with combination therapy. The most commonly reported events were headache and peripheral edema. Patients receiving amlodipine 10 mg had the highest incidence of peripheral edema; however rates were lower when amlodipine was used in combination with telmisartan.</p>
<p>Neutel et al.¹³⁸ (2012) TEAMSTA</p> <p>Telmisartan and amlodipine 80-10 mg QD (fixed-dose combination product)</p>	<p>DB, MC, PG, RCT</p> <p>Patients \geq18 years of age with severe HTN</p>	<p>N=858</p> <p>8 weeks</p>	<p>Primary: Change in baseline blood pressure, blood pressure goal and response rates</p> <p>Secondary: Safety</p>	<p>Primary: Reductions in seated trough cuff blood pressure (-47.5/-18.7 mm Hg) were significantly greater with combination therapy compared to telmisartan (P<0.001) or amlodipine (P=0.002). Significant reductions with combination therapy were observed at one, two, four, and six weeks.</p> <p>Blood pressure goal and response rates were consistently higher with combination therapy (50.4 and 91.4 to 99.7%) compared to monotherapy with either agent (24.1 and 69.3 to 91.5% and 35.6 and 83.9 to 98.5%).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs telmisartan 80 mg QD vs amlodipine 10 mg QD				Secondary: Combination therapy was well tolerated and fewer adverse events were reported with combination therapy compared to amlodipine (12.6 vs 16.4%). Peripheral edema was reported more frequently with amlodipine compared to combination therapy (13.2 vs 9.3%).
Oparil et al. ¹³⁹ (2007) Aliskiren 150 to 300 mg QD vs valsartan 160 to 320 mg QD vs aliskiren 150 to 300 mg and valsartan 160 to 320 mg QD vs placebo	DB, MC, PC, RCT Men and women aged 18 years or over with stage 1-2 essential HTN (mean sitting DBP 95 to 109 mm Hg and 8-hr ambulatory DBP \geq 90 mm Hg)	N=1,797 8 weeks	Primary: Change in mean sitting DBP Secondary: Change in mean sitting SBP, proportion of patients achieving a successful response to treatment (mean sitting DBP <90 mm Hg and/or \geq 10 mm Hg reduction from baseline) or achieving blood pressure control (mean sitting SBP/DBP <140/90 mm Hg), change in 24-hr ABPM, change in biomarkers, safety	Primary: The combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting DBP from baseline by 12.2 mm Hg, significantly more than either monotherapy with aliskiren 300 mg (-9.0 mm Hg; P<0.0001), valsartan 320 mg (-9.7 mm Hg; P<0.0001) or with placebo (-4.1 mm Hg; P<0.0001). Monotherapy with aliskiren or valsartan provided significantly greater reductions in mean sitting DBP than did placebo at week 8 (P<0.0001 for all). Secondary: The combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting SBP from baseline by 17.2 mm Hg, significantly more than either monotherapy with aliskiren 300 mg (-13.0 mm Hg; P<0.0001), valsartan 320 mg (-12.8 mm Hg; P<0.0001), or with placebo (-4.6 mm Hg; P<0.0001). Monotherapy with aliskiren or valsartan provided significantly greater reductions in mean sitting SBP than did placebo at week eight end point (all P<0.0001). The proportion of patients achieving a successful response to treatment at week eight was significantly higher with the combination of aliskiren and valsartan (66%) than with aliskiren alone (53%; P=0.0003) or valsartan alone (55%; P=0.0010). All active treatments were associated with significantly greater responder rates than placebo (30%; P<0.0001 for all). The proportion of patients achieving blood pressure control was significantly greater in the combination group (49%) than in the aliskiren (37%; P=0.0005) or valsartan (34%; P<0.0001) monotherapy groups. All active treatments were associated with significantly greater control rates than placebo (16%;

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>P<0.0001 for all).</p> <p>The combination of aliskiren and valsartan was significantly more effective in lowering mean 24-hr ambulatory SBP and DBP than was either agent alone (P<0.0001 for all). The greater reductions in ambulatory blood pressure with aliskiren plus valsartan were maintained throughout the entire 24-hour dosing interval.</p> <p>Aliskiren and valsartan (P<0.0001) and monotherapy with aliskiren (P<0.0001) or valsartan (P=0.0002) provided significant increases in plasma renin concentrations versus placebo. Increases in plasma renin concentrations were significantly greater for the combination than aliskiren (P=0.0014) or valsartan (P<0.0001) monotherapy.</p> <p>Valsartan monotherapy produced significantly greater increases in plasma renin activity than placebo (160 vs 18%; P=0.0003). By contrast, aliskiren alone significantly reduced plasma renin activity by 73% (P<0.0001 vs placebo), while the combination of aliskiren plus valsartan led to a reduction in plasma renin activity of 44% (P<0.0001 vs placebo).</p> <p>The combination of aliskiren and valsartan (-31%; P<0.0001) and valsartan monotherapy (-25%; P=0.0007) provided significantly greater reductions in plasma aldosterone concentration than did placebo (7%), while aliskiren monotherapy had no significant effect (-5.9%; P=0.1059).</p> <p>Rates of adverse events and laboratory abnormalities were similar in all groups.</p>
<p>Yarows et al.¹⁴⁰ (2008)</p> <p>Aliskiren 150 mg QD for 4 weeks, followed by 300 mg QD for 4 weeks</p> <p>vs</p>	<p>Post-hoc analysis of patients with stage 2 HTN from Oparil et al.</p> <p>Men and women ≥18 years of age with stage 1 to 2 essential HTN (mean sitting DBP</p>	<p>N=1,797</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, proportion of patients achieving a successful response</p>	<p>Primary: In patients with stage 2 HTN, significantly greater reductions in DBP were demonstrated in the aliskiren and valsartan 300-320 mg group compared to either higher-dose monotherapy group (P<0.05) and placebo (P<0.0001).</p> <p>Secondary: In patients with stage 2 HTN, significantly greater reductions in SBP were demonstrated in the aliskiren and valsartan 300-320 mg group compared to either higher-dose monotherapy group (P<0.05) and placebo (P<0.0001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>valsartan 160 mg QD for 4 weeks, followed by 320 mg QD for 4 weeks</p> <p>vs</p> <p>aliskiren and valsartan 150-160 mg QD for 4 weeks, followed by 300-320 mg QD for 4 weeks (fixed-dose combination products)</p> <p>vs</p> <p>placebo</p>	<p>95 to 109 mm Hg and 8-hour ambulatory DBP \geq90 mm Hg)</p>		<p>to treatment (mean sitting DBP <90 mm Hg and/or \geq10 mm Hg reduction from baseline) or achieving blood pressure control (mean sitting SBP/DBP <140/90 mm Hg)</p>	<p>DBP and SBP reductions in both monotherapy groups were significantly greater compared to placebo ($P < 0.0001$).</p> <p>The proportion of patients with stage 2 HTN achieving blood pressure control at week eight was significantly greater in the aliskiren and valsartan 300-320 mg group compared to both monotherapy groups and placebo ($P \leq 0.044$).</p> <p>Blood pressure control rates in the aliskiren group were significantly greater than placebo ($P < 0.001$). No significant difference was observed between the valsartan monotherapy and placebo groups.</p>
<p>Pool et al.¹⁴¹ (2007)</p> <p>Aliskiren 75 to 300 mg QD</p> <p>vs</p> <p>valsartan 80 to 320 mg</p> <p>vs</p> <p>aliskiren 75 to 300 mg and valsartan</p>	<p>DB, MC, PC, PG, RCT</p> <p>Men and women \geq18 years with mild-to-moderate essential HTN (mean sitting DBP \geq95 mm Hg after a 3- to 4-week single-blind placebo run-in period)</p>	<p>N=1,123</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, safety</p>	<p>Primary: Aliskiren 300 mg significantly ($P < 0.0001$) lowered mean sitting DBP compared with placebo. Reductions in mean sitting DBP for aliskiren 75 and 150 mg compared to placebo failed to reach statistical significance ($P = 0.052$ and $P = 0.051$, respectively).</p> <p>Secondary: Aliskiren 300 mg significantly ($P < 0.0001$) lowered mean sitting SBP compared with placebo.</p> <p>A statistically significant linear dose relationship was observed for the effect of aliskiren (75 to 300 mg) on mean sitting DBP ($P = 0.0002$) and mean sitting SBP ($P = 0.0005$). The effects of aliskiren monotherapy on mean sitting DBP and SBP across the 75 to 300 mg dose range were similar to the effects of valsartan 80 to 320 mg.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>80 to 320 mg</p> <p>vs</p> <p>valsartan and HCTZ 160-12.5 mg QD (fixed-dose combination)</p> <p>vs</p> <p>placebo</p>				<p>Coadministration of aliskiren and valsartan produced a greater antihypertensive effect than either drug alone. Reductions in mean sitting DBP and SBP obtained with aliskiren 150 mg plus valsartan 160 mg and aliskiren 300 mg plus valsartan 320 mg were not significantly different from those observed with valsartan 160 mg plus HCTZ 12.5 mg.</p> <p>Responder rates were significantly greater than placebo for all 3 aliskiren monotherapy groups and for all aliskiren plus valsartan combinations. The proportion of responders with aliskiren 75 mg plus valsartan 80 mg was significantly greater than either component monotherapy (P<0.05). There was no significant difference between the proportion of responders to aliskiren 150 mg plus valsartan 160 mg or aliskiren 300 mg plus valsartan 320 mg compared with valsartan 160 mg plus HCTZ 12.5 mg.</p> <p>Control rates were higher with aliskiren 300 mg compared with placebo and with valsartan 160 mg plus HCTZ 12.5 mg compared with aliskiren 150 mg plus valsartan 160 mg, but there were no significant differences between aliskiren plus valsartan combinations and the respective monotherapies.</p> <p>Aliskiren and valsartan were generally well tolerated either as monotherapy or in combination. The overall incidence of adverse events and rate of discontinuations because of adverse events were similar to placebo in all active treatment groups.</p>
<p>Geiger et al.¹⁴² (2009)</p> <p>Aliskiren 150 to 300 mg QD, added to existing HCTZ therapy</p> <p>vs</p> <p>valsartan 160 to 320 mg QD, added to existing HCTZ therapy</p>	<p>AC, DB, RCT</p> <p>Patients ≥18 years of age with mild to moderate essential HTN who were taking HCTZ for 4 weeks with a DBP ≥95 mm Hg</p>	<p>N=641</p> <p>8 weeks</p>	<p>Primary: Change in DBP at week 8</p> <p>Secondary: Change SBP at week 8, change in DBP and SBP at week 4, proportion of patients achieving blood pressure control (SBP/DBP <140/90 mm Hg), change in</p>	<p>Primary: After eight weeks of therapy, the triple therapy showed significantly greater reductions in SBP and DBP compared with the other groups. The additional SBP and DBP reductions were 7 and 5 mm Hg, respectively compared to aliskiren and HCTZ (P<0.0001), 3 and 2 mm Hg compared to valsartan and HCTZ (P<0.01), and 15 and 10 mm Hg compared to HCTZ monotherapy (P<0.001).</p> <p>Aliskiren and HCTZ and valsartan and HCTZ combination therapies were more effective compared to HCTZ monotherapy. Valsartan and HCTZ were more effective than aliskiren and HCTZ. SBP and DBP were reduced by 15 and 11 mm Hg, respectively in the aliskiren and HCTZ group. SBP and DBP were reduced by 18 and 14 mm Hg, respectively, in the valsartan and HCTZ group.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>aliskiren 150 to 300 mg and valsartan 160 to 320 mg QD, added to existing HCTZ therapy</p> <p>vs</p> <p>HCTZ 25 mg QD</p>			<p>plasma renin activity, plasma renin concentration</p>	<p>Secondary:</p> <p>Blood pressure control rate was significantly higher with triple therapy compared to aliskiren and HCTZ (40.9%, P<0.001), valsartan and HCTZ (48.7%, P<0.001), and HCTZ monotherapy (20.5%, P<0.001).</p> <p>At week four, a significantly greater blood pressure control rate was observed for the triple therapy group at lower doses (150-160-25 mg) compared to the respective doses of the other groups: aliskiren and valsartan and HCTZ (300-320-25 mg) group (56%) compared to aliskiren and HCTZ (36.6%, P<0.05), valsartan and HCTZ (42.2%, P<0.05), and HCTZ monotherapy (19.9%, P<0.01).</p> <p>At week eight, plasma renin concentration was unchanged in the HCTZ group, but was significantly increased in other groups. A significant decrease in plasma renin activity from baseline was observed in the aliskiren and HCTZ group (P<0.001) and a significant increase was observed in the valsartan and HCTZ (P<0.001). In the HCTZ and triple therapy groups, there was no change in plasma renin activity (both P>0.75).</p>
<p>Maciejewski et al.¹⁴³ (2006)</p> <p>Valsartan 80 to 160 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p> <p>If blood pressure exceeded 140/90 while on highest treatment dose, HCTZ 12.5mg/day was added to the</p>	<p>DB, PRO, RCT, XO</p> <p>African-Americans, older than 35 years, with baseline blood pressure >140/90 mm Hg and not on antihypertensive treatment</p>	<p>N=20</p> <p>8 to 10 weeks for each arm with 2 week washout period before crossover</p>	<p>Primary:</p> <p>Comparison of 24 hour ABPM recordings</p> <p>Secondary:</p> <p>Magnitude of change from baseline in SBP and DBP with each treatment, percent of patients who achieved goal <140/<90 with each treatment based on clinic blood pressure measurements</p>	<p>Primary:</p> <p>There was no difference between the groups based on 24 hour ABPM: SBP amlodipine 130±8 vs valsartan 127±17 (P=0.350) and DBP amlodipine 82±5 vs valsartan 84±16 (P=0.430).</p> <p>Secondary:</p> <p>There was no difference between groups in magnitude of change from baseline in blood pressure (amlodipine -25±8/-18±7 vs valsartan -25±9/-16±7; P=0.61), and in percent of patients achieving goal blood pressure, 70% in the valsartan group and 75% in the amlodipine group (P=0.62).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
regimen.				
<p>Ichihara et al.¹⁴⁴ (2006)</p> <p>Valsartan 40 to 160 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 10 mg QD</p>	<p>RCT</p> <p>Patients with untreated HTN (clinic SBP >140 mm Hg and/or DBP >90 mm Hg; or ABPM SBP >135 mm Hg and/or DBP >98 mm Hg)</p>	<p>N=100</p> <p>12 months</p>	<p>Primary: ABPM and clinic blood pressure</p> <p>Secondary: Pulse wave velocity, carotid intima-media thickness, urinary albumin excretion</p>	<p>Primary: Both treatments resulted in significant decreases in blood pressure, both ambulatory and clinic, over 12 months from baseline; blood pressure decreases were similar between treatment groups (between treatments: clinic SBP P=0.34; clinic DBP P=0.85; 24 hour ABPM P=0.14).</p> <p>Blood pressure variability decreased significantly in the amlodipine group compared to the valsartan group, where there was no change in blood pressure variability (P<0.01).</p> <p>Secondary: The decrease in pulse wave velocity was significant from baseline for both groups, but not significantly different from each other (P<0.05 from baseline).</p> <p>Intima-media thickness was not changed significantly from baseline for either treatment (P>0.05 for both from baseline).</p> <p>Urinary albumin excretion in the valsartan group decreased significantly both from baseline and compared to amlodipine treatment (P<0.05 from baseline, P value for comparison not reported).</p>
<p>Philipp et al.¹⁴⁵ (2007)</p> <p><u>Study 1</u></p> <p>Valsartan 40 to 320 mg QD and amlodipine 2.5 to 5 mg QD</p> <p>vs</p> <p>amlodipine 2.5 to 5 mg QD</p> <p>vs</p>	<p>DB, MC, PC, RCT</p> <p>Males and females, ages 18 years and older with HTN (mean sitting DBP ≥95 mm Hg and <110 mm Hg)</p>	<p>N=1,911</p> <p>8 weeks</p>	<p>Primary: Mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, response rate (proportion of patients with mean sitting DBP <90 mm Hg or a ≥10 mm Hg reduction from baseline), control rate (proportion of patients with mean</p>	<p>Primary: All treatments significantly decreased mean sitting DBP from baseline (P<0.05).</p> <p>Combination treatment resulted in significantly greater blood pressure reduction than either monotherapy (P<0.05 for all combinations compared to respective doses of monotherapy except amlodipine 2.5 mg and valsartan 40 mg QD).</p> <p>Secondary: All treatments significantly decreased mean sitting SBP from baseline (P<0.05).</p> <p>Combination treatment resulted in significantly greater blood pressure reduction than either monotherapy (P<0.05 for all combinations compared to respective doses of monotherapy).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>valsartan 40 to 320 mg QD</p> <p>vs</p> <p>placebo</p>			<p>sitting DBP <90 mm Hg), adverse events (combined with study 2)</p>	<p>Response rates were significantly different from placebo for all treatment groups (P<0.05).</p> <p>Response rates for combination products were significantly different than each monotherapy for the following combinations: amlodipine 5 mg plus valsartan 80 mg, amlodipine 5 mg plus valsartan 40 mg and amlodipine 2.5 mg plus valsartan 80 mg (P<0.05 for each combination compared to both monotherapy).</p> <p>Response rates for all combinations produced significantly improved compared to either one of the monotherapies except amlodipine 2.5 mg plus valsartan 40 mg (P<0.05 for each combination compared to one of the respective monotherapy).</p> <p>Control rates with therapy were significantly better than placebo, with the highest control rate achieved with amlodipine 5 mg plus valsartan 320 mg (P<0.05 compared to placebo, P value not reported for others).</p> <p>Adverse event rates were not significantly different among combination treatment, amlodipine treatment, and placebo.</p> <p>Adverse event rates were significantly different between amlodipine plus valsartan and valsartan monotherapy (P<0.05).</p> <p>The most commonly reported adverse events for combination treatment were: peripheral edema, headache, nasopharyngitis, upper respiratory tract infection and dizziness. Peripheral edema occurred significantly less frequently in the combination treatment group than the amlodipine monotherapy group (5.4 vs 8.7%; P=0.014) and significantly more frequently than in the valsartan monotherapy group (5.4 vs 2.1%; P<0.001). Peripheral edema occurrence in the valsartan group was similar to the rate in the placebo group.</p>
<p>Philipp et al.¹⁴⁵ (2007)</p> <p><u>Study 2</u></p> <p>Valsartan 160 or</p>	<p>DB, MC, PC, RCT</p> <p>Male and females, ages 18 years and older with</p>	<p>N=1,250</p> <p>8 weeks</p>	<p>Primary: Mean sitting DBP</p> <p>Secondary: Change in mean</p>	<p>Primary: Mean sitting DBP was significantly reduced for both combination as compared to the individual components and to placebo (P<0.05).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>320 mg QD and amlodipine 10 mg QD</p> <p>vs</p> <p>amlodipine 10 mg QD</p> <p>vs</p> <p>valsartan 160 to 320 mg QD</p> <p>vs</p> <p>placebo</p>	<p>hypertension (mean sitting DBP \geq95 mm Hg and $<$110 mm Hg)</p>		<p>sitting SBP, response rate (proportion of patients with mean sitting DBP $<$90 mm Hg or a \geq10 mm Hg reduction from baseline), control rate (proportion of patients with mean sitting DBP $<$90 mm Hg), adverse events (combined with study 1)</p>	<p>Response rates and control rates for combination treatments were significantly greater than valsartan monotherapy therapy and placebo therapy, but not different from amlodipine monotherapy ($P<0.05$).</p> <p>Adverse event rates were not significantly different between combination treatment, amlodipine treatment and placebo.</p> <p>Adverse event rates were significantly different between amlodipine plus valsartan and valsartan monotherapy ($P<0.05$).</p>
<p>Sinkiewicz et al.¹⁴⁶ (2009)</p> <p>Amlodipine and valsartan 10-160 mg or 5-160 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>valsartan 160 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Patients \geq18 years of age with essential HTN (mean sitting DBP \geq90 mm Hg and $<$110 mm Hg) who were inadequately controlled on valsartan 160 mg</p>	<p>N=947</p> <p>8 weeks</p>	<p>Primary: Change from baseline in mean DBP</p> <p>Secondary: Change from baseline in mean sitting SBP, responder rate (mean DBP $<$90 mm Hg or \geq10 mm Hg reduction from baseline), and DBP control rate (mean DBP $<$ 90 mm Hg)</p>	<p>Primary: At week eight, a significantly greater reduction in mean DBP was observed with both amlodipine and valsartan combinations (10-160 mg: -11.5 mm Hg, 5-160 mg: -9.6 mm Hg; $P<0.0001$ for both) compared to valsartan monotherapy (-6.7 mm Hg).</p> <p>Secondary: At week eight, a significantly greater reduction in mean SBP was observed in both amlodipine and valsartan combinations (10-160 mg: -14.3 mm Hg, 5-160 mg: -12.2 mm Hg; $P<0.0001$ for both) compared to valsartan monotherapy (-8.3 mm Hg).</p> <p>Overall mean SBP/DBP reductions of 22.5/15.5 and 21.3/13.7 mm Hg were observed in the amlodipine and valsartan 10-160 and 5-160 mg treatment groups, respectively compared to 16.7/11.4 mm Hg in the valsartan 160 mg group. The amlodipine and valsartan 10-160 mg combination showed a significantly greater reduction in mean SBP/DBP compared to amlodipine and valsartan 5-160 mg ($P<0.001$).</p> <p>Responder rates were higher in both amlodipine and valsartan groups (10-160</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>mg: 81% [P<0.0001]; 5-160 mg: 68% [P=0.0018], respectively) compared to valsartan monotherapy (57%).</p> <p>Peripheral edema was the most frequent adverse event, which was reported in 9.1% of patients receiving amlodipine and valsartan (10-160 mg), 0.9% of patients receiving amlodipine and valsartan (5-160 mg), and 1.3% of patients receiving valsartan monotherapy.</p>
<p>Philipp et al (abstract).¹⁴⁷ (2011)</p> <p>Amlodipine and valsartan 10-160 or 10-320 mg/day (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine 10 mg/day</p> <p>vs</p> <p>valsartan 160 or 320 mg/day</p> <p>vs</p> <p>placebo</p>	<p>Post-hoc analysis</p> <p>Patients with HTN</p>	<p>N=834</p> <p>Not reported</p>	<p>Primary:</p> <p>Rate of blood pressure control (<140/90 mm Hg), change in baseline blood pressure</p> <p>Secondary:</p> <p>Safety</p>	<p>Primary:</p> <p>Two weeks after starting therapy, blood pressure control rates were greater with amlodipine and valsartan 10-320 mg/day (49%) vs monotherapies (32 to 38%) and placebo (16%). Consistent results were observed in patients with stage 1 and 2 HTN. Among patients receiving combination therapy, statistically significant differences were observed at endpoint vs comparators. At all baseline blood pressure levels, the probability of achieving a blood pressure <140/90 or <130/80 mm Hg was greater with combination therapy compared to monotherapies and placebo.</p> <p>Secondary:</p> <p>Overall adverse events incidence was similar with combination therapy vs monotherapies and placebo.</p>
<p>Fogari et al.¹⁴⁸ (2009)</p> <p>Valsartan and amlodipine 160-5 to 10 mg/day</p>	<p>Blind end endpoint, OL, PG, PRO, RCT</p> <p>Patients 75 to 89 years of age with moderate essential</p>	<p>N=94</p> <p>24 weeks</p>	<p>Primary:</p> <p>Proportion of patients achieving DBP <90 mm Hg</p> <p>Secondary:</p>	<p>Primary:</p> <p>The proportion of patients receiving valsartan and amlodipine and irbesartan and HCTZ who achieved blood pressure <140/<90 mm Hg was 82.9 and 85.1% (P value not significant between groups).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
(fixed-dose combination) vs irbesartan and HCTZ 300-12.5 to 25 mg/day (fixed-dose combination product)	HTN (SBP \geq 160, DBP $>$ 95 to $<$ 110 mm Hg)		Changes in ambulatory blood pressure, lying and standing changes in blood pressure, safety	Both treatment combinations resulted in a significant decrease in ambulatory blood pressure without any differences between treatment groups (P $<$ 0.001 from baseline, P $>$ 0.05 between groups). Results were similar between groups for lying SBP/DBP but patients receiving irbesartan and HCTZ experienced greater changes in ambulatory blood pressure than those receiving valsartan and amlodipine (17.2/9.0 vs 10.1/1.9 mm Hg; P $<$ 0.05 for SBP and P $<$ 0.01 for DBP). Changes from baseline in serum potassium (decrease) and uric acid (increase) were significant for those receiving irbesartan and HCTZ, but not valsartan and amlodipine (P $<$ 0.05 for irbesartan and HCTZ).
Poldermans et al. ¹⁴⁹ (2007) Valsartan 160 mg QD and amlodipine 5 to 10 mg QD vs lisinopril 10 to 20 mg and HCTZ 12.5 mg QD	AC, DB, MC, PG, RCT Males and females, ages 18 years and older with HTN (mean DBP \geq 110 mm Hg and $<$ 120 mm Hg)	N=130 6 weeks	Primary: Safety/adverse events, vital signs, hematology, biochemistry variables Secondary: Efficacy (mean DBP, response rate, proportion of patients with mean DBP $<$ 90 mm Hg or a \geq 10 mm Hg reduction from baseline)	Primary: Both treatments were well tolerated, 26 (40.6%) of patients receiving amlodipine and valsartan and 21 (31.8%) of patients receiving lisinopril and HCTZ reported an adverse events and most were not considered drug related. Peripheral edema was reported more often in the amlodipine and valsartan group than the lisinopril and HCTZ group (7.7 vs 1.5%) and cough was reported less often in the amlodipine and valsartan group than the receiving lisinopril and hydrochlorothiazide group (1.6 vs 3.0%). No difference was found between the treatments in changes in laboratory values or biochemistry variables. Secondary: Both treatments led to a reduction in mean SBP and DBP (P $<$ 0.0001 for both from baseline) but were not significantly different from each other. Mean blood pressure for each group at study end: amlodipine and valsartan 135.0/83.6 mm Hg and lisinopril and HCTZ 138.7/85.2 mm Hg. The response rate was similar among the groups (100 vs 95.5%; P value not significant).
White et al. ¹⁵⁰ (2008) Val-DICTATE	AC, MC, PG, RCT Patients with stage 1 to 2 HTN whose BP	4 weeks Duration not reported	Primary: Percentage of patients whose clinic blood	Primary: A significantly higher proportion of hypertensive patients met blood pressure control levels in the valsartan and HCTZ group (37%) compared to the HCTZ group (16%; P $<$ 0.001).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Valsartan and HCTZ 160-12.5 mg QD (fixed-dose combination product) vs HCTZ 25 mg QD	remained uncontrolled on HCTZ 12.5 mg		pressure values were <140/90 mm Hg and blood pressure values Secondary: Not reported	Changes in SBP and DBP were significantly greater with valsartan and HCTZ (-12.4/-7.5 mm Hg) compared to HCTZ (-5.6/-2.1 mm Hg; P<0.001). Secondary: Not reported
Waeber et al. ¹⁵¹ (2001) Valsartan 80 mg QD, which was switched to valsartan 80 mg and HCTZ 12.5 mg QD or valsartan 80 mg and benazepril 10 mg QD	OL, RCT Patients with mild-to-moderate uncontrolled HTN (DBP ≥90) while on valsartan monotherapy	N=327 4 weeks	Primary: Efficacy and safety Secondary: Not reported	Primary: The two combinations produced an additional blood pressure reduction compared to monotherapy (P<0.001 for both), with similar DBP reductions reported for the two combination groups (-4.5 mm Hg with valsartan plus HCTZ and -3.3 mm Hg with valsartan plus benazepril). SBP reductions of -6.7 and -3.2 mm Hg with valsartan plus HCTZ and valsartan plus benazepril, respectively, were reported (P=0.1). At the end of the trial, the blood pressure of the responders to valsartan monotherapy was lower than that of patients requiring combination therapy. Valsartan given alone or in association with HCTZ or benazepril was well tolerated. Secondary: Not reported
Schweizer et al. ¹⁵² (2007) Valsartan and HCTZ 160-25 mg QD (fixed-dose combination)	OL Hypertensive patients not adequately controlled by free combination of candesartan and HCTZ for 4 weeks	N=197 8 weeks	Primary: Reduction in mean sitting DBP between week 4 and 8 Secondary: Reduction in mean sitting SBP from week 4 to 8	Primary: At baseline, DBP was 103.0 mm Hg. After four weeks of candesartan and HCTZ, DBP decreased to 93.8 mm Hg. Subsequent treatment with valsartan and HCTZ for four additional weeks reduced DBP to 88.7 mm Hg. This represented an additional decrease in DBP of 5.1 mm Hg (P<0.0001). Secondary: The valsartan and HCTZ fixed-dose combination reduced SBP by 3.4 mm Hg (P=0.0029).
Lai et al. ¹⁵³ (2011)	MC, OS	N=7,567	Primary: Safety, efficacy	Primary: After 24 weeks, basal blood pressure was 155.9±13.3/96.3±10.1 mm Hg. SBP

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Valsartan and HCTZ 80-12.5 mg QD (fixed-dose combination product)	Asian patients with stage 1 or 2 essential HTN	24 week (follow-up)	Secondary: Not reported	and DBP reductions were -25.4 ± 15.2 and -14.9 ± 13.5 mm Hg ($P < 0.001$). Response and control rates increased continuously from baseline to trial end (trial end: 94.3 and 73.6%, respectively). Based on a four point global assessment scale, 96.8% of patients and physicians reported good, very good, or excellent for subjective efficacy and tolerability assessments. Secondary: Not reported
Izzo Jr et al. ¹⁵⁴ (2011) ValVET Valsartan and HCTZ 160-12.5 mg QD (fixed-dose combination product) vs valsartan 160 mg QD vs HCTZ 12.5 mg QD All patients were allowed to up titrate study medication if blood pressure did not improve.	DB, RCT Patients ≥ 70 years of age with systolic HTN	N=384 16 weeks	Primary: Change in baseline SBP at week 4 Secondary: Time to blood pressure control	Primary: At week four, reductions in baseline SBP were significantly greater with combination therapy (-17.3 mm Hg) compared to valsartan (-8.6 mm Hg; $P < 0.001$). At this time, reductions with combination therapy and HCTZ were similar (-17.3 vs -13.6 mm Hg; $P = 0.096$). Secondary: Median time to blood pressure control was significantly shorter with combination therapy compared to HCTZ (four vs eight weeks; $P < 0.05$) and valsartan (four vs 12 weeks; $P < 0.0001$).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Duprez et al (abstract).¹⁵⁵ (2011) ValVET</p> <p>Valsartan and HCTZ 160-12.5 mg QD (fixed-does combination product)</p> <p>vs</p> <p>valsartan 160 mg QD</p> <p>vs</p> <p>HCTZ 12.5 mg QD</p> <p>All patients were allowed to up titrate study medication if blood pressure did not improve.</p>	<p>Subgroup analysis</p> <p>Patients \geq70 years of age with systolic HTN</p>	<p>N=108</p> <p>Duration not specified</p>	<p>Primary: Change in ambulatory SBP</p> <p>Secondary: Safety</p>	<p>Primary: Initiation of treatment with combination valsartan and HCTZ reduced ambulatory blood pressure more effectively compared to monotherapy with either valsartan or HCTZ throughout daytime, night-time, and 24 hr monitoring periods, as well as during the last four to six hour dosing periods.</p> <p>Twenty-four hour ambulatory blood pressure was reduced from 141.1/76.5 to 125.8/69.2 mm Hg by week four with combination valsartan and HCTZ compared to reductions from 142.2/78.7 to 139.1/77.5 mm Hg with HCTZ and 142.2/78.3 to 136.4/75.1 mm Hg with valsartan (P<0.01 for all).</p> <p>Secondary: In the overall study, tolerability was similar among the three treatment groups.</p>
<p>Fogari et al.¹⁵⁶ (2006)</p> <p>Valsartan 160 mg</p> <p>vs</p> <p>olmesartan 20 mg</p> <p>All patients were</p>	<p>PG, PRO, RCT</p> <p>Hypertensive patients aged 35 to 75 years with DBP 90 to 110 mm Hg after 4 weeks of monotherapy on either valsartan or olmesartan</p>	<p>N=130</p> <p>8 weeks (4 weeks of combination therapy)</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: Both combinations induced a greater ambulatory blood pressure reduction than monotherapy. However, mean reduction from baseline in the valsartan and HCTZ-treated patients (-21.5/-14.6 mm Hg for 24 hours, -21.8/-14.9 mm Hg for daytime, and -20.4/-13.7 mm Hg for nighttime SBP/DBP) was greater than in the olmesartan and HCTZ-treated patients (-18.8/-12.3 mm Hg for 24 hours, -19.3/-12.8 mm Hg for daytime, and -17.4/-10.6 mm Hg for nighttime SBP/DBP). The difference between the effects of the two treatments was significant (P<0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
also receiving HCTZ 12.5 mg QD.				Plasma concentrations of HCTZ were significantly greater with valsartan than with olmesartan at each determination time (P<0.05). Secondary: Not reported
White et al. ¹⁵⁷ (2008) Valsartan 160 mg and HCTZ 25 mg QD vs telmisartan 80 mg and HCTZ 25 mg QD vs placebo	DB, PC, RCT Hypertensive patients	N=1,181 8 weeks	Primary: Changes in DBP and SBP at 8 weeks Secondary: Safety	Primary: Changes from baseline in blood pressure following telmisartan and HCTZ (-24.6/-18.2 mm Hg) were significantly greater than both valsartan and HCTZ (-22.5/-17.0 mm Hg; P=0.017 for SBP and P=0.025 for DBP), and placebo (-4.1/-6.1 mm Hg; P<0.0001). Secondary: The total number of patients with at least one adverse event reported was similar among the 3 treatment groups and was 37% for valsartan and HCTZ, 36% for telmisartan and HCTZ, and 42% for placebo.
Sharma et al. ¹⁵⁸ (2007) SMOOTH Valsartan 160 mg for 4 weeks vs telmisartan 80 mg for 4 weeks After 4 weeks, all patients received add-on HCTZ 12.5 mg QD for 6 six	MC, OL, PRO, RCT, blinded-end point Men and women aged ≥30 years with mild-to-moderate HTN (mean seated SBP 140 to 179 mm Hg and/or DBP 95 to 109 mm Hg), with type 2 diabetes and BMI >27 kg/m ²	N=840 10 weeks	Primary: Change in mean ambulatory SBP and DBP Secondary: Not reported	Primary: At 10 weeks, telmisartan and HCTZ provided significantly greater reductions in the last six hours of mean ambulatory blood pressure (differences in SBP were 3.9 mm Hg; P<0.0001 and differences in DBP were 2.0 mm Hg; P=0.0007). Telmisartan and HCTZ also produced significantly greater reductions than valsartan and HCTZ in 24-hour mean ambulatory blood pressure (differences in SBP were 3.0 mm Hg; P=0.0002 and differences in DBP were 1.6 mm Hg; P=0.0006) and during morning, daytime and nighttime periods (P<0.003). Both treatments were well tolerated. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>weeks.</p> <p>Calhoun et al.¹⁵⁹ (2009)</p> <p>Valsartan and HCTZ 320-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and valsartan 10-320 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and HCTZ 10-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and valsartan and HCTZ 10-320-25 mg QD (fixed-dose combination product)</p>	<p>DB, MC, RCT</p> <p>Patients 18 to 85 years of age with moderate to severe essential HTN</p>	<p>N=2,271</p> <p>8 weeks</p>	<p>Primary: Difference in mean sitting diastolic blood pressure and mean sitting systolic blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: At each assessment after week three, a significantly greater proportion of patients receiving triple therapy achieved overall blood pressure control (<140/90 mm Hg) compared to those receiving any of the dual therapies (all P<0.0001).</p> <p>At end point, 70.8% of patients in the triple-therapy group achieved control, compared to 48.3% for valsartan and HCTZ, 54.1% for amlodipine and valsartan, and 44.8% for amlodipine and HCTZ (all P<0.0001).</p> <p>Triple therapy with amlodipine and valsartan and HCTZ improved blood pressure control significantly better than any of the dual therapies.</p> <p>Secondary: Not reported</p>
<p>Calhoun et al.¹⁶⁰ (2009)</p>	<p>Secondary analysis</p> <p>Patients 18 to 85</p>	<p>N=2,271</p> <p>8 weeks</p>	<p>Primary: Proportion and mean SBP of</p>	<p>Primary: The proportion of patients with mean SBP reductions ≥ 20 mm Hg was greater with triple therapy than dual therapy at week three (74.5 vs 58.8 to 65.5%) and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Valsartan and HCTZ 320-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and valsartan 10-320 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and HCTZ 10-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine and valsartan and HCTZ 10-320-25 mg QD (fixed-dose combination product)</p>	<p>years of age with moderate to severe HTN (mean SBP/DBP $\geq 145/\geq 100$ mm Hg)</p>		<p>patients with mean SBP reductions ≥ 60, ≥ 50, ≥ 40, ≥ 30 and ≥ 20 mm Hg at week three and at the end of the study</p> <p>Secondary: Changes from baseline in mean SBP based upon baseline severity, SBP control rates, safety</p>	<p>at study endpoint (87.6 vs 75.8 to 81.5%).</p> <p>More patients who received triple therapy, as compared to dual therapy, achieved mean SBP reductions of ≥ 30, ≥ 40, ≥ 50 and ≥ 60 mm Hg at week three and at study endpoint (P value not reported).</p> <p>In patients with severe SBP (≥ 180 mm Hg), triple therapy resulted in significantly greater reductions than those for each dual therapy at week three (P<0.01), except for amlodipine/valsartan (P=0.11).</p> <p>Secondary: Patients with higher baseline mean SBP had greater reductions in mean SBP than those with lower baseline mean SBP. Changes in mean SBP were significantly greater for triple therapy than dual therapy for all baseline SBP (P<0.05), except for valsartan and HCTZ and amlodipine and HCTZ in patients with baseline mean SBP 150 to <160 mm Hg (P value not reported).</p> <p>Significantly more patients (91.8%) receiving triple therapy achieved SBP control (≥ 20 mm Hg reduction or mean SBP <140 mm Hg) compared to those receiving amlodipine and HCTZ (80.1%), valsartan and HCTZ (80.8%) or valsartan and amlodipine (85.7%) (P<0.01 for all).</p> <p>The overall incidence of adverse events was comparable across treatments, regardless of baseline blood pressure severity.</p>
<p>Karotsis et al.¹⁶¹ (2006)</p> <p>Valsartan 80 mg QD</p> <p>vs</p>	<p>RCT</p> <p>Patients 25 to 79 years of age with uncontrolled HTN (average office blood pressure</p>	<p>N=211</p> <p>8 weeks</p>	<p>Primary: Blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: There was a significant decline in both office and home SBP and DBP during the trial with all treatments. The antihypertensive effect was more pronounced and reached significance when home blood pressure monitoring was used in comparison to office blood pressure without the white-coat effect (P<0.001 for all blood pressure changes). With or without the white-coat effect, blood pressure still declined and the differences were significant (P<0.0001 for all</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>lisinopril 10 mg QD vs chlorthalidone 12.5 mg QD vs felodipine 5 mg QD All patients also received diltiazem 240 mg QD.</p>	<p>>140/90 mm Hg for all or >153/85 mm Hg for diabetics or patients <65 years of age, confirmed on 2 office visits \geq1 week apart) after \geq4 weeks of OL monotherapy with diltiazem at 240 mg QD</p>			<p>blood pressure changes). Secondary: Not reported</p>
<p>Conlin et al.¹⁶² (2000) PREVAIL Candesartan 8 to 16 mg QD, irbesartan 150 to 300 mg QD, losartan 50 to 100 mg QD, and valsartan 80 to 160 mg QD vs another ARB vs ARB plus low-</p>	<p>MA Patients with HTN</p>	<p>N=11,281 (43 trials) Duration varied</p>	<p>Primary: Weighted average for SBP and DBP reduction with ARB monotherapy, dose titration, and with the addition of low-dose HCTZ were calculated; responder rates Secondary: Not reported</p>	<p>Primary: The absolute weighted-average reductions in DBP (8.2 to 8.9 mm Hg) and SBP (10.4 to 11.8 mm Hg) for ARB monotherapy were comparable for all ARBs. Responder rates for ARB monotherapy were 48 to 55%. Dose titration resulted in slightly greater blood pressure reductions and an increase in responder rates of 53 to 63%. ARB and HCTZ combinations produced substantially greater reductions in SBP (16.1 to 20.6 mm Hg) and DBP (9.9 to 13.6 mm Hg) than ARB monotherapy. Responder rates for ARB and HCTZ combinations were 56 to 70%. The authors concluded that candesartan, irbesartan, losartan, and valsartan produced comparable antihypertensive efficacy when administered at their recommended doses, a near flat dose response when titrating from starting to maximum recommended dose, and substantial potentiation of the antihypertensive effect with addition of HCTZ. Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
dose HCTZ				Not reported
Stanton et al. ¹⁶³ (2010) Aliskiren 300 mg QD vs irbesartan, losartan, valsartan, ramipril, HCTZ, placebo	MA Adults with mild to moderate essential HTN	N=4,877 (8 trials) 4 to 12 weeks	Primary: Paradoxical blood pressure rises, as well as the percentage of patients with SBP increases (>10 or >20 mm Hg) or DBP increases (>5 or >10 mm Hg) from baseline Secondary: Not reported	Primary: There were no significant differences among the pooled aliskiren, irbesartan, losartan, valsartan, ramipril, and HCTZ groups in the incidence of SBP increases >10 mm Hg (P=0.30) and >20 mm Hg (P=0.28) or DBP increases >5 mm Hg (P=0.65) and >10 mm Hg (P=0.5). Increases in SBP and DBP occurred significantly more frequently in the pooled placebo group than the aliskiren group (P<0.001). Secondary: Not reported
Lindholm et al. ¹⁶⁴ (2005) Other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide*, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil) or placebo	MA 13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both	N=105,951 2.1 to 10.0 years	Primary: Stroke, MI, all-cause mortality Secondary: Not reported	Primary: The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001). The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported). The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol, or propranolol)				
Van Bortel et al. ¹⁶⁵ (2008) ACE inhibitor, ARB, β-blocker, calcium channel blocker, or placebo vs nebivolol	MA 12 RCTs involving >25 patients with essential HTN where nebivolol 5 mg QD was compared to placebo or other active drugs for >1 month	N=2,653 Duration varied	Primary: Antihypertensive effect and tolerability Secondary: Not reported	Primary: Overall, higher response rates were observed with nebivolol than all other antihypertensive agents combined (OR, 1.41; 95% CI, 1.15 to 1.73; P=0.001) and compared to the ACE inhibitors (OR, 1.92; 1.30 to 2.85; P=0.001), but response rates to nebivolol were similar to β-blockers (OR, 1.29; 95% CI, 0.81 to 2.04; P=0.283), calcium channel blockers (OR, 1.19; 95% CI, 0.83 to 1.70; P=0.350) and losartan (OR, 1.35; 95% CI, 0.84 to 2.15; P=0.212). Overall, a higher percentage of patients obtained normalized blood pressure with nebivolol compared to the other antihypertensive agents combined (OR, 1.35; 95% CI, 1.07 to 1.72; P=0.012). A higher percentage of patient receiving nebivolol obtained normalized blood pressure compared to losartan (OR, 1.98; 95% CI, 1.24 to 3.15; P=0.004) and calcium channel blockers (OR, 1.96; 95% CI, 1.05 to 1.96; P=0.024), but not when compared to other β-blockers (OR, 1.29; 95% CI, 0.81 to 1.65; P=0.473). Overall, the percentage of adverse events was significantly lower with nebivolol compared to the other antihypertensive agents combined (OR, 0.59; 95% CI, 0.48 to 0.72; P<0.001) and similar to placebo (OR, 1.16; 95% CI, 0.76 to 1.67; P=0.482). In comparing nebivolol to the individual treatments, nebivolol had a lower percentage of adverse events compared to losartan (OR, 0.52; 95% CI, 0.30 to 0.89; P=0.016), the other β-blockers (OR, 0.56; 95% CI, 0.36 to 0.85; P=0.007) and calcium channel blockers (OR, 0.49; 95% CI 0.33 to 0.72; P<0.001), but was similar to ACE inhibitors (OR, 0.75; 95% CI 0.52 to 1.08). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Wiysonge et al.¹⁶⁶ (2007)</p> <p>Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>	<p>MA</p> <p>13 RCTs evaluating patients ≥18 years of age with HTN</p>	<p>N=91,561</p> <p>Duration varied</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions</p>	<p>Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p> <p>Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>
<p>Baguet et al.¹⁶⁷ (2007)</p>	<p>MA</p> <p>Patients greater than</p>	<p>N=10,818</p> <p>8 to 12</p>	<p>Primary: Weighted average reductions in SBP</p>	<p>Primary: Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren)</p> <p>Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>	<p>18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>weeks</p>	<p>and DBP</p> <p>Secondary: Not reported</p>	<p>-18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>
<p>Miscellaneous</p>				

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Papademetriou et al. ¹⁶⁸ (2004) SCOPE Candesartan 16 mg/day vs placebo in addition to conventional therapy (diuretics, ACE inhibitors, β -blockers, calcium channel blockers)	DB, MC, PC, PG, RCT Patients 7 to 89 years old with isolated systolic HTN (SBP >160 mm Hg and DBP <90 mm Hg) and MMSE scores \geq 24	N=1,518 3.7 years	Primary: First major coronary event including cardiovascular death, nonfatal MI, or nonfatal stroke Secondary: cardiovascular death, nonfatal and fatal stroke and MI	Primary: There was no difference in the first major cardiovascular event between patients (with isolated systolic hypertension) who were treated with candesartan vs placebo (RR, 0.89; 95% CI, 0.65 to 1.21; P>0.20). Secondary: A total of 20 fatal/nonfatal strokes occurred in the candesartan group and 35 in the control group (RR, 0.58; 95% CI, 0.33 to 1.0) for a RR reduction of 42% (P=0.050 unadjusted and P=0.049 adjusted for baseline risk). There were no marked or statistically significant differences between the treatment groups in other cardiovascular end points or all-cause mortality.
Ogihara et al. ¹⁶⁹ (2008) CASE-J Candesartan 4 to 12 mg QD vs amlodipine 2.5 to 10 mg QD	AC, MC, OL, RCT Patients with high risk HTN (SBP \geq 140 mm Hg or DBP \geq 90 mm Hg in patients <70 years old or SBP \geq 160 mm Hg or DBP \geq 90 mm Hg in patients \geq 70 years old), with either type 2 diabetes, history of stroke or ischemic attack, left ventricular hypertrophy, proteinuria or serum creatinine \geq 1.3 mg/dL	N=4,703 Up to 4 years	Primary: First fatal or nonfatal cardiovascular event Secondary: All-cause death, new-onset diabetes, discontinuation due to adverse events	Primary: A total of 134 patients experienced a cardiovascular event in each treatment regimen (HR, 1.0; 95% CI, 0.78 to 1.27; P=0.969). Secondary: All-cause death rates did not differ between treatments, 73 deaths in the candesartan group and 86 in the amlodipine group. New-onset diabetes occurred in significantly fewer patients in the candesartan group than the amlodipine group (HR, 0.64; 95% CI, 0.43 to 0.97; P=0.033). A total of 125 (5.4%) patients in the candesartan group and 134 (5.8%) of patients in the amlodipine group discontinued due to adverse events.
Taniguchi et al. ¹⁷⁰	DB, RCT, XO	N=97	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2006)</p> <p>Candesartan 8 mg in addition to spironolactone 25 mg QD for 6 months, after 6 months of candesartan monotherapy (combination group)</p> <p>vs</p> <p>candesartan 8 mg daily for 12 months</p>	<p>Patients, 67 years of age on average, with essential HTN and left ventricular hypertrophy</p>	<p>1 year</p>	<p>Change in blood pressure and relative wall thickness</p> <p>Secondary: Not reported</p>	<p>Both study groups experienced a statistically significant reduction in blood pressure from baseline (P<0.05).</p> <p>While candesartan was associated with a significant reduction in relative wall thickness among patients with concentric left ventricular remodeling or hypertrophy (P<0.05), the addition of spironolactone did not provide additional benefit.</p> <p>Secondary: Not reported</p>
<p>Montalescot et al.¹⁷¹ (2009) ARCHIPELAGO</p> <p>Enalapril 10 mg QD, followed by 20 mg QD on day 15</p> <p>vs</p> <p>irbesartan 150 mg QD, followed by 300 mg QD on day 15</p>	<p>AC, DB, MC, RCT</p> <p>Adults with non-ST elevation ACS</p>	<p>N=429</p> <p>60 days</p>	<p>Primary: Change from baseline in high-sensitivity C-reactive protein at day 60</p> <p>Secondary: Changes in other inflammatory markers such as troponin I</p>	<p>Primary: High-sensitivity C-reactive protein levels were comparable in both treatment groups (irbesartan: 15.2 mg/L at baseline, 6.5 mg/L at day 60; absolute change of -8.7 mg/L; enalapril: 12.6 mg/L at baseline, 5.5 mg/L at day 60; absolute change of -7.1 mg/L, P value not significant).</p> <p>Secondary: Similarly, mean levels of markers of myocardial injury (troponin I) and endothelial dysfunction (microalbuminuria) also decreased from baseline to day 60, with no significant differences between treatment groups.</p>
<p>Solomon et al.¹⁷² (2009) ALLAY</p>	<p>AC, RCT</p> <p>Adults with HTN</p>	<p>N=465</p> <p>9 months</p>	<p>Primary: Change in left ventricular mass</p>	<p>Primary: There were reductions in left ventricular mass from baseline in all treatment groups, with 4.9-g/m² (5.4%), 4.8-g/m² (4.7%), and 5.8-g/m² (6.4%) reductions</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Losartan 100 mg QD</p> <p>vs</p> <p>aliskiren 300 mg QD</p> <p>vs</p> <p>aliskiren 300 mg and losartan 100 mg QD</p>	<p>and increased left ventricular wall thickness</p>		<p>Secondary: Not reported</p>	<p>in the aliskiren, losartan, and combination arms, respectively (P<0.0001 for all treatment groups).</p> <p>The reduction in left ventricular mass in the combination group was not significantly different from that with losartan alone (P=0.52).</p> <p>The difference in left ventricular mass regression between the aliskiren and losartan arms was within the prespecified non-inferiority margin, suggesting that aliskiren was as effective as losartan in reducing left ventricular hypertrophy (P<0.0001 for non-inferiority).</p> <p>Secondary: Not reported</p>
<p>Fliser et al.¹⁷³ (2004) EUTOPIA</p> <p>Olmesartan 20 mg/day</p> <p>vs</p> <p>placebo</p> <p>All patients received pravastatin 20 mg/day after six weeks of therapy.</p>	<p>DB, PC, PG, RCT</p> <p>Patients ≥18 years old with HTN, atherosclerotic disease, type 2 diabetes mellitus, and/or LDL-C between 3.89 to 6.48 mmol/L</p>	<p>N=199</p> <p>12 weeks</p>	<p>Primary: Evaluate anti-inflammatory effects of olmesartan using a panel of inflammation markers: high-sensitivity C-reactive protein, high-sensitivity tumor necrosis factor-α, interleukin-6</p> <p>Secondary: Not reported</p>	<p>Primary: After six weeks of therapy, olmesartan treatment significantly reduced serum levels of C-reactive protein (-15.1%; P<0.05), tumor necrosis factor-α (-8.9%; P<0.02), interleukin-6 (-14.0%; P<0.05) and monocyte chemoattractant protein-1 (-6.5%; P<0.01), whereas placebo treatment had no major effect on inflammation markers.</p> <p>After 12 weeks of therapy, C-reactive protein (-21.1%; P<0.02), tumor necrosis factor-α (-13.6%; P<0.01), and interleukin-6 (-8.0%; P<0.01) decreased further with olmesartan and pravastatin cotherapy, but treatment with pravastatin alone did not significantly alter inflammation markers.</p> <p>In contrast, addition of pravastatin led to a significant (P<0.001) reduction in LDL-C in the olmesartan and placebo groups (-15.1 and -12.1%, respectively).</p> <p>Secondary: Not reported</p>
<p>Rosendorff et al.¹⁷⁴ (2009)</p> <p>Olmesartan 20 to 40 mg QD</p>	<p>DB, AC, RCT</p> <p>Adults with HTN and left ventricular hypertrophy</p>	<p>N=102</p> <p>52 weeks</p>	<p>Primary: Change in left ventricular mass from baseline to 52 weeks</p>	<p>Primary: Mean±SD left ventricular masses of 252.9±73.06 g in the olmesartan group and 236.9±59.94 g in the amlodipine group at baseline were decreased to 248.2±69.31 and 223.9±53.18 g, respectively, after 52 weeks of therapy. Neither of these changes was significantly different from baseline, and the difference between the two treatment groups was not significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs amlodipine 5 to 10 mg QD			Secondary: Change in left ventricular mass after 26 weeks of treatment	Secondary: At 26 weeks, adjusted percent changes in left ventricular mass were 8.0% with olmesartan and 6.0% with amlodipine. Changes occurring at the 26-week assessment were not significantly different from baseline or from each other.
ONTARGET Investigators ¹⁷⁵ (2008) Ramipril 10 mg/day vs telmisartan 80 mg/day vs ramipril 10 mg/day and telmisartan 80 mg/day	DB, MC, PC, RCT Patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage	N=25,620 56 months (median follow-up)	Primary: Death from cardiovascular causes, MI, stroke or hospitalization for heart failure Secondary: Composite of death from cardiovascular causes, MI or stroke; heart failure, worsening or new angina, new diagnosis diabetes mellitus, new atrial fibrillation, renal impairment, revascularization procedures	Primary: The primary outcome occurred in 16.5, 16.7, and 16.3% of patients receiving ramipril, telmisartan and combination therapy, respectively. Secondary: The composite of death from cardiovascular causes, MI or stroke occurred in 14.1% of patients in the ramipril group and 13.9% of patients in the telmisartan group (RR, 0.99; 95% CI, 0.91 to 1.17; P=0.001 for non-inferiority). Combination therapy was not significantly better than ramipril alone (RR, 0.99; 95% CI, 0.92 to 1.17). There were no significant differences in the rates of secondary outcomes, except for renal dysfunction, which occurred in 10.2% of patients receiving ramipril, 10.6% of patients receiving telmisartan and 13.5% of patients receiving combination therapy (P<0.001 vs ramipril; P value not reported vs telmisartan). As compared to the ramipril group, the telmisartan group had lower rates of cough (1.1 vs 4.2%; P<0.001) and angioedema (0.1 vs 0.3%; P=0.01) and a higher rate of hypotensive symptoms (2.6 vs 1.7%; P<0.001); the rate of syncope was the same in the two groups (0.2%). As compared to the ramipril group, combination therapy had an increased risk of hypotensive symptoms (4.8 vs 1.7%; P<0.001), syncope (0.3 vs 0.2%; P=0.03) and renal dysfunction (13.5 vs 10.2%; P<0.001).
Mann et al. ¹⁷⁶ (2013) ONTARGET Ramipril with telmisartan	Subanalysis Patients in the ONTARGET trial with diabetes mellitus	N=3163 with CKD N=6465 no CKD 56 months	Primary: Composite of death from cardiovascular cause, nonfatal MI, nonfatal stroke or hospitalization for	Primary: The stroke rate in all participants with diabetes was not different between the treatment groups, 1.19 and 1.22 per 100 patient-years in those on dual and monotherapy, respectively (HR, 0.99; 95% CI, 0.82 to 1.20). The results were consistent in those with or without renal disease (P value for interaction =0.60; 1.59 vs 1.55 and 1.01 vs 1.08 strokes per 100 patient-years, respectively). Results for other major outcomes indicated no differences and no interaction

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			<p>CHF</p> <p>Secondary: composite renal outcome for this analysis was defined posthoc as chronic dialysis (>2 months) or a doubling of baseline serum creatinine</p>	<p>of renal subgroups with treatment effects.</p> <p>Secondary: Dialysis-dependent acute kidney injury tended to occur more frequently in those allocated to dual than with monotherapy, 0.14 vs 0.08 cases per 100 patient-years, (HR, 1.55; 95% CI, 0.84 to 2.85), and hyperkalemia was more frequent, 1.82 vs 1.07 cases per 100 patient-years (HR, 1.71; 95% CI, 1.44 to 2.02). Both adverse outcomes were more frequent in those with renal disease; however, the excess due to dual therapy was similar in those with and without renal disease.</p>
<p>Julius et al.¹⁷⁷ (2004) VALUE</p> <p>Valsartan 80 to 160 mg QD</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD</p>	<p>DB, PG, RCT</p> <p>Patients ≥50 years old with treated or untreated HTN and history of cardiovascular disease, stroke, or diabetes, previous medications were discontinued at trial onset</p>	<p>N=15,245</p> <p>4.2 years (mean)</p>	<p>Primary: Time to first cardiac event (cardiac morbidity and mortality)</p> <p>Secondary: Fatal and nonfatal MI, fatal and nonfatal heart failure and fatal and nonfatal stroke, all-cause mortality, new onset diabetes</p>	<p>Primary: There were no differences in the primary composite end point between the valsartan and amlodipine groups (10.6 vs 10.4%; P=0.49).</p> <p>Secondary: There was a higher incidence of myocardial infarction (4.8 vs 4.1%; P=0.02) in patients receiving valsartan than amlodipine.</p> <p>There was no difference in the incidence of heart failure (4.6 vs 5.3%; P=0.12), stroke (4.2 vs 3.7%; P=0.08), and all-cause mortality (11 vs 10.8%; P=0.45) between valsartan- and amlodipine-treated patients.</p> <p>New onset diabetes occurred less with valsartan (13.1%) vs amlodipine (16.4%; P<0.001).</p> <p>Combined target blood pressure (<140/90 mm Hg) was achieved in 58% and 62% of patients receiving valsartan and amlodipine, respectively.</p>
<p>Zanchetti et al.¹⁷⁸ (2006) VALUE</p> <p>Amlodipine 5 mg QD</p> <p>vs</p>	<p>Subgroup analysis of VALUE</p> <p>Patients with HTN</p>	<p>N=15,245</p> <p>4.2 years</p>	<p>Primary: Time to first cardiac event, analyzed by subgroup</p> <p>Secondary: MI, heart failure and stroke</p>	<p>Primary: The only significant result of the analyses by subgroup for time to first cardiac event was sex; women in the valsartan group experienced more cardiac events as compared to men in the valsartan group (HR for women, 1.21; 95% CI, 1.3 to 1.42; HR for men, 0.94; 95% CI, 0.82 to 1.17; P=0.016).</p> <p>The VALUE trial showed no difference in the primary outcome as well as in cardiac morbidity and mortality between amlodipine treatment and valsartan treatment. SBP and DBP were lower, as was incidence of MI, in the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
valsartan 80 mg QD				<p>amlodipine treatment group as compared to the valsartan group.</p> <p>Secondary: Male patients treated with valsartan had a significantly lower incidence of heart failure than males treated with amlodipine (P<0.001 for male vs female difference; for men, HF rates with valsartan were 4.1% vs amlodipine 5.8% [HR, 0.73; 95% CI, 0.60 to 0.88]; for women, rates were valsartan 5.3% vs amlodipine 4.6%, [HR, 1.18; 95% CI, 0.95 to 1.47]).</p> <p>Patients without a history of stroke had a greater reduction in stroke risk if treated with amlodipine (valsartan 3.4% vs amlodipine 2.6%; HR, 1.34; 95% CI, 1.19 to 1.65).</p>
<p>Sawada et al.¹⁷⁹ (2009) KYOTO HEART</p> <p>Valsartan up to 160 mg QD plus an additional antihypertensive agent (other than an ACE inhibitor) if necessary to reach target blood pressure <140/90 or <130/80 mm Hg</p> <p>vs</p> <p>antihypertensive agents (other than ACE inhibitors and ARBs) to reach target blood pressure <140/90 or <130/80 mm Hg</p>	<p>MC, OL, BE, RCT</p> <p>Japanese adults with uncontrolled HTN and coronary artery disease, cerebral vascular disease, or peripheral vascular disease.</p>	<p>N=3,031</p> <p>Median 3.27 years</p>	<p>Primary: New onset cardiovascular or cerebrovascular events (stroke, TIA, acute MI, unstable angina, aortic aneurysm, emergency thrombosis, lower limb arterial obstruction, transition to dialysis)</p> <p>Secondary: Not reported</p>	<p>Primary: In both groups, blood pressure was identical at baseline and at the end of study (157/88 and 133/76, respectively).</p> <p>The primary endpoint was recorded in fewer patients given valsartan add-on (5.5%) than in those given additional non-ARB treatment (10.2%; HR, 0.55; 95% CI, 0.42-0.72; P=0.00001).</p> <p>The difference in the number of primary endpoints was mainly attributable to reduced frequency of stroke and TIA, and unstable angina. These benefits cannot be explained by a difference in blood pressure control.</p> <p>Secondary: Not reported</p>
The GISSI-AF	MC, DB, PC, RCT	N=1,442	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Investigators¹⁸⁰ (2009) GISSI-AF</p> <p>Valsartan up to 320 mg QD</p> <p>vs</p> <p>placebo</p>	<p>Adults in sinus rhythm who had a recent history of documented atrial fibrillation</p>	<p>1 year</p>	<p>Time to a first occurrence of atrial fibrillation and proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year</p> <p>Secondary: Not reported</p>	<p>Atrial fibrillation recurred in 371 of the 722 patients (51.4%) in the valsartan group, as compared to 375 of 720 (52.1%) in the placebo group (adjusted HR, 0.97; 96% CI, 0.83 to 1.14; P=0.73).</p> <p>More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9%) in the valsartan group and in 201 of 720 (27.9%) in the placebo group (adjusted OR, 0.89; 99% CI, 0.64 to 1.23; P=0.34).</p> <p>Secondary: Not reported</p>
<p>The Navigator Study Group¹⁸¹ (2010) NAVIGATOR</p> <p>Valsartan up to 160 mg QD or matching placebo</p> <p>and</p> <p>nateglinide or matching placebo</p>	<p>DB, MC, RCT</p> <p>Adults with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors.</p>	<p>N=9,306</p> <p>5 years</p>	<p>Primary: Incidence of diabetes and a composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina</p> <p>Secondary: Not reported</p>	<p>Primary: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared to 36.8% in the placebo group (HR in the valsartan group, 0.86; 95% CI, 0.80 to 0.92; P<0.001).</p> <p>Valsartan, as compared to placebo, did not significantly reduce the incidence of the composite cardiovascular outcome (14.5% vs 14.8%; HR, 0.96; 95% CI, 0.86 to 1.17; P=0.43).</p> <p>Secondary: Not reported</p>
<p>Blood Pressure Lowering Treatment Trialists' Collaboration¹⁸² (2007)</p> <p>ACE inhibitors (17 trials)</p>	<p>MA</p> <p>Patients with high blood pressure, diabetes, history or CHD or cerebrovascular disease</p>	<p>N=146,838 (26 trials)</p> <p>Variable duration</p>	<p>Primary: Nonfatal MI or death from CHD, including sudden death; heart failure causing death or requiring hospitalization; nonfatal stroke or</p>	<p>Primary: From a total of 146,838 individuals with high blood pressure or an elevated risk of cardiovascular disease, major cardiovascular events were documented in 22,666 patients during follow-up. The analyses showed comparable blood pressure-dependent reductions in risk with ACE inhibitors and ARBs (P≥0.3 for all three outcomes).</p> <p>ACE inhibitors produced a blood pressure-independent reduction in the relative risk of CHD of approximately 9% (95% CI, 3 to 14%). No similar</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs ARBs (9 trials)			death from cerebrovascular disease Secondary: Not reported	effect was detected for ARBs, and there was some evidence of a difference between ACE inhibitors and ARBs in this regard (P=0.002). For both stroke and heart failure, there was no evidence of any blood pressure-independent effects of either ACE inhibitors or ARBs. Secondary: Not reported

*Agent not available in the United States.

Study regimen abbreviations: QD=once daily, SR=sustained-release, TID=three times daily

Study design abbreviations: AC=active comparator, DB=double blind, DD=double dummy, ES=extension study, MA=meta-analysis, MC=multicenter, OL=open-label, OS=observational, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, XO=cross-over

Miscellaneous abbreviations: ABPM=ambulatory blood pressure monitoring, ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, ACS=acute coronary syndrome, BMI=body mass index, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, ESRD=end stage renal disease, eGFR=estimated glomerular filtration rate, GFR=glomerular filtration rate, HbA_{1c}=glycosylated hemoglobin, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HR=hazard ratio, HTN=hypertension, LDL-C=low-density lipoprotein cholesterol, LSM=least squares mean, LVEF=left ventricular ejection fraction, MAP=mean arterial pressure, MI=myocardial infarction, MMSE=Mini Mental State Examination, NYHA=New York Heart Association, OR=odds ratio, RR=relative risk, QOL=quality of life, SD=standard deviation, SBP=systolic blood pressure, TC=total cholesterol, TG=triglycerides, TIA=transient ischemic attack, UAER=urinary albumin excretion rate, WHO=World Health Organization, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 12. Relative Cost of the Angiotensin II Receptor Antagonists

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Azilsartan	tablet	Edarbi [®]	\$\$\$	N/A
Candesartan	tablet	Atacand [®] *	\$\$\$\$	\$\$\$\$
Eprosartan	tablet	Teveten [®] *	\$\$\$\$	\$\$\$
Irbesartan	tablet	Avapro [®] *	\$\$\$	\$
Losartan	tablet	Cozaar [®] *	\$\$\$\$	\$
Olmesartan	tablet	Benicar [®]	\$\$\$\$\$	N/A
Telmisartan	tablet	Micardis [®] *	\$\$\$\$	\$
Valsartan	tablet	Diovan [®] *	\$\$\$\$	\$\$
Combination Products				
Azilsartan and chlorthalidone	Tablet	Edarbyclor [®]	\$\$\$\$\$	N/A
Candesartan and HCTZ	tablet	Atacand HCT [®] *	\$\$\$\$	\$\$\$\$
Eprosartan and HCTZ	tablet	Teveten HCT [®]	\$\$\$\$	N/A
Irbesartan and HCTZ	tablet	Avalide [®] *	\$\$\$\$	\$
Losartan and HCTZ	tablet	Hyzaar [®] *	\$\$\$\$	\$
Olmesartan and amlodipine and hydrochlorothiazide	tablet	Tribenzor [®]	\$\$\$\$\$	N/A
Olmesartan and HCTZ	tablet	Benicar HCT [®]	\$\$\$\$\$	N/A

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Telmisartan and amlodipine	tablet	Twynsta [®] *	\$\$\$\$	\$\$\$
Telmisartan and HCTZ	tablet	Micardis HCT [®] *	\$\$\$\$	\$\$\$
Valsartan and HCTZ	tablet	Diovan HCT [®] *	\$\$\$\$	\$\$

*Generic is available in at least one dosage form or strength.
HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

All of the angiotensin II receptor blockers (ARBs) are approved for the treatment of hypertension. Some of the products are also approved for the treatment of diabetic nephropathy (irbesartan and losartan), heart failure (candesartan and valsartan), post-myocardial infarction (valsartan), as well as cardiovascular and cerebrovascular risk reduction (telmisartan and losartan, respectively).³⁻²⁰ The ARBs are available as single entity products, as well as in combination with hydrochlorothiazide (with the exception of azilsartan). Azilsartan is available in combination with chlorthalidone, telmisartan is available in combination with amlodipine, and olmesartan is available in combination with amlodipine and hydrochlorothiazide (triple therapy). There are other ARBs that are available in combination with amlodipine (olmesartan and valsartan); however, these products are included in the dihydropyridines class review (AHFS Class 242808). All single entity products with the exception of azilsartan and olmesartan are available generically. Fixed-dose combination products candesartan-hydrochlorothiazide, irbesartan-hydrochlorothiazide, losartan-hydrochlorothiazide, telmisartan-amlodipine, telmisartan-hydrochlorothiazide, and valsartan-hydrochlorothiazide are available in a generic formulation.

National and international guidelines recommend the use of ACE inhibitors or ARBs in patients with cerebrovascular disease, coronary artery disease, heart failure, hypertension, left ventricular dysfunction, left ventricular hypertrophy, diabetes, diabetic nephropathy, previous myocardial infarction, and renal disease.²³⁻⁴³ In general, guidelines do not give preference to one ARB over another.²³⁻⁴³ Some of the guidelines specifically recommend the use of ACE inhibitors as initial therapy, with the subsequent use of ARBs in patients who do not tolerate ACE inhibitors.^{23,25-33,39} Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.³⁴⁻⁴⁰ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).³⁴ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.³⁴⁻⁴² Most patients will require more than one antihypertensive medication to achieve blood pressure goals.³⁴⁻⁴¹

Numerous clinical trials have shown that the ARBs can effectively lower systolic and diastolic blood pressure, administered alone or in combination with other antihypertensive agents. Some comparative trials have demonstrated slight differences in blood pressure effects among the various ARBs; however, the clinical significance of these differences remains to be established.⁷⁶⁻¹⁶⁷ Guidelines do not give preference to one ARB over another for the treatment of hypertension. Most patients will require more than one antihypertensive agent to achieve blood pressure goals.³⁴⁻⁴¹ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{36-38,41} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations.

ARBs have been shown to reduce cardiovascular morbidity and mortality, as well as preserve renal function.⁴⁴⁻⁶⁵ The use of losartan also decreases the risk of stroke in patients with hypertension and left ventricular hypertrophy.^{7,15} It should be noted that the ACE inhibitors have also been shown to positively impact these endpoints as well (please refer to ACE inhibitor class review for additional information). Several studies comparing ARBs and ACE inhibitors have demonstrated similar efficacy with regards to cardiovascular events, heart failure and the rate of progression of nephropathy.^{44,45,48,53-56,59,65,67,72-75,175} ACE inhibitors inhibit the breakdown of bradykinin, which may lead to the development of a persistent non-productive cough. The ARBs do not increase bradykinin and may be better tolerated in some patients.^{21,22}

The FDA has evaluated data from two clinical trials (ROADMAP and ORIENT) in which patients with type 2 diabetes who were taking olmesartan had a higher rate of death from cardiovascular causes compared to those who were taking placebo. After the review was completed in April 2011, the FDA has determined that the benefits of olmesartan continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the approved drug label. Of note, olmesartan is not recommended as a treatment to delay or prevent protein in the urine in diabetic patients.¹⁸³ In June of 2011, the FDA also concluded that a review of a meta-analysis of 31 randomized-controlled trials comparing ARBs to other treatments found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs.¹⁸⁴

At this time, there is insufficient evidence to conclude that the angiotensin II receptor antagonists offer a significant clinical advantage over other alternatives in general use. Therefore, all brand angiotensin II receptor antagonists within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand angiotensin II receptor antagonist is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
2. Colucci WS. Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 May]. Available from: <http://www.utdol.com/utd/index.do>.
3. Edarbi® [package insert]. Atlanta (GA): Arbor Pharmaceuticals, LLC; 2014 Jul.
4. Atacand® [package insert]. Wilmington (DE): AstraZeneca LP; 2015 Feb.
5. Teveten® [package insert]. North Chicago (IL): AbbVie, Inc.; 2014 Jul.
6. Avapro® [package insert]. Bridgewater (NJ): Sanofi-Aventis US LLC; 2014 May.
7. Cozaar® [package insert]. Whitehouse Station (NJ): Merck & Co, Inc; 2014 Sep.
8. Benicar® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc; 2014 Sep.
9. Micardis® [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2014 Dec.
10. Diovan® [package insert]. East Hanover (NJ): Novartis Pharmaceutical Corp.; 2014 Sep.
11. Edarbyclor® [package insert]. Atlanta (GA): Arbor Pharmaceuticals, LLC; 2015 Apr.
12. Atacand HCT® [package insert]. Wilmington (DE): AstraZeneca LP; 2015 Feb.
13. Teveten HCT® [package insert]. North Chicago (IL): AbbVie Inc.; 2014 Jul.
14. Avalide® [package insert]. Bridgewater (NJ): Sanofi-Aventis US LLC; 2014 May.
15. Hyzaar® [package insert]. Whitehouse Station (NJ): Merck & Co, Inc; 2014 Sep.
16. Tribenzor® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2014 Sep.
17. Benicar HCT® [package insert]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2014 Sep.
18. Twynsta® [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2014 Dec.
19. Micardis HCT® [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals; 2014 Dec.
20. Diovan HCT® [package insert]. East Hanover (NJ): Novartis Pharmaceutical Corp.; 2014 Sep.
21. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 June]. Available from: <http://online.factsandcomparisons.com>
22. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 June]. Available from: <http://www.thomsonhc.com/>.
23. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
24. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/eh296.
25. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
26. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
27. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
28. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.
29. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.
30. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute

- for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.
31. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
 32. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
 33. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
 34. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
 35. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
 36. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
 37. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
 38. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
 39. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
 40. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
 41. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
 42. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
 43. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
 44. Pfeffer MA, McMurray JJV, Velazquez EJ, et al; for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003 Nov 13;349:1893-906.
 45. Dickstein K, Kjeksus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. *Lancet*. 2002 Sep 7;360:752-60.
 46. Graham DJ, Zhou EH, McKean S, et al. Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. *Pharmacoepidemiol Drug Saf*. 2014 Apr;23(4):331-9.
 47. Morgensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ*. 2000 Dec 9;321:1440-4.
 48. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*. 2001 Sep 20;345(12):851-60.
 49. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*. 2001 Sep 20;345(12):870-8.
 50. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. *Diabetes Care* 2009;32:1873-9.

51. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. *Clin J Am Soc Nephrol*. 2006 Mar;1(2):256-62.
52. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular disease. *Am J Kidney Dis* 2010;55:671-81.
53. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001 Sep 20;345(12):861-9.
54. Hou FF, Xie D, Zhang X, et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. *J Am Soc Nephrol*. 2007;18:1889-98.
55. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med*. 2013 Nov 14;369(20):1892-903.
56. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. *Lancet*. 2003 Jan 11;361:117-24.
57. Mann JF, Schmeider RE, Dyal L. Effect of telmisartan on renal outcomes: a randomized trial. *Ann Intern Med* 2009;151:1-10.
58. Foulquier S, Böhm M, Schmieder R, et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. *J Hypertens*. 2014 Jun;32(6):1334-41.
59. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med*. 2004 Nov 4;351:1952-61.
60. Galle J, Schwedhelm E, Pinnetti S, Boger Rh, Wanner C; on behalf of the VIVALDI Investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. *Nephrol Dial Transplant* 2008;23:3174-83.
61. Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. *Am J Hypertens* 2007;20:417-22.
62. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation*. 2002 Aug 6;106(6):672-8.
63. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet*. 2005 Dec 10;366:2026-33.
64. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. *BMJ*. 2004 Sep 30; 329:828-38.
65. Strippoli GFM, Bonifati C, Craig M, Navaneethan DS, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease (review). *Cochrane Database Syst Rev*. 2006 Oct 18;(4):CD006257.
66. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*. 2001 Dec 6;345(23):1667-75.
67. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003 Sep 6;362(9386):759-66.
68. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. 2003 Sep 6;362(9386):767-71.
69. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*. 2003 Sep 6;362(9386):772-6.
70. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*. 2003 Sep 6;362(9386):777-81.

71. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure. *J Am Coll Cardiol*. 2012;59:1785-95.
72. Pitt B, Segal R, Martinez FA, et al; on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*. 1997 Mar 15;349:747-52.
73. Pitt B, Poole-Wilson PA, Segal R, et al; on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study, ELITE II. *Lancet*. 2000 May 6;355:1582-7.
74. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators. *Circulation*. 1999 Sep 7;100:1056-64.
75. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med*. 2004 Nov 2;141(9):693-704.
76. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. *Hypertension Research*. 2012;35:552-558.
77. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. *J Clin Hypertens (Greenwich)*. 2011;13:467-472.
78. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. *Hypertension*. 2012;60:310-318.
79. Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. *J Hum Hypertens*. 2013 Aug;27(8):479-86.
80. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens*. 2003 May;21(5):875-86.
81. Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. *Int J Clin Pract* 2006;60:391-8.
82. Ohma KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide. *Blood Press*. 2000;9(4):214-20.
83. Mengden T, Hubner R, Bramlage P. Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of the CHILI CU Soon. *Vascular Health and Risk Management*. 2011;7:761-769.
84. McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. *J Hum Hypertens*. 2000 Apr;14(4):263-9.
85. Fogari R, Mugellini A, Derosa G; CANDIA Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. *J Renin Angiotensin Aldosterone Syst*. 2007 Sep;8(3):139-44.
86. Robles NR, Martin-Agueda B, Lopez-Munoz F, Almo C; Investigators of ESTEPP Study. Effectiveness of eprosartan in diabetic hypertensive patients. *Eur J Intern Med*. 2008 Jan;19(1):27-31.
87. Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. *Blood Pressure*. 2001;10:223-9.
88. Sachse A, Verboom C, Jager B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. *J Hum Hypertens*. 2002;16:169-76.
89. Ambrosioni E, Bombelli M, Cerasola G, Cipollone F, Ferri C, Grazioli I, et al. Ambulatory monitoring of systolic hypertension in the elderly: eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). *Adv Ther*. 2010;27(6):365-80.
90. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. *Circulation* 2005;111:1012-8.

91. Jordan J, Engeli S, Boye S, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension*. 2007 May;49:1047-55.
92. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. *Hypertension*. 2007 Feb;49(2):276-84.
93. Derosa G, Cicero AFG, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. *J Cardiovasc Pharmacol*. 2005;45(6):599-604.
94. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. *J Clin Hypertens (Greenwich)*. 2006 Dec;8(12):850-7.
95. Neutel JM. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review (abstract). *Postgrad Med*. 2011 Jul;123(4):126-34.
96. Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. *J Hum Hypertens* 2008;22:266-74.
97. Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high CV risk. *J Clin Hypertens (Greenwich)*. 2007 Dec;9(12 Suppl 5):23-30.
98. Bobrie G, Delonca J, Moulin C, et al; for the comparative study of efficacy of irbesartan/HCTZ with valsartan/HCTZ using home blood pressure monitoring in the treatment of mild-to-moderate hypertension (COSIMA) investigators. *Am J Hypertens*. 2005;18:1482-8.
99. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. *Hypertension*. 2003 Dec;42:1137-43.
100. Ribeiro AB, Mion D Jr, Marin MJ, et al; Latin American Hypertension Study (LAMHYST) Group. Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension. *J Int Med Res*. 2007 Nov-Dec;35(6):762-72.
101. Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. *Clin Ther*. 1996 Jul-Aug;18(4):608-25.
102. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002 Mar 23;359(9311):995-1003.
103. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. *J Am Coll Cardiol* 2004;43:1047-55.
104. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:1004-10.
105. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al, Snapinn S, Wedel H; LIFE (Losartan Intervention for End point Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for End point Reduction (LIFE) substudy. *JAMA*. 2002 Sep 25;288(12):1491-8.
106. Fossum E, Olsen M, Hoiieggen A, Wachtell K, Reims H, Kjeldsen S et al. Long-term effects of a losartan-compared with and atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. *J Clin Hypertens*. 2006;8:169-73.
107. Kizer J, Dahlöf B, Kjeldsen S, Julius S, Beevers G, de Faire U et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. *Hypertension*. 2005;45:46-52.
108. Wachtell K, Lehto M, Gerds E, Olsen M, Hornestam B, Dahlöf B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. *J Am Coll Cardiol*. 2005;45:712-9.
109. Wachtell K, Hornestam B, Lehto M, Slotwiner D, Gerds E, Olsen M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the losartan intervention for endpoint reduction in hypertension (LIFE) study. *J Am Coll Cardiol*. 2005;45:705-11.
110. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. *Am J Hypertens*. 2005 Aug;18(8):1060-6.

111. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *Journal of the American College of Cardiology* 2003;41(7):1148-55.
112. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. *Circulation*. 2007 Jul 17;116(3):268-75.
113. Maeda K, Adachi M, Kinoshita A, Koh N, Miura Y, Murohara T. Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination Therapy for Hypertension (ARCH) study. *Intern Med*. 2012;51:1167-1175.
114. Ueda T, Kai H, Imaizumi T, MAPPY Study Investigators. Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial (abstract). *Hypertens Res*. 2012 Jul;35(7):708-14.
115. Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. *J Clin Hypertens (Greenwich)*. 2004 Nov;6(11):614-20.
116. Minami J, Abe C, Akashiba A, Takahashi T, Kameda T, Ishimitsu T, Matsuoka H. Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. *Int Heart J*. 2007 Mar;48(2):177-86.
117. Lacourcière Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. *Int J Clin Pract*. 2003 May;57(4):273-9.
118. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. *Clin Drug Investig*. 2006;26(4):185-93.
119. Punzi HA, Lewin A, Li W, Chavanu KJ. Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension. *Adv Ther*. 2012;29(6):524-537.
120. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. *Clin Drug Investig*. 2006;26(4):185-93.
121. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. *Am J Hypertens*. 2004 Mar;17(3):252-9.
122. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. *Am J Cardiovasc Drugs*. 2007;7(5):36-72.
123. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial safety and efficacy study. *Clin Ther*. 2008;30:587-604.
124. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. *J Clin Hypertens. (Greenwich)* 2009;11:475-82.
125. Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. *J Cardiovasc Pharmacol*. 2009;54(5):427-36.
126. Braun N, Ulmer HJ, Handrock R, Klebs S. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination (abstract). *Current Medical Research & Opinion*. 2009;25(2):421-30.
127. Chrysant SG, Littlejohn T III, Izzo JL Jr, Kereiakes DJ, Oparil S, Melino M, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension. *Am J Cardiovasc Drugs*. 2012;12(4):233-243.
128. Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, Melino M, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study (abstract). *J Am Soc Hypertens*. 2011 Mar-Apr;6(2):132-41.
129. Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T III, Oparil S, Melino M, et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. *J Clin Hypertens (Greenwich)*. 2012;14:149-157.

130. Punzi HA. Efficacy and safety of olmesartan/amlopidine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. *Ther Adv Cardiovasc Dis.* 2014 Feb;8(1):12-21.
131. Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, et al. Single-pill combination of telmisartan/amlopidine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. *Clin Ther.* 2012;34(3):537-551.
132. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. *J Hum Hypertens.* 2009 Sep;23(9):610-9.
133. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. *J Hypertens.* 1999 Feb;17(2):293-302.
134. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. *Am J Hypertens.* 2008 May;21(5):546-52.
135. Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. *Clin Ther* 2007;29:2667-76.
136. Littlejohn TW 3rd, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlopidine in hypertensive patients. *J Clin Hypertens (Greenwich)* 2009;11:207-13.
137. Littlejohn T, Majul C, Olver R, Seeber M, Kobe M, Guthrie R et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4x4 factorial study. *Postgrad Med.* 2009;121(2):5-14.
138. Neutel JM, Mancia G, Black HR, Dahlof B, Defeo H, Ley L, et al. Single-pill combination of telmisartan/amlopidine in patients with severe hypertension: results from the TEAMSTA severe HTN study. *J Clin Hypertens (Greenwich).* 2012 Apr;14(4):206-215.
139. Oparil S, Yarows S, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. *Lancet.* 2007;370:221-9.
140. Yarows S, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension; subgroup analysis of a randomized, double-blind study. *Adv Ther.* 2008;25(12):1288-302.
141. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 2007;20(1):11-20.
142. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. *J Clin Hypertens (Greenwich).* 2009;11:324-32.
143. Maciejewski S, Mohiuddin SM, Packard KA, et al. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring. *Pharmacotherapy.* 2006 Jul;26(7):889-95.
144. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. *J Hum Hypertens.* 2006 Oct;20(10):787-94.
145. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. *Clin Ther.* 2007 Apr;29(4):563-80.
146. Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. *Curr Med Res Opin* 2009;25:315-24.
147. Philipp T, Glazer RD, Wernsing M, Yen J. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension (abstract). *J Amer Soc Hyperten.* 2011;5(5):417-424.
148. Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. *Archives of Gerontology and Geriatrics.* 2009;48:401-5.
149. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. *Clin Ther.* 2007 Feb;29(2):279-89.
150. White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for

- initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. *J Clin Hypertens* (Greenwich) 2008;10:450-8.
151. Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. *J Hypertens*. 2001 Nov;19(11):2097-104.
 152. Schweizer J, Hilsmann U, Neumann G, Handrock R, Klebs S. Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination. *Curr Med Res Opin*. 2007 Nov;23(11):2877-85.
 153. Lai WT, Park JE, Dongre N, Wang J. Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. *Adv Ther*. 2011;28(5):427-438.
 154. Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Smauel R, et al. Treating systolic hypertension in very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. 2011;13:722-730.
 155. Duprenz DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, et al. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. *Blood Press Monitor*. 2011 Aug;16(4):186-96.
 156. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. *Adv Ther*. 2006 Sep-Oct;23(5):680-95.
 157. White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. *Blood Press Monit* 2008;13:21-7.
 158. Sharma AM, Davidson J, Koval S, Lacourciere Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. *Cardiovasc Diabetol*. 2007 Oct 2;6:28.
 159. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized controlled trial. *Hypertension* 2009;54:32-9.
 160. Calhoun D, Crikelair N, Yen J, Glazer R. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. *Adv Ther*. 2009;26(11):1012-23.
 161. Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. *Clin Exp Hypertens*. 2006;28(7):655-62.
 162. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? *Am J Hypertens*. 2000 Apr;13(4 Pt 1):418-26.
 163. Stanton AV, Gradman AH, Schmieder RE, et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials. *Hypertension* 2010;55:54-60.
 164. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1545-53.
 165. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs*. 2008;8(1):35-44.
 166. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
 167. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig*. 2007;27(11):735-53.
 168. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension; the study on cognition and prognosis in the elderly (SCOPE). *J Am Coll Cardiol*. 2004;44:1175-80.
 169. Ogihara T, Nakao K, Fukui T, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. *Hypertension*. 2008 Feb;51(2):393-8.
 170. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. *Circ J*. 2006 Aug; 70(8):995-1000.
 171. Montalescot G, Drexler H, Gallo R, et al. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHPELAGO study. *Euro Heart J* 2009;30:2733-41.

172. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. *Circulation* 2009;119:530-7.
173. Fliser D, Buchholz K, Haller H; EUROPEAN Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. *Circulation*. 2004 Aug 31;110(9):1103-7.
174. Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. *Am J Cardiol* 2009;104:359-65.
175. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547-59.
176. Mann JF, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. *J Hypertens*. 2013 Feb;31(2):414-21.
177. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*. 2004 Jun 19;363(9426):2022-31.
178. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. *J Hypertens*. 2006 Nov;24(11):2163-8.
179. Sawada T, Yamada H, Dahlöf B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risk: Kyoto Heart Study. *Euro Heart J* 2009;30:2461-9.
180. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. *N Engl J Med* 2009;360:1606-17.
181. The Navigator Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010;362:1477-90.
182. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *J Hypertens*. 2007 Jun;25(5):951-8.
183. US FDA Medwatch [database on the internet]. Benicar (olmesartan) ongoing safety review. Rockville (MD): Food and Drug Administration (US); 2011 Apr 14 [cited 2013 Mar]. Available from: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm215249.htm>.
184. US FDA MedWatch [database on the internet]. Angiotensin Receptor Blockers (ARBs): Drug Safety Communication- Drug Safety Review Completed. Rockville (MD): Food and Drug Administration (US); 2011 Jun 2 [cited 2013 Mar]. Available from: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm219185.htm>.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Mineralocorticoid (Aldosterone) Receptor Antagonists
AHFS Class 243220
August 19, 2015**

I. Overview

Aldosterone is a component of the renin-angiotensin-aldosterone (RAAS) system, which is responsible for the regulation of extracellular volume and blood pressure. Upon binding to the mineralocorticoid receptor on the distal renal tubule, aldosterone activates the sodium-potassium exchange pump, leading to sodium and water retention, as well as potassium excretion. Increased levels of aldosterone are present in both primary and secondary hyperaldosteronism. Heart failure, hepatic cirrhosis, and the nephrotic syndrome are edematous conditions, which can lead to secondary aldosteronism. Volume depletion and sodium loss due to diuretic therapy may also cause secondary aldosteronism.^{1,2}

The mineralocorticoid (aldosterone) receptor antagonists are approved for the treatment of edema, heart failure, hypertension, hypokalemia, and primary hyperaldosteronism. Eplerenone and spironolactone bind to mineralocorticoid receptors, which blocks the binding of aldosterone.¹⁻⁵ They are available as single entity agents, and spironolactone is also available in combination with hydrochlorothiazide. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.^{1,2}

The mineralocorticoid (aldosterone) receptor antagonists that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Mineralocorticoid (Aldosterone) Receptor Antagonists Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Eplerenone	tablet	Inspira ^{®*}	eplerenone
Spironolactone	tablet	Aldactone ^{®*}	spironolactone
Combination Products			
Spironolactone and hydrochlorothiazide	tablet	Aldactazide ^{®*}	spironolactone and hydrochlorothiazide

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the mineralocorticoid (aldosterone) receptor antagonists are summarized in Table 2.

Table 2. Treatment Guidelines Using the Mineralocorticoid (Aldosterone) Receptor Antagonists

Clinical Guideline	Recommendations
American College of Cardiology/American Heart Association: 2007 Chronic Angina Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina (2007) ⁶	<ul style="list-style-type: none"> Aspirin should be started at 75 to 162 mg/day and continued indefinitely in all patients, unless contraindicated. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. Patients with hypertension and established coronary artery disease (CAD) should be treated with blood pressure medication(s) as tolerated, including angiotensin-converting enzyme inhibitors (ACE inhibitors) and/or β-adrenergic antagonists (β-blockers) with the addition of other medications as needed to achieve blood pressure goals of <140/90 or <130/80 mm Hg for patients with chronic kidney disease or diabetes.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Long-acting calcium-channel blocking agents or long-acting nitrates may be used if β-blockers are contraindicated. Immediate-release and short-acting dihydropyridine calcium channel blockers can increase adverse cardiac events and should not be used. • Long-acting calcium channel blockers or long-acting nitrates may be used with β-blockers if initial treatment is not successful. • ACE inhibitors should be used indefinitely in patients with a left ventricular ejection fraction (LVEF) of $\leq 40\%$ and in those with hypertension, diabetes or chronic kidney disease, unless contraindicated. • ACE inhibitors should also be used indefinitely in patients at lower risk (mildly reduced or normal LVEF in whom cardiovascular risk factors remain well controlled and revascularization has been performed), unless contraindicated. • Angiotensin II receptor blockers (ARBs) are recommended in patients with hypertension, those who have an indication for an ACE inhibitor and are intolerant to them, who have heart failure, or who have had a myocardial infarction (MI) and have a LVEF of $\leq 40\%$. • ARBs may be considered in combination with an ACE inhibitor for heart failure due to left ventricular systolic dysfunction. • Aldosterone blockade is recommended in patients post-MI without significant renal dysfunction or hyperkalemia who are already receiving therapeutic doses of an ACE inhibitor and a β-blocker, have a LVEF $\leq 40\%$ and have either diabetes or heart failure. • It is beneficial to start and continue β-blocker therapy indefinitely in all patients who have had a MI, acute coronary syndrome or left ventricular dysfunction with or without heart failure symptoms, unless contraindicated. • Annual influenza vaccination is recommended in patients with cardiovascular disease.
<p>European Society of Cardiology: Guidelines on the Management of Stable Coronary Artery Disease (2013)⁷</p>	<p><u>General management of stable coronary artery disease (SCAD) patients</u></p> <ul style="list-style-type: none"> • The goal of management of SCAD is to reduce symptoms and improve prognosis. • The management of CAD patients encompasses lifestyle modification, control of CAD risk factors, evidence-based pharmacological therapy, and patient education. <p><u>General considerations for pharmacological treatments in SCAD patients</u></p> <ul style="list-style-type: none"> • Optimal medical treatment indicates at least one drug for angina/ischaemia relief plus drugs for event prevention • It is recommended to educate patients about the disease, risk factors and treatment strategy. • It is indicated to review the patient's response soon after starting therapy. <p><u>Pharmacological treatments for angina/ischemia relief in SCAD patients</u></p> <ul style="list-style-type: none"> • Short-acting nitrates are recommended. • First-line treatment is indicated with β-blockers and/or calcium channel blockers to control heart rate and symptoms. • For second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil* or ranolazine, according to heart rate, blood pressure, and tolerance. • For second-line treatment, trimetazidine* may be considered. • According to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients. • In asymptomatic patients with large areas of ischaemia ($>10\%$), β-blockers should be considered. • In patients with vasospastic angina, calcium channel blockers and nitrates

Clinical Guideline	Recommendations
	<p>should be considered and beta-blockers avoided.</p> <p><u>Pharmacological treatments for event prevention in SCAD patients</u></p> <ul style="list-style-type: none"> • Low-dose aspirin daily is recommended in all SCAD patients. • Clopidogrel is indicated as an alternative in case of aspirin intolerance. • Statins are recommended in all SCAD patients. • It is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes). <p><u>Treatment in patients with microvascular angina</u></p> <ul style="list-style-type: none"> • It is recommended that all patients receive secondary prevention medications including aspirin and statins. • β-blockers are recommended as a first line treatment. • Calcium antagonists are recommended if β-blockers do not achieve sufficient symptomatic benefit or are not tolerated. • ACE inhibitors or nicorandil* may be considered in patients with refractory symptoms. • Xanthine derivatives (aminophylline, bamiphylline*) or non-pharmacological treatments such as neurostimulatory techniques may be considered in patients with symptoms refractory to the above listed drugs.
<p>American College of Physicians/ American College of Cardiology Foundation/ American Heart Association/ American Association for Thoracic Surgery/ Preventive Cardiovascular Nurses Association/ Society of Thoracic Surgeons: Management of Stable Ischemic Heart Disease (2012)⁸</p>	<p><u>Medical therapy to prevent MI and death in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Aspirin 75 to 162 mg daily should be continued indefinitely in the absence of contraindications. • Treatment with clopidogrel is a reasonable option when aspirin is contraindicated. • Dipyridamole should not be used as antiplatelet therapy. • Beta-blocker therapy should be initiated and continued for three years in all patients with normal left ventricular (LV) function following MI or acute coronary syndromes. • Metoprolol succinate, carvedilol, or bisoprolol should be used for all patients with systolic LV dysfunction (ejection fraction $\leq 40\%$) with heart failure or prior MI, unless contraindicated. • ACE inhibitors should be prescribed in all patients with stable IHD who also have hypertension, diabetes, LV systolic dysfunction (ejection fraction $\leq 40\%$), and/or chronic kidney disease, unless contraindicated. • Angiotensin-receptor blockers (ARBs) are recommended for patients with stable IHD who have hypertension, diabetes, LV systolic dysfunction, or chronic kidney disease and have indications for, but are intolerant of, ACE inhibitors. • Patients should receive an annual influenza vaccine. <p><u>Medical therapy for relief of symptoms in patients with stable IHD</u></p> <ul style="list-style-type: none"> • Beta-blockers are recommended as initial therapy for relief of symptoms. • Calcium channel blockers or long-acting nitrates should be prescribed for relief of symptoms when β-blockers are contraindicated or cause unacceptable side effects. • Calcium channel blockers or long-acting nitrates, in combination with β-blockers, should be prescribed for relief of symptoms when initial treatment with β-blockers is unsuccessful. • Nitroglycerin or nitroglycerin spray should be used for immediate relief of angina. • Ranolazine is a fourth-line agent reserved for patients who have contraindications to, do not respond to, or cannot tolerate β-blockers, calcium-channel blockers, or long-acting nitrates.
<p>American College of</p>	<p>Early hospital care- standard medical therapies</p>

Clinical Guideline	Recommendations
<p>Cardiology Foundation/American Heart Association: 2014 American Heart Association/ American College of Cardiology Foundation Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (2014)⁹</p>	<ul style="list-style-type: none"> • Supplemental oxygen should be administered to patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) with arterial oxygen saturation <90%, respiratory distress, or other high risk features of hypoxemia. • Anti-ischemic and analgesic medications <ul style="list-style-type: none"> ○ Nitrates <ul style="list-style-type: none"> ▪ Patients with NSTEMI-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 to 0.4 mg) every 5 minutes for up to three doses, after which an assessment should be made about the need for intravenous nitroglycerin. ▪ Intravenous nitroglycerin is indicated for patients with NSTEMI-ACS for the treatment of persistent ischemia, heart failure, or hypertension. ▪ Nitrates should not be administered to patients who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil. ○ Analgesic therapy <ul style="list-style-type: none"> ▪ In the absence of contraindications, it may be reasonable to administer morphine sulphate intravenously to patients with NSTEMI-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications. ▪ Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization due to the increased risk of major adverse cardiac event associated with their use ○ Beta-adrenergic blockers <ul style="list-style-type: none"> ▪ Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) ▪ In patients with concomitant NSTEMI-ACS, stabilized heart failure, and reduced systolic function, it is recommended to continue beta-blocker therapy with one of the three drugs proven to reduce mortality in patients with heart failure: sustained-release metoprolol succinate, carvedilol, or bisoprolol. ▪ Patients with documented contraindications to beta-blockers in the first 24 hours should be re-evaluated to determine subsequent eligibility. ○ Calcium channel blockers (CCBs) <ul style="list-style-type: none"> ▪ In patients with NSTEMI-ACS, continuing or frequently recurring ischemia, and a contraindication to beta-blockers, a nondihydropyridine CCB (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 seconds, or second or third degree atrioventricular block without a cardiac pacemaker. ▪ Oral nondihydropyridine calcium antagonists are recommended in patients with NSTEMI-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta-blockers and nitrates. ▪ CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects. ▪ Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ▪ Immediate-release nifedipine should not be administered to patients with NSTEMI-ACS in the absence of beta-blocker therapy. ○ Other anti-ischemic interventions <ul style="list-style-type: none"> ▪ Ranolazine is currently indicated for treatment of chronic angina; however, it may also improve outcomes in NSTEMI-ACS patients due to a reduction in recurrent ischemia. ○ Cholesterol management <ul style="list-style-type: none"> ▪ High-intensity statin therapy should be initiated or continued in all patients with NSTEMI-ACS and no contraindications to its use. Treatment with statins reduces the rate of recurrent MI, coronary heart disease mortality, need for myocardial revascularization, and stroke. ▪ It is reasonable to obtain a fasting lipid profile in patients with NSTEMI-ACS, preferably within 24 hours of presentation. • Inhibitors of renin-angiotensin-aldosterone system <ul style="list-style-type: none"> ○ ACE inhibitors should be started and continued indefinitely in all patients with LVEF <0.40 and in those with hypertension, diabetes mellitus, or stable CKD, unless contraindicated. ○ ARBs are recommended in patients with heart failure or myocardial infarction with LVEF <0.40 who are ACE inhibitor intolerant. ○ Aldosterone-blockade is recommended in patients post-MI without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta-blocker and have a LVEF <0.40, diabetes mellitus, or heart failure. • Initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTEMI-ACS treated with an initial invasive or ischemia-guided strategy <ul style="list-style-type: none"> ○ Non-enteric coated, chewable aspirin (162 to 325 mg) should be given to all patients with NSTEMI-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 to 162 mg/day) should be continued indefinitely. ○ In patients who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. ○ A P2Y₁₂ receptor inhibitor (clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTEMI-ACS without contraindications who are treated with an early invasive or ischemia-guided strategy. Options include: <ul style="list-style-type: none"> ▪ Clopidogrel: 300 or 600 mg loading dose, then 75 mg daily. ▪ Ticagrelor: 180 mg loading dose, then 90 mg twice daily. ▪ It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTEMI-ACS who undergo an early invasive or ischemia-guided strategy. ▪ In patients with NSTEMI-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a GP IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatid or tirofiban. <p><u>Percutaneous coronary intervention (PCI)- Antiplatelet and anticoagulant therapy</u></p> <ul style="list-style-type: none"> • Antiplatelet agents <ul style="list-style-type: none"> ○ Patients already taking daily aspirin before PCI should take 81 to 325 mg non-enteric coated aspirin before PCI ○ Patients not on aspirin therapy should be given non-enteric coated aspirin 325 mg as soon as possible before PCI. ○ After PCI, aspirin should be continued indefinitely.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ A loading dose of a P2Y₁₂ inhibitor should be given before the procedure in patients undergoing PCI with stenting. Options include clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg. ○ In patients with NSTEMI-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatid, or high-dose bolus tirofiban) at the time of PCI. ○ In patients receiving a stent (bare metal or drug eluting) during PCI, P2Y₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. ● Anticoagulant therapy <ul style="list-style-type: none"> ○ An anticoagulant should be administered to patients with NSTEMI-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. ○ Intravenous unfractionated heparin (UFH) is useful in patients with NSTEMI-ACS undergoing PCI. ○ Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH. ○ An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients with NSTEMI-ACS who have received fewer than two therapeutic subcutaneous doses or received the last subcutaneous enoxaparin dose eight to 12 hours before PCI. ○ If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). ○ Anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue. ● Timing of CABG in relation to use of antiplatelet agents <ul style="list-style-type: none"> ○ Non-enteric coated aspirin (81 to 325 mg daily) should be administered preoperatively to patients undergoing CABG. ○ In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least five days before surgery and prasugrel for at least seven days before surgery. ○ In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding. ○ In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatid or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion. ● <u>Late hospital care, hospital discharge, and posthospital discharge care</u> <ul style="list-style-type: none"> ● Medications at discharge <ul style="list-style-type: none"> ○ Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTEMI-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required. ○ All patients who are post-NSTEMI-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use. ○ Before hospital discharge, patients with NSTEMI-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> ○ Before hospital discharge, patients who are post-NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. ○ For patients who are post-NSTE-ACS and have initial angina lasting more than one minute, nitroglycerin (one dose sublingual or spray) is recommended if angina does not subside within three to five minutes; call 9-1-1 immediately to access emergency medical services. ○ If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. ○ Before discharge, patients should be educated about modification of cardiovascular risk factors. ● Late hospital and post-hospital oral antiplatelet therapy <ul style="list-style-type: none"> ○ Aspirin should be continued indefinitely. The dose should be 81 mg daily in patients treated with ticagrelor and 81 to 325 mg daily in all other patients. ○ In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. ○ In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months. ● Combined oral anticoagulant therapy and antiplatelet therapy in patients with NSTE-ACS <ul style="list-style-type: none"> ○ The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. ○ Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y₁₂ receptor inhibitor.
<p>European Society of Cardiology: Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation (2011)¹⁰</p>	<p><u>Anti-ischemic drugs</u></p> <ul style="list-style-type: none"> ● Oral or intravenous nitrate treatment is indicated to relieve angina. Intravenous nitrates are recommended in patients with recurrent angina and/or signs of heart failure. ● Patients on chronic β-blocker therapy admitted with acute coronary syndrome should be continued on β-blocker therapy if not in Killip class \geqIII. ● Oral β-blocker therapy is indicated in all patients with left ventricular dysfunction, unless contraindications are present. ● Calcium channel blockers are recommended for relief of symptoms in patients already receiving nitrates and β-blocker therapy, and in patients with contraindications to β-blockade. ● Calcium channel blockers are recommended in patients with vasospastic angina. ● Intravenous β-blocker therapy at the time of admission should be considered for patients with stable hemodynamics with hypertension and/or tachycardia. ● Nifedipine, or other dihydropyridines, are not recommended unless combined with β-blockers. <p><u>Recommendations for drugs in secondary prevention</u></p> <ul style="list-style-type: none"> ● β-blockers are recommended in all patients with reduced left ventricular (LV)

Clinical Guideline	Recommendations
	<p>systolic function (LVEF \leq40%).</p> <ul style="list-style-type: none"> • ACE inhibitors are indicated within 24 hours in all patients with LVEF \leq40% and in patients with heart failure, diabetes, hypertension, or CKD, unless contraindicated. • ACE inhibitors are recommended for all other patients to prevent recurrence of ischemic events, with preference given to agents and doses of proven efficacy. • ARBs are recommended for patients who are intolerant to ACE inhibitors, with preference given to agents and doses of proven efficacy. • Aldosterone blockade with eplerenone is indicated in patients after MI who are already being treated with ACE inhibitors and β-blockers and who have an LVEF \leq35% and either diabetes or heart failure, without significant renal dysfunction (serum creatinine $>$2.5 mg/dL for men and $>$2.0 mg/dL for women) or hyperkalemia. • Statin therapy with target LDL-C levels $<$70 mg/dL initiated early after admission is recommended.
<p>American College of Cardiology/American Heart Association: Guideline for the Management of ST-Elevation Myocardial Infarction (2013)¹¹</p>	<p><u>Routine medical therapies: β-blockers</u></p> <ul style="list-style-type: none"> • Oral β-blockers should be initiated within the first 24 hours in patients with an ST-segment elevation myocardial infarction (STEMI) who do not have any of the following: 1) signs of heart failure, 2) evidence of a low-output state, 3) increased risk of cardiogenic shock, 4) other contraindications to use of oral β-blockers (e.g., PR interval $>$24 seconds, second or third degree heart block, active asthma, reactive airway disease). • β-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications to their use. • Patients with initial contraindications to the use of β-blockers in the first 24 hours after STEMI should be re-evaluated to determine their subsequent eligibility. • It is reasonable to administer intravenous β-blockers at the time of presentation to patients with STEMI and no contraindications to their use who are hypertensive or have ongoing ischemia. <p><u>Routine medical therapies: renin-angiotensin-aldosterone system inhibitors</u></p> <ul style="list-style-type: none"> • An ACE inhibitor should be administered within the first 24 hours to all patients with ST-segment elevation myocardial infarction with anterior location, heart failure, or ejection fraction \leq40%, unless contraindicated. • An ARB should be given to patients who have indications for but are intolerant of ACE inhibitors. • ACE inhibitors are reasonable for all patients with no contraindications to their use. • An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and β-blocker and who have an EF \leq40% and either symptomatic heart failure or diabetes. <p><u>Routine medical therapies: Lipid management</u></p> <ul style="list-style-type: none"> • High-intensity statin therapy should be initiated or continued in all patients with STEMI and no contraindications to its use. • It is reasonable to obtain a fasting lipid profile in patients with STEMI, preferably within 24 hours of presentation.
<p>European Society of Cardiology: Management of Acute Myocardial Infarction in Patients Presenting with ST-segment Elevation</p>	<p><u>Routine therapies in the acute, subacute and long term phase of STEMI</u></p> <ul style="list-style-type: none"> • Active smokers with STEMI must receive counseling and be referred to a smoking cessation program. • Each hospital participating in the care of STEMI patients must have a smoking cessation protocol. • Exercise-based rehabilitation is recommended. • Antiplatelet therapy with low dose aspirin (75 to 100 mg) is indicated

Clinical Guideline	Recommendations
(2012) ¹²	<p>indefinitely after STEMI.</p> <ul style="list-style-type: none"> • In patients intolerant to aspirin, clopidogrel is indicated as an alternative. • Dual antiplatelet therapy with a combination of aspirin and prasugrel or aspirin and ticagrelor is recommended (over aspirin and clopidogrel) in patients treated with PCI. • Dual antiplatelet therapy with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 month for patients receiving bare metal stent and 6 months for patients receiving drug-eluting stent. • In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. • In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-VASc Score ≥ 2 or mechanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. • If patients require triple antithrombotic therapy, combining dual antiplatelet therapy and oral anticoagulant, e.g. because of stent placement and an obligatory indication for oral anticoagulation, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. • In selected patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. • Dual antiplatelet therapy should be used up to 1 year in patients with STEMI who did not receive a stent. • Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. • Oral treatment with β-blockers should be considered during hospital stay and continued thereafter in all patients without contraindications. • Oral treatment with β-blockers is indicated in patients with heart failure or left ventricular dysfunction. • Intravenous β-blockers must be avoided in patients with hypotension or heart failure. • Intravenous β-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia, and no signs of heart failure. • A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. • It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. • Reassessment of LDL-cholesterol should be considered after 4–6 weeks to ensure that a target value of ≤ 70 mg/dL has been reached. • Verapamil may be considered for secondary prevention in patients with absolute contraindications to β-blockers and no heart failure. • ACE inhibitors are indicated starting within the first 24 hours of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. • An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction, particularly those who are intolerant to ACE inhibitors. • ACE inhibitors should be considered in all patients in the absence of contraindications. • Aldosterone antagonists, e.g. eplerenone, are indicated in patients with an ejection fraction $\leq 40\%$ and heart failure or diabetes, provided no renal failure or hyperkalemia.
National Institute for Health and Clinical	<p><u>Drug therapy</u></p> <ul style="list-style-type: none"> • Offer all people who have had an acute MI treatment with the following drugs:

Clinical Guideline	Recommendations
<p>Excellence: Myocardial Infarction: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction (2013)¹³</p>	<ul style="list-style-type: none"> ○ Angiotensin-converting enzyme (ACE) inhibitor. ○ Dual antiplatelet therapy (aspirin plus a second agent). ○ β-blocker. ○ Statin. <ul style="list-style-type: none"> ● Ensure that a clear management plan is available to the person who has had an MI and is also sent to their provider. ● Offer all people who have had an MI an assessment of bleeding risk at their follow-up appointment. ● Offer an assessment of left ventricular (LV) function to all people who have had an MI. <p><u>ACE inhibitors</u></p> <ul style="list-style-type: none"> ● Offer people who present acutely with an MI an ACE inhibitor as soon as they are hemodynamically stable. Continue the ACE inhibitor indefinitely. ● Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during this time, it should be completed within 4 to 6 weeks of hospital discharge. ● Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. ● Renal function, serum electrolytes and blood pressure should be measured before starting an ACE inhibitor or ARB and again within 1 or 2 weeks of starting treatment. More frequent monitoring may be needed in patients who are at increased risk of deterioration in renal function. ● Offer an ACE inhibitor to people who have had an MI more than 12 months ago. Titrate to the maximum tolerated or target dose (over a 4 to 6 week period) and continue indefinitely. An ARB may be used as alternative therapy. <p><u>Antiplatelet therapy</u></p> <ul style="list-style-type: none"> ● Offer aspirin to all people after an MI and should be continued indefinitely, unless they are aspirin intolerant or have an indication for anticoagulation. Clopidogrel should not be offered as first-line monotherapy after a MI. ● Offer aspirin to people who have had an MI more than 12 months ago and continue it indefinitely. ● For patients with aspirin hypersensitivity, clopidogrel monotherapy should be considered as an alternative treatment. ● Special considerations should be made for people with dyspepsia. ● After appropriate treatment, people with a history of aspirin-induced ulcer bleeding whose ulcers have healed and who are negative for <i>Helicobacter pylori</i> should be considered for treatment in line with dyspepsia. Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with ACS (STEMI, PCI, or NSTEMI). ● Offer clopidogrel as a treatment option for up to 12 months to people who have had an NSTEMI, regardless of treatment, or people who have had a STEMI and received a bare-metal or drug-eluting stent. ● Offer clopidogrel as a treatment option for at least one month and consider continuing for up to 12 months in people who have had a STEMI and medical management with or without reperfusion treatment with a fibrinolytic agent. ● Continue the second antiplatelet agent for up to 12 months in people who have had a STEMI and who received CABG surgery. ● Offer clopidogrel instead of aspirin to people who also have other clinical vascular disease (had an MI and topped dual antiplatelet therapy or had an MI more than 12 months ago).

Clinical Guideline	Recommendations
	<p><u>Antiplatelet therapy in people with an indication for anticoagulation</u></p> <ul style="list-style-type: none"> • Take bleeding risk, thromboembolic risk and cardiovascular risk into account when deciding which people who have had an MI and have an indication for anticoagulation. • Unless there is a high risk of bleeding, continue anticoagulation and add aspirin to treatment in people who have had an MI who otherwise need anticoagulation and who have had their condition managed medically or have undergone balloon angioplasty or have undergone CABG surgery. • Continue anticoagulation and add clopidogrel to treatment in people who have had an MI, who have undergone PCI with bare-metal or drug-eluting stents and who otherwise need anticoagulation. • Offer clopidogrel with warfarin to people with a sensitivity to aspirin who otherwise need anticoagulation and aspirin and who have had an MI. • Do not routinely offer warfarin in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI. • After 12 months since the MI, continue anticoagulation and take into consideration the need for ongoing antiplatelet therapy, taking into account all of the following: indication for anticoagulation, thromboembolic risk, bleeding risk, cardiovascular risk and the person's wishes. • Do not add a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI. • Consider using warfarin and discontinuing treatment with a new oral anticoagulant (rivaroxaban, apixaban or dabigatran) in people who otherwise need anticoagulation and who have had an MI, unless there is a specific clinical indication to continue it. <p><u>Beta-blockers</u></p> <ul style="list-style-type: none"> • After an acute MI, all patients without left ventricular systolic dysfunction or with left ventricular systolic dysfunction should be offered treatment with a β-blocker. • β-blockers should be continued indefinitely after an acute MI. • After a proven MI in the past, asymptomatic patients with preserved left ventricular function should not routinely be offered a β-blocker unless they are at risk for further cardiovascular events or other compelling indications exist. <p><u>Calcium channel blockers</u></p> <ul style="list-style-type: none"> • Do not routinely offer calcium channel blockers to reduce cardiovascular risk after an MI. • If beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction. <p><u>Aldosterone antagonists in patients with heart failure and left ventricular dysfunction</u></p> <ul style="list-style-type: none"> • For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 3 to 14 days of the MI, preferably after ACE inhibitor therapy. • Monitor renal function and serum potassium before and during treatment with an aldosterone antagonist.
<p>American College of Cardiology/American Heart Association: Guideline for the</p>	<p><u>Treatment of Stage A heart failure (HF)</u></p> <ul style="list-style-type: none"> • Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) • Other conditions that may lead to or contribute to HF, such as obesity, diabetes

Clinical Guideline	Recommendations
<p>Management of Heart Failure (2013)¹⁴</p>	<p>mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C)</p> <p><u>Treatment of Stage B heart failure</u></p> <ul style="list-style-type: none"> • In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) • In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p><u>Pharmacological treatment for Stage C HFrEF</u></p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p><u>Pharmacological treatment for Stage C HFpEF</u></p>

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p><u>Treatment of Stage D (advanced/refractory) HF</u></p> <ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)¹⁵</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF \leq40%, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF \leq40%. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB)

Clinical Guideline	Recommendations
	<p>and a β-blocker.</p> <ul style="list-style-type: none"> • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure

Clinical Guideline	Recommendations
	<p>and worsening renal function, should be avoided.</p> <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors.

Clinical Guideline	Recommendations
	<p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible

Clinical Guideline	Recommendations
	<p>because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used.</p> <ul style="list-style-type: none"> • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk

Clinical Guideline	Recommendations
<p>and Chronic Heart Failure (2012)¹⁶</p>	<p>of premature death.</p> <ul style="list-style-type: none"> • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ◦ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ◦ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ◦ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. • Step 3: <ul style="list-style-type: none"> ◦ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ◦ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB),

Clinical Guideline	Recommendations
	<p>β-blocker, mineralocorticoid receptor antagonist, and diuretic.</p> <ul style="list-style-type: none"> ○ Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> • A β-blocker is recommended in patients with an ejection fraction ≤40%, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹⁷</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥60 years of age to lower blood pressure at systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥90 mm Hg and to a goal systolic blood pressure <150 mm Hg and goal diastolic blood pressure <90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥90 mm Hg to a goal diastolic blood pressure <90 mm Hg. • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥150 mm Hg to a goal diastolic blood pressure <140 mm Hg. • For patients ≥18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg and to a goal systolic blood pressure <140 mm Hg and goal diastolic blood pressure <90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).

Clinical Guideline	Recommendations
Hypertension (2003)¹⁸	
European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁹ , Reappraisal of Guidelines on Hypertension Management (2009)²⁰	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients

Clinical Guideline	Recommendations
	<p>when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure.</p> <ul style="list-style-type: none"> • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)²¹</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP \geq160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values \geq140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP \geq160 mmHg, it is

Clinical Guideline	Recommendations
	<p>recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions.</p> <ul style="list-style-type: none"> • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as

Clinical Guideline	Recommendations
	<p>additional drugs, preferably in association with a potassium-sparing agent.</p> <ul style="list-style-type: none"> • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal < 140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be

Clinical Guideline	Recommendations
	<p>considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation.</p> <ul style="list-style-type: none"> • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. <ul style="list-style-type: none"> ○ Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)²²</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. • If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)²³</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)²⁴</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated

Clinical Guideline	Recommendations
	<p>with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker.</p> <ul style="list-style-type: none"> • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)²⁵</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic

Clinical Guideline	Recommendations
	<p>and ≤ 80 mm Hg diastolic, irrespective of the level of urine albumin excretion.</p> <ul style="list-style-type: none"> In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²⁶</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure $>120/80$ mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure $>140/90$ mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at

Clinical Guideline	Recommendations
	<p>maximal doses) is generally required to achieve blood pressure targets.</p> <ul style="list-style-type: none"> • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p>Nephropathy</p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American Association for the Study of Liver Diseases: Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012 (2012)²⁷ [Reaffirmed Oct 2014]</p>	<p>Treatment of ascites</p> <ul style="list-style-type: none"> • First line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2,000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide). • Fluid restriction is not necessary unless serum sodium is <125 mmol/L. • Vasopressin antagonists may improve serum sodium in patients with cirrhosis and ascites. However their use does not currently appear justified in view of their expense, potential risks, and lack of evidence of efficacy in clinically meaningful outcomes. • An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated. • Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracentesis. • Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with cirrhosis and ascites may be harmful and must be carefully considered in each patient, monitoring blood pressure and renal function. • The use of nonsteroidal anti-inflammatory drugs should be avoided in patients with cirrhosis and ascites, except in special circumstances. • Liver transplantation should be considered in patients with cirrhosis and ascites.
<p>Endocrine Society: Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism (2008)²⁸</p>	<ul style="list-style-type: none"> • For patients with documented unilateral primary aldosteronism, treatment by unilateral laparoscopic adrenalectomy is recommended. • Medical treatment with a mineralocorticoid receptor antagonist is recommended for patients who cannot or who do not wish to undergo surgery. • Medical treatment with a mineralocorticoid receptor antagonist is recommended for patients with primary aldosteronism caused by bilateral adrenal disease. Spironolactone is suggested as the primary agent, with eplerenone as an alternative. • Use of the lowest dose of glucocorticoid that can normalize blood pressure and serum potassium levels is recommended in patients with glucocorticoid-remediable aldosteronism, rather than first-line treatment with a

Clinical Guideline	Recommendations
	mineralocorticoid receptor antagonist.
American Association of Clinical Endocrinologists: Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hypertension (2006) ²⁹	<p><u>Primary hyperaldosteronism</u></p> <ul style="list-style-type: none"> • Surgery is the preferred treatment modality for patients with unilateral adenomas. • Spironolactone may be used in lieu of surgery in female or elderly patients with small adenomas or hyperplasias. Since male patients may experience erectile dysfunction and gynecomastia with spironolactone therapy, a trial of eplerenone may be considered. • Glucocorticoid-remediable aldosteronism is treated with glucocorticoids.

*Agent not available in the United States.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the mineralocorticoid (aldosterone) receptor antagonists are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Mineralocorticoid (Aldosterone) Receptor Antagonists³⁻⁵

Indication(s)	Single Entity Agents		Combination Products
	Eplerenone	Spironolactone	Spironolactone and HCTZ
Edematous Conditions			
Maintenance therapy together with bed rest and the restriction of fluid and sodium in patients with cirrhosis of the liver accompanied by edema and/or ascites		✓	✓
Management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures		✓	✓
Nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response		✓	✓
Patients with congestive heart failure taking digitalis when other therapies are considered inappropriate		✓	✓
Heart Failure			
Increase survival and reduce the need for hospitalization for heart failure when used in addition to standard therapy in patients with severe heart failure (New York Heart Association functional class III-IV)		✓	
Hypertension			
Essential hypertension			✓ *
Hypertension	✓ †	✓ ‡	
Hypokalemia			
Prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate		✓	
Treatment of a diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate			✓
Treatment of diuretic-induced hypokalemia in patients with hypertension when other measures are considered			✓

Indication(s)	Single Entity Agents		Combination Products
	Eplerenone	Spirolactone	Spirolactone and HCTZ
inappropriate			
Treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate		✓	
Myocardial Infarction			
To improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction $\leq 40\%$) and clinical evidence of congestive heart failure after an acute myocardial infarction	✓		
Primary Hyperaldosteronism			
Establish the diagnosis of primary hyperaldosteronism by therapeutic trial		✓	
Short-term preoperative treatment of patients with primary hyperaldosteronism		✓	
Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery		✓	
Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism)		✓	

*In patients in whom other measures are considered inadequate or inappropriate.

†Alone or in combination with other antihypertensive agents.

‡Usually in combination with other drugs, in patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the mineralocorticoid (aldosterone) receptor antagonists are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Mineralocorticoid (Aldosterone) Receptor Antagonists²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Eplerenone	69	50	Liver (% not reported) Renal (% not reported)	Renal (67) Feces (32)	4 to 6
Spirolactone	73	90	Liver (% not reported) Renal (% not reported)	Renal (47 to 57) Feces (35 to 41)	1.3 to 1.4
Combination Products					
Spirolactone and HCTZ	73/ 60 to 80	90/40	Liver (% not reported) Renal (% not reported)	Feces (35 to 41) Renal (47 to 57)/ Renal (50 to 70)	1.3 to 1.4/ 4 to 5

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the mineralocorticoid (aldosterone) receptor antagonists are listed in Table 5.

Table 5. Significant Drug Interactions with the Mineralocorticoid (Aldosterone) Receptor Antagonists¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Mineralocorticoid receptor antagonists (eplerenone, spironolactone, spironolactone and HCTZ)	1	ACE inhibitors	Serious hyperkalemia, possibly with cardiac arrhythmias or arrest, may occur with the combination of aldosterone blockers and ACE inhibitors. Potassium sparing effects are additive when combining ACE inhibitors with aldosterone blockers. Aldosterone acts in the renal cortical collecting ducts by inducing synthesis of proteins that constitute the Na ⁺ , K ⁺ -ATPase pump. The pump acts to reabsorb sodium and water in exchange for potassium, which is then eliminated in the urine. Aldosterone antagonism can cause hyperkalemia.
Mineralocorticoid receptor antagonists (eplerenone, spironolactone, spironolactone and HCTZ)	1	Amiloride	Aldosterone blockers and amiloride may exert additive pharmacologic effects. Hyperkalemia with the potential for cardiac arrhythmias may result. Aldosterone blockers and amiloride may cause additive adverse effects when co-administered.
Mineralocorticoid receptor antagonists (eplerenone, spironolactone, spironolactone and HCTZ)	1	Potassium Preparations	Potassium preparations will increase serum potassium concentrations. This may increase the potential for clinically important hyperkalemia, especially when used concomitantly with aldosterone blockers.
Mineralocorticoid receptor antagonists (eplerenone, spironolactone, spironolactone and HCTZ)	1	Triamterene	Eplerenone and triamterene may exert additive pharmacologic effects. Hyperkalemia with the potential for cardiac arrhythmias may result.
Mineralocorticoid receptor antagonists (eplerenone)	1	HIV Protease Inhibitors	Inhibition of CYP3A4 isoenzymes by HIV protease inhibitors may decrease the metabolic elimination of aldosterone blockers. HIV protease inhibitors may increase plasma concentrations and pharmacologic or toxic effects of aldosterone blockers.
Mineralocorticoid receptor antagonists (eplerenone)	1	Imidazoles	Certain azole antifungal agents may decrease the elimination of eplerenone by inhibiting its hepatic metabolism via CYP3A4 isoenzyme resulting in increased concentration and consequently increased pharmacologic and toxic (hyperkalemia associated with potentially fatal arrhythmias) effects of eplerenone.
Mineralocorticoid receptor antagonists (eplerenone)	1	Macrolides	Macrolides may decrease the elimination of eplerenone by inhibiting its hepatic metabolism via CYP3A4 isoenzyme resulting in

Generic Name(s)	Significance Level	Interaction	Mechanism
			increased concentration and consequently increased pharmacologic and toxic (hyperkalemia associated with potentially fatal arrhythmias) effects of eplerenone.
Mineralocorticoid receptor antagonists (eplerenone)	1	Nefazodone	Nefazodone may decrease the elimination of eplerenone by inhibiting its hepatic metabolism via CYP3A4 isoenzyme resulting in increased concentration and consequently increased pharmacologic and toxic (hyperkalemia associated with potentially fatal arrhythmias) effects of eplerenone. Coadministration of eplerenone with nefazodone is contraindicated.
Mineralocorticoid receptor antagonists (eplerenone)	1	Spirolactone	Eplerenone and spironolactone may exert additive pharmacologic effects. Hyperkalemia with the potential for cardiac arrhythmias may result.
Mineralocorticoid receptor antagonists (spironolactone)	1	Angiotensin II Receptor Antagonists	Decreased aldosterone activity by angiotensin II receptor antagonists may function synergistically with potassium conservation by spironolactone to produce substantial hyperkalemia. The risk of hyperkalemia may be increased when spironolactone is co-administered with angiotensin II receptor antagonists.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes. The coadministration of dofetilide with a thiazide diuretic is contraindicated.
Mineralocorticoid receptor antagonists (eplerenone)	2	Verapamil	Inhibition of CYP3A4 isoenzymes by verapamil may decrease the metabolic elimination of eplerenone. Verapamil may increase plasma concentrations and pharmacologic or toxic effects of eplerenone.
Mineralocorticoid receptor antagonists (spironolactone)	2	Aliskiren	Decreased aldosterone activity by aliskiren may function synergistically with potassium conservation by spironolactone leading to the development of hyperkalemia. The risk of hyperkalemia may be increased when aliskiren is coadministered with spironolactone.
Mineralocorticoid receptor antagonists (spironolactone)	2	Macrolide immuno-suppressives	Macrolide immunosuppressives and spironolactone may exert additive effects on potassium leading to hyperkalemia.
Thiazide diuretics (HCTZ)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia though an unknown

Generic Name(s)	Significance Level	Interaction	Mechanism
			mechanism; therefore the combination should be avoided. When used together, blood and urine glucose levels should be frequently monitored, and dosage reductions may be required.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Thiazide diuretics may induce electrolyte disturbances which may predispose patients to digitalis-induced arrhythmias. Measure plasma levels of potassium and magnesium, supplement low levels, and use dietary sodium restriction or potassium-sparing diuretics to prevent further losses.

ACE inhibitors=angiotensin converting enzyme inhibitors, CYP=cytochrome P450 isoenzyme, HCTZ=hydrochlorothiazide, HIV=human immunodeficiency virus

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the mineralocorticoid (aldosterone) receptor antagonists are listed in Table 6. The boxed warning for the mineralocorticoid (aldosterone) receptor antagonists are listed in Tables 7 and 8.

Table 6. Adverse Drug Events (%) Reported with the Mineralocorticoid (Aldosterone) Receptor Antagonists¹⁻⁵

Adverse Events	Single Entity Agents		Combination Products
	Eplerenone	Spirolactone	Spirolactone and HCTZ
Cardiovascular			
Orthostatic hypotension	-	-	✓
Central Nervous System			
Ataxia	-	✓	✓
Confusion	-	✓	✓
Dizziness	3	-	✓
Drowsiness	-	✓	✓
Fatigue	2	✓	✓
Fever	-	✓	✓
Headache	-	✓	✓
Insomnia	-	-	✓
Lethargy	-	✓	✓
Restlessness	-	-	✓
Vertigo	-	-	✓
Dermatological			
Alopecia	-	-	✓
Cutaneous vasculitis	-	-	✓
Erythema multiforme	-	-	✓
Exfoliative dermatitis	-	-	✓
Maculopapular eruptions	-	-	✓
Necrotizing angitis	-	-	✓
Photosensitivity	-	-	✓
Pruritus	-	-	✓
Purpura	-	-	✓

Adverse Events	Single Entity Agents		Combination Products
	Eplerenone	Spironolactone	Spironolactone and HCTZ
Rash	<1	✓	✓
Stevens-Johnson syndrome	-	-	✓
Toxic epidermal necrolysis	-	-	✓
Urticaria	-	✓	✓
Endocrine and Metabolic			
Amenorrhea	-	✓	✓
Breast cancer	-	✓	✓
Deepening of the voice	-	✓	✓
Dehydration	-	✓	✓
Gynecomastia	≤1	9	9
Hyperchloremic metabolic acidosis	-	✓	✓
Irregular menses	-	✓	✓
Mastodynia	≤1	2	2
Postmenopausal bleeding	-	✓	✓
Gastrointestinal			
Abdominal pain	1	-	✓
Anorexia	-	✓	✓
Cholestatic toxicity	-	✓	✓
Constipation	-	-	✓
Cramping	-	✓	✓
Diarrhea	2	✓	✓
Gastric bleeding	-	✓	✓
Gastritis	-	✓	✓
Nausea	-	✓	✓
Pancreatitis	-	-	✓
Sialoadenitis	-	-	✓
Ulceration	-	✓	✓
Vomiting	-	✓	✓
Xerostomia	-	✓	✓
Genitourinary			
Abnormal vaginal bleeding	≤2	-	-
Albuminuria	1	-	-
Glucosuria	-	-	✓
Impotence	-	✓	✓
Interstitial nephritis	-	-	✓
Renal dysfunction	-	✓	✓
Renal failure	-	✓	✓
Hematologic			
Agranulocytosis	-	✓	✓
Aplastic anemia	-	-	✓
Eosinophilia	-	✓	✓
Hemolytic anemia	-	-	✓
Leukopenia	-	-	✓
Thrombocytopenia	-	-	✓
Laboratory Test Abnormalities			
Blood urea nitrogen increased	<1	✓	✓
Creatinine increased	6	-	-
Hypercholesterolemia	≤1	-	-
Hyperglycemia	-	-	✓
Hyperkalemia	≤32	≤40	≤40
Hypertriglyceridemia	<15	-	-
Hyponatremia	2	✓	✓

Adverse Events	Single Entity Agents		Combination Products
	Eplerenone	Spirolactone	Spirolactone and HCTZ
Hyperuricemia	<1	-	✓
Liver function tests increased	<1	-	-
Respiratory			
Cough	2	-	-
Respiratory distress	-	-	✓
Other			
Anaphylaxis	-	✓	✓
Angioneurotic edema	<1	-	-
Blurred vision	-	-	✓
Flu-like syndrome	2	-	-
Hepatocellular toxicity	-	✓	✓
Jaundice	-	-	✓
Muscle cramps	-	-	✓
Vasculitis	-	✓	✓
Weakness	-	-	✓
Xanthopsia	-	-	✓

✓ Percent not specified
-Event not reported

Table 7. Boxed Warning for Spirolactone³

WARNING
Spirolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spirolactone should be used only in those conditions described under Indications and Usages. Unnecessary use of this drug should be avoided.

Table 8. Boxed Warning for Spirolactone and HCTZ⁵

WARNING
Spirolactone, an ingredient of Aldactazide [®] , has been shown to be a tumorigen in chronic toxicity studies in rats. Aldactazide [®] should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. Fixed-dose combination drugs are not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension and edema is not static but must be reevaluated as conditions in each patient warrant.

VII. Dosing and Administration

The usual dosing regimens for the mineralocorticoid (aldosterone) receptor antagonists are listed in Table 9.

Table 9. Usual Dosing Regimens for the Mineralocorticoid (Aldosterone) Receptor Antagonists¹⁻⁵

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Eplerenone	<u>Heart Failure:</u> Tablet: initial, 25 mg once daily for four weeks; maintenance, 50 mg once daily <u>Hypertension:</u> Tablet: initial, 50 mg once daily; maximum, 50 mg twice daily	Safety and efficacy in children have not been established.	Tablet: 25 mg 50 mg
Spirolactone	<u>Edema (congestive heart failure, hepatic cirrhosis, nephrotic syndrome):</u>	Safety and efficacy in children have not been	Tablet: 25 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>Tablet: initial, 100 mg once daily in a single or divided dose(s); maintenance, 25 to 200 mg once daily</p> <p><u>Heart failure (Severe NYHA function class III to IV)</u> Tablet: initial, 25 mg once daily; maintenance, 25 mg every other day to 50 mg once daily</p> <p><u>Hypertension</u> Tablet: initial, 50 to 100 mg once daily in a single or divided dose(s); maintenance, 25 to 200 mg once daily; maximum, 400 mg/day</p> <p><u>Hypokalemia:</u> Tablet: 25 to 100 mg once daily</p> <p><u>Primary hyperaldosteronism (diagnosis):</u> Tablet (long test): 400 mg/day for three to four weeks</p> <p>Tablet (short test): 400 mg daily for four days</p> <p><u>Primary hyperaldosteronism (short-term preoperative therapy):</u> Tablet: 100 to 400 mg/day prior to surgery</p> <p><u>Primary hyperaldosteronism (long-term maintenance therapy):</u> Tablet: initial, 100 to 400 mg/day; maximum, 400 mg/day</p>	<p>established.</p>	<p>50 mg 100 mg</p>
Combination Products			
<p>Spirolactone and HCTZ</p>	<p><u>Edema (congestive heart failure, hepatic cirrhosis, nephrotic syndrome):</u> Tablet: maintenance, 100-100 mg/day in a single or divided dose(s); maintenance, 25-25 to 200-200 mg/day</p> <p><u>Hypertension:</u> Tablet: maintenance, 50-50 to 100-100 mg/day in a single or divided dose(s)</p>	<p>Safety and efficacy in children have not been established.</p>	<p>Tablet: 25-25 mg 50-50 mg</p>

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the mineralocorticoid (aldosterone) receptor antagonists are summarized in Table 10.

Table 10. Comparative Clinical Trials with the Mineralocorticoid (Aldosterone) Receptor Antagonists

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Diabetes/Diabetic Nephropathy/Renal Disease				
<p>Bianchi et al.³⁰ (2006)</p> <p>Spirolactone 25 mg/day</p> <p>vs</p> <p>placebo</p> <p>All patients were receiving conventional therapy (ACE inhibitor and/or ARB).</p>	<p>OL, PC, PRO, RCT</p> <p>Adult patients with chronic kidney disease</p>	<p>N=165</p> <p>1 year</p>	<p>Primary: Change in proteinuria, eGFR, blood pressure, and serum potassium</p> <p>Secondary: Not reported</p>	<p>Primary: While there was a significant reduction in proteinuria from baseline among spironolactone-treated patients (P<0.001), there was no difference in placebo-treated patients (P>0.05).</p> <p>At one year, there was no significant difference between spironolactone- and placebo-treated patients in eGFR (P value not reported). However, spironolactone-treated patients exhibited a lower monthly rate of decrease in eGFR from baseline compared to conventional therapy-treated patients (P<0.01). Patients whose baseline eGFR was <60 mL/min experienced a greater decline in eGFR compared to patients with baseline eGFR >60 mL/min (P<0.01).</p> <p>At one year of therapy, spironolactone-treated patients experienced a reduction in blood pressure from baseline (P<0.05). In contrast, placebo-treated patients did not exhibit blood pressure reduction from baseline (P value not reported).</p> <p>While there was a significant increase in serum potassium from baseline among spironolactone-treated patients (P<0.001), there was no difference in placebo-treated (P>0.05).</p> <p>Secondary: Not reported</p>
<p>Bianchi et al.³¹ (2010)</p> <p>Spirolactone 25 mg, ramipril 10 mg, irbesartan 300 mg, and atorvastatin 10</p>	<p>RCT, OL</p> <p>Patients with a clinical diagnosis of idiopathic chronic glomerulonephritis and urine</p>	<p>N=128</p> <p>36 months</p>	<p>Primary: Changes over time in proteinuria and eGFR</p> <p>Secondary: Adverse events,</p>	<p>Primary: SBP decreased more in the intensive-therapy group (from 156.6 to 113.5 mm Hg) than in the conventional therapy group (from 155.7 to 122.7 mm Hg; P<0.01).</p> <p>Urine protein excretion decreased from 2.65 to 0.45 g/g creatinine with intensive therapy (P<0.001). With conventional therapy, urine protein</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg QD (intensive therapy)</p> <p>vs</p> <p>ramipril 10 mg and atorvastatin 10 mg QD (conventional therapy)</p> <p>The addition of diuretics, calcium antagonists, β-blockers or α1-receptor antagonists were added to achieve blood pressure <130/80 mm Hg</p>	<p>protein-creatinine ratio >1 g/g</p>		<p>drop outs</p>	<p>excretion decreased from 2.60 to 1.23 g/g creatinine (P<0.001).</p> <p>With intensive therapy, eGFR did not significantly change over time (64.6 vs 62.9 mL/min/1.73 m²). With conventional therapy, eGFR decreased from 62.5 to 55.8 mL/min/1.73 m² (P<0.01).</p> <p>Secondary: In the conventional therapy group, eight patients discontinued the study due to hyperkalemia, cough, and rapid deterioration in kidney function. In the intensive therapy group, 15 dropped out due to hyperkalemia, cough, and hypotension. Nine patients in the intensive therapy group developed gynecomastia. Twelve patients on conventional and 31 on intensive therapy had to interrupt the study temporarily because of low blood pressure. No patient developed an increase in creatine kinase, alanine aminotransferase, and alkaline phosphatase levels during the study.</p>
<p>Ogawa et al.³² (2006)</p> <p>Spirololactone 25 mg/day plus imidapril* 5 mg/day</p> <p>vs</p> <p>furosemide 20 mg/day plus imidapril* 5 mg/day</p> <p>All patients were pre-treated with imidapril* for 1 year prior to trial onset.</p>	<p>PRO, RCT</p> <p>Adult patients with HTN and type 2 diabetes, with a urine albumin/creatinine ratio >30 mg/g creatinine, and plasma BNP levels >100 pg/mL (suggestive of mild heart failure)</p>	<p>N=30</p> <p>24 months</p>	<p>Primary: Change in BNP, urine albumin/creatinine ratio and blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: At 12 months, spironolactone-treated patients exhibited a significant reduction in BNP level from baseline compared to furosemide-treated patients (P<0.05).</p> <p>At 12 months, spironolactone-treated patients exhibited a significant reduction in urine albumin/creatinine ratio from baseline compared to furosemide-treated patients (P<0.05).</p> <p>Both treatments exhibited similar reductions in blood pressure from baseline (P value not reported).</p> <p>No adverse events were reported in this trial.</p> <p>Secondary: Not reported</p>
<p>Chrysostomou et</p>	<p>DB, PC, RCT</p>	<p>N=41</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>al.³³ (2006)</p> <p>Spironolactone 25 mg/day plus irbesartan 150 mg/day and ramipril 5 mg/day</p> <p>vs</p> <p>ramipril 5 mg/day plus spironolactone 25 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus irbesartan 150 mg/day and placebo</p> <p>vs</p> <p>ramipril 5 mg/day plus placebo and placebo</p>	<p>Patients 18 to 75 years of age, with a 24 hour urinary protein excretion >1.5 g/24 hours on ≥2 occasions ≥3 months apart, serum creatinine level ≤200 μmol/L with <20% variability in the preceding 3 months and treatment with an ACE inhibitor ≥6 months</p>	<p>6 months</p>	<p>Change in 24 hour urinary protein excretion at three months</p> <p>Secondary: Change in 24 hour urinary protein excretion at six months, change in blood pressure and creatinine clearance, adverse effects</p>	<p>Compared to ramipril-treated patients, the 24 hour urinary protein excretion reduction at three months was significantly greater in ramipril plus spironolactone-treated patients (P=0.004).</p> <p>Ramipril-, irbesartan- and spironolactone-treated patients exhibited a significant reduction in 24 hour urinary protein excretion compared to ramipril-treated patients (P<0.001).</p> <p>There was no significant difference in 24 hour urinary protein excretion with ramipril- and ramipril plus irbesartan-treated patients (P=1.00).</p> <p>At three months, spironolactone-treated patients exhibited a significant reduction in proteinuria from baseline (P≤0.001). In contrast, non-spironolactone-treated patients did not experience a significant reduction in proteinuria from baseline (P=0.840).</p> <p>Secondary: At six months, spironolactone-treated patients exhibited the greatest reduction in proteinuria compared to the other treatments (P<0.05).</p> <p>At six months, DBP was higher among ramipril monotherapy-treated patients compared to the other treatments (P=0.046). There was no difference in SBP among the treatments (P value not reported).</p> <p>There were no differences in creatinine clearance among the treatments (P>0.05).</p> <p>Gynecomastia was not observed with any of the treatments.</p>
<p>Furumatsu et al.³⁴ (2008)</p> <p>Spironolactone 25 mg/day (triple blockade group)</p> <p>vs</p>	<p>MC, OL, PRO, RCT</p> <p>Patients 20 to 70 years of age, with controlled blood pressure <130/80 mm Hg, chronic nephropathy (defined by serum</p>	<p>N=32</p> <p>12 months</p>	<p>Primary: Reduction in proteinuria, urinary type IV collagen, SBP, DBP, mean blood pressure, creatinine, creatinine clearance,</p>	<p>Primary: At one year of therapy, patients randomized to the triple blockage group experienced a statistically significant 58% reduction in urinary protein level from baseline (P<0.05), while there was no difference in the control group. Compared to the control group, the triple blockade group experienced a significant reduction in proteinuria at one year of therapy (P<0.05).</p> <p>At one year of therapy, patients randomized to the triple blockage group</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>trichlormethiazide* 1 mg/day or furosemide 10 mg/day (control group)</p> <p>Study medications were added to ongoing therapy consisting of enalapril 5 mg/day and losartan 50 mg/day.</p>	<p>creatinine level <3 mg/dL or calculated creatinine concentration <30 mL/min), daily treatment with enalapril 5 mg and losartan 50 mg for at least 12 weeks, and persistent proteinuria (urinary protein excretion >0.5 g/day)</p>		<p>potassium, urinary aldosterone</p> <p>Secondary: Not reported</p>	<p>experienced a statistically significant 40% reduction in urinary type IV collagen from baseline (P<0.05); while there was no difference in the control group. However there was no statistically significant difference in the change of urinary type IV collagen from baseline between the two study groups.</p> <p>There were no statistically significant differences between the two study groups in the following outcome measures: SBP, DBP, mean blood pressure, creatinine, creatinine clearance, potassium, and urinary aldosterone.</p> <p>Secondary: Not reported</p>
<p>van den Meiracker et al.³⁵ (2006)</p> <p>Spironolactone 25 mg BID</p> <p>vs</p> <p>placebo</p> <p>All patients were also receiving their ongoing antihypertensive therapy.</p>	<p>DB, PC, PG, RCT</p> <p>Adult patients with type 2 diabetes, macroalbuminuria (24 hour urinary albumin excretion >300 mg or urinary albumin to creatinine ratio >20 mg/mmol) despite use of an ACE inhibitor or ARB in recommended dosages for ≥1 year</p>	<p>N=59</p> <p>1 year</p>	<p>Primary: Change in albuminuria, DBP and SBP, GFR, aldosterone level, plasma renin activity and serum potassium</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to placebo-treated patients, spironolactone-treated patients exhibited a significant 40.6% reduction in albuminuria from baseline (P=0.002).</p> <p>Compared to placebo, spironolactone-treated patients exhibited a significant reduction in SBP from baseline (P=0.04), with a comparable reduction in DBP (P value not reported).</p> <p>Both treatments exhibited comparable changes in GFR from baseline (P value not reported).</p> <p>Compared to placebo, spironolactone-treated patients exhibited a significant increase in aldosterone level and plasma renin activity from baseline (P<0.05).</p> <p>There was a significant increase in serum potassium level in spironolactone-treated patients compared to placebo (P=0.02).</p> <p>Secondary: Not reported</p>
<p>Schjoedt et al.³⁶ (2006)</p>	<p>DB, RCT, XO</p> <p>Patients with</p>	<p>N=20</p> <p>2 weeks</p>	<p>Primary: Change in proteinuria,</p>	<p>Primary: Compared to placebo, spironolactone therapy was associated with a significant 32% reduction in proteinuria from baseline (P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Spirolactone 25 mg/day</p> <p>vs</p> <p>placebo</p> <p>Study medications were added to ongoing antihypertensive therapy (ACE inhibitor or ARB).</p>	<p>diabetic nephropathy and nephrotic range albuminuria (>2,500 mg/24 hour) despite recommended antihypertensive treatment</p>		<p>ambulatory DBP and SBP, GFR, fractional albumin clearance, aldosterone level, plasma renin activity, and serum potassium</p> <p>Secondary: Not reported</p>	<p>Compared to placebo, spironolactone therapy was associated with a significant reduction in systolic and diastolic ambulatory 24-hr blood pressures from baseline (P=0.004, P=0.001, respectively).</p> <p>Both groups exhibited comparable changes in GFR from baseline (P=0.13).</p> <p>Compared to placebo, spironolactone therapy was associated with a significant 31% reduction in fractional albumin clearance from baseline (P<0.001).</p> <p>Compared to placebo, spironolactone therapy was associated with significant increases in aldosterone level and plasma renin activity from baseline, 80 and 91%, respectively (P<0.005).</p> <p>There was a trend towards an increase in the serum potassium level with spironolactone therapy compared to placebo (P=0.054).</p> <p>Secondary: Not reported</p>
<p>Davidson et al.³⁷ (2008)</p> <p>Spirolactone 25 mg added to existing ACE inhibitor therapy</p>	<p>OL</p> <p>Patients ≥18 years of age with type 2 diabetes on an ACE inhibitor for >1 month with a urinary albumin to creatinine ratio >100 mg/g</p>	<p>N=24</p> <p>12 weeks</p>	<p>Primary: Change in urinary albumin excretion</p> <p>Secondary: Changes in serum creatinine, serum potassium, and SBP</p>	<p>Primary: Urinary albumin excretion decreased 25.7% from a 404.6 mg/day to 302.7 mg/day (P<0.001). Urinary albumin excretion decreased 27.2% in the microalbuminuria group (P=0.05) and 24.3% in the macroalbuminuria group (P=0.02).</p> <p>Secondary: There were no significant changes in serum sodium, potassium, creatinine, or glucose.</p> <p>There was a significant decrease in SBP with the addition of spironolactone (141.2 to 132.5 mm Hg; P=0.002).</p>
<p>Saklayen et al.³⁸ (2008)</p> <p>Spirolactone 25</p>	<p>DB, PC, RCT, XO</p> <p>Patients with diabetic nephropathy</p>	<p>N=30</p> <p>7 months</p>	<p>Primary: Blood pressure, serum creatinine, and spot urine</p>	<p>Primary: With spironolactone, the mean SBP at the beginning of the treatment period was 153.64 mm Hg and 141.60 at the end (P=0.01). DBP was 79.56 mm Hg at baseline and 76.68 at study endpoint (P=0.25). The mean SBP</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
to 50 mg/day vs placebo Study medications were added to existing ACE inhibitor or ARB therapy.	with any level of proteinuria who were already being treated with ACE inhibitor (lisinopril) or ARB (losartan) at moderate to maximum dose		protein/creatinine Secondary: Not reported	with placebo was 154.52 mm Hg at the beginning of the treatment period and 148.82 mm Hg at the end of the study period (P=0.34). DBP was 79.74 mm Hg at baseline and 77.91 at study endpoint (P=0.49). The urine protein/creatinine increased from 1.24 to 1.57 (24%) with placebo (P=0.35) and decreased from 1.80 to 0.79 (57%) with spironolactone (P=0.004). Serum creatinine increased from 1.43 to 1.50 on placebo (P=0.19) and from 1.35 to 1.56 on spironolactone (P=0.006). Secondary: Not reported
Sengul et al. ³⁹ (2009) Spironolactone 25 mg QD Study medication was added to existing ACE inhibitor or ARB therapy.	PRO Patients with overt proteinuria (>300 mg/day) despite the regular use of ACE inhibitors and/or ARBs for ≥6 months	N=33 8 weeks	Primary: Proteinuria, blood pressure Secondary: Not reported	Primary: At week four, there was a 25.4% reduction in proteinuria with spironolactone (P=0.003). SBP and DBP were significantly reduced (P=0.013 and P=0.040, respectively). Serum potassium level increased 0.28 mEq/L (P<0.001). At week eight, the 24-hr median urinary protein excretion decreased from 1,428 to 743 mg/day (47.9%) with spironolactone. SBP and DBP were significantly reduced (P<0.004 and P<0.001, respectively). Serum potassium level increased 0.55 mEq/L (P<0.001). There was no difference in creatinine clearance or serum creatinine levels. Serum albumin increased from 3.88 to 4.01 g/dL (P=0.003). Secondary: Not reported
Tylicki et al. ⁴⁰ (2008) Spironolactone 25 mg QD plus background therapy for 8 weeks (triple RAAS blockade)	OL, RCT, XO Patients with chronic nondiabetic proteinuric kidney diseases	N=18 16 weeks	Primary: 24-hr urine excretion of protein, blood pressure, serum creatinine, serum potassium, plasma renin activity	Primary: A total of 17 patients achieved blood pressure goal of <130/80 mm Hg. There was no difference in ambulatory SBP and DBP between the treatments (P=0.9 and P=0.1). Serum creatinine and eGFR remained stable during the study periods (P=0.6 and P=0.9, respectively). A significant increase in plasma renin activity was observed after

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>background therapy for 8 weeks (double RAAS blockade)</p> <p>Background therapy included HCTZ, telmisartan, cilazapril (ACE inhibitor).</p>			<p>Secondary: Not reported</p>	<p>treatment with triple RAAS blockade compared to double RAAS blockade (P=0.02).</p> <p>Triple RAAS therapy provided an additional 55.37% decrease in proteinuria compared to double RAAS blockade (P=0.01). The decrease in proteinuria was shown in 16 of 18 patients. Changes in proteinuria did not correlate with changes in SBP, DBP, or plasma renin activity.</p> <p>There was a significant increase in potassium levels after triple RAAS blockade compared to baseline (P=0.02).</p> <p>Secondary: Not reported</p>
Heart Failure				
<p>Pitt et al.⁴¹ (2003) EPHESUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE inhibitors, ARBs, diuretics, β-blockers, coronary reperfusion therapy)</p>	<p>DB, MC, RCT</p> <p>Patients with acute MI, left ventricular dysfunction (ejection fraction \leq40%) and heart failure (patients with diabetes were not required to have heart failure)</p>	<p>N=6,632</p> <p>16 months (mean follow-up)</p>	<p>Primary: Death from any cause, composite of death from cardiovascular causes or hospitalization for a cardiovascular event (heart failure, recurrent acute MI, stroke or ventricular arrhythmia)</p> <p>Secondary: Death from any cause or any hospitalization, death from cardiovascular causes, any hospitalization, hospitalization for</p>	<p>Primary: Significantly fewer eplerenone-treated patients died from any cause compared to placebo-treated patients (478 vs 554; RR, 0.85; 95% CI, 0.75 to 0.96; P=0.008).</p> <p>Significantly fewer eplerenone-treated patients died from or required hospitalization for cardiovascular events compared to placebo-treated patients (885 vs 993; RR, 0.87; 95% CI, 0.79 to 0.95; P=0.002).</p> <p>Secondary: Significantly fewer eplerenone-treated patients died from any cause or required hospitalization (1,730 vs 1,829; RR, 0.92; 95% CI, 0.86 to 0.98; P=0.02).</p> <p>Death from cardiovascular causes was 12.3 and 14.6% in eplerenone- and placebo-treated patients (RR, 0.83; 95% CI, 0.72 to 0.94; P=0.005).</p> <p>Fewer eplerenone-treated patients required hospitalization (1,493 vs 1,526; RR, 0.95; 95% CI, 0.89 to 1.02; P=0.2); however, the difference was not significant.</p> <p>Fewer eplerenone-treated patients required hospitalization due to a cardiovascular event (606 vs 649; RR, 0.91; 95% CI, 0.81 to 1.01;</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			cardiovascular causes, hospitalization for heart failure, adverse events	<p>P=0.09); however, the difference was not significant.</p> <p>There was a RR of 15% in the risk of hospitalization for heart failure in the eplerenone-treated patients (RR, 0.85; P=0.03) and 23% fewer episodes of hospitalization for heart failure were reported in these patients (RR, 0.77; P=0.002).</p> <p>Serious hyperkalemia (serum potassium ≥ 6.0 mmol/L) occurred in 5.5 and 3.9% of eplerenone- and placebo-treated patients (P=0.002). The incidence of hyperkalemia was higher among patients with a lower baseline creatinine clearance (P<0.001).</p> <p>At one year, the serum creatinine concentration had increased by 0.02 and 0.06 mg/dL in placebo- and eplerenone-treated patients (P<0.001).</p> <p>There were no significant differences between eplerenone- and placebo-treated patients in the incidence of sex hormone-related adverse events, including gynecomastia, impotence, breast pain and abnormal vaginal bleeding (P>0.05).</p>
<p>Pitt et al.⁴² (2005) EPHEBUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE</p>	<p>Subanalysis of EPHEBUS</p> <p>Patients with acute MI, left ventricular dysfunction (ejection fraction $\leq 40\%$) and heart failure (patients with diabetes were not required to have heart failure)</p>	<p>N=6,632</p> <p>30 days post randomization</p>	<p>Primary: Death from any cause, composite of death from cardiovascular causes or hospitalization for a cardiovascular event at 30 days</p> <p>Secondary: Death from cardiovascular causes, sudden cardiac death, fatal or nonfatal heart failure hospitalization,</p>	<p>Primary: A significantly lower percentage of eplerenone-treated patients died from any cause (3.2 vs 4.6%; P=0.004).</p> <p>A lower percentage of eplerenone-treated patients died from or required hospitalization for cardiovascular events (8.6 vs 9.9%; P=0.074); however, the difference was not significant.</p> <p>Secondary: A significantly lower percentage of eplerenone-treated patients died from cardiovascular cause (3.0 vs 4.4%; P=0.003).</p> <p>A lower incidence of sudden cardiac death was noted among eplerenone-treated patients (0.9 vs 1.4%; P=0.051); however, the difference was not significant.</p> <p>A lower percentage of eplerenone-treated patients required hospitalization for fatal/nonfatal heart failure (3.4 vs 4.2%; P=0.106); however, the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
inhibitors, ARBs, diuretics, β -blockers, coronary reperfusion therapy)			adverse events	<p>difference was not significant.</p> <p>There was no significant difference between the two treatments in the number of patients experiencing at least one adverse event during 30 days of therapy (P=0.29).</p> <p>At 30 days, the serum potassium concentration had increased by 0.17 and by 0.24 mmol/L in placebo- and eplerenone-treated patients (P<0.001).</p>
<p>Pitt et al.⁴³ (2006) EPHESUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE inhibitors, ARBs, diuretics, β-blockers, coronary reperfusion therapy)</p>	<p>Subanalysis of EPHESUS evaluating effects of eplerenone in patients with LVEF \leq30%</p> <p>Patients with acute MI, left ventricular dysfunction (ejection fraction \leq40%) and heart failure (patients with diabetes were not required to have heart failure)</p>	<p>N=2,106</p> <p>16 months</p>	<p>Primary: Death from any cause, composite of death from cardiovascular causes or hospitalization for a cardiovascular event</p> <p>Secondary: Death from cardiovascular causes, sudden cardiac death, composite of heart failure death and heart failure hospitalizations</p>	<p>Primary: Eplerenone therapy was associated with a significant 21% reduction in the risk of all-cause mortality compared to placebo (P=0.012).</p> <p>Eplerenone therapy was associated with a significant reduction in the risk of the composite endpoint of death from cardiovascular causes or hospitalization for a cardiovascular event compared to placebo (P=0.001).</p> <p>Secondary: Eplerenone therapy was associated with a significant 23% reduction in the risk of cardiovascular mortality compared to placebo (P=0.008).</p> <p>The RR of sudden cardiac death was reduced by 33% (P=0.01) and the heart failure mortality/heart failure hospitalization composite endpoint was reduced by 25% (P=0.005) in eplerenone-treated patients compared to placebo-treated patients.</p> <p>At 30 days, eplerenone therapy was associated with RRRs of 43 (P=0.002), 29 (P=0.006) and 58% (P=0.008) for all-cause mortality, the cardiovascular mortality/cardiovascular hospitalization composite endpoint for sudden cardiac death.</p>
<p>O'Keefe et al.⁴⁴ (2007) EPHESUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by</p>	<p>Subanalysis of EPHESUS evaluating effects of eplerenone in patients with diabetes</p>	<p>N=1,483</p> <p>16 months</p>	<p>Primary: Death from any cause, composite of death from cardiovascular causes or hospitalization for</p>	<p>Primary: Eplerenone therapy was not associated with a significant reduction in the risk of all-cause mortality compared to placebo (P=0.131).</p> <p>Eplerenone therapy in diabetic patients was associated with a significant 17% reduction in the risk of death from cardiovascular causes or hospitalization for a cardiovascular event compared to placebo (P=0.031).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE inhibitors, ARBs, diuretics, β-blockers, coronary reperfusion therapy)</p>	<p>Patients with acute MI, left ventricular dysfunction (ejection fraction $\leq 40\%$) and heart failure (patients with diabetes were not required to have heart failure)</p>		<p>a cardiovascular event</p> <p>Secondary: Death from cardiovascular causes, sudden cardiac death, hyperkalemia</p>	<p>Secondary: Eplerenone therapy was not associated with a significant reduction in the risk of cardiovascular mortality compared to placebo (P=0.128).</p> <p>Eplerenone therapy was not associated with a significant reduction in the risk of sudden cardiac death compared to placebo (P=0.533).</p> <p>Eplerenone therapy was associated with a greater incidence of hyperkalemia compared to placebo (5.6 vs 3.0%; P=0.015).</p>
<p>Gheorghide et al.⁴⁵ (2009) EPHESUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE inhibitors, ARBs, diuretics, β-blockers, coronary reperfusion therapy)</p>	<p>Subanalysis of EPHESUS evaluating effects of eplerenone on length of stay and total days of heart failure hospitalization</p> <p>Patients with acute MI, left ventricular dysfunction (ejection fraction $\leq 40\%$) and heart failure (patients with diabetes were not required to have heart failure)</p>	<p>N=828</p> <p>16 months</p>	<p>Primary: Mean length of stay/episode of heart failure hospitalization, total number of days of heart failure hospitalizations following the index hospitalization during the subsequent follow up period</p> <p>Secondary: Determine the difference between the five regions in the mean length of stay and the total number of days for</p>	<p>Primary: Over a mean follow up of 16 months, eplerenone therapy was associated with a significant reduction in the mean length of hospital stay/episode of heart failure hospitalization of 1.6 days (9.2 vs 10.8 days; P=0.019).</p> <p>Eplerenone-treated patients achieved a reduction in the total number of days of heart failure hospitalization/patient of 3.6 days (13.3 vs 16.9 days; P=0.0006).</p> <p>Secondary: The length of stay/heart failure hospitalization episode and total number of days of heart failure hospitalization/patient were consistently and similarly reduced in eplerenone-treated patients in all geographic regions as demonstrated by the nonsignificant interaction of study region on treatment effect (P=0.63 for length of stay/episode and P=0.45 for total hospitalization days for heart failure, respectively).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			heart failure hospitalization	
<p>Adamopoulos et al.⁴⁶ (2010) EPHESUS</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by titration to 50 mg/day</p> <p>vs</p> <p>placebo</p> <p>Patients were allowed to receive optimal medical therapy (ACE inhibitors, ARBs, diuretics, β-blockers, coronary reperfusion therapy)</p>	<p>Subanalysis of EPHESUS evaluating the differential effects of time-to-eplerenone initiation vs placebo</p> <p>Patients with acute MI, left ventricular dysfunction (ejection fraction $\leq 40\%$) and heart failure (patients with diabetes were not required to have heart failure)</p>	<p>N=6,632</p> <p>16 months</p>	<p>Primary: Death from any cause, composite of death from cardiovascular causes or hospitalization for a cardiovascular event (heart failure, recurrent acute MI, stroke or ventricular arrhythmia)</p> <p>Secondary: Sudden cardiac death</p>	<p>Primary: “Earlier” eplerenone-treated patients had significantly lower event rates when compared to “earlier” placebo-treated patients for all-cause mortality (11.5 vs 16.1%) and the composite of cardiovascular hospitalization or death (24.0 vs 30.3%). No significant differences were found between “later” eplerenone- and placebo-treated patients.</p> <p>“Earlier” eplerenone therapy significantly reduced the risk for all-cause mortality (HR, 0.72; 95% CI, 0.58 to 0.89; P=0.002) and cardiovascular hospitalization or death (HR, 0.78; 95% CI, 0.67 to 0.90; P=0.001).</p> <p>Secondary: “Earlier” eplerenone-treated patients had significantly lower event rates when compared to “earlier” placebo-treated patients for sudden cardiac death (3.7 vs 6.9%). No significant differences were found between “later” eplerenone- and placebo-treated patients.</p> <p>“Earlier” eplerenone therapy significantly reduced the risk for sudden cardiac death (HR, 0.54; 95% CI, 0.38 to 0.77; P=0.001).</p> <p>In a head-to-head comparison between the two eplerenone treatment groups, “earlier” therapy was associated with significantly lower risk with respect to all endpoints. No significant difference was found in a direct comparison between the two placebo treatment groups.</p>
<p>Udelson et al.⁴⁷ (2010)</p> <p>Eplerenone 25 mg/day for 4 weeks, followed by 50 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients ≥ 21 years of age with current symptoms consistent of mild to moderate heart failure (NYHA Class II and III) who had LVEF $\leq 35\%$ and were on therapy</p>	<p>N=226</p> <p>36 weeks</p>	<p>Primary: Change in left ventricular end-diastolic volume index</p> <p>Secondary: Changes in left ventricular end-systolic volume index and LVEF,</p>	<p>Primary: Over 36 weeks, there was no evidence of an effect of eplerenone therapy on left ventricular end-diastolic volume index compared to placebo (P value not reported).</p> <p>Secondary: Over 36 weeks, there was no evidence of an effect of eplerenone therapy on left ventricular end-systolic volume index compared to placebo (P value not reported).</p> <p>Over 36 weeks, there was no evidence of an effect of eplerenone therapy</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	with an ACE inhibitor and/or ARB and β -blocker for ≥ 3 months and at a dose that has not been adjusted within the previous 4 weeks		markers of collagen turnover	<p>on LVEF compared to placebo (P value not reported).</p> <p>During the course of treatment, eplerenone-treated patients exhibited a greater reduction in PINP and BNP compared to placebo-treated patients (P=0.01 and P=0.04, respectively). No difference between the two treatments was observed in the change from baseline to week 36 in PIIINP (P value not reported).</p>
<p>Zannad et al.⁴⁸ (2011) EMPHASIS-HF</p> <p>Eplerenone 25 mg QD for 4 weeks, followed by 50 mg QD</p> <p>vs</p> <p>placebo</p> <p>Randomization occurred within 6 months after hospitalization for a cardiovascular reason.</p> <p>Patients who had not been hospitalized for a cardiovascular reason within 6 months of the screening visit</p>	<p>DB, RCT</p> <p>Patients ≥ 55 years of age with NYHA Class II symptoms, and ejection fraction $\leq 30\%$ and treatment with an ACE inhibitor, ARB or both and a β-blocker at the recommended dose or maximal tolerated dose</p>	<p>N=2,737</p> <p>21 months (median follow up)</p>	<p>Primary: Composite of death from cardiovascular causes or a first hospitalization for heart failure</p> <p>Secondary: Hospitalization for heart failure or death from any cause, death from any cause, death from cardiovascular causes, hospitalization for any reason, hospitalization for heart failure</p>	<p>Primary: The primary composite endpoint occurred in 18.3 and 25.9% of eplerenone- and placebo-treated patients (HR, 0.63; 95% CI, 0.54 to 0.74; P<0.001).</p> <p>Secondary: Death from any cause or hospitalization for heart failure occurred in 19.8 and 27.4% of eplerenone- and placebo-treated patients (HR, 0.65; 95% CI, 0.55 to 0.76; P<0.001).</p> <p>A total of 12.5 and 15.5% of eplerenone- and placebo-treated patients died (HR, 0.76; 95% CI, 0.62 to 0.93; P=0.008).</p> <p>A total of 10.8 and 13.5% of deaths were attributed to cardiovascular causes in eplerenone- and placebo-treated patients (HR, 0.76; 95% CI, 0.61 to 0.94; P=0.01).</p> <p>A total of 29.9 and 35.8% of eplerenone- and placebo-treated patients were hospitalized for any reason (HR, 0.77; 95% CI, 0.67 to 0.88; P<0.001).</p> <p>Of the hospitalized patients, 12.0 vs 18.4% of eplerenone- and placebo-treated patients were hospitalized for heart failure (HR, 0.58; 95% CI, 0.47 to 0.70; P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>could be enrolled if the plasma BNP was ≥ 250 pg/mL or if the plasma N-terminal pro-BNP was ≥ 500 pg/mL in men and ≥ 750 pg/mL in women.</p>				
<p>Eschalier et al.⁴⁹ (2013) EMPHASIS-HF</p> <p>Eplerenone 25 mg QD for 4 weeks, followed by 50 mg QD</p> <p>vs</p> <p>placebo</p>	<p>Subgroup analysis of EMPHASIS-HF</p> <p>Patients included in the EMPHASIS-HF trial aged ≥ 75 years with diabetes, CKD, and SBP $<$median (123 mm Hg)</p>	<p>N=2,737</p> <p>21 months (median follow up)</p>	<p>Primary: Hospitalization for HF or death from cardiovascular causes</p> <p>Secondary: Serum potassium, hyperkalemia leading to study drug discontinuation, hospitalization for hyperkalemia and hospitalization for worsening renal function (WRF), change in eGFR</p>	<p>Primary: Eplerenone was effective at reducing the risk of cardiovascular death or HF hospitalization in the high-risk subgroups, which is consistent with result in the overall EMPHASIS-HF study population (HR, 0.63; 95% CI, 0.54 to 0.74; $P < 0.001$). The HR for the primary outcome in the eplerenone group as compared with the placebo group was 0.66 (95% CI, 0.49 to 0.88; $P = 0.005$) in patients ≥ 75 years of age, 0.54 (95% CI, 0.42 to 0.70; $P < 0.0001$) in patients with diabetes, 0.62 (95% CI, 0.49 to 0.79; $P = 0.0001$) in patients with CKD, and 0.63 (95% CI, 0.51 to 0.79; $P < 0.0001$) in patients with SBP $<$ median.</p> <p>Secondary: The number of patients with study drug stopped due to adverse events was evenly distributed within and among the study high-risk subgroups in patients age ≥ 75 years (18.2% in eplerenone vs 19.0% in placebo), in patients with SBP < 123 mm Hg (16.6% in eplerenone vs 18.0% in placebo), in patients with CKD (16.1% in eplerenone vs 22.3% in placebo), and in patients with diabetes mellitus (15.1% in eplerenone vs 18.1% in placebo). In patients with CKD (eGFR < 60 ml/min/1.73 m²), there were fewer patients in eplerenone group who had their treatment stopped due to an adverse event or due to any other reason than in placebo group.</p>
<p>Krum et al.⁵⁰ (2013) EMPHASIS-HF</p> <p>Eplerenone 25 mg QD for 4 weeks, followed by 50 mg</p>	<p>Subgroup analysis of EMPHASIS-HF</p> <p>Patients included in the EMPHASIS-HF trial analyzed according to the use</p>	<p>N=2,737</p> <p>21 months (median follow up)</p>	<p>Primary: Hospitalization for HF or death from cardiovascular causes</p> <p>Secondary:</p>	<p>Primary: The beneficial clinical effects of eplerenone (as observed in the main study) were preserved for the EMPHASIS-HF primary end point in patients receiving higher doses of ACE Inhibitor or ARB, β-blocker, or both. P values for interaction between high and low doses for the EMPHASIS-HF primary end point were not significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD vs placebo</p>	<p>and dose of ACE inhibitors/ARBs, β-blockers, or both</p>		<p>Not reported</p>	<p>Secondary: Not reported</p>
<p>Pitt et al.⁵¹ (1999) RALES Spironolactone 25 mg/day; in the absence of hyperkalemia, the dose could be increased to 50 mg/day after 8 weeks; if hyperkalemia developed the dose could be decreased to 25 mg every other day vs placebo</p>	<p>DB, MC, RCT Patients with NYHA class 4 heart failure within 6 months and with NYHA class 3 to 4 at study onset, diagnosed with CHF ≥ 6 weeks, treated with an ACE inhibitor and a loop diuretic, with a LVEF $\leq 35\%$</p>	<p>N=1,663 24 months (mean follow-up)</p>	<p>Primary: Death from any cause Secondary: Death from cardiac causes, hospitalization for cardiac causes, combined incidence of death or hospitalization for cardiac causes, combined end point of death or hospitalizations from any cause, combined end point of death from any cause or hospitalizations from cardiac causes, change in the NYHA class, adverse events</p>	<p>Primary: There were 386 and 284 deaths from any cause in placebo- and spironolactone-treated patients (RR, 0.70; 95% CI, 0.60 to 0.82; P<0.001). Secondary: There were 314 and 226 deaths in placebo- and spironolactone-treated patients that were attributed to cardiac causes (RR, 0.69; 95% CI, 0.58 to 0.82; P<0.001). There were 753 and 515 hospitalizations for cardiac causes in placebo- and spironolactone-treated patients (RR, 0.70; 95% CI, 0.59 to 0.82; P<0.001). The combined end point of death from cardiac causes or hospitalizations from cardiac causes showed a 32% reduction in risk among spironolactone-treated patients compared to placebo-treated patients (RR, 0.68; 95% CI, 0.59 to 0.78; P<0.001). The combined end point of death or hospitalizations from any cause showed a 23% reduction in risk among spironolactone-treated patients compared to placebo-treated patients (RR, 0.77; 95% CI, 0.68 to 0.86; P<0.001). The combined end point of death from any cause or hospitalizations from cardiac causes showed a 32% reduction in risk among spironolactone-treated patients as compared to placebo-treated patients (RR, 0.68; 95% CI, 0.60 to 0.77; P<0.001). A significantly greater percentage of spironolactone-treated patients experienced improvement in the NYHA class compared to placebo-treated patients (41 vs 33%; P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Gynecomastia or breast pain was reported in 10 and 1% of spironolactone- and placebo-treated men (P<0.001). The incidence of hyperkalemia was minimal with both treatments.
<p>Vardeny et al.⁵² (2012) RALES</p> <p>Spironolactone 25 or 50 mg/day</p> <p>vs</p> <p>placebo</p>	<p>Post-hoc analysis</p> <p>Patients with NHYA class III or IV heart failure with an ejection fraction <35%</p>	<p>N=1,658</p> <p>24 months (mean follow-up)</p>	<p>Primary: Death from any cause</p> <p>Secondary: Death from cardiac causes, hospitalization for cardiac causes, combined incidence of death or hospitalization for cardiac causes, combined end point of death or hospitalizations from any cause, combined end point of death from any cause or hospitalizations from cardiac causes, change in the NYHA class, adverse events</p>	<p>Primary: Patients with reduced baseline eGFR exhibited similar RR reductions in all cause mortality and the composite of death or hospital stays for heart failure compared to patients with a baseline eGFR >60 mL/min/1.73 m², and a greater absolute risk reduction compared to patients with a higher baseline eGFR (10.3 vs 6.4%).</p> <p>Worsening renal failure (17 vs 7%; P<0.001) was associated with an increased adjusted risk of death with placebo (HR, 1.9; 95% CI, 1.3 to 2.6) but not with spironolactone (HR, 1.1; 95% CI, 0.79 to 1.5; P=0.009).</p> <p>The risk of hyperkalemia and renal failure was higher in patients with worse baseline renal function and patients with worsening renal failure, particularly with spironolactone.</p> <p>Secondary:</p>
<p>Vizzardi et al.⁵³ (2010)</p> <p>Spironolactone 25 mg QD, followed by up-titration every 2 weeks to 50 or 100 mg QD</p>	<p>DB, PC, RCT</p> <p>Patients with clinical evidence of heart failure, NYHA class I to 2 severity of symptoms at the time of enrollment and receiving</p>	<p>N=158</p> <p>6 months</p>	<p>Primary: Change in LVEF, left ventricular end-diastolic and -systolic volumes, left ventricular mass and laboratory examinations</p>	<p>Primary: After six months, LVEF increased (P<0.001) and left ventricular end-diastolic and -systolic volumes decreased (P<0.001 for both) significantly in spironolactone-treated patients compared to placebo-treated patients.</p> <p>After six months, left ventricular mass decreased significantly in spironolactone-treated patients compared to placebo-treated patients (from 269±74 to 243±67 g vs 250±43 to 247±38 g; P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	optimal medical treatment maintained at stable doses for ≥ 6 months		Secondary: Not reported	Serum potassium increased in spironolactone-treated patients from 4.2 ± 0 to 4.6 ± 0.3 mmol/L ($P < 0.001$). Serum aldosterone and renin levels increased, respectively, from 157.1 ± 1.03 to 205 ± 56.5 pg/mL ($P = 0.08$) and from 3.7 ± 10.5 to 6.2 ± 2.8 ng/mL/hr ($P = 0.03$) in these patients. No significant changes were found in serum creatinine, serum urea nitrogen and uric acid. Secondary: Not reported
Chan et al. ⁵⁴ (2007) Spironolactone 25 mg QD vs placebo All patients received candesartan 8 mg/day.	DB, PC, RCT Patients with LVEF $< 40\%$ on ACE inhibitors for > 6 months	N=48 1 year	Primary: Change in LVEF, left ventricular end-diastolic volume index, end-systolic volume index, left ventricular mass index, SBP, quality of life Secondary: Not reported	Primary: At one year, combination therapy was associated with a significant improvement in LVEF from baseline ($P < 0.01$). At one year, combination therapy was associated with a significant reduction in left ventricular end-diastolic volume index from baseline ($P < 0.001$). At one year, combination therapy was associated with a significant reduction in end-systolic volume index from baseline ($P < 0.0005$). At one year, combination therapy was associated with a significant reduction in left ventricular mass index from baseline ($P = 0.002$). At one year, combination therapy was associated with a significant reduction in SBP from baseline ($P < 0.05$). The control group was not associated with significant improvements in any of the above primary outcome measures. The quality of life score improved in both study groups. Secondary: Not reported
Edelmann et al. ⁵⁵ (2013) Aldo-DHF	DB, MC, PC, PRO, RCT Patients with chronic	N=422 12 months	Primary: Change in diastolic function and maximal exercise	Primary: Diastolic function decreased from 12.7 ± 3.6 to 12.1 ± 3.7 with spironolactone and increased from 12.8 ± 4.4 to 13.6 ± 4.3 with placebo (adjusted mean difference, -1.5 ; 95% CI, -2.0 to -0.9 ; $P < 0.001$).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Spirolactone 25 mg QD</p> <p>vs</p> <p>placebo</p>	<p>NYHA class II or III heart failure, preserved LVEF $\geq 50\%$, and evidence of diastolic dysfunction</p>		<p>capacity</p> <p>Secondary: Left ventricular mass index, neuroendocrine activation, symptoms of heart failure, QOL, 6-minute walking distance</p>	<p>With regards to exercise capacity, peak VO₂ did not significantly change with spironolactone vs placebo (from 16.3\pm3.6 to 16.8\pm4.6 vs from 16.4\pm3.5 to 16.9\pm4.4 mL/min/kg, respectively; adjusted mean difference, 0.1 mL/min/kg; 95% CI, -0.6 to 0.8; P=0.81).</p> <p>Secondary: Compared to placebo, treatment with spironolactone induced reverse remodeling (left ventricular mass index declined; adjusted mean difference, -6 g/m²; 95% CI, -10 to -1; P=0.009) and improved neuroendocrine activation (N-terminal pro-brain-type natriuretic peptide geometric mean ratio, 0.86; 95% CI, 0.75 to 0.99; P=0.03).</p> <p>Compared to placebo, spironolactone did not improve heart failure symptoms or QOL.</p> <p>Compared to placebo, spironolactone slightly reduced 6-minute walking distance (-15 m; 95% CI, -27 to -2; P=0.03).</p>
<p>Pitt et al.⁵⁶ (2014) TOPCAT</p> <p>Spirolactone</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, RCT</p> <p>Patients ≥ 50 years of age with at least 1 sign and 1 symptom of HF, a LVEF $\geq 45\%$, controlled BP, and potassium < 5.0 mmol/L who were hospitalized in the previous year</p>	<p>N=3445</p> <p>3 years</p>	<p>Primary: Composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure</p> <p>Secondary: Death from any cause, hospitalization for any cause, hyperkalemia (K ≥ 5.5 mmol/L), hypokalemia (K < 3.5 mmol/L), an</p>	<p>Primary: 18.6% of patients in the spironolactone group and 20.4% of patients in the placebo group had at least one confirmed primary-outcome event (P=0.14).</p> <p>Secondary: There were no significant differences between study groups in time to death from any cause or first hospitalization for any reason. Frequency of hospitalization for any reason (including recurrent hospitalization) did not differ significantly according to study group (36.8 hospitalizations per 100 person-years in the spironolactone group and 36.3 per 100 person-years in the placebo group; P=0.71).</p> <p>The spironolactone group had a higher rate of hyperkalemia (18.7 vs 9.1% in the placebo group) and a lower rate of hypokalemia (16.2 vs 22.9%). The spironolactone group was more likely to have a doubling of the serum creatinine level to a value above the upper limit of the normal range (10.2 vs 7.0%). However, there were no significant between-group differences in the proportion of patients with a serum creatinine level of 3.0 mg per</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			<p>elevated serum creatinine level (≥ 2 times the baseline value and above the upper limit of normal), and a serum creatinine level ≥ 3.0 mg/deciliter</p>	<p>deciliter or higher or who required dialysis.</p>
<p>Levy et al.⁵⁷ (1977)</p> <p>Spironolactone and HCTZ 25-25 mg/day (fixed-dose combination product) for 16 weeks following 8 weeks of furosemide monotherapy</p> <p>vs</p> <p>furosemide 25 mg daily for 24 weeks</p>	<p>DB, RCT</p> <p>Patients 27 to 79 years of age with arteriosclerotic heart disease, hypertensive heart disease, or rheumatic heart disease classes 1 to 3, and congestive heart failure requiring diuretic therapy</p>	<p>N=32</p> <p>24 weeks</p>	<p>Primary: Change in heart failure symptoms, glucose, renin concentration, calcium, blood urea nitrogen, uric acid, creatinine, aldosterone, serum potassium level, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: The combination therapy group and furosemide monotherapy group exhibited comparable control of heart failure symptoms.</p> <p>The combination therapy group was associated with a significant decrease in glucose and an increase in plasma renin concentration compared to furosemide monotherapy group (P<0.01).</p> <p>There were no significant differences in calcium, blood urea nitrogen, uric acid, or creatinine between the study groups.</p> <p>There was a significant increase in aldosterone secretion among patients randomized to the spironolactone and HCTZ group compared to the furosemide group (P<0.01).</p> <p>There was no significant difference in serum potassium level between treatment groups.</p> <p>No serious adverse effects were observed in either of the study groups.</p> <p>Secondary: Not reported</p>
<p>Lee et al.⁵⁸ (2013)</p> <p>Patients receiving spironolactone</p>	<p>OBS</p> <p>Patients with newly diagnosed HF with documented LVEF of <40% who had no</p>	<p>N=2358</p> <p>Median follow-up of 2.5 years</p>	<p>Primary: all-cause mortality, all-cause hospitalization, severe hyperkalemia, and</p>	<p>Primary: Incident spironolactone use was associated with lower crude rates of mortality (5.5 vs 9.8 per 100 person-years; P<0.01) and all-cause hospitalization (49.4 vs 56.1 per 100 person-years, P<0.05) compared with nonuse. After adjustment for differences in patient characteristics and concurrent use of other HF therapies, use of spironolactone was not</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>patients not receiving spironolactone</p>	<p>aldosterone receptor antagonist use in the 12 months before study entry</p>		<p>acute kidney injury</p> <p>Secondary: Not reported</p>	<p>significantly associated with either death (adjusted HR, 0.93; 95% CI, 0.60 to 1.44) or all-cause hospitalization (adjusted HR, 0.91; 95% CI, 0.77 to 1.08).</p> <p>Crude rates of acute kidney injury were also significantly lower during periods of spironolactone use (7.2 per 100 person-years) compared with periods of nonuse (16.2 per 100 person-years). Conversely, spironolactone use was associated with higher crude rates of severe hyperkalemia (4.8 per 100 person-years) compared with nonuse (1.6 per 100 person-years, P<0.001). After adjustment for potential confounders, incident spironolactone use was associated with a higher adjusted rate of severe hyperkalemia (adjusted HR, 3.46; 95% CI, 1.97 to 6.06) but not with acute kidney injury (adjusted HR, 0.66; 95% CI, 0.42 to 1.05).</p> <p>Secondary: Not reported</p>
<p>Inampudi et al.⁵⁹ (2014)</p> <p>Spironolactone on discharge</p> <p>vs</p> <p>No spironolactone on discharge</p>	<p>OBS</p> <p>hospitalized Medicare beneficiaries with HFrEF (EF <45%) and advanced CKD</p>	<p>N=1140</p> <p>1 year post-discharge</p>	<p>Primary: 30-day all-cause readmission</p> <p>Secondary: 30-day all-cause mortality, HF readmissions, and combined end point of all-cause mortality or all-cause readmission</p>	<p>Primary: Within 30 days postdischarge, unadjusted all-cause readmissions rates were 30% and 25% for patients receiving and not receiving spironolactone, respectively. Propensity score (PS)-adjusted HR (95% CI) associated with spironolactone use was 1.41 (1.04 to 1.90).</p> <p>Secondary: The risk of all-cause readmission (PS-adjusted HR, 1.36; 95% CI, 1.13 to 1.63) and the combined end point of all-cause readmission or all-cause mortality (PS-adjusted HR, 1.30; 95% CI, 1.09 to 1.54) during 1 year postdischarge were higher among patients in the spironolactone group.</p>
<p>Maisel et al.⁶⁰ (2014)</p> <p>COACH</p> <p>Spironolactone-treated patients</p> <p>vs</p>	<p>Secondary analysis</p> <p>Patients enrolled in the COACH biomarker substudy</p>	<p>N=534</p> <p>30 days</p>	<p>Primary: 30-day mortality and HF-related rehospitalization</p> <p>Secondary: Biomarker levels (NT-proBNP, ST2, Gal-3, and</p>	<p>Primary: Spironolactone significantly reduced the 30-day composite of mortality and HF-related rehospitalization (HR, 0.538; 95% CI, 0.299 to 0.968; P=0.039).</p> <p>Secondary: Elevated NT-proBNP, creatinine, and ST2 were associated with increased 30-day mortality and HF-related hospitalizations. Spirionolactone treatment was significantly beneficial in groups with elevations of Gal-3,</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
patients not treated with spironolactone			creatinine)	ST-2, NT-proBNP, or creatinine (P=0.037, 0.007, 0.035, and 0.009, respectively). In contrast, spironolactone treatment effects were not significant for groups with lower levels of any biomarker.
Hyperaldosteronism				
<p>Karagiannis et al.⁶¹ (2008)</p> <p>Eplerenone 25 mg BID, titrated up to 200 mg/day if blood pressure remained $\geq 140/90$ mm Hg</p> <p>vs</p> <p>spironolactone 25 mg BID, titrated up to 400 mg/day if blood pressure remained $\geq 140/90$ mm Hg</p> <p>HCTZ 12.5 mg was added to the study regimen if blood pressure remained uncontrolled at week 16.</p>	<p>OL, PRO, RCT</p> <p>Patients with bilateral hyperaldosteronism</p>	<p>N=34</p> <p>16 weeks</p>	<p>Primary: Percentage of patients whose blood pressure <140/90 mm Hg at week 16</p> <p>Secondary: Adverse events</p>	<p>Primary: At 16 weeks, 76.5 and 82.4% of spironolactone- and eplerenone-treated patients, respectively, exhibited reductions in blood pressure to <140/90 mm Hg (P=1.00).</p> <p>Secondary: Serum potassium levels were normalized with both treatments after four weeks of therapy (P value not reported). Mild hyperkalemia was noted in two spironolactone 400 mg-treated patients and in three eplerenone 150 mg-treated patients.</p> <p>Two spironolactone-treated patients reported bilateral gynecomastia at week 16 (P value not reported). Switching from spironolactone 400 mg/day to eplerenone 150 mg/day was effective in resolving gynecomastia symptoms without disrupting blood pressure control.</p>
Hypertension				
<p>Kohvakka et al.⁶² (1979)</p> <p>Amiloride 5 mg QD</p> <p>vs</p> <p>triamterene 75 mg</p>	<p>PC, RCT, XO</p> <p>Patients 41 to 70 years of age with uncomplicated HTN, previously treated with antihypertensive</p>	<p>N=31</p> <p>3 months</p>	<p>Primary: Changes in blood pressure, serum potassium, sodium, creatinine, urate and total body potassium</p>	<p>Primary: No significant changes in blood pressure were observed with any of the treatments (P values not reported).</p> <p>Mean serum potassium was reduced with all treatments except with spironolactone. KCl supplementation was least effective in elevating serum potassium. Total body potassium remained constant throughout treatment (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD</p> <p>vs</p> <p>KCl 1,500 mg QD</p> <p>vs</p> <p>spironolactone 50 mg QD</p> <p>vs</p> <p>placebo</p> <p>All patients were also receiving HCTZ 50 mg QD.</p>	<p>agents for 1 to 6 years</p>		<p>Secondary: Not reported</p>	<p>Serum sodium remained within normal limits with all treatments (P values not reported).</p> <p>There were no significant changes in mean serum creatinine with any of the treatments (P values not reported).</p> <p>Serum urate concentration increased significantly with all treatments, including HCTZ monotherapy (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Dahlöf et al.⁶³ (1991)</p> <p>Hypertension (STOP)</p> <p>Atenolol 50 mg QD, HCTZ 25 mg QD plus amiloride 2.5 mg QD, metoprolol 100 mg QD, or pindolol 5 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, RCT</p> <p>Swedish men and women 70 to 84 years old with treated or untreated essential HTN defined as SBP \geq180 mm Hg with a DBP of \geq90 mm Hg, or DBP >105 mm Hg irrespective of the SBP measured on 3 separate occasions during a 1-month placebo run-in phase in previously untreated patients</p>	<p>N=1,627</p> <p>25 months</p>	<p>Primary: Frequency of stroke, MI, and other cardiovascular death</p> <p>Secondary: Not reported</p>	<p>Primary: The active treatments significantly reduced the number of all primary endpoints (94 vs 58; RR, 0.60; 95% CI, 0.43 to 0.85; P=0.0031), frequency of stroke (53 vs 29; RR, 0.53; 95% CI, 0.33 to 0.86; P=0.0081) and frequency of other cardiovascular deaths (13 vs 4; RR, 0.30; 95% CI, 0.07 to 0.97) compared to placebo.</p> <p>There was not a statistically significant decrease observed in the rate of MI between the active treatments and placebo (28 vs 25; RR, 0.87; 95% CI, 0.49 to 1.56).</p> <p>Secondary: Not reported</p>
<p>White et al.⁶⁴</p>	<p>DB, MC, RCT</p>	<p>N=400</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2003)</p> <p>Eplerenone 25 mg QD</p> <p>vs</p> <p>eplerenone 50 mg QD</p> <p>vs</p> <p>eplerenone 100 mg QD</p> <p>vs</p> <p>eplerenone 200 mg BID</p> <p>vs</p> <p>placebo</p>	<p>Adult patients with untreated HTN and seated SBP <180 mm Hg, DBP between 95 to 110 mm Hg, and the 24 hour mean DBP ≥85 mm Hg</p>	<p>12 weeks</p>	<p>Mean change from baseline in seated DBP at 12 weeks</p> <p>Secondary: Change from baseline in SBP, 24 hour SBP and DBP, heart rate, adverse events</p>	<p>Eplerenone 50, 100 and 200 mg-treated patients experienced significant mean reductions in DBP from baseline compared to placebo (P≤0.01). The reduction in BP in eplerenone 25 mg-treated patients failed to meet significance (P=0.10).</p> <p>Secondary: Eplerenone 50, 100 and 200 mg-treated patients experienced significant mean reductions in SBP from baseline compared to placebo (P≤0.01).</p> <p>All eplerenone-treated patients experienced significant reductions in 24 hour ambulatory blood pressure measurements compared to placebo (P<0.006 for SBP and P<0.005 for DBP).</p> <p>There were no significant differences from baseline in 24 hour mean heart rate with any eplerenone-treated patient compared to placebo (P value not reported).</p> <p>Treatment emergent adverse events were reported in 48 and 49% of eplerenone- and placebo-treated patients. None of the adverse events were significantly different between the treatments (P value not reported). Two cases of impotence, gynecomastia, menstrual abnormalities and female breast pain were reported during the trial; one case occurred in a placebo-treated patient and the other in an eplerenone 100 mg/day-treated patient.</p>
<p>Krum et al.⁶⁵ (2002)</p> <p>Eplerenone 50 to 100 mg/day</p> <p>vs</p> <p>placebo</p> <p>All patients were receiving background ACE inhibitor or ARB</p>	<p>DB, MC, PG, RCT</p> <p>Patients 18 to 85 years of age taking an ACE inhibitor or an ARB for mild to moderate HTN (DBP ≥95 but <110 mm Hg and SBP <180 mm Hg), with potassium >3 mEq/L but ≤5 mEq/L</p>	<p>N=341</p> <p>8 weeks</p>	<p>Primary: Mean change from baseline in trough cuff seated DBP and SBP at week eight</p> <p>Secondary: Percentage of responders (DBP <90 mm Hg or exhibited a ≥10 mm Hg reduction from baseline),</p>	<p>Primary: Eplerenone-treated patients exhibited a significant mean reduction from baseline in SBP compared to placebo-treated patients at eight weeks of therapy (P≤0.05), regardless of concurrent ACE inhibitor or ARB use.</p> <p>While eplerenone plus ARB-treated patients exhibited a significant mean reduction from baseline in DBP compared to ARB-treated patients at week eight (P≤0.05), eplerenone plus ACE inhibitor-treated patients experienced a reduction in baseline DBP similar to ACE inhibitor-treated patients (P value not reported).</p> <p>Secondary: A significantly greater percentage of eplerenone plus ARB-treated patients exhibited a positive response to therapy compared to ARB-treated patients</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
monotherapy.			adverse events	<p>(P=0.003). No significant differences in response rate were observed between eplerenone plus ACE inhibitor- and ACE inhibitor-treated patients (P value not reported).</p> <p>Adverse effects were mild to moderate and were similar in eplerenone- and placebo-treated groups (P value not reported).</p>
<p>Weinberger et al.⁶⁶ (2002)</p> <p>Eplerenone 50 mg QD</p> <p>vs</p> <p>eplerenone 25 mg BID</p> <p>vs</p> <p>eplerenone 100 mg QD</p> <p>vs</p> <p>eplerenone 50 mg BID</p> <p>vs</p> <p>eplerenone 400 mg QD</p> <p>vs</p> <p>eplerenone 200 mg BID</p>	<p>DB, MC, PG, RCT</p> <p>Patients 21 to 80 years of age, with seated, cuff-assessed DBP ≥ 95 but < 114 mm Hg, a 24 hour mean DBP > 85 mm Hg</p>	<p>N=409</p> <p>8 weeks</p>	<p>Primary: Mean change in seated DBP from baseline</p> <p>Secondary: Mean change from baseline in SBP, 24 hour SBP and DBP, renin, aldosterone levels</p>	<p>Primary: Eplerenone therapy, across all doses studied, was associated with a significant reduction from baseline in seated and standing DBP compared to placebo (P<0.05).</p> <p>The eplerenone 50 mg BID regimen was associated with a significant reduction in baseline seated and standing DBP compared to the eplerenone 100 mg QD regimen (P<0.05). However, there were no differences in DBP reduction between any of the other QD and BID eplerenone regimens (P value not reported).</p> <p>Compared to placebo, spironolactone therapy was associated with significant reductions in DBP (P\leq0.001).</p> <p>The eplerenone 50 mg BID and 100 mg QD regimens were associated with DBP reductions comparable to 50 to 75% of the effect observed with the spironolactone 50 mg BID regimen (P value not reported).</p> <p>Secondary: Eplerenone therapy, across all doses studied, was associated with a significant reduction from baseline in seated and standing SBP compared to placebo therapy (P<0.05).</p> <p>The eplerenone 200 mg BID regimen was associated with a significant reduction in baseline seated and standing SBP compared to the eplerenone 400 mg QD regimen (P<0.05). However, there were no differences in SBP reduction between any of the other QD and BID eplerenone regimens (P value not reported).</p> <p>Eplerenone therapy, across all doses studied, was associated with a significant reduction in ambulatory SBP and DBP compared to placebo</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs spironolactone 50 mg BID vs placebo				<p>therapy, as observed during a 24 hour monitoring (P<0.05).</p> <p>Compared to placebo, spironolactone was associated with a significant reduction in SBP (P≤0.001).</p> <p>The eplerenone 50 mg BID and 100 mg QD regimens were associated with SBP reductions comparable to 50 to 75% of the effect observed with the spironolactone 50 mg BID regimen (P value not reported).</p> <p>The incidence of adverse events in eplerenone-treated patients was similar to placebo-treated patients (P value not reported). Additionally, the incidence of adverse events was comparable with eplerenone- and spironolactone-treated patients (P value not reported).</p> <p>The spironolactone 50 mg BID regimen was associated with a significant increase from baseline in serum potassium level compared to the eplerenone 50 mg QD and 100 mg QD regimens, regardless of QD or BID dosing (P<0.05).</p> <p>Eplerenone therapy was not associated with an increased incidence of gynecomastia or impotence compared to placebo therapy. There were no treatment-related menstrual abnormalities reported with eplerenone therapy, while one spironolactone-treated patient reporting treatment related intermenstrual bleeding.</p>
Hollenberg et al. ⁶⁷ (2003) Eplerenone 50 mg/day vs amlodipine 2.5 mg/day Both medications were titrated to a	RCT Patients ≥50 years of age, with untreated SBP between 140 to 190 mm Hg	N=269 24 weeks	Primary: Change in SBP and DBP, discontinuation rate, symptom distress index, SF-36 Health Survey Secondary: Not reported	Primary: Both treatments exhibited similar reductions in SBP and DBP from baseline (P=0.01). The dropout rate was 50% greater in amlodipine-treated patients compared to eplerenone-treated patients (P value not reported). Symptom distress (technique used to assess the influence of drug treatment on quality of life) index was assessed and results favored eplerenone therapy (P=0.03). SF-36 Health Survey showed no significant difference between the two treatments (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
maximum of 200 (eplerenone) or 10 (amlodipine) mg/day to achieve a SBP<140 mm Hg.				Both treatments experienced similar incidences of adverse effects (P value not reported). Eplerenone-treated patients did not experience breast pain/tenderness, breast enlargement, changes in menstruation, gynecomastia or loss of libido. Secondary: Not reported
White et al. ⁶⁸ (2003) Eplerenone 50 mg/day vs amlodipine 2.5 mg/day Both medications were titrated to a maximum of 200 (eplerenone) or 10 (amlodipine) mg/day to achieve a SBP<140 mm Hg.	AC, DB, MC, RCT Patients ≥50 years of age with systolic HTN (seated clinic SBP 150 to 165 mm Hg with a pulse pressure ≥70 mm Hg or 165 to 200 mm Hg with a DBP ≤95 mm Hg)	N=269 24 weeks	Primary: Mean change from baseline in SBP, DBP, 24 hour ambulatory BP, pulse pressure, and heart rate at week 24; urine albumin/creatinine ratio; adverse events Secondary: Not reported	Primary: Mean reduction in SBP from baseline was comparable in eplerenone- and amlodipine-treated patients (P=0.83). Eplerenone-treated patients exhibited significant reductions in DBP from baseline at 24 weeks of therapy compared to amlodipine-treated patients (P=0.014). The two treatments exhibited comparable decreases in 24 hour ambulatory BP, pulse pressure and heart rate after 24 weeks of therapy (P>0.05). Eplerenone-treated patients exhibited a significant reduction from baseline in the urine albumin/creatinine ratio compared to amlodipine-treated patients (P=0.002). Treatment-emergent adverse events were reported in 64 and 70% of eplerenone- and amlodipine-treated patients. The only adverse event that was significant between the two treatments was the incidence of edema (3.7 vs 25.5%; P<0.05). There were no reports of gynecomastia, breast tenderness or menstrual irregularities with either treatment. Secondary: Not reported
Williams et al. ⁶⁹ (2004) Eplerenone 50 mg QD	AC, DB, MC, PG, RCT Patients ≥18 years of age with stage 1 to 2 HTN (seated DBP	N=499 12 months	Primary: Change in seated trough DBP at 6 months Secondary:	Primary: At six months, both treatments exhibited comparable reductions in DBP from baseline (P=0.91). Secondary: At six months, both treatments exhibited comparable reductions in SBP

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>enalapril 10 mg QD</p> <p>Both medications were titrated to 200 (eplerenone) or 40 (enalapril) mg/day if needed for optimal blood pressure control (DBP < 90 mm Hg).</p>	<p>≥90 but <110 mm Hg, with a seated SBP <190 mm Hg)</p>		<p>Change in seated trough SBP at 6 months, reduction in SBP and DBP at 12 months, reduction in urine albumin/ creatinine ratio, adverse events</p>	<p>from baseline (P=0.20).</p> <p>At 12 months, both treatments exhibited comparable reductions in SBP and DBP from baseline (P=0.25 and P=0.33).</p> <p>Eplerenone-treated patients exhibited a significant reduction from baseline in urine albumin/creatinine ratio compared to enalapril-treated patients (61.5 vs 25.7%; P=0.01).</p> <p>There were no significant differences in overall treatment-emergent adverse events between the two treatments (P value not reported). There were no sex hormone related adverse events in eplerenone-treated patients. There were no clinically significant differences between the two treatments in any of the laboratory tests assessed. There were two eplerenone- and enalapril-treated patients that experienced hyperkalemia of ≥5.5 mmol/L.</p>
<p>Flack et al.⁷⁰ (2003)</p> <p>Eplerenone 50 mg QD</p> <p>vs</p> <p>losartan 50 mg QD</p> <p>vs</p> <p>placebo</p> <p>Doses were increased if blood pressure remained uncontrolled.</p>	<p>DB, MC, PG, RCT</p> <p>Men and women ≥18 years old, with mild to moderate HTN, with SBP <180 mm Hg and DBP 95 to 109 mm Hg (off medication) or if patients were receiving antihypertensive therapy their blood pressure was <140/90 mm Hg</p>	<p>N=551</p> <p>16 weeks</p>	<p>Primary: Mean change from baseline in DBP at 16 weeks</p> <p>Secondary: Mean change from baseline at 16 weeks in SBP, SBP and DBP within and between racial groups, response rate (defined as the percentage of patients with DBP <90 mm Hg or DBP ≥90 mm Hg but ≥10 mm Hg below baseline), urinary albumin/creatinine</p>	<p>Primary: At 16 weeks, patients randomized to eplerenone exhibited significantly greater mean changes in DBP from baseline compared to either losartan- or placebo-treated groups (P<0.001).</p> <p>Secondary: At 16 weeks, patients randomized to eplerenone exhibited significantly greater mean changes in SBP from baseline compared to either losartan- or placebo-treated groups (P<0.001).</p> <p>At 16 weeks, African American patients randomized to eplerenone exhibited significantly greater mean changes in SBP and DBP from baseline compared to the placebo-treated African American patients (P<0.001).</p> <p>At 16 weeks, African American patients randomized to eplerenone exhibited significantly greater mean changes in SBP and DBP from baseline compared to the losartan-treated African American patients (P≤0.001).</p> <p>At 16 weeks, white patients randomized to eplerenone exhibited</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			ratio, effect of eplerenone in patients with various baseline renin and aldosterone levels, adverse effects	<p>significantly greater mean changes in SBP and DBP from baseline compared to the placebo-treated white patients (P=0.001). However, the difference in SBP- and DBP-lowering effects was not significant different between the eplerenone ad losartan groups (P=0.126, P=0.068, respectively).</p> <p>Significantly greater percentage of patients randomized to eplerenone exhibited a positive response to therapy compared to either placebo (64.5 vs 41.2%; P<0.001) or losartan group (64.5 vs 48.3%; P=0.003).</p> <p>The eplerenone group (regardless of race) exhibited statistically significant improvement in urinary albumin/creatinine ratio from baseline compared to placebo (P=0.003). However, the difference in urinary albumin/creatinine ratio change from baseline was not significantly different between the eplerenone and losartan groups (P=0.652).</p> <p>Compared to losartan, eplerenone was more effective in lowering SBP and DBP in patients with low-moderate baseline renin levels (P<0.05). However, the difference was not statistically significant in patients with high baseline renin levels.</p> <p>Compared to losartan, eplerenone was more effective in lowering SBP in patients with low or high baseline aldosterone levels (P<0.05). However, the difference was not statistically significant in patients with moderate baseline aldosterone levels.</p> <p>Compared to losartan, eplerenone was more effective in lowering DBP in patients with low baseline aldosterone levels (P<0.05). However, the difference was not statistically significant in patients with moderate-high baseline aldosterone levels.</p> <p>There were no significant differences in the incidence of adverse events noted in eplerenone, placebo or losartan groups. The reported incidence of gynecomastia, breast pain, menstrual abnormalities, impotence, hyperkalemia and decreased libido with eplerenone was low and comparable to losartan and placebo.</p>
Hanazawa et al. ⁷¹	PRO	N=86	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(abstract) (2011)</p> <p>Spironolactone 12.5 or 25 mg/day</p> <p>In addition to existing antihypertensive regimens (monotherapy with a calcium channel blocker, ACE inhibitor, or ARB).</p>	<p>Patients with uncontrolled HTN</p>	<p>Not reported</p>	<p>Change in baseline blood pressure</p> <p>Secondary: Not reported</p>	<p>Morning home SBP/DBP reduction was similar among patients not controlled on a calcium channel blocker (n=30, -8.2/-2.6 mmHg), ACE inhibitor (n=22, -13.0/-4.7 mmHg), and ARB (n=34, -11.5/-5.1 mmHg).</p> <p>An increase in serum potassium correlated positively with the decline in morning SBP.</p> <p>Secondary: Not reported</p>
<p>Schersten et al.⁷² (2002)</p> <p>Spironolactone 50 mg/day</p> <p>vs</p> <p>spironolactone 100 mg/day</p> <p>vs</p> <p>spironolactone 200 mg/day</p> <p>vs</p> <p>placebo</p>	<p>RCT, SB, XO</p> <p>Patients <75 years of age, with DBP 105 to 135 mm Hg, after 10 to 15 minutes of supine rest</p>	<p>N=45</p> <p>11 months</p>	<p>Primary: Change from baseline in DBP and SBP, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: All spironolactone-treated patients exhibited a significantly reduced BP level from baseline as compared to placebo (P<0.001).</p> <p>While spironolactone 200 mg/day-treated patients exhibited a significantly greater lowered mean supine SBP compared to spironolactone 50 mg/day-treated patients (P<0.05), the difference between spironolactone 50 mg- and 100 mg/day-treated patients was not significant (P value not reported).</p> <p>Spironolactone 200 mg/day-treated patients exhibited a significant reduction in mean upright SBP from baseline compared to spironolactone 100 mg/day- and 50 mg/day-treated patients (P<0.01).</p> <p>The difference in the lowering of DBP from baseline was not significantly different among any of the spironolactone-treated patients (P value not reported).</p> <p>Spironolactone 100 mg/day-treated patients exhibited a significant increase in baseline potassium and serum creatinine concentrations (P<0.05). However, spironolactone 50 mg/day-treated patients did not exhibit a change in potassium level from baseline (P value not reported).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Not reported
Oxlund et al. ⁷³ (2013) Spironolactone 25 mg (option to titrate to twice daily) vs placebo	DB, MC, RCT Patients aged 30 to 74 years with blood pressure at or above 130/80 mmHg despite triple antihypertensive therapy	N=119 16 weeks	Primary: Reduction of mean SBP and DBPs Secondary: Glycemic control, urinary albumin excretion, adverse effects	Primary: All measures of BP by office as well as ambulatory monitoring showed marginal, insignificant reductions in the placebo group and significant reductions in the spironolactone group. Maximum reduction of office BP (11.3/5.3 mmHg) was found at 8 weeks of treatment (P<0.0001), after which no further reduction was found. Mean daytime SBP/DBP at 16 weeks of follow-up was 137 (13)/75 (8) mmHg in the spironolactone group and 145 (12)/79 (7) mmHg in the placebo group, P=0.0001 for difference of systolic measures and P=0.0038 for diastolic. Secondary: Urinary albumin/creatinine ratio was reduced significantly in the spironolactone group (P=0.001), but not in the placebo group. There was a nonsignificant decrease of eGFR in the spironolactone group. Hb1Ac did not change during intervention. The frequency of adverse events was comparable in the two groups.
Václavík et al. ⁷⁴ (2014) ASPIRANT-EXT Spironolactone 25 mg vs placebo	DB, MC, RCT Patients with office SBP >140 mm Hg or DBP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic	N=150 8 weeks	Primary: Comparison of the fall of daytime systolic and diastolic pressure on ABPM between the spironolactone and placebo groups after 8 weeks of treatment Secondary: Nighttime BP, serum sodium, potassium, and creatinine, change in body weight	Primary: At 8 weeks, BP values were decreased more by spironolactone, with differences in mean fall of SBP of -9.8, -13.0, -10.5, and -9.9 mm Hg (P<0.001 for all) in daytime, nighttime, and 24-hour ambulatory BP monitoring and in the office. The respective DBP differences were -3.2, -6.4, -3.5, and -3.0 mm Hg (P=0.013, P<0.001, P=0.005, and P=0.003). Secondary: A small comparable weight gain was observed in both study groups. With spironolactone treatment, serum sodium decreased by a median of 1.0 mmol/L, and serum potassium increased by a median 0.4 mmol/L. The mean serum potassium increased during the 8 weeks of spironolactone treatment from 4.10 to 4.49 mmol/L, the highest reached serum potassium value at 8 weeks was 5.6 mmol/L.
Li et al. ⁷⁵ (2010)	DB, MC, PC, RCT Children 4 to 16	N=304	Primary: Change in SBP during phase B	Primary: Change in SBP from baseline of phase B to the end of the study (differences from placebo) were -2.61, 2.32, and -2.76 mm Hg for the low-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p><u>Phase A</u> Spironolactone 25 mg QD (low-dose), 25 mg BID (middle-dose), 50 mg BID (high-dose) for 6 weeks</p> <p><u>Phase B</u> Spironolactone 25 mg QD, 25 mg BID, 50 mg BID for 4 weeks</p> <p>vs placebo</p>	<p>years of age with SBP \geq95th percentile</p>		<p>Secondary: Change in DBP, safety</p>	<p>, middle-, and high-dose groups, respectively (P value not significant, P value not significant, P=0.048, respectively).</p> <p>Secondary: There were no significant effects of eplerenone on change in DBP from baseline of phase B to end of study compared to placebo.</p> <p>During phase A, adverse events were reported by 40.2% of subjects in the high-dose group, 30.6% of those in the middle-dose group, and 37.9% of those in the low-dose group. In phase B, there were no differences in adverse event frequencies between active therapy and placebo (high-dose: 38.4 vs 45.2%; middle-dose: 50.0 vs 25.0%; low-dose 26.9 vs 34.6%, eplerenone vs, placebo, respectively).</p> <p>Serious adverse events in phase A included diarrhea, sleep apnea, syncope, pericarditis, arthritis, pneumonia, sepsis, and pleural effusion. In phase B, serious adverse events included sleep apnea, abdominal pain, and fever.</p>
<p>Hood et al.⁷⁶ (2007) SALT</p> <p>Spironolactone 50 mg/day</p> <p>vs spironolactone 100 mg/day</p> <p>vs amiloride 20 mg/day</p> <p>vs amiloride 40</p>	<p>DB, RCT, XO</p> <p>Adult patients with seated blood pressure of 140/90 to 170/110 mm Hg, plasma renin of \leq12 mU/L, plasma aldosterone-renin ratio $>$750, previous fall in SBP \geq20 mm Hg after 1 month of OL treatment with spironolactone 50 mg/day</p>	<p>N=57</p> <p>42 weeks</p>	<p>Primary: Change in blood pressure and plasma renin from baseline between spironolactone 100 mg/day and bendroflumethiazide 5 mg/day</p> <p>Secondary: Change in blood pressure and plasma renin from baseline between amiloride and other diuretics and between lower and higher doses of</p>	<p>Primary: Spironolactone 100 mg/day- and bendroflumethiazide 5 mg/day-treated patients did not exhibit a significant difference in BP reduction from baseline (P value not reported).</p> <p>Secondary: Spironolactone 50 mg/day-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.01).</p> <p>Losartan 100 mg-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.05).</p> <p>High-dose bendroflumethiazide- and amiloride-treated patients exhibited significantly greater reductions in blood pressure compared to the lower doses (P<0.05).</p> <p>Spironolactone-treated patients exhibited a four-fold increase in baseline renin level compared to a two-fold increase observed in</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs bendroflumethiazide* 2.5 mg/day vs bendroflumethiazide* 5 mg/day vs losartan 100 mg/day vs placebo			each diuretic	bendroflumethiazide-treated patients (P=0.003).
Nash et al. ⁷⁷ (1977) Spironolactone 50 mg BID vs spironolactone 100 mg BID vs spironolactone 200 mg BID	DB, RCT Male outpatients between the ages of 21 to 65 years, with essential HTN, DBP between 90 to 114 mm Hg	N=79 12 weeks	Primary: Change in SBP, DBP, blood urea nitrogen, serum potassium, gynecomastia Secondary: Not reported	Primary: At week 12, all study groups exhibited significant reductions in SBP and DBP from baseline (P<0.05). At week 12, all three spironolactone monotherapy groups exhibited statistically significant increases in blood urea nitrogen from baseline (P<0.05). At week 12, the HCTZ monotherapy group was associated with a statistically significant decrease in serum potassium levels (P<0.001). At week 12, all three spironolactone monotherapy groups exhibited statistically significant increases in serum potassium levels from baseline (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>HCTZ 50 mg BID</p> <p>vs</p> <p>spironolactone and HCTZ 25-25 mg BID (fixed-dose combination product)</p>				<p>At week 12, the spironolactone and HCTZ combination group was not associated with statistically significant increases in serum potassium levels from baseline.</p> <p>A dose-related risk of gynecomastia was observed in the spironolactone-treated patients. Among patients treated with spironolactone 50, 100, or 200 mg BID; 5.5, 11.8, and 40% reported gynecomastia symptoms. Of the patients randomized to spironolactone and HCTZ combination product, 7.7% reported gynecomastia symptoms.</p> <p>Secondary: Not reported</p>
<p>Schrijver et al.⁷⁸ (1979)</p> <p>Spironolactone 50 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IA)</p> <p>vs</p> <p>spironolactone 50 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IB)</p>	<p>DB</p> <p>Patients, between 24 to 63 years of age, with DBP between 90 to 114 mm Hg</p>	<p>N=49</p> <p>20 weeks (4-week placebo run-in, 8-week single drug therapy, 4-week two-drug therapy, 4-week recovery)</p>	<p>Primary: Change in MABP, serum potassium, uric acid level, blood glucose, blood urea nitrogen, creatinine, plasma renin activity, aldosterone, side effects</p> <p>Secondary: Not reported</p>	<p>Primary: Following eight weeks of therapy with a single drug, all study groups exhibited a statistically significant reduction in MABP from baseline (P<0.01). There were no significant differences in MABP reduction among the study groups.</p> <p>The addition of a second drug to the antihypertensive regimen was not associated with a significant improvement in MABP. At the end of the two-drug treatment period, there were no differences in MABP among any of the study groups.</p> <p>Spironolactone therapy was associated with a significant decrease in serum potassium concentration from baseline (P<0.001).</p> <p>Spironolactone regimens were not associated with a significant change in potassium levels from baseline.</p> <p>Following eight weeks of therapy with a single drug, HCTZ-treated patients experienced a statistically significant increase in uric acid from baseline (P<0.001). Groups IIA and IIB also experienced a significant but smaller increase in uric acid level from baseline (P<0.05) with no change in groups I and IV.</p> <p>During the single-drug treatment phase, patients randomized to group I experienced a significant increase in blood glucose from baseline</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>spironolactone 100 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IIA)</p> <p>vs</p> <p>spironolactone 100 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IIB)</p> <p>vs</p> <p>spironolactone 200 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IIIA)</p> <p>vs</p>				<p>(P<0.05).</p> <p>During the single-drug treatment phase, all patients except those randomized to group I experienced a significant increase in blood urea nitrogen from baseline (P<0.05).</p> <p>During the single-drug treatment phase, patients randomized to groups I and II experienced a significant increase in serum creatinine from baseline (P<0.05).</p> <p>During the single-drug treatment phase, all treatment groups experienced a significant increase in plasma renin activity from baseline (P<0.01). The addition of HCTZ in the two-drug study phase was associated with a rise in plasma renin activity in all study groups (P<0.05).</p> <p>All treatment groups experienced a significant increase in plasma aldosterone from baseline (P<0.05).</p> <p>Gynecomastia was reported only by patients randomized to the higher-dose spironolactone groups.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>spironolactone 200 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IIIB)</p> <p>vs</p> <p>HCTZ 50 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IVA)</p> <p>vs</p> <p>HCTZ 50 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IVB)</p>				
<p>Wray et al.⁷⁹ (2010)</p> <p>Spironolactone 25 to 100 mg QD</p>	<p>DB, RCT</p> <p>Patients ≥60 years of age with stage 1 HTN</p>	<p>N=36</p> <p>6 months</p>	<p>Primary: Blood pressure, sympathetic nervous system activity</p>	<p>Primary: Arterial blood pressure decreased significantly with spironolactone (SBP: 160 to 134 mm Hg and DBP: 77 to 68 mm Hg) and with HCTZ (SBP: 161 to 145 mm Hg and 78 to 73 mm Hg). There was no significant difference between the groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>HCTZ 12.5 to 50 mg QD</p> <p>Patients also received potassium 0 to 40 mEq to maintain blinding.</p>			<p>Secondary: Not reported</p>	<p>Sympathetic nervous system activity was significantly reduced after spironolactone (plasma norepinephrine: 378 to 335 pg/mL; P=0.04; [3H]-norepinephrine release rate: 2.74 to 1.97 µg/min/m²; P=0.04), but not with HCTZ (plasma norepinephrine: 368 to 349 pg/mL; P=0.47; [3H]-norepinephrine release rate: 2.63 to 2.11 µg/min/m²; P=0.21).</p> <p>There were no instances of hyperkalemia, and no other adverse effects were reported.</p> <p>Secondary: Not reported</p>
<p>Bomback et al.⁸⁰ (2009)</p> <p>Spironolactone 12.5 mg QD for 4 weeks in addition to ACE inhibitor therapy</p>	<p>OL</p> <p>Patients with obesity, longstanding hypertension and evidence of target organ damage who were treated with ACE inhibitors</p>	<p>N=21</p> <p>8 weeks</p>	<p>Primary: Change in 24-hour ambulatory blood pressure, changes in office blood pressure, nocturnal blood pressure, and urine albumin: creatinine ratio</p> <p>Secondary: Not reported</p>	<p>Primary: Mean office, 24-hr ambulatory, and nocturnal ambulatory blood pressures declined significantly during the four weeks of spironolactone therapy from 110.6 to 105.0 mm Hg (office P=0.004), 100.6 to 95.5 mm Hg (24-hr P=0.03) and 95.3 to 87.5 mm Hg (nocturnal P=0.004).</p> <p>The mean urine albumin: creatinine ratio dropped from 13.8 to 8.5 mg/g (P=0.002) during spironolactone therapy and returned to 13.2 mg/g after the drug was withdrawn.</p> <p>Serum potassium was not significantly affected by spironolactone therapy. There was a significant increase in serum creatinine from 0.95 before therapy to 1.03 mg/dl after spironolactone. The eGFR decreased from 81.9 to 76.8 mL/min/1.73m².</p> <p>Secondary: Not reported</p>
<p>Chapman et al.⁸¹ (2007)</p> <p>ASCOT-BPLA</p> <p>Atenolol 50 to 100 mg titrated to target blood pressure <140/90 mm Hg (or</p>	<p>Subanalysis of ASCOT-BPLA evaluating effects of spironolactone on treatment-resistant HTN</p> <p>Patients 40 to 79</p>	<p>N=1,411</p> <p>1.3 years</p>	<p>Primary: Change in DBP and SBP, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: Spironolactone-treated patients lead to a significant 21.9 mm Hg reduction in SBP among patients whose blood pressure was previously uncontrolled on at least three other antihypertensive drugs (95% CI, 20.8 to 23.0 mm Hg; P<0.001).</p> <p>Spironolactone-treated patients lead to a significant 9.5 mm Hg reduction in DBP among patients whose blood pressure was previously uncontrolled</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p><130/90 mm Hg in diabetic patients); bendroflumethiazide* plus potassium 1.25 to 2.5 mg plus doxazosin were added for additional blood pressure control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p> <p>vs</p> <p>amlodipine 5 to 10 mg titrated to target blood pressure <140/90 mm Hg (or <130/90 mm Hg in diabetic patients); perindopril 4 to 8 mg and doxazosin were added for additional control; if blood pressure remained elevated on the 3 above drugs, spironolactone 25 mg was added to the regimen</p>	<p>years of age with HTN and ≥ 3 cardiovascular risk factors, with SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg (not on antihypertensive therapy) or SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg (on antihypertensive therapy)</p>			<p>on at least three other antihypertensive drugs (95% CI, 9.0 to 10.1; $P < 0.001$).</p> <p>Spironolactone-treated patients exhibited small but significant decreases in sodium, LDL-C and TC as well as increases in potassium, glucose, creatinine and HDL-C ($P < 0.05$).</p> <p>The most common adverse effect reported in the trial was gynecomastia in men (P value not reported).</p> <p>Secondary: Not reported</p>
Miscellaneous				

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Pitt et al.⁸² (2003) 4E-Left Ventricular Hypertrophy Study</p> <p>Eplerenone 200 mg QD</p> <p>vs</p> <p>enalapril 40 mg QD</p> <p>vs</p> <p>enalapril 10 mg plus eplerenone 200 mg</p> <p>If the blood pressure was uncontrolled on study medication at week 8, OL HCTZ 12.5 to 25 mg/day and/or amlodipine 10 mg/day were allowed.</p>	<p>AC, DB, PG, RCT</p> <p>Patients with left ventricular hypertrophy, a history of HTN and predominantly in sinus rhythm</p>	<p>N=153</p> <p>9 months</p>	<p>Primary: Change in left ventricular mass as assessed by MRI</p> <p>Secondary: Reduction in SBP and DBP, response rate (DBP <90 mm Hg), change in urine albumin creatinine ratio</p>	<p>Primary: Both treatments were associated with a significant reduction in left ventricular mass from baseline (P<0.001). The difference in left ventricular mass reduction from baseline between the two treatments was not significant (P=0.258).</p> <p>While enalapril plus eplerenone therapy demonstrated a significantly greater reduction in left ventricular mass from baseline compared to eplerenone therapy (P=0.007); the effect was not statistically different from that observed with enalapril therapy (P=0.107).</p> <p>Secondary: The SBP was reduced significantly more in enalapril plus eplerenone-treated patients compared to eplerenone-treated patients (P=0.048). The other treatment groups exhibited statistically comparable reductions from baseline in mean SBP and DBP (P value not reported).</p> <p>While 70.0% of eplerenone-treated patients responded to therapy, 40.7% of enalapril-treated patients responded (P=0.003). In addition, 79.6% of enalapril plus eplerenone-treated patients responded to therapy compared to 40.7% enalapril-treated patients (P=0.001).</p> <p>Enalapril plus eplerenone therapy was associated with a significant reduction in urine albumin creatinine ratio compared to either eplerenone or enalapril therapy (P<0.05).</p> <p>Adverse events were reported with similar incidence among all treatment groups (P value not reported). Cough was significant in enalapril-treated patients compared to eplerenone-treated patients (P=0.033). Two cases of gynecomastia were reported (one eplerenone- and one enalapril plus eplerenone-treated patients). Four patients (three enalapril- and one enalapril plus eplerenone-treated patients) experienced impotence during the trial. Seven eplerenone-, two enalapril- and three enalapril plus eplerenone-treated patients experienced serious hyperkalemia (≥ 6.0 mmol/L).</p>
<p>Taniguchi et al.⁸³ (2006)</p>	<p>DB, RCT, XO</p>	<p>N=97</p>	<p>Primary: Change in blood</p>	<p>Primary: Both study groups experienced a statistically significant reduction in blood</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Candesartan 8 mg in addition to spironolactone 25 mg QD for 6 months, after 6 months of candesartan monotherapy (combination group)</p> <p>vs</p> <p>candesartan 8 mg daily for 12 months</p>	<p>Patients, 67 years of age on average, with essential HTN and left ventricular hypertrophy</p>	<p>1 year</p>	<p>pressure and relative wall thickness</p> <p>Secondary: Not reported</p>	<p>pressure from baseline (P<0.05).</p> <p>While candesartan was associated with a significant reduction in relative wall thickness among patients with concentric left ventricular remodeling or hypertrophy (P<0.05), the addition of spironolactone did not provide additional benefit.</p> <p>Secondary: Not reported</p>
<p>Edwards et al.⁸⁴ (2009)</p> <p>Spironolactone 25 mg QD</p> <p>vs</p> <p>placebo</p> <p>Study medications were added to existing ACE inhibitor or ARB therapy.</p>	<p>DB, PC, RCT</p> <p>Patients 18 to 80 years of age with stage 2 and 3 chronic kidney disease with controlled blood pressure (mean daytime ambulatory blood pressure <130/85 mm Hg) on and ACE inhibitors or ARB for 6 months</p>	<p>N=115</p> <p>36 weeks</p>	<p>Primary: Change in left ventricular mass and arterial stiffness measured</p> <p>Secondary: Aortic distensibility, Aug A_{1x}, blood pressure, and albuminuria</p>	<p>Primary: Treatment with spironolactone resulted in significant reductions in left ventricular mass and left ventricular mass index. The prevalence of left ventricular hypertrophy decreased by 50% with spironolactone, but was unchanged with placebo. Spironolactone did not affect left ventricular volumes or ejection fraction.</p> <p>Secondary: Treatment with spironolactone resulted in a significant decrease in pulse wave velocity, central aortic pressure augmentation, Aug I_x, and Aug I_x 75. Aortic distensibility increased with the use of spironolactone compared to placebo.</p> <p>Treatment with spironolactone resulted in a significant decrease in office systolic blood pressure (-11 vs -5 mm Hg, P<0.05), office pulse pressure (-5 mm Hg vs -1 mm Hg, P<0.05), central systolic blood pressure (-12 mm Hg vs -4 mm Hg, P<0.01), central mean arterial pressure (-8 mm Hg vs -4 mm Hg, P<0.05), and central pulse pressure (-5 mm Hg vs -1 mm Hg, P<0.01). Office, central, and ambulatory diastolic pressures were not different between treatment groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Treatment with spironolactone was not associated with a significant decrease in eGFR compared to placebo (-3 vs -1 mL/min/1.73 m ² , respectively; P value not significant). Treatment with spironolactone reduced albuminuria by -21 mg/mmol compared to -8 mg/mmol with placebo (P<0.05).

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily

Study regimen abbreviations: AC=active comparator, BE=blinded endpoint, DB=double blind, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, SB=single blind, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, BNP=brain natriuretic peptide, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, eGFR=estimated glomerular filtration rate, GFR=glomerular filtration rate, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HR=hazard ratio, HTN=hypertension, KCl=potassium chloride, LDL-C=low-density lipoprotein cholesterol, LVEF=left ventricular ejection fraction, MABP=mean arterial blood pressure, MI=myocardial infarction, MRI=magnetic resonance imaging, NYHA=New York Heart Association, OR=odds ratio, PINP=procollagen type 1 N-terminal peptide, QOL=quality of life, RAAS=renin-angiotensin-aldosterone system, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol

Additional Evidence

Dose Simplification

Ludbrook et al. evaluated the differences in blood pressure control and adverse events with spironolactone 300 to 400 mg administered either once daily or in divided doses. Both administration schedules were associated with comparable systolic and diastolic blood pressure reductions. None of the regimens reduced the incidence of adverse effects (85% in both groups).⁸⁵

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 11. Relative Cost of the Mineralocorticoid (Aldosterone) Receptor Antagonists

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Eplerenone	tablet	Inspra®*	\$\$\$\$\$	\$\$\$\$
Spironolactone	tablet	Aldactone®*	\$\$	\$
Combination Products				
Spironolactone and HCTZ	tablet	Aldactazide®*	\$\$\$	\$\$

*Generic is available in at least one dosage form or strength.

HCTZ=hydrochlorothiazide

X. Conclusions

The mineralocorticoid (aldosterone) receptor antagonists are approved for the treatment of hypertension.³⁻⁵

Eplerenone is also indicated to improve survival in patients with left ventricular systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.⁴

Spironolactone is approved for the management of hyperaldosteronism, hypokalemia, and edema associated with

congestive heart failure, cirrhosis, or the nephrotic syndrome. It is also indicated for patients with severe heart failure (NYHA class III to IV) to increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.³ Spironolactone is available as single entity agents, as well as in combination with hydrochlorothiazide as a fixed-dose combination product. All of the mineralocorticoid (aldosterone) receptor antagonist products are available in a generic formulation.

There are several national and international guidelines that provide recommendations regarding the use of the mineralocorticoid (aldosterone) receptor antagonists.⁶⁻²⁹ For the treatment of heart failure, a mineralocorticoid (aldosterone) receptor antagonist is routinely recommended in addition to standard therapy (ACE inhibitor or ARB, and β -blocker) in patients with symptoms and an LVEF $\leq 35\%$. A mineralocorticoid (aldosterone) receptor antagonist is also recommended following a myocardial infarction in patients with an LVEF $\leq 40\%$ who also have either diabetes or heart failure. Once again, therapy should be in addition to standard heart failure therapy (ACE inhibitor or ARB, and β -blocker).¹⁴⁻¹⁶ There are several national and international organizations that have published guidelines on the treatment of hypertension. Most of the guidelines do not address the use of the mineralocorticoid (aldosterone) receptor antagonists. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.¹⁷⁻²⁴ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹⁷ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹⁷⁻²⁴ Most patients will require more than one antihypertensive agent to achieve blood pressure goals.¹⁷⁻²⁴

For the treatment of cirrhosis and ascites, spironolactone is recommended as first line therapy in addition to sodium restriction.²⁷ Spironolactone is also recommended for the treatment of patients with unilateral primary aldosteronism (in lieu of surgery) and in those with bilateral adrenal disease. Eplerenone is considered an alternative treatment option, especially in men who experience erectile dysfunction and gynecomastia with spironolactone therapy.^{28,29}

Eplerenone and spironolactone have been shown to reduce cardiovascular morbidity and mortality in patients with heart failure when added to standard therapy.^{41-46,48-52} These agents have also been shown to effectively lower blood pressure.⁶²⁻⁸¹ Only one trial in hypertensive patients included both eplerenone and spironolactone. Both products significantly decreased blood pressure compared to placebo; however, statistical analyses were not performed among the two agents. The authors noted that there was a greater reduction in blood pressure with spironolactone 50 mg twice daily compared to eplerenone 50 mg twice daily. This information suggests that eplerenone may only be 50 to 75% as potent as spironolactone.⁶⁶ Most patients will require more than one antihypertensive agent to achieve blood pressure goals.¹⁷⁻²⁴ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{19-21,24,85} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations. Several studies in diabetic and non-diabetic patients with renal disease have demonstrated a reduction in proteinuria with the addition of spironolactone to existing ACE inhibitor and/or ARB therapy.³⁰⁻⁴⁰

In general, adverse events are similar with the mineralocorticoid (aldosterone) receptor antagonists and both agents can increase serum potassium levels. While eplerenone is a selective aldosterone receptor antagonist, spironolactone may also antagonize glucocorticoid, progesterone, and androgen receptors. Consequently, there is an increased risk of steroid-related adverse effects with spironolactone (e.g., gynecomastia, impotence, menstrual abnormalities).¹⁻⁵

There is insufficient evidence to support that one brand mineralocorticoid (aldosterone) receptor antagonist is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand mineralocorticoid (aldosterone) receptor antagonists within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand mineralocorticoid (aldosterone) receptor antagonist is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 June]. Available from: <http://online.factsandcomparisons.com>
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 June]. Available from: <http://www.thomsonhc.com/>.
3. Aldactone® [package insert]. New York (NY): Pfizer Inc; 2014 Oct.
4. Inspra® [package insert]. New York (NY): Pfizer Inc; 2013 May.
5. Aldactazide® [package insert]. New York (NY): Pfizer Inc; 2014 Oct.
6. Fraker T, Fihn S, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007 Dec 4;116(23):2762-72.
7. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J* 2013;34:2949–3003; doi:10.1093/eurheartj/eh296.
8. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med*. 2012;157:735-743. doi:10.7326/0003-4819-157-10-201211200-00011.
9. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, *Journal of the American College of Cardiology* (2014), doi: 10.1016/j.jacc.2014.09.017.
10. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2011;32:2999-3054.
11. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012. doi:10.1016/j.jacc.2012.11.019.
12. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012;33:2569-2619.
13. National Institute for Health and Clinical Excellence. MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London (UK): National Institute for Health and Clinical Excellence (NICE); 2013 May [cited 2014 Dec]. Available from: <http://www.nice.org.uk/guidance/cg172>.
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
15. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
16. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
17. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
18. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.

20. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
21. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
22. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
23. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
24. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
25. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
26. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
27. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. 2012 [cited 2015 Apr]. Available from: http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf.
28. Funder JW, Carey RM, Fardella C, et al.; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2008;93:3266-81.
29. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract*. 2006 May/Apr;12(2):193-222.
30. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. *Kidney Int*. 2006 Dec; 70(12):2116-23.
31. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. *Am J Kidney Dis* 2010;55:671-81.
32. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. *Clin Exp Pharmacol Physiol*. 2006 May-Jun;33(5-6):477-9.
33. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. *Clin J Am Soc Nephrol*. 2006 Mar;1(2):256-62.
34. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. *Hypertens Res*. 2008 Jan;31(1):59-67.
35. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. *J Hypertens*. 2006 Nov;24(11):2285-92.
36. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. *Kidney Int*. 2006 Aug;70(3):536-42.
37. Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. *Endocr Pract* 2008;14:985-92.
38. Saklayen MG, Gyebe LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. *J Investig Med* 2008;56:714-9.
39. Sengul E, Sahin T, Sevin E, et al. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. *Ren Fail* 2009;31:928-32.
40. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. *Am J Kidney Dis* 2008;52:486-93.

41. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med.* 2003;348(14):1309-21.
42. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. *J Am Coll Cardiol.* 2005;46(3):425-31.
43. Pitt B, Gheorghide M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H; EPHEUS Investigators. Evaluation of eplerenone in the subgroup of EPHEUS patients with baseline left ventricular ejection fraction $\leq 30\%$. *Eur J Heart Fail* 2006;8:295-301.
44. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHEUS. *Diabetes Obes Metab.* 2007 May 8; [Epub ahead of print].
45. Gheorghide M, Khan S, Blair JE, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction (EPHEUS). *Am Heart J* 2009;158:437-43.
46. Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHEUS trial. *Eur J Heart Fail* 2009;11:1099-105.
47. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. *Circ Heart Fail* 2010;3:347-53.
48. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med.* 2011;364:11-21.
49. Eschaliel R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). *J Am Coll Cardiol.* 2013 Oct 22;62(17):1585-93.
50. Krum H, Shi H, Pitt B, et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. *Circ Heart Fail.* 2013 Jul;6(4):711-8.
51. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med.* 1999;341(10):709-17.
52. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. *J Am Coll Cardiol.* 2012;60(20):2089-9.
53. Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. *Am J Cardiol.* 2010;106:1292-6.
54. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. *J Am Coll Cardiol.* 2007 Aug 14;50(7):591-6.
55. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. *JAMA.* 2013;309(8):781-791.
56. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med.* 2014 Apr 10;370(15):1383-92.
57. Levy B. The efficacy of safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure. *J Clin Pharmacol.* 1977;17(7):420-30.
58. Lee KK, Shilane D, Hlatky MA, Yang J, Steimle AE, and Go AS. Effectiveness and safety of spironolactone for systolic heart failure. *Am J Cardiol.* 2013 Nov 1;112(9):1427-32.
59. Inampudi C, Parvataneni S, Morgan CJ, et al. Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction $< 45\%$, and estimated glomerular filtration rate < 45 ml/min/1.73 m². *Am J Cardiol.* 2014 Jul 1;114(1):79-82.
60. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). *Am J Cardiol.* 2014 Sep 1;114(5):737-42.
61. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelis ED, Anagnostis P, Athyros VG, Mikhailidis DP. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. *Expert Opin Pharmacother.* 2008 Mar;9(4):509-15.

62. Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. *Acta Med Scand.* 1979;205(4):319-24.
63. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet.* 1991 Nov 23;338(8778):1281-5.
64. White WB, Carr AA, Krause S et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. *Am J Cardiol.* 2003; 92(1):38-42.
65. Krum, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. *Hypertension* 2002;40(2):117-23.
66. Weinberger MH, Roniker B, Krause SL et al. Eplerenone, a Selective Aldosterone Blocker, in Mild-to-Moderate Hypertension. *Am Journal Hypertens.* 2002;15(8):709-16.
67. Hollenberg HK, Williams GH, Anderson H et al. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium-channel blocking agent in patients with systolic hypertension. *Arch Intern Med.* 2003;163(13):1543-8.
68. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. *Hypertension* 2003;41(5):1021-6.
69. Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. *Am J of Cardiol.* 2004;93(8):990-6.
70. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *Journal of the American College of Cardiology* 2003;41(7):1148-55.
71. Hanazawa T, Obara T, Ogasawara K, Shinki T, Katada S, Inaue R, et al. Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home (abstract). *Clin Exp Hypertens.* 2011;33(7):427-36.
72. Schersten B, Thulin T, Kuylenskierna J et al. Clinical and biochemical effects of spironolactone administered once daily in primary hypertension, Multicenter Sweden study. *Hypertension* 1980;2(5):672-79.
73. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, and Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. *J Hypertens.* 2013 Oct;31(10):2094-102.
74. Václavík J, Sedlák R, Jarkovský J, Kociánová E, and Táborský M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). *Medicine (Baltimore).* 2014 Dec;93(27):e162.
75. Li JS, Flynn JT, Portman R, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. *J Pediatr* 2010;157:282-7.
76. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. *Circulation.* 2007 Jul 17;116(3):268-75.
77. Nash DT. Antihypertensive effect and serum potassium homeostasis: comparison of hydrochlorothiazide and spironolactone alone and in combination. *J Med.* 1977;8(5):367-77.
78. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. *Clin Pharmacol Ther.* 1979;25(1):33-42.
79. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. *Hypertension* 2010;55:1217-23.
80. Bomback AS, Muskala P, Bald E, et al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. *Clin Nephrol* 2009;72:449-56.
81. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension.* 2007 Apr;49(4):839-45.
82. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003;108(15):1831-8.
83. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. *Circ J.* 2006 Aug; 70(8):995-1000.

84. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. *J Am Coll Cardiol* 2009;54:505-12.
85. Ludbrook A, Dynon M, Mendelsohn FA, Louis WJ. Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension. *Med J Aust.* 1980 Feb 9;1(3):124-5.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Renin Inhibitors
AHFS Class 243240
August 19, 2015**

I. Overview

The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure.¹ Excessive activity of the RAAS may lead to hypertension, as well as fluid and electrolyte disorders. Renin catalyzes the conversion of angiotensinogen to angiotensin I, which is the first and rate-limiting step of the RAAS.¹⁻³ Angiotensin I is then cleaved to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase). Through a negative feedback mechanism, angiotensin II inhibits renin release. Angiotensin II can increase blood pressure by direct vasoconstriction, as well as through actions on the brain and autonomic nervous system. In addition, angiotensin II induces aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental effects, including ventricular hypertrophy, remodeling and myocyte apoptosis.^{4,5}

Aliskiren is the only renin inhibitor that is currently available and it is approved for the treatment of hypertension. It decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. It is unknown if aliskiren affects other RAAS components, such as ACE or non-ACE pathways. Aliskiren is available as a single entity product, as well as in combination with amlodipine, amlodipine and hydrochlorothiazide, or hydrochlorothiazide.⁶⁻⁹ Amlodipine is a dihydropyridine calcium-channel blocking agent that is a potent vasodilator that has little effect on cardiac muscle contractility or conduction. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.^{4,5} Previously, aliskiren was available in combination with valsartan under the name Valturna[®]; however, this agent was removed from the market in 2012 due to evidence suggesting an increased risk of renal impairment, hypotension, and hyperkalemia in patients taking aliskiren and ACE inhibitors or ARBs concomitantly.¹⁰

The renin inhibitors that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. There are no generic renin inhibitor products currently available; however, amlodipine and hydrochlorothiazide are available generically. This class was last reviewed in May 2013.

Table 1. Renin Inhibitors Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Aliskiren	tablet	Tekturna [®]	none
Combination Products			
Aliskiren and amlodipine	tablet	Tekamlo [®]	none
Aliskiren and amlodipine and hydrochlorothiazide	tablet	Amturnide [®]	none
Aliskiren and hydrochlorothiazide	tablet	Tekturna HCT [®]	none

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the renin inhibitors are summarized in Table 2.

Table 2. Treatment Guidelines Using the Renin Inhibitors

Clinical Guideline	Recommendations
Eighth Joint National Committee (JNC 8):	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic

Clinical Guideline	Recommendations
<p>2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹¹</p>	<p>blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life.</p> <ul style="list-style-type: none"> • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹²</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹³, Reappraisal of Guidelines on Hypertension</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel

Clinical Guideline	Recommendations
<p>Management (2009)¹⁴</p>	<p>blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight

Clinical Guideline	Recommendations
	<p>glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.</p>
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)¹⁵</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly.

Clinical Guideline	Recommendations
	<p>although diuretics and calcium antagonists may be preferred in isolated systolic hypertension.</p> <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic

Clinical Guideline	Recommendations
	<p data-bbox="594 205 927 233">syndrome and high normal BP.</p> <p data-bbox="550 264 1235 291"><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul data-bbox="561 298 1414 699" style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p data-bbox="558 732 1365 760"><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul data-bbox="561 766 1414 1136" style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p data-bbox="550 1169 1240 1197"><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul data-bbox="561 1203 1414 1904" style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. <ul style="list-style-type: none"> ○ Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁶</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. • If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁷</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)¹⁸</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)¹⁹</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently \leq140 mm Hg systolic and \leq90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently \leq130 mm Hg systolic and \leq80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently \leq130 mm Hg systolic and \leq 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently \leq140 mm Hg systolic and \leq90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently \leq130 mm Hg systolic and \leq80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently \leq130 mm Hg systolic and \leq80 mm Hg diastolic, irrespective of the level of urine albumin excretion.

Clinical Guideline	Recommendations
	<ul style="list-style-type: none"> In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²⁰</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB,

Clinical Guideline	Recommendations
	<p>at maximal doses) is generally required to achieve blood pressure targets.</p> <ul style="list-style-type: none"> If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p>Nephropathy</p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) and is recommended for those with urinary albumin excretion >300 mg/day. When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the renin inhibitors are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Renin Inhibitors⁶⁻⁹

Indication(s)	Single Entity Agents	Combination Products		
	Aliskiren	Aliskiren and Amlodipine	Aliskiren and Amlodipine and HCTZ	Aliskiren and HCTZ
Hypertension				
Treatment of hypertension	✓	✓ *	✓ †	✓

*Alone or in combination with other antihypertensives.

†This fixed combination drug is not indicated for initial therapy of hypertension.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the renin inhibitors are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Renin Inhibitors⁵

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Aliskiren	2.5	47 to 51	Liver, minor (%) not reported)	Feces (91) Renal (<1)	40
Combination Products					

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Aliskiren and amlodipine	2.5/64 to 90	47 to 51/93	Liver, minor (% not reported)/ Liver (90)	Feces (91) Renal (0.6)/ Feces (20 to 25) Renal (10)	40/30 to 50
Aliskiren and amlodipine and HCTZ	2.5/ 64 to 90/ 60 to 80	47 to 51/ 93/ 40	Liver, minor (% not reported)/ Liver (90)/ Not metabolized	Feces (91)/ Feces (20 to 25) Renal (60)/ Renal (61)	40/ 30 to 50/ 5.8 to 18.9
Aliskiren and HCTZ	2.5/50 to 75	47 to 51/ 40 to 68	Liver, minor (% not reported)/ Not reported	Feces (91) Renal (<1)/ Renal (>95)	40/6 to 15

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the renin inhibitors are listed in Table 5.

Table 5. Significant Drug Interactions with the Renin Inhibitors⁴

Generic Name(s)	Significance Level	Interaction	Mechanism
Renin Inhibitors (aliskiren)	1	ACE inhibitors	Aliskiren is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension. In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) <60 mL/min.
Renin Inhibitors (aliskiren)	1	ARBs	Aliskiren is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension. In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl <60 mL/min.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics may induce hypokalemia and increase the risk of torsades de pointes.
Thiazide diuretics (HCTZ)	1	Lithium	Decreased lithium clearance may occur with thiazide use, which may lead to increased serum lithium levels and possibly lithium toxicity.
Renin Inhibitors (aliskiren)	2	Azole antifungals	Increased absorption of aliskiren resulting from inhibition of P-gp expression by certain azole antifungal agents may occur. In addition, azole antifungal agents may inhibit aliskiren metabolism (CYP3A4).
Renin Inhibitors (aliskiren)	2	Cyclosporine	Concurrent use of aliskiren and cyclosporine may result in increased aliskiren exposure and plasma concentrations.
Renin Inhibitors (aliskiren)	2	Potassium preparations	Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur

Generic Name(s)	Significance Level	Interaction	Mechanism
			with the combination of aliskiren and potassium preparations.
Renin Inhibitors (aliskiren)	2	Potassium-sparing diuretics	The risk of hyperkalemia may be increased when aliskiren is coadministered with potassium-sparing diuretics. Decreased aldosterone activity by aliskiren may function synergistically with potassium conservation by potassium-sparing diuretics leading to the development of hyperkalemia.
Thiazide diuretics (HCTZ)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia, hyperuricemia, and hypotension.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Thiazide diuretics may induce electrolyte disturbances which may predispose patients to digitalis-induced arrhythmias.

ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor antagonist
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the renin inhibitors are listed in Table 6. The boxed warning for aliskiren-containing products is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Renin Inhibitors⁴⁻⁹

Adverse Events	Single Entity Agents	Combination Products		
	Aliskiren	Aliskiren and Amlodipine	Aliskiren and Amlodipine and HCTZ	Aliskiren and HCTZ
Cardiovascular				
Hypotension	<1	-	-	<1
Peripheral edema	✓	8.9	7.1	✓
Central Nervous System				
Dizziness	>1	-	3.6	2
Fatigue	>1	-	-	>1
Headache	>1	-	3.6	>1
Paresthesia	-	-	-	-
Restlessness	-	-	-	✓
Seizure	✓	-	-	✓
Vertigo	1	-	-	1
Dermatologic				
Erythema multiforme	-	-	-	✓
Exfoliative dermatitis	-	-	-	✓
Photosensitivity	-	-	-	✓
Rash	1	-	-	1
Stevens-Johnson syndrome	-	-	-	✓
Toxic epidermal necrolysis	-	-	-	✓
Urticaria	-	-	-	✓
Endocrine and Metabolic				
Gout	<1	-	-	<1
Gastrointestinal				
Abdominal pain	✓	-	-	✓
Cramping	-	-	-	✓
Diarrhea	2	-	-	2
Dyspepsia	✓	-	-	✓
Gastric irritation	-	-	-	✓
Gastroesophageal reflux	✓	-	-	✓
Genitourinary				
Glycosuria	-	-	-	✓
Impotence	-	-	-	-

Adverse Events	Single Entity Agents	Combination Products		
	Aliskiren	Aliskiren and Amlodipine	Aliskiren and Amlodipine and HCTZ	Aliskiren and HCTZ
Urinary tract infection	-	-	-	-
Hematologic				
Agranulocytosis	-	-	-	✓
ALT increased	-	-	-	1
Anemia	✓	-	-	-
Aplastic anemia	-	-	-	✓
Hematocrit decreased	✓	-	-	✓
Hemoglobin decreased	✓	-	-	✓
Hemolytic anemia	-	-	-	✓
Leukopenia	-	-	-	✓
Thrombocytopenia	-	-	-	✓
Laboratory Test Abnormalities				
Alanine aminotransaminase increased	-	-	-	1
Blood urea nitrogen increased	7	-	-	12
Creatine kinase increased	1	-	-	-
Hyperglycemia	-	-	-	✓
Hyperkalemia	1	-	-	1
Hypokalemia	-	-	-	2
Serum creatinine increased	7	-	-	1
Uric acid increased	<1	-	-	<1
Musculoskeletal				
Arthralgia	-	-	-	1
Asthenia	-	-	-	1
Back pain	>1	-	-	>1
Muscle cramps	-	-	-	-
Muscle spasm	-	-	-	✓
Myositis	<1	-	-	-
Rhabdomyolysis	<1	-	-	-
Weakness	-	-	-	✓
Renal				
Interstitial nephritis	-	-	-	✓
Renal dysfunction	-	-	-	✓
Renal failure	-	-	-	✓
Renal stones	<1	-	-	<1
Respiratory				
Cough	1	-	-	1

Adverse Events	Single Entity Agents	Combination Products		
	Aliskiren	Aliskiren and Amlodipine	Aliskiren and Amlodipine and HCTZ	Aliskiren and HCTZ
Influenza	-	-	-	2
Nasopharyngitis	✓	-	2.6	>1
Pharyngitis	-	-	-	-
Respiratory distress	-	-	-	✓
Sinusitis	-	-	-	-
Upper respiratory infection	>1	-	-	>1
Other				
Allergic reaction	-	-	-	-
Angioedema	✓	-	-	✓
Blurred vision	-	-	-	✓
Edema (face, hands, or whole body)	<1	-	-	<1
Fever	-	-	-	✓
Jaundice	-	-	-	✓
Necrotizing angitis	-	-	-	✓
Pancreatitis	-	-	-	✓
Periorbital edema	✓	-	-	✓
Purpura	-	-	-	✓
Xanthopsia	-	-	-	✓

✓ Percent not specified.

- Event not reported.

Table 7. Boxed Warning for Aliskiren Products⁴

WARNING
When pregnancy is detected, discontinue aliskiren as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

VII. Dosing and Administration

The usual dosing regimens for the renin inhibitors are listed in Table 8.

Table 8. Usual Dosing Regimens for the Renin Inhibitors⁴⁻⁹

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Aliskiren	<u>Hypertension:</u> Tablet: initial, 150 mg once daily; maintenance, titrate as needed; maximum, 300 mg/day	Safety and efficacy in children have not been established.	Tablet: 150 mg 300 mg
Combination Products			
Aliskiren and amlodipine	<u>Hypertension:</u> Tablet: initial, 150-5 mg once daily; maintenance, titrate as needed; maximum, 300-10 mg/day	Safety and efficacy in children have not been established.	Tablet: 150-5 mg 150-10 mg 300-5 mg 300-10 mg
Aliskiren and amlodipine and HCTZ	<u>Hypertension:</u> Tablet: maximum, titrate as needed up to 300/10/25 mg once daily	Safety and efficacy in children have not been established.	Tablet: 150-5-12.5 mg 300-5-12.5 mg 300-5-25 mg 300-10-12.5 mg 300-10-25 mg
Aliskiren and HCTZ	<u>Hypertension:</u> Tablet: initial, 150-12.5 mg once daily; maximum, 300-25 mg/day	Safety and efficacy in children have not been established.	Tablet: 150-12.5 mg 150-25 mg 300-12.5 mg 300-25 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the renin inhibitors are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Renin Inhibitors

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cardiovascular Risk Reduction				
<p>Parving et al.²¹ (2012) ALTITUDE Aliskiren vs placebo Both in addition to standard treatment</p>	<p>DB, PC, RCT Patients ≥35 years of age with type 2 diabetes and evidence of microalbuminuria, macroalbuminuria, or cardiovascular disease</p>	<p>N=8,561 Median of 32.9 months</p>	<p>Primary: Composite of death from cardiovascular causes or the first occurrence of cardiac arrest with resuscitation; nonfatal MI; nonfatal stroke; unplanned hospitalization for HF; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or a serum creatinine value that was at least double the baseline value and that exceeded the upper limit of the normal range Secondary: Composite of cardiovascular</p>	<p>The independent data and safety monitoring committee recommended termination of the study medication, on the basis of their assessment that the excess risk of adverse events in the aliskiren group could not be offset by a reduction in major cardiovascular and renal events. Primary: The primary outcome occurred in 783 participants in the aliskiren group (18.3%) and 732 in the placebo group (17.1%). The hazard ratio for this outcome in the aliskiren group as compared with the placebo group was 1.08 (95% CI, 0.98 to 1.20; P=0.12). Secondary: The secondary cardiovascular composite outcome occurred in 590 participants in the aliskiren group (13.8%) and 539 in the placebo group (12.6%); the HR in the aliskiren group was 1.11 (95% CI, 0.99 to 1.25; P=0.09). The secondary renal composite outcome occurred in 257 participants in the aliskiren group (6.0%) and 251 in the placebo group (5.9%); the HR in the aliskiren group was 1.03 (95% CI, 0.87 to 1.23; P=0.74). The number of deaths from any cause did not differ significantly between the study groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			components and of renal components of the primary composite end point	
Hypertension				
Tocci et al. ²² (abstract) 2012 Aliskiren 150 to 300 mg/day	MC, OL, OS, PRO Patient with HTN not adequately controlled on ≥ 2 other antihypertensive agents	N=1,186 12 months	Primary: Efficacy, safety Secondary: Not reported	Primary: SBP and DBP was 141.1/82.4, 134.9/79.8, and 133.6/78.9 mmHg at one, six and 12 month follow-up visits, respectively ($P < 0.0001$ vs baseline for all comparisons). These effects were consistent in all predefined subgroups, including those with left ventricular hypertrophy, renal disease, diabetes mellitus, CAD, or cerebrovascular disease. Reduced levels of microalbuminuria were reported, without affecting other renal and electrolyte parameters. Secondary: Not reported
Oh et al. ²³ (2007) Aliskiren 150, 300, or 600 mg QD vs placebo	DB, MC, PC, PG, RCT Men and women ≥ 18 years (mean age 53 years) with mild-to-moderate essential HTN (DBP ≥ 95 and < 110 mm Hg)	N=672 8 weeks	Primary: Change in mean sitting DBP Secondary: Change in mean sitting SBP, 24-hour ABPM, proportion achieving a successful treatment response (DBP < 90 mm Hg or ≥ 10 mm Hg pressure reduction from baseline) or blood pressure control ($< 140/90$ mm Hg), plasma renin activity and concentration,	Primary: All three doses investigated provided significantly greater reductions in mean sitting DBP from baseline compared to placebo ($P < 0.0001$ for all). The mean sitting DBP reductions were 10.3 mm Hg with 150 mg, 11.1 mm Hg with 300 mg and 12.5 mm Hg with 600 mg compared to 4.9 mm Hg with placebo. Secondary: All three doses provided significantly greater reductions in mean sitting SBP from baseline compared to placebo ($P < 0.0001$ for all). The mean sitting SBP reductions were 13.0 mm Hg with 150 mg, 14.7 mm Hg with 300 mg and 15.8 mm Hg with 600 mg compared to 3.8 mm Hg with placebo. Reduction in the 24-hour ABPM was significantly greater in all doses of aliskiren compared to placebo ($n=216$; $P < 0.0001$ for all). Reductions in mean ambulatory DBP and SBP were consistent across the 24-hour dosing interval with all aliskiren doses. The proportion of patients achieving a successful treatment response was

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			safety and tolerability	<p>59.3% with aliskiren 150 mg, 63.3% with 300 mg and 69.3% with 600 mg compared to 36.2% with placebo (P<0.0001 for all).</p> <p>The proportion of patients achieving blood pressure control was 35.9% with 150 mg, 41.6% with 300 mg and 46.4% with 600 mg compared to 20.3% with placebo (P<0.0001 for all).</p> <p>Plasma renin activity decreased 79.5% with 150 mg, 81.1% with 300 mg and 75.0% with 600 mg compared to an increase of 19.5% with placebo. Aliskiren resulted in dose-dependent increases from baseline in renin concentrations (51.5%, 101.6%, and 228.5% for 150, 300 and 600 mg, respectively). Renin concentrations were almost unchanged with placebo.</p>
<p>Kushiro et al.²⁴ (2006)</p> <p>Aliskiren 75, 150, or 300 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Japanese men and women between the ages of 20 and 80 years with essential HTN (mean sitting DBP of ≥ 90 mm Hg and < 110 mm Hg during the run-in period and ≥ 95 mm Hg and < 110 mm Hg at baseline)</p>	<p>N=455</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean trough sitting SBP, proportion of patients responding to treatment (mean sitting DBP < 90 mm Hg and/or ≥ 10 mm Hg decrease in mean sitting DBP from baseline), dose-response relationship, safety</p>	<p>Primary: All three aliskiren doses provided significantly greater reductions in mean sitting DBP from baseline compared to placebo. The placebo-corrected reductions in mean sitting DBP were 4.0 mm Hg with 75 mg aliskiren, 4.5 mm Hg with 150 mg and 7.5 mm Hg with 300 mg (P<0.0005 for all).</p> <p>Secondary: The mean sitting SBP reductions were significantly lower with all aliskiren doses when compared to placebo. The placebo-corrected reductions in mean sitting SBP were 5.7 mm Hg with 75 mg aliskiren, 5.9 mm Hg with 150 mg and 11.2 mm Hg with 300 mg (P<0.001 for all).</p> <p>The proportion of responders at study end point was 47.8% with aliskiren 75 mg, 48.2% with 150 mg and 63.7% with 300 mg compared to 27.8% with placebo (P<0.005 for all).</p> <p>Dose-response analysis showed that the relationship between reductions in mean sitting DBP and SBP and aliskiren dose was almost linear. However, further analyses revealed that a pattern of similar reductions with aliskiren 75 and 150 mg and greater reductions with aliskiren 300 mg was a better fit for both mean sitting DBP and SBP.</p> <p>The incidence of drug-related adverse events was comparable between aliskiren (53 to 55%) and placebo (50%). There was no evidence of a dose-dependent increase in the incidence of all-causality adverse events at the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				aliskiren doses evaluated in this study.
Musini et al. ²⁵ (2009) Aliskiren (variable doses) vs placebo	MA Patients ≥18 years of age with mild to moderate essential HTN (defined as mean sitting DBP ≤95 mm Hg and ≤110 mm Hg at baseline)	N=3,694 (6 trials) 8 weeks	Primary: Changes in dose-related SBP and DBP Secondary: Variability of blood pressure, pulse pressure, heart rate, withdrawals due to adverse effects, and rates of specific adverse effects	Primary: Aliskiren monotherapy was more effective than placebo in lowering mean sitting SBP. The additional magnitude of blood pressure lowering minus the placebo effect: aliskiren 75 mg vs placebo -2.94 (95% CI, -4.56 to -1.31); aliskiren 150 mg vs placebo -5.45 (95% CI, -6.46 to -4.43); aliskiren 300 mg vs placebo -8.66 (95% CI, -9.68 to 7.64); aliskiren 600 mg vs placebo -11.36 (95% CI, -13.53 to -9.19). Aliskiren monotherapy was more effective than placebo in lowering mean sitting DBP. The additional magnitude of blood pressure lowering minus the placebo effect: aliskiren 75 mg vs placebo -2.29 (95% CI, -3.31 to -1.26); aliskiren 150 mg vs placebo -3.00 (95% CI, -3.65 to -2.34); aliskiren 300 mg vs placebo -4.97 (95% CI, -5.62 to -4.31); aliskiren 600 mg vs placebo -6.57 (95% CI, -7.92 to -5.23). Secondary: No trials reported on pulse pressure at baseline or end point. Two trials recorded baseline heart rate, but no data were provided at week eight. There were no significant differences in withdrawals between placebo and aliskiren at any dose. The relative risk for aliskiren 75 mg vs placebo was 0.97 (95% CI, 0.49 to 1.89); for aliskiren 150 mg vs placebo was 1.01 (95% CI, 0.61 to 1.69); for aliskiren 300 mg vs placebo was 0.91 (95% CI, 0.57 to 1.47) and for aliskiren 600 mg vs placebo was 0.63 (9% CI, 0.21 to 1.89). One trial reported on the incidence of dry cough: placebo (1.1%); aliskiren 75 mg (1.1%); aliskiren 150 mg (2.8%); aliskiren 300 mg (0.6%). No trials reported angioedema. The blood pressure lowering efficacy of aliskiren 150 mg vs 75 mg, as well as aliskiren 600 mg vs 300 mg was not significantly different. Aliskiren 300 mg significantly lowered both SBP and DBP as compared to 150 mg (SBP: -2.97; 95% CI, -3.99 to -1.95; DBP: -1.66; 95% CI, -2.32 to -1.0).
Braun-Dullaеus et	DB, MC, RCT	N=485	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>al.²⁶ (2012)</p> <p>Aliskiren 150 mg QD, up titrated to 300 mg QD</p> <p>vs</p> <p>placebo</p> <p>All patients received amlodipine 5 mg/day, up titrated up to 10 mg/day.</p>	<p>Patients with HTN (mean sitting SBP \geq160 to <200 mm Hg)</p>	<p>8 weeks</p>	<p>Change in baseline mean sitting SBP and DBP, blood pressure control rate (<140/90 mm Hg)</p> <p>Secondary: Safety</p>	<p>After eight weeks, add-on treatment with aliskiren resulted in significantly greater reductions in mean sitting SBP and DBP compared to placebo (-37.7/-16.1 vs -30.6/-12.3 mm Hg; P<0.0001).</p> <p>After eight weeks, significantly more patients receiving aliskiren add-on therapy achieved blood pressure control compared to placebo (67.0 vs 49.1%; P=0.0001).</p> <p>Secondary: The overall incidence of adverse events was similar between both treatments. The most commonly reported adverse event was peripheral edema, with a higher incidence occurring in patients receiving placebo (18.3 vs 14.4%).</p>
<p>Weinberger et al (abstract).²⁷ 2012 ACCESS</p> <p>Aliskiren 150 mg/day, up titrated to 300 mg/day</p> <p>vs</p> <p>placebo</p> <p>All patients were receiving amlodipine 5 mg/day, up titrated to 10 mg/day</p>	<p>DB, RCT</p> <p>African American patients with stage 2 HTN (mean sitting SBP 160 to 199 mm Hg) with obesity or metabolic syndrome</p>	<p>N=489</p> <p>8 weeks</p>	<p>Primary: Change in baseline mean sitting SBP</p> <p>Secondary: Not reported</p>	<p>Primary: LSM reductions in mean sitting SBP were significantly higher with add-on aliskiren compared to placebo in both obese (-33.7 vs -27.9 mm Hg; P<0.001) and metabolic syndrome patients (-36.4 vs -28.5 mm Hg; P<0.001).</p> <p>Secondary: Not reported</p>
<p>Teo et al.²⁸ (2014)</p>	<p>DB, PC, RCT</p>	<p>N=11,000</p>	<p>Primary: Original endpoints</p>	<p>Primary: Postrandomization, aliskiren reduced adjusted mean SBP by 3.5 (SE</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>APOLLO</p> <p>Aliskiren 300 mg daily vs placebo and amlodipine 5 mg daily or HCTZ 25 mg daily</p>	<p>Patients ≥65 years with SBP between 130 and 159 mm Hg with either CVD or one additional CV risk factor</p>	<p>5 years</p> <p>Study was terminated by sponsor after 1759 subjects were randomized and followed for 0.6 year due to non-scientific reasons without any knowledge of blinded trial data and despite objections of the Steering Committee</p>	<p>(risks of the composite of CV death, non-fatal MI, non-fatal stroke, and clinically significant heart failure) could not be assessed, so tolerability and effects on BP lowering were reported</p> <p>Secondary: Not reported</p>	<p>[standard error] 0.5) mmHg, (P<0.001), and DBP by 1.7 (SE 0.3) mmHg (P<0.001) compared with placebo (first co-primary outcome), HCTZ or amlodipine by 6.8 (SE 0.5) mmHg, (P<0.001) for SBP and 3.3 (SE 0.3) mmHg (P<0.001) for DBP. The reduction in SBP in the double therapy compared with double placebo (second co-primary outcome) was 10.3 (SE 0.8) mmHg (P<0.001) for SBP, and 5.0 (SE 0.5) mmHg, P<0.001 in mean DBP.</p> <p>There were few serious adverse events, both during run-in and after randomization, with no excess associated with any treatment group.</p> <p>Secondary: Not reported</p>
<p>Schmieder et al.²⁹ (2009)</p> <p>Aliskiren 150 to 300 mg QD (with optional addition of amlodipine 5 to 10 mg QD) vs HCTZ 12.5 to 25 mg QD (with optional addition of amlodipine 5 to</p>	<p>AC, DB, RCT</p> <p>Adults with essential HTN</p>	<p>N=1,124</p> <p>12 months</p>	<p>Primary: Safety and change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP</p>	<p>Primary: The proportion of patients who experienced adverse events during the six week placebo-controlled period was similar in the aliskiren monotherapy, HCTZ monotherapy, and placebo groups (26.4, 24.5, and 28.5%, respectively).</p> <p>During the 52 week double-blind treatment period, adverse events were reported by a similar proportion of patients receiving the aliskiren and hydrochlorothiazide regimens. Most adverse events were mild or moderate in intensity.</p> <p>At week 26, the aliskiren regimen provided significantly greater reductions from baseline in DBP compared to HCTZ (-14.2 and -13.0 mm Hg, respectively; P<0.05). The greater reduction in DBP with the aliskiren regimen compared to the HCTZ regimen was maintained at week 52 (-16.0</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
10 mg QD) vs placebo for 6 weeks, then randomized to either aliskiren 300 mg QD or HCTZ 25 mg QD				and -15.0 mm Hg, respectively; P<0.05). Secondary: At week 26, the aliskiren regimen provided significantly greater reductions from baseline in SBP compared to HCTZ (-20.3 and -18.6 mm Hg, respectively; P<0.05). Reductions in SBP at week 52 were not inferior to those of HCTZ (-22.1 and -21.2 mm Hg, respectively; P<0.0001 for non-inferiority).
Schmieder et al. ³⁰ (2009) Aliskiren 150 mg QD, followed by 300 mg QD after 3 weeks vs HCTZ 12.5 mg QD, followed by 25 mg QD after 3 weeks vs placebo, followed by aliskiren 300 mg QD or HCTZ 25 mg QD after 6 weeks	Subgroup analysis of obese patients in Schmieder et al. ²⁵ Patients 18 years of age and older with essential HTN, a mean sitting DBP ≥ 90 and <110 mm Hg; at randomization, patients had to have a mean sitting DBP ≥ 95 and <110 mm Hg and show a difference of ≤ 10 mm Hg since the previous visit	N=1,124 52 weeks	Primary: Mean sitting DBP Secondary: Mean sitting SBP at week 26, mean sitting DBP and SBP at week 52, proportion of patients with response to treatment, blood pressure control at weeks 26 and 52, and safety	Primary: The LSM DBP and SBP reductions at week 12 were significantly greater with aliskiren compared to HCTZ (P<0.0001 and P=0.001 respectively). Secondary: At week 52, aliskiren resulted in significantly greater mean sitting DBP reductions compared to HCTZ (P<0.001). Blood pressure response rates were significantly greater with aliskiren compared to HCTZ at both week 12 and week 52 (P<0.05). Significantly more obese patients achieved blood pressure control with aliskiren compared to HCTZ at week 12 (P=0.0013). Blood pressure control rates were similar between groups at week 52 (P value not reported).
Littlejohn et al. ³¹ (2009) Aliskiren 150 to 300 mg and	OL, MC Patients ≥ 18 years of age with essential HTN (mean sitting	N=556 12 months	Primary: Safety and tolerability Secondary:	Primary: Long-term treatment with aliskiren and amlodipine was generally well tolerated. In total, 76.3% of patients reported at least one adverse event. The majority were mild or moderate in severity and transient. The most frequently reported adverse events were peripheral edema, upper

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>amlodipine 5 to 10 mg QD</p> <p>HCTZ may be added if additional blood pressure control was required.</p>	<p>DBP \geq90 mm Hg and <110 mm Hg)</p>		<p>Blood pressure-lowering efficacy</p>	<p>respiratory tract infection, headache, and bronchitis.</p> <p>Peripheral edema was reported in 20.5% of patients who received aliskiren and amlodipine and in 14.0% of patients who received aliskiren and amlodipine and HCTZ.</p> <p>Edema was reported as mild in 59.5%, moderate in 33.3% and severe in 7.1% of patients.</p> <p>Secondary: At week two, treatment with aliskiren/amlodipine led to a mean reduction in blood pressure of 13.5/8.3 mm Hg. At week 10, there was a mean reduction in blood pressure of 23.5/15.1 mm Hg. Blood pressure reductions were sustained from week 10 until the end of the study. At week 54, aliskiren and amlodipine decreased mean blood pressure from 153.5/97.6 mm Hg at baseline to 129.4/82.2 mm Hg (P<0.001).</p> <p>The BP control rate was 74.3% with aliskiren/amlodipine at week 54.</p>
<p>Drummond et al.³² (2007)</p> <p>Aliskiren and amlodipine 150-5 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>amlodipine 5 mg QD</p> <p>vs</p> <p>amlodipine 10 mg QD</p>	<p>AC, DB, MC, PG, RCT</p> <p>Patients 18 years of age and older with mild to moderate HTN</p>	<p>N=545</p> <p>6 weeks</p>	<p>Primary: Change in DBP at 6 weeks</p> <p>Secondary: SBP, comparison of SBP and DBP reductions between combination therapy group and amlodipine 10 mg group, proportion of patients responding to treatment, and proportion of patients achieving blood pressure control</p>	<p>Primary: DBP reduction was significantly greater in the combination therapy group compared to those in the amlodipine 5 mg group (P<0.0001).</p> <p>Secondary: SBP reduction was significantly greater in the combination therapy group compared to those in the amlodipine 5 mg group (P<0.0001).</p> <p>No significant differences were observed in DBP or SBP reduction between the combination therapy group and the amlodipine 10 mg group (P=0.6167 and P=0.2666 respectively).</p> <p>The proportion of patients responding to treatment was significantly higher in the combination therapy group compared to the amlodipine 5 mg group (P<0.0001). No significant difference was observed between the combination therapy group and the amlodipine 10 mg group (P value not reported).</p> <p>The proportion of patients achieving blood pressure control was</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Patients not responding to amlodipine 5 mg QD at the end of 4 week single-blind run-in period received combination therapy, continuation of amlodipine 5 mg QD or titration to amlodipine 10 mg QD.</p>				<p>significantly higher in the combination therapy group compared to the amlodipine 5 mg group (P<0.0001). No significant difference was observed between the combination therapy group and the amlodipine 10 mg group (P=0.5229).</p>
<p>Villamil et al.³³ (2007)</p> <p>Aliskiren 75 to 300 mg QD</p> <p>vs</p> <p>HCTZ 6.25 to 25 mg QD</p> <p>vs</p> <p>aliskiren and HCTZ (every dose combination except aliskiren 300 mg and HCTZ 6.25 mg) QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Men and women ≥18 years with mild-to-moderate essential HTN</p>	<p>N=2,776</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, dose-response efficacy for all treatment groups, proportion achieving a successful response (DBP <90 mm Hg or ≥10 mm Hg), proportion achieving blood pressure control (<140/90 mm Hg), plasma renin activity, renin concentrations, safety</p>	<p>Primary: Aliskiren monotherapy significantly reduced mean sitting DBP (P=0.0002). Only the aliskiren 150 and 300 mg doses were more effective than placebo (P=0.09 for aliskiren 75 mg). HCTZ monotherapy significantly reduced DBP from baseline (P<0.01 for all vs placebo).</p> <p>All combinations were more effective than placebo (P<0.0001) with reductions in DBP ranging from 10.4 to 14.3 mm Hg. Most combination regimens were more effective than monotherapy with the individual components (exceptions were aliskiren 150 mg and HCTZ 6.25 mg vs monotherapy, and aliskiren 75 mg and HCTZ 12.5 mg vs HCTZ monotherapy).</p> <p>Secondary: After eight weeks of therapy, aliskiren 150 and 300 mg regimens (both P<0.0001) were more effective than placebo in lowering mean sitting SBP, but the 75 mg dose was not (P=0.151).</p> <p>Combination therapy was consistently more effective in reducing SBP than monotherapy with the individual components, with the exception of aliskiren 75 mg plus HCTZ 12.5 vs HCTZ monotherapy. Reductions in SBP with combination therapy ranged from 14.3 to 21.2 mm Hg.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Blood pressure reductions were related to the doses of both aliskiren and HCTZ.</p> <p>Responder rates were significantly higher with aliskiren 300 mg (63.9%; P=0.0005), HCTZ 12.5 and 25 mg (60.6 and 59.0%, respectively; both P<0.02) and all combination doses (58.4 to 80.6%; all P<0.05) than placebo (45.8%). Responder rates for all combinations of aliskiren and HCTZ 25 mg, and aliskiren 300 mg and HCTZ 12.5 mg were higher than both monotherapies (P<0.05), while aliskiren 75 mg and HCTZ 12.5 mg and aliskiren 150 mg and HCTZ 12.5 mg were more effective than their respective aliskiren monotherapies (P<0.05).</p> <p>In the aliskiren and HCTZ monotherapy groups, only aliskiren 300 mg led to statistically significantly greater control rates than placebo (46.7 vs 28.1%; P=0.0001). Control rates for all combinations, with the exception of aliskiren 75 mg and HCTZ 6.25 mg, were higher than placebo (all P<0.02). There was a trend towards improved control rates with combination therapy (37.4 to 59.5%) compared to aliskiren monotherapy (29.0 to 46.7%) or HCTZ monotherapy (32.5 to 37.8%). Combinations utilizing the higher doses of one or both drugs (aliskiren 75 to 300 mg with HCTZ 25 mg or aliskiren 150 to 300 mg with HCTZ 12.5 mg) yielded control rates that were significantly higher than monotherapy with either component.</p> <p>While all doses of aliskiren decreased plasma renin activity and all doses of HCTZ increased plasma renin activity, combination therapy resulted in decreased plasma renin activity of 46.1 to 63.5%. Renin concentrations increased in all monotherapy and combination regimens with the exception of HCTZ 6.25 and 12.5 mg.</p> <p>All active treatments were well tolerated with 37.3 to 39.2% of patients experiencing adverse events with aliskiren monotherapy, 38.7 to 42.0% with HCTZ monotherapy, 34.6 to 45.3% with aliskiren and HCTZ, and 44% with placebo. Hypokalemia (serum potassium <3.5 mmol/L) occurred with the highest frequency with HCTZ 12.5 and 25 mg (3.9 and 5.2%, respectively). When administered in combination with aliskiren, the frequency of hypokalemia was 0.7 to 2.0% with HCTZ 12.5 mg and 2.2% to 3.4% with HCTZ 25 mg.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Maddury et al.³⁴ (2013)</p> <p>aliskiren vs aliskiren + hydrochlorothiazide (HCT) single-pill combination</p>	<p>MC, OBS, OL, PRO</p> <p>Patients ≥18 years of age with a diagnosis of hypertension for which aliskiren or aliskiren HCT therapy had been prescribed by the treating physician</p>	<p>N=4,826</p> <p>26 ± 8 weeks</p>	<p>Primary: Proportion of patients who achieved therapeutic goal, defined as a target BP <140/90 mmHg</p> <p>Secondary: Absolute change from baseline to end of study in mean sitting SBP (msSBP) and mean sitting DBP (msDBP), and the proportion of patients achieving a BP response, safety</p>	<p>Primary: The proportion of patients who reached the defined therapeutic BP goal at week 26 was 49.2% overall, 49.5% for aliskiren, and 48.3% for aliskiren HCT.</p> <p>Secondary: At week 26, the proportion of aliskiren-treated patients achieving the predefined response for SBP and DBP was 83.6 and 84.4%, respectively; the corresponding BP response rates in patients receiving aliskiren HCT were 84.4 and 86.5%. Treatment with aliskiren and aliskiren HCT was also associated with significant reductions from baseline to the end of study in msSBP and msDBP (P<0.001 vs baseline for both treatments).</p> <p>Adverse effects occurred in a total of 101 (2.1%) patients. The most common AEs included headache, onset of diabetes mellitus, abdominal discomfort, and dizziness.</p>
<p>Fukutomi et al.³⁵ (2014)</p> <p>Aliskiren 150 mg/amlodipine 5 mg group (AL/AM), after 8 weeks aliskiren dose was doubled to 300 mg for another 8 weeks vs high-dose amlodipine 10 mg (AM) group</p>	<p>MC, OL, RCT</p> <p>Hypertensive patients who were untreated or being treated with 5mg amlodipine</p> <p>During a 4-week run-in period, untreated patients started 5 mg amlodipine monotherapy and treated patients continued their medication. At the end of the run-in</p>	<p>N=87</p> <p>4-week run-in plus 16 weeks of treatment</p>	<p>Primary: Brachial flow-mediated vasodilation (FMD) and nitroglycerin-mediated vasodilation (NMD)</p> <p>Secondary: Not reported</p>	<p>Primary: FMD significantly improved in the AL/AM group but significantly decreased in the AM group. At the end of the study, FMD was significantly higher in the AL/AM group than in the AM group (3.7±1.9% vs. 2.3±1.1%; P<0.001). NMD did not change after the treatment period in either group.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	<p>period, patients with BP \geq140mm Hg and/or diastolic BP (DBP) \geq90mm Hg were considered eligible for the study</p>			
<p>Jordan et al.³⁶ (2007)</p> <p>Aliskiren 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>irbesartan 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>HCTZ 25 mg QD (existing therapy)</p>	<p>DB, DD, MC, PG, RCT</p> <p>Obese men and women (BMI \geq30 kg/m²) \geq18 years with essential HTN (mean sitting DBP 95 to 109 mm Hg and SBP $<$180 mm Hg) who had not responded to 4 weeks of treatment with HCTZ 25 mg</p>	<p>N=489</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting DBP with aliskiren 300 mg plus HCTZ vs HCTZ alone at 8 weeks</p> <p>Secondary: Comparisons of mean sitting DBP and SBP with aliskiren plus HCTZ vs the other treatment groups, percentage of responders (mean sitting DBP $<$90 mm Hg or \geq10 mm Hg reduction from baseline), proportion of patients achieving blood pressure control (mean sitting blood pressure $<$140/90 mm Hg), plasma renin activity, safety and tolerability</p>	<p>Primary: Aliskiren 300 mg added to HCTZ 25 mg significantly reduced mean sitting DBP compared to HCTZ alone at week eight (mean difference, -4.0; P$<$0.0001).</p> <p>Secondary: Aliskiren 300 mg added to HCTZ caused numerically larger reductions in mean sitting DBP and SBP compared to amlodipine 10 mg plus HCTZ and irbesartan 300 mg plus HCTZ at week eight, but there were no statistically significant differences between treatment groups (P$>$0.05).</p> <p>Responder rates were significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0193) and week 12 (P=0.004) but comparable to responder rates observed with amlodipine plus HCTZ (P$>$0.05) and irbesartan plus HCTZ (P$>$0.05).</p> <p>The proportion of patients achieving blood pressure control was significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0005) and week 12 (P=0.0001) but not statistically different than amlodipine plus HCTZ (P$>$0.05) and irbesartan plus HCTZ (P$>$0.05).</p> <p>Plasma renin activity significantly increased (P$<$0.05) during four weeks of HCTZ monotherapy. Combination with aliskiren neutralized this increase and led to an overall significant reduction in plasma renin activity compared to pretreatment baseline (P$<$0.05) whereas amlodipine and irbesartan led to further significant increases (P$<$0.05).</p> <p>All of the study treatments were generally well tolerated. Amlodipine plus HCTZ (45.2%) was associated with a higher incidence of adverse events than the other treatment groups (36.1 to 39.3%), largely due to a higher rate</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				of peripheral edema (11.1 vs 0.8 to 1.6%).
Nickenig et al. ³⁷ (2008) Aliskiren and HCTZ 300-25 mg QD (fixed-dose combination) vs aliskiren and HCTZ 300-12.5 mg QD (fixed-dose combination) vs aliskiren 300 mg QD (existing therapy)	DB, MC, RCT Patients with HTN and an inadequate response to aliskiren (mean sitting DBP >90 and ≤110 mm Hg following 4 weeks of aliskiren 300 mg)	N=880 8 weeks	Primary: Changes in mean sitting SBP and DBP, rates of blood pressure control (<140/90 mm Hg) Secondary: Not reported	Primary: Treatment with aliskiren and HCTZ 300-25 mg and 300-12.5 mg led to significantly greater reductions in mean sitting SBP/DBP from baseline (15.9/11.0 mm Hg and 13.5/10.5 mm Hg, respectively) compared to aliskiren 300 mg (8.0/7.4 mm Hg; both P<0.001). Rates of blood pressure control were significantly higher with aliskiren and HCTZ 300-25 mg (60.2%) and 300-12.5 mg (57.9%) compared to aliskiren 300 mg (40.9%; both P<0.001). Patients treated with aliskiren and HCTZ or aliskiren monotherapy demonstrated similar tolerability. Secondary: Not reported
Blumenstein et al. ³⁸ (2009) Aliskiren and HCTZ 300-25 mg QD (fixed-dose combination product) vs aliskiren and HCTZ 150-25 mg QD (fixed-dose combination)	DB, MC, RCT Patients with HTN and an inadequate response to HCTZ (mean sitting DBP >90 and ≤110 mm Hg following 4 weeks of HCTZ 25 mg)	N=722 8 weeks	Primary: Changes in mean sitting SBP/DBP, proportion of patients achieving blood pressure control (mean sitting blood pressure <140/90 mm Hg), and blood pressure response rates (msDBP <90 mm Hg or a ≥10 mm Hg decrease from	Primary: The mean reductions in mean sitting SBP/DBP from baseline with aliskiren and HCTZ 300-25 and 150-25 mg were significantly greater compared to those achieved with HCTZ monotherapy (P<0.001 for all). Rates of blood pressure control were significantly higher with aliskiren and HCTZ 300-25 and 150-25 mg compared to HCTZ monotherapy (P<0.001 for both). Aliskiren and HCTZ 300-25 mg provided significantly greater reductions in mean sitting SBP/DBP and rates of blood pressure control compared to aliskiren and HCTZ 150-25 mg dose (P<0.05 for all). Blood pressure response rates were significantly higher with aliskiren and HCTZ 300-25mg (78.5%) and aliskiren and HCTZ 150-25 mg (67.4%) compared to HCTZ monotherapy (47.1%; P<0.001 for both comparisons).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>product)</p> <p>vs</p> <p>HCTZ 25 mg (existing therapy)</p>			<p>baseline)</p> <p>Secondary: Not reported</p>	<p>All treatments were generally well-tolerated and the proportion of patients experiencing adverse events was similar across treatment groups. The majority of adverse events were mild and transient. Adverse events reported in >2% of patients were nasopharyngitis, dizziness, back pain, and vertigo.</p> <p>The proportion of patients with serum potassium <3.5 mmol/L was lower with aliskiren and HCTZ (1.3 to 2.2%) compared to HCTZ monotherapy (3.4%). Hyperkalemia (serum potassium >5.5 mmol/L) was observed in only one patient receiving aliskiren and HCTZ and two patients in the HCTZ monotherapy group. No patient had increases in serum creatinine above the pre-specified clinically significant threshold.</p> <p>Secondary: Not reported</p>
<p>Lacourciere et al.³⁹ (2012)</p> <p>Aliskiren and amlodipine and HCTZ 150-5-12.5 mg /day (fixed-dose combination product), up titrated to double the initial dose</p> <p>vs</p> <p>aliskiren and amlodipine 150-5 mg/day (fixed-dose combination product) , up titrated to double the initial dose</p>	<p>DB, RCT</p> <p>Patients ≥18 years of age with moderate to severe HTN</p>	<p>N=1,191</p> <p>8 weeks</p>	<p>Primary: Change in baseline mean sitting SBP and DBP, blood pressure control rate (<140/90 mm Hg)</p> <p>Secondary: Safety</p>	<p>Primary: Treatment with aliskiren and amlodipine and HCTZ resulted in significant LSM reductions in mean sitting SBP/DBP (week 4: -30.7/-15.9 mm Hg; week 8: -37.9/-20.6 mm Hg) compared to any combination therapy (P<0.001 for all). Significant reductions with triple therapy were observed as early as two weeks compared to dual therapies (P<0.05).</p> <p>Significantly more patients receiving aliskiren and amlodipine and HCTZ achieved blood pressure control compared to dual therapies with moderate to severe (62.3%) and severe (57.5%) HTN.</p> <p>Secondary: The majority of adverse events were mild or moderate in nature. The overall incidence of events was comparable among treatments (36.2 vs 33.4 vs 32.3 vs 33.6%). Peripheral edema was the most commonly reported adverse event.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>aliskiren and HCTZ 150-12.5 mg/day (fixed-dose combination product) , up titrated to double the initial dose</p> <p>vs</p> <p>amlodipine and HCTZ 5-12.5 mg/day (fixed-dose combination product)* , up titrated to double the initial dose</p>				
<p>Ferdinand et al (abstract).⁴⁰ (2012)</p> <p>Aliskiren and amlodipine and HCTZ 300-10-25 mg /day (fixed-dose combination product)</p> <p>vs</p> <p>aliskiren and amlodipine 150-5 mg/day (fixed-dose combination</p>	<p>Subgroup analysis</p> <p>Patients with HTN and any of the following: diabetes, cardiometabolic syndrome, obesity, or black patients</p>	<p>N=not reported</p> <p>8 weeks</p>	<p>Primary: Change in baseline mean sitting SBP</p> <p>Secondary: Not reported</p>	<p>Primary: LSM reductions in mean sitting SBP, across all subgroups ranged from 35 to 37 mm Hg with aliskiren and amlodipine and HCTZ compared to 28 to 30 mm Hg with aliskiren and amlodipine (P<0.01).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
product)				
<p>Gradman et al.⁴¹ (2005)</p> <p>Aliskiren 150 to 600 mg QD</p> <p>vs</p> <p>irbesartan 150 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Men and women, age 18 years or older, with mild-to-moderate essential HTN (mean sitting DBP \geq95 mm Hg and $<$110 mm Hg)</p>	<p>N=652</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP and SBP</p> <p>Secondary: Proportion of patients achieving blood pressure control ($<$140/90 mm Hg), safety</p>	<p>Primary: Decreases in mean sitting DBP at eight weeks were significantly greater with all doses of aliskiren compared to placebo ($P<$0.001). The least-squares mean reductions in trough DBP for aliskiren 150, 300, and 600 mg were 9.3, 11.8, and 11.5 mm Hg, respectively, vs 6.3 mm Hg for placebo.</p> <p>Decreases in mean sitting SBP at eight weeks were significantly greater with all doses of aliskiren compared to placebo ($P<$0.001). The least-squares mean reductions in trough SBP for aliskiren 150, 300, and 600 mg were 11.4, 15.8, and 15.7 mm Hg, respectively, vs 5.3 mm Hg for placebo.</p> <p>The antihypertensive effect of aliskiren 150 mg was comparable to irbesartan 150 mg with reductions of 8.9 and 12.5 mm Hg for mean sitting DBP and SBP, respectively. Aliskiren 300 and 600 mg produced significantly greater mean sitting DBP reductions than irbesartan 150 mg ($P<$0.05). While the reductions in mean sitting SBP were greater with aliskiren 300 and 600 mg than irbesartan 150 mg, these differences were not statistically significant).</p> <p>Secondary: The percentage of patients achieving blood pressure control was significantly greater with all doses of aliskiren (37.8%-150 mg, 50.0%-300 mg, 45.7%-600 mg) and irbesartan (33.8%) compared to placebo (20.8%; $P<$0.05). More patients on aliskiren 300 and 600 mg achieved blood pressure control compared to irbesartan ($P<$0.05).</p> <p>Drug-related adverse events for both aliskiren and irbesartan were comparable to placebo and the most commonly reported adverse events were headache, dizziness, and diarrhea. The number of patients discontinuing therapy was similar in all groups.</p>
<p>O'Brien et al.⁴² (2007)</p> <p>Aliskiren 150 mg QD for 3 weeks, then HCTZ 25 mg</p>	<p>3 OL studies</p> <p>Men and women 18 to 80 years with ambulatory SBP \geq140 and \leq180 mm</p>	<p>N=67</p> <p>6 to 9 weeks</p>	<p>Primary: Change in daytime systolic ABPM with combination therapy compared to monotherapy</p>	<p>Primary: Aliskiren coadministered with HCTZ ($P=$0.0007) or ramipril ($P=$0.03) led to significantly greater reductions in daytime systolic ABPM compared to monotherapy. There was a trend for a reduction in daytime systolic ABPM with the addition of aliskiren to irbesartan; however, this trend was not statistically significant.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD was added for an additional 3 weeks (if ABPM remained \geq135/85 mm Hg)</p> <p>vs</p> <p>irbesartan 150 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p> <p>vs</p> <p>ramipril 5 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p>	<p>Hg without treatment</p>		<p>Secondary: Change in daytime diastolic ABPM, nighttime systolic and diastolic ABPM, daytime and nighttime heart rates, plasma renin activity</p>	<p>Secondary: Aliskiren plus HCTZ significantly lowered daytime diastolic ABPM compared to aliskiren monotherapy (P=0.0006). Changes in nighttime systolic and diastolic ABPM followed similar trends but did not achieve statistical significance (P=0.06 and P=0.09, respectively). No changes in heart rate were observed with either aliskiren regimen.</p> <p>Aliskiren added to irbesartan did not significantly change diastolic ABPM compared to irbesartan monotherapy; however, nighttime systolic and diastolic ABPM were significantly reduced (P<0.05 for all). No changes in heart rate were observed with either irbesartan regimen.</p> <p>Mean diastolic ABPM was significantly decreased with the addition of aliskiren 150 mg (P<0.05) but not aliskiren 75 mg to ramipril monotherapy. Both aliskiren doses significantly decreased nighttime systolic and diastolic ABPM (P<0.05 for all). No changes in heart rate were observed with either ramipril regimen.</p> <p>Aliskiren alone significantly inhibited plasma renin activity by 65% (P<0.0001), while ramipril and irbesartan monotherapy increased renin activity by 90 and 175%, respectively. When aliskiren was coadministered with HCTZ, ramipril or irbesartan, plasma renin activity remained similar to baseline levels or decreased.</p>
<p>Strasser et al.⁴³ (2007)</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>lisinopril 20 to 40 mg QD</p>	<p>AC, DB, DD, MC, PG, RCT</p> <p>Men and women with uncomplicated severe HTN (mean sitting DBP 105 to 119 mm Hg)</p>	<p>N=183</p> <p>8 weeks</p>	<p>Primary: Safety</p> <p>Secondary: Change in mean sitting DBP and SBP, percentage of responders</p>	<p>Primary: Both active treatments were well tolerated with an incidence of adverse events of 32.8% for aliskiren and 29.3% for lisinopril. The proportion of patients discontinuing treatment due to adverse events was 3.2% for aliskiren and 3.4% for lisinopril. The most frequently reported adverse events in both groups were headache, nasopharyngitis and dizziness.</p> <p>Secondary: Aliskiren showed similar reductions from baseline to lisinopril in mean sitting DBP (-18.5 vs -20.1 mm Hg) and SBP (-20.0 and -22.3 mm Hg).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ may be added if additional blood pressure control was required.				Responder rates were 81.5% with aliskiren and 87.9% with lisinopril. Approximately half of patients required the addition of HCTZ to achieve blood pressure control (53.6% for aliskiren and 44.8% for lisinopril).
Stanton et al. ⁴⁴ (2003) Aliskiren 37.5 to 300 mg QD vs losartan 100 mg QD	AC, DB, MC, RCT Men and women 21 to 70 years of age with mild-to-moderate HTN (SBP \geq 140 mm Hg)	N=226 4 weeks	Primary: Change in daytime ambulatory SBP Secondary: Changes in clinic SBP and DBP, plasma renin activity, plasma aliskiren levels, adverse events	Primary: A dose-dependent reduction in daytime ambulatory SBP was observed with increasing aliskiren doses (with mean changes of -0.40 mm Hg with aliskiren 37.5 mg, -5.3 mm Hg with aliskiren 75 mg, -8.0 mm Hg with aliskiren 150 mg, and -11 mm Hg with aliskiren 300 mg; P=0.0002). The change in daytime SBP with losartan 100 mg (-10.9 mm Hg) was significantly different than aliskiren 37.5 mg, but not the other higher aliskiren dosages). Secondary: Clinic SBP and DBP, both in the sitting and standing positions, decreased with aliskiren in a dose-dependent manner, whereas heart rate was unaltered. The decreases in clinic blood pressures were similar for losartan 100 mg and aliskiren 150 and 300 mg. Dose-dependent reductions in plasma renin activity were also observed (median change -55, -60, -77, and -83% with 37.5, 75, 150, and 300 mg aliskiren, respectively; P=0.0008). By contrast, plasma renin activity increased by 110% with losartan 100 mg. Rate of adverse events was 22% with aliskiren 37.5 mg, 35% with aliskiren 75 mg, 25% with aliskiren 150 mg, 23% with aliskiren 300 mg, and 32% with losartan 100 mg. There was no increase in the number of adverse events when increasing the dose of aliskiren.
Uresin et al. ⁴⁵ (2007) Aliskiren 150 to 300 mg QD vs	DB, MC, RCT Patients \geq 18 years of age with type 1 or type 2 diabetes mellitus and stage 1 to 2 HTN (mean	N=837 8 weeks	Primary: Change in mean sitting DBP Secondary: Change in mean sitting SBP,	Primary: Aliskiren monotherapy, ramipril monotherapy, and aliskiren and ramipril combination therapy lowered mean sitting DBP by 11.3, 10.7, and 12.8 mm Hg, respectively. Treatment with aliskiren and ramipril combination therapy produced significantly greater reductions from baseline in mean sitting DBP compared to either aliskiren monotherapy (P=0.043) or ramipril monotherapy (P=0.004). Aliskiren 300 mg was statistically non-

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ramipril 5 to 10 mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg and ramipril 5 to 10 mg QD</p>	<p>sitting DBP >95 and <110 mm Hg)</p>		<p>proportion of patients with a successful response to treatment (trough mean sitting DBP <90 mm Hg and/or ≥10 mm Hg reduction from baseline), rates of blood pressure control (blood pressure <130/80 mm Hg), changes from baseline in 24-hour ABPM measurements, and changes in biomarkers (plasma renin concentration, plasma renin activity, aldosterone)</p>	<p>inferior (P=0.0002) to ramipril 10 mg for the change in mean sitting DBP.</p> <p>Secondary: Aliskiren monotherapy, ramipril monotherapy, and aliskiren and ramipril combination therapy lowered mean sitting SBP by 14.7, 12.0, and 16.6 mm Hg, respectively. Treatment with aliskiren and ramipril combination therapy produced significantly greater reductions from baseline in mean sitting SBP compared to ramipril monotherapy (P<0.0001), but not aliskiren monotherapy (P=0.088). Aliskiren monotherapy was statistically superior to ramipril for the change in mean sitting SBP (P=0.021).</p> <p>The proportion of patients with a successful response to therapy was similar for aliskiren and ramipril combination therapy (74.1%) and aliskiren monotherapy (73.1%). The responder rates in both groups were significantly higher (P<0.05) compared to ramipril monotherapy (65.8%).</p> <p>Rates of blood pressure control with aliskiren and ramipril combination pressure (13.1%) were not significantly different compared to aliskiren monotherapy (8.2%) or ramipril monotherapy (8.4%).</p> <p>All treatments significantly lowered mean 24-hour ambulatory blood pressure. Aliskiren and ramipril combination therapy was significantly more effective compared to ramipril monotherapy in lowering 24-hour mean ambulatory DBP (P=0.034). There was no significant difference in 24-hour ambulatory SBP compared to ramipril monotherapy.</p> <p>Aliskiren significantly reduced plasma renin activity from baseline as monotherapy (by 66%, P<0.0001) or in combination with ramipril (by 48%, P<0.0001).</p>
<p>Duprez et al.⁴⁶ (2010) AGELESS</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p>	<p>AC, DB, MC, RCT</p> <p>Patients ≥65 years of age with essential HTN (mean sitting SBP ≥140 and <180 mm Hg and mean sitting DBP</p>	<p>N=901</p> <p>36 weeks</p>	<p>Primary: Change in mean seated SBP at week 12</p> <p>Secondary: Change in mean sitting SBP at week</p>	<p>Primary: At week 12, aliskiren lowered mean sitting SBP by 14 mm Hg and ramipril decreased mean sitting SBP by 11.6 mm Hg (difference, -2.3 mm Hg; 95% CI, -4.3 to -0.3). Aliskiren monotherapy showed statistically non-inferior (P<0.001) and statistically superior (P=0.02) reductions in mean sitting SBP compared to ramipril monotherapy.</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ramipril 5 to 10 mg QD</p> <p>The addition of HCTZ was allowed at week 12 and amlodipine was allowed at week 22 in patients not achieving adequate blood pressure control.</p>	<p><110mm Hg)</p>		<p>36, change in mean sitting DBP at week 12 and week 36, percentage of patients who achieved blood pressure control (mean sitting SBP/DBP <140/90 mm Hg in non-diabetic patients and <130/80 mm Hg in diabetic patients) at week 12 and week 36, percentage of patients who required add-on therapy</p>	<p>At week 22, aliskiren decreased mean sitting SBP by 19.6 mm Hg and ramipril decreased mean sitting SBP by 17 mm Hg (difference, -2.4 mm Hg; 95% CI, -4.5 to -0.3; P=0.03).</p> <p>At week 36, aliskiren decreased mean sitting SBP by 20 mm Hg and ramipril decreased mean sitting SBP by 18.1 mm Hg (difference, -1.9 mm Hg; 95% CI, -4.0 to 0.2; P=0.07).</p> <p>At week 12, aliskiren decreased mean sitting DBP by 5.1 mm Hg and ramipril decreased mean sitting DBP by 3.6 mm Hg (difference, -1.5 mm Hg; 95% CI, -2.6 to -0.5; P<0.01).</p> <p>At week 22, aliskiren decreased mean sitting DBP by 8.2 mm Hg and ramipril decreased mean sitting DBP by 7.3 mm Hg (difference, -0.8 mm Hg; 95% CI, -2.0 to 0.3; P=0.14).</p> <p>At week 36, aliskiren decreased mean sitting DBP by 8.2 mm Hg and ramipril decreased mean sitting DBP by 7.0 mm Hg (difference, -1.2 mm Hg; 95% CI, -2.3 to -0.1; P=0.03).</p> <p>The percentage of patients achieving blood pressure control was significantly greater with aliskiren (42%) compared to ramipril (33%) at week 12 (P<0.01). At week 22, a significantly greater proportion of patients achieved blood pressure control with aliskiren (62%) compared to ramipril (50%; P<0.001). At week 36, similar blood pressure control rates were achieved with aliskiren (59%) and ramipril (51%; P=0.01).</p> <p>By week 36, a significantly greater percentage of patients receiving ramipril compared to aliskiren required additional HCTZ (56 vs 46%; P<0.01).</p> <p>By week 36, a greater percentage of patients receiving ramipril (16%) compared to aliskiren (12%) required add-on therapy with both HCTZ and amlodipine (P=0.048).</p> <p>More patients receiving aliskiren were receiving monotherapy (42%) than patients receiving ramipril (29%) at week 36.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Anderson et al.⁴⁷ (2008)</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>ramipril 5 to 10 mg QD</p> <p>The addition of HCTZ was allowed in patients not achieving adequate blood pressure control.</p> <p>The study did not specifically analyze the effects of HCTZ on either treatment regimen.</p>	<p>AC, DB, MC, PC, RCT</p> <p>Men and women ≥18 years with essential HTN (mean sitting DBP 90 to 109 mm Hg)</p>	<p>N=842</p> <p>26 weeks</p>	<p>Primary: Change in mean sitting DBP at week 26</p> <p>Secondary: Change in mean sitting SBP at week 26, change in mean sitting SBP and DBP at week 6 and 12 (comparing aliskiren and ramipril monotherapy), proportion achieving blood pressure control (<140/90 mm Hg), proportion achieving SBP control (<140 mm Hg), safety</p>	<p>Primary: Reductions in mean sitting DBP at week 26 were significantly greater with aliskiren-based therapies (-13.2 mm Hg) compared to ramipril-based therapies (-12.0 mm Hg; P=0.0250).</p> <p>Secondary: Reductions in mean sitting SBP at week 26 were significantly greater with aliskiren-based therapies (-17.9 mm Hg) compared to ramipril-based therapies (-15.2 mm Hg; P=0.0036).</p> <p>Mean changes in sitting SBP were significantly greater with aliskiren (-12.9 and -14.0 mm Hg, respectively) compared to ramipril (-10.5 and -11.3, respectively) at weeks six and 12 (P=0.0041 and P=0.0027, respectively).</p> <p>Mean changes in sitting DBP were not significantly greater with aliskiren (-10.5 and -11.3 mm Hg, respectively) compared to ramipril (-9.5 and -9.7, respectively) at week six, but were significantly greater at week 12 (P=0.0689 and P=0.0056, respectively).</p> <p>The proportion of patients achieving overall blood pressure control (<140/90 mm Hg) was significantly higher with aliskiren-based therapy (61.4%) compared to ramipril-based therapy (53.1%; P=0.0205) at week 26. Also, the proportion of patients achieving SBP control (<140 mm Hg) was significantly higher with aliskiren-based therapy (72.5%) compared to ramipril-based therapy (64.1%; P=0.0075) at week 26.</p> <p>The majority of adverse events reported during the active treatment period were mild or moderate in intensity and transient. Most events occurred at a similar incidence in the two groups with the exception of cough which was considered treatment-related in 5.5% of patients receiving ramipril vs 2.1% of patients receiving aliskiren.</p>
<p>Oparil et al.⁴⁸ (2007)</p> <p>Aliskiren 150 to 300 mg QD</p>	<p>DB, MC, PC, RCT</p> <p>Men and women aged 18 years or over with stage 1-2</p>	<p>N=1,797</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary:</p>	<p>Primary: The combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting DBP from baseline by 12.2 mm Hg, significantly more than either monotherapy with aliskiren 300 mg (-9.0 mm Hg; P<0.0001), valsartan 320 mg (-9.7 mm Hg; P<0.0001) or with placebo (-4.1 mm Hg; P<0.0001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>valsartan 160 to 320 mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg and valsartan 160 to 320 mg QD (single entity products)</p> <p>vs</p> <p>placebo</p>	<p>essential HTN (mean sitting DBP 95 to 109 mm Hg and 8-hr ambulatory DBP \geq90 mm Hg)</p>		<p>Change in mean sitting SBP, proportion of patients achieving a successful response to treatment (mean sitting DBP $<$90 mm Hg and/or \geq10 mm Hg reduction from baseline) or achieving blood pressure control (mean sitting SBP/DBP $<$140/90 mm Hg), change in 24-hr ABPM, change in biomarkers, safety</p>	<p>Monotherapy with aliskiren or valsartan provided significantly greater reductions in mean sitting DBP than did placebo at week 8 ($P<0.0001$ for all).</p> <p>Secondary: The combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitting SBP from baseline by 17.2 mm Hg, significantly more than either monotherapy with aliskiren 300 mg (-13.0 mm Hg; $P<0.0001$), valsartan 320 mg (-12.8 mm Hg; $P<0.0001$), or with placebo (-4.6 mm Hg; $P<0.0001$). Monotherapy with aliskiren or valsartan provided significantly greater reductions in mean sitting SBP than did placebo at week eight end point (all $P<0.0001$).</p> <p>The proportion of patients achieving a successful response to treatment at week eight was significantly higher with the combination of aliskiren and valsartan (66%) than with aliskiren alone (53%; $P=0.0003$) or valsartan alone (55%; $P=0.0010$). All active treatments were associated with significantly greater responder rates than placebo (30%; $P<0.0001$ for all).</p> <p>The proportion of patients achieving blood pressure control was significantly greater in the combination group (49%) than in the aliskiren (37%; $P=0.0005$) or valsartan (34%; $P<0.0001$) monotherapy groups. All active treatments were associated with significantly greater control rates than placebo (16%; $P<0.0001$ for all).</p> <p>The combination of aliskiren and valsartan was significantly more effective in lowering mean 24-hr ambulatory SBP and DBP than was either agent alone ($P<0.0001$ for all). The greater reductions in ambulatory blood pressure with aliskiren plus valsartan were maintained throughout the entire 24-hour dosing interval.</p> <p>Aliskiren and valsartan ($P<0.0001$) and monotherapy with aliskiren ($P<0.0001$) or valsartan ($P=0.0002$) provided significant increases in plasma renin concentrations versus placebo. Increases in plasma renin concentrations were significantly greater for the combination than aliskiren ($P=0.0014$) or valsartan ($P<0.0001$) monotherapy.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Valsartan monotherapy produced significantly greater increases in plasma renin activity than placebo (160 vs 18%; P=0.0003). By contrast, aliskiren alone significantly reduced plasma renin activity by 73% (P<0.0001 vs placebo), while the combination of aliskiren plus valsartan led to a reduction in plasma renin activity of 44% (P<0.0001 vs placebo).</p> <p>The combination of aliskiren and valsartan (-31%; P<0.0001) and valsartan monotherapy (-25%; P=0.0007) provided significantly greater reductions in plasma aldosterone concentration than did placebo (7%), while aliskiren monotherapy had no significant effect (-5.9%; P=0.1059).</p> <p>Rates of adverse events and laboratory abnormalities were similar in all groups.</p>
<p>Yarows et al.⁴⁹ (2008)</p> <p>Aliskiren 150 mg QD for 4 weeks, followed by 300 mg QD for 4 weeks</p> <p>vs</p> <p>valsartan 160 mg QD for 4 weeks, followed by 320 mg QD for 4 weeks</p> <p>vs</p> <p>aliskiren and valsartan 150-160 mg QD for 4 weeks, followed by 300-320 mg</p>	<p>Post-hoc analysis of patients with stage 2 HTN from Oparil et al.⁴⁸</p> <p>Men and women ≥18 years of age with stage 1 to 2 essential HTN (mean sitting DBP 95 to 109 mm Hg and 8-hour ambulatory DBP ≥90 mm Hg)</p>	<p>N=1,797</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, proportion of patients achieving a successful response to treatment (mean sitting DBP <90 mm Hg and/or ≥10 mm Hg reduction from baseline) or achieving blood pressure control (mean sitting SBP/DBP <140/90 mm Hg)</p>	<p>Primary: In patients with stage 2 HTN, significantly greater reductions in DBP were demonstrated in the aliskiren and valsartan 300-320 mg group compared to either higher-dose monotherapy group (P<0.05) and placebo (P<0.0001).</p> <p>Secondary: In patients with stage 2 HTN, significantly greater reductions in SBP were demonstrated in the aliskiren and valsartan 300-320 mg group compared to either higher-dose monotherapy group (P<0.05) and placebo (P<0.0001).</p> <p>DBP and SBP reductions in both monotherapy groups were significantly greater compared to placebo (P<0.0001).</p> <p>The proportion of patients with stage 2 HTN achieving blood pressure control at week eight was significantly greater in the aliskiren and valsartan 300-320 mg group compared to both monotherapy groups and placebo (P≤0.044).</p> <p>Blood pressure control rates in the aliskiren group were significantly greater than placebo (P<0.001). No significant difference was observed between the valsartan monotherapy and placebo groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD for 4 weeks (fixed-dose combination products)</p> <p>vs</p> <p>placebo</p>				
<p>Bakris et al.⁵⁰ (2013) ViVID</p> <p>Therapy with aliskiren/valsartan 150/160 mg titrated to 300/320 mg</p> <p>vs</p> <p>valsartan monotherapy 160 mg titrated to 320 mg</p>	<p>AC, DB, RCT</p> <p>Hypertensive adults with type 2 diabetes and stage 1 or 2 chronic kidney disease (CKD)</p>	<p>N=1143</p> <p>8 weeks</p>	<p>Primary: ABP</p> <p>Secondary: Safety</p>	<p>Primary: Both treatments produced significant reductions from baseline to week 8 in all ABPM measures (P<0.0001). The addition of aliskiren to valsartan was associated with an incremental benefit of 4.0 mm Hg of lowering in 24-hour mean ambulatory (ma)SBP and 2.4 mm Hg of lowering in 24-hour maDBP (both P<0.001).</p> <p>Secondary: Adverse events were experienced by 202 participants (35.2%) in the combination aliskiren/valsartan group and by 182 participants (32.2%) in the valsartan group.</p>
<p>Pool et al.⁵¹ (2007)</p> <p>Aliskiren 75 to 300 mg QD</p> <p>vs</p> <p>valsartan 80 to 320 mg</p> <p>vs</p>	<p>DB, MC, PC, PG, RCT</p> <p>Men and women ≥18 years with mild-to-moderate essential HTN (mean sitting DBP ≥95 mm Hg after a 3- to 4-week single-blind placebo run-in period)</p>	<p>N=1,123</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP, safety</p>	<p>Primary: Aliskiren 300 mg significantly (P<0.0001) lowered mean sitting DBP compared to placebo. Reductions in mean sitting DBP for aliskiren 75 and 150 mg compared to placebo failed to reach statistical significance (P=0.052 and P=0.051, respectively).</p> <p>Secondary: Aliskiren 300 mg significantly (P<0.0001) lowered mean sitting SBP compared to placebo.</p> <p>A statistically significant linear dose relationship was observed for the effect of aliskiren (75 to 300 mg) on mean sitting DBP (P=0.0002) and mean sitting SBP (P=0.0005). The effects of aliskiren monotherapy on</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>aliskiren 75 to 300 mg and valsartan 80 to 320 mg</p> <p>vs</p> <p>valsartan and HCTZ 160-12.5 mg QD (fixed-dose combination)</p> <p>vs</p> <p>placebo</p>				<p>mean sitting DBP and SBP across the 75 to 300 mg dose range were similar to the effects of valsartan 80 to 320 mg.</p> <p>Coadministration of aliskiren and valsartan produced a greater antihypertensive effect than either drug alone. Reductions in mean sitting DBP and SBP obtained with aliskiren 150 mg plus valsartan 160 mg and aliskiren 300 mg plus valsartan 320 mg were not significantly different from those observed with valsartan 160 mg plus HCTZ 12.5 mg. Responder rates were significantly greater than placebo for all 3 aliskiren monotherapy groups and for all aliskiren plus valsartan combinations. The proportion of responders with aliskiren 75 mg plus valsartan 80 mg was significantly greater than either component monotherapy (P<0.05). There was no significant difference between the proportion of responders to aliskiren 150 mg plus valsartan 160 mg or aliskiren 300 mg plus valsartan 320 mg compared to valsartan 160 mg plus HCTZ 12.5 mg.</p> <p>Control rates were higher with aliskiren 300 mg compared to placebo and with valsartan 160 mg plus HCTZ 12.5 mg compared to aliskiren 150 mg plus valsartan 160 mg, but there were no significant differences between aliskiren plus valsartan combinations and the respective monotherapies.</p> <p>Aliskiren and valsartan were generally well tolerated either as monotherapy or in combination. The overall incidence of adverse events and rate of discontinuations because of adverse events were similar to placebo in all active treatment groups.</p>
<p>Geiger et al.⁵² (2009)</p> <p>Aliskiren 150 to 300 mg QD, added to existing HCTZ therapy</p> <p>vs</p> <p>valsartan 160 to 320 mg QD, added</p>	<p>AC, DB, RCT</p> <p>Patients ≥18 years of age with mild to moderate essential HTN who were taking HCTZ for 4 weeks with a DBP ≥95 mm Hg</p>	<p>N=641</p> <p>8 weeks</p>	<p>Primary: Change in DBP at week 8</p> <p>Secondary: Change SBP at week 8, change in DBP and SBP at week 4, proportion of patients achieving blood pressure control</p>	<p>Primary: After eight weeks of therapy, the triple therapy showed significantly greater reductions in SBP and DBP compared to the other groups. The additional SBP and DBP reductions were 7 and 5 mm Hg, respectively compared to aliskiren and HCTZ (P<0.0001), 3 and 2 mm Hg compared to valsartan and HCTZ (P<0.01), and 15 and 10 mm Hg compared to HCTZ monotherapy (P<0.001).</p> <p>Aliskiren and HCTZ and valsartan and HCTZ combination therapies were more effective compared to HCTZ monotherapy. Valsartan and HCTZ was more effective than aliskiren and HCTZ. SBP and DBP were reduced by 15 and 11 mm Hg, respectively in the aliskiren and HCTZ group. SBP and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>to existing HCTZ therapy</p> <p>vs</p> <p>aliskiren 150 to 300 mg and valsartan 160 to 320 mg QD, added to existing HCTZ therapy</p> <p>vs</p> <p>HCTZ 25 mg QD</p>			<p>(SBP/DBP <140/90 mm Hg), change in plasma renin activity, plasma renin concentration</p>	<p>DBP were reduced by 18 and 14 mm Hg, respectively, in the valsartan and HCTZ group.</p> <p>Secondary: Blood pressure control rate was significantly higher with triple therapy compared to aliskiren and HCTZ (40.9%, P<0.001), valsartan and HCTZ (48.7%, P<0.001), and HCTZ monotherapy (20.5%, P<0.001).</p> <p>At week four, a significantly greater blood pressure control rate was observed for the triple therapy group at lower doses (150-160-25 mg) compared to the respective doses of the other groups: aliskiren and valsartan and HCTZ (300-320-25 mg) group (56%) compared to aliskiren and HCTZ (36.6%, P<0.05), valsartan and HCTZ (42.2%, P<0.05), and HCTZ monotherapy (19.9%, P<0.01).</p> <p>At week eight, plasma renin concentration was unchanged in the HCTZ group, but was significantly increased in other groups. A significant decrease in plasma renin activity from baseline was observed in the aliskiren and HCTZ group (P<0.001) and a significant increase was observed in the valsartan and HCTZ (P<0.001). In the HCTZ and triple therapy groups, there was no change in plasma renin activity (both P>0.75).</p>
<p>Dietz et al.⁵³ (2008)</p> <p>Aliskiren 150 to 300 mg QD</p> <p>vs</p> <p>atenolol 50 to 100 mg QD</p> <p>vs</p> <p>aliskiren 150 to 300 mg and atenolol 50 to 100</p>	<p>RCT, DB, MC</p> <p>Patients ≥18 years of age with HTN (mean sitting DBP ≥95 and <110 mm Hg)</p>	<p>N=694</p> <p>12 weeks</p>	<p>Primary: Changes in mean sitting SBP and mean sitting DBP, rates of blood pressure control (<140/90 mm Hg), pulse pressure and pulse rate, plasma renin concentration, plasma renin activity</p> <p>Secondary: Not reported</p>	<p>Primary: Treatment with aliskiren and atenolol combination therapy led to a significantly greater reduction in mean sitting SBP by 17.3 mm Hg compared to aliskiren monotherapy (difference, -2.9 mm Hg; P=0.039) or atenolol monotherapy (difference, -3.0 mm Hg; P=0.034). There was no difference between mean sitting SBP reductions with aliskiren and atenolol monotherapy (difference, -0.1 mm Hg; P=0.954).</p> <p>Treatment with aliskiren and atenolol combination therapy led to a significantly greater reduction in mean sitting DBP by 14.1 mm Hg compared to aliskiren monotherapy (difference, -2.9 mm Hg; P<0.001), but not atenolol monotherapy (difference, -0.5 mm Hg; P=0.545). Reductions in mean sitting DBP with atenolol were larger compared to those observed with aliskiren (difference, 2.4 mm Hg; P=0.003).</p> <p>Rates of blood pressure control were higher with aliskiren and atenolol</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD				<p>combination therapy (51.3%) compared to aliskiren monotherapy (36.1%, $P<0.001$) or atenolol monotherapy (42.2%, $P=0.009$). There was no significant difference in blood pressure control rates between aliskiren and atenolol monotherapy ($P=0.388$).</p> <p>Mean pulse pressure was reduced by 3.0 mm Hg with aliskiren and atenolol combination therapy and aliskiren monotherapy. Atenolol monotherapy did not affect pulse pressure. Aliskiren monotherapy did not affect pulse rate. Significant mean reductions in pulse rate of >10 bpm were observed with atenolol monotherapy and the aliskiren and atenolol combination ($P<0.001$ vs aliskiren monotherapy for both).</p> <p>Aliskiren monotherapy increased plasma renin concentration by 241% and aliskiren/atenolol increased plasma renin concentration by 85% ($P=0.010$ vs aliskiren). Atenolol monotherapy decreased plasma renin concentration by 24% ($P<0.001$ vs aliskiren and aliskiren/atenolol). Aliskiren, atenolol and aliskiren/atenolol reduced plasma renin activity by 65, 52, and 61%, respectively.</p> <p>Secondary: Not reported</p>
<p>Stanton et al.⁵⁴ (2010)</p> <p>Aliskiren 300 mg QD</p> <p>vs</p> <p>irbesartan, losartan, valsartan, ramipril, HCTZ, placebo</p>	<p>MA</p> <p>Adults with mild to moderate essential HTN</p>	<p>N=4,877 (8 trials)</p> <p>4 to 12 weeks</p>	<p>Primary: Paradoxical blood pressure rises, as well as the percentage of patients with SBP increases (>10 or >20 mm Hg) or DBP increases (>5 or >10 mm Hg) from baseline</p> <p>Secondary: Not reported</p>	<p>Primary: There were no significant differences among the pooled aliskiren, irbesartan, losartan, valsartan, ramipril, and HCTZ groups in the incidence of SBP increases >10 mm Hg ($P=0.30$) and >20 mm Hg ($P=0.28$) or DBP increases >5 mm Hg ($P=0.65$) and >10 mm Hg ($P=0.5$).</p> <p>Increases in SBP and DBP occurred significantly more frequently in the pooled placebo group than the aliskiren group ($P<0.001$).</p> <p>Secondary: Not reported</p>
<p>Wysong et al.⁵⁵ (2007)</p>	<p>MA</p>	<p>N=91,561</p>	<p>Primary: All-cause mortality</p>	<p>Primary: There was not a significant difference observed in all-cause mortality</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>	<p>13 RCTs evaluating patients ≥18 years of age with HTN</p>	<p>Duration varied</p>	<p>Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions</p>	<p>between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p> <p>Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07], diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>
<p>Baguet et al.⁵⁶ (2007)</p>	<p>MA</p>	<p>N=10,818</p>	<p>Primary: Weighted average</p>	<p>Primary: Data did not reflect outcomes from direct, head-to-head comparative trials</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren)</p> <p>Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>	<p>Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>8 to 12 weeks</p>	<p>reductions in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Diabetes/Diabetic Nephropathy/Renal Dysfunction				
<p>Persson et al.⁵⁷(2009)</p> <p>Aliskiren 300 mg QD</p> <p>vs</p> <p>irbesartan 300 mg QD</p> <p>vs</p> <p>aliskiren 300 mg QD and irbesartan 300 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, RCT, XO</p> <p>Adults with type 2 diabetes, HTN, and albuminuria</p>	<p>N=26</p> <p>Four 2-month treatment periods</p>	<p>Primary: Albuminuria (urinary albumin excretion rate)</p> <p>Secondary: 24-hour blood pressure, GFR</p>	<p>Primary: Treatment with aliskiren led to a significant reduction in albuminuria by 48% compared to placebo (P<0.001). Treatment with irbesartan led to a significant reduction in albuminuria by 58% compared to placebo (P<0.001). There was no significant difference in albuminuria between aliskiren and irbesartan (P value not reported). The combination of aliskiren and irbesartan significantly reduced albuminuria by 71% compared to placebo (P<0.001), which was also significantly better than with monotherapy (P<0.001 for aliskiren and P=0.028 for irbesartan).</p> <p>Secondary: SBP and DBP 24-hr blood pressure were reduced by 3 and 4 mm Hg, respectively by aliskiren (P value not significant and P=0.009, respectively), 12 and 5 mm Hg, respectively by irbesartan (P<0.001 and P=0.002, respectively), and 10 and 6 mm Hg, respectively with the combination (P=0.001 and P <0.001, respectively) compared to placebo. There was no significant change in 24-hr blood pressure with irbesartan compared to combination therapy.</p> <p>GFR was significantly reduced 4.6 mL/min/1.73 m² with aliskiren (P=0.037), 8.0 mL/min/1.73 m² with irbesartan (P<0.001), and 11.7 mL/min/1.73 m² with the combination (P<0.001) compared to placebo.</p>
<p>Parving et al.⁵⁸ (2008)</p> <p>AVOID</p> <p>Aliskiren 150 mg QD for 3 months, followed by 300 mg QD for 3 months</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Hypertensive patients who were 18 to 85 years of age who had type 2 diabetes and nephropathy</p>	<p>N=599</p> <p>6 months</p>	<p>Primary: Reduction in albumin:creatinine ratio at 6 months</p> <p>Secondary: Blood pressure reductions, adverse events</p>	<p>Primary: Treatment with aliskiren 300 mg/day as compared to placebo reduced the mean urinary albumin:creatinine ratio by 20% (95% CI, 9 to 30; P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as compared to 12.5% of those who received placebo (P<0.001).</p> <p>Secondary: A small difference in blood pressure was seen between the treatment groups by the end of the study period with SBP and DBP pressures 2 and 1 mm Hg lower, respectively, in the aliskiren group (P=0.07 and P=0.08, respectively).</p> <p>The total numbers of adverse and serious adverse events were similar in the groups.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Study medications were added to losartan 100 mg and other pre-existing antihypertensive treatments.				
Miscellaneous				
Solomon et al. ⁵⁹ (2009) ALLAY Aliskiren 300 mg QD vs losartan 100 mg QD vs aliskiren 300 mg and losartan 100 mg QD	AC, RCT Adults with HTN and increased left ventricular wall thickness	N=465 9 months	Primary: Change in left ventricular mass Secondary: Not reported	Primary: There were reductions in left ventricular mass from baseline in all treatment groups, with 4.9 g/m ² (5.4%), 4.8 g/m ² (4.7%), and 5.8 g/m ² (6.4%) reductions in the aliskiren, losartan, and combination arms, respectively (P<0.0001 for all treatment groups). The reduction in left ventricular mass in the combination group was not significantly different from that with losartan alone (P=0.52). The difference in left ventricular mass regression between the aliskiren and losartan arms was within the prespecified non-inferiority margin, suggesting that aliskiren was as effective as losartan in reducing left ventricular hypertrophy (P<0.0001 for non-inferiority). Secondary: Not reported
McMurray et al. ⁶⁰ (2008) ALOFT Aliskiren 150 mg QD vs placebo	DB, MC, PC, RCT Patients ≥18 years of age with NYHA class II to IV heart failure, current or past history of NTH, and plasma brain natriuretic peptide concentration >100 pg/mL who had	N=302 3 months	Primary: N-terminal pro-brain natriuretic peptide, brain natriuretic peptide, aldosterone, signs and symptoms of heart failure echocardiographic measures of cardiac size and ventricular function, blood	Primary: Plasma N-terminal pro- brain natriuretic peptide increased by 762 pg/mL with placebo and decreased by 244 pg/mL with aliskiren (P=0.0106). Brain natriuretic peptide decreased by a mean of 12.2 pg/mL in the placebo group and by 61.0 pg/mL in the aliskiren group (P=0.0160). Plasma aldosterone did not differ between groups. Urinary aldosterone decreased with aliskiren by 9.24 nmol/day and by 6.96 nmol/day with placebo (P=0.0150). Plasma renin activity decreased 5.71 ng·mL ⁻¹ ·h ⁻¹ with aliskiren compared

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	<p>been treated with an ACE inhibitor (or angiotensin receptor blocker) and β-blocker</p>		<p>pressure, heart rate variability, quality of life, neurohumoral and inflammatory biomarkers, and glycemic measures</p> <p>Secondary: Not reported</p>	<p>to a decrease of $0.97 \text{ ng} \cdot \text{mL}^{-1} \cdot \text{h}^{-1}$ with placebo ($P < 0.0001$).</p> <p>There was no difference between treatments for change in signs or symptoms of heart failure, echocardiographic measurements of wall thickness, chamber volumes, or LVEF.</p> <p>The mean decrease in seated systolic blood pressure was 1.7 mm Hg in the placebo group and 4.1 mm Hg in the aliskiren group ($P = 0.2257$). The mean decrease in seated diastolic blood pressure was 0.2 mm Hg in the placebo group and 2.9 mm Hg in the aliskiren group ($P = 0.0599$). The mean increase in seated heart rate was 0.2 bpm in the placebo group and 1.1 bpm in the aliskiren group ($P = 0.6774$).</p> <p>Mean standing systolic blood pressure decreased by 1.7 mm Hg in the placebo group and by 3.5 mm Hg in the aliskiren group ($P = 0.497$). The mean standing diastolic blood pressure increased by 0.7 mm Hg with placebo and decreased by 3.5 mm Hg with aliskiren ($P = 0.0045$). The mean standing heart rate decreased by 0.3 bpm in the placebo group and increased by 0.7 bpm in the aliskiren group ($P = 0.466$).</p> <p>There were no differences between treatments in any of the other prespecified comparisons, including autonomic measurements, the Kansas City Cardiomyopathy questionnaire, inflammatory and other plasma and urinary biomarkers (including urinary protein excretion), or measurements of glucose/insulin metabolism.</p> <p>Secondary: Not reported</p>

*Agent not available in the United States.

Drug regimen abbreviations: QD=once daily, SR=sustained-release

Study design abbreviations: AC=active comparator, DB=double blind, DD=double dummy, MA=meta-analysis, MC=multicenter, OL=open-label, OS=observational, PC=placebo-controlled, PG=parallel-group, PRO=prospective, RCT=randomized-controlled trial, XO=cross-over

Miscellaneous abbreviations: ABPM=ambulatory blood pressure monitoring, ACE inhibitors=angiotensin converting enzyme inhibitors, ARB=angiotensin II receptor blocker, BMI=body mass index, CAD=coronary artery disease, CHD=coronary heart disease, CI=confidence interval, DBP=diastolic blood pressure, GFR=glomerular filtration rate, HCTZ=hydrochlorothiazide, HTN=hypertension, LVEF=left ventricular ejection fraction, LSM=least squares mean, NYHA=New York Heart Association, RR=relative risk, SBP=systolic blood pressure

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of ‘\$’ signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Renin Inhibitors

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Aliskiren	tablet	Tekturna®	\$\$\$\$\$	N/A
Combination Products				
Aliskiren and amlodipine	tablet	Tekamlo®	\$\$\$\$	N/A
Aliskiren and amlodipine and HCTZ	tablet	Amturnide®	\$\$\$\$	N/A
Aliskiren and HCTZ	tablet	Tekturna HCT®	\$\$\$\$	N/A

*Generic is available in at least one dosage form or strength.

HCTZ=hydrochlorothiazide, N/A=not available

X. Conclusions

Aliskiren is the only renin inhibitor in this class and it is approved for the treatment of hypertension.⁶⁻⁹ It is available as a single entity product, as well as in combination with amlodipine, amlodipine and hydrochlorothiazide, or hydrochlorothiazide. There are no generic renin inhibitor products currently available; however, amlodipine and hydrochlorothiazide are available generically.

There are several national and international organizations that have published guidelines on the treatment of hypertension. Most of the guidelines do not address the use of the renin inhibitors, with the exception of European

Society of Hypertension and European Society of Cardiology which state that evidence is available to justify the use of aliskiren for the management of hypertension, particularly in combination with other antihypertensive agents.¹¹⁻²⁰ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹¹ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹¹⁻²⁰ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹¹⁻²⁰

Several clinical trials have demonstrated that renin inhibitors effectively lower blood pressure. The reduction in blood pressure with aliskiren monotherapy was similar to monotherapy with ACE inhibitors, angiotensin II receptor blockers, β -blockers, and dihydropyridines. In clinical trials comparing combination therapy to monotherapy, the more aggressive treatment regimen lowered blood pressure to a greater extent than the less-intensive treatment regimen.²²⁻⁶⁰ Most patients will require more than one antihypertensive medication to achieved blood pressure goals.¹¹⁻²⁰ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{13,14,17} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations. Aliskiren is not recommended for use in combination with ACE inhibitors or ARBs, largely due to the findings of the ALITUTUDE trial in which the risk of renal impairment, hypotension, and hyperkalemia increased in patients with GFR <60 mL/min and patients with diabetes.^{6-10,21} Aliskiren has been shown to have positive effects on surrogate markers of cardiovascular and renal damage in patients with type 2 diabetes and nephropathy, heart failure and left ventricular hypertrophy.⁵⁷⁻⁶⁰ However, the effects of aliskiren on hard cardiovascular and renal endpoints have not been established.

At this time, there is insufficient evidence to conclude that the renin inhibitors offer a significant clinical advantage over other alternatives in general use. Therefore, all brand renin inhibitors within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand renin inhibitor is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: a pathophysiologic approach*. 9th edition. New York (NY): McGraw-Hill; 2014.
2. Aliskiren (Tekturna) for hypertension. *Med Lett Drugs Ther*. 2007 Apr 9;49(1258):29-31.
3. Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. *Ann Pharmacother*. 2007 Mar;41:456-64.
4. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 June]. Available from: <http://online.factsandcomparisons.com>
5. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 June]. Available from: <http://www.thomsonhc.com/>.
6. Tekturna® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015 Mar.
7. Tekamlo® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015 Mar.
8. Amturnide® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015 Mar.
9. Tekturna HCT® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015 Mar.
10. FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna) [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2013 Mar 15 [cited 2015 June 12]. Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm>.
11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
12. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
15. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
16. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
17. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
18. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
19. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
20. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
21. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. *N Engl J Med* 2012; 367:2204-2213.
22. Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granantelli A, et al. An observational, prospective, open-label multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy. *High Blood Pressure Cardiovasc Prev*. 2012 Jun 1;19(2):78-83.
23. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. *J Am Coll Cardiol*. 2007 Mar 20;49(11):1157-63.
24. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. *Hypertens Res*. 2006;29(12):997-1005.

25. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. *J Hum Hypertens* 2009;23:495-502.
26. Braun-Dullaues RC, Shustov SB, Alvarez C, Rogelio GG, Zhang J, Hristoskova S, et al. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. *Int J Clin Pract*. 2012;66(9):834-842.
27. Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African American patients with stage 2 hypertension and obesity or metabolic syndrome. *J Am Soc Hypertens*. 2011 Nov-Dec;5(6):489-97.
28. Teo KK, Pfeffer M, Mancia G, et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. *Eur Heart J*. 2014 Jul;35(26):1743-51.
29. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation* 2009;119:417-25.
30. Schmieder R, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe D. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. *J Hypertens*. 2009;27:1493-1501.
31. Littlejohn T, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. *Curr Med Res Opin* 2009;25:951-959.
32. Drummond W, Munger M, Essop M, Maboudian M, Khan M, Keefe D. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. *J Clin Hypertens*. 2007;9:742-50.
33. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. *J Hypertens*. 2007 Jan;25(1):217-26.
34. Maddury SR, Pande A, Haque KM, et al. Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting. *Adv Ther*. 2013 Feb;30(2):176-89.
35. Fukutomi M, Hoshida S, Mizuno H, and Kario K. Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients. *Am J Hypertens*. 2014 Jan;27(1):14-20.
36. Jordan J, Engeli S, Boye S, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension*. 2007 May;49:1047-55.
37. Nickenig G, Simanenkova V, Lembo G, et al. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. *Blood Press Suppl* 2008;2:31-40.
38. Blumenstein M, Romaszko J, Calderón A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. *Curr Med Res Opin* 2009;25:903-910.
39. Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinical and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. *J Hypertens*. 2012;30:2047-2055.
40. Ferdinand KC, Weitzman R, Purkayastha D, Sridharan K, Jaimes EA. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension (abstract). *J Am Soc Hypertens*. 2012 May-Jun;6(3):219-27.
41. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. *Circulation*. 2005 Mar 1;111(8):1012-8.
42. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. *Hypertension*. 2007 Feb;49(2):276-84.
43. Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. *J Hum Hypertens*. 2007 Oct;21(10):780-7.
44. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. *Hypertension*. 2003 Dec;42:1137-43.
45. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. *J Renin Angiotensin Aldosterone Syst* 2007;8:190-8.
46. Duprez D, Munger M, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. *J Hum Hypertens* 2010;24:600-608.

47. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. *J Hypertens*. 2008;26(3):589-99.
48. Oparil S, Yarows S, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. *Lancet*. 2007;370:221-9.
49. Yarows S, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension; subgroup analysis of a randomized, double-blind study. *Adv Ther*. 2008;25(12):1288-302.
50. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, and Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. *J Clin Hypertens (Greenwich)*. 2013 Feb;15(2):92-100.
51. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 2007;20(1):11-20.
52. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. *J Clin Hypertens (Greenwich)* 2009;11:324-32.
53. Dietz R, Dechend R, Yu C, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. *J Renin Angiotensin Aldosterone Syst* 2008;9:163-175.
54. Stanton AV, Gradman AH, Schmieder RE, et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials. *Hypertension* 2010;55:54-60.
55. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
56. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig*. 2007;27(11):735-53.
57. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. *Diabetes Care* 2009;32:1873-9.
58. Parving HH, Persson F, Lewis JB, et al; for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *N Engl J Med*. 2008 Jun 5;358(23):2433-46.
59. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. *Circulation* 2009;119:530-7.
60. McMurray JJ, Pitt B, Latini R, et al; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. *Circ Heart Fail* 2008;1:17-24.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Loop Diuretics
AHFS Class 402808
August 19, 2015**

I. Overview

Diuretics are commonly used for the treatment of hypertension, heart failure, and various edematous conditions.^{1,2} These agents act at different sites within the nephron, which leads to the increased urinary excretion of sodium, chloride and water.² The diuretics are categorized into several different AHFS classes, including loop diuretics, potassium-sparing diuretics, thiazide diuretics, thiazide-like diuretics, vasopressin antagonists, and miscellaneous diuretics. The agents which make up these classes differ with regards to their Food and Drug Administration (FDA)-approved indications, mechanism of action, efficacy, safety profiles, tolerability, and ease of use.

The loop diuretics are approved for the treatment of edema and hypertension.³⁻¹⁰ They primarily act in the thick ascending limb of the loop of Henle to increase the urinary excretion of sodium, chloride, and water. Furosemide and ethacrynic acid also inhibit the absorption of sodium and chloride in the proximal and distal tubules. Bumetanide may also have an additional action in the proximal tubule. The loop diuretics are considered to be the most potent diuretics.³⁻¹² When given at their maximum dosages, they can lead to the excretion of up to 20% to 25% of the filtered sodium. As renal function declines (glomerular filtration rate <30 mL/minute), a loop diuretic should be considered rather than a thiazide diuretic. Loop diuretics do not possess the added property of arterial vasodilation, as seen with the thiazide diuretics.^{1,2} Some studies have suggested that hydrochlorothiazide (a thiazide diuretic) is more effective in lowering blood pressure than the loop diuretics.¹³

The loop diuretics that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. Bumetanide, furosemide, and torsemide are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Loop Diuretics Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Bumetanide	injection, tablet	N/A	bumetanide
Ethacrynate sodium	injection [^]	Sodium Edecrin [®]	none
Ethacrynic acid	tablet	Edecrin [®]	none
Furosemide	injection, solution, tablet	Lasix ^{®*}	furosemide
Torsemide	injection, tablet	Demadex ^{®*}	torsemide

*Generic is available in at least one dosage form or strength.

[^]Product is primarily administered in an institution.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the loop diuretics are summarized in Table 2.

Table 2. Treatment Guidelines Using the Loop Diuretics

Clinical Guideline	Recommendation(s)
American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013) ¹⁴	<p>Treatment of Stage A heart failure (HF)</p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C)

Clinical Guideline	Recommendation(s)
	<p>Treatment of Stage B heart failure</p> <ul style="list-style-type: none"> • In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) • In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p>Pharmacological treatment for Stage C HFrEF</p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p>Pharmacological treatment for Stage C HFpEF</p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B)

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p><u>Treatment of Stage D (advanced/refractory) HF</u></p> <ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)¹⁵</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-

Clinical Guideline	Recommendation(s)
	<p>African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy.</p> <ul style="list-style-type: none"> • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided.

Clinical Guideline	Recommendation(s)
	<p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p>

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid

Clinical Guideline	Recommendation(s)
	<p>management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used.</p> <ul style="list-style-type: none"> • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to

Clinical Guideline	Recommendation(s)
(2012) ¹⁶	<p>reduce the risk of heart failure hospitalization and the risk of premature death.</p> <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ◦ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ◦ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ◦ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. • Step 3: <ul style="list-style-type: none"> ◦ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ◦ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ◦ Felodipine should be considered when hypertension persists despite

Clinical Guideline	Recommendation(s)
	<p>treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic.</p> <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> ○ A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹⁷</p>	<ul style="list-style-type: none"> ● Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. ● In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. ● In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. ● For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. ● Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. ● Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. ● For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. ● The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. ● If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. ● If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. ● An ACE inhibitor and ARB should not be used together. ● Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. ● If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹⁸</p>	<ul style="list-style-type: none"> ● When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. ● Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).

Clinical Guideline	Recommendation(s)
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁹, Reappraisal of Guidelines on Hypertension Management (2009)²⁰</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in

Clinical Guideline	Recommendation(s)
	<p>favor of initiating treatment with high normal blood pressure.</p> <ul style="list-style-type: none"> • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)²¹</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP \geq160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients <80 years old antihypertensive treatment may be considered at SBP values \geq140 mmHg with a target SBP <140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP \geq160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they

Clinical Guideline	Recommendation(s)
	<p>are in good physical and mental conditions.</p> <ul style="list-style-type: none"> • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as

Clinical Guideline	Recommendation(s)
	<p>additional drugs, preferably in association with a potassium-sparing agent.</p> <ul style="list-style-type: none"> • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal < 140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and

Clinical Guideline	Recommendation(s)
	<p>mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation.</p> <ul style="list-style-type: none"> • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. <ul style="list-style-type: none"> ○ Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)²²</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic

Clinical Guideline	Recommendation(s)
	<p>should be utilized.</p> <ul style="list-style-type: none"> • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. • If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)²³</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)²⁴</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-MI with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-MI (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high CAD risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)²⁵</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion > 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion > 300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office

Clinical Guideline	Recommendation(s)
	<p>blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion.</p> <ul style="list-style-type: none"> In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²⁶</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be

Clinical Guideline	Recommendation(s)
	<p>substituted.</p> <ul style="list-style-type: none"> Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American Association for the Study of Liver Diseases: Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012 (2012)²⁷ [Reaffirmed Oct 2014]</p>	<p><u>Treatment of ascites</u></p> <ul style="list-style-type: none"> First line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2,000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide). Fluid restriction is not necessary unless serum sodium is <125 mmol/L. Vasopressin antagonists may improve serum sodium in patients with cirrhosis and ascites. However their use does not currently appear justified in view of their expense, potential risks, and lack of evidence of efficacy in clinically meaningful outcomes. An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated. Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracentesis. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with cirrhosis and ascites may be harmful and must be carefully considered in each patient, monitoring blood pressure and renal function. The use of nonsteroidal anti-inflammatory drugs should be avoided in patients with cirrhosis and ascites, except in special circumstances. Liver transplantation should be considered in patients with cirrhosis and ascites.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the loop diuretics are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Loop Diuretics³⁻¹⁰

Indication	Bumetanide	Ethacrynic Acid	Furosemide	Torsemide
Edema				
Adjunctive therapy in acute pulmonary edema			✓* (injection)	
Treatment of edema associated with congestive heart failure, hepatic disease, and renal disease	✓ †	✓ ‡	✓ §	✓
Rapid onset of diuresis is desired (e.g., in acute pulmonary edema) or when gastrointestinal absorption is impaired or oral medication is not practical				✓ (injection)
Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema		✓		
Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or nephrotic syndrome		✓		
Hypertension				
Treatment of hypertension			✓ ¶	✓

*The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired.

†If impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route.

‡Treatment of edema when an agent with greater diuretic potential than those commonly employed is required.

§If impaired gastrointestinal absorption is suspected or oral administration is not practical, furosemide should be given by the intramuscular or intravenous route.

|| Alone or in combination with other antihypertensive agents.

¶If impaired gastrointestinal absorption is suspected or oral administration is not practical, furosemide should be given by the intramuscular or intravenous route.

IV. Pharmacokinetics

The pharmacokinetic parameters of the loop diuretics are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Loop Diuretics¹²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Bumetanide	80 to 95	90 to 99	Liver, partial (% not reported)	Bile (2) Feces (10 to 20) Renal (50 to 81)	1 to 1.5
Ethacrynic acid	100	90	Liver (% not reported)	Renal (66)	1 to 4
Furosemide	47 to 70	91 to 99	Liver (10)	Feces (7 to 9) Renal (60 to 90)	0.5 to 2
Torsemide	80 to 90	99	Liver (80)	Renal (69)	3 to 6

V. Drug Interactions

Significant drug interactions with the loop diuretics are listed in Table 5.

Table 5. Significant Drug Interactions with the Loop Diuretics¹¹

Generic Name(s)	Significance Level	Interaction	Mechanism
Loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide)	1	Cisapride	Possible additive prolongation of the QT interval due to electrolyte loss increases the risk of life-threatening cardiac arrhythmias, including torsades de pointes.
Loop diuretics (bumetanide, ethacrynic acid, furosemide)	1	Digitalis Glycosides	Diuretic-induced electrolyte disturbances may predispose patients to digitalis-induced arrhythmias.
Loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide)	1	Aminoglycosides	Auditory toxicity may be increased by possible synergistic activity. The mechanism is unknown.
Loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide)	2	Cisplatin	The combination of loop diuretics and cisplatin may cause additive ototoxicity through an unknown mechanism.
Loop diuretics (furosemide)	2	Cholestyramine, colestipol	Cholestyramine and colestipol (anion exchange resins) bind to furosemide, decreasing absorption and pharmacologic effects of furosemide.
Loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide)	2	Lithium	Increased plasma lithium concentrations increase risk of toxicity. The mechanism is unknown.
Loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide)	2	Thiazide diuretics	The two classes of agents exhibit their diuretic action at different sites in the renal tubules and have synergistic effects that may result in profound diuresis and serious electrolyte abnormalities.

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the loop diuretics are listed in Table 6. The boxed warning for the loop diuretics is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Loop Diuretics³⁻¹²

Adverse Events	Bumetanide	Ethacrynic Acid	Furosemide	Torsemide
Cardiovascular				
Atrial Fibrillation	-	-	-	✓
Chest pain	<1	-	-	1
Edema	-	-	-	1
Electrocardiogram changes	<1	-	-	2
Hypotension	<1	-	✓	✓

Adverse Events	Bumetanide	Ethacrynic Acid	Furosemide	Torsemide
Hypovolemia	-	✓	-	✓
Myalgia	-	-	-	2
Orthostatic hypotension	<1	-	✓	✓
Shunt thrombosis	-	-	-	✓
Syncope	-	-	-	✓
Ventricular tachycardia	-	-	-	✓
Central Nervous System				
Apprehension	-	✓	-	-
Asterixis	<1	-	-	-
Asthenia	-	-	✓	2
Confusion	-	✓	-	-
Dizziness	1	-	✓	3
Fatigue	<1	✓	-	✓
Headache	<1	✓	✓	7
Insomnia	-	-	-	1
Nervousness	-	-	-	1
Paresthesia	-	-	✓	-
Restlessness	-	-	✓	-
Vertigo	<1	✓	✓	-
Xanthopsia	-	-	✓	-
Dermatologic				
Erythema multiforme	-	-	✓	-
Exfoliative dermatitis	-	-	✓	-
Hives	<1	-	-	-
Itching	<1	-	-	-
Pruritus	<1	-	✓	✓
Rash	<1	✓	✓	✓
Photosensitivity	-	-	✓	-
Purpura	-	-	✓	-
Scaling eczema	-	-	✓	-
Stevens-Johnson Syndrome	-	-	✓	-
Urticaria	-	-	✓	-
Endocrine and Metabolic				
Acute gout	-	✓	-	✓
Dehydration	<1	-	-	-
Electrolyte imbalance	-	-	✓	✓
Nipple tenderness	<1	-	-	-
Gastrointestinal				
Abdominal discomfort/pain	<1	✓	-	-
Anorexia	-	✓	✓	-
Constipation	-	-	✓	2
Diarrhea	<1	✓	✓	2
Dry mouth	<1	-	-	-
Dyspepsia	<1	-	✓	2
Dysphagia	-	✓	-	✓
Gastrointestinal bleed	-	✓	-	✓
Loss of appetite	-	-	✓	-
Malaise	-	✓	-	-
Nausea	<1	✓	✓	2
Pancreatitis	-	✓	✓	-
Polydipsia	-	-	-	✓
Vomiting	<1	✓	✓	✓
Genitourinary				

Adverse Events	Bumetanide	Ethacrynic Acid	Furosemide	Torsemide
Difficulty maintaining an erection	<1	-	-	-
Premature ejaculation	<1	-	-	-
Hematologic				
Agranulocytosis	-	✓	✓	-
Anemia	-	-	✓	-
Aplastic anemia	-	-	✓	-
Deviations in differential counts	<1	-	-	-
Deviations in hematocrit	<1	-	-	-
Deviations in hemoglobin	<1	-	-	-
Deviations in prothrombin time	<1	-	-	-
Deviations in white blood cell count	<1	-	-	-
Hemolytic anemia	-	-	✓	-
Henoch-Schönlein purpura	-	✓	-	-
Leukopenia	-	-	✓	-
Neutropenia	-	✓	-	-
Thrombocytopenia	<1	✓	✓	-
Hepatic				
Abnormal liver enzymes	✓	✓	-	-
Encephalopathy	<1	-	-	-
Jaundice	-	✓	✓	-
Laboratory Test Abnormalities				
Azotemia	11	-	-	-
Changes in alkaline phosphatase	<1	-	-	-
Changes in cholesterol	<1	-	-	-
Changes in serum proteins	<1	-	-	-
Changes in total serum bilirubin	<1	-	-	-
Hyperlipidemia	✓	✓	✓	✓
Hyperglycemia	7	✓	✓	✓
Hyperuricemia	18	✓	✓	✓
Hypernatremia	<1	-	-	-
Hypocalcemia	✓	✓	✓	✓
Hypochloremia	15	-	-	-
Hypoglycemia	-	✓	-	-
Hypokalemia	15	✓	✓	✓
Hypomagnesemia	✓	✓	✓	✓
Hyponatremia	9	-	-	-
Serum creatinine increased	7	-	-	-
Variations in bicarbonate	3	-	-	-
Variations in calcium	2	-	-	-
Variation in CO ₂ content	4	-	-	-
Variations in phosphorus	5	-	-	-
Musculoskeletal				
Arthralgia	-	-	-	2
Arthritic pain	<1	-	-	✓
Muscle cramps	1	-	✓	✓
Musculoskeletal pain	<1	-	-	-
Spasticity	-	-	✓	-
Renal				
Changes in creatinine clearance	<1	-	-	-
Glycosuria	<1	-	✓	-
Hematuria	-	✓	-	-
Interstitial nephritis	-	-	✓	-
Polyuria	-	-	-	7

Adverse Events	Bumetanide	Ethacrynic Acid	Furosemide	Torsemide
Proteinuria	<1	-	-	-
Renal Failure	<1	-	-	-
Respiratory				
Cough	-	-	-	2
Hyperventilation	<1	-	-	-
Rhinitis	-	-	-	3
Special Senses				
Blurred vision	-	✓	✓	-
Deafness	-	✓	-	-
Ear discomfort	<1	-	-	-
Fullness of ears	-	✓	-	-
Impaired hearing	<1	✓	✓	-
Ototoxicity	✓	✓	✓	✓
Tinnitus	-	✓	✓	-
Other				
Angioedema	-	-	-	✓
Chills	-	✓	-	-
Fever	-	✓	✓	-
Necrotizing angitis	-	-	✓	-
Systemic vasculitis	-	-	✓	-
Sore Throat	-	-	-	2
Sweating	<1	-	-	-
Thrombophlebitis	-	-	✓	-
Weakness	<1	-	✓	✓

✓ Percent not specified
- Event not reported

Table 7. Boxed Warning for the Loop Diuretics (excluding torsemide)¹¹

WARNING
Loop diuretics are potent diuretics which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dosage schedule have to be adjusted to the individual patient's needs.

VII. Dosing and Administration

The usual dosing regimens for the loop diuretics are listed in Table 8.

Table 8. Usual Dosing Regimens for the Loop Diuretics³⁻¹²

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Bumetanide	<u>Edema:</u> Injection: 0.5 to 1 mg over one minute; maximum, 10 mg/day Tablet: 0.5 to 2 mg/day; maximum, 10 mg/day	Safety and efficacy in children have not been established.	Injection: 0.25 mg/mL Tablet: 0.5 mg 1 mg 2 mg
Ethacrynic acid	<u>Edema:</u> Tablet: 50 to 200 mg/day	<u>Edema:</u> Tablet: initial, 25 mg/kg; maximum, 3 mg/kg/day	Tablet: 25 mg
Furosemide	<u>Edema:</u> Injection (acute pulmonary edema): 40 mg intravenously over 1 to 2 minutes; maintenance, may increase	<u>Edema:</u> Injection: initial, 1 mg/kg; maintenance, may increase by 1 mg/kg not sooner than	Injection: 10 mg/mL Solution:

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>to 80 mg intravenously</p> <p>Injection: 20 to 40 mg as a single intravenous or intramuscular injection; maintenance, may repeat in two hours or increased by 20 mg until desired response</p> <p>Oral: 20 to 80 mg/days; maximum, 600 mg/day</p> <p><u>Hypertension:</u> Injection, solution, tablet: 80 mg/day</p>	<p>two hours after the previous dose; maximum, 6 mg/kg per dose</p> <p>Solution, tablet: 2 mg/kg as a single dose; maximum, 6 mg/kg per dose</p>	<p>10 mg/ mL 40 mg/5 mL</p> <p>Tablet: 20 mg 40 mg 80 mg</p>
Toremide	<p><u>Edema:</u> Injection, tablet (chronic renal failure): initial, 20 mg once daily; maintenance, 200 mg/day</p> <p>Injection, tablet (congestive heart failure): initial, 10 to 20 mg once daily; maximum, 200 mg/day</p> <p>Injection, tablet (hepatic cirrhosis): initial, 5 to 10 mg once daily; maximum, 40 mg/day</p> <p><u>Hypertension:</u> Injection, tablet: initial, 5 to 10 mg/day; maximum, 10 mg/day</p>	Safety and efficacy in children have not been established.	<p>Injection: 10 mg/mL</p> <p>Tablet: 5 mg 10 mg 20 mg 100 mg</p>

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the loop diuretics are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Loop Diuretics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Cirrhosis				
Laffi et al. ²⁸ (1991) Furosemide 25 mg/day vs torasemide* 10 mg/day	DB, RCT Nonazotemic cirrhotic patients with ascites	N=24 3 days	Primary: Percent increase in natriuresis, body weight loss, percent increase in diuresis, plasma aldosterone concentration, plasma renin activity Secondary: Not reported	Primary: Treatment with torasemide led to significantly greater natriuresis than furosemide (P<0.02). There was a greater percentage increase in basal values (day 1: 130 vs 50%; day 2: 104 vs 42%; and day 3: 65 vs 26%, respectively). Body weight loss was significantly higher with torasemide (2.5 kg) than with furosemide (1.3 kg; P<0.02). There was no significant difference (P=0.08) in the percent increase in diuresis among the treatment groups (day 1: 60 vs 26%; day 2: 35 vs 27%; day 3: 31 vs 24%). Plasma aldosterone concentrations (ng/mL) with torasemide were 0.79 and 0.94 at baseline and day three, respectively. Plasma aldosterone concentrations with furosemide were 0.54 and 0.52 at baseline and day three, respectively. Plasma renin activity (ng/mL/hr) with torasemide were 5.8 and 9.4 at baseline and day three, respectively. Plasma renin activity with furosemide were 4.2 and 5.4 at baseline and day three, respectively. Secondary: Not reported
Gerbes et al. ²⁹ (1993) Furosemide 80 mg as a single dose vs	DB, RCT, XO Patients with cirrhosis and ascites	N=28 24 hours	Primary: Urine volume, urine sodium volume, urine potassium volume, plasma aldosterone concentration,	Primary: Treatment with torasemide led to greater cumulative 24 hour diuresis than furosemide (2,863 vs 2,111; P<0.05). There was no difference in cumulative 0 to 6 hour sodium excretion with torasemide or furosemide (95.7 vs 92.1 mmol, respectively; P value not significant). There was greater cumulative 6 to 24 hour sodium excretion

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>torasemide* 20 mg as a single dose</p>			<p>plasma renin activity</p> <p>Secondary: Not reported</p>	<p>with torasemide compared to furosemide (38.4 vs 16.6 mmol; P<0.05). There was no difference in cumulative 0 to 24 hour sodium excretion with torasemide or furosemide (134.0 vs 108.5 mmol, respectively; P value not significant).</p> <p>There was no difference in cumulative 0 to 6 hour potassium excretion with torasemide or furosemide (57.5 vs 39.9 mmol, respectively; P value not significant). There was greater cumulative 6 to 24 hour potassium excretion with torasemide compared to furosemide (36.0 vs 27.6 mmol; P<0.05). There was no difference in cumulative 0 to 24 hour potassium excretion with torasemide or furosemide (88.3 vs 68.0 mmol, respectively; P value not significant).</p> <p>Plasma aldosterone concentrations (ng/100 mL) with torasemide were 111.9 and 132 at baseline and 24 hours, respectively. Plasma aldosterone concentrations with furosemide were 105.7 and 131 at baseline and 24 hours, respectively.</p> <p>Plasma renin activity (ng/mL/hr) with torasemide were 29.9 and 30.6 at baseline and 24 hours, respectively. Plasma renin activity with furosemide were 34.7 and 36.8 at baseline and 24 hours, respectively.</p> <p>Secondary: Not reported</p>
<p>Fiaccadori et al.³⁰ (1993)</p> <p>Furosemide 50 mg/day</p> <p>vs</p> <p>torasemide* 20 mg/day</p> <p>Patients also received</p>	<p>DB, RCT</p> <p>Nonazotemic cirrhotic patients with controlled ascites</p>	<p>N=28</p> <p>10 weeks</p>	<p>Primary: Excretion of phosphate, free water, sodium, potassium, calcium, and uric acid</p> <p>Secondary: Not reported</p>	<p>Primary: Furosemide produced more excretion of phosphates (P<0.001) and magnesium (P<0.05) compared to torasemide.</p> <p>Torasemide produced more excretion of free water (P<0.02).</p> <p>There was no difference in the excretion of sodium, potassium, calcium, or uric acid among the treatment groups.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
spironolactone 200 mg/day				
Abecasis et al. ³¹ (2001) Frusemide† 40 mg/day vs torsemide 20 mg/day Patients also received spironolactone 200 mg/day	OL, RCT Cirrhotic patients with ascites	N=46 11 to 12 days	Primary: Resolution of ascites, weight loss, diuretic dosage, diuretic response Secondary: Not reported	Primary: There was no difference in the percentages of patients with resolution of ascites with torsemide compared to frusemide (73 vs 75%; P value not significant). There was no difference in weight loss with torsemide compared to frusemide (8 vs 8.5 kg; P value not significant). More patients receiving frusemide required an increase in diuretic dosage (37.5%) than with torsemide (9%; P<0.05). Torsemide produced a greater diuretic response in 24 hours than frusemide (P<0.007).
Heart Failure/Edema				
Galløe et al. ³² (2006) Bumetanide 0.5 mg (0, 1, 2 or 4 tablets BID) plus trandolapril 0.5 mg (0, 1, 2 or 4 tablets QD) Treatment was combined to achieve 16 different dosage combinations.	DB, DD, RCT, multiple XO Patients with previous MI ≥3 years ago, had medical treatment for heart failure and ejection fraction between 0.36 and 0.54 estimated by echocardiography	N=16 14 days	Primary: Patient reported quality of life Secondary: Effects on kidney function, left ventricular function and blood pressure	Primary: Bumetanide 0.5 mg-treated patients experienced a 12% increase in well-being, but higher doses of bumetanide decreased patient's well-being by 12% compared to placebo (P<0.002). Increasing doses of bumetanide tended to increase tiredness (P=0.072). There were no significant effects of bumetanide therapy on the patients' opinion of their health, degree of dyspnea, appetite or work capacity. Secondary: Bumetanide therapy increased 24 hour urine production in a straight dose-dependent manner (P<0.0001), while trandolapril therapy had no effect (P=0.53). Bumetanide and trandolapril therapy did not alter the 24 hour creatinine excretion and creatinine clearance (P=0.33, P=0.11 and P=0.53, P=0.97, respectively). Bumetanide therapy decreased left ventricular function and increased heart rate in a dose-dependent manner (P<0.001). Left ventricular function was also nonsignificantly decreased with trandolapril therapy (P>0.062).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Trandolapril therapy significantly reduced SBP by maximally of 7.6 mm Hg (5.8%) with the lowest dose of 0.5 mg/day (P=0.007). Bumetanide therapy had no significant effect on DBP (P=0.23).
Hutcheon et al. ³³ (1981) Bumetanide 1 to 2 mg/day vs furosemide 80 mg/day	DB, PG Patients with severe edema associated with CHF	N=20 3 days	Primary: Edema, symptoms of heart failure, safety and tolerability Secondary: Not reported	Primary: Each agent was effective in decreasing the edema and relieving the symptoms of heart failure. Side effects were not severe and were similar in both treatment groups. Muscle cramps and abdominal pain were deemed not severe. Electrolyte shifts indicative of hypochloremic alkalosis and hyponatremia were seen in two patients in the bumetanide group. Secondary: Not reported
Konecke et al. ³⁴ (1981) Bumetanide vs furosemide No dose or frequency reported.	OL, PG, RCT Men and women with clinically detectable edema and signs and symptoms of CHF (e.g., rales, gallop rhythm, orthopnea, dyspnea, engorged neck veins, paroxysmal nocturnal dyspnea, congested liver, etc.)	N=42 6 months	Primary: Changes in weight, blood pressure, pulse, signs and symptoms of CHF, electrolytes and functional capacity, safety and tolerability Secondary: Not reported	Primary: There were no statistical differences in changes in body weight, blood pressure, edema, abdominal girth, and hepatomegaly and other signs and symptoms of CHF in patients receiving bumetanide vs furosemide. There were variable minor changes in serum sodium, potassium, chloride, and uric acid in both groups throughout the treatment. Changes remained within normal limits and reached significance for chloride at weeks eight and 16 in the bumetanide group. Functional capacity improved slightly or remained unchanged throughout treatment in both treatment groups. There were no major side effects that were medication related in both treatment groups. Secondary: Not reported
Nicholson et al. ³⁵ (1977) Bumetanide 1 mg/day alternating	RCT, XO Patients with cirrhosis and fluid overload	N=10 6 months	Primary: Ascites and edema Secondary: Adverse events	Primary: Bumetanide and frusemide were both effective in controlling ascites and edema, with nine out of 10 patients showing a satisfactory response. Secondary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>with 3 mg/day for 3 months</p> <p>vs</p> <p>frusemide† 40 mg/day alternating with 160 mg/day for 3 months</p>				<p>Side effects were reported in six patients. The most common side effects were urinary frequency and nocturia, which occurred in four patients taking bumetanide and 1 patient taking frusemide. There was one patient on bumetanide and one patient on frusemide who developed symptoms of postural hypotension.</p>
<p>Eshaghian et al.³⁶ (2006)</p> <p>Furosemide 0 to 40 mg/day (group 1)</p> <p>vs</p> <p>furosemide 41 to 80 mg/day (group 2)</p> <p>vs</p> <p>furosemide 81 to 160 mg/day (group 3)</p> <p>vs</p> <p>furosemide >160 mg/day (group 4)</p>	<p>Cohort</p> <p>Men and women with advanced systolic heart failure referred to a single university medical center for heart failure management and/or transplant evaluation from 1985 to 2004</p>	<p>N=1,354</p> <p>2 years</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Composite endpoint of death or urgent transplant</p>	<p>Primary: There were 269 deaths during the two year follow-up, with 182 deaths by year one and 87 deaths during year two. Of the 269 deaths, 91 deaths were due to progressive heart failure, 72 deaths were sudden, eight deaths were secondary to myocardial infarction and 101 were unknown.</p> <p>Survival estimates at one year were 91, 88, 80, and 69% for groups 1, 2, 3, and 4, respectively (P<0.0001). Survival estimates at two years were 83, 81, 68, and 53%, respectively (P<0.0001).</p> <p>Secondary: There were a total of 431 patients who received heart transplants by the end of the two year follow up: 223 urgent and 208 elective.</p> <p>The HRs for death from any cause, death and urgent transplantation, death from progressive heart failure, and sudden death for group 4 compared with group 1 were similar.</p> <p>On univariate analysis, compared with group 1, increasing loop diuretic dose were associated with a progressive increase in mortality (group 2: HR, 1.2; 95% CI, 0.8 to 1.7, group 3: HR, 2.1; 95% CI, 1.5 to 2.9, and group 4: HR, 3.4; 95% CI, 2.4 to 4.7).</p>
<p>Murray et al.³⁷ (2001)</p> <p>Furosemide</p> <p>vs</p>	<p>OL, RCT</p> <p>Patients with CHF</p>	<p>N=234</p> <p>12 months</p>	<p>Primary: Readmission to the hospital for heart failure</p> <p>Secondary:</p>	<p>Primary: Patients receiving torsemide were less likely to need readmission for heart failure (32%) compared to furosemide (17%; P<0.01).</p> <p>Secondary: Patients receiving torsemide were less likely to need readmission for all</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
torseamide			Readmission for all cardiovascular causes and for all causes, numbers of hospital days, health-related quality of life	cardiovascular causes (59%) compared to furosemide (44%; P=0.03). There was no difference in the rate of admissions for all causes among the treatment groups (76 vs 71%; P=0.36). Patients treated with torseamide had significantly fewer hospital days for heart failure (106 vs 296 days; P=0.02). Improvements in fatigue scores from baseline were significantly greater among patients treated with torseamide compared to furosemide at months 2, 8, and 12 (P<0.05).
Cosin et al. ³⁸ (2002) Furosemide 40 mg/day orally or other diuretics vs torasemide* 10 mg/day orally	OL Patients with NYHA functional class II to III heart failure	N=1,377 12 months	Primary: Mortality, morbidity, functional class and serum potassium levels (<3.5 or >5 mEq/L) Secondary: Not reported	Primary: Total mortality was significantly lower in the torasemide group (2.2%) compared to the furosemide/other diuretics group (4.5%; P<0.05). Cardiac mortality was lower in patients receiving torasemide (1.4%) than in those receiving furosemide/other diuretics (3.5%; P<0.05). NYHA improvement in at least 1 class occurred in more patients who received torasemide (45.8%) than those who received furosemide/other diuretics (37.2%; P=0.00017). Abnormal potassium levels were observed in fewer torasemide patients (12.9%) than furosemide/other diuretics patients (17.9%; P=0.013).
Muller et al. ³⁹ (2003) Furosemide vs torasemide*	R, OL Patients with NYHA functional class II-IV congestive heart failure	N=237 9 months	Primary: Clinical improvement in heart failure, quality of life, hospitalizations, safety and tolerability Secondary: Not reported	Primary: Clinical improvement in chronic heart failure was seen in both groups, but the trend to improve by at least one NYHA class was significant with torasemide (P=0.014) compared to furosemide-treated patients. There were no differences in adverse reactions and hospitalizations due to CHF. Secondary: Not reported
Kasama et al. ⁴⁰ (2006)	RCT	N=40	Primary: Effect on cardiac	Primary: In the furosemide group at the end of treatment, mean heart to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Furosemide 20 to 40 mg/day</p> <p>vs</p> <p>torasemide* 4 to 8 mg/day</p>	<p>Patients with non-ischemic CHF (LVEF <45%) also being treated with an ACE inhibitor</p>	<p>6 months</p>	<p>sympathetic nerve activity (delayed heart to mediastinum count ratio, delayed total defect score, washout rate)</p> <p>Secondary: Effect on left ventricular remodeling (left ventricular end diastolic volume, left ventricular end systolic volume)</p>	<p>mediastinum count ratio increased from 1.68±0.18 to 1.71±0.19 (P value not significant), mean total defect score decreased from 42±11 to 40±12 (P value not significant), and mean washout rate decreased from 50±8% to 47±12% (P value not significant).</p> <p>In the torasemide group at the end of treatment, mean heart to mediastinum count ratio increased from 1.61±0.19 to 1.77±0.24 (P<0.001), mean total defect score decreased from 44±8 to 36±8 (P<0.001), and mean washout rate decreased from 52±12 to 41±14% (P=0.001).</p> <p>Secondary: In the furosemide group left ventricular end diastolic volume decreased from 174±24 to 165±34 mL (P value not significant), left ventricular end systolic volume decreased from 120±15 to 109±33 mL (P value not significant), and LVEF increased from 31±7 to 32±7% (P value not significant).</p> <p>In the torasemide group left ventricular end diastolic volume decreased from 173±22 to 147±30 mL (P<0.01), left ventricular end systolic volume decreased from 117±19 to 95±25 mL (P<0.001), and LVE increased from 31±7 to 34±7% (P value not significant).</p>
<p>Levy et al.⁴¹ (1977)</p> <p>Furosemide 25 mg daily for 24 weeks</p> <p>vs</p> <p>spironolactone and HCTZ 25-25 mg/day (fixed-dose combination product) for 16 weeks following 8</p>	<p>DB, RCT</p> <p>Patients 27 to 79 years of age with arteriosclerotic heart disease, hypertensive heart disease, or rheumatic heart disease classes 1 to 3, and congestive heart failure requiring diuretic therapy</p>	<p>N=32</p> <p>24 weeks</p>	<p>Primary: Change in heart failure symptoms, glucose, renin concentration, calcium, blood urea nitrogen, uric acid, creatinine, aldosterone, serum potassium level, adverse effects</p> <p>Secondary: Not reported</p>	<p>Primary: The combination therapy group and furosemide monotherapy group exhibited comparable control of heart failure symptoms.</p> <p>The combination therapy group was associated with a significant decrease in glucose and an increase in plasma renin concentration compared to furosemide monotherapy group (P<0.01).</p> <p>There were no significant differences in calcium, blood urea nitrogen, uric acid, or creatinine between the study groups.</p> <p>There was a significant increase in aldosterone secretion among patients randomized to the spironolactone and HCTZ group compared to the furosemide group (P<0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
weeks of furosemide monotherapy				<p>There was no significant difference in serum potassium level between treatment groups.</p> <p>No serious adverse effects were observed in either of the study groups.</p> <p>Secondary: Not reported</p>
<p>Austin et al.⁴² (1976)</p> <p>Furosemide 40 to 60 mg infused through a pulmonary artery catheter</p> <p>vs</p> <p>ethacrynic acid 25 to 50 mg infused through a pulmonary artery catheter</p>	<p>OS</p> <p>Men and women who underwent diagnostic right and transeptal left heart catheterization with chronic postcapillary pulmonary HTN with heart failure NYHA class II to IV</p>	<p>N=27</p> <p>1 hour</p>	<p>Primary: Hemodynamic response (in the control state and at 20, 40, and 60 minutes after diuretic administration) including cardiac index, pulmonary artery, left atrial and systemic artery mean pressures, plasma volume, PBV and PEV</p> <p>Secondary: Not reported</p>	<p>Primary: The hemodynamic response with each medication was similar. When compared to control state, the reductions in pulmonary artery mean pressure at 20, 40, and 60 minutes after diuretic infusion with either ethacrynic acid or furosemide were significant (P<0.001).</p> <p>The average left atrial mean pressure also decreased from 22 mm Hg during the control period to 18 mm Hg at 20 minutes and to 15 mm Hg at 60 minutes post diuretic infusion (ethacrynic acid or furosemide; P<0.001).</p> <p>The mean cardiac index decreased significantly at 20, 40, and 60 minutes compared to the control state after diuretic infusion with either ethacrynic acid or furosemide (P<0.001).</p> <p>There was a significant decrease in plasma volume at 60 minutes post drug infusions (ethacrynic acid or furosemide; P<0.001).</p> <p>In contrast, there was no significant change in PBV, PEV, PEV/PBV, and systemic arterial pressure throughout the study period with ethacrynic acid or furosemide.</p> <p>Secondary: Not reported</p>
<p>Patterson et al.⁴³ (1994)</p> <p>Torsemide 5 mg QD</p>	<p>DB, MC, PC, PG</p> <p>Men and women diagnosed with NYHA class II or</p>	<p>N=66</p> <p>7 days</p>	<p>Primary: Change in body weight from baseline</p>	<p>Primary: Patients receiving torsemide 10 and 20 mg had a significant decrease in weight (-1.62 and -1.30 kg, respectively) as compared to placebo.</p> <p>Torsemide 5 mg did not demonstrated a significant reduction in body</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>torsemide 10 mg QD</p> <p>vs</p> <p>torsemide 20 mg QD</p> <p>vs</p> <p>placebo QD</p>	<p>III CHF and edema</p>		<p>Secondary: Change in urinary sodium, potassium, chloride excretion and urine volume after the first dose of drug</p>	<p>weight compared to placebo (-0.60 kg).</p> <p>Secondary: Severity of edema decreased as the dose of torsemide increased. The adverse events did not increase with higher doses of torsemide.</p>
<p>Senzaki et al.⁴⁴ (2008)</p> <p>Torasemide* (de novo group)</p> <p>vs</p> <p>torasemide* (replacement group) was converted from furosemide dosage using 0.2 mg torasemide* corresponding to 1 mg furosemide</p>	<p>RCT</p> <p>Pediatric patients (age range from 3 weeks to 17 years) with congested heart failure, patients newly diagnosed with CHF or previously treated with furosemide</p>	<p>N=102</p> <p>3 to 4 weeks</p>	<p>Primary: Clinical signs and symptoms of congestive heart failure</p> <p>Secondary: Humoral factors, serum potassium levels, and adverse events</p>	<p>Primary The de novo torasemide group significantly improved the congestive heart failure index from 7.2±1.6 to 5.7±1.4 (P<0.05); however the replacement group did not. The replacement group baseline value of the congestive heart failure index was 7.4±2.4 and after treatment the mean value was 6.8±2.3.</p> <p>Secondary: The de novo and replacement groups significantly improved brain natriuretic peptide and aldosterone levels (P<0.05); however, plasma rennin activity was not significantly decreased among both groups.</p> <p>Serum potassium levels were significantly increased in the replacement group (P<0.05), but not in the de novo group.</p> <p>The most commonly reported adverse events of torasemide were those associated with loop diuretics in general.</p>
<p>Faris et al.⁴⁵ (2006)</p> <p>Loop diuretics (furosemide, bumetanide),</p>	<p>MA</p> <p>Adult patients with chronic heart failure</p>	<p>N=525 (14 trials)</p> <p>2 to 52 weeks</p>	<p>Primary: Mortality</p> <p>Secondary: Effect of diuretic withdrawal on</p>	<p>Primary: Mortality was reported in three of the seven placebo-controlled trials, and this analysis showed that mortality was lower for patients treated with diuretics than with placebo (3/111[2.7%] vs 12/110 [10.9%], respectively; OR, 0.24; 95% CI, 0.07 to 0.83; P=0.02).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>thiazide diuretics (chlorothiazide), or potassium-sparing diuretics (amiloride, triamterene)</p> <p>vs</p> <p>placebo or active control (ACE inhibitors, digoxin)</p>			worsening of heart failure and exercise capacity	<p>These results showed that patients treated with diuretics had an absolute risk reduction of 8% when compared to placebo and a number needed to treat of 12.5.</p> <p>Secondary: An analysis of pooled data from two trials showed lower admission rates for worsening heart failure in patients taking diuretics than in patients taking placebo (OR, 0.07; 95% CI, 0.01 to 0.52; P=0.01).</p> <p>Diuretics were found to improve exercise capacity, with a difference in means of 0.74 (95% CI, 0.37 to 1.11; P<0.0001) and of 0.67 (95% CI, 0.02 to 1.31; P=0.04.), respectively. The combined results of these 4 trials indicated that diuretics improved exercise capacity in participants with chronic heart failure with a difference in means of 0.72 (95% CI, 0.40 to 1.4; P<0.0001).</p>
Hypertension				
<p>Van der Heijden et al.⁴⁶ (1998)</p> <p>Bumetanide 1 mg/day for 6 weeks</p> <p>vs</p> <p>furosemide 40 mg/day for 6 weeks</p>	<p>DB, PC, XO</p> <p>Patients with HTN</p>	<p>N=27</p> <p>24 weeks</p>	<p>Primary: Changes in blood pressure, serum lipid levels, lab values, safety and tolerability</p> <p>Secondary: Not reported</p>	<p>Primary: Bumetanide and furosemide reduced SBP by 8.2% (P<0.0002) and DBP by 4.5% (P<0.002). Overall SBP and DBP measurements were 12 and 4 mm Hg lower, respectively, when receiving bumetanide or furosemide vs placebo.</p> <p>Both furosemide and bumetanide increased TC by 5.0% (P<0.002), HDL-C by 1.7% (P value not significant), LDL-C by 4.8% (P<0.01), and TG by 12.4% (P<0.01).</p> <p>Serum glucose, magnesium, sodium, and potassium levels were unchanged in both treatment groups; whereas serum creatinine tended to increase (3.2%; P=0.09).</p> <p>Side effects were mild in severity with no discontinuation reported. In both bumetanide and furosemide treated patients, four patients reported hypertonic muscles, but was resolved within a couple of days.</p> <p>Secondary: Not reported</p>
De Berrazueta et	RCT	N=59	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>al.⁴⁷ (2007)</p> <p>Furosemide infused in 3 progressive solutions containing 475, 950, and 1,900 nmol/mL for arterial studies and 240, 480, and 960 nmol/mL for venous studies</p> <p>vs</p> <p>torasemide* infused in 3 solutions containing 400, 800, and 1,600 nmol/mL for arterial studies and 200, 400, and 800 nmol/mL for venous studies</p>	<p>Patients with HTN and healthy controls</p>	<p>Single dose</p>	<p>Dilatory effect on arteries and veins</p> <p>Secondary: Not reported</p>	<p>There were no significant changes in arterial dilation. Furosemide increased vasodilatation from 0.56 ± 0.09 to 0.88 ± 0.06 ($P=0.000$) in healthy control subjects and from 0.49 ± 0.10 to 0.75 ± 0.12 ($P=0.000$) in hypertensive patients.</p> <p>Torsemide increased venodilation from 0.46 ± 0.06 to 0.70 ± 0.11 ($P=0.007$) in control subjects and from 0.48 ± 0.09 to 0.67 ± 0.12 ($P=0.03$) in hypertensive patients.</p> <p>Secondary: Not reported</p>
<p>von Dossow et al.⁴⁸ (2008)</p> <p>Furosemide 40 mg IV and 80 mg PO 2 hours after extubation on day 1 after surgery</p>	<p>DB, RCT</p> <p>Patients with secondary pulmonary HTN scheduled for elective valve replacement and/or coronary artery bypass graft</p>	<p>N=21</p> <p>Day 1 after surgery</p>	<p>Primary: Cardiac output</p> <p>Secondary: Endothelin-1 and angiotensin-II</p>	<p>Primary: Cardiac output increased significantly ($P=0.03$) in the torasemide group compared to the furosemide group.</p> <p>Secondary: Endothelin-1 and angiotensin-II increased significantly ($P=0.031$) in the furosemide group compared to the torasemide group.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs torasemide* 20 mg IV and 20 mg PO 2 hours after extubation on day 1 after surgery				
Vasavada et al. ⁴⁹ (2003) <u>Phase 1: Inpatient</u> Furosemide 200 mg/day with sodium-free water (10 mL/kg) vs torsemide 100 mg/day with sodium-free water (10 mL/kg) <u>Phase 2: Outpatient</u> Furosemide 80 mg/day vs torsemide 40 mg/day	DB, RCT, two-phase, XO Patients ≥18 years of age with chronic kidney disease (serum creatinine >1.4 mg/dL) and volume overload	N=14 3 weeks	Primary: <u>Phase 1: Inpatient</u> Change in 24-hour urinary sodium excretion <u>Phase 2: Outpatient</u> Primary: 24-hour ambulatory SBP Secondary: Potassium, calcium, protein excretion, diurnal variation of electrolyte and protein excretion, and glomerular filtration rate	Primary <u>Phase 1: Inpatient</u> Furosemide and torsemide increased urinary sodium excretion from 199 to 357 mEq/day and 213 to 398 mEq/day, respectively. These differences between the two diuretics were not statistically significant. <u>Phase 2: Outpatient</u> Both treatments had similar effects in reducing SBP (P=0.43). The SBP was reduced from baseline to post treatment by 9.7 mm Hg for torsemide (P=0.007) and 9.2 mm Hg for furosemide (P=0.021). Secondary: There were no significant differences in excretion rate profiles between torsemide and furosemide (P>0.17).
Pupita et al. ⁵⁰ (1983) Furosemide 25 mg QD	RCT, XO Men and women with a mean age of 53.9±9.2 years with mild to moderate	N=36 12 months	Primary: Blood pressure Secondary: Plasma electrolytes,	Primary: Patients taking chlorthalidone had significantly lower SBP at each monthly measurement compared to baseline (P<0.01). However, only DBP values at month five were significant compared to baseline (P<0.05). Patients taking furosemide had significantly lower SBP at months three,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs chlorthalidone 50 mg QD	HTN		adverse events	<p>four, and five compared to baseline ($P<0.05$ for month three, and $P<0.01$ for months four and five). DBP values were significantly lower at all monthly measurements compared to baseline in patients taking furosemide ($P<0.01$).</p> <p>At month one, SBP decreased by 19.4 mm Hg with chlorthalidone and by 21.2 mm Hg with furosemide ($P<0.001$). DBP decreased by 11 mm Hg with chlorthalidone and by 12.6 mm Hg with furosemide at month one ($P<0.001$).</p> <p>Secondary: There were no significant changes in serum sodium levels with either chlorthalidone or furosemide. Patients taking chlorthalidone had significantly lower serum chloride levels compared to baseline at all points ($P<0.01$), whereas patients taking furosemide had significantly lower levels only at month six ($P<0.05$). Both chlorthalidone and furosemide significantly reduced serum potassium levels at all points compared to baseline ($P<0.01$).</p> <p>Patient taking chlorthalidone reported adverse effects including dizziness, transient abdominal disorder, and slight weakness. Patients taking furosemide reported transient early weakness and irritability. The rate of adverse events was not statistically significant in either treatment group.</p>
Valmin K et al. ⁵¹ (1975) Furosemide 12.5, 25 or 40 mg BID vs HCTZ 12.5 mg BID vs placebo	DB, RCT, XO, 5 experimental periods each of 4 weeks Men and women with essential HTN	N=34 20 weeks	Primary: Blood pressure, urinary output, serum electrolytes, safety and tolerability Secondary: Not reported	Primary: When compared to placebo, there was a significant reduction of blood pressure with HCTZ 12.5 mg BID and furosemide 12.5 mg BID ($P<0.05$). Paired comparison showed that HCTZ 12.5 mg BID and furosemide 25 and 40 mg BID had a similar hypotensive effect, irrespective of the initial blood pressure ($P>0.10$). When compared to placebo, the urinary output increased significantly with furosemide 12.5, 25, or 40 mg BID ($P<0.05$, $P<0.01$ and $P<0.001$, respectively) but not with the HCTZ group ($P>0.10$). Sodium level did not alter during the various treatment periods when compared with the placebo period, or between the individual treatment

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>periods ($P>0.10$).</p> <p>Potassium level fell significantly during the HCTZ period ($P<0.001$) and furosemide 25 mg and 40 mg BID period ($P<0.01$ and $P<0.001$, respectively). Potassium level was not significantly affected with furosemide 12.5 mg BID ($P>0.10$).</p> <p>Secondary: Not reported</p>
<p>Araoye et al.¹³ (1978)</p> <p>Furosemide 40 mg BID</p> <p>vs</p> <p>HCTZ 50 mg BID</p>	<p>DB, XO</p> <p>Patients with HTN</p>	<p>N=not specified</p> <p>3 months</p>	<p>Primary: Blood Pressure</p> <p>Secondary: Not reported</p>	<p>Primary: Furosemide and HCTZ significantly reduced blood pressure. The decrease in blood pressure was consistently greater in the HCTZ group than with furosemide; however the difference was significant in regards to SBP only.</p> <p>Secondary: Not reported</p>
<p>Ogawa et al.⁵² (2006)</p> <p>Furosemide 20 mg/day plus imidapril‡ 5 mg/day</p> <p>vs</p> <p>spironolactone 25 mg/day plus imidapril‡ 5 mg/day</p> <p>All patients were pre-treated with imidapril‡ for 1 year prior to trial</p>	<p>PRO, RCT</p> <p>Adult patients with HTN and type 2 diabetes, with a urine albumin/creatinine ratio >30 mg/g creatinine, and plasma BNP levels >100 pg/mL (suggestive of mild heart failure)</p>	<p>N=30</p> <p>24 months</p>	<p>Primary: Change in BNP, urine albumin/creatinine ratio, and blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: At 12 months, spironolactone-treated patients exhibited a significant reduction in BNP level from baseline compared to furosemide-treated patients ($P<0.05$).</p> <p>At 12 months, spironolactone-treated patients exhibited a significant reduction in urine albumin/creatinine ratio from baseline compared to furosemide-treated patients ($P<0.05$).</p> <p>Both treatments exhibited similar reductions in blood pressure from baseline (P value not reported).</p> <p>No adverse events were reported in this trial.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>onset.</p> <p>Furumatsu et al.⁵³ (2008)</p> <p>Spirolactone 25 mg/day (triple blockade group)</p> <p>vs</p> <p>trichlormethiazide * 1 mg/day or furosemide 10 mg/day (control group)</p> <p>Study medications were added to ongoing therapy consisting of enalapril 5 mg/day and losartan 50 mg/day.</p>	<p>MC, OL, PRO, RCT</p> <p>Patients 20 to 70 years of age, with controlled blood pressure <130/80 mm Hg, chronic nephropathy (defined by serum creatinine level <3 mg/dL or calculated creatinine concentration <30 mL/min), daily treatment with enalapril 5 mg and losartan 50 mg for at least 12 weeks, and persistent proteinuria (urinary protein excretion >0.5 g/day)</p>	<p>N=32</p> <p>12 months</p>	<p>Primary: Reduction in proteinuria, urinary type IV collagen, SBP, DBP, mean blood pressure, creatinine, creatinine clearance, potassium, urinary aldosterone</p> <p>Secondary: Not reported</p>	<p>Primary: At one year of therapy, patients randomized to the triple blockage group experienced a statistically significant 58% reduction in urinary protein level from baseline (P<0.05), while there was no difference in the control group. Compared to the control group, the triple blockade group experienced a significant reduction in proteinuria at one year of therapy (P<0.05).</p> <p>At one year of therapy, patients randomized to the triple blockage group experienced a statistically significant 40% reduction in urinary type IV collagen from baseline (P<0.05); while there was no difference in the control group. However there was no statistically significant difference in the change of urinary type IV collagen from baseline between the two study groups.</p> <p>There were no statistically significant differences between the two study groups in the following outcome measures: SBP, DBP, mean blood pressure, creatinine, creatinine clearance, potassium, and urinary aldosterone.</p> <p>Secondary: Not reported</p>
<p>Hansson et al.⁵⁴ (2000)</p> <p>NORDIL</p> <p>Conventional therapy (diuretic, β-blocker or both)</p> <p>vs</p> <p>diltiazem 180 to 360 mg QD</p>	<p>BE, MC, OL, PRO, RCT</p> <p>Patients 50 to 74 years of age with DBP ≥100 mm Hg and previously untreated</p>	<p>N=10,881</p> <p>4.5 years</p>	<p>Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death</p> <p>Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI</p>	<p>Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97).</p> <p>Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04).</p> <p>Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17).</p> <p>Other endpoints were not statistically different between the groups</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Wiysonge et al.⁵⁵ (2007)</p> <p>Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>	<p>MA</p> <p>13 RCTs evaluating patients ≥18 years of age with HTN</p>	<p>N=91,561</p> <p>Duration varied</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions</p>	<p>including cardiovascular death (P=0.41), all cardiac events (P=0.57 and congestive heart failure (P=0.42).</p> <p>Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p> <p>Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.
Miscellaneous				
Bagshaw et al. ⁵⁶ (2007) Loop diuretics (frusemide†, torasemide*) vs placebo	MA Patients with acute renal failure	N=555 Variable duration	Primary: Mortality, need for renal replacement therapy, and renal recovery Secondary: Urine output, serum potassium level and acid-base status, duration of acute renal failure or renal replacement therapy, length of hospital stay, toxicity	Primary: There was no statistical difference in mortality between loop diuretics compared to placebo (OR, 1.28; 95% CI, 0.89 to 1.84; P=0.18). There was no statistical difference in renal recovery between loop diuretics and control (OR, 0.88; 95% CI, 0.59 to 1.31; P=0.5). Secondary: Loop diuretics were associated with a shorter duration of renal replacement therapy (weighted mean difference of 1.4 days; 95% CI, 0.2 to 2.3; P=0.02), shorter time to spontaneous decline in serum creatinine level (WMD, 2.1 days; 95% CI, 0.4 to 3.7; P=0.01), and a greater increase in urine output from baseline (OR, 2.6; 95% CI, 1.4 to 4.9; P=0.004). There was no data available on acid-base status, hospital status, hospital length of stay or health costs.
Galloe et al. ⁵⁷ (2006) Bumetanide 0.5 mg (0, 1, 2, or 4 tablets BID) vs trandolapril 0.5 mg (0, 1, 2, or 4 tablets QD)	DB, PC, RCT, XO Men and women with previous MI ≥3 years ago, had medical treatment for heart failure and ejection fraction between 0.36 and 0.54 estimated by echo-cardiography (wall motion index)	N=16 14 days	Primary: Patient reported quality of life Secondary: Effects on the involved organs: kidney function, left ventricular function, blood pressure	Primary: Patient's well-being increased 12% with 0.5 mg bumetanide BID but higher doses bumetanide decreased patient's well-being by 12% compared to placebo (P<0.002). Increasing doses of bumetanide tended to increase tiredness (P=0.072). There were no statistically significant effects of bumetanide on the patient's opinion of their health, degree of dyspnea, appetite or work capacity. Secondary: Bumetanide increased 24-hour urine production in a straight dose-dependent manner (P<0.0001) while trandolapril had no effect (P=0.53). Bumetanide and trandolapril did not alter the 24-hour creatinine excretion and creatinine clearance (P=0.33, P=0.11 and P=0.53, P=0.97, respectively). Bumetanide decreased left ventricular function and increased heart rate in a dose dependent manner (P<0.001). Left ventricular function was also

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>decreased with trandolapril but did not reach statistically significant. (P>0.062).</p> <p>Trandolapril significantly reduced SBP by maximally of 7.6 mm Hg (5.8%) with the lowest dose of 0.5 mg/day (P=0.007). Bumetanide had no significant effect on DBP (P=0.23).</p>

*Synonym for torsemide.

†Synonym for furosemide.

‡Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, IV=intravenous, PO=oral, QD=once daily

Study design abbreviations: BE=blinded endpoint, DB=double blind, DD=double dummy, MA=meta analysis, MC=multicenter, OL=open label, OS=observational, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitors, BNP=brain natriuretic peptide, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HTN=hypertension, HR=hazard ratio, LDL-C=low-density lipoprotein cholesterol, LVEF=left ventricular ejection fraction, MI=myocardial infarction, NYHA=New York Heart Association, PBV=pulmonary blood volume, PEV=pulmonary extravascular fluid volume, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TG=triglycerides

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Loop Diuretics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Bumetanide	injection, tablet	N/A	N/A	\$\$\$
Ethacrynic acid	tablet	Edecrin®	\$\$\$\$\$	N/A
Furosemide	injection, solution, tablet	Lasix®*	\$	\$
Torsemide	injection, tablet	Demadex®*	\$\$\$	\$

*Generic is available in at least one dosage form or strength.

N/A=Not available

X. Conclusions

All of the loop diuretics are approved for the treatment of edema associated with congestive heart failure, hepatic disease, or renal disease. Furosemide and torsemide are also approved for the treatment of hypertension. Additionally, ethacrynic acid is approved for the short-term treatment of ascites (due to malignancy, idiopathic edema, and lymphedema) and for the short-term treatment of hospitalized pediatric patients with congenital heart disease or the nephrotic syndrome.³⁻¹⁰ Bumetanide, furosemide, and torsemide are available in a generic formulation.

Guidelines recommend the use of diuretics and sodium restriction for the management of ascites due to cirrhosis. Spironolactone is recommended as first-line therapy, either as monotherapy or in combination with furosemide.

Amiloride is an alternative treatment option in patients experiencing gynecomastia with spironolactone. Triamterene, metolazone, and hydrochlorothiazide have also been used to treat ascites.²⁷ Several studies have compared furosemide and torsemide in cirrhotic patients with ascites. Although torsemide significantly increased natriuresis and diuresis compared to furosemide, these effects were not consistently demonstrated across the studies. There was no difference in plasma renin or aldosterone concentrations among the treatment groups.²⁸⁻³¹

For the treatment of chronic heart failure, guidelines recommend the use of diuretics in all patients who have evidence of volume overload. Loop diuretics are generally recommended as initial therapy in patients with left ventricular dysfunction. For those with persistent fluid retention despite treatment with a loop diuretic, a thiazide diuretic or metolazone may be added to the regimen. In patients with normal left ventricular function, either a thiazide diuretic or loop diuretic may be used as initial therapy to manage fluid overload.¹⁴⁻¹⁶ There are relatively few studies that have directly compared the loop diuretics for the treatment of chronic heart failure. In open-label trials, torsemide decreased mortality, hospitalizations and improved NYHA functional class compared to treatment with furosemide. However, due to limitations in the study designs, it is difficult to draw firm conclusions about the results of these studies.³⁷⁻³⁹ The most commonly used loop diuretic for the treatment of heart failure is furosemide; however, some patients may respond more favorably to other agents. Torsemide is better absorbed than furosemide and has a longer duration of action. It may be appropriate to use in patients exhibiting an erratic diuretic effect and in those with refractory fluid retention despite high doses of other loop diuretics.¹⁵

There are several published guidelines on the treatment of hypertension. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.¹⁷⁻²⁵ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹⁷ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹⁷⁻²⁵ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹⁷⁻²⁵

In clinical trials, the thiazide diuretics have been shown to effectively lower blood pressure.⁴⁶⁻⁵⁵ Some studies suggest that hydrochlorothiazide is more effective than a loop diuretic for lowering blood pressure.¹³ However, a loop diuretic should be used when the glomerular filtration rate is <30 mL/min.^{1,2}

Serious adverse events reported with the loop diuretics include electrolyte abnormalities, hypersensitivity reactions, and ototoxicity. Ethacrynic acid has a higher rate of ototoxicity than other loop diuretics and is less commonly used. Patients allergic to sulfonamides may also show hypersensitivity to bumetanide, furosemide, and torsemide. Ethacrynic acid is the only loop diuretic that is not a sulfonamide derivative and can be safely used in patients with a sulfonamide allergy.³⁻¹²

There is insufficient evidence to support that one brand loop diuretic is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand loop diuretics within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand loop diuretic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: a pathophysiologic approach*. 9th edition. New York (NY): McGraw-Hill; 2014.
2. Kaplan NM. Thiazides versus loop diuretics in treatment of hypertension. In: Basow DS (Ed). *UpToDate* [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Jun]. Available from: <http://www.utdol.com/utd/index.do>
3. Bumetanide [package insert]. Sellersville (PA): Teva Pharmaceuticals USA Inc.; 2013 Sep.
4. Bumetanide injection [package insert]. Deerfield (IL): Baxter Healthcare Corporation; 2009 Dec.
5. Edecrin® [package insert]. Whitehouse Station (NJ): Merck&Co., Inc.; 2005 Feb.
6. Lasix® [package insert]. Bridgewater (NJ): sanofi-Aventis; 2012 Mar.
7. Furosemide injection [package insert]. Lake Forest (IL): Hospira, Inc; 2013 Oct.
8. Furosemide solution [package insert]. Morton Grove (IL): Morton Grove Pharmaceuticals, Inc; 2014 Dec.
9. Demadex® [package insert]. Somerset (NJ): Meda Pharmaceuticals; 2012 Aug.
10. Torsemide injection [package insert]. Shirley (NY): American Regent Inc.; 2014 Feb.
11. *Drug Facts and Comparisons 4.0* [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Jun]. Available from: <http://online.factsandcomparisons.com>
12. *Micromedex® Healthcare Series* [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Jun]. Available from: <http://www.thomsonhc.com/>.
13. Araoye MA, Chang MY, Khatri IM, et al. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. *JAMA* 1978;240(17):1863.
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
15. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
16. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
17. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
18. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
20. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
21. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
22. National Institute for Health and Clinical Excellence (NICE). *Hypertension: the clinical management of primary hypertension in adults* [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
23. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
24. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
25. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
26. American Diabetes Association. *Standards of Medical Care in Diabetes-2015*. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.

27. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. 2012 [cited 2015 Apr]. Available from: http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf.
28. Laffi G, Marra F, Buzzelli G, et al. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized, double-blind study. *Hepatology* 1991;13:1101-5.
29. Gerbes AL, Bertheau-Reitha U, Falkner C et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. *J Hepatol* 1993;17:353-8.
30. Fiaccadori F, Pedretti G, Pasetti G et al. Torsemide versus furosemide in cirrhosis: a long-term double-blind, randomized clinical study. *Clin Investig* 1993;71:579-84.
31. Abecasis R, Guevera M, Miguez C, et al. Long-term efficacy of torsemide compared to frusemide in cirrhotic patients with ascites. *Scand J Gastroenterol* 2001;3:309-13.
32. Galløe AM, Skagen K, Christensen NJ, Nielsen SL, Frandsen EK, Bie P, et al. Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. *J Clin Pharm Ther.* 2006 Apr;31(2):139-47.
33. Hutcheon D, Vincent ME, Sandhu RS. Clinical use of diuretics in congestive heart failure. *J Clin Pharmacol.* 1981;21(11-12 Pt 2):668-72.
34. Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. *J Clin Pharmacol.* 1981;21(11-12 Pt 2):688-90.
35. Nicholson G. Treatment of fluid retention in cirrhosis: a comparison of bumetanide and furosemide. *Curr Med Res Opin.* 1977;4(9):675-9.
36. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. *Am J Cardiol.* 2006 Jun 15;97(12):1759-64. Epub 2006 Apr 27.
37. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. *Am J Med* 2001;111:513-20.
38. Cosín J, Díez J; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. *Eur J Heart Fail* 2002;4:507-13.
39. Muller K, Gamba G, Jaquet F, et al. Torsemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. *Eur J Heart Fail.* 2003;5(6):793-801.
40. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. *Heart.* 2006 Oct;92(10):1434-40. Epub 2006 Apr 18.
41. Levy B. The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure. *J Clin Pharmacol.* 1977;17(7):420-30.
42. Austin SM, Schreiner BF, Kramer DH, et al. The acute hemodynamic effects of ethacrynic acid and furosemide in patients with chronic postcapillary pulmonary hypertension. *Circulation* 1976;53(2):364-69.
43. Patterson JH, Adams KF, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. *Pharmacotherapy* 1994;14(5):514-21.
44. Senzaki H, Kamiyama M, Phard, Masutani S, Ishido H, Taketazu M, Kobayashi T, et al. Efficacy and safety of Torasemide in children with heart failure. *Arch Dis Child.* 2008 Mar 12.
45. Faris R, Flather MD, Purcell H, et al. Diuretics for heart failure. *Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD003838. DOI: 10.1002/14651858.CD003838.pub2.
46. Van der Heijden M, Donders SH, Cleophas TJ, et al. A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report. *J Clin Pharmacol.* 1998;38(7):630-5.
47. De Berrazueta JR, González JP, de Mier I, Poveda JJ, García-Unzueta MT. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. *J Cardiovasc Pharmacol.* 2007 Feb;49(2):90-5.
48. von Dossow V, Spies C, Schenk H, Schlesinger S, von Heymann C. Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide. *Clin Drug Investig.* 2008;28(1):17-26.
49. Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. *Kidney Int.* 2003;64(2):632-40.
50. Pupita F, Belogi M, Ansuini R, et al. Long-acting and short-acting diuretics in the treatment of hypertension. *Pharmatherapeutica* 1983;3(7):475-81.
51. Valmin K, Hansen T. Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide. *Eur J Clin Pharmacol.* 1975;8(6):393-401.

52. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. *Clin Exp Pharmacol Physiol*. 2006 May-Jun;33(5-6):477-9.
53. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. *Hypertens Res*. 2008 Jan;31(1):59-67.
54. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000 Jul 29;356(9227):359-65.
55. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
56. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. *Crit Care Resusc*. 2007 Mar;9(1):60-8.
57. Galløe AM, Skagen K, Christensen NJ, Nielsen SL, Frandsen EK, Bie P, et al. Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. *J Clin Pharm Ther*. 2006 Apr;31(2):139-47.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Potassium-Sparing Diuretics
AHFS Class 402816
August 19, 2015**

I. Overview

The potassium-sparing diuretics are approved for the treatment of congestive heart failure, edema, and hypertension.¹⁻⁴ They inhibit sodium-potassium ion exchange at the distal convoluted tubule, cortical collecting tubule, and collecting duct. This reduces both potassium and hydrogen secretion and their subsequent excretion.¹⁻⁸ When used alone, amiloride has a weak diuretic and antihypertensive effect and increases the risk of hyperkalemia.¹ The potassium-sparing diuretics are generally used in combination with other diuretics to help restore normal serum potassium levels or to prevent the development of hypokalemia.¹⁻⁴ Amiloride and triamterene are both available as a fixed-dose combination with hydrochlorothiazide. Hydrochlorothiazide inhibits the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride.⁵⁻⁸

The potassium-sparing diuretics that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the products are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Potassium-Sparing Diuretics Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Amiloride	tablet	N/A	amiloride
Combination Products			
Amiloride and hydrochlorothiazide	tablet	N/A	amiloride and hydrochlorothiazide
Triamterene and hydrochlorothiazide	capsule, tablet	Dyazide ^{®*} , Maxzide ^{®*}	triamterene and hydrochlorothiazide

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the potassium-sparing diuretics are summarized in Table 2.

Table 2. Treatment Guidelines Using the Potassium-Sparing Diuretics

Clinical Guideline	Recommendation(s)
American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013) ⁹	<p>Treatment of Stage A heart failure (HF)</p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p>Treatment of Stage B heart failure</p> <ul style="list-style-type: none"> In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: A)

Clinical Guideline	Recommendation(s)
	<p>B)</p> <ul style="list-style-type: none"> • In patients with MI, statins should be used to prevent HF. (LoE: A) • ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p><u>Pharmacological treatment for Stage C HFrEF</u></p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p><u>Pharmacological treatment for Stage C HFpEF</u></p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF.

Clinical Guideline	Recommendation(s)
	<p>(LoE: C)</p> <p>Treatment of Stage D (advanced/refractory) HF</p> <ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C) • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)¹⁰</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF \leq40%, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF \leq40%. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients

Clinical Guideline	Recommendation(s)
	<p>with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF (<35%) while receiving standard therapy, including diuretics.</p> <ul style="list-style-type: none"> • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine

Clinical Guideline	Recommendation(s)
	<p>are preferred in patients with decreased systolic function.</p> <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF $\leq 40\%$. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF $\leq 40\%$. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF ($< 35\%$) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent

Clinical Guideline	Recommendation(s)
	<p>and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used.</p> <ul style="list-style-type: none"> • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Acute and Chronic</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the

Clinical Guideline	Recommendation(s)
<p>Heart Failure (2012)¹¹</p>	<p>risk of premature death.</p> <ul style="list-style-type: none"> • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ○ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ○ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ○ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. • Step 3: <ul style="list-style-type: none"> ○ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE

Clinical Guideline	Recommendation(s)
	<p>inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic.</p> <ul style="list-style-type: none"> ○ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ○ Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> ○ A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹²</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American

Clinical Guideline	Recommendation(s)
<p>Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹³</p>	<p>patients and older patients.</p> <ul style="list-style-type: none"> ● Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-MI (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁴, Reappraisal of Guidelines on Hypertension Management (2009)¹⁵</p>	<ul style="list-style-type: none"> ● In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. ● In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. ● There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous MI (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics). ● Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. ● Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. ● Fixed combination medications can favor compliance and simplify regimens. ● When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. <ul style="list-style-type: none"> ○ Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. ○ Avoid β-blocker/diuretic combination unless required for other reasons. ○ If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. ○ A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. ● Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium

Clinical Guideline	Recommendation(s)
	<p>channel blocker, ARB or β-blocker.</p> <ul style="list-style-type: none"> • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)¹⁶</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-

Clinical Guideline	Recommendation(s)
	<p><u>office hypertension.</u></p> <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP > 160 mmHg or DBP > 110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg. • A SBP goal < 140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be < 85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes

Clinical Guideline	Recommendation(s)
	<p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of < 140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal < 140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina).

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁷</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is

Clinical Guideline	Recommendation(s)
	<p>required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes.</p> <ul style="list-style-type: none"> • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁸</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most

Clinical Guideline	Recommendation(s)
<p>in Chronic Kidney Disease (2004)¹⁹</p>	<p>patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-myocardial infarction with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-myocardial infarction (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high coronary artery disease risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers).</p> <ul style="list-style-type: none"> • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)²⁰</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion > 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be

Clinical Guideline	Recommendation(s)
	<p>treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure -lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. • The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> • Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²¹</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be

Clinical Guideline	Recommendation(s)
	<p>appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.</p> <ul style="list-style-type: none"> • Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.

*Agent is not available in the United States

III. Indications

The Food and Drug Administration (FDA)-approved indications for the potassium-sparing diuretics are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Potassium-Sparing Diuretics¹⁻⁴

Indication(s)	Single Entity Agents	Combination Products	
	Amiloride	Amiloride and HCTZ	Triamterene and HCTZ
Congestive Heart Failure (or Edema) and Hypertension			
Help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic	✓ *		
Prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop	✓ *		
Use in patients who develop hypokalemia when thiazide or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important		✓ †	
Use in patients who develop hypokalemia on hydrochlorothiazide alone, or in whom require a thiazide diuretic and in whom the development of hypokalemia cannot be risked			✓ †

*As adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents.

†The fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the potassium-sparing diuretics are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Potassium-Sparing Diuretics⁶

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Amiloride	30 to 90	Not significant (% not reported)	Not metabolized	Feces (40 to 50) Renal (50)	6 to 9
Combination Products					
Amiloride and HCTZ	30 to 90/60 to 80	Not significant (% not reported)/ 10	Not metabolized	Feces (40 to 50) Renal (50)/ Renal (>60)	6 to 9/ 10 to 12
Triamterene and HCTZ	30 to 70/60 to 80	55 to 67/40	Liver (80)/ not reported	Renal (21)/ Renal (>60)	1.5 to 2.5/ 10 to 12

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the potassium-sparing diuretics are listed in Table 5.

Table 5. Significant Drug Interactions with the Potassium-Sparing Diuretics⁵

Generic Name(s)	Significance Level	Interaction	Mechanism
Potassium-sparing diuretics (amiloride, triamterene)	1	Aldosterone blockers	Aldosterone blockers and potassium-sparing diuretics may exert additive pharmacologic effects. Hyperkalemia with the potential for cardiac arrhythmias may result.
Potassium-sparing diuretics (amiloride, triamterene)	1	Potassium preparations	Use of potassium preparations and potassium-sparing diuretics may increase the risk of hyperkalemia. Cardiac arrhythmias or cardiac arrest may occur.
Potassium-sparing diuretics (amiloride)	1	ACE inhibitors	Hyperkalemia, possibly with cardiac arrhythmias or arrest may occur with the combination of amiloride and ACE inhibitors. Decreased aldosterone activity by ACE inhibitors may function synergistically with potassium conservation by amiloride to produce substantial hyperkalemia.
Potassium-sparing diuretics (amiloride)	1	ARBs	The risk of hyperkalemia may be increased when amiloride is co-administered with ARBs. Decreased aldosterone activity by ARBs may function synergistically with potassium conservation by amiloride to produce substantial hyperkalemia.
Thiazide diuretics (HCTZ)	1	Dofetilide	Thiazide diuretics increase potassium excretion. Hypokalemia may occur, increasing the risk of torsades de pointes.
Thiazide diuretics (HCTZ)	1	Lithium	Thiazide diuretics decrease the renal clearance of lithium which leads to increased serum lithium levels. Lithium toxicity has occurred.
Potassium-sparing diuretics (amiloride)	2	Aliskiren	Hyperkalemia risk may be increased when aliskiren is coadministered with potassium-sparing diuretics. Decreased aldosterone activity by aliskiren may function synergistically with potassium conservation leading to the development of hyperkalemia.
Potassium-sparing diuretics (amiloride)	2	Macrolide immunosuppressants	Macrolide immunosuppressants and potassium-sparing diuretics may exert additive effects on potassium leading to hyperkalemia.
Thiazide diuretics (HCTZ)	2	Diazoxide	Hyperglycemia may occur with symptoms similar to diabetes. The mechanism is unknown.
Thiazide diuretics (HCTZ)	2	Digitalis glycosides	Diuretic-induced electrolyte disturbances may predispose the patient to digitalis-induced cardiac arrhythmias.
Potassium-sparing diuretics (triamterene)	2	Indomethacin and derivatives	The combination of indomethacin and derivatives and triamterene may cause a sudden onset of nephrotoxicity.

ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, HCTZ=hydrochlorothiazide
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the potassium-sparing diuretics are listed in Table 6. The boxed warning for amiloride and amiloride and hydrochlorothiazide are listed in Tables 7 and 8.

Table 6. Adverse Drug Events (%) Reported with the Potassium-Sparing Diuretics¹⁻⁶

Adverse Events	Single Entity Agents	Combination Products	
	Amiloride	Amiloride And HCTZ	Triamterene and HCTZ
Cardiovascular			
Arrhythmia	≤1	≤1	✓
Bradycardia	-	-	1 to 10
Chest pain	≤1	≤1	-
Congestive heart failure	-	-	1 to 10
Edema	-	-	1 to 10
Hypotension	-	1 to 10	1 to 10
Orthostatic hypotension	≤1	1 to 10	1 to 10
Palpitations	≤1	≤1	-
Central Nervous System			
Dizziness	1 to 10	1 to 10	1 to 10
Fatigue	1 to 10	1 to 10	1 to 10
Headache	1 to 10	1 to 10	1 to 10
Dermatological			
Alopecia	≤1	≤1	≤1
Erythema multiforme	-	≤1	≤1
Exfoliative dermatitis	-	≤1	≤1
Photosensitivity	-	1 to 10	1 to 10
Rash	-	-	1 to 10
Stevens-Johnson syndrome	-	<1	<1
Toxic epidermal necrolysis	-	<1	<1
Endocrine and Metabolic			
Dehydration	1 to 10	1 to 10	<1
Gynecomastia	1 to 10	1 to 10	<1
Metabolic acidosis	1 to 10	1 to 10	<1
Postmenopausal bleeding	-	-	<1
Gastrointestinal			
Abdominal pain	1 to 10	1 to 10	✓
Anorexia	-	1 to 10	1 to 10
Appetite changes	1 to 10	1 to 10	-
Constipation	1 to 10	1 to 10	1 to 10
Diarrhea	1 to 10	1 to 10	✓
Epigastric distress	-	1 to 10	1 to 10
Flatulence	≤1	≤1	-
Gastrointestinal bleeding	≤1	≤1	-
Nausea	1 to 10	1 to 10	1 to 10
Pancreatitis	-	<1	<1
Vomiting	1 to 10	1 to 10	✓
Genitourinary			
Bladder spasms	≤1	≤1	-
Dysuria	≤1	≤1	-
Impotence	1 to 10	1 to 10	<1
Polyuria	≤1	≤1	-
Renal dysfunction	-	≤1	≤1
Hematological			
Agranulocytosis	-	≤1	≤1

Adverse Events	Single Entity Agents	Combination Products	
	Amiloride	Amiloride And HCTZ	Triamterene and HCTZ
Aplastic anemia	-	≤1	≤1
Hemolytic anemia	-	<1	<1
Leukopenia	-	≤1	≤1
Thrombocytopenia	-	≤1	≤1
Laboratory Test Abnormalities			
Hypercalcemia	-	<1	<1
Hyperkalemia	<10	-	-
Hypokalemia	-	1 to 10	1 to 10
Hyponatremia	1 to 10	1 to 10	1 to 10
Musculoskeletal			
Muscle cramps	1 to 10	1 to 10	✓
Weakness	1 to 10	1 to 10	✓
Renal			
Interstitial nephritis	-	<1	<1
Renal failure	-	<1	<1
Respiratory			
Cough	1 to 10	1 to 10	-
Dyspnea	1 to 10	1 to 10	1 to 10
Eosinophilic pneumonitis	-	<1	<1
Respiratory distress	-	<1	<1
Other			
Allergic myocarditis	-	<1	<1
Allergic reactions	-	<1	<1
Hepatic function impairment	-	<1	<1
Increased intraocular pressure	≤1	≤1	-
Jaundice	≤1	≤1	-
Tinnitus	≤1	≤1	-
Visual disturbance	-	≤1	≤1

✓ Percent not specified
- Event not reported

Table 7. Boxed Warning for Amiloride⁵

WARNING
Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When amiloride is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1 to 2%. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.

Table 8. Boxed Warning for Amiloride and Hydrochlorothiazide²

WARNING
Like other potassium-conserving diuretic combinations, amiloride and hydrochlorothiazide may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter). In patients without renal impairment or diabetes mellitus, the risk of hyperkalemia with this combination product is about 1 to 2 percent. This risk is higher in patients with renal impairment or diabetes mellitus (even without recognized diabetic nephropathy). Since hyperkalemia, if uncorrected, is potentially fatal, it is essential to monitor serum potassium levels carefully in any patient receiving amiloride hydrochloride and hydrochlorothiazide, particularly when it is first introduced, at the time of dosage adjustments, and during any illness that could affect renal function.

VII. Dosing and Administration

The usual dosing regimens for the potassium-sparing diuretics are listed in Table 9.

Table 9. Usual Dosing Regimens for the Potassium-Sparing Diuretics¹⁻⁶

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Amiloride	<u>Congestive heart failure (or edema) and hypertension:</u> Initial: 5 mg daily; may increase to 10 mg daily if needed; maximum, 20 mg	Safety and efficacy in children have not been established.	Tablet: 5 mg
Combination Products			
Amiloride and HCTZ	<u>Congestive heart failure (or edema) and hypertension:</u> Tablet: initial, 5-50 mg once daily; maintenance, 5-50 to 10-100 mg once daily or in divided doses	Safety and efficacy in children have not been established.	Tablet: 5-50 mg
Triamterene and HCTZ	<u>Congestive heart failure (or edema) and hypertension:</u> Capsule, tablet: initial, 37.5-25 mg once daily; maintenance: 37.5-25 to 75-50 mg once daily	Safety and efficacy in children have not been established.	Capsule: 37.5-25 mg 50-25 mg Tablet: 37.5-25 mg 75-50 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the potassium-sparing diuretics are summarized in Table 10.

Table 10. Comparative Clinical Trials with the Potassium-Sparing Diuretics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Edema/Heart Failure				
Bayliss et al. ²² (1987) Amiloride 5 mg QD and furosemide 40 mg	OS Patients with heart failure, 22 to 75 years of age, referred with breathlessness on moderate exertion (NYHA class 2 to 3) who were not previously treated	N=12 1 month	Primary: Average weight, heart rate at rest and maximal exercise, maximal treadmill exercise time, plasma renin, plasma aldosterone, noradrenaline at rest and maximal exercise Secondary: Not reported	Primary: Average weight was significantly reduced during treatment from 72.4 to 68.5 kg (P=0.0003). Resting heart rate decreased from 89 to 75 bpm (P=0.03). There was no significant change during exercise. Maximal treadmill exercise time significantly increased from 9.1 to 17.6 minutes (P=0.007). Plasma concentrations of renin increased from 1.1 to 4.2 ng/mL/hr at rest and from 2.5 to 11.3 ng/mL/hr upon exercise (P<0.007). Plasma concentrations of aldosterone increased from 169 to 488 pmol/L at rest and from 223 to 737 pmol/L upon exercise (P<0.007). Plasma concentrations of noradrenaline were significantly reduced (decreased to within normal ranges) at rest following treatment (P=0.005) but remained abnormally high at maximal exercise following treatment. Secondary: Not reported
Rengo et al. ²³ (1979) Amiloride 15 mg QD vs amiloride and	RCT Patients 35 to 60 years of age with liver cirrhosis and ascites or CHF	N=30 15 days	Primary: Body weight, 24 hour diuresis, serum sodium, serum potassium, sodium and potassium urinary loss	Primary: All treatment groups had a significant reduction in body weight from baseline (P<0.001 for all). Amiloride and HCTZ-treated patients achieved a significantly greater reduction compared to amiloride-treated patients (P<0.001). All treatment groups significantly differed from baseline in 24 hour diuresis (P<0.01). Amiloride and HCTZ- and HCTZ-treated patients achieved greater diuresis compared to amiloride-treated patients (P<0.001 for both).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 15-150 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>HCTZ 150 mg QD</p>			<p>Secondary: Not reported</p>	<p>Serum sodium was reduced from baseline in all treatment groups. HCTZ-treated patients had a significantly greater reduction than amiloride- (P<0.01) and amiloride and HCTZ-treated patients (P<0.001). Sodium urinary loss was seen with all treatments at day two, amiloride and HCTZ therapy had maintained the loss at day five (P<0.001 for both).</p> <p>Serum potassium decreased in HCTZ-treated patients but increased in amiloride- and amiloride and HCTZ-treated patients. HCTZ-treated patients had a marked increase in potassium urinary loss (P<0.001).</p> <p>Secondary: Not reported</p>
<p>Cheitlin et al.²⁴ (1991)</p> <p>Amiloride 5 or 10 mg QD for 7 days, followed by placebo plus HCTZ 50 or 100 mg QD for 14 days</p> <p>vs</p> <p>placebo for 14 days, followed by amiloride 5 or 10 mg plus HCTZ 50 or 100 mg QD for the next 7 days</p>	<p>DB, PC, RCT, XO</p> <p>Patients with a history CHF and ≥1 episode of pulmonary edema (NYHA class 2 to 3) who were not previously treated</p>	<p>N=11</p> <p>21 days</p>	<p>Primary: Hemodynamic changes at rest and exercise</p> <p>Secondary: Not reported</p>	<p>Primary: At rest, there were no significant differences between placebo- and amiloride-treated patients in right atrial pressure, pulmonary atrial pressure, heart rate, pulmonary artery wedge pressure, systemic arterial pressure, right ventricular stroke work index, left ventricular stroke work index, systemic vascular resistance, cardiac index or stroke volume index (P values not reported).</p> <p>During exercise, there were significant differences between placebo- and amiloride-treated patients at the 50-watt stage in right atrial pressure (15.0 vs 10.5 mm Hg), pulmonary artery wedge pressure (28.6 vs 22.1 mm Hg), pulmonary artery diastolic pressure (32.2 vs 21.6 mm Hg), mean pulmonary artery pressure (44.4 vs 38.9 mm Hg), left ventricular stroke work index (69.5 vs 77.9 g-m/m²) and stroke volume index (44.9 vs 46.2 cc/beat/m²), respectively (P values not reported).</p> <p>There were no significant differences between placebo and amiloride therapy during exercise in right ventricular stroke work index, heart rate, aortic pressure, cardiac index and total systemic vascular resistance (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Ghosh et al.²⁵ (1987)</p>	<p>PG, RCT, SB</p>	<p>N=60</p>	<p>Primary: Body weight,</p>	<p>Primary: Body weight was reduced with both treatments (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Amiloride and HCTZ 2.5-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>triamterene and HCTZ 50-25 mg QD (fixed-dose combination product)</p>	<p>Elderly patients with stable, mild to moderate CHF</p>	<p>8 weeks</p>	<p>clinical score, biochemistry</p> <p>Secondary: Not reported</p>	<p>Both treatments resulted in improvements in clinical scores; 95 and 88% of the amiloride/HCTZ- and triamterene/HCTZ-treated patients showed an improvement in heart failure signs with no patient's symptoms becoming worse (P values were not reported).</p> <p>Eighty five and 84% of amiloride/HCTZ- and triamterene/HCTZ-treated patients showed an improvement in heart failure symptoms (P values were not reported).</p> <p>There were no significant differences in serum sodium, potassium or urea between the two treatments (P values were not reported).</p> <p>Secondary: Not reported</p>
<p>Kohvakka.²⁶ (1998)</p> <p>HCTZ 50 mg BID</p> <p>vs</p> <p>amiloride 5 mg BID plus HCTZ 50 mg BID</p> <p>vs</p> <p>triamterene 75 mg BID plus HCTZ 50 mg BID</p> <p>vs</p> <p>KCl 1,000 mg BID plus HCTZ 50 mg BID</p>	<p>RCT, XO</p> <p>Patients 41 to 69 years of age with CHF (NYHA class 2 to 3) who developed persistent hypokalemia on HCTZ alone</p>	<p>N=25</p> <p>5 months</p>	<p>Primary: Changes in weight, blood pressure, serum sodium, serum potassium and total body potassium</p> <p>Secondary: Percentage with hypokalemia, median days until hypokalemia detection, serum magnesium</p>	<p>Primary: Weight loss was significant in amiloride plus HCTZ- and triamterene plus HCTZ-treated patients (P=0.05 for both), but not in KCl plus HCTZ-treated patients (P value not reported), compared to HCTZ-treated patients.</p> <p>No significant changes in blood pressure were observed (P values not reported).</p> <p>No differences in serum sodium were observed in amiloride plus HCTZ- or triamterene plus HCTZ-treated patients (P values not reported). Serum sodium levels were slightly higher in KCl plus HCTZ-patients compared to HCTZ-treated patients (P=0.01).</p> <p>Serum potassium was found to be significantly higher in all combination treated-patients compared to HCTZ-treated patients (P=0.01 for all comparisons). Total body potassium was significantly higher in amiloride plus HCTZ- and triamterene plus HCTZ-treated patients (P=0.05 for both), but not in KCl plus HCTZ-treated patients (P value not reported), compared to HCTZ-treated patients.</p> <p>Secondary: The percentages of patients that became hypokalemic were 39, 52 and 52% in</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>amiloride plus HCTZ-, triamterene plus HCTZ- and KCl plus HCTZ-treated patients (P values not reported).</p> <p>The median days until hypokalemia detection were 114.0, 75.0 and 51.5 for amiloride plus HCTZ-, triamterene plus HCTZ- and KCl plus HCTZ-treated patients (P values not reported).</p> <p>Serum magnesium was maintained at a significantly higher rate in amiloride plus HCTZ- and triamterene plus HCTZ- patients compared to KCl plus HCTZ-treated patients (P values not reported).</p>
<p>Faris et al.²⁷ (2006)</p> <p>Potassium-sparing diuretics (amiloride, triamterene), loop diuretics (furosemide, bumetanide), or thiazide diuretics (chlorothiazide)</p> <p>vs</p> <p>placebo or active control (ACE inhibitors, digoxin)</p>	<p>MA (14 trials)</p> <p>Adult patients with chronic heart failure</p>	<p>N=525</p> <p>2 to 52 weeks</p>	<p>Primary: Mortality</p> <p>Secondary: Effect of diuretic withdrawal on worsening of heart failure and exercise capacity</p>	<p>Primary: Pooled data from three PC trials (n=202) reporting on mortality revealed that mortality was lower for diuretic-treated patients compared to placebo-treated patients (2.7 vs 10.9%, respectively; OR, 0.24; 95% CI, 0.07 to 0.83; P=0.02). The difference represents an absolute risk reduction of 8% in mortality in diuretic-treated patients (NNT, 12.5).</p> <p>Secondary: Pooled data from two PC trials (n=169) reporting on the effect of diuretics on worsening heart failure revealed lower admission rates for worsening heart failure in diuretic-treated patients compared to placebo-treated patients (OR, 0.07; 95% CI, 0.01 to 0.52; P=0.01).</p> <p>Pooled data from two parallel RCTs (n=43) reporting on the effect of diuretics on exercise capacity revealed that diuretic therapy improved exercise capacity compared to active control (WMD, 0.74; 95% CI, 0.37 to 1.11; P<0.0001). Pooled data from two XO RCTs (n=48) revealed similar results (WMD, 0.67; 95% CI, 0.02 to 1.31; P=0.04). In total (n=91), diuretic therapy improved exercise capacity in patients with chronic heart failure (WMD, 0.72; 95% CI, 0.40 to 1.04; P<0.0001).</p>
Hypertension				
<p>Heran et al.²⁸ (2010)</p> <p>Potassium sparing diuretics (amiloride,</p>	<p>SR (6 RCTs)</p> <p>Patients with a baseline office SBP ≥140 mm Hg and/or DBP ≥90</p>	<p>N=496</p> <p>3 to 12 weeks</p>	<p>Primary: Quantify the dose-related SBP and DBP lowering efficacy of potassium sparing</p>	<p>Primary: <i>Blood pressure lowering efficacy of potassium sparing diuretics as a second drug:</i></p> <p>There was no effect on SBP (-0.03 mm Hg; 95% CI, -2.90 to 2.83) and DBP (-0.22 mm Hg; 95% CI, -2.01 to 1.57) when potassium sparing diuretics were initiated at a dose of half the recommended starting dose. Due to the lack of</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>triamterene)</p> <p>Monotherapy vs placebo and as combination therapy with another antihypertensive drug class (ACE inhibitor, ARB, β-blocker, calcium channel blocker, centrally-acting drugs, diuretics and renin inhibitors)</p>	<p>mm Hg</p>		<p>diuretics</p> <p>Secondary: Variability of blood pressure, pulse pressure, heart rate, withdrawals due to adverse effects</p>	<p>data, an estimate of the effect of higher doses or whether there was a dose response effect could not be determined.</p> <p>Secondary: <i>Blood pressure lowering efficacy of potassium sparing diuretics as a second drug:</i> The limited data did not suggest any effect of potassium sparing on blood pressure variability.</p> <p>Analysis of six trials assessing amiloride and triamterene did not suggest any effect of potassium sparing diuretics on pulse pressure.</p> <p>Two trials provided heart rate data and did not suggest any effect of potassium sparing diuretics on heart rate.</p> <p>An analysis of withdrawals due to adverse effects during three to 12 weeks of treatment with potassium sparing diuretics was reported in five of trials. The overall estimate showed no significant effect of potassium sparing diuretics on this outcomes (RR, 0.53; 95% CI, 0.19 to 1.51).</p>
<p>Multicenter Diuretic Cooperative Study Group²⁹ (1981)</p> <p>Amiloride 5 mg QD</p> <p>vs</p> <p>amiloride and HCTZ 5-50 mg QD (fixed-dose combination product)</p> <p>vs</p>	<p>DB, MC, RCT</p> <p>Patients 21 to 69 years of age with mild to moderate essential HTN (supine DBP 95 to 115 mm Hg)</p>	<p>N=179</p> <p>12 weeks</p>	<p>Primary: Change from baseline in average supine SBP and DBP</p> <p>Secondary: Heart rate, body weight, serum potassium</p>	<p>Primary: Baseline vs 12 week average supine blood pressure was 153/101 vs 139/93 for amiloride-, 160/100 vs 137/90 for amiloride and HCTZ- and 154/101 vs 134/89 mm Hg for HCTZ-treated patients. Reductions in supine blood pressure were significant with all treatments (P<0.01). The SBP reduction was significantly greater with amiloride and HCTZ-treated patients compared to amiloride-treated patients at all weeks and HCTZ-treated patients at four and eight weeks (P<0.05, both).</p> <p>Secondary: No significant changes from baseline in heart rate were observed in amiloride and HCTZ-treated patients (P values not reported). An increase in heart rate of 3.3 bpm was observed in these patients (P<0.05).</p> <p>Changes in body weight from baseline were -1.17 kg in amiloride and HCTZ-, -0.72 kg in HCTZ- and 0.045 kg in amiloride-treated patients (P<0.05, for amiloride plus HCTZ only).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 50 mg QD				Changes in serum potassium from baseline were 0.23 in amiloride- (P<0.01), -0.38 in amiloride and HCTZ- (P<0.01) and -0.59 mEq/L in HCTZ-treated patients (P<0.01). The change in HCTZ-treated patients was statistically greater than the change in the amiloride and HCTZ-treated patients (P<0.05). Twenty three, two and zero percent of HCTZ-, amiloride and HCTZ- and amiloride-treated patients experienced hypokalemia.
<p>Salmela et al.³⁰ (1986)</p> <p>Amiloride 2.5 mg/day and HCTZ 25 mg/day</p> <p>vs</p> <p>HCTZ 25 mg/day daily</p>	<p>DB, MC, PG, RCT</p> <p>Adult patients with mild to moderate HTN</p>	<p>N=40</p> <p>12 weeks</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>At the end of the first treatment period (four weeks), mean supine SBP and DBP was 161 and 91 mm Hg in amiloride plus HCTZ-treated patients (P<0.01 and P<0.001, respectively).</p> <p>At the end of the first treatment period (four weeks), mean supine SBP and DBP was 165 and 96 mm Hg in HCTZ-treated patients (P<0.01 for both).</p> <p>At the end of the second treatment period (eight weeks), mean supine SBP and DBP was 154 and 86 mm Hg in amiloride plus HCTZ-treated patients (P<0.01 and P<0.001).</p> <p>At the end of the second treatment period (eight weeks), mean supine SBP and DBP was 155 and 90 mm Hg in HCTZ-treated patients (P<0.001 and P<0.001).</p> <p>There were no significant differences in blood pressure reduction between the two treatments (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Hood et al.³¹ (2007)</p> <p>SALT study</p> <p>Amiloride 20 mg/day</p> <p>vs</p> <p>amiloride 40</p>	<p>DB, RCT, XO</p> <p>Adult patients with seated blood pressure of 140/90 to 170/110 mm Hg, plasma renin of ≤12 mU/L, plasma aldosterone-renin</p>	<p>N=57</p> <p>42 weeks</p>	<p>Primary: Change in blood pressure and plasma renin from baseline between spironolactone 100 mg/day and bendroflumethiazide 5 mg/day</p>	<p>Primary: Spironolactone 100 mg/day- and bendroflumethiazide 5 mg/day-treated patients did not exhibit a significant difference in blood pressure reduction from baseline (P value not reported).</p> <p>Secondary: Spironolactone 50 mg/day-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day vs spironolactone 50 mg/day vs spironolactone 100 mg/day vs bendroflumethiazide* 2.5 mg/day vs bendroflumethiazide* 5 mg/day vs losartan 100 mg/day vs placebo	ratio >750, previous fall in SBP \geq 20 mm Hg after 1 month of OL treatment with spironolactone 50 mg/day		Secondary: Change in blood pressure and plasma renin from baseline between amiloride and other diuretics and between lower and higher doses of each diuretic	Losartan 100 mg-treated patients exhibited a significant decrease in blood pressure from baseline compared to bendroflumethiazide 2.5 mg/day-treated patients (P<0.05). High-dose bendroflumethiazide- and amiloride-treated patients exhibited significantly greater reductions in blood pressure compared to the lower doses (P<0.05). Spironolactone-treated patients exhibited a four-fold increase in baseline renin level compared to a two-fold increase observed in bendroflumethiazide-treated patients (P=0.003).
Kohvakka et al. ³² (1979) Amiloride 5 mg QD	PC, RCT, XO Patients 41 to 70 years of age with uncomplicated	N=31 3 months	Primary: Changes in blood pressure, serum potassium, sodium, creatinine, urate	Primary: No significant changes in blood pressure were observed with any of the treatments (P values not reported). Mean serum potassium was reduced with all treatments except with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs triamterene 75 mg QD vs KCl 1,500 mg QD vs spironolactone 50 mg QD vs placebo</p> <p>All patients were also receiving HCTZ 50 mg QD.</p>	<p>HTN, previously treated with antihypertensive agents for 1 to 6 years</p>		<p>and total body potassium</p> <p>Secondary: Not reported</p>	<p>spironolactone. KCl supplementation was least effective in elevating serum potassium. Total body potassium remained constant throughout treatment (P values not reported).</p> <p>Serum sodium remained within normal limits with all treatments (P values not reported).</p> <p>There were no significant changes in mean serum creatinine with any of the treatments (P values not reported).</p> <p>Serum urate concentration increased significantly with all treatments, including HCTZ monotherapy (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Larochelle et al.³³ (1985)</p> <p>Amiloride 5 mg/day and HCTZ 50 mg/day</p> <p>vs</p> <p>HCTZ 50 mg/day</p>	<p>DB, RCT</p> <p>Ambulant patients 18 to 70 years of age with essential HTN who after not being treated for ≥ 2 weeks prior to the trial had a supine DBP of 95 to 109 mm Hg and a serum potassium level of >3.5 mmol/L</p>	<p>N=266</p> <p>8 weeks</p>	<p>Primary: Blood pressure, serum potassium concentration</p> <p>Secondary: Not reported</p>	<p>Primary: At eight weeks, there were no differences between the two treatments in the mean blood pressure reductions (P value not reported).</p> <p>During the eight weeks of treatment, the HCTZ plus amiloride-treated patients experienced a decrease in mean supine blood pressure (159/99 to 138/88 mm Hg) and serum potassium levels (4.23 to 3.91 mmol/L) (P values not reported).</p> <p>During the eight weeks of treatment, HCTZ-treated patients experienced a reduction in mean supine blood pressure (157/99 to 138/87 mm Hg) and serum potassium levels (4.16 to 3.69 mmol/L) (P values not reported).</p> <p>Hypokalemia occurred less frequently in HCTZ plus amiloride-treated patients compared to HCTZ-treated patients (14 and 29%, respectively; P=0.0026). However, the proportions of patients with a potassium level exceeding 4.5</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>mmol/L were similar (4.5 vs 3.9%, respectively; P value not reported).</p> <p>Secondary: Not reported</p>
<p>Dean et al.³⁴ (1984)</p> <p>Amiloride and HCTZ 5-50 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>triamterene and HCTZ 50-25 mg QD (fixed-dose combination product)</p>	<p>RCT, SB, XO</p> <p>Patients with mild to moderate HTN (DBP 95 to 110 mm Hg)</p>	<p>N=20</p> <p>8 weeks</p>	<p>Primary: Blood pressure, hypokalemia, hyperkalemia, renal function tests</p> <p>Secondary: Not reported</p>	<p>Primary: Both treatments produced a comparable effect on blood pressure. The baseline standing and lying blood pressure was 168/105 and 168/104 mm Hg, respectively. After eight weeks, amiloride and HCTZ-treated patients had a standing and lying blood pressure of 145/92 and 145/90 mm Hg, respectively (P values not reported). After eight weeks, triamterene and HCTZ-treated patients had a standing and lying blood pressure of 142/93 and 143/91 mm Hg, respectively (P values were not reported).</p> <p>There were no cases of hypokalemia or hyperkalemia and no renal function changes with either treatment (P values were not reported).</p> <p>Secondary: Not reported</p>
<p>Maxwell et al.³⁵ (1985)</p> <p>Amiloride and HCTZ 50-25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>triamterene and HCTZ 5-50 mg QD (fixed-dose combination product)</p>	<p>OL, PRO, RCT</p> <p>Patients with mild to moderate HTN, mean supine DBP <90 or >114 mm Hg at the end of a 3 week placebo, run-in phase</p>	<p>N=84</p> <p>9 weeks</p>	<p>Primary: Mean blood pressure changes</p> <p>Secondary: Not reported</p>	<p>Primary: Seventy three (n=30) and 81% (n=35) of triamterene and HCTZ- and amiloride and HCTZ-treated patients were maintained on the initial dosage throughout the trial, with no significant differences between the two treatments (P value not reported).</p> <p>At week nine, mean SBP and DBP was 136.2 and 87.4 mm Hg in triamterene and HCTZ-treated patients (P value not reported). At week nine, mean SBP and DBP was 132.6 and 85.7 mm Hg in amiloride and HCTZ-treated patients (P value not reported).</p> <p>At week nine, mean serum potassium levels were 4.13 and 3.98 mEq/L in triamterene and HCTZ- and amiloride and HCTZ-treated patients (P<0.05).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>All patients received placebo for 3 weeks prior to the treatment phase.</p> <p>After 2 weeks of treatment, dosage could be doubled.</p>				
<p>Hansson et al.³⁶ (1999) HYPERTENSION -2 (STOP)</p> <p><u>Conventional drug group</u> Atenolol 50 mg QD, HCTZ 25 mg QD plus amiloride 2.5 mg QD, metoprolol 100 mg QD, or pindolol 5 mg QD</p> <p>vs</p> <p><u>Newer drug group</u> ACE inhibitors (enalapril 10 mg QD or lisinopril 10 mg QD) or calcium channel blockers (felodipine 2.5 mg QD, or isradipine 2 to 5 mg QD)</p>	<p>BE, MC, OL, RCT</p> <p>Swedish men and women between 70 to 84 years old with treated or untreated essential with HTN on 3 separate occasions defined by SBP ≥ 180 mm Hg, DBP >105 mm Hg, or both</p>	<p>N=6,614</p> <p>60 months</p>	<p>Primary: Combined fatal stroke, MI, and other fatal cardiovascular disease; combined fatal and nonfatal stroke, MI, and other cardiovascular Mortality</p> <p>Secondary: Not reported</p>	<p>Primary: The combined fatal mortality endpoints occurred in 221 of the 2,213 patients in the conventional drugs group and in 438 of 4,401 in the newer drugs group (RR, 0.99; 95% CI, 0.84 to 1.16; P=0.89).</p> <p>The combined fatal and nonfatal mortality endpoints occurred in 460 patients taking conventional drugs and in 887 taking newer drugs (RR, 0.96; 95% CI, 0.86 to 1.08; P=0.49).</p> <p>Secondary: Not reported</p>
<p>Williams et al.³⁷</p>	<p>3 phase, OL</p>	<p>N=156</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(1984)</p> <p>Phase 1 (Baseline, 2 weeks): Triamterene and HCTZ 75-50 mg/day (fixed-dose combination product) (Group 1)</p> <p>vs</p> <p>triamterene and HCTZ 150-100 mg/day (fixed-dose combination product) (Group 3)</p> <p>vs</p> <p>no antihypertensive medications (Group 3)</p> <p>Phase 2 (4 weeks): Triamterene and HCTZ 75-50 mg/day (fixed-dose combination product) (Groups 1, 2 and 3)</p> <p>Phase 3 (up to 8 months): Triamterene and HCTZ 75-50</p>	<p>Patients 21 to 70 years of age, with essential HTN</p>	<p>6 to 32 weeks</p>	<p>Blood pressure and weight comparisons between Phase 1 and 2</p> <p>Secondary: Serum potassium concentrations</p>	<p>During Phase 1, mean standing DBP, mean standing SBP and weight for Group 1-treated patients were: 91 mm Hg, 138 mm Hg and 82 kg (P values not reported). During Phase 2, the comparisons in these patients were: 88 mm Hg, 135 mm Hg and 82 kg (P values not reported).</p> <p>During Phase 1, mean standing DBP, mean standing SBP and weight for Group 2-treated patients were: 93 mm Hg, 139 mm Hg and 87 kg (P values not reported). During Phase 2, the comparisons in these patients were: 98 mm Hg, 149 mm Hg and 79 kg (P value not reported).</p> <p>During Phase 1, mean standing DBP, mean standing SBP and weight for Group 3-treated patients were: 98 mm Hg, 149 mm Hg and 80 kg (P values not reported). During Phase 2, the comparisons in these patients were: 94 mm Hg, 136 mm Hg and 78 kg (P value not reported).</p> <p>Of these Phase 1 and 2 comparisons, mean standing DBP and SBP differences were reported to be significant during Phase 2 for Group 1- and Group 3-treated patients (P values not reported).</p> <p>Secondary: When Group 2-treated patients were switched 75/50 mg/day, no patient became hypokalemic (serum potassium concentration <3.5 mEq/L) (P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day (fixed-dose combination product) (Groups 1, 2 and 3)				
<p>Hannson et al.³⁸ (2000) NORDIL</p> <p>Conventional therapy (diuretic, β-blocker or both)</p> <p>vs</p> <p>diltiazem 180 to 360 mg QD</p>	<p>BE, MC, OL, PRO, RCT</p> <p>Patients 50 to 74 years of age with DBP \geq100 mm Hg and previously untreated</p>	<p>N=10,881</p> <p>4.5 years</p>	<p>Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death</p> <p>Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI</p>	<p>Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97).</p> <p>Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04).</p> <p>Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17).</p> <p>Other endpoints were not statistically different between the groups including cardiovascular death (P=0.41), all cardiac events (P=0.57 and congestive heart failure (P=0.42).</p>
<p>Messerli et al.³⁹ (1998)</p> <p>Diuretics (amiloride, chlorthalidone, HCTZ, HCTZ and triamterene [fixed-dose combination product], or thiazide)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol or pindolol)</p>	<p>MA</p> <p>10 RCTs lasting \geq1 year, which used as first line agents diuretics and/or β-blockers and reported morbidity and mortality outcomes in patients \geq60 years of age with HTN</p>	<p>N=16,164</p> <p>1 year</p>	<p>Primary: Cardiovascular morbidity and mortality, all-cause morbidity</p> <p>Secondary: Not reported</p>	<p>Primary: Diuretic treatment significantly reduced the odds for cardiovascular mortality by 25% (OR, 0.75; 95% CI, 0.64 to 0.87), while β-blockers did not reduce cardiovascular mortality (OR, 0.98; 95% CI, 0.78 to 1.23; P values not reported).</p> <p>Diuretic treatment significantly reduced the odds for all-cause mortality by 14% (OR, 0.86; 95% CI, 0.77 to 0.96), while β-blockers did not reduce all-cause mortality (OR, 1.05; 95% CI, 0.88 to 1.25; P values not reported).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Lindholm et al.⁴⁰ (2005)</p> <p>β-blocker therapy (atenolol, metoprolol, oxprenolol*, pindolol or propranolol)</p> <p>vs</p> <p>other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan or verapamil)</p> <p>or</p> <p>placebo</p>	<p>MA</p> <p>13 RCTs evaluating the treatment of primary HTN with a β-blocker as first line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both</p>	<p>N=105,951</p> <p>2.1 to 10.0 years</p>	<p>Primary: Stroke, MI, all-cause mortality</p> <p>Secondary: Not reported</p>	<p>Primary: The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001).</p> <p>The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported).</p> <p>The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14).</p> <p>Secondary: Not reported</p>
<p>Wiysonge et al.⁴¹ (2007)</p> <p>Other antihypertensive therapies (i.e.,</p>	<p>MA</p> <p>13 RCTs evaluating patients ≥18 years of age with HTN</p>	<p>N=91,561</p> <p>Duration varied</p>	<p>Primary: All-cause mortality</p> <p>Secondary: Stroke, CHD, cardiovascular</p>	<p>Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)</p>			<p>death, total cardiovascular disease, adverse reactions</p>	<p>β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04).</p> <p>Secondary: There was a significant decrease in stroke observed with β-blocker therapy compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily

Study regimen abbreviations: BE=blinded endpoint, DB=double blind, MA=meta analysis, MC=multicenter, OL=open label, OS=observational, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, SB=single blind, SR=systematic review, XO=cross over

Miscellaneous abbreviations: ACE inhibitor=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HTN=hypertension, MI=myocardial infarction, NNT=number needed to treat, NYHA=New York Heart Association, OR=odds ratio, RR=relative risk, SBP=systolic blood pressure, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of ‘\$’ signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 11. Relative Cost of the Potassium-Sparing Diuretics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Amiloride	tablet	N/A	N/A	\$\$\$
Combination Products				
Amiloride and HCTZ	tablet	N/A	N/A	\$
Triamterene and HCTZ	capsule, tablet	Dyazide ^{®*} , Maxzide ^{®*}	\$\$\$	\$

*Generic is available in at least one dosage form or strength.

HCTZ=hydrochlorothiazide, N/A=Not available

X. Conclusions

The potassium-sparing diuretics are approved for the treatment of congestive heart failure, edema, and hypertension.¹⁻⁴ When used alone, amiloride has a weak diuretic and antihypertensive effect and increases the risk of hyperkalemia. It should be used alone only when persistent hypokalemia has been documented.¹ The potassium-sparing diuretics are generally used in combination with other diuretics to help restore normal serum potassium levels or to prevent the development of hypokalemia.¹⁻⁴ Amiloride and triamterene are available as a fixed-dose combination with hydrochlorothiazide. All of the products are available in a generic formulation.

For the treatment of chronic heart failure, guidelines recommend the use of diuretics in all patients who have evidence of volume overload. The loop diuretics are generally recommended as initial therapy in patients with left

ventricular dysfunction. For those with persistent fluid retention despite treatment with a loop diuretic, a thiazide diuretic or metolazone may be added to the regimen. In patients with normal left ventricular function, either a thiazide diuretic or loop diuretic may be used as initial therapy to manage fluid overload.⁹⁻¹¹ As indicated by the FDA-approved indications of the potassium-sparing diuretics, these agents are typically used as adjunctive therapy in patients receiving thiazide diuretics to prevent the development of hypokalemia or to restore normal serum potassium levels.¹⁻⁴

There are several national and international organizations that have published guidelines on the treatment of hypertension.¹²⁻²⁰ Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension. According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another antihypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹² Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹²⁻¹⁹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹²⁻¹⁹ The use of a fixed-dose combination product may simplify the treatment regimen and improve adherence.^{14,15,19} However, there are no prospective, randomized trials that have demonstrated better clinical outcomes with a fixed-dose combination product compared to the coadministration of the individual components as separate formulations.

Amiloride has been shown to be effective for the treatment of edema, hypertension, as well as for the prevention of serum potassium loss in patients taking a thiazide or loop diuretic. Clinical trials have also demonstrated comparable efficacy with the fixed-dose combination of amiloride/hydrochlorothiazide and triamterene/hydrochlorothiazide in patients with hypertension and heart failure.²²⁻⁴¹

There is insufficient evidence to support that one brand potassium-sparing diuretic is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand potassium-sparing diuretics within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand potassium-sparing diuretic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Amiloride [package insert]. Spring Valley (NY): Par Pharmaceuticals, Inc.; 2012 Feb.
2. Amiloride and hydrochlorothiazide [package insert]. Pomona (NY): Barr Laboratories, Inc; 2013 Dec.
3. Maxzide® [package insert]. Morgantown (WV): Mylan Pharmaceuticals, Inc.; 2011 Mar.
4. Dyazide® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2011 Mar.
5. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 May]. Available from: <http://online.factsandcomparisons.com>
6. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 May]. Available from: <http://www.thomsonhc.com/>.
7. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th edition. New York (NY): McGraw-Hill; 2014.
8. Reilly RF and Jackson EK. Regulation of Renal Function and Vascular Volume. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill: 2011.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
10. Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1-e194.
11. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
12. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
13. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
15. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
16. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281-1357.
17. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
18. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
19. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
20. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
21. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1-S93.
22. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. *Br Heart J*. 1987 Jan;57(1):17-22.
23. Rengo F, Trimarco B, Bonaduce D, Petretta M, Ferrara N, D'Ascia C, et al. Potassium-sparing effect of amiloride in patients receiving diuretics: a quantitative review. *Acta Cardiol*. 1979;34(4)259-67.
24. Cheitlin MD, Byrd R, Benowitz N, Liu E, Modin G. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. *Cardiovasc Drugs Ther*. 1991 Aug;5(4):719-25.

25. Ghosh AK, Mankikar G, Strouthidis T, Windsor A, Long C, Glover DR. A single-blind, comparative study of hydrochlorothiazide/amiloride ('Moduret' 25) and hydrochlorothiazide/triamterene ('dyazide') in elderly patients with congestive heart failure. *Curr Med Res Opin.* 1987;10(9):573-9.
26. Kohvakka A. Maintenance of potassium balance during long-term diuretic therapy in chronic heart failure patients with thiazide-induced hypokalemia: comparison of potassium supplementation with potassium chloride and potassium-sparing agents, amiloride and triamterene. *Int J Clin Pharmacol Ther Toxicol.* 1988;26(5):273-7.
27. Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. *Cochrane Database Syst Rev.* 2006 Jan 25;(1):CD003838.
28. Heran BS, Chen JMH, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. *Cochrane Database of Systemic Reviews.* 2010, Issue 1. Art. No.:CD008167. DOI:10.1002/14651858.CD008167.pub2.
29. Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group. *Arch Intern Med.* 1981 Mar;141(4):482-6.
30. Salmela P, Juustila H, Kinnunen O, and Koistinen P. Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients. *Ann Clin Res.* 1986;18:88-92.
31. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. *Circulation.* 2007;116(3):268-75.
32. Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. *Acta Med Scand.* 1979;205(4):319-24.
33. Larochelle P, Logan AG. Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level. *Can Med Assoc J.* 1985;132(7):801-5.
34. Dean S, Spencer-Mills L. Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension. *Curr Med Res Opin.* 1984;9(5):287-9.
35. Maxwell MH, Brachfeld J, Itskovitz H, et al. Blood pressure lowering and potassium conservation by triamterene-hydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension. *Clin Pharmacol Ther.* 1985;37(1):61-5.
36. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstén B, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 (STOP) study. *Lancet.* 1999 Nov 20;354(9192):1751-6.
37. Williams RL, Clark T, Blume CD. Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension. *Am J Med.* 1984 Nov 5;77(5A):62-6.
38. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet.* 2000 Jul 29;356(9227):359-65.
39. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA.* 1998 Jun 17;279(23):1903-7.
40. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet.* 2005 Oct 29-Nov 4;366(9496):1545-53.
41. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev.* 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Thiazide Diuretics
AHFS Class 402820
August 19, 2015**

I. Overview

The thiazide diuretics are approved for the treatment hypertension and edema due to renal dysfunction. They are also approved as adjunctive therapy for the management of edema associated with congestive heart failure, hepatic cirrhosis, as well as corticosteroid and estrogen therapy.¹⁻⁶ The thiazide diuretics inhibit the reabsorption of sodium and chloride in the cortical thick ascending limb of the loop of Henle and the early distal tubules. This action leads to an increase in the urinary excretion of sodium and chloride in approximately equivalent amounts.¹⁻⁸ Additionally, increased potassium and bicarbonate excretion, decreased calcium excretion, and uric acid retention may be observed. During initial thiazide therapy a reduction in cardiac output and extracellular volume occurs. However, with chronic therapy cardiac output normalizes and both peripheral vascular resistance and extracellular volume are reduced. In general, similar therapeutic and adverse effects are seen when equipotent doses are used. Thiazide diuretics are generally recommended when the glomerular filtration rate is above 30 mL/min.⁷⁻⁹

The thiazide diuretics that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the agents are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Thiazide Diuretics Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Chlorothiazide	injection*, suspension, tablet*	Diuril®	chlorothiazide
Hydrochlorothiazide	capsule, tablet	Microzide®*	hydrochlorothiazide
Methyclothiazide	tablet	N/A	methyclothiazide

*Generic is available in at least one dosage form or strength.

PDL=Preferred Drug List

N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the thiazide diuretics are summarized in Table 2.

Table 2. Treatment Guidelines Using the Thiazide Diuretics

Clinical Guideline	Recommendation(s)
American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013) ¹⁰	<p>Treatment of Stage A heart failure (HF)</p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p>Treatment of Stage B heart failure</p> <ul style="list-style-type: none"> In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) In patients with MI, statins should be used to prevent HF. (LoE: A) ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively)

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) • Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF. (LoE: C) <p>Pharmacological treatment for Stage C HFrEF</p> <ul style="list-style-type: none"> • Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) • Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) • ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) • Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) • Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) • The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) • Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) • Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) • Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) • Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p>Pharmacological treatment for Stage C HFpEF</p> <ul style="list-style-type: none"> • Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) • Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) • The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p>Treatment of Stage D (advanced/refractory) HF</p> <ul style="list-style-type: none"> • Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) • Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute

Clinical Guideline	Recommendation(s)
	<p>precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance. (LoE: C)</p> <ul style="list-style-type: none"> • Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) • Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)¹¹</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. • ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. • The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. • The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. • The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. • ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. • Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. • ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. • A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. • A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. • Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF ($<35\%$) while receiving standard therapy, including diuretics. • Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF $<40\%$. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. • The triple combination of an ACE inhibitor, an ARB, and an aldosterone

Clinical Guideline	Recommendation(s)
	<p>antagonist is not recommended because of the high risk of hyperkalemia.</p> <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent. • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever

Clinical Guideline	Recommendation(s)
	<p>possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients.</p> <ul style="list-style-type: none"> • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients. • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing

Clinical Guideline	Recommendation(s)
	<p>therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention.</p> <ul style="list-style-type: none"> • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy. • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)¹²</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate

Clinical Guideline	Recommendation(s)
	<p>response to a β-blocker.</p> <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias. <p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. Step 3: <ul style="list-style-type: none"> Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in</p>	<ul style="list-style-type: none"> Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life.

Clinical Guideline	Recommendation(s)
<p>Adults (2014)¹³</p>	<ul style="list-style-type: none"> • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure <90 mm Hg. • In patients <60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure <140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure <140 mm Hg and goal diastolic blood pressure <90 mm Hg. • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹⁴</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-myocardial infarction (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹⁵, Reappraisal of Guidelines on Hypertension Management (2009)¹⁶</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous myocardial infarction (ACE inhibitors, β-blockers and ARBs), angina (calcium channel

Clinical Guideline	Recommendation(s)
	<p>blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).</p> <ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p>

Clinical Guideline	Recommendation(s)
<p>management of arterial hypertension (2013)¹⁷</p>	<p><u>Treatment strategies and choice of antihypertensive drugs</u></p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage. • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP >160 mmHg or DBP >110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP \geq150/95 mmHg, and in those with BP \geq140/90 mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks until delivery may be considered. • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is \geq160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is \geq140 mmHg. • A SBP goal <140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be <85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a 'pre-diabetic' state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is \geq140/90 mmHg after a suitable period of lifestyle changes, and to maintain BP <140/90 mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to <140 mmHg should be considered. • When overt proteinuria is present, SBP values <130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is

Clinical Guideline	Recommendation(s)
	<p>recommended to combine RAS blockers with other antihypertensive agents.</p> <ul style="list-style-type: none"> • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement should be used in the face of very high SBP values. • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all

Clinical Guideline	Recommendation(s)
	<p>antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved.</p> <ul style="list-style-type: none"> • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
<p>National Institute for Health and Clinical Excellence: Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁸</p> <p>Reviewed Oct 2013</p>	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of hypertension. • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁹</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic;

Clinical Guideline	Recommendation(s)
	<p>however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic.</p> <ul style="list-style-type: none"> • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension, whether or not pharmacotherapy is planned. • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)²⁰</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-myocardial infarction with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-myocardial infarction (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high coronary artery disease risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office

Clinical Guideline	Recommendation(s)
(2012) ²¹	<p>blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic.</p> <ul style="list-style-type: none"> • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. • The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. • The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. • The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). • The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> • The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. • In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> • The Work Group recommends that in children with CKD ND, blood pressure - lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. • The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p>
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²²</p>	<p><u>Hypertension/blood pressure control</u></p> <ul style="list-style-type: none"> Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p><u>Nephropathy</u></p> <ul style="list-style-type: none"> Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). Either an ACE inhibitor or ARB is suggested for the treatment of the

Clinical Guideline	Recommendation(s)
	<p>nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) C and is recommended for those with urinary albumin excretion >300 mg/day.</p> <ul style="list-style-type: none"> When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American Association for the Study of Liver Diseases: Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012 (2012)²³ [Reaffirmed Oct 2014]</p>	<p>Treatment of ascites</p> <ul style="list-style-type: none"> First line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2,000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide). Fluid restriction is not necessary unless serum sodium is <125 mmol/L. Vasopressin antagonists may improve serum sodium in patients with cirrhosis and ascites. However their use does not currently appear justified in view of their expense, potential risks, and lack of evidence of efficacy in clinically meaningful outcomes. An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated. Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracentesis. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with cirrhosis and ascites may be harmful and must be carefully considered in each patient, monitoring blood pressure and renal function. The use of nonsteroidal anti-inflammatory drugs should be avoided in patients with cirrhosis and ascites, except in special circumstances. Liver transplantation should be considered in patients with cirrhosis and ascites.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the thiazide diuretics are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Thiazide Diuretics¹⁻⁶

Indication	Chloro-thiazide*	HCTZ*	Methyclo-thiazide*
Edema			
Adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy	✓	✓ (tablet)	✓
Hypertension			
Treatment of hypertension	✓ † (oral)	✓ †	✓ †

*Has been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

†Alone or in combination with other antihypertensive agents.

HCTZ=hydrochlorothiazide

IV. Pharmacokinetics

The pharmacokinetic parameters of the thiazide diuretics are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Thiazide Diuretics⁸

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life
Chlorothiazide	Poor	Not reported	Not metabolized	Renal (96)	45 to 120 minutes
HCTZ	60 to 80	40	Not metabolized	Renal (50 to 70)	10 to 12 hours
Methyclothiazide	Rapid	Not reported	Not reported	Renal	Not reported

HCTZ=hydrochlorothiazide

V. Drug Interactions

Significant drug interactions with the thiazide diuretics are listed in Table 5.

Table 5. Significant Drug Interactions with the Thiazide Diuretics⁷

Generic Name(s)	Significance Level	Interaction	Mechanism
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	1	Cisapride	Possible additive prolongation of the QT interval because of electrolyte loss which increases risk of life-threatening cardiac arrhythmias, including torsades de pointes.
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	1	Digitalis glycosides	Thiazide diuretics may induce electrolyte disturbances which may predispose patients to digitalis-induced arrhythmias.
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	1	Dofetilide	Thiazide diuretics may induce hypokalemia which may increase the risk of torsades de pointes.
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	2	Diazoxide	The combination of diazoxide with a thiazide diuretic may lead to hyperglycemia though an unknown mechanism; therefore the combination should be avoided.
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	2	Lithium	Thiazide diuretics may promote enhanced proximal tubular reabsorption of lithium leading to elevated serum concentrations. Thiazide diuretics may increase the therapeutic and toxic effects of lithium.
Thiazide diuretics (chlorothiazide, HCTZ, methyclothiazide)	2	Loop diuretics	Both groups have synergistic effects that may result in profound diuresis and serious electrolyte abnormalities
Chlorothiazide	2	Metronidazole	The combination of metronidazole and chlorothiazide may produce alcohol intolerance reactions. Metronidazole may inhibit aldehyde dehydrogenase-mediated metabolism of ethanol and cause a toxic accumulation of acetaldehyde.
Thiazide diuretics (chlorothiazide, HCTZ,	2	Sulfonylureas	Thiazide diuretics may decrease insulin tissue sensitivity, decrease insulin

Generic Name(s)	Significance Level	Interaction	Mechanism
methyclothiazide)			secretion, or increase potassium loss, causing hyperglycemia.

HCTZ=hydrochlorothiazide

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the thiazide diuretics are listed in Table 6.

Table 6. Adverse Drug Events (%) Reported with the Thiazide Diuretics¹⁻⁸

Adverse Events	Chlorothiazide	HCTZ	Methyclothiazide
Cardiovascular			
Hypotension	✓	✓	-
Necrotizing angitis	✓	✓	✓
Orthostatic hypotension	✓	✓	✓
Central Nervous System			
Dizziness	✓	✓	✓
Fever	✓	✓	✓
Headache	✓	✓	✓
Restlessness	✓	✓	✓
Vertigo	✓	✓	✓
Dermatological			
Alopecia	✓	✓	-
Cutaneous vasculitis	-	✓	✓
Erythema multiforme	✓	✓	<1
Exfoliative dermatitis	✓	✓	-
Photosensitivity	✓	✓	✓
Purpura	✓	✓	✓
Rash	✓	✓	✓
Stevens-Johnson syndrome	✓	✓	✓
Toxic epidermal necrolysis	✓	✓	-
Urticaria	✓	✓	✓
Vasculitis	-	✓	✓
Gastrointestinal			
Abdominal cramping	✓	✓	✓
Anorexia	✓	✓	✓
Constipation	✓	✓	✓
Diarrhea	✓	✓	✓
Epigastric distress	-		-
Gastric irritation	✓	✓	✓
Nausea	✓	✓	✓
Pancreatitis	✓	✓	✓
Sialadenitis	✓	✓	✓
Vomiting	✓	✓	✓
Genitourinary			
Impotence	✓	✓	-
Hematologic			
Agranulocytosis	✓	✓	✓
Aplastic anemia	✓	✓	✓
Hemolytic anemia	✓	✓	✓
Leukopenia	✓	✓	✓
Thrombocytopenia	✓	✓	✓
Hepatic			

Adverse Events	Chlorothiazide	HCTZ	Methyclothiazide
Hepatic function impairment	-	-	-
Jaundice	✓	✓	✓
Laboratory Test Abnormalities			
Cholesterol increased	✓	-	-
Electrolyte imbalance	✓	✓	✓
Hypercalcemia	-	✓	✓
Hyperglycemia	✓	✓	✓
Hyperuricemia	✓	✓	✓
Hypochloremic alkalosis	✓	-	-
Hypokalemia	✓	-	-
Hypomagnesemia	✓	-	-
Hyponatremia	✓	-	-
Triglycerides increased	✓	-	-
Musculoskeletal			
Muscle spasm	✓	✓	✓
Paresthesia	✓	✓	✓
Weakness	✓	✓	✓
Ocular			
Blurred vision	✓	✓	✓
Xanthopsia	✓	✓	✓
Renal			
Glycosuria	✓	✓	✓
Interstitial nephritis	✓	✓	-
Renal dysfunction	✓	✓	-
Renal failure	✓	✓	-
Respiratory			
Pneumonitis	✓	✓	✓
Pulmonary edema	✓	✓	✓
Respiratory distress	✓	✓	✓
Other			
Allergic myocarditis	-	-	-
Allergic reactions	-	-	-
Anaphylactic reactions	✓	✓	✓
Eosinophilic pneumonitis	-	-	-
Systemic lupus erythematosus	✓	-	-

✓ Percent not specified
-Event not reported
HCTZ=hydrochlorothiazide

VII. Dosing and Administration

The usual dosing regimens for the thiazide diuretics are listed in Table 7.

Table 7. Usual Dosing Regimens for the Thiazide Diuretics¹⁻⁸

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Chlorothiazide	<u>Edema:</u> Injection, suspension, tablet: 0.5 to 1 g once or twice daily, often administered on alternate days or on three to five days each week <u>Hypertension:</u> Injection, suspension, tablet:	Safety and efficacy in children have not been established.	Injection: 500 mg Suspension 250 mg/5 mL Tablet: 250 mg 500 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	initial, 0.5 or 1 g/day as a single dose or in divided dose(s); maintenance, adjust according to blood pressure response, some patients may require up to 2 g/day in divided doses		
HCTZ	<u>Edema:</u> Capsule, tablet: maintenance, 25 to 100 mg/day in a single or divided dose(s) <u>Hypertension:</u> Capsule, tablet: initial, 12.5 to 25 mg once daily; maintenance, 50 to 100 mg daily in a single or divided dose(s)	Safety and efficacy in children have not been established.	Capsule: 12.5 mg Tablet: 12.5 mg 25 mg 50 mg
Methyclothiazide	<u>Edema:</u> Tablet: maintenance, 2.5 to 10 mg once daily; maximum, 10 mg/day <u>Hypertension:</u> Tablet: 2.5 to 5 mg once daily	Safety and efficacy in children have not been established.	Tablet: 5 mg

HCTZ=hydrochlorothiazide

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the thiazide diuretics are summarized in Table 8.

Table 8. Comparative Clinical Trials with the Thiazide Diuretics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Edema				
Rengo et al. ²⁴ (1979) HCTZ 150 mg QD vs amiloride 15 mg QD vs amiloride and HCTZ 15-150 mg QD (fixed-dose combination product)	RCT Patients 35 to 60 years of age with liver cirrhosis and ascites or CHF	N=30 15 days	Primary: Body weight, 24 hour diuresis, serum sodium, serum potassium, sodium and potassium urinary loss Secondary: Not reported	Primary: All treatment groups had a significant reduction in body weight from baseline (P<0.001 for all). Amiloride and HCTZ-treated patients achieved a significantly greater reduction compared to amiloride-treated patients (P<0.001). All treatment groups significantly differed from baseline in 24 hour diuresis (P<0.01). Amiloride and HCTZ- and HCTZ-treated patients achieved greater diuresis compared to amiloride-treated patients (P<0.001 for both). Serum sodium was reduced from baseline in all treatment groups. HCTZ-treated patients had a significantly greater reduction than amiloride- (P<0.01) and amiloride and HCTZ-treated patients (P<0.001). Sodium urinary loss was seen with all treatments at day two, amiloride and HCTZ therapy had maintained the loss at day five (P<0.001 for both). Serum potassium decreased in HCTZ-treated patients but increased in amiloride- and amiloride and HCTZ-treated patients. HCTZ-treated patients had a marked increase in potassium urinary loss (P<0.001). Secondary: Not reported
Cheitlin et al. ²⁵ (1991) Amiloride 5 or 10 mg QD for 7 days, followed by placebo plus HCTZ 50 or 100	DB, PC, RCT, XO Patients with a history CHF and ≥1 episode of pulmonary edema (NYHA class 2 to 3) who were not	N=11 21 days	Primary: Hemodynamic changes at rest and exercise Secondary: Not reported	Primary: At rest, there were no significant differences between placebo- and amiloride-treated patients in right atrial pressure, pulmonary atrial pressure, heart rate, pulmonary artery wedge pressure, systemic arterial pressure, right ventricular stroke work index, left ventricular stroke work index, systemic vascular resistance, cardiac index or stroke volume index (P values not reported).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg QD for 14 days</p> <p>vs</p> <p>placebo for 14 days, followed by amiloride 5 or 10 mg plus HCTZ 50 or 100 mg QD for the next 7 days</p>	<p>previously treated</p>			<p>During exercise, there were significant differences between placebo- and amiloride-treated patients at the 50-watt stage in right atrial pressure (15.0 vs 10.5 mm Hg), pulmonary artery wedge pressure (28.6 vs 22.1 mm Hg), pulmonary artery diastolic pressure (32.2 vs 21.6 mm Hg), mean pulmonary artery pressure (44.4 vs 38.9 mm Hg), left ventricular stroke work index (69.5 vs 77.9 g-m/m²) and stroke volume index (44.9 vs 46.2 cc/beat/m²), respectively (P values not reported).</p> <p>There were no significant differences between placebo and amiloride therapy during exercise in right ventricular stroke work index, heart rate, aortic pressure, cardiac index and total systemic vascular resistance (P values not reported).</p> <p>Secondary: Not reported</p>
<p>Kohvakka²⁶ (1988)</p> <p>HCTZ 50 mg BID</p> <p>vs</p> <p>amiloride 5 mg BID plus HCTZ 50 mg BID</p> <p>vs</p> <p>triamterene 75 mg BID plus HCTZ 50 mg BID</p> <p>vs</p> <p>KCl 1,000 mg BID plus HCTZ 50 mg BID</p>	<p>RCT, XO</p> <p>Patients 41 to 69 years of age with CHF (NYHA class 2 to 3) who developed persistent hypokalemia on HCTZ alone</p>	<p>N=25</p> <p>5 months</p>	<p>Primary: Changes in weight, blood pressure, serum sodium, serum potassium and total body potassium</p> <p>Secondary: Percentage with hypokalemia, median days until hypokalemia detection, serum magnesium</p>	<p>Primary: Weight loss was significant in amiloride plus HCTZ- and triamterene plus HCTZ-treated patients (P=0.05 for both), but not in KCl plus HCTZ-treated patients (P value not reported), compared to HCTZ-treated patients.</p> <p>No significant changes in blood pressure were observed (P values not reported).</p> <p>No differences in serum sodium were observed in amiloride plus HCTZ- or triamterene plus HCTZ-treated patients (P values not reported). Serum sodium levels were slightly higher in KCl plus HCTZ-patients compared to HCTZ-treated patients (P=0.01).</p> <p>Serum potassium was found to be significantly higher in all combination treated-patients compared to HCTZ-treated patients (P=0.01 for all comparisons). Total body potassium was significantly higher in amiloride plus HCTZ- and triamterene plus HCTZ-treated patients (P=0.05 for both), but not in KCl plus HCTZ-treated patients (P value not reported), compared to HCTZ-treated patients.</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>The percentages of patients that became hypokalemic were 39, 52 and 52% in amiloride plus HCTZ-, triamterene plus HCTZ- and KCl plus HCTZ-treated patients (P values not reported).</p> <p>The median days until hypokalemia detection were 114.0, 75.0 and 51.5 for amiloride plus HCTZ-, triamterene plus HCTZ- and KCl plus HCTZ-treated patients (P values not reported).</p> <p>Serum magnesium was maintained at a significantly higher rate in amiloride plus HCTZ- and triamterene plus HCTZ- patients compared to KCl plus HCTZ-treated patients (P values not reported).</p>
<p>Faris et al.²⁷ (2006)</p> <p>Thiazide diuretics (chlorothiazide), loop diuretics (furosemide, bumetanide), or potassium-sparing diuretics (amiloride, triamterene)</p> <p>vs</p> <p>placebo or active control (ACE inhibitors, digoxin)</p>	<p>MA (14 trials)</p> <p>Adult patients with chronic heart failure</p>	<p>N=525</p> <p>2 to 52 weeks</p>	<p>Primary: Mortality</p> <p>Secondary: Effect of diuretic withdrawal on worsening of heart failure and exercise capacity</p>	<p>Primary: Pooled data from three PC trials (n=202) reporting on mortality revealed that mortality was lower for diuretic-treated patients compared to placebo-treated patients (2.7 vs 10.9%, respectively; OR, 0.24; 95% CI, 0.07 to 0.83; P=0.02). The difference represents an absolute risk reduction of 8% in mortality in diuretic-treated patients (NNT, 12.5).</p> <p>Secondary: Pooled data from two PC trials (n=169) reporting on the effect of diuretics on worsening heart failure revealed lower admission rates for worsening heart failure in diuretic-treated patients compared to placebo-treated patients (OR, 0.07; 95% CI, 0.01 to 0.52; P=0.01).</p> <p>Pooled data from two parallel RCTs (n=43) reporting on the effect of diuretics on exercise capacity revealed that diuretic therapy improved exercise capacity compared to active control (WMD, 0.74; 95% CI, 0.37 to 1.11; P<0.0001). Pooled data from two XO RCTs (n=48) revealed similar results (WMD, 0.67; 95% CI, 0.02 to 1.31; P=0.04). In total (n=91), diuretic therapy improved exercise capacity in patients with chronic heart failure (WMD, 0.72; 95% CI, 0.40 to 1.04; P<0.0001).</p>
Hypertension				
<p>Hua et al.²⁸ (1976)</p> <p>Chlorothiazide up to 5 g BID</p>	<p>XO</p> <p>Patients with HTN</p>	<p>N=20</p> <p>Duration not specified</p>	<p>Primary: Blood pressure, serum potassium</p> <p>Secondary:</p>	<p>Primary: Blood pressures on metolazone tended to be lower than on chlorothiazide, but the difference was not statistically significant.</p> <p>Both agents significantly lowered serum potassium concentrations and</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs metolazone 5 mg QD			Not reported	total body potassium to a similar degree. However, the serum potassium did not fall below the normal range in any patient and no potassium supplements were required. Secondary: Not reported
Carter et al. ²⁹ (2004) HCTZ 12.5 to 450 mg/day vs chlorthalidone 12.5 to 600 mg/day	MA Included trials which evaluate the pharmacokinetic and blood pressure lowering effects of chlorthalidone and HCTZ	N=200 Duration varied per study	Primary: Blood pressure Secondary: Serum potassium	Primary: In a dose equivalence study comparing HCTZ 100 mg QD to chlorthalidone 50 mg QD, blood pressure (SBP/DBP) reduced by 18/8 and 25/10 mm Hg compared to baseline, respectively. In another study comparing HCTZ 25 mg and triamterene 50 mg QD, HCTZ 50 mg and triamterene 100 mg QD, and chlorthalidone 50 mg QD, the blood pressure reduction was 15/8, 18/12, and 25/16 mm Hg, respectively. One other dose equivalence study comparing HCTZ 50 mg BID and chlorthalidone 50 mg QD, blood pressure reduction was 22/16 and 18/15 mm Hg, respectively. All available studies were inspected and it was concluded that HCTZ 50 mg is approximately equivalent to chlorthalidone 25 to 37 mg. Furthermore, it was suggested that chlorthalidone doses should generally be approximately 50% to 75% of the typical HCTZ dose. Secondary: In a study comparing HCTZ 100 mg QD and chlorthalidone 50 mg QD, potassium increased slightly with chlorthalidone (0.02 mEq/L) and decreased significantly with HCTZ (0.22 mEq/L; P=0.009). However, in another study comparing HCTZ 50 mg BID and chlorthalidone 50 mg QD, serum potassium decreased by 0.38 mEq/L with HCTZ and by 0.03 mEq/L with chlorthalidone. The difference was not statistically significant (P<0.07).
Ernst et al. ³⁰ (2006)	RCT, SB, XO Men and women	N=30 8 weeks plus 4	Primary: Comparison of the change in 24-hour	Primary: At week eight, there was a greater reduction in 24-hr mean SBP with chlorthalidone 25 mg/day compared to HCTZ 50 mg/day compared to

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 25 mg in the morning</p> <p>vs</p> <p>chlorthalidone 12.5 mg in the morning</p> <p>At week 4, both HCTZ and chlorthalidone were titrated to 50 mg in the morning and 25 mg in the morning, respectively for the remainder of the trial.</p>	<p>aged 18 to 79 years with pre-HTN or a new or established diagnosis of HTN (stage 1 or 2), not receiving antihypertensive medications, and had an average office blood pressure value in the last 6 months between 140 and 179 mm Hg systolic or 90 and 109 mm Hg diastolic</p>	<p>week washout period</p>	<p>mean SBP and DBP from baseline to week 8</p> <p>Secondary: Comparison of changes in mean SBP and mean DBP for office blood pressure at each visit, change in ambulatory daytime and nighttime mean SBP and DBP from baseline to week 8, development of hypokalemia</p>	<p>baseline (-12.4±1.8 vs -7.4±1.7 mm Hg, respectively; P=0.054).</p> <p>Secondary: There was a trend in favor of greater reduction in SBP with chlorthalidone than with HCTZ at each office visit. However, the difference was only statistically significant at week 2 (-15.7±2.2 vs -4.5±2.1 mm Hg, respectively; P=0.001).</p> <p>Although mean reductions in DBP was also greater with chlorthalidone compared to HCTZ at each study visit, the differences were not statistically significant at any visit (P>0.89 for all).</p> <p>The reduction in SBP during nighttime hours was -13.5±1.9 mm Hg for chlorthalidone and -6.4±1.7 mm Hg for HCTZ (P=0.009). The reduction in daytime mean SBP between both groups was not significantly different (-11.4±2.0 vs -8.1±1.9 mm Hg, respectively; P=0.230).</p> <p>Changes in serum potassium were similar between treatment groups (P=0.76). The incidence of hypokalemia was 50% in patients taking HCTZ and 46% in patients taking chlorthalidone (P=0.682).</p>
<p>Finnerty et al.³¹ (1980)</p> <p>HCTZ 50 mg plus reserpine 0.125 mg</p> <p>vs</p> <p>chlorthalidone 50 mg plus reserpine 0.25 mg</p>	<p>DB</p> <p>Patients with essential HTN unresponsive to diet control and diuretic therapy</p>	<p>N=57</p> <p>6 weeks</p>	<p>Primary: The change in mean DBP from baseline</p> <p>Secondary: Incidence of frequent or severe side effects</p>	<p>Primary: The chlorthalidone plus reserpine group had a mean decrease in DBP of 17.0 mm Hg at study endpoint compared with a mean decrease of 18.6 mm Hg in the HCTZ plus reserpine group.</p> <p>At study completion both treatment groups achieved diastolic control of at least 5 mm Hg below the targeted diastolic goal of 90 mm Hg.</p> <p>Secondary: There were no reports of frequent or severe side effects in either treatment group.</p>
<p>Bakris et al.³² (2012)</p> <p>Azilsartan medoxomil and chlorthalidone</p>	<p>DB, RCT</p> <p>Patients aged ≥18 years with stage 2 primary HTN</p>	<p>N=609</p> <p>10 weeks (after 2 week placebo run-in)</p>	<p>Primary: Change in trough, seated clinic systolic blood pressure at weeks 6 and 10</p>	<p>Primary: Change in SBP at week six demonstrated a mean difference of -5.6 mm Hg (95% CI, -8.3 to -2.9; P<0.001) in favor of the chlorthalidone group. Fewer patients in the chlorthalidone group required titration to a higher dose of diuretic (P<0.001). At the end of week 10, a greater mean SBP reduction was maintained in the chlorthalidone group compared to the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(single pill)</p> <p>vs</p> <p>azilsartan medoxomil and HCTZ (co-administered)</p> <p>Treatments were titrated to a target of <140/90 mm Hg (or <130/80 mm Hg if diabetes of chronic kidney disease)</p>			<p>Secondary:</p> <p>Change from baseline in clinic DBP and 24-hour mean systolic and diastolic blood pressures by ambulatory blood pressure monitoring</p>	<p>HCTZ group (-5.0 mm Hg; 95% CI, -7.5 to -2.5; P<0.001).</p> <p>Secondary:</p> <p>The chlorthalidone group demonstrated a significantly greater reduction in 24-hour mean SBP at weeks six and 10. For both clinica and 24-hour mean DBP, greater blood pressure reduction was observed in the chlorthalidone group compared to the HCTZ group at both study points.</p>
<p>Valmin et al.³³ (1975)</p> <p>HCTZ 12.5 mg BID</p> <p>vs</p> <p>furosemide 12.5, 25, or 40 mg BID</p> <p>vs</p> <p>placebo</p>	<p>DB, RCT, XO, 5 experimental periods each of 4 weeks</p> <p>Men and women with essential HTN</p>	<p>N=34</p> <p>20 weeks</p>	<p>Primary:</p> <p>Blood pressure, urinary output, serum electrolytes, safety and tolerability</p> <p>Secondary:</p> <p>Not reported</p>	<p>Primary:</p> <p>When compared to placebo, there was a significant reduction of blood pressure with HCTZ 12.5 mg BID and furosemide 12.5 mg BID (P<0.05).</p> <p>Paired comparison showed that HCTZ 12.5 mg BID and furosemide 25 and 40 mg BID had a similar hypotensive effect, irrespective of the initial blood pressure (P>0.10).</p> <p>When compared to placebo, the urinary output increased significantly with furosemide 12.5, 25, or 40 mg BID (P<0.05, P<0.01 and P<0.001, respectively) but not with the HCTZ group (P>0.10).</p> <p>Sodium level did not alter during the various treatment periods when compared with the placebo period, or between the individual treatment periods (P>0.10).</p> <p>Potassium level fell significantly during the HCTZ period (P<0.001) and furosemide 25 mg and 40 mg BID period (P<0.01 and P<0.001, respectively). Potassium level was not significantly affected with furosemide 12.5 mg BID (P>0.10).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Araoye et al. ³⁴ (1978) HCTZ 50 mg BID vs furosemide 40 mg BID	DB, XO Patients with HTN	N=not specified 3 months	Primary: Blood Pressure Secondary: Not reported	Primary: Furosemide and HCTZ significantly reduced blood pressure. The decrease in blood pressure was consistently greater in the HCTZ group than with furosemide; however the difference was significant in regards to SBP only. Secondary: Not reported
Madkour et al. ³⁵ (1996) HCTZ 50 mg QD vs indapamide 2.5 mg QD	RCT Patients aged 32 to 70 years with impaired renal function for 1 to 15 years and moderate HTN for 2 to 27 years, initial creatinine clearance between 32 and 80 mL/min/1.73 m ² BSA	N=28 24 months	Primary: Blood pressure, changes in creatinine clearance Secondary: Not reported	Primary: Blood pressure normalized in all patients taking either indapamide or HCTZ. There were no significant differences in SBP or DBP between groups. At 24 months, creatinine clearance progressively increased from 58±4.4 to 72±4.4 mL/min/1.73 m ² BSA in patients treated with indapamide (P<0.01). Creatinine clearance progressively decreased from 65±3.0 to 53±3.0 mL/min/1.73 m ² BSA in patients treated with HCTZ (P<0.01). Creatinine clearance significantly increased by 28.5±4.4% with indapamide and decreased by 17.4±3.0% with thiazide therapy (P<0.01). Secondary: Not reported
Ames ³⁶ (1996) HCTZ ≤25 mg (or its equivalent in other thiazides) up to 112.5 mg QD vs	MA (13 trials) Patients with HTN	N=1,547 1 to 25 months	Primary: Comparison of the effects of thiazides and indapamide on blood lipids and blood pressure Secondary: Not reported	Primary: The mean change from baseline was 1.4% for TC, 5.5% for HDL-C, and -0.5% for TG with indapamide. None of the differences were statistically significant. Low-dose thiazide therapy did not decrease TC at any data point. The mean percent increase in TC was 3.8%, in HDL-C was 3.1%, and in TG was 10.8% with low-dose HCTZ. The increases in TC and TG from baseline was statistically significant (P<0.01).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
indapamide 2.5 mg QD				<p>The mean change in TC was 6.3%, in HDL-C was -0.5%, and in TGs was 19.5% for higher doses of HCTZ. Increases from baseline in TC and TG were statistically significant.</p> <p>SBP decreased more with higher doses of HCTZ than with low-dose thiazide therapy (P<0.05). The effects of indapamide on systolic arterial pressure were intermediate between, and not statistically different from, either thiazide dose. Decreases in DBP did not differ among groups.</p> <p>Secondary: Not reported</p>
<p>Larochelle et al.³⁷ (1985)</p> <p>HCTZ 50 mg</p> <p>vs</p> <p>amiloride 5 mg/day and HCTZ 50 mg/day</p>	<p>DB, RCT</p> <p>Ambulant patients 18 to 70 years of age with essential HTN who after not being treated for ≥2 weeks prior to the trial had a supine DBP of 95 to 109 mm Hg and a serum potassium level of >3.5 mmol/L</p>	<p>N=266</p> <p>8 weeks</p>	<p>Primary: Blood pressure, serum potassium concentration</p> <p>Secondary: Not reported</p>	<p>Primary: At eight weeks, there were no differences between the two treatments in the mean blood pressure reductions (P value not reported).</p> <p>During the eight weeks of treatment, the HCTZ plus amiloride-treated patients experienced a decrease in mean supine blood pressure (159/99 to 138/88 mm Hg) and serum potassium levels (4.23 to 3.91 mmol/L) (P values not reported).</p> <p>During the eight weeks of treatment, HCTZ-treated patients experienced a reduction in mean supine blood pressure (157/99 to 138/87 mm Hg) and serum potassium levels (4.16 to 3.69 mmol/L) (P values not reported).</p> <p>Hypokalemia occurred less frequently in HCTZ plus amiloride-treated patients compared to HCTZ-treated patients (14 and 29%, respectively; P=0.0026). However, the proportions of patients with a potassium level exceeding 4.5 mmol/L were similar (4.5 vs 3.9%, respectively; P value not reported).</p> <p>Secondary: Not reported</p>
<p>Salmela et al.³⁸ (1986)</p> <p>HCTZ 25 mg daily</p>	<p>DB, MC, PG, RCT</p> <p>Adult patients with mild to moderate HTN</p>	<p>N=40</p> <p>12 weeks</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary:</p>	<p>Primary: At the end of the first treatment period (four weeks), mean supine SBP and DBP was 161 and 91 mm Hg in amiloride plus HCTZ-treated patients (P<0.01 and P<0.001, respectively).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs amiloride 2.5 mg/day and HCTZ 25 mg/day			Not reported	<p>At the end of the first treatment period (four weeks), mean supine SBP and DBP was 165 and 96 mm Hg in HCTZ-treated patients (P<0.01 for both).</p> <p>At the end of the second treatment period (eight weeks), mean supine SBP and DBP was 154 and 86 mm Hg in amiloride plus HCTZ-treated patients (P<0.01 and P<0.001).</p> <p>At the end of the second treatment period (eight weeks), mean supine SBP and DBP was 155 and 90 mm Hg in HCTZ-treated patients (P<0.001 and P<0.001).</p> <p>There were no significant differences in blood pressure reduction between the two treatments (P value not reported).</p> <p>Secondary: Not reported</p>
Multicenter Diuretic Cooperative Study Group ³⁹ (1981) HCTZ 50 mg QD vs amiloride and HCTZ 5-50 mg QD (fixed-dose combination product) vs amiloride 5 mg QD	DB, MC, RCT Patients 21 to 69 years of age with mild to moderate essential HTN (supine DBP 95 to 115 mm Hg)	N=179 12 weeks	Primary: Change from baseline in average supine SBP and DBP Secondary: Heart rate, body weight, serum potassium	Primary: Baseline vs 12 week average supine blood pressure was 153/101 vs 139/93 for amiloride-, 160/100 vs 137/90 for amiloride and HCTZ- and 154/101 vs 134/89 mm Hg for HCTZ-treated patients. Reductions in supine blood pressure were significant with all treatments (P<0.01). The SBP reduction was significantly greater with amiloride and HCTZ-treated patients compared to amiloride-treated patients at all weeks and HCTZ-treated patients at four and eight weeks (P<0.05, both). Secondary: No significant changes from baseline in heart rate were observed in amiloride and HCTZ-treated patients (P values not reported). An increase in heart rate of 3.3 bpm was observed in these patients (P<0.05). Changes in body weight from baseline were -1.17 kg in amiloride and HCTZ-, -0.72 kg in HCTZ- and 0.045 kg in amiloride-treated patients (P<0.05, for amiloride plus HCTZ only). Changes in serum potassium from baseline were 0.23 in amiloride- (P<0.01), -0.38 in amiloride and HCTZ- (P<0.01) and -0.59 mEq/L in HCTZ-treated patients (P<0.01). The change in HCTZ-treated patients

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				was statistically greater than the change in the amiloride and HCTZ-treated patients (P<0.05). Twenty three, two and zero percent of HCTZ-, amiloride and HCTZ- and amiloride-treated patients experienced hypokalemia.
Wray et al. ⁴⁰ (2010) HCTZ 12.5 to 50 mg QD vs spironolactone 25 to 100 mg QD Patients also received potassium 0 to 40 mEq to maintain blinding.	DB, RCT Patients ≥60 years of age with stage 1 HTN	N=36 6 months	Primary: Blood pressure, sympathetic nervous system activity Secondary: Not reported	Primary: Arterial blood pressure decreased significantly with spironolactone (SBP: 160 to 134 mm Hg and DBP: 77 to 68 mm Hg) and with HCTZ (SBP: 161 to 145 mm Hg and 78 to 73 mm Hg). There was no significant difference between the groups. Sympathetic nervous system activity was significantly reduced after spironolactone (plasma norepinephrine: 378 to 335 pg/mL; P=0.04; [³ H]-norepinephrine release rate: 2.74 to 1.97 μg/min/m ² ; P=0.04), but not with HCTZ (plasma norepinephrine: 368 to 349 pg/mL; P=0.47; [³ H]-norepinephrine release rate: 2.63 to 2.11 μg/min/m ² ; P=0.21). There were no instances of hyperkalemia, and no other adverse effects were reported. Secondary: Not reported
Nash et al. ⁴¹ (1977) HCTZ 50 mg BID vs spironolactone 50 mg BID vs spironolactone 100 mg BID vs	DB, RCT Male outpatients between the ages of 21 to 65 years, with essential HTN, DBP between 90 to 114 mm Hg	N=79 12 weeks	Primary: Change in SBP, DBP, blood urea nitrogen, serum potassium, gynecomastia Secondary: Not reported	Primary: At week 12, all study groups exhibited significant reductions in SBP and DBP from baseline (P<0.05). At week 12, all three spironolactone monotherapy groups exhibited statistically significant increases in blood urea nitrogen from baseline (P<0.05). At week 12, the HCTZ monotherapy group was associated with a statistically significant decrease in serum potassium levels (P<0.001). At week 12, all three spironolactone monotherapy groups exhibited statistically significant increases in serum potassium levels from baseline (P<0.05). At week 12, the spironolactone and HCTZ combination group was not

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
spironolactone 200 mg BID vs spironolactone and HCTZ 25-25 mg BID (fixed-dose combination product)				associated with statistically significant increases in serum potassium levels from baseline. A dose-related risk of gynecomastia was observed in the spironolactone-treated patients. Among patients treated with spironolactone 50, 100, or 200 mg BID; 5.5, 11.8, and 40% reported gynecomastia symptoms. Of the patients randomized to spironolactone and HCTZ combination product, 7.7% reported gynecomastia symptoms. Secondary: Not reported
Schrijver et al. ⁴² (1979) Spironolactone 50 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IA) vs spironolactone 50 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IB) vs	DB Patients, between 24 to 63 years of age, with DBP between 90 to 114 mm Hg	N=49 20 weeks (4-week placebo run-in, 8-week single drug therapy, 4-week two-drug therapy, 4-week recovery)	Primary: Change in MABP, serum potassium, uric acid level, blood glucose, blood urea nitrogen, creatinine, plasma renin activity, aldosterone, side effects Secondary: Not reported	Primary: Following eight weeks of therapy with a single drug, all study groups exhibited a statistically significant reduction in MABP from baseline (P<0.01). There were no significant differences in MABP reduction among the study groups. The addition of a second drug to the antihypertensive regimen was not associated with a significant improvement in MABP. At the end of the two-drug treatment period, there were no differences in MABP among any of the study groups. Spironolactone therapy was associated with a significant decrease in serum potassium concentration from baseline (P<0.001). Spironolactone regimens were not associated with a significant change in potassium levels from baseline. Following eight weeks of therapy with a single drug, HCTZ-treated patients experienced a statistically significant increase in uric acid from baseline (P<0.001). Groups IIA and IIB also experienced a significant but smaller increase in uric acid level from baseline (P<0.05) with no change in groups I and IV. During the single-drug treatment phase, patients randomized to group I experienced a significant increase in blood glucose from baseline (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>spironolactone 100 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IIA)</p> <p>vs</p> <p>spironolactone 100 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IIB)</p> <p>vs</p> <p>spironolactone 200 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IIIA)</p> <p>vs</p> <p>spironolactone 200</p>				<p>During the single-drug treatment phase, all patients except those randomized to group I experienced a significant increase in blood urea nitrogen from baseline (P<0.05).</p> <p>During the single-drug treatment phase, patients randomized to groups I and II experienced a significant increase in serum creatinine from baseline (P<0.05).</p> <p>During the single-drug treatment phase, all treatment groups experienced a significant increase in plasma renin activity from baseline (P<0.01). The addition of HCTZ in the two-drug study phase was associated with a rise in plasma renin activity in all study groups (P<0.05).</p> <p>All treatment groups experienced a significant increase in plasma aldosterone from baseline (P<0.05).</p> <p>Gynecomastia was reported only by patients randomized to the higher-dose spironolactone groups.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IIIB)</p> <p>vs</p> <p>HCTZ 50 mg BID for 8 weeks (single drug phase), with the addition of a placebo for subsequent 4 weeks (group IVA)</p> <p>vs</p> <p>HCTZ 50 mg BID for 8 weeks (single drug phase), subsequently HCTZ 50 mg BID was added to the regimen for an additional 4 weeks (group IVB)</p>				
<p>Johnson et al.⁴³ (2009)</p> <p>HCTZ 12.5 to 25 mg QD for 9</p>	<p>RCT</p> <p>Patients 17 to 65 years of age mild to moderate essential</p>	<p>N=368</p> <p>15 to 18 weeks</p>	<p>Primary: Blood pressure lowering effect of drug initiation order: the addition</p>	<p>Primary: When analyzed by order of initiation of the two drugs, the response to HCTZ and atenolol was greater overall than that seen for atenolol and HCTZ (P=0.0007 and P<0.0001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>weeks, followed by HCTZ 12.5 to 25 mg QD and atenolol 50 to 100 mg QD for 9 weeks</p> <p>vs</p> <p>atenolol 50 to 100 mg QD for 9 weeks, followed by atenolol 50 to 100 mg QD and HCTZ 12.5 to 25 mg QD for 9 weeks</p>	<p>HTN</p>		<p>of a β-blocker to a thiazide versus the addition of a thiazide to a β-blocker</p> <p>Secondary: Not reported</p>	<p>This study suggests that initiation of HCTZ followed by atenolol results in greater blood pressure lowering as compared with initiation in the reverse order, with differences that are potentially clinically important.</p> <p>Secondary: Not reported</p>
<p>Dahlöf et al.⁴⁴ (1991) Hypertension (STOP)</p> <p>Atenolol 50 mg QD, HCTZ 25 mg QD plus amiloride 2.5 mg QD, metoprolol 100 mg QD, or pindolol 5 mg QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, RCT</p> <p>Swedish men and women 70 to 84 years old with treated or untreated essential HTN defined as SBP \geq180 mm Hg with a DBP of \geq90 mm Hg, or DBP $>$105 mm Hg irrespective of the SBP measured on 3 separate occasions during a 1-month placebo run-in phase in previously untreated patients</p>	<p>N=1,627</p> <p>25 months</p>	<p>Primary: Frequency of stroke, MI, and other cardiovascular death</p> <p>Secondary: Not reported</p>	<p>Primary: The active treatments significantly reduced the number of all primary endpoints (94 vs 58; RR, 0.60; 95% CI, 0.43 to 0.85; P=0.0031), frequency of stroke (53 vs 29; RR, 0.53; 95% CI, 0.33 to 0.86; P=0.0081) and frequency of other cardiovascular deaths (13 vs 4; RR, 0.30; 95% CI, 0.07 to 0.97) compared to placebo.</p> <p>There was not a statistically significant decrease observed in the rate of MI between the active treatments and placebo (28 vs 25; RR, 0.87; 95% CI, 0.49 to 1.56).</p> <p>Secondary: Not reported</p>
<p>Frishman et al.⁴⁵</p>	<p>DB, MC, PC, RCT</p>	<p>N=512</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(1994)</p> <p>HCTZ 6.25 or 25 mg QD</p> <p>vs</p> <p>bisoprolol 2, 5, 10, or 40 mg QD</p> <p>vs</p> <p>bisoprolol plus HCTZ, all possible combinations</p>	<p>Patients 21 years and older with mild to moderate essential HTN whose weight was 35% of the ideal for height and frame and mean sitting DBP was stable and between 95 to 115 mm Hg</p>	<p>12 weeks</p>	<p>Changes in DBP and SBP</p> <p>Secondary: Not reported</p>	<p>All treatment groups (all doses) of bisoprolol, HCTZ and the combination of bisoprolol and HCTZ significantly reduced sitting DBP from baseline (P<0.01).</p> <p>The reduction in blood pressure was significantly greater as the doses of the bisoprolol, HCTZ and the combination of bisoprolol-HCTZ were increased (P<0.05).</p> <p>The combination bisoprolol and HCTZ significantly reduced sitting DBP compared to the separate agents as monotherapy (P<0.01).</p> <p>With higher doses of HCTZ, there was a significantly higher incidence of hypokalemia, defined as potassium <3.5 mmol/L (P<0.01). Incidence of hyperuricemia also significantly increased with the increase in HCTZ dose (P<0.01). Adverse events associated with hypokalemia and hyperuricemia were not reported.</p> <p>As the dose of bisoprolol was increased, the frequency and severity of adverse events reported significantly increased (P<0.05). Adverse events reported included asthenia, diarrhea, dyspepsia and somnolence, but severity of effects was not reported.</p> <p>Secondary: Not reported</p>
<p>Frishman et al.⁴⁶ (1995)</p> <p>HCTZ 25 mg QD</p> <p>vs</p> <p>bisoprolol 5 mg QD</p> <p>vs</p> <p>bisoprolol and</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients ≥21 years with mild to moderate (stage II or II) systemic HTN whose body weight was not >10% below or 35% above the ideal weight for height and frame, and were off all</p>	<p>N=547</p> <p>10 weeks</p>	<p>Primary: Changes in blood pressure and adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: All active treatment groups significantly reduced sitting DBP and SBP from baseline compared to placebo (P<0.01).</p> <p>Addition of HCTZ 6.25 mg contributed significantly to the blood pressure lowering effects of bisoprolol 5 mg.</p> <p>The combination bisoprolol and HCTZ 5-6.25 mg produced a significantly greater reduction in mean sitting DBP from baseline (-12.6±0.5 mm Hg) compared to bisoprolol 5 mg alone (-10.5±0.5 mm Hg; P=0.02) and HCTZ 25 mg alone (-8.5±0.5 mm Hg; P<0.01). Bisoprolol 5 mg monotherapy was significantly better a reducing DBP compared to HCTZ 25 mg alone (P=0.03).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 5-6.25 mg QD (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>antihypertensive medications before study entry and sitting DBP was 95 to 115 mm Hg on 3 consecutive weekly visits</p>			<p>The combination bisoprolol and HCTZ 5-6.25 mg produced a significantly greater reduction in mean sitting SBP from baseline (-15.8 mm Hg) compared to bisoprolol 5 mg alone (-10 mm Hg; P<0.01) and HCTZ 25 mg alone (-15.8 mm Hg; P<0.01). There was not a significant difference in mean reduction between bisoprolol 5 mg alone and HCTZ 25 mg alone.</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination had a 73% response rate compared to 61% for the bisoprolol group and 47% for the HCTZ group.</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination was found to be significantly more effective compared to bisoprolol 5 mg or HCTZ 25 mg in all subgroups of patients regardless of age, race, gender, or smoking history (P>0.05 for all comparisons).</p> <p>Bisoprolol and HCTZ 5-6.25 mg in combination did not have an increase in frequency or severity of adverse events. The adverse events were comparable to that in the placebo group and frequency among groups was not significant. The most common adverse events reported were headache, dizziness, fatigue, and cough.</p> <p>Significantly greater number patients in the HCTZ 25 mg group (6.5%) experienced hypokalemia (potassium <3.4 mEq/L) compared to the bisoprolol 5 mg group (0.7%; P<0.01), the bisoprolol and HCTZ combination group (0.7%; P<0.01), and placebo (0%; P<0.01).</p> <p>Hyperglycemia occurred in 7.4% of patients in the HCTZ 25 mg group, which was significantly higher than in the placebo group (5.2%; P=0.03). Also, the incidence of hyperuricemia (uric acid >7.5 mg/dL) was significantly higher in the HCTZ 25 mg group (24.4%) compared to placebo (2.7%; P<0.01).</p> <p>Secondary: Not reported</p>
<p>Dafgard et al.⁴⁷ (1981)</p>	<p>DB, MC, RCT</p> <p>Patients with</p>	<p>N=31</p> <p>32 weeks</p>	<p>Primary: Blood pressure, heart rate, adverse</p>	<p>Primary: After the eight week run-in period with HCTZ 25 mg alone, the mean supine blood pressure was significantly reduced from 183/110 to 172/103</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>HCTZ 50 mg QD in the morning</p> <p>vs</p> <p>HCTZ 25 mg QD in the morning</p> <p>vs</p> <p>metoprolol and HCTZ 200-25 mg QD in the morning (fixed-dose combination product)</p>	<p>essential HTN (WHO stages I or II) not adequately controlled ($\geq 160/95$ mm Hg) on HCTZ 25 mg/day</p>		<p>events, laboratory values</p> <p>Secondary: Not reported</p>	<p>mm Hg ($P < 0.01/P < 0.01$). The increased dose of HCTZ 50 mg following the run-in period did not further significantly reduce the mean blood pressure (165/104 mm Hg).</p> <p>A small but statistically significant reduction in supine heart rate was seen when the HCTZ dose was increased from 25 to 50 mg (82 down to 78 bpm; $P < 0.05$).</p> <p>After the 12 week double-blind period, the mean supine blood pressure was 153/98 mm Hg in the HCTZ 50 mg group. After the 12 week follow-up period, there was not any additional decrease in blood pressure (153/97 mm Hg).</p> <p>Fixed-dose combination product of metoprolol and HCTZ produced a significant reduction in supine blood pressure after 12 weeks of therapy from 172/105 mm Hg on HCTZ 25 mg alone to 154/97 mm Hg on the combination therapy ($P < 0.001/P < 0.01$). Similar results were found with the standing blood pressure reductions, from 165/108 to 147/97 mm Hg ($P < 0.001/P < 0.001$).</p> <p>After the eight week run-in period, the supine heart rate was 80 bpm which decreased to 64 bpm with the metoprolol and HCTZ fixed-dose combination ($P < 0.001$). The values for standing heart rate demonstrated similar significant reductions (85 to 66 bpm; $P < 0.001$).</p> <p>After the additional 12 week follow-up, the patients in the metoprolol and HCTZ fixed-dose combination group did not demonstrate a significant further reduction in heart rate or blood pressure in any position.</p> <p>Both agents were tolerated and the most common adverse events reported included insomnia, headache, tiredness, and shortness of breath. The majority of events were mild, few were moderate, and none were severe. The only significant changes in laboratory values occurred with the HCTZ 25 and 50 mg groups, where an increase in serum uric acid was observed from 0.30 to 0.34 and 0.35 mmol/L, respectively ($P < 0.01$ and $P < 0.05$; respectively).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				Secondary: Not reported
Smilde et al. ⁴⁸ (1983) Metoprolol 400 mg QD in the morning for 5 weeks, followed by metoprolol and HCTZ 200-25 mg QD in the morning (fixed-dose combination product) (group 1) vs metoprolol and HCTZ 200-25 mg QAM for 5 weeks (fixed-dose combination product), followed by metoprolol 400 mg QD in the morning for 5 weeks (group 2)	DB, PG, RCT, XO Patients <65 years with essential HTN (supine DBP \geq 95 mm Hg) not controlled on metoprolol 200 mg alone	N=37 15 weeks	Primary: Changes in DBP, SBP, and heart rate Secondary: Not reported	Secondary: Not reported Primary: Both group 1 and 2 significantly reduced DBP (P<0.01) from baseline and the two groups were not significantly different from each other. The combination products significantly reduced SBP from baseline (P<0.05, P<0.01 depending on comparison) Group 2 significantly reduced heart rate at the end of the study compared to baseline (P<0.05). Clinically relevant changes in laboratory parameters or mean body weight were not observed between the groups. Secondary: Not reported
Stevens et al. ⁴⁹ (1982) <u>Dose-finding phase:</u> propranolol and HCTZ 80-50, 160-50, 240-50, 320-50 mg/day in 2	DB, PG, RCT Patients with mild to moderate essential HTN (DBP 100 to 125 mm Hg)	N=158 25 weeks	Primary: Mean changes of SBP and DB, heart rate, lab values Secondary: Not reported	Primary: After the 12 week dose finding-phase, 94% of patients had a decrease \geq 10 mm Hg in DBP. The mean SBP and DBP reduced from 158.0 (\pm 17.3)/105.6 (\pm 6.0) mm Hg to 131.5 (\pm 14.4)/86.4 (\pm 6.7) mm Hg (P<0.001). After the 10 week portion of the study, there were significantly greater increases (P<0.05) in mean SBP or DBP with propranolol and HCTZ alone vs the combination product of propranolol and HCTZ from the end

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>divided doses (fixed-dose combination product)</p> <p>vs</p> <p>propranolol 80, 160, 240, or 320 mg/day in 2 divided doses</p> <p><u>Double-blind phase:</u> HCTZ</p> <p>vs</p> <p>propranolol</p> <p>vs</p> <p>propranolol and HCTZ (fixed-dose combination product)</p>				<p>of the dose-finding to the last four biweekly visits to the mean of those visits, and to the last visit. The mean increases of SBP and DBP at the endpoint were: propranolol, 10.2/6.3 mm Hg; HCTZ 13.1/9.3 mm Hg; propranolol-HCTZ combination product 3/1.5 mm Hg.</p> <p>There was a significant decrease in heart rate as the dose of propranolol was increased though the trial ($P>0.30$).</p> <p>The only lab value that showed a statistically significant change was serum chloride. The percent of patients that fell outside of the normal range were as follows: propranolol 6/36 (17%), HCTZ 14/37 (38%), and combination 4/28 (14%); $P<0.05$.</p> <p>Secondary: Not reported</p>
<p>Borhani et al.⁵⁰ (1996) MIDAS</p> <p>HCTZ 12.5 to 25 mg QD</p> <p>vs</p> <p>isradipine 2.5 to 5 mg BID</p>	<p>DB, MC, positive-control, RCT</p> <p>Patients, average of 58.5 years old, with HTN</p>	<p>N=883</p> <p>3 years</p>	<p>Primary: Rate of progression of intimal-medial thickness in carotid arteries</p> <p>Secondary: Rate of cardiovascular events (MI, stroke, CHF, angina,</p>	<p>Primary: There was no difference in the rate of progression of intimal-medial thickness between the treatment groups ($P=0.68$).</p> <p>Secondary: The rate of cardiovascular events was greater in the isradipine group than in the HCTZ group (5.65 vs 3.17%; $P=0.07$).</p> <p>The rate of non-major cardiovascular events was greater in the isradipine group than in the HCTZ group (9.05 vs 5.22%; $P=0.02$).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			sudden death), rate of non-major cardiovascular events and procedures (TIAs, dysrhythmia, aortic valve replacement, femoral popliteal bypass graft), blood pressure	There was a significant decrease in SBP in the HCTZ group as compared to isradipine (-19.5 vs -16.0 mm Hg; P=0.002). There was no difference in change in DBP (both groups, -13.0 mm Hg).
Manyemba et al. ⁵¹ (1997) HCTZ 25 mg QD plus reserpine 0.25 mg QD vs HCTZ 25 mg QD plus nifedipine SR 20 mg BID	OL, RCT, XO African American patients aged 21 to 65 years with HTN (blood pressure >140/95 mm Hg) after 4 weeks of daily HCTZ therapy	N=32 10 weeks	Primary: The change in blood pressure from baseline to the end of each 4-week treatment period Secondary: Not reported	Primary: Reserpine reduced SBP by 15.9 mm Hg (95% CI, 8.4 to 23.4) and DBP by 11.1 mm Hg (95% CI, 7.5 to 14.6). Nifedipine SR reduced SBP by 18.9 mm Hg (95% CI, 12.1 to 25.7) and DBP by 9.6 mm Hg (95% CI, 7.2 to 12.0). There was no significant difference between the two groups. Secondary: Not reported
Jamerson et al. ⁵² (2007) ACCOMPLISH HCTZ 12.5 to 25 mg QD and benazepril 20 to 40 mg QD vs benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD	DB, MC, RCT Patients >60 years of age with HTN and at high risk of cardiovascular events	N=10,704 Analysis performed at 6 months (complete trial duration 5 years)	Primary: Changes in mean SBP from baseline to 6 months, blood pressure control rates (SBP/DBP <140/90 mm Hg or <130/89 mm Hg for patients with diabetes and chronic kidney disease) Secondary: Not reported	Primary: At baseline, 97% of subjects were treated with antihypertensive medications at entry, but only 37% of participants had blood pressure control. Mean blood pressure fell from 145/80 to 132/74 mm Hg after six months of treatment with either combination regimen (P<0.001). The six month blood pressure control rate was 73% in the overall trial (78% in the United States), 43% in diabetics, and 40% in patients with renal disease. Of the patients uncontrolled, 61% were not on maximal medications. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Jamerson et al.⁵³ (2008) ACCOMPLISH</p> <p>HCTZ 12.5 to 25 mg QD and benazepril 20 to 40 mg QD</p> <p>vs</p> <p>benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Patients >60 years of age with HTN and at high risk of cardiovascular events</p>	<p>N=11,506</p> <p>36 months (mean)</p>	<p>Primary: The composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.</p> <p>Secondary: Death from cardiovascular causes, nonfatal MI, and nonfatal stroke</p>	<p>Primary: There were 552 primary-outcome events in the benazepril plus amlodipine group (9.6%) and 679 events in the benazepril plus HCTZ group (11.8%). The absolute risk reduction with benazepril plus amlodipine therapy was 2.2% and the relative risk reduction was 19.6% compared to benazepril plus HCTZ (HR, 0.80; 95% CI, 0.72 to 0.90; P<0.001).</p> <p>Secondary: For the secondary end point of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, there were 288 (5%) events in the benazepril plus amlodipine group compared to 364 (6.3%) events in the benazepril plus HCTZ group. The absolute risk reduction with benazepril plus amlodipine therapy was 1.3% and the RR reduction was 21.2% compared to benazepril plus HCTZ (HR, 0.79; 95% CI, 0.67 to 0.92; P=0.002).</p>
<p>Bakris et al.⁵⁴ (2013) ACCOMPLISH</p> <p>HCTZ 12.5 to 25 mg QD and benazepril 20 to 40 mg QD (B+H)</p> <p>vs</p> <p>benazepril 20 to 40 mg QD and amlodipine 5 to 10 mg QD (B+A)</p>	<p>Post hoc analysis</p> <p>Patients included in the ACCOMPLISH trial (>60 years of age with HTN and at high risk of cardiovascular events) stratified by presence of known CAD at baseline</p>	<p>N=11,506</p> <p>36 months (mean)</p>	<p>Primary: The composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.</p>	<p>Primary: Among the patients with CAD, 13% in the B+A group and 16% in the B+H group reached the primary end point, representing an absolute risk reduction of 3% and a hazard reduction of 18%. The difference in event rates of the composite primary end point between the B+A and B+H groups was significant (HR, 0.80; 95% CI, 0.69 to 0.92; P=0.0016).</p> <p>Among the patients without CAD, fewer patients in the B+A treatment arm (204 of 3,096) reached the primary end point compared with those in the B+H arm (251 of 3,095). The difference in event rates between the B+A and B+H groups was significant (HR, 0.81; 95% CI, 0.67 to 0.98; P=0.026).</p> <p>A comparison of patients with and without CAD event rates for the primary end points demonstrated that the patients with CAD had a greater</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Secondary: Death from cardiovascular causes, nonfatal MI, and nonfatal stroke	CV event rate than those without CAD (15 vs 7%; P<0.0001). Secondary: The composite secondary end point of CV mortality, MI, and stroke occurred in 5.74% in the B+A group and 8% in the B+H group, resulting in an absolute risk reduction of 1.95% and a hazard reduction of 25% (HR, 0.73; 95% CI, 0.59 to 0.9; P=0.033). The rate of all-cause mortality differed significantly between the treatment arms (HR, 0.77; 95% CI, 0.6 to 0.99; P=0.042). Among the patients without CAD, the rates of CV mortality, MI, and stroke did not differ between the two arms (HR, 0.86; 95% CI, 0.68 to 1.08). The secondary end point events were lower in the group of patients without CAD.
Wing et al. ⁵⁵ (2003) ANBP2 HCTZ vs enalapril The choice of the specific agent and dose was made by the family practitioner.	MC, OL, PRO, RCT Patients 65 to 84 years of age with average SBP while sitting of ≥ 160 mm Hg or an average DBP of ≥ 90 mm Hg (if the SBP was ≥ 140 mm Hg)	N=6,083 4.1 years (median)	Primary: All cardiovascular events or death from any cause (both initial and subsequent fatal and nonfatal cardiovascular events) Secondary: Not reported	Primary: By the end of the study, blood pressure had decreased to a similar extent in both groups (a decrease of 26/12 mm Hg). There were 695 cardiovascular events or deaths from any cause in the ACE inhibitor group (56.1 per 1,000 patient-years; HR, 0.89; 95% CI, 0.79 to 1.0; P=0.05) compared to 736 in the diuretic group (59.8 per 1,000 patient-years). The beneficial effects of ACE inhibitor treatment were more evident in male subjects (HR, 0.83; 95% CI, 0.71 to 0.97; P=0.02). The rates of nonfatal cardiovascular events and MI decreased with ACE inhibitor treatment, whereas a similar number of strokes occurred in each group (although there were more fatal strokes in the ACE inhibitor group). Secondary: Not reported
Poldermans et al. ⁵⁶ (2007) HCTZ 12.5 mg QD and lisinopril 10 to 20 mg	AC, DB, MC, PG, RCT Males and females, ages 18 years and older with HTN (mean DBP ≥ 110)	N=130 6 weeks	Primary: Safety/adverse events, vital signs, hematology, biochemistry variables	Primary: Both treatments were well tolerated, 26 (40.6%) of patients receiving amlodipine and valsartan and 21 (31.8%) of patients receiving lisinopril and HCTZ reported an adverse events and most were not considered drug related. Peripheral edema was reported more often in the amlodipine and valsartan

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs amlodipine 5 to 10 mg QD and valsartan 160 mg QD	mm Hg and <120 mm Hg)		Secondary: Efficacy (mean DBP, response rate, proportion of patients with mean DBP <90 mm Hg or a \geq 10 mm Hg reduction from baseline)	group than the lisinopril and HCTZ group (7.7 vs 1.5%) and cough was reported less often in the amlodipine and valsartan group than the receiving lisinopril and hydrochlorothiazide group (1.6 vs 3.0%). No difference was found between the treatments in changes in laboratory values or biochemistry variables. Secondary: Both treatments led to a reduction in mean SBP and DBP (P<0.0001 for both from baseline) but were not significantly different from each other. Mean blood pressure for each group at study end: amlodipine and valsartan 135.0/83.6 mm Hg and lisinopril and HCTZ 138.7/85.2 mm Hg. The response rate was similar among the groups (100 vs 95.5%; P value not significant).
Fogari et al. ⁵⁷ (2007) CANDIA HCTZ 12.5 mg QD and candesartan 16 mg vs amlodipine 10 mg QD	DB, MC, RCT Patients, 20 to 80 years old, with mild to moderate uncomplicated HTN not controlled on monotherapy with an antihypertensive (SBP <180 mm Hg and DBP 90 to 110 mm Hg)	N=203 8 weeks	Primary: Decrease in DBP Secondary: Sitting SBP, reduction of the orthostatic blood pressure at least two minutes after standing, change in heart rate, percentage of patients normalized (DBP <90 mm Hg and SBP <140 mm Hg), percentage of responders (reduction in DBP \geq 5 mm Hg)	Primary: There was no significant difference in the mean decrease in DBP between treatment groups; the difference in final DBP was -0.02 mm Hg (95% CI, -1.48 to 1.52 mm Hg; P=0.979). Secondary: There was no significant difference between the groups at week eight for the following: sitting SBP (P=0.835), heart rate (P<0.500), orthostatic SBP (P=0.883), orthostatic DBP (P=0.264), percentage of patients normalized (P=10), percentage of responders (P=0.900). The number of patients reporting an adverse event was greater in the amlodipine group (P=0.001). The number of patients reporting an adverse drug-related event was greater in the amlodipine group (P<0.001). Changes in blood chemistry and other secondary measurements were not significantly different between the treatment groups.
Neutel et al. ⁵⁸ (2008)	AC, DB, RCT	N=538	Primary: Change in SBP	Primary: At week eight, there was a reduction in SBP of 27.1 mm Hg with

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 25 mg QD and irbesartan 300 mg vs irbesartan 300 mg QD vs HCTZ 25 mg QD	Patients with moderate HTN (seated SBP 160 to 179 mm Hg when DBP <110 mm Hg; or DBP 100 to 109 mm Hg when SBP <180 mm Hg)	12 weeks	after week 8 Secondary: Change from baseline in DBP at weeks 8 and 12, SBP at week 12, proportion of responders (SBP <140 mm Hg and DBP <90 mm Hg) at weeks 8 and 12	irbesartan and HCTZ compared to 22.1 mm Hg with irbesartan monotherapy (P=0.0016) and 15.7 mm Hg with HCTZ (P<0.0001). Secondary: At week eight, there was a reduction in DBP of 14.6 mm Hg with irbesartan and HCTZ compared to 11.6 mm Hg with irbesartan monotherapy (P=0.0013) and 7.3 mm Hg with HCTZ (P<0.0001). A significantly greater percentage of patients reached a treatment goal of SBP <140 mm Hg and DBP <90 mm Hg by week eight with irbesartan and HCTZ (53.4%) compared with irbesartan (40.6%; P=0.0254) and HCTZ (20.2%; P<0.0001) alone. Treatment was well tolerated in all three treatment groups with a slight increase in adverse events in the combination therapy group.
Salerno et al. ⁵⁹ (2004) HCTZ 12.5 mg QD and losartan 50 mg vs losartan 50 to 100 mg QD Doses were titrated as needed to reach blood pressure goal (<90 mm Hg).	DB, RCT Patients with severe HTN	N=585 6 weeks	Primary: Proportion of patients achieving goal blood pressure Secondary: Adverse events	Primary: Almost twice as many patients achieved goal blood pressure at four weeks on losartan 50 mg and HCTZ 12.5 mg vs losartan 50 to 100 mg monotherapy (P=0.002). Almost three times as many patients achieved goal blood pressure at six weeks with losartan and HCTZ vs losartan monotherapy (P<0.001). Adverse experiences on losartan and HCTZ (43%) were significantly less than with losartan monotherapy (53%).
Minami et al. ⁶⁰ (2007) HCTZ 12.5 mg/day and losartan 50 mg/day	OL Japanese outpatients with essential HTN treated for ≥2 months with either	N=15 12 months	Primary: Changes in blood pressure Secondary: Not reported	Primary: In patients who had previously received candesartan, 24-hour blood pressure decreased significantly from 137/89 mm Hg to 126/81 mm Hg after three months (P<0.05/P<0.001) and to 123/81 mm Hg after 12 months (P<0.01/P<0.001) of treatment with losartan and HCTZ.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs candesartan 8 mg QD or amlodipine 5 mg QD	candesartan or amlodipine and 24-hour ambulatory blood pressure $\geq 135/80$ mm Hg			In patients who had previously received amlodipine, 24-hour blood pressure decreased significantly from 137/81 to 125/75 mm Hg after three months ($P < 0.05/P < 0.05$) and to 124/77 mm Hg after 12 months ($P < 0.05/P$ value not significant) of treatment with losartan and HCTZ. There were significant decreases in SBP during the daytime, nighttime and early morning after 12 months in both groups. No adverse changes in the indices of glucose or lipid metabolism were observed in either group. Secondary: Not reported
Chrysant et al. ⁶¹ (2004) HCTZ 12.5 to 25 mg QD and olmesartan 10 to 40 mg QD vs olmesartan 10 to 40 mg QD vs HCTZ 12.5 to 25 mg QD vs placebo	DB, RCT, factorial design Patients with a baseline mean seated DBP of 110 to 115 mm Hg	N=502 8 weeks	Primary: Change in DBP at week 8 Secondary: Change in SBP at week 8	Primary: Olmesartan and HCTZ produced greater reductions in seated DBP at week eight than did monotherapy with either component. All olmesartan and HCTZ combinations significantly reduced DBP compared with placebo in a dose-dependent manner. Reductions in mean trough DBP were 8.2, 16.4, and 21.9 mm Hg with placebo, olmesartan 20 mg plus HCTZ 12.5 mg, and olmesartan 40 mg plus HCTZ 25 mg, respectively. Secondary: Olmesartan and HCTZ produced greater reductions in seated SBP at week eight than did monotherapy with either component. All olmesartan and HCTZ combinations significantly reduced DBP compared with placebo in a dose-dependent manner. Reductions in mean trough SBP were 3.3, 20.1, and 26.8 mm Hg with placebo, olmesartan 20 mg plus HCTZ 12.5 mg, and olmesartan 40 mg plus HCTZ 25 mg, respectively. All treatments were well tolerated.
White et al. ⁶² (2008) Val-DICTATE	DB, MB, RCT Patients with stage 1	4 weeks Duration not	Primary: Percentage of patients whose	Primary: A significantly higher proportion of hypertensive patients met blood pressure control levels in the valsartan and HCTZ group (37%) compared

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
HCTZ 25 mg QD vs valsartan and HCTZ 160-12.5 mg QD (fixed-dose combination product)	to 2 HTN whose BP remained uncontrolled on HCTZ 12.5 mg	reported	clinic blood pressure values were <140/90 mm Hg and blood pressure values Secondary: Not reported	with the HCTZ group (16%; P<0.001). Changes in SBP and DBP were significantly greater with valsartan and HCTZ (-12.4/-7.5 mm Hg) compared to HCTZ (-5.6/-2.1 mm Hg; P<0.001). Secondary: Not reported
White et al. ⁶³ (2008) HCTZ 25 mg QD and valsartan 160 mg vs HCTZ 25 mg QD and telmisartan 80 mg vs placebo	DB, PC, RCT Hypertensive patients	N=1,181 8 weeks	Primary: Changes in DBP and SBP at 8 weeks Secondary: Safety	Primary: Changes from baseline in blood pressure following telmisartan and HCTZ (-24.6/-18.2 mm Hg) were significantly greater than both valsartan and HCTZ (-22.5/-17.0 mm Hg; P=0.017 for SBP and P=0.025 for DBP), and placebo (-4.1/-6.1 mm Hg; P<0.0001). Secondary: The total number of patients with at least one adverse event reported was similar among the three treatment groups and was 37% for valsartan and HCTZ, 36% for telmisartan and HCTZ, and 42% for placebo.
Waeber et al. ⁶⁴ (2001) Valsartan 80 mg QD, which was switched to valsartan 80 mg and HCTZ 12.5 mg QD or valsartan 80 mg and benazepril 10	OL, RCT Patients with mild-to-moderate uncontrolled HTN (DBP ≥90) while on valsartan monotherapy	N=327 4 weeks	Primary: Efficacy and safety Secondary: Not reported	Primary: The two combinations produced an additional blood pressure reduction compared to monotherapy (P<0.001 for both), with similar DBP reductions reported for the two combination groups (-4.5 mm Hg with valsartan plus HCTZ and -3.3 mm Hg with valsartan plus benazepril). SBP reductions of -6.7 and -3.2 mm Hg with valsartan plus HCTZ and valsartan plus benazepril, respectively, were reported (P=0.1). At the end of the trial, the blood pressure of the responders to valsartan monotherapy was lower than that of patients requiring combination

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg QD				<p>therapy.</p> <p>Valsartan given alone or in association with HCTZ or benazepril was well tolerated.</p> <p>Secondary: Not reported</p>
<p>Izzo Jr et al.⁶⁵ (2011) ValVET</p> <p>Valsartan and HCTZ 160-12.5 mg QD (fixed-does combination product)</p> <p>vs</p> <p>valsartan 160 mg QD</p> <p>vs</p> <p>HCTZ 12.5 mg QD</p> <p>All patients were allowed to up titrate study medication if blood pressure did not improve.</p>	<p>DB, RCT</p> <p>Patients \geq70 years of age with systolic HTN</p>	<p>N=384</p> <p>16 weeks</p>	<p>Primary: Change in baseline SBP at week 4</p> <p>Secondary: Time to blood pressure control</p>	<p>Primary: At week four, reductions in baseline SBP were significantly greater with combination therapy (-17.3 mm Hg) compared to valsartan (-8.6 mm Hg; P<0.001). At this time, reductions with combination therapy and HCTZ were similar (-17.3 vs -13.6 mm Hg; P=0.096).</p> <p>Secondary: Median time to blood pressure control was significantly shorter with combination therapy compared to HCTZ (four vs eight weeks; P<0.05) and valsartan (four vs 12 weeks; P<0.0001).</p>
<p>Duprez et al (abstract).⁶⁶ (2011) ValVET</p>	<p>Subgroup analysis</p> <p>Patients \geq70 years of age with systolic</p>	<p>N=108</p> <p>Duration not specified</p>	<p>Primary: Change in ambulatory SBP</p>	<p>Primary: Initiation of treatment with combination valsartan and HCTZ reduced ambulatory blood pressure more effectively compared to monotherapy with either valsartan or HCTZ throughout daytime, night-time, and 24 hr</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Valsartan and HCTZ 160-12.5 mg QD (fixed-does combination product)</p> <p>vs</p> <p>valsartan 160 mg QD</p> <p>vs</p> <p>HCTZ 12.5 mg QD</p> <p>All patients were allowed to up titrate study medication if blood pressure did not improve.</p>	<p>HTN</p>		<p>Secondary: Safety</p>	<p>monitoring periods, as well as during the last four to six hour dosing periods.</p> <p>Twenty-four hour ambulatory blood pressure was reduced from 141.1/76.5 to 125.8/69.2 mm Hg by week four with combination valsartan and HCTZ compared to reductions from 142.2/78.7 to 139.1/77.5 mm Hg with HCTZ and 142.2/78.3 to 136.4/75.1 mm Hg with valsartan (P<0.01 for all).</p> <p>Secondary: In the overall study, tolerability was similar among the three treatment groups.</p>
<p>Schmieder et al.⁶⁷(2009)</p> <p>HCTZ 12.5 to 25 mg QD (with optional addition of amlodipine 5 to 10 mg QD)</p> <p>vs</p> <p>aliskiren 150 to 300 mg QD (with optional addition</p>	<p>AC, DB, RCT</p> <p>Adults with essential HTN</p>	<p>N=1,124</p> <p>12 months</p>	<p>Primary: Safety and change in mean sitting DBP</p> <p>Secondary: Change in mean sitting SBP</p>	<p>Primary: The proportion of patients who experienced adverse events during the six week placebo-controlled period was similar in the aliskiren monotherapy, HCTZ monotherapy, and placebo groups (26.4, 24.5, and 28.5%, respectively).</p> <p>During the 52 week double-blind treatment period, adverse events were reported by a similar proportion of patients receiving the aliskiren and hydrochlorothiazide regimens. Most adverse events were mild or moderate in intensity.</p> <p>At week 26, the aliskiren regimen provided significantly greater reductions from baseline in DBP compared to HCTZ (-14.2 and -13.0 mm Hg, respectively; P<0.05). The greater reduction in DBP with the aliskiren</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>of amlodipine 5 to 10 mg QD)</p> <p>vs</p> <p>placebo for 6 weeks, then randomized to either aliskiren 300 mg QD or HCTZ 25 mg QD</p>				<p>regimen compared with the HCTZ regimen was maintained at week 52 (-16.0 and -15.0 mm Hg, respectively; P<0.05).</p> <p>Secondary: At week 26, the aliskiren regimen provided significantly greater reductions from baseline in SBP compared to HCTZ (-20.3 and -18.6 mm Hg, respectively; P<0.05). Reductions in SBP at week 52 were not inferior to those of HCTZ (-22.1 and -21.2 mm Hg, respectively; P<0.0001 for non-inferiority).</p>
<p>Schmieder et al.⁶⁸ (2009)</p> <p>HCTZ 12.5 mg QD, followed by 25 mg QD after 3 weeks</p> <p>vs</p> <p>aliskiren 150 mg QD, followed by 300 mg QD after 3 weeks</p> <p>vs</p> <p>placebo, followed by aliskiren 300 mg QD or HCTZ 25 mg QD after 6 weeks</p>	<p>Subgroup analysis of obese patients in Schmieder et al.</p> <p>Patients 18 years of age and older with essential HTN, a mean sitting DBP ≥ 90 and <110 mm Hg; at randomization, patients had to have a mean sitting DBP ≥ 95 and <110 mm Hg and show a difference of ≤ 10 mm Hg since the previous visit</p>	<p>N=1,124</p> <p>52 weeks</p>	<p>Primary: Mean sitting DBP</p> <p>Secondary: Mean sitting SBP at week 26, mean sitting DBP and SBP at week 52, proportion of patients with response to treatment, blood pressure control at weeks 26 and 52, and safety</p>	<p>Primary: The least squares mean DBP and SBP reductions at week 12 were significantly greater with aliskiren compared to HCTZ (P<0.0001 and P=0.001 respectively).</p> <p>Secondary: At week 52, aliskiren resulted in significantly greater mean sitting DBP reductions compared to HCTZ (P<0.001).</p> <p>Blood pressure response rates were significantly greater with aliskiren compared to HCTZ at both week 12 and week 52 (P<0.05).</p> <p>Significantly more obese patients achieved blood pressure control with aliskiren compared to HCTZ at week 12 (P=0.0013). Blood pressure control rates were similar between groups at week 52 (P value not reported).</p>
<p>Villamil et al.⁶⁹ (2007)</p> <p>HCTZ 6.25 to 25</p>	<p>DB, MC, PC, RCT</p> <p>Men and women ≥ 18 years with</p>	<p>N=2,776</p> <p>8 weeks</p>	<p>Primary: Change in mean sitting DBP</p>	<p>Primary: Aliskiren monotherapy significantly reduced mean sitting DBP (P=0.0002). Only the aliskiren 150 and 300 mg doses were more effective than placebo (P=0.09 for aliskiren 75 mg). HCTZ monotherapy</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg QD</p> <p>vs</p> <p>aliskiren 75 to 300 mg QD</p> <p>vs</p> <p>aliskiren and HCTZ (every dose combination except aliskiren 300 mg and HCTZ 6.25 mg) QD</p> <p>vs</p> <p>placebo</p>	<p>mild-to-moderate essential HTN</p>		<p>Secondary: Change in mean sitting SBP, dose-response efficacy for all treatment groups, proportion achieving a successful response (DBP <90 mm Hg or ≥10 mm Hg), proportion achieving blood pressure control (<140/90 mm Hg), plasma renin activity, renin concentrations, safety</p>	<p>significantly reduced DBP from baseline (P<0.01 for all vs placebo).</p> <p>All combinations were more effective than placebo (P<0.0001) with reductions in DBP ranging from 10.4 to 14.3 mm Hg. Most combination regimens were more effective than monotherapy with the individual components (exceptions were aliskiren 150 mg and HCTZ 6.25 mg vs monotherapy, and aliskiren 75 mg and HCTZ 12.5 mg vs HCTZ monotherapy).</p> <p>Secondary: After eight weeks of therapy, aliskiren 150 and 300 mg regimens (both P<0.0001) were more effective than placebo in lowering mean sitting SBP, but the 75 mg dose was not (P=0.151).</p> <p>Combination therapy was consistently more effective in reducing SBP than monotherapy with the individual components, with the exception of aliskiren 75 mg plus HCTZ 12.5 vs HCTZ monotherapy. Reductions in SBP with combination therapy ranged from 14.3 to 21.2 mm Hg.</p> <p>Blood pressure reductions were related to the doses of both aliskiren and HCTZ.</p> <p>Responder rates were significantly higher with aliskiren 300 mg (63.9%; P=0.0005), HCTZ 12.5 and 25 mg (60.6 and 59.0%, respectively; both P<0.02) and all combination doses (58.4 to 80.6%; all P<0.05) than placebo (45.8%). Responder rates for all combinations of aliskiren and HCTZ 25 mg, and aliskiren 300 mg and HCTZ 12.5 mg were higher than both monotherapies (P<0.05), while aliskiren 75 mg and HCTZ 12.5 mg and aliskiren 150 mg and HCTZ 12.5 mg were more effective than their respective aliskiren monotherapies (P<0.05).</p> <p>In the aliskiren and HCTZ monotherapy groups, only aliskiren 300 mg led to statistically significantly greater control rates than placebo (46.7 vs 28.1%; P=0.0001). Control rates for all combinations, with the exception of aliskiren 75 mg and HCTZ 6.25 mg, were higher than placebo (all P<0.02). There was a trend towards improved control rates with combination therapy (37.4 to 59.5%) compared to aliskiren monotherapy</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>(29.0 to 46.7%) or HCTZ monotherapy (32.5 to 37.8%). Combinations utilizing the higher doses of one or both drugs (aliskiren 75 to 300 mg with HCTZ 25 mg or aliskiren 150 to 300 mg with HCTZ 12.5 mg) yielded control rates that were significantly higher than monotherapy with either component.</p> <p>While all doses of aliskiren decreased plasma renin activity and all doses of HCTZ increased plasma renin activity, combination therapy resulted in decreased plasma renin activity of 46.1 to 63.5%. Renin concentrations increased in all monotherapy and combination regimens with the exception of HCTZ 6.25 and 12.5 mg.</p> <p>All active treatments were well tolerated with 37.3 to 39.2% of patients experiencing adverse events with aliskiren monotherapy, 38.7 to 42.0% with HCTZ monotherapy, 34.6 to 45.3% with aliskiren and HCTZ, and 44% with placebo. Hypokalemia (serum potassium <3.5 mmol/L) occurred with the highest frequency with HCTZ 12.5 and 25 mg (3.9 and 5.2%, respectively). When administered in combination with aliskiren, the frequency of hypokalemia was 0.7 to 2.0% with HCTZ 12.5 mg and 2.2% to 3.4% with HCTZ 25 mg.</p>
<p>Blumenstein et al.⁷⁰ (2009)</p> <p>HCTZ 25 mg (existing therapy)</p> <p>vs</p> <p>aliskiren and HCTZ 300-25 mg QD (fixed-dose combination product)</p> <p>vs</p>	<p>DB, MC, RCT</p> <p>Patients with HTN and an inadequate response to HCTZ (mean sitting DBP >90 and ≤110 mm Hg following 4 weeks of HCTZ 25 mg)</p>	<p>N=722</p> <p>8 weeks</p>	<p>Primary:</p> <p>Changes in mean sitting SBP/DBP, proportion of patients achieving blood pressure control (mean sitting blood pressure <140/90 mm Hg), and blood pressure response rates (msDBP <90 mm Hg or a ≥10 mm Hg decrease from baseline)</p>	<p>Primary:</p> <p>The mean reductions in mean sitting SBP/DBP from baseline with aliskiren and HCTZ 300-25 and 150-25 mg were significantly greater compared to those achieved with HCTZ monotherapy (P<0.001 for all).</p> <p>Rates of blood pressure control were significantly higher with aliskiren and HCTZ 300-25 and 150-25 mg compared to HCTZ monotherapy (P<0.001 for both).</p> <p>Aliskiren and HCTZ 300-25 mg provided significantly greater reductions in mean sitting SBP/DBP and rates of blood pressure control compared to aliskiren and HCTZ 150-25 mg dose (P<0.05 for all).</p> <p>Blood pressure response rates were significantly higher with aliskiren and HCTZ 300-25mg (78.5%) and aliskiren and HCTZ 150-25 mg (67.4%) compared to HCTZ monotherapy (47.1%; P<0.001 for both comparisons).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
aliskiren and HCTZ 150-25 mg QD (fixed-dose combination product)			Secondary: Not reported	<p>All treatments were generally well-tolerated and the proportion of patients experiencing adverse events was similar across treatment groups. The majority of adverse events were mild and transient. Adverse events reported in >2% of patients were nasopharyngitis, dizziness, back pain, and vertigo.</p> <p>The proportion of patients with serum potassium <3.5 mmol/L was lower with aliskiren and HCTZ (1.3 to 2.2%) compared to HCTZ monotherapy (3.4%). Hyperkalemia (serum potassium >5.5 mmol/L) was observed in only one patient receiving aliskiren and HCTZ and two patients in the HCTZ monotherapy group. No patient had increases in serum creatinine above the pre-specified clinically significant threshold.</p> <p>Secondary: Not reported</p>
<p>Jordan et al.⁷¹ (2007)</p> <p>HCTZ 25 mg QD (existing therapy)</p> <p>vs</p> <p>aliskiren 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)</p> <p>vs</p> <p>amlodipine 5 to 10 mg QD, added to existing HCTZ therapy (single entity products)</p>	<p>DB, DD, MC, PG, RCT</p> <p>Obese men and women (BMI ≥30 kg/m²) ≥18 years with essential HTN (mean sitting DBP 95 to 109 mm Hg and SBP <180 mm Hg) who had not responded to 4 weeks of treatment with HCTZ 25 mg</p>	<p>N=489</p> <p>12 weeks</p>	<p>Primary: Change in mean sitting DBP with aliskiren 300 mg plus HCTZ vs HCTZ alone at 8 weeks</p> <p>Secondary: Comparisons of mean sitting DBP and SBP with aliskiren plus HCTZ vs the other treatment groups, percentage of responders (mean sitting DBP <90 mm Hg or ≥10 mm Hg reduction from baseline), proportion of</p>	<p>Primary: Aliskiren 300 mg added to HCTZ 25 mg significantly reduced mean sitting DBP compared with HCTZ alone at week eight (mean difference, -4.0; P<0.0001).</p> <p>Secondary: Aliskiren 300 mg added to HCTZ caused numerically larger reductions in mean sitting DBP and SBP compared with amlodipine 10 mg plus HCTZ and irbesartan 300 mg plus HCTZ at week eight, but there were no statistically significant differences between treatment groups (P>0.05).</p> <p>Responder rates were significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0193) and week 12 (P=0.004) but comparable to responder rates observed with amlodipine plus HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>The proportion of patients achieving blood pressure control was significantly higher with aliskiren plus HCTZ than HCTZ alone at week eight (P=0.0005) and week 12 (P=0.0001) but not statistically different than amlodipine plus HCTZ (P>0.05) and irbesartan plus HCTZ (P>0.05).</p> <p>Plasma renin activity significantly increased (P<0.05) during four weeks</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs irbesartan 150 to 300 mg QD, added to existing HCTZ therapy (single entity products)			patients achieving blood pressure control (mean sitting blood pressure <140/90 mm Hg), plasma renin activity, safety and tolerability	of HCTZ monotherapy. Combination with aliskiren neutralized this increase and led to an overall significant reduction in plasma renin activity compared with pretreatment baseline (P<0.05) whereas amlodipine and irbesartan led to further significant increases (P<0.05). All of the study treatments were generally well tolerated. Amlodipine plus HCTZ (45.2%) was associated with a higher incidence of adverse events than the other treatment groups (36.1 to 39.3%), largely due to a higher rate of peripheral edema (11.1 vs 0.8 to 1.6%).
Geiger et al. ⁷² (2009) HCTZ 25 mg QD vs aliskiren 150 to 300 mg QD, added to existing HCTZ therapy vs valsartan 160 to 320 mg QD, added to existing HCTZ therapy vs aliskiren 150 to 300 mg and valsartan 160 to 320 mg QD, added to existing HCTZ therapy	AC, DB, RCT Patients ≥18 years of age with mild to moderate essential HTN who were taking HCTZ for 4 weeks with a DBP ≥95 mm Hg	N=641 8 weeks	Primary: Change in DBP at week 8 Secondary: Change SBP at week 8, change in DBP and SBP at week 4, proportion of patients achieving blood pressure control (SBP/DBP <140/90 mm Hg), change in plasma renin activity, plasma renin concentration	Primary: After eight weeks of therapy, the triple therapy showed significantly greater reductions in SBP and DBP compared with the other groups. The additional SBP and DBP reductions were 7 and 5 mm Hg, respectively compared to aliskiren and HCTZ (P<0.0001), 3 and 2 mm Hg compared to valsartan and HCTZ (P<0.01), and 15 and 10 mm Hg compared to HCTZ monotherapy (P<0.001). Aliskiren and HCTZ and valsartan and HCTZ combination therapies were more effective compared to HCTZ monotherapy. Valsartan and HCTZ was more effective than aliskiren and HCTZ. SBP and DBP were reduced by 15 and 11 mm Hg, respectively in the aliskiren and HCTZ group. SBP and DBP were reduced by 18 and 14 mm Hg, respectively, in the valsartan and HCTZ group. Secondary: Blood pressure control rate was significantly higher with triple therapy compared to aliskiren and HCTZ (40.9%, P<0.001), valsartan and HCTZ (48.7%, P<0.001), and HCTZ monotherapy (20.5%, P<0.001). At week four, a significantly greater blood pressure control rate was observed for the triple therapy group at lower doses (150-160-25 mg) compared to the respective doses of the other groups: aliskiren and valsartan and HCTZ (300-320-25 mg) group (56%) compared to aliskiren and HCTZ (36.6%, P<0.05), valsartan and HCTZ (42.2%, P<0.05), and HCTZ monotherapy (19.9%, P<0.01). At week eight, plasma renin concentration was unchanged in the HCTZ

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>group, but was significantly increased in other groups. A significant decrease in plasma renin activity from baseline was observed in the aliskiren and HCTZ group (P<0.001) and a significant increase was observed in the valsartan and HCTZ (P<0.001). In the HCTZ and triple therapy groups, there was no change in plasma renin activity (both P>0.75).</p>
<p>O'Brien et al.⁷³ (2007)</p> <p>Aliskiren 150 mg QD for 3 weeks, then HCTZ 25 mg QD was added for an additional 3 weeks (if ABPM remained ≥135/85 mm Hg)</p> <p>vs</p> <p>irbesartan 150 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg QD added for 3 weeks</p> <p>vs</p> <p>ramipril 5 mg QD for 3 weeks, then aliskiren 75 mg QD added for 3 weeks, then aliskiren 150 mg</p>	<p>3 OL studies</p> <p>Men and women 18 to 80 years with ambulatory SBP ≥140 and ≤180 mm Hg without treatment</p>	<p>N=67</p> <p>6 to 9 weeks</p>	<p>Primary: Change in daytime systolic ABPM with combination therapy compared with monotherapy</p> <p>Secondary: Change in daytime diastolic ABPM, nighttime systolic and diastolic ABPM, daytime and nighttime heart rates, plasma renin activity</p>	<p>Primary: Aliskiren coadministered with HCTZ (P=0.0007) or ramipril (P=0.03) led to significantly greater reductions in daytime systolic ABPM compared to monotherapy. There was a trend for a reduction in daytime systolic ABPM with the addition of aliskiren to irbesartan; however, this trend was not statistically significant.</p> <p>Secondary: Aliskiren plus HCTZ significantly lowered daytime diastolic ABPM compared to aliskiren monotherapy (P=0.0006). Changes in nighttime systolic and diastolic ABPM followed similar trends but did not achieve statistical significance (P=0.06 and P=0.09, respectively). No changes in heart rate were observed with either aliskiren regimen.</p> <p>Aliskiren added to irbesartan did not significantly change diastolic ABPM compared to irbesartan monotherapy; however, nighttime systolic and diastolic ABPM were significantly reduced (P<0.05 for all). No changes in heart rate were observed with either irbesartan regimen.</p> <p>Mean diastolic ABPM was significantly decreased with the addition of aliskiren 150 mg (P<0.05) but not aliskiren 75 mg to ramipril monotherapy. Both aliskiren doses significantly decreased nighttime systolic and diastolic ABPM (P<0.05 for all). No changes in heart rate were observed with either ramipril regimen.</p> <p>Aliskiren alone significantly inhibited plasma renin activity by 65% (P<0.0001), while ramipril and irbesartan monotherapy increased renin activity by 90 and 175%, respectively. When aliskiren was coadministered with HCTZ, ramipril or irbesartan, plasma renin activity remained similar to baseline levels or decreased.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
QD added for 3 weeks				
<p>Pepine et al.⁷⁴ (2003) INVEST</p> <p>Verapamil SR 240 mg/day (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist strategy)</p> <p>vs</p> <p>atenolol 50 mg/day (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)</p> <p>Trandolapril was recommended for all patients with heart failure, diabetes, or renal insufficiency.</p>	<p>MC, OL, RCT</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: First occurrence of death (all cause), nonfatal MI or stroke</p> <p>Secondary: Cardiovascular death, angina, cardiovascular hospitalization, angina, blood pressure control (SBP/DBP <140/90 mm Hg or <130/85 mm Hg if diabetic or renal impairment), safety</p>	<p>Primary: At 24 months, in the calcium antagonist strategy subgroup, 81.5% of patients were taking verapamil SR, 62.9% trandolapril, and 43.7% HCTZ. In the non-calcium antagonist strategy, 77.5% of patients were taking atenolol, 60.3% HCTZ, and 52.4% trandolapril.</p> <p>After a follow-up of 61,835 patient-years (mean, 2.7 years per patient), 2,269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in calcium antagonist strategy vs 10.17% in non-calcium antagonist strategy; RR, 0.98; 95% CI, 0.90 to 16; P=0.57).</p> <p>Secondary: There was no significant difference in the rate of cardiovascular death (P=0.94) or cardiovascular hospitalization (P=0.59) between the two treatment groups.</p> <p>At 24 months, angina episodes decreased in both groups, but the mean frequency was lower in the calcium antagonist strategy group (0.77 episodes/week) compared to the non-calcium antagonist strategy group (0.88 episodes/week; P=0.02).</p> <p>Two-year blood pressure control was similar between groups. The blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of calcium antagonist strategy patients and 64.0% (systolic) and 88.1% (diastolic) of non-calcium antagonist strategy patients. A total of 71.7% of calcium antagonist strategy patients and 70.7% of non-calcium antagonist strategy patients achieved an SBP <140 mm Hg and DBP <90 mm Hg.</p> <p>Both regimens were generally well tolerated. Patients in the calcium antagonist strategy group reported constipation and cough more frequently than patients in the non-calcium antagonist strategy group, while non-calcium antagonist strategy patients experienced more dyspnea, lightheadedness, symptomatic bradycardia and wheezing (all were statistically significant with P≤0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Hansson et al.⁷⁵ (1999) STOP-Hypertension</p> <p>Atenolol 50 mg or metoprolol 100 mg or pindolol 5 mg QD and/or HCTZ 25 mg with amiloride 2 to 5 mg QD</p> <p>vs</p> <p>enalapril 10 mg or lisinopril 10 mg QD</p> <p>vs</p> <p>felodipine 2.5 mg or isradipine 2.5 mg QD</p>	<p>MC, OL, PRO, RCT</p> <p>Men and women, age 70 to 84 years with HTN (SBP \geq180 mm Hg or DBP \geq105 mm Hg or both)</p>	<p>N=6,614</p> <p>4 years</p>	<p>Primary: Fatal stroke, fatal MI, other fatal cardiovascular events</p> <p>Secondary: Blood pressure</p>	<p>Primary: The rate of prevention of cardiovascular deaths was similar in all groups (RR, 0.97 to 1.4; 95% CI, 0.86 to 1.26).</p> <p>Fatal cardiovascular events, including fatal stroke and fatal myocardial infarction MI, occurred in 19.8 per 1,000 patient-years in the β-blocker and/or HCTZ group, in the felodipine or isradipine group and in the enalapril or lisinopril group (RR, 0.99; 95% CI, 0.84 to 1.16).</p> <p>The RR of cardiovascular death in patients in the enalapril or lisinopril group as compared to the felodipine or isradipine group was 1.4 (95% CI, 0.86 to 1.26; P=0.67.)</p> <p>Secondary: Decreases in blood pressure were similar among the groups.</p>
<p>Pepine et al.⁷⁶ (2006) INVEST</p> <p>Verapamil SR (step 1), then add trandolapril if needed (step 2), then increase doses of both (step 3), then add HCTZ (step 4) (calcium antagonist</p>	<p>Post hoc analysis of INVEST</p> <p>Patients with essential HTN</p>	<p>N=22,576</p> <p>24 months</p>	<p>Primary: Risk for adverse outcome associated with baseline factors, follow-up blood pressure and drug treatments</p> <p>Secondary: Not reported</p>	<p>Primary: Previous heart failure (adjusted HR, 1.96), as well as diabetes (HR, 1.77), increased age (HR, 1.63), United States residency (HR, 1.61), renal impairment (HR, 1.50), stroke/TIA (HR, 1.43), smoking (HR, 1.41), MI (HR, 1.34), PVD (HR, 1.27), and revascularization (HR, 1.15) predicted increased risk.</p> <p>Follow-up SBP <140 mm Hg (HR, 0.82) or DBP <90 mm Hg (HR, 0.70) and trandolapril with verapamil SR (HR, 0.78 and 0.79) were associated with reduced risk.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
strategy) vs atenolol (step 1), then add HCTZ if needed (step 2), then increase doses of both (step 3), then add trandolapril (step 4) (non-calcium antagonist strategy)				
Conlin et al. ⁷⁷ (2000) PREVAIL Low-dose HCTZ plus ARB vs candesartan 8 to 16 mg QD, irbesartan 150 to 300 mg QD, losartan 50 to 100 mg QD, and valsartan 80 to 160 mg QD vs another ARB	MA Patients with HTN	N=11,281 (43 trials) Duration varied	Primary: Weighted average for SBP and DBP reduction with ARB monotherapy, dose titration, and with the addition of low-dose HCTZ were calculated; responder rates Secondary: Not reported	Primary: The absolute weighted-average reductions in DBP (8.2 to 8.9 mm Hg) and SBP (10.4 to 11.8 mm Hg) for ARB monotherapy were comparable for all ARBs. Responder rates for ARB monotherapy were 48 to 55%. Dose titration resulted in slightly greater blood pressure reductions and an increase in responder rates of 53 to 63%. ARB and HCTZ combinations produced substantially greater reductions in SBP (16.1 to 20.6 mm Hg) and DBP (9.9 to 13.6 mm Hg) than ARB monotherapy. Responder rates for ARB and HCTZ combinations were 56 to 70%. The authors concluded that candesartan, irbesartan, losartan, and valsartan produced comparable antihypertensive efficacy when administered at their recommended doses, a near flat dose response when titrating from starting to maximum recommended dose, and substantial potentiation of the antihypertensive effect with addition of HCTZ. Secondary: Not reported
Stanton et al. ⁷⁸ (2010)	MA	N=4,877 (8 trials)	Primary: Paradoxical blood	Primary: There were no significant differences among the pooled aliskiren,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Irbesartan, losartan, valsartan, ramipril, HCTZ, placebo</p> <p>vs</p> <p>aliskiren 300 mg QD</p>	<p>Adults with mild to moderate essential HTN</p>	<p>4 to 12 weeks</p>	<p>pressure rises, as well as the percentage of patients with SBP increases (>10 or >20 mm Hg) or DBP increases (>5 or >10 mm Hg) from baseline</p> <p>Secondary: Not reported</p>	<p>irbesartan, losartan, valsartan, ramipril, and HCTZ groups in the incidence of SBP increases >10 mm Hg (P=0.30) and >20 mm Hg (P=0.28) or DBP increases >5 mm Hg (P=0.65) and >10 mm Hg (P=0.5).</p> <p>Increases in SBP and DBP occurred significantly more frequently in the pooled placebo group than the aliskiren group (P<0.001).</p> <p>Secondary: Not reported</p>
<p>Hansson et al.⁷⁹ (2000) NORDIL</p> <p>Conventional therapy (diuretic, β-blocker or both)</p> <p>vs</p> <p>diltiazem 180 to 360 mg QD</p>	<p>BE, MC, OL, PRO, RCT</p> <p>Patients 50 to 74 years of age with DBP ≥100 mm Hg and previously untreated</p>	<p>N=10,881</p> <p>4.5 years</p>	<p>Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death</p> <p>Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI</p>	<p>Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97).</p> <p>Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04).</p> <p>Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17).</p> <p>Other endpoints were not statistically different between the groups including cardiovascular death (P=0.41), all cardiac events (P=0.57 and congestive heart failure (P=0.42).</p>
<p>Messerli et al.⁸⁰ (1998)</p> <p>Diuretics (amiloride, chlorthalidone, HCTZ, HCTZ and triamterene [fixed-dose combination product], or</p>	<p>MA</p> <p>10 RCTs lasting ≥1 year, which used as first line agents diuretics and/or β-blockers and reported morbidity and mortality</p>	<p>N=16,164</p> <p>1 year</p>	<p>Primary: Cardiovascular morbidity and mortality, all-cause morbidity</p> <p>Secondary: Not reported</p>	<p>Primary: Diuretic treatment significantly reduced the odds for cardiovascular mortality by 25% (OR, 0.75; 95% CI, 0.64 to 0.87), while β-blockers did not reduce cardiovascular mortality (OR, 0.98; 95% CI, 0.78 to 1.23; P values not reported).</p> <p>Diuretic treatment significantly reduced the odds for all-cause mortality by 14% (OR, 0.86; 95% CI, 0.77 to 0.96), while β-blockers did not reduce all-cause mortality (OR, 1.05; 95% CI, 0.88 to 1.25; P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
thiazide) vs β-blockers (atenolol, metoprolol or pindolol)	outcomes in patients ≥60 years of age with HTN			Secondary: Not reported
Baguet et al. ⁸¹ (2007) Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and aliskiren) Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.	MA Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)	N=10,818 8 to 12 weeks	Primary: Weighted average reductions in SBP and DBP Secondary: Not reported	Primary: Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported). The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported). The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively. Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>				<p>Secondary: Not reported</p>
<p>Lindhölm et al.⁸² (2005)</p> <p>Other antihypertensive therapies (amiloride, amlodipine, bendroflumethiazide*, captopril, diltiazem, enalapril, felodipine, HCTZ, isradipine, lacidipine, lisinopril, losartan, or verapamil)</p> <p>or</p> <p>placebo</p> <p>vs</p> <p>β-blocker therapy (atenolol,</p>	<p>MA</p> <p>13 RCTs evaluating the treatment of primary HTN with a β-blocker as first-line treatment (in ≥50% of all patients in one treatment group) and outcome data for all-cause mortality, cardiovascular morbidity or both</p>	<p>N=105,951</p> <p>2.1 to 10.0 years</p>	<p>Primary: Stroke, MI, all-cause mortality</p> <p>Secondary: Not reported</p>	<p>Primary: The RR of stroke was 16% higher with β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 1.04 to 1.30; P=0.009). The RR of stroke was the highest with atenolol (26% higher) compared to other non β-blockers (RR, 1.26%; 95% CI, 1.15 to 1.38; P<0.0001).</p> <p>The relative risk of MI was 2% higher for β-blocker therapy than for the comparator therapies (RR, 1.02; 95% CI, 0.93 to 1.12), which was not significant (P value not reported).</p> <p>The RR of all-cause mortality was 3% higher for β-blocker therapy than for the comparator therapies (RR, 1.16; 95% CI, 0.99 to 1.08; P=0.14).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
metoprolol, oxprenolol*, pindolol, or propranolol)				
Hilleman et al. ⁸³ (1999) Monotherapy (atenolol, HCTZ, captopril, enalapril, lisinopril, amlodipine, diltiazem, nifedipine, verapamil) vs amlodipine-benazepril (fixed-dose combination)	MA (82 trials) Patients with mild-to-moderate essential HTN	N=not reported ≥4 weeks	Primary: Absolute change in supine DBP from baseline Secondary: Percent of patients who achieved blood pressure control, safety	Primary: The mean absolute decrease in supine DBP ranged from 9.7 to 13.3 mm Hg with verapamil showing the greatest effect and captopril the least. When studies were weighted by sample size, amlodipine and benazepril, atenolol, lisinopril, and verapamil showed the greatest blood pressure effect. Secondary: The average percentage of patients defined as controlled after treatment varied from 53.5 to 79.0%, with amlodipine and benazepril (74.3%) and lisinopril (79.0%) showing the highest percentage control (P=0.096). The incidence of adverse events ranged from 12.1 to 41.8%, with lisinopril and verapamil showing the lowest incidences (12.1% and 14.1%, respectively) and nifedipine the highest incidence. Lisinopril demonstrated significantly less overall side effects compared to nifedipine (P=0.030). Nifedipine demonstrated a higher withdrawal rate due to side effects compared to atenolol, HCTZ, enalapril, amlodipine, and diltiazem (P=0.002). Although amlodipine and benazepril had the lowest rate of withdrawals due to adverse events, lack of significant change was due to the low number of cohorts available for analysis.
Wiysonge et al. ⁸⁴ (2007) Other antihypertensive therapies (i.e., placebo, diuretics, calcium channel blockers, or renin-angiotensin system inhibitors)	MA 13 RCTs evaluating patients ≥18 years of age with HTN	N=91,561 Duration varied	Primary: All-cause mortality Secondary: Stroke, CHD, cardiovascular death, total cardiovascular disease, adverse reactions	Primary: There was not a significant difference observed in all-cause mortality between β-blocker therapy and placebo (RR, 0.99; 95% CI, 0.88 to 1.11; P value not reported), diuretics (RR, 1.04; 95% CI, 0.91 to 1.19; P value not reported) or renin-angiotensin system inhibitors (RR, 1.10; 95% CI, 0.98 to 1.24; P value not reported). There was a significantly higher rate in all-cause mortality with β-blocker therapy compared to calcium channel blockers (RR, 1.07; 95% CI, 1.00 to 1.14; P=0.04). Secondary: There was a significant decrease in stroke observed with β-blocker therapy

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs β-blockers (atenolol, metoprolol, oxprenolol*, or propranolol)				<p>compared to placebo (RR, 0.80; 95% CI, 0.66 to 0.96). Also there was a significant increase in stroke with β-blocker therapy compared to calcium channel blockers (RR, 1.24; 95% CI, 1.11 to 1.40) and renin-angiotensin system inhibitors (RR, 1.30; 95% CI, 1.11 to 1.53), but there was no difference observed compared to diuretics (RR, 1.17; 95% CI, 0.65 to 2.09).</p> <p>CHD risk was not significantly different between β-blocker therapy and placebo (RR, 0.93; 95% CI, 0.81 to 1.07]), diuretics (RR, 1.12; 95% CI, 0.82 to 1.54), calcium channel blockers (RR, 1.05; 95% CI, 0.96 to 1.15) or renin-angiotensin system inhibitors (RR, 0.90; 95% CI, 0.76 to 1.06).</p> <p>The risk of total cardiovascular disease was lower with β-blocker therapy compared to placebo (RR, 0.88; 95% CI, 0.79 to 0.97). The effect of β-blocker therapy on cardiovascular disease was significantly worse than that of calcium channel blockers (RR, 1.18; 95% CI, 1.08 to 1.29), but was not significantly different from that of diuretics (RR, 1.13; 95% CI, 0.99 to 1.28) or renin-angiotensin system inhibitors (RR, 1.00; 95% CI, 0.72 to 1.3).</p> <p>There was a significantly higher rate of discontinuation due to side effects with β-blocker therapy compared to diuretics (RR, 1.86; 95% CI, 1.39 to 2.50) and renin-angiotensin system inhibitors (RR, 1.41; 95% CI, 1.29 to 1.54), but there was no significant difference compared to calcium channel blockers (RR, 1.20; 95% CI, 0.71 to 2.04). Actual side effects were not reported.</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily, SR=sustained-release

Study Design abbreviations: AC=active comparator, BE=blinded endpoint, DB=double blind, DD=double dummy, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, SB=single blind, XO=cross over

Miscellaneous abbreviations: ACE inhibitors=angiotensin converting enzyme inhibitors, ABPM=ambulatory blood pressure monitoring, BSA=body surface area, CHD=coronary heart disease, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HDL-C=high-density lipoprotein cholesterol, HR=hazard ratio, HTN=hypertension, KCl=potassium chloride, MI=myocardial infarction, NNT=number needed to treat, NYHA=New York Heart Association, OR=odds ratio, PVD=peripheral arterial disease, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TG=triglyceride, TIA=transient ischemic attack, WHO=World Health Organization, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 9. Relative Cost of the Thiazide Diuretics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Chlorothiazide	injection*, suspension, tablet*	Diuril®	\$\$	\$\$\$
HCTZ	capsule, tablet	Microzide®*	\$	\$
Methyclothiazide	tablet	N/A	N/A	\$\$

*Generic is available in at least one dosage form or strength.

HCTZ=hydrochlorothiazide, N/A=Not available

X. Conclusions

The thiazide diuretics are approved for the treatment of hypertension and edema due to renal dysfunction. They are also approved as adjunctive therapy for the management of edema associated with congestive heart failure, hepatic cirrhosis, as well as corticosteroid and estrogen therapy.¹⁻⁶ All of the agents are available in a generic formulation.

Guidelines recommend the use of diuretics and sodium restriction for the management of ascites due to cirrhosis. Spironolactone is recommended as first-line therapy, either as monotherapy or in combination with furosemide. Amiloride is an alternative treatment option in patients experiencing gynecomastia with spironolactone. Triamterene, metolazone and hydrochlorothiazide have also been used to treat ascites.²³

For the treatment of chronic heart failure, guidelines recommend the use of diuretics in all patients who have evidence of volume overload. Loop diuretics are generally recommended as initial therapy in patients with left ventricular dysfunction. For those with persistent fluid retention despite treatment with a loop diuretic, a thiazide diuretic or metolazone may be added to the regimen. In patients with normal left ventricular function, either a thiazide diuretic or loop diuretic may be used as initial therapy to manage fluid overload.¹⁰⁻¹²

There are several published guidelines on the treatment of hypertension. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.¹³⁻²⁰ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹³ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹³⁻²¹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹³⁻²⁰

In clinical trials, the thiazide diuretics have been shown to effectively lower blood pressure.²⁸⁻⁸⁴ There were no studies found in the medical literature that directly compared the efficacy and safety of the thiazide diuretics for the treatment of hypertension.

There is insufficient evidence to support that one brand thiazide diuretic is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand thiazide diuretics within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand thiazide diuretic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Diuril® Oral Suspension [package insert]. Morrisville (NC): Salix Pharm, Inc; 2009 Jun.
2. Chlorothiazide [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc.; 2006 Mar.
3. Chlorothiazide sodium [package insert]. Lake Forest (IL): Akron, Inc.; 2012 Jun.
4. Microzide® [package insert]. Morristown (NJ): Watson Pharma, Inc; 2011 Feb.
5. Hydrochlorothiazide [package insert]. Elizabeth (NJ): Actavis Elizabeth, LLC; 2011 Sep.
6. Methyclothiazide [package insert]. Morgantown (WV): Mylan Pharmaceuticals Inc; 2012 Apr.
7. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Apr]. Available from: <http://online.factsandcomparisons.com>.
8. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Apr]. Available from: <http://www.thomsonhc.com/>.
9. Kaplan NM. Use of thiazide diuretics in patients with primary essential hypertension. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Apr]. Available from: <http://www.uptodate.com/utd/index.do>.
10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
11. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16:475-539.
12. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
14. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
16. Mancia G, Laurent S, Agabiti-Rosei E, Ambosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
17. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
18. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
19. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
20. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
21. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
22. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
23. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. 2012 [cited 2015 Apr]. Available from: http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf.
24. Rengo F, Trimarco B, Bonaduce D, Petretta M, Ferrara N, D'Ascia C, et al. Potassium-sparing effect of amiloride in patients receiving diuretics: a quantitative review. *Acta Cardiol*. 1979;34(4):259-67.
25. Cheitlin MD, Byrd R, Benowitz N, Liu E, Modin G. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. *Cardiovasc Drugs Ther*. 1991 Aug;5(4):719-25.

26. Kohvakka A. Maintenance of potassium balance during long-term diuretic therapy in chronic heart failure patients with thiazide-induced hypokalemia: comparison of potassium supplementation with potassium chloride and potassium-sparing agents, amiloride and triamterene. *Int J Clin Pharmacol Ther Toxicol.* 1988 May;26(5):273-7.
27. Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. *Cochrane Database Syst Rev.* 2006 Jan 25;(1):CD003838. DOI: 10.1002/14651858.CD003838.pub2.
28. Hua AS, Kincaid-Smith P. A comparison of the effects of chlorothiazide and of metolazone in the treatment of hypertension. *Clin Sci Mol Med Suppl.* 1976 Dec;3:627s-9s.
29. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. *Hypertension.* 2004 Jan;43(1):4-9.
30. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. *Hypertension.* 2006 Mar;47(3):352-8.
31. Finnerty FA Jr. Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. *J Clin Pharmacol.* 1980;20(5-6 Pt 1):357-63.
32. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. *Am J Med.* 2012 Dec;125(12):1229.e1-1229.e10.
33. Valmin K, Hansen T. Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide. *Eur J Clin Pharmacol.* 1975;8(6):393-401.
34. Araoye MA, Chang MY, Khatri IM, et al. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. *JAMA.* 1978;240(17):1863.
35. Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. *Am J Cardiol.* 1996 Feb 22;77(6):23B-5B.
36. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. *Am J Cardiol.* 1996 Feb 22;77(6):12b-6b.
37. Larochelle P, Logan AG. Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level. *Can Med Assoc J.* 1985;132(7):801-5.
38. Salmela PI, Juustila H, Kinnunen O, et al. Comparison of low doses of hydrochlorothiazide plus amiloride and hydrochlorothiazide alone in hypertension in elderly patients. *Ann Clin Res.* 1986;18(2):88-92.
39. Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group. *Arch Intern Med.* 1981 Mar;141(4):482-6.
40. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. *Hypertension.* 2010;55:1217-23.
41. Nash DT. Antihypertensive effect and serum potassium homeostasis: comparison of hydrochlorothiazide and spironolactone alone and in combination. *J Med.* 1977;8(5):367-77.
42. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. *Clin Pharmacol Ther.* 1979;25(1):33-42.
43. Johnson JA, Gong Y, Bailey KR, et al. Hydrochlorothiazide and atenolol combination antihypertensive therapy: Effects of drug initiation order. *Clin Pharmacol Ther.* 2009;86:533-9.
44. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet.* 1991 Nov 23;338(8778):1281-5.
45. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. *Arch Intern Med.* 1994 Jul 11;154(13):1461-8.
46. Frishman WH, Burrell JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. *J Clin Pharmacol.* 1995 Feb;35(2):182-8.
47. Dafgard T, Forsen B, Lindahl T. Comparative study of hydrochlorothiazide and a fixed combination of metoprolol and hydrochlorothiazide essential hypertension. *Ann Clin Res.* 1981;13 Suppl 30:37-44.
48. Smilde JG. Comparison of the antihypertensive effect of a double dose of metoprolol versus the addition of hydrochlorothiazide to metoprolol. *Eur J Clin Pharmacol.* 1983;25(5):581-3.
49. Stevens JD, Mullane JF. Propranolol-hydrochlorothiazide combination in essential hypertension. *Clin Ther.* 1982;4(6):497-509.
50. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. *JAMA.* 1996; 276:785-791.

51. Manyemba J. A randomized crossover comparison of reserpine and sustained-release nifedipine in hypertension. *Cent Afr J Med*. 1997 Dec;43(12):344-9.
52. Jamerson K, Bakris GL, Dahlof B, et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. *Blood Press*. 2007;16(2):80-6.
53. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. *N Engl J Med* 2008;359:2417-28.
54. Bakris G, Briasoulis A, Dahlof B, et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. *Am J Cardiol*. 2013 Jul 15;112(2):255-259.
55. Wing LMH, Reid CM, Ryan P, et al; for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003 Feb 13;348(7):583-92.
56. Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. *Clin Ther*. 2007 Feb;29(2):279-89.
57. Fogari R, Mugellini A, Derosa G; CANDIA Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. *J Renin Angiotensin Aldosterone Syst*. 2007 Sep;8(3):139-44.
58. Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. *J Hum Hypertens* 2008;22:266-74.
59. Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. *J Clin Hypertens (Greenwich)*. 2004 Nov;6(11):614-20.
60. Minami J, Abe C, Akashiba A, Takahashi T, Kameda T, Ishimitsu T, Matsuoka H. Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. *Int Heart J*. 2007 Mar;48(2):177-86.
61. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. *Am J Hypertens*. 2004 Mar;17(3):252-9.
62. White WB, Calhoun DA, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. *J Clin Hypertens (Greenwich)* 2008;10:450-8.
63. White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. *Blood Press Monit* 2008;13:21-7.
64. Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. *J Hypertens*. 2001 Nov;19(11):2097-104.
65. Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Smauel R, et al. Treating systolic hypertension in very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. 2011;13:722-730.
66. Duprenz DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, et al. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. *Blood Press Monitor*. 2011 Aug;16(4):186-96.
67. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation* 2009;119:417-25.
68. Schmieder R, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe D. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. *J Hypertens*. 2009;27:1493-1501.
69. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. *J Hypertens*. 2007 Jan;25(1):217-26.
70. Blumenstein M, Romaszko J, Calderón A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. *Curr Med Res Opin* 2009;25:903-910.
71. Jordan J, Engeli S, Boye S, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. *Hypertension*. 2007 May;49:1047-55.

72. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. *J Clin Hypertens (Greenwich)* 2009;11:324-32.
73. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. *Hypertension*. 2007 Feb;49(2):276-84.
74. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial. *JAMA*. 2003 Dec 3;290(21):2805-16.
75. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999 Nov 20;354(9192):1751-6.
76. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol*. 2006;47(3):547-51.
77. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? *Am J Hypertens*. 2000 Apr;13(4 Pt 1):418-26.
78. Stanton AV, Gradman AH, Schmieder RE, et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials. *Hypertension* 2010;55:54-60.
79. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000 Jul 29;356(9227):359-65.
80. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA*. 1998 Jun 17;279(23):1903-7.
81. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig*. 2007;27(11):735-53.
82. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1545-53.
83. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. *J Hum Hypertens*. 1999;13:477-83.
84. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Thiazide-Like Diuretics
AHFS Class 402824
August 19, 2015**

I. Overview

The thiazide-like diuretics are approved for the treatment of edema and hypertension.¹⁻⁵ They inhibit sodium reabsorption in the distal convoluted tubule of the nephron. This results in an initial modest reduction in plasma volume and cardiac output. However, long-term maintenance of decreased blood pressure has been shown to be associated with partial reversal of the hemodynamic changes as plasma volume and cardiac output return to baseline. Although thiazide-like diuretics are pharmacologically similar to thiazide diuretics, there are chemical differences in the molecular structure that differentiate these agents. Indapamide may produce an independent vascular action, which results in a reduction in total peripheral resistance. Metolazone may produce diuresis in patients with glomerular filtration rates below 20 mL/minute.¹⁻⁷

The thiazide-like diuretics that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. All of the agents are available in a generic formulation. This class was last reviewed in May 2013.

Table 1. Thiazide-Like Diuretics Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Chlorthalidone	tablet	N/A	chlorthalidone
Indapamide	tablet	N/A	indapamide
Metolazone	tablet	Zaroxolyn®*	metolazone

*Generic is available in at least one dosage form or strength.
PDL=Preferred Drug List
N/A=Not available

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the thiazide-like diuretics are summarized in Table 2.

Table 2. Treatment Guidelines Using the Thiazide-Like Diuretics

Clinical Guideline	Recommendation(s)
American College of Cardiology/American Heart Association: Guideline for the Management of Heart Failure (2013)⁸	<p>Treatment of Stage A heart failure (HF)</p> <ul style="list-style-type: none"> Hypertension and lipid disorders should be controlled in accordance with guidelines to lower the risk of HF. (Level of Evidence (LoE): A) Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. (LoE: C) <p>Treatment of Stage B heart failure</p> <ul style="list-style-type: none"> In patients with a history of MI and reduced EF, ACE inhibitors or ARBs should be used to prevent HF. (LoE: A) In patients with MI and reduced EF, evidence-based beta blockers (using one of three proven to reduce mortality [i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate]) should be used to prevent HF. (LoE: B) In patients with MI, statins should be used to prevent HF. (LoE: A) ACE inhibitors and beta-blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI. (LoE: A and C, respectively) Blood pressure should be controlled to prevent symptomatic HF. (LoE: A) Nondihydropyridine calcium channel blockers may be harmful in patients with

Clinical Guideline	Recommendation(s)
	<p data-bbox="558 205 781 233">low LVEF. (LoE: C)</p> <p data-bbox="513 264 1008 291">Pharmacological treatment for Stage C HFrEF</p> <ul data-bbox="513 298 1421 1377" style="list-style-type: none"> <li data-bbox="513 298 1349 359">• Recommendations for patients in Stages A and B are recommended where appropriate for patients in Stage C. (LoE: A, B, and C as appropriate) <li data-bbox="513 363 1398 424">• Diuretics are recommended in patients with HFrEF who have evidence of fluid retention, unless contraindicated, to improve symptoms. (LoE: C) <li data-bbox="513 428 1406 541">• ACE inhibitors are recommended in patients with HFrEF and current or prior symptoms, unless contraindicated, to reduce morbidity and mortality. ARBs are recommended as alternative therapy in ACE inhibitor intolerant patients. (LoE: A) <li data-bbox="513 546 1398 638">• Use of one of the three beta-blockers proven to reduce mortality is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality. (LoE: A) <li data-bbox="513 642 1421 940">• Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV HF and who have LVEF of $\leq 35\%$, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II HF should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine should be ≤ 2.5 mg/dL in men or ≤ 2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. (LoE: A) <li data-bbox="513 945 1414 1058">• The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III–IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated. (LoE: A) <li data-bbox="513 1062 1365 1123">• Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to decrease hospitalizations for HF. (LoE: B) <li data-bbox="513 1127 1414 1241">• Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional risk factor for cardioembolic stroke (history of hypertension, diabetes mellitus, previous stroke or transient ischemic attack, or ≥ 75 years of age) should receive chronic anticoagulant therapy. (LoE: A) <li data-bbox="513 1245 1382 1306">• Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications for their use. (LoE: A) <li data-bbox="513 1310 1414 1371">• Calcium channel blockers are not recommended as routine treatment for patients with HFrEF. (LoE: A) <p data-bbox="513 1409 1008 1436">Pharmacological treatment for Stage C HFpEF</p> <ul data-bbox="513 1442 1398 1654" style="list-style-type: none"> <li data-bbox="513 1442 1365 1503">• Blood pressure should be controlled according to published clinical practice guidelines. (LoE: B) <li data-bbox="513 1507 1398 1568">• Diuretics should be used for relief of symptoms due to volume overload. (LoE: C) <li data-bbox="513 1572 1365 1654">• The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (LoE: C) <p data-bbox="513 1692 1008 1719">Treatment of Stage D (advanced/refractory) HF</p> <ul data-bbox="513 1726 1414 1900" style="list-style-type: none"> <li data-bbox="513 1726 1300 1787">• Fluid restriction (1.5 to 2 L/d) is reasonable, especially in patients with hyponatremia, to reduce congestive symptoms. (LoE: C) <li data-bbox="513 1791 1414 1900">• Until definitive therapy (e.g., coronary revascularization, mechanical circulatory support, heart transplantation) or resolution of the acute precipitating problem, patients with cardiogenic shock should receive temporary intravenous inotropic support to maintain systemic perfusion and preserve end-organ performance.

Clinical Guideline	Recommendation(s)
	<p>(LoE: C)</p> <ul style="list-style-type: none"> Continuous intravenous inotropic support is reasonable as “bridge therapy” in patients with stage D HF refractory to medical therapy and device therapy who are eligible for and awaiting mechanical circulatory support or cardiac transplantation. (LoE: B) Long-term use of either continuous or intermittent, intravenous parenteral positive inotropic agents, in the absence of specific indications or for reasons other than palliative care, is potentially harmful in the patient with HF. (LoE: B)
<p>Heart Failure Society of America: Heart Failure Society of America 2010 Comprehensive Heart Failure Practice Guidelines (Executive Summary) (2010)⁹</p>	<p><u>Patients with left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> ACE inhibitors should be used in all patients with a LVEF $\leq 40\%$, unless otherwise contraindicated. ARBs may be used in patients who are intolerant to ACE inhibitors. Hydralazine and a nitrate may be used in patients intolerant to ACE inhibitors and ARBs, or in whom such therapy is contraindicated. The combination of an ACE inhibitor and a β-blocker is recommended in all patients with a LVEF $\leq 40\%$. The routine use of an ARB with a combination of an ACE inhibitor and β-blocker in patients who have had a MI and have left ventricular dysfunction is not recommended. The addition of an ARB can be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. Individual ARBs may be considered as initial therapy (instead of an ACE inhibitor) in patients with heart failure who have had a MI and in patients with chronic heart failure and systolic dysfunction. ARBs are recommended in patients who cannot tolerate ACE inhibitors due to cough. The combination of hydralazine and an oral nitrate may be considered in such patients not tolerating ARB therapy. Patients intolerant to ACE inhibitors from hyperkalemia or renal insufficiency are likely to experience the same side effects with ARBs. In these cases, the combination of hydralazine and an oral nitrate should be considered. ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and with recognition that angioedema has been reported infrequently with ARBs. The combination of hydralazine and oral nitrates may be considered in such patients not tolerating ARB therapy. A combination of hydralazine and an oral nitrate is recommended in African American patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are on a standard regimen of an ACE inhibitor (or ARB) and a β-blocker. A combination of hydralazine and an oral nitrate may be considered in non-African American patients with heart failure and reduced LVEF who are symptomatic despite optimization of standard therapy. Administration of an aldosterone antagonist is recommended for patients with New York Heart Association (NYHA) class IV (or class III, previously class IV) heart failure from reduced LVEF ($<35\%$) while receiving standard therapy, including diuretics. Administration of an aldosterone antagonist should be considered in patients following an acute MI, with clinical heart failure signs and symptoms or history of diabetes mellitus, and an LVEF $<40\%$. Patients should be on standard therapy, including an ACE inhibitor (or ARB) and a β-blocker. The triple combination of an ACE inhibitor, an ARB, and an aldosterone antagonist is not recommended because of the high risk of hyperkalemia. <p><u>Patients with hypertension and symptomatic left ventricular dysfunction with left ventricular dilation and low LVEF</u></p>

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • ACE inhibitors, ARBs, β-blockers, aldosterone inhibitors, and isosorbide dinitrate/hydralazine in various combinations (with a loop diuretic if needed) are recommended. • If blood pressure remains >130/80 mm Hg, a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) may be considered or other antihypertensive medication doses increased. <p><u>Managing heart failure in special populations</u></p> <ul style="list-style-type: none"> • The combination of hydralazine/isosorbide dinitrate is recommended for African American women with moderate to severe heart failure symptoms who are on background neurohormonal inhibition. • A combination of hydralazine and isosorbide dinitrate is recommended as part of standard therapy in addition to β-blockers and ACE-inhibitors for African Americans with left ventricular systolic dysfunction and NYHA class II-IV heart failure. • As in all patients, but especially in the elderly, careful attention to volume status, the possibility of symptomatic cerebrovascular disease and the presence of postural hypotension are recommended during therapy with ACE inhibitors, β-blockers and diuretics. <p><u>Patients with heart failure and preserved LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs should be considered in this patient population. • ACE inhibitors should be considered in patients with heart failure and symptomatic atherosclerotic cardiovascular disease or diabetes and at least one other risk factor. ARBs may be used in patients who are intolerant to ACE inhibitors. • Beta blocker treatment is recommended in patients with HF and preserved LVEF who have prior MI, hypertension, or AF. • Calcium channel blockers should be considered in patients with heart failure and preserved LVEF who have atrial fibrillation requiring ventricular rate control and intolerance to β-blockers (consider diltiazem or verapamil), symptom-limiting angina, or hypertension. • Diuretic therapy is recommended in all patients with heart failure and clinical evidence of volume overload, including those with preserved LVEF. • Treatment may begin with either a thiazide or loop diuretic. In more severe volume overload or if response to a thiazide is inadequate, treatment with a loop diuretic should be implemented. • Excessive diuresis, which may lead to orthostatic changes in blood pressure and worsening renal function, should be avoided. <p><u>Patients with heart failure and CAD</u></p> <ul style="list-style-type: none"> • Calcium channel blockers should be considered in patients who have angina despite optimization of β-blocker and nitrates. Amlodipine and felodipine are preferred in patients with decreased systolic function. <p><u>Patients with heart failure and hypertension</u></p> <ul style="list-style-type: none"> • Patients with left ventricular hypertrophy or left ventricular dysfunction without left ventricular dilation should be treated to a goal blood pressure of <130/80 mm Hg. Treatment with several drugs may be necessary, including an ACE inhibitor (or ARB), a diuretic and a β-blocker or calcium channel blocker. • Patients with asymptomatic left ventricular dysfunction and left ventricular dilation and a reduced ejection fraction should receive an ACE inhibitor and a β-blocker. If blood pressure remains elevated (>130/80 mm Hg), the addition of a diuretic is recommended, followed by a calcium channel blocker or other antihypertensive agent.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • If blood pressure remains >130/80 mm Hg, then the addition of a thiazide diuretic is recommended, followed by a dihydropyridine calcium channel blocker (e.g., amlodipine or felodipine) or other antihypertensive drugs. <p><u>Patients at risk for development of heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in patients who are at risk for the development of heart failure including patients with CAD, peripheral vascular disease, stroke, diabetes and another major risk factor, and patients with diabetes who smoke and have microalbuminuria. <p><u>Patients with asymptomatic heart failure and reduced LVEF</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • Routine use of a combination of ACE inhibitors and ARBs is not recommended. • β-blocker therapy should be considered. <p><u>Patients with heart failure and ischemic heart disease</u></p> <ul style="list-style-type: none"> • ACE inhibitor therapy is recommended in all patients with either reduced or preserved LVEF after a MI. • Beta blockers are recommended for the management of all patients with reduced LVEF or post-MI. • ACE inhibitor and β-blocker therapy should be initiated early (<48 hours) during hospitalization in hemodynamically stable patients who are post-MI with reduced LVEF or heart failure. • Calcium channel blockers may be considered in patients with HF who have angina despite the optimal use of beta blockers and nitrates. <p><u>Managing heart failure in the elderly, women and African Americans</u></p> <ul style="list-style-type: none"> • Standard regimens of ACE inhibitors and β-blockers are recommended in elderly patients with heart failure. • ACE inhibitor and β-blocker therapy are recommended in all women with heart failure and left ventricular systolic dysfunction. • ACE inhibitor and β-blocker therapy are recommended in all African American patients with heart failure and left ventricular systolic dysfunction. ARBs may be substituted in patients who are intolerant to ACE inhibitors. <p><u>Heart failure in patients with reduced ejection fraction</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended in asymptomatic patients with reduced LVEF (<40%). • ARBs may be used in patients who are intolerant to ACE inhibitors. • β-blockers shown to be effective in clinical trials of patients with heart failure are recommended for patients with a LVEF \leq40%. • The combination of a β-blocker and an ACE inhibitor is recommended as routine therapy for asymptomatic patients with a LVEF \leq40%. The evidence is stronger in patients with a history of MI. • β-blocker therapy is recommended for patients with a recent decompensation of heart failure after optimization of volume status and successful discontinuation of intravenous diuretics and vasoactive drugs. Whenever possible, β-blocker therapy should be initiated in the hospital setting at a low dose prior to discharge of stable patients. • β-blocker therapy is recommended in the great majority of patients with heart failure and reduced LVEF, even if there is concurrent diabetes, chronic obstructive pulmonary disease or peripheral vascular disease. Caution may be warranted in these patients.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • It is recommended that β blockade be initiated at low doses and uptitrated gradually. • It is recommended that β-blocker therapy be continued in most patients experiencing a symptomatic exacerbation of heart failure during chronic maintenance treatment, unless they develop cardiogenic shock, refractory volume overload or symptomatic bradycardia. • The routine use of an ARB is not recommended in addition to an ACE inhibitor and a β-blocker in patients with a recent acute MI and reduced LVEF. • The addition of an ARB should be considered in patients with heart failure due to reduced LVEF who have persistent symptoms or progressive worsening despite optimized therapy with an ACE inhibitor and a β-blocker. • Administration of an aldosterone antagonist is recommended for patients with NYHA class IV (or class III, previously class IV) HF from reduced LVEF (<35%) while receiving standard therapy, including diuretics. • Diuretic therapy is recommended to restore and maintain normal volume status in patients with clinical evidence of fluid overload, generally manifested by congestive symptoms or signs of elevated filling pressures. Loop diuretics rather than thiazide-type diuretics are typically necessary to restore normal volume status in patients with heart failure. • The initial dose of diuretic may be increased as necessary to relieve congestion, and restoration of normal volume status may require multiple adjustments, especially in patients with severe fluid overload evidenced by massive edema or ascites. After a diuretic effect is achieved with loop diuretics (short acting), increasing administration frequency to twice or even three times/day will provide more diuresis with less physiologic perturbation than larger single doses. • Oral torsemide may be considered in patients in whom poor absorption of oral medication or erratic diuretic effect may be present. Particularly in patients with right-sided heart failure and refractory fluid retention despite high doses of other loop diuretics. • Intravenous administration of diuretics may be necessary to relieve congestion. • Diuretic refractoriness may represent patient nonadherence, a direct effect of diuretic use on the kidney or progression of underlying cardiac dysfunction. • Addition of chlorothiazide or metolazone, once or twice daily, to loop diuretics should be considered in patients with persistent fluid retention despite high dose loop diuretic therapy. Chronic daily use should be avoided if possible because of the potential for electrolyte shifts and volume depletion. These drugs may be used periodically (every other day or weekly) to optimize fluid management. Metolazone will generally be more potent and much longer acting in this setting and in patients with chronic renal insufficiency, so administration should be adjusted accordingly. Volume status and electrolytes must be monitored closely when multiple diuretics are used. • Careful observation for the development of side effects is recommended in patients treated with diuretics, especially when high doses or combination therapy are used. Patients should undergo routine laboratory studies and clinical examination as dictated by their clinical response. • Patients requiring diuretic therapy to treated fluid retention associated with heart failure generally require chronic treatment, although often at lower doses than those required initially to achieve diuresis. Decreasing or discontinuing therapy may be considered in patients experiencing significant improvement in clinical status and cardiac function or in those who successfully restrict dietary sodium intake. These patients may undergo cautious weaning of diuretic dose and frequency with careful observation for recurrent fluid retention. • Patients and caregivers should be given education on the early signs of fluid retention and the plan for initial therapy.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Selected patients may be educated to adjust daily dose of diuretic in response to weight gain from fluid overload. <p><u>Evaluation and management of patients with acute decompensated heart failure</u></p> <ul style="list-style-type: none"> • Patients admitted with acute decompensated heart failure and evidence of fluid overload be treated initially with loop diuretics; usually given intravenously rather than orally. Ultrafiltration may be considered in lieu of diuretics. • Diuretics should be administered at doses needed to produce a rate of diuresis sufficient to achieve optimal volume status with relief of signs and symptoms of congestion, without inducing an excessively rapid reduction in intravascular volume or serum electrolytes. • Monitoring of daily weights, intake and output is recommended to assess clinical efficacy of diuretic therapy. • Careful observation for development of a variety of side effects, including renal dysfunction, electrolyte abnormalities, symptomatic hypotension and gout is recommended in patients treated with diuretics, especially when high doses or combination therapy is used. • Careful observation for the development of renal dysfunction is recommended in patients treated with diuretics. Patients with moderate to severe renal dysfunction and evidence of fluid retention should continue to be treated with diuretics. In the presence of severe fluid overload, renal dysfunction may improve with diuresis. • When congestion fails to improve in response to diuretic therapy, the following options should be considered: <ul style="list-style-type: none"> ○ Re-evaluating the presence/absence of congestion. ○ Sodium and fluid restriction. ○ Increasing doses of loop diuretic. ○ Continuous infusion of a loop diuretic. ○ Addition of a second type of diuretic orally (metolazone or spironolactone) or intravenously (chlorothiazide). ○ Ultrafiltration may be considered as well.
<p>European Society of Cardiology: European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2012)¹⁰</p>	<p><u>Treatments recommended in potentially all patient with symptomatic (New York Heart Association [NYHA] functional class II-IV) systolic heart failure</u></p> <ul style="list-style-type: none"> • ACE inhibitors are recommended, in addition to a β-blocker, for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of hospitalization and the risk of premature death. • A β-blocker is recommended, in addition to an ACE inhibitor (or ARB if ACE inhibitor is not tolerated), for all patients with an ejection fraction $\leq 40\%$ to reduce the risk of heart failure hospitalization and the risk of premature death. <p><u>Recommendations for controlling the ventricular rate in patients with symptomatic heart failure (NYHA functional class II-IV), left ventricular systolic dysfunction, persistent/permanent atrial fibrillation and no evidence of acute decompensation</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to control the ventricular rate because of the associated benefits of this treatment (i.e., reducing the risk of hospitalization for worsening heart failure, reducing the risk of premature death). • Step 2: digoxin is recommended as the preferred second drug, in addition to a β-blocker, to control the ventricular rate in patients with an inadequate response to a β-blocker. <p><u>Recommendations for the management of ventricular arrhythmias in heart failure</u></p> <ul style="list-style-type: none"> • It is recommended that treatment with an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist should be optimized in patients with ventricular arrhythmias.

Clinical Guideline	Recommendation(s)
	<p><u>Recommendations for the pharmacological treatment of stable angina pectoris in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: a β-blocker is recommended as the preferred first line treatment to relieve angina because of the associated benefits of this treatment (i.e., reducing the risk of heart failure hospitalization, risk of premature death). <ul style="list-style-type: none"> ◦ Amlodipine should be considered as a potential alternative to a β-blocker in patients unable to tolerate a β-blocker, to relieve angina. • Step 2: add a second anti-anginal drug to a β-blocker. <ul style="list-style-type: none"> ◦ The addition of amlodipine is recommended when angina persists despite treatment with a β-blocker (or alternative agent), to relieve angina. • Step 3: Coronary revascularization is recommended when angina persists despite treatment with two antianginal drugs. <ul style="list-style-type: none"> ◦ Diltiazem or verapamil are not recommended because of their negative inotropic action and risk of worsening heart failure. <p><u>Recommendations for the treatment of hypertension in patients with symptomatic heart failure (NYHA functional class II-IV) and left ventricular systolic dysfunction</u></p> <ul style="list-style-type: none"> • Step 1: one or more of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist is recommended as first, second, and third line therapy, respectively, because of their associated benefits (i.e., reducing the risk of heart failure hospitalization, reducing the risk of premature death). • Step 2: a thiazide diuretic (or if the patient is treated with a thiazide diuretic, switching to a loop diuretic) is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, and mineralocorticoid receptor antagonist. • Step 3: <ul style="list-style-type: none"> ◦ Amlodipine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ◦ Hydralazine is recommended when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. ◦ Felodipine should be considered when hypertension persists despite treatment with a combination of as many as possible of an ACE inhibitor (or ARB), β-blocker, mineralocorticoid receptor antagonist, and diuretic. <p><u>Treatment of acute heart failure</u></p> <ul style="list-style-type: none"> ◦ A β-blocker is recommended in patients with an ejection fraction $\leq 40\%$, after stabilization, to reduce the risk of death and recurrent MI.
<p>Eighth Joint National Committee (JNC 8): 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults (2014)¹¹</p>	<ul style="list-style-type: none"> • Pharmacologic treatment should be initiated in patients ≥ 60 years of age to lower blood pressure at systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 150 mm Hg and goal diastolic blood pressure < 90 mm Hg. Adjustment of treatment is not necessary if treatment results in lower blood pressure and treatment is well tolerated and without adverse effects on health or quality of life. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at diastolic blood pressure ≥ 90 mm Hg to a goal diastolic blood pressure < 90 mm Hg. • In patients < 60 years of age, pharmacologic treatment should be initiated to lower blood pressure at systolic blood pressure ≥ 150 mm Hg to a goal diastolic blood pressure < 140 mm Hg. • For patients ≥ 18 years of age with chronic kidney disease or diabetes, pharmacologic treatment should be initiated to lower blood pressure at systolic

Clinical Guideline	Recommendation(s)
	<p>blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg and to a goal systolic blood pressure < 140 mm Hg and goal diastolic blood pressure < 90 mm Hg.</p> <ul style="list-style-type: none"> • Initial antihypertensive treatment for the general nonblack population, including those with diabetes, should include thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or ARB. • Initial antihypertensive treatment for the general black population, including those with diabetes, should include thiazide-type diuretic or CCB. • For patients ≥ 18 years of age with chronic kidney disease regardless of race or diabetes status, initial (or add-on) treatment should include an ACE inhibitor or ARB to improve kidney outcomes. • The main goal of antihypertensive treatment is to attain and maintain goal blood pressure. • If goal blood pressure is not attained within a month of treatment, the dose of the initial drug should be increased or second drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • If goal is not achieved with two drugs, a third drug from the thiazide-type diuretic, CCB, ACE inhibitor, or ARB classes should be added. • An ACE inhibitor and ARB should not be used together. • Antihypertensive classes can be used if the patient is unable to achieve goal blood pressure with three agents or had a contraindication to a preferred class. • If blood pressure is not able to be achieved or in complicated patients, referral to a hypertension specialist may be indicated.
<p>World Health Organization/ International Society of Hypertension: 2003 World Health Organization/ International Society of Hypertension Statement on Management of Hypertension (2003)¹²</p>	<ul style="list-style-type: none"> • When used as monotherapy, a diuretic or a calcium channel blocker may be more effective than an ACE inhibitor or a β-blocker in African American patients and older patients. • Compelling indications for the use of a medication from a specific drug class include elderly patients with isolated systolic hypertension (diuretics and dihydropyridine calcium channel blockers), renal disease (ACE inhibitors and ARBs), post-myocardial infarction (ACE inhibitors and β-blockers), left ventricular dysfunction (ACE inhibitors), congestive heart failure (β-blockers, ACE inhibitors and diuretics), left ventricular hypertrophy (ARBs) and cerebrovascular disease (diuretics and ACE inhibitors).
<p>European Society of Hypertension/European Society of Cardiology: 2007 Guidelines for the Management of Hypertension (2007)¹³, Reappraisal of Guidelines on Hypertension Management (2009)¹⁴</p>	<ul style="list-style-type: none"> • In order to optimize treatment initiation, intensity and goals, it is important to assess total cardiovascular risk in patients with hypertension which must include a search for subclinical organ damage. • In general, early introduction of blood pressure lowering treatments, before organ damage develops or becomes irreversible or before cardiovascular events occur, is recommended. • There is evidence that certain drug classes may be preferred in specific patient populations: left ventricular hypertrophy (ACE inhibitors, ARBs and calcium channel blockers), asymptomatic atherosclerosis (calcium channel blockers and ACE inhibitors), microalbuminuria and renal dysfunction (ACE inhibitors and ARBs), previous stroke (any antihypertensive), previous myocardial infarction (ACE inhibitors, β-blockers and ARBs), angina (calcium channel blockers and β-blockers), heart failure (diuretics, ACE inhibitors, β-blockers, ARBs and aldosterone antagonists), recurrent atrial fibrillation (ACE inhibitors and ARBs), permanent atrial fibrillation (β-blockers and nondihydropyridine calcium channel blockers), end stage renal disease/proteinuria (ACE inhibitors, ARBs and loop diuretics), metabolic syndrome (ACE inhibitors, ARBs and calcium channel blockers), diabetes (ACE inhibitors and ARBs), pregnancy (methyldopa, calcium channel blockers and β-blockers) and African American patients (calcium channel blockers and diuretics).

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Available evidence justifies the use of aliskiren in hypertension, particularly in combination with other agents. • Many patients will require more than one medication to control blood pressure. Patients may be started on monotherapy or combination therapy. Initial combination therapy should be considered in patients with grade II or III hypertension or patients with high or very high cardiovascular risk. • Fixed combination medications can favor compliance and simplify regimens. • When combining different classes of antihypertensive medications, consider medications which have different and complementary mechanisms of action, and that there is evidence that the antihypertensive effect of the combination is greater than that of either combination component and the combination is likely to be well tolerated. • Combinations that can be recommended for priority use based on trial evidence of outcome reduction include a diuretic with an ACE inhibitor, ARB or calcium channel blocker and an ACE inhibitor with a calcium channel blocker. • Avoid β-blocker/diuretic combination unless required for other reasons. • If triple therapy is needed, the most rational combination is a blocker of the rennin-angiotensin system, a calcium channel blocker and a diuretic at effective doses. • A β- or α-blocker may be included in a triple therapy approach depending on clinical circumstances. • Antihypertensive treatment is highly beneficial in elderly patients and treatment may be initiated with a thiazide diuretic, ACE inhibitor, calcium channel blocker, ARB or β-blocker. • Blood pressure lowering drugs should be continued or initiated in patients 80 years of age, starting with monotherapy and adding a second drug, if needed. The decision to treat should be made on an individual basis and patients should be carefully monitored. • Calcium channel blockers, ARBs and thiazide diuretics have been shown to be effective in treating isolated systolic hypertension. • Antihypertensive treatment should always be initiated in diabetic patients when blood pressure is 140/90 mm Hg or higher; however, there is evidence in favor of initiating treatment with high normal blood pressure. • The blood pressure goal of <130/80 mm Hg is not supported by outcome evidence from trials and is difficult for the majority of patients to achieve; therefore, its realistic to recommend only to pursue a sizeable blood pressure reduction without indicating a goal that is unproven. • In hypertensive diabetic patients, tight blood glucose control (glycosylated hemoglobin to 6.5%) is beneficial, particularly in combination with effective blood pressure control, on improving microvascular complications. Tight glucose control should not be pursued abruptly and patients should be monitored closely due to the increased risk of severe hypoglycemic episodes.
<p>European Society of Hypertension/European Society of Cardiology: 2013 Guidelines for the management of arterial hypertension (2013)¹⁵</p>	<p>The 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology follow the guidelines jointly issued by the two societies in 2003 and 2007.</p> <p>Treatment strategies and choice of antihypertensive drugs</p> <ul style="list-style-type: none"> • Diuretics (including thiazides, chlorthalidone, and indapamide), beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some combinations. • Some agents should be considered as the preferential choice in specific conditions because used in trials in those conditions or because of greater effectiveness in specific types of organ damage.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Initiation of antihypertensive therapy with a two-drug combination may be considered in patients with markedly high baseline blood pressure (BP) or at high cardiovascular (CV) risk. • The combination of two antagonists of the renin-angiotensin system (RAS) is not recommended and should be discouraged. • Other drug combinations should be considered and probably are beneficial in proportion to the extent of BP reduction. However, combinations that have been successfully used in trials may be preferable. • Combinations of two antihypertensive drugs at fixed doses in a single tablet may be recommended and favored, because reducing the number of daily pills improves adherence, which is low in patients with hypertension. <p><u>Treatment strategies in white-coat and masked hypertension</u></p> <ul style="list-style-type: none"> • In white-coat hypertensives without additional risk factors, therapeutic intervention may be limited to lifestyle changes only, but this decision should be accompanied by close follow-up. • In white-coat hypertensives with a higher CV risk because of metabolic derangements or asymptomatic organ damage, drug treatment may be considered in addition to lifestyle changes. • In masked hypertension, both lifestyle measures and antihypertensive drug treatment should be considered, because this type of hypertension has been consistently found to have a CV risk very close to that of in- and out-of-office hypertension. <p><u>Antihypertensive treatment strategies in the elderly</u></p> <ul style="list-style-type: none"> • In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 150 and 140 mmHg. • In fit elderly patients < 80 years old antihypertensive treatment may be considered at SBP values ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. • In individuals older than 80 years with an initial SBP ≥ 160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions. • In frail elderly patients, it is recommended to leave decisions on antihypertensive therapy to the treating physician, and based on monitoring of the clinical effects of treatment. • Continuation of well-tolerated antihypertensive treatment should be considered when a treated individual becomes an octogenarian. • All hypertensive agents are recommended and can be used in the elderly, although diuretics and calcium antagonists may be preferred in isolated systolic hypertension. <p><u>Treatment strategies in hypertensive women</u></p> <ul style="list-style-type: none"> • Hormone therapy and selective estrogen receptor modulators are not recommended and should not be used for primary or secondary prevention of CVD. • If treatment of younger perimenopausal women is considered for severe menopausal symptoms, the benefits should be weighed against potential risks. • Drug treatment of severe hypertension in pregnancy (SBP > 160 mmHg or DBP > 110 mmHg) is recommended. • Drug treatment may also be considered in pregnant women with persistent elevation of BP $\geq 150/95$ mmHg, and in those with BP $\geq 140/90$ mmHg in the presence of gestational hypertension, subclinical organ damage or symptoms. • In women at high risk of pre-eclampsia, provided they are at low risk of gastrointestinal hemorrhage, treatment with low dose aspirin from 12 weeks

Clinical Guideline	Recommendation(s)
	<p>until delivery may be considered.</p> <ul style="list-style-type: none"> • In women with child-bearing potential RAS blockers are not recommended and should be avoided. • Methyldopa, labetalol, and nifedipine should be considered preferential antihypertensive drugs in pregnancy. Intravenous labetalol or infusion of nitroprusside should be considered in case of emergency (pre-eclampsia). <p><u>Treatment strategies in patients with diabetes</u></p> <ul style="list-style-type: none"> • While initiation of antihypertensive drug treatment in diabetic patients whose SBP is ≥ 160 mmHg is mandatory, it is strongly recommended to start drug treatment also when SBP is ≥ 140 mmHg. • A SBP goal < 140 mmHg is recommended in patients with diabetes. • The DBP target in patients with diabetes is recommended to be < 85 mmHg. • All classes of antihypertensive agents are recommended and can be used in patients with diabetes; RAS blockers may be preferred, especially in the presence of proteinuria or microalbuminuria. • It is recommended that individual drug choice takes comorbidities into account. • Simultaneous administration of two blockers of the RAS is not recommended and should be avoided in patients with diabetes <p><u>Treatment strategies in hypertensive patients with metabolic syndrome</u></p> <ul style="list-style-type: none"> • Lifestyle changes, particularly weight loss and physical exercise, are to be recommended to all individuals with the metabolic syndrome. These interventions improve not only BP, but the metabolic components of the syndrome and delay diabetes onset. • As the metabolic syndrome can be considered a ‘pre-diabetic’ state, antihypertensive agents potentially improving or at least not worsening insulin sensitivity, such as RAS blockers and calcium antagonists, should be considered as the preferred drugs. Beta-blockers (with the exception of vasodilating beta-blockers) and diuretics should be considered only as additional drugs, preferably in association with a potassium-sparing agent. • It is recommended to prescribe antihypertensive drugs with particular care in hypertensive patients with metabolic disturbances when BP is $\geq 140/90$ mmHg after a suitable period of lifestyle changes, and to maintain BP $< 140/90$ mmHg. • BP lowering drugs are not recommended in individuals with metabolic syndrome and high normal BP. <p><u>Therapeutic strategies in hypertensive patients with nephropathy</u></p> <ul style="list-style-type: none"> • Lowering SBP to < 140 mmHg should be considered. • When overt proteinuria is present, SBP values < 130 mmHg may be considered, provided that changes in eGFR are monitored. • RAS blockers are more effective in reducing albuminuria than other antihypertensive agents, and are indicated in hypertensive patients in the presence of microalbuminuria or overt proteinuria. • Reaching BP goals usually requires combination therapy, and it is recommended to combine RAS blockers with other antihypertensive agents. • Combination of two RAS blockers, though potentially more effective in reducing proteinuria, is not recommended. • Aldosterone antagonists cannot be recommended in chronic kidney disease (CKD), especially in combination with a RAS blocker, because of the risk of excessive reduction in renal function and of hyperkalemia. <p><u>Therapeutic strategies in hypertensive patients with cerebrovascular disease</u></p> <ul style="list-style-type: none"> • It is not recommended to intervene with BP-lowering therapy during the first week after acute stroke irrespective of BP level, although clinical judgement

Clinical Guideline	Recommendation(s)
	<p>should be used in the face of very high SBP values.</p> <ul style="list-style-type: none"> • Antihypertensive treatment is recommended in hypertensive patients with a history of stroke or transient ischemic attack (TIA), even when initial SBP is in the 140 to 159 mmHg range. • In hypertensive patients with a history of stroke or TIA, a SBP goal of <140 mmHg should be considered. • In elderly hypertensives with previous stroke or TIA, SBP values for intervention and goal may be considered to be somewhat higher. • All drug regimens are recommended for stroke prevention, provided that BP is effectively reduced. <p><u>Therapeutic strategies in hypertensive patients with heart disease</u></p> <ul style="list-style-type: none"> • In hypertensive patients with CHD, a SBP goal <140 mmHg should be considered. • In hypertensive patients with a recent myocardial infarction, beta-blockers are recommended. In case of other CHD all antihypertensive agents can be used, but beta-blockers and calcium antagonists are to be preferred for symptomatic reasons (angina). • Diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, and/or mineralocorticoid receptor antagonists are recommended in patients with heart failure or severe left ventricular (LV) dysfunction to reduce mortality and hospitalization. • In patients with heart failure and preserved ejection fraction (EF), there is no evidence that antihypertensive therapy per se or any particular drug is beneficial. However, in these patients, as well as in patients with hypertension and systolic dysfunction, lowering SBP to around 140 mmHg should be considered. Treatment guided by relief of symptoms (congestion with diuretics, high heart rate with beta-blockers, etc.) should also be considered. • ACE inhibitors and angiotensin receptor blockers (and beta-blockers and mineralocorticoid receptor antagonists if heart failure coexists) should be considered as antihypertensive agents in patients at risk of new or recurrent atrial fibrillation. • It is recommended that all patients with left ventricular hypertrophy (LVH) receive antihypertensive agents. • In patients with LVH, initiation of treatment with one of the agents that have shown a greater ability to regress LVH should be considered, i.e. ACE inhibitors, angiotensin receptor blockers, and calcium antagonists. <p><u>Therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease (PAD)</u></p> <ul style="list-style-type: none"> • In the presence of carotid atherosclerosis, prescription of calcium antagonists and ACE inhibitors should be considered as these agents have shown a greater efficacy in delaying atherosclerosis progression than diuretics and beta-blockers. • In hypertensive patients with a pulse wave velocity above 10 m/s, all antihypertensive drugs should be considered provided that a BP reduction to <140/90 mmHg is consistently achieved. • Antihypertensive therapy is recommended in hypertensive patients with PAD to achieve a goal of <140/90 mmHg, because of their high risk of myocardial infarction, stroke, heart failure, and CV death. • Though a careful follow up is necessary, beta-blockers may be considered for the treatment of arterial hypertension in patients with PAD, since their use does not appear to be associated with exacerbation of PAD symptoms.
National Institute for Health and Clinical Excellence:	<ul style="list-style-type: none"> • Patients <55 years should be offered a step 1 antihypertensive with an ACE inhibitor or ARB. If an ACE inhibitor is not tolerated, offer an ARB. • Do not combine an ACE inhibitor with an ARB for the treatment of

Clinical Guideline	Recommendation(s)
<p>Hypertension: The Clinical Management of Primary Hypertension in Adults (2011)¹⁶</p> <p>Reviewed Oct 2013</p>	<p>hypertension.</p> <ul style="list-style-type: none"> • Offer a step 1 antihypertensive (ACE inhibitor, ARB) with a calcium channel blocker to patients >55 years of age and to black patients of African or Caribbean origin of any age. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For patients who are already receiving treatment with bendroflumethiazide or hydrochlorothiazide and who are stable and well controlled, continue treatment as is. • β-blockers are not a preferred initial therapy for hypertension; however, β-blockers may be considered in younger patients, particularly: <ul style="list-style-type: none"> ○ Patients with an intolerance or contraindication to ACE inhibitors and ARBs. ○ Women of child-bearing potential. ○ People with evidence of increased sympathetic drive. • If treatment is initiated with a β-blocker and a second antihypertensive is required, add a calcium channel blocker over a thiazide-like diuretic to reduce the risk of developing diabetes. • If blood pressure is not controlled with a step 1 antihypertensive, offer a step 2 antihypertensive with a calcium channel blocker in combination with an ACE inhibitor or an ARB. If a calcium channel blocker is not appropriate or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic. • For black patients of African or Caribbean origin, consider an ARB over an ACE inhibitor, in combination with a calcium channel blocker. • If three drugs are required to control blood pressure, the combination of an ACE inhibitor or ARB, calcium channel blocker, and a thiazide-like diuretic should be utilized. • Resistant hypertension should be considered with clinic blood pressure remains >140/90 mm Hg after treatment with the optimal or best tolerated doses of an ACE inhibitor or an ARB plus a calcium channel blocker plus a diuretic. • For treatment of resistant hypertension at step 4: <ul style="list-style-type: none"> ○ Consider further diuretic therapy with low-dose spironolactone. ○ Consider higher-dose thiazide-like diuretic treatment. ○ If further diuretic therapy for resistant hypertension at step 4 is not tolerated or is contraindicated or ineffective, consider an α-blocker or β-blocker.
<p>International Society on Hypertension in Blacks: Management of High Blood Pressure in Blacks (2010)¹⁷</p>	<ul style="list-style-type: none"> • To attain and maintain blood pressure (BP) below target levels, multiple antihypertensive drugs will be required in most hypertensive blacks. • Use of two-drug combination therapy when SBP is >15 mm Hg and/or DBP is >10 mm Hg above goal levels is increasingly recommended as first-line therapy. • Two-drug regimens have generally contained a thiazide-type diuretic; however, the combination of a calcium channel blocker (CCB) with either an ACE inhibitor or an ARB has been shown equally efficacious in BP lowering but with demonstrated superiority (CCB+ACE) for hard clinical outcomes compared with the same ACE inhibitor plus a thiazide-type diuretic. • In secondary prevention patients, the combination therapy should include a drug(s) with the appropriate compelling indications. • Certain classes of antihypertensive medications, specifically diuretics and CCBs, lower BP on average more than β-blockers and renin-angiotensin system (RAS) blockers in black patients when used as monotherapies. • In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a CCB is preferred. • Lifestyle modifications should be initiated in all patients with hypertension,

Clinical Guideline	Recommendation(s)
	<p>whether or not pharmacotherapy is planned.</p> <ul style="list-style-type: none"> • ACE inhibitors or ARBs are recommended as alternative monotherapy options in the treatment of hypertension in blacks. The rationale for their lower tier monotherapy recommendation is because they have consistently achieved lesser average reductions in BP relative to that observed with monotherapy using either a diuretic or CCB.
<p>National Kidney Foundation, Kidney Disease Outcomes Quality Initiative: Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004)¹⁸</p>	<ul style="list-style-type: none"> • All antihypertensives can be used to lower blood pressure in chronic kidney disease. • Combination therapy is likely to be necessary to achieve blood pressure goals. If combination therapy is required, separate prescriptions or fixed-dose combinations may be used as initial therapy. • Antihypertensive regimens should be simplified as much as possible and long-acting agents should be used when possible. • Diuretics should be a component of the antihypertensive regimen in most patients. Other agents should be chosen based on cardiovascular risk profile and compelling indications as follows: heart failure with systolic dysfunction (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers, aldosterone antagonists), post-myocardial infarction with systolic dysfunction (ACE inhibitors, ARBs, β-blockers, aldosterone antagonists), post-myocardial infarction (β-blockers), chronic stable angina (calcium channel blockers, β-blockers), high coronary artery disease risk (diuretics, ACE inhibitors, ARBs, β-blockers, calcium channel blockers), recurrent stroke prevention (diuretics, ACE inhibitors, ARBs), and supraventricular tachycardia (β-blockers, nondihydropyridine calcium channel blockers). • Patients with diabetic kidney disease with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Patients with nondiabetic kidney disease and spot urine total protein to creatinine ratio of ≥ 200 mg/g with or without hypertension should be treated with an ACE inhibitor or ARB. If additional medication is needed, diuretics are preferred, followed by a β-blocker or calcium channel blocker. • Kidney transplant patients with chronic kidney disease may be treated with calcium channel blockers, diuretics, ACE inhibitors, ARBs, or β-blockers to reach blood pressure goals.
<p>Kidney Disease Improving Clinical Outcomes Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2012)¹⁹</p>	<p><u>Blood pressure management in chronic kidney disease (CKD) non-dialysis (ND) patients without diabetes mellitus</u></p> <ul style="list-style-type: none"> • The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion < 30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 140 mm Hg systolic or > 90 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion > 300 mg per 24 hours (or equivalent*) whose office blood pressure is consistently > 130 mm Hg systolic or > 80 mm Hg diastolic be treated with blood pressure -lowering drugs to maintain a blood pressure that is consistently ≤ 130 mm Hg systolic and ≤ 80 mm Hg diastolic. • The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is

Clinical Guideline	Recommendation(s)
	<p>indicated.</p> <ul style="list-style-type: none"> The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion >300 mg per 24 hours (or equivalent*) in whom treatment with blood pressure -lowering drugs is indicated. <p><u>Blood pressure management in CKD ND patients with diabetes mellitus</u></p> <ul style="list-style-type: none"> The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion <30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic. The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion >30 mg per 24 hours (or equivalent*) whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic. The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion >300 mg per 24 hours (or equivalent*). <p><u>Blood pressure management in kidney transplant recipients (non-dialysis-dependent CKD of any stage with a kidney transplant [CKD T])</u></p> <ul style="list-style-type: none"> The Work Group suggests that adult kidney transplant recipients whose office blood pressure is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated to maintain a blood pressure that is consistently ≤130 mm Hg systolic and ≤80 mm Hg diastolic, irrespective of the level of urine albumin excretion. In adult kidney transplant recipients, choose a blood pressure -lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. <p><u>Blood pressure management in children with CKD ND</u></p> <ul style="list-style-type: none"> The Work Group recommends that in children with CKD ND, blood pressure - lowering treatment is started when blood pressure is consistently above the 90th percentile for age, sex, and height. The Work Group suggests that in children with CKD ND (particularly those with proteinuria), blood pressure is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with blood pressure -lowering drugs is indicated, irrespective of the level of proteinuria. <p><u>Blood pressure management in elderly persons with CKD ND</u></p> <ul style="list-style-type: none"> Tailor blood pressure treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to blood pressure treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. <p>*Approximate equivalents for albumin excretion rate per 24 hours is expressed as</p>

Clinical Guideline	Recommendation(s)
<p>American Diabetes Association: Standards of Medical Care in Diabetes (2015)²⁰</p>	<p>protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results.</p> <p>Hypertension/blood pressure control</p> <ul style="list-style-type: none"> • Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day. • People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of <140 mmHg. Lower systolic targets, such as <130 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Individuals with diabetes should be treated to a diastolic blood pressure (DBP) <90 mmHg. Lower diastolic targets, such as <80 mmHg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden. • Patients with blood pressure >120/80 mmHg should be advised on lifestyle changes to reduce blood pressure. • Patients with confirmed office-based blood pressure >140/90 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely subsequent titration of pharmacological therapy to achieve blood pressure goals. • Lifestyle therapy for elevated blood pressure consists of weight loss, if overweight or obese; a Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. • Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted. • Multiple-drug therapy (including a thiazide diuretic and ACE inhibitor/ARB, at maximal doses) is generally required to achieve blood pressure targets. • If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate and serum potassium levels should be monitored. • In pregnant patients with diabetes and chronic hypertension, blood pressure targets of 110 to 129/65 to 79 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth. ACE inhibitors and ARBs are contraindicated during pregnancy. <p>Nephropathy</p> <ul style="list-style-type: none"> • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. • An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal urine albumin-to-creatinine ratio (UACR) (<30 mg/g). • Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30 to 299 mg/day) and is recommended for those with urinary albumin excretion >300 mg/day. • When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium.
<p>American Association for the Study of Liver Diseases: Management of Adult Patients with Ascites Due to Cirrhosis:</p>	<p>Treatment of ascites</p> <ul style="list-style-type: none"> • First line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2,000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide). • Fluid restriction is not necessary unless serum sodium is <125 mmol/L. • Vasopressin antagonists may improve serum sodium in patients with cirrhosis

Clinical Guideline	Recommendation(s)
<p>Update 2012 (2012)²¹</p> <p>[Reaffirmed Oct 2014]</p>	<p>and ascites. However their use does not currently appear justified in view of their expense, potential risks, and lack of evidence of efficacy in clinically meaningful outcomes.</p> <ul style="list-style-type: none"> • An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated. • Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracentesis. • Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with cirrhosis and ascites may be harmful and must be carefully considered in each patient, monitoring blood pressure and renal function. • The use of nonsteroidal anti-inflammatory drugs should be avoided in patients with cirrhosis and ascites, except in special circumstances. • Liver transplantation should be considered in patients with cirrhosis and ascites.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the thiazide-like diuretics are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Thiazide-Like Diuretics¹⁻⁵

Indication	Chlorthalidone*	Indapamide	Metolazone
Edema			
Adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy	✓		
Treatment of salt and fluid retention associated with congestive heart failure		✓	
Treatment of salt and water retention, including edema accompanying congestive heart failure			✓
Treatment of salt and water retention, including edema accompanying renal disease, including the nephrotic syndrome and states of diminished renal function			✓
Hypertension			
Treatment of hypertension	✓ †	✓ †	✓ †

*Chlorthalidone is also useful in the treatment of edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

†Alone or in combination with other antihypertensive agents.

IV. Pharmacokinetics

The pharmacokinetic parameters of the thiazide-like diuretics are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Thiazide-Like Diuretics⁷

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Chlorthalidone	65	75	Not reported	Renal (50 to 74)	40 to 89
Indapamide	100	71 to 79	Liver, extensive (%)	Bile (23) Feces (16 to 20)	14 to 15

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
			not reported)	Renal (60 to 70)	
Metolazone	40 to 65	Not reported	Not reported	Renal (56)	8 to 14

V. Drug Interactions

Significant drug interactions with the thiazide-like diuretics are listed in Table 5.

Table 5. Significant Drug Interactions with the Thiazide-Like Diuretics⁶

Generic Name(s)	Significance Level	Interaction	Mechanism
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	1	Cisapride	Possible additive prolongation of the QT interval because of electrolyte loss. The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	1	Dofetilide	Increased potassium excretion caused by thiazide diuretic administration. Hypokalemia may occur.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	2	Lithium	Thiazide-like diuretics may decrease the renal excretion of lithium and produce elevated serum lithium concentrations with toxicity.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	2	Diazoxide	The pharmacologic effects of thiazide-like drugs and diazoxide may be increased. Hyperglycemia, hyperuricemia and hypotension may occur.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	1	Digitalis glycosides	Excretion of potassium and magnesium is increased by thiazide-like diuretics. Potassium and magnesium depletion can sensitize the myocardium to the toxic effects of digitalis glycosides.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	2	Loop diuretics (Bumetanide, ethacrynic acid, furosemide, torsemide)	Both groups have synergistic effects that may result in profound diuresis and serious electrolyte abnormalities.
Thiazide-like diuretics (chlorthalidone, indapamide, metolazone)	2	Sulfonylureas	Thiazide diuretics increase fasting blood glucose and may decrease sulfonylurea hypoglycemia. This effect may occur after several days to many months of thiazide therapy. Hyponatremia also may occur.

Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the thiazide-like diuretics are listed in Table 6. The boxed warning for metolazone is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Thiazide-Like Diuretics¹⁻⁷

Adverse Event(s)	Chlorthalidone	Indapamide	Metolazone
Cardiovascular			

Adverse Event(s)	Chlorthalidone	Indapamide	Metolazone
Chest pain	-	<5	✓
Irregular heartbeat	-	<5	-
Orthostatic hypotension	✓	<5	✓
Palpitations	-	<5	✓
Peripheral edema	-	<5	-
Premature ventricular contractions	-	<5	-
Venous thrombosis	-	-	✓
Volume depletion	-	-	✓
Central Nervous System			
Anxiety	-	≥5	-
Blurred vision	-	<5	✓
Depression	-	<5	-
Dizziness	✓	≥5	✓
Drowsiness	-	<5	✓
Fatigue	-	≥5	✓
Headache	✓	≥5	✓
Insomnia	-	<5	-
Lethargy	-	≥5	-
Lightheadedness	-	<5	✓
Nervousness	-	<5	-
Neuropathy	-	-	✓
Paresthesia	✓	<5	✓
Restlessness	✓	-	✓
Syncope	-	-	✓
Tension	-	≥5	-
Vertigo	✓	<5	✓
Weakness	✓	≥5	✓
Xanthopsia	✓	-	-
Dermatological			
Dermatitis	-	-	✓
Petechiae	-	-	✓
Photosensitivity	✓	-	✓
Pruritus	-	<5	✓
Purpura	✓	-	✓
Rash	✓	<5	✓
Skin necrosis	-	-	✓
Stevens-Johnson syndrome	-	-	✓
Toxic epidermal necrolysis	✓	✓	✓
Urticaria	✓	<5	✓
Gastrointestinal			
Abdominal pain	-	<5	✓
Anorexia	✓	<5	✓
Constipation	✓	<5	✓
Cramping	✓	-	-
Diarrhea	✓	<5	✓
Dry mouth	-	<5	✓
Dyspepsia	-	<5	-
Epigastric distress	-	-	✓
Gastric irritation	✓	<5	-
Nausea	✓	<5	✓
Pancreatitis	✓	-	✓
Vomiting	✓	<5	✓
Genitourinary			
Impotence	✓	<5	✓

Adverse Event(s)	Chlorthalidone	Indapamide	Metolazone
Nocturia	-	<5	✓
Polyuria	-	<5	-
Hematologic			
Agranulocytosis	✓	-	✓
Aplastic anemia	✓	-	✓
Leukopenia	✓	-	✓
Thrombocytopenia	✓	-	✓
Laboratory Test Abnormalities			
Blood urea nitrogen increased	-	<5	✓
Hypercalcemia	✓	✓	✓
Hyperglycemia	✓	<5	✓
Hyperlipidemia	✓	-	-
Hyperuricemia	✓	<5	✓
Hypochloremia	-	<5	✓
Hypokalemia	✓	3-7	✓
Hypomagnesemia	✓	✓	✓
Hyponatremia	✓	<5	-
Hypophosphatemia	-	-	✓
Serum creatinine increased	-	-	✓
Musculoskeletal			
Asthenia	-	<5	-
Back pain	-	≥5	-
Joint pain	-	-	✓
Hypertonia	-	<5	-
Muscle spasm	✓	≥5	✓
Renal			
Glycosuria	✓	<5	✓
Respiratory			
Cough	-	<5	-
Pharyngitis	-	<5	-
Rhinitis	-	≥5	-
Sinusitis	-	<5	-
Other			
Chills	-	-	✓
Conjunctivitis	-	<5	-
Gout	-	-	✓
Hemoconcentration	-	-	✓
Hepatitis	-	-	✓
Infection	-	≥5	-
Jaundice	✓	-	✓
Necrotizing angiitis/vasculitis	-	-	✓
Vasculitis	✓	<5	-
Weight loss	-	<5	-

✓ Percent not specified
- Event not reported

Table 7. Boxed Warning for Metolazone^{4,5}

WARNING
Do not interchange Zaroxolyn [®] tablets and other formulations of metolazone that share its slow and incomplete bioavailability and are not therapeutically equivalent at the same doses to Mykrox ^{®*} tablets, a more rapidly available and completely bioavailable metolazone product. Formulations bioequivalent to Zaroxolyn [®] and formulations bioequivalent to Mykrox ^{®*} should not be interchanged for one another.

* Mykrox[®] is no longer available in the United States.

VII. Dosing and Administration

The usual dosing regimens for the thiazide-like diuretics are listed in Table 8.

Table 8. Usual Dosing Regimens for the Thiazide-Like Diuretics¹⁻⁷

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Chlorthalidone	<p><u>Edema:</u> Tablet: initial, 30 to 60 mg/day or 60 mg on alternate days; maintenance, 90 to 120 mg on alternate days or 120 mg/day</p> <p><u>Hypertension:</u> Tablet: initial, 15 to 30 mg/day; maintenance, 45 to 50 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 25 mg 50 mg
Indapamide	<p><u>Edema:</u> Tablet: initial, 2.5 mg/day; maintenance, 2.5 to 5 mg/day</p> <p><u>Hypertension:</u> Tablet: initial, 1.25 mg/day; maintenance, 2.5 to 5 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 1.25 mg 2.5 mg
Metolazone	<p><u>Edema:</u> Tablet: 5 to 20 mg/day</p> <p><u>Hypertension:</u> Tablet: initial, 2.5 to 5 mg/day, maintenance, 5 to 20 mg/day</p>	Safety and efficacy in children have not been established.	Tablet: 2.5 mg 5 mg 10 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the thiazide-like diuretics are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Thiazide-Like Diuretics

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>SHEP Cooperative Research Group²² and Kostis et al.²³ (1991 and 1995) SHEP</p> <p>Chlorthalidone 12.5 mg QD</p> <p>vs</p> <p>placebo</p> <p>Dosage was doubled for patients failing to achieve SBP goals. If SBP goal was not reached with chlorthalidone 25 mg QD, atenolol 25 mg QD or matching placebo was added to the drug regimen. Reserpine 0.05 mg QD or matching placebo was substituted in patients with contraindications to atenolol.</p>	<p>DB, MC, PC, RCT</p> <p>Patients aged ≥60 years with SBP between 160 and 219 mm Hg and DBP <90 mm Hg</p>	<p>N=4,736</p> <p>Mean 4.5 years</p>	<p>Primary: Total stroke</p> <p>Secondary: Sudden or rapid cardiac death (defined as death within 1 hour or within 1 to 24 hours of the onset of severe cardiac symptoms), nonfatal or fatal MI, other cardiovascular death, TIA</p>	<p>Primary: With a mean follow-up of 4.5 years, the stroke occurred in 103 patients in the active treatment group compared to 159 patients in the placebo group (RR, 0.64; 95% CI, 0.5 to 0.82; P=0.0003).</p> <p>Stroke incidence was lower in patients taking active treatment compared to placebo in all baseline age groups: 60 to 69 years (34 vs 47 events, respectively), 70 to 79 years (48 vs 74 events, respectively), 80+ years (21 vs 38 events, respectively).</p> <p>The results were stratified according to whether patients had had previous antihypertensive therapy or not. In both stratified groups, there was a decrease in the risk of stroke with active treatment compared to placebo. For patients who were not receiving antihypertensive medication at initial contact, the RR, of stroke was 0.69 (95% CI, 0.51 to 0.95; P=0.02).</p> <p>For patients who had been receiving antihypertensive medication at initial contact, the RR, of stroke was 0.57 (95% CI, 0.38 to 0.85; P=0.01).</p> <p>Secondary: There were 23 sudden and 21 rapid deaths in the active treatment group compared to 23 sudden and 24 rapid deaths in the placebo group (RR, 1.0; 95% CI, 0.56 to 1.78 vs RR, 0.87; 95% CI, 0.48 to 1.56, respectively).</p> <p>There were 50 nonfatal and 15 fatal MIs in the active treatment group compared to 74 nonfatal and 26 fatal MIs in the placebo group (RR, 0.67; 95% CI, 0.47 to 0.96 vs RR, 0.57; 95% CI, 0.30 to 1.0, respectively).</p> <p>There were 21 other cardiovascular deaths in the active treatment group compared to 25 in the placebo group (RR, 0.87; 95% CI, 0.49 to 1.55).</p> <p>There were 62 TIAs in the active treatment group compared to 82 in the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>placebo group (RR, 0.75; 95% CI, 0.54 to 1.4).</p> <p>In the combined endpoints, the RR, of nonfatal MI or coronary heart disease death was 0.73 (95% CI, 0.57 to 0.94), CHD was 0.75 (95% CI, 0.60 to 0.94), cardiovascular disease was 0.68 (95% CI, 0.58 to 0.79).</p> <p>The RR, for atenolol were 0.84 (95% CI, 0.54 to 1.30) for death, 1.34 (95% CI, 0.80 to 2.28) for stroke, and 1.17 (95% CI, 0.71 to 1.61) for cardiovascular disease.</p> <p>The RR, for reserpine were 0.65 (95% CI, 0.26 to 1.59) for death, 0.27 (95% CI, 0.04 to 2.26) for stroke, and 0.55 (95% CI, 0.20 to 1.49) for cardiovascular disease.</p>
<p>ALLHAT Collaborative Research Group²⁴ (2000) ALLHAT</p> <p>Chlorthalidone 12.5 to 25 mg QD</p> <p>vs</p> <p>doxazosin 2 to 8 mg QD</p>	<p>AC, DB, MC, RCT</p> <p>Patients aged 55 years or older who had stage 1 or stage 2 HTN with ≥1 additional risk factor for CHD events (including previous MI or stroke >6 months ago, left ventricular hypertrophy or echocardiography, history of type 2 diabetes, current cigarette smoking, high density lipoprotein cholesterol <35 mg/dL, or documentation of other atherosclerotic cardiovascular</p>	<p>N=24,335</p> <p>Median 3.3 years</p>	<p>Primary: Fatal CHD or nonfatal MI combined</p> <p>Secondary: All cause mortality, fatal and nonfatal stroke, combined CHD, combined cardiovascular disease, cancer, end-stage renal disease</p>	<p>Primary: There was no significant difference in the primary outcome between doxazosin and chlorthalidone treatments (risk ratio, 1.13; 95% CI, 0.90 to 1.17; P=0.71).</p> <p>Secondary: Total mortality did not differ between the doxazosin and chlorthalidone treatments (four year rates, 9.62 and 9.08%, respectively; RR, 1.13; 95% CI, 0.90 to 1.15; P=0.56).</p> <p>The doxazosin group, compared with the chlorthalidone group, had a higher risk of stroke (RR 1.19; 95% CI, 1.01 to 1.40; P=0.04) and combined cardiovascular disease (four year rates 25.45 vs 21.76%; RR, 1.25; 95% CI, 1.17 to 1.33; P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	disease)			
Black et al. ²⁵ (2008) ALLHAT Chlorthalidone 12.5 to 25 mg QD vs amlodipine 2.5 to 10 mg QD vs lisinopril 10 to 40 mg QD	MC, RCT Men and women, age 55 years old and older, with HTN and metabolic syndrome	N=17,515 4.9 years (mean)	Primary: Fatal coronary heart disease and nonfatal MI Secondary: All cause mortality, fatal and nonfatal stroke, combined coronary heart disease, combined cardiovascular disease	Primary: For patients with metabolic syndrome, there was no significant difference in rates of coronary heart disease and nonfatal MI with amlodipine vs chlorthalidone (RR, 0.96; 95% CI, 0.79 to 1.16), or lisinopril vs chlorthalidone (RR, 1.15; 95% CI, 0.88 to 1.27). Secondary: For patients with metabolic syndrome, there were no significant differences found between amlodipine vs chlorthalidone in all secondary endpoints (P value not significant). For patients without metabolic syndrome, amlodipine treatment was associated with significantly more heart failure, but in patients with metabolic syndrome, there was no difference (P=0.03). Patients with metabolic syndrome who received lisinopril experienced more heart failure and cardiovascular disease than those who received chlorthalidone (RR, 1.31; 95% CI, 1.04 to 1.64 and RR, 1.19; 95% CI, 1.07 to 1.32).
ALLHAT Collaborative Research Group ²⁶ (2002) ALLHAT Chlorthalidone 12.5 to 25 mg/day vs amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40	DB, MC, RCT Patients ≥55 years with HTN and ≥1 additional CHD risk factor	N=33,357 4.9 years (mean)	Primary: Combined fatal CHD or nonfatal MI Secondary: All-cause mortality, fatal and nonfatal stroke, combined CHD, combined cardiovascular disease (combined CHD, stroke, treated angina without hospitalization,	Primary: There were no significant differences in the primary outcome between lisinopril (11.4%), amlodipine (11.3%), and chlorthalidone (11.5%). Secondary: All-cause mortality did not differ between groups. Five year SBPs were significantly higher in the lisinopril (2 mm Hg; P<0.001) and amlodipine groups (0.8 mm Hg; P=0.03) compared to chlorthalidone, and five year DBPs were significantly lower with amlodipine (0.8 mm Hg; P<0.001). Amlodipine had a higher six year rate of heart failure compared to chlorthalidone (10.2 vs 7.7%; RR, 1.38; 95% CI, 1.25 to 1.52). Lisinopril had a higher six year rate of combined cardiovascular disease (33.3 vs 30.9%; RR, 1.10; 95% CI, 1.05 to 1.16); stroke (6.3 vs 5.6%; RR,

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
mg/day			heart failure, and PAD)	1.15; 95% CI, 1.02 to 1.30) and heart failure (8.7 vs 7.7%; RR, 1.19; 95% CI, 1.07 to 1.31).
Rahman et al. ²⁷ (2012) ALLHAT Chlorthalidone 12.5 to 25 mg/day vs amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day	Long-term, post-trial, follow-up Patients in ALLHAT stratified based on eGFR	N=31,350 4 to 8 years	Primary: Cardiovascular mortality Secondary: Total mortality, CHD, cardiovascular disease, stroke, heart failure, ESRD	Primary: After an average of 8.8 years of follow-up, total mortality was significantly higher in patients with moderate/severe eGFR reduction (eGFR <60 mL/min/1.73 m ²) compared to patients with normal/increased (eGFR ≥90 mL/min/1.73 m ²) and mildly reduced eGFR (eGFR 60 to 89 mL/min/1.73 m ²) (P<0.001). In patients with moderate/severe eGFR reduction, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Secondary: No significant differences were observed for any of the secondary endpoints among eGFR reduction groups.
Muntner et al. ²⁸ (2014) ALLHAT Chlorthalidone 12.5 to 25 mg/day vs amlodipine 2.5 to 10 mg/day vs lisinopril 10 to 40 mg/day	Post-hoc analysis of ALLHAT Patients in ALLHAT with 5, 6, or 7 visits in 6 to 28 months of follow-up	N=24,004 6 to 28 months	Primary: Visit-to-visit variability (VVV) of blood pressure Secondary: Not reported	Primary: Each measure of VVV of SBP was lower among participants randomized to chlorthalidone and amlodipine compared with those randomized to lisinopril. All four VVV of SBP metrics were lower among participants randomized to amlodipine vs chlorthalidone after full multivariable adjustment. After multivariable adjustment including mean SBP across visits and compared with participants randomized to chlorthalidone, participants randomized to amlodipine had a 0.36 (standard error [SE]: 0.07) lower standard deviation (SD) of SBP and participants randomized to lisinopril had a 0.77 (SE=0.08) higher SD of SBP. Results were consistent using other VVV of SBP metrics. These data suggest chlorthalidone and amlodipine are associated with lower VVV of SBP than lisinopril. Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Pupita et al.²⁹ (1983)</p> <p>Chlorthalidone 50 mg QD</p> <p>vs</p> <p>furosemide 25 mg QD</p>	<p>RCT, XO</p> <p>Men and women with a mean age of 53.9±9.2 years with mild to moderate HTN</p>	<p>N=36</p> <p>12 months</p>	<p>Primary: Blood pressure</p> <p>Secondary: Plasma electrolytes, adverse events</p>	<p>Primary: Patients taking chlorthalidone had significantly lower SBP at each monthly measurement compared to baseline (P<0.01). However, only DBP values at month five were significant compared to baseline (P<0.05).</p> <p>Patients taking furosemide had significantly lower SBP at months three, four, and five compared to baseline (P<0.05 for month three, and P<0.01 for months four and five). DBP values were significantly lower at all monthly measurements compared to baseline in patients taking furosemide (P<0.01).</p> <p>At month one, SBP decreased by 19.4 mm Hg with chlorthalidone and by 21.2 mm Hg with furosemide (P<0.001). DBP decreased by 11 mm Hg with chlorthalidone and by 12.6 mm Hg with furosemide at month one (P<0.001).</p> <p>Secondary: There were no significant changes in serum sodium levels with either chlorthalidone or furosemide. Patients taking chlorthalidone had significantly lower serum chloride levels compared to baseline at all points (P<0.01), whereas patients taking furosemide had significantly lower levels only at month six (P<0.05). Both chlorthalidone and furosemide significantly reduced serum potassium levels at all points compared to baseline (P<0.01).</p> <p>Patient taking chlorthalidone reported adverse effects including dizziness, transient abdominal disorder, and slight weakness. Patients taking furosemide reported transient early weakness and irritability. The rate of adverse events was not statistically significant in either treatment group.</p>
<p>Bakris et al.³⁰ (2012)</p> <p>Azilsartan medoxomil and chlorthalidone (single pill)</p>	<p>DB, RCT</p> <p>Patients aged ≥18 years with stage 2 primary HTN</p>	<p>N=609</p> <p>10 weeks (after 2 week placebo run-in)</p>	<p>Primary: Change in trough, seated clinic systolic blood pressure at weeks 6 and 10</p> <p>Secondary:</p>	<p>Primary: Change in SBP at week six demonstrated a mean difference of -5.6 mm Hg (95% CI, -8.3 to -2.9; P<0.001) in favor of the chlorthalidone group. Fewer patients in the chlorthalidone group required titration to a higher dose of diuretic (P<0.001). At the end of week 10, a greater mean SBP reduction was maintained in the chlorthalidone group compared to the HCTZ group (-5.0 mm Hg; 95% CI, -7.5 to -2.5; P<0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>azilsartan medoxomil and HCTZ (co-administered)</p> <p>Treatments were titrated to a target of <140/90 mm Hg (or <130/80 mm Hg if diabetes or chronic kidney disease)</p>			<p>Change from baseline in clinic DBP and 24-hour mean systolic and diastolic blood pressures by ambulatory blood pressure monitoring</p>	<p>Secondary:</p> <p>The chlorthalidone group demonstrated a significantly greater reduction in 24-hour mean SBP at weeks six and 10. For both clinic and 24-hour mean DBP, greater blood pressure reduction was observed in the chlorthalidone group compared to the HCTZ group at both study points.</p>
<p>Ernst et al.³¹ (2006)</p> <p>Chlorthalidone 12.5 mg in the morning</p> <p>vs</p> <p>HCTZ 25 mg in the morning</p> <p>At week 4, both HCTZ and chlorthalidone were titrated to 50 mg in the morning and 25 mg in the morning, respectively for the remainder of the trial.</p>	<p>RCT, SB, XO</p> <p>Men and women aged 18 to 79 years with pre-HTN or a new or established diagnosis of HTN (stage 1 or 2), not receiving antihypertensive medications, and had an average office blood pressure value in the last 6 months between 140 and 179 mm Hg systolic or 90 and 109 mm Hg diastolic</p>	<p>N=30</p> <p>8 weeks plus 4 week washout period</p>	<p>Primary:</p> <p>Comparison of the change in 24-hour mean SBP and DBP from baseline to week 8</p> <p>Secondary:</p> <p>Comparison of changes in mean SBP and mean DBP for office blood pressure at each visit, change in ambulatory daytime and nighttime mean SBP and DBP from baseline to week 8, development of hypokalemia</p>	<p>Primary:</p> <p>At week eight, there was a greater reduction in 24-hour mean SBP with chlorthalidone 25 mg/day compared to HCTZ 50 mg/day compared to baseline (-12.4±1.8 vs -7.4±1.7 mm Hg, respectively; P=0.054).</p> <p>Secondary:</p> <p>There was a trend in favor of greater reduction in SBP with chlorthalidone than with HCTZ at each office visit. However, the difference was only statistically significant at week 2 (-15.7±2.2 vs -4.5±2.1 mm Hg, respectively; P=0.001).</p> <p>Although mean reductions in DBP was also greater with chlorthalidone compared to HCTZ at each study visit, the differences were not statistically significant at any visit (P>0.89 for all).</p> <p>The reduction in SBP during nighttime hours was -13.5±1.9 mm Hg for chlorthalidone and -6.4±1.7 mm Hg for HCTZ (P=0.009). The reduction in daytime mean SBP between both groups was not significantly different (-11.4±2.0 vs -8.1±1.9 mm Hg, respectively; P=0.230).</p> <p>Changes in serum potassium were similar between treatment groups (P=0.76). The incidence of hypokalemia was 50% in patients taking HCTZ and 46% in patients taking chlorthalidone (P=0.682).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Carter et al.³² (2004)</p> <p>Chlorthalidone 12.5 to 600 mg/day</p> <p>vs</p> <p>HCTZ 12.5 to 450 mg/day</p>	<p>MA</p> <p>Included trials which evaluate the pharmacokinetic and blood pressure lowering effects of chlorthalidone and HCTZ</p>	<p>N=200</p> <p>Duration varied per study</p>	<p>Primary: Blood pressure</p> <p>Secondary: Serum potassium</p>	<p>Primary:</p> <p>In a dose equivalence study comparing HCTZ 100 mg QD to chlorthalidone 50 mg QD, blood pressure (SBP/DBP) reduced by 18/8 and 25/10 mm Hg compared to baseline, respectively.</p> <p>In another study comparing HCTZ 25 mg and triamterene 50 mg QD, HCTZ 50 mg and triamterene 100 mg QD, and chlorthalidone 50 mg QD, the blood pressure reduction was 15/8, 18/12, and 25/16 mm Hg, respectively.</p> <p>One other dose equivalence study comparing HCTZ 50 mg BID and chlorthalidone 50 mg QD, blood pressure reduction was 22/16 and 18/15 mm Hg, respectively.</p> <p>All available studies were inspected and it was concluded that HCTZ 50 mg is approximately equivalent to chlorthalidone 25 to 37 mg. Furthermore, it was suggested that chlorthalidone doses should generally be approximately 50% to 75% of the typical HCTZ dose.</p> <p>Secondary:</p> <p>In a study comparing HCTZ 100 mg QD and chlorthalidone 50 mg QD, potassium increased slightly with chlorthalidone (0.02 mEq/L) and decreased significantly with HCTZ (0.22 mEq/L; P=0.009).</p> <p>However, in another study comparing HCTZ 50 mg BID and chlorthalidone 50 mg QD, serum potassium decreased by 0.38 mEq/L with HCTZ and by 0.03 mEq/L with chlorthalidone. The difference was not statistically significant (P<0.07).</p>
<p>Karotsis et al.³³ (2006)</p> <p>Chlorthalidone 12.5 mg QD</p> <p>vs</p> <p>felodipine 5 mg</p>	<p>RCT</p> <p>Patients 25 to 79 years of age with uncontrolled HTN (average office blood pressure >140/90 mm Hg for all or >153/85 mm</p>	<p>N=211</p> <p>8 weeks</p>	<p>Primary: Blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>There was a significant decline in both office and home SBP and DBP during the trial with all treatments. The antihypertensive effect was more pronounced and reached significance when home blood pressure monitoring was used in comparison to office blood pressure without the white-coat effect (P<0.001 for all blood pressure changes). With or without the white-coat effect, blood pressure still declined and the differences were significant (P<0.0001 for all blood pressure changes).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>QD</p> <p>vs</p> <p>lisinopril 10 mg QD</p> <p>vs</p> <p>valsartan 80 mg QD</p> <p>All patients also received diltiazem 240 mg QD.</p>	<p>Hg for diabetics or patients <65 years of age, confirmed on 2 office visits \geq1 week apart) after \geq4 weeks of OL monotherapy with diltiazem at 240 mg QD</p>			<p>Secondary: Not reported</p>
<p>Nissinen et al.³⁴ (1980)</p> <p>Atenolol 100 mg QD plus chlorthalidone 25 mg in the morning</p> <p>vs</p> <p>atenolol and chlorthalidone 100-25 mg in the morning (fixed-dose combination product)</p> <p>vs</p> <p>placebo</p>	<p>DB, RCT</p> <p>Patients with newly diagnosed mild to moderate HTN (supine DBP 100 mm Hg on \geq3 occasions)</p>	<p>N=23</p> <p>16 weeks</p>	<p>Primary: Changes in blood pressure and heart rate</p> <p>Secondary: Not reported</p>	<p>Primary: Each of the active drug combinations lowered standing, supine, and post-exercise blood pressure significantly compared to placebo at two and four weeks (P<0.001, P<0.01 and P<0.05). There was not a statistical difference between the active treatment regimens (P value not significant).</p> <p>Each of the active drug combinations lowered standing, supine, and post-exercise heart rate significantly compared to placebo at two and four weeks (P<0.001, P<0.01 and P<0.05). There was not a statistical difference between the active treatment regimens (P value not significant).</p> <p>Side effects did not differ between treatment groups and placebo in terms of frequency or severity. Reported side effects included dizziness, headache and tiredness.</p> <p>Secondary: Not reported</p>
<p>Fogari et al.³⁵ (1984)</p>	<p>RCT, SB</p>	<p>N=38</p>	<p>Primary: Changes in blood</p>	<p>Primary: After the first four weeks, atenolol (from 177.5 to 161.1 mm Hg)</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p><u>Weeks 1 to 4:</u> chlorthalidone 12.5 mg QD</p> <p>vs</p> <p>atenolol 50 mg QD</p> <p><u>Weeks 5 to study end:</u> atenolol and chlorthalidone 50- 12.5 mg QD (fixed-dose combination product)</p>	<p>Patients 61 to 80 years inadequately controlled (SBP >170 mm Hg and/or DBP >100 mm Hg) on antihypertensive medications</p>	<p>6 months</p>	<p>pressure</p> <p>Secondary: Not reported</p>	<p>significantly reduced blood pressure compared to baseline, but chlorthalidone did not (from 176.6 to 179.1 mm Hg).</p> <p>The combination atenolol-chlorthalidone therapy significantly reduced mean standing SBP and DBP, supine SBP and DBP, supine and standing heart rate, compared to previous therapies (P<0.001 for all comparisons).</p> <p>The combination atenolol-chlorthalidone therapy significantly reduced mean standing SBP and DBP, supine SBP and DBP, supine and standing heart rate, compared to atenolol and chlorthalidone monotherapy (P<0.001 or P<0.01 for all comparisons).</p> <p>Mean blood pressure reduction obtained by the atenolol and chlorthalidone combination product was 30/15 mm Hg in the standing position (P<0.001).</p> <p>Serum potassium increased with atenolol-chlorthalidone (4.45 mEq/L) compared to chlorthalidone alone (4.01 mEq/L; P<0.001).</p> <p>Secondary: Not reported</p>
<p>Leonetti et al.³⁶ (1986)</p> <p>Atenolol 50 mg QD</p> <p>vs</p> <p>atenolol 100 mg QD</p> <p>vs</p> <p>chlorthalidone 12.5 mg QD</p>	<p>DB, RCT</p> <p>Patients 24 to 68 years with mild to moderate HTN (WHO stage I or II), with supine DBP ≥95 mm Hg at the end of the 4-week washout period</p>	<p>N=28</p> <p>16 weeks</p>	<p>Primary: Changes in blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: Mean supine blood pressure was significantly reduced in all treatment groups compared to placebo: 153±18/93±9 mm Hg for atenolol 50 mg patients, 155±22/91±8 mm Hg for atenolol 100 mg patients, 148±17/93±11 mm Hg for chlorthalidone 12.5 mg patients, and 144±16/89±6 mm Hg for the atenolol-chlorthalidone combination patients. All of the changes in blood pressure were significant (P<0.01) versus placebo.</p> <p>Supine SBP was lower with atenolol-chlorthalidone than with the atenolol 100 mg alone (P<0.05).</p> <p>Upright SBP was lower with atenolol-chlorthalidone than with atenolol 50 mg alone (P<0.05) and atenolol 100 mg alone (P<0.05).</p> <p>Mean supine heart rate was 77±7 bpm after placebo which decreased to</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>atenolol and chlorthalidone 50-12.5 mg QD (fixed-dose combination product)</p>				<p>69±10 bpm (P<0.01) after atenolol 50 mg, to 67±6 bpm (P<0.01) after atenolol 100 mg, to 77±10 bpm (P=not significant, was not reported) after chlorthalidone alone.</p> <p>Chlorthalidone alone demonstrated a significant reduction in serum potassium levels compared to placebo (3.88 vs 4.09 mEq/L; P<0.05) and no change when the atenolol-chlorthalidone combination was compared to placebo (3.98 vs 4.09; P=not significant, value was not reported).</p> <p>Chlorthalidone alone and atenolol-chlorthalidone demonstrated a significant increase in serum uric acid levels compared to placebo (4.90±1.52 mg/dL, 5.07±1.33 mg/dL, respectively, vs 4.24±1.12 for placebo; P<0.05 for both).</p> <p>All treatments were well tolerated. Some adverse events reported included dyspnea, precordial discomfort and cold extremities. Incidence, severity and P values were not reported.</p>
<p>Finnerty et al.³⁷ (1980)</p> <p>Chlorthalidone 50 mg plus reserpine 0.25 mg</p> <p>vs</p> <p>HCTZ 50 mg plus reserpine 0.125 mg</p>	<p>DB</p> <p>Patients with essential HTN unresponsive to diet control and diuretic therapy</p>	<p>N=57</p> <p>6 weeks</p>	<p>Primary: The change in mean DBP from baseline</p> <p>Secondary: Incidence of frequent or severe side effects</p>	<p>Primary: The chlorthalidone plus reserpine group had a mean decrease in DBP of 17.0 mm Hg at study endpoint compared with a mean decrease of 18.6 mm Hg in the HCTZ plus reserpine group.</p> <p>At study completion both treatment groups achieved diastolic control of at least 5 mm Hg below the targeted diastolic goal of 90 mm Hg.</p> <p>Secondary: There were no reports of frequent or severe side effects in either treatment group.</p>
<p>Akram et al.³⁸ (2007)</p> <p>NATIVE</p> <p>Indapamide SR 1.5 mg QD added to background antihypertensive therapy</p>	<p>OL</p> <p>Patients remaining hypertensive (145 to 180/95 to 105 mm Hg) while receiving an ACE inhibitor, β-blocker, calcium-channel blocker,</p>	<p>N=1,941</p> <p>3 months</p>	<p>Primary: Blood pressure</p> <p>Secondary: Glucose and cholesterol levels</p>	<p>Primary: At three months, SBP and DBP both decreased significantly compared to baseline. SBP had a change from 166±16 mm Hg at baseline to 132±12 mm Hg at three months. DBP had a change from 102±8 mm Hg at baseline to 83±6 mm Hg at three months (P<0.0001 for both).</p> <p>At study end, 84% of patients achieved target SBP of ≤140 mm Hg and 61% achieved blood pressure normalization (SBP/DBP <140/90 mm Hg).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	ARBs, α -blocker, or other therapy			Secondary: Glucose and cholesterol levels were unaffected by indapamide SR.
Beckett et al. ³⁹ (2008) HYVET Indapamide 1.5 mg/day vs placebo Perindopril 2 to 4 mg/day or matching placebo was added if necessary to achieve the target blood pressure of 150/80 mm Hg.	DB, MC, PC, RCT Patients \geq 80 years (mean age 84 years) with sustained SBP \geq 160 mm Hg	N=3,845 1.8 years (mean)	Primary: Fatal or nonfatal stroke Secondary: Death from any cause, death from cardiovascular causes, death from stroke	Primary: At two years, 73.4% of patients in the active-treatment groups were receiving indapamide plus perindopril. Mean blood pressure while sitting was 15.0/6.1 mm Hg lower with active-treatment than placebo. Active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% CI, -1 to 51; P=0.06). Secondary: Active treatment was associated with a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06) and a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05). Active treatment was associated with a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358 vs 448; P=0.001).
Milia et al. ⁴⁰ (2006) Indapamide 2.5 mg QD vs bendroflumethiazide* 2.5 mg QD	DB, PG, PRO, RCT Ambulant patients with a first-ever minor hemispheric ischemic stroke or TIA	N=26 28 days	Primary: Blood pressure, cerebral blood flow Secondary: Not reported	Primary: Both indapamide and bendroflumethiazide significantly reduced blood pressure from baseline (-14.7 \pm 12.5 mm Hg and -7.7 \pm 9.16 mm Hg, respectively; P<0.001 and P=0.02, respectively). A nonsignificant trend toward greater blood pressure reduction was seen in patients taking indapamide. There were no statistically significant differences in blood pressure reduction between both treatment groups. There was a nonsignificant trend toward increases in blood flow in both treatment groups. However, there was no statistically significant differences in carotid blood flow between both treatment groups (P=0.04 for between-group comparison). Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Madkour et al.⁴¹ (1996)</p> <p>Indapamide 2.5 mg QD</p> <p>vs</p> <p>HCTZ 50 mg QD</p>	<p>RCT</p> <p>Patients aged 32 to 70 years with impaired renal function for 1 to 15 years and moderate HTN for 2 to 27 years, initial creatinine clearance between 32 and 80 mL/min/1.73 m² BSA</p>	<p>N=28</p> <p>24 months</p>	<p>Primary: Blood pressure, changes in creatinine clearance</p> <p>Secondary: Not reported</p>	<p>Primary: Blood pressure normalized in all patients taking either indapamide or HCTZ. There were no significant differences in SBP or DBP between groups.</p> <p>At 24 months, creatinine clearance progressively increased from 58±4.4 to 72±4.4 mL/min/1.73 m² BSA in patients treated with indapamide (P<0.01).</p> <p>Creatinine clearance progressively decreased from 65±3.0 to 53±3.0 mL/min/1.73 m² BSA in patients treated with HCTZ (P<0.01). Creatinine clearance significantly increased by 28.5±4.4% with indapamide and decreased by 17.4±3.0% with thiazide therapy (P<0.01).</p> <p>Secondary: Not reported</p>
<p>PROGRESS⁴² (2001)</p> <p>Perindopril 4 mg/day</p> <p>vs</p> <p>perindopril 4 mg/day and indapamide 2 to 2.5 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients with a history of prior stroke or TIA within the previous 5 years</p>	<p>N=6,105</p> <p>4 years</p>	<p>Primary: Fatal or nonfatal stroke</p> <p>Secondary: Fatal or disabling stroke, total major vascular events comprising the composite of nonfatal stroke, nonfatal MI, or death due to any vascular cause (including unexplained sudden death); total and cause specific deaths; hospital admissions</p>	<p>Primary: Patients receiving active treatment experienced a 28% reduction in nonfatal or fatal stroke (95% CI, 17 to 38; P<0.0001).</p> <p>There were similar reductions in the risk of stroke in hypertensive and non-hypertensive subgroups (32 vs 27%; P<0.01)</p> <p>A trend towards a greater effect of active treatment among patients treated with combination therapy (43% risk reduction) than in those treated with single drug therapy (5% risk reduction) was reported.</p> <p>Secondary: There was a 33% reduction in fatal or disabling strokes in the active treatment group.</p> <p>Active treatment reduced the risk of total major vascular events by 26% (P=0.02).</p> <p>There were no significant differences between active treatment and placebo in total deaths from vascular or nonvascular causes.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Among those assigned active treatment, there was a 9% RR reduction in hospitalization, with a median reduction of 2.5 days in the time spent in the hospital during follow-up.</p> <p>Combination therapy with perindopril plus indapamide reduced blood pressure by 12/5 mm Hg and stroke risk by 43%. Single drug therapy reduced blood pressure by 5/3 mm Hg and produced no discernible reduction in the risk of stroke.</p>
<p>Hua et al.⁴³ (1976)</p> <p>Metolazone 5 mg QD</p> <p>vs</p> <p>chlorothiazide up to 5 g BID</p>	<p>XO</p> <p>Patients with HTN</p>	<p>N=20</p> <p>Duration not specified</p>	<p>Primary: Blood pressure, serum potassium</p> <p>Secondary: Not reported</p>	<p>Primary: Blood pressures on metolazone tended to be lower than on chlorothiazide, but the difference was not statistically significant.</p> <p>Both agents significantly lowered serum potassium concentrations and total body potassium to a similar degree. However, the serum potassium did not fall below the normal range in any patient and no potassium supplements were required.</p> <p>Secondary: Not reported</p>
<p>ADVANCE Collaborative Group⁴⁴ (2007)</p> <p>Perindopril (2 to 4 mg) and indapamide (0.625 to 1.25 mg) QD</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Adults 55 years of age or older who were diagnosed with type 2 diabetes at age 30 or older, and a history of cardiovascular disease or ≥1 other risk factor for cardiovascular disease</p>	<p>N=11,140</p> <p>Mean 4.3 years</p>	<p>Primary: Composites of major macrovascular and microvascular events (death from cardiovascular disease, nonfatal stroke, nonfatal MI, or new renal or diabetic eye disease)</p> <p>Secondary: Macrovascular and microvascular endpoints analyzed separately</p>	<p>Primary: The relative risk of a major macrovascular or microvascular event was reduced by 9% (861 [15.5%] active vs 938 [16.8%] placebo; HR, 0.91, 95% CI 0.83 to 1.0, P=0.04).</p> <p>Secondary: The RR of death from cardiovascular disease was reduced by 18% (211 [3.8%] active vs 257 [4.6%] placebo; 0.82, 0.68-0.98, p=0.03) and death from any cause was reduced by 14% (408 [7.3%] active vs 471 [8.5%] placebo; 0.86, 0.75-0.98, P=0.03).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Hansson et al.⁴⁵ (2000) NORDIL</p> <p>Conventional therapy (diuretic, β-blocker or both)</p> <p>vs</p> <p>diltiazem 180 to 360 mg QD</p>	<p>BE, MC, OL, PRO, RCT</p> <p>Patients 50 to 74 years of age with DBP \geq100 mm Hg and previously untreated</p>	<p>N=10,881</p> <p>4.5 years</p>	<p>Primary: Combined fatal and nonfatal stroke, fatal and nonfatal MI, other cardiovascular death</p> <p>Secondary: Fatal plus nonfatal stroke and fatal plus nonfatal MI</p>	<p>Primary: The primary endpoint occurred in 403 of the diltiazem patients and 400 of the diuretic/β-blocker patients (RR, 1.00; 95% CI, 0.87 to 1.15; P=0.97).</p> <p>Secondary: Rates of secondary endpoints were similar between the groups. Fatal plus nonfatal stroke occurred in 159 of the diltiazem patients and 196 of the diuretic/β-blocker patients (P=0.04).</p> <p>Fatal plus nonfatal MI occurred in 183 of the diltiazem patients and 157 of the diuretic/β-blocker patients (P=0.17).</p> <p>Other endpoints were not statistically different between the groups including cardiovascular death (P=0.41), all cardiac events (P=0.57 and congestive heart failure (P=0.42).</p>
<p>Ames⁴⁶ (1996)</p> <p>Indapamide 2.5 mg QD</p> <p>vs</p> <p>HCTZ \leq25 mg or its equivalent in other thiazides, up to 112.5 mg QD</p>	<p>MA (13 trials)</p> <p>Patients with HTN</p>	<p>N=1,547</p> <p>1 to 25 months</p>	<p>Primary: Comparison of the effects of thiazides and indapamide on blood lipids and blood pressure</p> <p>Secondary: Not reported</p>	<p>Primary: The mean change from baseline was 1.4% for TC, 5.5% for HDL-C, and -0.5% for TG with indapamide. None of the differences were statistically significant.</p> <p>Low-dose thiazide therapy did not decrease TC at any data point. The mean percent increase in TC was 3.8%, in HDL-C was 3.1%, and in TG was 10.8% with low-dose HCTZ. The increases in TC and TG from baseline was statistically significant (P<0.01).</p> <p>The mean change in TC was 6.3%, in HDL-C was -0.5%, and in TGs was 19.5% for higher doses of HCTZ. Increases from baseline in TC and TG were statistically significant.</p> <p>SBP decreased more with higher doses of HCTZ than with low-dose thiazide therapy (P<0.05). The effects of indapamide on systolic arterial pressure were intermediate between, and not statistically different from, either thiazide dose. Decreases in DBP did not differ among groups.</p> <p>Secondary: Not reported</p>
<p>Messerli et al.⁴⁷</p>	<p>MA</p>	<p>N=16,164</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(1998)</p> <p>Diuretics (amiloride, chlorthalidone, HCTZ, HCTZ and triamterene [fixed-dose combination product], or thiazide)</p> <p>vs</p> <p>β-blockers (atenolol, metoprolol or pindolol)</p>	<p>10 RCTs lasting ≥1 year, which used as first line agents diuretics and/or β-blockers and reported morbidity and mortality outcomes in patients ≥60 years of age with HTN</p>	<p>1 year</p>	<p>Cardiovascular morbidity and mortality, all-cause morbidity</p> <p>Secondary: Not reported</p>	<p>Diuretic treatment significantly reduced the odds for cardiovascular mortality by 25% (OR, 0.75; 95% CI, 0.64 to 0.87), while β-blockers did not reduce cardiovascular mortality (OR, 0.98; 95% CI, 0.78 to 1.23; P values not reported).</p> <p>Diuretic treatment significantly reduced the odds for all-cause mortality by 14% (OR, 0.86; 95% CI, 0.77 to 0.96), while β-blockers did not reduce all-cause mortality (OR, 1.05; 95% CI, 0.88 to 1.25; P values not reported).</p> <p>Secondary: Not reported</p>
<p>Baguet et al.⁴⁸ (2007)</p> <p>Antihypertensive drugs (enalapril, ramipril, trandolapril, candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, HCTZ, indapamide SR*, atenolol, amlodipine, lercanidipine*, manidipine*, enalapril, ramipril, trandolapril, and</p>	<p>MA</p> <p>Patients greater than 18 years of age with mild or moderate essential HTN (SBP 140 to 179 mm Hg and/or DBP 90 to 109 mm Hg)</p>	<p>N=10,818</p> <p>8 to 12 weeks</p>	<p>Primary: Weighted average reductions in SBP and DBP</p> <p>Secondary: Not reported</p>	<p>Primary: Data did not reflect outcomes from direct, head-to-head comparative trials or formal comparisons between drugs. Diuretics (-19.2 mm Hg; 95% CI, -20.3 to -18.0), calcium channel blockers (-16.4 mm Hg; 95% CI, -17.0 to -15.8) and ACE inhibitors (-15.6 mm Hg; 95% CI, -17.6 to -13.6) produced the greatest reductions in SBP from baseline (P values not reported).</p> <p>The magnitude of DBP reductions were generally similar among all drug classes; however, the greatest reductions in DBP from baseline were observed with the β-blocker, atenolol (-11.4 mm Hg; 95% CI, -12.0 to -10.9), calcium channel blockers (-11.4 mm Hg; 95% CI, -11.8 to -11.1) and diuretics (-11.1 mm Hg; 95% CI, -11.7 to -10.5) (P values were not reported).</p> <p>The weighted average reduction of SBP and DBP for each drug class were as follows: Diuretics: -19.2 (95% CI, -20.3 to -18.0) and -11.1 mm Hg (95% CI, -11.7 to -10.5), respectively. β-blockers: -14.8 (95% CI, -15.9 to -13.7) and -11.4 mm Hg (95% CI, -12.0 to -10.9), respectively.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>aliskiren)</p> <p>Drugs were used as monotherapy, either at a fixed daily dosage or in increasing dosages.</p> <p>Although cicletanine*, furosemide and spironolactone were considered for inclusion, none of the trials relating to these agents satisfied all inclusion criteria.</p>				<p>Calcium channel blockers: -16.4 (95% CI, -17.0 to -15.8) and -11.4 mm Hg (95% CI, -11.8 to -11.1), respectively. ACE inhibitors: -15.6 (95% CI, -17.6 to -13.6) and -10.8 mm Hg (95% CI, -11.9 to -9.7), respectively. ARBs: -13.2 (95% CI, -13.6 to -12.9) and -10.3 mm Hg (95% CI, -10.5 to -10.1), respectively. Renin inhibitor: -13.5 (95% CI, -14.2 to -12.9) and -11.3 mm Hg (95% CI, -11.7 to -10.9), respectively.</p> <p>Secondary: Not reported</p>

*Agent not available in the United States.

Drug regimen abbreviations: BID=twice daily, QD=once daily, SR=systematic review

Study design abbreviations: BE=blinded endpoint, DB=double blind, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, PG=parallel group, PRO=prospective,

RCT=randomized controlled trial, SB=single blind, XO=cross over

Miscellaneous abbreviations=ACE inhibitors=angiotensin converting enzyme inhibitors, ARB=angiotensin II receptor blocker, BSA=body surface area, CHD=coronary heart disease, CI=confidence interval, DBP=diastolic blood pressure, HCTZ=hydrochlorothiazide, HR=hazard ratio, HTN=hypertension, MI=myocardial infarction, PAD=peripheral artery disease, RR=relative risk, SBP=systolic blood pressure, TC=total cholesterol, TG=triglycerides, TIA=transient ischemic attack, WHO=World Health Organization

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of ‘\$’ signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Thiazide-Like Diuretics

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Chlorthalidone	tablet*	N/A	N/A	\$\$
Indapamide	tablet	N/A	N/A	\$\$
Metolazone	tablet	Zaroxolyn®*	\$\$	\$\$\$

*Generic is available in at least one dosage form or strength.

N/A=Not available

X. Conclusions

The thiazide-like diuretics are approved for the treatment of hypertension and edema associated with congestive heart failure. Chlorthalidone and metolazone are also indicated for the treatment of edema due to renal dysfunction. Additionally, chlorthalidone is approved for the adjunctive treatment of edema associated with hepatic cirrhosis, as well as corticosteroid and estrogen therapy.¹⁻⁵ All of the agents are available in a generic formulation.

Guidelines recommend the use of diuretics and sodium restriction for the management of ascites due to cirrhosis. Spironolactone is recommended as first-line therapy, either as monotherapy or in combination with furosemide. Amiloride is an alternative treatment option in patients experiencing gynecomastia with spironolactone. Triamterene, metolazone, and hydrochlorothiazide have also been used to treat ascites.²¹

For the treatment of chronic heart failure, guidelines recommend the use of diuretics in all patients who have evidence of volume overload. Loop diuretics are generally recommended as initial therapy in patients with left ventricular dysfunction. For those with persistent fluid retention despite treatment with a loop diuretic, a thiazide diuretic or metolazone may be added to the regimen. In patients with normal left ventricular function, either a thiazide diuretic or loop diuretic may be used as initial therapy to manage fluid overload.⁸⁻¹⁰

There are several national and international organizations that have published guidelines on the treatment of hypertension. Thiazide-type diuretics are frequently recommended as initial therapy in patients with uncomplicated hypertension.¹¹⁻¹⁸ According to the National Heart, Lung, and Blood Institute's Eighth Report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8), thiazide-type diuretics should be utilized first-line for most patients with hypertension, either alone or in combination with another hypertensive from a different medication class (e.g., ACE inhibitors, ARBs, β -blockers, calcium channel blockers).¹¹ Several guidelines consistently recommend that the selection of an antihypertensive agent be based on compelling indications for use.¹¹⁻¹⁹ Most patients will require more than one antihypertensive medication to achieve blood pressure goals.¹¹⁻¹⁸

In clinical trials, the thiazide-like diuretics have been shown to effectively lower blood pressure.²²⁻⁴⁸ There were no studies found in the medical literature that directly compared the efficacy and safety of the thiazide-like diuretics for the treatment of hypertension.

There is insufficient evidence to support that one brand thiazide-like diuretic is safer or more efficacious than another. Formulations without a generic alternative should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand thiazide-like diuretics within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand thiazide-like diuretic is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Chlorthalidone [package insert]. Morgantown (WV): Mylan Pharmaceuticals, Inc; 2006 Mar.
2. Thalitone[®] [package insert]. Bristol (TN): Monarch Pharmaceuticals, Inc.; 2011 Jul.
3. Indapamide [package insert]. Carole Park (Australia): Alphapharm PTY LTD; 2007 Apr.
4. Metolazone [package insert]. Morgantown (WV): Mylan Pharmaceuticals, Inc; 2010 Jul.
5. Zaroxolyn[®] [package insert]. Smyrna (GA): UCB Manufacturing, Inc.; 2012 Feb.
6. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Apr]. Available from: <http://online.factsandcomparisons.com>.
7. Micromedex[®] Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Apr]. Available from: <http://www.thomsonhc.com/>.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
9. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16:475-539.
10. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787-1847.
11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20.
12. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. *Journal of Hypertension*. 2009;27(11):2121-58.
15. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Journal of Hypertension* 2013; 31:1281–1357.
16. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults [guideline on the Internet]. London (UK): NICE; 2011 Aug [cited 2015 Mar]. Available from: <http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf>.
17. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. *Hypertension*. 2010; 56:780-800.
18. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004 May;43(5 Suppl 1):S1-290.
19. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl*. 2012 Dec;2(5):337-414.
20. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(Suppl. 1):S1–S93.
21. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: update 2012. 2012 [cited 2015 Apr]. Available from: http://www.aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf.
22. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *JAMA*. 1991 Jun 26;265(24):3255-64.
23. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). *Am J Hypertens*. 1995 Dec;8(12 Pt 1):1147-53.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2000;283:1967-75.

25. Black HR, Davis B, Barzilay J, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Diabetes Care*. 2008 Feb;31(2):353-60.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981-97.
27. Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, et al. Long-term renal and cardiovascular outcomes in antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR. *Clin J Am Soc Nephrol*. 2012;7:989-1002.
28. Muntner P, Levitan EB, Lynch AI, et al. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *J Clin Hypertens (Greenwich)*. 2014 May;16(5):323-330.
29. Pupita F, Belogi M, Ansuini R, Campolucci G. Long-acting and short-acting diuretics in the treatment of hypertension. *Pharmatherapeutica*. 1983;3(7):475-81.
30. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. *Am J Med*. 2012 Dec;125(12):1229.e1-1229.e10.
31. Ernst ME, Carter BL, Goerd CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. *Hypertension*. 2006 Mar;47(3):352-8.
32. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. *Hypertension*. 2004 Jan;43(1):4-9.
33. Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS; Home-Di-Plus Study Group. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. *Clin Exp Hypertens*. 2006 Oct;28(7):655-62.
34. Nissinen A, Tuomilehto J. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. *Pharmatherapeutica*. 1980;2(7):462-8.
35. Fogari R, Zoppi A. Half-strength atenolol-chlorthalidone combination (Tenoretic mite) in the treatment of elderly hypertensive patients. *Int J Clin Pharmacol Ther Toxicol*. 1984 Jul;22(7):386-93.
36. Leonetti G, Pasotti C, Capra A. Low-dose atenolol-chlorthalidone combination for treatment of mild hypertension. *Int J Clin Pharmacol Ther Toxicol*. 1986 Jan;24(1):43-7.
37. Finnerty FA Jr. Chlorthalidone plus reserpine versus hydrochlorothiazide plus reserpine in a stepped-care approach to the treatment of essential hypertension. *J Clin Pharmacol*. 1980;20(5-6 Pt 1):357-63.
38. Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. *Curr Med Res Opin*. 2007 Dec;23(12):2929-36.
39. Beckett NS, Peters R, Fletcher AE, et al; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*. 2008 May 1;358(18):1887-98.
40. Milia P, Muir S, Alem M, Lees K, Walters M. Comparison of the effect of diuretics on carotid blood flow in stroke patients. *J Cardiovasc Pharmacol*. 2006 Mar;47(3):446-9.
41. Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. *Am J Cardiol*. 1996 Feb 22;77(6):23B-25B.
42. PROGRESS Collaborative group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. *Lancet*. 2001 Sep 29;358:1033-41.
43. Hua AS, Kincaid-Smith P. A comparison of the effects of chlorothiazide and of metolazone in the treatment of hypertension. *Clin Sci Mol Med Suppl*. 1976 Dec;3:627s-9s.
44. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomized controlled trial. *Lancet* 2007;370:829-40.
45. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000 Jul 29;356(9227):359-65.

46. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. *Am J Cardiol.* 1996 Feb 22;77(6):12b-6b.
47. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA.* 1998 Jun 17;279(23):1903-7.
48. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. *Clin Drug Investig.* 2007;27(11):735-53.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Vasopressin Antagonists
AHFS Class 402828
August 19, 2015**

I. Overview

In July 2010, conivaptan and tolvaptan were moved from the miscellaneous diuretics class (AHFS 402892) to a new diuretic subclass, the vasopressin antagonists (AHFS 402828). Conivaptan is an injectable product that is Food and Drug Administration (FDA)-approved for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. Conivaptan is not indicated for the treatment of congestive heart failure as the effectiveness of this agent has not been established in such patients.¹ Tolvaptan is an oral vasopressin antagonist that is FDA-approved for the treatment of clinically significant euvolemic and hypervolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).² The major disorders associated with euvolemic hyponatremia include SIADH, nephrogenic syndrome of inappropriate antidiuresis (NSIAD), glucocorticoid deficiency, hypothyroidism, exercise-associated hyponatremia (EAH), low solute intake, and primary polydipsia. Hypervolemic hyponatremia is most often caused by heart failure, cirrhosis, nephrotic syndrome, as well as acute and chronic renal failure.³

Hyponatremia is frequently associated with elevated plasma levels of arginine vasopressin (AVP). AVP is normally secreted in response to increased plasma osmolality, decreased blood volume, or decreased blood pressure. Suppression of AVP secretion occurs when osmolality falls below a certain threshold, which results in renal excretion of free water. Failure to suppress AVP secretion may result in water retention and hyponatremia.³ The use of traditional diuretics leads to both water and electrolyte excretion (diuresis); whereas, the use of tolvaptan leads to an increase in water excretion only (aquaresis), a decrease in urine osmolality, and an increase in serum sodium concentration. Urinary excretion of sodium and potassium, as well as plasma potassium concentrations, are not significantly affected by tolvaptan.²

The management of hyponatremia depends on the clinical presentation and duration of the disease (acute versus chronic hyponatremia). Therapeutic options include treating the underlying disease (if possible), fluid restriction, sodium chloride administration, and diuresis. Patients with chronic mild hyponatremia are often asymptomatic and treatment consists of fluid restriction or isotonic saline administration.⁴ Acute severe hyponatremia requires more aggressive initial therapy as it may increase morbidity and mortality. Treatment of hyponatremia must be approached carefully as overly rapid correction may cause osmotic demyelination. Symptoms of osmotic demyelination are often irreversible and include quadriparesis, paraparesis, dysphagia, dysarthria, diplopia, seizures, coma, and death.^{3,4}

The vasopressin antagonists that are included in this review are listed in Table 1. This review encompasses all dosage forms and strengths. There are no generic products currently available. This class was last reviewed in May 2013.

Table 1. Vasopressin Antagonists Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Conivaptan	injection [^]	Vaprisol [®]	none
Tolvaptan	tablet	Samsca [®]	none

[^]Product is primarily administered in an institution.
PDL=Preferred Drug List

II. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the vasopressin antagonists are summarized in Table 2.

Table 2. Treatment Guidelines Using the Vasopressin Antagonists

Clinical Guideline	Recommendation(s)
<p>American Journal of Medicine: Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations (2013)³</p>	<p><u>General information</u></p> <ul style="list-style-type: none"> • There are no data to suggest that the etiology of the hyponatremia, nor the methodology used to correct hyponatremia, alters the susceptibility for producing osmotic demyelination with overly rapid correction. • The rate of correction of hyponatremia must be taken into account before deciding on the most appropriate therapy for any patient with hyponatremia. • Patients with acute (<48 hours) hyponatremia may present with alarming neurologic findings, and they sometimes die of brain herniation. When hyponatremia develops over several days, brain swelling is minimized so that patients with chronic (>48 hours) hyponatremia have more modest symptoms and almost never die of brain herniation. <p><u>Rate of correction of hyponatremia</u></p> <ul style="list-style-type: none"> • To reverse serious manifestations of acute hyponatremia, increasing serum sodium by 4 to 6 mmol/L is sufficient to prevent brain herniation and neurological damage from cerebral ischemia. • The rate of correction does not need to be restricted in patients with true acute hyponatremia, nor is re-lowering of excessive corrections indicated; however, if there is any uncertainty as to whether the hyponatremia is chronic versus acute, then the limits for correction of chronic hyponatremia should be followed. • In patients with chronic hyponatremia, neurologic sequelae are associated with more rapid rates of correction. The osmotic demyelination syndrome (ODS) can usually be avoided by limiting correction of chronic hyponatremia to 4 to 8 mmol/L in 24 hours for those at low-risk of ODS and to 4 to 6 mmol/L/day for patients at high-risk. • Limits not to exceed: 8 mmol/L in any 24-hour period for high-risk patients and 10 to 12 mmol/L in any 24-hour period or 18 mmol/L in any 48-hour period in patients at normal risk. • Factors that place patients at high risk of developing ODS include serum sodium concentration ≤ 105 mmol/L, hypokalemia, alcoholism, malnutrition, and advanced liver disease. <p><u>Conventional therapy of euvolemic hyponatremia</u></p> <ul style="list-style-type: none"> • Treatment of patients with euvolemic hyponatremia will vary greatly depending on their presentation. The single most important factor guiding initial therapy is the presence of neurologic symptoms. • Cases of acute hyponatremia (≤ 48 hours in duration) are usually symptomatic if the hyponatremia is severe (≤ 120 mmol/L). These patients are at greatest risk from neurologic complications from the hyponatremia itself and should be corrected to higher serum sodium levels promptly. • Patients with more chronic hyponatremia (>48 hours in duration) who have minimal neurologic symptomatology are at little risk from complications of hyponatremia itself, but can develop osmotic demyelination following rapid correction. There is no indication to correct these patients rapidly, and they should be treated using slower-acting therapies. • Syndrome of inappropriate antidiuretic hormone secretion: <ul style="list-style-type: none"> ○ Correction of acute symptomatic hyponatremia is best accomplished with hypertonic (3%) saline given via bolus or continuous infusion. Intravenous furosemide 20 to 40 mg should be used to treat volume

Clinical Guideline	Recommendation(s)
	<p>overload. Acute treatment should be discontinued when the patient's symptoms are abolished, a safe serum sodium level (≥ 120 mmol/L) is achieved, or a total correction of 18 mmol/L is achieved.</p> <ul style="list-style-type: none"> ○ For the treatment of mild-to-moderate chronic hyponatremia, fluid restriction represents the least toxic therapy, and has generally been the treatment of choice. Several days of restriction are usually necessary before a significant increase in plasma osmolality occurs. ○ Pharmacologic interventions are reserved for refractory cases where the degree of fluid restriction required to avoid hypo-osmolality is so severe that the patient is unable, or unwilling, to maintain it. The preferred drug is demeclocycline, which causes a nephrogenic form of diabetes insipidus. Treatment must be continued for several days to achieve maximal diuretic effects. Other agents, such as lithium, have similar renal effects but are less desirable because of inconsistent results and significant side effects and toxicities. Urea is as an alternative treatment for syndrome of inappropriate antidiuretic hormone secretion. <ul style="list-style-type: none"> ● Glucocorticoid deficiency: <ul style="list-style-type: none"> ○ Glucocorticoid replacement should be started immediately after completion of a rapid adrenocorticotrophic hormone stimulation test. Several days of glucocorticoids are sometimes required for normalization of the plasma osmolality. Primary treatment of hyponatremia may be indicated if significant neurologic symptoms are present. ● Hypothyroidism: <ul style="list-style-type: none"> ○ The primary therapy of hypothyroidism is thyroid hormone replacement. ○ Hyponatremia with hypothyroidism is infrequent and generally of mild severity; therefore, modest fluid restriction is generally the only treatment necessary. ○ Symptomatic hyponatremia may be seen in patients with more severe hypothyroidism and altered mental status, primary treatment of hyponatremia may be indicated to ascertain whether the hyponatremia is contributing to the patient's neurologic symptoms. ● Exercise-associated hyponatremia (EAH): <ul style="list-style-type: none"> ○ EAH can be severe and life threatening as a result of cerebral edema and noncardiogenic pulmonary edema. ○ Hyponatremia occurring in the setting of endurance exercise is acute, and treatment of symptomatic hyponatremia should be rapid. ○ With significant central nervous system impairment, hypertonic saline should begin immediately and continued until the serum sodium reaches 125 mmol/L or symptoms resolve. ● Low solute intake: <ul style="list-style-type: none"> ○ Hyponatremia from low solute intake is corrected by instituting proper nutrition, with increased content of solute both as electrolytes and protein. ● Primary polydipsia: <ul style="list-style-type: none"> ○ Therapy should be directed at reducing fluid intake into the normal range. ○ Fluid ingestion in patients with psychogenic causes of polydipsia responds variably to behavior modification and pharmacologic therapy (e.g., clozapine). <p><u>Conventional therapy of hypervolemic hyponatremia</u></p> <ul style="list-style-type: none"> ● For all diseases associated with edema formation, dietary sodium restriction and diuretic therapy are the mainstays of therapy.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Congestive heart failure (CHF): <ul style="list-style-type: none"> ○ For severely symptomatic patients with very low or rapidly falling serum sodium, treatment should consist of hypertonic (3%) NaCl combined with loop diuretics to prevent fluid overload; for patients with mild to moderate symptoms, begin with fluid restriction (1 L/d total) and, if signs of volume overload are present, administer loop diuretics. ○ If the serum sodium does not correct to the desired level, lift the fluid restriction and start either conivaptan (if intravenous route is preferred or required) or tolvaptan (if oral therapy is preferred). ○ Hyponatremia in HF is almost always chronic, so current limits for rate of correction of chronic hyponatremias should be observed. ○ If tolvaptan is used, it may be up-titrated from 15 to 30 to 60 mg/d as necessary to achieve the desired level of correction of serum sodium. ○ Continue treatment until the serum sodium has either normalized, symptoms have improved, or the level of serum sodium is no longer compromising administration of needed diuretic therapy. • The stimuli for AVP secretion may be more dynamic than in other disease states; if prescribed after discharge, assessing the need for chronic therapy of hyponatremia by providing a window of observation off therapy two to four weeks after treatment initiation is a reasonable approach. • Cirrhosis: <ul style="list-style-type: none"> ○ There are no guidelines specifically regarding treatment of hyponatremia in cirrhosis. ○ Demeclocycline is relatively contraindicated because of a high incidence of nephrotoxicity, and urea has not been used often. Fluid restriction is the usual approach, but without outcome studies to assess its effectiveness. • Nephrotic syndrome, acute and chronic renal failure: <ul style="list-style-type: none"> ○ In patients with hyponatremia with advanced acute and chronic renal failure and glomerular filtration rate <20 mL/min, fluid restriction to amounts less than insensible losses plus urine output is generally necessary to cause a negative solute-free water balance and correction of hyponatremia. ○ Vaptans can be employed in selected cases where fluid restriction is not successful or not well tolerated. <p><u>Use of vasopressin receptor antagonists in hyponatremia</u></p> <ul style="list-style-type: none"> • Exclude hypovolemic hyponatremia. • Do not use in conjunction with other treatments for hyponatremia. • Do not use immediately after cessation of other treatments for hyponatremia, particularly 3% NaCl. • Monitor serum sodium closely (every 6 to 8 hours) for the first 24 to 48 hours after initiating treatment. • Maintain ad libitum fluid intake during the first 24 to 48 hours of treatment; hyponatremia can correct too quickly with coincidental fluid restriction; in patients with a defective or impaired thirst mechanism (e.g., intubated or unconscious patients), provide sufficient fluid to prevent overly rapid correction due to unopposed aquaresis. • Increase the frequency of serum sodium monitoring and consider stopping the vaptan if there is a change or deterioration in the patient's condition (e.g., nothing-by-mouth status, intubation) that limits the ability to request, access, or ingest fluid. • Severe, symptomatic hyponatremia should be treated with 3% NaCl, as this provides a quicker and more certain correction of serum sodium than vaptans.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Currently, there are insufficient data for use of vaptans in severe asymptomatic hyponatremia (serum sodium <120 mmol/L)—use vaptans with caution and with more frequent monitoring in these patients. • If overcorrection occurs, consider re-lowering the serum sodium to safe limits. • For the treatment of acute severe hyponatremia, there is insufficient data from clinical trials to know if sufficiently rapid correction can be achieved with vasopressin receptor antagonists without the use of hypertonic saline. • Most studies to date in patients with hyponatremia have only been of relatively short duration. The most appropriate way to use these agents, their long-term response rates, how important the role of water restriction will remain during chronic use, and whether correction of chronic hyponatremia will result in improved cognitive function as suggested by 30-day studies of tolvaptan, and quality of life, or functional status, as suggested by initial studies of gait stability and falls, are unknown at the present time and will require additional study. • Safety issues must be considered carefully with any new class of drugs. The possibility of overcorrection has been of significant concern in all of the vasopressin receptor antagonist clinical trials, but to date osmotic demyelination has not been reported with any agent. The potential for serious drug interactions via interference with cytochrome P450 3A4-mediated metabolism of other drugs must also be recognized. Whether there will be any adverse effect of V₂ receptor inhibition in vascular endothelium is unknown. • Further studies will be needed to assess the appropriate use of vasopressin receptor antagonists, such as for correction of symptomatic hyponatremia either alone or in conjunction with hypertonic saline infusions; to assess the benefits of correction of hyponatremia in hospitalized patients in terms of disease outcomes and decreased lengths of intensive care unit and hospital stay; and for long-term treatment of minimally symptomatic hyponatremia in order to decrease the risks of neurocognitive dysfunction and gait instability.

III. Indications

The Food and Drug Administration (FDA)-approved indications for the vasopressin antagonists are noted in Table 3. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 3. FDA-Approved Indications for the Vasopressin Antagonists²

Indication	Tolvaptan ^{**†}
Treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone	✓

*Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan.

†It has not been established that tolvaptan provides a symptomatic benefit to patients.

IV. Pharmacokinetics

The pharmacokinetic parameters of the vasopressin antagonists are listed in Table 4.

Table 4. Pharmacokinetic Parameters of the Vasopressin Antagonists⁵

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Tolvaptan	≥40	99	Liver, extensive (% not reported)	Non-renal routes	12

V. Drug Interactions

Significant drug interactions with the vasopressin antagonists are listed in Table 5. Tolvaptan is metabolized by cytochrome P450 (CYP) 3A, and use with strong CYP3A inhibitors causes a marked (5-fold) increase in exposure.¹ Tolvaptan is contraindicated in combination with strong cytochrome CYP3A inhibitors, such as clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin.¹ The use of tolvaptan in combination with CYP3A inducers and moderate CYP3A inhibitors should also be avoided.¹

Table 5. Significant Drug Interactions with the Vasopressin Antagonists⁶

Generic Name	Significance Level	Interaction	Mechanism
Vasopressin antagonists (tolvaptan)	1	HIV protease inhibitors	Inhibition of CYP3A4 by HIV protease inhibitors may decrease the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be increased by HIV protease inhibitors.
Vasopressin antagonists (tolvaptan)	1	Imidazoles	Inhibition of CYP3A4 by imidazoles may decrease the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be increased by imidazoles.
Vasopressin antagonists (tolvaptan)	1	Macrolides and ketolides	Inhibition of CYP3A4 and P-glycoprotein by macrolides and ketolides may decrease the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be increased by macrolides and ketolides.
Vasopressin antagonists (tolvaptan)	1	Nefazodone	Inhibition of CYP3A4 by nefazodone may decrease the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be increased by nefazodone.
Vasopressin antagonists (tolvaptan)	2	Moderate CYP3A4 Inhibitors	Inhibition of CYP3A isoenzymes by moderate CYP3A4 inhibitors may decrease the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be increased by moderate CYP3A4 inhibitors.
Vasopressin antagonists (tolvaptan)	2	Rifamycins	Induction of CYP3A isoenzymes by rifamycins may increase the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be decreased by rifamycins compromising therapeutic effectiveness.
Vasopressin antagonists (tolvaptan)	2	St. John's wort	Induction of CYP3A isoenzymes by St. John's wort may increase the metabolic elimination of tolvaptan. Plasma concentrations and pharmacologic effects of tolvaptan may be decreased by St. John's

Generic Name	Significance Level	Interaction	Mechanism
			wort compromising therapeutic effectiveness.

CYP=cytochrome P450 isoenzymes, HIV=human immunodeficiency virus
Significance level 1 = major severity, significance level 2 = moderate severity

VI. Adverse Drug Events

The most common adverse drug events reported with the vasopressin antagonists are listed in Table 6. The boxed warning for tolvaptan is listed in Table 7.

Table 6. Adverse Drug Events (%) Reported with the Vasopressin Antagonists⁶

Adverse Events	Tolvaptan
Cardiovascular	
Ventricular fibrillation	<1
Central Nervous System	
Cerebrovascular accident	<1
Pyrexia	4
Endocrine and Metabolic	
Diabetic ketoacidosis	<1
Hyperglycemia	6
Hypernatremia	<2
Gastrointestinal	
Anorexia	4
Constipation	7
Ischemic colitis	<1
Nausea	21
Xerostomia	7 to 13
Genitourinary	
Pollakiuria	4 to 11
Polyuria	4 to 11
Urethral bleeding	<1
Vaginal hemorrhage	<1
Laboratory Abnormalities	
Bilirubin increased	<1
Prothrombin time prolonged	<1
Musculoskeletal	
Rhabdomyolysis	<1
Weakness	9
Respiratory	
Pulmonary embolism	<1
Respiratory failure	<1
Other	
Deep vein thrombosis	<1
Disseminated intravascular coagulation	<1
Hepatotoxicity	≤4
Hypersensitivity reaction	<1
Skin rash	<1
Thirst	12 to 16

✓ Percent not specified
- Event not reported

Table 7. Boxed Warning for Tolvaptan²

WARNING
<p>Tolvaptan should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely.</p> <p>Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.</p>

VII. Dosing and Administration

The usual dosing regimens for the vasopressin antagonists are listed in Table 8.

Table 8. Usual Dosing Regimens for the Vasopressin Antagonists²

Generic Name	Usual Adult Dose	Usual Pediatric Dose	Availability
Tolvaptan	<p><u>Hypervolemic and euvolemic hyponatremia:</u> Tablet: initial, 15 mg once daily; maintenance, increase to 30 mg once daily after ≥24 hours as needed to achieve the desired level of serum sodium; maximum, 60 mg once daily</p>	Safety and effectiveness have not been established in pediatric patients.	Tablet: 15 mg 30 mg

VIII. Effectiveness

Clinical studies evaluating the safety and efficacy of the vasopressin antagonists are summarized in Table 9.

Table 9. Comparative Clinical Trials with the Vasopressin Antagonists

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Gheorghide et al.⁷ (2006)</p> <p>Tolvaptan 10 mg/day, with titration to larger doses (15, 30, 45, and 60 mg/day) as needed to achieve serum sodium concentrations within normal limits</p> <p>vs</p> <p>fluid restriction (initially 1,200 mL/24 hrs) plus placebo</p>	<p>AC, MC, OL, RCT</p> <p>Patients ≥18 years, serum sodium <135 mmol/L for ≥2 consecutive days, and normovolemia or signs of fluid overload</p>	<p>N=28</p> <p>Inpatient treatment: 14 days</p> <p>Outpatient treatment: 14 days</p> <p>Follow-up: 65 days</p>	<p>Primary: Normalization of serum sodium concentration (defined as ≥135 mmol/L or an increase of >10% from baseline to the last inpatient assessment)</p> <p>Secondary: Changes in serum sodium from baseline to the last outpatient visit (day 65), urine osmolality, urine volume, urine sodium concentration, body weight, total fluid intake, thirst score from baseline to the last inpatient assessment</p>	<p>Primary: A higher proportion of subjects in the tolvaptan group had achieved the normalization of serum sodium compared to those in the fluid restriction group by the last inpatient visit (P=0.049). The normalization of serum sodium was achieved more rapidly in the tolvaptan group than in the fluid restriction group, occurring in 50% of tolvaptan-treated subjects by day four, compared to day eight in the fluid restriction group (P<0.03).</p> <p>Patients in the tolvaptan group had a significantly greater increase in serum sodium concentration 4 hours after the first dose (1.6 mmol/L; P=0.016), at day 5 (5.2 mmol/L; P=0.019) and at the last inpatient visit (5.7 mmol/L; P=0.0065) compared to patients receiving fluid restriction (-0.8, 0.7, and 1.0, respectively).</p> <p>Secondary: At day 65, the mean change in serum sodium was 4.7 mmol/L in the tolvaptan group compared to -0.3 mmol/L in the placebo group (P=0.039).</p> <p>Urine sodium was significantly lower (P=0.021) and urine output was significantly greater (P=0.014) in the tolvaptan group compared to the placebo group.</p> <p>No significant differences in urine osmolality (P=0.058), serum potassium (P=0.45), blood pressure, heart rate, body weight (P value not significant), thirst score (P=0.8) or adverse events requiring drug discontinuation were observed between the treatment groups.</p>
<p>Schrier et al.⁸ (2006)</p> <p>SALT-1 and SALT-2</p> <p>Tolvaptan 15</p>	<p>DB, MC, PC, RCT</p> <p>Patients ≥18 years of age with euvolemic or hypervolemic</p>	<p>N=102 (SALT-1)</p> <p>N=123 (SALT-2)</p>	<p>Primary: Change in the average daily AUC for the serum sodium from baseline to day 4</p>	<p>Primary: By day four, the increase in the average daily AUC for the serum sodium concentration was 3.62 and 4.33 for tolvaptan (SALT-1 and SALT-2, respectively) compared to 0.25 and 0.42 for placebo (P<0.001 for all comparisons).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>mg/day for 30 days (dose could be titrated to 60 mg/day)</p> <p>vs</p> <p>placebo</p>	<p>hyponatremia (serum sodium <135 mmol/L). Patients also had chronic heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in association with the hyponatremia.</p>	<p>37 days</p>	<p>and from baseline to day 30</p> <p>Secondary: Change in the AUC for the serum sodium in patients with marked hyponatremia, serum sodium concentration at each visit, time to normalization of the serum sodium, percent of patients with serum sodium concentrations that normalized at day 4 and day 30, serum sodium concentration on day 4 and day 30 for patients with mild or marked hyponatremia at baseline, change from baseline in scores on the Physical Component Summary and Mental component summary of the medical outcomes Study 12-item Short-Form General Health</p>	<p>By day 30, the increase in the average daily AUC for the serum sodium concentration was 6.22 and 6.20 for tolvaptan (SALT-1 and SALT-2, respectively) compared to 1.66 and 1.84 for placebo (P<0.001 for all comparisons).</p> <p>Secondary: By day 30, the increase in the average daily AUC for the serum sodium concentration in patients with marked hyponatremia was 8.24 and 7.60 for tolvaptan (SALT-1 and SALT-2, respectively) compared to 2.54 and 2.72 for placebo (P<0.001 for all comparisons).</p> <p>By day four, serum sodium concentrations were 133.9 and 135.3 mmol/L for tolvaptan (SALT-1 and SALT-2, respectively) compared to 129.7 and 129.6 mmol/L for placebo (P<0.001 for all comparisons). By day 30, serum sodium concentrations were 135.7 and 135.9 mmol/L for tolvaptan (SALT-1 and SALT-2, respectively) compared to 131 and 131.5 mmol/L for placebo (P<0.001 for all comparisons).</p> <p>By day four, 40 and 55% of patients receiving tolvaptan (SALT-1 and SALT-2, respectively) had normal serum sodium concentrations compared to 13 and 11% for placebo (P<0.001 for all comparisons). By day 30, 53 and 58% of patients receiving tolvaptan (SALT-1 and SALT-2, respectively) had normal serum sodium concentrations compared to 25 and 25% for placebo (P<0.001 for all comparisons).</p> <p>Scores on the Physical Component Summary did not differ significantly between groups. Scores for the Mental Component Summary improved in the tolvaptan group when the data from SALT-1 and SALT-2 were combined (P=0.02), as well as in SALT-1 (P=0.04). Scores improved significantly in the combined subgroup of patients with marked hyponatremia (P=0.04). There was no significant difference between the groups found in SALT-2 (P=0.14).</p> <p>Adverse event profiles in the two study groups were similar for all comparisons. The most common adverse events occurring during the study in the tolvaptan groups were thirst and dry mouth. Overall, there were 26 serious adverse events potentially related to the study treatment in SALT-1</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			Survey	<p>and SALT-2. The number of deaths in the two study groups was similar (14 deaths among 223 patients in the tolvaptan groups and 13 deaths among 220 patients in the placebo groups), and they occurred within the defined observation period.</p> <p>In four of the patients in the tolvaptan group, the desirable rates of sodium correction were exceeded during the first 24 hours of the study (>0.5 mmol/L per hour). In four patients (1.8%), the predefined serum sodium concentration (>146 mmol per liter) was exceeded.</p>
<p>Berl et al.⁹ (2010) SALTWATER</p> <p>Tolvaptan QD (dose varied based on response)</p>	<p>OL, ES (Extension of SALT-1 and SALT-2)</p> <p>Patients ≥18 years of age with euvolemic or hypervolemic hyponatremia (serum sodium <135 mmol/L). Patients also had chronic heart failure, cirrhosis, or the SIADH in association with the hyponatremia</p>	<p>N=111</p> <p>4 years (mean 1.9 years)</p>	<p>Primary: Safety, efficacy</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>During the follow-up period, 105 of 111 patients experienced an adverse event. The most common adverse events that were potentially related to tolvaptan use were pollakiuria, thirst, fatigue, dry mouth, polydipsia, polyuria, hypotension, hypernatremia, dizziness, headache, peripheral edema, and acute renal failure.</p> <p>A total of 19 patients died during the follow-up period (9 deaths per 100 patient-years of exposure). The death rate during SALTWATER was lower than that observed for SALT (86.9 deaths per 100 patient-years of exposure).</p> <p>In five patients, serum sodium correction exceeded the rate of 1 mmol/L per h at the eight hour time point. There were 18 patients who had serum sodium levels >145 mmol/L at individual time points.</p> <p>Correction of serum sodium levels during the first eight hours of therapy occurred at similar rates in SALTWATER compared to SALT-1 and SALT-2. After the initial titration period, mean serum sodium levels remained within the normal range throughout the four year treatment period.</p> <p>In all patient subgroups, serum sodium levels declined by seven days of withholding tolvaptan. On drug discontinuation, the proportion of patients who declined by ≥3 mEq/L was 68%, and an equal proportion fell from ≥135mEq/L to below this threshold of normal.</p> <p>The mean time to first fluid restriction was 122.3 and 162.5 days in the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				mild and marked hyponatremia subgroups, respectively; 13.2% of patients in the mild hyponatremia group and 5.4% in the marked hyponatremia group required fluid restriction. Secondary: Not reported
Cardenas et al. (abstract) ¹⁰ (2012) SALT-1 and SALT-2 Tolvaptan 15 mg/day for 30 days (dose could be titrated to 60 mg/day) vs placebo	Subgroup analysis Patients with cirrhosis and hyponatremia	N=120 30 days	Primary: Change in the average daily AUC for the serum sodium from baseline to day 4 and from baseline to day 30 Secondary: Mental component summary of the medical outcomes Study 12-item Short-Form General Health Survey, safety	Primary: Treatment with tolvaptan effectively raised serum sodium. Average daily AUC for serum sodium was significantly greater with tolvaptan from baseline to day 4 (P<0.0001) and day 30 (P<0.0001) compared to placebo. Superiority of tolvaptan was maintained after stratification by baseline hyponatremia (mild and marked), eGFR (≤ 60 and >60 mL/min), or serum creatinine levels (<1.5 and ≥ 1.5 mg/dL). Hyponatremia recurred seven days after discontinuation of tolvaptan. Secondary: Mean mental component summary scores of the Short-Form General Health Survey improved from baseline to day 30 with tolvaptan but not with placebo (4.68 vs 0.08; P=0.02). Major adverse events with tolvaptan were dry mouth and thirst. Gastrointestinal bleeding occurred in 10 and 2% of patients receiving tolvaptan and placebo, respectively (P=0.11). Rates of adverse events, withdrawals, and deaths were similar with both treatments.
Udelson et al. ¹¹ (2008) Tolvaptan 15, 30, or 60 mg administered as a single dose vs placebo	DB, MC, PC, RCT Patients ≥ 18 years of age with symptomatic heart failure (NYHA class III or IV) of ≥ 3 months' duration caused by LVEF $<40\%$. Patients were also required to be on standard	N=181 12 hours	Primary: PCWP peak change from baseline within 3 to 8 h after treatment administration Secondary: AUC for the change from baseline PCWP	Primary: The pairwise comparisons of 15, 30, and 60 mg tolvaptan versus placebo each showed a statistically significant decrease in peak change in PCWP from three to eight hours post-dose (P=0.003, P=0.044, and P=0.033, respectively). Secondary: For the AUC _{0-8h} , the 15 mg tolvaptan group was the only tolvaptan dose group that was statistically significantly different from placebo. All tolvaptan doses produced statistically significantly greater changes than placebo in peak change in pulmonary artery pressure (P<0.01 for 15

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	background therapy for heart failure for ≥ 1 month.		and other hemodynamic parameters over an 8 hour evaluation period and renal and electrolyte parameters	<p>mg; $P < 0.05$ for 30 and 60 mg).</p> <p>Tolvaptan 15 and 30 mg doses resulted in statistically significant reductions in peak change in right atrial pressure as compared to placebo ($P < 0.01$ and $P < 0.05$, respectively).</p> <p>No significant changes in cardiac index, pulmonary vascular resistance, and systemic vascular resistance were observed after tolvaptan administration compared to placebo.</p> <p>The single dose of tolvaptan produced a dose-dependent increase in urine output ($P < 0.0001$ for all tolvaptan groups vs placebo). Urine osmolality was significantly reduced by all doses of tolvaptan relative to placebo ($P < 0.0001$ for all tolvaptan groups vs placebo). Free water clearance was significantly greater for all tolvaptan doses relative to placebo at all time points. Plasma osmolality increased in all of the tolvaptan-treated groups compared to placebo. Serum sodium levels showed a dose-related increase compared to placebo (1.2, 3.3, 4.6, and -0.7 mEq/L for the tolvaptan 15, 30, 60 mg, and placebo groups, respectively). Potassium levels were not different from placebo in any of the tolvaptan dosing groups. No significant changes in serum creatinine, blood urea nitrogen, serum potassium, and vital signs were observed after study drug administration.</p> <p>Tolvaptan was well tolerated relative to placebo. Patient-reported adverse events in this short-term study occurred in 45.5, 44.2, 54.3, and 33.3% of the 15, 30, and 60 mg tolvaptan and placebo groups, respectively.</p>
Udelson et al. ¹² (2007) Tolvaptan 30 mg/day vs placebo	DB, MC, PC, RCT Patients ≥ 18 years of age with CHF (NYHA class II to III) with a LVEF $< 30\%$. Patients were also required to be on standard background therapy for heart failure for	N=240 55 weeks	Primary: Change from baseline in LVEDV index Secondary: Change from baseline in LVESV index, comparison of the change from baseline in	<p>Primary: In the placebo group, there was no change in LVEDV index over the year of follow-up. After one year of tolvaptan therapy, there was a small reduction in LVEDV index; however, this was not significantly different from placebo (-1.8 mL/m²; $P = 0.21$ vs placebo). There was also no difference in the change of volumes from baseline at the week 55 study.</p> <p>Secondary: In the placebo group, LVEDV index decreased 0.4 mL/m² compared to a decrease of 3.3 mL/m² in the tolvaptan group ($P = 0.09$). There was no difference in the change of LVESV index from baseline at week 55.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	<p>≥3 months before enrollment.</p>		<p>LVEDV index after drug withdrawal (week 55), assessment of symptoms (using subject-assessed symptom scales and the Minnesota Living With Heart Failure Questionnaire)</p>	<p>Ejection fraction changes were small and similar in both treatment groups.</p> <p>Only minor changes in blood pressure and heart rate were observed over the course of the trial; there were no significant differences in the tolvaptan versus placebo groups. There were no significant between-group differences in serum sodium or potassium across the course of the trial. There were also no differences in renal function parameters (BUN and serum creatinine) across the year of therapy.</p> <p>No statistically significant differences were observed between the tolvaptan group and the placebo group for the change from baseline in Minnesota Living With Heart Failure Questionnaire score or for the Visual Analog Scale assessment of global status or respiratory status. More subjects in the tolvaptan group reported a score of “better” in the subject-assessed overall treatment effect at each visit than did subjects in the placebo group; however, no statistically significant differences were observed between treatment groups.</p> <p>There were six deaths (5%) and 21 hospitalizations of patients with heart failure (18%) in the tolvaptan-treated group, compared to 11 deaths (9%) and 34 heart failure hospitalizations (28%) in the placebo-treated group (P<0.03 for the composite of death and heart failure hospitalizations).</p> <p>Adverse events including urinary frequency, thirst, and dry mouth occurred more frequently with tolvaptan than with placebo therapy. There was no difference in the number of patients withdrawn from the trial as the result of bothersome side effects between the two randomization groups.</p>
<p>Gheorghide et al.¹³ (2007) EVEREST Tolvaptan 30 mg/day within 48 hours of admission vs</p>	<p>DB, MC, PC, RCT Patients ≥18 years of age with a history of chronic heart failure who had been hospitalized for worsening CHF and who had a LVEF ≤40%.</p>	<p>N=2,048 (Trial A) N=2,085 (Trial B) 7 days</p>	<p>Primary: Composite score of changes from baseline in patient-assessed global clinical status and body weight at day 7 or discharge</p>	<p>Primary: The composite score of changes from baseline in patient-assessed global clinical status and body weight at day seven or discharge was greater with tolvaptan compared to placebo (Trial A, mean 16 vs 0.99; P<0.001; Trial B, mean 17 vs 0.97; P<0.001).</p> <p>Improvement in patient-assessed global clinical status (assessed alone), measured by a 100-point visual analog scale at day seven or discharge, was similar between the tolvaptan and placebo groups (Trial A, mean 18.25 vs 17.73; P=0.51; Trial B, mean 18.72 vs 18.28; P=0.52).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo</p>	<p>Patients also received conventional heart failure therapy.</p>		<p>Secondary: Patient-assessed changes in dyspnea at day 1, global clinical status at day 7 or discharge, body weight at days 1 and 7 or discharge, and peripheral edema at day 7 or discharge</p>	<p>Mean body weight reductions at day seven or discharge in the tolvaptan and placebo groups were 3.35 vs 2.73 kg, respectively, in Trial A (P<0.001) and 3.77 vs 2.79 kg, respectively, in Trial B (P<0.001).</p> <p>Secondary: More patients in the tolvaptan groups (76.74% in Trial A and 72.06% in Trial B) reported an improvement dyspnea at day one (for those patients with dyspnea at baseline) compared to placebo (70.61% in Trial A and 65.32% in Trial B; P<0.001 in both Trials).</p> <p>There was no significant difference in global clinical status at day seven or discharge between the tolvaptan or placebo treatment groups (Trial A, P=0.51; Trial B, P=0.52).</p> <p>Changes in mean body weight were significantly greater with tolvaptan at day one (Trial A, -1.71 kg; Trial B -1.82 kg) than with placebo (Trial A, -0.99 kg; Trial B, 0.95 kg; P<0.001 in both trials).</p> <p>There was no difference in peripheral edema at inpatient day seven or discharge with tolvaptan vs placebo in Trial A. In Trial B, 73.67% of patients experienced at least a 2-grade improvement in pedal edema with tolvaptan compared to placebo (P=0.02).</p> <p>An overall in-hospital mortality rate of 2.4 and 2.9% was observed in the tolvaptan and placebo groups, respectively. Through day seven or discharge, adverse events were reported in 49.1 and 40.0% of patients in Trial A, and in 55.9 and 47.9% of patients in Trial B in the tolvaptan and placebo groups, respectively.</p>
<p>Konstam et al.¹⁴ (2007) EVEREST Tolvaptan 30 mg/day within 48 hours of admission</p>	<p>DB, MC, PC, RCT Patients ≥18 years of age with a history of chronic heart failure who had been hospitalized for worsening CHF</p>	<p>N=4,133 ≥60 days</p>	<p>Primary: All-cause mortality, composite of cardiovascular death or hospitalization for heart failure</p>	<p>Primary: The median duration of follow-up was 9.9 months. A total of 537 patients in the tolvaptan group (25.9%) and 543 patients in the placebo group (26.3%) died (HR, 0.98; 95% CI, 0.87 to 1.11; P=0.68). A total of 871 patients in the tolvaptan group (42.0%) and 829 patients in the placebo group (40.2%) died from cardiovascular causes or had a first hospitalization for heart failure (HR, 1.14; 95% CI, 0.95 to 1.34; P=0.55).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
vs placebo	and who had a LVEF ≤40%. Patients also received conventional heart failure therapy.		Secondary: Composite of cardiovascular mortality or cardiovascular hospitalization, incidence of cardiovascular mortality, incidence of clinical worsening of heart failure (death, hospitalization for heart failure, or unscheduled visit for heart failure), changes from baseline in body weight at day 1, serum sodium level at day 7 or discharge, edema score at day 7 or discharge, patient-assessed dyspnea at day 1, and Kansas City Cardiomyopathy Questionnaire overall summary score at outpatient week 1	<p>Secondary: The composite of cardiovascular death or cardiovascular hospitalization, the incidence of cardiovascular mortality, and the incidence of clinical worsening of heart failure did not differ between the two treatment groups (P=0.52, P=0.67 and P=0.62, respectively).</p> <p>In patients with dyspnea at baseline, patient-assessed dyspnea scores significantly improved at day one in patients receiving tolvaptan compared to placebo (P<0.001), with 74.3% of the tolvaptan group and 68.0% of the placebo group demonstrating an improvement in dyspnea score.</p> <p>Mean body weight at day one was reduced by 1.76 kg in the tolvaptan group and by 0.97 kg in the placebo group (P<0.001).</p> <p>Among patients with baseline serum sodium levels less than 134 mEq/L, mean serum sodium concentrations increased by 5.49 mEq/L at day 7 or discharge with tolvaptan compared to 1.85 mEq/L in the placebo group (P<0.001). This effect was observed as early as day one and was maintained through 40 weeks of treatment.</p> <p>In patients with baseline pedal edema, edema scores significantly improved at day seven or discharge in patients receiving tolvaptan compared to placebo (P=0.003), with 73.8% of tolvaptan patients and 70.5% of placebo patients manifesting improvement in edema by at least two grades.</p> <p>A significant improvement in physician assessed pedal edema was observed as early as day one and continued through post discharge week four.</p> <p>No significant changes were observed at outpatient week one in the Kansas City Cardiomyopathy Questionnaire overall summary score. Statistically significant changes favoring tolvaptan were observed at the time of the last scheduled on-treatment assessment at study end for the quality-of life domain (P=0.003), the social limitation domain (P=0.05), and the overall summary score (P=0.02). The other domains (clinical summary, physical limitation, total symptom, symptom frequency,</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>symptom burden, symptom stability, and self-efficacy) did not reach significance at the time of the last on-treatment assessment.</p> <p>Adverse events occurred in 89.0% of tolvaptan patients and 86.1% of placebo patients.</p>
<p>Pang et al.¹⁵ (2009) EVEREST</p> <p>Tolvaptan 30 mg/day within 48 hours of admission</p> <p>vs</p> <p>placebo</p>	<p>Post-hoc analysis of EVEREST</p> <p>Patients ≥18 years of age with a history of chronic heart failure who had been hospitalized for worsening CHF with LVEF ≤40%. Patients also received conventional heart failure therapy.</p>	<p>N=3,664</p> <p>1 to 3 days</p>	<p>Primary: Patient-assessed dyspnea using a seven-point Likert scale administered on day 1 after randomization</p> <p>Secondary: Not reported</p>	<p>Primary: Tolvaptan was associated with improved patient-assessed dyspnea on inpatient day one compared to placebo (74.3 vs 68.0%; P<0.0001) as reported in the primary EVEREST analysis. The greatest treatment differences were seen in subjects with continuous dyspnea at baseline.</p> <p>Patients were divided post hoc into five groups, based on time (in hours) of dyspnea assessment after the first dose of tolvaptan. The percentage improvement with placebo stayed relatively constant, whereas improvement with tolvaptan was greatest when measured early (P<0.05). The majority of patients had an improvement in dyspnea at all time points relative to hospital admission; however, there was a significantly higher rate of improvement with tolvaptan compared to placebo (P<0.05).</p> <p>There was also a linear association between reductions in body weight and improvements in patient-assessed dyspnea.</p> <p>Secondary: Not reported</p>
<p>Hauptman et al.¹⁶ (2013) EVEREST</p> <p>Tolvaptan 30 mg/day within 48 hours of admission</p> <p>vs</p> <p>placebo</p>	<p>Post-hoc analysis of EVEREST</p> <p>Patients ≥18 years of age with a history of chronic heart failure who had been hospitalized for worsening CHF with LVEF ≤40%. Patients also received conventional heart</p>	<p>N=475</p> <p>≥60 days</p>	<p>Primary: Body weight at day 1, serum sodium at day 7 or discharge in patients with a baseline serum sodium <135 mEq/L, edema score at day 7 or discharge for those with peripheral edema at baseline, dyspnea at day 1</p>	<p>Primary: Mean change from baseline in serum sodium was 4.72 mEq/L vs 1.18 mEq/L at day one and 4.90 mEq/L vs 1.93 mEq/L at day seven in the tolvaptan and placebo groups, respectively (P<0.0001 at each time point). Tolvaptan was more likely to lead to normalization of serum sodium defined by a value of ≥135 mEq/L at both day one and at discharge compared with placebo (58 vs 20% and 64 vs 29%, respectively; P<0.001 for both comparisons).</p> <p>In patients with dyspnea and hyponatremia at baseline (n=409), the changes in dyspnea were more favorable in the tolvaptan group versus placebo (van Elteren analysis: 0.56, 95% CI 0.51 to 0.62; P=0.028).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	failure therapy. This analysis included the hyponatremic cohort.		<p>for those with dyspnea at baseline, long-term clinical course</p> <p>Secondary: Not reported</p>	<p>Mean body weight at day one was reduced by 1.69 kg in the tolvaptan group and by 0.96 kg in the placebo group (P<0.0001). Changes observed in physician-assessed edema at day seven (or discharge if earlier) were not significantly different between the groups (P=0.79).</p> <p>Serum sodium increases observed in the short term among the patients with hyponatremia continued during the outpatient portion of the study, with results significantly favoring tolvaptan.</p> <p>There was a favorable effect of tolvaptan treatment on first occurrence of cardiovascular mortality or morbidity in those with more severe reduction in serum sodium at baseline (HR, 0.60; 95% CI, 0.37 to 0.98; P=0.04). There was no effect of tolvaptan on CV mortality or morbidity in the mild hyponatremia group, with baseline serum sodium 130 to 134 mEq/L (HR, 0.96; 95% CI, 0.74 to 1.25; P=0.77).</p> <p>Secondary: Not reported</p>
<p>Gheorghiade et al.¹⁷ (2004) ACTIV IN CHF</p> <p>Tolvaptan 30, 60, or 90 mg/day</p> <p>vs placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients ≥18 years of age admitted for worsening CHF with LVEF <40% within 1 year of admission and systemic congestion (JVD, rales, or peripheral edema after initial in-hospital therapy for heart failure). Patients also received conventional heart failure therapy.</p>	<p>N=319</p> <p>Inpatient: 10 days</p> <p>Outpatient: 7 weeks</p>	<p>Primary: Change in body weight at 24 hrs after the administration of the first dose of study drug; worsening heart failure at 60 days</p> <p>Secondary: Changes in dyspnea, JVD, rales, edema, body weight, urine output, serum electrolyte levels, length of hospital stay after</p>	<p><u>Inpatient Phase</u></p> <p>Primary: A greater median reduction in body weight was found in patients treated with tolvaptan compared to placebo 24 hrs after the administration of the first dose of study drug (-1.80, -2.10, -2.05, and -0.60 kg for tolvaptan 30, 60, and 90 mg, and placebo, respectively; P=0.002, P=0.002, and P=0.009 for the 3 tolvaptan groups compared to the placebo group).</p> <p>Secondary: The median body weight reductions from baseline to discharge were greater in the tolvaptan groups compared to the placebo group (-3.30, -2.80, -3.20, and -1.90 kg in the groups receiving tolvaptan 30, 60, and 90 mg, and placebo, respectively; P=0.006, P=0.002, and P=0.06 for the three tolvaptan groups compared to placebo).</p> <p>The mean urine output at 24 hrs was 4,056.2, 4,175.2, 4,127.3, and 2,296.5 mL for the tolvaptan 30, 60, and 90 mg, and placebo groups, respectively (P =0.02, P<0.001, and P<0.001 for the three tolvaptan groups compared to the placebo group).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
			<p>randomization, use of diuretics, and patient/physician-assessed symptom scales</p>	<p>Signs and symptoms of heart failure improved in all patients during the period of hospitalization. There were no significant differences in JVD, and peripheral edema between the treatment groups (dyspnea P=0.04).</p> <p>Global assessment scales did not show a significant difference among the treatment groups.</p> <p>The median length of time between randomization and discharge was 4 days in both treatment groups.</p> <p><u>Outpatient Phase</u> Primary: There was no significant difference in worsening heart failure between the tolvaptan groups and the placebo group.</p> <p>Secondary: Diuretic use decreased in all patients after discharge. There was no significant difference in mean dose reduction between the treatment groups.</p>
<p>Gheorghiade et al.¹⁸ (2003)</p> <p>Tolvaptan 30, 45, or 60 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Patients ≥18 years of age with a diagnosis of CHF irrespective of LVEF. Patients also received conventional heart failure therapy.</p>	<p>N=254</p> <p>25 days</p>	<p>Primary: Changes in body weight</p> <p>Secondary: Ankle edema measurements, urine sodium excretion, urine volume, urine osmolality, safety</p>	<p>Primary: Mean decreases from baseline in body weight were observed on the first day of tolvaptan treatment at all doses and maintained throughout the study (P<0.001 vs placebo). The decrease in body weight was similar in all tolvaptan-treated patients irrespective of the LVEF. Patients receiving placebo experienced an increase in body weight from baseline.</p> <p>Secondary: Improvements in ankle edema scores were significantly better with tolvaptan 45 mg compared to placebo (P<0.05). None of the other doses studied differed significantly from placebo.</p> <p>Tolvaptan-treated patients had significantly greater mean total urinary sodium excretions (339.9, 373.0, and 355 mEq for the 30, 45, and 60 mg tolvaptan groups, respectively) than placebo-treated patients (193.7 mEq; P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>Urine volumes were greater in tolvaptan-treated patients (3,909, 4,232, and 4,597 mL for the 30, 45, and 60 mg tolvaptan groups, respectively) than in placebo-treated patients (2,328 mL; P<0.05).</p> <p>At day one, urine osmolality decreased by 15.5, 52.4, and 118.8 mOsm/kg in the 30, 45, and 60 mg tolvaptan groups, respectively compared to an increase of 135.8 mOsm/kg in the placebo group (P<0.05 for all comparisons).</p> <p>No significant differences were found between the tolvaptan groups and the placebo group in the QOL assessment. No changes in heart rate or systolic or diastolic blood pressure, supine or standing, were observed in the tolvaptan groups during the study.</p> <p>Dry mouth, thirst, and polyuria, including urinary frequency, were higher in the tolvaptan-treated patients.</p>
<p>Salahudeen et al.¹⁹ (2014)</p> <p>Tolvaptan vs placebo</p> <p>Both groups received the standard of care for hyponatremia, except that patients were allowed to drink to thirst</p>	<p>DB, RCT</p> <p>Adult patients with cancer who were admitted to MD Anderson and met the eligibility criteria for nonhypovolemic hyponatremia (125 to 130 mmol/L serum sodium)</p>	<p>N=30</p> <p>14 days</p>	<p>Primary: To compare the rate of tolvaptan-treated correction of hyponatremia with that of placebo on day 14</p> <p>Secondary: To compare the length of hospital stay and the change in mental test scores between the tolvaptan-treated and placebo groups</p>	<p>Primary: Sixteen of 17 patients in the tolvaptan group and one of 13 patients in the placebo group achieved the primary endpoint of serum sodium correction on day 14 (94 vs 8%, respectively; P<0.001). The study met the predefined stopping rule of superiority for tolvaptan over placebo and further patient recruitment was halted.</p> <p>Secondary: The secondary endpoints between the tolvaptan and placebo groups (mean ± standard deviation) for length of stay (21 ± 15 vs 26 ± 15 days, respectively) and changes in the MMSE score (-0.35 ± 1.66 vs 0.31 ± 2.42, respectively) were not significantly different.</p>
<p>Dahl et al.²⁰ (2012)</p> <p>Vaptans</p>	<p>MA (12 RCTs)</p> <p>Patients with cirrhosis and</p>	<p>N=2,266</p> <p>Duration not specified</p>	<p>Primary: Mortality</p> <p>Secondary:</p>	<p>Primary: No clear difference between vaptans and control was found regarding mortality (22 vs 20%; RR, 1.06; 95% CI, 0.90 to 1.26).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(tolvaptan, satavaptan*, lixivaptan*)</p> <p>vs</p> <p>control (no intervention, placebo, other diuretics)</p>	<p>hyponatremia or ascites</p>		<p>Complications to cirrhosis (variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome), renal failure, serum sodium levels, mobilization of ascites, safety</p>	<p>Secondary:</p> <p>No clear differences between vaptans and control were found regarding complications to cirrhosis and renal failure.</p> <p>Treatment with vaptans increased serum sodium levels (WMD, 1.8 mmol/L; 95% CI, 0.79 to 2.96).</p> <p>Treatment with vaptans reduced weight (WMD, -1.82 kg; 95% CI, -2.86 to 0.79), time to first paracentesis (RR, 0.76; 95% CI, 0.63 to 0.90), and the clinical severity of ascites (RR, 0.71; 95% CI, 0.60 to 0.83).</p> <p>Adverse events were more likely with vaptan therapy compared to control (RR, 3.97; 95% CI, 1.78 to 8.83), including an excessive urine volume (RR, 9.96; 95% CI, 1.38 to 71.68). Treatment with vaptans had no effect on SBP and DBP. Treatment with vaptans increased vasopressin and renin levels; however, there is no clear difference between treatments in aldosterone levels.</p>

*Drug not available in the United States.

Drug regimen abbreviations: QD

Study design abbreviations: AC=active comparator, DB=double blind, ES=extended study, MA=meta analysis, MC=multicenter, OL=open label, PC=placebo controlled, RCT=randomized controlled trial
Miscellaneous abbreviations: AUC=area under the curve, CHF=congestive heart failure, CI=confidence interval, DBP=diastolic blood pressure, eGFR=estimated glomerular filtration rate, HR=hazard ratio, JVD=jugular venous distention, LVEDV=left ventricular end diastolic volume, LVEF=left ventricular ejection fraction, LVESV=left ventricular end systolic volume, PCWP=pulmonary capillary wedge pressure, QOL=quality of life, RR=relative risk, SBP=systolic blood pressure, SIADH=syndrome of inappropriate antidiuretic hormone secretion, WMD=weighted mean difference

Additional Evidence

Dose Simplification

A search of Medline and PubMed did not reveal data pertinent to this topic.

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

IX. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For branded products with little or no recent utilization data, the average cost per prescription is calculated by the average wholesale price (AWP) and the standard daily dosing per product labeling. For generic products with little or no recent utilization data, the average cost per prescription is calculated by the Alabama Medicaid maximum allowable cost (MAC) and the standard daily dosage per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 10. Relative Cost of the Vasopressin Antagonists

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Tolvaptan	tablet	Samsca®	\$\$\$\$\$	N/A

N/A=not available

X. Conclusions

Tolvaptan, the only oral vasopressin antagonist, is FDA-approved for the treatment of clinically significant euvolemic and hypervolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and SIADH.² The management of hyponatremia depends on the clinical presentation and duration of the disease. Treatment must be approached carefully as overly rapid correction of hyponatremia (>10 to 12 mEq/L per 24 hours) may cause osmotic demyelination.²⁻⁴

There are limited guidelines available that discuss the management of hyponatremia. An expert panel provided treatment recommendations in 2013, which includes fluid restriction, sodium chloride administration, and diuresis. The panel concluded that the current role for vasopressin antagonists in SIADH is in treating mild to moderate hyponatremia and asymptomatic severe hyponatremia. Because there is a paucity of data for patients with severely symptomatic hyponatremia, hypertonic saline remains the treatment of choice in this group until more evidence-based data are available. In patients with heart failure, a vasopressin antagonist is recommended if

serum sodium does not correct to the desired level with hypertonic saline or fluid restriction. The fluid restriction should be lifted before starting these agents.³

Three short-term trials evaluating the safety and efficacy of tolvaptan in a relatively small number of patients with euvolemic or hypervolemic hyponatremia demonstrated significant improvements in serum sodium concentrations compared to fluid restriction or placebo.^{7,8} An open-label, long-term extension study (mean follow-up of 701 days) assessed the drug-related adverse effects of tolvaptan and maintenance of efficacy, and concluded that prolonged administration of tolvaptan maintained an increased serum sodium level with an acceptable margin of safety.⁹ Evidence suggests that hyponatremia recurs after discontinuation of tolvaptan.^{9,10} Several other studies have evaluated the use of tolvaptan in patients with congestive heart failure as an add-on to conventional treatments.^{11-14,16,18,19} Significant changes in body weight have been observed; however, the long-term use of tolvaptan (median duration 9.9 months) failed to demonstrate any improvements in mortality or hospitalizations for worsening heart failure.¹⁴ A meta-analysis also failed to demonstrate a benefit in mortality with vaptan therapy compared to control in patients with cirrhosis and hyponatremia or ascites.²⁰

Data supporting the use of tolvaptan are limited. It has not been established that raising serum sodium with tolvaptan provides a symptomatic benefit to patients. Patients requiring intervention to raise serum sodium urgently should not be treated with tolvaptan. Hospitalization is required for initiation and reinitiation of tolvaptan therapy so that serum sodium can be monitored closely.²

There is insufficient evidence to conclude that tolvaptan offers a significant clinical advantage over other alternatives in general use. Since tolvaptan is not indicated as first-line therapy for the management of hyponatremia, it should be managed through the medical justification portion of the prior authorization process.

Therefore, all brand vasopressin antagonists within the class reviewed are comparable to each other and to the generic products in the class (if applicable) and offer no significant clinical advantage over other alternatives in general use.

XI. Recommendations

No brand vasopressin antagonist is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XII. References

1. Vaprisol® [package insert]. Deerfield (IL): Astellas Pharma US, Inc.; 2007 Feb.
2. Samsca® [package insert]. Tokyo: Otsuka Pharmaceutical Co., Ltd.; 2014 Feb.
3. Verbalis J, Goldsmith S, Greenberg A, et al. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations. *Am J Med* 2013;126(10;Suppl 1):S1-S42.
4. Sterns RH. Overview of the treatment of hyponatremia in adults. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015 [cited 2015 Apr]. Available from: <http://www.utdol.com/utd/index.do>.
5. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Apr]. Available from: <http://www.thomsonhc.com/>.
6. Drug Facts and Comparisons 4.0 [database on the Internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited 2015 Apr]. Available from: <http://online.factsandcomparisons.com>.
7. Gheorghide M, Gottlieb S, Udelson J, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. *Am J Cardiol* 2006;97:1064-7.
8. Schrier R, Gross P, Gheorghide M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006;355:2099-112.
9. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. *J Am Soc Nephrol* 2010;21:705-12.
10. Cardenas A, Gines P, Marotta P, Czerwiec F, Ouyang J, Guevara M, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis (abstract). *J Hepatol.* 2012 Mar;56(3):571-8.
11. Udelson J, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. *J Am Coll Cardiol* 2008;52:1540-5.
12. Udelson J, McGrew F, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. *J Am Coll Cardiol* 2007;49:2151-9.
13. Gheorghide M, Konstam M, Burnett J, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *JAMA* 2007;297:1332-43.
14. Konstam M, Gheorghide M, Burnett J, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA* 2007;297:1319-31.
15. Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. *Eur Heart J* 2009;30:2233-40.
16. Hauptman PJ, Burnett J, Gheorghide M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. *J Card Fail.* 2013 Jun;19(6):390-397.
17. Gheorghide M, Gattis W, O'Connor C, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. *JAMA* 2004;291:1963-71.
18. Gheorghide M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. *Circulation* 2003;107:2690-6.
19. Salahudeen AK, Ali N, George M, Lahoti A, Palla S. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. *Cancer.* 2014 Mar 1;120(5):744-751.
20. Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatremia. *Aliment Pharmacol Ther.* 2012;36:619-626.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of Diuretics, Miscellaneous
AHFS Class 402892
August 19, 2015**

I. Overview

In July 2010, conivaptan and tolvaptan were moved from the miscellaneous diuretics class (AHFS Class 402892) to the vasopressin antagonists class (AHFS Class 402828). Currently, there are no drugs classified by AHFS as miscellaneous diuretics.

II. Conclusions

There are no drugs available in the miscellaneous diuretics class (AHFS Class 402892).

III. Recommendations

No brand miscellaneous diuretic is recommended for preferred status. Alabama Medicaid should continue to include AHFS Class 402892 in the PDL screening process. If new outpatient miscellaneous diuretics are added, it is recommended that this class be re-reviewed at that time.

**Alabama Medicaid Agency
Pharmacy and Therapeutics Committee Meeting
Pharmacotherapy Review of HCV Antivirals
AHFS Class 081840
August 19, 2015**

IV. Overview

The hepatitis C antivirals are all Food and Drug Administration (FDA)-approved for the treatment of chronic hepatitis C virus (HCV) infection, although differences in indications exist relating to use in specific genotypes. Many patient factors need to be considered when initiating HCV treatment, including but not limited to viral subtype, prior treatment regimen, including response, and presence of cirrhosis. The HCV antivirals also vary with regards to use in combination versus single-product therapy and duration of treatment.¹⁻⁵

HCV is an enveloped ribonucleic acid (RNA) virus that is transmitted through exposure with infected blood. HCV infection is one of the main causes of chronic liver disease worldwide, and the long-term impact of infection is highly variable, from minimal changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma.⁶ HCV has a highly variable genome and multiple genotypes and subgenotypes, with genotype 1 being the most common in the United States, followed by genotypes 2 and 3.⁶ Genotyping is helpful in the clinical management of patients with hepatitis C for determining the choice of therapy. Assessment of liver disease severity is also recommended for predicting prognosis and determining the timing of therapy.⁶⁻⁹ The goal of hepatitis C treatment is HCV eradication in order to prevent complications and death. Due to the slow evolution of chronic infection, it is difficult to demonstrate if treatment prevents complications of liver disease; therefore, response to treatment is defined by surrogate virological parameters. Sustained virologic response (SVR), defined as the absence of HCV RNA 24 weeks following discontinuation of treatment, has historically been the most important primary endpoint in clinical trials. Recently, SVR 12 (undetectable HCV RNA 12 weeks after the end of therapy) has also been accepted as a primary endpoint for regulatory approval in the United States due to concordance with SVR 24.⁶⁻⁹

Over the past 20 years, the success of treatment as evidenced by SVR has steadily increased as new treatments have become available. Treatments with standard interferon resulted in SVR rates of 30 to 60%, depending on genotype. The introduction of peginterferon increased SVR rates to 40 to 70%, and the introduction of direct-acting antivirals has increased SVR to >90%.⁶ The direct-acting antiviral agents act via several different mechanisms of action and include inhibition of non-structural (NS) 3/4A protease, NS5B polymerase, and HCV NS5A.¹⁻⁶ The hepatitis C protease inhibitors boceprevir (Victrelis[®]) and simeprevir (Olysio[®]) both work via inhibition of the HCV NS3/4A protease of HCV genotype 1a and 1b, thus preventing replication of HCV host cells.¹⁻² Similarly, sofosbuvir (Sovaldi[®]) inhibits HCV NS5B polymerase which also prevents the replication of HCV host cells; however, it is active against multiple genotypes of HCV.³ The two combination HCV antiviral products include ledipasvir-sofosbuvir (Harvoni[®]) and a 4-drug regimen of ombitasvir-paritaprevir-ritonavir-dasabuvir (Viekira Pak[®]). Paritaprevir and dasabuvir exert their mechanisms of action in the same way as other agents, inhibiting NS3/4A protease and NS5B polymerase, respectively. Ledipasvir and ombitasvir work similarly to the other agents, specifically inhibiting HCV non-structural protein NS5A. Ritonavir, when used in Viekira Pak[®], is a boosting agent that increases the peak and trough plasma drug concentrations of paritaprevir along with overall drug exposure; it has no direct effect on the hepatitis C virus.⁴⁻⁵ Prior to the availability of direct-acting antiviral agents, combination of peginterferon alfa and ribavirin has been the standard of care for the treatment of chronic hepatitis C.^{6,10} Newly published guidelines developed by the American Association for the Study of Liver Diseases, Infectious Diseases Society of America and International Antiviral Society-USA have included all current treatments in their recommendations.⁷ In general, combination regimens that include newer direct hepatitis C antivirals are preferred over older pegylated interferon-based regimens (including those containing older protease inhibitors) due to a higher SVR rate, improved side effects profile, and reduced pill burden. However, many different regimens with direct-acting agents or combinations, which may or may not also include ribavirin or pegylated interferon, are recommended based on HCV genotype, previous treatment experience, presence of cirrhosis, and certain special populations.^{7,8}

The HCV antivirals that are included in this review are listed in Table 1. SVR rates for the each agent in patients with HCV genotype 1 are included in Table 2. Boceprevir (Victrelis[®]) is being voluntarily discontinued in the

United States by the manufacturer and will no longer be available after December 31, 2015.¹¹ This review encompasses all dosage forms and strengths. There are no generic products available. This class was last reviewed in November 2014.

Table 1. HCV Antivirals Included in this Review

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Current PDL Agent(s)
Single Entity Agents			
Boceprevir	capsule	Victrelis®	none
Simeprevir	capsule	Olysio®	none
Sofosbuvir	tablet	Sovaldi®	none
Combination Products			
Ledipasvir and sofosbuvir	tablet	Harvoni®	none
Ombitasvir, paritaprevir, and ritonavir; dasabuvir	dose pack (tablets)	Viekira Pak®	none

PDL=Preferred Drug List

Table 2. Sustained Virologic Response Rates Amongst HCV Antivirals in Genotype 1 Patients¹⁻⁵

Patient Characteristics	Boceprevir*	Simeprevir*	Sofosbuvir*	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
Treatment-naïve	63 to 66%	80%	89%	94 to 99%	90 to 100%
Prior relapser	69 to 75%	79%	71%†	95 to 100%	90 to 100%
Prior partial responder	40 to 52%	67%		92 to 98%	86 to 100%
Prior null responder	38%	45%			80 to 100%

*Added to peginterferon alfa and ribavirin. Direct-acting antivirals have not been directly compared in clinical trials.

†FDA estimate in treatment-experienced subjects

V. Evidence-Based Medicine and Current Treatment Guidelines

Current treatment guidelines that incorporate the use of the HCV antivirals are summarized in Table 3. Previous treatment guidelines for Hepatitis C are summarized in Table 13 entitled “Archived Guidelines.”

Table 3. Treatment Guidelines Using the HCV Antivirals

Clinical Guideline	Recommendation(s)
American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA: Recommendations for testing, managing, and treating hepatitis C (2015) ⁷	<ul style="list-style-type: none"> This summary will focus on the recommendations for treatment of hepatitis C virus (HCV) infection <p>Goal of treatment</p> <ul style="list-style-type: none"> The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response (SVR). <p>When and in whom to initiate treatment</p> <ul style="list-style-type: none"> Treatment is recommended for patients with chronic HCV infection. Immediate treatment is assigned the highest priority for those patients with the highest risk for severe complications. <ul style="list-style-type: none"> Advanced fibrosis (Metavir F3) or compensated cirrhosis (Metavir F4) Liver transplant recipients Type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations (e.g., vasculitis) Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis Based on available resources, immediate treatment should be prioritized as necessary so that patients at high risk for liver-related complications and severe

Clinical Guideline	Recommendation(s)
	<p>extrahepatic hepatitis C complications are given high priority.</p> <ul style="list-style-type: none"> ○ Fibrosis (Metavir F2) ○ HIV-1 coinfection ○ Hepatitis B virus (HBV) coinfection ○ Other coexistent liver disease (e.g., nonalcoholic steatohepatitis [NASH]) ○ Debilitating fatigue ○ Type 2 Diabetes mellitus (insulin resistant) ○ Porphyria cutanea tarda <ul style="list-style-type: none"> ● Treatment of individuals at high risk to transmit HCV to others may yield long-term future benefits from decreased transmission and a potential decrease in HCV disease prevalence. Patients at substantial risk of transmitting HCV should be counseled on ways to decrease transmission and minimize the risk of reinfection. <ul style="list-style-type: none"> ○ Men who have sex with men (MSM) with high-risk sexual practices ○ Active injection drug users ○ Incarcerated persons ○ Persons on long-term hemodialysis ○ HCV-infected women of child-bearing potential wishing to get pregnant ● An assessment of the degree of hepatic fibrosis, using noninvasive testing or liver biopsy, is recommended. ● Ongoing assessment of liver disease is recommended for persons in whom therapy is deferred. <p><u>Initial treatment of HCV infection (treatment naïve)</u></p> <ul style="list-style-type: none"> ● <u>Genotype 1a</u> (three options with similar efficacy are recommended) <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice-daily dasabuvir 250 mg plus weight-based ribavirin for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis) ○ Daily sofosbuvir 400 mg plus simeprevir 150 mg with or without ribavirin for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis) ○ Shortening treatment to less than 12 weeks for patients without cirrhosis should be done with caution and performed at the discretion of the practitioner. ● <u>Genotype 1b</u> (three options with similar efficacy are recommended) <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice-daily dasabuvir 250 mg for 12 weeks <ul style="list-style-type: none"> ▪ The addition of weight-based ribavirin is recommended in patients with cirrhosis ○ Daily sofosbuvir 400 mg plus simeprevir 150 mg for 12 weeks ● The following regimens are <u>NOT recommended</u> for treatment-naïve patients with HCV genotype 1 <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ○ Peginterferon alfa and ribavirin with or without sofosbuvir, simeprevir, telaprevir, or boceprevir for 12 to 48 weeks ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral ● <u>Genotype 2</u> <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight based ribavirin for 12 weeks <ul style="list-style-type: none"> ▪ Extending to 16 weeks is recommended in patients with cirrhosis ○ There are no alternate regimens recommended for treatment-naïve patients with hepatitis C genotype 2 ● The following regimens are <u>NOT recommended</u> for treatment-naïve patients with HCV genotype 2 <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 weeks

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir-, boceprevir-, or ledipasvir-containing regimens • <u>Genotype 3</u> <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ○ Alternate: Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks is acceptable for interferon-eligible, treatment-naïve patients with HCV genotype 3 • The following regimens are <u>NOT recommended</u> for treatment-naïve patients with HCV genotype 3 <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 to 48 weeks ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral ○ Telaprevir-, boceprevir-, or ledipasvir-containing regimens • <u>Genotype 4</u> <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 and weight-based ribavirin for 12 weeks ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ○ Alternate: <ul style="list-style-type: none"> ▪ Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ▪ Daily sofosbuvir 400 mg plus simeprevir 150 mg with or without weight-based ribavirin for 12 weeks • The following regimens are <u>NOT recommended</u> for treatment-naïve patients with HCV genotype 4 <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without simeprevir for 24 to 48 weeks ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral ○ Telaprevir- or boceprevir-based regimens • <u>Genotype 5</u> <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ○ Alternate: Weekly peginterferon alfa plus weight-based ribavirin for 48 weeks • <u>Genotype 6</u> <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Alternate: Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks • The following regimens are <u>NOT recommended</u> for treatment-naïve patients with HCV genotype 5 or 6 <ul style="list-style-type: none"> ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral ○ Telaprevir- or boceprevir-based regimens • <u>Mixed Genotypes</u> <ul style="list-style-type: none"> ○ Treatment data for mixed genotypes with direct-acting antivirals are sparse, and awaiting availability of a pangenotypic regimen may be considered. ○ When treatment is necessary, the choice of antiviral combination and duration of treatment should maximize efficacy against each genotype represented in the assay. <p><u>Retreatment after failed therapy (peginterferon alfa and ribavirin)</u></p> <ul style="list-style-type: none"> • <u>Genotype 1a (no cirrhosis)</u> <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus

Clinical Guideline	Recommendation(s)
	<p>twice daily dasabuvir 250 mg and weight-based ribavirin for 12 weeks</p> <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg plus simeprevir 150 mg with or without weight-based ribavirin for 12 weeks <ul style="list-style-type: none"> ● Genotype 1b (no cirrhosis) <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice daily dasabuvir 250 mg for 12 weeks ○ Daily sofosbuvir 400 mg plus simeprevir 150 mg with or without weight-based ribavirin for 12 weeks ● Genotype 1a or 1b (with cirrhosis) <ul style="list-style-type: none"> ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg for 24 weeks ○ Daily fixed-dose ledipasvir/sofosbuvir 90/400 mg plus weight-based ribavirin for 12 weeks ○ Daily fixed-dose paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice daily dasabuvir 250 mg and weight-based ribavirin for 24 weeks (genotype 1a) or 12 weeks (genotype 1b) ○ Daily sofosbuvir 400 mg plus simeprevir 150 mg with or without weight-based ribavirin for 24 weeks ● Genotype 2 <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 12 to 16 weeks ○ Alternate (peginterferon alfa eligible): Retreatment with daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ● The following regimens are NOT recommended for patients with HCV genotype 2 who have failed peginterferon alfa and ribavirin <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without telaprevir or boceprevir ○ Fixed-dose combination ledipasvir/sofosbuvir 90/400 mg ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ● Genotype 3 <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ○ Alternate (peginterferon alfa eligible): Retreatment with daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ● The following regimens are NOT recommended for patients with HCV genotype 3 who have failed peginterferon alfa and ribavirin <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 weeks to 48 weeks ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir-, boceprevir-, or simeprevir-based regimens ● Genotype 4 <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Daily paritaprevir/ritonavir/ombitasvir 150/100/25 mg and weight-based ribavirin for 12 weeks ○ Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ○ Daily sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ● The following regimens are NOT recommended for patients with HCV genotype 4 who have failed peginterferon alfa and ribavirin <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without telaprevir or boceprevir ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral <p>Retreatment after failed therapy (sofosbuvir-containing regimen)</p> <ul style="list-style-type: none"> ● Patients with advanced fibrosis <ul style="list-style-type: none"> ○ Patients without an urgent need for HCV treatment should defer antiviral therapy pending additional data or consider treatment within clinical trial settings. ○ Daily ledipasvir/sofosbuvir 90/400 mg with or without weight-based

Clinical Guideline	Recommendation(s)
	<p>ribavirin for 24 weeks</p> <p>Retreatment after failed therapy (peginterferon alfa, ribavirin and an HCV protease inhibitor regimen)</p> <ul style="list-style-type: none"> • Genotype 1 (no cirrhosis) <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg for 12 weeks • Genotype 1 (with cirrhosis) <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg for 24 weeks ○ Daily ledipasvir/sofosbuvir 90/400 mg plus weight-based ribavirin for 12 weeks • The following regimens are NOT recommended for patients with HCV genotype 1 who have failed an HCV protease inhibitor containing regimen <ul style="list-style-type: none"> ○ Any regimen containing peginterferon alfa, including: <ul style="list-style-type: none"> ▪ Simeprevir, ribavirin and peginterferon alfa ▪ Sofosbuvir, ribavirin and peginterferon alfa ▪ Telaprevir or boceprevir, ribavirin and peginterferon alfa ▪ Ribavirin and peginterferon alfa dual therapy ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Any interferon-free regimen containing an HCV protease inhibitor <ul style="list-style-type: none"> ▪ Simeprevir or paritaprevir <p>Retreatment after failed therapy (genotypes 5 and 6)</p> <ul style="list-style-type: none"> • Few data are available to help guide decision making for patients infected with HCV genotype 5 or 6. • Recommendations for genotypes 5 and 6 do not specify which treatments have been failed previously. • Genotype 5 <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon alfa for 12 weeks ○ Alternate: Weekly peginterferon alfa plus weight-based ribavirin for 48 weeks • Genotype 6 <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg for 12 weeks ○ Alternate (peginterferon eligible): Daily sofosbuvir 400 mg and weight-based ribavirin plus weekly peginterferon for 12 weeks • The following regimens are NOT recommended for patients with HCV genotypes 5 or 6 who have failed previous therapy <ul style="list-style-type: none"> ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir- or boceprevir-based regimens <p>Monitoring at onset, during treatment and after completion of HCV therapy</p> <ul style="list-style-type: none"> • Recommended assessments prior to starting antiviral therapy <ul style="list-style-type: none"> ○ Assessment of potential drug-drug interactions ○ Laboratory tests within 12 weeks prior to starting: <ul style="list-style-type: none"> ▪ Complete blood count (CBC); international normalized ratio (INR) ▪ Hepatic function ▪ Thyroid-stimulating hormone (TSH) (if interferon is used) ▪ Calculated glomerular filtration rate (GFR) ○ Laboratory tests any time prior to starting: <ul style="list-style-type: none"> ▪ HCV genotype and subtype ▪ Quantitative HCV viral load, except in the circumstance that a quantitative viral load will influence duration of therapy • Monitoring during antiviral therapy <ul style="list-style-type: none"> ○ Routine monitoring for HCV drug resistance-associated variants during therapy is not recommended ○ Clinic visits or telephone contact are recommended as clinically indicated

Clinical Guideline	Recommendation(s)
	<p>during treatment to ensure medication adherence and to monitor for adverse events and potential drug-drug interactions with newly prescribed medications.</p> <ul style="list-style-type: none"> ○ Laboratory <ul style="list-style-type: none"> ▪ After four weeks of treatment or as clinically indicated: <ul style="list-style-type: none"> • CBC, creatinine level, calculated GFR, hepatic function ▪ Every 12 weeks of treatment (for patients receiving interferon) <ul style="list-style-type: none"> • TSH ○ More frequent assessment for drug-related toxic effects (e.g., CBC for patients receiving RBV) is recommended as clinically indicated. ○ Prompt discontinuation of therapy is recommended for <ul style="list-style-type: none"> ▪ A 10-fold increase in alanine aminotransferase (ALT) activity at week four ▪ Any increase in ALT of less than 10-fold at week 4 that is accompanied by any weakness, nausea, vomiting, or jaundice, or accompanied by increased bilirubin, alkaline phosphatase, or INR. Asymptomatic increases in ALT of less than 10-fold elevated at week four should be closely monitored and repeated at week six and week eight. ○ Quantitative HCV viral load testing is recommended after 4 weeks of therapy and at 12 weeks following completion of therapy. <ul style="list-style-type: none"> ▪ Antiviral therapy should NOT be interrupted or discontinued if HCV RNA levels are not performed or available during treatment. ○ Quantitative HCV viral load testing can be considered at the end of treatment and 24 weeks or longer following the completion of therapy. • Recommendations for <u>discontinuation of treatment due to lack of efficacy</u> <ul style="list-style-type: none"> ○ HCV viral load is detectable at week four, repeat quantitative HCV viral load after two additional weeks of treatment (treatment week six). <ul style="list-style-type: none"> ▪ If quantitative HCV viral load has increased by greater than 10-fold ($>1 \log_{10}$ IU/mL) on repeat testing at week six (or thereafter), discontinue HCV treatment. ○ The significance of a positive HCV RNA test result at week 4 that remains positive, but lower, at week six or week eight is unknown. <ul style="list-style-type: none"> ▪ No recommendation to stop therapy or extend therapy can be provided at this time. • Recommended monitoring in <u>patients who have failed to achieve a sustained virologic response</u>: <ul style="list-style-type: none"> ○ Disease progression assessment every 6 to 12 months with a hepatic function panel, CBC, and INR is recommended. ○ Surveillance for hepatocellular carcinoma with ultrasound testing every 6 months is recommended for patients with advanced fibrosis (i.e., Metavir stage F3 or F4). ○ Endoscopic surveillance for esophageal varices is recommended if cirrhosis is present. ○ Evaluation for retreatment is recommended as effective alternative treatments become available. • Recommended follow-up for <u>patients who achieve a sustained virologic response</u> <ul style="list-style-type: none"> ○ For patients who do not have advanced fibrosis (i.e., those with Metavir stage F0-F2), recommended follow-up is the same as if they were never infected with HCV. ○ Assessment for HCV recurrence or reinfection is recommended only if the patient has ongoing risk for HCV infection or otherwise unexplained hepatic dysfunction develops. In such cases, a quantitative HCV RNA assay rather than an anti-HCV serology test is recommended to test for HCV recurrence or reinfection.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ Surveillance for hepatocellular carcinoma with twice-yearly ultrasound testing is recommended for patients with advanced fibrosis (i.e., Metavir stage F3 or F4) who achieve an SVR. ○ A baseline endoscopy is recommended to screen for varices if cirrhosis is present. Patients in whom varices are found should be treated and followed up as indicated. ○ Assessment of other causes of liver disease is recommended for patients who develop persistently abnormal liver tests after achieving an SVR. ● Prospective monitoring for HCV recurrence among patients who achieved a sustained virologic response and who are receiving immunosuppressive treatments (systemic corticosteroids, antimetabolites, chemotherapy, etc.) is NOT routinely recommended <p><u>Special populations - pregnancy:</u></p> <ul style="list-style-type: none"> ● Monitoring for pregnancy-related issues prior to and during antiviral therapy (treatment includes ribavirin) <ul style="list-style-type: none"> ○ Women of childbearing age should be cautioned not to become pregnant while receiving RBV-containing antiviral regimens, and for up to six months after stopping. ○ Serum pregnancy testing is recommended for women of childbearing age prior to beginning treatment with a regimen that includes ribavirin. ○ Assessment of contraceptive use and of possible pregnancy is recommended at appropriate intervals during (and for six months after) ribavirin treatment for women of childbearing potential, and for female partners of men who receive ribavirin treatment. ● The following regimens are <u>NOT recommended</u> with regard to pregnancy-related issues <ul style="list-style-type: none"> ○ Treatment is NOT recommended for pregnant women or for women who are unwilling to adhere to use of adequate contraception, including those who are receiving ribavirin themselves or are sexual partners of male patients who are receiving ribavirin. ○ Female patients who have received ribavirin and sexual partners of male patients who have received ribavirin should not become pregnant for at least 6 months after stopping ribavirin. <p><u>Special populations – Human Immunodeficiency Virus (HIV)/HCV coinfection</u></p> <ul style="list-style-type: none"> ● HIV/HCV-coinfected persons should be treated and re-treated the same as persons without HIV infection, after recognizing and managing interactions with antiretroviral medications. ● The following regimens are <u>NOT recommended</u> for treatment-naïve or treatment-experienced HIV/HCV-coinfected patients <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without simeprevir, telaprevir or boceprevir for 24 to 48 weeks ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ● When switching antiviral drugs as needed for drug interactions between HIV and HCV antivirals, consult an HIV practitioner. <ul style="list-style-type: none"> ○ For the HIV antiretroviral and HCV direct-acting antiviral combinations not addressed below, expert consultation is recommended. ● For combinations expected to increase tenofovir levels, baseline and ongoing assessment for tenofovir nephrotoxicity is recommended ● <u>Ledipasvir/sofosbuvir</u> <ul style="list-style-type: none"> ○ Ledipasvir increases tenofovir levels, creatinine clearance (CrCl) should be considered. <ul style="list-style-type: none"> ▪ Avoid ledipasvir if CrCl <60 mL/min. ▪ Avoid if tenofovir is boosted by ritonavir (pending further data) unless antiretroviral regimen cannot be changed and the urgency of

Clinical Guideline	Recommendation(s)
	<p style="text-align: center;">treatment is high.</p> <ul style="list-style-type: none"> • Paritaprevir/ritonavir/ombitasvir/dasabuvir <ul style="list-style-type: none"> ○ Use with antiretroviral drugs with no substantial interactions: raltegravir (and probably dolutegravir), enfuvirtide, tenofovir, emtricitabine, lamivudine and atazanavir ○ The dose of ritonavir used for boosting of HIV protease inhibitors may need to be adjusted (or held) when administered with this combination and then restarted when HCV treatment is completed. <ul style="list-style-type: none"> ▪ Administer the HIV protease inhibitor at the same time as the fixed-dose HCV combination. • Simeprevir <ul style="list-style-type: none"> ○ Only use with antiretrovirals with which it does not have clinically significant interactions: raltegravir (and probably dolutegravir), rilpivirine, maraviroc, enfuvirtide, tenofovir, emtricitabine, lamivudine and abacavir • The following are NOT recommended or should not be used: <ul style="list-style-type: none"> ○ Antiretroviral treatment interruption to allow HCV therapy ○ Ledipasvir/sofosbuvir with cobicistat and elvitegravir ○ Sofosbuvir or ledipasvir/sofosbuvir with tipranavir ○ Paritaprevir/ritonavir/ombitasvir/dasabuvir with efavirenz, rilpivirine, darunavir or ritonavir-boosted lopinavir ○ Paritaprevir/ritonavir/ombitasvir/dasabuvir should not be used in HIV/HCV-coinfected patients who are not taking antiretroviral therapy ○ Simeprevir with efavirenz, etravirine, nevirapine, cobicistat or any HIV protease inhibitors ○ Ribavirin with didanosine, stavudine or zidovudine <p>Special populations - decompensated cirrhosis</p> <ul style="list-style-type: none"> • Patients with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh [CTP] class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center). <ul style="list-style-type: none"> ○ The following regimens should only be used by highly experienced HCV practitioners. • Genotype 1 or 4 (patients who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma); <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg and ribavirin (initial dose 600 mg, increased as tolerated) for 12 weeks ○ Alternate (anemia or ribavirin intolerant): Daily ledipasvir/sofosbuvir 90/400 mg for 24 weeks ○ Alternate (prior failure with a sofosbuvir-based regimen): Daily ledipasvir/sofosbuvir 90/400 mg and ribavirin (initial dose 600 mg, increased as tolerated) for 24 weeks • Genotype 2 or 3 (patients who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma) <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg and weight-based ribavirin (with consideration of the patient's CrCl and hemoglobin level) for up to 48 weeks • The following regimens are NOT recommended for patients with decompensated cirrhosis: <ul style="list-style-type: none"> ○ Any interferon-based therapy ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir-, boceprevir-, or simeprevir-based regimens ○ Paritaprevir-, ombitasvir-, or dasabuvir-based regimens <p>Special populations - recurrent HCV infection post-liver transplantation</p> <ul style="list-style-type: none"> • Genotype 1 or 4 infection in the allograft (including compensated cirrhosis), treatment-naïve or treatment-experienced

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg with weight-based ribavirin for 12 weeks ○ Alternative (ribavirin intolerant): ledipasvir/sofosbuvir 90/400 mg for 24 weeks ○ Alternative (genotype 1 only): sofosbuvir 400 mg plus simeprevir 150 mg with or without weight-based ribavirin for 12 weeks ○ Alternative (genotype 1, including early [Metavir fibrosis stage F0-F2] recurrence): Daily paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice-daily dasabuvir 250 mg and weight-based ribavirin for 24 weeks ● Genotype 1 or 4 infection in the allograft, liver transplant recipients (with decompensated cirrhosis), treatment-naïve or treatment-experienced <ul style="list-style-type: none"> ○ Daily ledipasvir/sofosbuvir 90/400 mg with a low initial dose of ribavirin (600 mg, increasing as tolerated) for 12 weeks ● Genotype 2 infection in the allograft (including compensated cirrhosis), treatment-naïve or treatment-experienced <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg plus weight-based ribavirin for 24 weeks ● Genotype 2 infection in the allograft, liver transplant recipients (with decompensated cirrhosis), treatment-naïve or treatment-experienced <ul style="list-style-type: none"> ○ Daily sofosbuvir 400 mg with a low initial dose of ribavirin (600 mg, increased monthly by 200 mg/day as tolerated to a weight-based dose) for 24 weeks ● Genotype 3 infection in the allograft (including compensated cirrhosis), treatment-naïve or treatment-experienced <ul style="list-style-type: none"> ○ Sofosbuvir 400 mg and weight-based ribavirin for 24 weeks ● Genotype 3 infection in the allograft, liver transplant recipients (with decompensated cirrhosis), treatment-naïve or treatment-experienced <ul style="list-style-type: none"> ○ Sofosbuvir 400 mg and low initial dose of ribavirin (600 mg, increasing as tolerated) for 24 weeks ● The following regimens are NOT recommended for treatment-naïve patients with compensated allograft HCV infection <ul style="list-style-type: none"> ○ Regimens containing peginterferon alfa ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir- or boceprevir-based regimens ● The following regimens are NOT recommended for treatment-naïve patients with decompensated allograft HCV infection <ul style="list-style-type: none"> ○ Regimens containing peginterferon alfa ○ Regimens containing simeprevir ○ Daily paritaprevir/ritonavir/ombitasvir 150/100/25 mg plus twice-daily dasabuvir 250 mg and weight-based ribavirin ○ Monotherapy with peginterferon alfa, ribavirin or a direct-acting antiviral ○ Telaprevir- or boceprevir-based regimens <p>Special populations - renal impairment</p> <ul style="list-style-type: none"> ● Mild to moderate renal impairment (CrCl >30 mL/min) <ul style="list-style-type: none"> ○ Sofosbuvir: no dosage adjustment is required ○ Simeprevir: no dosage adjustment is required ○ Ledipasvir/sofosbuvir: no dosage adjustment is required ○ Paritaprevir/ritonavir/ombitasvir and dasabuvir: no dosage adjustment is required ● For CrCL<30 mL/min, treatment can be contemplated after consultation with an expert; no safety and efficacy data are available for these patients <p>Management of acute HCV infection</p> <ul style="list-style-type: none"> ● HCV antibody and HCV RNA testing are recommended when acute HCV infection is suspected due to exposure, clinical presentation, or elevated aminotransferase levels

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Preexposure or postexposure prophylaxis with antiviral therapy is NOT recommended. • Medical management and monitoring <ul style="list-style-type: none"> ○ Regular laboratory monitoring is recommended in the setting of acute HCV infection until the ALT level normalizes and HCV RNA becomes undetectable. ○ Monitoring HCV RNA (every 4 to 8 weeks) for 6 to 12 months is recommended to detect spontaneous clearance of HCV infection. ○ Counseling is recommended for patients with acute HCV infection to avoid hepatotoxic insults including hepatotoxic drugs and alcohol consumption and to reduce the risk of HCV transmission to others. ○ Referral to an addiction medicine specialist is recommended for patients with acute HCV infection related to injectable drug use. • <u>Treatment</u> for patients with acute HCV infection <ul style="list-style-type: none"> ○ If treatment is delayed, monitoring for spontaneous clearance is recommended for a minimum of 6 months. ○ If treatment is to begin during the acute infection period, monitor HCV RNA for at least 12 to 16 weeks to allow for spontaneous clearance before starting treatment. ○ Treatment is NOT recommended if HCV spontaneously clears. ○ Treatment with the same standard regimens are recommended for chronic and acutely-infected patients ○ Alternate (peginterferon eligible): Peginterferon alfa with or without ribavirin for 16 weeks (genotype 2 or 3 with a rapid virologic response) to 24 weeks (genotype 1).
<p>Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health: HCV Infection: Treatment Considerations (2015)⁸</p>	<p><u>Goal of treatment</u></p> <ul style="list-style-type: none"> • The goal of hepatitis C antiviral treatment is to achieve a sustained virological response (SVR), defined as undetectable HCV RNA in the blood 12 or more weeks after completing antiviral treatment. <p><u>Principles for patient selection for HCV treatment</u></p> <ul style="list-style-type: none"> • The urgency of treating HCV should be based on the risk of developing decompensated cirrhosis or dying from liver or liver-related disease, and prolonging graft survival in liver transplant recipients. • Urgent treatment should be considered in patients with advanced cirrhosis, selected patients with hepatocellular carcinoma (HCC) awaiting liver transplant, post-transplant recipients with cirrhosis, and patients with serious extra-hepatic manifestations of HCV. • Patients with mild liver disease (METAVIR F0-2) have less urgency for treatment in the short term, but should be informed of new treatments and their potential to cure HCV. • Treatment is not indicated in patients with limited life expectancy (i.e., multiple comorbidities, non-curative hepatocellular cancer) unless there is reason to anticipate that duration or quality of life can be improved by eradication of HCV. • Factors that may complicate adherence, such as active substance abuse, neurocognitive disorders, and lack of social support, should be addressed before initiating medications. <p><u>Pre-treatment evaluation</u></p> <ul style="list-style-type: none"> • HCV genotype, including subtype • HCV RNA (quantitative viral load) preferably within the past 6 months • Clinical assessment for cirrhosis • If cirrhotic, exclusion of hepatocellular carcinoma based on appropriate imaging study within the prior 6 months

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Previous HCV treatment history and outcome • HIV status and, if HIV seropositive, current antiretroviral regimen and degree of viral suppression • Documented use of two forms of birth control in patient and sex partners in whom a ribavirin-containing regimen is chosen <p><u>Treatment of HCV genotype 1 in treatment-naïve patients without cirrhosis</u></p> <ul style="list-style-type: none"> • Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily for 12 weeks OR 8 weeks if baseline HCV RNA <6 million IU/mL. • Ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg): 2 tablets once daily in the morning with food + dasabuvir (250 mg): 1 tablet twice daily (in the morning and in the evening with food) for 12 weeks; genotype (GT)1a: add ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses), GT1b: ribavirin not required. <p><u>Treatment of HCV genotype 1 in treatment-naïve patients with cirrhosis</u></p> <ul style="list-style-type: none"> • Child-Turcotte-Pugh A <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily with or without ribavirin for 12 weeks. ○ Ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg): 2 tablets once daily in the morning with food + dasabuvir (250 mg): 1 tablet twice daily (in the morning and in the evening with food) + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks; may consider 24 weeks for GT1a. • Child-Turcotte-Pugh B and C <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (600 mg/day with food, and increase by 200 mg/day every 2 weeks only as tolerated if hemoglobin remains above 10 g/dL) for 12 weeks. NOT FDA APPROVED. <p><u>Treatment of HCV genotype 1 in treatment-experienced patients without cirrhosis (prior peginterferon/ribavirin experienced only)</u></p> <ul style="list-style-type: none"> • Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily for 12 weeks. • Ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg): 2 tablets once daily in the morning with food + dasabuvir (250 mg): 1 tablet twice daily (in the morning and in the evening with food) for 12 weeks; GT1a: add ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses), GT1b: ribavirin not required. <p><u>Treatment of HCV genotype 1 in treatment-experienced patients with cirrhosis (prior peginterferon/ribavirin experienced only)</u></p> <ul style="list-style-type: none"> • Child-Turcotte-Pugh A <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily for 24 weeks. ○ Ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg): 2 tablets once daily in the morning with food + dasabuvir (250 mg): 1 tablet twice daily (in the morning and in the evening with food) + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks if GT1a prior relapser or partial responder (may consider 24 weeks, refer to Table 4a for details) or 24 weeks if GT1a null responder; 12 weeks if GT1b. • Child-Turcotte-Pugh (CTP) B and C <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (600 mg/day with food and increase by 200 mg/day every 2 weeks only as

Clinical Guideline	Recommendation(s)
	<p>tolerated if hemoglobin remains above 10 g/dL) for 12 weeks. NOT FDA APPROVED.</p> <p><u>Treatment of HCV genotype 1 in treatment-naïve or experienced patients, with or without cirrhosis (prior DAA experienced)</u></p> <ul style="list-style-type: none"> Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. <p><u>Treatment of HCV genotype 2 in treatment-naïve patients with or without cirrhosis</u></p> <ul style="list-style-type: none"> Sofosbuvir (400 mg/day) in combination with ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. <p><u>Treatment of HCV genotype 2 in treatment-experienced patients with or without cirrhosis</u></p> <ul style="list-style-type: none"> Sofosbuvir (400 mg/day) in combination with ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks or 16 weeks. Sofosbuvir (400 mg/day) in combination with peginterferon alfa-2a 180 mcg subcutaneously weekly or alfa-2b 1.5 mcg/kg subcutaneously weekly plus ribavirin (1,000 mg/day if <75kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. <p><u>Treatment of HCV genotype 3 in treatment-naïve and treatment-experienced patients without cirrhosis</u></p> <ul style="list-style-type: none"> Ledipasvir/sofosbuvir (90/400 mg/day) plus ribavirin (1,000mg/day if <75kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. Sofosbuvir (400 mg/day) plus ribavirin (1,000 mg/day if <75 kg or 1,200 mg if ≥75 kg with food, in divided doses) for 24 weeks. <p><u>Treatment of HCV genotype 3 in treatment-naïve patients with cirrhosis</u></p> <ul style="list-style-type: none"> Ledipasvir/sofosbuvir (90/400 mg/day) plus ribavirin (1,000mg/day if <75kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. <p><u>Treatment of HCV genotype 3 in treatment-experienced patients with cirrhosis</u></p> <ul style="list-style-type: none"> Sofosbuvir (400 mg/day) in combination with peginterferon alfa-2a 180 mcg subcutaneously weekly or alfa-2b 1.5 mcg/kg subcutaneously weekly plus ribavirin (1,000 mg/day if <75kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. <p><u>Treatment of HCV genotype 4 in treatment-naïve and treatment-experienced patients with or without cirrhosis</u></p> <ul style="list-style-type: none"> Sofosbuvir (400 mg/day): 1 tablet daily in combination with ribavirin (1,000 mg/day if <75 kg and 1,200 mg/day if ≥75 kg with food, in divided doses) and peginterferon for 12 weeks. Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily ± ribavirin for 12 weeks. NOT FDA APPROVED. Ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg): 2 tablets once daily in the morning with food + ribavirin (1,000 mg/day if <75kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks; dasabuvir not needed. NOT FDA APPROVED. Note: DO NOT USE if patient virologically failed DAA-based therapy. <p><u>Treatment monitoring considerations</u></p>

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Patients should have an HCV RNA level assessed at week 4 of treatment. • If the HCV RNA is detectable at week 4 or at any time point thereafter, reassess HCV RNA in 2 weeks. If the repeated HCV RNA increases (i.e., >1 log₁₀ IU/mL from nadir), discontinuation of all treatment should be strongly considered. • HCV RNA levels should be assessed at 12 weeks after completion of treatment to determine whether SVR was achieved. <p><u>Use in HIV/HCV-coinfection</u></p> <ul style="list-style-type: none"> • HIV/ HCV-coinfected patients receive the same HCV antiviral regimen as HCV-monoinfected patients, provided the patient is receiving appropriate HIV care and drug-drug interactions are addressed appropriately. <p><u>Treatment in pre-liver transplant</u></p> <ul style="list-style-type: none"> • Genotype 1, including patients with CTP A, B, or C and suitable patients with HCC <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses including patients with CTP A; in CPT B and C patients, ribavirin 600 mg/day and increase by 200 mg/day every 2 weeks only as tolerated if hemoglobin remains above 10 g/dL) for 12 weeks. NOT FDA APPROVED. • Genotype 2, including patients including suitable patients with HCC <ul style="list-style-type: none"> ○ Sofosbuvir (400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg if ≥75 kg with food, in divided doses) for 24 to 48 weeks or until the time of transplantation, whichever occurs first. • Genotype 3 or 4 <ul style="list-style-type: none"> ○ Consult with a transplant center prior to starting treatment. In general, the preferred treatment is the same treatment as is recommended for treatment-naïve or treatment-experienced (as appropriate) patients. <p><u>Treatment in post-liver transplant</u></p> <ul style="list-style-type: none"> • Genotype 1 <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. ○ If ribavirin intolerant: Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily for 24 weeks. NOT FDA APPROVED. • Genotype 2 <ul style="list-style-type: none"> ○ Sofosbuvir (400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 24 weeks. NOT FDA APPROVED. • Genotype 3 <ul style="list-style-type: none"> ○ The decision to treat, regimen selection, and management of treatment should be coordinated with the transplant center and/or by specialists with extensive experience in the treatment of pre- or post-transplant patients. • Genotype 4 <ul style="list-style-type: none"> ○ Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily + ribavirin (1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg with food, in divided doses) for 12 weeks. NOT FDA APPROVED. ○ If ribavirin intolerant: Ledipasvir/sofosbuvir (90/400 mg/day): 1 tablet daily for 24 weeks. NOT FDA APPROVED.
European Association for the Study of the Liver:	<p><u>Goals and endpoints of HCV therapy</u></p> <ul style="list-style-type: none"> • The goal of therapy is to eradicate HCV infection, to prevent hepatic cirrhosis, decompensation of cirrhosis, hepatocellular carcinoma, and death.

Clinical Guideline	Recommendation(s)
<p>Treatment of Hepatitis (2014)⁹</p>	<ul style="list-style-type: none"> • The endpoint of therapy is SVR, defined by undetectable HCV RNA 12 and 24 weeks after the end of treatment; SVR usually equates to cure of infection in more than 99% of patients. • Both SVR 12 and SVR 24 have been accepted in the US and Europe, given that their concordance is 99%. <p><u>Indications for treatment</u></p> <ul style="list-style-type: none"> • All treatment-naïve and -experienced patients with compensated disease due to HCV should be considered for therapy. • Treatment should be prioritized for patients with significant fibrosis (F3 to F4). • Treatment is justified in patients with moderate fibrosis (F2). • In patients with no or mild disease (F0 to F1), the indication for and timing of therapy can be individualized. • Patients with decompensated cirrhosis who are on the transplant list should be considered for interferon-free, ideally ribavirin-free therapy. <p><u>Treatment considerations for HIV/HCV-coinfection</u></p> <ul style="list-style-type: none"> • Indications for HCV treatment and treatment regimens in HCV/HIV co-infected persons are identical to those in patients with HCV mono-infection. • The use of cobicistat-based regimens, efavirenz, delavirdine, etravirine, nevirapine, ritonavir, and any HIV protease inhibitor, boosted or not by ritonavir, is not recommended in HIV-infected patients receiving simeprevir. • Daclatasvir dose should be adjusted to 30 mg daily in HIV-infected patients receiving atazanavir/ritonavir and to 90 mg daily in those receiving efavirenz. • No drug-drug interaction has been reported between sofosbuvir and antiretroviral drugs. <p><u>Treatment options for HCV genotype 1 infection</u></p> <ul style="list-style-type: none"> • Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. <ul style="list-style-type: none"> ○ The most efficacious and the easiest to use interferon alfa-containing option, without the risk of selecting resistant viruses in case of treatment failure. • Simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks (in treatment-naïve and prior relapsers, including cirrhotics) or 48 weeks (in prior partial and null responders, including cirrhotics). <ul style="list-style-type: none"> ○ Not recommended for HCV genotype 1a with Q80K polymorphism. ○ HCV RNA levels should be monitored on treatment. Treatment should be stopped if HCV RNA level is ≥ 25 IU/mL at week four, 12, or 24. • Daclatasvir plus peginterferon alfa and ribavirin for 24 weeks (HCV genotype 1b only). <ul style="list-style-type: none"> ○ Not recommended for HCV genotype 1a given the preliminary data available, pending results of on-going large-scale studies. ○ Daclatasvir should be given for 12 weeks in combination with peginterferon alfa and ribavirin. Daclatasvir, in combination with peginterferon alfa and ribavirin, should be continued for an additional 12 weeks (24 weeks total) in patients who do not achieve an HCV RNA level < 25 IU/mL at week 4 and undetectable at week 10. Peginterferon alfa and ribavirin should be continued alone between week 12 and 24 (24 weeks total) in patients who achieve an HCV RNA level < 25 IU/mL at week 4 and undetectable at week 10. • Sofosbuvir plus ribavirin for 24 weeks. <ul style="list-style-type: none"> ○ Due to suboptimal SVR rates, reserve for interferon alfa ineligible patients when no other interferon-free option is available. • Sofosbuvir plus simeprevir for 12 weeks. <ul style="list-style-type: none"> ○ The addition of ribavirin should be considered in patients with

Clinical Guideline	Recommendation(s)
	<p>predictors of poor response to anti-HCV therapy, especially prior non-responders and/or patients with cirrhosis.</p> <ul style="list-style-type: none"> • Sofosbuvir plus daclatasvir for 12 weeks (treatment-naïve) or 24 weeks (treatment-experienced, including prior telaprevir or boceprevir failures). <ul style="list-style-type: none"> ○ The addition of ribavirin should be considered in patients with predictors of poor response to anti-HCV therapy, especially prior non-responders and/or patients with cirrhosis. <p><u>Treatment options for HCV genotype 2 infection</u></p> <ul style="list-style-type: none"> • Sofosbuvir plus ribavirin for 12 weeks (or 16 to 20 weeks in cirrhotics, especially treatment-experienced). • Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks is an option for cirrhotic and/or treatment-experienced patients. <p><u>Treatment options for HCV genotype 3 infection</u></p> <ul style="list-style-type: none"> • Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks • Sofosbuvir plus ribavirin for 24 weeks <ul style="list-style-type: none"> ○ Suboptimal in treatment-experienced cirrhotics, who should be proposed an alternative treatment option. • Sofosbuvir plus daclatasvir for 12 weeks (treatment-naïve) or 24 weeks (treatment-experienced, pending data with 12 weeks of therapy). <ul style="list-style-type: none"> ○ The addition of ribavirin should be considered in patients with predictors of poor response to anti-HCV therapy, especially prior non-responders and/or patients with cirrhosis. <p><u>Treatment options for HCV genotype 4 infection</u></p> <ul style="list-style-type: none"> • Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. • Simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks (in treatment-naïve and prior relapsers, including cirrhotics) or 48 weeks (in prior partial and null responders, including cirrhotics). <ul style="list-style-type: none"> ○ HCV RNA levels should be monitored on treatment. Treatment should be stopped if HCV RNA level is ≥ 25 IU/mL at week four, 12, or 24. • Daclatasvir plus peginterferon alfa and ribavirin for 24 weeks. <ul style="list-style-type: none"> ○ Daclatasvir should be given for 12 weeks in combination with peginterferon alfa and ribavirin. Daclatasvir, in combination with peginterferon alfa and ribavirin, should be continued for an additional 12 weeks (24 weeks total) in patients who do not achieve an HCV RNA level < 25 IU/mL at week four and undetectable at week 10. Peginterferon alfa and ribavirin should be continued alone between week 12 and 24 (24 weeks total) in patients who achieve an HCV RNA level < 25 IU/mL at week four and undetectable at week 10. • Sofosbuvir plus ribavirin for 24 weeks. <ul style="list-style-type: none"> ○ Should be reserved for interferon alfa intolerant or -ineligible patients. • Sofosbuvir plus simeprevir for 12 weeks. <ul style="list-style-type: none"> ○ The addition of ribavirin should be considered in patients with predictors of poor response to anti-HCV therapy, especially prior non-responders and/or patients with cirrhosis. • Sofosbuvir plus daclatasvir for 12 weeks (treatment-naïve) or 24 weeks (treatment-experienced). <ul style="list-style-type: none"> ○ The addition of ribavirin should be considered in patients with predictors of poor response to anti-HCV therapy, especially prior non-responders and/or patients with cirrhosis. <p><u>Treatment options for HCV genotype 5 or 6 infection</u></p> <ul style="list-style-type: none"> • Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Sofosbuvir plus ribavirin for 24 weeks. <ul style="list-style-type: none"> ○ Should be reserved for interferon alfa intolerant or ineligible patients. <p><u>Treatment monitoring</u></p> <ul style="list-style-type: none"> • A real-time polymerase chain reaction-based assay with a lower limit of detection of <15 IU/mL should be used to monitor HCV RNA levels during and after therapy. • In patients treated with sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks, HCV RNA should be measured at baseline and at weeks 4, 12, and 12 or 24 weeks after the end of therapy. • In patients treated with simeprevir for 12 weeks plus peginterferon alfa and ribavirin for an additional 24 or 48 weeks, HCV RNA should be measured at baseline, week four, 12, 24 (end of treatment in treatment-naïve and prior relapsers), week 48 (end of treatment in prior partial and null responders), and 12 or 24 weeks after the end of therapy. • In patients treated with daclatasvir for 12 to 24 weeks plus peginterferon alfa and ribavirin for 24 weeks, HCV RNA should be measured at baseline, week four, 10, and 24 (end of treatment), and 12 or 24 weeks after the end of therapy. • In patients treated with sofosbuvir plus simeprevir with or without ribavirin for 12 weeks; sofosbuvir plus daclatasvir with or without ribavirin for 12 or 24 weeks; and sofosbuvir plus ribavirin 12 or 24 weeks, HCV RNA should be measured at baseline, week 2 (assessment of adherence), week four, week 12 or 24 (end of treatment), and 12 or 24 weeks after the end of therapy. <p><u>Stopping (futility) rules</u></p> <ul style="list-style-type: none"> • Treatment with simeprevir plus peginterferon alfa and ribavirin should be stopped if HCV RNA level is ≥ 25 IU/mL at treatment week four, 12 or 24. • No futility rules have been defined for other treatment regimens. <p><u>Virological response-guided triple therapy</u></p> <ul style="list-style-type: none"> • With the triple combination of daclatasvir plus peginterferon alfa and ribavirin, patients who do not achieve an HCV RNA level <25 IU/mL at week 4 and undetectable at week 10 should receive the three drugs for 24 weeks. • Patients who achieve an HCV RNA level <25 IU/mL at week four and undetectable at week 10 should stop daclatasvir at week 12 and continue with peginterferon alfa and ribavirin dual therapy until week 24. • No response-guided therapy is used in other treatment regimens. <p><u>Measures to improve treatment adherence</u></p> <ul style="list-style-type: none"> • HCV treatment should be delivered within a multidisciplinary team setting, with experience in HCV assessment and therapy. • Counseling on the importance of adherence is recommended. • In persons who actively inject drugs, access to harm reduction programs is mandatory. • Patients should be counseled to abstain from alcohol during antiviral therapy; patients with on-going alcohol consumption during treatment should receive additional support during antiviral therapy. • HCV treatment can be considered also for patients actively using drugs if they wish to receive treatment and are able and willing to maintain regular appointments. <p><u>Retreatment of non-sustained virological responders</u></p> <ul style="list-style-type: none"> • Patients who failed on a regimen containing sofosbuvir as the only direct-acting antiviral can be retreated with a combination of sofosbuvir and simeprevir (HCV genotypes 1 or 4 only), or a combination of sofosbuvir and daclatasvir

Clinical Guideline	Recommendation(s)
	<p>(all genotypes).</p> <ul style="list-style-type: none"> • Patients who failed on a regimen containing simeprevir, telaprevir or boceprevir as the only direct-acting antiviral can be retreated with a combination of sofosbuvir and daclatasvir. • Patients who failed on a regimen containing daclatasvir as the only direct-acting antiviral can be retreated with a combination of sofosbuvir and simeprevir (HCV genotypes 1 or 4 only). • Patients who failed on a regimen containing sofosbuvir and simeprevir can be retreated with a combination of sofosbuvir and daclatasvir. • Patients who failed on a regimen containing sofosbuvir and daclatasvir can be retreated with a combination of sofosbuvir and simeprevir (HCV genotypes 1 or 4 only). • Alternatively, patients who failed on any of the new treatment regimens including sofosbuvir, simeprevir and/or daclatasvir can wait until new treatment combinations are available if they do not need urgent therapy. • The utility of HCV resistance testing prior to retreatment in patients who failed on any of the new treatment regimens including sofosbuvir, simeprevir and/or daclatasvir is unknown. <p><u>Treatment of patients with severe liver disease</u></p> <ul style="list-style-type: none"> • Patients with compensated cirrhosis should be treated, in the absence of contraindications, in order to prevent short- to mid-term complications; interferon-free regimens are preferred. • If a 12 to 24 week interferon-based direct-acting antiviral regimen is considered tolerable in patients with compensated cirrhosis and good liver function and without cytopenia, these patients can be treated as recommended above across genotypes. • Patients with cirrhosis should undergo regular surveillance for hepatocellular carcinoma, irrespective of SVR. <p><u>Patients with an indication for liver transplantation</u></p> <ul style="list-style-type: none"> • In patients awaiting liver transplantation, antiviral therapy is indicated, because it prevents graft infection if HCV RNA has been undetectable at least 30 days prior to transplantation. • Patients with conserved liver function (Child Pugh class A) in whom the indication for transplantation is hepatocellular carcinoma should be treated with sofosbuvir plus ribavirin until liver transplantation. • Patients with conserved liver function (Child Pugh class A) in whom the indication for transplantation is hepatocellular carcinoma can also be treated with sofosbuvir, peginterferon alfa and ribavirin for 12 weeks. • In patients with conserved liver function (Child Pugh class A) in whom the indication for transplantation is hepatocellular carcinoma, the addition of another direct acting antiviral drug is likely to improve the prevention of HCV recurrence post-transplant; therefore, patients awaiting liver transplantation with genotype 1 to 4 infection can be treated with sofosbuvir, daclatasvir and ribavirin for 12 weeks prior to transplantation. • Patients with decompensated cirrhosis awaiting liver transplantation (Child Pugh class B and C) can be treated with sofosbuvir plus ribavirin until liver transplantation in experienced centers under close monitoring. Interferon alfa is contraindicated in these patients. • The addition of another direct-acting antiviral drug is likely to improve the prevention of HCV recurrence post-transplant; therefore, patients with decompensated cirrhosis awaiting liver transplantation (Child Pugh class B and C) with genotype 1 to 4 infection should be treated with sofosbuvir, daclatasvir and ribavirin until liver transplantation in experienced centers under close

Clinical Guideline	Recommendation(s)
	<p>monitoring.</p> <ul style="list-style-type: none"> • Patients with decompensated cirrhosis not on transplant waiting list should only be offered an interferon-free regimen within a clinical trial, an expanded access program or within experienced centers, because the efficacy, safety and outcomes have not yet been established for this group. <p><u>Post-liver transplantation recurrence</u></p> <ul style="list-style-type: none"> • Patients with post-transplant recurrence of HCV infection should be considered for therapy. • Patients with HCV genotype 2 infection must sofosbuvir plus ribavirin for 12 to 24 weeks, pending more data in this population. • Patients with HCV genotype 1, 3, 4, 5 or 6 infection can be treated with sofosbuvir plus daclatasvir for 12 to 24 weeks, with or without ribavirin, pending more data in this population. • Patients with HCV genotype 1 or 4 infection can be treated with sofosbuvir plus simeprevir for 12 to 24 weeks, with or without ribavirin, pending more data in this population. • No dose adjustment is required for tacrolimus or cyclosporine with any of the above combinations. Careful monitoring is important in the absence of safety data in this population. <p><u>Hepatitis B virus (HBV) co-infection</u></p> <ul style="list-style-type: none"> • Patients should be treated with the same regimens, following the same rules as HCV mono-infected patients. • If HBV replicates at significant levels before, during or after HCV clearance, concurrent HBV nucleoside/nucleotide analogue therapy is indicated. <p><u>Hemodialysis patients</u></p> <ul style="list-style-type: none"> • Hemodialysis patients, particularly those who are suitable candidates for renal transplantation, should be considered for antiviral therapy. • Hemodialysis patients should receive an interferon alfa-free and ribavirin-free regimen. • Due to the lack of safety and efficacy data, the need for dose adjustments for sofosbuvir, simeprevir and daclatasvir is unknown. • Given the lack of data, extreme caution is recommended and sofosbuvir should not be administered to patients with an estimated glomerular filtration rate <30 mL/min/1.73 m² or with end-stage renal disease. <p><u>Non-hepatic solid organ transplant recipients</u></p> <ul style="list-style-type: none"> • HCV treatment before kidney transplantation may avoid liver-related mortality in the post-transplant patient, and may prevent HCV-specific causes of renal graft dysfunction. • Where possible, interferon-free and ribavirin-free antiviral regimen should be given to potential transplant recipients before listing for renal transplantation; however, no safety and efficacy data is available in this population. • Given the lack of data, extreme caution is recommended and sofosbuvir should not be administered to patients with an estimated glomerular filtration rate <30 mL/min/1.73 m² or with end-stage renal disease. • In non-hepatic solid organ transplant recipients, patients with an indication for anti-HCV therapy should receive an interferon-free regimen. • Patients with HCV genotype 2 infection must be treated with sofosbuvir plus ribavirin for 12 to 24 weeks, pending more data in this population. • Patients with HCV genotype 1, 3, 4, 5 or 6 infection can be treated with sofosbuvir plus daclatasvir for 12 to 24 weeks, with or without ribavirin, pending more safety data in this population.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Patients with HCV genotype 1 or 4 infection can be treated with sofosbuvir plus simeprevir for 12 to 24 weeks, with or without ribavirin, pending more data in this population. • No dose adjustment is required for tacrolimus or cyclosporine with any of these combinations. Careful monitoring is important in the absence of safety data in this population. <p><u>Active drug addicts and patients on stable maintenance substitution</u></p> <ul style="list-style-type: none"> • HCV treatment for people who inject drugs (PWIDs) should be considered on an individualized basis and delivered within a multidisciplinary team setting. • Sofosbuvir and simeprevir can be used in PWIDs on opioid substitution therapy. They do not require specific methadone and buprenorphine dose adjustment, but monitoring for signs of opioid toxicity or withdrawal should be undertaken. More data is needed with daclatasvir. • Consideration of interferon-containing or interferon-free therapy in PWIDs should be undertaken on an individualized basis, but those with early liver disease can be advised to await further data and/or potential development of improved therapies. • The regimens that can be used in PWIDs are the same as in non-PWIDs. • Awareness should be raised that liver transplantation is a therapeutic option in those with a history of injection drug use. • Opioid substitution therapy is not a contraindication for liver transplantation and individuals on opioid substitution should not be advised to reduce or stop therapy. <p><u>Treatment of acute hepatitis C</u></p> <ul style="list-style-type: none"> • Peginterferon alfa monotherapy for 24 weeks can be used in patients with acute hepatitis C, who will achieve SVR in as many as 90% of cases. • Peginterferon alfa plus ribavirin for 24 weeks is recommended in patients with acute hepatitis C who are HIV-coinfection. • Although no data is available yet, interferon-free regimens can theoretically be used in patients with acute hepatitis C and are expected to achieve high SVR rates. <ul style="list-style-type: none"> • Note: Daclatasvir is not currently Food and Drug Administration-approved in the United States.
<p>World Health Organization: Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection (2014)⁶</p>	<p><u>Recommendations for treatment of HCV infection</u></p> <ul style="list-style-type: none"> • All adults and children with chronic HCV infection, including people who inject drugs, should be assessed for antiviral treatment. • Peginterferon alfa in combination with ribavirin is recommended for the treatment of chronic HCV infection rather than standard non-peginterferon alfa with ribavirin. • Where access to treatment for HCV infection is limited, priority for treatment should be given to patients with advanced liver disease (F3 and F4). • Treatment with the direct-acting antivirals telaprevir or boceprevir, given in combination with peginterferon alfa and ribavirin, is suggested for genotype 1 chronic HCV infection rather than peginterferon alfa and ribavirin alone. • In high-income settings, HCV treatment with peginterferon alfa and ribavirin and with boceprevir or telaprevir plus peginterferon alfa and ribavirin has been evaluated as being cost-effective. • Sofosbuvir, given in combination with ribavirin with or without peginterferon alfa (depending on the HCV genotype), is recommended in genotypes 1, 2, 3, and 4 HCV infection rather than peginterferon alfa and ribavirin alone (or no treatment for persons who cannot tolerate peginterferon alfa); recommendation made without taking resource use into consideration.

Clinical Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Simeprevir, given in combination with peginterferon alfa and ribavirin, is recommended for persons with genotype 1b HCV infection and for persons with genotype 1a HCV infection without the Q80K polymorphism rather than peginterferon alfa and ribavirin alone; recommendation made without taking resource use into consideration. • Absolute contraindications to peginterferon alfa: <ul style="list-style-type: none"> ○ Uncontrolled depression, psychosis, or epilepsy. ○ Uncontrolled autoimmune disease. ○ Decompensated cirrhosis (Child–Pugh \geqB7 or B6 in HCV/HIV coinfection). ○ Pregnancy or unwillingness to use contraception. ○ Breastfeeding women. ○ Severe concurrent medical disease including severe infections. ○ Poorly controlled hypertension, cardiac failure, or diabetes. ○ Solid organ transplant (except liver transplant recipients). ○ Chronic obstructive pulmonary disease. ○ Age $<$2 years old. • Relative contraindications to peginterferon alfa: <ul style="list-style-type: none"> ○ Abnormal hematological indices: <ul style="list-style-type: none"> ▪ Hemoglobin $<$13 g/dL in men or $<$12 g/dL in women. ▪ Neutrophil count $<$1.5\times10⁹/L. ▪ Platelet count $<$90\times10⁹/L. ○ Serum creatinine $>$1.5 mg/dL. ○ Hemoglobinopathies (sickle cell disease or thalassemia). ○ Significant coronary artery disease. ○ Untreated thyroid disease. • Treatment for HCV infection is both efficacious and cost-effective in people who inject drugs and is therefore recommended. • Specialist care needs to address the additional needs of special populations of patients, including people who inject drugs, persons coinfecting with (or at risk for infection with) HIV, children and adolescents, and those with cirrhosis. • The decision to initiate treatment for HCV/HIV-coinfection is more complex than in those with HCV monoinfection, as response rates are lower, risk of potential toxicities is higher and treatment is complicated by a high pill burden, overlapping toxicities, and interactions between drugs used for treating HCV and HIV.

VI. Indications

The Food and Drug Administration (FDA)-approved indications for the HCV antivirals are noted in Table 4. While agents within this therapeutic class may have demonstrated positive activity via in vitro trials, the clinical significance of this activity remains unknown until fully demonstrated in well-controlled, peer-reviewed in vivo clinical trials. As such, this review and the recommendations provided are based exclusively upon the results of such clinical trials.

Table 4. FDA-Approved Indications for the HCV Antivirals¹⁻⁵

Indication	Boceprevir	Simeprevir	Sofosbuvir	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
Hepatitis C					
Treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with	✓ *				

Indication	Boceprevir	Simeprevir	Sofosbuvir	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy, including prior null responders, partial responders, and relapsers					
Treatment of chronic hepatitis C genotype 1 infection as a component of a combination antiviral treatment regimen		✓ ^			
Treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen			✓ †		
Treatment of chronic hepatitis C genotype 1 infection in adults				✓	✓

*Boceprevir efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes this or another HCV NS3/4A protease inhibitor.

^Simeprevir efficacy in combination with peginterferon alfa and ribavirin is substantially reduced in patients infected with HCV genotype 1a with an NS3 Q80K polymorphism at baseline compared to patients infected with hepatitis C virus (HCV) genotype 1a without the Q80K polymorphism. Screening patients with HCV genotype 1a infection for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended. Alternative therapy should be considered for patients infected with HCV genotype 1a containing the Q80K polymorphism.

†Sofosbuvir efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.

VII. Pharmacokinetics

The pharmacokinetic parameters of the HCV antivirals are listed in Table 5.

Table 5. Pharmacokinetic Parameters of the HCV Antivirals¹²

Generic Name(s)	Bioavailability (%)	Protein Binding (%)	Metabolism (%)	Excretion (%)	Half-Life (hours)
Single Entity Agents					
Boceprevir	Not reported	75	Liver	Renal (9) Feces (79)	3.4
Simeprevir	Not reported	>99	Liver	Renal (<1) Feces (91)	41
Sofosbuvir	Not reported	61 to 65	Liver	Renal (78) Feces (14)	0.5
Combination Products					
Ledipasvir and sofosbuvir	Not reported	L: >99 S: 61 to 65	L: Unknown S: Liver	L: Feces (86) S: Renal (78) Feces (14)	L: 47 S: 0.5
Ombitasvir, paritaprevir, and ritonavir; dasabuvir	OPR: Not reported D: 70	O: >99 P: 97 to 99 R: >99 D: >99	O: Amide hydrolysis P: Liver R: Liver D: Liver	O: Renal (2) Feces (90); P: Renal (9) Feces (88); R: Renal (11) Feces (86); D: Renal (2) Feces (94)	O: 21 to 25 P: 5.5 R: 4 D: 5.5 to 6

L=ledipasvir, S=sofosbuvir, O=ombitasvir, P=paritaprevir, R=ritonavir, D=dasabuvir.

VIII. Drug Interactions

Significant drug interactions with the HCV antivirals are listed in Tables 6 through 8. Due to lack of availability for all agents, significance levels for drug interactions are not included.

Table 6. Drug Interactions – Protease Inhibitors (Not All Inclusive)^{1,2,12,13}

Generic Name	Interaction	Potential Result
Hepatitis C protease inhibitors (all)	Barbiturates	Hepatitis C protease inhibitor plasma concentrations may be reduced, leading to loss of virologic response.
Hepatitis C protease inhibitors (all)	HMG-CoA Reductase Inhibitors	HMG-CoA Reductase Inhibitors plasma concentrations may be elevated, increasing the pharmacologic effects and risk of myopathy and rhabdomyolysis. Coadministration of boceprevir or telaprevir with either lovastatin or simvastatin is contraindicated. Coadministration of atorvastatin with telaprevir is contraindicated. Atorvastatin dose should not exceed 40 mg daily when coadministered with either boceprevir or simeprevir. Rosuvastatin dose should not exceed 10 mg daily when coadministered with simeprevir.
Hepatitis C protease inhibitors (all)	Human Immunodeficiency Virus Protease Inhibitors	Hepatitis C protease inhibitor plasma concentrations may be altered by certain Human Immunodeficiency Virus Protease Inhibitors. Co-administration of simeprevir with any Human Immunodeficiency Virus Protease Inhibitor, with or without ritonavir, is not recommended. Co-administration of boceprevir or telaprevir with either darunavir/ritonavir or lopinavir/ritonavir is not recommended. Co-administration of boceprevir with atazanavir/ritonavir is not recommended. Co-administration of telaprevir with fosamprenavir/ritonavir is not recommended.
Hepatitis C protease inhibitors (all)	Hydantoins	Hepatitis C protease inhibitor plasma concentrations may be reduced, leading to loss of virologic response. Hydantoin concentrations may be elevated or reduced.
Hepatitis C protease inhibitors (all)	Non-Nucleoside Reverse Transcriptase Inhibitors	Hepatitis C protease inhibitor plasma concentrations may be altered by certain Non-Nucleoside Reverse Transcriptase Inhibitors. Co-administration of boceprevir or simeprevir with efavirenz is not recommended. Telaprevir dosage should be increased to 1,125 mg every eight hours when co-administered with efavirenz. Co-administration of any Hepatitis C protease inhibitor with nevirapine is not recommended. Co-administration of simeprevir with delavirdine or etravirine is not recommended.
Hepatitis C protease inhibitors (all)	Rifamycins	Hepatitis C protease inhibitor plasma concentrations may be reduced, leading to loss of virologic response. Rifamycin concentrations may be elevated by boceprevir or telaprevir, increasing the risk of adverse reactions.
Hepatitis C protease inhibitors (all)	Carbamazepine	Hepatitis C protease inhibitor plasma concentrations may be reduced, leading to loss of virologic response.
Hepatitis C protease inhibitors (all)	Cisapride	Cisapride plasma concentrations may be elevated, increasing the pharmacologic effects and risk of cardiac arrhythmias.
Hepatitis C protease inhibitors (all)	St. John's Wort	Hepatitis C protease inhibitor plasma concentrations may be reduced, leading to loss of virologic response
Boceprevir	α -1 adrenergic blockers	α -1 adrenergic blocker plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions.
Boceprevir	Benzodiazepines	Plasma concentrations of certain benzodiazepines may be elevated, increasing the pharmacologic effects and risk of severe sedation and prolonged respiratory depression.

Generic Name	Interaction	Potential Result
Boceprevir	Contraceptives, hormonal	Plasma concentrations of certain progestins may be elevated, increasing the risk of hyperkalemia. Estrogen concentrations may be reduced, increasing the risk of unintended pregnancy.
Boceprevir	Cyclosporine	Cyclosporine plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions.
Boceprevir	Ergot derivatives	Ergot derivative plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions.
Boceprevir	Phosphodiesterase Type 5 Inhibitors	Phosphodiesterase type 5 inhibitor plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions. Coadministration with a phosphodiesterase type 5 inhibitor for pulmonary hypertension is contraindicated. Coadminister phosphodiesterase type 5 inhibitors for erectile dysfunction with caution.
Boceprevir	Lomitapide	Lomitapide plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions, including hepatotoxicity
Boceprevir	Pimozide	Pimozide plasma concentrations may be elevated, increasing the pharmacologic effects and risk of life-threatening cardiac arrhythmias.
Boceprevir	Tacrolimus	Tacrolimus plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions, including QT prolongation.
Simeprevir	Antifungals	Simeprevir plasma concentrations may be increased by certain antifungals. Co-administration with systemic itraconazole, fluconazole, ketoconazole, posaconazole, and voriconazole is not recommended.
Simeprevir	Clarithromycin, erythromycin, telithromycin	Simeprevir plasma concentrations may be increased. Erythromycin plasma concentration may also be increased. Co-administration with clarithromycin, erythromycin or telithromycin is not recommended.
Simeprevir	Dexamethasone	Simeprevir plasma concentrations may be reduced by systemic dexamethasone. Co-administration with systemic dexamethasone is not recommended.
Simeprevir	Elvitegravir/cobicistat/emtricitabine/tenofovir	Simeprevir plasma concentrations may be increased by cobicistat-containing product elvitegravir/cobicistat/emtricitabine/tenofovir. Co-administration with cobicistat-containing product is not recommended.
Simeprevir	Oxcarbazepine	Simeprevir plasma concentrations may be reduced, leading to loss of virologic response.

Table 7. Drug Interactions – Ledipasvir and Sofosbuvir (Not All Inclusive)^{3,4,12,13}

Generic Name	Interaction	Potential Result
Ledipasvir	Antacids: aluminum and magnesium hydroxide	Coadministration may result in decreased plasma concentrations of ledipasvir. It is recommended to separate antacid and ledipasvir/sofosbuvir administration by four hours.
Ledipasvir	H ₂ -receptor antagonists: famotidine	H ₂ -receptor antagonists may be administered simultaneously with or 12 hours apart from ledipasvir/sofosbuvir at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.
Ledipasvir	Proton-pump inhibitors: omeprazole	Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be administered simultaneously with ledipasvir/sofosbuvir under fasted conditions.
Ledipasvir	Antiarrhythmics: digoxin	Coadministration with digoxin may increase the concentration of digoxin. Monitor therapeutic concentration of digoxin during

Generic Name	Interaction	Potential Result
		coadministration.
Ledipasvir, Sofosbuvir	Amiodarone	Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with sofosbuvir in combination with an investigational NS5A inhibitor or simeprevir.
Ledipasvir, Sofosbuvir	Carbamazepine, oxcarbazepine, phenobarbital, phenytoin	Coadministration may result in decreased plasma concentrations of sofosbuvir and/or ledipasvir leading to loss of therapeutic effect of sofosbuvir. Coadministration is not recommended.
Ledipasvir, Sofosbuvir	Rifampin, rifabutin, rifapentine	Coadministration may result in decreased plasma concentrations of sofosbuvir leading to reduced therapeutic effect of sofosbuvir. Coadministration is not recommended.
Ledipasvir, Sofosbuvir	St. John's wort (<i>Hypericum perforatum</i>)	Coadministration may result in decreased plasma concentrations of sofosbuvir leading to reduced therapeutic effect of sofosbuvir. Coadministration is not recommended.
Ledipasvir, Sofosbuvir	Tipranavir/ritonavir	Coadministration may result in decreased plasma concentrations of sofosbuvir and/or ledipasvir leading to reduced therapeutic effect of sofosbuvir. Coadministration is not recommended.

Table 8. Drug Interactions - Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (Not All Inclusive)^{5,12,13}

Generic Name	Interaction	Potential Result
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Alfuzosin	Increased alfuzosin concentration, increased risk for hypotension; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Anticonvulsants (carbamazepine, phenytoin, phenobarbital)	Decreased ombitasvir/paritaprevir/ritonavir/dasabuvir concentration; loss of therapeutic effect; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Gemfibrozil	Increased concentration of dasabuvir (10x); increased risk of QT prolongation; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Rifampin	Decreased ombitasvir/paritaprevir/ritonavir/dasabuvir concentration; loss of therapeutic effect; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Ergot derivatives (ergotamine, dihydroergotamine, ergonovine, methylergonovine)	Increased ergot derivative concentrations; acute ergot toxicity characterized by vasospasm and tissue ischemia; contraindicated.
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	St. John's Wort	Decreased ombitasvir/paritaprevir/ritonavir/dasabuvir concentration; loss of therapeutic effect; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Statins (lovastatin, simvastatin)	Increased concentrations of lovastatin and simvastatin; potential for myopathy; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Efavirenz	Coadministration was poorly tolerated and resulted in liver enzyme elevations.
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Sildenafil	Increased concentrations of sildenafil; potential for visual disturbances, hypotension, priapism and syncope; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Sedatives/hypnotics (triazolam midazolam [oral])	Coadministration may cause large increases in benzodiazepine concentration. The potential exists for serious and/or life threatening events such as sedation or respiratory depression; contraindicated
Ombitasvir/paritaprevir/ ritonavir/dasabuvir	Antiarrhythmics (amiodarone, bepridil, disopyramide, flecainide, lidocaine, mexiletine,	Decreased concentration of antiarrhythmics; caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered.

Generic Name	Interaction	Potential Result
	propafenone, quinidine)	
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Ketoconazole	Increased ketoconazole concentration; limit max daily dose of ketoconazole to 200 mg per day
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Voriconazole	Decreased voriconazole concentration; coadministration not recommended (benefit-to-risk justifies use)
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Amlodipine	Increased concentration of amlodipine; dose adjust
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Fluticasone	Increased fluticasone concentration; may alter cortisol levels; use an alternate corticosteroid
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Furosemide	Furosemide concentration increased, dose adjust
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Atazanavir/ritonavir, lopinavir/ritonavir	Increased concentrations of paritaprevir; only coadminister atazanavir without ritonavir and limit to 300 mg in the morning; do not coadminister lopinavir/ritonavir
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Darunavir/ritonavir	Decreased concentration of darunavir; coadministration is not recommended
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Rilpivirine	Increased concentration of rilpivirine; increased risk of QT interval prolongation
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Statins (rosuvastatin, pravastatin)	Increased concentrations of the statins; limit dose to 10 mg (rosuvastatin) and 40 mg (pravastatin)
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Cyclosporine	Increased concentration of cyclosporin; when coadministered, reduce cyclosporine dose to 1/5th of the current dose. Measure cyclosporine blood concentrations to determine subsequent dose modifications. Frequent assessment of renal function and cyclosporine-related side effects is recommended.
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Tacrolimus	Increased concentration of tacrolimus; when coadministered, reduce tacrolimus dose. Measure tacrolimus blood concentrations to determine subsequent dose modifications. Frequent assessment of renal function and tacrolimus-related side effects is recommended.
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Salmeterol	Increased concentration of salmeterol; increased risk of cardiovascular event; coadministration not recommended
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Buprenorphine (±naloxone)	Increased concentration of buprenorphine; no dose adjustment required; monitor for adverse effects
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Omeprazole	Decreased concentration of omeprazole; limit dose to 40 mg or less
Ombitasvir/paritaprevir/ritonavir/dasabuvir	Alprazolam	increased concentration of alprazolam; monitor for side effects; dose adjust based on clinical response

IX. Adverse Drug Events

The most common adverse drug events reported with the HCV antivirals are listed in Table 9.

Table 9. Adverse Drug Events (%) Reported with the HCV Antivirals^{1-5,13}

Adverse Events	Boceprevir	Simeprevir	Sofosbuvir	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
Central Nervous System					
Asthenia	15 to 21	-	-	-	4 to 14
Chills	33 to 34	-	2 to 17	-	-

Adverse Events	Boceprevir	Simeprevir	Sofosbuvir	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
Dizziness	16 to 19	-	-	-	-
Fatigue	55 to 58	-	30 to 59	13 to 18	34 to 50
Headache	>10	-	24 to 36	11 to 17	16 to 44
Insomnia	30 to 34	-	-	3 to 6	5 to 26
Irritability	21 to 22	-	10 to 13	-	10
Dermatologic					
Alopecia	22 to 27	-	-	-	-
Angioedema	✓	-	-	-	-
Dry skin	18 to 22	-	-	-	-
Photosensitivity	-	5	-	-	-
Pruritus	-	22	11 to 27	-	7 to 18
Rash	16 to 17	28	8 to 18	-	7 to 24
Urticaria	✓	-	-	-	-
Gastrointestinal					
Abnormal taste	35 to 44	-	-	-	-
Anal pruritus	-	-	-	-	-
Anorectal discomfort	-	-	-	-	-
Appetite decreased	25 to 26	-	18	-	-
Diarrhea	24 to 25	-	9 to 12	3 to 7	-
Hemorrhoids	-	-	-	-	-
Increased serum lipase	-	-	≤2	≤3	-
Mouth ulceration	✓	-	-	-	-
Nausea	43 to 46	22	22 to 34	6 to 9	8 to 22
Stomatitis	✓	-	-	-	-
Vomiting	15 to 20	-	-	-	-
Xerostomia	11 to 15	-	-	-	-
Hematologic					
Anemia	45 to 50	-	6 to 21	-	-
Decreased hemoglobin	-	-	2 to 23	-	<1 to 29
Lymphopenia	-	-	-	-	-
Neutropenia	14 to 31	-	1 to 17	-	-
Thrombocytopenia	1 to 10	-	≤1	-	-
Musculoskeletal					
Arthralgia	19 to 23	-	-	-	-
Muscle spasm	-	-	-	-	21
Myalgia	-	16	6 to 14	-	-
Weakness	15 to 21	-	5 to 21	-	4 to 14
Other					
Cough	-	-	-	-	11 to 32
Dyspnea	8 to 11	12	-	-	✓
Fever	-	-	4 to 18	-	-
Flu-like symptoms	-	-	6 to 16	-	-
Hyperbilirubinemia	-	<50	3	≤3	2 to 15
Hyperuricemia	-	-	-	-	-
Increased alanine aminotransferase	-	-	-	-	1
Increased creatine phosphokinase	-	-	1 to 2	✓	-
Increased serum alkaline phosphatase	-	<4	-	-	-
Scleral Icterus	-	-	-	-	10

Adverse Events	Boceprevir	Simeprevir	Sofosbuvir	Ledipasvir and sofosbuvir	Ombitasvir, paritaprevir, and ritonavir; dasabuvir
Thromboembolic events	<1	-	-	-	-

✓ Percent not specified

- Event not reported

X. Dosing and Administration

The usual dosing regimens for the HCV antivirals are listed in Table 10.

Table 10. Usual Dosing Regimens for the HCV Antivirals¹⁻⁵

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
Single Entity Agents			
Boceprevir	<p><u>Treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy, including prior null responders, partial responders, and relapsers:</u></p> <p>Capsule: 800 mg administered orally three times daily (every 7 to 9 hours) with food (a meal or light snack) in combination with peginterferon alfa and ribavirin; initiate therapy with peginterferon alfa and ribavirin for four weeks, then add boceprevir to peginterferon alfa and ribavirin regimen; the duration of treatment is based on viral response, prior response status, and presence of cirrhosis (ranging from a total treatment time of 28 to 48 weeks)</p>	Safety and efficacy in children have not been established	Capsule: 200 mg
Simeprevir	<p><u>Treatment of chronic hepatitis C genotype 1 infection as a component of a combination antiviral treatment regimen:</u></p> <p>Capsule: 150 mg once daily with food in combination with both peginterferon alfa and ribavirin; the recommended treatment duration with peginterferon alfa and ribavirin is 12 weeks, followed by either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on prior response status</p> <p>Capsule: 150 mg once daily with food in combination with sofosbuvir; the recommended treatment duration is either 12 or 24 weeks of simeprevir with sofosbuvir depending on presence of cirrhosis</p>	Safety and efficacy in children have not been established	Capsule: 150 mg
Sofosbuvir	<p><u>Treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen:</u></p>	Safety and efficacy in children have not been established	Tablet: 400 mg

Generic Name(s)	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>Tablet: 400 mg once daily taken with or without food in combination with ribavirin or in combination with pegylated interferon and ribavirin for 12 or 24 weeks, depending on genotype; patients with genotype 1 infection who are interferon ineligible can consider sofosbuvir and ribavirin for 24 weeks; patients with hepatocellular carcinoma awaiting liver transplantation should use sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation, whichever occurs first</p>		
Combination Products			
<p>Ledipasvir-sofosbuvir</p>	<p><u>Treatment of chronic hepatitis C genotype 1 infection in adults:</u> Tablet: One tablet orally once daily taken with or without food; the duration of treatment is based on prior response status and presence of cirrhosis (ranging from a total treatment time of 8 to 24 weeks)</p>	<p>Safety and efficacy in children have not been established</p>	<p>Tablet: 90-40 mg</p>
<p>Ombitasvir-paritaprevir-ritonavir, dasabuvir</p>	<p><u>Treatment of chronic hepatitis C genotype 1 infection in adults:</u> Dose pack: Two ombitasvir, paritaprevir, ritonavir tablets once daily (in the morning) and one dasabuvir tablet twice daily (morning and evening) with a meal; the duration of treatment and use with or without ribavirin is based on viral subtype, prior response status, and presence of cirrhosis (ranging from a total treatment time of 12 to 24 weeks)</p>	<p>Safety and efficacy in children have not been established</p>	<p>Dose pack: 12.5-75-50 mg tablet and 250 mg tablet</p>

XI. Effectiveness

Clinical studies evaluating the safety and efficacy of the HCV antivirals are summarized in Table 11.

Table 11. Comparative Clinical Trials with the HCV Antivirals

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
Treatment of Chronic Hepatitis C: Treatment-Naïve Patients				
<p>Kwo et al.¹⁴ (2010) SPRINT-1</p> <p>Peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 800 to 1,400 mg/day for 48 weeks (PR48)</p> <p>vs</p> <p>peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 800 to 1,400 mg/day for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg 3 times a day for 24 weeks (PRB24)</p> <p>vs</p> <p>peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 800 to 1,400 mg/day for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg 3 times a day for 44 weeks (PRB44)</p> <p>vs</p>	<p>MC, OL, RCT</p> <p>Patients 18 to 60 years of age with hepatitis C genotype 1 who were treatment-naïve</p>	<p>N=595</p> <p>72 weeks</p>	<p>Primary: SVR and viral breakthrough</p> <p>Secondary: Not reported</p>	<p>Primary: All four boceprevir groups had significantly better SVR than the PR48 control group.</p> <p>In the 28-week treatment groups, the SVR was 56% in the PR4/PRB24 group (P=0.005 vs control) and 54% in the PRB28 group (P=0.013 vs control). In the 48-week treatment groups, the SVR was 75% in the PR4/PRB44 group (P<0.0001 vs control) compared to 67% in the PRB48 group (P<0.0001 vs control).</p> <p>There were significantly lower relapse rates in the 48-week treatment groups compared to PR48 control (PRB48, P=0.0079; PR4/PRB44, P=0.0002).</p> <p>Low-dose ribavirin was associated with a high rate of viral breakthrough (27%), and a rate of relapse (22%) similar to control (24%).</p> <p>The rate of breakthrough in the boceprevir lead-in groups was 4% compared to 9% in the boceprevir groups with no lead in (P=0.057).</p> <p>In the 28-week treatment groups, 82% of patients in the PR4/PRB24 group and 74% in the PRB28 group who had rapid virological response achieved SVR. In the 48-week treatment groups, 94% of patients assigned to PR4/PRB44 and 84% assigned to PRB48 who achieved undetectable hepatitis C virus RNA by week four of boceprevir achieved SVR.</p> <p>The most common side effects in the boceprevir group were fatigue, anemia, nausea and headache, which was similar to PR48 control. The rate of dysgeusia and anemia was higher in boceprevir groups</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 800 to 1,400 mg/day plus boceprevir 800 mg 3 times a day for 28 weeks (PRB28)</p> <p>vs</p> <p>peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 800 to 1,400 mg/day plus boceprevir 800 mg 3 times a day for 48 weeks (PRB48)</p> <p>vs</p> <p>peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 400 to 1,000 mg/day for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg 3 times a day for 48 weeks (PRB48)</p>				<p>than other groups. Treatment discontinuation was nine to 19% in boceprevir studies compared to 8% in the PR48 control group.</p> <p>Secondary: Not reported</p>
<p>Poordad et al.¹⁵ (2011) SPRINT-2</p> <p>Group 1 (control): Peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 44 weeks</p> <p>vs</p> <p>Group 2 (response-guided therapy): boceprevir 800 mg three times a day plus peginterferon</p>	<p>MC, PC, PG, RCT</p> <p>Patients ≥18 years of age with a history of no previous treatment for HCV infection, weight 40 to 125 kg, chronic infection with HCV genotype 1 and plasma</p>	<p>N=1,097 (N=938 [nonblack], N=159 [black])</p> <p>48 weeks (plus 24 weeks of follow up)</p>	<p>Primary: SVR and safety</p> <p>Secondary: Not reported</p>	<p>Primary: Among nonblack patients, the rate of SVR was 40, 67, and 68% in Groups 1, 2 and 3 (P<0.001 vs Group 1 for both Group 2 and 3). The corresponding numbers in black patients were 23, 42 (P=0.04 vs Group 1), and 53% (P=0.004 vs Group 1). Subgroup analyses revealed that at four weeks, 23 and 38% of nonblack and black patients had a decrease of <1 log₁₀ IU/mL in HCV RNA level from baseline, which was associated with lower rates of SVR and higher rates of boceprevir-resistance-associated variants compared to those achieving a decrease of ≥1 log₁₀ IU/mL from baseline. However, regardless of the degree of reduction achieved at week four, patients receiving boceprevir achieved consistently higher rates of SVR compared to patients who received control overall.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 24 weeks, followed by an additional 20 weeks of peginterferon alfa-2b plus ribavirin in detectable HCV RNA levels at any visit from week 8 to 24</p> <p>vs</p> <p>Group 3 (fixed duration therapy): boceprevir 800 mg three times a day plus peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 44 weeks</p> <p>All patients entered a 4 week lead in period in which peginterferon alfa-2b and ribavirin were administered.</p> <p>The trial consisted of two cohorts enrolling nonblacks and blacks separately.</p> <p>Treatment was considered complete in Group 2 if the HCV RNA level was undetectable from week 8 through week 24 (total duration, 28 weeks).</p> <p>In all 3 treatment groups, treatment was discontinued for all patients with a detectable HCV RNA level at week 24 based on futility rules; these patients then</p>	<p>HCV RNA level ≥10,000 IU/mL</p>			<p>Response rates at the end of therapy (undetectable HCV RNA level at the time that the study therapy was discontinued) were significantly higher with boceprevir-containing regimens compared to the control regimen.</p> <p>Among nonblack patients, viral breakthrough (undetectable HCV RNA level and subsequent occurrence of an HCV RNA level >1,000 IU/mL) occurred in one to two percent of all patients, regardless of treatment regimen. In addition, relapse rates (undetectable HCV RNA level at the end of treatment but a detectable HCV RNA level at some point during the follow up period) were lower with boceprevir compared to control. The numbers of events among black patients were too few to permit comparison between the treatment groups.</p> <p>Adverse events occurred in more than 98% of all patients, with serious adverse events in 9, 11 and 12% of patients in Groups 1, 2 and 3, respectively. There were six deaths during the trial; four deaths in Group 1 and two deaths from boceprevir-containing regimens. Two suicides (one in Group 1 and one in Group 2) were determined to have possibly been related to treatment with peginterferon. Fatigue, headache, and nausea were the most commonly reported adverse events. The incidence of dysgeusia was higher with boceprevir treatment. Anemia was reported in 29 and 49% of patients receiving control and boceprevir, respectively. Overall, 13 and 21% of control- and boceprevir-treated patients required dose reductions because of anemia and erythropoietin was administered in 24 and 43% of patients. Neutropenia and thrombocytopenia also occurred more frequently with boceprevir treatment.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>entered the follow up period.</p> <p>Afdhal et al.¹⁶ (2014) ION 1</p> <p>Ledipasvir 90 mg and sofosbuvir 400 mg once daily for 12 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 24 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 24 weeks and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 24 weeks</p>	<p>MC, OL, R</p> <p>Patients ≥18 years of age with chronic HCV genotype 1 infection who had not previously received treatment for HCV infection</p>	<p>N=865</p> <p>12 to 24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: Not reported</p>	<p>Primary: The SVR12 rates in all four treatment groups were higher than the historical rate of 60% (P<0.001 for all comparisons).</p> <p>The SVR rates were 99% (95% CI, 96 to 100) in the group that received 12 weeks of ledipasvir/sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 weeks of ledipasvir/sofosbuvir with ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of ledipasvir/sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 weeks of ledipasvir/sofosbuvir with ribavirin.</p> <p>Secondary: Not reported</p>
<p>Kowdley et al.¹⁷ (2014)</p>	<p>MC, OL, R</p>	<p>N=647</p>	<p>Primary: SVR12</p>	<p>Primary: The SVR12 rates in all four treatment groups were higher than the</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ION 3</p> <p>Ledipasvir 90 mg and sofosbuvir 400 mg once daily for 8 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 8 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 12 weeks</p>	<p>Patients ≥18 years of age with chronic HCV genotype 1 infection without cirrhosis who had not previously received treatment for HCV infection</p>	<p>8 to 12 weeks</p>	<p>Secondary: Noninferiority of eight weeks of ledipasvir/sofosbuvir to the other treatment regimens</p>	<p>historical rate of 60% (P<0.001 for all comparisons).</p> <p>The SVR12 rate was 94% (95% CI, 90 to 97) with eight weeks of ledipasvir/sofosbuvir, 93% (95% CI, 89 to 96) with eight weeks of ledipasvir/sofosbuvir with ribavirin, and 95% (95% CI, 92 to 98) with 12 weeks of ledipasvir/sofosbuvir.</p> <p>Secondary: Treatment with ledipasvir/sofosbuvir for eight weeks was noninferior to both the 8-week ledipasvir/sofosbuvir + ribavirin treatment arm (treatment difference 0.9%; 95% CI, -3.9 to 5.7%) and the 12-week ledipasvir/sofosbuvir treatment arm (treatment difference -1.4%; 95% CI, -6.4 to 3.6%).</p>
<p>Feld et al.¹⁸ (2014) SAPPHIRE-I</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75</p>	<p>DB, MC, PC, R</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1 infection, no cirrhosis, who had not previously received treatment for HCV infection, and HCV RNA > 10,000 IU/mL</p>	<p>N=631</p> <p>12 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: Normalization of the alanine aminotransferase level, SVR12 by HCV subtype (1a or 1b), virologic failure during treatment, and posttreatment relapse</p>	<p>Primary: The SVR12 rate in group A (96.2%; 95% CI, 94.5 to 97.9) was statistically noninferior and superior to the calculated historical control rate of 78% (95% CI, 75 to 80) in treatment-naïve patients without cirrhosis who received telaprevir and PEG/RBV.</p> <p>Secondary: The SVR12 rate was 95.3% (95% CI, 93.0 to 97.6) among patients with HCV genotype 1a infection and 98.0% (95% CI, 95.8 to 100) among those with HCV genotype 1b infection. These rates were statistically superior to the historical control rates in the respective subgroups (72%; 95% CI, 68 to 75 in patients with HCV genotype 1a infection and 80%; 95% CI, 75 to 84 in those with HCV genotype 1b infection).</p> <p>The rate of normalization of the alanine aminotransferase</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>kg) or 1,200 mg/day (weight \geq75 kg) in two divided doses for 12 weeks (Group A)</p> <p>vs</p> <p>placebo for 12 weeks of double-blind period followed by active regimen as open-label therapy for 12 weeks (Group B)</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>				<p>level was 97.0% in group A as compared with 14.9% in group B (P<0.001).</p> <p>Virologic failure during treatment and relapse after treatment occurred in 0.2% and 1.5%, respectively, of the patients in group A.</p>
<p>Ferenci et al.¹⁹ (2014) PEARL-III and PEARL-IV</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight \geq75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily</p>	<p>DB, MC, R</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1b infection (PEARL-III) or HCV genotype 1a infection (PEARL-IV), no cirrhosis, who had not previously received treatment for HCV infection, and HCV RNA > 10,000 IU/mL</p>	<p>PEARL-III N=419 12 weeks</p> <p>PEARL-IV N=305 12 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: Superiority of the SVR12 rate at each group as compared with the historical rate with telaprevir plus PEG/RBV, noninferiority of the SVR12 rate in the groups that did and did not receive ribavirin, hemoglobin level below the</p>	<p>Primary: In the genotype 1a study, the SVR12 rates were 97.0% (95% CI, 93.7 to 100) in patients who received the regimen with ribavirin and 90.2% (95% CI, 86.2 to 94.3) in patients who received the regimen without ribavirin.</p> <p>In the genotype 1b study, the SVR12 rates were 99.5% (95% CI, 98.6 to 100.0) in patients who received the regimen with ribavirin and 99.0% (95% CI, 97.7 to 100.0) in patients who received the regimen without ribavirin.</p> <p>Secondary: In the genotype 1a study, the SVR rates among patients who received ribavirin and those who did not were both noninferior and superior to the historical rate with telaprevir and PEG/RBV in treatment-naïve adults with HCV genotype 1a infection and no cirrhosis. The regimen without ribavirin did not meet the noninferiority criterion as compared with the regimen with ribavirin, because the lower boundary of the CI for the difference (-6.8%; 95% CI, -12.0 to -1.5) crossed the noninferiority margin of 10.5%. In addition, the upper boundary of the confidence interval did not cross zero, indicating a significant difference between groups.</p> <p>In the genotype 1b study, the SVR rates among patients who received</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p> <p>placebo</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>			<p>lower limit of the normal range at the end of treatment, and the percentage of patients in each group with virologic failure during treatment or relapse after treatment</p>	<p>ribavirin and those who did not were both noninferior and superior to the historical rate with telaprevir and PEG/RBV among previously untreated adults with HCV genotype 1b infection and no cirrhosis. In addition, the SVR rate among patients who did not receive ribavirin was noninferior to the rate among those who received ribavirin (difference, -0.5%; 95% CI, -2.1 to 1.1).</p> <p>Among the patients in the genotype 1a study who had a hemoglobin level within the normal range at baseline, 42.0% of patients who received the antiviral regimen with ribavirin and 3.9% of patients who received the ribavirin-free regimen had a hemoglobin level below the lower limit of the normal range at the end of treatment (P<0.001). Similarly, in the genotype 1b study, 51.2% of patients who received ribavirin had a low hemoglobin level at the end of treatment, as compared with 3.4% of patients who did not receive ribavirin (P<0.001).</p> <p>Among patients with genotype 1a infection, the rate of virologic failure was higher in the ribavirin-free group than in the group receiving ribavirin (7.8 vs 2.0%). Of patients with genotype 1b infection, none had virologic failure in the ribavirin-free group and one had virologic failure (0.48%) in the group receiving ribavirin.</p>
<p>Poordad et al.²⁰ (2014) TURQUOISE-II</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p>	<p>MC, OL, R</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1 infection, treatment-naïve or previously treated with PEG/RBV, documented cirrhosis by means of liver biopsy,</p>	<p>N=380</p> <p>12 to 24 weeks</p>	<p>Primary: SVR12 compared to historical control</p> <p>Secondary: SVR12 with 12- vs 24-week treatment, virologic failure during treatment or relapse after</p>	<p>Primary: The SVR12 rates were 91.8% (97.5% CI, 87.6 to 96.1) in the 12-week group and 95.9% (97.5% CI, 92.6 to 99.3) in the 24-week group. These rates were statistically noninferior and superior to the historical control rate with telaprevir and PEG/RBV among patients with HCV genotype 1 infection and cirrhosis (47%; 95% CI, 41 to 54).</p> <p>Secondary: The difference in the SVR12 rates between the 12- and 24-week treatment groups was not significant (P=0.09).</p> <p>The SVR rates with 12- vs 24-week treatment were 88.6 vs 94.2% in genotype 1a patients; 98.5 vs 100% in genotype 1b patients; 94.2 vs 94.6% in treatment-naïve patients; 96.6 vs 100% in relapsers with</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 24 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 24 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 24 weeks</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>	<p>Child–Pugh class A score <7, no current or past clinical evidence of Child–Pugh class B or C, HCV RNA >10,000 IU/mL, platelets ≥60,000/mm³, serum albumin ≥2.8 g/dL, total bilirubin <3 mg/dL, INR≤2.3, and serum alpha-fetoprotein ≤100 ng/mL</p>		<p>treatment</p>	<p>prior PEG/RBV; 94.4 vs 100% in prior partial responders to PEG/RBV; and 86.7 vs 95.2% in prior null responders to PEG/RBV.</p> <p>Among patients with HCV genotype 1a infection and a prior null response to PEG/RBV, SVR was achieved in 92.9% (95% CI, 85.1 to 100) in the 24-week group as compared to 80.0% (95% CI, 68.9 to 91.1) in the 12-week group.</p> <p>Virologic failure during treatment or relapse after treatment occurred in 6.2% and 2.3% of patients in the 12-week and 24-week groups, respectively. Virologic failure during treatment occurred 0.5% (95% CI, 0 to 1.4) and 1.7% (95% CI, 0 to 3.7) of patients in the 12-week and 24-week groups, respectively.</p> <p>Significantly more patients in the 12-week group than in the 24-week group had a relapse: 5.9% (95% CI, 2.7 to 9.2) vs 0.6% (95% CI, 0 to 1.8).</p>
<p>Jacobson et al.²¹ (2014) QUEST-1</p> <p>Simeprevir 150 mg once daily plus peginterferon alfa-2a plus ribavirin for 12 weeks, followed by peginterferon alfa-2a plus ribavirin (simeprevir group)</p> <p>vs</p>	<p>DB, MC, PC, RCT</p> <p>Patients (aged ≥18 years) with chronic HCV genotype 1 infection and no history of HCV treatment</p>	<p>N=394</p> <p>72 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: SVR24, rapid virological response (RVR), adverse effects</p>	<p>Primary: SVR12 was achieved in a higher percentage of patients in the simeprevir group than in the placebo group (80 vs 50%), and the difference stratified by HCV genotype 1 subtype and IL28B genotype was significant (29.3%; 95% CI, 20.1 to 38.6; P<0.0001).</p> <p>Secondary: RVR was higher in the simeprevir group than in the placebo group (80 vs 12%). In the simeprevir group, 181 (90%) of 202 patients with RVR achieved SVR12.</p> <p>A higher proportion of patients in the simeprevir group had SVR24</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>placebo plus peginterferon alfa-2a plus ribavirin for 12 weeks, followed by peginterferon alfa-2a plus ribavirin (placebo group)</p>				<p>than in the placebo group (83 vs 60%; weighted difference 18.1%; 95% CI, -0.4 to 36.6; P=0.0253).</p> <p>Overall frequencies of adverse events were similar in the two groups during the first 12 weeks of treatment and for the entire treatment. The adverse events resulted in less than 1% of patients permanently discontinuing simeprevir or placebo in the first 12 weeks and during the entire treatment period. In the first 12 weeks, 3% of patients in the simeprevir group discontinued all study drugs compared with 2% in the placebo group.</p>
<p>Manns et al.²² (2014) QUEST-2</p> <p>Simeprevir 150 mg once daily plus peginterferon alfa-2a or 2b plus ribavirin for 12 weeks, followed by peginterferon alfa-2a or 2b plus ribavirin (simeprevir group)</p> <p>vs</p> <p>placebo plus peginterferon alfa-2a or 2b plus ribavirin for 12 weeks, followed by peginterferon alfa-2a or 2b plus ribavirin (placebo group)</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients (aged ≥18 years) with chronic HCV genotype 1 infection and no history of HCV treatment</p>	<p>N=391</p> <p>72 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: Rapid virological response (RVR), activity, safety, and tolerability of simeprevir in the two subpopulations of patients who were given peginterferon alfa 2a or 2b, adverse events</p>	<p>Primary: Significantly more patients achieved SVR12 in the simeprevir group than in the placebo group (209 [81%] of 257 vs 67 [50%] of 134). The adjusted difference weighted by HCV subtype, IL28B genotype, and peginterferon type as stratification factors was 32.2% (95% CI, 23.3 to 41.2; P<0.0001).</p> <p>Secondary: A significantly higher percentage of patients achieved SVR12 in the simeprevir group than in the placebo group, irrespective of the type of peginterferon they were given: 68 (88%) of 77 patients in the simeprevir group randomly assigned to peginterferon alfa-2a achieved SVR12 compared with 28 (62%) of 45 in the placebo group difference 33.9%; 95% CI, 21.0 to 46.8; P<0.0001). Of the patients randomly assigned to peginterferon alfa-2b, 62 (78%) of 80 patients in the simeprevir group versus 18 (42%) of 43 in the placebo group achieved SVR12 (46.1%; 33.9 to 58.3; P<0.0001).</p> <p>Overall, the proportions of patients who had adverse events in the first 12 weeks of treatment were similar in the simeprevir and placebo groups, and the proportions were similar in the two groups for the entire treatment.</p>
<p>Fried et al.²³ (2013) PILLAR</p> <p>Simeprevir at doses of either 75</p>	<p>DB, PC, RCT</p> <p>Adult patients with chronic hepatitis C with</p>	<p>N=386</p> <p>48 weeks (plus 24 weeks of</p>	<p>Primary: proportion of patients with HCV RNA <25</p>	<p>Primary: SVR at week 72 ranged between 70.7 and 84.8% for simeprevir regimens, compared with 64.9% of those treated with Peg-IFN and RBV alone. The differences between simeprevir 150 mg groups and placebo control were statistically significant (P<0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>or 150 mg administered orally once daily for 12 or 24 weeks in combination with pegylated interferon (Peg-IFN) alpha-2a 180 µg/week and ribavirin (RBV) 1,000 to 1,200 mg/day</p> <p>vs</p> <p>Placebo in combination with Peg-IFN alpha-2a 180 µg/week and RBV 1,000 to 1,200 mg/day</p> <p>Participants who were randomized to 12 weeks of simeprevir therapy received an additional 12 weeks of placebo plus Peg-IFN and RBV.</p>	<p>plasma HCV RNA >100,000 IU/mL, infection with HCV genotype 1, never received Peg-IFN, RBV, or other approved or investigational agents for chronic HCV infection</p>	<p>follow up)</p>	<p>IU/mL undetectable at week 72</p> <p>Secondary: SVR12, SVR24, adverse events</p>	<p>Secondary: SVR24 was achieved in 74.7 to 86.1% of those treated with simeprevir regimens, compared to 64.9% of those treated with placebo. All SVR24 comparisons between simeprevir treatment groups and placebo controls were statistically significant (P<0.05 or 0.005), except for simeprevir 75 mg for 24 weeks.</p> <p>The most frequent adverse events (fatigue, influenza-like illness, pruritus, headache, and nausea) were those typically associated with Peg-IFN and RBV therapy and were similar across simeprevir and placebo treatment groups.</p>
<p>Kowdley et al.²⁴ (2013) ATOMIC</p> <p>Cohort A: sofosbuvir 400 mg orally once daily, peginterferon 180 µg subcutaneously once a week, and ribavirin orally as a divided weight-based daily dose (<75 kg received 1000 mg and those ≥75 kg received 1200 mg) for 12 weeks</p> <p>vs</p> <p>Cohort B received the same drugs at the same doses for 24 weeks</p> <p>vs</p>	<p>MC, OL, R</p> <p>Patients with chronic HCV infection (genotypes 1, 4, 5, or 6), aged 18 years or older, and had not previously received treatment for HCV infection</p>	<p>N=316</p> <p>12 to 24 weeks (plus 24 weeks of follow up)</p>	<p>Primary: SVR24</p> <p>Secondary: Safety</p>	<p>Primary: Cohort A: 46 of 52 (89%; 95% CI, 77 to 96%) Cohort B: 97 of 109 (89%; 95% CI, 82 to 94%) Cohort C: 135 of 155 (87%; 95% CI, 81 to 92%) No difference was found in the proportions of patients achieving SVR24 between cohorts A and B (P=0.94) or between cohorts A and C (P=0.78), suggesting no additional benefit of treatment durations longer than 12 weeks.</p> <p>Secondary: Most patients (97 to 99%) had at least one adverse event during the study. The most common adverse events were those consistent with the known safety profile for peginterferon and ribavirin: fatigue, headache, and nausea.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Cohort C received the same regimen as individuals in cohort A followed by an additional 12 weeks of sofosbuvir monotherapy for half the patients, or sofosbuvir plus ribavirin for the other half (with patients randomly allocated to these subcohorts)</p>				
<p>Lawitz et al.²⁵ (2013) NEUTRINO and FISSION</p> <p><u>NEUTRINO:</u> Sofosbuvir 400 mg once daily for 12 weeks, peginterferon alfa-2a 180 µg once weekly for 12 weeks, and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) for 12 weeks</p> <p><u>FISSION:</u> Sofosbuvir 400 mg once daily for 12 weeks and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) for 12 weeks</p> <p>vs</p> <p>peginterferon alfa-2a 180 µg once weekly for 24 weeks and ribavirin 800 mg/day in two divided doses for 24 weeks</p>	<p><u>NEUTRINO:</u> MC, OL, SG</p> <p>Patients ≥18 years of age with confirmed diagnosis of chronic HCV infection (genotypes 1, 4, 5, or 6), serum HCV RNA levels of ≥10,000 IU/mL during screening, and who had never received treatment for HCV infection</p> <p><u>FISSION:</u> AC, MC, OL, R</p> <p>Patients ≥18 years of age with confirmed</p>	<p><u>NEUTRINO:</u> N=327</p> <p>12 weeks</p> <p><u>FISSION:</u> N=499</p> <p>24 weeks</p>	<p><u>NEUTRINO:</u> Primary: SVR12</p> <p>Secondary: Not reported</p> <p><u>FISSION:</u> Primary: SVR12</p> <p>Secondary: Not reported</p>	<p><u>NEUTRINO:</u> Primary: Treatment with sofosbuvir added to peginterferon alfa-2a and ribavirin achieved a SVR12 in 90% of patients (95% CI, 87 to 93). In addition, this regimen was found to be more effective in achieving a SVR12 compared to an adjusted historical response rate of 60% (P<0.001) observed in studies of telaprevir and boceprevir.</p> <p>The rate of SVR12 was 92% (95% CI, 89 to 95) among patients without cirrhosis and 80% (95% CI, 67 to 89) among those with cirrhosis. A SVR12 occurred in 98% of patients with the CC genotype of IL28B, as compared to 87% of patients with the non-CC IL28B genotype.</p> <p>Rates of SVR12 were similar among various HCV genotypes: 89% for patients with genotype 1 (92% for genotype 1a and 82% for genotype 1b) and 96% for those with genotype 4. The single patients with genotype 5 and all six patients with genotype 6 achieved SVR12.</p> <p>Secondary: Not reported</p> <p><u>FISSION:</u> Primary: A SVR12 was achieved in 67% of patients in both sofosbuvir plus ribavirin group and peginterferon alfa-2a plus ribavirin group.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	diagnosis of chronic HCV infection (genotypes 2 or 3), serum HCV RNA levels of $\geq 10,000$ IU/mL during screening, and who had never received treatment for HCV infection			<p>Response rates in patients receiving sofosbuvir plus ribavirin were lower among patients with genotype 3 infection than among those with genotype 2 infection (56 vs 97%).</p> <p>Among patients with cirrhosis at baseline, 47% of patients receiving sofosbuvir plus ribavirin had a SVR12 compared to 38% of those receiving peginterferon alfa-2a plus ribavirin.</p> <p>Secondary: Not reported</p>
<p>Lawitz et al.²⁶ (2013)</p> <p>Cohort A (HCV genotype 1 patients): sofosbuvir 200 mg, sofosbuvir 400 mg, or placebo (randomized 2:2:1) for 12 weeks in combination with peginterferon (180 μg per week) and ribavirin (1000 to 1200 mg daily), followed by peginterferon and ribavirin for an additional 12 weeks or 36 weeks (depending on viral response)</p> <p>Cohort B (genotypes 2 or 3): open-label sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks</p>	<p>DB, RCT</p> <p>Treatment-naïve patients aged 18 to 70 with HCV genotypes 1, 2, and 3 and no cirrhosis</p>	<p>N=122 (Cohort A)</p> <p>N=25 (Cohort B)</p>	<p>Primary: Safety and tolerability</p> <p>Secondary: SVR12, SVR24</p>	<p>Primary: The most common adverse events during sofosbuvir dosing (up to week 12) were fatigue, headache, nausea, chills, pain, and insomnia. Most adverse events were mild or moderate in severity. Eight patients in cohort A discontinued treatment because of an adverse event, six within the first 12 weeks of treatment (three in the placebo group and three in the 400 mg sofosbuvir group).</p> <p>Secondary: In cohort A, compared with the placebo group, SVR12 and SVR24 were more common in the 200 mg sofosbuvir group (differences of 30%; 95% CI, 12 to 49; P=0.001, and 28%, nine to 46; P=0.0017, respectively) and in the 400 mg sofosbuvir group (differences of 32%; 13 to 51; P=0.0005, and 30%, 11 to 49; P=0.0006, respectively).</p> <p>Of the 25 patients in cohort B, most achieved both SVR12 and SVR24 (23 patients (92%) for both SVR12 and 24; 95% CI, 74 to 99).</p>
Treatment of chronic hepatitis C: Treatment-experienced patients				
<p>Bacon et al.²⁷ (2011)</p> <p>RESPOND-2</p>	<p>DB, MC, PC, RCT</p>	<p>N=403</p> <p>48 weeks</p>	<p>Primary: SVR, safety</p>	<p>Primary: Rates of SVR were significantly higher with boceprevir-containing regimens compared to control, with overall rates of SVR of 21, 59,</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Group 1 (control): Peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 44 weeks</p> <p>vs</p> <p>Group 2 (response-guided therapy): boceprevir 800 mg three times a day plus peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 32 weeks, followed by an additional 12 weeks of peginterferon alfa-2b plus ribavirin in detectable HCV RNA levels at week 8 but undetectable at week 12</p> <p>vs</p> <p>Group 3 (fixed duration therapy): boceprevir 800 mg three times a day plus peginterferon alfa-2b 1.5 µg/kg weekly plus ribavirin 600 to 1,400 mg/day for 44 weeks</p> <p>All patients entered a 4 week lead in period in which peginterferon alfa-2b and ribavirin were administered.</p> <p>Treatment was considered complete in Group 2 if the HCV RNA level was undetectable at weeks 8 and 12 (total duration, 36</p>	<p>Previously treated adults with HCV genotype 1 infection with responsiveness to interferon therapy for a minimum of 12 weeks</p>	<p>(plus 24 weeks of follow up)</p>	<p>Secondary: Proportion of patients with an early response in whom a SVR was achieved, proportion of patients with a relapse</p>	<p>and 66% in Groups 1, 2, and 3, respectively (P<0.001). The increase observed with Groups 2 and 3 was largely due to end of treatment rates of response being higher (70 and 77 vs 31%) and relapse rates being lower (15 and 12 vs 32%) compared to Group 1. The absolute difference between Groups 2 and 1 was 34.7 percentage points (95% CI, 25.7 to 49.1), and between Groups 3 and 1 it was 45.2 percentage points (95% CI, 33.7 to 56.8). There was no difference in SVR rates between Groups 2 and 3 (OR, 1.4; 95% CI, 0.9 to 2.2).</p> <p>Overall, the most common adverse events were flulike symptoms, while dysgeusia, rash and dry skin were more commonly reported with boceprevir-containing regimens. A greater proportion of patients receiving boceprevir reported serious adverse events, and there were more discontinuations and dose modifications due to adverse events with boceprevir. Anemia occurred more frequently with boceprevir (43 to 46 vs 20%), and erythropoietin was administered more frequently to patients receiving boceprevir.</p> <p>Secondary: The proportion of patients with an undetectable HCV RNA level at week eight in Groups 2 and 3 (46 and 52%) was approximately six times the proportion in Group 1 (9%). Early response was associated with a high rate of SVR in all three treatment groups (100, 86, and 88% in Groups 1, 2, and 3; P values not reported).</p> <p>The rates of SVR among patients with prior relapse (undetectable HCV RNA level at the end of prior therapy, without subsequent attainment of a SVR) were 29, 69, and 75% in Groups 1, 2, and 3; respectively (P values not reported). And the patients with prior nonresponse (a decrease in the HCV RNA level of ≥2 log₁₀ IU/mL by week 12 of prior therapy but a detectable HCV RNA level throughout the course of prior therapy, without subsequent attainment of a SVR), the corresponding rates were 7, 40, and 52% (P values not reported).</p> <p>Virologic breakthrough (achievement of an undetectable HCV RNA level and subsequent occurrence of an HCV RNA level >1,000</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>weeks).</p> <p>In addition, in all 3 treatment groups, treatment was discontinued for all patients with a detectable HCV RNA level at week 12 based on futility rules; these patients then entered the follow up period.</p>				<p>IU/mL) and incomplete virologic response (an increase of 1 log₁₀ IU/mL in the HCV RNA level from the nadir, with an HCV RNA level >1,000 IU/mL) were infrequent during the treatment period.</p> <p>Multivariable stepwise logistic-regression analysis served to identify five baseline factor that were significantly associated with achievement of a SVR: assignment to boceprevir (OR for Groups 2 and 3 vs Group 1, 7.3 and 10.7, respectively; P<0.001 for both), previous relapse (OR vs previous nonresponse, 3.1; P<0.001), low viral load at baseline (OR vs high load, 2.5; P=0.02) and absence of cirrhosis (OR vs presence, 2.1; P=0.04).</p>
<p>Flamm et al.²⁸ (2013)</p> <p>Peginterferon alfa-2a 180 µg weekly plus ribavirin 1,000 or 1,200 mg/day plus placebo for 48 weeks total</p> <p>vs</p> <p>boceprevir 800 mg three times a day plus peginterferon alfa-2a 180 µg weekly plus ribavirin 1,000 or 1,200 mg/day for 44 weeks (total treatment duration of 48 weeks)</p> <p>All patients entered a 4 week lead in period in which peginterferon alfa-2a and ribavirin were administered.</p> <p>In addition, in all treatment groups, treatment was discontinued for all patients with a detectable HCV RNA level at</p>	<p>PC, PG, RCT</p> <p>Patients with chronic HCV genotype 1 infection who were relapsers or nonresponders to a previous course of peginterferon alfa and ribavirin</p>	<p>N=201</p> <p>48 weeks (plus 24 weeks of follow up)</p>	<p>Primary: SVR</p> <p>Secondary: Proportion of patients whom a SVR was achieved by prior response (relapse and nonresponse), safety</p>	<p>Primary: Rates of SVR were significantly higher with boceprevir-containing regimens compared to placebo, with overall rates of SVR of 21% in the peginterferon/ribavirin only treatment group compared to and SVR rate of 64% with boceprevir (P<0.001).</p> <p>Secondary: The rates of SVR among patients with prior relapse (undetectable HCV RNA level at the end of prior therapy, without subsequent attainment of a SVR) were 28% in the peginterferon/ribavirin only treatment group compared to and SVR rate of 70% with boceprevir (P values not reported).</p> <p>The rates of SVR among patients with prior nonresponse (a decrease in the HCV RNA level of ≥2 log₁₀ IU/mL by week 12 of prior therapy, without subsequent attainment of a SVR), were 5% in the peginterferon/ribavirin only treatment group compared to and SVR rate of 47% with boceprevir (P values not reported).</p> <p>Overall, the most common adverse events were flulike symptoms, while dysgeusia, diarrhea, rash, myalgia, leukopenia and vomiting were more commonly reported with boceprevir-containing regimens.</p> <p>A greater proportion of patients receiving boceprevir reported serious adverse events (13 vs 10%), and there were more discontinuations (17</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>week 12 based on futility rules; these patients then entered the follow up period.</p>				<p>vs 3%) and dose modifications (43 vs 22%) due to adverse events with boceprevir.</p> <p>Anemia occurred more frequently with boceprevir (50 vs 57%). Anemia was managed with dose reduction in 8% of control group and 0% in the boceprevir group. Erythropoietin was administered more frequently to patients receiving boceprevir (28 vs 29%) and a combination of both interventions in 56% of the placebo group and 57% of the boceprevir group). Neutropenia occurred more frequently with boceprevir (31 vs 18%), and granulocyte colony-stimulating factor administered more frequently with boceprevir (14 vs 12%).</p> <p>Secondary: Not reported</p>
<p>Afdhal et al.²⁹ (2014) ION 2</p> <p>Ledipasvir 90 mg and sofosbuvir 400 mg once daily for 12 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 24 weeks</p>	<p>MC, OL, R</p> <p>Patients ≥18 years of age with chronic HCV genotype 1 infection who had not had a SVR with either PEG/ribavirin or NS3/4A protease inhibitor combined with PEG/ribavirin</p>	<p>N=440</p> <p>12 to 24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: SVR24</p>	<p>Primary: In all four treatment groups, the SVR12 rate was higher than the adjusted historical response rate of 25% (P<0.001 for all comparisons).</p> <p>The SVR12 rates was 94% (95% CI, 87 to 97) in the group that received 12 weeks of ledipasvir/sofosbuvir; 96% (95% CI, 91 to 99) in the group that received 12 weeks of ledipasvir/sofosbuvir with ribavirin; 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir/sofosbuvir; and 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir/sofosbuvir with ribavirin.</p> <p>Among patients with cirrhosis who were assigned to 12 weeks of treatment, the SVR12 rates were 86% for those who received ledipasvir/sofosbuvir and 82% for those who received ledipasvir/sofosbuvir with ribavirin; the respective rates among patients without cirrhosis were 95% and 100%.</p> <p>Among patients with cirrhosis who were assigned to 24 weeks of treatment, the SVR12 rates were 100% for those who received ledipasvir/sofosbuvir and 100% for those who received ledipasvir/sofosbuvir with ribavirin; the respective rates among patients without cirrhosis were 99% and 99%.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>ledipasvir 90 mg and sofosbuvir 400 mg once daily for 24 weeks and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 24 weeks</p>				<p>The difference between the SVR rates among patients with cirrhosis who received 12 weeks of treatment and the SVR among patients with cirrhosis who received 24 weeks of treatment was statistically significant (P=0.007).</p> <p>Secondary: All patients who had a SVR12 also had a SVR24. No patient had a relapse after post-treatment week 12.</p>
<p>Bourlière et al.³⁰ (2015) SIRIUS</p> <p>Ledipasvir 90 mg and sofosbuvir 400 mg in a fixed-dose combination tablet plus placebo for 12 weeks, followed by ledipasvir-sofosbuvir once daily plus ribavirin given in a divided daily dose for 12 weeks</p> <p>vs</p> <p>once daily ledipasvir-sofosbuvir 90-400 mg plus placebo for 24 weeks</p>	<p>DB, MC, RCT</p> <p>Patients with HCV genotype 1 and compensated cirrhosis who had not achieved SVR after successive treatments with pegylated interferon and protease-inhibitor regimens</p>	<p>N=155</p> <p>24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: SVR12 rates between the two treatment groups by randomization stratification factors</p>	<p>Primary: SVR12 rates were 96% (95% CI, 89 to 99) in the ledipasvir-sofosbuvir plus ribavirin group and 97% (91 to 100) in the ledipasvir-sofosbuvir group (P=0.63).</p> <p>Secondary: SVR12 rates when compared with previous treatment response were 97% in ledipasvir-sofosbuvir plus ribavirin group and 94% in the ledipasvir-sofosbuvir group in patients who had never achieved undetectable HCV RNA, vs 96% and 100%, respectively, in patients who had previously achieved undetectable HCV RNA.</p>
<p>Zeuzem et al.³¹ (2014) SAPPHIRE-II</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p>	<p>DB, MC, PC, R</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1 infection without cirrhosis,</p>	<p>N=394</p> <p>12 weeks</p>	<p>Primary: SVR12 compared to historical control</p> <p>Secondary: Normalization of the alanine</p>	<p>Primary: Treatment with the active-regimen lead to a SVR12 of 96.3% (95% CI, 94.2 to 98.4) which was noninferior and superior to the historical control SVR rate of 65% (95% CI, 60 to 70) among previously treated patients with HCV genotype 1 infection and no cirrhosis who had received retreatment with telaprevir and PEG/RBV (P value not reported).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p> <p>vs</p> <p>placebo</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>	<p>relapsers or nonresponders with prior PEG/RBV treatment, and HCV RNA >10,000 IU/mL</p>		<p>aminotransferase level, SVR by HCV genotype (1a or 1b), virologic failure during treatment, and post-treatment relapse</p>	<p>The rate of normalization of the alanine aminotransferase level was significantly higher in the active-regimen group than in the placebo group (96.9 vs 12.8%, P<0.001).</p> <p>The SVR rates were similar between patients with HCV genotype 1a infection (96.0%; 95% CI, 93.0 to 98.9) and those with HCV genotype 1b infection (96.7%; 95% CI, 93.6 to 99.9). The HCV genotype (1a or 1b) could not be determined for one patient, who had a SVR12.</p> <p>No patient had virologic failure during treatment. Of the 293 patients who completed therapy, 2.4% had a post-treatment viral relapse.</p>
<p>Andreone et al.³² (2014) PEARL-II</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>and</p> <p>ribavirin 1,000 mg (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) in two divided doses for 12 weeks</p>	<p>MC, OL, R</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1b infection for at least six months, and HCV RNA >10,000 IU/mL, no cirrhosis, and prior failure of therapy with PEG/RBV</p>	<p>N=179</p> <p>12 weeks</p>	<p>Primary: SVR12 compared to historical control</p> <p>Secondary: Proportion of patients with decreased hemoglobin level to less than the lower limit of normal at the end of treatment, superiority of both groups to historical SVR</p>	<p>Primary: The SVR12 rate was 96.6% (95% CI, 92.8 to 100) in the group receiving ribavirin and 100% (95% CI, 95.9 to 100) in the group not being treated with ribavirin. These rates were statistically noninferior to the historical SVR rate for telaprevir and PEG/RBV in comparable treatment-experienced patients.</p> <p>Secondary: Hemoglobin levels less than the lower limit of normal at the end of treatment were more common in patients receiving ribavirin compared to those that did not (42.0 vs 5.5%, respectively; P<0.001), although clinically significant grade 2 hemoglobin level declines to <10 g/dL at the end of treatment occurred in only two patients (1.1%), both in the group receiving ribavirin.</p> <p>The SVR12 rates in the group receiving ribavirin (96.6%) and in the group not being treated with ribavirin (100%) were statistically superior to the historical SVR rate for telaprevir and PEG/RBV in comparable treatment-experienced patients.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 12 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 12 weeks</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>			<p>rate, noninferiority of both treatment groups, virologic failure during treatment, and post-treatment relapse</p>	<p>The SVR12 rates in the group not receiving ribavirin were noninferior to those in the group receiving ribavirin (difference, 3.4%; 95% CI, -0.4 to 7.2)</p> <p>No patients from either treatment group experienced on-treatment virologic failure or post-treatment relapse. Of the three patients in the group receiving ribavirin who did not achieve SVR12, there were two patients (2.3%) who discontinued study drug.</p>
<p>Forns et al.³³ (2014)</p> <p>Simeprevir 150 mg once daily plus peginterferon alfa-2a 180 µg weekly plus ribavirin 1,000 or 1,200 mg/day depending on body weight, respectively (PR) for 12 weeks followed by response-guided treatment with PR alone for 12 or 36 weeks</p> <p>vs</p> <p>placebo with PR for 12 weeks followed by PR alone for 36 weeks</p>	<p>DB, MC, PC, PG, RCT</p> <p>Adults >18 years with confirmed genotype 1 HCV infection and screening plasma HCV-RNA levels >10,000 IU/mL, who had relapsed after 24 weeks or more of interferon-based therapy (undetectable HCV-RNA at end of treatment [EOT] or within 2 months after</p>	<p>N=393</p> <p>24 or 48 weeks (plus 72 weeks of follow up)</p>	<p>Primary: SVR12 rates</p> <p>Secondary: SVR24, rapid virologic response (RVR) rate, viral breakthrough, on-treatment failure, viral relapse, adverse events</p>	<p>Primary:</p> <p>In the simeprevir/PR arm, an SVR12 rate of 79.2% (206 of 260) was observed compared with 36.1% (48 of 133) with placebo/PR. The difference between the two groups (controlling for HCV 1 subtype and IL28B genotype as stratification factors) was statistically significant at 43.8% (95% CI, 34.6 to 53.0; P<0.001).</p> <p>Secondary:</p> <p>The RVR rate was 77.2% (200 of 259) in the simeprevir/PR group compared with 3.1% (four of 129) treated with placebo/PR. Among simeprevir-treated patients who achieved RVR, 86.5% (173 of 200) subsequently achieved SVR12.</p> <p>The rate of on-treatment failure was 3.1% (eight of 260) for simeprevir/PR and 27.1% (36 of 133) for placebo/PR.</p> <p>During the first 12 weeks of treatment, the most frequent adverse events in the simeprevir/PR group (>25% of patients) were headache, fatigue, and influenza-like illness. Rash, pruritus, neutropenia, and anemia were comparable between the simeprevir and placebo groups. No patient discontinued simeprevir or placebo alone owing to adverse events.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	EOT, with documented relapse within 1 year after therapy).			
<p>Zeuzem et al.³⁴ (2014) ASPIRE</p> <p>Group 1: 12 weeks of simeprevir 100 mg plus peginterferon alfa-2a (PegIFN)/ ribavirin (RBV), followed by 36 weeks of PegIFN/RBV</p> <p>group 2: 12 weeks of simeprevir 150 mg plus PegIFN/RBV, followed by 36 weeks of PegIFN/RBV</p> <p>group 3: 24 weeks of simeprevir 100 mg plus PegIFN/RBV, followed by 24 weeks of PegIFN/RBV</p> <p>group 4: 24 weeks of simeprevir 150 mg plus PegIFN/RBV, followed by 24 weeks of PegIFN/RBV</p> <p>group 5: 48 weeks of simeprevir 100 mg plus PegIFN/RBV</p> <p>group 6: 48 weeks of simeprevir 150 mg plus PegIFN/RBV</p> <p>group 7 (placebo control group):</p>	<p>DB, MC, PC, RCT</p> <p>Adults aged 18 to 70 years, chronically infected with HCV genotype 1 and with plasma HCV RNA >10,000 IU/mL at screening were included in the study. All patients must have received at least one prior course of PegIFN/RBV for >12 consecutive weeks and not discontinued therapy due to tolerability</p>	<p>N=462</p> <p>48 weeks (plus 72 weeks of follow up)</p>	<p>Primary: SVR24</p> <p>Secondary: Rapid virologic Response, SVR12, adverse effects</p>	<p>Primary: In the overall population, SVR24 was achieved in 60.6 to 80.0% of simeprevir arms and 22.7% of the placebo arm (P<0.001).</p> <p>When pooling dosage dosages, SVR24 was achieved by 129 of 197 patients (65.5%; range, 60.6 to 69.7%) of the simeprevir 100 mg group and 145 of 199 patients (72.9%; range, 66.7 to 80.0%) of the simeprevir 150 mg group, compared with 15 of 66 patients (22.7%) on placebo (P<0.001 for both comparisons).</p> <p>Pooling treatment duration, SVR24 was achieved by 90 of 132 patients (68.2%; range, 66.7 to 69.7%) on simeprevir for 12 weeks, 92 of 133 (69.2%; range, 66.2 to 72.1%) of those on simeprevir for 24 weeks, and in 92 of 131 (70.2%; range, 0.6 to 80.0%) of those on simeprevir for 48 weeks.</p> <p>Secondary: The proportions of patients achieving SVR12 (60.6 to 80.0% of simeprevir- and 23% of placebo-treated patients) were very similar to the proportions achieving SVR24.</p> <p>The most frequently reported adverse events (>25% of patients) with simeprevir plus PegIFN/RBV were fatigue, headache, pruritus, influenza-like illness, and neutropenia. No major difference was reported with respect to the incidence of serious adverse events, occurring in 7.8% (N=31) and 6.1% (N=4) of patients treated with simeprevir and placebo, respectively.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>48 weeks of simeprevir-matched placebo plus PegIFN/RBV</p> <p>In all simeprevir treatment arms, when patients were not receiving simeprevir, they received a matched placebo</p>				
Treatment of chronic hepatitis C: Treatment-naïve and experienced patients				
<p>Sitole et al.³⁵ (2013)</p> <p>Triple therapy with boceprevir or placebo, pegylated interferon, and ribavirin</p> <p>vs</p> <p>triple therapy with telaprevir or placebo, pegylated interferon, and ribavirin</p>	<p>MA</p> <p>Treatment-naïve and treatment-experienced patients with chronic HCV genotype 1 infection</p>	<p>N=4144 (8 studies)</p> <p>24 to 48 weeks after completion of treatment</p>	<p>Primary: SVR</p> <p>Secondary: Rate of rapid (at four weeks with telaprevir or eight weeks with boceprevir) viral response, adverse events</p>	<p>Primary:</p> <p>In the treatment-naïve patients, SVR at 24 weeks was greater in the telaprevir treated group compared with the control group (OR, 3.31; 95% CI, 2.27 to 4.82; P <0.0001). In the treatment-experienced patients, the SVR rates at 24 weeks were similar between the active and control groups (OR, 4.21; 95% CI, 1.83 to 9.72; P<0.001). In the treatment-naïve patients, SVR at 48 weeks was greater in the telaprevir treated group compared with the control group (OR, 1.98; 95% CI, 1.42 to 2.76; P<0.0001). In the treatment-experienced patients, 48-week SVR rates were similar between the triple-therapy and control groups (OR, 8.46; 95% CI, 5.72 to 12.50; P<0.0001).</p> <p>In treatment-naïve patients, 24-week SVR was improved in the group that received boceprevir compared with controls (OR, 3.55; 95% CI, 2.66 to 4.56; P<0.0001); this finding was also true in the treatment-experienced subgroup. In the treatment-naïve subgroup, 48-week SVR was improved in the group that received boceprevir compared with the control group (OR, 1.98; 95% CI, 1.42 to 2.76); this finding was also true in the treatment-experienced subgroup.</p> <p>An indirect treatment comparison between telaprevir and boceprevir favored telaprevir for inducing 24-week SVR in treatment-naïve patients (OR, 1.78; 95% CI, 1.39 to 2.28; P<0.0001); however, the rates of 48-week SVR in treatment-naïve patients were similar between telaprevir and boceprevir (OR, 0.82; 95% CI, 0.60 to 1.11; P=0.2).</p> <p>Secondary:</p> <p>Treatment with telaprevir-based triple therapy did not result in more</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
				<p>discontinuations due to adverse drug reactions compared with controls (OR, 1.43; 95% CI, 0.42 to 4.92; P=0.57). Telaprevir was associated with an increase in treatment-associated adverse events compared with placebo. Boceprevir was associated with increased prevalences of anemia and dysgeusia.</p> <p>Telaprevir and boceprevir were also similar regarding discontinuation from adverse drug reactions (OR, 1.23; 95% CI, 0.95 to 1.60; P=0.11).</p>
<p>Kwo et al.³⁶ (2014) CORAL-I</p> <p>ABT-450 150 mg/ ritonavir 100 mg/ ombitasvir 25 mg once daily for 24 weeks</p> <p>and</p> <p>dasabuvir 250 mg twice daily for 24 weeks</p> <p>and</p> <p>ribavirin (dosing at investigator's discretion) for 24 weeks</p> <p>A stable tacrolimus- or cyclosporine-based immunosuppressive regimen was required, and glucocorticoids were allowed at a dose of ≤5 mg/day.</p> <p>(ABT-450 is the experimental name for paritaprevir)</p>	<p>MC, OL</p> <p>Patients 18 to 70 years of age with chronic HCV genotype 1 infection, HCV RNA >10,000 IU/mL who received a liver transplant ≥12 months before screening because of chronic HCV infection, and Metavir score ≤F2 on liver biopsy performed ≤6 months before screening</p>	<p>N=34</p> <p>24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: SVR24, virologic failure during treatment, and post-treatment relapse</p>	<p>Primary: The SVR12 rate was 97% (95% CI, 85 to 100). All five patients infected with genotype 1b (100%) and 28 of 29 patients infected with genotype 1a (97%) had a SVR.</p> <p>Secondary: The SVR24 rate was 97% (95% CI, 85 to 100).</p> <p>All the patients also had HCV RNA <25 IU/mL at the end of treatment.</p> <p>One patient did not have a SVR owing to a relapse on post-treatment day three. No relapses occurred after post-treatment week 12.</p>
<p>Gane et al.³⁷</p>	<p>OL</p>	<p>N=95</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>(2013)</p> <p>Group 1: Sofosbuvir 400 mg and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) for 12 weeks</p> <p>Group 2: Group 1 treatment plus 4 weeks of concomitant peginterferon alfa-2a 180 µg once weekly</p> <p>Group 3: Group 1 treatment plus 8 weeks of concomitant peginterferon alfa-2a 180 µg once weekly</p> <p>Group 4: Group 1 treatment plus 8 weeks of concomitant peginterferon alfa-2a 180 µg once weekly</p> <p>(additional groups amended):</p> <p>Group 5: Sofosbuvir 400 mg daily monotherapy for 12 weeks</p> <p>Group 6: Sofosbuvir plus peginterferon and ribavirin for 8 weeks</p>	<p>Patients 19 years of age or older, who had chronic HCV infection without cirrhosis</p>		<p>Serum HCV RNA levels, safety</p> <p>Secondary: Not reported</p>	<p>Viral suppression was rapid in all patients, regardless of genotype, status with respect to previous treatment, baseline viral load, race or ethnic group, IL28B status, and presence or absence of interferon in the regimen. All 95 patients had an undetectable level of HCV RNA by week four, with viral suppression sustained through the end of treatment.</p> <p>All 40 patients with HCV genotype 2 or 3 infection who received sofosbuvir and ribavirin for 12 weeks had an undetectable level of serum HCV RNA at two, four, eight, 12, 24, and 48 weeks after treatment. The presence or absence of peginterferon alfa-2a appeared to have no effect on viral kinetics or rate of sustained virologic response. Six of the 10 patients in the sofosbuvir monotherapy group had a sustained virologic response at 12 and 24 weeks after treatment.</p> <p>All 95 patients completed treatment. The most common adverse events were headache, fatigue, insomnia, nausea, rash, and anemia. Hematologic abnormalities were more common among patients who received interferon than among those who did not. Neutropenia and thrombocytopenia were not observed in the groups that did not receive interferon. However, sofosbuvir monotherapy was associated with a modest decrease in the hemoglobin level.</p> <p>Secondary: Not reported</p>
<p>Molina et al.³⁸ (2015) PHOTON-2</p> <p>Once-daily sofosbuvir 400 mg plus twice-daily ribavirin (1000 mg in patients with bodyweights</p>	<p>MC, non-randomized, OL, uncontrolled</p> <p>Patients (aged ≥18 years) co-</p>	<p>N=274</p> <p>12 or 24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: Not reported</p>	<p>Primary: Overall rates of SVR12 were 85% (95% CI, 77 to 91) in patients with genotype-1 HCV, 88% (69 to 98) in patients with genotype-2 HCV, 89% (81 to 94) in patients with genotype-3 HCV, and 84% (66 to 95) in patients with genotype-4.</p> <p>Response rates in treatment-naïve patients with HCV genotypes 2 or</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p><75 kg and 1200 mg in those with weights ≥75 kg) was given for 24 weeks to all patients except treatment-naïve patients with genotype-2 HCV, who received a 12-week regimen</p>	<p>infected with stable HIV and chronic HCV genotypes 1–4, including those with compensated cirrhosis</p>			<p>3 (89% [95% CI, 67 to 99] and 91% [81 to 97], respectively) were similar to those in treatment-experienced patients infected with those genotypes (83% [36 to 100] and 86% [73 to 94], respectively).</p> <p>Secondary: Not reported</p>
<p>Jacobson et al.³⁹ (2013) POSITRON and FUSION</p> <p><u>POSITRON:</u> Sofosbuvir 400 mg once daily for 12 weeks and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight ≥75 kg) for 12 weeks</p> <p>vs placebo</p> <p><u>FUSION:</u> Sofosbuvir 400 mg once daily for 12 weeks and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight of ≥75 kg) for 12 weeks</p> <p>vs sofosbuvir 400 mg once daily for 16 weeks and ribavirin 1,000 mg/day (weight <75 kg) or 1,200 mg/day (weight of ≥75 kg) for 16 weeks</p>	<p><u>POSITRON:</u> DB, MC, PC, R</p> <p>Patients ≥18 years of age with confirmed diagnosis of chronic HCV infection (genotypes 2 or 3), serum HCV RNA levels of ≥10,000 IU/mL during screening, and who are not candidates for interferon therapy</p> <p><u>FUSION:</u> AC, DB, MC, R</p> <p>Patients ≥18 years of age with confirmed diagnosis of chronic HCV</p>	<p><u>POSITRON:</u> N=278</p> <p>12 weeks</p> <p><u>FUSION:</u> N=201</p> <p>12 to 16 weeks</p>	<p><u>POSITRON:</u> Primary: SVR12</p> <p>Secondary: Not reported</p> <p><u>FUSION:</u> Primary: SVR12</p> <p>Secondary: Not reported</p>	<p><u>POSITRON:</u> Primary: Treatment with sofosbuvir plus ribavirin achieved a SVR12 in 78% of patients (95% CI, 72 to 83) compared to 0% among those receiving placebo (P<0.001).</p> <p>Response rates in patients receiving sofosbuvir plus ribavirin were lower among patients with genotype 3 infection than among those with genotype 2 infection (61 vs 93%).</p> <p>Among patients with genotype 3 infection receiving sofosbuvir plus ribavirin, 21% of patients with cirrhosis achieved a SVR12 compared to 68% without cirrhosis.</p> <p>Among patients with genotype 2 infection receiving sofosbuvir plus ribavirin, 94% of patients with cirrhosis achieved a SVR12 compared to 92% without cirrhosis.</p> <p>Secondary: Not reported</p> <p><u>FUSION:</u> Primary: Treatment with sofosbuvir plus ribavirin resulted in higher rates of SVR12 in the 12-week group (50%; 95% CI, 40 to 60) and 16-week group (73%; 95% CI, 63 to 81) compared to historical control rate of 25%.</p> <p>Patients receiving 16 weeks of treatment had a significantly higher</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
	infection (genotypes 2 or 3), serum HCV RNA levels of $\geq 10,000$ IU/mL during screening, and who have previously not responded to treatment with an interferon containing regimen			<p>rate of SVR than patients receiving 12 weeks of treatment (difference, -23%; 95% CI, -35 to -11; $P < 0.001$).</p> <p>Response rates in patients with genotype 2 infection who received 12 weeks of treatment were lower than among those who received 16 weeks of treatment (86 vs 94%; difference of -8%; 95% CI, -24 to 9); however, the difference was not statistically significant.</p> <p>Response rates in patients with genotype 3 infection who received 12 weeks of treatment were significantly lower than among those who received 16 weeks of treatment (difference, -32%; 95% CI, -48 to -15).</p> <p>Among patients with cirrhosis who received 12 weeks of treatment, the rate of response was 31% (60% with HCV genotype 2 infection and 19% with HCV genotype 3 infection), as compared to 61% among patients without cirrhosis (96% with HCV genotype 2 infection and 37% with HCV genotype 3 infection).</p> <p>Among patients with cirrhosis who received 16 weeks of treatment, the rate of response was 66% (78% with HCV genotype 2 infection and 61% with HCV genotype 3 infection) as compared to 76% among patients without cirrhosis (100% with HCV genotype 2 infection and 63% with HCV genotype 3 infection).</p> <p>Secondary: Not reported</p>
<p>Zeuzem et al.⁴⁰ (2014) VALENCE</p> <p>Sofosbuvir 400 mg once daily for 12 weeks and ribavirin 1,000 mg/day (weight < 75 kg) or 1,200 mg/day (weight ≥ 75 kg) for 12 weeks</p>	<p>DB, MC, PC, R</p> <p>Patients ≥ 18 years of age with confirmed diagnosis of chronic HCV infection (genotypes 2 or</p>	<p>N=419</p> <p>12 weeks (genotype 2) or 24 weeks (genotype 3)</p>	<p>Primary: SVR12</p> <p>Secondary: Not reported</p>	<p>Primary: Treatment with sofosbuvir plus ribavirin achieved a SVR12 in 93% (95% CI, 85 to 98) of patients with HCV genotype 2 receiving 12 weeks of therapy and 85% (95% CI, 80 to 89) of patients with HCV genotype 3 receiving 24 weeks of therapy.</p> <p>Among patients with genotype 2 infection receiving sofosbuvir plus ribavirin, high SVR12 rates were observed in treatment-naïve non-cirrhotics (96.7%; 95% CI, 82.8 to 99.9), treatment-naïve cirrhotics</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>vs placebo</p> <p>After study initiation, on the basis of emerging data from phase 3 trials, the study was unblinded, treatment for all patients with genotype 3 infection was extended to 24 weeks, the placebo group was terminated, and the goals of the study were redefined to be descriptive and not include hypothesis testing.</p>	<p>3) and serum HCV RNA levels of $\geq 10,000$ IU/mL during screening</p>			<p>(100%; 95% CI, 15.8 to 100), and treatment-experienced non-cirrhotics (93.8%; 95% CI, 79.2 to 99.2), whereas lower SVR12 rate was observed in treatment-experienced cirrhotics with genotype 2 infection (77.8%; 40.0 to 97.2).</p> <p>Similarly, among patients with genotype 3 infection receiving sofosbuvir plus ribavirin, high SVR12 rates were observed in treatment-naïve non-cirrhotics (94.6%; 95% CI, 86.3 to 97.6), treatment-naïve cirrhotics (92.3%; 95% CI, 64.0 to 99.8), and treatment-experienced non-cirrhotics (86.7%; 95% CI, 78.4 to 92.7), whereas lower SVR12 rate was observed in treatment-experienced cirrhotics with genotype 3 infection (61.7%; 46.4 to 75.5).</p> <p>Secondary: Not reported</p>
<p>Lawitz et al.⁴¹ (2014) COSMOS</p> <p>Group 1: simeprevir and sofosbuvir with ribavirin for 24 weeks</p> <p>vs</p> <p>Group 2: simeprevir and sofosbuvir without ribavirin for 24 weeks</p> <p>vs</p> <p>Group 3: simeprevir and sofosbuvir with o ribavirin for 12 weeks</p> <p>vs</p>	<p>OL, RCT</p> <p>Patients ≥ 18 years of age with chronic HCV genotype 1 infections who had previously not responded to pegylated interferon and ribavirin or were treatment naïve</p>	<p>N=167</p> <p>12 or 24 weeks</p>	<p>Primary: SVR12</p> <p>Secondary: SVR4, SVR24, on-treatment failure, viral relapse</p>	<p>Primary: 154 (92%) of 167 of patients achieved SVR12, 90% (95% CI, 81 to 96) in cohort 1 and 94% (87 to 98) in cohort 2.</p> <p>SVR12 was seen in 98 (91%) of 108 patients who received ribavirin vs 56 (95%) of 59 of those who did not. Rates were similar by treatment status (38 [95%] of 40 treatment-naïve patients vs 116 [91%] of 127 previous non-responders) or treatment duration (77 [94%] of 82 after 12 weeks of treatment vs 77 [91%] of 85 after 24 weeks).</p> <p>Secondary: All patients who achieved SVR12 also achieved SVR4. More than 91% of patients overall achieved SVR4. Rapid virological response was achieved in 81% of patients overall, but SVR12 was still achieved in all but one who had detectable HCV RNA titers four weeks after the start of treatment.</p> <p>No patients experienced on-treatment virological failure, including viral breakthrough. Six patients had viral relapse after the end of treatment. At the time of relapse, five of the six had developed resistance-associated mutations to simeprevir, but none to sofosbuvir.</p>

Study and Drug Regimen	Study Design and Demographics	Study Size and Study Duration	End Points	Results
<p>Group 4: simeprevir and sofosbuvir without ribavirin for 12 weeks</p> <p>[Cohort 1: previous non-responders to peginterferon and ribavirin with moderate liver fibrosis (METAVIR score F0–F2); Cohort 2: previous non-responders to peginterferon and ribavirin or treatment naïve with severe liver fibrosis (METAVIR score F3–F4)]</p>				

Study abbreviations: AC=active control, CI=confidence interval, DB=double-blind, MA=meta-analysis, MC=multicenter, NI=non-inferiority, OL=open-label, OR=odds ratio, PC=placebo-controlled, PG=parallel-group, R=randomized, RCT=randomized controlled trial, RR=relative risk, SG=single group
 Other abbreviations: ALT=alanine aminotransferase, HCV=hepatitis C virus, HIV=human immunodeficiency virus, IU=international units, RNA=ribonucleic acid, SVR=sustained virologic response

Additional Evidence

Dose Simplification

Kowdley et al compared SVR24 between 12- and 24-week treatment courses with sofosbuvir, finding no difference in the proportion of patients achieving SVR24 between cohorts A (12 weeks) and B (24 weeks) (P=0.94) or between cohorts A (12 weeks) and C (24 weeks) (P=0.78), suggesting no additional benefit of treatment durations longer than 12 weeks.²⁴

Stable Therapy

A search of Medline and PubMed did not reveal data pertinent to this topic.

Impact on Physician Visits

A search of Medline and PubMed did not reveal data pertinent to this topic.

XII. Cost

A "relative cost index" is provided below as a comparison of the average cost per prescription for medications within this American Hospital Formulary Service (AHFS) drug class. To differentiate the average cost per prescription from one product to another, a specific number of '\$' signs from one to five is assigned to each medication. Assignment of relative cost values is based upon current Alabama Medicaid prescription claims history and the average cost per prescription as paid at the retail pharmacy level. For brand or generic products with little or no recent utilization data, the average cost per prescription is calculated by using the Alabama Medicaid average acquisition cost (AAC) and the standard daily dosing per product labeling. Please note that the relative cost index does not factor in additional cost offsets available to the Alabama Medicaid program via pharmaceutical manufacturer rebating.

The relative cost index scale for this class is as follows:

Relative Cost Index Scale	
\$	\$0-\$30 per Rx
\$\$	\$31-\$50 per Rx
\$\$\$	\$51-\$100 per Rx
\$\$\$\$	\$101-\$200 per Rx
\$\$\$\$\$	Over \$200 per Rx

Rx=prescription

Table 12. Relative Cost of the HCV Antivirals

Generic Name(s)	Formulation(s)	Example Brand Name(s)	Brand Cost	Generic Cost
Single Entity Agents				
Boceprevir	capsule	Victrelis®	N/A	N/A
Simeprevir	capsule	Olysio®	\$\$\$\$\$	N/A
Sofosbuvir	tablet	Sovaldi®	\$\$\$\$\$	N/A
Combination Products				
Ledipasvir and sofosbuvir	tablet	Harvoni®	\$\$\$\$\$	N/A
Ombitasvir, paritaprevir, and ritonavir; dasabuvir	dose pack (tablets)	Viekira Pak®	\$\$\$\$\$	N/A

N/A=Not available

XIII. Conclusions

The hepatitis C virus (HCV) antiviral agents act via several different mechanisms of action and include inhibition of non-structural (NS) 3/4A protease, NS5B polymerase, and HCV NS5A.¹⁻⁶ There are no generic products available. This class was last reviewed in November 2014.

The HCV antivirals are all Food and Drug Administration (FDA)-approved for the treatment of chronic HCV infection, although differences in indications exist relating to use in specific genotypes. Many patient factors need to be considered when initiating HCV treatment, including but not limited to viral subtype, prior treatment regimen, including response, and presence of cirrhosis. The HCV antivirals also vary with regards to use in combination versus single-product therapy and duration of treatment.¹⁻⁵ These direct-acting antiviral agents act via several different mechanisms of action and include inhibition of non-structural (NS) 3/4A protease, NS5B polymerase, and HCV NS5A.¹⁻⁶ Boceprevir was one of the first direct-acting antiviral agents available, but its use is no longer recommended by the current guidelines, and it is being voluntarily discontinued by the manufacturer with distribution ending by December 2015.^{7,10,11} Simeprevir is currently only recommended in regimens that also include sofosbuvir.⁷ Sofosbuvir is a once-daily NS5B polymerase inhibitor FDA-approved for the treatment of HCV genotype 1, 2, 3, or 4 infection, including patients with hepatocellular carcinoma (HCC) awaiting liver transplantation or HCV/human immunodeficiency virus co-infection. It is indicated for use in combination with peginterferon alfa and ribavirin in the treatment of HCV genotype 1 and 4 infection and in combination with ribavirin alone in the treatment of HCV genotype 2 and 3 infection, and in patients with HCC awaiting liver transplant. Use in combination with ribavirin alone can be considered in patients with HCV genotype 1 infection who are not candidates for an interferon-based regimen.³ Ledipasvir-sofosbuvir is a once-daily combination of ledipasvir, an HCV NS5A inhibitor, and sofosbuvir, an HCV NS5B polymerase inhibitor. Both drugs interfere with the enzymes required for viral replication. Ledipasvir-sofosbuvir is indicated for the treatment of chronic HCV genotype 1 infection in adults. The FDA-approved treatment duration is eight, 12, or 24 weeks depending on prior treatment history, cirrhosis status, and baseline viral load. Eight weeks of treatment can be considered for treatment-naïve patients without cirrhosis and baseline HCV viral load <6 million IU/mL. It is the first FDA-approved regimen that does not require administration with peginterferon alfa or ribavirin.⁴ Ombitasvir-paritaprevir-ritonavir-dasabuvir (Viekira Pak[®]) includes fixed-dose ombitasvir, an HCV NS5A inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor, co-packaged with dasabuvir, an HCV non-nucleoside NS5B polymerase inhibitor. Viekira Pak[®] with or without ribavirin is indicated for the treatment of patients with chronic HCV genotype 1 infection including those with compensated cirrhosis. The FDA-approved treatment duration is 12 or 24 weeks depending on prior treatment history and cirrhosis status.⁵ Co-administration of Viekira Pak[®] with drugs that are highly dependent on CYP3A for clearance, strong inducers of CYP3A and CYP2C8, and strong inhibitors of CYP2C8 is contraindicated.⁵

Newly published guidelines developed by the American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA have included all current treatments in their recommendations.⁷ In general, combination regimens that include newer direct HCV antivirals are preferred over older pegylated interferon-based regimens (including those containing older protease inhibitors) due to a higher SVR rate, improved side effects profile, and reduced pill burden. Three options with similar efficacy are recommended for many patient groups, including daily fixed-dose ledipasvir-sofosbuvir, daily fixed-dose paritaprevir-ritonavir-ombitasvir plus twice-daily dasabuvir plus ribavirin, and daily sofosbuvir plus simeprevir with or without ribavirin.⁷ However, many different regimens with direct-acting agents or combinations, which may or may not also include ribavirin or pegylated interferon, are recommended based on HCV genotype, previous treatment experience, presence of cirrhosis, and certain special populations.^{7,8}

Overall, data from clinical trials support the FDA-approved indications and dosing recommendations for these agents.¹⁻⁵ The trials demonstrate that treatment with newer HCV antiviral agents (simeprevir when used with sofosbuvir, sofosbuvir, ledipasvir-sofosbuvir, and ombitasvir-paritaprevir-ritonavir-dasabuvir) result in a significant improvement in SVR when compared to historical response rates or placebo. Direct-acting antivirals have not been directly compared in clinical trials.¹⁴⁻⁴¹

Therefore, of the agents included in this review, sofosbuvir, ledipasvir-sofosbuvir, and ombitasvir-paritaprevir-ritonavir-dasabuvir offer significant clinical advantages over the other brand and generic products in the same class (if applicable). Boceprevir in any combination and simeprevir except when used in combination with sofosbuvir offer a clinical disadvantage to the other brand and generic products in the same class (if applicable).

The drugs in this AHFS class are used in a specific patient population. Because these agents have narrow indications with limited usage, and very specific criteria must be met prior to initiating therapy, these agents should be managed through the medical justification portion of the prior authorization process.

XIV. Recommendations

No brand HCV antiviral is recommended for preferred status. Alabama Medicaid should accept cost proposals from manufacturers to determine the most cost effective products and possibly designate one or more preferred brands.

XV. Archived Guidelines

Previous treatment guidelines for Hepatitis C are summarized in Table 13 in reverse chronological order.

Table 13. Previous Guidelines for the Treatment of Hepatitis C

Archived Guideline	Recommendation(s)
<p>American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA: Recommendations for testing, managing, and treating hepatitis C (2014)⁴²</p>	<ul style="list-style-type: none"> • It may be advisable to delay treatment for some patients with documented early fibrosis stage (F0 to 2), because waiting for future highly effective, pangenotypic, direct-acting antiviral combinations in interferon-free regimens may be prudent. Potential advantages of waiting to begin treatment will be provided in a future consensus guideline update. • A regimen is classified as either "recommended" when it is favored for most patients or "alternative" when optimal in a particular subset of patients in that category. When a treatment is clearly inferior or is deemed harmful, it is classified as "not recommended." • Recommendations for peginterferon alfa and ribavirin relapsers are the same as for treatment-naïve persons as described below. • Interferon ineligible criteria: <ul style="list-style-type: none"> ○ Intolerance to interferon alfa. ○ Autoimmune hepatitis and other autoimmune disorders. ○ Hypersensitivity to peginterferon alfa or any of its components. ○ Decompensated hepatic disease. ○ Major uncontrolled depressive illness. ○ A baseline neutrophil count below 1,500/μL, a baseline platelet count below 90,000/μL, or baseline hemoglobin below 10 g/dL. ○ A history of preexisting cardiac disease. <p><u>When and in whom to initiate HCV therapy</u></p> <ul style="list-style-type: none"> • Treatment is recommended for patients with chronic HCV infection. • Liver-related complications in which HCV treatment is most likely to provide the most immediate and impactful benefits are assigned "highest" and "high" priorities. • Highest priority due to highest risk for severe complications: <ul style="list-style-type: none"> ○ Advanced fibrosis (F3) or compensated cirrhosis (F4) ○ Organ transplant recipients ○ Severe extrahepatic hepatitis C (type 2 or 3 essential mixed cryoglobulinemia with end-organ manifestations e.g., vasculitis) ○ Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis • High priority due to high risk for complications: <ul style="list-style-type: none"> ○ Fibrosis (F2) ○ Human immunodeficiency virus (HIV) or hepatitis B virus (HBV)-coinfection ○ Other coexistent liver disease (e.g., non-alcoholic steatohepatitis) ○ Debilitating fatigue ○ Type 2 Diabetes mellitus (insulin resistant) ○ Porphyria cutanea tarda • Persons whose risk of HCV transmission is high and in whom HCV treatment may yield transmission reduction benefits: <ul style="list-style-type: none"> ○ Men who have sex with men with high-risk sexual practices ○ Active injection drug users ○ Incarcerated persons ○ Persons on long-term hemodialysis • Factors associated with accelerated fibrosis progression: <ul style="list-style-type: none"> ○ Fibrosis stage

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ Inflammation grade ○ Older age at time of infection ○ Male sex ○ Organ transplant ○ Alcohol consumption ○ Nonalcoholic fatty liver disease ○ Obesity ○ Insulin resistance ○ Genotype 3 ○ HIV or HBV-coinfection <p><u>Treatment of HCV genotype 1 in treatment-naïve patients and relapsers with prior peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> ● Recommended treatments: <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. ○ Interferon ineligible: sofosbuvir plus simeprevir with or without ribavirin for 12 weeks. ● Alternative treatments: <ul style="list-style-type: none"> ○ Interferon eligible: simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks (for genotype 1a, baseline resistance testing for Q80K should be performed and alternative treatments considered if this mutation is present). ○ Interferon ineligible: sofosbuvir plus ribavirin for 24 weeks. ● Treatments that are not recommended: <ul style="list-style-type: none"> ○ Boceprevir or telaprevir plus peginterferon alfa and ribavirin for 24 or 48 weeks. ○ Peginterferon alfa and ribavirin for 48 weeks. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Treatment of HCV genotype 2 in treatment-naïve patients and relapsers with prior peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> ● Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 12 weeks. ● Alternative treatments: <ul style="list-style-type: none"> ○ None. ● Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 weeks. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ Any regimen with boceprevir, telaprevir, or simeprevir. <p><u>Treatment of HCV genotype 3 in treatment-naïve patients and relapsers with prior peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> ● Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 24 weeks. ● Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. ● Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 to 48 weeks. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ Any regimen with boceprevir, telaprevir, or simeprevir. <p><u>Treatment of HCV genotype 4 in treatment-naïve patients and relapsers with prior peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> ● Recommended treatments: <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon alfa and ribavirin for 12

Archived Guideline	Recommendation(s)
	<p>weeks.</p> <ul style="list-style-type: none"> ○ Interferon ineligible: sofosbuvir plus ribavirin for 24 weeks. <ul style="list-style-type: none"> • Alternative treatments: <ul style="list-style-type: none"> ○ Simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 to 48 weeks. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 48 weeks. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ Any regimen with boceprevir or telaprevir. <p><u>Treatment of HCV genotype 5 or 6 in treatment-naïve patients and relapsers with prior peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 48 weeks. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ Any regimen with boceprevir or telaprevir. <p><u>Recommendations for patients with HCV genotype 1 with prior null or partial response to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus simeprevir with or without ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir for 12 weeks plus peginterferon alfa and ribavirin for 12 to 24 weeks. ○ Sofosbuvir plus ribavirin for 24 weeks. ○ Simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks (for genotype 1a, baseline resistance testing for Q80K should be performed and alternative treatments considered if this mutation is present). • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Boceprevir or telaprevir plus peginterferon alfa and ribavirin. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Recommendations for patients with HCV genotype 1 with prior null or partial response to peginterferon alfa and ribavirin plus either boceprevir or telaprevir</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir for 12 weeks plus peginterferon alfa and ribavirin for 12 to 24 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Interferon eligible: Sofosbuvir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks. ○ Interferon ineligible: Sofosbuvir plus ribavirin for 24 weeks. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Boceprevir, simeprevir, or telaprevir plus peginterferon alfa and ribavirin. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ A recommendation for simeprevir use for patients with previous telaprevir or boceprevir exposure has not been provided due to potential risk of preexistent resistance to protease inhibitor treatment. <p><u>Recommendations for patients with HCV genotype 2 with prior null or partial response to peginterferon alfa and ribavirin</u></p>

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 12 weeks; <ul style="list-style-type: none"> ▪ In treatment-experienced cirrhotics only, the decision to extend therapy to 16 weeks should be made on a case-by-case basis. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks (cirrhotics only). • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Boceprevir or telaprevir plus peginterferon alfa and ribavirin. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Recommendations for patients with HCV genotype 3 with prior null or partial response to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 24 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 16 weeks (cirrhotics only). ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without protease inhibitor. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Recommendations for patients with HCV genotype 4 with prior null or partial response to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 24 weeks. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without protease inhibitor ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Recommendations for patients with HCV genotype 5 or 6 with prior null or partial response to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ None. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin with or without protease inhibitor. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. <p><u>Initial treatment of human immunodeficiency virus (HIV)/HCV co-infected patients with HCV genotype 1 who are treatment-naïve or prior peginterferon alfa and ribavirin relapsers</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon and ribavirin for 12 weeks. ○ Interferon ineligible: <ul style="list-style-type: none"> ▪ Sofosbuvir plus ribavirin for 24 weeks. ▪ Sofosbuvir plus simeprevir with or without ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Interferon eligible: simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 24 weeks (for genotype 1a, baseline resistance testing for Q80K should be performed and alternative treatments considered if this

Archived Guideline	Recommendation(s)
	<p>mutation is present).</p> <ul style="list-style-type: none"> ○ Interferon ineligible: none. • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Boceprevir or telaprevir plus peginterferon alfa and ribavirin for 24 or 48 weeks. ○ Peginterferon alfa and ribavirin for 48 weeks. ○ Simeprevir for 12 weeks plus peginterferon alfa and ribavirin for 48 weeks. • Allowable antiretroviral therapy: <ul style="list-style-type: none"> ○ For sofosbuvir use: all except didanosine, zidovudine, or tipranavir. ○ For simeprevir use: limited to raltegravir, rilpivirine, maraviroc, enfuvirtide, tenofovir, emtricitabine, lamivudine, abacavir. <p><u>Recommendations for HIV/HCV co-infected patients with HCV genotype 1 with prior null or partial response to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Recommended treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus simeprevir with or without ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. ○ Interferon ineligible: sofosbuvir plus ribavirin for 24 weeks. • Treatments that are not recommended: same as for treatment-naïve or prior peginterferon alfa and ribavirin relapsers above. • Allowable antiretroviral therapy: same as for treatment-naïve or prior peginterferon alfa and ribavirin relapsers above. <p><u>Treatment of HIV/HCV co-infected patients with HCV genotype 2</u></p> <ul style="list-style-type: none"> • Recommended treatments (regardless of treatment history): <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 12 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks (only in prior nonresponders to peginterferon alfa and ribavirin eligible for peginterferon alfa). • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 to 48 weeks. ○ Any regimen with boceprevir, telaprevir, or simeprevir. ○ Allowable antiretroviral therapy: same as above. <p><u>Treatment of HIV/HCV co-infected patients with HCV genotype 3</u></p> <ul style="list-style-type: none"> • Recommended treatments (regardless of treatment history): <ul style="list-style-type: none"> ○ Sofosbuvir plus ribavirin for 24 weeks. • Alternative treatments: <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks (only in prior nonresponders to peginterferon alfa and ribavirin eligible for peginterferon alfa). • Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 24 to 48 weeks. ○ Any regimen with boceprevir, telaprevir, or simeprevir. ○ Allowable antiretroviral therapy: same as above. <p><u>Treatment of HIV/HCV co-infected patients with HCV genotype 4</u></p> <ul style="list-style-type: none"> • Recommended treatments (regardless of treatment history): <ul style="list-style-type: none"> ○ Interferon eligible: sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. ○ Interferon ineligible: sofosbuvir plus ribavirin for 24 weeks. • Alternative treatments:

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ None. ● Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 48 weeks. ○ Any regimen with boceprevir, telaprevir, or simeprevir. ○ Allowable antiretroviral therapy: same as above. <p><u>Treatment of HIV/HCV co-infected patients with HCV genotype 5 or 6</u></p> <ul style="list-style-type: none"> ● Recommended treatments (regardless of treatment history): <ul style="list-style-type: none"> ○ Sofosbuvir plus peginterferon alfa and ribavirin for 12 weeks. ● Alternative treatments: <ul style="list-style-type: none"> ○ None. ● Treatments that are not recommended: <ul style="list-style-type: none"> ○ Peginterferon alfa and ribavirin for 48 weeks. ○ Any regimen with boceprevir, telaprevir, or simeprevir. ○ Allowable antiretroviral therapy: same as above. <p><u>Treatment of patients with cirrhosis</u></p> <ul style="list-style-type: none"> ● Treatment-naïve patients with compensated cirrhosis, including those with hepatocellular carcinoma, should receive the same treatment as recommended for patients without cirrhosis. ● Patients with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center). ● Recommended regimen for patients with any HCV genotype who have decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh class B or C) who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma. <ul style="list-style-type: none"> ○ Sofosbuvir plus weight-based ribavirin (with consideration of the patient's creatinine clearance and hemoglobin level) for up to 48 weeks. ○ This regimen should be used only by highly experienced HCV provider. ● The following regimens are not recommended for patients with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh class B or C): <ul style="list-style-type: none"> ○ Any interferon-based therapy. ○ Monotherapy with peginterferon alfa, ribavirin, or a direct-acting antiviral. ○ Telaprevir, boceprevir, or simeprevir-based regimens. <p><u>Treatment of patients who develop recurrent HCV infection post-liver transplant</u></p> <ul style="list-style-type: none"> ● Recommended regimen for treatment-naïve patients with HCV genotype 1 in the allograft liver, including those with compensated cirrhosis. <ul style="list-style-type: none"> ○ Sofosbuvir plus simeprevir with or without dose-adjusted ribavirin for 12 to 24 weeks. ● Alternate regimen for treatment-naïve patients with genotype 1 HCV in the allograft liver, including those with compensated cirrhosis. <ul style="list-style-type: none"> ○ Sofosbuvir and dose-adjusted ribavirin (with consideration of the patient's creatinine clearance and hemoglobin level), with or without peginterferon alfa, for 24 weeks. ● Recommended regimen for treatment-naïve patients with HCV genotype 2 or 3 in the allograft liver, including those with compensated cirrhosis. <ul style="list-style-type: none"> ○ Sofosbuvir plus dose-adjusted ribavirin (with consideration for creatinine clearance and hemoglobin level) for 24 weeks. ○ Treatment-naïve patients with decompensated allograft HCV infection should receive the same treatment as recommended for patients with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh class B or C).

Archived Guideline	Recommendation(s)
<p>European Association for the Study of the Liver: Management of Hepatitis C Virus Infection (2013)⁴³</p>	<p><u>Goals and endpoints of HCV therapy</u></p> <ul style="list-style-type: none"> • The goal of therapy is to eradicate HCV infection. • The endpoint of therapy is SVR, defined by undetectable HCV RNA 24 weeks after the end of therapy; SVR usually equates to cure of infection in more than 99% of patients. • Undetectable HCV RNA at 12 weeks after the end of therapy (SVR 12) has been accepted in the US and Europe given concordance with SVR 24 is 99%; however, this concordance needs to be further validated in ongoing clinical trials. <p><u>Indications for treatment</u></p> <ul style="list-style-type: none"> • All treatment-naïve patients with compensated disease due to HCV should be considered for therapy. • Treatment should be scheduled, not deferred, for patients with significant fibrosis (F3 to F4). • In patients with less severe disease, indication for and timing of therapy can be individualized. <p><u>First line treatment of chronic hepatitis C genotype 1</u></p> <ul style="list-style-type: none"> • Triple therapy with boceprevir or telaprevir added to peginterferon alfa and ribavirin is the approved standard of care for chronic hepatitis C genotype 1. There is no head-to-head comparison to allow recommendation of boceprevir or telaprevir as preferred therapy. • Patients with cirrhosis should never receive abbreviated treatment with boceprevir or telaprevir regimens. • Selected patients with high likelihood of SVR to peginterferon alfa and ribavirin or with contraindications to boceprevir or telaprevir can be treated with dual therapy. • When lead-in is used to identify patients with peginterferon alfa sensitive infection, the possibility of continuation of dual therapy should have been discussed with the patient prior to initiation of treatment. • Both peginterferon alfa-2a (180 µg/week) and peginterferon alfa-2b (1.5 µg/kg/week) can be used in dual or triple therapy. • Ribavirin should be dosed following the peginterferon alfa label for triple therapy. • Ribavirin should be administered at a weight-based dose of 15 mg/kg/day in dual therapy <p><u>First line treatment of chronic hepatitis C genotypes 2, 3, 4, 5, and 6</u></p> <ul style="list-style-type: none"> • The combination of peginterferon alfa and ribavirin is the approved standard of care for chronic hepatitis C genotypes 2, 3, 4, 5, and 6. • Ribavirin should be administered at a weight-based dose of 15 mg/kg/day for genotypes 4, 5 and 6, and at a flat dose of 800 mg/day for genotypes 2 and 3. • Patients with genotypes 2 and 3 with baseline factors suggesting low responsiveness should receive weight-based ribavirin at a dose of 15 mg/kg/day. <p><u>Treatment monitoring</u></p> <ul style="list-style-type: none"> • A real-time polymerase chain reaction-based assay with a lower limit of detection of <15 IU/mL should be used to monitor triple therapy. • During triple therapy in HCV genotype 1 patients, HCV RNA measurements should be performed at weeks four, eight, 12, 24, and end of treatment when administering boceprevir, and at weeks four, 12, 24, and end of treatment when administering telaprevir. • During dual therapy in any HCV genotype, HCV RNA levels should be assessed at baseline, weeks four, 12, 24 and end of treatment.

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • The end-of-treatment virological response and the SVR at 12 or 24 weeks after the end of treatment must be assessed. • Whether the baseline HCV RNA level is low or high may be a useful criterion to guide treatment decisions during dual therapy. The safest threshold level for discriminating low and high baseline HCV RNA is 400,000 IU/mL. • Dual therapy for all HCV genotypes should be stopped at week 12 if the HCV RNA decrease is $<2 \log_{10}$ IU/mL and at week 24 if HCV RNA is still detectable. • Triple therapy with boceprevir should be stopped if HCV RNA is >100 IU/mL at treatment week 12 or if HCV RNA is detectable at treatment week 24. • Triple therapy with telaprevir should be stopped if HCV RNA is $>1,000$ IU/mL at weeks four or 12 of therapy. • Dual therapy duration should be tailored to the on-treatment virological response at weeks four and 12. The likelihood of SVR is directly proportional to the rapidity of HCV RNA disappearance. • For patients receiving dual therapy who achieve an RVR and who have low baseline viral titre ($<400,000$ IU/mL), treatment for 24 weeks (genotype 1) or 16 weeks (genotype 2 or 3) can be considered. If negative predictors of response (i.e., advanced fibrosis/cirrhosis, metabolic syndrome, insulin resistance, hepatic steatosis) are present, published evidence for equal efficacy of shortened treatment is lacking. • Patients receiving dual therapy with genotypes 2 or 3, and with any adverse predictor of SVR, and who achieve an early virological response or a delayed virological response without an RVR, can be treated for 48 weeks. • Genotype 1 patients receiving dual therapy who demonstrate a delayed virological response can be treated for 72 weeks, provided that their HCV RNA is undetectable at week 24. <p><u>Treatment dose reductions and stopping rules</u></p> <ul style="list-style-type: none"> • The peginterferon alfa dose should be reduced if the absolute neutrophil count falls below $750/\text{mm}^3$, or the platelet count falls below $50,000/\text{mm}^3$. Peginterferon alfa should be stopped if the neutrophil count falls below $500/\text{mm}^3$ or the platelet count falls below $25,000/\text{mm}^3$ or if severe unmanageable depression develops. • If neutrophil or platelet counts rise, treatment can be restarted, but at a reduced peginterferon alfa dose. • If hemoglobin <10 g/dL occurs, the dose of ribavirin should be adjusted downward by 200 mg at a time, and ribavirin should be stopped if hemoglobin falls below 8.5 g/dL. • Treatment should be stopped in case of a severe hepatitis flare or severe sepsis. • Boceprevir or telaprevir doses should not be reduced during therapy due to the risk of the development of antiviral resistance. If boceprevir or telaprevir have been stopped, they should never be reintroduced in the same course of treatment. <p><u>Measures to improve treatment success rates</u></p> <ul style="list-style-type: none"> • Full adherence to all antiviral drugs should be the aim in order to optimize SVR rates and to reduce the risk of emergence of specific drug resistance. • Body weight adversely influences the response to peginterferon alfa and ribavirin; therefore, a reduction of body weight in overweight patients prior to therapy may increase the likelihood of SVR. • Insulin resistance is associated with treatment failure for dual therapy; however, insulin sensitizers have no proven efficacy in improving SVR rates in these patients. • Counseling on abstaining from alcohol during antiviral therapy should be

Archived Guideline	Recommendation(s)
	<p>provided.</p> <ul style="list-style-type: none"> • In dual therapy, recombinant erythropoietin can be administered when the hemoglobin level falls <10 g/dL in order to reduce the need for ribavirin dose reduction. • In patients receiving boceprevir or telaprevir-based triple therapy, ribavirin dose reduction should be the initial response to significant anemia. • There is no evidence that neutropenia during peginterferon alfa and ribavirin therapy is associated with more frequent infection episodes, or that the use of granulocyte colony stimulating factor reduces the rate of infections and/or improves SVR rates. • Patients with a history and/or signs of depression should be seen by a psychiatrist before therapy. Patients who develop depression during therapy should be treated with antidepressants. Preventative antidepressant therapy in selected patients may reduce the incidence of this condition during treatment, without any impact on SVR. <p><u>Post treatment follow up of patients who achieve an SVR</u></p> <ul style="list-style-type: none"> • Noncirrhotic patients with SVR should be retested for alanine transaminase and HCV RNA at 48 weeks post-treatment, and then discharged if alanine transaminase is normal and HCV RNA is negative. • Cirrhotic patients with SVR should undergo surveillance for hepatocellular carcinoma every six months by means of ultrasound. • If present, portal hypertension and esophageal varices should be managed, though index variceal bleed is seldom observed in low-risk patients after the achievement of SVR. • Patients with ongoing drug use should not be excluded from HCV treatment on the basis of perceived risk of reinfection. • Following SVR, monitoring for HCV reinfection through annual HCV RNA assessment should be undertaken on people who inject drugs with ongoing risk behavior. <p><u>Retreatment of nonsustained virological responders to peginterferon alfa and ribavirin</u></p> <ul style="list-style-type: none"> • Patients infected with HCV genotype 1 who failed to eradicate HCV in prior therapy with peginterferon alfa and ribavirin should be considered for retreatment with the triple combination of peginterferon alfa, ribavirin and a protease inhibitor. • The previous response to interferon-based therapy is an important predictor of success of triple therapy. If the pattern of prior response to dual therapy is not clearly documented, the patient should not be treated with abbreviated response-guided therapy. • Patients with cirrhosis and prior null responders have a lower chance of cure and should not be treated with response-guided therapy with either boceprevir or telaprevir. • Patients infected with HCV genotypes other than 1 and who failed on prior therapy with non-pegylated interferon alfa, with or without ribavirin, can be re-treated with pegylated interferon alfa and ribavirin. <p><u>Treatment of patients with severe liver disease</u></p> <ul style="list-style-type: none"> • Patients with compensated cirrhosis should be treated, in the absence of contraindications, in order to prevent short to midterm complications. • Monitoring and management of side effects, especially those linked to portal hypertension, low platelet count, and low serum albumin should be done particularly carefully. Growth factors may be useful in this group. • Patients with cirrhosis should undergo regular surveillance for hepatocellular

Archived Guideline	Recommendation(s)
	<p>carcinoma, irrespective of SVR.</p> <ul style="list-style-type: none"> • In patients awaiting liver transplantation, antiviral therapy, when feasible, prevents graft reinfection if an SVR is achieved. • Antiviral therapy may be started while awaiting liver transplantation, with the goal of achieving SVR or HCV RNA negativity before transplantation. • In patients with Child-Pugh B cirrhosis, antiviral therapy is offered on an individual basis in experienced centers, preferentially in patients with predictors of good response. • Patients with Child-Pugh C cirrhosis should not be treated with the current interferon alfa-based antiviral regimens due to a high risk of life-threatening complications. • Treatment can be started at low doses of peginterferon alfa and ribavirin, following a low accelerated dose regimen or at full doses. In the latter case, dose reductions and treatment interruptions are required in >50% of cases. • Patients with post-transplant recurrence of HCV infection should initiate therapy once chronic hepatitis is established and histologically proven. Significant fibrosis or portal hypertension one year after transplantation predicts rapid disease progression and graft loss and indicates urgent antiviral treatment. • For patients with HCV genotype 1, protease inhibitor-based therapy can be used, but frequent monitoring and dose adjustment of tacrolimus and cyclosporine are required. • Graft rejection is rare but may occur during peginterferon alfa treatment. A liver biopsy should be performed whenever liver tests worsen on antiviral therapy. <p><u>Treatment of special groups</u></p> <ul style="list-style-type: none"> • Indications for HCV treatment in patients with HIV coinfection are identical to those in patients with HCV mono-infection. The same peginterferon alfa regimen should be used in HIV coinfecting patients. Longer treatment duration may be considered for patients with genotype 2 and 3 who exhibit slow early viral kinetics. • Patients coinfecting with HIV and HCV genotype 1 should be considered for telaprevir or boceprevir triple therapy regimen, but special care should be taken to minimize or avoid potential drug-drug interactions. • HIV patients with a diagnosis of acute HCV infection should be treated with peginterferon and ribavirin, with duration dependent on viral kinetics independent of HCV genotype. • Patients coinfecting with hepatitis B should be treated with telaprevir or boceprevir triple therapy regimen, following the same rules as mono-infected patients. • If hepatitis B virus replicates at significant levels before, during or after HCV clearance, concurrent hepatitis B virus nucleoside/nucleotide analogue therapy is indicated. • Patients on hemodialysis, particularly those who are suitable candidates for renal transplantation, should be considered for antiviral therapy. • Antiviral treatment should comprise peginterferon alfa at an appropriately reduced dose. • Ribavirin can be used at very low doses, but with caution. • Boceprevir or telaprevir can be used with caution in patients with impaired creatinine clearance, and dose adjustment is probably unnecessary. • Patients with HCV and end stage renal disease scheduled for kidney transplantation should undergo antiviral therapy prior to transplantation due to the increased risk of acute transplant rejection. • Interferon alfa-based antiviral treatment is associated with a significant risk of renal graft rejection, and it should be avoided unless there is a powerful indication for antiviral treatment (e.g., aggressive cholestatic hepatitis).

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Regular alcohol consumption should be strongly discouraged. • Treatment of patients with active illicit drug abuse has to be individualized. • Patients with hemoglobinopathies can be treated with combination therapy but need careful monitoring. <p><u>Follow up of untreated patients and of patients with treatment failure</u></p> <ul style="list-style-type: none"> • Untreated patients with chronic hepatitis C and those who failed prior treatment should be followed regularly. • Non-invasive methods for staging fibrosis are best suited for follow-up assessment at intervals. • Hepatocellular carcinoma screening must be continued indefinitely in patients with cirrhosis. <p><u>Treatment of acute hepatitis C</u></p> <ul style="list-style-type: none"> • Peginterferon alfa monotherapy for 24 weeks is recommended in patients with acute hepatitis C and achieves SVR in >90% of patients. • Patients failing to respond to monotherapy should be retreated according to the standard of care for chronic hepatitis C.
<p>Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office: Update on the management and treatment of hepatitis C virus infection (2012)⁴⁴</p>	<p><u>Recommendations in patients being considered for HCV therapy</u></p> <ul style="list-style-type: none"> • All patients with chronic HCV infection should be evaluated for HCV antiviral treatment. • Patients should be counseled on their likelihood of achieving SVR, based upon individual factors such as body mass index, genotype, race, stage of fibrosis, and viral load before initiating therapy. • IL28B genotype testing can be performed before peginterferon-ribavirin therapy with or without a protease inhibitor, if the results would alter treatment decisions. <p><u>Recommendations for treatment-naïve patients with genotype 1 infection</u></p> <ul style="list-style-type: none"> • Peginterferon alfa and ribavirin, in combination with boceprevir (800 mg three times daily with food) or telaprevir (750 mg three times daily with 20 grams of fat), is the standard of care for most treatment-naïve genotype 1-infected patients. • If a telaprevir-containing regimen is used in treatment-naïve noncirrhotic patients who achieve an extended rapid virologic response (eRVR), telaprevir should be discontinued at week 12 and peginterferon-ribavirin should be continued for an additional 12 weeks. If HCV RNA is detectable at week four, but <1,000 IU/mL and remains <1,000 IU/mL or becomes undetectable at week 12, telaprevir should be discontinued at week 12, and peginterferon-ribavirin can be continued for another 36 weeks. • If a telaprevir-containing regimen is used in treatment-naïve cirrhotics who achieve an HCV RNA that is undetectable or <1,000 IU/mL at treatment weeks four and 12, telaprevir should be discontinued at week 12, and peginterferon-ribavirin can be continued for 36 more weeks. • If a boceprevir-containing regimen is used in treatment-naïve noncirrhotics, if HCV RNA declines by $\geq 1 \log_{10}$ during the four-week lead-in, and HCV RNA is undetectable at weeks eight to 24, treatment with boceprevir-peginterferon-ribavirin for 24 weeks is sufficient. If HCV RNA is detectable at week eight, but <100 IU/mL at week 12, and negative at week 24, boceprevir-peginterferon-ribavirin should be continued until week 36, followed by peginterferon-ribavirin alone for 12 more weeks. If HCV RNA declines by $< 1 \log_{10}$ during the lead-in, boceprevir-peginterferon-ribavirin can be continued for 44 weeks. • If a boceprevir-containing regimen is used in treatment-naïve cirrhotics, 44 weeks of boceprevir-peginterferon-ribavirin is required after the four-week lead-in.

Archived Guideline	Recommendation(s)
	<p data-bbox="511 233 1370 289"><u>Recommendations for treatment of nonresponders and relapsers with genotype 1 infection</u></p> <ul data-bbox="511 296 1421 1062" style="list-style-type: none"> <li data-bbox="511 296 1365 386">• For patients who previously failed peginterferon-ribavirin, retreatment with boceprevir or ribavirin and peginterferon-ribavirin may be considered, particularly in patients who were relapsers. <li data-bbox="511 392 1409 569">• If a boceprevir-containing regimen is used for retreatment of noncirrhotic prior partial responders or relapsers, the treatment duration is 36 weeks if HCV RNA is undetectable from weeks eight to 24. If HCV RNA is detectable at week 12, but <100 IU / mL and is undetectable from weeks 24 to 36, boceprevir can be discontinued at week 36 and peginterferon-ribavirin can be continued for an additional 12 weeks. <li data-bbox="511 575 1409 665">• If a boceprevir-containing regimen is used for re-treatment in cirrhotics, the treatment duration is 48 weeks if HCV RNA is detectable at week 12, but <100 IU/mL, and becomes undetectable from weeks 24 to 36. <li data-bbox="511 672 1365 762">• If a boceprevir-containing regimen is used for retreatment of prior null responders, the treatment duration is 48 weeks if HCV RNA is detectable at week 12, but <100 IU/mL, and becomes undetectable from weeks 24 to 36. <li data-bbox="511 768 1421 942">• If a telaprevir-containing regimen is used for retreatment of prior relapsers, and HCV RNA is undetectable from weeks four and 12, telaprevir should be discontinued at week 12 and peginterferon-ribavirin should be continued for an additional 12 weeks. If HCV RNA is detectable, but <1,000 IU/mL at week four and/or 12, telaprevir can be discontinued at week 12, and peginterferon-ribavirin can be continued for an additional 36 weeks. <li data-bbox="511 949 1421 1062">• If a telaprevir-containing regimen is used for re-treatment of prior partial responders or null responders, and HCV RNA is <1,000 IU/mL at weeks four and 12, telaprevir should be discontinued at week 12 and peginterferon-ribavirin should be continued for an additional 36 weeks. <p data-bbox="511 1100 948 1127"><u>Recommendations for dose modification</u></p> <ul data-bbox="511 1134 1421 1591" style="list-style-type: none"> <li data-bbox="511 1134 1317 1190">• Peginterferon alfa and ribavirin doses should be reduced in response to decreases in white blood cells, neutrophils, hemoglobin or platelets. <li data-bbox="511 1197 1421 1310">• If ribavirin is stopped for seven or more days in patients concomitantly receiving boceprevir or telaprevir, then the protease inhibitor should also be permanently discontinued. The protease inhibitors should be either continued at full dose or discontinued. <li data-bbox="511 1316 1421 1465">• A ribavirin dose reduction should be used as initial management of HCV treatment-related anemia in a symptomatic patient with a hemoglobin <10 g/dL. Erythropoietin may be administered in patients with symptomatic anemia related to peginterferon-ribavirin therapy with or without protease inhibitors to limit anemia-related ribavirin dose reductions or dose discontinuations. <li data-bbox="511 1472 1421 1591">• A peginterferon dose reduction should be used as initial management of HCV treatment-related neutropenia (an absolute neutrophil count of <750, or as clinically indicated). Granulocyte colony-stimulating factor should not be given as primary therapy to prevent peginterferon alfa dose reductions. <p data-bbox="511 1629 984 1656"><u>Recommendations for treatment monitoring</u></p> <ul data-bbox="511 1663 1421 1898" style="list-style-type: none"> <li data-bbox="511 1663 1421 1753">• Patients should be monitored for treatment-related adverse effects at least every two weeks early in the course of therapy, and every one to two months during treatment as clinically indicated. <li data-bbox="511 1759 1349 1816">• Assessment of treatment adherence and screening for depression, suicidal ideation, alcohol, and illicit drug use should be performed at every visit. <li data-bbox="511 1822 1421 1898">• Patients should be counseled about avoiding pregnancy through the use of two forms of contraception during treatment and for six months posttreatment. If a patient is receiving a boceprevir- or telaprevir-containing regimen, two

Archived Guideline	Recommendation(s)
	<p>alternative effective methods of contraception, such as intrauterine devices and barrier methods, should be used in at-risk patients and partners during and for at least six months after treatment.</p> <ul style="list-style-type: none"> • In patients receiving telaprevir-peginterferon-ribavirin, all treatment should be stopped if any of the following occur: <ul style="list-style-type: none"> ○ HCV RNA level >1,000 IU/mL at week four or 12. ○ Detectable HCV RNA levels at week 24 or at any time point thereafter. ○ HCV RNA rebounds at any time point ($\geq 1 \log_{10}$ increase from the nadir HCV RNA). • In patients receiving boceprevir-peginterferon-ribavirin, all treatment should be stopped if any of the following occur: <ul style="list-style-type: none"> ○ HCV RNA level ≥ 100 IU/mL at week 12 with a boceprevir-containing regimen. ○ Detectable HCV RNA levels at week 24 or at any time point thereafter. ○ HCV RNA rebounds at any time point ($\geq 1 \log_{10}$ increase from the nadir HCV RNA). • Do not switch to the other protease inhibitor if virologic failure occurs with one protease inhibitor. <p><u>Recommendations for groups with special considerations for therapy</u></p> <ul style="list-style-type: none"> • Peginterferon alfa monotherapy may be used to treat patients with contraindications to ribavirin. • For patients who achieve RVR and have a low baseline viral load (HCV RNA <400,000 IU/mL), 24-weeks of treatment with peginterferon-ribavirin may be sufficient. • Treatment can be deferred in patients with minimal inflammation and/or minimal portal fibrosis on liver biopsy. • HCV genotype 1-infected patients with compensated cirrhosis (Child-Pugh Class <7), adequate neutrophils ($>1.5 \text{ k/mm}^3$), and adequate platelet counts ($>75 \text{ k/mm}^3$) should be considered for treatment with boceprevir (for 44 weeks) or telaprevir (for 12 weeks) combined with peginterferon-ribavirin at standard doses for 48 weeks. • Patients with cirrhosis continue to be at risk for hepatocellular carcinoma and should undergo routine screening regardless of viral clearance status. <p><u>Recommendations for treatment-naïve and -experienced patients with genotype 2 or 3 infection</u></p> <ul style="list-style-type: none"> • Treatment-naïve patients should be treated with peginterferon-ribavirin for 24 weeks. • For patients with low viral load (HCV RNA <600,000 IU/mL) and mild fibrosis who achieve a RVR, 12 to 18 weeks of treatment may be sufficient. • For patients with genotype 3 infection and a high HCV RNA ($>600,000$ IU/mL), steatosis or advanced fibrosis, treatment beyond 24 weeks may improve response. • Retreatment duration is 48 weeks. <p><u>Recommendations in patients with genotype 4 infection</u></p> <ul style="list-style-type: none"> • Appropriate candidates with HCV genotype 4 infections should be treated with peginterferon alfa-2a 180 μg per week or peginterferon alfa-2b 1.5 $\mu\text{g/kg}$ per week, plus ribavirin up to 1,400 mg per day for 48 weeks. <p><u>Recommendations in patients with decompensated cirrhosis</u></p> <ul style="list-style-type: none"> • Liver transplantation is the treatment of choice in patients with decompensated cirrhosis. • Antiviral therapy is contraindicated in most patients with decompensated

Archived Guideline	Recommendation(s)
	<p>cirrhosis.</p> <ul style="list-style-type: none"> • Interferon-based therapy in combination with ribavirin can be considered for patients awaiting liver transplantation if they have a Child-Pugh score <7 and a Model for End-Stage Liver Disease score ≤18. • If beginning antiviral therapy, the interferon dose should be reduced and growth factors may be used to for treatment-associated cytopenias. <p><u>Recommendations in patients following solid organ transplantation</u></p> <ul style="list-style-type: none"> • Interferon-based antiviral therapy is contraindicated in patients who have received a heart, lung or kidney transplant. • In patients with biopsy-proven chronic HCV disease following liver transplantation, peginterferon-ribavirin for 48 weeks may be considered. • Monitor antiviral therapy in post-liver transplant patients on antiviral therapy and discontinue if rejection is documented. Pre-emptive antiviral therapy early post-transplantation in patients without histological recurrence should be avoided. <p><u>Recommendations in patients with renal disease</u></p> <ul style="list-style-type: none"> • Considered modified doses of antiviral therapy with interferon (standard or pegylated). • Antiviral therapy for HCV treatment is not recommended in patients following renal transplant; however, it may be considered if patients develop fibrosing cholestatic hepatitis. <p><u>Recommendations in patients with comorbid conditions</u></p> <ul style="list-style-type: none"> • Antiviral therapy is not recommended in patients with a limited life expectancy. In addition, peginterferon-ribavirin, treatment should be avoided in comorbid conditions that may be exacerbated by treatment. <p><u>Recommendations for patients on methadone</u></p> <ul style="list-style-type: none"> • Antiviral therapy should be offered to patients enrolled in a methadone maintenance program who meet criteria for therapy. Coordinated HCV treatment between providers and substance abuse specialists should occur. <p><u>Recommendations in patients with ongoing alcohol use</u></p> <ul style="list-style-type: none"> • Encourage patients to decrease alcohol consumption or to abstain, and refer for behavioral intervention to reduce alcohol use. Antiviral therapy may be used in patients who are otherwise appropriate candidates, regardless of prior alcohol use. Alcohol reduces adherence and treatment response. <p><u>Recommendations in obese patients and those with hepatic steatosis</u></p> <ul style="list-style-type: none"> • Patients with a body mass index >30 should be considered for antiviral treatment. Control comorbid conditions prior to initiation of antiviral therapy. <p><u>Recommendations in patients with human immunodeficiency virus (HIV)/HCV coinfection</u></p> <ul style="list-style-type: none"> • Patients with controlled HIV infection and evidence of liver disease on biopsy should be considered for HCV antiviral therapy. Treatment should consist of peginterferon-ribavirin at doses similar to those with HCV for a duration of 48 weeks. <p><u>Recommendations in patients with acute HCV infection</u></p> <ul style="list-style-type: none"> • Observe patients for eight to 20 weeks from time of initial exposure to monitor for spontaneous resolution of infection. • In patients who fail to resolve infection spontaneously, treatment with

Archived Guideline	Recommendation(s)
<p>American Association for the Study of Liver Diseases: An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection (2011)⁴⁵</p>	<p>peginterferon alfa, with or without ribavirin for 24 to 48 weeks should be used, based on genotype and HCV RNA response during therapy.</p> <ul style="list-style-type: none"> • The optimal therapy for HCV genotype 1 is the use of boceprevir or telaprevir in combination with peginterferon alfa and ribavirin. • Boceprevir and telaprevir should not be used without peginterferon alfa and weight-based ribavirin. <p><u>Treatment-naïve patients</u></p> <ul style="list-style-type: none"> • The recommended dose of boceprevir is 800 mg three times daily (every seven to nine hours) with food plus peginterferon alfa and weight-based ribavirin for 24 to 44 weeks, preceded by four weeks of lead in peginterferon alfa plus ribavirin alone. <ul style="list-style-type: none"> ○ Patients without cirrhosis treated with boceprevir, peginterferon alfa and ribavirin, whose HCV ribonucleic acid (RNA) levels at weeks eight and 24 is undetectable, may be considered for a shortened duration of treatment of 28 weeks in total (four weeks lead in of peginterferon alfa and ribavirin, followed by 24 weeks of triple therapy). ○ Triple therapy should be stopped if the HCV RNA level is >100 IU/mL at treatment week 12 or detectable at treatment week 24. • The recommended dose of telaprevir is 750 mg three times daily (every seven to nine hours) with food (not low fat) plus peginterferon alfa and weight-based ribavirin for 12 weeks followed by an additional 12 to 36 weeks of peginterferon alfa plus ribavirin (without telaprevir). <ul style="list-style-type: none"> ○ Patients without cirrhosis treated with telaprevir, peginterferon alfa and ribavirin, whose HCV RNA level at weeks four and 12 is undetectable should be considered for a shortened duration of therapy of 24 weeks. ○ Triple therapy should be stopped if the HCV RNA levels is >1,000 IU/mL at treatment weeks four or 12 and/or detectable at treatment week 24. • Patients with cirrhosis treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin should receive therapy for a duration of 48 weeks. <p><u>Treatment-experienced patients</u></p> <ul style="list-style-type: none"> • Re-treatment with boceprevir or telaprevir, in combination with peginterferon alfa and weight-based ribavirin, can be recommended for patients who had virological relapse or were partial responders after a prior course of treatment with standard interferon alfa or peginterferon alfa and/or ribavirin. • Retreatment with telaprevir, in combination with peginterferon alfa and weight-based ribavirin, may be considered for prior null responders to a course of standard interferon alfa or peginterferon alfa and/or weight-based ribavirin. • Response-guided therapy of treatment-experienced patients using either a boceprevir- or telaprevir-based regimen can be considered for relapsers, may be considered for partial responders, but cannot be recommended for null responders. • Patients re-treated with boceprevir plus peginterferon alfa and ribavirin who continue to have detectable HCV RNA >100 IU at week 12 should be withdrawn from all therapy because of the high likelihood of developing antiviral resistance. • Patients re-treated with telaprevir plus peginterferon alfa and ribavirin who continue to have detectable HCV RNA >1,000 IU at weeks four or 12 should be withdrawn from all therapy because of the high likelihood of developing antiviral resistance. <p><u>Adverse events</u></p> <ul style="list-style-type: none"> • Patients who develop anemia on protease inhibitor-based therapy for chronic

Archived Guideline	Recommendation(s)
	<p>hepatitis C should be managed by reducing the ribavirin dose.</p> <ul style="list-style-type: none"> • Patients on protease inhibitor-based therapy should undergo close monitoring of HCV RNA levels and the protease inhibitors should be discontinued if virological breakthrough (greater than one log increase in serum HCV RNA above nadir) is observed. • Patients who fail to have a virological response, who experience virological breakthrough, or who relapse on one protease inhibitor should not be re-treated with other protease inhibitors. <p><u>Use and Interpretation of HCV RNA results during triple therapy</u></p> <ul style="list-style-type: none"> • An HCV assay with a lower limit of quantification of equal to or less than 25 IU/mL and a limit of HCV RNA detection of approximately 10 to 15 IU/mL should be used for monitoring response to therapy and decision making during triple therapy. • Response-guided therapy should only be considered when no virus is detected by a sensitive assay four weeks after initiation of the HCV protease inhibitor. <p><u>IL28B testing</u></p> <ul style="list-style-type: none"> • IL28B genotype is a robust pretreatment predictor of sustained virologic response (SVR) to peginterferon alfa and ribavirin as well as to protease inhibitor triple therapy in patients with chronic HCV genotype 1. Testing may be considered when the patient or provider wish additional information on the probability of treatment response or on the probable treatment needed.
<p>American Association for the Study of Liver Diseases (AASLD): Diagnosis, Management, and Treatment of Hepatitis C: Update (2009)⁴⁶</p>	<p><u>General Information</u></p> <ul style="list-style-type: none"> • The goal of therapy is to prevent complications and death from HCV infection. Treatment responses are defined by a surrogate virological parameter rather than a clinical endpoint. Short-term outcomes can be measured biochemically (normalization of serum ALT levels), virologically (absence of HCV RNA from serum by a sensitive PCR-based assay), and histologically (point improvement in necroinflammatory score with no worsening in fibrosis score). • Several types of virological responses may occur, labeled according to their timing relative to treatment. The most important is the sustained virological response (SVR), defined as the absence of HCV RNA from serum by a sensitive PCR assay 24 weeks following discontinuation of therapy (virological cure). Undetectable virus at the end of either a 24-week or 48-week course of therapy is referred to as an end-of-treatment response (ETR). An ETR does not accurately predict that an SVR will be achieved, but is necessary for it to occur. • The currently recommended therapy of chronic HCV infection is the combination of a pegylated interferon alfa and ribavirin. • Treatment decisions should be individualized based on the severity of liver disease, the potential for serious side effects, the likelihood of treatment response, the presence of comorbid conditions, and the patient's readiness for treatment. <p><u>Genotype 1 and Genotype 4 HCV Infection</u></p> <ul style="list-style-type: none"> • Treatment with peginterferon plus ribavirin should be planned for 48 weeks. • Treatment may be discontinued in patients who do not achieve an early virological response (EVR; >2 log reduction in HCV RNA at week 12 of treatment). • Patients who do not achieve a complete EVR (undetectable HCV RNA at week 12 of treatment) should be re-tested at week 24, and if HCV RNA remains positive, treatment should be discontinued. • For patients with genotype 1 infection who have delayed virus clearance (HCV RNA test becomes negative between weeks 12 and 24), consideration should be given to extending therapy to 72 weeks. <p><u>Genotype 2 or Genotype 3 HCV Infection</u></p>

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> • Treatment with peginterferon plus ribavirin should be administered for 24 weeks. <p><u>Retreatment</u></p> <ul style="list-style-type: none"> • Retreatment with peginterferon plus ribavirin in patients who did not achieve an SVR after a prior full course of peginterferon plus ribavirin is not recommended, even if a different type of peginterferon is administered. • Retreatment with peginterferon plus ribavirin can be considered for non-responders or relapsers who have previously been treated with non-pegylated interferon with or without ribavirin, or with peginterferon monotherapy, particularly if they have bridging fibrosis or cirrhosis. • Maintenance therapy is not recommended for patients with bridging fibrosis or cirrhosis who have failed a prior course of peginterferon and ribavirin. <p><u>Treatment of Persons with Normal Serum Aminotransferase Values</u></p> <ul style="list-style-type: none"> • Regardless of the serum alanine aminotransferase level, the decision to initiate therapy with pegylated interferon and ribavirin should be individualized based on the severity of liver disease by liver biopsy, the potential for serious side effects, the likelihood of response, and the presence of comorbid conditions. • The treatment regimen for HCV-infected persons with normal aminotransferase levels should be the same as that used for persons with elevated serum aminotransferase levels. <p><u>Treatment of Children</u></p> <ul style="list-style-type: none"> • Children aged 2-17 years who are infected with HCV should be considered appropriate candidates for treatment using the same criteria as that used for adults. • Children should be treated with pegylated interferon alfa-2b, 60 mcg/m² weekly in combination with ribavirin, 15 mg/kg daily for a duration of 48 weeks. <p><u>Treatment of HIV-infected Persons</u></p> <ul style="list-style-type: none"> • Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy. • Initial treatment of hepatitis C in most HIV-infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients. • When possible, patients receiving zidovudine (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin. • HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation.
<p>American Gastroenterological Association: Medical Position Statement on the Management of Hepatitis C (2006)⁴⁷</p>	<ul style="list-style-type: none"> • Therapy is indicated for previously untreated patients with chronic hepatitis C, circulating HCV RNA, elevated aminotransferase levels, evidence on liver biopsy of moderate to severe hepatitis grade and stage, and compensated liver disease. • Patients with normal ALT activity are candidates for antiviral therapy or for monitoring without intervention, as determined on an individual basis and as influenced by patient factors such as motivation, genotype, histologic activity, and fibrosis. • Patients with compensated cirrhosis who can tolerate therapy are candidates for treatment. • The treatment of choice is pegylated interferon alfa plus ribavirin. • Patients with genotypes 1 and 4 require 48 weeks of therapy with pegylated interferon and high daily doses of ribavirin (1,000 to 1,200 mg, depending on weight). • Patients with genotypes 2 and 3 can be treated for only 24 weeks with pegylated interferon and with 800 mg of ribavirin daily, with the following exceptions:

Archived Guideline	Recommendation(s)
	<ul style="list-style-type: none"> ○ A longer duration of therapy may be considered on an individual patient basis taking into account factors such as elevated viral level, cirrhosis, or delayed response to therapy. ○ 12 weeks of therapy suffices in patients in whom HCV RNA levels are undetectable at week 4. ○ Patients with genotype 3, with high levels of HCV RNA or advanced fibrosis on liver biopsy, may require treatment for 48 weeks. ● Therapy with peginterferon alfa and ribavirin should be strongly considered for patients who experienced a relapse after a course of standard interferon alfa/ribavirin combination therapy, while a longer duration of therapy in patients who experienced a relapse after 12 months of treatment with peginterferon alfa plus ribavirin is of unproven efficacy. ● For children, the general principles of management are the same as those for adults, except that treatment is not recommended for children younger than 3 years. ● For HIV-infected individuals, the optimal therapy consists of peginterferon alfa plus ribavirin for 48 weeks, regardless of genotype. Because of potential drug-drug interactions in patients on HIV treatment regimens that include didanosine, HIV regimens should be altered in those starting combination therapy for HCV infection. If didanosine is critical to the HIV regimen, ribavirin should be avoided.

XVI. References

7. Victrelis® [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2014 Jul.
8. Olysio® [package insert]. Titusville (NJ): Janssen Therapeutics; 2015 Apr.
9. Sovaldi® [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2015 Mar.
10. Harvoni® [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2015 Mar.
11. Viekira Pak® [package insert]. North Chicago (IL): AbbVie, Inc.; 2015 Mar.
12. World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection [guideline on the Internet]. Geneva (Switzerland): WHO 2014 Apr [cited 2015 March 11]. Available at: <http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/>.
13. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Accessed June 11, 2015.
14. Department of Veteran Affairs National Hepatitis C Resource Center Program and the Office of Public Health. Chronic hepatitis C Virus (HCV) infection: Treatment considerations [guideline on the Internet]. Washington (DC): VA 2015 Feb [cited 2015 March 6]. Available at: <http://www.hepatitis.va.gov/pdf/treatment-considerations-2015-02.pdf>
15. European Association for the Study of the Liver (EASL): Treatment of Hepatitis [guideline on the Internet]. Geneva (Switzerland): EASL 2014 Apr [cited 2015 March 11]. Available at: <http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf>.
16. Hussar DA and Kavelak HL. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir. *J Am Pharm Assoc.* 2015 Mar 1;55(2):216-223.
17. Merck. "Merck Voluntarily Discontinuing VICTRELIS® (boceprevir) 200 Mg Capsules." Letter. Jan. 2015. North Wales, PA. Available at: <http://www.fda.gov/downloads/drugs/drugsafety/drugshortages/ucm430818.pdf>.
18. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Micromedex; 2015 [cited 2015 Mar]. Available from: <http://www.thomsonhc.com/>.
19. Facts and Comparisons® eAnswers [database on the internet]. St. Louis: Wolters Kluwer Health, Inc.; 2015 [cited Mar 2015]. Available from: <http://online.factsandcomparisons.com>.
20. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized multicentre phase 2 trial. *Lancet* 2010;376:705-16.
21. Poordad F, McCone J, Bacon BR, et al. Bocepravir for untreated chronic HCV genotype 1 Infection. *N Eng J Med* 2011;364:1195-1206.
22. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med.* 2014 May 15;370(20):1889-98.
23. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med.* 2014 May 15;370(20):1879-88.
24. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med.* 2014 Apr 24;370(17):1594-603.
25. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med.* 2014 May 22;370(21):1983-92.
26. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. *N Engl J Med.* 2014 May 22;370(21):1973-82.
27. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa-2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet* 2014;384:403–13.
28. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2014; 384: 414-26.
29. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. *Hepatology* 2013;58(6):1918-1929.
30. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2013;381:2100-07.
31. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med.* 2013 May 16;368(20):1878-87.

32. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. *Lancet Infect Dis* 2013;13:401-08.
33. Bacon B, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011;364:1207-17.
34. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. *Clin Gastroenterol Hepatol*. 2013 Jan;11(1):81-87.
35. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med*. 2014 Apr 17;370(16):1483-93.
36. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). *Lancet Infect Dis*. 2015 Apr;15(4):397-404.
37. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med*. 2014 Apr 24;370(17):1604-14.
38. Andreone P, Colombo MG, Enejosa JV, Koksai I, Ferenci P, Maieron A, et al. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. *Gastroenterology*. 2014 May 9.
39. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial. *Gastroenterology* 2014;146:1669–1679.
40. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial. *Gastroenterology* 2014;146:430-441.
41. Sitole M, Silva M, Spooner L, et al. Telaprevir versus boceprevir in chronic hepatitis C: A meta-analysis of data from phase II and III trials. *Clinical Therapeutics* 2013;35(2):190-197.
42. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. *N Engl J Med*. 2014 Dec 18;371(25):2375-82.
43. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med* 2013;368:34-44.
44. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. *Lancet*. 2015 Mar 21;385(9973):1098-106.
45. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med*. 2013 May 16;368(20):1867-77.
46. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med*. 2014 May 22;370(21):1993-2001.
47. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. *Lancet*. 2014 Jul 28.
48. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), International Antiviral Society-USA (IAS-USA). Recommendations for testing, managing, and treating hepatitis C [guideline on the Internet]. Alexandria (VA): AASLD/IDSA/IAS-USA 2014 Apr [cited 2014 Jun 1]. Available at: <http://www.hcvguidelines.org>.
49. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. *J Hepatol*. 2013 Dec 4.
50. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. *Am J Gastroenterol*. 2012 May;107(5):669-89.
51. American Association for the Study of Liver Diseases (AASLD). An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases [guideline on the internet]. Geneva, Switzerland: American Association for the Study of Liver Diseases; 2013 [cited 2014 Jun 1]. Available from: <http://www.aasld.org/practiceguidelines/Documents/AASLDUpdateTreatmentGenotype1HCV11113.pdf>.
52. Ghany M, Strader D, Thomas D, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009;49:1335-1374.

53. Dienstag JL, McHutchison JG. American Gastroenterological Association Medical position statement on the management of hepatitis C. *Gastroenterology*. 2006;130(1):225-30.